

Overview information for

Toluene

TOXICOLOGICAL PROFILE FOR TOLUENE

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

June 2017

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

UPDATE STATEMENT

A Toxicological Profile for Toluene, Draft for Public Comment was released in September 2015. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch
1600 Clifton Road NE
Mailstop F-57
Atlanta, Georgia 30329-4027

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances may find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (e.g., death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Chapter 1	How Can (Chemical X) Affect Children?
Chapter 1	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.8	Biomarkers of Exposure and Effect
Section 3.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)

Internet: <http://www.atsdr.cdc.gov>

The following additional materials are available online:

Case Studies in Environmental Medicine are self-instructional publications designed to increase primary health care providers' knowledge of a hazardous substance in the environment and to aid in the evaluation of potentially exposed patients (see <https://www.atsdr.cdc.gov/csem/csem.html>).

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident (see <https://www.atsdr.cdc.gov/MHMI/index.asp>). Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances (see <https://www.atsdr.cdc.gov/toxfaqs/Index.asp>).

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015 • Web Page: <https://www.cdc.gov/nceh/>.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 395 E Street, S.W., Suite 9200, Patriots Plaza Building, Washington, DC 20201 • Phone: 202-245-0625 or 1-800-CDC-INFO (800-232-4636) • Web Page: <https://www.cdc.gov/niosh/>.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212 • Web Page: <https://www.niehs.nih.gov/>.

Clinical Resources (Publicly Available Information)

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266 • Web Page: <http://www.acoem.org/>.

The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with recognized expertise in medical toxicology. Contact: ACMT, 10645 North Tatum Boulevard,

Suite 200-111, Phoenix AZ 85028 • Phone: 844-226-8333 • FAX: 844-226-8333 • Web Page:
<http://www.acmt.net>.

The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists who respond to questions from public health professionals, clinicians, policy makers, and the public about the impact of environmental factors on the health of children and reproductive-aged adults. Contact information for regional centers can be found at <http://pehsu.net/findhelp.html>.

The American Association of Poison Control Centers (AAPCC) provide support on the prevention and treatment of poison exposures. Contact: AAPCC, 515 King Street, Suite 510, Alexandria VA 22314 • Phone: 701-894-1858 • Poison Help Line: 1-800-222-1222 • Web Page:
<http://www.aapcc.org/>.

This page is intentionally blank.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Jessilynn Taylor, M.S., CDR USPHS

Mike Fay, Ph.D.

Robert Williams, Ph.D.

Sharon Wilbur, M.A.

ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA

Peter McClure, Ph.D., DABT

Kimberly Zaccaria, Ph.D.

H. Danielle Johnson, B.S.

Mario Citra, Ph.D.

SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for toluene. The panel consisted of the following members:

1. Luis Haro Garcia, Ph.D., Departamento de Salud Pública, Facultad de Medicina, Universidad Nacional Autónoma de México, México DF, México;
2. Zemin Wang, M.D., Ph.D., DABT, Department of Environmental Health, Indiana University, Bloomington, Indiana; and
3. Scott E. Bowen, Ph.D., Associate Professor and BCN Area Chair, President, Michigan Chapter of the Society for Neuroscience, WSU Psi Chi Advisor, Department of Psychology, Wayne State University, Detroit, Michigan.

These experts collectively have knowledge of toluene's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS	xi
PEER REVIEW	xiii
CONTENTS.....	xv
LIST OF FIGURES	xix
LIST OF TABLES	xxi
1. PUBLIC HEALTH STATEMENT FOR TOLUENE.....	1
2. RELEVANCE TO PUBLIC HEALTH	9
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TOLUENE IN THE UNITED STATES	9
2.2 SUMMARY OF HEALTH EFFECTS.....	9
2.3 MINIMAL RISK LEVELS (MRLs)	24
3. HEALTH EFFECTS.....	31
3.1 INTRODUCTION.....	31
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	31
3.2.1 Inhalation Exposure	32
3.2.1.1 Death	33
3.2.1.2 Systemic Effects.....	101
3.2.1.3 Immunological and Lymphoreticular Effects	120
3.2.1.4 Neurological Effects	132
3.2.1.5 Reproductive Effects.....	161
3.2.1.6 Developmental Effects.....	166
3.2.1.7 Cancer	172
3.2.2 Oral Exposure.....	175
3.2.2.1 Death	175
3.2.2.2 Systemic Effects.....	176
3.2.2.3 Immunological and Lymphoreticular Effects	201
3.2.2.4 Neurological Effects	202
3.2.2.5 Reproductive Effects.....	205
3.2.2.6 Developmental Effects.....	206
3.2.2.7 Cancer	208
3.2.3 Dermal Exposure.....	208
3.2.3.1 Death	208
3.2.3.2 Systemic Effects.....	208
3.2.3.3 Immunological and Lymphoreticular Effects	211
3.2.3.4 Neurological Effects	211
3.2.3.5 Reproductive Effects.....	211
3.2.3.6 Developmental Effects.....	211
3.2.3.7 Cancer	211
3.3 GENOTOXICITY	212
3.4 TOXICOKINETICS.....	218
3.4.1 Absorption.....	219
3.4.1.1 Inhalation Exposure	219

3.4.1.2	Oral Exposure	220
3.4.1.3	Dermal Exposure	221
3.4.2	Distribution	223
3.4.2.1	Inhalation Exposure	223
3.4.2.2	Oral Exposure	226
3.4.2.3	Dermal Exposure	227
3.4.2.4	Other Routes of Exposure	227
3.4.3	Metabolism	227
3.4.4	Elimination and Excretion	232
3.4.4.1	Inhalation Exposure	232
3.4.4.2	Oral Exposure	234
3.4.4.3	Dermal Exposure	235
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	235
3.5	MECHANISMS OF ACTION	247
3.5.1	Pharmacokinetic Mechanisms	247
3.5.2	Mechanisms of Toxicity	249
3.5.2.1	Mechanisms of Neurotoxicity	249
3.5.2.2	Mechanisms of Toxicity to Other Systems	257
3.5.2.3	Potential Mechanisms of Metabolite-mediated Toxicity	258
3.5.3	Animal-to-Human Extrapolations	259
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	260
3.7	CHILDREN'S SUSCEPTIBILITY	263
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	270
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Toluene	271
3.8.2	Biomarkers Used to Characterize Effects Caused by Toluene	271
3.9	INTERACTIONS WITH OTHER CHEMICALS	272
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	277
3.11	METHODS FOR REDUCING TOXIC EFFECTS	280
3.11.1	Reducing Peak Absorption Following Exposure	280
3.11.2	Reducing Body Burden	281
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	281
3.12	ADEQUACY OF THE DATABASE	282
3.12.1	Existing Information on Health Effects of Toluene	282
3.12.2	Identification of Data Needs	284
3.12.3	Ongoing Studies	295
4.	CHEMICAL AND PHYSICAL INFORMATION	297
4.1	CHEMICAL IDENTITY	297
4.2	PHYSICAL AND CHEMICAL PROPERTIES	297
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	301
5.1	PRODUCTION	301
5.2	IMPORT/EXPORT	301
5.3	USE	301
5.4	DISPOSAL	304
6.	POTENTIAL FOR HUMAN EXPOSURE	305
6.1	OVERVIEW	305
6.2	RELEASES TO THE ENVIRONMENT	307
6.2.1	Air	308
6.2.2	Water	313

6.2.3	Soil	314
6.3	ENVIRONMENTAL FATE	314
6.3.1	Transport and Partitioning.....	314
6.3.2	Transformation and Degradation	316
6.3.2.1	Air	316
6.3.2.2	Water.....	316
6.3.2.3	Sediment and Soil	317
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	318
6.4.1	Air	319
6.4.2	Water.....	332
6.4.3	Sediment and Soil	333
6.4.4	Other Environmental Media.....	333
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	333
6.6	EXPOSURES OF CHILDREN.....	339
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	341
6.8	ADEQUACY OF THE DATABASE	342
6.8.1	Identification of Data Needs	343
6.8.2	Ongoing Studies	345
7.	ANALYTICAL METHODS	347
7.1	BIOLOGICAL MATERIALS.....	347
7.2	ENVIRONMENTAL SAMPLES	352
7.3	ADEQUACY OF THE DATABASE	357
7.3.1	Identification of Data Needs	357
7.3.2	Ongoing Studies	358
8.	REGULATIONS, ADVISORIES, AND GUIDELINES.....	359
9.	REFERENCES	367
10.	GLOSSARY	437
APPENDICES		
A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B.	USER'S GUIDE.....	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	C-1

This page is intentionally blank.

LIST OF FIGURES

2-1. Health Effects of Breathing Toluene	22
2-2. Health Effects of Ingesting Toluene	23
3-1. Levels of Significant Exposure to Toluene – Inhalation	90
3-2. Levels of Significant Exposure to Toluene – Oral	192
3-3. Scheme for Toluene Metabolism in Humans and Animals	228
3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	237
3-5. Existing Information on Health Effects of Toluene	283
6-1. Frequency of NPL Sites with Toluene Contamination	306

This page is intentionally blank.

LIST OF TABLES

3-1. Levels of Significant Exposure to Toluene – Inhalation	34
3-2. Mean Spleen Weight (SE) for PND 21 Mice (n=6/Group) Exposed to Toluene 6 Hours/Day on GD 14 Through PND 21 With and Without Exposure to PGN	129
3-3. Levels of Significant Exposure to Toluene – Oral	177
3-4. Levels of Significant Exposure to Toluene – Dermal.....	210
3-5. Genotoxicity of Toluene <i>In Vivo</i>	213
3-6. Genotoxicity of Toluene <i>In Vitro</i>	215
3-7. Ongoing Research for Toluene.....	296
4-1. Chemical Identity of Toluene	298
4-2. Physical and Chemical Properties of Toluene	299
5-1. Facilities that Produce, Process, or Use Toluene.....	302
6-1. Releases to the Environment from Facilities that Produce, Process, or Use Toluene	309
6-2. 2011 NEI Total National Emissions of Toluene.....	311
6-3. Toluene Levels in Ambient Air	320
6-4. Percentile Distribution of Annual Mean Toluene Concentrations (ppbv) Measured in Ambient Air at Locations Across the United States.....	328
6-5. Weekly Mean Toluene Concentrations ($\mu\text{g}/\text{m}^3$) in Indoor Air at 16 Newspaper Stands and the Corresponding Outdoor Air Levels.....	330
6-6. Geometric Mean and Selected Percentiles of Blood Toluene in Whole Blood Concentrations (in mg/L) for the U.S. Population from NHANES.....	334
7-1. Analytical Methods for Determining Toluene in Biological Materials.....	348
7-2. Analytical Methods for Determining Biomarkers of Toluene in Biological Samples.....	351
7-3. Analytical Methods for Determining Toluene in Environmental Samples	353
8-1. Regulations, Advisories, and Guidelines Applicable to Toluene	362

This page is intentionally blank.

1. PUBLIC HEALTH STATEMENT FOR TOLUENE

This Public Health Statement summarizes the Agency for Toxic Substances and Disease Registry's (ATSDR) findings on toluene, including chemical characteristics, exposure risks, possible health effects from exposure, and ways to limit exposure.

The U.S. Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the nation. These sites make up the National Priorities List (NPL) and are sites targeted for long-term federal clean-up activities. The EPA has found toluene in at least 990 of the 1,832 current or former NPL sites. The total number of NPL sites evaluated for toluene is not known. But the possibility remains that as more sites are evaluated, the sites where toluene is found may increase. This information is important because these future sites may be sources of exposure, and exposure to toluene may be harmful.

If you are exposed to toluene, many factors determine whether you'll be harmed. These include how much you are exposed to (dose), how long you are exposed (duration), how often you are exposed (frequency), and how you are exposed (route of exposure). You must also consider the other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and state of health.

WHAT IS TOLUENE?

Toluene is a clear, colorless liquid with a distinctive smell. It is a good solvent (a substance that can dissolve other substances). Toluene occurs naturally in crude oil and in the tolu tree. It is produced in the process of making gasoline and other fuels from crude oil and in making coke from coal.

Toluene is used in making paints, paint thinners, fingernail polish, lacquers, adhesives, and rubber and in some printing and leather tanning processes. It is used in the production of benzene, nylon, plastics, and polyurethane and the synthesis of trinitrotoluene (TNT), benzoic acid, benzoyl chloride, and toluene diisocyanate. It is also added to gasoline along with benzene and xylene to improve octane ratings.

WHAT HAPPENS TO TOLUENE WHEN IT ENTERS THE ENVIRONMENT?

Toluene can be released into the air, water, and soil at places where it is produced or used. Toluene is commonly found in air, particularly when there is heavy vehicular traffic. Monitoring data of outdoor air in the United States shows that toluene is present at average levels of approximately 1–35 parts per billion

1. PUBLIC HEALTH STATEMENT

by volume (ppbv). Indoor air samples can contain higher levels of toluene in places where products such as paint thinners, solvents, or tobacco products are used.

Toluene can enter surface waters and groundwater (e.g. wells) from solvent and petroleum products spills. Toluene can also leak from underground storage tanks at gasoline stations and other facilities. When toluene-containing products are placed in landfills or waste disposal sites, toluene can enter the soil and water near the waste site. It is possible for toluene to be broken down in subsurface (below ground) water primarily by anaerobic microorganisms. Toluene will readily evaporate into the air or be degraded by microorganisms in surface waters. Leaking underground storage tanks can contaminate the soil with toluene and other petroleum-product components. Toluene in surface soils rapidly evaporates into the air. Toluene is readily broken down to other chemicals by microorganisms in the soil.

HOW MIGHT I BE EXPOSED TO TOLUENE?

Toluene enters the environment when you use materials that contain it, such as paints, paint thinners, adhesives, fingernail polish, and gasoline; it evaporates rapidly from these materials and becomes mixed with the air you breathe.

Individuals who work with gasoline, paint, lacquer, or dyes have greater exposures to toluene, as do individuals who smoke or intentionally inhale products containing toluene for its euphoric effects.

HOW CAN TOLUENE ENTER AND LEAVE MY BODY?

Toluene can enter your body from the air, water, or soil. You are exposed to toluene by breathing outdoor or indoor air containing this substance. Gasoline contains toluene and so do some other products used in occupational or home settings (e.g., solvents, paint thinners). Inhalation and dermal exposure is possible when using these products.

Toluene is not frequently detected in drinking water. If you are using a well that has been contaminated by toluene from an accidental spill, you may ingest some; however, this route of exposure is less likely than breathing in toluene from air. Toluene evaporates quickly from soils. Therefore, it is unlikely you will be exposed to it from soil, unless you come in contact with soil near a hazardous waste site containing it or an accidental spill.

1. PUBLIC HEALTH STATEMENT

When you breathe toluene, it is taken directly into your blood from your lungs. Similarly, when you touch products containing toluene (e.g., nail polish remover) or bathe in water containing toluene, toluene can pass through your skin into your bloodstream. When you ingest food or drink containing toluene, it is also absorbed from your GI tract into your bloodstream. Factors such as your age, sex, body composition, and health status affect what happens to toluene once it is in your body.

After being taken into your body, the majority of toluene is removed from your body within a day; however, a small amount may accumulate in fat tissue with daily exposure. Toluene may leave your body unchanged in the air you breathe out or in your urine after some of it has been changed to other chemicals. Generally, your body turns toluene into less harmful chemicals such as hippuric acid. More information on how toluene can enter and leave your body can be found in Chapter 3.

HOW CAN TOLUENE AFFECT MY HEALTH?

A serious health concern is that toluene may have an effect on your nervous system (brain and nerves). Nervous system effects can be temporary, such as headaches, dizziness, or unconsciousness. However, effects such as incoordination, cognitive impairment, and vision and hearing loss may become permanent with repeated exposure, especially at high levels associated with intentional solvent abuse. High levels of toluene exposure during pregnancy, such as those associated with solvent abuse, may lead to developmental effects, such as retardation of mental abilities and growth in children. Other health effects of potential concern may include immune, kidney, liver, and reproductive effects.

Single exposures to toluene or repeated exposures over a few weeks can cause headaches and sleepiness, and can impair your ability to think clearly. Whether or not toluene does this to you depends on the amount you take in, how long you are exposed, how frequently you are exposed, and your genetic susceptibility and age. One very dangerous activity is to expose yourself to a large amount of toluene in a short time by deliberately inhaling/sniffing paint or glue. At first, you will feel light-headed. If exposure continues, you can become dizzy, sleepy, or unconscious. When exposure is stopped, the sleepiness and dizziness usually goes away. However, you could die, because high-level toluene can interfere with the way you breathe and the way your heart beats. If you deliberately breathe in large amounts of toluene during pregnancy, developmental effects, such as retardation of mental abilities and growth, may occur in your children.

1. PUBLIC HEALTH STATEMENT

Day-after-day exposure to low to moderate levels of toluene in the workplace may cause tiredness, confusion, weakness, drunken-type actions, memory loss, nausea, and loss of appetite in some people. These symptoms usually disappear when exposure is stopped. You may experience some hearing and color vision loss after long-term daily exposure to toluene in the workplace. Combinations of toluene and some common medicines like aspirin and acetaminophen may increase the effects of toluene on your hearing. Researchers do not know if the low levels of toluene that you breathe at work will cause any permanent effects on your brain or body after many years. If you choose to repeatedly breathe in toluene from glue or paint thinners, you may permanently damage your brain. You may also experience problems with your speech, vision, or hearing, have loss of muscle control, loss of memory, poor balance, and decreased mental ability.

Some studies in people have shown reproductive effects, such as an increased risk of spontaneous abortions, from repeated, low to moderate levels of toluene in the workplace. However, other factors, such as exposure to other chemicals, smoking, and alcohol use, may have affected the results of the studies, so it is not possible to say definitively whether toluene has reproductive effects in people. No reports are available of developmental effects in children of pregnant women exposed to low to moderate levels of toluene in the workplace.

The effects of toluene on animals are similar to those seen in humans. The main effect of toluene is on the brain and nervous system, but animals exposed to moderate or high levels of toluene also show harmful effects in their liver, kidneys, and lungs and impaired immune function. Animal studies do not indicate that toluene exposure results in reproductive effects (e.g., damage to reproductive organs, infertility, abortion, premature birth), but do indicate that high levels of toluene during pregnancy can produce developmental effects, similar to those observed in human mothers who intentionally breathed in high levels of toluene during pregnancy (see next section regarding how toluene may affect children).

Studies in workers and animals exposed to toluene generally indicate that toluene is not carcinogenic (cancer-causing). The International Agency for Research on Cancer determined that toluene is not classifiable as to its carcinogenicity in humans (Group 3). The EPA determined there is inadequate information to assess the carcinogenic potential of toluene. The American Conference of Governmental Industrial Hygienists (ACGIH) determined that toluene is not classifiable as a human carcinogen (A4). The U.S. National Toxicology Program (NTP) has not considered the carcinogenic potential of toluene.

See Chapters 2 and 3 for more information on health effects of toluene.

1. PUBLIC HEALTH STATEMENT

HOW CAN TOLUENE AFFECT CHILDREN?

This section discusses potential health effects of toluene exposure in humans from when they're first conceived to 18 years of age.

Children may breathe air contaminated with toluene by family use of glues, paints, or cleaning solvents, or by accidents involving products containing toluene. Toluene vapors are heavier than air and since young children are closer to the ground or floor because of their height, they may breathe more toluene than adults during accidental exposures. Also, children have faster breathing rates than adults and may therefore breathe in more toluene. Older children and adolescents may be exposed to toluene if they breathe household products containing it to get "high". Nursing mothers who breathe toluene in workplace air may transfer some toluene in breast milk to their infants. Toluene is not stored in the body. Toluene in the body either rapidly leaves or is turned into less harmful chemicals. Thus, nursing mothers, who do not currently work in jobs with toluene and who do not deliberately breathe large amounts of toluene, are expected to transfer very little toluene in breast milk.

The effects of toluene on children have not been studied very much, but toluene is likely to produce the same types of effects on the brain and nervous system in children as it does in adults. Some older children and adolescents who have repeatedly breathed large amounts of toluene to get high have developed loss of muscle control, loss of memory, poor balance, and decreased mental abilities. Some of these changes may last for a long time after toluene has left the body. Young animals exposed to toluene have shown changes in behavior, hearing loss, and chemical changes in their brains.

Human fetuses and newborn babies may be more sensitive to toluene than adults, because their bodies may not be as able to turn toluene into less harmful chemicals. Some animal studies suggest that young animals might be more susceptible to toluene effects on health; however, shortly after birth, human babies begin to develop the ability to turn toluene into less harmful chemicals. By the time children are 1–3 years of age, they may be equal to adults in this ability.

Some mothers who breathed large amounts of toluene during pregnancy to get high have had children with birth defects, including retardation of mental abilities and growth. Results from animal studies have found similar effects in newborn animals that had mothers that breathed large amounts of toluene during pregnancy; however, when the animal mothers breathed small amounts of toluene during pregnancy, no

1. PUBLIC HEALTH STATEMENT

birth defects were found in their newborn animals. When pregnant animals breathe small amounts of toluene during pregnancy, studies show that very little toluene reaches the developing fetus.

More information on the effects of toluene on children can be found in Chapter 3.

HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO TOLUENE?

If your doctor finds that you have been exposed to significant amounts of toluene, ask whether your children might also be exposed. Your doctor might need to ask your state health department to investigate. You may also contact the state or local health department with health concerns.

Toluene is a solvent that is used in making paints, paint thinners, fingernail polish, lacquers, adhesives, and rubber. Toluene is added to gasoline and is used in some printing and leather tanning processes. Follow instructions on product labels to minimize exposure to toluene. Families can reduce their risk of exposure to toluene by using consumer products containing the chemical (such as paints, glues, inks, and stain removers) in well-ventilated areas or using consumer products without toluene. When not in use, toluene-containing products should be tightly covered to prevent evaporation into the air. Household chemicals should be stored out of the reach of young children to prevent accidental poisonings. Storing items that contain toluene in a locked shed or another secure area outside location may reduce the potential for accidental exposure in young children (or intentional exposure by older youth). Always store household chemicals in their original labeled containers. Never store household chemicals in containers that children would find attractive to eat or drink from, such as old soda bottles. Keep your Poison Control Center's number next to the phone.

If you have concerns about the presence of toluene in your tap water, you can call your local health department and request information on testing results of local public drinking water or ask how to get your well tested. If concerns remain, use bottled water for drinking. Prevent children from eating or playing in the dirt if you live near a waste site that has been contaminated with toluene, and always have them wash their hands prior to eating in case of potential exposure.

Your children may be exposed to toluene by inhaling products that contain it. Sometimes, older children sniff household chemicals in an attempt to get high. Talk with children about the dangers of sniffing chemicals such as toluene.

1. PUBLIC HEALTH STATEMENT

ARE THERE MEDICAL TESTS TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO TOLUENE?

Toluene and its breakdown products (metabolites) can be measured in blood and urine. However, the detection of toluene or its metabolites cannot predict the kind of health effects that might develop from that exposure. Because toluene and its metabolites leave the body fairly rapidly, the tests need to be conducted within days after exposure.

For more information on the different substances formed by toluene breakdown and on tests to detect these substances in the body, see Chapters 3 and 7.

WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?

The federal government develops regulations and recommendations to protect public health. Regulations can be enforced by law. Federal agencies that develop regulations for toxic substances include the Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA), and the Food and Drug Administration (FDA). Recommendations provide valuable guidelines to protect public health but are not enforceable by law. Federal organizations that develop recommendations for toxic substances include the Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety and Health (NIOSH).

Regulations and recommendations can be expressed as “not-to-exceed” levels; that is, levels of a toxic substance in air, water, soil, or food that do not exceed a critical value usually based on levels that affect animals; levels are then adjusted to help protect humans. Sometimes these not-to-exceed levels differ among federal organizations. Different organizations use different exposure times (e.g., an 8-hour workday or a 24-hour day), different animal studies, or emphasize some factors over others, depending on their mission.

Recommendations and regulations are also updated periodically as more information becomes available. For the most current information, check with the federal agency or organization that issued the regulation or recommendation.

The EPA has recommended a drinking water guideline value of 1 mg/L for toluene. OSHA has set a legal limit for workers of 200 ppm for toluene in air averaged over an 8-hour workday. NIOSH has set a

1. PUBLIC HEALTH STATEMENT

recommended limit of 100 ppm for toluene in air averaged over a 10-hour workday. ACGIH recommends that toluene in workplace air not exceed 20 ppm (average levels over 8 hours).

More information on federal and state government regulations and guidelines for toluene in air and water can be found in Chapter 8.

WHERE CAN I GET MORE INFORMATION?

If you have any questions or concerns, please contact your community or state health or environmental quality department, or contact ATSDR at the address and phone number below. You may also contact your doctor if experiencing adverse health effects or for medical concerns or questions. ATSDR can also provide publicly available information regarding medical specialists with expertise and experience recognizing, evaluating, treating, and managing patients exposed to hazardous substances.

- Call the toll-free information and technical assistance number at 1-800-CDCINFO (1-800-232-4636) or
- Write to:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
1600 Clifton Road NE
Mailstop F-57
Atlanta, GA 30329-4027

Toxicological profiles and other information are available on ATSDR's web site:
<http://www.atsdr.cdc.gov>.

2. RELEVANCE TO PUBLIC HEALTH

2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TOLUENE IN THE UNITED STATES

Toluene is a clear colorless liquid possessing high vapor pressure and low to moderate water solubility. It is used as a solvent and as an additive in gasolines to improve octane ratings. It is also frequently used to produce other chemicals such as benzene and toluene diisocyanate.

Given its vapor pressure, toluene tends to partition to the atmosphere. Automobile emissions are the principal source of toluene in ambient air, with levels fluctuating in proportion to automobile traffic. Toluene can also be a common indoor contaminant, and indoor air concentrations are often several times higher than outside air. This is likely due to release of toluene from common household products (paints, paint thinners, adhesives, and nail polish in which it is used as a solvent) and from cigarette smoke.

In the atmosphere, toluene is principally degraded by reaction with photochemically generated hydroxyl radicals, but may also degrade through reaction with nitrate radicals and ozone. When released to water surfaces, toluene is expected to volatilize quickly. It may also be biodegraded under aerobic and anaerobic conditions, but hydrolysis is not an important environmental fate process. Toluene does not bioconcentrate or bioaccumulate significantly in aquatic organisms. If released to soil, toluene is expected to volatilize quickly. In the case of a large spill, some toluene may leach into groundwater because it possesses high mobility in soils. Biodegradation in soils may also occur with half-lives ranging from a few hours to several days depending upon the environmental conditions.

The general population is primarily exposed to toluene through the inhalation of ambient air. Ingestion of toluene from contaminated water and food is possible; however, this is a less likely exposure route since toluene is not frequently detected in drinking water and food. Dermal exposure from gasoline or solvents that contain toluene is also possible. Occupational exposure to toluene is expected to be greater than general population exposure for persons employed in heavy traffic occupations (e.g., toll attendants, automobile workers etc.) and persons who frequently use solvents or other products that contain toluene.

2.2 SUMMARY OF HEALTH EFFECTS

Death. Case studies that reported on deaths in humans due to exposure to toluene have generally not provided information on dose. In one instance, ingestion of approximately 625 mg/kg resulted in death

2. RELEVANCE TO PUBLIC HEALTH

within 30 minutes. The cause of death appeared to be profound disruption of central nervous system function.

An acute 7-hour inhalation LC_{50} value of 5,320 ppm has been reported for mice and acute oral LD_{50} values in adult rats ranged from 5,500 to 7,400 mg/kg. In 13-week gavage studies, all rats and mice that received 5,000 mg/kg died within the first week. Mortality was also high for groups receiving 2,500 mg/kg, with 8/10 male rats, 1/10 female rats, and 4/10 male and female mice dying before the end of the study. A dose of 1,250 mg/kg/day was lethal in 1/10 female mice, but no deaths occurred in male mice or in rats of either sex.

Systemic Effects.

Respiratory Effects. The primary effect of toluene on the respiratory tract following inhalation is irritation. Studies with volunteers and exposed workers have demonstrated that toluene is a mild-to-moderate respiratory irritant. Early animal studies reported respiratory irritation and pulmonary lesions in rats exposed to high concentrations of toluene. These findings are supported by more recent observations of nasal lesions (including metaplasia of olfactory epithelium and degeneration of respiratory epithelium) in rats exposed to concentrations ranging from 600 to 1,200 ppm, 6.5 hours/day, 5 days/week for 2 years. Mice exposed by the same exposure protocol to a similar range of concentrations, however, did not display upper or lower respiratory tract lesions. In shorter duration studies, reversible nasal olfactory degeneration was observed in mice exposed to 1,000 ppm, 5 hours/day, 5 days/week for 4 weeks and inflammatory cell infiltration in peribronchial and alveolar regions, alveolar edema, and interstitial fibrosis and necrosis was observed in rats exposed to 3,000 ppm, 8 hours/day, 6 days/week for 12 weeks.

Only limited data regarding respiratory effects following oral exposure to toluene were located. Following lethal ingestion of approximately 625 mg/kg toluene, lung congestion and hemorrhage were reported in an adult male. Mucosal lesions and pronounced edema were observed during a bronchoscopy following a nonlethal ingestion of paint thinner by a 15-month-old girl. No respiratory effects were reported in mice or rats after oral exposure to toluene at dosage levels up to 2,500 mg/kg/day for 13 weeks or 590 mg/kg/day for 6 months. No changes in lung weight or histology were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls.

Cardiovascular Effects. Inhalation exposure to toluene at concentrations >1,000 ppm has been associated with alterations of the heart rhythm in both humans and animals, but exposure of rats or mice

2. RELEVANCE TO PUBLIC HEALTH

to concentrations as high as 12,000 ppm (3 hours/day) for intermediate durations and up to 1,200 ppm (6–6.5 hours/day) for chronic durations produced no histological changes in heart tissue. Additionally, no histological changes in the heart were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (6 hours/day; pre-mating and mating, gestation, and lactation) in a multigenerational study. There may be intraspecies differences in the cardiac response to toluene that make some individuals more susceptible than others to potentially fatal arrhythmias; the degree of hypoxia may also be important.

Cardiac effects have been noted following oral exposure to doses >1,200 mg/kg. Cardiac edema and congestion were observed in rats given single gavage doses of 5,200 mg/kg, compared with controls. Increased relative heart weights were noted in rats exposed to toluene at 1,250 mg/kg/day for 13 weeks and myocardial degeneration was present in mice exposed to 5,000 mg/kg/day. All of the mice receiving 5,000 mg/kg/day died during the first weeks of exposure. No effects on the weight or gross morphology of the heart were noted in rats receiving 590 mg/kg/day for 6 months, and no significant treatment-related findings were observed in electrocardiograms or cardiac histology in rats given single oral doses of up to 1,000–1,200 mg/kg.

Gastrointestinal Effects. Gastric pain was reported by a man who accidentally ingested 30 mL of an organic solvent containing toluene and other chemicals. Gastrointestinal effects were not reported in other case studies of oral exposure.

The only gastrointestinal effect reported after exposure to toluene was ulceration of the forestomach of rats exposed to 600 and 1,200 ppm by inhalation for 2 years. Similar effects were not seen in mice exposed under the same conditions or in rats or mice orally exposed to 2,500 mg/kg/day for 13 weeks. Additionally, no gastrointestinal effects were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (6 hours/day; pre-mating and mating; gestation, and lactation) in a multigenerational reproductive toxicity study.

Hematological Effects. Before the mid-1950s, chronic occupational exposure to toluene was associated with hematological effects. However, these effects are now attributed to benzene, a common contaminant of toluene at that time. More recent studies of workers exposed to toluene or to mixed solvents containing toluene have not found consistent evidence for abnormal hematological parameters. Following acute exposures, no effects on leukocyte counts were observed in volunteers exposed to 800 ppm toluene for 3 hours, and two workers accidentally exposed to about 1,862 ppm for 2–3 hours had

2. RELEVANCE TO PUBLIC HEALTH

normal values for hematological variables. Decreased leukocyte and white blood cell counts were observed in dogs and rats repeatedly exposed to airborne toluene, but have not been observed consistently in other studies of rats and mice repeatedly exposed by inhalation or by oral administration. In one study, rats exposed to high concentrations (2,500 or 5,000 ppm) of toluene for 7 hours each day had decreased leukocyte counts following exposure; however, the leukocyte numbers generally returned to normal by the next day. The toxicological significance of a transitory decrease in numbers of leukocytes is not apparent. In chronic-duration studies, rats exposed to 100 or 300 ppm toluene had significantly reduced hematocrit levels, but no consistent effects on hematological variables were reported for mice or rats exposed to toluene at levels up to 1,200 ppm for 15 months or 2 years.

Musculoskeletal Effects. Rhabdomyolysis (an acute disease of the skeletal muscles leading to breakdown of muscle tissue, leading to release of myoglobin into the blood and urine) was reported in two case studies of chronic toluene abuse: a man who had been sniffing glue containing toluene for 18 years, and a 48-year-old man who was a chronic toluene abuser who had been inhaling one tube of toluene-containing glue per day in the month preceding admission.

No musculoskeletal effects were reported in mice or rats after inhalation exposure up to 1,200 ppm for 15 months or 2 years or oral exposure to toluene at dosage levels up to 2,500 mg/kg/day for 13 weeks. Additionally, no musculoskeletal effects were reported in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study. However, bone mineral density and bone mineral content were significantly ($p < 0.05$) decreased in the right femoral neck of mice exposed to 300 ppm toluene 6 hours/day for 8 weeks.

Hepatic Effects. Studies of chronic toluene abusers, occupationally exposed workers, and laboratory animals have provided little support for irreversible liver damage due to inhaled toluene. Some studies of workers who were occupationally exposed to average concentrations between about 30 and 350 ppm toluene reported liver effects such as increased serum levels of alkaline phosphatase (AP), but others recorded no adverse effects on serum liver enzyme levels. Results from studies of animals exposed by inhalation for acute, intermediate, or chronic durations indicate that daily 6–8-hour exposures to concentrations above 300 ppm, but not below, can lead to increased liver weights and induction of hepatic cytochrome P450 levels. There are a few reports of toluene-induced effects that may be associated with liver damage (e.g., increased serum levels of liver enzymes in rats exposed to 2,000 ppm for 48 hours, rats exposed to 3,000 ppm, 1 hour/day for 30 days, and rats exposed to 300 ppm, 6 hours/day for 4 weeks;

2. RELEVANCE TO PUBLIC HEALTH

increased hepatic fibrosis and apoptosis in rats exposed to 3,000 ppm, 1 hour/day for 30 days or 8 hours/day, 6 hours/week for 12 weeks; and increased endoplasmic reticulum in hepatocytes after exposure of rats, mice, and rabbits to 795 ppm 8 hours/day for 7 days), but no significant histopathological liver changes or liver weight changes were observed in well-conducted chronic-duration studies in which rats and mice were exposed to concentrations as high as 1,200 ppm, 6.5 hours/day, 5 days/week for 2 years. Results from intermediate-duration oral studies in rats and mice support the idea that toluene does not cause degenerative liver effects, but, at sufficiently high doses, produces liver weight increases that are likely associated with enzyme induction.

Studies of liver effects following oral exposure in humans are limited to two case studies. The liver of an adult male who died from toluene ingestion (625 mg/kg) was found to be enlarged on autopsy; however, clinical chemistry did not reveal abnormal liver function in a 15-month-old girl following accidental ingestion of paint thinner. Evidence from intermediate-duration animal studies indicates that exposure to toluene results in increased liver weights; however, reported effective dose levels vary widely between studies, species, and sex. Increased liver weight has been reported in male mice exposed to 105 mg/kg/day in drinking water for 28 days, but not at 5, 22, or 84 mg/kg/day. Following exposure to 0, 312, 625, 1,250, 2,500, or 5,000 mg/kg/day via gavage for 12 weeks, significant increases in liver weight were observed in male and female rats exposed to ≥ 625 and $\geq 1,250$ mg/kg/day, respectively, and male and female mice exposed to $\geq 1,250$ and ≥ 312 mg/kg/day, respectively. No treatment-related changes in liver weight were observed in female rats exposed to 590 mg/kg/day via gavage for 6 months. No treatment-related gross or histopathological lesions of the liver were reported in any of these intermediate-duration oral studies in laboratory animals.

An acute oral study in rats reports that single gavage doses of 5,200 mg/kg produced slight degeneration of hepatocytes, mononuclear cell infiltration, increased apoptosis, and increased serum levels of AST and ALT; however, no alterations in liver weight or histology were reported in pregnant rats exposed to 1,250 mg/kg/day toluene via gavage from gestation day (GD) 16 to 19 or female mice exposed to 600 mg/kg/day toluene via gavage for 14 days. Increased hepatic cell apoptosis was also reported in rats exposed to 650 mg/kg/day via gavage for 45 days.

Renal Effects. Studies of chronic toluene abusers, occupationally exposed workers, and laboratory animals have provided little support for irreversible kidney damage due to inhaled toluene. Chronic abuse of toluene can produce acidosis, but in most cases, renal dysfunction is transient, and normal function returns when exposure ceases. Studies of workers occupationally exposed to 100–200 ppm toluene,

2. RELEVANCE TO PUBLIC HEALTH

which assessed changes in tests of kidney function, have not shown consistent effects across studies. Animal studies indicate that inhalation of toluene causes concentration-dependent kidney damage in rats, but only after repeated exposure to concentrations ≥ 600 ppm for at least 6 hours/day.

The majority of oral exposure studies in animals do not report renal effects. No treatment-related changes in kidney weight were reported in female rats exposed to 590 mg/kg/day via gavage for 6 months, male and female mice exposed up to 2,500 mg/kg/day via gavage for 13 weeks, male mice exposed to 5–105 mg/kg/day in drinking water for 28 days, or female mice exposed to 600 mg/kg/day via gavage for 14 days. However, following exposure to 0, 312, 625, 1,250, 2,500, or 5,000 mg/kg/day via gavage for 12 weeks, significant increases in kidney weight were observed in male and female rats exposed to ≥ 625 and $\geq 1,250$ mg/kg/day, respectively. No changes in histopathology or renal function were reported in any intermediate-duration study. However, evidence for renal pathology was reported in dams exposed to 1,250 mg/kg/day toluene via gavage from GD 16 to 19. Kidneys from toluene-exposed dams demonstrated swollen tubules, tissue adhesion to Bowman's capsule, and areas of solidification within glomeruli that were not observed in control dams. No exposure-related changes were observed in kidney weight.

Endocrine Effects. Current data do not provide consistent evidence of endocrine disruption in toluene-exposed humans. Elevated plasma levels of triiodothyronine (T3), but not free thyroxine (T4) or thyroid stimulating hormone (TSH), were observed in male printers exposed to 36 ppm toluene compared to an unexposed referent group. No change was observed in serum prolactin levels. Studies of blood levels of reproductive hormones in repeatedly exposed workers or acutely exposed human subjects have not provided strong and consistent evidence of exposure-related endocrine effects.

Similarly, evidence for endocrine effects in animals following acute- or intermediate-duration inhalation exposure to toluene is not consistent across studies and does not clearly identify toluene as an endocrine disrupting chemical. Elevated prolactin levels were reported in rats after exposure to 80 ppm toluene 6 hours/day, 5 days/week for 4 weeks or 80–1,000 ppm 6 hours/day for 3 days. However, no changes in prolactin levels were found in rats after exposure to 40–320 ppm 6 hours/day, 5 days/week for 4 weeks, 500 ppm toluene 6 hours/day for 3 days, or 1,000 ppm 6 hours/day for 5 days. No statistically significant, dose-related changes in serum levels of, luteinizing hormone (LH), follicle stimulating hormone (FSH), corticosterone levels, growth hormone, or TSH were reported in male Sprague-Dawley rats exposed up to 3,000 ppm toluene 6 hours/day for 3 days or 1,000 ppm 6 hours/day for 5 days. Increased serum adrenocorticotrophic hormone (ACTH) and corticosterone levels, along with increased adrenal weight and

2. RELEVANCE TO PUBLIC HEALTH

adrenocortical cell size, were observed in male rats exposed to 1,500 ppm 4 hours/day for 7 days. This exposure scenario was shown to cause, in companion studies, neuronal damage and an increase in glucocorticoid receptor in the hippocampus, suggesting a possible disruption in the neuroendocrine axis. However, no effects on endocrine glands (pancreas, adrenal, or thyroid) were reported in other studies of rats exposed to 200–5,000 ppm toluene for 7 hours/day for 5 weeks, F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation, mice exposed to up to 2,500 ppm for 14 weeks, rats exposed to up to 3,000 ppm for 15 weeks, or mice and rats exposed to up to 1,200 ppm for 2 years.

Limited data are available regarding endocrine effects following oral exposure. Serum corticosterone and ACTH levels were significantly elevated in male mice exposed to 105 mg/kg/day toluene in drinking water for 28 days, compared with controls. Levels were not significantly elevated following exposure to 5 or 22 mg/kg/day. Microscopic examination revealed no effects on the adrenal or thyroid glands in rats and mice administered 312–2,500 mg/kg/day toluene by gavage for 13 weeks.

Dermal Effects. Skin irritation can occur in humans and animals dermally exposed to toluene. In humans, this may be due to the degreasing action of toluene and its removal of protective skin oils. However, exposure to toluene vapors of 100–2,000 ppm for 95 days (pre-mating, mating, gestation, and lactation) in a multigenerational study had no effects on the skin in F0 and F1 parental rats or F1 and F2 weanlings. Repeated or continuous contact with undiluted toluene in guinea pigs and mice leads to swelling, inflammatory cell infiltration, and increased epidermal thickness.

Ocular Effects. Humans have reported eye irritation following exposure to toluene vapors at concentrations ≥ 100 ppm. This is probably the result of direct contact of toluene vapor with the outer surface of the eye and thus, is not a true systemic effect. Slight to moderately severe irritation of rabbit eyes has been reported following direct application of toluene to the conjunctiva. Reports of color vision deficits in occupationally exposed workers have been postulated to involve toluene interference with dopaminergic mechanisms of retinal cells or toxic demyelination of optic nerve fibers.

Body Weight Effects. Findings regarding body weight effects in animals following inhalation exposure are inconsistent across studies. Weight loss has been reported to occur in rats following acute-duration exposure of 1,500–2,000 ppm; and intermediate-duration exposure (3–23 weeks) to toluene concentrations ranging from 200 to 12,000 ppm. In mice, weight loss has been reported following intermediate-duration exposure (8–14 weeks) to toluene concentrations ranging from 100 to 12,000 ppm.

2. RELEVANCE TO PUBLIC HEALTH

In contrast, no exposure-related effects on body weights were observed in rats or mice following intermediate-duration exposure (20–95 days) at concentrations ranging from 1,000 to 6,000 ppm or chronic-duration exposure (2 years) up to 1,200 ppm.

The majority of oral exposure animal studies do not report body weight effects. No dose-related changes in body weight were reported in male rats following single gavage administration of up to 1,000 mg/kg, female mice exposed to 600 mg/kg/day via gavage for 14 days, male mice administered 5–105 mg/kg/day toluene in their drinking water for 28 days, or female rats and female mice given gavage doses of up to 2,500 mg/kg/day for 13 weeks. However, body weights were 16% lower in male mice given 1,250 mg/kg/day and 19% lower in male rats given 2,500 mg/kg/day by gavage for 13 weeks. Maternal weight gain was 24% lower in rats given 520 mg/kg/day toluene by gavage from GD 6 to 19, compared with control rats, but there was no change in maternal body weight gain in rat dams exposed to 1,250 mg/kg/day toluene via gavage from GD 16 to 19.

Immunological and Lymphoreticular Effects. Only limited data are available on the immunological effects of toluene in humans. These studies do not identify consistent or strong evidence for toluene effects on immune system end points such as counts of blood lymphocytes or levels of blood immunoglobulins or development of autoimmune disorders.

In animals, there is evidence that toluene may lead to immune depression. A series of studies evaluated immune end points in male CD-1 mice (5/group) administered toluene in their drinking water for 28 days at concentrations of 0, 5, 22, or 105 mg/kg/day or 0, 22, or 84 mg/kg/day. In one study, significantly decreased thymus weight and significantly depressed immune responses were observed in all *in vitro* immune assays (mitogen-stimulated lymphocyte proliferation, mixed lymphocyte reaction, interleukin 2 [IL-2] production assay, and antibody plaque-forming cell [PFC] response) at 105 mg/kg/day, compared with controls. IL-2 production and mitogen-stimulated lymphocyte proliferation were also significantly increased at 22 mg/kg/day, compared with controls. Significantly depressed immune responses were observed in the PFC assay and mixed lymphocyte reaction at 84 mg/kg/day. The mixed lymphocyte reaction was also significantly depressed at 22 mg/kg/day. In another study, the IL-2 production assay was significantly depressed at 105 mg/kg/day. Taken together, these studies consistently reported diminished immune responses in multiple *in vitro* immune assays following *in vivo* exposure to 84–105 mg/kg/day in drinking water for 28 days, compared with controls. A couple of immune assays were altered at 22 mg/kg/day, but findings were not consistent between the Hsieh studies. Additionally, the antibody PFC assay was significantly altered at 84 and 105 mg/kg/day, but not at 22 mg/kg/day. The

2. RELEVANCE TO PUBLIC HEALTH

PFC *in vitro* assay is considered the most predictive assay of impaired immune function. Collectively, results from these studies support a no-observed-adverse-effect level (NOAEL) of 22 mg/kg/day for immune effects. Decreased resistance to mortality from respiratory infection by *Streptococcus zooepidemicus* was observed in a study of mice exposed for 3 hours to toluene concentrations as low as 2.5 ppm, but not 1 ppm. However, in an acute oral study, exposure to 600 mg/kg/day via gavage for 14 days did not diminish immune response in *in vitro* immune assays or decrease host resistance to *Listeria monocytogenes*, *Streptococcus pneumoniae*, *Plasmodium yoelii*, B16F10 melanoma cells, or PYB6 fibrosarcoma in female mice, compared with controls.

No evidence for exposure-related adverse changes in weight or histology of the spleen or thymus has been reported in animals exposed by inhalation for intermediate or chronic durations. Thymus weight was significantly decreased in male mice exposed to 105 mg/kg/day via gavage for 28 days, but not to 5–84 mg/kg/day. No changes in spleen weight were observed at any dose. No changes in thymus or spleen weight were observed in female mice exposed to 600 mg/kg/day via gavage for 14 days or rats or mice exposed up to 2,500 mg/kg/day via gavage for 13 weeks. No gross or histopathological lesions of the spleen or thymus were reported in any oral study.

Neurological Effects. Dysfunction of the central nervous system is a critical human health concern following acute, intermediate, or chronic inhalation exposure to toluene. Chronic toluene abuse in humans has been associated with neurotoxic symptoms, narcosis, permanent damage to the central nervous system, and death. Self-reported neurological symptoms, reduced ability in tests of cognitive and neuromuscular function, and hearing and color vision loss have been observed in humans occupationally exposed to average concentrations ranging from 35 to 200 ppm; several occupational studies identify NOAELs for these effects in the range of 20–187 ppm toluene. Performance deficits in tests of neurobehavior have also been observed in volunteers acutely exposed to controlled concentrations >50 ppm.

Numerous studies in animals have also reported clinical signs of neurotoxicity and neurobehavioral alterations following acute, intermediate, or chronic inhalation exposure to toluene. Consistently reported effects following acute exposure include overt signs of neurotoxicity (ataxia, tremors, inability to walk); increased, followed by decreased, locomotor activity at ≥ 500 ppm; impaired learning and/or memory at 125–4,000 ppm; and impaired motor coordination and reflexes at ≥ 100 ppm. However, studies of rodents exposed for intermediate durations to concentrations as high as 1,000 ppm have not found strong and consistent evidence for exposure-related changes for these neurological end points. Following repeated

2. RELEVANCE TO PUBLIC HEALTH

abuse-like exposures ($>1,000$ ppm), neurobehavioral alterations have been observed in several animal studies.

Various other neurological effects have also been reported in animal inhalation studies. Hearing loss in animals has been observed following acute- and intermediate-duration exposure to toluene at concentrations of ≥ 250 ppm in guinea pigs and $\geq 1,000$ ppm in rats. Observed hearing loss may not be solely due to neurological damage, as animal studies indicate that exposure to 500–2,000 ppm damages the cells in the inner ear (cochlea) that are responsible for amplifying incoming sound waves prior to initiation of the nerve signal from the ear to the brain. Other effects that have been reported include alterations in visual-evoked brain potentials (VEPs) or electroretinograms (ERGs), altered pain perception, decreased olfactory sensitivity, altered sleep patterns, altered brain weight and volume in rats, altered levels of glial fibrillary acidic protein (GFAP) and markers of oxidative stress, and altered levels of neurotransmitters, precursors, and receptors.

Limited data are available regarding neurological effects following oral exposure. Neurological effects were reported in three case reports of toluene ingestion: severe depression of central nervous system function was the probable cause of death for a 51-year-old man who ingested approximately 60 mL (625 mg/kg) of toluene; a man who accidentally ingested 30 mL of an organic solvent containing toluene and other chemicals was drowsy and complained of dizziness; and depressed consciousness, lethargy, hypotonia, and nystagmus were observed in a 15-month-old girl following accidental ingestion of paint thinner. Effects reported following acute-duration oral exposure in animals include transient increases in motor activity in rats; decreased in the flash-evoked brain potential (FEP) wave pattern amplitudes in male rats; and outer hair cell (OHC) loss in the cochlea of rats. However, no changes in brain weight or histology were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls. Effects reported following intermediate-duration oral exposure in animals include regional specific neurotransmitter alterations; increased relative brain weights in male and female rats and male, but not female, mice; cellular necrosis in the hippocampus and cerebellum of male and female rats; and overt signs of neurotoxicity.

Reproductive Effects. Current data do not provide convincing evidence that acute or repeated inhalation exposure to toluene may cause reproductive effects in humans. Limited evidence in humans indicates that occupational exposure to toluene (and other solvents) may lead to an increased incidence of spontaneous abortion or decreased fecundity in female workers. One study reports increased risk of preterm birth with increasing environmental toluene exposure; however, concurrent exposure to multiple

2. RELEVANCE TO PUBLIC HEALTH

pollutants limits the conclusions that can be drawn from this study. A few studies in animals exposed to toluene via inhalation at concentrations $\geq 2,000$ ppm reported effects on male and female reproductive tissues, including abundant vacuoles, lytic areas, and mitochondrial degeneration in the antral follicles of the ovaries of female rats and reduced sperm count, motility, and quality and altered reproductive organ weight and histology in male rats. However, changes in sperm count and epididymis weight were not accompanied by any change in indices of reproductive performance (e.g., fertility) in male rats exposed to 2,000 ppm for 60 days before mating. The majority of animal studies provide little evidence for toluene reproductive toxicity. Studies in rats exposed repeatedly by inhalation to toluene, including a 2-generation reproductive toxicity study, have shown no evidence of adverse effects on mating or fertility at tested concentrations as high as 1,200–2,000 ppm. In addition, the majority of numerous gestational exposure studies in rodents reported no exposure-related changes in reproductive indices.

Available data from oral exposure studies in animals do not provide evidence of reproductive effects following toluene exposure. No significant differences in the mean number of implantations per dam, corpora lutea per dam, live fetuses per litter, total number of resorptions per dam, and/or pre- or post-implantation loss were reported when rats and mice were exposed to toluene during gestation. Increased relative testicular weights were reported in male mice exposed to 1,250 and 2,500 mg/kg/day by gavage for 13 weeks. However, no effects on the weight of the prostate, testes, uterus, or ovaries were observed in rats and female mice exposed to 312–2,500 mg/kg/day. Reproductive performance was not evaluated in these 13-week studies.

Developmental Effects. There are a number of published reports of birth defects, similar to those associated with fetal alcohol syndrome, that have been described in children born to women who intentionally inhaled large quantities of toluene or other organic solvents during pregnancy. Defects described include microcephaly, central nervous system dysfunction, growth deficiency, cranofacial and limb abnormalities, and reversible renal tubular acidosis. Studies of women exposed during pregnancy to much lower concentrations of toluene in the workplace are restricted to a retrospective study of 14 women in Finland occupationally exposed to mixed solvents that suggested that solvent exposure may increase risk for central nervous system anomalies and neural tube closure defects.

The reports of birth defects in solvent abusers suggest that high-level exposure to toluene during pregnancy can be toxic to the developing fetus. The available human data, however, do not establish causality between low-level or occupational exposure to toluene and birth defects, because of the small sample size and the mixed solvent exposure experienced by the subjects, the lack of other studies of

2. RELEVANCE TO PUBLIC HEALTH

possible birth defects in children of occupationally exposed women, and the likelihood that the high exposure levels experienced by pregnant solvent abusers (4,000–12,000 ppm) overwhelm maternal protection of the developing fetus from absorbed toluene. Experiments with pregnant mice demonstrated that 10-minute exposures to 2,000 ppm resulted in low uptake of toluene into fetal tissue and suggest that, at lower exposure levels, absorbed toluene is preferentially distributed to maternal adipose tissue before distribution to the developing fetus.

A number of developmental toxicity studies with rats, mice, and rabbits involving toluene exposure by inhalation during gestation have been conducted to further describe developmentally toxic effects from toluene and exposure-response relationships. The results indicate that toluene did not cause maternal or developmental toxic effects in animals at exposure levels <1,000 ppm administered for 6–7 hours/day during gestation. Predominant effects reported at concentrations ranging from 1,000 to 3,000 ppm include retarded fetal growth and skeletal development and altered development of behavior in offspring; these effects were almost always accompanied by signs of maternal toxicity. Other animal studies reported that continuous, 24-hour/day exposure during gestation caused maternal body weight depression and effects on fetuses including depressed body weight and delayed skeletal ossification at toluene concentrations as low as 133–399 ppm in rats, mice, and rabbits. Impaired learning and memory, increased malformations, and fetal death have been observed when animals were exposed during gestation to higher concentrations modeling solvent abuse (8,000–16,000 ppm, 15–30 minutes/day).

In animal studies of oral exposure during gestation, toluene was not a developmental toxicant when administered orally at 1,800 or 2,350 mg/kg/day to pregnant mice during the period of organogenesis in two developmental screening studies. In a comprehensive developmental toxicity study in rats, a statistically significant increase in the incidence of a dilated renal pelvis in the left kidney was observed in fetuses from dams exposed to 1,250 mg/kg on GDs 16–19 via gavage, compared with controls. No changes were observed in any other developmental end point. In other studies, exposure of pregnant rats to gavage doses of 650 mg/kg/day toluene in corn oil on GDs 6–19 produced offspring with decreased body weights, delayed ossification, smaller brain volumes, decreased forebrain myelination per cell, and decreased cortical cell proliferation and migration, compared with controls.

Performance deficits in a few neurobehavioral tests were observed in one study in offspring of pregnant mouse dams exposed by inhalation to 2,000 ppm, but not 200 or 400 ppm, for 60 minutes 3 times/day on GDs 12–17. Performance deficits were not observed in offspring of pregnant rat dams exposed by inhalation to up to 2,000 ppm for 6 hours/day during gestation. Drinking water exposure during gestation


2. RELEVANCE TO PUBLIC HEALTH

and lactation at doses of 106 mg/kg/day resulted in changes in postweaning open-field locomotor activity in rat offspring.


Cancer. Human and animal studies generally do not support a concern for the carcinogenicity of toluene. Numerous human epidemiology studies were located that assessed toluene exposure as a possible risk factor for cancer. Five of the studies examined workers exposed predominantly to toluene, whereas the remainder of the human studies primarily involved subjects exposed to mixtures of solvents including toluene. Cancers of most sites were not significantly associated with toluene exposure, and there was weak consistency in the findings of those studies that did find association of a particular cancer type with toluene exposure. The information from these studies is inadequate to assess the carcinogenic potential of toluene, predominantly because of the lack of consistent findings across the studies and the likelihood that many of the studied groups were exposed to multiple chemicals. The validated animal inhalation bioassays were negative; however, one available oral study showed a nondose-related increase in a variety of tumors. Dermally administered toluene markedly inhibits skin tumorigenesis in the two-stage mouse model utilizing phorbol-12-myristate-13-acetate (PMA) as a promoter. The reduction in tumorigenesis was observed in mice initiated with dermal applications of benzo(a)pyrene or 7,12-dimethylbenz(a)anthracene. Thus, the data do not support a firm conclusion regarding the carcinogenicity of toluene. As such, the EPA determined that there is inadequate information to assess the carcinogenic potential of toluene, IARC determined that toluene is not classifiable as to its carcinogenicity in humans (Group 3), and ACGIH determined that toluene is not classifiable as a human carcinogen (A4). The NTP has not considered the carcinogenic potential of toluene.

Major health effects of toluene inhalation in humans and animals and ingestion in animals and the lowest concentrations at which these effects have been observed are shown in Figures 2-1 and 2-2. An estimate of exposure levels posing minimal risk to humans (MRL) are also presented in these figures. An MRL is an estimate of the daily human exposure that is likely to be safe over a certain period of exposure. MRLs are not intended to define clean-up or action levels, but are intended only to serve as a screening tool to help public health professionals decide where to look more closely. Therefore, MRLs are set at levels well below those where effects have been observed.

2. RELEVANCE TO PUBLIC HEALTH

Figure 2-1. Health Effects of Breathing Toluene^aBirth defects similar to fetal alcohol syndrome^bNasal lesions^cNephropathy^dIncreased liver weight, induction of hepatic P450 levels, increased serum levels of liver enzymes^eDepressed fetal body weight and delayed skeletal ossification^fIncreased locomotor activity^gImpairments in psychomotor testing^hAltered measures of visual and auditory electrophysiologyⁱIrritation of nose and throat^jAltered open-field behavior^kImpairments in neuropsychological testing

2. RELEVANCE TO PUBLIC HEALTH

Figure 2-2. Health Effects of Ingesting Toluene

^aDecreased body weights, delayed ossification, smaller brain volumes, decreased forebrain myelination per cell, and decreased cortical cell proliferation and migration

^bIncreased kidney weight

^cAltered measures of visual electrophysiology

^dIncreased open-field activity (lack of habituation)

^eIncreased liver weight

^fDiminished immune responses in multiple *in vitro* immune assays following *in vivo* exposure

2. RELEVANCE TO PUBLIC HEALTH

2.3 MINIMAL RISK LEVELS (MRLs)

Estimates of exposure levels posing minimal risk to humans (MRLs) have been established for toluene. An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration within a given route of exposure. MRLs are based on noncancerous health effects only and do not consider carcinogenic effects. MRLs can be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate methodology does not exist to develop MRLs for dermal exposure.

Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an example, acute inhalation MRLs may not be protective for health effects that are delayed in development or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic bronchitis. As these kinds of health effects data become available and methods to assess levels of significant human exposure improve, these MRLs will be revised.

Adverse effects on the nervous system are critical effects of concern from acute, intermediate, or chronic exposure to toluene. Acute exposure is associated with reversible neurological symptoms progressing from fatigue, headaches, and decreased manual dexterity to narcosis with increasing exposure levels. Reversible neurological impairment from acute exposure likely involves the direct interaction of toluene with nervous system membranes. Degenerative changes in white matter regions of the brain have been correlated with the severity of persistent neurological impairment in individuals who abused solvents and have repeatedly inhaled toluene at high exposure levels (4,000–12,000 ppm). Results from studies of groups of occupationally exposed workers suggest that chronic exposure to toluene at lower exposure levels (from about 50 to 200 ppm) can produce subtle changes in neurological functions including cognitive and neuromuscular performance, hearing, and color discrimination. Supporting data come from studies of toluene-exposed animals showing changes in behavior, hearing loss, and subtle changes in brain structure, electrophysiology, and levels of neurotransmitters.

Other effects of concern include immune system effects, liver effects, kidney effects, and developmental effects. Evidence from a few animal studies suggests that repeated exposure to toluene can suppress the

2. RELEVANCE TO PUBLIC HEALTH

immune system, although current data from human studies are limited and inconclusive. Various reports indicate hepatic and renal effects following inhalation and oral exposure to toluene; however, there is little support for irreversible damage to the liver or kidney. Case reports of birth defects in children of mothers who abused toluene during pregnancy suggest that exposure to high levels of toluene may be toxic to the developing fetus. Results from animal studies indicate that toluene is not a teratogenic agent, but can retard fetal growth and skeletal development, and adversely influence behavior of offspring at exposure levels that produce maternal toxicity.

Available evidence does not support adverse effects on reproductive performance as a noncancer health effect of concern from toluene exposure.

Issues relevant to children are explicitly discussed in Section 3.7, Children's Susceptibility and Section 6.6, Exposures of Children.

Inhalation MRLs

- An MRL of 2 ppm (7.6 mg/m³) has been derived for acute-duration (14 days or less) inhalation exposure to toluene.

This MRL is based on a study by Little et al. (1999) in which the effects of toluene on human subjects with a history of solvent exposure and adverse reactions to toluene (i.e., clinically sensitive to toluene) were assessed in a battery of neuropsychological tests prior to and after a 20-minute exposure to 15 ppm toluene (see Appendix A). The battery of tests included immediate and delayed prose memory, reaction time, letter cancellations, digit symbol, focal length, and STROOP color and color-word tasks. Statistically significant ($p < 0.05$) impairments were measured in immediate and delayed prose memory (number of items recalled decreased 31%), the digit symbol test (number of correct items decreased 11%), and the letter cancellation test (percent correct decreased 5%) following a 15-minute exposure to 15 ppm toluene, compared with pre-exposure scores. A near-significant 15% increase in reaction time was also observed ($p = 0.06$). No significant difference between pre- and post-exposure values was found for focal length or the STROOP tests. The minimally adverse lowest-observed-adverse-effect level (LOAEL) of 15 ppm was divided by an uncertainty factor of 9 (3 for use of a minimally adverse LOAEL and 3 to account for human variability [a full uncertainty factor of 10 is not necessary as the observed effects were noted in a susceptible/sensitive group of individuals]) to derive the MRL of 2 ppm. More details of the development of this MRL can be found in Appendix A.

2. RELEVANCE TO PUBLIC HEALTH

- No MRL has been derived for intermediate-duration (15–364 days) inhalation exposure to toluene.

No data were considered suitable for use in deriving an intermediate-duration MRL for inhalation exposures. ATSDR believes that the chronic inhalation MRL would also be protective for intermediate-duration exposures.

- An MRL of 1 ppm (3.8 mg/m³) was derived for chronic-duration (365 days or more) inhalation exposure to toluene.

The chronic inhalation MRL is based on a NOAEL of 45 ppm toluene for neurological effects based on a series of studies by the same group of investigators assessing subjective neurological symptoms, performance on psychomotor tasks, color vision, and hearing in groups of German photogravure printers employed for an average duration of 13.5 years (Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002). These studies compared neurological end points in high-exposure printers (n=106–181) and low-exposure end-processors (n=86–152). Current toluene air exposure levels for printers and end-processors were 24.6–26 and 3–3.5 ppm, respectively (measured twice yearly from 1996 to 2001). Historical exposure levels for printers prior to 1995 and prior to 1975 were 40 and 140 ppm, respectively. Historical exposure levels for end-processors prior to 1995 and prior to 1975 were 5 and 40 ppm, respectively. Using job history and current exposure and historical exposure levels, individual time-weighted average (TWA) exposure levels were calculated. The average TWA levels for printers and end-processors were calculated to be 45 and 10 ppm for subjects included in analyses by Schäper et al. (2003, 2008), 45 and 9 ppm for subjects included in analyses by Seeber et al. (2004, 2005) and Zupanic et al. (2002), and 43 and 9 ppm for subjects included in analyses by Schäper et al. (2004). Schäper et al. (2003, 2008) did not find any statistically significant differences in audiometric readings from four readings over 5 years in 181 printers, compared with 152 end-processors; Schäper et al. (2004) did not find any differences in color vision assessed 4 times over 5 years in 154 printers, compared with 124 end-processors; and Seeber et al. (2004, 2005) and Zupanic et al. (2002) did not find any increase in subjective neurological complaints or decreased performance in psychomotor tasks in 106–154 printers, compared with 86–124 end-processors. The NOAEL of 45 ppm was adjusted for continuous exposure (45 ppm x 5 days/7 days x 8 hours/24 hours = 10.7 ppm) and was divided by an uncertainty factor of 10 to account for human variability to derive the MRL of 1 ppm.

Most of the data on health effects in humans chronically exposed to toluene come from occupational studies or medical reports of solvent abusers. In both situations, concurrent exposure to other chemicals

2. RELEVANCE TO PUBLIC HEALTH

can limit the usefulness of the data for development of guidelines or standards. In addition, there are other confounding variables, especially in the occupational setting, such as alcohol consumption patterns, employment history, diet, use of medications, noise, and fluctuations in atmospheric toluene levels during different portions of the day, all of which complicate evaluation of dose-response patterns. These complexities were considered in selecting the studies for derivation of the MRL (see Appendix A for more details).

EPA (2005a) has recommended a similar chronic RfC of 5 mg/m³ (1.33 ppm) based on the arithmetic mean (34 ppm) of the NOAELs from a subset of the highest quality studies investigating neurological effects in workers occupationally exposed predominantly to toluene (Abbate et al. 1993; Boey et al. 1997; Cavalleri et al. 2000; Eller et al. 1999; Foo et al. 1990; Murata et al. 1993; Nakatsuka et al. 1992; Neubert et al. 2001; Vrca et al. 1995; Zavalic et al. 1998a). ACGIH (2007) has recommended a Threshold Limit Value (TLV) of 20 ppm toluene based on subclinical changes in blue-yellow color vision and the potential for spontaneous abortion in female workers (Campagna et al. 2001; Cavalleri et al. 2000; Ng et al. 1992b). This value is designed to be protective for healthy adult workers exposed 8 hours/day, 5 days/week for up to 45 years. Adjusting the value for a continuous exposure lasting up to 70 years yields a value of 4 ppm (25 ppm x 5 days/7 days x 8 hours/24 hours x 45 years/70 years = 4 ppm). This figure is slightly higher than the current chronic-duration MRL, but does not include an uncertainty factor to protect susceptible populations. Use of an uncertainty factor of 10 (10 for human variability) would arrive at a value to 0.4 ppm, which is slightly lower than the current MRL.

Oral MRLs

- An MRL of 0.8 mg/kg has been derived for acute (14 days or less) oral exposure to toluene.

This MRL was based on a LOAEL of 250 mg/kg from a study of FEP wave forms in male Long-Evans rats administered doses of 0, 250, 500, or 1,000 mg/kg toluene by gavage (Dyer et al. 1988). FEP tests were administered 45 minutes later as a test of the ability of the nervous system to process visual information. The amplitude of the N3 peak of the FEP was decreased by toluene exposure at all doses ($p < 0.0001$). This decrease in peak amplitude was not dose-related. Dyer et al. (1988) also carried out a time-course study in which toluene was administered to male Long-Evans rats (16 per group) at doses of 0 and 500 mg/kg by gavage, and FEP tests were performed 4, 8, 16, and 30 hours later. In the time course study, 500 mg/kg also decreased the amplitude of the FEP; at this dose, little change in magnitude of peak N3 depression had occurred 8 hours posttreatment; by 16 hours, recovery was complete. The LOAEL of

2. RELEVANCE TO PUBLIC HEALTH

250 mg/kg was divided by an uncertainty factor of 300 (3 for use of a minimally adverse LOAEL, 10 for interspecies extrapolation, and 10 for intraspecies variability) to derive the MRL of 0.8 mg/kg. More details of the development of this MRL can be found in Appendix A.

- An MRL of 0.2 mg/kg/day has been derived for intermediate-duration (15–364 days) oral exposure to toluene.

This MRL was based on a NOAEL of 22 mg/kg/day from a series of studies evaluating immune end points in male CD-1 mice administered toluene in their drinking water for 28 days at concentrations of 0, 5, 22, or 105 mg/kg/day (Hsieh et al. 1989, 1991) or 0, 22, or 84 mg/kg/day (Hsieh et al. 1990a). In Hsieh et al. (1989, 1990a), rats were weighed, sacrificed, and examined for gross pathological lesions at 28 days. Spleen and thymus were weighed and hematology was performed. Spleens were assessed for cellularity, and splenocytes were used in *in vitro* immune assays (mitogen-stimulated lymphocyte proliferation, mixed lymphocyte reaction, IL-2 production assay, and antibody PFC response). Hsieh et al. (1990a) also measured the *in vitro* cell-mediated cytotoxicity response. In Hsieh et al. (1991), immune function was only assessed using the IL-2 assay in cultured splenocytes. In Hsieh et al. (1989), significantly decreased thymus weight and significantly depressed immune responses were observed in all *in vitro* immune assays at 105 mg/kg/day, compared with controls. IL-2 production and mitogen-stimulated lymphocyte proliferation were also significantly increased at 22 mg/kg/day compared with controls. In Hsieh et al. (1990a), significantly depressed immune responses were observed in the PFC assay and mixed lymphocyte reaction at 84 mg/kg/day. The mixed lymphocyte reaction was also significantly depressed at 22 mg/kg/day. In Hsieh et al. (1991), the IL-2 production assay was significantly depressed at 105 mg/kg/day. Taken together, these studies consistently reported diminished immune responses in multiple *in vitro* immune assays following *in vivo* exposure to 84–105 mg/kg/day in drinking water for 28 days, compared with controls. A couple of immune assays were altered at 22 mg/kg/day, but findings were not consistent between the three Hsieh studies. Additionally, the antibody PFC assay was significantly altered at 84 and 105 mg/kg/day, but not at 22 mg/kg/day (Hsieh et al. 1989, 1990a). The PFC *in vitro* assay is considered the most predictive assay of impaired immune function (Luster et al. 1992). Collectively, results from these studies support a NOAEL of 22 mg/kg/day for immune depression. The NOAEL of 22 mg/kg/day was divided by an uncertainty factor of 100 (10 for interspecies extrapolation and 10 for intraspecies variability) to derive the MRL of 0.2 mg/kg/day. More details of the development of this MRL (including consideration of other effects as bases of the intermediate-duration oral MRL) can be found in Appendix A.

2. RELEVANCE TO PUBLIC HEALTH

- No MRL was derived for chronic-duration (365 days or more) oral exposures because there were no suitable data for toluene.

EPA (2005a) has recommended a chronic oral reference dose (RfD) of 0.08 mg/kg/day based on a benchmark dose limit (BMDL) of 238 mg/kg/day for increased kidney weight in male rats from the 13-week NTP (1990) study. The derivation included an uncertainty factor of 3,000 (10 for interspecies extrapolation, 10 for intraspecies variability, 10 for use of a subchronic study, and 3 for database uncertainties). If the UF for subchronic to chronic is removed, the value is 0.8 mg/kg/day, which is well within an order of magnitude of the derived intermediate MRL of 0.2 mg/kg/day.

2. RELEVANCE TO PUBLIC HEALTH

This page is intentionally blank.

3. HEALTH EFFECTS

3.1 INTRODUCTION

The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of toluene. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.

A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.

3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE

To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, oral, and dermal) and then by health effect (e.g., death, systemic, immunological, neurological, reproductive, developmental, and carcinogenic effects). These data are discussed in terms of three exposure periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).

Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a considerable amount of judgment may be required in establishing whether an end point should be classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be insufficient data to decide whether the effect is indicative of significant dysfunction. However, the Agency has established guidelines and policies that are used to classify these end points. ATSDR believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between "less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is considered to be important because it helps the users of the profiles to identify levels of exposure at which major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not

3. HEALTH EFFECTS

the effects vary with dose and/or duration, and place into perspective the possible significance of these effects to human health.

The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and figures may differ depending on the user's perspective. Public health officials and others concerned with appropriate actions to take at hazardous waste sites may want information on levels of exposure associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans (Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.

A User's Guide has been provided at the end of this profile (see Appendix B). This guide should aid in the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.

3.2.1 Inhalation Exposure

Adverse effects on the nervous system are critical effects of concern from inhalation exposure to toluene as evidenced by results from studies of workers acutely or chronically exposed to toluene in workplace air, studies of volunteers under controlled acute exposure conditions, and studies of chronic solvent abusers predominantly exposed to toluene. Observed effects include reversible neurological symptoms from acute exposure progressing from fatigue, headache, and decreased manual dexterity to narcosis with increasing exposure level, degenerative changes in white matter in chronic solvent abusers, and subtle changes in neurological functions including cognitive and neuromuscular performance, hearing, and color discrimination in chronically exposed workers. Studies of toluene-exposed animals provide supporting data showing changes in behavior, hearing loss, and subtle changes in brain structure, brain electrophysiology, and brain chemistry. Case reports of birth defects and developmental delays in children of mothers who abused solvents, including toluene, during pregnancy suggest that exposure to high levels of toluene may be toxic to the developing fetus. A number of developmental toxicity studies with rats, mice, and rabbits exposed to airborne toluene indicate that toluene was not a developmental toxicant at levels below those inducing maternal toxicity. At doses that impaired maternal body weight gain, developmental effects observed included retarded fetal growth and skeletal development, and altered development of behavior in offspring. At high concentrations modeling solvent abuse, increased malformations and fetal death were also observed.

3. HEALTH EFFECTS

3.2.1.1 Death

Limited data are available on toluene-associated deaths due to solvent abuse or occupational exposure and these studies do not indicate exposure concentrations. Paterson and Sarvesvaran (1983) reported on a teenager who died following an episode of glue sniffing. In Virginia, 39 deaths were attributed to inhalant abuse from 1987 to 1996 (Bowen et al. 1999). The majority of deaths (70%) occurred at ≤ 22 years of age, and males accounted for 95% of all inhalant abuse deaths; however, only two deaths were attributed to intentional toluene inhalation. In a case-series report from Mexico, 3/20 patients with a history of substance abuse died due to severe acidosis and renal failure following acute toluene intoxication (Camarra-Lemarroy et al. 2015). In Japan, a man died of cardiac arrest after painting a bathroom using a sealer containing 65% toluene (Shibata et al. 1994) and a woman died of adrenal hemorrhage after sniffing thinner containing 67% toluene (Kamijo et al. 1998). In Great Britain, approximately 80 deaths per year have been associated with solvent abuse (Anderson et al. 1985). Approximately half these cases were attributed to cardiac arrhythmias, central nervous system depression, asphyxia, and hepatic and renal failure (Anderson et al. 1982). Among the 52 cases with a toxicological report, 42 mentioned toluene (Anderson et al. 1982). Toxicokinetic extrapolation from blood toluene concentration in a deceased patient was used to estimate that 1 hour of exposure to 1,800–2,000 ppm toluene may be fatal to humans (Hobara et al. 2000a, 2000b).

There are only a few animal inhalation studies that have examined the lethality of toluene, and there is evidence from an intermediate-duration study suggesting that mice may be more sensitive than rats. An inhalation LC_{50} value (concentrations causing death in of 50% of the animals) of 5,320 ppm has been reported for mice (Svirbely et al. 1943). In 14 to 15 week studies, exposure to 3,000 ppm toluene for 6.5 hours/day, 5 days/week, caused 80% mortality in male rats, 60% mortality in male mice, and 100% mortality in female mice, but no deaths among female rats (NTP 1990). Death also occurred among female mice exposed to 625 (10%), 1,250 (10%), and 2,500 (40%) ppm toluene (NTP 1990).

LOAEL values for deaths in the NTP (1990) study and the LC_{50} from the Svirbely et al. (1943) report are recorded in Table 3-1 and plotted in Figure 3-1.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
ACUTE EXPOSURE								
Death								
1	Mouse (Swiss-Webster)	7 hr				5320 (LC50)	Svirbely et al. 1943	
Systemic								
2	Human	6 hr	Resp	40 M	100 M (irritation of the nose)		Andersen et al. 1983	
			Ocular	40 M	100 M (irritation of the eyes)			
3	Human	6.5 hr (Occup)	Resp		100 M (irritation of the nose and throat)		Baelum et al. 1985	
			Ocular		100 M (irritation of the eyes)			
4	Human	7-8 hr	Resp		200 M (mild throat irritation)		Carpenter et al. 1944	
			Ocular		200 M (eye irritation)			
5	Human	40 min (WB)	Endocr	200			Kobald et al. 2015	Endpoint examined: Cortisol levels in saliva.
6	Human	2 hr	Resp	1862 M			Meulenbelt et al. 1990	Non-fatal case report.
			Cardio		1862 M (sinus tachycardia)			
			Hemato	1862 M				
			Hepatic		1862 M (liver enlargement)			
			Ocular		1862 M (ocular irritation)			

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
7	Human	3 hr	Resp	1862 M			Meulenbelt et al. 1990	Non-fatal case report.
			Cardio		1862 M (sinus bradycardia)			
			Hemato	1862 M				
			Hepatic	1862 M				
			Ocular		1862 M (ocular irritation)			
8	Human	4.5 hr	Resp		50 M (irritation of the throat)		Muttray et al. 2005	
9	Human	6.5 hr	Renal	102 M			Nielsen et al. 1985	Endpoint examined: renal excretion rates of albumin and beta-2-microglobulin examined.
10	Human	2 hr	Resp		48 M (mucous membrane irritation)		Orbaek et al. 1998	
11	Human	2 hr	Resp		48 F (mucous membrane irritation)		Osterberg et al. 2003	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
12	Human	6 hr/d	Resp	100			Rahill et al. 1996	No change in lung function.
13	Human	3 hr	Resp	800			von Oettingen et al. 1942	No effects of irritation and no change in respiratory rate, minute volume, leukocyte counts, blood pressure, or pulse in 3 exposed subjects.
			Cardio	800				
			Hemato	800				
14	Rat (Sprague-Dawley)	3 d 6 hr/d	Endocr		500 M (increased serum corticosterone)		Andersson et al. 1980	Endpoints assessed: Serum levels of corticosterone, prolactin, growth hormone, FSH, and LH.
15	Rat (Sprague-Dawley)	5 d 6 hr/d	Endocr	1000 M			Andersson et al. 1980	Endpoints assessed: Serum levels of corticosterone, prolactin, growth hormone, FSH, and LH.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
16	Rat (Sprague- Dawley)	3 d 6 hr/d	Endocr		80 M (increased serum prolactin)		Andersson et al. 1983a	Endpoints assessed: Serum corticosterone, prolactin, growth hormone, FSH, and LH.
17	Rat (Wistar)	7 d 4 hr/d	Endocr		1500 M (18% increase in adrenal weight and increased adrenocortical cell size; increased serum ACTH and corticosterone)		Gotohda et al. 2005	
			Bd Wt		1500 M (8% decreased body weight)			
18	Rat (Wistar)	7 d 4 hr/d	Hepatic		3000 M (increased biochemical markers of liver fibrosis)		Gotohda et al. 2009	
19	Rat (Wistar)	Gd 7-20 6 hr/d	Endocr		1500 F (reduced maternal plasma corticosterone levels)		Hougaard et al. 2003	
20	Rat (Fischer- 344)	6 hr/d 3 or 7 d	Endocr		1000 M (significantly increased serum corticosterone)		Little et al. 1998	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
21	Rat (Sprague- Dawley)	48 hr	Hemato		2000 M (increased hematocrit and blood glucose)		Tahti et al. 1983	
			Hepatic		2000 M (increased serum ALT and AST)			
			Bd Wt		2000 M (body weight decrease 10%)			
22	Rat	7 d 8 hr/d	Hepatic		795 F (increased liver weight 12%, increased smooth and rough endoplasmic reticulum)		Ungvary et al. 1982	
23	Rat (Wistar)	6 hr	Hepatic		4000 (increased CYP2E1 and decreased CYP 2 C11 in liver)		Wang et al. 1996	
24	Mouse	7 d 8 hr/d	Hepatic		795 F (increased liver weight 11% and cytochrome P-450 30%)		Ungvary et al. 1982	
25	Dog	1 hr	Hemato	200	500 (decreased leukocytes)		Hobara et al. 1984a	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
26	Dog	4 hr	Hemato		700	(decreased leukocytes)	Hobara et al. 1984a	
27	Rabbit	7 d 8 hr/d	Hepatic		795 F	(increased liver weight 14%, cytochrome P-450- 35%, and cytochrome b5- 25%)	Ungvary et al. 1982	
Immuno/ Lymphoret								
28	Rat (Sprague- Dawley)	Gd 7-17 6 hr/d			600 F	(decreased thymus weights in dams)	Ono et al. 1995	
29	Mouse (CD-1)	3 hr		1 F	2.5 F	(decreased survival following infection with S. zooepidemicus)	Aranyi et al. 1985	
Neurological								
30	Human	6 hr		40 M	100 M	(headaches, dizziness, intoxication)	Andersen et al. 1983	
31	Human	6.5 hr (Occup)			100 M	(intoxication, dizziness, decreased manual performance and color perception)	Baelum et al. 1985	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
32	Human	8 hr			100	(impaired performance on visual-vigilance task)	Dick et al. 1984	
33	Human	7 hr			75	(dose-related impairment of performance on recognition, pattern memory, and one-hole test results)	Echeverria et al. 1991	
34	Human	20 min		100 M	300 M	(increased simple and choice reaction time)	Gamberale and Hultengren 1972	
35	Human	4 hr		80 M			Iregren 1986	Endpoints evaluated: choice reaction time, simple reaction time, color-word vigilance, or memory reproduction.
36	Human	40 min (WB)			200	(altered EEG; impaired performance on visual attention task)	Kobald et al. 2015	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
37	Human	4 hr		40 F			Lammers et al. 2005a	Endpoints evaluated: battery of neurobehavioral tasks, sleep quality questionnaire.
38	Human	4 hr 30 min on, 30 min off		110 M			Lammers et al. 2005a	Endpoints evaluated: battery of neurobehavioral tasks, sleep quality questionnaire.
39	Human	20 min			^b 15	(decreased performance on neuropsychological tests in toluene-sensitive subjects)	Little et al. 1999	
40	Human	28-41 min (Occup)		332 M			Muttray et al. 1999	Endpoint evaluated: color vision before and after cleaning a print machine with toluene.
41	Human	4.5 hr		50 M			Muttray et al. 2005	Endpoints evaluated: subjective symptoms, pupillographic sleepiness test.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
42	Human	4 hr		80 M			Olson et al. 1985	Endpoints evaluated: subjective symptoms, simple reaction time, choice reaction time, and memory-reproduction.
43	Human	2 hr			48 M (self-reported fatigue in individuals with toxic encephalopathy)		Orbaek et al. 1998	Endpoints assessed: subjective symptoms in healthy subjects and subjects with toxic encephalopathy.
44	Human	2 hr		48 M			Osterberg et al. 2000	Endpoints assessed: attention and motor speed in healthy subjects and subjects with toxic encephalopathy.
45	Human	2 hr			48 F (self-reported fatigue in individuals with multiple chemical sensitivity)		Osterberg et al. 2003	Endpoints assessed: subjective symptoms and attention and motor speed in healthy subjects and subjects with MCS.
46	Human	6 hr			100 (decreased performance on neuropsychological tests)		Rahill et al. 1996	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
47	Human	3 or 8 hr		100	200	(drowsiness, headache, confusion, weakness)	von Oettingen et al. 1942	
48	Monkey (Cynomolgus)	50 min		1000 F	2000 F	(cognitive and motor skills impaired)	3000 F (overt signs of neurotoxicity)	Taylor and Evans 1985
49	Rat	8 hr			900 M	(altered patterns of sleep and wakefulness)		Arito et al. 1988
50	Rat (Long- Evans)	1-4 hr			1000 M	(decreased F2 amplitude in VEPs)		Boyes et al. 2007
51	Rat (Fischer- 344) (W)	2 hr			110 M	(decreased REM sleep)		Ghosh et al. 1989
52	Rat (Fischer- 344)	2 hr			110 M	(changes in sleep pattern)		Ghosh et al. 1990
53	Rat (DA/HAN)	4 hr or 5 d, 3 hr/d			100 M	(nystagmus and altered optokinetic response)		Hogie et al. 2009

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
54	Rat (Wistar)	30 min			1000 M (impaired learning and memory, decline in conditioned avoidance response)		Huerta-Rivas et al. 2012	
55	Rat (Sprague-Dawley)	10 d 16 hr/d			1000 M (diminished auditory response)		Johnson 1992	
56	Rat (Sprague-Dawley)	2 wk 5 d/wk 16 hr/d			1000 M (diminished auditory response)		Johnson et al. 1988	
57	Rat	20 min			1000 (increased locomotor activity)		Kim et al. 1998	
58	Rat (Wistar)	4 hr			125 M (a temporary decline in conditioned avoidance response)		Kishi et al. 1988	
59	Rat (Fischer- 344)	6 hr/d 3 or 7 d			1000 M (decreased GFAP in thalamus and increased corticosterone)		Little et al. 1998	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
60	Rat (Wistar)	10 d 6 hr/d		1500 M			Lund and Kristiansen 2008	Endpoints examined: brainstem auditory responses, distortion product otoacoustic emissions.
61	Rat (CD)	4 hr		810 M	1660 M (decreased lift reflex, vertical bar placing, and horizontal rod grasping)	3100 M (overt signs of neurotoxicity)	Mullin and Krivanek 1982	
62	Rat (Fischer- 344)	30 min			500 M (changes in flash-evoked and somatosensory -evoked potentials)		Rebert et al. 1989b	
63	Rat	4 hr			1000 M (sleep pattern disturbances- reduced slow wave sleep and increased paradoxical phase)		Takeuchi and Hisanaga 1977	
64	Rat	2-4 hr			480 (decreased performance in rewarded task)		Wood et al. 1983	
65	Mouse CFW (ChasRiver Swiss) albino	30 min		250	500 (increased locomotor activity)		Bowen and Balster, 1998	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
66	Mouse (CFW)	30 min		1000 M	2000 M (decreased anxiety)		Bowen et al. 1996	
67	Mouse (Multiple)	30 min			100 M (increased locomotor activity)		Bowen et al. 2010	Balb/CBYJ, C57BL/6J, and DBA/2J showed effects at identified LOAEL; Swiss Webster mice showed similar effects at higher concentrations.
68	Mouse (C57BL/6N)	5 d 72 min/d		100 M	1000 M (increased locomotor activity)		Bushnell et al. 1985	
69	Mouse (C57BL/6N)	30 min		1000 M	2000 M (increased locomotor activity)		Conti et al. 2012	
70	Mouse (Swiss-Webster)	30 min		500 M	1000 M (increased nociception)		Cruz et al. 2001	
71	Mouse (CBA/CA; C57BL/6J)	7 d 12 hr/d			1000 F (accelerated hearing loss in genetically predisposed mice)		Li et al. 1992	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
72	Mouse (129/Sv-ter)	30 min			1000 M (increased locomotor activity)		Lopez-Rubalcava and Cruz 2000	
73	Mouse (ddy)	8 hr		500 M			Matsuoka et al 1997	Endpoints examined: GFAP, c-jun, and c-fos mRNA levels in cerebrum.
74	Mouse (Swiss-Webster)	30 min		500	1000 (increased nociception)		Paez-Martinez et al. 2003	
75	Mouse (Swiss-Webster)	7 d 30 min/d		1000 M	2000 M (increased locomotor activity)		Tomaszycki et al. 2013	
76	Mouse (CD-1)	6x 1 hr/x		300 M	560 M (increased activity)		Wood and Colotla 1990	
77	Gn Pig (pigmented)	5 d 8 hr/d			250 (transient mid- and high-frequency hearing loss)		McWilliams et al. 2000	
78	Other	10 d 8 or 12 hr/d		2000			Davis et al. 2002	Endpoints examined: auditory brainstem responses in chinchillas.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
Reproductive								
79	Human	3 hr			50	(altered LH secretion)	Luderer et al. 1999	
80	Rat (CrI:CD (SD) BR VAF/Plus)	Gd 6-15 6 hr/d		3000 F			API 1991; Roberts et al. 2007	Pregnancy outcomes examined.
81	Rat (CrI:CD BR VAF/Plus)	Gd 6-15 6 hr/d		3500 F		5000 F (increased post-implantation loss; total fetal resorption in 6/9 dams)	API 1992	
82	Rat (Sprague- Dawley)	Gd 8-20 2x/d 15 or 30 min		12000 F			Bowen and Hannigan 2013; Bowen et al. 2005, 2007, 2009a, 2009b	Pregnancy outcomes examined.
83	Rat (Wistar)	Gd 7-20 6 hr/d		1800 F			Dalgaard et al. 2001	Pregnancy outcomes examined.
84	Rat (Wistar)	Gd 7-20 6 hr/d		1500 F			Hougaard et al. 2003; Ladefoged et al. 2004	Pregnancy outcomes examined.
85	Rat (Sprague- Dawley)	Gd 7-17 6 hr/d		2000 F			Ono et al. 1995	Pregnancy outcomes examined.
86	Rat (Sprague- Dawley)	Gd 6-20 6 hr/d		1500 F			Saillenfait et al. 2007	Pregnancy outcomes examined.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
87	Rat (Wistar)	7 d 8 hr/d			3000 F (structural variations in antral follicles in ovary)		Tap et al. 1996	
88	Rat (Wistar)	Gd 9-21 6 hr/d		1200			Thiel and Chahoud 1997	Pregnancy outcomes examined.
89	Mouse (CD-1)	Gd 7-16 7 hr/d		400 F			Courtney et al. 1986	Pregnancy outcomes examined.
90	Mouse (CD-1)	Gd 12-17 3x/d 60 min		2000 F			Jones and Balster, 1997	Pregnancy outcomes examined.
91	Rabbit	Gd 6-18 6 hr/d		500 F			Klimisch et al. 1992	Pregnancy outcomes examined.
92	Rabbit	Gd 7-20 24 hr/d		133 F		266 (4/8 dams aborted)	Ungvary and Tatrai 1985	
Developmental								
93	Rat (CRL:COBS CD (SD) BR)	Gd 6-15 6 hr/d		400			API 1978	Endpts examined: number of implantation sites, live and dead fetuses, and resorptions; fetuses were weighed and examined for external malformations.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
94	Rat (CrI:CD (SD) BR VAF/Plus)	Gd 6-15 6 hr/d		1500	3000 (decreased fetal weight and increased incidence of fetuses with unossified sternebrae)		API 1991; Roberts et al. 2007	
95	Rat (CrI:CD BR VAF/Plus)	Gd 6-15 6 hr/d		2000		3500 (20% decrease in fetal body weight, total absorption at higher exposure levels)	API 1992	
96	Rat (Sprague- Dawley)	Gd 8-20 2x/d 30 min			8000 (decreased postnatal growth)	12000 (increased number of litters with malformed, runted, or dead pups)	Bowen and Hannigan 2013	
97	Rat (Sprague- Dawley)	Gd 8-20 2x/day 15 min			8000 (impaired negative geotaxis in offspring)	12000 (decreased pup body weight, increased number of litters with malformed, runted, or dead pups, impaired negative geotaxis in offspring)	Bowen et al. 2005	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments		
					Less Serious (ppm)	Serious (ppm)				
98	Rat (Sprague-Dawley)	Gd 8-20 2x/d 15 min		8000	12000	(decreased pup birth weight; decreased sensitivity to amphetamine-induced locomotion in males on Pnd 28)	Bowen et al. 2007	Endpoints examined: pup weight on Ppd 1 and 21, open-field activity on Ppd 22, 42, and 63, amphetamine-induced locomotion on Ppd 28.		
99	Rat (Sprague-Dawley)	Gd 8-20 2x/day 30 min			8000	(decreased fetal weight and length, decreased placental weight)	12000	(decreased fetal weight and length, decreased placental weight, increased skeletal malformations and soft tissue anomalies)	Bowen et al. 2009a	
100	Rat (Sprague-Dawley)	Gd 8-20 2x/d 15 min			8000	(altered reward-seeking behavior and increased impulsivity in offspring)		Bowen et al. 2009b		Endpoints examined: standard dev't endpoints, waiting-for-reward task and amphetamine-induced locomotion on Ppd 60.
101	Rat (Sprague-Dawley)	Gd 8-20 2 x/d 15 min (WB)		8000	12000	(decreased birth weight; impaired learning and memory in offspring)		Callan et al. 2015		Endpoints examined: Pup weight, external malformations, spatial learning and memory on Pnd 28-44.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
102	Rat (Wistar)	Gd 7-20 6 hr/d			1800 M (decreased neonatal weight, increased apoptosis in cerebral granule layer of cerebellum at Ppd 21)		Dalgaard et al. 2001	Endpoints examined: pup weight, external malformations, paired testes weight and histopathology, brain weight, and brain apoptosis.
103	Rat (Wistar)	Gd 7-20 6 hr/d			1500 (reduced pup birth weight)		Hougaard et al. 2003	No other developmental endpoints were examined.
104	Rat CFY	Gd 1-8 24 hr/d			399 (increased incidence of fetuses with skeletal retardation)	399 F (5/14 dams died)	Hudak and Ungvary 1978	
105	Rat CFY	Gd 9-14 24 hr/d			399 (increased incidence of fetal skeletal anomalies)		Hudak and Ungvary 1978	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
106	Rat (Sprague- Dawley)	Gd 8-20 2x/day 15 min		8000	12000	(decreased pup birth weight)	Jarosz et al. 2008	Endpoints examined: pup weight on Ppd 1 and 30, metabolism in offspring (energy expenditure, respiratory quotient, body fat content).
107	Rat (Wistar)	Gd 7-20 6 hr/d			1500	(reduced postnatal growth, increased apoptosis in the cerebellum of offspring)	Ladefoged et al. 2004	Endpoints examined: pup weight (Ppd 1, 7, 23), external malformations, spatial learning in females (Pnw 5); brain apoptosis (Ppd 6, 22, 24, 27).
108	Rat (Sprague- Dawley)	Gd 7-17 6 hr/d		2000			Ono et al. 1995	Dams sacrificed on Gd 20; standard developmental endpoints assessed.
109	Rat (Sprague- Dawley)	Gd 7-17 6 hr/d		600	2000	(decreased pup weight)	Ono et al. 1995	Endpts examined: pup weight, growth, dev't, survival, reflex dev't (Ppd 6-10); neurobehavior (Pnw 4); hemato, biochem, and organ wt (Ppd 21 and 56).

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL			Reference Chemical Form	Comments	
					Less Serious (ppm)	Serious (ppm)				
110	Rat (Sprague-Dawley)	Gd 6-20 6 hr/d		500	1500	(decreased fetal weight)		Saillenfait et al. 2007		
111	Rat (Wistar)	Gd 9-21 6 hr/d		600	1000	(decreased pup weight and delayed vaginal opening)	1200	(significantly increased postnatal/preweaning mortality in offspring)	Thiel and Chahoud 1997	Endpoints examined: pup weight, survival, development, ontogeny of reflexes, neurobehavior, and F1 mating and fertility.
112	Mouse (CD-1)	Gd 7-16 7 hr/d			200	(increased number of litters with fetuses with dilated renal pelvis)			Courtney et al. 1986	
113	Mouse CFLP	Gd 6-13 24 hr/d			133	(decreased fetal body weight)	399	(maternal mortality)	Hudak and Ungvary 1978	
114	Mouse (CD-1)	Gd 12-17 3x/d 60 min		400			2000	(performance deficits in tests of reflexes, muscle strength and motor coordination in offspring)	Jones and Balster, 1997	Endpoints examined: pup weight, growth, reflex ontogeny, neurobehavior.
115	Mouse	Gd 6-15 3-4 hr/d		133	266	(decreased fetal body weight and retardation of fetal skeletal development)			Ungvary and Tatrai 1985	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
116	Rabbit	gd 6-18 6 hr/d		500			Klimisch et al. 1992	
117	Rabbit	Gd 7-20 14 d 24 hr/d		133 F		266 F (4/8 does aborted)	Ungvary and Tatrai 1985	
INTERMEDIATE EXPOSURE								
Death								
118	Rat (Fischer- 344)	15 wk 5 d/wk 6.5 hr/d				3000 M (8/10 died)	NTP 1990	
119	Mouse (B6C3F1)	14 wk 5 d/wk 6.5 hr/d				3000 M (6/10 died) 625 F (1/10 died)	NTP 1990	
Systemic								
120	Human	2-14 mo 8 hr/d (Occup)	Hepatic	167 F			Seiji et al. 1987	Endpoint evaluated: clinical chemistry.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
121	Rat (CD)	95 d 7 d/wk 6 hr/d	Resp	2000			API 1985; Roberts et al. 2003	Endpts evaluated in 2-generation study: body, liver, kidney, and reproductive organ weight and organ histology in F0/F1 parents and F1/F2 weanlings.
			Cardio	2000				
			Gastro	2000				
			Musc/skel	2000				
			Hepatic	2000				
			Renal	2000				
			Endocr	2000				
			Dermal	2000				
			Ocular	2000				
			Bd Wt	2000				
122	Rat (Fischer- 344)	42 d 5 d/wk 6 hr/d	Bd Wt	1000 M			API 1997	
123	Rat (Long- Evans)	13 wk 5 d/wk 6 hr/d	Bd Wt	1000 M			Beasley et al. 2010	
124	Rat (Long- Evans)	4 wk 5 d/wk 6 hr/d	Bd Wt	1000 M			Beasley et al. 2012	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
125	Rat Long-Evan	4 wk 5 d/wk 6 hr/d (WB)	Ocular	1000 M			Boyes et al. 2015	Ocular endpoint: ophthalmic examination.
			Bd Wt	1000 M				
126	Rat Long-Evan	13 wk 5 d/wk 6 hr/d (WB)	Ocular	1000 M			Boyes et al. 2015	Ocular endpoint: ophthalmic examination.
			Bd Wt	1000 M				
127	Rat (albino)	8 wk 5 d/wk 70 min/d	Resp	12000 M			Bruckner and Peterson 1981b	Endpoints evaluated: body weight, organ weight and histology; upper respiratory tract histology not assessed.
			Cardio	12000 M				
			Hepatic		12000 M (11% decrease in liver weight, elevated liver enzymes in serum)			
			Renal		12000 M (27% decrease in kidney weight)			
			Bd Wt		12000 M (20% reduction in body weight gain)			

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
128	Rat (Wistar)	4-8 wk 3 d/wk 1 hr/d (WB)	Hepatic	3000 M			Dick et al. 2014	Endpoints evaluated: organ weight, histopathology.
			Bd Wt	3000 M				
129	Rat (Wistar)	4 wk 3-5 d/wk 1 hr/d (WB)	Bd Wt	3000 M	10000 M (14% decrease in body weight)		Dick et al. 2015	
130	Rat (Sprague- Dawley)	4 wk 5 d/wk 6 hr/d	Endocr	320 M			Hillefors-Berglund et al. 1995	No change in serum prolactin levels.
			Bd Wt	320 M				
131	Rat (Wistar)	30 d 24 hr/d	Hepatic	400 M			Ikeda et al. 1986	
			Bd Wt		200 M (decreased body weight gain)			
132	Rat (Wistar)	20 d 4 hr/d	Bd Wt		1500 M (body weight decrease 18%)		Ishigami et al. 2005	
133	Rat (Wistar)	28 d 5 d/wk 2 hr/d (N)	Resp	200 M			Jain et al. 2013	Endpoints examined: lung histopathology, lung and BAL biochemistry.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
134	Rat (Wistar)	12 wk 6 d/wk 8 hr/d	Resp		3000 M (increased pulmonary inflammation, edema, fibrosis, and necrosis)		Kanter 2011a	
135	Rat (Wistar)	12 wk 6 d/wk 8 hr/d	Hepatic		3000 M (enlarged hepatic sinusoids filled with blood and minimal hepatic fibrosis, increased number of apoptotic liver cells)		Kanter 2012	
136	Rat (Sprague- Dawley)	30 d 24 hr/d	Hepatic	320 M			Kyrklund et al. 1987	Endpoint assessed: liver weight.
			Bd Wt		320 M (10% decreased body weight)			
137	Rat (Fischer- 344)	13 wk 5 d/wk 15-35 min 4-9 x/d	Bd Wt			8000 M (23% decreased body weight gain)	Mattsson et al. 1990	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
138	Rat (Fischer- 344)	15 wk 5 d/wk 6.5 hr/d	Resp	1250	2500	(9-15% increased relative lung weight)	NTP 1990	Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
			Cardio	1250	2500	(6-11% increased relative heart weight)		
			Gastro	3000				
			Hemato	3000 M 625 F	1250 F	(decreased leukocytes)		
			Hepatic	625 M 1250 F	1250 M	(9% increase in relative liver weight)		
					2500 F	(16% increase in relative liver weight)		
			Renal	625	1250	(increased relative kidney weights)		
			Endocr	3000				
139	Rat (Sprague- Dawley)	21 d 6 hr/d	Bd Wt	1250	2500	(15% decrease in body weight)	3000 M (25% decrease in body weight)	
			Ocular	600	2000 F	(lacrimation)		Ono et al. 1996

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
140	Rat (Sprague- Dawley)	90 d 6 hr/d	Hemato	2000 M			Ono et al. 1996	
			Renal	600 M	2000 M (increase in kidney weights, necrosis of kidney tubules)			
			Bd Wt	2000 M				
141	Rat (Sprague- Dawley)	4 wk 5 d/wk 6 hr/d	Resp	300			Poon et al. 1994	Endpoints evaluated: organ weight and histology, upper respiratory tract histology.
			Hemato	300				
			Hepatic	30	300 (significantly increased serum alkaline phosphatase in males & variation hepatocellular size in females)			
			Renal	300				
			Endocr	300 M	30 F (mild reduction in follicle size in thyroid)			
			Bd Wt	300				
142	Rat (Fischer- 344)	23 wk 7 d/wk 8 hr/d 60, 30, or 15 min/hr	Bd Wt		2200 M (decreased body weight gain)		Pryor 1991	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
143	Rat (Fischer- 344)	11 wk 7 d/wk 8 hr/d	Bd Wt		2000 M (decreased body weight gain)		Pryor 1991	
144	Rat (Wistar)	30 d 1 hr/d	Hepatic		1000 M (hepatocyte degeneration, pericentral fibrosis, increased markers of apoptosis)		Tas et al. 2011	
145	Rat (Wistar)	30 d 1 hr/d	Hepatic		1000 M (hepatocyte degeneration, increased number of apoptotic liver cells)		Tas et al. 2013a	
146	Rat (Sprague-Dawley)	4 wk 5 d/wk 6 hr/d	Endocr		80 (increase in serum prolactin levels)		von Euler et al. 1994	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
147	Rat (NS)	5 wk 5 d/wk 7 hr/d	Resp		600	(irritation of the lung)	von Oettingen et al. 1942	Endpoints evaluated: hematology, organ histology.
			Hemato	600	2500	(transient decrease in leukocytes)		
			Hepatic	5000				
			Renal		600	(renal casts)		
			Endocr	5000				
148	Mouse (BALB/c)	8 wks 6 hr/d	Musc/skel		300 M	(decreased bone mineral density and content in femoral neck)	Atay et al. 2005	
149	Mouse (Swiss- Webster)	40 d 30 min/d	Bd Wt	6000 M			Bowen and McDonald 2009	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
150	Mouse (ICR)	8 wk 5 d/wk 70 min/d	Resp	12000 M			Bruckner and Peterson 1981b	Endpoints evaluated: body weight, organ weight and histology; upper respiratory tract histology not assessed.
			Cardio	12000 M				
			Hepatic		12000 M (decreased liver weight)			
			Renal		12000 M (decreased kidney weight)			
			Bd Wt		12000 M (20% reduction in body weight)			
151	Mouse (ICR)	8 wk 3 hr/d 5 d/wk	Resp	4000 M			Bruckner and Peterson 1981b	Endpoints evaluated: body weight, organ weight and histology; upper respiratory tract histology not assessed.
			Cardio	4000 M				
			Hepatic		4000 M (increased relative liver weight, elevated serum glutamic oxaloacetic transaminase)			
			Renal	4000 M				
			Bd Wt		4000 M (5-10% decrease in body weight gain)			

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
152	Mouse (C3H/HeN)	12 wk 5 d/wk 6 hr/d	Resp	50 F			Fujimaki et al. 2007	Endpoints examined: histology of nose, trachea, lung.
153	Mouse	20 d 6 hr/d	Hemato		10 M (decreased white blood cells and thrombocytes)		Horiguchi and Inoue 1977	
			Bd Wt	1000 M				
154	Mouse (OF-1)	4 wk 5 d/wk 5 hr/d	Resp		1000 F (inflammation and decreased cell number in olfactory epithelium)		Jacquot et al. 2006	
155	Mouse	30 d 24 hr/d	Hepatic		150 F (increased liver weight [9.6%])		Kjellstrand et al. 1985	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
156	Mouse (B6C3F1)	14 wk 5 d/wk 6.5 hr/d	Resp	1250 M	2500 M (5% increase in relative lung weight)		NTP 1990	Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
					100 F (12% increase in relative lung weight)			
			Cardio	2500 M	2500 F (14% increase in relative heart weight)			
				1250 F				
			Gastro	2500				
			Hemato	2500				
			Hepatic	625 M	1250 M (9% increase in relative liver weight)			
				100 F				
					625 F (6% increase in relative liver weight)			
			Renal	2500 M	1250 F (7% increase in relative kidney weight)			
				625 F				
			Endocr	2500				
			Bd Wt	1250 M	2500 M (12% decrease in body weight)			
					100 F (13% decrease in body weight)			

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
Immuno/ Lymphoret								
157	Rat (CD)	95 d 7 d/wk 6 hr/d		2000			API 1985; Roberts et al. 2003	Endpoints evaluated: thymus and spleen histology in F0/F1 parents and F1/F2 weanlings.
158	Rat (Fischer- 344)	42 d 5 d/wk 6 hr/d		1000 M			API 1997	Endpoint evaluated: thymus weight.
159	Rat (Fischer- 344)	15 wk 5 d/wk 6.5 hr/d		3000			NTP 1990	Endpoints evaluated: spleen and thymus weight and histology.
160	Rat (Sprague- Dawley)	90 d 6 hr/d		600	2000 M (decrease in thymus weights)		Ono et al. 1996	
161	Rat (Sprague- Dawley)	4 wk 5 d/wk 6 hr/d		300			Poon et al. 1994	Endpoints evaluated: spleen and thymus weight and histology.
162	Rat (NS)	5 wk 5 d/wk 7 hr/d		5000			von Oettingen et al. 1942	Endpoints evaluated: spleen and thymus weight and histology.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
163	Mouse (B6C3F1)	14 wk 5 d/wk 6.5 hr/d		2500			NTP 1990	Endpoints evaluated: spleen and thymus weight and histology.
Neurological								
164	Rat (CD)	95 d 7 d/wk 6 hr/d		2000			API 1985; Roberts et al. 2003	Endpoints evaluated in 2-generation study: brain weight, brain and spinal cord histology in F0/F1 parents and F1/F2 weanlings.
165	Rat (Fischer- 344)	42 d 5 d/wk 6 hr/d			100 M (changes in GFAP levels in brain)	3000 M (overt signs of neurotoxicity)	API 1997	
166	Rat	3 wk 5 d/wk 8 hr/d			900 M (prolonged slow-wave sleep and paradoxical sleep latencies)		Arito et al. 1988	
167	Rat (Long- Evans)	4 or 13 wk 5 d/wk 6 hr/d		1000 M			Beasley et al. 2010	Endpoints evaluated: neurobehavioral battery.
168	Rat (Long- Evans)	4 wk 5 d/wk 6 hr/d		1000 M			Beasley et al. 2012	Endpoints evaluated: neurobehavioral battery.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
169	Rat (Sprague- Dawley)	16 wk 104 hr/wk			40	(decreased rearing behavior)	Berenguer et al. 2003	
170	Rat (Sprague- Dawley)	16 wk 104 hr/wk			40	(decreased rearing activity)	Berenguer et al. 2004	
171	Rat Long-Evan	4 wk 5 d/wk 6 hr/d (WB)		1000 M			Boyes et al. 2015	
172	Rat Long-Evan	13 wk 5 d/wk 6 hr/d (WB)		100 M	1000 M	(decrease in wave amplitudes of ERG)	Boyes et al. 2015	Endpoints examined: VEP at 2-3 weeks post-exposure, ERG and photoreceptor density at 5-6 weeks and 1 year post-exposure.
173	Rat (Long- Evans)	4 wk 5 d/wk 6 hr/d			1000 M	(loss of hair cells in organ of Corti)	Campo et al. 1997	
174	Rat (Sprague- Dawley)	30 d 24 hr/d			320 M	(decreased weight of brain and cerebral cortex)	Kyrklund et al. 1987	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
175	Rat (Wistar)	90 d 5 d/wk 6 hr/d		500 M			Lund and Kristiansen 2008	Endpoints examined: brainstem auditory responses, distortion product otoacoustic emissions.
176	Rat (Fischer- 344)	50 d 24 hr/d		600 M			Miyagawa et al. 1995	Endpoint examined: learning and memory (radial arm maze).
177	Rat (Fischer- 344)	15 wk 5 d/wk 6.5 hr/d		1250	2500	(ataxia, increased relative brain weight)	NTP 1990	Endpoints assessed: brain weight and histology, clinical signs.
178	Rat (Fischer- 344)	16 wk + 5 wk 7 d/wk 14 hr/d		700 M	1000 M	(diminished auditory response)	Pryor et al. 1984b	
179	Rat (Sprague- Dawley)	4 wk 5 d/wk 6 hr/d		80			Rogers et al. 1999	Endpoints examined: operant training (appetively-motivated lever-press).
180	Rat (Sprague- Dawley)	13 wk 8 hr/d		1000 M			Tahti et al. 1983	Endpoint examined: motor coordination (tilting plane test, rotarod test).

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
181	Rat (Sprague- Dawley)	4 wk 5 d/wk 6 hr/d			80 M (decreased cortical area in parietal cortex, impaired motor coordination)		von Euler et al. 2000	No changes in brain weight, overall brain volume, or cortical thickness.
182	Rat (NS)	5 wk 5 d/wk 7 hr/d		600		2500 (overt signs of neurotoxicity)	von Oettingen et al. 1942	
183	Rat (Wistar)	4 wk 5 d/wk 6 hr/d		25 M	100 M (increased escape response in hot-plate test)		Wiaderna and Tomas 2002	
184	Rat (Long- Evans)	3 wk 2x/wk 2 hr/d			178 M (increased nose poking)		Wood and Cox 1995	
185	Mouse (B6C3F1)	14 wk 5 d/wk 6.5 hr/d		2500			NTP 1990	Endpoints assessed: brain weight and histology, clinical signs.
186	Mouse (C3H/HeN)	6 wk 5 d/wk 6 hr/d		50 M			Win-Shwe et al. 2010c	Endpoint examined: learning and memory (Morris water maze).

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
187	Mouse (BALB/c)	30 min/d for 3 d, then 1 d/wk for 4 wk		90 M			Win-Shwe et al. 2010d	Endpoint examined: learning and memory (Morris water maze).
188	Gn Pig (pigmented)	4 wk 5 d/wk 8 hr/d			500	(transient mid- and high-frequency hearing loss)	McWilliams et al. 2000	
Reproductive								
189	Rat (CD)	95 d 7 d/wk 6 hr/d		2000			API 1985; Roberts et al. 2003	Endpoints examined: reproductive performance in 2-generation study (F0 and F1 parental animals).
190	Rat (Wistar)	Gd 7 - Ppd 18 6 hr/d		1200 F			Dalgaard et al. 2001	Pregnancy outcomes examined.
191	Rat (Wistar)	Gd 7 - Ppd 18 6 hr/d		1200 F			Hass et al. 1999	Pregnancy outcomes examined.
192	Rat (Wistar)	20 d 4 hr/d		1500 M			Ishigami et al. 2005	Endpoints examined: reproductive organ weights, spermatogenesis.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
193	Rat (Wistar)	12 wk 6 d/wk 8 hr/d				3000 M (impaired spermatogenesis, decreased seminiferous tubule diameter, ultrastructural abnormalities in testes)	Kanter 2011b	
194	Rat (Fischer- 344)	15 wk 5 d/wk 6.5 hr/d		1250 M 3000 F	2500 M (15% increase in testis weight)		NTP 1990	Endpoints evaluated: organ weight and histology; reproductive function not assessed.
195	Rat (Sprague-Dawley)	90 d 6 hr/d			600 M (slightly decreased [13%] sperm count)	2000 M (significantly decreased [26%] sperm count and decrease [15%] in weights of epididymides, but no effect on indices of fertility)	Ono et al. 1996	
196	Rat (Sprague-Dawley)	5 wk 7 d/wk 2 hr/d		4000 M		6000 M (significantly decreased sperm count [66%], motility [78%], and ovum penetration [76%])	Ono et al. 1999	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
197	Mouse (CD-1)	8 wk 5 d/wk 6 hr/d		400 M			API 1981	Endpoints examined: dominant lethal mutations, pre- and postimplantation losses after mating with unexposed females.
198	Mouse (B6C3F1)	14 wk 5 d/wk 6.5 hr/d		2500			NTP 1990	Endpoints evaluated: organ weight and histology; reproductive function not assessed.
Developmental								
199	Rat (CD)	95 d + Gd 1-20 and Ppd 5-21 7 d/wk 6 hr/d		500	2000	(reduced fetal and pup body weights in F1 and F2 generations)	API 1985; Roberts et al. 2003	2-generation reproduction study.
200	Rat (Wistar)	Gd 7 - Ppd 18 6 hr/d			1200 M	(decreased neonatal body weight)	Dalgaard et al. 2001	Endpoints examined: pup weight, external malformations, offspring sperm parameters at Ppd 100.
201	Rat (Wistar)	Gd 7 - Ppd 18 6 hr/d				1200 (decreased neonatal body weight, delayed development of reflexes and increased locomotor activity in offspring)	Hass et al. 1999	Pregnancy outcomes examined.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
202	Rat CFY	Gd 1-21 8 hr/d			266	(increased incidence of fetal skeletal retardation)	Hudak and Ungvary 1978	
203	Rat (Wistar)	Ppd 1-28 12 hr/d			100	(decreased growth of hippocampus)	Slomianka et al. 1990	Endpoints examined: body weight, brain histology and hippocampal volume on Ppd 29.
204	Rat (Wistar)	Ppd 1-28 12 hr/d			500 M	(reversible decrease in growth of hippocampus)	Slomianka et al. 1992	Endpoint examined: hippocampal volume on Ppd 29 and 120.
CHRONIC EXPOSURE								
Systemic								
205	Human	NS (Occup)	Renal	93 M			Askergren et al. 1981a,b	Endpoints measured: glomerular filtration rate, albumin and beta-2-microglobulin excretion.
206	Human	>3 yr	Hemato	600			Banfer 1961	
207	Human	>5 yr (avg = 20 yr) (Occup)	Resp		186	(mucosal irritation)	Deschamps et al. 2001	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
208	Human	20+ yr (Occup)	Cardio	24 M			Gericke et al. 2001	Endpoints examined: blood pressure, clinical chemistry, glomerular filtration rate.
			Hepatic	24 M				
			Renal	24 M				
209	Human	40 mo (avg) (Occup)	Hemato	83 F			Matsushita et al. 1975	Endpoints evaluated: hematology, clinical chemistry.
			Hepatic	83 F				
210	Human	16 +/- 13 years	Renal	44			Stengel et al. 1998	No changes in biomarkers of renal damage when 17 subjects with hypertension were excluded.
211	Human	3-39 yr (Occup)	Hepatic		29 M (increased levels of alkaline phosphatase)		Svensson et al. 1992b	
212	Human	>10 yr	Hemato		110 (increased leukocytes)		Tahti et al. 1981	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
213	Human	NS (Occup)	Hemato	24.7			Ukai et al. 1993	Endpoints evaluated: hematology, clinical chemistry.
			Hepatic	24.7				
214	Human	73-96 mo (Occup)	Hemato		46 M (significant decrease in relative number of lymphocytes)		Yin et al. 1987	
					41 F (significant decrease in relative number of lymphocytes)			
215	Rat (Fischer- 344)	106 wk 5 d/wk 6 hr/d	Resp	300			CIIT 1980; Gibson and Hardisty 1983	Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
			Cardio	300				
			Hemato		100 (decreased hematocrit)			
			Hepatic	300				
			Renal	300				
			Bd Wt	300				

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
216	Rat (Fischer- 344)	2 yr 5 d/wk 6.5 hr/d	Resp		600	(nasal inflammation, degeneration of olfactory and nasal respiratory epithelium)	NTP 1990	Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
			Cardio	1200				
			Gastro	1200				
			Hemato	1200				
			Musc/skel	1200				
			Hepatic	1200				
			Renal		600	(increased severity of nephropathy)		
			Endocr	1200				
			Bd Wt	1200				

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
217	Rat (Fischer- 344)	15 mo 5 d/wk 6.5 hr/d	Resp		600	(mild-to-moderate degeneration of the olfactory and respiratory epithelium)	NTP 1990	Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
			Cardio	1200				
			Gastro	1200				
			Hemato	1200				
			Musc/skel	1200				
			Hepatic	1200				
			Renal	1200				
			Endocr	1200				
			Bd Wt	1200				

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
218	Mouse (B6C3F1)	2 yr 5 d/wk 6.5 hr/d	Resp	1200			NTP 1990	Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
			Cardio	1200				
			Gastro	1200				
			Hemato	1200				
			Musc/skel	1200				
			Hepatic	1200				
			Renal	1200				
			Endocr	1200				
			Bd Wt	1200				

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
219	Mouse (B6C3F1)	15 mo 5 d/wk 6.5 hr/d	Resp	1200 M 600 F	1200 F (minimal hyperplasia of the bronchial epithelium)		NTP 1990	Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
			Cardio	1200				
			Gastro	1200				
			Hemato	1200				
			Musc/skel	1200				
			Hepatic	1200				
			Renal	1200				
			Endocr	1200				
			Bd Wt	1200				
Immuno/ Lymphoret								
220	Human	13 yr (avg)		637 M			Pelclova et al. 1990	Endpoint evaluated: serum immunoglobulin levels.
221	Human	16 +/- 13 yr		44			Stengel et al. 1998	Endpoint evaluated: serum IgE levels.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
222	Human	73-96 mo (Occup)			46 M (significantly decreased lymphocytes and increased eosinophils)		Yin et al. 1987	
					41 F (significantly decreased lymphocytes and increased eosinophils)			
223	Rat (Fischer- 344)	2 yr 5 d/wk 6.5 hr/d		1200			NTP 1990	Endpoints evaluated: spleen and thymus weight and histology.
224	Mouse (B6C3F1)	2 yr 5 d/wk 6.5 hr/d		1200 F	120 M (increased incidence of pigmentation of the spleen)		NTP 1990	Endpoints evaluated: spleen and thymus weight and histology.
Neurological								
225	Human	12-14 yr (Occup)			97 M (increased wave latencies for BAEPs)		Abbate et al. 1993	
226	Human	4.9 yr (avg)			90.9 (statistically significant performance deficits on neurobehavioral tests)		Boey et al. 1997	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
227	Human	0-40 yr (avg = 14 yr) (Occup)		27			Chouaniere et al. 2002	Endpoints examined: battery of psychomotor function tasks, self-reported neurotoxic symptoms.
228	Human	>5 yr (avg = 20 yr) (Occup)		186			Deschamps et al. 2001	Endpoints examined: subjective symptoms, battery of psychomotor tests.
229	Human	5.7 yr (Occup)			88 F (statistically significant performance deficits on neurobehavioral tests)		Foo et al. 1990	
230	Human	20+ yr (Occup)		24 M			Gericke et al. 2001	Endpoints examined: subjective symptoms, color vision, battery of psychomotor tests.
231	Human	99 mo (avg) (Occup)		20	75 (statistically significant impairments in attention and motor performance)		Kang et al. 2005	
232	Human	40 mo (avg) (Occup)			83 F (abnormal tendon reflex, decreased grasping power and agility of fingers, general weakness)		Matsushita et al. 1975	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
233	Human	1-25 yr (Occup)			122 M (hearing loss)		Morata et al. 1997	
234	Human	1-36 yr (Occup)			83 M (lowered coefficient of variation in electrocardiographic R-R intervals and maximal motor and sensory nerve conduction velocities in median nerve)		Murata et al 1993	
235	Human	NS (Occup)		46 F			Nakatsuka et al. 1992	Endpoint evaluated: color vision.
236	Human	unspecified (Occup)		33	75 (impaired visual perception)		Neubert et al. 2001	Endpoints evaluated: subjective symptoms, battery of neurobehavioral tasks.
237	Human	4-43 yr (median = 29 yr) (Occup)			140 M (increased incidence of self-reported neurological symptoms [initial]; statistically significant performance deficits on neurobehavioral tests [follow-up])		Orbaek and Nise 1989; Nordling Nilson et al. 2010	Initial examination was in 1985; follow-up was in 2005.
238	Human	13.4 yr (avg) (Occup)		45 ^c			Schaper et al. 2003; 2008	Endpoint examined: audiometry.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
239	Human	7 or 23 yr (avg) (Occup)		43 ^c			Schaper et al. 2004	Endpoint evaluated: color vision.
240	Human	13.4 yr (avg) (Occup)		45 ^c			Seeber et al. 2004; 2005	Endpoints examined: symbol digit substitution, switching attention, memory span, self-reported symptoms.
241	Human	(Occup)		36	76	(increased self-reported neurological symptoms)	Ukai et al. 1993	
242	Human	21.4 yr (avg) range 4-30 yr (Occup)			50	(increased wave latency and amplitude of visual evoked potentials)	Vrca et al. 1995	
243	Human	4-30 years			50	(decrease in wave amplitudes and increased in wave latencies of BAEP)	Vrca et al. 1996	
244	Human	3-33 years			50	(increased wave latency and decreased amplitude of visual evoked potentials)	Vrca et al. 1997b	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
245	Human	73-96 mo (Occup)			46 M (headaches, dizziness) 41 F (headaches, dizziness)		Yin et al. 1987	
246	Human	17 yr (avg) (Occup)			35 (increased color confusion index)		Zavalic et al. 1998a, c	
247	Human	16.8 +/- 5.94 yr			120 (increased color confusion index)		Zavalic et al. 1998b	
248	Human	15 yr (avg) (Occup)		^c 45 M			Zupanic et al. 2002	Endpoints examined: subjective symptoms, manual dexterity.
249	Rat (Fischer- 344)	2 yr 5 d/wk 6.5 hr/d		1200			NTP 1990	Endpoints assessed: brain weight and histology, clinical signs.
250	Rat (Fischer- 344)	15 mo 5 d/wk 6.5 hr/d		1200			NTP 1990	Endpoints assessed: brain weight and histology, clinical signs.
251	Mouse (B6C3F1)	2 yr 5 d/wk 6.5 hr/d		1200			NTP 1990	Endpoints assessed: brain weight and histology, clinical signs.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
252	Mouse (B6C3F1)	15 mo 5 d/wk 6.5 hr/d		1200			NTP 1990	Endpoints assessed: brain weight and histology, clinical signs.
Reproductive								
253	Human	20+ yr (Occup)		24 M			Gericke et al. 2001	Endpoint examined: serum reproductive hormone levels in male workers.
254	Human	40 mo (avg) (Occup)			83 F (dysmenorrhea)		Matsushita et al. 1975	
255	Human	6 yr (Occup)		88 F			Ng et al. 1992a	Endpoints examined: cycle irregularities, extent of uterine bleeding, and the presence of dysmenorrhea.
256	Human	10 yr (Occup)				88 (increased incidence of spontaneous abortions [12.4/100] compared to 2 control groups [2.9/100 and 4.5/100])	Ng et al. 1992b	

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
257	Human	25 yr (median) 0.5-37 yr (Occup)			36 M (decreased levels of LH, FSH, and free testosterone)		Svensson et al. 1992a	
258	Human	3-39 yr (Occup)		29 M			Svensson et al. 1992b	Increasing workplace air concentrations were not significantly (p>0.05) associated with plasma concentrations of repro hormones after age adjustment.
259	Rat (Fischer- 344)	106 wk 5 d/wk 6 hr/d		300			CIIT 1980; Gibson and Hardisty 1983	Endpoints evaluated: reproductive organ weight and histology.
260	Rat (Fischer- 344)	2 yr 5 d/wk 6.5 hr/d		1200			NTP 1990	Endpoints evaluated: organ weight and histology; reproductive function was not assessed.

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to Toluene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
261	Mouse (B6C3F1)	2 yr 5 d/wk 6.5 hr/d		1200			NTP 1990	Endpoints evaluated: organ weight and histology; reproductive function not assessed.

a The number corresponds to entries in Figure 3-1.


b Used to derive an acute inhalation minimal risk level (MRL); concentration (15 ppm) divided by an uncertainty factor of 9 (3 for use of a minimal LOAEL and 3 for human variability [observed effects were noted in a susceptible/sensitive group of individuals, therefore a full uncertainty factor of 10 for human variability is not necessary]), resulting in an MRL of 2 ppm (7.6 mg/m³).

c Used to derive a chronic inhalation minimal risk level (MRL) along with 5 companion studies supporting a NOAEL of 45 ppm for neurological effects; concentration was adjusted to a continuous exposure basis (45 ppm x 5d/7d x 8hr/24hr = 10.7 ppm) and divided by an uncertainty factor of 10 for human variability, resulting in an MRL of 1 ppm (3.8 mg/m³).

ACTH = adrenocorticotrophic hormone; ALT = alanine amino transferase; AST = aspartate aminotransferase; BAEP = brainstem auditory evoked potential; BAL = bronchioalveolar lavage; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; ERG = electroretinogram; F = Female; FSH = follicle stimulating hormone; Gastro = gastrointestinal; Gd = gestational day; GFAP = glial fibrillary acidic protein; Gn Pig = guinea pig; Hemato = hematological; hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LC50 = lethal concentration, 50% kill; LH = luteinizing hormone; LOAEL = lowest-observed-adverse-effect level; M = male; min = minute(s); MCS = multiple chemical sensitivity; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; Occup = occupational; Pnd = post-natal day; Pnw = post-natal week; Ppd = post-parturition day; REM = rapid eye movement; Resp = respiratory; VEP = visual evoked potential; wk = week(s); x = time(s); yr = year(s)

3. HEALTH EFFECTS


Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation




3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)

Acute (≤14 days)




3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (*Continued*)Acute (≤ 14 days)

3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)


Acute (≤14 days)



3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (*Continued*)


Intermediate (15-364 days)



3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (*Continued*)

Intermediate (15-364 days)



3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)





Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)


Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (Continued)

[illegible]


3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (*Continued*)


Chronic (≥ 365 days)



3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (*Continued*)Chronic (≥ 365 days)

3. HEALTH EFFECTS

Figure 3-1 Levels of Significant Exposure to Toluene - Inhalation (*Continued*)Chronic (≥ 365 days)

3. HEALTH EFFECTS

3.2.1.2 Systemic Effects

Data are available pertaining to respiratory, cardiovascular, hematological, musculoskeletal, hepatic, renal, endocrine and ocular effects in humans and animals after inhalation exposure to toluene. In addition, there are data on gastrointestinal, dermal, body weight, and other systemic effects in animals after inhalation exposure to toluene. All systemic effects are discussed below. The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

Respiratory Effects.

Overview. In humans, respiratory tract irritation has been reported from exposure to toluene under controlled and occupational exposure conditions (Andersen et al. 1983; Baelum et al. 1985; Carpenter et al. 1944; Hellquist et al. 1983; Orbaek et al. 1998; Osterberg et al. 2003; Winchester and Madjar 1986). Limited epidemiological data suggest that exposure to benzene-toluene-ethylbenzene-xylene (BTEX) solvents may increase the risk of acute asthma attacks in urban settings (Lemke et al. 2014). In animal studies, evidence for histological damage to the nose or lung has been reported following intermediate- and chronic-duration inhalation exposure to toluene, most clearly at concentrations ≥ 600 ppm 6 hours/day (Fujimaki et al. 2007; Jacquot et al. 2006; Kanter 2011a; NTP 1990; Poon et al. 1994; von Oettingen et al. 1942).

Controlled Exposure Human Studies. Irritation of the nose and throat was reported in printers exposed to 100 ppm toluene for 6.5 hours (Baelum et al. 1985) and in volunteers exposed to 200 ppm toluene for 7–8 hours (Carpenter et al. 1944). Exposure of volunteers to 40 ppm of toluene for 6 hours did not produce statistically significant differences in the results of tests measuring nasal mucus flow and lung function or in subjective evaluations of air quality, but irritation of the nose was noted at 100 ppm (Andersen et al. 1983). Scores for throat irritation were significantly increased in 20 males during a 4.5-hour exposure to 50 ppm toluene, compared with pre-exposure scores, but no significant increases were observed for nasal irritation or coughing (Muttray et al. 2005). Mucous membrane irritation of progressive severity was reported by volunteers during exposure to progressively higher toluene concentrations of 0, 3, 6, 12, 24, and 48 ppm toluene over a 90-minute period (Orbaek et al. 1998; Osterberg et al. 2003); median maximal scores for mucous membrane irritation (scale of 0–100) at 48 ppm were about 70 for subjects with multiple chemical sensitivity diagnosis and about 30 for healthy subjects (Osterberg et al. 2003). In other controlled-exposure studies, volunteers reported that they did

3. HEALTH EFFECTS

not experience respiratory or mucous membrane irritation during exposure to 800 ppm toluene for 3 hours (von Oettingen et al. 1942) or 1,862 ppm for 2 hours (Meulenbelt et al. 1990). No changes in lung function were reported for volunteers exposed to 100 ppm toluene for 6 hours, 30 minutes of which were spent exercising (Rahill et al. 1996).

Occupational Exposure Human Studies. Ten paint-sprayers exposed to 13 detected solvents (primarily 0.8–4.8 ppm toluene and isobutylacetate) and dusts had morphological changes in the nasal mucosa (Hellquist et al. 1983). However, there was no conclusive association between duration of exposure and mucosal abnormalities. Forty-two workers exposed to mixtures of solvents, of which toluene was generally a major component, reported symptoms of nasal irritation, in addition to eye irritation, nausea, skin conditions, dizziness, and headaches (Winchester and Madjar 1986). The concentrations of toluene to which the workers were exposed ranged from 1 to 80 ppm (mean of 15 ppm). However, concurrent exposure to a mixture of solvents and dusts in these studies precludes establishing an unequivocal causal relationship between exposure to toluene and mucosal irritation. Eight workers from a print factory exposed to <200 ppm toluene for >18 months had normal chest roentgenograms and did not report breathing difficulty (Guzelian et al. 1988). In another study, increased mucosal irritation scores were reported in 72 workers exposed to toluene for an average of 20 years, compared with 61 unexposed referents (Deschamps et al. 2001). The toluene-exposed group consisted of 36 printer and machine factory workers and 36 laboratory workers exposed to toluene (but no other solvent) at toluene concentrations of 9–83 and 184–467 ppm, respectively. Since the exposed groups were analyzed together, the LOAEL for this assessment is determined to be the average of the midpoints of the exposed ranges (midpoint of 46 ppm for factory workers; midpoint of 325.5 ppm for laboratory workers; average of 186 ppm).

Environmental Exposure Human Studies. A single epidemiological study evaluated the potential associations between air pollutants and acute asthma attacks in 5–89-year-old residents in Detroit, Michigan, United States and Windsor, Ontario, Canada (Lemke et al. 2014). Air pollutants (including summed BTEX) were measured at 100 sites during two 2-week sampling periods in 2008 and 2009. Acute asthma attack rates in each city were calculated using emergency room visits and hospitalizations. Using linear regression analysis, annual 2008 asthma rates were significantly correlated with total BTEX levels in Detroit (β 6.34; 95% confidence interval [CI] 4.23–8.45), but not Windsor. Mean BTEX levels in Detroit and Windsor during the two sampling periods were 6.6–10.3 and 3.2–5.9 $\mu\text{g}/\text{m}^3$, respectively. This study suggests that exposure to BTEX solvents may increase the risk of acute asthma attacks in

3. HEALTH EFFECTS

urban settings; however, major limitations include coarse temporal resolution and multiple chemical exposures.

Intermediate-Duration Animal Studies. Following intermediate-duration exposure of animals to concentrations ≥ 600 ppm 6 hours/day, signs of pulmonary or nasal inflammation have been observed in a number of studies. Rats exposed to 600 ppm for 5 weeks, 7 hours/day showed irritation of the lungs and rats exposed to 2,500 and 5,000 ppm had pulmonary lesions (von Oettingen et al. 1942). Rats exposed to 3,000 ppm 8 hours/day 6 days/week for 12 weeks showed signs of pulmonary inflammatory responses including inflammatory cell infiltration in peribronchial and alveolar regions, alveolar edema, and interstitial fibrosis and necrosis (Kanter 2011a). Mice exposed to 1,000 ppm 5 hours/day, 5 days/week for 4 weeks showed time-dependent and reversible changes in the number of cells in, and the thickness of, the nasal olfactory epithelium that were indicative of degenerative processes followed by regenerative processes (Jacquot et al. 2006). Significantly ($p > 0.05$) increased relative lung weights were reported in male and female rats and male and female mice exposed to 2,500 and 3,000 ppm (6.5 hours/day, 5 days/week for 14–15 weeks); these concentrations also induced ataxia in rats and dyspnea and increased early mortality in mice (NTP 1990). Relative lung weights were also increased at lower exposure levels (100, 625, and 1,250 ppm) in female mice, but the degree of change did not increase with increasing concentration (NTP 1990). The increased lung weights observed in the NTP (1990) studies were not accompanied with increased incidences of histological lesions in the lung, trachea, or nose in the 2500- or 3,000-ppm groups, compared with controls. No signs of respiratory distress or histological abnormalities were observed in the lungs of mice exposed to 4,000 ppm 3 hours/day, for 8 weeks, or in rats and mice exposed to 12,000 ppm for seven 10-minute periods per day separated by a 20-minute recovery period (Bruckner and Peterson 1981b). Additionally, no histological abnormalities in the lung were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003). However, these studies did not include a histological examination of the upper respiratory tract and may therefore not have observed damage to this region. In addition, the lack of pulmonary abnormalities in Bruckner and Peterson (1981b) at higher concentrations than those in the NTP (1990) studies may be explained by the shorter daily duration of exposure (3 hours/day versus 6 hours/day).

Following intermediate-duration to concentrations < 600 ppm, histological lesions in the respiratory tract have not been observed consistently across studies. Sprague-Dawley rats exposed to 30 or 300 ppm toluene 6 hours/day, 5 days/week for 4 weeks showed no clear-cut evidence for exposure-related histological lesions in the nose, trachea, or lung (Poon et al. 1994). Incidences of epithelial degeneration

3. HEALTH EFFECTS

of the nasolacrimal ducts (with average severity scores in parentheses on a scale of 1=minimal, 2=mild, 3=moderate, and 4=marked) were 4/6 (0.5), 6/6 (1.50), and 3/6 (0.42) in control through high-concentration males, respectively, and 1/6 (0.25), 5/6 (0.38), and 3/6 (0.33) in females, respectively. In the trachea, subepithelial lymphoid proliferation was observed in 3/6 (0.15), 3/6 (0.35), and 3/6 (0.25) male rats, respectively, and 5/6 (0.29), 3/6 (1.15), and 3/6 (0.71) female rats, respectively (Poon et al. 1994). In Wistar rats, exposure to 200 ppm toluene via nose-only inhalation 2 hours/day, 5 days/week for 28 days did not induce histopathological changes in the lung or increase markers of inflammation in the lung or bronchoalveolar lavage (BAL) fluid; nasal passages were not evaluated (Jain et al. 2013). In a mouse study, no exposure-related changes were detected by light microscopy in the nose, trachea, or lung of female C3H/HeN mice exposed to 0 or 50 ppm 6 hours/day, 5 days/week for 12 weeks, but significant ($p<0.05$) changes were found in a few BAL indices of airway inflammation and a few neurotrophic factors in exposed mice, compared with control mice (Fujimaki et al. 2007). Significant changes after 12 weeks of exposure included increased numbers of inflammatory cells and macrophages (~1.95 times control values), but no changes in the number of lymphocytes or levels of 5/6 cytokines (tumor necrosis factor [TNF- α], monocyte chemoattractant protein [MCP-1], macrophage inflammatory protein [MIP-1 α], interleukin-1 β and interleukin-6); levels of interferon-gamma (IFN- γ) were significantly lower than control levels (~0.7 times control value). BAL fluid from exposed mice showed increased levels of neurotrophin-3 (~1.12 times control value) and decreased levels of substance P (~0.5 times control value), but no significant changes in nerve growth factor (NGF) levels (Fujimaki et al. 2007). The biological adversity of the observed changes in BAL fluid end points at 50 ppm is currently uncertain, but the histological results clearly identify 50 ppm 6 hours/day, 5 days/week for 12 weeks as a NOAEL for histological signs of respiratory irritation in mice.

Chronic-Duration Animal Studies. Inflammation of the nasal mucosa, erosion and metaplasia of the olfactory epithelium, and degeneration of the respiratory epithelium were reported in male and female rats exposed to 600 or 1,200 ppm for 15 months or 2 years (6.5 hours/day, 5 days/week) (NTP 1990). At the end of 2 years, there were significant ($p<0.05$) increases in the incidence of erosion of the olfactory epithelium (males: 0/50, 3/50, and 8/49; females: 2/49, 11/50, and 10/50 at 0, 600, and 1,200 ppm, respectively) and degeneration of the respiratory epithelium (males: 15/50, 37/50, and 31/49; females: 29/49, 45/50, and 39/50 at 0, 600, and 1,200 ppm, respectively). Exposed female rats also showed significant increases in inflammation of the nasal mucosa (27/49, 41/50, and 41/50 at 0, 600, and 1,200 ppm, respectively) and metaplasia of the olfactory epithelium (0/49, 1/50, and 5/50 at 0, 600, and 1,200 ppm, respectively). Exposed rats showed no increased incidences of lung lesions compared with controls (NTP 1990). Increased incidences of nasal or lung lesions were not observed in mice exposed to

3. HEALTH EFFECTS

the same concentrations for 2 years, but minimal hyperplasia of the bronchial epithelium was observed in 4/10 female mice exposed to 1,200 ppm for 15 months (NTP 1990). No histopathological lesions were observed in the upper respiratory tract or lungs of rats exposed for 2 years to 300 ppm toluene (6 hours/day, 5 days/week) (CIIT 1980; Gibson and Hardisty 1983).

Cardiovascular Effects.

Overview. Cardiac arrhythmia has been reported as a cause of death in fatal acute inhalation of solvents containing toluene (Anderson et al. 1982; Shibata et al. 1994). Following nonfatal acute exposures to high concentrations of toluene (>1,500 ppm), transient tachycardia and bradycardia have been reported (Camarra-Lemarroy et al. 2015; Einav et al. 1997; Meulenbelt et al. 1990). In addition, several cases of cardiac abnormalities associated with chronic toluene abuse have been reported (see Vural and Ogel 2006 for review). A single pregnancy cohort study suggests a weak potential association between environmental levels of toluene and increased risk of adverse cardiovascular events during delivery (Mannisto et al. 2015). However, repeated inhalation exposure studies in laboratory animals at concentrations as high as 1,200 ppm do not provide convincing support for a direct effect of toluene on the cardiovascular system (Bruckner and Peterson 1981b; CIIT 1980; NTP 1990). One study of acute exposure of dogs to a lethal concentration of toluene (~30,000 ppm) reported the induction of arrhythmia, but the authors suggested that this was due to a predisposing arrhythmia-producing heart abnormality (Ikeda et al. 1990). Other studies of acute exposure have reported a nonsignificant increase in heart rate in rats exposed to 66,276 ppm toluene for 30 minutes (Vidrio et al. 1986) and a reduction of experimentally-induced arrhythmia in rats exposed to 6,867 ppm toluene, 10 minutes before aconitine treatment to induce arrhythmias (Magos et al. 1990).

Human Exposure Studies. Cardiac arrhythmias were noted in two adult males who were found semi-conscious after suffering from toluene intoxication (>7,000 mg/m³ toluene, 1,862 ppm) while removing glue from tiles in a swimming pool (Meulenbelt et al. 1990). Response seemed to be variable between these individuals. One man was exposed for 2 hours and exhibited a rapid heartbeat (sinus tachycardia), while the second man, exposed for 3 hours, exhibited a slow heartbeat (bradycardia) (Meulenbelt et al. 1990). Severe sinus bradycardia was also reported in a comatose man with severe toluene intoxication who had sniffed vapors from approximately 250 mL of thinner containing more than 50% toluene (Einav et al. 1997). In a case-series report of patients with acute toluene intoxication, 20/20 cases exhibited tachycardia upon admission; EKG alterations included ST segment depression (10/20), AV block (6/20), U-waves (4/20), and prolonged QT (4/20) (Camarra-Lemarroy et al. 2015). No effects on systolic or

3. HEALTH EFFECTS

diastolic blood pressure or pulse rate were reported in volunteers exposed to 800 ppm toluene for 3 hours (von Oettingen et al. 1942), but several cases of cardiac abnormalities associated with toluene abuse have been reported (see Vural and Ogel 2006 for review). No significant differences in prevalences of subjects with abnormally high blood pressure were found between a group of German rotogravure printers expected to have been exposed to toluene and a reference group of non-exposed paper industry workers (Gericke et al. 2001).

In the Consortium on Safe Labor pregnancy cohort in the United States (n=223,502 singleton births), environmental toluene levels 5 days prior to delivery were significantly associated with an increased risk of adverse cardiovascular events during delivery (including ischaemic heart disease, stroke, heart failure, cardiac arrest/failure, and other/unspecified cardiovascular event) after adjustment for hospital site, maternal age, race/ethnicity, insurance status, smoking during pregnancy, and pre-pregnancy body mass index (BMI) (odds ratio [OR] 1.42, 99% CI 1.02–1.97) (Mannisto et al. 2015). Toluene exposure levels were estimated using the Community Multiscale Air Quality Model, developed by the EPA (estimated air levels were not reported). Toluene exposure levels on the day of delivery or 1, 2, 3, 4, 6, or 7 days prior to delivery were not significantly associated with risk of adverse cardiovascular events during delivery. This study provides weak evidence that toluene exposure near delivery date may increase the risk of adverse cardiovascular events during delivery; however, concurrent exposure to multiple pollutants (which were not controlled for in statistical analyses) limits the conclusions that can be drawn from this study.

Animal Studies. Cardiovascular response was assessed in 25 dogs killed by rebreathing 1 L of air containing 30,000 ppm toluene via an endotracheal tube (Ikeda et al. 1990). In most cases, death was due to hypoxia, but four of the dogs developed transient arrhythmia and in one case, death was due to ventricular fibrillation. The authors suggested that toluene had a direct effect on the septal and ventricular muscles of the heart, which permitted the development of fatal arrhythmias in sensitive dogs (Ikeda et al. 1990). Inhalation by anesthetized rats of 66,276 ppm toluene for 30 minutes (35 minutes inhalation of this concentration was fatal) produced a nonsignificant increase in heart rate and changes in electrocardiographs indicative of depressed ventricular conduction (Vidrio et al. 1986). However, in rats with arrhythmias induced by aconitine injection or coronary ligation, a 15-minute exposure to 6,867 ppm toluene, 10 minutes before aconitine treatment significantly reduced the number of ventricular ectopic beats (Magos et al. 1990).

3. HEALTH EFFECTS

No histological abnormalities were observed in the hearts of mice exposed to 4,000 ppm for 3 hours/day, for 8 weeks or to mice and rats exposed to 12,000 ppm for 70 minutes/day for 8 weeks (Bruckner and Peterson 1981b). Additionally, no histological abnormalities in the heart were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003). There were also no histopathological lesions of the heart that could be attributed to toluene in rats exposed to 300 ppm for 24 months (6 hours/day) (CIIT 1980; Gibson and Hardisty 1983) or in rats or mice exposed to up to 1,200 ppm for 24 months (6.5 hours/day) (NTP 1990). However, there were increased heart weights in rats and female mice exposed to 2,500 ppm toluene for 14–15 weeks (6.5 hours/day) (NTP 1990).

Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans after inhalation exposure to toluene.

The incidence of ulcers of the forestomach was marginally, but not significantly, increased in male rats exposed to concentrations of 600–1,200 ppm toluene for 2 years (NTP 1990). These effects were not reported in mice or female rats exposed under the same conditions or in rats and mice exposed for only 15 months. There were no gastrointestinal effects in rats and mice exposed to up to 2,500–3,000 ppm toluene for 14–15 weeks (NTP 1990). Additionally, no histological abnormalities in the gastrointestinal tract were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003).

Hematological Effects. Consistent evidence for hematological effects has not been reported after inhalation exposure to toluene in the majority of recent human and animal studies. However, before the mid-1950s, chronic occupational exposure to toluene was associated with hematological effects in some studies (Greenburg et al. 1942; Wilson 1943). These effects are now attributed to concurrent exposure to benzene, a common contaminant of toluene at that time (EPA 1985). More recent studies of workers exposed to toluene or to mixed solvents containing toluene have not found consistent evidence for abnormal hematological parameters (Banfer 1961; Matsushita et al. 1975; Tahti et al. 1981; Ukai et al. 1993; Yin et al. 1987).

Human Studies. Following acute exposures, no effects on leukocyte counts were observed in volunteers exposed to 800 ppm toluene for 3 hours (von Oettingen et al. 1942), and two workers accidentally

3. HEALTH EFFECTS

exposed to about 1,862 ppm for 2–3 hours had normal values for hematological variables (Meulenbelt et al. 1990). White blood cell counts were below the reference range in a case-series report of 20 patients with acute toluene intoxication (4/20); no other hematological parameters were reported (Camarra-Lemarroy et al. 2015).

Consistent evidence for hematological effects has not been reported in workers chronically exposed to toluene. Ukai et al. (1993) reported no hematologic effects in 452 toluene-exposed shoemakers and printers (average exposure of 24.7 ppm) compared with unexposed controls from the same factories. Exposure was estimated from personal monitoring data, and at least 90% of total solvent exposure was due to toluene. No significant hematological effects were observed in workers engaged in shoemaking (Matsushita et al. 1975) or printing (Banfer 1961) who were exposed to toluene for several years. The studies were limited by small cohort size and a lack of historical exposure data. Shoemakers were exposed to toluene concentrations that varied from 65 ppm (15–100 ppm) in winter to 100 ppm (10–200 ppm) in summer and printers were exposed to atmospheric concentrations of toluene up to 600 ppm, but individual exposure monitoring was generally not performed. As a result, the studies had only limited power to detect adverse hematological effects in toluene-exposed workers. Workers involved in printing, shoemaking, and audio equipment production, and exposed to toluene at 41 ppm (females) or 46 ppm (males) had significantly decreased relative (but not absolute) lymphocyte counts when compared to controls; leukocyte counts were not different between exposed and nonexposed workers (Yin et al. 1987). In contrast, workers exposed for several years to toluene (benzene concentration <0.01%) in a tarpaulin factory had increased blood leukocyte counts (Tahti et al. 1981). Toluene exposure concentrations, which ranged from 20 to 200 ppm, were similar to those reported by Banfer (1961). However, this study is limited by small cohort size, a lack of historical exposure monitoring, and the probability that workers were exposed to mixtures of chemicals. Lymphocyte and leukocyte counts were not significantly ($p>0.05$) different in a group of 25 nonsmoking subjects with >5 years of exposure to toluene in shoe-repair facilities, compared with 25 nonsmokers without occupational exposure to toluene (Akbas 2004).

Animal Studies. Results of animal studies do not provide consistent evidence for hematological effects following inhalation exposure to toluene.

Following acute inhalation exposure, increased hematocrit and blood glucose levels have been observed in male rats exposed to 2,000 ppm toluene for 48 hours (Tahti et al. 1983). Erythrocyte membranes were stronger and less susceptible to lysis in rats exposed to 2,000 ppm of toluene than in controls (Korpela et al. 1983). This was demonstrated to be a reversible phenomenon since membrane strength returned to

3. HEALTH EFFECTS

normal after toluene had dissipated from the system (Korpela and Tahti 1984). Other lipophilic agents such as anesthetics, tranquilizers, narcotics, and steroids have a similar effect on membrane strength (Magos et al. 1990).

In another acute exposure study, decreased leukocyte counts were observed in dogs exposed acutely to ≥ 500 ppm toluene for 1 hour or 700 ppm for 4 hours (Hobara et al. 1984a), but intermediate-duration exposure studies provide conflicting evidence for this effect. Positive reports include concentration-related decreases in thrombocytes in mice exposed to 10–1,000 ppm for 20 days (Horiguchi and Inoue 1977), reversible decreased leukocyte counts in rats exposed to 2,500 or 5,000 ppm for 5 weeks (von Oettingen et al. 1942), and decreased leukocytes in female rats exposed to concentrations $>1,250$ ppm for 15 weeks (NTP 1990). In contrast, no hematological effects were reported for male rats exposed to up to 3,000 ppm for 15 weeks or male or female mice exposed to up to 1,200 ppm for 14 weeks (NTP 1990), male rats exposed to 2,000 ppm 6 hours/day for 90 days (Ono et al. 1996), or rats exposed to 300 ppm 6 hours/day, 5 days/week for 4 weeks (Poon et al. 1994).

In chronic-duration studies, rats exposed to 100 or 300 ppm toluene had significantly reduced hematocrit levels (CIIT 1980; Gibson and Hardisty 1983), but no consistent effects on hematological variables were reported for mice or rats exposed to toluene at levels up to 1,200 ppm for 15 months or 2 years (NTP 1990).

Musculoskeletal Effects. A 29-year-old man who had been sniffing glue containing toluene (concentration not specified) for 18 years and complained of severe muscle weakness was diagnosed with rhabdomyolysis (an acute disease of the skeletal muscles evidenced by myoglobin in the blood and urine) (Hong et al. 1996). Rhabdomyolysis was also diagnosed in a 48-year-old man, who was a chronic toluene abuser and had been inhaling one tube of toluene-containing glue per day in the month preceding admission (Karmakar and Roxburgh 2008). In a case-series report of patients with acute toluene intoxication, 16/20 cases presented with rhabdomyolysis; 3 of these cases were fatal (Camarra-Lemarroy et al. 2015).

No histological effects on bone were reported in mice or rats exposed to toluene at concentrations up to 1,200 ppm for 15 months or 2 years (NTP 1990). Additionally, no histological abnormalities were observed in bone or skeletal tissue from F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003). However, bone mineral density and bone mineral content were

3. HEALTH EFFECTS

significantly ($p < 0.05$) decreased in the right femoral neck of mice exposed to 300 ppm toluene 6 hours/day for 8 weeks (Atay et al. 2005).

Hepatic Effects.

Overview. Studies of chronic toluene abusers or occupationally-exposed humans have provided inconsistent evidence for liver damage due to inhaled toluene. Some studies of workers who were occupationally exposed to average concentrations between about 30 and 350 ppm toluene reported liver effects such as increased serum levels of AP (Guzelian et al. 1988; Svensson et al. 1992b), but others recorded no adverse effects on serum liver enzyme levels (Gericke et al. 2001; Lundberg and Hakansson 1985; Matsushita et al. 1975; Seijii et al. 1987; Ukai et al. 1993). A number of animal studies have reported increased liver sizes or histological changes in mice or rats repeatedly exposed to concentrations ranging from 300 ppm 6 hours/day, 5 days/week for 4 weeks to 3,000 ppm 6 hours/day for 15 weeks (Bruckner and Peterson 1981b; Gotohda et al. 2009; Kanter 2012; Kjellstrand et al. 1985; NTP 1990; Poon et al. 1994; Tas et al. 2011, 2013a), but other studies have recorded no effects on liver histology in rats exposed to 320 ppm for 30 days (Kyrklund et al. 1987), rats intermittently exposed to 3,000 ppm for 4–8 weeks (Dick et al. 2014), or rats or mice exposed at concentrations up to 1,200 ppm for 2 years (CIIT 1980; Gibson and Hardisty 1983; NTP 1990).

Human Studies. Evidence for toluene-induced liver toxicity from occupational studies is limited and inconsistent. Eight men from a printing factory employing 289 workers exposed to toluene at concentrations of less than 200 ppm (further information on air toluene levels not reported) exceeded the upper end of the normal range for blood levels of bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (AP), and had an ALT/AST ratio > 1 (Guzelian et al. 1988). Liver biopsies showed centrilobular and periportal fat accumulation and Kupffer cell hyperplasia. None of the men reported drinking alcohol to excess, but they may have had minimal occupational exposure to methyl alcohol, ethyl alcohol, diethyl ether, trichloroethylene, and lacquer thinners which could have confounded the results. Serum AP values were significantly greater than controls in a group of 47 rotogravure workers occupationally exposed to a TWA toluene concentration of 11–47 ppm (midpoint 29 ppm) for 3–39 years than in controls (Svensson et al. 1992b). The difference in AP values remained significant when the data were corrected to eliminate nine workers who reported consumption of alcoholic beverages. No significant elevations in serum liver enzymes were found in another group of 452 shoemakers and printers (exposed to average concentrations of 24.7 ppm toluene) compared with unexposed workers from the same factories (Ukai et al. 1993). Serum ALT and AST levels were not

3. HEALTH EFFECTS

altered in printers and non-printers exposed to median toluene levels of 24 and 4.1 ppm toluene for at least 20 years, compared with unexposed referents (Gericke et al. 2001). Women working in a shoe factory for an average of >3 years and exposed to toluene concentrations that varied from 65 ppm (15–100 ppm) in winter to 100 ppm (10–200 ppm) in summer (average of winter and summer exposure, 83 ppm) showed no changes in several serum variables indicative of liver damage compared with a control group of unexposed workers from the same factory (Matsushita et al. 1975). A group of 157 female shoemakers exposed for 2–14 months to toluene (7–324 ppm) had decreased serum levels of lactate dehydrogenase (LDH) as compared to controls, but levels of eight other serum enzymes monitored as indices of liver damage were normal (Seiji et al. 1987). These workers were also exposed to *n*-hexane, cyclohexane, and methyl ethyl ketone at concentrations generally 1/10th of the toluene concentration. A group of 47 Swedish paint industry workers exposed for >10 years to mixed organic solvents (xylene, toluene, isobutanol, *n*-butanol, ethanol, ethylacetate, *n*-butylacetate, mineral spirits, methylacetate, methylene chloride, methyl ethyl ketone, and isopropanol) did not have elevated serum concentrations of liver enzymes when compared with nonexposed controls (Lundberg and Hakansson 1985). An early study of 106 painters exposed to toluene in an airplane factory reported enlargement of the liver in 30.2% of the exposed men, versus 7% of the control group (Greenburg et al. 1942). However, before the mid-1950s, chronic occupational exposure to toluene was associated with exposure to benzene, a common contaminant of toluene at that time (EPA 1985), and this is a confounding factor for this study.

Several case studies have reported effects on the liver from toluene exposure, although the exposure concentration is generally unknown. Acute fatty liver during pregnancy was reported in a 26-year-old woman exposed for at least 2 months to toluene in glue. A liver biopsy done 9 days postpartum showed cytoplasmic change in the hepatocytes; however, there was no clinical or biochemical evidence of liver disease 1 month later (Paraf et al. 1993). A painter who had been exposed to toluene for 5 years exhibited hepatotoxicity, with fatty degeneration of hepatocytes and infiltration by lymphocytes (Shiomi et al. 1993). No effects on blood levels of bilirubin, AP activity, serum AST activity, or serum ALT activity were reported for two workers accidentally exposed to 1,862 ppm toluene for 2–3 hours; however, the liver was enlarged upon palpation in one man (Meulenbelt et al. 1990). In a case-series report of 20 patients with acute toluene intoxication, the average AST, AP, and gamma-glutamyl transferase (GGT) values were above the reference range; half of the patients evaluated had a previous history of drug abuse, including cocaine and marijuana, in addition to toluene inhalation (Camarra-Lemarroy et al. 2015).

3. HEALTH EFFECTS

Animal Studies. Acute exposure to toluene has been reported to produce biochemical and ultrastructural changes in the livers of experimental animals. Mice, rats, and rabbits exposed to 795 ppm of toluene for 7 days showed increased liver weights and cytochrome P450 levels compared to unexposed controls (Ungvary et al. 1982). Electron microscopy revealed ultrastructural changes (increased rough or smooth endoplasmic reticulum) in the livers of all three species (Ungvary et al. 1982). Cytochrome b₅ levels were also increased in exposed rats and rabbits but were not measured in mice (Ungvary et al. 1982). Male rats exposed to 2,000 ppm toluene for 48 hours had increased serum levels of ALT and AST (Tahti et al. 1983). Exposure of rats to 4,000 ppm toluene for 6 hours resulted in significant increases in hepatic levels of cytochrome P450 (CYP) 2E1, increased hepatic activities of nitrosodimethylamine demethylase and 7-pentoxoresorufin O-depentyase and decreased levels of CYP2C11 (Wang et al. 1996). Increased expression of markers of fibrosis (α -smooth muscle actin, collagen, glucocorticoid receptors, and leptin receptors) was observed in livers of male rats exposed to 1,500 ppm 4 hours/day for 7 days (Gotohda et al. 2009). Rats exposed to 1,500 ppm toluene, 4 hours/day for 7 days demonstrated increased markers of oxidative stress, including 8-Oxo-2'-deoxyguanosine (8-OH-dG) and superoxide dismutase in the liver; however, no significant changes in lipid peroxidase or 4-hydroxy-nonenal levels were seen (Tokunaga et al. 2003).

Intermediate exposure of animals to inhaled toluene has been associated with changes in liver weight, histology, or biochemistry in some, but not all, studies. Increased liver weights were reported for male mice exposed to 4,000 ppm toluene, 3 hours/day, 5 days/week for 8 weeks (Bruckner and Peterson 1981b), female mice exposed to 150 ppm continuously for 30 days (Kjellstrand et al. 1985), rats exposed to $\geq 1,200$ ppm (males) or $\geq 2,500$ ppm (females), or mice exposed to ≥ 625 ppm for 14 or 15 weeks (NTP 1990). In other studies, male rats and mice exposed to 12,000 ppm toluene for 8 weeks (seven 10-minute exposures separated by 20-minute recovery periods) had decreased liver weights (Bruckner and Peterson 1981b), and no change in liver weight was observed in rats or mice exposed continuously to 150–400 ppm (Ikeda et al. 1986; Kjellstrand et al. 1985; Kyrklund et al. 1987) or rats exposed to 30 or 300 ppm toluene 6 hours/day, 5 days/week for 4 weeks (Poon et al. 1994). No effect on the liver was reported for rats exposed to 200–5,000 ppm toluene for 7 hours/day for 5 weeks (von Oettingen et al. 1942) or rats exposed to 3,000 ppm toluene 1 hour/day, 3 days/week, for 4–8 weeks (Dick et al. 2014). Several other studies have reported histological or biochemical changes associated with liver damage in animals after intermediate-duration inhalation exposure to toluene. These effects include: increased serum AP activity in male rats exposed to 300 ppm for 6 hours/day, 5 days/week for 4 weeks (Poon et al. 1994); centrilobular hepatocellular hypertrophy in male mice exposed to 2,500–3,000 ppm 6.5 hours/day, 5 days/week for 14 weeks (NTP 1990); enlarged hepatic sinusoids filled with blood, minimal hepatic

3. HEALTH EFFECTS

fibrosis (mean severity score of 0.78 on a scale of 0 for no fibrosis through 4 for complete cirrhosis), and increased apoptotic cells in livers in male rats exposed to 3,000 ppm 8 hours/day, 6 days/week for 12 weeks (Kanter 2012); and increased serum activities of ALT and AST (but not AP), hepatocyte degeneration, mild pericentral fibrosis, and increased levels of Bax protein (a marker of apoptosis) and apoptotic cells in livers of male rats exposed to 3,000 ppm 1 hour/day for 30 days (Tas et al. 2011, 2013a). No weight changes or histological abnormalities in the liver were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003).

In chronic studies, no exposure-related increased incidences of gross or histopathological liver lesions or changes in liver weight were found in rats exposed to toluene at 300 ppm 6 hours/day, 5 days/week for 2 years (CIIT 1980; Gibson and Hardisty 1983) or rats or mice exposed to up to 1,200 ppm 6.5 hours/day, 5 days/week for 15 months or 2 years (NTP 1990).

Renal Effects.

Overview. Studies of chronic toluene abusers, occupationally exposed workers, and laboratory animals have provided little support for irreversible kidney damage due to inhaled toluene. Chronic abuse of toluene can produce acidosis, but in most cases, renal dysfunction was transient, and normal function returned when exposure ceased (Baskerville et al. 2001; Camarra-Lemarroy et al. 2015; Dickson and Luks 2009; Goodwin 1988; Kamijo et al. 1998; Meulenbelt et al. 1990; Patel and Benjamin 1986; Tang et al. 2005). Studies of workers occupationally exposed to 100–200 ppm toluene, which assessed changes in tests of kidney function, have not shown consistent effects across studies (Askergren et al. 1981a, 1981b; Gericke et al. 2001; Gonzalez-Yerba et al. 2006; Nielsen et al. 1985; Stengel et al. 1998). Animal studies indicate that inhalation of toluene caused concentration-dependent kidney damage in rats, but only after repeated exposure to concentrations ≥ 600 ppm for at least 6 hours/day (Bruckner and Peterson 1981b; CIIT 1980; Gibson and Hardisty 1983; NTP 1990; Ono et al. 1996; von Oettingen et al. 1942).

Human Studies. Numerous cases have been reported where toluene abuse was associated with acidosis (Baskerville et al. 2001; Camarra-Lemarroy et al. 2015; Dickson and Luks 2009; Gerkin and LoVecchio 1998; Goodwin 1988; Jone and Wu 1988; Kamijima et al. 1994; Kamijo et al. 1998; Kaneko et al. 1992; Meulenbelt et al. 1990; Patel and Benjamin 1986; Tang et al. 2005; Tsao et al. 2011). Acidosis generally reflects the inability of the kidneys to maintain the pH balance of the blood due either to saturation of kidney transport of hydrogen ions or a defect in tubular function. Associated changes with toluene-

3. HEALTH EFFECTS

induced acidosis and renal tubular dysfunction are low serum levels of potassium (hypokalemia) and phosphate (hypophosphatemia) (Baskerville et al. 2001; Camarra-Lemarroy et al. 2015; Tang et al. 2005; Tsao et al. 2011). Oliguric renal failure was observed in 3/20 patients who died in a case-series report of acute toluene intoxication hospitalizations; rhabdomyolysis was considered a key factor in renal failure (Camarra-Lemarroy et al. 2015). Severe renal tubular acidosis was observed in five pregnant women who were chronic abusers of paints containing toluene (Goodwin 1988). When paint-sniffing ended, normal acid-base balance returned within 72 hours, indicating that permanent damage to the tubules had not occurred. Recovery of normal acid-base balance after abuse was stopped also was reported in several other cases (e.g., Baskerville et al. 2001; Dickson and Luks 2009; Tsao et al. 2011). However, one 19-year-old male chronic solvent abuser was found, through a renal biopsy, to have severe tubular interstitial nephritis and focal tubular necrosis indicative of prolonged irritation of the kidney (Taverner et al. 1988). This patient required hemodialysis to correct hematuria and oliguria which was present at the time of his hospital admission. Hemodialysis was also required for a 22-year-old male chronic solvent abuser with acidosis and hypokalemia (Gerkin and LoVecchio 1998). A 22-year-old woman, who had sniffed approximately 6 L of toluene during the previous month, was found to have metabolic acidosis and histological evidence of tubular injury. The acidosis normalized, but both proximal and distal tubular dysfunction persisted (Kamijima et al. 1994). Proteinuria, hematuria, and urinary calculi were reported in three solvent abuse case studies (Kaneko et al. 1992); the abused product was primarily toluene in one case. An autopsy of a 19-year-old woman, who had sniffed thinner containing 67% toluene for 5 years, revealed severe renal tubular degeneration and necrosis (Kamijo et al. 1998).

A group of 43 printing trade workers exposed to inks containing toluene, alcohols, and ethyl acetate for 9–25 years were experimentally exposed to 382 mg/m³ (102 ppm) of toluene for 6.5 hours (Nielsen et al. 1985). No significant differences in excretion of albumin and β -2-microglobulin were observed either before or after exposure when the workers were compared to controls matched by age, educational level, and smoking habits (Nielsen et al. 1985).

In a longitudinal study of 92 printers exposed to 97–232 mg/m³ (26–62 ppm) toluene, markers of early renal damage (microalbumin, N-acetyl-b-D-glucosaminidase, and alanine-aminopeptidase) were not significantly elevated in urine, but creatinine clearance was higher among exposed workers than 74 unexposed control subjects (Stengel et al. 1998). Multiple regression analysis indicated a slight increase in N-acetyl- β -D-glucosaminidase urinary levels with increasing cumulative toluene exposure (+2% per 100 ppm x years), but this relationship was not apparent when 17 subjects with hypertension were excluded from the analysis.

3. HEALTH EFFECTS

Albumin excretion levels were significantly increased in a group of 134 workers exposed to 5–23 ppm styrene (52 plastic boat manufacturers), 80–106 ppm toluene (42 printers), or unspecified levels of xylene and toluene (40 paint manufacturers), compared with 48 unexposed referents (Askergren et al. 1981a). However, when the solvent-specific subgroups were analyzed separately, only the styrene-exposed workers varied significantly from control. β -2-microglobulin excretion levels were not significantly altered compared with controls when workers were analyzed together or by solvent-specific exposure group (Askergren et al. 1981a). Similarly, no significant changes in glomerular filtration rate between a group of 107 workers exposed to styrene (33 plastic boat manufacturers), toluene (34 printers), and xylene and toluene (40 paint manufacturers), compared with 48 unexposed referents (Askergren et al. 1981b). For the studies by Askergren et al. (1981a), a NOAEL for renal function in this assessment was determined to be the midpoint of the toluene exposure range in printers (93 ppm). Glomerular filtration rate and serum creatinine levels were also not altered in printers and non-printers exposed to median toluene levels of 24 and 4.1 ppm toluene for at least 20 years, compared with unexposed referents (Gericke et al. 2001).

An increased ($p < 0.05$) prevalence of abnormally high urinary activities of N-acetyl- β -D-glucosaminidase (NAG) was observed in a group of 50 toluene-exposed shoe workers (exposure level unspecified), compared with 25 control subjects (26/50 versus 4/25; Gonzalez-Yerba et al. 2006). However, the prevalences of abnormally high urinary albumin excretion, another indicator of renal damage, were not significantly different between the exposed and control groups.

Animal Studies. The only renal effects reported in an acute-duration study were increased markers of oxidative stress, including 8-OH-dG and superoxide dismutase, in the kidneys of rats exposed to 1,500 ppm toluene, 4 hours/day for 7 days; however, no significant changes in lipid peroxidase or 4-hydroxy-nonanal levels were seen (Tokunaga et al. 2003). In intermediate-duration animal studies, histological changes in the kidney have not been observed consistently across studies. Reports of toluene-induced renal histological changes include renal casts in rats exposed to 600–5,000 ppm 7 hours/day for 5 weeks (von Oettingen et al. 1942) and slight to mild necrosis of kidney tubules (5/8 versus 0/8 in controls) with increased kidney weights in male rats exposed to 2,000 ppm toluene (but not 600 ppm), 6 hours/day for 90 days (Ono et al. 1996). No exposure-related renal histological changes were observed in mice exposed to 4,000 ppm 3 hours/day for 8 weeks showing decreased absolute, but not relative, kidney weight (Bruckner and Peterson 1981b); mice and rats showing decreased absolute kidney weights following exposure to 12,000 ppm for 70 minutes/day, 5 days/week for 8 weeks (Bruckner and Peterson

3. HEALTH EFFECTS

1981b); female mice showing increased relative kidney weight following exposure to 1,250 ppm 6.5 hours/day, 5 days/week for 14 weeks (NTP 1990); male or female rats showing increased relative kidney weight after exposure to concentrations between 1,250 to 3,000 ppm 6.5 hours/day, 5 days/week for 15 weeks (NTP 1990); male or female rats exposed to 30 or 300 ppm 6 hours/day, 5 days/week for 4 weeks (Poon et al. 1994); or F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation in a multigenerational study (API 1985; Roberts et al. 2003).

In chronic-duration animal inhalation studies, evidence for exposure-related renal histological changes is not consistent across studies. No exposure-related renal histological lesions were found in rats exposed to 300 ppm 6 hours/day, 5 days/week for 2 years (CIIT 1980; Gibson and Hardisty 1983) or mice exposed to up to 1,200 ppm 6.5 hours/day, 5 days/week for up to 2 years (NTP 1990). In male and female rats in the 2-year NTP (1990) study, nearly all control and exposed rats showed nephropathy at sacrifice, but the mean severity score for nephropathy was statistically significantly ($p < 0.05$) increased in the high-exposure group (1,200 ppm), compared with the controls (3.2 versus 2.8 in males and 2.7 versus 2.4 in females). In addition, the incidence of renal tubule casts increased with increasing exposure level in male rats: 1/50 in controls; 2/50 at 600 ppm; and 5/50 at 1,200 ppm (NTP 1990).

Endocrine Effects.

Human Studies. Evidence for endocrine effects in humans exposed to toluene is not consistent across studies and does not clearly identify toluene as an endocrine-disrupting chemical.

Serum levels of T3 were significantly increased in printers exposed to toluene for an average of 25 years (current median exposure level, 36 ppm), compared with unexposed controls (Svensson et al. 1992a). Serum levels of T4, TSH, and prolactin were not altered between exposed and referent groups; however, TSH levels were significantly inversely related with cumulative toluene exposure. Serum levels of prolactin were not changed in workers exposed to median toluene levels of 29 ppm for 3–39 years, compared with control subjects (Svensson et al. 1992b). Hypothyroidism was diagnosed in a 29-year-old man who had been sniffing glue containing toluene (concentration not specified) for 18 years (Hong et al. 1996).

An autopsy of a 19-year-old woman who had been sniffing thinner (67% toluene) for 5 years revealed histological evidence of massive bilateral adrenal hemorrhage with severe degeneration and necrosis of

3. HEALTH EFFECTS

the adrenal cortex (Kamijo et al. 1998). However, no exposure-related changes in salivary cortisol levels were observed in volunteers exposed to a peak exposure of 200 ppm (measured pre- and postexposure); the peak exposure condition was obtained by slowly flooding the exposure chamber with toluene starting at a concentration of 0 ppm until the peak exposure of 200 ppm was obtained at 25 minutes and held constant for an additional 15 minutes (40-minute exposure) (Kobald et al. 2015).

Several studies of blood levels of reproductive hormones in repeatedly exposed workers or acutely exposed human subjects have not provided strong and consistent evidence of exposure-related effects. These studies are discussed in Section 3.2.1.5, Reproductive effects.

Workers exposed to a mixture of styrene (0–5.9 ppm), toluene (0–2.02 ppm), and xylene (0–32.65 ppm) demonstrated an increase in fasting insulin and glucose levels compared with unexposed controls (Won et al. 2011). A homeostasis model assessment of insulin resistance levels (HOMA-IR) was significantly higher in the exposed group. After adjustment for age, smoking, alcohol consumption, waist and hip circumference, weight, and regular exercise, fasting glucose levels were still significantly higher in the exposed group, but HOMA-IR was no longer significant. Adjusted analysis was not reported for fasting insulin levels. The results of this study are confounded by mixed exposure and its significance is therefore uncertain.

Animal Studies. Evidence for endocrine effects in animals following acute- or intermediate-duration inhalation exposure to toluene is not consistent across studies and does not clearly identify toluene as an endocrine-disrupting chemical.

Serum prolactin levels were significantly ($p < 0.05$) increased (by 62% compared with control values) in male Sprague-Dawley rats, 17 days after exposure to 80 ppm toluene 6 hours/day, 5 days/week for 4 weeks (Von Euler et al. 1994). A companion study found no significant changes in serum prolactin levels in rats 29–40 days after exposure to 40, 80, 160, or 320 ppm by the same exposure protocol (Hillefors-Berglund et al. 1995).

Significant ($p < 0.05$) decreases (28 or 47%) in rat brain glial fibrillary acidic protein (GFAP) induced by exposure to 1,000 ppm toluene, 6 hours/day for 3 or 7 days was associated with significantly increased serum levels of corticosterone (about 393 or 600% increased, compared with control) (Little et al. 1998). Thymus and adrenal weights in exposed rats were not significantly different from nonexposed control values.

3. HEALTH EFFECTS

Male rats exposed to 1,500 ppm 4 hours/day for 7 days showed significantly ($p < 0.05$) increased adrenal weight (118.2% of control) and adrenocortical cell size (150.7% of control), but not adrenocortical cell number; increased serum levels of ACTH (151.5% of control) and corticosterone (176.1% of control); increased adrenal gland levels of mRNA for a steroid metabolism enzyme, cytochrome P450 side-chain cleavage (P450scc; 131.5% of control); and decreased body weight (92.1% of control) (Gotohda et al. 2005). This exposure scenario was shown to cause, in companion studies, neuronal damage and an increase in glucocorticoid receptor in the hippocampus, suggesting a possible link between the elevated serum levels of ACTH and corticosterone and elevated hippocampal glucocorticoid receptor mRNA (Gotohda et al. 2000a, 2000b, 2002).

No statistically significant ($p < 0.05$) changes in serum levels of prolactin, LH, or FSH were reported in male Sprague-Dawley rats exposed to 500 ppm toluene 6 hours/day for 3 days or to 1,000 ppm 6 hours/day for 5 days, compared with values in nonexposed controls (Andersson et al. 1980). Mean serum level of corticosterone was significantly increased (162% of control value) in rats exposed to 500 ppm, but the mean level in rats exposed to 1,000 ppm rats (79% of control value) was not significantly different from the control mean (Andersson et al. 1980).

No statistically significant ($p > 0.05$) trends for changed levels of FSH, LH, corticosterone, growth hormone, or TSH with increasing exposure level were found in male Sprague-Dawley rats exposed to 80, 500, 1,500, or 3,000 ppm toluene 6 hours/day for 3 days (Andersson et al. 1983b). A significant ($p < 0.01$) trend for increased serum prolactin levels with increasing exposure level was found. The mean prolactin level in rats exposed to 3,000 ppm rats was about 250% of the control value, whereas means in rats exposed to 80, 500 and 1,500 ppm were about 180, 150, and 160% of the control mean, respectively.

In pregnant Wistar rats exposed to 0 or 1,500 ppm 6 hours/day on GDs 7–20, significantly ($p < 0.05$) depressed serum levels of corticosterone were found in exposed dams when measured on GD 14 (88% of control) and GD 18 (60% of control) (Hougaard et al. 2003). Other endocrine end points were not measured in this study.

Female, but not male, rats exposed to 30 or 300 ppm toluene for 6 hours/day, 5 days/week for 4 weeks showed a treatment-related reduction in follicle size of the thyroid (Poon et al. 1994).

3. HEALTH EFFECTS

No effect on the adrenal glands was reported for rats exposed to 200–5,000 ppm toluene for 7 hours/day for 5 weeks (Von Oettingen et al. 1942). In a multigenerational study, no histological abnormalities on the pancreas, adrenal, or thyroid glands were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation (API 1985; Roberts et al. 2003). Mice exposed to up to 2,500 ppm for 14 weeks (NTP 1990), rats exposed to up to 3,000 ppm for 15 weeks, and mice and rats exposed to up to 1,200 ppm for 2 years (NTP 1990) showed no histological abnormalities in the pancreas, adrenal, or thyroid glands.

Dermal Effects. No studies were located regarding dermal effects in humans after inhalation exposure to toluene.

In a multigenerational study, no effects on the skin were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation (API 1985; Roberts et al. 2003).

Ocular Effects. Humans exposed for 6–8 hours to toluene concentrations of ≥ 100 ppm developed irritation of the eyes (Andersen et al. 1983; Baelum et al. 1985; Carpenter et al. 1944; Meulenbelt et al. 1990). No irritation was reported with 6 hours of exposure to 40 ppm toluene (Andersen et al. 1983). Reports of color vision deficits in occupationally exposed workers have linked increased color confusion with chronic exposure to toluene (Campagna et al. 2001; Cavalleri et al. 2000; Muttray et al. 1997, 1999; Zavalic et al. 1998a, 1998b, 1998c). These studies are discussed in the Section 3.2.1.4, Neurological Effects.

Pregnant rats exposed to 2,000 ppm 6 hours/day for 21 days showed lacrimation (Ono et al. 1996), but no lacrimation or discharge was reported for male, female, or pregnant female rats exposed to 100–2,000 ppm, 6 hours/day for 95 days (API 1985; Roberts et al. 2003). No exposure-related lesions were observed in rats exposed at concentrations up to 1,000 ppm 6 hours/day, 5 days/week for 4 or 13 weeks during ophthalmic examinations conducted 2–6 weeks or 1 year postexposure (Boyes et al. 2016). Results from studies of visual impairment in rats after acute or intermediate inhalation exposure to toluene are discussed in Section 3.2.1.4, Neurological Effects.

Body Weight Effects. No studies were located regarding body weight effects in humans after inhalation exposure to toluene.

3. HEALTH EFFECTS

Findings regarding body weight effects in animals are inconsistent. Body weights in rats decreased compared with controls following inhalation exposure to toluene concentrations of 2,000 ppm for 48 hours (Tahti et al. 1983); 1,500 ppm, 4 hours/day for 7 or 20 days (Gotohda et al. 2005; Ishigami et al. 2005); 2,000 ppm, 8 hours/day, 7 days/week for 11 or 23 weeks (Pryor 1991); 320 ppm, 24 hours/day for 30 days (Kyrklund et al. 1987); 8,000 ppm 2–2.5 hours/day, 5 days/week for 13 weeks (Mattsson et al. 1990); 10,000 ppm 1 hour/day, 3 days/week for 4 weeks (Dick et al. 2015); 12,000 ppm 70 minutes/day, 5 days/week for 8 weeks (Bruckner and Peterson 1981b); and 2,500 ppm, 6.5 hours/day for 15 weeks (NTP 1990). Significantly decreased body weight gain was observed in male rats continuously exposed to 200 or 400 ppm for 30 days (Ikeda et al. 1986). Decreased body weights were seen in female and male mice exposed 6.5 hours/day for 14 weeks to concentrations ≥ 100 and 2,500 ppm, respectively (NTP 1990), and in male mice exposed to 4,000 ppm, 3 hours/day or 12,000 ppm 70 minutes/day for 8 weeks (Bruckner and Peterson 1981b). In contrast, no exposure-related effects on body weights were observed in rats or mice exposed to 1,000 ppm toluene for 6 hours/day, 5 days/week, for 3–13 weeks (API 1997; Beasley et al. 2010, 2012; Boyes et al. 2016; Horiguchi and Inoue 1977), mice exposed to up to 6,000 ppm toluene 30 minutes/day for 40 days (Bowen and McDonald 2009), rats exposed to 3,000 ppm toluene 1 hour/day, 3 days/week for 4–8 weeks (Dick et al. 2014), rats exposed to up to 2,000 ppm toluene 6 hours/day for 90 or 95 days (API 1985; Ono et al. 1996; Roberts et al. 2003), or rats or mice exposed to up to 1,200 ppm toluene 6–6.5 hours/day for 15 months or 2 years (CIIT 1980; Gibson and Hardisty 1983; NTP 1990); mean body weights in exposed animals were within 10% of control means.

Other Systemic Effects. No studies were located regarding other systemic effects in humans or animals after inhalation exposure to toluene.

3.2.1.3 Immunological and Lymphoreticular Effects

Overview. Human studies of immunological end points in toluene-exposed subjects do not identify consistent or strong evidence for toluene effects on immune system end points such as counts of blood lymphocytes or levels of blood immunoglobulins (Little et al. 1999; Pelclova et al. 1990; Stengel et al. 1998; Yin et al. 1987). Human studies also provide conflicting evidence regarding the potential role of occupational exposure to toluene and development of autoimmune disorders (Diot et al. 2002; Chaigne et al. 2015; Marie et al. 2014). In animal studies, evidence for toluene effects on the immune system includes the finding of decreased survival following respiratory infection by *S. zooepidemicus* in a study of mice exposed for 3 hours to toluene concentrations as low as 2.5 ppm, but not 1 ppm (Aranyi et al. 1985). No evidence for exposure-related adverse changes in weight or histology of the spleen or thymus

3. HEALTH EFFECTS

has been reported in animals exposed by inhalation for intermediate (NTP 1990; Poon et al. 1994; von Oettingen et al. 1942) or chronic durations (NTP 1990). In a series of studies from a single laboratory, intermediate-duration inhalation exposures of normal or allergy-challenged [ovalbumin (OVA)-immunized and challenged] mice to toluene concentrations <100 ppm have been reported to modulate immune system end points, but mechanistic understanding of the observed changes is insufficient to determine their biological adversity (Fujimaki et al. 2009a, 2009b, 2010, 2011; Liu et al. 2010; Takeda et al. 2013; Win-Shwe et al. 2007a, 2010a, 2010b, 2012a, 2012b; Yamamoto et al. 2009).

Occupational Human Exposure Studies. No differences in serum IgG, IgA, or IgM values were noted between a group of 42 rotogravure printers exposed to concentrations of 104–1,170 ppm (midpoint, 637 ppm) for an average of 13 years and a group of 16 office and technical workers exposed to toluene concentrations ranging from 2.1 to 4.3 ppm at the same facility (Pelclova et al. 1990). Blood IgE levels in 92 printers exposed to 97–232 mg/m³ (26–62 ppm) toluene for an average of 16 years were not significantly elevated compared to unexposed controls, but a dose-response relationship was observed between cumulative toluene exposure and IgE levels (Stengel et al. 1998). Relative lymphocyte counts in blood (but not absolute counts) were significantly decreased in a group of workers who were involved in shoemaking, printing, or audio equipment production and were predominately exposed to toluene (Yin et al. 1987). Mean toluene exposures were 41 ppm for females and 46 ppm for males over an average of 82 months.

A number of other studies have examined immune-related end points in toluene exposed workers, but the results of these studies are confounded by mixed exposure to other solvents. A decrease in the T lymphocyte count of workers occupationally exposed to a mixture of benzene (0–116 ppm), toluene (0–160 ppm), and xylene (0–85 ppm) was observed (Moszczynsky and Lisiewicz 1984). However, no signs of diminished immunological function or disturbances in immune skin reactions against such antigens as tuberculin or distreptase were observed in the subjects studied. The reduction of T lymphocytes may have been the result of the depressive effect of benzene on the lymphocyte system. Workers exposed to a mixture of 0.8–40 ppm toluene (0.003–0.16 mg/L), 56–940 ppm benzene (0.18–3.0 mg/L), and 40–609 ppm xylene (0.18–3.0 mg/L) had significantly lower serum IgG and IgA levels than unexposed controls (Lange et al. 1973). Leukocyte agglutinins for autologous leukocytes and increased leukoagglutination titer in human sera after incubation with the solvents were also observed (Lange et al. 1973). No effects on natural killer cell activity or serum levels of IL-2 or γ -IFN were observed in shoe factory workers, compared with a control group of workers not exposed to solvents (Yucesoy et al. 1999). Mean 8-hour TWA breathing zone concentrations of solvents in shoe workplaces were about 58 ppm for

3. HEALTH EFFECTS

n-hexane, 27 ppm for toluene, and 11 ppm for methyl ethyl ketone. Mean concentrations of hippuric acid and 2,5-hexadione in exposed workers were about 2- and 3-fold higher than concentrations in nonexposed controls (Yucesoy et al. 1999). Multiple linear regression analysis showed significantly ($p < 0.05$) decreased production of TNF, but not IL-10 or IL-12, in cultured peripheral blood mononuclear cells from a high accumulated exposure group of paint factory workers, compared with a low-exposure group (Haro-Garcia et al. 2012). Mean 8-hour TWA concentrations of solvents in the factory were about 12 mg/m³ for benzene, 28 mg/m³ (7 ppm) for toluene, and 19.5 mg/m³ for xylene. Mean urinary concentrations of S-phenylmercapturic acid were about 3.4 and 2.4 $\mu\text{mol/mol}$ creatinine in the high- and low-exposure groups, respectively (Haro-Garcia 2012). Workers exposed to a mixture of styrene (0–5.9 ppm), toluene (0–2.02 ppm), and xylene (0–32.65 ppm) demonstrated a significant increase in serum TNF α compared with unexposed controls (Won et al. 2011). No change was observed in IL-1 β or IL-6. However, alterations in serum TNF α were significantly associated with urinary phenylglyoxylic acid levels, not urinary hippuric acid levels, indicating that alterations are associated with styrene exposure rather than toluene exposure (Won et al. 2011).

A few case-control studies have evaluated potential occupational risk factors for autoimmune diseases using retrospective exposure analysis based on work history and job-exposure matrices. Chaigne et al. (2015) reported a significantly increased risk of the autoimmune disorder primary Sjögren's syndrome (175 cases, 250 controls) with history of occupational toluene exposure (OR 4.18, 95% CI 1.41–12.43). The risk was also significantly increased using final toluene exposure scores, calculated based on the probability and intensity of exposure (estimated from a job-exposure matrix) and the reported duration of exposure (OR 4.69, 95% CI 1.42–15.45). Diot et al. (2002) similarly reported a significantly increased risk of systemic sclerosis (80 patients, 160 controls) with history of occupational toluene exposure (OR 3.44, 95% CI 1.09–10.90). However, the risk was not significantly increased with a “high” final cumulative toluene exposure score (>1), calculated based on the probability, intensity, and frequency of exposure (estimated from a job-exposure matrix) and the reported duration of exposure (OR 6.19, 95% CI 0.63–60.53). In another case-control study of systemic sclerosis (100 cases, 300 controls), the risk of systemic sclerosis was not increased with a history of any occupational exposure to toluene (OR 2.04, 95% CI 0.41–11.06) or a high cumulative toluene exposure score (OR 4.59; 95% CI 0.52–55.61) (Marie et al. 2014).

Controlled Exposure Human Studies. Serum levels of T-cell proteins specific for a benzoic acid-human serum albumin antigen were elevated following a 20-minute exposure to 15 ppm in a group of 20 subjects who were clinically sensitive to toluene, compared with a group of 16 subjects who were not sensitive to

3. HEALTH EFFECTS

toluene (Little et al. 1999). No significant differences in levels of IgG specific to the antigen were found between the groups following exposure to toluene. These findings may indicate sensitization to benzoic acid, a metabolite of toluene.

Animal Studies. Single 3-hour exposures of mice to 2.5, 10, 25, 50, 100, 250 or 500 ppm toluene, immediately before inhalation exposure to aerosols of *S. zooepidemicus*, significantly ($p < 0.05$) decreased the ability to survive the respiratory infection (Aranyi et al. 1985). For example, the respective mortality percentages in exposed and control groups were: 500 ppm, 56.8 and 20.7%; 50 ppm, 25.0 and 6.4%; and 2.5 ppm, 26.1 and 12.6%. A 3-hour exposure to 1.0 ppm toluene once or for 5 or 20 consecutive days did not significantly change the number of animals that died following experimental exposure to *S. zooepidemicus*, compared with control mice exposed only to aerosols of *S. zooepidemicus*. In another assay, mice were exposed to varying concentrations (0.1, 2.5, 5, 10, 25, 50, 100, 250, or 500 ppm) of toluene for 3 hours, followed immediately by inhalation exposure to aerosols of ^{35}S -labeled *Klebsiella pneumonia* and determination of the percent of bacteria killed in the lungs 3 hours later (Aranyi et al. 1985). Exposure before infection to toluene at all concentrations except 5 and 50 ppm significantly ($p < 0.05$) decreased pulmonary bactericidal activity, but no clear dose-response relationship was apparent. For example, the percentages of bacteria killed in 3 hours in respective exposed and control groups were: 500 ppm, 85.9 and 71.9%; 100 ppm, 87.3 and 73.4%; 50 ppm, 82.3 and 84.1%; and 2.5 ppm, 84.6 and 79.2%. A 3-hour exposure to 1.0 ppm toluene once or for 5 or 20 consecutive days before infection did not consistently produce significant ($p < 0.05$) changes in pulmonary bactericidal activities against *K. pneumonia*. The results show most clearly that acute exposure to toluene concentrations ≥ 2.5 ppm decreased the ability to survive following respiratory infection with *S. zooepidemicus*.

No changes in weight or histology of the spleen were recorded for rats exposed to 30–5,000 ppm toluene, 6–7 hours/day for 4–5 weeks (Poon et al. 1994; von Oettingen et al. 1942) or for rats and mice exposed to toluene concentrations up to 3,000 ppm for 14–15 weeks (NTP 1990). In rats and mice exposed to concentrations of toluene up to 1,200 ppm, 6.5 hours/day for 2 years, an increased incidence of pigmentation of the spleen was observed in male mice exposed to concentrations ≥ 120 ppm (NTP 1990).

Decreased thymus weights were observed in male rats exposed to 2,000 ppm 6 hours/day for 90 days (Ono et al. 1996) and in dams exposed to 600 ppm 6 hours/day during GDs 7–17 (Ono et al. 1995). However, no effects on the thymus were reported in rats and mice exposed 6 hours/day to up to 1,200 ppm for 2 years or up to 3,000 ppm toluene for 14–15 weeks (NTP 1990) or in male rats exposed to 1,000 ppm toluene for 6 hours/day for up to 42 days (API 1997).

3. HEALTH EFFECTS

In a multigenerational study, no histological abnormalities were observed the thymus or spleen from F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation (API 1985; Roberts et al. 2003).

The highest NOAEL values and all LOAEL values for each reliable study for immunological effects in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

In a series of studies from a single laboratory, intermediate-duration inhalation exposures of normal or allergy-challenged (OVA-immunized and challenged) adult mice to toluene concentrations <100 ppm have been reported to modulate a number of immune system end points (Fujimaki et al. 2009a, 2009b, 2010, 2011; Liu et al. 2010; Takeda et al. 2013; Win-Shwe et al. 2007a, 2010a). Examined end points included BAL fluid cell counts, mRNA or protein levels for inflammatory cytokines, anti-microbial peptides, neurotrophins, neurotrophin receptors or other immune regulatory transcription factors in lung, BAL fluid or hippocampus, and plasma levels of antibodies. Another series of studies from the same laboratory examined immune system end points in postnatal day (PND) 21 male BALB/c mice exposed to 0, 5, or 50 ppm toluene 6 hours/day on GD 14 through 21 (Yamamoto et al. 2009) or on GDs 14–18, PNDs 2–6, or PNDs 8–12 (Win-Shwe et al. 2010b, 2012a, 2012b). Examined end points included brain, thymus, or spleen weights, plasma levels of antibodies, and mRNA levels for cytokines and transcription factors in the spleen or hippocampus. Current mechanistic understanding of the observed findings in these studies, which include evidence for non-monotonic dose-related changes in several end points (described in more detail in the following paragraphs), is insufficient to determine their possible biological adversity, and NOAEL or LOAELs from these studies are not included in Table 3-1 or Figure 3-1.

In allergy-challenged male C3H/HeN mice exposed nose-only to 0, 9, or 90 ppm 30-minutes on days 0, 1, 2, 7, 14, 21, and 28, significantly ($p<0.05$) changed numbers of macrophages were found in BAL fluid samples from mice exposed to 9 ppm (~50% increased over non-exposed control) and 90 ppm (~25% decreased over control) (Win-Shwe et al. 2007a). Significantly increased numbers of macrophages also were found in BAL fluid in normal C3H/HeN mice exposed to 9 ppm (~130% increased) and 90 ppm (~260% increased). No significant exposure-related changes were found in other cellular end points in BAL fluid from exposed normal or allergy-challenged mice: numbers of total inflammatory cells, neutrophils, lymphocytes, or eosinophils. Levels of mRNAs for certain cytokines in lungs of allergy-challenged mice were significantly changed at 9 ppm (IL-5, ~100% increased) and 90 ppm (IFN- γ , ~70%

3. HEALTH EFFECTS

decreased), but no exposure-related changes were noted in mRNAs for IL-4 or IL-12. In allergy-challenged mice, significant ($p < 0.05$) changes were found in plasma levels of total IgE at 90 ppm (~100% increased), anti-OVA IgE at 9 ppm (~500% increased), total IgG₁ at 9 and 90 ppm (~75% increased at each concentration), and anti-OVA IgG₁ at 9 ppm (~90% increased); no significant changes were found in plasma levels of total IgG₂ and anti-OVA IgG₂. In allergy-challenged mice, toluene exposure led to several significant biochemical changes in the lungs, including increased plasma NGF at 9 ppm (~200% increased) and decreased lung levels of mRNA for brain-derived nerve factor (BDNF, ~40% decreased) and tropomyosin-related kinase A (Trk A, ~50% decreased) at 9 and 90 ppm; no significant exposure-related changes were found in lung levels of mRNAs for NGF, neurotrophin-3 (NT-3), or Trk B. The neurotrophins were measured in these studies to investigate a hypothesis that low-level toluene exposure may aggravate airway inflammation responses in allergy-challenged mice by modulating signaling pathways in neurological and immune systems (i.e., modulating neuroimmune cross talk).

In another study with allergy-challenged male C3H/HeN mice exposed nose-only to 0 or 9 ppm for 30 minutes on days 0, 1, 2, 7, 14, 21, and 28, significantly ($p < 0.05$) increased total cell and macrophage counts (both ~200% increased) were found in BAL fluid from mice exposed to 9 ppm, compared with controls (Fujimaki et al. 2009a). No significant exposure-related changes were found in numbers of polymorphonuclear leukocytes and lymphocytes. Levels of BDNF in BAL fluid from mice exposed to 9 ppm were also significantly increased (~130%). Levels of NGF in BAL fluid were not increased in exposed mice, but plasma levels of NGF were significantly increased by about 120% above levels in non-exposed mice. Exposure-related effects were diminished by treatment with anti-CD4 antibody. The latter result suggests that the observed toluene-induced effects may involve CD4⁺ cells, which have been reported to produce BDNF and NGF.

In allergy-challenged male C3H/HeN mice exposed nose-only to 0, 9, or 90 ppm 30 minutes/day on days 0, 1, 2, 7, 14, 21, 28, 35, 42, 49, and 56, significant ($p < 0.05$) exposure-related changes were found in lung levels of mRNAs for NGF (~70% increased over nonexposed controls), the NGF receptor, Trk A (~100% increased), CCL2 (~140% increased), and CCL3 (~90% increased) at 9 ppm, but not at 90 ppm (Fujimaki et al. 2009b). No significant exposure-related changes were found in lung levels of mRNA for p75 neurotrophin receptor (p75NTR). Light microscopy of lungs from allergy-challenged mice exposed to 9 ppm showed peribronchial inflammation with eosinophil infiltration, but incidences of mice with this condition were not reported by the study authors. In mice that were not allergy challenged (“unchallenged” mice), exposure to 9 ppm led to slight hyperplasia of bronchial epithelia without accumulation of macrophages and neutrophils. Immunohistological examination for NGF-positive cells

3. HEALTH EFFECTS

showed a “few” NGF-positive bronchial epithelial cells in unchallenged mice exposed to 9 ppm toluene and “marked increase” in allergy-challenged mice exposed to 9 ppm toluene. The study report did not mention histological findings for unchallenged or allergy-challenged mice exposed to 90 ppm.

Similarly, C3H/HeN mice exposed nose-only to 0 or 9 ppm for 30 minutes/day on days 0, 1, 2, 7, and 14 or days 0, 1, 2, 7, 14, 21, 28, 35, 42, and 49 demonstrated qualitative damage to the tracheal epithelial structure in exposed groups with >50% of the epithelial cells in the trachea being “remarkably damaged” in mice exposed up to day 49 (Takeda et al. 2013). Again, incidences of mice with these findings were not reported by the study authors. The allergy-challenged group did not differ from the toluene-only group. No damage was observed with a single 30-minute exposure to 9 ppm, and no lymphocyte infiltration was observed in any group. This study also examined protein expression of biophylaxis factors in the lungs, including toll-like receptor 2 (TLR2), α defensin (NP-3), and β defensins (BD 1-4). BD-2 was significantly decreased with exposure until day 14 or 49 (~10 and 50%, respectively) while BD-4 was significantly increased (~80%) with the shorter exposure group, but significantly decreased (~35%) with longer exposure. No changes were observed in NP-3, BD-1, BD-3, or TLR2 levels. Protein expressions in allergy-challenge mice were not reported.

Thymus cells, but not spleen cells, from normal male C3H/HeN mice exposed to 50 ppm 6 hours/day, 5 days/week for 3 weeks (in inhalation chambers) showed enhanced proliferation in culture (measured by rate of thymidine incorporation into DNA) by concanavalin A (Con A), compared with cells from nonexposed mice (Liu et al. 2010). Thymocytes from toluene-exposed mice also showed increased levels of the cytokine, IL-2, in response to Con A, and enhanced DNA-binding activities of transcription factors involved in IL-2 production (NF- κ B, STAT5, and NF-AT), compared with thymocytes from non-exposed mice (Liu et al. 2010).

Cultured spleen cells from male B10.BR mice exposed to 50 ppm toluene 6 hours/day, 5 days/week for 6 weeks in inhalation chambers showed significantly enhanced LPS-stimulated proliferation in normal mice and decreased LPS-stimulated proliferation in allergy-challenged, compared with spleen cells from B10.BR mice exposed to 0 or 5 ppm toluene (Fujimaki et al. 2010). In contrast, cultured spleen cells from normal or allergy-challenged male C57Bl/10 mice exposed to 0, 5, or 50 ppm by the same protocol for 6 weeks showed no significant ($p>0.05$) difference in Con A- or LPS-stimulated proliferation. Spleens from allergy-challenged B10.BR mice exposed to 5 ppm showed significantly increased mRNA levels, compared with controls, for transcription factors Foxp3, STAT5, and STAT6, but no changes in

3. HEALTH EFFECTS

these transcription factors were apparent in spleens from normal or allergy-challenged B10.BR mice exposed to 50 ppm or in normal or allergy-challenged C57Bl/10 mice (Fujimaki et al. 2010).

Levels of hippocampal mRNAs for two neurotrophins and their receptors (NGF, Trk A, BDNF, and Trk B) were significantly ($p < 0.05$) increased in normal male C3H/HeN mice exposed to 500 ppm 6 hours/day, 5 days/week for 6 weeks in inhalation chambers, but not after exposure to 5 or 50 ppm (Win-Shwe et al. 2010a). In allergy-challenged male C3H/HeN mice, hippocampal mRNA levels for NGF were significantly increased at 50 ppm, but not at 5 or 500 ppm. Exposure of normal male BALB/c and C57Bl/10 mice by the same protocol to 5, 50, or 500 ppm did not produce significant ($p > 0.05$) changes in these end points, except for increased mRNA for BDNF in normal BALB/c mice exposed to 500 ppm. The results demonstrate differences among mouse strains in responsiveness of these end points to toluene exposure.

Significantly ($p < 0.05$) increased number of total cells in BAL fluid samples (~50% increased over the non-exposed control value) was observed in allergy-challenged male C3H/HeN mice exposed to 50 ppm toluene 6 hours/day, 5 days/week for 6 weeks, but no significant changes were observed in allergy-challenged mice exposed to 5 or 500 ppm, or to allergy-challenged mice after 3 weeks of exposure to any of the three tested concentrations (5, 50, or 500 ppm; Fujimaki et al. 2011). No significant changes were found in numbers of other cell types found in BAL fluid (macrophages, lymphocytes, neutrophils, eosinophils) at any of the three tested concentrations in allergy-challenged mice after 3 or 6 weeks of exposure. No significant ($p > 0.05$) exposure-related changes in BAL fluid cell counts were noted in normal mice (not allergy-challenged) exposed to 5, 50, or 500 ppm, compared with normal controls. Other effects reported in allergy-challenged mice exposed to 50 ppm included increased hypertrophy and hyperplasia in bronchial epithelium and mucus secretion in lungs without accumulation of alveolar inflammatory cells (incidence data not reported by the study authors) and significantly increased lung levels of fibronectin (35% increased compared with allergy-challenged mice without toluene exposure). These findings were not observed in normal mice exposed to 50 ppm, compared with normal controls. The report did not mention histological findings in lungs of normal or allergy-challenged mice exposed to 5 or 500 ppm. Significantly ($p < 0.05$) increased splenic mRNA levels for immune regulatory transcription factors (STAT3, STAT4, STAT5, STAT6, GATA3, Foxp3, IL-4, and IL-12) were measured in allergy-challenged mice exposed to 50 ppm; mRNA levels for most of these transcription factors in spleens were not significantly different in allergy-challenged mice exposed to 5 or 500 ppm, compared with allergy-challenged mice without toluene exposure. The only significant ($p < 0.05$) change in levels of plasma immunoglobins in exposed allergy-challenged mice was for increased total IgG₁ at 50 ppm (~90%

3. HEALTH EFFECTS

increased); no significant exposure-related changes were found in levels of total IgE, IgG_{2a}, or antigen-specific antibodies (anti-OVA IgE, anti-OVA IgG₁, anti-OVA IgG_{2a}). The authors concluded that although exposure to 50 ppm toluene increased the expression of transcription factors in the spleen and plasma levels of total IgG₁, the overall results “did not show a strong correlation between toluene exposure and exacerbation of allergic responses.”

Yamamoto et al. (2009) examined spleen weight, plasma antibody levels, and splenic mRNA levels for cytokines and transcription factors in PND 21 male mice exposed to 0, 5, or 50 ppm 6 hours/day on GD 14 through PND 21 with or without exposure to peptidoglycan (PGN, a putative suppressor of type 2 humoral allergic responses). Findings for PND 21 mice exposed to toluene without peptidoglycan exposure were:

- increased absolute (29% increased) and relative (24% increase) spleen weight at 50 ppm, compared with mice exposed to 0 or 5 ppm (see Table 3-2);
- significantly decreased plasma levels of IgE and IgG_{2a} antibodies at 50 ppm and significantly increased levels of IgG₁ antibodies at 5 and 50 ppm; and
- significantly decreased splenic mRNA levels for transcription factors T-bet, GATA-3, and Foxp, but no exposure-related changes in splenic mRNA levels of cytokines IFN- γ , IL-12, IL-4, or IL-5.

When the dams and offspring were exposed to PGN several times during gestation and through PND 21, a different pattern of findings emerged in PND 21 male offspring:

- increased absolute ($\geq 32\%$ increase) and relative ($\geq 35\%$ increase) spleen weights in all PGN+toluene groups, compared with 0-ppm toluene alone controls, but no significant differences among the PGN+toluene groups (see Table 3-2);
- no significant differences in IgE levels among PGN+ toluene groups; significantly decreased plasma levels of IgG₁ at PGN+50 ppm and IgG_{2a} at PGN+5 ppm and PGN+50 ppm, compared with PGN+0 ppm controls;
- significantly decreased splenic mRNA levels for Foxp3 at PGN+5 ppm and PGN+50 ppm, compared with PGN+0 ppm, but no exposure-related changes in splenic mRNA levels of cytokines IFN- γ , IL-12, IL-4, IL-5, T-bet or GATA-3 among PGN+toluene groups.

This study found toluene-induced increased spleen weight in offspring exposed to 50 ppm toluene alone, but no apparent response of spleen weight to toluene with co-exposure to PGN, a suppressor of type 2 humoral allergic responses. Mechanistic understanding is insufficient to determine the biological adversity of the observed pattern of changes in plasma immunoglobulins and splenic mRNA levels for transcription factors related to type 1 and type 2 immune responses in the spleen.

3. HEALTH EFFECTS

Table 3-2. Mean Spleen Weight (SE) for PND 21 Mice (n=6/Group) Exposed to Toluene 6 Hours/Day on GD 14 Through PND 21 With and Without Exposure to PGN

Exposure group	Spleen weight (mg)	Relative spleen weight (% spleen: body weight)
0 ppm	74.73 (3.63)	0.81 (0.043)
5 ppm	68.75 (3.10)	0.71 (0.028)
50 ppm	96.40 (5.84) ^a	1.01 (0.054) ^b
0 ppm + PGN	105.03 (5.39) ^b	1.16 (0.055) ^b
5 ppm + PGN	105.68 (3.65) ^a	1.15 (0.037) ^a
50 ppm + PGN	98.62 (5.31)	1.09 (0.058)

^ap<0.01, compared with 5-ppm toluene group, as reported by study authors.

^bp<0.01, compared with 0-ppm toluene group, as reported by study authors.

GD = gestation day; PGN = peptidoglycan; PND = postnatal day; SE = standard error

Source: Yamamoto et al. 2009

3. HEALTH EFFECTS

Win-Shwe et al. (2010b) examined weights of brain, lung, thymus, and spleen, and hippocampal mRNA levels for neurotrophic factors, inflammatory cytokines, astrocyte marker GFAP, microglia marker Iba1, and several other transcription factors in PND 21 male mice exposed to 0, 5, or 50 ppm 6 hours/day on GDs 14–18, PNDs 2–6, or PNDs 8–12. No significant ($p>0.05$) exposure-related changes were found in body weight or weights of brain, lung, thymus, or spleen. Statistically significant changes (compared with nonexposed controls) were reported in hippocampal mRNA levels for the following neuroimmune factors in PND 21 male mice:

- increased NGF at 50 ppm with PND 2–6 exposure and at 5 ppm (but not 50 ppm) with PND 8–12 exposure;
- increased BDNF at 5 and 50 ppm with PND 8–12 exposure;
- increased CCL3 at 5 ppm with PND 8–12 exposure;
- increased TNF- α at 50 ppm with PND 2–6 exposure, and at 5 ppm with PND 8–12 exposure;
- increased GFAP at 5 ppm with PND 8–12 exposure;
- increased Iba1 at 50 ppm with GD 14–18 exposure, and at 5 ppm with PND 8–12 exposure;
- increased HO-1 at 50 ppm with PND 2–6, and 5 ppm with PND 8–12;
- increased TLR4 at 5 ppm with PND 8–12 exposure; and
- increased NF- κ B at 50 ppm with PND 2–6, and at 5 and 50 ppm with PND 8–12 exposure.

Most of the examined neuroimmune factors were upregulated at 5 ppm (but not 50 ppm) with PND 8–12 exposure. Of the 10 factors examined, only one (CCL2) was not upregulated. It is unclear why exposure to 50 ppm in this period did not upregulate most of the factors upregulated by 5 ppm with PND 8–12 exposure. Exposure during GDs 14–18 upregulated only GFAP at 5 ppm and Iba1 at 50 ppm, whereas exposure during PNDs 2–6 upregulated only NGF, TNF- α , HO-1, and NF- κ B at 50 ppm.

Win-Shwe et al. (2012a) examined lung, spleen, and thymus weights, plasma levels of antibodies, percentage distribution of splenic T lymphocytes, and splenic mRNA levels for inflammatory cytokines and transcription factors in PND 21 male mice exposed to 0, 5, or 50 ppm 6 hours/day on GDs 14–18, PNDs 2–6, or PNDs 8–12. The only significant ($p<0.05$) exposure-related changes found in body weight or weights of thymus, left lung, or spleen were decreased weight of thymus and spleen at 5 ppm (but not 50 ppm) with PND 8–12 exposure. The magnitudes of these decreases were not reported. Statistically significant changes ($p<0.05$, compared with nonexposed controls) reported in blood and splenic immune system end points in PND 21 male mice included:

3. HEALTH EFFECTS

- decreased plasma levels of total IgG2a antibodies at 5 ppm (but not 50 ppm) with PND 2–6 exposure, and increased levels at 5 ppm (but not 50 ppm) with PND 8–12 exposure;
- decreased plasma levels of total IgG1 antibody at 5 and 50 ppm with GDs 14–18 and PND 8–12 exposure, and at 50 ppm with PND 2–6 exposure;
- decreased percentage CD+4 splenic T lymphocytes at 50 ppm with PND 2–6 and 8–12 exposure;
- decreased percentage CD8+ T lymphocytes at 50 ppm with PND 8–12 exposure;
- decreased IL-12 mRNA levels in spleen at 5 and 50 ppm with PNDs 2–6 and 8–12 exposure; and
- decreased T-bet and Foxp3 mRNA levels in spleen at 5 and 50 ppm with PND 2–6 and 8–12 exposure.

No significant exposure-related changes were found in IFN- γ or GATA3 mRNA levels in spleen.

Exposure during PNDs 8–12 produced changes in a greater number of examined end points in PND 21 mice than exposure during GDs 14–18 (decreased plasma total IgG1 at 5 and 50 ppm) or PNDs 2–6 (decreased IgG2a antibodies, IgG1 antibodies, and percentage of CD+4 lymphocytes in spleen at 5 ppm, and decreased splenic IL-12, T-bet, and Foxp3 mRNA at 5 and 50 ppm) (Win-Shwe et al. 2012a). End points modulated with PND 8–12 exposure were:

- decreased thymus and spleen weight at 5 ppm;
- increased IgG2a antibodies at 5 ppm;
- decreased plasma IgG1 antibodies and decreased splenic mRNA levels for IL-12, T-bet, and Foxp3 at 5 and 50 ppm; and
- decreased percentage of CD+4 and CD8+ lymphocytes in the spleen at 50 ppm.

Following the same gestational and postnatal exposure protocol, mRNA levels of neurotrophic factors (NGF, BDNF), pro-inflammatory cytokines (CCL2, CCL3, TNF- α), NGF transcription factor NF- κ B, neurogenesis modulator toll-like receptor 4 (TLR4), oxidative stress marker HO-1, astrocyte marker GFAP, and microglia marker Iba-1 were determined in the hippocampus of offspring on PND 21 (Win-Shwe et al. 2012b). Significantly increased mRNA levels (~133-600%) were reported for NGF, BDNF, TNF- α , CCL3, NF- κ B, TLR4, GFAP, Iba-1, and HO-1 in the 5 ppm group exposed from PND 8 to 12, NGF, TNF- α , NF- κ B, and HO-1 in the 50 ppm group exposed from PND 2 to 6, and NF- κ B in the 50 ppm group exposed from PND 8 to 12. No mRNA alterations were observed with exposure from GD 14 to 18, compared with controls. No changes were found in neonatal body weight or relative organ weights of the brain, thymus, lung, or spleen at any exposure in this study.

3. HEALTH EFFECTS

3.2.1.4 Neurological Effects

Overview. Dysfunction of the central nervous system is a critical human health concern following acute, intermediate, or chronic inhalation exposure to toluene. Chronic toluene abuse in humans has been associated with neurotoxic symptoms, narcosis, permanent damage to the central nervous system, and death (Aydin et al. 2002, 2003; Byrne et al. 1991; Caldemeyer et al. 1996; Camarra-Lemarroy et al. 2015; Capron and Logan 2009; Deleu and Hanssens 2000; Devathanan et al. 1984; Filley et al. 1990; Ryu et al. 1998; Gupta et al. 2011; Hormes et al. 1986; Hunnewell and Miller 1998; Ikeda and Tsukagoshi 1990; Kamran and Bakshi 1998; King et al. 1981; Kiyokawa et al. 1999; Kucuk et al. 2000; Maas et al. 1991; Maruff et al. 1998; Meulenbelt et al. 1990; Miyagi et al. 1999; Nomura et al. 2016; Papageorgiou et al. 2009; Poblano et al. 1996; Rosenberg et al. 1988a, 1988b, 2002; Ryu et al. 1998; Suzuki et al. 1983; Uchino et al. 2002; Yamanouchi et al. 1995). Self-reported neurological symptoms, reduced ability in tests of cognitive and neuromuscular function, and hearing and color vision loss have been observed in humans occupationally exposed to average concentrations of toluene ranging from 35 to 200 ppm (Abbate et al. 1993; Boey et al. 1997; Campagna et al. 2001; Cavalleri et al. 2000; Eller et al. 1999; Foo et al. 1990; Guzelian et al. 1988; Kang et al. 2005; Matsushita et al. 1975; Orbaek and Nise 1989; Ukai et al. 1993; Yin et al. 1987; Vrca et al. 1995, 1996, 1997a, 1997b; Zavalic et al. 1998a, 1998b, 1998c); several occupational studies identify NOAELs for these effects in the range of 20–187 ppm toluene (Deschamps et al. 2001; Gericke et al. 2001; Kang et al. 2005; Nakatsuka et al. 1992; Neubert et al. 2001; Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002). Performance deficits in tests of neurobehavior have also been observed in volunteers acutely exposed to controlled concentrations >50 ppm (Andersen et al. 1983; Baelum et al. 1985; Dick et al. 1984; Echeverria et al. 1991; Kobald et al. 2015; Rahill et al. 1996; von Oettingen et al. 1942).

Numerous studies in animals have also reported clinical signs of neurotoxicity and neurobehavioral alterations following acute exposure ≥ 100 ppm (Bowen and Balster 1998; Bushnell et al. 1985; Conti et al. 2012; Hogue et al. 2009; Huerta-Rivas et al. 2012; Kim et al. 1998; Kishi et al. 1988; Lopez-Rubalcava and Cruz 2000; Mullin and Krivanek 1982; Paez-Martinez et al. 2003, 2008; Taylor and Evans 1985; Tomaszewski et al. 2013; Wood and Colotla 1990; Wood et al. 1983); however, studies of rodents exposed for intermediate durations to concentrations as high as 1,000 ppm have not found strong and consistent evidence for exposure-related changes for these neurological endpoints (API 1997; Beasley et al. 2010, 2012; Miyagawa et al. 1995; NTP 1990; Rogers et al. 1999; Tahti et al. 1983; von Euler et al. 2000; von Oettingen et al. 1942; Win-Shwe et al. 2010c, 2010d; Wood and Cox 1995). Following repeated abuse-

3. HEALTH EFFECTS

like exposures ($>1,000$ ppm), neurobehavioral alterations have been observed in several animal studies (Baydas et al. 2005; Bikashvili et al. 2012; Bowen et al. 2007; Castilla-Serna et al. 1991; Dashiniani et al. 2014; Duncan et al. 2012; Lorenzana-Jimenez and Salas 1990; Mattsson et al. 1990; Miyagawa et al. 1998; Oshiro et al. 2007; Pryor 1991; Pryor and Rebert 1992). Hearing loss has also been reported in laboratory animals exposed to 250–2,000 ppm toluene (Campo et al. 1997, 1998; Davis et al. 2002; Johnson 1992; Johnson and Canlon 1994; Johnson et al. 1988; Lataye and Campo 1997; McWilliams et al. 2000; Pryor and Rebert 1992; Pryor et al. 1984a, 1984b, 1991; Waniusiow et al. 2008, 2009).

Controlled Human Exposures

Overview. Acute exposure of healthy human subjects to toluene concentrations ≤ 50 ppm did not result in adverse neurological effects in a number of studies (Andersen et al. 1983; Lammers et al. 2005a; Muttray et al. 2005; Osterberg et al. 2000, 2003), and concentrations ≥ 75 ppm resulted in subtle neurological impairments in most studies (Andersen et al. 1983; Baelum et al. 1985; Dick et al. 1984; Echeverria et al. 1991; Gamberale and Hultengren 1972; Kobald et al. 2015; Rahill et al. 1996; von Oettingen et al. 1942). In contrast, studies examining individuals who were clinically sensitive to toluene (e.g., multiple chemical sensitivities) found minor neurological deficits at concentrations as low as 12–48 ppm (Little et al. 1999; Orbaek et al. 1998; Osterberg et al. 2003).

Healthy Volunteers. No significant, dose-related increases in subjective complaints of neurological effects and/or altered performance on neurobehavioral tasks were observed in a number of studies of healthy volunteers following exposure to toluene concentrations of 10–50 ppm for 2–6 hours (Andersen et al. 1983; Muttray et al. 2005; Osterberg et al. 2000, 2003). Similarly, 11 males exposed to 40 ppm toluene for 4 hours did not attain impaired scores on six neurobehavioral measures designed to assess mood, cognitive and motor functions, compared with pre-exposure scores (Lammers et al. 2005a). However, blood toluene levels, measured at 60, 120, 240, and 360 minutes after onset of exposure, were significantly associated with impaired performance on one motor performance test (finger tapping with alternating hands). Similar results were observed when the same 11 males were exposed to 110 ppm for four 30-minute exposures over 4 hours, 1 week later (Lammers et al. 2005a). Since blood toluene levels were only correlated with 1/6 neurobehavioral measures, and there were no significant differences between pre- and post-exposure scores, 40 ppm for 4 hours and 110 ppm for four 30-minute exposures are considered NOAELs for neurological effects. In other studies, volunteers exposed to 80 ppm toluene for 4 hours did not demonstrate impairments in choice reaction time, simple reaction time, color-word vigilance, or memory reproduction (Iregren et al. 1986; Olson et al. 1985).

3. HEALTH EFFECTS

In repeat-measure experiments, increased subjective complaints and deficits in neurological effects were observed between 75 and 200 ppm after exposure for 7–8 hours (Andersen et al. 1983; Echeverria et al. 1991; von Oettingen et al. 1942) and 300 ppm toluene after exposure for 20 minutes (Gamberale and Hultengren 1972). Concentration-related impairments were observed during the digit span, pattern recognition, pattern memory, and one-hole tests in 42 volunteers exposed to 0, 75, and 150 ppm toluene for 7 hours on sequential days, compared with their own pre-exposure measures (Echeverria et al. 1991). There were no exposure-related changes in the results on simple reaction time, mood (profile on mood scale), visual memory, hand-eye coordination, verbal short-term memory, finger tapping, reaction time, continuous performance test, or critical tracking test (Echeverria et al. 1991). Sixteen volunteers exposed to 0, 10, 40, and 100 ppm toluene for 6 hours on sequential days reported a statistically significant increase in the occurrence of headache, dizziness, and feeling of intoxication during the 100 ppm exposure, but not during the other concentrations (Andersen et al. 1983). Statistically significant exposure-related deficits were not observed in any of the eight performance tests designed to assess concentration, vigilance, motor coordination, visual perception, and cognitive function. However, for three of the tests (screw-plate [motor coordination], Landolt's ring [visual perception], and multiplication), there was a borderline significant deficit associated with toluene exposure ($p=0.05-0.1$), and the subjects felt that the tests were more difficult and strenuous during the 100 ppm exposure (Andersen et al. 1983). Following acute exposures to toluene at concentrations of 0, 50, 100, 200, 400, and 600 ppm for 8 hours and 800 ppm for 3 hours on subsequent days, three volunteers reported drowsiness and headache at 200 ppm that became more severe with exposure duration and at higher concentrations, characterized by impaired intellectual, psychomotor, and neuromuscular effects (von Oettingen et al. 1942). Concentration-dependent increases in simple and choice reaction times were measured in 12 volunteers exposed to increasing concentrations of toluene at 0, 100, 300, 500, and 700 ppm for 20-minute intervals (Gamberale and Hultengren 1972). Compared with 0 ppm values, these increases were significant at 300 ppm. Perception speed was also impaired, but not significantly different from 0 ppm values until exposure to concentrations of 700 ppm (Gamberale and Hultengren 1972).

Single-measure studies consistently report impaired performance on neurobehavioral tasks following exposure to 100 ppm for 6–8 hours (Baelum et al. 1985; Dick et al. 1984; Rahill et al. 1996). Forty-three solvent-exposed printers and 43 referents without history of exposure were exposed to 0 or 100 ppm toluene for 6.5 hours (Baelum et al. 1985). Within each group (printers and referents), about half of subjects were exposed to 100 ppm and the other half were exposed to normal air. Both printers and referents exposed to 100 ppm had increased complaints of fatigue, sleepiness, and feelings of

3. HEALTH EFFECTS

intoxication, compared with mean values for unexposed control subjects. Both exposed groups also showed significant decreases in manual dexterity (peg-board task), visual perception (Landolt's ring test), and color discrimination, compared with control values. No consistent differences were observed in neurobehavioral performance between exposed printers and exposed referents (Baelum et al. 1985). Six volunteers exposed to 100 ppm toluene for 6 hours, followed by exercise, showed significantly lower results on neuropsychological tests than volunteers exposed to clean air only (Rahill et al. 1996). Additionally, exposure to 100 ppm for 8 hours led to impaired performance on the visual-vigilance task, but not choice-reaction time or pattern recognition, compared with unexposed controls (Dick et al. 1984).

Additionally, volunteers exposed to a peak exposure of 200 ppm showed impaired performance in a visual attention task when an irrelevant distractor was given (compared with pre-exposure performance); the peak exposure condition was obtained by slowly flooding the exposure chamber with toluene starting at a concentration of 0 ppm until the peak exposure of 200 ppm was obtained at 25 minutes and held constant for an additional 15 minutes (40-minute exposure) (Kobald et al. 2015). This visual attention deficit was accompanied by a significant decrease in the N1 component of the event-related potential (ERP) measured in the parieto-occipital lobe via EEG (Kobald et al. 2015).

Susceptible Populations. Individuals with multiple chemical sensitivity or toxic encephalopathy had significantly higher self-reported scores of fatigue (headache, drowsiness, decreased concentration) during exposure to increasing toluene concentrations over 2 hours (0 ppm [20 minutes], 3 ppm [10 minutes], 6 ppm [10 minutes], 12 ppm [20 minutes], 24 ppm [10 minutes], 48 ppm [20 minutes], and 0 ppm [10 minutes]), compared with healthy referents (Orbaek et al. 1998; Osterberg et al. 2003). During these studies, psychomotor tests were performed before exposure and during the 12- and 48-ppm exposure periods. Both healthy referents and individuals with multiple chemical sensitivity showed increased response time in the reaction-time test (visual stimuli) following exposure, compared with pre-exposure scores (Osterberg et al. 2003). However, the increase was not dose-related in healthy individuals, and exposure-related impairments were not observed in the reaction time-inhibition test (with auditory alarm) or digit symbol test in either group (Osterberg et al. 2003). In a companion study, there were no observed psychomotor impairments in exposed individuals with toxic encephalopathy or healthy referents using the same protocol (Osterberg et al. 2000). A LOAEL of 48 ppm for the studies conducted by Orbaek et al. (1998) and Osterberg et al. (2003) was determined for susceptible individuals based on increased self-reported fatigue. A NOAEL could not be determined, as fatigue scores were not reported at individual exposure concentrations.

3. HEALTH EFFECTS

Little et al. (1999) reported that 20 subjects who were clinically sensitive to toluene showed statistically significant impairments in immediate and delayed prose memory (number of items recalled decreased 31%), the digit symbol test (number of correct items decreased 11%), and the letter cancellation test (percent correct decreased 5%) following a 15-minute exposure to 15 ppm toluene, compared with their pre-exposure scores. A near-significant 15% increase in reaction time was also observed ($p=0.06$). No significant differences between pre- and post-exposure values were found for focal length or the STROOP tests. An acute inhalation MRL of 2 ppm was calculated as described in the footnote in Table 3-1 and Appendix A, based on the minimally adverse LOAEL (15 ppm) for neurological effects in susceptible populations from the study by Little et al. (1999).

The highest NOAEL values and all LOAEL values for each reliable controlled human exposure study for neurological effects are recorded in Table 3-1 and plotted in Figure 3-1.

Occupational Exposure Human Studies

Overview. Several studies of workers repeatedly exposed predominantly to toluene in workplace air at concentrations ranging from 35 to 200 ppm have found evidence for increased incidence of self-reported neurological symptoms (Guzelian et al. 1988; Matsushita et al. 1975; Orbaek and Nise 1989; Ukai et al. 1993; Yin et al. 1987); performance deficits in neurobehavioral tests (Boey et al. 1997; Eller et al. 1999; Foo et al. 1990; Kang et al. 2005; Matsushita et al. 1975; Orbaek and Nise 1989); hearing loss (Morata et al. 1997); changes in auditory-evoked potentials and/or VEPs (Abbate et al. 1993; Vrca et al. 1995, 1996, 1997a, 1997b), and color vision loss (Campagna et al. 2001; Cavalleri et al. 2000; Zavalic et al. 1998a, 1998b, 1998c). Several occupational studies identify NOAELs for these effects in the range of 20–187 ppm toluene (Deschamps et al. 2001; Gericke et al. 2001; Kang et al. 2005; Nakatsuka et al. 1992; Neubert et al. 2001; Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanec et al. 2002). A series of studies investigating a number of neurological end points in German rotogravure printers support a NOAEL of 45 ppm (Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanec et al. 2002), and served as the basis for the chronic-duration inhalation MRL of 1 ppm for toluene (see footnote of Table 3-1, Section 2.3 and Appendix A).

Neurobehavioral Effects and Self-Reported Neurological Symptoms. The majority of studies show that workers (e.g., rotogravure printers) with long-term occupational exposure to toluene at concentrations <50 ppm did not report increased neurological symptoms or show impaired overall performance on neuropsychological or psychomotor tests (Eller et al. 1999; Gericke et al. 2001; Kang et al. 2005; Neubert

3. HEALTH EFFECTS

et al. 2001; Seeber et al. 2004, 2005; Zupanic et al. 2002). One study of 89 rotogravure and offset printers exposed to toluene for an average of 14 years reported a statistically significant correlation between current exposure levels (0–27 ppm) and impaired performance for the digit span memory test after adjustment for sex, age, synonym score, history of central nervous system diseases, alcohol consumption, psycho-active drug consumption in the last day, concentration in performing tests, and computer experiments (Chouanière et al. 2002). However, no significant association was observed between current exposure levels and scores for three other memory tasks (associate learning, associate recall, pattern memory), simple reaction time tests, symbol digit substitution tests, or self-reported neurotoxic symptoms. Using work history and historical exposure levels (0–179 ppm), a cumulative exposure index for toluene exposure was calculated for each individual (0–2,353 ppm-years [mean 392 ppm-years]). There were no significant correlations between cumulative exposure indices and performance on any psychomotor task or self-reported neurotoxic symptoms (Chouanière et al. 2002). Since current exposure levels were only correlated with 1/6 neurobehavioral measures, and there were no correlations between cumulative exposure indices and performance in any of the tests, 27 ppm is considered an occupational NOAEL for neurological effects.

In contrast, the majority of studies with average exposure estimates in the range of 70–100 ppm reported subtle, but statistically significant, performance deficits in neurobehavioral and psychomotor tests (Boey et al. 1997; Eller et al. 1999; Foo et al. 1990; Kang et al. 2005). Twenty workers from oil refinery, gravure printing, and rubber boat manufacturing exposed to 70–80 ppm toluene had significant impairments on the finger tapping and selective attention tests and nonsignificant impairments in the digit span backward test, compared with 21 referent workers with exposure <10 ppm (Kang et al. 2005). However, 30 workers exposed to 10–30 ppm toluene did not differ from the referent group (Kang et al. 2005). Based on these findings, NOAEL and LOAEL levels were estimated at 20 and 75 ppm, respectively. Abnormal tendon reflexes, decreased grasping power and agility of fingers, and generalized weakness were significantly decreased in 38 female shoemakers who were exposed to toluene concentrations that varied from 65 ppm (15–100 ppm) in winter to 100 ppm (10–200 ppm) in summer for an average of 40 months, compared with 16 controls (Matsushita et al. 1975). The LOAEL for neurological effects is estimated at 83 ppm (the average between summer and winter exposures). A strong correlation between impaired neurobehavioral performance and toluene exposure was seen in 30 female workers exposed to 88 ppm toluene, compared with 30 workers in the same facility exposed to only 13 ppm (Foo et al. 1990). The higher exposure group received poorer test scores in tests of visual retention, visual reproduction, trail making, grooved peg board, digit span, and digit symbol, but not on tests of simple reaction time and finger tapping. Another group of 29 exposed workers in Singapore

3. HEALTH EFFECTS

(average TWA toluene exposure of 90.9 ppm) showed performance deficits on eight neurobehavioral tests, compared with a control group (average TWA exposure of 12.2 ppm). The exposed group showed significantly impaired verbal and nonverbal memory, compared with controls, as measured by the digit span and visual reproduction tests (Boey et al. 1997). Similarly, statistically significant impairments in tests for visuospatial function, number learning, and word recognition were observed in 49 rotogravure workers exposed to <20 ppm for 12 years plus >100 ppm for 4–27 years, compared with 19 referents (Eller et al. 1999). Thirty workers in the same plant only exposed to <20 ppm for 1–12 years did not differ from the referent group. Reported exposure level information was inadequate to determine NOAEL/LOAEL levels.

Increased self-reporting of neurological symptoms has also been associated with occupational toluene exposure at concentrations ≥ 40 ppm (Guzelian et al. 1988; Orbaek and Nise 1989; Ukai et al. 1993; Yin et al. 1997). Forty-four men and 57 women exposed to TWA concentrations of 46 and 41 ppm toluene, respectively, during shoemaking, printing, and audio equipment production had increased complaints of headaches, dizziness, and sleep difficulties, compared with 127 control subjects (Yin et al. 1987). Increased subjective complaints of neurological symptoms both during and after work was reported in a group of 452 workers exposed predominantly to toluene (geometric mean 24.7 ppm) compared with 517 unexposed referents (Ukai et al. 1993). Statistically ($p < 0.01$) increased complaints during work included headache and floating sensation, and statistically increased complaints regarding symptoms outside work over the past 3 months included inability to concentrate, hearing loss, speech difficulties, anosmia, and reduced strength. When exposed workers were analyzed by toluene exposure levels (1–20, 21–50, 51–100, and >100 ppm), workers exposed to >100 and >50 ppm demonstrated significantly increased subjective complaints during and after work, respectively, compared with workers exposed to 1–20 ppm (Ukai et al. 1993). No increase in complaints was observed between the groups exposed to 1–20 and 21–50 ppm. The NOAEL and LOAEL values for increased self-reported neurological symptoms were determined to be 36 and 75 ppm for this assessment, based on the midpoints of the 21–50 and 51–100 ppm group (Ukai et al. 1993). Workers in a printing factory (exposed to <200 ppm toluene) returning to work after a 4-day vacation reported a feeling of mild intoxication to which they became tolerant within 1 or 2 days (Guzelian et al. 1988).

Complaints of fatigue, recent short-term memory problems, concentration difficulties, and mood lability were significantly ($p < 0.05$) increased in 30 rotogravure printers exposed to 11.6–453 ppm toluene for 4–43 years in two plants; taking the midpoints in the ranges of concentration estimates, a representative exposure concentration of 140 ppm was determined (Orbaek and Nise 1989). However, no significant

3. HEALTH EFFECTS

impairments were found between printers and controls in a battery of psychometric tests. In a 20-year follow-up of 12 printers and 19 controls from the cohort, there was no longer any significant ($p>0.05$) differences in incidences of reported subjective neurological symptoms (Nordling Nilson et al. 2010). In follow-up psychometric testing, the general performance deteriorated in 10/11 tests measured in both groups, compared with the initial assessments. In two measures (reasoning and associative learning), the deterioration in the exposed group was significantly greater than the referents. When the results of the 20-year follow-up were compared between the groups, the exposed group performed significantly worse on 2/11 tests (verbal memory and sustained attention). Taken together, these two studies indicate a LOAEL of 140 ppm for increased incidence of self-reported neurological symptoms in the initial assessment and statistically significant performance deficits on neurobehavioral tests during the 20-year follow-up study.

Consistent with the data presented above, a meta-analysis of the findings from studies of workers predominantly exposed to toluene concluded that occupational toluene exposure has a negative impact on neurobehavior at exposure concentrations >89 ppm (Meyer-Baron 2005). However, one study included in the meta-analysis reported no alterations in subjective neurological complaints or performance in neurobehavioral tests in 26 printer factory workers, 10 machine factory workers, and 36 laboratory workers who were exposed exclusively to toluene for at least 5 years (average 19.9 years), compared with 61 unexposed workers (Deschamps et al. 2001). Toluene air concentrations, measured by personal air monitoring over an entire work-shift, ranged from 9 to 83 ppm in the factories and from 184 to 467 ppm in the laboratories; however, the two groups were combined for analysis. Since neurological evaluations were conducted after 2 days without exposure (toluene in expired air <0.3 ppm), the lack of observed effects may indicate that impaired neurological effects do not persist after the solvent is eliminated from the body. Since the exposed groups were analyzed together, the NOAEL for this assessment is determined to be the average of the midpoints of the exposed ranges (midpoint factory, 46 ppm; midpoint laboratory, 325.5 ppm; average, 186 ppm).

A number of studies of humans chronically exposed to mixtures of solvents containing toluene provide supporting evidence for toluene-mediated general neurological and neurobehavioral effects, but concurrent exposure to other solvents limits the conclusions that can be drawn from the results. Impaired performance on multiple tasks measuring visual intelligence, cognition, memory, and perception were observed in 100 car painters exposed to mixed solvents including toluene, xylene, and various aliphatic hydrocarbons, alcohols, esters, ketones, and terpenes for 1–40 years, compared with 101 unexposed railway workers (Hanninen et al. 1976). In a group of 325 paint factory workers exposed to benzene,

3. HEALTH EFFECTS

toluene, xylene, n-hexane, methyl iso-butyl ketone, n-butyl acetate, and acetone for an average of 5 years, reduced ability in pattern comparison and memory tasks was correlated with combined solvent exposure (Tsai et al. 1997). A significant reduction in the Santa Ana dexterity test and a nonsignificant reduction in visual retention were observed in 40 female shoemakers exposed to toluene, methyl ethyl ketone, n-hexane, cyclohexane, dichloroethylene, trichloroethylene, benzene, and xylene, compared with 28 unexposed referents (Lee et al. 1998a). Self-reported neurological symptoms (headache, sweating, palpitation, lethargy, fatigue, nausea, vomiting, etc.) were increased in 92 paint manufacturers from two factories in eastern Thailand exposed to xylene (0.1–13.1 ppm) and toluene (0.5–48.7 ppm), compared with a referent group of 100 frozen food factory workers (Thetkathuek et al. 2015). Self-reported neurological symptoms were also increased in lacquer-ware manufacturers exposed to toluene, butyl-acetate, and ethyl-acetate, compared with nine unexposed referents (Tanaka et al. 2003). Similarly, increased self-reported neurological symptoms were significantly associated with a “solvent summation index” in 637 printers exposed to one or more of the following solvents: toluene (0–90.9 ppm), n-hexane (0.12–94.5 ppm), benzene (0–8.8 ppm), and isopropyl alcohol (0–374 ppm), compared with 125 unexposed referents (Yu et al. 2004). However, self-reported neurological symptoms in a furniture factory were not increased in painters/varnishers exposed to toluene, benzene, and xylene compared to unexposed referents (Mandiracioglu et al. 2011). A case-study of a worker exposed to paint thinner (containing 60% toluene; other solvents present included xylene, ethyl acetate, and butyl acetate) for 5 years in an unventilated workspace reports chronic headache, encephalitis, and white matter lesions; however, no neurological deficits were observed during a clinical exam (Kobayashi 2014). Another neurological effect reported with occupational mixed solvent exposure is increased postural sway in U.S. Air Force workers exposed to jet fuel (mean cumulative exposure 23.8 ppm toluene) (Smith et al. 1997).

Auditory System Effects

Overview. The limited number of occupational studies assessing hearing loss suggest that effects may occur at exposure concentrations >50 ppm, consistent with findings for other neurological end points. One occupational study indicated that exposure to an average of 122 ppm toluene may lead to hearing deficits (Morata et al. 1997), and altered brainstem auditory-evoked potential (BAEP) have also been reported following occupational exposure to 50–100 ppm (Abbate et al. 1993; Vrca et al. 1996, 1997a). However, no evidence for hearing loss was found in workers exposed to 45 ppm (Schäper et al. 2003, 2008). Hearing loss produced by toluene exposure may not be due solely to neurological damage, as animal studies indicate that solvent exposure damaged the OHCs in the cochlea that are responsible for amplifying incoming sound waves prior to signal transduction (Campo et al. 1997, 1998; Johnson and

3. HEALTH EFFECTS

Canlon 1994; Lataye and Campo 1997; Lataye et al. 1999; Waniusiow et al. 2008). However, a battery of audiological tests performed for a case-series report indicated that hearing loss observed in seven workers exposed to toluene and/or xylene was due to retrocochlear or central abnormalities, rather than cochlear damage (Gopal 2008).

Hearing Loss. In a cross-sectional examination of 124 Brazilian workers exposed to various levels of noise and a variety of organic solvents, including toluene at TWA concentrations ranging from 0.037 to 244 ppm, (midpoint=122 ppm), 49% of workers experienced hearing loss (Morata et al. 1997). Toluene exposure (and exposure to a number of other solvents including ethanol and ethyl acetate) was estimated by personal monitoring and measurement of hippuric acid in urine samples. Confidence in the study is limited because of exposure to multiple solvents and possible confounding from noise exposure. However, logistic regression analysis showed hippuric acid concentration to be significantly associated with hearing loss and the OR estimates for hearing loss were 1.76 times greater for each gram of hippuric acid per gram creatinine (95% CI 1.00–2.98).

Schäper et al. (2003, 2008) found no evidence of hearing loss in a longitudinal 5-year study in rotogravure printers exposed to TWA levels of 45 ppm (n=181), compared with a low-exposure group of end-process workers exposed to TWA levels of 10 ppm (n=152). Both groups had average noise exposure levels of 82 dB(A). Additionally, a stepwise regression analysis of a subgroup of 80 workers with toluene exposure ranging from 1 to 69 ppm for 3–38 years did not find a correlation between hearing loss and toluene exposure levels, urinary hippuric acid concentration, or length of employment (Schäper et al. 2003, 2008).

Multiple studies of humans chronically exposed to mixtures of solvents containing toluene provide supporting evidence for toluene-mediated hearing loss, but concurrent exposure to other solvents limits the conclusions that can be drawn about toluene toxicity. Reduced upper limit of hearing was observed in workers currently exposed to styrene, toluene, and methanol for at least 5 years during the production of plastic buttons or bathtubs (Morioka et al. 1999). In a large study of 1,319 aluminum workers, multivariate analysis identified exposure to solvents (toluene, xylene, and methyl ethyl ketone) as a risk factor for high-frequency hearing loss (Rabinowitz et al. 2008). High-frequency hearing loss was also associated with cumulative total solvent exposure in paint and varnish workers exposed to ethylbenzene, xylene, trimethylbenzene, and toluene (Sulkowski et al. 2002). Similarly, paint and lacquer workers exposed to solvent mixtures including toluene had increased incidences of hearing loss, compared to unexposed controls (Juárez-Pérez et al. 2014; Zamysłowska-Szmythke et al. 2011). Workers from

3. HEALTH EFFECTS

various industries exposed to a mixture of *n*-hexane and toluene and noise demonstrated increased mean hearing thresholds, compared with workers exposed to noise-only and unexposed referents (Sliwinska-Kowalska et al. 2005). Further analysis showed that workers exposed to the mixture of *n*-hexane and toluene and noise had a 5.3-fold increased risk of developing hearing loss (single hearing threshold in either ear exceeding 25 dB HL) compared with unexposed referents, after adjusting for age, gender, and noise exposure. A group of workers exposed to mixed solvents (white spirits, thinner, toluene, and xylene) who were admitted to the hospital due to suspicion of solvent-induced chronic toxic encephalopathy had reduced scores in tests of distorted speech and cortical response audiometry compared to unexposed controls (Niklasson et al. 1998).

BAEPs. Studies reporting altered BAEP following occupational exposure provide supporting evidence that toluene exposure may lead to hearing loss. Occupational exposure to an average of 97 ppm toluene for 12–14 years had an apparent effect on hearing in 40 rotogravure workers when BAEP results were compared to a group of 40 workers who were of comparable age but were not exposed to toluene (Abbate et al. 1993). Workers were carefully screened to eliminate slight hearing abnormalities or exposure to other chemicals. Two series of stimuli were used, one with 11 repetitions/second and one with 90 repetitions/second. In both cases the intensity was 80 dB/nHL. Mean latencies were significantly higher for the exposed group than the control group for each BAEP wave evaluated (I, III, and V). Discernment mean values for the exposed and control groups were distributed homogeneously with very little overlap of exposed and control responses for both the 11-repetition and 90-repetition cycles. Wave I showed the most pronounced increase in latency. According to the authors, the effects on Wave I could be due to either a change in the membrane of the peripheral receptor, a modification of the structure of the junction, or a change in the stimulus transduction mechanism.

In another study, BAEPs in 49 printers exposed to toluene for an average 20 years were found to be affected, with a significant decrease in all wave amplitudes and a significant increase in all wave latencies, compared with 59 unexposed referents (Vrca et al. 1996). Average toluene blood levels in printers and controls were 0.036 and 0.00096 mg/L, respectively. Based on blood levels, companion studies estimated averaged toluene exposure levels to be between 40 and 60 ppm (Vrca et al. 1995, 1997a). In the 49 exposed printers, increased wave latencies were significantly correlated with increased duration of exposure, except for the P2 wave (Vrca et al. 1997a).

Additionally, BAEPs in 77 paint factory workers exposed to a mixture of 14 solvents (including toluene) for an average of 10 years were found to be affected, with differences observed between right and left ear

3. HEALTH EFFECTS

mean latencies in waves I, III, and V and intervals I-V, I-III, and III-V, compared with 84 unexposed referents (Juárez-Pérez et al. 2014). Multiple linear regression models for waves and interpeak interval latencies for both ears showed a significant increase in latencies in the exposed group. The TWA median toluene exposure was 3.5 ppm and industrial noise was <85 dBA; however, concurrent exposure to other solvents limits the conclusions that can be drawn about toluene toxicity from this study.

Visual System Effects

Overview. Occupational studies indicate that long-term exposure to toluene may result in color vision loss (Campagna et al. 2001; Cavalleri et al. 2000; Muttray et al. 1997; Zavalic et al. 1998a, 1998b, 1998c) and altered VEPs (Vrca et al. 1995, 1997a, 1997b). However, it is not clear whether the impairment of color vision produced by toluene exposure is due solely to neurological damage or also involves damage to other parts of the eye. Toluene exposure causes eye irritation in humans (Andersen et al. 1983; Baelum 1990; Carpenter et al. 1944; Meulenbelt et al. 1990) and animals (Ono et al. 1996, 1999), but no studies examining the eyes for structural damage following chronic toluene exposure were located.

Color Vision. Multiple studies indicate that long-term occupational exposure to toluene can cause color vision loss. The color confusion index (CCI) was statistically significantly increased by 14% in 32 printers exposed to geometric mean toluene concentrations of 156 ppm, compared with 83 unexposed controls on Monday morning prior to their work shift (Zavalic et al. 1998a). The CCI in 41 shoemakers exposed to geometric mean toluene concentrations of 35 ppm was not significantly elevated when compared with controls. When alcohol consumers were excluded, the CCI in 27 shoemakers and 10 printers was significantly increased by 4 and 11%, respectively, compared with 36 controls. When adjusted for age and alcohol consumption, CCIs were significantly higher in both shoemakers and printers (adjusted mean CCI values were not reported). Individual adjusted CCIs were significantly correlated with individual exposure estimates (air, blood, or urine) in printers, but not shoemakers. Further analysis of color vision loss in these groups of workers demonstrated that total dychromatopsia (combined incidence of blue-yellow and red-green color confusion [dyschromatopsia type II] and just blue-yellow color confusion [dyschromatopsia III]) was significantly increased in printers, but not shoemakers, compared with unexposed workers, (Zavalic et al. 1998c). Dyschromatopsia type I (red-green color confusion only) was not observed in any exposed or unexposed workers. Taken together, these studies indicate a clear LOAEL of 156 ppm for color vision loss in printers, based on increased CCIs significantly associated with individual estimates of toluene exposure and increased prevalence of dyschromatopsia. A NOAEL of 35 ppm was identified, as it is unclear if the statistically significant

3. HEALTH EFFECTS

findings for increased CCI in the small sample of non-alcohol consuming workers or adjusted CCIs in all workers represents an adverse effect, especially since the magnitude of change was small and individual CCIs in this group were not associated with toluene exposure estimates in the air, blood, or urine.

Statistically significant increases in color confusion and total confusion indices were also reported in 33 toluene-exposed rubber workers, compared with 16 unexposed controls of similar age (Cavalleri et al. 2000). The indices were positively correlated with cumulative toluene exposure indices calculated from urinary toluene levels and duration of employment; however, air concentration levels were not reported.

Additional studies indicate that observed color vision impairments result from chronic, rather than acute, exposure. Color vision was assessed on Monday and Wednesday mornings in 45 male printers exposed to mean concentrations of ~120 ppm toluene (Zavalic et al. 1998b). Compared with unexposed controls, printers demonstrated a statistically significant increase in CCI, but results did not differ between examinations on Monday and Wednesday. Similarly, in 59 male rotogravure workers occupationally exposed to unspecified levels of toluene for periods of 1 month to 36 years (mean of 10 years), results of color vision testing did not differ between the beginning and the end of the workweek (Muttray et al. 1995). A second study compared color vision in eight printers (occupationally exposed to toluene) and eight workers previously unexposed to toluene, before and after cleaning a print machine with toluene (Muttray et al. 1999). The task took 28–41 minutes and involved exposure to 300–362 ppm toluene (1,115–1,358 mg/m³). No impairment in color vision was recorded for either group. However, a comparison of the precleaning performance of the printers with that of a group of matched controls showed a nonsignificant decrease in color vision for the printers, which may indicate a chronic effect of toluene exposure on color vision (Muttray et al. 1999).

In contrast, no alterations were observed in red/green or blue/yellow color vision in 74 workers who were exposed to solvents (primarily [$>90\%$] toluene: 46 ppm geometric mean), compared with 120 age-matched controls from clerical sections of the same factories (Nakatsuka et al. 1992). Likewise, a 5-year longitudinal study in 333 rotogravure workers exposed to “high” or “low” TWA toluene levels of 43 or 9 ppm, respectively, did not find an increase in CCI associated with toluene exposure levels or duration using multiple regression analysis (Schäper et al. 2004). The analysis was adjusted for exposure level and duration, age, eye (right/left), occupational qualification, and examination year.

Color vision impairment has also been reported in humans chronically exposed to mixtures of solvents containing toluene, but concurrent exposure to other solvents limits the conclusions that can be drawn

3. HEALTH EFFECTS

concerning toluene toxicity in these particular studies. Campagna et al. (2001) reported statistically significant increased incidence of dyschromatopsia and increased CCI in 72 printers (high-exposure) and 34 non-printers (ambient exposure) in a French photogravure plant for an average of 18–19 years, compared with 19 unexposed bookbinding workers of similar age from the same town. Geometric means of current toluene exposure levels, past cumulative toluene exposure, and past cumulative hydrocarbon exposure (e.g., toluene, xylene) were 136 mg/m³ (36 ppm), 1,299 mg/m³ x years, and 1,793 mg/m³ x years in printers and 32 mg/m³ (8.5 ppm), 299 mg/m³ x years, and 534 mg/m³ x years in non-printers, respectively. After adjusting for age and alcohol consumption, CCIs were significantly correlated ($p < 0.05$) with current toluene exposure, past cumulative toluene exposure, and past cumulative hydrocarbon exposure (Campagna et al. 2001). Therefore, the significant effects observed may not be attributable specifically to toluene exposure, especially in the ambient-exposure group in which toluene exposure only accounted for 56% of past cumulative hydrocarbon exposure. Similarly, workers exposed to mixed solvents (including toluene, xylene, ethyl benzene, propyl benzene, ethyl toluene, methyl ethyl ketone, methyl isobutyl ketone, and perchloroethylene) during a spraying process showed a significant impairment of color vision with errors of the blue-yellow type, compared with unexposed referents similar in age, consumption of alcohol, and smoking habits (Muttray et al. 1997).

VEPs. Occupational exposure to toluene may also affect VEPs. A series of studies evaluated VEPs (P300, N75, N145, and P100 waves) in printers occupationally exposed to average concentrations of 50 ppm toluene for an average of 20 years and unexposed controls (Vrca et al. 1995, 1997b). There was a significant increase in the number of exposed individuals displaying reduced amplitude of P300R waves and prolonged latency of the accompanying spontaneous wave P300F (Vrca et al. 1997b). The amplitudes of the N75, P100, and N145 waves (Vrca et al. 1995) and the latency of the P100 wave were significantly increased in exposed subjects compared with controls (Vrca et al. 1995). In the exposed printers, wave amplitudes decreased significantly with the duration of exposure (Vrca et al. 1997a).

Visual Perception. Toluene exposure may also alter visual perception; however, the available evidence is limited to one study. The frequency at which individual flickers of light appeared to be a steady light source (flicker fusion frequency) was assessed in a large cohort of 1,290 printers occupationally exposed to toluene for an undefined number of years (Neubert et al. 2001). In a subgroup of 47 workers exposed to toluene concentrations of 70–80 ppm, 4 and 5% decreases in flicker fusion frequency before and after their 6-hour work shift, respectively, were found, compared with 200 unexposed referents. This small decrease was only statistically significant after the acute work-shift exposure. There was no change in flicker fusion frequency in the remaining workers exposed to 4–70 ppm, compared with unexposed

3. HEALTH EFFECTS

referents. From these findings, NOAEL and LOAEL values for impaired visual perception were estimated at 33 and 75 ppm, respectively, based on the midpoint of the exposure ranges for the high- and low-exposure groups.

Nerve Conduction Impairment. There is limited evidence that occupational exposure to toluene may alter nerve conduction in the peripheral and autonomic nervous systems. Murata et al. (1993) compared cardiac autonomic function in printers exposed to 83 ppm airborne toluene for 1–36 years with matched controls. Autonomic function was evaluated from measurements of heart rate, the coefficient of variation in electrocardiographic R-R intervals, the distribution of nerve conduction velocities, and the maximal motor and sensory nerve conduction velocities in the median nerve. Some printers reported subjective symptoms such as fatigue, headache, and irritation. Heart rate was not significantly different in exposed individuals and controls. However, there were statistically significant reductions in electrocardiographic R-R intervals, indicating possible dysfunction of the autonomic nervous system. There was a significant decrease in the motor and sensory conduction velocity in the palm segment of the median nerve in toluene-exposed workers, but there was no significant difference in the distribution of the nerve conductance velocities between exposed and control subjects (Murata et al. 1993).

In support, altered nerve conduction has been observed in workers exposed to solvent mixtures. Compared with unexposed referents, bone glue factory workers exposed to an undefined solvent mixture had an increased incidence of paresthesia and abnormal electromyography readings (Al-Batanony et al. 2012), and paint and lacquer workers exposed to white spirit, toluene, butyl acetate, ethyl acetate, and xylene had altered peripheral nerve conduction (Jovanovic et al. 2004).

The highest NOAEL values and all LOAEL values for each reliable human occupational exposure for neurological effects following exposure predominantly to toluene are recorded in Table 3-1 and plotted in Figure 3-1. Supporting studies reporting neurological effects following exposures to solvent mixtures are not included in Table 3-1.

Accidental and Intentional High-Dose Human Exposure

Humans exposed to high levels of toluene as a result of solvent abuse or industrial accidents have displayed serious central nervous system dysfunction. Accurate exposure data are not available for these individuals, but the concentrations inhaled by chronic abusers have been estimated to range from 4,000 to 12,000 ppm (Gospe et al. 1994). In some cases, the degree of central nervous system depression was

3. HEALTH EFFECTS

sufficient to result in death. Prolonged abuse has been reported to cause permanent damage resulting in abnormal electroencephalogram (EEG) activity, ataxia, tremors, muscle weakness, temporal lobe epilepsy, paranoid psychosis, personality changes, hallucinations, nystagmus (involuntary eye movement), altered brain chemistry and impaired speech, intelligence, hearing, and vision (Aydin et al. 2003; Byrne et al. 1991; Camarra-Lemarroy et al. 2015; Capron and Logan 2009; Devathanan et al. 1984; Gupta et al. 2011; Hunnewell and Miller 1998; King et al. 1981; Kiyokawa et al. 1999; Maas et al. 1991; Maruff et al. 1998; Meulenbelt et al. 1990; Miyagi et al. 1999; Papageorgiou et al. 2009; Peralta and Chang 2012; Poblano et al. 1996; Ryu et al. 1998; Suzuki et al. 1983; Uchino et al. 2002).

Results from case studies of toluene abusers suggest that some of the neurological symptoms associated with chronic toluene abuse may be the result of permanent structural changes in the brain. Evaluation of chronic toluene abusers by magnetic resonance imaging (MRI) and single photon emission computed tomography (SPECT) has shown an increase in the white matter signal, a loss of gray and white matter differentiation, and decreased perfusion in the cerebral cortex, basal ganglia, and thalami (Aydin et al. 2002, 2003; Caldemeyer et al. 1996; Filley et al. 1990; Ikeda and Tsukagoshi 1990; Kamran and Bakshi 1998; Kucuk et al. 2000; Nomura et al. 2016; Rosenberg et al. 1988a, 2002; Ryu et al. 1998; Uchino et al. 2002; Yamanouchi et al. 1995). Cerebral, cerebellar, and brainstem atrophy were also present (Deleu and Hanssens 2000; Ryu et al. 1998; Gupta et al. 2011; Kamran and Bakshi 1998; Papageorgiou et al. 2009; Rosenberg et al. 1988b). Correlations between clinical signs of neurological impairment and damage visible in MRI images have also been reported (Caldemeyer et al. 1996; Hormes et al. 1986; Kiyokawa et al. 1999; Rosenberg et al. 1988b, 2002; Uchino et al. 2002). Abnormalities in MRI and brainstem auditory-evoked response (BAER) results were still present in chronic abusers who had refrained from toluene exposure for two to nine months (Rosenberg et al. 1988b).

Animal Studies

Neurobehavior

Overview. Numerous studies have evaluated neurobehavior in animals following toluene exposure using tests to evaluate locomotor activity, exploratory behavior, learning and memory, and anxiety-like behaviors. Acute-duration studies consistently demonstrated increased, followed by decreased, locomotor activity at exposure levels ≥ 500 ppm, cognitive deficits have been reported at concentrations as low as 125 ppm, and anti-anxiety-like effects at higher concentrations ($\geq 2,000$ ppm). In contrast, studies of rodents exposed for intermediate durations to concentrations as high as 1,000 ppm have not found strong and consistent evidence for exposure-related changes in neurobehavioral end points.

3. HEALTH EFFECTS

Acute-Duration Studies. Most acute exposure studies have reported a biphasic response with low-concentration stimulation and high-concentration depression of locomotor activity. Single or repeated exposure to toluene exposure for 30–72 minutes at concentrations of 500–3,000 ppm produced increased locomotor activity in mice; however, initial increases in locomotion were followed by a decrease in activity at concentrations of 3,000–10,000 ppm or repeated exposure to lower concentrations (Bowen and Balster 1998; Bowen et al. 2010; Bushnell et al. 1985; Conti et al. 2012; Kim et al. 1998; Lopez-Rubalcava and Cruz 2000; Tomaszynski et al. 2013; Wood and Colotla 1990). In adolescent and young adult rats exposed to 0, 1,000, 2,000, 4,000, or 6,000 ppm for 30 minutes, increased locomotor activity compared with controls was found only at concentrations $\geq 4,000$ ppm, although exploratory behavior was significantly reduced in the 6,000 ppm group (Huerta-Rivas et al. 2012). Exploratory behavior during the conditioned defensive burying task was increased in mice exposed to 4,000 or 6,000 ppm, but not 500–2,000 ppm (Paez-Martinez et al. 2003).

In several animal studies, acute exposure to toluene also diminished cognitive ability, but the lowest exposure levels required to impair learning and/or memory ranged from 125 to 4,000 ppm, depending upon the species, task, and duration of exposure. Monkeys exposed to concentrations of 0, 100, 200, 500, 1,000, 2,000, 3,000, or 4,500 ppm toluene (head only) for 50 minutes on 2 days separated by 3 days without exposure showed significantly increased response time and decreased accuracy on a test of conditioned response to a reward stimulus for concentrations $\geq 2,000$ ppm, compared with controls (Taylor and Evans 1985). Exposure of rats to 125, 250, or 500 ppm toluene for 4 hours caused a decline in lever-press shock avoidance performance 20 minutes after exposure, compared with pre-exposure performance, but recovery was complete 2 hours later (Kishi et al. 1988). Exposure to ≥ 480 ppm toluene for 4 hours decreased the ability of trained rats to perform a sequence of lever press actions associated with a reward (milk) (Wood et al. 1983). Statistically significant impaired learning and memory in the object recognition task and a decline in the conditioned step-through inhibition avoidance response were found in adolescent and young adult rats exposed to 1,000, 2,000, 4,000, or 6,000 ppm for 30 minutes, compared with unexposed controls (Huerta-Rivas et al. 2012). These effects were also present in adolescent and young adult rats exposed to 6,000 ppm for 30 minutes 2 times/day for 10 days (lower exposure levels were not evaluated). Similarly, impaired learning coupled with decreased anxiety-like behavior during the conditioned defensive burying task were reported in mice exposed to 4,000 or 6,000 ppm for 30 minutes, compared with unexposed controls, but not in mice exposed to 500, 1,000, or 2,000 ppm (Paez-Martinez et al. 2003). Decreased anxiety was also observed during the elevated-plus

3. HEALTH EFFECTS

maze in male mice exposed to $\geq 2,000$ ppm for 30 minutes, compared with unexposed controls, but not in mice exposed to 1,000 ppm (Bowen et al. 1996).

Intermediate-Duration studies. Studies of rodents exposed for intermediate durations to concentrations as high as 1,000 ppm have not found strong and consistent evidence for exposure-related changes in neurobehavioral end points. In rats exposed to 0, 10, 100, or 1,000 ppm 6 hours/day 5 days/week for 4 weeks, statistically significant decreased accuracy was observed in a signal detection task in 1,000-ppm rats, but no exposure-related changes were found in motor activity, anxiety-like behavior, or acquisition of a visual discrimination task or lever-press response at any exposure level (Beasley et al. 2012). In contrast, rats similarly exposed for 13 weeks were delayed in their acquisition of the lever-press response at 1,000 ppm, compared with unexposed controls, but no impairments were observed in a signal detection task, motor activity, anxiety-like behavior, acquisition of a visual discrimination task, or fear conditioning (Beasley et al. 2010). When rats exposed to 100–1,000 ppm toluene for 13 weeks were challenged with acute exposures of 1,200–2,400 ppm toluene 33–42 weeks later, previous exposure did not alter performance in the signal detection task (Beasley et al. 2010). In another study, prior exposure to 80 ppm for 4 weeks (5 days/week, 6 hours/day) did not influence the performance of rats 2 weeks later in a lever-press task following acute challenges to 20 daily “trigger” exposures of 10 ppm toluene for 1 hour (Rogers et al. 1999). Trigger-exposed animals, with or without prior exposure, showed statistically significant ($p < 0.05$) increased lever presses and increased incorrect lever presses during training, compared with unexposed rats, indicating that these effects are mediated by the acute 10-ppm triggers rather than prior 80-ppm exposures. Similarly, no adverse effects were observed in spatial learning, open-field activity, and/or passive or active avoidance tasks in mice exposed to 0 or 50 ppm for 6 weeks (Win-Shwe et al. 2010c), mice exposed to 0, 9, or 90 ppm toluene for 4 weeks (Win-Shwe et al. 2010d), rats exposed to 0, 25, 100, or 250 for 4 weeks (Wiaderna and Tomas 2002), rats exposed to 0 or 80 ppm for 4 weeks (von Euler et al. 2000), or young rats exposed to 0 or 600 ppm toluene for 50 days (Miyagawa et al. 1995). No statistically significant changes in general locomotor activity were observed in rats exposed to 40 ppm toluene for 16 weeks, compared with controls; however, there was a statistically significant decrease in rearing behavior (Berenguer et al. 2003, 2004). Nose-poking exploratory behavior was increased in rats exposed to 178, 300, or 560 ppm toluene for 3 weeks (2 times/week, 2 hours/day), compared with their pre-exposure behavior (Wood and Cox 1995).

3. HEALTH EFFECTS

Impaired Motor Coordination and Reflexes

Overview. Impaired motor coordination and decreased reflexes have been observed in animals following acute- and intermediate-duration exposures to toluene; however, acute-duration studies are limited and findings from intermediate-duration studies are inconsistent.

Acute-Duration Studies. Acute exposure in monkeys and rats to concentrations $\geq 3,000$ ppm caused overt signs of neurological motor impairments such as ataxia, tremors, and inability to walk (Mullin and Krivanek 1982; Taylor and Evans 1985). Concentration-related impairments in motor coordination and reflexes were observed in rats following a single 4-hour exposure to concentrations of 0, 810, 1,660, 3,100, or 6,250 ppm, resulting in decreased lift and pinna reflexes and impaired performance during vertical bar placing and horizontal rod grasping (Mullin and Krivanek 1982). The impairment observed at 810 ppm was borderline, but the majority of rats in the 1,600 group failed reflex testing. Overt signs of neurotoxicity, including ataxia, tremors, and inability to walk, were observed at $\geq 3,100$ ppm (Mullin and Krivanek 1982). A few rats failed reflex testing and demonstrated tremors in the 810 ppm group. Impaired motor coordination on the rotarod was found in mice exposed to 6,000 ppm toluene for 30 minutes, compared with unexposed controls, but lower exposures (500–4,000 ppm) did not change motor coordination (Paez-Martinez et al. 2003). In another study, no exposure-related impairment of rotarod test performance was reported for mice exposed to toluene at concentrations up to 8,000 ppm for 30 minutes (Cruz et al. 2001).

Rats exposed to 100 ppm for 4 hours or 3 hours/day for 5 days exhibited an altered optokinetic response, displaying slower and more irregular eye movements while tracking a moving object, compared with pre-exposure values (Hogie et al. 2009). Following exposure, rats also demonstrated unsteady eye positions at rest (nystagmus). These findings indicate potential disturbances in the vestibular and opto-oculomotor systems, suggesting that the cerebellum may be a target site for toluene.

Intermediate-Duration Studies. Overt signs of neurological motor impairments, such as ataxia, tremors, and inability to walk, were observed in rats, but not in mice, exposed to $\geq 2,500$ ppm for 5–15 weeks, compared with unexposed controls (API 1997; NTP 1990; von Oettingen et al. 1942). In rats exposed to 80 ppm for 4 weeks, impaired motor skills in beam walking were found, requiring a significantly wider beam to maintain balance (von Euler et al. 2000). The study authors reported that the impairment was predominantly due to improper placement of hindlimbs. In contrast, motor impairments in the tilting

3. HEALTH EFFECTS

plane or rotarod test were not found in rats exposed to 1,000 ppm toluene for 8 hours/day, 7 days/week for 13 weeks (Tahti et al. 1983).

Nociception. Toluene exposure can alter pain perception in animals; however, alterations in nociception may be species-, concentration-, and duration-dependent. Mice exposed to toluene at 500–8,000 ppm for 30 minutes exhibited a dose-related increase in nociception in the hotplate test (Cruz et al. 2001; Paez-Martinez et al. 2008). In both studies, mice exhibited decreased latencies for paw-licking that were significantly shorter at 1,000 ppm, compared with unexposed controls. Cruz et al. (2001) also reported statistically significant decreases in latencies for the antialgesic flexor reflex and escape responses at 2,000 and 6,000 ppm, respectively. In rats exposed to 0, 25, 100, or 250 ppm 6 hours/day, 5 days/week for 4 weeks, increased escape behavior in the hot-plate test in the 100- and 250-ppm groups was observed, which likely accounts for the observed increased paw-lick latencies (rather than decreased nociception) (Wiaderna and Tomas 2002). A clearer demonstration of decreased nociception was found in rats exposed to 6,000 ppm toluene for 30 minutes that required significantly increased shock intensity to elicit flinch, jump, or vocalization responses, compared with unexposed controls (Huerta-Rivas et al. 2012). No change in nociception was observed at 1,000, 2,000, or 4,000 ppm, and this effect was not observed in rats exposed to 6,000 ppm for 30 minutes, 2 times/day for 10 days (Huerta-Rivas et al. 2012).

Auditory System

Overview. Hearing loss in animals has been observed following acute- and intermediate-duration exposure to toluene at concentrations in ≥ 250 ppm in guinea pigs (McWilliams et al. 2000) and $\geq 1,000$ ppm in rats (Johnson 1992; Johnson et al. 1988; Pryor et al. 1984b). Observed hearing loss may not be solely due to neurological damage, as exposure to 500–2,000 ppm damages the outer hair cells (OHCs) in the cochlea that are responsible for amplifying incoming sound waves prior to signal transduction (Campo et al. 1997; McWilliams et al. 2000). This type of damage is referred to as sensorineural hearing loss.

Hearing loss was examined in rats exposed to 0, 400, 700, or 1,000 ppm 14 hours/day for 16 weeks using both behavioral and electrophysiological methods (Pryor et al. 1984b). Diminished auditory responses in a conditioned pole-climb avoidance response (CAR) task using a 20-kHz tone and increased BAER thresholds were measured in rats exposed to 1,000 ppm, compared with unexposed controls (Pryor et al. 1984b). Similarly, diminished auditory brainstem responses were measured in rats exposed to 1,000 ppm toluene for 16 hours/day for 10 days or 2 weeks, compared with controls (Johnson 1992; Johnson et al.

3. HEALTH EFFECTS

1988). The effects persisted at least 4–6 months post-exposure and were compounded by post-exposure high noise levels. However, following shorter daily durations (6 hours/day), diminished brainstem auditory responses or distortion product otoacoustic emissions (DPOAE) were only observed in rats exposed to up to 1,500 ppm for 10 days when exposure was combined with wide-band or impulse noise (92 dB SPL; peak level for impulse 130 dB), compared with unexposed and noise-only exposed groups (Lund and Kristiansen 2008). Toluene exposure for 6 hours/day, 5 days/week for 90 days did not impair hearing at levels up to 500 ppm, with or without noise exposure at 90 dB SPL (Lund and Kristiansen 2008).

Sensitivity to toluene-induced hearing loss may be species-specific. Guinea pigs may be more sensitive than rats to toluene-induced hearing loss. Transient, dose-related impairments in mid- to high-frequency hearing were observed in guinea pigs exposed to 250, 500, or 1,000 ppm toluene 8 hours/day for 5 days, compared with controls, as measured by brainstem auditory responses or DPOAE (McWilliams et al. 2000). When guinea pigs in the 500 ppm group were exposed for an additional 3 weeks, hearing loss was more pronounced (McWilliams et al. 2000). However, chinchillas may be less sensitive than rats. While toluene led to decreased auditory evoked potentials in rats exposed to 2,000 ppm toluene for 10 days (8 or 12 hours/day), compared with unexposed controls, auditory evoked potentials were not altered in similarly exposed chinchillas (Davis et al. 2002).

Toluene had a more pronounced effect on hearing loss in mice that had a genetic predisposition for early onset spontaneous auditory degeneration than on mice that were predisposed to late onset moderate hearing loss following exposure to 1,000 ppm toluene for 12 hours/day for 7 days (Li et al. 1992). Thus, the severity of toluene-induced hearing loss appears to be influenced by genetic susceptibility.

Visual System. FEP responses were abnormal in rats exposed to single 30-minute exposures to 500–16,000 ppm toluene (Rebert et al. 1989a, 1989b). This technique measures the electrical response of the visual components of the nervous system to a high intensity flashing strobe light. Distortion of the FEP waveform is indicative of impaired visual response to light. Similarly, F2 wave amplitudes of VEPs were decreased 40–65% in rats exposed to 1,000–4,000 ppm toluene for 1–4 hours in a dose-related manner (Boyes et al. 2007). Two hours after exposure ended, partial recovery was found in the 4,000-ppm group but not in the 3,000 ppm group.

In a series of intermediate-duration experiments, Boyes et al. (2016) reported subtle, but persistent, changes in visual function in rats exposed to 1,000 ppm toluene 6 hours/day, 5 days/week for 13 weeks,

3. HEALTH EFFECTS

but not 4 weeks; no visual system effects were observed at ≤ 100 ppm. Specifically, significant decreases were observed in the maximal b-wave amplitude induced by a scotopic flash, measured by electroretinogram (ERG) at 5–6 weeks and 1 year after the 13-week exposure period (but not 2–3 weeks after the 4-week exposure period). Reduction of the b-wave amplitude indicates altered firing patterns of non-bipolar cells. No exposure-related effects were noted in the ultraviolet (UV) or green flicker data or the photopic flash data from ERGs, and no exposure-related changes were observed in VEPs measured 2–3 weeks after the 13-week exposure period (not measured in the 4-week study). Additionally, the density of rod and M-cone photoreceptors were comparable between exposed and control animals.

Olfactory System. Decreased avoidance of a toluene-containing arm in a T-maze was observed in female mice exposed following exposure to 1,000 ppm toluene 5 hours/day, 5 days/week for 4 weeks, compared with pre-exposure measures (Jacquot et al. 2006). Decreased olfactory sensitivity continued for 2 weeks following cessation of exposure. This behavior was accompanied by reversible olfactory inflammation and decreased numbers of olfactory epithelial cells, perhaps indicating that olfactory sensitivity was decreased by exposure to toluene (Jacquot et al. 2006). However, this could instead indicate tolerance to toluene odor with repeat exposures and/or toluene-seeking behavior (see the section on Animal Studies Modeling High-Concentration Solvent Abuse).

Sleep Patterns. Toluene exposure also changes sleep patterns in animals. Both single 4- or 8-hour episodes of toluene exposure (900–4,000 ppm) and repeated exposures, 8 hours/day for 3 weeks (900 and 2,700 ppm), changed patterns of sleep and wakefulness in rats (Arito et al. 1988; Takeuchi and Hisanaga 1977). After the single exposures, there was a decrease in wakefulness and an increase in slow-wave sleep; a prolonged sleep latency was apparent for the 2 days following exposure. Latency was defined as the time interval between the end of the exposure period and the beginning of a particular phase of the sleep cycle. Following the 3-week exposures, there was an increase in wakefulness during the dark period on the 2 days after exposure and a decrease in slow wave sleep on the first day. Exposure to concentrations of 100–700 ppm for 2 hours increased the duration of the wake cycle and decreased both rapid-eye movement and nonrapid eye movement sleep in a concentration-related fashion in young and adult male rats (Ghosh et al. 1989, 1990).

Brain Weight, Volume, and Histology. Altered brain weight and volume have been reported in rats, but not in mice, following intermediate-duration exposure to toluene. In rats exposed to 80 ppm 6 hours/day, 5 days/week for 4 weeks, the area of the cerebral cortex measured by MRI and D₃ receptor autoradiography was decreased significantly by 4 and 10%, respectively, compared with controls (von

3. HEALTH EFFECTS

Euler et al. 2000). MRI analysis indicated that the main effect was in the parietal cortex, which was significantly decreased in area by 6%. However, no change was observed in total brain weight or volume (von Euler et al. 2000). Similarly, no change in total brain weight was reported in rats up to 320 ppm using the same protocol (Hillefors-Berglund et al. 1995). In contrast, rats exposed continuously to 320 ppm for 30 days, both cerebrocortical and total brain weight were significantly decreased compared with control by 4 and 8%, respectively (Kyrklund et al. 1987). There was also a decrease in the total phospholipid content of the cerebral cortex accompanied by a small increase in phosphatidic acid levels. These data suggest a breakdown of phospholipids resulting in a loss of gray matter (Kyrklund et al. 1987). The mechanism of action for this effect is uncertain. Following exposure to toluene at 0, 100, 625, 1,250, 2,500, or 3,000 ppm 6.5 hours/day, 5 days/week, for 15 weeks, relative brain weights were increased significantly in rats exposed to 2,500 or 3,000 ppm, compared with controls (NTP 1990). However, no changes in brain weights were observed in mice similarly exposed to concentrations up to 2,500 ppm for 14 weeks or in rats or mice exposed by the same protocol to toluene at concentrations up to 1,200 ppm for 2 years (NTP 1990). The mechanism(s) underlying the apparent species difference in the intermediate-duration NTP study is unknown. In a multigenerational study, no changes in brain weight were observed in F0 and F1 parental rats or F1 and F2 weanlings exposed to 100–2,000 ppm toluene for 95 days (pre-mating and mating), gestation, and lactation (API 1985; Roberts et al. 2003). No gross or microscopic brain tissue changes were observed in any of the mouse or rat studies described above.

GFAP Levels. Changes in brain levels of GFAP, a structural marker for astrocytes, have been found in toluene-exposed rats. Rats exposed to 1,000 ppm toluene for 3 or 7 days exhibited a significant decrease in GFAP levels in the thalamus (Little et al. 1998). Rats exposed to 100–3,000 ppm toluene 6 hours/day, 5 days/week for up to 42 days exhibited changes in the concentration of GFAP in the cerebellum, hippocampus, and thalamus (API 1997). For the first week of exposure, GFAP concentration of exposed animals was significantly increased in the cerebellum and hippocampus, and decreased in the thalamus compared with unexposed controls (API 1997). After 21 days, the concentration of GFAP in the hippocampus was significantly decreased in rats exposed to 1,000 ppm compared with controls, while at 42 days, rats exposed to 300 ppm had significantly higher concentrations of GFAP in the cerebellum compared with controls, but rats exposed to 1,000 ppm did not (API 1997). In mice exposed to 500–2,000 ppm for 8 hours, no significant alterations in c-Fos, c-Jun, or GFAP mRNA levels in the cerebrum were found (Matsuoka et al. 1997).

Oxidative Stress Markers in Brain Tissue. Increased oxidative stress has been observed in the rat brain following acute- or intermediate-duration inhalation exposure. Increased glutathione peroxidase activity

3. HEALTH EFFECTS

and H₂O₂-induced chemiluminescence in cortical brain tissue were reported for rats exposed to 500 ppm toluene for 4 hours/day, 5 days/week for 1 month, compared with controls, indicating toluene-induced free radical processes (Burmistrov et al. 2001). These effects were not seen at 50 ppm. However, no changes in free or total malondialdehyde levels, another marker of oxidative stress, were observed in rats exposed to 1,000 ppm, 6 hours/day for 10 days, compared with controls (Chalansonnet et al. 2013). Similarly, no significant changes in brain levels in markers of oxidative stress, including lipid peroxidase, superoxide dismutase, or 4-hydroxy-nonenal, or total brain DNA levels of 8-OH-dG were observed in rats exposed to 1,500 ppm, 4 hours/day for 7 days (Tokunaga et al. 2003). The biological adversity of these findings are unclear, therefore NOAELs and LOAELs for changes in brain oxidative stress markers are not included in Table 3-1.

Brain Tissue Changes in Levels of Neurotransmitters, Synthesis, and Binding Sites

Overview. Changes in the levels of brain neurotransmitters and their precursors and metabolites have been observed in rodents exposed by inhalation to toluene for acute and intermediate durations. Alterations in neurotransmitter synthesis and binding have also been reported. Current mechanistic understanding is inadequate to determine the biological adversity of the observed changes and findings from these studies are not included in Table 3-1.

Following exposure to 1,000–4,000 ppm toluene for 20 minutes, dopamine (DA) levels were increased in the cerebellum and striatum of rats, while norepinephrine (NE) and serotonin (5-HT) were significantly increased in the cerebellum and cortex (Kim et al. 1998). Increased concentrations of DA in the striatum, NE in the medulla and midbrain, and 5-HT in the cerebellum, medulla, and striatum were observed in rats exposed to 1,000 ppm, but not 100 or 300 ppm, for 8 hours, compared with controls (Rea et al. 1984). In other studies, increased levels of DA and noradrenaline were observed in several brain regions in rats exposed to 80–3,000 ppm, 6 hours/day for 3–5 days (Andersson et al. 1980, 1983b); however, decreased DA levels and rates of turnover were observed in several areas of the nucleus caudate in the brain of rats exposed to 80 ppm toluene, 6 hours/day for 3 days (Fuxe et al. 1982). Altered DA turnover was also reported in rats exposed to 40 ppm toluene for 16 weeks, compared with controls, as demonstrated by significant localized increases in DA levels, as well as decreases in the levels of its metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) and its precursor dihydroxyphenylalanine (DOPA) (Berenguer et al. 2003, 2004). No statistically significant exposure-related changes were observed in the 5-HT neurotransmitter system. Altered levels of noradrenaline and DA were observed in select brain areas of male rats continuously exposed to 400 ppm toluene for 30 days, compared with controls (Ikeda et al.

3. HEALTH EFFECTS

1986). The directionality and magnitude of change varied across brain regions, and no effects were observed at 200 ppm. The biological adversity of region-specific neurotransmitter changes in the absence of behavioral effects is unknown.

Several statistically significant changes in the activities of enzymes responsible for neurotransmitter synthesis (glutamic acid decarboxylase, choline acetyltransferase, and aromatic amino acid decarboxylase) in different areas of the brain were seen in male rats exposed to toluene at concentrations of 50–1,000 ppm for 4 weeks or 500 ppm for 12 weeks (Bjornaes and Naalsund 1988). Concentration-response trends were not apparent in the data and there were variant responses by different areas of the brain. Exposure to 400 ppm toluene 7 hours/day for 10 days produced a statistically significant increase in the total dehydrogenase activity in the brains of female mice (Courtney et al. 1986). Minimal, but statistically significant, alterations in monoamine neurotransmitter synthesis (tyrosine and tryptophan hydroxylase enzyme activities) were reported in the brainstem and hypothalamus of rats exposed to 40 ppm toluene 104 hours/week for 16 weeks, but not in other brain regions (Soulaige et al. 2004). The direction and magnitude of changes (17–44%) differed between brain regions and sexes. Due to the lack of concentration-related effects and/or variability of the responses between brain regions and sexes, NOAEL/LOAEL values for these studies could not be determined for this assessment.

Toluene exposure at 80 ppm for 4 weeks was found to affect DA D₂ agonist binding in the rat caudate-putamen (Hillefors-Berglund et al. 1995; von Euler et al. 1993). Von Euler et al. (1994) also reported that rats exposed to 80 ppm had increased serum prolactin levels, which could be related to a possible interaction between toluene and the pituitary DA D₂ receptor since this receptor normally inhibits the release of prolactin into serum. However, in another study, no significant exposure-related changes in serum prolactin levels were reported with 4-week exposures to concentrations up to 320 ppm (Hillefors-Berglund et al. 1995). There were also no changes in DA D₃ receptor binding 4 weeks after cessation of a 4-week exposure to 80 ppm toluene (von Euler et al. 2000). There is some evidence of changes in glutamate and gamma amino butyric acid (GABA) binding in male rats exposed to toluene at concentrations of 50–1,000 ppm for 4 weeks or 500 ppm for 12 weeks (Bjornaes and Naalsund 1988). Binding increased in most of the brain areas studied, but decreased in some areas. Because of the variability in response, the biological adversity of the observed changes cannot be determined.

3. HEALTH EFFECTS

Gene Expression Changes in Brain Tissue

Overview. Numerous gene expression changes have been observed in brain tissue of rats and mice following acute or intermediate inhalation exposure. Results of these studies vary greatly, and indicate that gene expression changes are species-, strain-, dose-, duration-, and lifestage-dependent, and that immune status may affect gene expression changes in the brain. Current mechanistic understanding is inadequate to determine the biological adversity of the observed changes in gene expression, and findings from these studies are not included in Table 3-1.

In rats, microarray analysis 6 and 18 hours following an acute 6-hour exposure to 1,000 ppm identified 226 and 3,352 differentially expressed genes in the striatum ($p < 0.05$), respectively, compared with controls (Hester et al. 2011). Pathway analysis identified synaptic transmission and plasticity as the predominate pathways affected by acute toluene exposure (Hester et al. 2011). However, gene expression changes from the acute study by Hester et al. (2011) were not predictive of gene expression changes in rats exposed to 0, 10, 100, or 1,000 ppm toluene for 6 hours/day, 5 days/week for 64 days (Hester et al. 2012). In the intermediate-duration study, microarray analysis 18 hours after the final exposure identified 22, 57, and 94 differentially expressed genes in the striatum ($p < 0.05$) in the 10-, 100-, and 1,000-ppm groups, respectively, compared with control. However, only 57 differentially expressed genes were found in both the acute study (Hester et al. 2011) and the intermediate-duration study (Hester et al. 2012), and the direction of change (up- or down-regulation) was inconsistent. Additionally, altered gene expression in the intermediate-duration study did not demonstrate consistent dose-related changes in gene expression (Hester et al. 2012).

Win-Shwe et al. (2007a) reported upregulation of memory-related genes in the hippocampus in BALB/c mice following 30-minute exposures to 9 ppm toluene for 3 consecutive days followed by 1 day/week for 4 weeks. These changes may be mediated by T-cell activation, as nude mice similarly exposed did not demonstrate memory-gene upregulation (Win-Shwe et al. 2007a). However, when the study was repeated in C3H/HeN mice, changes in expression of memory-related genes in the hippocampus were not statistically significant in mice exposed to 9 or 90 ppm, compared with unexposed C3H/HeN mice (Win-Shwe et al. 2010c). Gestational and prenatal exposure studies found that exposure to toluene during development significantly altered hippocampal memory-related gene expression with exposure to 5 or 50 ppm from PND 8 to 12 and 50 ppm from PND 2 to 6, but not with exposure to 5 or 50 ppm from GD 14 to 16 (Win-Shwe et al. 2010b).

3. HEALTH EFFECTS

When C3H/HeN, BALB/c, and C57BL/10 mice were exposed to 0, 5, 50, or 500 ppm toluene for 6 hours/day, 5 days/week for 6 weeks, changes in mRNA levels of neurotrophins (NGF, BDNF) and their receptors (TrkA, TrkB) in the hippocampus differed between strains (Win-Shwe et al. 2010a). In C3H/HeN mice, mRNA levels for NGF, BDNF, TrkA, and TrkB were all significantly upregulated ($p < 0.01$) in the 500-ppm group, compared with controls. However, only BDNF was significantly upregulated in BALB/C mice exposed to 500 ppm, and no significant changes were observed in C57BL/10 mice (Win-Shwe et al. 2010a). There were no significant, dose-related gene expression changes in marker genes for NGF signal-transduction or dopamine signaling pathways; however, HO-1 mRNA levels (a marker for oxidative stress) were significantly upregulated in the 500-ppm C3H/HeN group. The immune system may have a role, as neurotrophin mRNA levels were increased in allergy-challenged C3H/HeN mice exposed to 50 ppm, compared with controls, but not in allergy-challenged mice exposed to 500 ppm (Win-Shwe et al. 2010a). Similarly, in a separate study, the same exposure protocol led to upregulation of mRNA levels of neuroinflammatory genes TLR4 and NF- κ B in the hippocampus following exposure to 50 ppm, but not 5 or 500 ppm, in C3H/HeN mice (Win-Shwe et al. 2011).

Following exposure to 0 or 50 ppm, 6 hours/day, 5/days week for 6 or 12 weeks, mRNA levels for synaptic plasticity genes were measured in the hippocampus of C3H/HeN mice (Ahmed et al. 2007). Significant upregulation ($p < 0.05$) was found in mRNA levels of N-methyl-D-aspartate (NMDA) receptor subunit 2B, CaMKIV, CREB-1, and FosB/ Δ FosB in mice exposed to 50 ppm for 12 weeks, compared with controls. No changes were found in NMDA receptor NR2 or CREB-2 after 12 weeks, and no significant changes in any mRNA levels for these genes were observed after exposure for 6 weeks (Ahmed et al. 2007).

Neurodevelopment. Studies examining neurotoxic effects of gestational and/or neonatal exposure during critical periods of neurodevelopment are discussed in Section 3.2.1.6, Developmental Effects.

The highest NOAEL values and all LOAEL values for each reliable study for neurological effects in each species and duration category in are recorded in Table 3-1 and plotted in Figure 3-1.

Animal Studies Modeling High-Concentration Solvent Abuse

Overview. Numerous animal studies model human solvent abuse using single or repeat exposure to high concentrations of toluene (most concentrations $> 1,000$ ppm). Examined end points in these studies were

3. HEALTH EFFECTS

the same as those examined in animal studies at lower exposure levels or included abuse-related behaviors (e.g., reward-seeking, tolerance) or brain systems (e.g., mesolimbic system). Due to adequate dose-response information from lower-dose studies, LOAELs from these studies are not included in Table 3-1.

Adverse Neurological Effects. Effects observed in these high-exposure studies (>1,000 ppm) include overt signs of neurological impairment (e.g., ataxia, tremors, loss of consciousness) (Beyer et al. 2001; Bruckner and Peterson 1981a, 1981b; Davis et al. 2002; Lorenzana-Jimenez and Salsas 1990; NTP 1990; Ono et al. 1999; Pryor 1991; Pryor and Rebert 1992), neurobehavioral alterations (Apawu et al. 2014; Batis et al. 2010; Baydas et al. 2005; Bikashvili et al. 2012; Bowen et al. 2007; Bushnell et al. 2007; Castilla-Serna et al. 1991; Dashniani et al. 2014; Duncan et al. 2012; Galliot et al. 2012; Gmaz et al. 2012; Harabuchi et al. 1993; Hinman 1987; Huerta-Rivas et al. 2012; Lammers et al. 2005b; Lorenzana-Jimenez and Salas 1990; Mattsson et al. 1990; Miyagawa et al. 1998; Oshiro et al. 2007, 2011; Paez-Martinez et al. 2013; Pryor 1991; Pryor and Rebert 1992; Samuel-Herter et al. 2013), impaired motor coordination (Gmaz et al. 2012; Lorenzana-Jimenez and Salas 1990; Samuel-Herter et al. 2013; Tahti et al. 1983), altered pain perception (Lopez-Rubalcava and Cruz 2000; Paez-Martinez et al. 2008), altered sleep patterns (Alfaro-Rodriguez et al. 2011), auditory effects (Campo et al. 1998; Johnson and Canlon 1994; Lataye and Campo 1997; Lataye et al. 1999; Mattsson et al. 1990; Pryor 1991; Pryor and Rebert 1992; Pryor et al. 1984a, 1984b; Waniusiow et al. 2008, 2009), decreased FEPs (Bale et al. 2007; Mattsson et al. 1990), nystagmus (Larsby et al. 1986; Tham et al. 1982), altered neurotransmitters and receptors in nervous system tissues (Alfaro-Rodriguez et al. 2011; Apawu et al. 2014; Gerasimov et al. 2002c; Koga et al. 2007; O'Leary-Moore et al. 2007, 2009; Ono et al. 1999; Paez-Martinez et al. 2008; Tsuga and Honma 2000; Williams et al. 2005), increased GFAP levels in brains (Baydas et al. 2003; Gotohda et al. 2000a, 2000b, 2007), damage to olfactory and hippocampal neurons (Gelazonia et al. 2006a, 2006b), reduced brain weight (Edelfors et al. 2002), increased markers of oxidative stress (Baydas et al. 2003, 2005; Coskun et al. 2005), and gene expression changes in the brain (Gotohda et al. 2000b; Ikematsu et al. 2007; Sanchez-Serrano et al. 2011).

Abuse-Specific Behaviors. Since toluene is often intentionally inhaled to become intoxicated, multiple animal studies have been conducted assessing dependence, reward-seeking behavior, and tolerance following toluene exposure. Removal of mice following exposure to 250 ppm toluene continuously for 4 days resulted in chemical withdrawal, as evidenced by increased handling-induced convulsions (Wiley et al. 2003). Multiple studies report that mice and rats show conditioned place preference after acute exposure to toluene concentrations of ≥ 700 and $\geq 1,895$ ppm, respectively, preferring the toluene-filled

3. HEALTH EFFECTS

chamber over an air-filled chamber (Funada et al. 2002; Gerasimov et al. 2003; Lee et al. 2006; Schiffer et al. 2006). When rats were evaluated in a wait-for-reward task 22–23 hours after daily 30-minute exposures to 0, 1,000, 3,600, or 6,000 ppm for 40 days, a higher response-to-reinforcer ratio and decreased number of rewards received was observed in the 3,600- and 6,000-ppm groups, compared with controls (Bowen and McDonald 2009). Altered performance persisted during the 40-day recovery period. Tolerance to toluene and toluene-induced effects with repeated exposure to >1,000 ppm has been noted in various neurobehavioral tests, including the righting-reflex (Lorenzana-Jimenez and Salas 1990), pain perception (Huerta-Rivas et al. 2012), visual signal detection (Oshiro et al. 2007, 2011), and locomotor activity (Bowen et al. 2007). However, intermittent exposure to 3,000 ppm toluene during adolescence in rats did not increase ethanol-seeking behaviors in adulthood (Dick et al. 2014).

Mesolimbic System. Consistent with observed patterns of abuse in humans, acute exposure to high toluene levels of 4,000–10,000 ppm in animals can affect the mesolimbic system, which plays an important role in drug dependence. This system contains both multiple neurotransmitter pathways, and includes several brain structures such as the frontal cortex, hippocampus, basal ganglia, nucleus accumbens, specific areas of the brainstem, and the white matter tracts connecting them. Effects observed include increased c-Fos activity (neural activity) in catecholaminergic cells of the nucleus accumbens shell (Tomaszycki et al. 2013), increased c-Fos activity in the forebrain and midbrain structures implicated in reward, emotion, and olfactory stimulation (Perit et al. 2012), persistent alterations in excitatory synaptic strength of mesolimbic dopamine (DA) neurons (Beckley et al. 2013), increased activation of DA neurons in the ventral tegmental area of the midbrain (Riegel and French 2002), increased DA and noradrenaline levels in the medial prefrontal cortex and nucleus accumbens (Koga et al. 2007), and altered glutamatergic signaling in corticostriatal circuitry (Dick et al. 2015). Effects on the dopaminergic system may be changed with continued abuse, and may indicate potential compensatory mechanisms following repeat exposure. Mice exposed once to 2,000–4,000 ppm showed significant increases in DA release in the caudate-putamen and nucleus accumbens; however, repeated exposures to the same concentrations over 7 days resulted in a significant decrease in DA release in the nucleus accumbens (Apawu et al. 2014). Toluene abuse may also lead to cross-sensitization to other drugs, as acute exposure to toluene increased diazepam-induced locomotion (Wiley et al. 2003), apomorphine-induced locomotion (Wiaderna and Tomas 2002), cocaine-induced locomotion (Beyer et al. 2001), and cocaine-induced increases in DA levels in the nucleus accumbens (Gerasimov et al. 2002c).

Effects observed in the mesolimbic system may result from permanent brain injury. Numerous animal studies report injury to multiple regions of the brain following acute or repeated exposure to

3. HEALTH EFFECTS

concentrations of toluene ranging from 1,500 to 6,000 ppm, including degenerative changes and ultrastructural damage in the hippocampus, frontal cortex, and brain stem (Kanter 2008a, 2008b, 2011c, 2013), decreased or shrunken cells in the hippocampus (Gotohda et al. 2002; Korbo et al. 1996; Zhvania et al. 2012), impaired dendritic outgrowth in the frontal cortex (Pascual and Bustamante 2010), and white matter damage in anterior commissure (Duncan et al. 2012).

3.2.1.5 Reproductive Effects

Overview. Current data do not provide convincing evidence that acute or repeated inhalation exposure to toluene may cause reproductive effects in humans. Limited evidence in humans indicates that occupational exposure to toluene may lead to an increased incidence of spontaneous abortion (Lindbohm et al. 1992; Ng et al. 1992b; Taskinen et al. 1989) or decreased fecundity in female workers (Plenge-Böenig and Karmaus 1999). One population-based cohort study reported increased risk of preterm birth with increasing environmental toluene exposure (Poirier et al. 2015); however, concurrent exposure to multiple pollutants (which were not controlled for in statistical analyses) limits the conclusions that can be drawn from this study. A few studies in animals exposed to toluene via inhalation at concentrations $\geq 2,000$ ppm reported effects on male and female reproductive tissues, including abundant vacuoles, lytic areas, and mitochondrial degeneration in the antral follicles of the ovaries of female rats (Tap et al. 1996) and reduced sperm count, motility, and quality and altered reproductive organ weight and histology in male rats (Kanter 2011b; Ono et al. 1996, 1999). However, changes in sperm count and epididymis weight were not accompanied by any change in indices of reproductive performance (e.g., fertility) in male rats exposed to 2,000 ppm for 60 days before mating (Ono et al. 1996). The majority of animal studies provided little evidence for toluene reproductive toxicity. Studies in rats exposed repeatedly by inhalation to toluene, including a 2-generation reproductive toxicity study, have shown no evidence of adverse effects on mating or fertility at tested concentrations as high as 1,200–2,000 ppm (API 1981, 1985; Ono et al. 1996; Roberts et al. 2003; Thiel and Chaboud 1997). In addition, the majority of gestational exposure studies reported no exposure-related changes in reproductive indices (see citations below).

Occupational Exposure Human Studies. Ng et al. (1992b) reported a significant increase in spontaneous abortion for women employed in an audio speaker factory and exposed to 50–150 ppm (mean of 88 ppm) for 10 years (12.4%), compared with controls exposed to 0–25 ppm toluene from the same factory (2.9%) and unexposed controls from the general population (4.5%). The majority of women examined did not smoke or drink and were of similar socioeconomic status (Ng et al. 1992b). Exposed workers did not

3. HEALTH EFFECTS

report increased incidence for menstrual cycle irregularities, altered extent of uterine bleeding, or occurrence of dysmenorrhea (Ng et al. 1992a). Other possible confounding factors such as exposure to chemicals other than toluene were minimized by inclusion of controls who carried out similar types of work, but did not use toluene-based adhesives (Ng et al. 1992b). Increased incidence of dysmenorrhea was reported in 38 female shoemakers who were exposed to toluene concentrations that varied from 65 ppm (15–100 ppm) in winter to 100 ppm (10–200 ppm) in summer for an average of 40 months, compared with 16 controls (Matsushita et al. 1975). No other reproductive end points were assessed by Matsushita et al. (1975). The concentration for reproductive effects is estimated at 83 ppm (the average between summer and winter exposures). The incidence of spontaneous abortions exceeded population norms among five female workers (Lindbohm et al. 1992) and among the wives of small groups of 28–48 male workers (Lindbohm et al. 1992; Taskinen et al. 1989) exposed to toluene; however, exposure levels were not reported in these studies and only a small number of cases were included.

Fecundity (probability of conception) was decreased in female workers, but not in male workers, in German printing facilities for periods when they were employed in printing facilities and exposed to toluene, compared with periods when they were employed in other jobs without toluene exposure (Plenge-Böenig and Karmaus 1999). Toluene exposure was divided into three groups based on work history and exposure measurements from previous years (conducted by industrial hygienists of the Employer's Liability Insurer): low exposure (e.g., stacking and book binding; <10 ppm), medium exposure (cylinder preparation, galvanisers; 10–30 ppm), and high exposure (printers; <200 ppm before 1984, <100 ppm in 1984–1994, and <50 ppm after 1994). Actual air concentrations of toluene were not reported. Reproductive and work history data collected from workers were analyzed to determine fecundability ratios based on time to pregnancy and periods of unprotected intercourse during exposed and unexposed employment. The analysis included adjustments for age, ethnicity, smoking, parity, pelvic inflammatory diseases, and frequency of sexual intercourse. In women, the fecundability ratio was significantly reduced for periods of toluene exposure (0.47, 95% CI 0.29–0.77), whereas fecundity was not significantly affected in toluene-exposed periods in male workers and their partners. Female workers in this study were exclusively employed in areas of printing facilities (stacking and book binding), with air concentrations expected to be lower than areas of high (operating printing machines) and medium (preparing cylinders) toluene exposure. Men were employed in all three areas.

Several studies of blood levels of reproductive hormones in repeatedly exposed workers have not provided strong and consistent evidence of exposure-related effects. No statistically significant changes were observed in serum FSH, LH, or testosterone levels in 1,225 male rotogravure workers exposed to

3. HEALTH EFFECTS

median toluene concentrations of 24 ppm (printers) or 4.5 ppm (non-printers) for at least 20 years, compared with 109 unexposed referents (Gericke et al. 2001). Significantly decreased serum levels of LH, FSH, and testosterone were found in 20 male toluene-exposed rotogravure printers, compared with 44 unexposed referents (Svensson et al. 1992a). TWA air concentration estimates for the exposed workers during the period when blood was sampled ranged from 8 to 111 ppm, with a median of 36 ppm. Increasing workplace air concentrations were not significantly ($p>0.05$) associated with plasma concentrations of LH, FSH, testosterone, or prolactin, after adjustments for age, in a study of 47 male toluene-exposed printers from two factories (Svensson et al. 1992b). Median serum levels of these hormones in exposed workers were not significantly different from median levels in 46 unexposed referents (Svensson et al. 1992b). TWA air concentrations for the exposed workers during the period when blood was sampled ranged from 1 to 108 ppm (median 11 ppm) in one factory and from 1 to 142 ppm (median 47 ppm) in the second factory (Svensson et al. 1992b). In female U.S. Air Force personnel with mixed exposure to fuel (primarily JP-8 jet fuel) and several solvents, pre-ovulatory LH levels were significantly reduced compared with unexposed female U.S. Air Force personnel (Reutman et al. 2002). No air exposure levels were reported; instead, mean breath concentrations of aromatic and aliphatic hydrocarbons were measured. While mean toluene breath concentrations in the unexposed and exposed group were reported (1.3 and 9 ppb, respectively), analysis was only conducted for the combined concentrations of BTEX (3.8 and 73.5 ppb, respectively). Since no toluene-specific analysis was conducted, and toluene only accounted for 12% of the BTEX breath concentration in the exposed group, it cannot be determined if toluene exposure influenced preovulatory LH levels in this study.

Environmental Human Exposure. In a population-based cohort study, the potential associations between exposure to air pollutants and adverse birth outcomes (preterm birth, term low birth weight, and small for gestational age) were evaluated in 15,284 mothers who gave birth between 2008 and 2012 in Halifax, Nova Scotia (Poirier et al. 2015). The median (range) toluene concentration in Urban Halifax during this time period, determined using land-use regression-modeled air pollution data, was 0.4 (0.2–1.1) $\mu\text{g}/\text{m}^3$ (0.0001 [0.00005–0.003] ppm). A significant increased risk of preterm birth was observed in mothers exposed to the 2nd, 3rd, or 4th quartile of toluene, compared with mothers exposed to the 1st quartile of toluene exposure, before and after adjustment for mother's age, parity, and smoking. However, after adjustment for age, parity, smoking, and neighborhood income, the risk was only significantly elevated in mothers in the 2nd quartile (OR 1.35, 95% CI 1.12–1.63). Interquartile ranges were not reported; however, following piecewise logistic regression breakpoint analysis for exposure to toluene and preterm birth, a cut point of 0.36 $\mu\text{g}/\text{m}^3$ (95% CI 0.33–0.40) was determined. Mothers exposed to toluene levels above the cut point were at a significantly higher risk of preterm birth after

3. HEALTH EFFECTS

adjustment for age, parity, smoking, and neighborhood income (OR 1.19, 95% CI 1.01–1.39). No significant increases in risk of low birth weight or small for gestational age were observed with increasing toluene exposure. This study suggests that low-level toluene exposure may increase the risk of preterm birth; however, the likelihood of concurrent exposure to multiple pollutants (which were not controlled for in statistical analyses) limits the conclusions that can be drawn from this study.

Controlled Human Exposure. LH, FSH, and testosterone levels were determined in blood samples collected at 20-minute intervals from five men, five women in the luteal phase of the menstrual cycle, and five women in the follicular phase, before, during, and after a 3-hour exposure to 0 or 50 ppm (Luderer et al. 1999). Analysis of variance in data for men and women indicated no statistically significant direct effects of exposure on any hormone end point, with the exception of a significant interaction between exposure and sampling period for LH levels in men, indicating a greater LH decline during toluene exposure than clean-air exposure. Interpretation of these reproductive hormone data from a biological adversity perspective is constrained by the lack of data on reproductive function and the variance across studies in applying adjustments for confounding factors such as age, smoking and alcohol consumption.

Intentional Human Exposure. A single case report of testicular atrophy and aspermia involving chronic solvent abuse was located (Suzuki et al. 1983).

Acute-Duration and Gestational Exposure Animal Studies. Exposure of female rats to 3,000 ppm toluene for 7 days produced abundant vacuoles, lytic areas, and mitochondrial degeneration in the antral follicles of the ovaries (Tap et al. 1996). However, the majority of gestational exposure studies in rodents did not report exposure-related changes in reproductive end points (e.g., number of litters, gestational age, implantations, pre- or post-implantation loss, number of live and dead pups, sex ratio) at concentrations ranging from 50 to 12,000 ppm (API 1978, 1991, 1992; Bowen and Hannigan 2013; Bowen et al. 2005, 2007, 2009a, 2009b; Courtney et al. 1986; Dalgaard et al. 2001; Hougaard et al. 2003; Jones and Balster 1997; Klimisch et al. 1992; Ladefoged et al. 2004; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997), despite evidence for maternal toxicity (decreased maternal weight gain) at concentrations as low as 1,200 ppm (API 1991; Dalgaard et al. 2001; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997). However, continuous exposure of pregnant rabbits to 267 ppm during days 7–20 of pregnancy produced maternal toxicity (decreased weight gain) and abortions in 4/8 does (Ungvary and Tatrai 1985). Additionally, rats exposed to 5,000 ppm 6 hours/day during days 6–15 of pregnancy resulted in increased post-implantation loss and complete fetal resorption in 6/9 litters (API 1992). These effects were not observed at 133 ppm in rabbits or

3. HEALTH EFFECTS

≤3,500 ppm toluene in rats (API 1992; Ungvary and Tatrai 1985). Another rat study found no exposure-related effects on mating, fertility, or pregnancy indices for F1 rats that had been exposed *in utero* to 0, 300, 600, 1,000, or 1,200 ppm toluene for 6 hours/day during GDs 9–21 (Thiel and Chahoud 1997).

Other studies examining reproductive effects in offspring following exposure to toluene during gestation are discussed in Section 3.2.1.6, Developmental Effects.

Intermediate-Duration Animal Studies. Significantly decreased sperm counts (26%) and decreased weights of the epididymides (15%) were reported in male rats exposed to 2,000 ppm 6 hours/day for a total of 90 days, including 60 days before mating to females that were exposed for 14 days before and 7 days after mating (Ono et al. 1996). A slight decrease in sperm count (13%) was also observed at 600 ppm, but histological examination of the testes and epididymides found no abnormalities at either concentration. No significant exposure-related effects on mating behavior or fertility indices were found in this study (Ono et al. 1996). Exposure to 3,000 ppm toluene 8 hours/day, 6 days/week for 12 weeks resulted in a statistically significant 23% decrease in mean seminiferous tubule diameter, decreased immunohistological staining for proliferating cell nuclear antigen (PCNA) in spermatogonia and early-stage spermatocytes, decreased spermatogenesis, increased apoptosis in testes, and various histological and ultrastructural abnormalities in testes (Kanter 2011b). In contrast, no statistically significant changes in numbers of spermatogenic cells at various stages in seminiferous tubules, testes weight, testicular histology, or serum hormone levels were found in rats exposed to 4,000 or 6,000 ppm 2 hours/day for 5 weeks, compared with controls, but significant changes in sperm parameters were found in rats exposed to 6,000 ppm (Ono et al. 1999). Changes included a 66% decrease in sperm head counts, a 78% decrease in motility, and a 76% decrease in ovum penetration (Ono et al. 1999). In rats exposed to 0 or 1,500 ppm 4 hours/day for 20 days, no exposure-related effects were revealed by histological examination of testis and epididymis sections, by immunohistochemical analysis of testis and epididymis for heat shock protein 70 (HSP70), c-Fos protein, and PCNA, or on testis or epididymis weights, although body weights of exposed rats were significantly lower than controls (Ishigami et al. 2005). In rats exposed to paint thinner (66% toluene) at toluene concentrations of 1,500 ppm for 2 hours for up to 30 days, significantly reduced seminiferous tubule diameter, testicular weight, and serum and testicular testosterone levels were found (Yilmaz et al. 2006). Other components in paint thinner (acetone, isobutyl acetate, butyl glycol, and isobutanol) may have contributed to these effects.

Exposure of male mice to concentrations of 100 or 400 ppm for 8 weeks did not induce dominant lethal mutations or cause pre- and post-implantation losses after they were mated with nonexposed females (API

3. HEALTH EFFECTS

1981). There were no treatment-related histopathological lesions in the testes of rats or mice exposed to up to 3,000 ppm toluene for 14–15 weeks although rats showed a 15% increase in testes weight (NTP 1990). In 2-generation reproduction studies in rats, exposure of males and females to concentrations of 100, 500, or 2,000 ppm 6 hours/day for up to 95 days did not adversely affect reproductive parameters (e.g., fertility) or offspring survival compared with unexposed controls (API 1985; Roberts et al. 2003). No effects on reproductive performance or offspring survival were found when males only or females only were exposed to 2,000 ppm by a similar protocol and mated to unexposed partners (Roberts et al. 2003). Additionally, no effects on pregnancy outcomes or offspring survival were observed following exposure to 1,200 ppm 6 hours/day from GD 7 to PND 18 (Dalgaard et al. 2001; Hass et al. 1999).

Chronic-Duration Animal Studies. Toluene did not cause altered weight or histopathological lesions of the ovaries or testes in rats exposed to toluene concentrations up to 300 ppm toluene for 24 months (CIIT 1980) or in rats or mice at concentrations up to 1,200 ppm for 2 years (NTP 1990).

The highest NOAEL values and all LOAEL values for each reliable study for reproductive effects in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

3.2.1.6 Developmental Effects

Overview. A number of published reports have described birth defects, similar to those associated with fetal alcohol syndrome, in children born to women who intentionally inhaled large quantities of toluene or other organic solvents during pregnancy (Arnold and Wilkins-Haug 1990; Arnold et al. 1994; Erramouspe et al. 1996; Goodwin 1988; Hersh 1988; Hersh et al. 1985; Lindemann 1991; Pearson et al. 1994; Wilkins-Haug and Gabow 1991a). These reports suggest that exposure to high concentrations of toluene during pregnancy can be toxic to the developing fetus. Studies of women exposed during pregnancy to much lower concentrations of toluene in the workplace are restricted to a retrospective study of 14 women in Finland occupationally exposed to mixed solvents, which suggested that solvent exposure may increase risk for central nervous system anomalies and neural tube closure defects (Holmberg 1979). A number of developmental toxicity studies with rats, mice, and rabbits involving toluene exposure by inhalation during gestation have been conducted to further describe developmentally toxic effects from toluene and exposure-response relationships. The results indicate that toluene did not cause maternal or developmental toxic effects in animals at exposure levels <1,000 ppm administered for 6–7 hours/day during gestation (API 1978, 1991, 1992; Jones and Balster 1997; Klimisch et al. 1992; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997; Tsukahara et al. 2009; Win-Shwe et

3. HEALTH EFFECTS

al. 2012a, 2012b; Yamamoto et al. 2009). Predominant effects reported at concentrations ranging from 1,000 to 3,000 ppm included retarded fetal growth and skeletal development, altered development of behavior in offspring, and were almost always accompanied by signs of maternal toxicity (API 1991, 1992; Dalgaard et al. 2001; Hass et al. 1999; Hougaard et al. 2003; Jones and Balster 1997; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997). Other animal studies reported that continuous, 24-hour/day exposure during gestation caused maternal body weight depression and effects on fetuses including depressed body weight and delayed skeletal ossification at toluene concentrations as low as 133–399 ppm in rats, mice, and rabbits (Hudak and Ungvary 1978; Ungvary and Tatrai 1985). Performance deficits in a few neurobehavioral tests were observed in one study of offspring of pregnant mouse dams exposed by inhalation to 2,000 ppm, but not to 200 or 400 ppm, for 60 minutes 3 times/day on GDs 12–17 (Jones and Balster 1997). Performance deficits were not observed in offspring of pregnant rat dams exposed by inhalation to concentrations up to 2,000 ppm for 6 hours/day during gestation (Hougaard et al. 2003; Ono et al. 1995; Thiel and Chahoud 1997). Impaired learning and memory, increased malformations, and fetal death have been observed when animals are exposed during gestation to higher concentrations modeling solvent abuse (8,000–16,000 ppm, 15–30 minutes/day) (Bowen and Hannigan 2013; Bowen et al. 2005, 2009a; Callan et al. 2015).

Human Studies. Microcephaly, central nervous system dysfunction, attentional deficits, minor craniofacial and limb anomalies, developmental delay, and variable growth have been described in case reports of children who were exposed to toluene *in utero* as a result of maternal solvent abuse during pregnancy (Arnold and Wilkins-Haug 1990; Arnold et al. 1994; Hersh 1988; Hersh et al. 1985; Lindemann 1991; Pearson et al. 1994; Wilkins-Haug and Gabow 1991a). Growth retardation and dysmorphism were reported in five infants born to women who were chronic paint sniffers (Goodwin 1988).

Children born to toluene abusers have exhibited renal tubular acidosis immediately after birth that is thought to be due to alterations in ion gradient maintenance in the renal tubules. The kidney effects are often associated with hyperchloremia (Erramouspe et al. 1996; Goodwin 1988; Lindemann 1991). In one report (Goodwin 1988), the acidosis was resolved within 3 days of birth, while in the other two reports, it took about 2 weeks for the resolution of the metabolic acidosis. There were no abnormalities in the urinary tract of two children born to chronic toluene abusers based on results of a renal ultrasound evaluation (Hersh 1988).

3. HEALTH EFFECTS

Studies of women exposed during pregnancy to much lower concentrations of toluene in the workplace are restricted to a single study. A retrospective study of 14 women in Finland occupationally exposed to mixed solvents (some of which included toluene), as well as various drugs including aspirin, vasodilators, and diuretics, suggested that solvent exposure may increase the risk of central nervous system anomalies and defects of neural tube closure in children exposed *in utero* (Holmberg 1979).

While these findings suggest that occupational exposure to solvents may be toxic to the developing fetus, the small sample size coupled with multiple chemical exposures cannot support definitive conclusions regarding developmental toxicity of exposure to low toluene levels in humans.

Standard Developmental Toxicity Studies in Animals. Numerous studies in rats, mice, and rabbits with inhalation exposure to concentrations <1,000 ppm toluene for 1–8 hours/day during various gestational periods have found no exposure-related effects on maternal and developmental end points (API 1978, 1991, 1992; Jones and Balster 1997; Klimisch et al. 1992; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997). Exposure to 1,000–3,500 ppm during gestation resulted in decreased fetal/pup weight and/or decreased neonatal growth in a number of studies (API 1991, 1992; Dalgaard et al. 2001; Hass et al. 1999; Hougaard et al. 2003; Ladefoged et al. 2004; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997). Significantly decreased maternal body weight gain was observed at exposure levels causing decreased weight or growth in offspring, except in studies by Hass et al. (1999), which reported no significant change in maternal body weight gain at 1,200 ppm and Thiel and Chahoud (1997), which reported fetal body weight effects at 1,000 ppm and maternal body weight effects at 1,200 ppm. Additional developmental effects observed in these studies include delayed ossification in rat fetuses following exposure to 3,000 ppm for 6 hours/day from GD 6 to 15 (API 1991; Roberts et al. 2007), increased postnatal/preweaning mortality in rat pups following exposure to 1,200 ppm for 6 hours/day from GD 9 to 21 (Thiel and Chahoud 1997), and total resorption of rat litters with exposure to 5,000 ppm for 6 hours/day from GD 6 to 15 (API 1992). In another study, exposure of pregnant mice to 200 or 400 ppm, 7 hours/day on GDs 7–16 produced significantly increased litters with fetuses with enlarged renal pelvises in the 200-ppm group (but not in the 400-ppm group) and a difference in the distribution of fetuses with varying numbers of ribs in the 400-ppm group, compared with the control group (Courtney et al. 1986). Similarly, exposure of pregnant mice to 133 or 266 ppm, 3–4 hours/day on GDs 6–15, did not significantly affect maternal or fetal survival, or incidences of fetuses with visceral or skeletal anomalies or malformations. However, incidences of fetuses with decreased body weight and skeletal retardations were significantly increased in the group exposed to 266 ppm (Ungvary and Tatrai 1985).

3. HEALTH EFFECTS

A series of studies indicate that continuous, 24-hour/day exposure during gestation can cause maternal and developmental toxicity at toluene concentrations as low as 133–399 ppm in rats, mice, and rabbits (Hudak and Ungvary 1978; Ungvary and Tatrai 1985). In pregnant rats exposed to 399 ppm, 24 hours/day on GDs 1–8 or 9–14, no statistically significantly increased incidences of fetuses with visceral or skeletal malformations were found (Hudak and Ungvary 1978). However, 5/14 dams died, fetal body weight was decreased, and retardation of fetal skeletal development occurred with exposure on GDs 1–8, and 2/21 dams died and increased incidences of skeletal anomalies (extra ribs, fused sternbrae) were found with exposure on GDs 9–14 (Hudak and Ungvary 1978). No maternal mortality, fetal weight loss, or fetal malformations were found in another group of rats exposed to 266 ppm, 8 hours/day on GDs 1–21, but significantly increased incidence of fetuses with skeletal retardation occurred (Hudak and Ungvary 1978). In mice exposed to 133 ppm, 24 hours/day on GDs 6–13, no effects on maternal survival or incidences of fetuses with malformations were found, but fetal body weight was significantly decreased (Hudak and Ungvary 1978). All 15 pregnant mice died that were exposed to 399 ppm, 24 hours/day on GDs 6–13 (Hudak and Ungvary 1978). In rabbits exposed to 133 ppm, 24 hours/day on GDs 7–20, no significant effects were found on maternal or fetal survival, fetal body weight, or incidences of fetuses with skeletal retardation, minor anomalies, skeletal or visceral malformations (Ungvary and Tatrai 1985). Following exposure to 266 ppm by the same protocol, 2/8 rabbit dams died, 4/8 dams aborted, and no live fetuses were found at sacrifice (Ungvary and Tatrai 1985).

Studies of Reproductive System Development in Animals. Studies of inhalation exposure of rats to concentrations as high as 1,800 ppm for 6 hours/day during gestation and/or early postnatal periods have provided little evidence of adverse effects on reproductive performance in adulthood. Female offspring of dams exposed to 1,200 ppm toluene, 6 hours/day on GDs 9–21 showed a significant delay in reproductive development (vaginal opening) compared with unexposed controls, but no significant exposure-related effects on mating, fertility, or pregnancy indices were observed in groups of male and female F1 offspring exposed during gestation to 300, 600, 1,000, or 1,200 ppm (Thiel and Chahoud 1997). In another study, no exposure-related changes were observed in the appearance of sexual maturation landmarks in male or female rat offspring of dams exposed to 1,200 ppm toluene, 6 hours/day on GD 7 to PND 18 (Hass et al. 1999). No significant changes in the percent of motile sperm or any parameters of sperm motility on PND 100 were observed in male offspring of dams exposed to 1,200 ppm toluene, 6 hours/day from GD 7 to PND 18 (Dalgaard et al. 2001). In male offspring of dams exposed to 1,800 ppm toluene, 6 hours/day from GD 7 to 20, no significant changes in testicular weight or histology at PND 11, 21, or 90 were found, compared with controls (Dalgaard et al. 2001). Additionally, no

3. HEALTH EFFECTS

significant changes in serum prolactin or LH were observed in 8-week-old male rats following neonatal exposure to 80 ppm for 6 hours/day from PND 1 to 7, compared with controls (von Euler et al. 1989). However, Tsukahara et al. (2009) reported that nose-only exposures of 0.09–9 ppm for 90 minutes/day in dams from GD 14.5 to 18.5 resulted in statistically significant decreased fetal serum testosterone and 3 β -HSD steroidogenic enzyme immunoreactivity in fetal testes in the 0.9 and 9 ppm groups, and significantly decreased 3 β -HSD mRNA levels in the 0.9 ppm group only. These effects were more pronounced at 0.9 ppm than 9 ppm and were not accompanied by any histological changes in the fetal testes; mechanistic understanding is inadequate to determine biological adversity of the observed effects.

Studies of Neurological Development in Animals. Gestational exposure by inhalation to toluene concentrations as high as 1000–1,500 ppm did not affect the performance of offspring in neurobehavioral tests in several animal studies (Jones and Balster 1997; Ladefoged et al. 2004; Ono et al. 1995; Thiel and Chahoud 1997); at 2,000 ppm, one study reported some statistically significant performance deficits in mouse offspring (Jones and Balster 1997), whereas another found no statistically significant deficits in rat offspring (Ono et al. 1995).

Mouse pups from dams exposed to 2,000 ppm for 60 minutes, 3 times/day on GDs 12–17 gained less weight between PND 2 and 8 compared with unexposed controls, and showed statistically significant increased latency of righting reflex on PNDs 1, 5, and 6, decreased forelimb grip strength on PNDs 5–7 and 9–11, and increased latency to climb in the inverted screen test on PNDs 14–17 (Jones and Balster 1997). No statistically significant effects on these end points were observed after exposure to 200 or 400 ppm by the same protocol, and no effects on times to reach developmental landmarks such as incisor eruption and eye opening were noted in any of the exposure groups (Jones and Balster 1997).

In another study, offspring of rat dams exposed to 600 or 2,000 ppm, 6 hours/day on GDs 7–17 showed no statistically significant differences from control rats in postnatal viability or physical development through PND 21, tests of reflexes on PNDs 6–10, locomotor activity during postnatal week 4, balance on a rotating rod during postnatal week 7, or learning ability in the Biel water maze test during postnatal week 6 (Ono et al. 1995).

No consistent, concentration-dependent performance deficits were found in tests of reflexes on PND 3, balance on a rotating rod on PND 18, locomotor activity on PNDs 31–34, or discrimination learning on

3. HEALTH EFFECTS

PNDs 70–81 in rat offspring of dams exposed to 300, 600, 1,000, or 1,200 ppm, 6 hours/day on GDs 9–21, compared with controls (Thiel and Chahoud 1997).

No changes were observed in Morris water maze spatial learning and memory in female offspring following exposure to 1,500 ppm for 6 hours/day from GD 7 to 20, compared with controls (Ladefoged et al. 2004).

Exposure of pregnant rats to 1,200 ppm toluene, 6 hours/day from GD 7 to PND 18 produced statistically significant decreased postnatal growth (PNDs 0–10), delayed ontogeny of reflexes between PND 2 and 13, and increased open-field locomotor activity on PND 28 in male and female offspring, compared with unexposed controls (Hass et al. 1999). Significantly increased latency to find the hidden platform in the Morris water maze test after platform relocation was found in 13-week-old exposed female offspring, compared with nonexposed female offspring, when data were analyzed on an individual basis, but not on a litter basis. No consistent significant effects were observed in rotarod performance on PNDs 22–26, auditory brainstem responses at 4 months, or in physical development (e.g., eye opening) on PND 14 (Hass et al. 1999).

Decreased neonatal growth, impaired auriculonascephalic reflex (reflexive movement to thermal and olfactory stimuli, e.g., “dummy dam”), impaired ability to locate a visible platform in the Morris water maze, and impaired learning in the passive avoidance task were reported for neonatal rats exposed by inhalation to 500 ppm on PNDs 7–30 (Museridze et al. 2010). However, the available report did not indicate the daily exposure duration used in this study, provided no indication that air concentrations were measured during the exposure periods, and used mongrel rats.

Significant localized changes in dopamine and noradrenaline neurotransmitter levels and utilization were observed in 8-week-old adult male rats that were exposed to 80 ppm for 6 hours/day from PND 1 to 7, compared with controls (von Euler et al. 1989). Neurotransmitter levels were increased in some areas of the brain, were decreased in some areas, and remained the same in other areas. Localized changes in dopamine and noradrenaline neurotransmitter levels and utilization were also observed in 8-week-old rats exposed both neonatally on PNDs 1–7 and again for 3 days during postnatal week 8 to 80 ppm (6 hours/day), compared with previously unexposed 8-week-old rats (von Euler et al. 1989). The biological adversity of region-specific neurotransmitter alterations in the absence of neurobehavioral changes is unknown.

3. HEALTH EFFECTS

Biochemical and cellular changes in brain tissues have been reported in several studies of animals exposed to toluene by inhalation during gestation or during early postnatal periods. In rats, offspring of dams exposed to 1,500–1,800 ppm during gestation had elevated levels of cerebellar apoptosis during postnatal development (Dalgaard et al. 2001; Ladefoged et al. 2004) and increased *in vitro* generation of reactive oxygen species in cultured synaptosomes (Edelfors et al. 2002), and neonatal rats exposed to 100–500 ppm had reversible decreases in the volume of the granular cell layer in the dentate of the hippocampus (Slomianka et al. 1990). In mice, offspring of dams exposed to 400 ppm had elevated LDH activity on PND 21 (Courtney et al. 1986). Mechanistic understanding is inadequate to determine the biological adversity of these effects.

Animal Studies Modeling High Concentration Solvent Abuse. A series of studies in rats were designed to model human solvent abuse during pregnancy to determine if repeated brief exposures to very high concentrations during gestation could cause adverse developmental effects. These studies found that exposure to 8,000–16,000 ppm for 15–30 minutes twice daily from GD 8 to 20 caused decreased maternal body weight gain; decreased pup/fetal weight, length, and postnatal growth; decreased placental weight; increased number of litters with malformed, runted, or dead pups; impaired motor coordination in offspring; impaired learning and memory in offspring, and altered reward-seeking behavior with increased impulsivity in offspring (Bowen and Hannigan 2013; Bowen et al. 2005, 2007, 2009a, 2009b; Callan et al. 2015; Jarosz et al. 2008). No changes were found in the achievement of physical landmarks (Bowen and Hannigan 2013; Bowen et al. 2005).

The highest NOAEL values and all LOAEL values for each reliable study for developmental effects in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

3.2.1.7 Cancer

Human Studies. Numerous human epidemiology studies were located that assessed toluene exposure as a possible risk factor for cancer. Cancers of most sites were not significantly associated with toluene exposure in any study, and there was weak consistency in the findings of those studies that did find association of a particular cancer type with toluene exposure. Five cohort studies involved occupationally exposed workers exposed predominantly to toluene (Antilla et al. 1998; Lehman and Hein 2006; Svensson et al. 1990; Walker et al. 1993; Wiebelt and Becker 1999), whereas the remainder of the human studies primarily involved subjects exposed to mixtures of solvents including toluene (Austin and Schnatter 1983; Blair et al. 1998; Carpenter et al. 1988; Gao et al. 2014; Gérin et al. 1998; Heck et al.

3. HEALTH EFFECTS

2013, 2014, 2015; Lundberg and Milatou-Smith 1998; Olsson and Brandt 1980; Wen et al. 1985; Wilcosky et al. 1984). The information from these studies is inadequate to assess the carcinogenic potential of toluene, predominantly because of the lack of consistent findings across the studies and the likelihood that many of the studied groups were exposed to multiple chemicals.

Svensson et al. (1990) compared cancer incidence and mortality in a cohort of Swedish printers, exposed primarily to toluene and employed for at least 3 months between 1925 and 1985, to mortality and cancer incidence for the region. Current and historical monitoring data were used to estimate yearly average concentrations of toluene in the air. Concentrations had declined from about 450 ppm in the 1940s to 30 ppm by the mid-1980s. There were indications of excess risk of morbidity (standardized incidence ratio, SIR) and mortality (standardized mortality ratio, SMR) for respiratory tract cancer (SMR, 1.4; 95% CI, 0.7–2.5; n=11; SIR, 1.8; 95% CI, 1.0–2.9; n=16), stomach cancer (SMR 1.4, 95% CI 0.7–2.5, n=11; SIR 1.8, 95% CI 1.0–2.9, n=16), stomach cancer (SMR 2.7, 95% CI 1.1–5.6, n=7; SIR 2.3, 95% CI 0.9–4.8, n=7), and colo-rectal cancer (SMR 2.2, 95% CI 0.9–4.5, n=7; SIR 1.5, 95% CI 0.7–2.8, n=9), but there was no significant association between increased risk and cumulative exposure.

Walker et al. (1993) conducted a cohort mortality study among 7,814 shoe-manufacturing workers (2,529 men and 5,285 women) from two plants in Ohio in operation since the 1930s. Workers were exposed to solvents and solvent-based adhesives. Based on results of a hygiene survey (1977–1979), exposure was thought to be primarily to toluene (10–72 ppm), but other chemicals (e.g., 2-butanone, acetone, and hexane) were also recorded at similar concentrations. IARC (1999) noted that benzene may have been present as an impurity of toluene. Mortality follow up was from 1940 to 1982 and relative risk estimates (SMRs) were derived using the general population of the United States as controls. There were excess risks of lung cancer for both men (SMR 1.6, 95% CI 1.2–2.0, n=68) and women (SMR 1.3, 95% CI 0.9–1.9, n=31), but smoking may have been a confounding factor and relative risk of lung cancer did not increase with increasing duration of employment. There was a slight excess risk for colon cancer among men (SMR 1.3, 95% CI 0.8–2.1, n=18) and women (SMR 1.2, 95% CI 0.8–1.8, n=28). Other cancers showed no excess risk. In a follow-up study of this cohort, an excess of lung cancer deaths persisted with additional follow-up through 1999 (SMR 1.36, 95% CI 1.19–1.54, n=248), but the relative risk of lung cancer still did not increase with increasing duration of employment (Lehman and Hein 2006). No other cancers showed excess risk in this follow-up.

Antilla et al. (1998) carried out a retrospective cohort analysis of 5,301 workers (3,922 male and 1,379 female) monitored for biological markers of occupational exposure to styrene, toluene or xylene

3. HEALTH EFFECTS

over the period 1973–1992. No increase in overall cancer risk or risk for cancers at specific tissue sites was associated with exposure to toluene, except for a nonsignificant increase in the incidence of lung cancer in individuals exposed to toluene for more than 10 years (SIR 1.62, 95% CI 0.33–4.73, three cases). Antilla et al. (1998) noted, however, that these workers may also have been exposed to benzene.

Wiebelt and Becker (1999) examined cancer incidence and mortality in a cohort of 6,830 German males employed in rotogravure printing plants for at least one year between 1960 and 1992, and compared them to mortality and cancer incidence for West Germany. Workers were divided into three work areas: printing/proof printing (<100 ppm after 1985, <200 ppm 1960–1985), printing cylinder preparation (<30 ppm) and finishing (<30 ppm). When the three groups were examined together, no statistically significant increases in overall cancer risk or risk for cancers at specific tissue sites were associated with exposure to toluene. When analyzed by work area, a strong increase in mortality from bone and connective tissue cancers was found in the workers from the highest exposure group (printers) based on a small number of observed cases. SMRs for bone and connective tissue cancers were 8.1 (95% CI 1.4–32.4; three cases) and 6.3 (95% CI 1.2–25.9; three cases), respectively. Wiebelt and Becker (1999) noted that the significance of these findings is unclear as they have not been previously associated with toluene exposure. Nonsignificant increases in mortality from lung cancer were observed in printers (SMR 1.3, 95% CI 0.7–2.5) and finishers (SMR 1.8, 95% CI 0.8–4.4); however, the risk was greater in the group with the lower toluene exposure levels.

Many of the other human epidemiological cancer studies showed positive associations between exposure to toluene and cancer at one or more tissue site, but individuals were exposed to multiple chemicals in all of these studies (Austin and Schnatter 1983; Blair et al. 1998; Carpenter et al. 1988; Gao et al. 2014; Gérin et al. 1998; Heck et al. 2013, 2014, 2015; Lundberg and Milatou-Smith 1998; Olsson and Brandt 1980; Wen et al. 1985; Wilcosky et al. 1984). Nested case-control studies included studies of prostate and brain cancer within cohorts of Texas petrochemical plant workers (Austin and Schnatter 1983; Wen et al. 1985), of lung cancer, stomach cancer, and leukemia among U.S. rubber workers (Wilcosky et al. 1984), cancer of the central nervous system among a group of Tennessee nuclear facility workers (Carpenter et al. 1988), prostate cancer and multiple myeloma among Swedish paint industry workers (Lundberg and Milatou-Smith 1998), and multiple myeloma, nonHodgkin's lymphoma, and breast cancer among aircraft maintenance facility workers (Blair et al. 1998). Community-based case-control studies report possible associations between Hodgkin's disease in Swedish patients and controls (Olsson and Brandt 1980), childhood leukemia in Chinese or Californian patients and controls (Gao et al. 2014; Heck

3. HEALTH EFFECTS

et al. 2014), childhood retinoblastoma (but not neuroblastoma) in Californian patients and controls (Heck et al. 2013, 2015), and esophageal and rectal cancer in Canadian patients and controls (Gérin et al. 1998).

Animal Studies. Inhalation cancer bioassays carried out in experimental animals have produced no evidence to support toluene as a potential carcinogen. No increased incidences of treatment-related neoplastic lesions were observed in Fischer 344 rats or B6C3F1 mice exposed to toluene concentrations up to 1,200 ppm for 6.5 hours/day, 5 days/week for 2 years (Huff 2003; NTP 1990). Similar results were reported for another study in which Fischer 344 rats were exposed to toluene concentrations up to 300 ppm 6 hours/day, 5 days/week for 2 years, but the maximum exposure concentration in this study was likely below that necessary to approach a maximum tolerated dose (CIIT 1980; Gibson and Hardisty 1983). The NTP (1990) study was well conducted, achieved the maximum tolerated dose, and provides evidence suggesting a lack of carcinogenicity of toluene in experimental animals.

3.2.2 Oral Exposure

Studies of the effects of oral exposure to toluene are limited. Only four case studies were located regarding health effects in humans after oral exposure to toluene and there are only a minimal number of animal studies.

3.2.2.1 Death

Human Case Study. Ingestion of approximately 60 mL (625 mg/kg) of toluene proved fatal for a 51-year old male (Ameno et al. 1989). Death occurred within 30 minutes of ingestion. The autopsy results revealed constriction and necrosis of the myocardial fibers, a markedly swollen liver, congestion and hemorrhage of the lungs, and acute tubular kidney necrosis. The probable cause of death was determined to be severe depression of central nervous system function.

Acute-Duration Animal Studies. The limited number of studies on the acute oral toxicity of toluene in animals have focused on lethal effects. The acute oral LD₅₀ of toluene in adult rats ranged from 5.5 to 7.4 g/kg (Kimura et al. 1971; Smyth et al. 1969; Withey and Hall 1975; Wolf et al. 1956). Age may play a role in determining the lethal dose for toluene. The LD₅₀ value for 14-day-old rats was 3.0 g/kg, which is markedly lower than the adult values (Kimura et al. 1971).

Intermediate-Duration Animal Studies. Mice were more sensitive than rats to the lethal effects of toluene in 13-week gavage studies. All rats and mice that received 5,000 mg/kg died within the first

3. HEALTH EFFECTS

week. Mortality was also high for groups receiving 2,500 mg/kg with eight out of ten male rats, one out of ten female rats, and with four out of ten male and female mice dying before the end of the study. A dose of 1,250 mg/kg/day was lethal in 10% of female mice but no deaths occurred in male mice or in rats of either sex (NTP 1990). LOAEL values from each reliable study for death in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

3.2.2.2 Systemic Effects

Overview. Human data pertaining to the systemic effects of oral exposure to toluene are limited to four case studies (Ameno et al. 1989; Caravati and Bjerk 1997; Einav et al. 1997; Malingre et al. 2002). Animal data are also limited, but include evidence for cardiovascular, hematological, hepatic, renal, and body weight effects in rats and mice exposed orally to toluene at dosage levels ranging from 312 to 2,500 mg/kg/day for 13 weeks (NTP 1990), hepatic effects in mice exposed to 105 mg/kg/day for 28 days (Hsieh et al. 1989), and hepatic effects in rats exposed to 5,200 mg/kg/day for up to 45 days (Kamel and Shehata 2008). However, no cardiovascular, hematological, hepatic, or renal effects were reported in rats exposed to 590 mg/kg/day for 6 months (Wolf et al. 1956). Acute exposure to single doses $\geq 1,000$ mg/kg have resulted in cardiovascular and hepatic effects (Ayan et al. 2013; Gordon et al. 2010; Tas et al. 2013b). All systemic effects are discussed below. The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

Respiratory Effects.

Human Case Studies. Lung congestion and hemorrhage were reported in one case report involving lethal ingestion of approximately 625 mg/kg toluene by an adult male (Ameno et al. 1989). A 15-month-old girl who accidentally ingested paint thinner was intubated after presenting with severe central nervous system depression (Malingre et al. 2002). Extubation the following day resulted in serious respiratory stridor and bronchoscopy showed mucosal lesions and pronounced edema. The patient was re-intubated for an additional 8 days. No residual damage was observed following extubation (Malingre et al. 2002). No additional studies were located regarding respiratory effects in humans after oral exposure to toluene.

Animal Studies. No respiratory effects were reported in mice or rats after oral exposure to toluene at dosage levels up to 2,500 mg/kg/day for 13 weeks (NTP 1990) or 590 mg/kg/day for 6 months (Wolf et

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
ACUTE EXPOSURE								
Death								
1	Human	once				625 (death in 30 minutes)	Ameno et al. 1989	Case report.
2	Rat (Sprague-Dawley)	NS (G)				5568 (LD50 young adult rat)	Kimura et al. 1971	
3	Rat (Sprague-Dawley)	NS (G)				6438 (LD50 adult rat)	Kimura et al. 1971	
4	Rat (Sprague-Dawley)	NS (G)				2610 (LD50 14-day-old rat)	Kimura et al. 1971	
5	Rat	NS (G)				7300 (LD50)	Smyth et al. 1969	
6	Rat	once (G)				5580 M (LD50 adult rats)	Withey and Hall 1975	
7	Rat (Wistar)	once (G)				7000 (LD50 young adult rats)	Wolf et al. 1956	

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
Systemic								
8	Human	once	Resp			625 M (lung congestion and hemorrhage)	Ameno et al. 1989	Case report.
			Cardio			625 M (necrosis of myocardial fibers)		
			Gastro	625 M				
			Hepatic			625 M (enlarged liver)		
			Renal			625 M (acute tubular necrosis)		
9	Rat (Wistar)	once	Hepatic		5200 M (Slight degeneration of hepatocytes and mononuclear cell infiltration; increased serum AST, ALT; increased apoptosis)		Ayan et al. 2013	
10	Rat (Long- Evans)	once (GO)	Cardio	1200 M			Gordon et al. 2007	Observed tachycardia and hypertension attributed to increased locomotion; no change in ECG.
11	Rat (Brown Norway)	once (GO)	Cardio	600 M	1000 M (6, 8, and 13% decrease in relative heart weight in young, middle aged, and aged rats)		Gordon et al. 2010	
			Bd Wt	1000 M				

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
12	Rat (Sprague- Dawley)	Gd 6-19 1x/d (GO)	Bd Wt			520 F (24% decrease in maternal body wt gain)	Gospe et al. 1994	
13	Rat (Wistar)	once (G)	Cardio		5200 M (congestion, edema and apoptosis in cardiac tissue)		Tas et al. 2013b	
14	Rat (Sprague- Dawley)	Gd 16-19 (GO)	Hepatic	1250 F			Warner et al. 2008	Hepatic NOAEL is for maternal liver weight and histology.
			Renal		1250 F (swollen tubules, tissue adhesion to Bowman's capsule, areas of solidification within glomeruli)			
			Bd Wt	1250 F				

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
15	Mouse (B6C3F1)	14 d (GO)	Resp	600 F			Burns et al. 1994	Endpoints examined: organ weight and histology, clinical chemistry, hematology.
			Hemato		600 F (increased reticulocytes)			
			Hepatic	600 F				
			Renal	600 F				
			Bd Wt	600 F				
Immuno/ Lymphoret								
16	Mouse (B6C3F1)	14 d (GO)		600 F			Burns et al. 1994	Endpoints examined: spleen and thymus weight and histology, bone marrow cell count, immune function. assays, host-resistance assays
Neurological								
17	Human	once				625 M (severe central nervous system depression)	Ameno et al. 1989	Case report.
18	Rat (Long- Evans)	once (GO)			^b 250 M (decrease in amplitude in FEP N3 peak)		Dyer et al. 1988	
19	Rat (Long- Evans)	once (GO)		400 M	800 M (increased locomotor activity)		Gordon et al. 2007	

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
20	Rat (Brown Norway)	once (GO)		300 M	650 M (increased locomotor activity)		Gordon et al. 2010	
21	Rat (Sprague- Dawley)	once (G)			2610 M (increase in motor activity, lacrimation and salivation)		Mehta et al. 1998	
22	Mouse (B6C3F1)	14 d (GO)		600 F			Burns et al. 1994	Endpoints examined: brain weight and histology.
Reproductive								
23	Rat (Sprague- Dawley)	Gd 6-21 (GO)		650 F			Gospe and Zhou 2000	Endpoints evaluated: litter size.
24	Rat (Sprague- Dawley)	Gd 16-19 (GO)		1250 F			Warner et al. 2008	Endpoints evaluated: number of corpora lutea, implantations, pre- and post-implantation loss, resorptions, and live fetuses/litter.
25	Mouse (CD-1)	Gd 7-14 1x/d (GO)		2350 F			NIOSH 1983	Endpoints evaluated: number viable and totally resorbed litters.

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
26	Mouse (ICR)	Gd 8-12 5 d (G)		1800 F			Seidenberg et al. 1986	Endpoints evaluated: litter size.
Developmental								
27	Rat	Gd 6-19				650 (delayed brain development of fetus)	Gospe and Zhou 1998	Gd 19: decreased brain volume, cell size, number of nuclei, and myelination; Pnd 21: decrease myelination (no standard dev't endpoints assessed).
28	Rat (Sprague- Dawley)	Gd 6-21 (GO)				650 (decreased neurogenesis and altered migration of cortical neurons during development)	Gospe and Zhou 2000	Endpoints assessed: litter means for body and brain weight, generation and migration of cortical neurons.
29	Rat (Sprague- Dawley)	Gd 6-19 1x/d (GO)			520 (9.4% reduction in fetal weight)		Gospe et al. 1994	
30	Rat (Sprague- Dawley)	Gd 6-19 1x/d (GO)				650 (11.9% decrease in fetal brain weights, 21% decrease in fetal weights, delayed skeletal ossification)	Gospe et al. 1996	

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
31	Rat (Sprague- Dawley)	Gd 16-19 (GO)			1250	(increased incidence of grade 3 or 4 left renal pelvis dilation)	Warner et al. 2008	
32	Mouse (CD-1)	Gd 7-14 1x/d (GO)		2350			NIOSH 1983	Endpoints evaluated: total litter weights, number of viable and totally resorbed litters, number of live and dead pups per litter.
33	Mouse (ICR)	Gd 8-12 5 d (G)		1800			Seidenberg et al. 1986	Endpoints evaluated: litter size, litter weight, external malformations of dead neonates.
INTERMEDIATE EXPOSURE								
Death								
34	Rat (Fischer- 344)	13 wk 5 d/wk 1x/d (GO)				2500 (8/10 males and 1/10 females died)	NTP 1990	
35	Mouse (B6C3F1)	13 wk 5 d/wk 1x/d (GO)				2500 M (4/10 died) 1250 F (1/10 died)	NTP 1990	

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to ^a Figure	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
Systemic								
36	Rat (albino)	45 d (G)	Hepatic		650 M (increased levels of markers for hepatic apoptosis and oxidative stress)		Kamel and Shehata 2008	Organ weight and histology were not assessed.
			Renal		650 M (increased levels of markers for renal oxidative stress)			

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
37	Rat (Fischer- 344)	13 wk 5 d/wk 1x/d (GO)	Resp	2500			NTP 1990	Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
			Cardio	1250 M	2500 M (38% increase in relative heart weight)			
				625 F	1250 F (11% increase in relative heart weight)			
			Gastro	2500				
			Hemato	2500				
			Musc/skel	2500				
			Hepatic	312 M	625 M (8% increase in liver weight)			
				625 F	1250 F (22% increase in liver weight)			
			Renal	312 M	625 M (6% increase in kidney weight)			
				625 F	1250 F (8% increase in kidney weight)			
			Endocr	2500				
			Bd Wt	1250 M	2500 M (body weight 19% lower than controls)			
				2500 F				

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments	
					Less Serious (mg/kg/day)	Serious (mg/kg/day)			
38	Rat (Wistar)	6 mo 5 d/wk 1x/d (G)	Resp	590 F			Wolf et al. 1956		
			Cardio	590 F					
			Hemato	590 F					
			Hepatic	590 F					
			Renal	590 F					
39	Mouse (CD-1)	28 d (W)	Hemato	105 M			Hsieh et al. 1989		
			Hepatic	22 M	105 M (significant increase in liver weight [19%])				
			Renal	105 M					
			Bd Wt	105 M					
40	Mouse (CD-1)	28 d (W)	Hemato	84 M			Hsieh et al. 1990a	Hepatic and renal NOAELs are for organ weight and gross pathology.	
			Hepatic	84 M					
			Renal	84 M					
			Bd Wt	84 M					

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
41	Mouse (CD-1)	28 d (W)	Bd Wt	105 M			Hsieh et al. 1990b	
42	Mouse (CD-1)	28 d (W)	Endocr	22 M	105 M (increased serum corticosterone and ACTH)		Hsieh et al. 1991	
			Bd Wt	105 M				

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
43	Mouse (B6C3F1)	13 wk 5 d/wk 1x/d (GO)	Resp	2500			NTP 1990	Endpoints evaluated: body and organ weight, organ histology, hematology, clinical chemistry, urinalysis.
			Cardio	2500		5000 (myocardial degeneration)		
			Gastro	2500				
			Hemato	2500				
			Musc/skel	2500				
			Hepatic	625 M	1250 M (10% increase in relative liver weight)			
					312 F (7% increase in relative liver weight)			
			Renal	2500				
			Endocr	2500				
			Bd Wt	625 M 2500 F	1250 M (body weight 16% lower than controls)			
Immuno/ Lymphoret								
44	Rat (Fischer- 344)	13 wk 5 d/wk 1x/d (GO)		2500			NTP 1990	Endpoints evaluated: spleen and thymus weight and histology.

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
45	Mouse (CD-1)	28 d (W)		22 ^C M	105 M (decreased thymus weight; diminished response in immune assays)		Hsieh et al. 1989	
46	Mouse (CD-1)	28 d (W)		22 ^C M	84 M (diminished response in immune assays)		Hsieh et al. 1990a	
47	Mouse (CD-1)	28 d (W)		22 ^C M	105 M (decreased interleukin-2 immune response)		Hsieh et al. 1991	
48	Mouse (B6C3F1)	13 wk 5 d/wk 1x/d (GO)		2500			NTP 1990	Endpoints evaluated: spleen and thymus weight and histology.
Neurological								
49	Rat (albino)	15, 30, or 45 d (G)			650 M (increased levels of markers for cortical and cerebellar apoptosis and oxidative stress)		Kamel and Shehata 2008	
50	Rat (Fischer- 344)	13 wk 5 d/wk 1x/d (GO)		625		1250 (brain necrosis)	NTP 1990	Endpoints assessed: brain weight and histology, clinical signs.

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
51	Mouse (B6C3F1)	13 wk 5 d/wk 1x/d (GO)		625 M 1250 F	1250 M (12% increase in relative brain weight)	2500 (ataxia, hypoactivity, prostration)	NTP 1990	Endpoints assessed: brain weight and histology, clinical signs.
Reproductive								
52	Rat (albino)	15, 30, or 45 d (G)			650 M (increased levels of markers for testicular oxidative stress)		Kamel and Shehata 2008	Reproductive organ weight and histology were not assessed. Reproductive function was not assessed.
53	Rat (Fischer- 344)	13 wk 5 d/wk 1x/d (GO)		2500			NTP 1990	Endpoints evaluated: organ weight and histology; reproductive function not assessed.
54	Mouse (B6C3F1)	13 wk 5 d/wk 1x/d (GO)		625 M 2500 F	1250 M (7% increase in relative testicular weight)		NTP 1990	Endpoints evaluated: organ weight and histology; reproductive function not assessed.

3. HEALTH EFFECTS

Table 3-3 Levels of Significant Exposure to Toluene - Oral

(continued)

Key to Figure ^a	Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL (mg/kg/day)	LOAEL		Reference Chemical Form	Comments
					Less Serious (mg/kg/day)	Serious (mg/kg/day)		
Developmental								
55	Mouse (Hybrid)	Gd 0-21 + Ppd 0-55 (W)		21	106	(increased open-field activity; lack of habituation)	Kostas and Hotchin 1981	

a The number corresponds to entries in Figure 3-2.


b Used to derive an acute oral minimal risk level (MRL); dose (250 mg/kg/day) divided by an uncertainty factor of 300 (3 for use of a minimally adverse LOAEL, 10 for interspecies differences in response, and 10 for human variability), resulting in an MRL of 0.8 mg/kg/day

c Used to derive an intermediate oral minimal risk level (MRL) along with 2 companion studies supporting a NOAEL of 22 mg/kg/day for immunological effects; dose divided by an uncertainty factor of 100 (10 for interspecies differences in response and 10 for human variability), resulting in an MRL of 0.2 mg/kg/day


ACTH = adrenocorticotrophic hormone; ALT = alanine amino transferase; AST = aspartate aminotransferase; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); ECG = electrocardiogram; Endocr = endocrine; F = Female; FEP = flash evoked potential; (G) = gavage; Gastro = gastrointestinal; Gd = gestational day; (GO) = gavage in oil; Hemato = hematological; Immuno/Lymphoret = immunological/lymphoreticular; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; Ppd = post-parturition day; Resp = respiratory; x = time(s); (W) = drinking water; wk = week(s)

3. HEALTH EFFECTS

Figure 3-2 Levels of Significant Exposure to Toluene - Oral
Acute (≤ 14 days)




3. HEALTH EFFECTS

Figure 3-2 Levels of Significant Exposure to Toluene - Oral (*Continued*)Acute (≤ 14 days)

3. HEALTH EFFECTS

Figure 3-2 Levels of Significant Exposure to Toluene - Oral (*Continued*)


Intermediate (15-364 days)



3. HEALTH EFFECTS

Figure 3-2 Levels of Significant Exposure to Toluene - Oral (*Continued*)

Intermediate (15-364 days)



3. HEALTH EFFECTS

al. 1956). No changes in lung weight or histology were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls (Burns et al. 1994).

Cardiovascular Effects.

Human Case Studies. One case study involving lethality in humans reported necrosis of myocardial fibers after oral exposure to 625 mg/kg toluene (Ameno et al. 1989). Severe sinus bradycardia was reported in a man who accidentally ingested 30 mL of an organic solvent containing toluene and other chemicals (Einav et al. 1997). No cardiovascular effects were reported in a 15-month-old girl following ingestion of paint thinner (Malingre et al. 2002).

Acute-Duration Animal Studies. Cardiac edema and congestion were observed in rats given single gavage doses of 5,200 mg/kg, compared with controls (Tas et al. 2013b). The number of TUNEL-labeled cardiac cells were significantly increased by ~7-fold in treated rats and semi-quantitative caspase-3 labeling was increased, compared with controls, indicating increased apoptosis in heart tissue. Blood levels of troponin T, a marker for ischemic heart damage, were also significantly increased 14-fold in toluene-exposed rats, compared with controls. No significant changes in heart rate or blood pressure were observed (Tas et al. 2013b).

In a multi-dose study, rats were given single oral doses of 0, 400, 800, and 1,200 mg/kg in random order, with 72 hours between each dose (Gordon et al. 2007). Heart rate and blood pressure were significantly elevated following the 800 and 1,200 mg/kg doses for ~1 hour, compared with the vehicle control dose; however, these findings coincided with significant, dose-related increases in motor activity. Therefore, they likely do not represent adverse cardiac effects of toluene exposure. No significant treatment-related findings were observed in electrocardiograms (Gordon et al. 2007), indicating a 1,200 mg/kg NOAEL for cardiac effects.

Transient increases in heart rate and motor activity were also observed in young, middle aged, and aged rats following single gavage doses of 0, 300, 650, or 1,000 mg/kg, and no treatment-related histopathological changes were observed in cardiac tissue in any age group (Gordon et al. 2010). However, relative heart weights of young, middle aged, and aged rats given 1,000 mg/kg were statistically significantly reduced by 6, 8, and 13%, respectively, compared with controls, indicating adverse cardiac effects. Several changes in iron content, enzyme activities and mRNA levels for genes involved in thrombosis, vasoconstriction, and inflammation were also noted in cardiac tissue by Gordon

3. HEALTH EFFECTS

et al. (2010). Activity of aconitase was significantly decreased in the young and middle aged rats at 1,000 mg/kg, activity of ferritin was significantly increased in the middle aged rats at 1,000 mg/kg, and activity of mitochondrial ubiquinone reductase was significantly increased in the middle-aged rats at 650 and 1,000 mg/kg. No exposure-related changes in other cardiac biochemical end points (superoxide dismutase, glutathione transferase, glutathione, mitochondrial aconitase, mitochondrial isocitrate dehydrogenase, or mitochondrial ferritin) were found. Additionally, cardiac mRNA levels for genes involved in thrombosis, oxidative stress, vasoconstriction, and inflammation were assessed in cardiac tissue from rats in the control and 1,000-mg/kg groups. Statistically significant alterations in mRNA levels, compared with controls, included: decreased tissue factor (TF, a thrombosis marker) in exposed young rats; increased macrophage inflammatory protein-2 (MIP-2, an inflammatory marker) and decreased endothelin-1 and endothelin receptor-B (ET-1, ET-B, vasoconstriction markers) in exposed middle-aged rats; and decreased MIP-2 and ET-1 in exposed aged rats. Overall, exposure-induced changes in relative heart weight and in biochemical end points and gene expression in cardiac tissue did not reveal clear age-related effects.

Intermediate-Duration Animal Studies. Increased relative heart weights were noted in rats exposed to toluene at 1,250 mg/kg/day for 13 weeks and myocardial degeneration was present in mice exposed to 5,000 mg/kg/day (NTP 1990). All of the mice receiving 5,000 mg/kg/day died during the first weeks of exposure. No effects on the weight or gross morphology of the heart were noted in rats receiving 590 mg/kg/day for 6 months (Wolf et al. 1956).

Gastrointestinal Effects. Gastric pain was reported by a man who accidentally ingested 30 mL of an organic solvent containing toluene and other chemicals (Einav et al. 1997). Gastrointestinal effects were not reported in other case studies of oral exposure (Ameno et al. 1989; Malingre et al. 2002).

No gastrointestinal effects were reported in mice or rats after oral exposure to toluene at dosage levels up to 2,500 mg/kg/day for 13 weeks (NTP 1990).

Hematological Effects. No studies were located regarding hematological effects in humans after oral exposure to toluene.

There were no changes in erythrocytes, hemoglobin, hematocrit, leukocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), or mean corpuscular hemoglobin concentration (MCHC) in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls (Burns et al.

3. HEALTH EFFECTS

1994). However, reticulocytes were significantly increased by 87%, compared with controls (Burns et al. 1994). There were no changes in total erythrocytes in male mice administered 5–105 mg/kg/day toluene in their drinking water for 28 days, although there was a nonsignificant decrease in the concentrations of leukocytes, lymphocytes, and neutrophils (Hsieh et al. 1989). No significant changes were found in the concentrations of erythrocytes, leukocytes, lymphocytes, or neutrophils in male mice administered 22 or 84 mg/kg/day toluene in their drinking water for 28 days, compared with controls (Hsieh et al. 1990a). No effect on erythrocyte counts, leukocyte counts, or hemoglobin concentrations resulted in rats exposed to 590 mg/kg/day for 6 months (Wolf et al. 1956). Neither rats nor mice given doses of 312–2,500 mg/kg/day for 13 weeks displayed any compound-related differences in hematological parameters (NTP 1990).

Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans after oral exposure to toluene.

No musculoskeletal effects were reported in mice or rats after oral exposure to toluene at dosage levels up to 2,500 mg/kg/day for 13 weeks (NTP 1990).

Hepatic Effects.

Human Case Studies. The liver of an adult male who died from toluene ingestion (625 mg/kg) was found to be enlarged on autopsy (Ameno et al. 1989). Clinical chemistry did not reveal abnormal liver function in a 15-month-old girl following accidental ingestion of paint thinner (Malingre et al. 2002).

Acute-Duration Animal Studies. Slight degeneration of hepatocytes and mononuclear cell infiltration were observed in rats given single gavage doses of 5,200 mg/kg, compared with controls (Ayan et al. 2013). The number of TUNEL-labeled hepatic cells were significantly increase by ~6-fold in exposed rats and semi-quantitative Bax and caspase-3 labeling was increased, compared with controls, indicating increased apoptosis in hepatic tissue. Serum levels of AST and ALT were significantly increased in toluene-treated rats by 119 and 60%, respectively, compared with controls (Ayan et al. 2013). However, no alterations in liver weight or histology were reported in pregnant rats exposed to 1,250 mg/kg/day toluene via gavage from GD 16 to 19 (Warner et al. 2008) or female mice exposed to 600 mg/kg/day toluene via gavage for 14 days (Burns et al. 1994), compared with controls.

3. HEALTH EFFECTS

Intermediate-Duration Animal Studies. In male mice, there was a significant increase in liver weight after 28 days of ingestion of 105 mg/kg/day toluene in drinking water, but not at doses of 22 mg/kg/day or lower (Hsieh et al. 1989). In a separate study, 22 or 84 mg/kg/day in drinking water for 28 days did not alter liver weight in exposed male mice, compared with controls (Hsieh et al. 1990a). Relative liver weights increased significantly over control levels in mice administered toluene by gavage for 13 weeks with doses ≥ 312 mg/kg/day in females and $\geq 1,250$ mg/kg/day in males (NTP 1990). In female rats, the liver weights were increased by exposure to doses $\geq 1,250$ mg/kg/day and in male rats by exposure to doses ≥ 625 mg/kg/day. No treatment-related gross or histopathological lesions of the liver were reported by NTP (1990) in these 13-week studies. When rats were exposed for a longer duration, liver weights were not affected and there were no treatment-related lesions in rats that received 590 mg/kg/day toluene by gavage for 6 months (Wolf et al. 1956).

Increased hepatic cell apoptosis, indicated by increased caspase-3 activity, and changed markers of oxidative stress were observed in the liver of rats exposed to 650 mg/kg/day via gavage for 45 days, compared with controls (Kamel and Shehata 2008). Exposed rats showed significant increases in hepatic levels of thiobarbituric acid reactive substances (end products of lipid peroxidation), glutathione disulfide, and glutathione-S-transferase activities, as well as significantly decreased reduced glutathione levels and glutathione reductase activities. Effects were more pronounced at 45 days than after 15 or 30 days of exposure. No exposure-related changes were seen in hepatic activities of superoxide dismutase, glutathione peroxidase, or the inflammation marker COX-2 (Kamel and Shehata 2008).

Renal Effects.

Human Case Studies. Acute tubular necrosis was reported after a lethal exposure to 625 mg/kg (Ameno et al. 1989), and acidosis was noted in a nonlethal case report of thinner consumption (Caravati and Bjerk 1997). Clinical chemistry did not reveal abnormal kidney function in a 15-month-old girl following accidental ingestion of paint thinner (Malingre et al. 2002).

Acute-Duration Animal Studies. Evidence for renal pathology was reported in dams exposed to 1,250 mg/kg/day toluene via gavage from GD 16 to 19 (Warner et al. 2008). Kidneys from toluene-exposed dams demonstrated swollen tubules, tissue adhesion to Bowman's capsule, and areas of solidification within glomeruli that were not observed in control dams. No exposure-related changes were observed in kidney weight. No changes in kidney weight or histology were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls (Burns et al. 1994).

3. HEALTH EFFECTS

Intermediate-Duration Animal Studies. There were no changes in kidney weight for male mice administered doses of 5–105 mg/kg/day in drinking water for 28 days (Hsieh et al. 1989, 1990a) or in female mice given doses of 312–2,500 mg/kg/day by gavage for 13 weeks (NTP 1990). There was a significant decrease in the absolute kidney weight for male mice administered 2,500 mg/kg/day for 13 weeks but no change in the relative kidney weight (NTP 1990). There were significant increases in the relative kidney weights in male rats administered toluene doses ≥ 625 mg/kg/day by gavage for 13 weeks and in females administered doses of 1,250 mg/kg/day (NTP 1990). In addition, lethal exposures of the rats to 5,000 mg/kg/day resulted in hemorrhages of the urinary bladder. No effects on the weight or gross morphology of the kidney were recorded for rats receiving 590 mg/kg/day toluene for 6 months (Wolf et al. 1956).

Minor changes in several markers of oxidative stress were observed in kidneys of rats following exposure to 650 mg/kg/day for 15, 30, or 45 days via gavage (Kamel and Shehata 2008). Exposure resulted in significant increases in renal levels of thiobarbituric acid reactive substances and glutathione disulfide and significantly decreased glutathione reductase activity, compared with controls. Effects were most pronounced after 45 days of exposure. No exposure-related changes were seen in renal levels of reduced glutathione or activities of superoxide dismutase, glutathione peroxidase, glutathione-S-transferase, COX-2 or caspase-3 (Kamel and Shehata 2008).

Endocrine Effects. No studies were located regarding endocrine effects in humans after oral exposure to toluene.

Serum corticosterone and ACTH levels were significantly elevated in male mice exposed to 105 mg/kg/day toluene in drinking water for 28 days, compared with controls (Hsieh et al. 1991). Levels were not significantly elevated following exposure to 5 or 22 mg/kg/day. Microscopic examination revealed no effects on the adrenal or thyroid glands in rats and mice administered 312–2,500 mg/kg/day toluene by gavage for 13 weeks (NTP 1990).

Dermal Effects. No studies were located regarding dermal effects in humans or animals after oral exposure to toluene.

Ocular Effects. No studies were located regarding ocular effects in humans or animals after oral exposure to toluene.

3. HEALTH EFFECTS

Body Weight Effects. No studies were located regarding body weight effects in humans after oral exposure to toluene.

Acute-Duration Animal Studies. There were no dose-related changes in body weight for male rats following single gavage administration of 0, 300, 650, or 1,000 mg/kg (Gordon et al. 2010). No body weight effects were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls (Burns et al. 1994). There was also no change in maternal body weight gain in rat dams exposed to 1,250 mg/kg/day toluene via gavage from GD 16 to 19, compared with controls (Warner et al. 2008). However, maternal weight gain was 24% lower in rats given 520 mg/kg/day toluene by gavage from GD 6 to 19, compared with control rats (Gospe et al. 1994).

Intermediate-Duration Animal Studies. There were no changes in body weight for male mice administered 5–105 mg/kg/day toluene in their drinking water for 28 days (Hsieh et al. 1989, 1990a, 1990b, 1991). There was also no significant difference in body weights for female rats and female mice given gavage doses of up to 2,500 mg/kg/day for 13 weeks (NTP 1990). However, body weights were 16% lower in male mice given 1,250 mg/kg/day and 19% lower in male rats given 2,500 mg/kg/day by gavage for 13 weeks (NTP 1990).

3.2.2.3 Immunological and Lymphoreticular Effects

No studies were located regarding immunological effects in humans after oral exposure to toluene.

A series of studies investigated the effects of exposure to toluene in drinking water for 28 days on the immune system end points in male mice (Hsieh et al. 1989, 1990a, 1991). Thymus weights, mixed lymphocyte culture responses, and antibody PFC responses were decreased at doses of 105 mg/kg/day, and mitogen-stimulated lymphocyte proliferation and IL-2 immunity were depressed by doses of 22 and 105 mg/kg/day, compared with controls (Hsieh et al. 1989). A dose of 5 mg/kg/day had no effect upon any of these indicators of immune system function. In another study, IL-2 immune response was significantly decreased only at 105 mg/kg/day (no other immune end points were evaluated) (Hsieh et al. 1991). In another study, antibody PFC responses were depressed at doses of 84 mg/kg/day, and mixed lymphocyte culture responses were depressed at 22 or 84 mg/kg/day (Hsieh et al. 1990a). No significant changes were observed in thymus weight, mitogen-stimulated lymphocyte proliferation, IL-2 immunity, or cell-mediated cytotoxicity at doses up to 84 mg/kg/day (Hsieh et al. 1990a). Collectively, these studies

3. HEALTH EFFECTS

support a NOAEL of 22 mg/kg/day for immune effects, as consistent immune effects were not observed until dose levels of 84–105 mg/kg/day. No effects on the histology or weight of the spleen or thymus were reported in rats and mice given gavage doses of up to 2,500 mg/kg/day toluene for 13 weeks (NTP 1990). The NOAEL of 22 mg/kg/day for immune effects based on the studies by Hsieh (1989, 1990a, 1991) was used as the basis for the intermediate-duration oral MRL (0.2 mg/kg/day) (see Section 2.3 and Appendix A).

In an acute-duration 14-day study, neither diminished *in vitro* immune responses nor impaired host-resistance was observed in female mice exposed to 600 mg/kg/day toluene via gavage, compared with vehicle controls (Burns et al. 1994). Spleen and thymus weights and histology were also not altered in exposed animals.

The highest NOAEL values and all LOAEL values for each reliable study for immunological effects in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

3.2.2.4 Neurological Effects

Human Case Studies. Severe depression of central nervous system function was the probable cause of death for a 51-year-old man who ingested approximately 60 mL (625 mg/kg) of toluene (Ameno et al. 1989). A man who accidentally ingested 30 mL of an organic solvent containing toluene and other chemicals was drowsy and complained of dizziness (Einav et al. 1997). In a nonlethal case study, depressed consciousness, lethargy, hypotonia, and nystagmus were observed in a 15-month-old girl following accidental ingestion of paint thinner (Malingre et al. 2002).

Acute-Duration Animal Studies. Male and female rats exposed to single gavage doses of 2,610, 3,915, or 5,220 mg/kg exhibited changes on a variety of neurological tests (Mehta et al. 1998). Significantly greater increases in motor activities were seen at all doses in both male and female rats on day 1; by day 14 after exposure, there were no significant differences, except for vertical motor activity in female rats was significantly reduced at the 2,620 and 3,915 mg/kg/day doses. A dose-dependent increase in abnormal gait was seen on day 1 for male rats at all doses, while female rats exhibited abnormal gait at 3,915 and 5,220 mg/kg. A dose-dependent increase in lacrimation and salivation was seen on day 1 for both males and females at all doses (Mehta et al. 1998).

3. HEALTH EFFECTS

Dose-related increases in motor activity were observed in rats given single oral doses of 0, 400, 800, and 1,200 mg/kg in random order, with 72 hours between each dose (Gordon et al. 2007). Changes were transient in nature, lasting ~60 minutes, and were statistically significant at 800 and 1,200 mg/kg, compared with the vehicle control. Similarly, transient dose-related increases in motor activity were observed in young (4 months), middle-aged (12 months), and aged (24 months) male rats given single gavage doses of 0, 300, 650, or 1,000 mg/kg (Gordon et al. 2010). Changes were only statistically significantly increased in young rats given 650 or 1,000 mg/kg and aged rats given 1,000 mg/kg.

In another study, 24-month-old rats showed more pronounced increased horizontal activity in response to single gavage doses of 650 or 1,000 mg/kg toluene than younger rats (1, 4, or 12 months of age) (MacPhail et al. 2012).

Two studies have examined changes in oxidative stress markers (Kodavanti et al. 2011) and gene expression (Royland et al. 2012) in rats following single gavage doses of 0, 650, or 1,000 mg/kg toluene, but mechanistic understanding is inadequate to determine the biological adversity of the observed changes. Kodavanti et al. (2011) measured levels of reactive oxygen species (NQO1, UBIQ-RD), total antioxidant substances, enzymes involved in antioxidant homeostasis (super oxide dismutase, gamma-glutamylcysteine synthetase, glutathione transferase, glutathione peroxidase, and glutathione reductase) and markers of oxidative damage (total aconitase and protein carbonyls) in the frontal cortex, cerebellum, striatum, and hippocampus of young, middle-aged, and aged rats 4 hours after single gavage doses of 0, 650, or 1,000 mg/kg toluene. Multiple indicators of oxidative stress were found to increase with toluene exposure, but findings varied greatly between brain regions and age groups. Multivariate analysis indicated that 12-month-old “middle-aged” rats were more susceptible to oxidative damage in the frontal cortex and cerebellum than younger or older age groups (Kodavanti et al. 2011). Microarray analysis of the hippocampi of young, middle-aged, and aged rats following single gavage doses of 0, 650, or 1,000 mg/kg indicated that only two genes reached a significant threshold (>1.25-fold, dose-related change) with toluene exposure, but 56 genes demonstrated a significant age-toluene interaction (Royland et al. 2012). Toluene-related genes were *Lrpap1* and *Ralgps2*, which are both associated with dementia and Alzheimer’s. Age-toluene interaction genes include those involved in immune response, cytoskeleton, protein and energy metabolism, and oxidative stress.

No changes in brain weight or histology were reported in female mice exposed to 600 mg/kg/day via gavage for 14 days, compared with controls (Burns et al. 1994).

3. HEALTH EFFECTS

Outer hair cell loss was observed in the area of the cochlea responsive to medium frequencies (10–25 kHz) of rats exposed to 780 mg/kg toluene via gavage 5 days/week for 2 weeks (Gagnaire and Langlais 2005). Apical and basal portions of the cochlea were spared. Cell counts were determined with cochleograms and using electron microscopy, but the available report did not specify whether or not unexposed controls were assessed in this study.

Single doses of 250–1,000 mg/kg administered by gavage to male rats caused a decrease in the FEP wave pattern amplitudes (Dyer et al. 1988). This suggests that toluene may have an effect on the visual system at high doses. The minimally adverse LOAEL of 250 mg/kg for the effects of FEP waveform was used as the basis for the acute-duration oral MRL (0.8 mg/kg) (see Section 2.3 and Appendix A).

Intermediate-Duration Animal Studies. Brain levels of norepinephrine (NE), dopamine (DA), serotonin (5-HT), and their respective metabolites, vanillylmandelic acid (VMA), homovanillic acid (HVA), and 5-hydroxyindolacetic acid (5-HIAA) were altered in six areas of the brain in male CD-1 mice administered toluene (5–105 mg/kg/day) in their drinking water for a 28-day period (Hsieh et al. 1990b). Significant increases of NE, DA, and 5-HT were present in the hypothalamus at all dose levels. The maximum increase occurred with the 22 mg/kg/day dose and there were lesser increases for both the 5 and 105 mg/kg/day doses. Roughly similar fluctuations were seen in the concentrations of VMA and HVA, which are metabolites of DA and NE, and 5-HIAA, a serotonin metabolite. In the corpus striatum, the levels of DA and 5-HT were significantly increased at the two highest doses. The level of VMA was also increased significantly at the same doses. In the medulla oblongata, the concentrations of NE, VMA, and 5-HIAA were significantly increased at the 22 mg/kg/day dose, but not at the other doses, while the levels of 5-HT were significantly increased at the 22 and 105 mg/kg/day doses. NE concentrations were elevated in the midbrain. An additional study confirmed increased NE, but not VMA, in the hypothalamus using the same protocol (Hsieh et al. 1991). Again, the maximum increase occurred with the 22 mg/kg/day dose and there were lesser increases for both the 5 and 105 mg/kg/day doses (no other neurotransmitters were examined). Due to the lack of dose response, lack of information on persistence of changes, and unclear association with neurobehavior, it cannot be determined if these changes are adverse. Therefore, a NOAEL/LOAEL was not established for the brain biochemical changes reported in this study.

Exposure to 1,250 and 2,500 mg/kg/day for 13 weeks resulted in increased relative brain weights in male mice (NTP 1990). Cellular necrosis was present in the hippocampus and cerebellum of rats exposed to 1,250 and 2,500 mg/kg/day, but increases in brain weight were only apparent with the 2,500 mg/kg/day

3. HEALTH EFFECTS

dose (NTP 1990). Clinical signs in rats and mice exposed to 2,500 and 5,000 mg/kg/day included ataxia, hypoactivity, prostration, and tremors. No neurological effects were seen in mice or rats at dose levels of 625 mg/kg/day (NTP 1990).

In a study of rats exposed to 0 or 650 mg/kg/day for 15, 30, or 45 days, exposed rats showed increased caspase-3 activity and changed markers of oxidative stress in the cerebellum and cerebral cortex, compared with unexposed controls (Kamel and Shehata 2008). Altered markers of oxidative stress included increased levels of thiobarbituric acid reactive substances and glutathione disulfide, increased activity of superoxide dismutase, and decreased levels of reduced glutathione and activities of glutathione reductase and glutathione peroxidase. No changes were seen in the activities of glutathione-S-transferase or the inflammation marker COX-2 (Kamel and Shehata 2008).

Studies examining neurotoxic effects of gestational exposure during critical periods of neurodevelopment are discussed in Section 3.2.2.6, Developmental Effects.

The highest NOAEL values and all LOAEL values for each reliable study for neurological effects in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

3.2.2.5 Reproductive Effects

No studies were located regarding reproductive effects in humans after oral exposure to toluene.

There was no significant difference in the mean number of implantations per dam, corpora lutea per dam, live fetuses per litter, the total number of resorptions per dam, or pre- or post-implantation loss in pregnant rats exposed to 1,250 mg/kg on GDs 16–19, compared with controls (Warner et al. 2008). Similarly, there was no effect on the number of mice producing viable litters following oral administration of 2,350 mg/kg on GDs 7–14 (NIOSH 1983). Litter size was not changed in mice administered 1,800 mg/kg on GDs 8–12 (Seidenberg et al. 1986) or rats administered 650 mg/kg on GDs 6–21 (Gospe and Zhou 2000).

Increased relative testicular weights were reported in male mice exposed to 1,250 and 2,500 mg/kg/day by gavage for 13 weeks (NTP 1990). However, no effects on the weight of the prostate, testes, uterus, or ovaries were observed in rats or female mice exposed to 312–2,500 mg/kg/day (NTP 1990).

Reproductive performance was not evaluated in these 13-week studies.

3. HEALTH EFFECTS

Changes in several biochemical markers of oxidative stress were observed in testes of rats following exposure to 650 mg/kg/day for 15, 30 or 45 days via gavage (Kamel and Shehata 2008). Testicular levels of glutathione disulfide were increased and levels of reduced glutathione and glutathione reductase activity were significantly decreased, compared with control values. No exposure-related changes were seen in activities of superoxide dismutase, glutathione peroxidase, or glutathione-S-transferase, levels of thiobarbituric acid reactive substances or activities of COX-2 or caspase-3 (Kamel and Shehata 2008).

The highest NOAEL values and all LOAEL values for each reliable study for reproductive effects in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

3.2.2.6 Developmental Effects

No studies were located regarding developmental effects in humans after oral exposure to toluene.

Toluene was not a developmental toxicant when administered orally to pregnant mice during the period of organogenesis in two developmental screening studies (NIOSH 1983; Seidenberg et al. 1986). No changes were observed in litter size, litter weight, or external malformations of dead neonates following exposure to 1,800 mg/kg/day via gavage on GDs 8–12, compared with vehicle controls (Seidenberg et al. 1986). Similarly, no changes were observed in total litter weights, numbers of animals producing litters and with totally resorbed litters, or number of live and dead pups per litter following exposure to 2,350 mg/kg/day via gavage on GDs 7–14, compared with vehicle controls (NIOSH 1983).

In a comprehensive developmental toxicity study in rats, a statistically significant increase in the incidence of a dilated renal pelvis in the left kidney was observed in fetuses from dams exposed to 1,250 mg/kg/day on GDs 16–19 via gavage, compared with controls (Warner et al. 2008). Renal pelvis dilation was graded from 1 to 4, with grade 1 representing a normal kidney and grade 4 showing >50% dilation. The incidence of fetuses with grade 3 or 4 dilated left and right renal pelvis in treated fetuses was 14.6 and 12.4%, respectively, compared with respective control incidences of 5.5 and 8.9%. Incidences of litters with fetuses with grade 3 or 4 renal pelvis dilation were 7/8 for left kidney for exposed versus 2/8 in controls and 6/8 for right kidney in exposed versus 5/8 in controls. No changes were observed in any other soft-tissue anomalies, malformations, skeletal variations, ossification, or fetal body weight. Warner et al. (2008) also reported accelerated development of the cochlea in treated fetuses accompanied by increased numbers of apoptotic cells in the cochlea, compared with controls. The

3. HEALTH EFFECTS

biological significance of this finding is unknown. Based on the result of apoptosis analysis in the cochlea, the investigators suggested that toluene may induce excessive cell death resulting in premature maturation of the cochlea.

Following exposure of pregnant rats to gavage doses of 520 or 650 mg/kg/day toluene in corn oil on GDs 6–19, fetuses showed significantly reduced body weight, delayed skeletal ossification, smaller brain volumes, and decreases in forebrain myelination per cell compared with controls (Gospe and Zhou 1998; Gospe et al. 1994, 1996). The difference in forebrain myelination was the only difference that remained between exposed and control offspring by PND 21 (Gospe and Zhou 1998). Cortical cell proliferation and migration were also altered in offspring following exposure of pregnant rats to gavage doses of 650 mg/kg/day toluene in corn oil on GDs 6–19 (Gospe and Zhou 2000). Cortical cell density was significantly decreased by 12.5% in all layers of the cerebral cortex in toluene-exposed pups on PND 21, compared with controls. The greatest decrease (26.8%) was observed in layer IV. Decreased density was attributed to altered neurogenesis, as neurons labeled with bromodeoxyuridine (BrdU) from injections on GDs 13–21 were decreased in numbers and exhibited altered migration patterns (Gospe and Zhou 2000).

Neurological development was assessed in mice exposed to 0, 4, 21, or 106 mg/kg/day toluene from GD 0 through PND 55 (via their dams during gestation and lactation and drinking water thereafter) (Kostas and Hotchin 1981). No exposure-related changes were observed in neonatal survival or growth, attainment of physical landmarks (eye opening, pinnae detachment), surface righting, or startle-response. Significantly decreased habituation (i.e., less activity with time in chamber) during a 20-minute open-field activity assessment was observed in mice receiving 106 mg/kg/day toluene, compared with controls. In controls, activity counts during the last 5 minutes of the trial were reduced by ~45% compared with counts during the first 5 minutes; however, activity counts were only decreased by ~17% in mice exposed to 106 mg/kg/day. Habituation was not altered in other exposure groups. Additionally, rotorod performance was impaired during the first two of four consecutive trials in all exposed mice when measured on PNDs 45–55, compared with controls. However, the effect on rotorod performance diminished with increasing dose. Time spent on the rod in the 4, 21, and 106 mg/kg/day groups was decreased by approximately 20, 16, and 8%, respectively, in trial 1 and by 27, 16, and 9%, respectively, in trial 2, compared with controls. Although time spent on the rod was statistically significantly decreased compared with controls at 4 and 21 mg/kg/day for trial 1, and at all exposures for trial 2, the changes are interpreted to be of questionable exposure-related adversity because the magnitude of effect diminished with increasing dose. The lack of impairments in the later trial may be due to compensation by the mice, as suggested by the study authors. The NOAEL and LOAEL values for neurodevelopmental effects in

3. HEALTH EFFECTS

this study are 21 and 106 mg/kg/day, respectively, based on increased open-field activity and lack of habituation in high-dose mice.

The highest NOAEL values and all LOAEL values for each reliable study for developmental effects in each species and duration category are recorded in Table 3-3 and plotted in Figure 3-2.

3.2.2.7 Cancer

No studies were located regarding carcinogenic effects in humans after oral exposure to toluene.

There is one oral study on the carcinogenic effects of toluene in animals. Toluene was administered at doses of 500 and 800 mg/kg/day to male and female rats for 104 weeks (Maltoni et al. 1997). A nondose-related increase in total malignant tumors in both males and females at all dose levels, in mammary gland tumors in females at the lower dose, in head cancers in males at the higher dose and females at the lower dose, in lymphomas and leukemias in males at the higher dose and females at both doses, were observed (Maltoni et al. 1997). However, the increased incidences were not dose-related and confidence in the study is low.

3.2.3 Dermal Exposure

There are limited data on the effects of dermal exposure to toluene. There are studies describing occupational exposure of humans to toluene (see Section 3.2.1). Toxicokinetic data (Section 3.4) indicate that humans and animals can absorb toluene across the skin. Studies of dermal exposure to toluene in humans and animals are discussed below.

3.2.3.1 Death

No studies were located regarding lethal effects in humans or animals after dermal exposure to toluene.

3.2.3.2 Systemic Effects

Data are available regarding dermal effects in humans and animals after dermal exposure to toluene. No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, or musculo-skeletal effects in humans or animals after dermal exposure to toluene. In addition, there are data on hepatic, renal, and ocular effects in animals after dermal exposure to toluene. The highest NOAEL values

3. HEALTH EFFECTS

and all LOAEL values for each reliable study for systemic effects in each species and duration category are recorded in Table 3-4.

Hepatic Effects. No studies were located regarding hepatic effects in humans after dermal exposure to toluene.

Application of 1 mL toluene to the skin of guinea pigs for 16 hours did not alter liver morphology (Kronevi et al. 1979). Because only one dose of toluene was applied and more sensitive indicators of liver toxicity were not monitored, conclusions cannot be derived regarding the hepatic effects of toluene following dermal exposure.

Renal Effects. No studies were located regarding renal effects in humans after dermal exposure to toluene.

Application of toluene to the skin of guinea pigs for 16 hours did not alter renal morphology (Kronevi et al. 1979). The limitations of this study were discussed in the previous section.

Dermal Effects. In humans, dermal contact with toluene may cause skin damage because it removes skin lipids (EPA 1983a). Workers exposed to mixtures of solvents, of which toluene was generally the major component, reported problems with the skin of their hands (Winchester and Madjar 1986). The specific symptoms associated with the reported skin abnormalities were not reported. Increased complaints of itching and dermatitis of the hands was reported in 38 female shoemakers who were exposed to toluene vapor concentrations that varied from 65 ppm (15–100 ppm) in winter to 100 ppm (10–200 ppm) in summer for an average of 40 months, compared with 16 controls (Matsushita et al. 1975). Eye irritation in humans occupationally exposed to toluene vapors has also been reported (Meulenbelt et al. 1990).

Repeated application of undiluted toluene (amount unstated) to the rabbit ear or shaved skin produced slight to moderate irritation (Wolf et al. 1956). In guinea pigs, continuous contact with toluene resulted in shrinkage and dissolution of the cell nuclei, cellular edema, and cellular infiltration of the dermis (Kronevi et al. 1979). Application of toluene to the skin of guinea pigs, 3 times/day for 3 days, resulted in redness and an increase in epidermal thickness (Anderson et al. 1986). In mice, application of 25 μ L undiluted toluene once weekly for 5 weeks to the dorsal surface of the ear lobe resulted in significant ear swelling that peaked at 1 hour post application starting on week 2 (Saito et al. 2011). After the 5-week

3. HEALTH EFFECTS

Table 3-4 Levels of Significant Exposure to Toluene - Dermal

Species (Strain)	Exposure/ Duration/ Frequency (Route)	System	NOAEL	LOAEL		Reference Chemical Form	Comments
				Less Serious	Serious		
ACUTE EXPOSURE							
Systemic							
Gn Pig (albino)	3 d 3x/d	Dermal		10 M (skin irritation) uL		Anderson et al. 1986	
Gn Pig (albino)	0.25-16 hr	Hepatic	1 mL			Kronevi et al. 1979	
		Renal	1 mL				
		Dermal		1 mL (karyopyknosis, karyolysis, perinuclear edema, spongiosis, junctional separation, cellular infiltration)			
Rabbit	once	Ocular		0.1 mL (eye irritation)		Exxon Chemical Co. 1962	
INTERMEDIATE EXPOSURE							
Systemic							
Mouse (BALB/c)	5 wk 1x/wk	Dermal		25 F uL (swelling at application site [ear lobe], inflammatory cell invasion)		Saito et al. 2011	No effects were observed with diluted preparations (25 or 50% in acetone).

d = day(s); F = Female; Gn pig = guinea pig; hr = hour(s); LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect level; x = time(s); wk = weeks(s)

3. HEALTH EFFECTS

exposure, microscopic examination of the ears revealed marginal inflammatory cell invasion. No significant dermal changes were observed following five applications of diluted toluene (25 or 50% in acetone) (Saito et al. 2011). Collectively, these data suggest that undiluted toluene is slightly-to-moderately irritating to the skin.

Ocular Effects. No studies were located regarding ocular effects in humans after dermal exposure to toluene.

Slight irritation of the conjunctival membranes, but no corneal injury, was observed in rabbit eyes following direct application of toluene (Exxon Chemical Co. 1962; Mobil Oil Corp. 1975; Wolf et al. 1956). Moderately severe injury to the eyes of rabbits following direct application of a 40% solution of toluene has also been reported (Carpenter and Smyth 1946). These data suggest that toluene is slightly-to-moderately irritating to the eyes.

No studies were located regarding the following effects in humans or animals after dermal exposure to toluene:

3.2.3.3 Immunological and Lymphoreticular Effects

3.2.3.4 Neurological Effects

3.2.3.5 Reproductive Effects

3.2.3.6 Developmental Effects

3.2.3.7 Cancer

No studies were located for cancer effects in humans after dermal exposure to toluene.

Dermally administered toluene markedly inhibits skin tumorigenesis in the two-stage mouse model utilizing phorbol-12-myristate-13-acetate (PMA) as a promoter (Weiss et al. 1986). The reduction in tumorigenesis was observed in mice initiated with dermal applications of benzo(a)pyrene or 7,12-dimethylbenz(a)anthracene. The pattern of inhibition indicated that the observed effect was not likely to be due to a direct chemical effect on the promoter. The authors speculated that toluene competed for a PMA receptor site, interfered with a biochemical process within the cell membrane, or affected the intracellular cascade between the membrane and the nucleus.

3. HEALTH EFFECTS

3.3 GENOTOXICITY

Overview. There is no conclusive evidence to support that toluene is a genotoxic agent. Results from human occupational exposure studies are inconsistent, and are limited by small cohort size (15–45/group), lack of historical exposure monitoring, and (in some cases) concurrent exposure to other chemicals. Most short-term *in vivo* tests in laboratory animals have not found genotoxic effects. Similarly, genotoxic effects were not induced in the majority of *in vitro* assays. Results of *in vivo* studies and *in vitro* genotoxicity studies are summarized in Table 3-5 and Table 3-6, respectively.

Human Occupational Studies. Multiple studies have assessed genotoxic end points in printers with occupational exposure predominately to toluene; however, cohort sizes are small and the results are inconsistent between studies. Chromosomal abnormalities (e.g., aberrations, breaks, gaps) have been reported in peripheral lymphocytes of printers exposed to a median time-weighted air level of 150 mg/m³ (40 ppm) toluene per week (Nise et al. 1991), printers exposed to 104–1,170 ppm toluene and office and technical workers exposed to 2.1–4.3 ppm plus 0–2 hours/day in the rotogravure workshop (Pelclová et al. 1990), printers exposed to 30–1,550 mg/m³ (8–410 ppm) (Pelclová et al. 2000), and printers exposed to 200–300 ppm toluene (Bauchinger et al. 1982), compared with unexposed referents. Examination of former printers 4 months to 2 years after cessation of exposure to toluene found that more than 2 years without exposure was necessary to remove a significantly higher incidence of chromatid aberrations in workers than in never-exposed controls (Schmid et al. 1985). In other studies, exposure-related changes in chromosomal abnormalities were not induced in printers exposed to 7–112 ppm toluene (Maki-Paakkanen et al. 1980) or printers exposed to 56–824 ppm toluene (Forni et al. 1971). Increased sister chromatid exchanges have been reported in peripheral lymphocytes of printers exposed to 200–300 ppm toluene (Bauchinger et al. 1982), printers exposed to a median air toluene concentration of 252 mg/m³ (67 ppm) (Hammer 2002; Hammer et al. 1998), and paint workers (toluene air levels not quantified; mean urinary hippuric acid levels were 2.5-fold higher in workers compared with unexposed referents) (Priya et al. 2015), compared with unexposed referents. In printers, the number of sister chromatid exchanges was significantly correlated with urinary *para*-cresol levels and the urinary cresol/hippuric acid ratio (Hammer 2002); weak correlations with urinary hippuric acid and *ortho*-cresol were not significant ($0.05 < p < 0.1$). When smokers were excluded, only the urinary cresol/hippuric acid ratio was significantly associated with the number of sister chromatid exchanges (Hammer 2002). In other studies, exposure-related changes in sister chromatid exchanges were not induced in peripheral lymphocytes from printers exposed to 7–112 ppm toluene (Maki-Paakkanen et al. 1980), or printers exposed to 104–1,170 ppm toluene and

3. HEALTH EFFECTS

Table 3-5. Genotoxicity of Toluene *In Vivo*

Species (test system)	End point	Results	Reference
Non-mammalian cells:			
Grasshopper (vapor)	Mitotic arrest in embryos (intact chorion)	+	Liang et al. 1983
Mammalian cells:			
Rats (inhalation)	Chromosomal aberrations in bone marrow cells	+	Dobrokhotov and Enikeev 1977
Human ^a	Chromatid breaks and gaps in peripheral lymphocytes	+	Bauchinger et al. 1982
Human ^a	Chromosome changes in peripheral lymphocytes	–	Forni et al. 1971
Human ^b	Chromosomal aberrations in peripheral lymphocytes	–	Haglund et al. 1980
Human ^a	Chromosome changes in peripheral lymphocytes	–	Maki-Paakkenen et al. 1980
Human ^a	Chromosome gaps in peripheral lymphocytes	+	Nise et al. 1991
Human ^a	Aberrant cells and chromosome breaks in peripheral lymphocytes	+	Pelclova et al. 1990
Human ^a	Aberrant cells in peripheral lymphocytes	+	Pelclova et al. 2000
Human ^a	Chromosome aberrations in peripheral lymphocytes	+	Schmid et al. 1985
Human ^a	Chromatid exchanges in peripheral lymphocytes	+	Bauchinger et al. 1982
Human ^b	Sister chromatid exchange in peripheral lymphocytes	–	Haglund et al. 1980
Human ^a	Sister chromatid exchange in peripheral lymphocytes	+	Hammer 2002; Hammer et al. 1998
Human ^a	Sister chromatic exchange in peripheral lymphocytes	–	Maki-Paakanen et al. 1980
Human ^b	Sister chromatid exchange in peripheral lymphocytes	–	Pitarque et al. 2002
Human ^a	Sister chromatid exchange in peripheral lymphocytes	–	Pelclova et al. 1990
Human ^a	Sister chromatid exchange in peripheral lymphocytes	+	Priya et al. 2015
Human ^c	Sister chromatid exchange in peripheral lymphocytes	–	Richer et al. 1993
Human ^a	Sister chromatid exchange in peripheral lymphocytes	–	Schmid et al. 1985
Rats (inhalation)	DNA damage and repair in lymphocytes	–	Martinez-Alfaro et al. 2010
Mice (inhalation)	DNA damage in blood, bone marrow and liver	–	Plappert et al. 1994
Human ^d	DNA damage in peripheral lymphocytes	+	Cok et al. 2004
Human ^b	DNA damage in whole blood	+	Heuser et al. 2005
Human ^b	DNA damage in leukocytes	+	Heuser et al. 2007
Human ^b	DNA damage in whole blood	+	Moro et al. 2012
Human ^b	DNA damage in leukocytes	–	Pitarque et al. 1999
Mice (inhalation)	Micronuclei in erythrocytes	–	Bird et al. 2010
Mice (inhalation)	Micronuclei in bone marrow cells	–	Wetmore et al. 2008

3. HEALTH EFFECTS

Table 3-5. Genotoxicity of Toluene *In Vivo*

Species (test system)	End point	Results	Reference
Human ^b	Micronuclei in buccal cells	+	Gonzalez-Yebra et al. 2009
Human ^b	Micronuclei in peripheral lymphocytes and buccal cells	–	Heuser et al. 2005
Human ^b	Micronuclei in peripheral lymphocytes and buccal cells	–	Heuser et al. 2007
Human ^b	Micronuclei in buccal cells	–	Moro et al. 2012
Human ^a	Micronuclei in peripheral lymphocytes	+	Nise et al. 1991
Human ^b	Micronuclei in peripheral lymphocytes	+	Pitarque et al. 2002
Mice (inhalation)	Dominant lethal mutations in sperm cells	–	API 1981
Human ^c	Cell cycle delay, cell mortality in peripheral lymphocytes	–	Richer et al. 1993 ^f

^aOccupational exposure to predominantly toluene (printers).

^bOccupational exposure to mixed solvents (e.g., shoe makers, paint manufacturers).

^cControlled exposure in healthy volunteers.

^dIntentional exposure in chronic glue sniffers.

+ = positive result; – = negative result

3. HEALTH EFFECTS

Table 3-6. Genotoxicity of Toluene *In Vitro*

Species (test system)	End point	Results		Reference
		With activation	Without activation	
Prokaryotic organisms:				
<i>Salmonella typhimurium</i> (TA98, TA100, TA1535, TA1537, TA1538)	Gene mutation	–	–	Bos et al. 1981
<i>S. typhimurium</i> (TA98, TA100, UTH8413, 8414)	Gene mutation	–	–	Connor et al. 1985
<i>S. typhimurium</i> (TA1535, PSK1002)	Gene mutation	No data	–	Nakamura et al. 1987
<i>S. typhimurium</i>	Gene mutation	No data	–	Nestmann et al. 1980
<i>S. typhimurium</i> (TA98, TA100, TA1535, TA1537)	Gene mutation	–	–	NTP 1990
<i>Escherichia coli</i> (P3478)	Gene mutation	No data	–	Fluck et al. 1976
Mammalian cells:				
Human lymphocytes	Sister chromatid exchange and chromosomal aberrations	No data	–	Gerner-Smidt and Friedrich 1978
Human lymphocytes	Sister chromatid exchange and chromosomal aberrations	No data	–	NTP 1990
Human HL-60 cells	DNA damage	No data	+	Sarma et al. 2011
Human lymphocytes	Micronuclei	–	–	Zarani et al. 1999

+ = positive result; – = negative result

3. HEALTH EFFECTS

office and technical workers exposed to 2.1–4.3 ppm plus 0–2 hours/day in the rotogravure workshop (Pelclová et al. 1990). Additionally, increased sister chromatid exchange frequencies were not observed in peripheral lymphocytes from former printers, 4 months to 2 years after cessation of exposure to toluene, compared with never-exposed controls (Schmid et al. 1985). Lymphocytes from printers exposed to a median time-weighted air level of 150 mg/m³ (40 ppm) toluene per week were found to be significantly more sensitive to the production of micronuclei after stimulation with pokeweed mitogen than lymphocytes from unexposed controls (Nise et al. 1991).

Some studies indicate that exposure to rotogravure ink mist may contribute to genotoxic findings in some rotogravure printers, as they are potential sources of polycyclic aromatic hydrocarbons from carbon black (Hammer et al. 1998; Pelclova et al. 1990, 2000). However, printing inks were not mutagenic in *Salmonella typhimurium* bacterial assays (Pelclova et al. 2000).

Evidence for genotoxicity in occupational studies of industries with exposure to toluene plus other solvents is also inconsistent. Solvent exposure-related changes in chromosome aberrations or sister chromatid exchanges in peripheral lymphocytes were not induced in Swedish paint industry workers exposed to toluene air concentrations ranging from 1 to 1,257 mg/m³ (1–334 mg/m³), compared with matched controls (Haglund et al. 1980). Sister chromatid exchanges were also not increased in Bulgarian shoe workers exposed to mean current TWA toluene concentrations of 76 or 236 mg/m³ toluene (20 or 63 ppm), compared with unexposed referents (Pitarque et al. 2002). DNA damage, assessed by the Comet assay, was increased in whole blood or leukocytes in Brazilian shoe workers exposed to solvent-based adhesive (mainly toluene, air concentration not reported) (Heuser et al. 2005, 2007) and Mexican painters exposed to unreported concentrations of toluene (Moro et al. 2012), compared with unexposed controls. However, no exposure-related differences in DNA damage in leukocytes were found between Bulgarian shoe workers exposed to 96.0–412.3 mg/m³ toluene (28–121 ppm) and unexposed controls, as assessed by the Comet Assay (Pitarque et al. 1999). Increased micronuclei induction was observed in peripheral lymphocytes or buccal cells in Bulgarian shoe workers exposed to mean current TWA toluene concentrations of 76 or 236 mg/m³ toluene (20 or 63 ppm) (Pitarque et al. 2002) and Mexican shoe workers exposed to median toluene air concentrations of 31.6 mg/m³ (8 ppm) (Gonzalez-Yebra et al. 2009), compared with controls. Using multivariate analysis of age, BMI, smoking, alcohol consumption, exposure duration, and exposure levels of acetone, ethyl acetate, methyl ethyl ketone, and toluene in Mexican shoe workers, the only variable statistically significantly associated with micronuclei induction was toluene concentration (Gonzalez-Yebra et al. 2009). However, micronuclei induction was not

3. HEALTH EFFECTS

associated with solvent exposure in Brazilian shoe makers exposed to solvent-based adhesive (Heuser et al. 2005, 2007) or Mexican painters exposed to unreported concentrations of toluene (Moro et al. 2012).

Human Solvent Abuse Study. DNA damage, determined by the Comet assay, was significantly increased in peripheral lymphocytes of chronic glue sniffers, compared with age-matched controls (Cok et al. 2004). However, when only nonsmokers were assessed, there was no difference in the mean total comet score between glue sniffers and controls. Exposure levels are unknown; however, the mean value of the hippuric acid and *ortho*-cresol excretion rates for glue sniffers were 73- and 1,582-fold higher, respectively, than in controls.

Controlled Exposure Study. Toluene did not induce sister chromatid exchanges in lymphocytes of volunteers exposed to 50 ppm airborne toluene for 7 hours/day for 3 days on three occasions at 2-week intervals (Richer et al. 1993).

Animal Studies. Most *in vivo* tests in laboratory animals have not reported toluene-induced genotoxicity. Toluene did not induce DNA damage in the blood, bone marrow, or liver of mice exposed to 500 ppm toluene for 6 hours/day, 5 days/week for 8 weeks, as assessed by Comet assay (Plappert et al. 1994). Similarly, DNA damage and repair were not induced in lymphocytes of rats exposed to paint thinner composed of toluene, acetone, ethanol, isobutyl acetate, isobutanol, butyl glycol, ethyl-benzene, and trimethylbenzene at toluene levels of 3,000 ppm twice daily for 15 minutes for 6 weeks, as assessed by Comet assay and H₂O₂ damage and repair (Martinez-Alfaro et al. 2010). Toluene did not induce micronuclei formation in bone marrow cells or erythrocytes of mice following exposure to 100 ppm 6 hours/day for 8 days (Bird et al. 2010; Wetmore et al. 2008). Toluene did not induce dominant lethal mutations in sperm cells of mice exposed to 400 ppm for 6 hours/day, 5 days/week for 8 weeks, but female mice were not assessed for genotoxic effects (API 1981). In a Russian study, toluene was reported to induce chromosomal aberrations in the bone marrow cells of rats following chronic inhalation exposure (duration and concentrations not available) (Dobrokhotov and Enikeev 1977). Additionally, when grasshopper (*Melanoplus sanguinipes*) embryos (chorion intact) were suspended in sealed containers and exposed to toluene vapors of 0, 40,000, 200,000, 400,000, or 800,000 ppm for 16 hours, mitotic arrest was induced at 200,000 ppm (higher concentrations were lethal) (Liang et al. 1983).

In vitro Studies. Toluene did not induce gene mutations in bacterial cells with or without metabolic activation (Bos et al. 1981; Fluck et al. 1976; Connor et al. 1985; Nakamura et al. 1987; Nestmann et al. 1980; NTP 1990), sister chromatid exchange or chromosomal aberrations in human lymphocytes without

3. HEALTH EFFECTS

metabolic activation (Gerrner-Smidt and Friedrich 1978; NTP 1990), or micronuclei in human lymphocytes with or without metabolic activation (Zarani et al. 1999). DNA damage was increased in human promyelocytic leukemia HL-60 cells treated with 1.14 and 2.74 nM toluene without metabolic activation, compared with untreated controls, as evidenced by significant, dose-related increases in tail moment in the Comet assay (Sarma et al. 2011).

3.4 TOXICOKINETICS

Overview. Studies with volunteers and laboratory animals indicate that toluene is rapidly absorbed from the respiratory tract with less rapid absorption occurring in the gastrointestinal tract and skin (Bushnell et al. 2007; Nadeau et al. 2006; Pykko et al. 1977; Sullivan and Conolly 1988; Thrall and Woodstock 2002; Thrall et al. 2002a). Studies with animals exposed by inhalation or oral routes showed that absorbed toluene is distributed widely to tissues throughout the body with preferential distribution to adipose tissue, brain, bone marrow, liver, and kidney. Absorbed toluene is distributed in pregnant animals, as well as to the developing fetus. The primary initial steps in toluene metabolism in humans and laboratory animals are side-chain hydroxylation (to form benzyl alcohol) catalyzed predominantly by the cytochrome P450 (CYP) isozyme, CYP2E1 (Nakajima and Wang 1994; Nakajima et al. 1991, 1992a, 1992b, 1993, 1997; Tassaneeyakul et al. 1996) followed by oxidation to benzoic acid. Most of the benzoic acid is then conjugated with glycine to form hippuric acid, but a small portion can be conjugated with UDP-glucuronate to form the acyl-glucuronide. Studies with volunteers and human liver microsomes indicate that a very small portion (<1–5%) of absorbed toluene can be converted by CYP1A2, CYP2B2, or CYP2E1 to *ortho*- or *para*-cresol, which are excreted in the urine as sulfate or glucuronate conjugates (Baelum et al. 1993; Nakajima et al. 1997; Tassaneeyakul et al. 1996). In both humans and rats, up to about 75–80% of inhaled toluene that is absorbed can be accounted for as hippuric acid in the urine (Lof et al. 1993; Wang and Nakajima 1992). Remaining absorbed toluene is excreted unchanged in exhaled air and urine and as conjugates of minor metabolites in urine (Ducos et al. 2008; Janasik et al. 2008, 2010; Lof et al. 1993; Ogata 1984; Pierce et al. 2002; Tardif et al. 1998). Analyses of kinetic data for toluene concentrations in blood, exhaled breath, adipose tissue, or urine following inhalation exposure of humans indicate that most absorbed toluene is rapidly eliminated from the body and that a smaller portion (that which gets into adipose tissues) is slowly eliminated (Janisik et al. 2008; Leung and Paustenbach 1988; Lof et al. 1993; Nise et al. 1989; Pellizzari et al. 1992; Pierce et al. 1996, 1999, 2002). For example, elimination kinetics for toluene-exposed workers have been described by a three-phase elimination model with half-times of 9 minutes, 2 hours, and 90 hours for toluene in blood and a single median elimination half-time of 79 hours for toluene in fat (Nise et al. 1989). In a study of

3. HEALTH EFFECTS

volunteers exposed by inhalation to about 50 ppm for 4 hours, a two-phase decline of urinary toluene concentration was observed with half-lives of 0.88 and 12.9 hours (Janisik et al. 2008).

3.4.1 Absorption

3.4.1.1 Inhalation Exposure

In humans exposed to 80 ppm toluene, uptake was rapid as shown by the appearance of toluene (2–5 $\mu\text{mol/L}$) in the blood within 10–15 minutes of exposure (Hjelm et al. 1988) and by a high correlation between the alveolar and arterial concentrations of toluene both during and after exposure (Carlsson 1982). About 50% of deuterium labeled toluene was absorbed from the lungs in volunteers exposed to 53 ppm for 2 hours during a period of light exercise (Lof et al. 1993). Seven humans exposed to 50 ppm toluene in a closed chamber showed an average retention of 83% of the inspired concentration (Benoit et al. 1985). In volunteers exposed to 50 ppm toluene for 7 hours while exercising or at rest, concentrations of toluene in expired air and *ortho*-cresol (a toluene metabolite), in urine collected at the end of exposure were higher during exercise than during periods at rest (~140–200% increase for blood concentrations and ~120% increase for urinary *ortho*-cresol) (Nadeau et al. 2006). The results are indicative of higher rates of uptake (and excretion) of inhaled toluene during exercise than at rest.

Toluene was rapidly absorbed via the lungs of rats; the log concentrations of toluene in the blood and brain were linear functions of the log concentration of toluene in the air (Benignus et al. 1984). In dogs, toluene was found in the arterial and venous blood 2 minutes after the start of exposure (Hobara et al. 1984b). Toluene concentrations in blood and brain increased rapidly during 60-minute inhalation exposures of physically active and sedentary rats to 2,000 ppm (Bushnell et al. 2007). Physical activity during inhalation increased the uptake of toluene into the blood and brain. After 60 minutes of exposure, physically active rats showed toluene concentrations in blood and brain that were ~26 and ~40% higher, respectively, than concentrations in sedentary rats (Bushnell et al. 2007).

No information was located regarding possible differences in absorption of inhaled toluene by humans or animals with differences in age.

3. HEALTH EFFECTS

3.4.1.2 Oral Exposure

Complete gastrointestinal absorption of toluene in human subjects was indicated by monitoring exhaled air for toluene and urine for toluene metabolites (hippuric acid and *ortho*-cresol) following oral administration of toluene as a 2 mg/min infusion for 3 hours through a feeding tube into the stomach (Baelum et al. 1993). Absorption of orally administered toluene has also been observed in rats, but oral absorption rates appear to be slower than pulmonary absorption (Pyykko et al. 1977; Sullivan and Conolly 1988). In these rat studies, maximum blood concentrations were observed 1.5–3 hours after gavage administration, whereas maximum blood levels following inhalation were reached in 15–30 minutes.

No statistically significant differences between physically active and sedentary rats were found in the time course of the increase of concentrations of toluene in blood and brain following administration of single gavage doses of ~800 mg/kg (Bushnell et al. 2007). Comparison with results from inhalation exposure suggests that physical activity may not influence the uptake of orally administered toluene to the same degree that it influences uptake of inhaled toluene.

Ingestion of soil contaminated with toluene can be a concern at hazardous waste sites. Binding to soil does not prevent absorption. The time course for absorption of toluene mixed with sandy soil or clay soil was increased when compared to the time course for pure toluene, but the total amount absorbed was the same based on the area under the blood toluene concentration curve (Turkall et al. 1991).

Studies with brush border membrane vesicles isolated from rat intestines and exposed to toluene indicate that toluene absorption occurs through the lipophilic matrix of the membrane (Alcorn et al. 1991). The removal of proteins from the membrane surface had no effect upon the toluene partition coefficient, but factors affecting the nonesterified membrane fatty acids reduced absorption. In this same *in vitro* study of membrane partitioning, vesicles harvested from the proximal, middle, and distal intestinal segments showed no differences, indicating that concentration and surface area, rather than membrane structure, are the factors determining the amount of toluene absorbed from each portion of the small intestines. Since toluene absorption occurs through the lipid matrix of the membrane, absorption can occur through the mouth and stomach, as well as the small intestines. The amount of toluene absorbed from each organ of the gastrointestinal tract will depend on residence time, absorptive surface area, and partitioning between membrane lipids and lipids in the gastrointestinal tract.

3. HEALTH EFFECTS

No information was located regarding possible differences in absorption of ingested toluene by humans or animals with differences in age.

3.4.1.3 Dermal Exposure

Results from early studies indicated that toluene is absorbed slowly through human skin (Dutkiewicz and Tyras 1968). The rate of absorption of toluene in human forearm skin was found to range from 14 to 23 mg/cm²/hour. EPA (1992b) estimated a human dermal permeability coefficient, K_p, of 1 cm/hour, based on these data. Based on these estimates, Brown et al. (1984) calculated that bathing in water containing 0.005–0.5 mg toluene/L (15 minutes/day) would result in absorbed dermal dose ranges of 0.0002–0.02 mg/kg/day for a 70-kg adult and 0.0004–0.04 mg/kg/day for a 10.5-kg infant. Transdermal uptake of toluene directly from the air is expected to be low, accounting for 1–2% of the total body burden received following exposure to toluene vapors (Brooke et al. 1998; Weschler and Nazaroff, 2014).

Soaking the skin of two volunteers with toluene for 5 minutes resulted in a maximum concentration of toluene in blood of 5.4 µmol/L (Aitio et al. 1984). Individual differences were marked, and dramatic changes in blood concentrations were observed over short periods of time. Similar individual differences and highly variable results were reported by Sato and Nakajima (1978) in a study using five volunteers.

Monster et al. (1993) investigated dermal absorption of toluene in 6 rotogravure printing workers. The workers washed their hands with toluene for 5 minutes, and alveolar air samples were collected up to 24 hours after exposure. The concentrations measured the next morning in exhaled air ranged between 0.5 and 10 mg/m³, clearly demonstrating dermal absorption of toluene.

Dermal permeability coefficients were estimated for human subjects wearing swimsuits who were submerged to neck level for up to 25–30 minutes in warm tap water initially containing 500 µg/L toluene (Thrall et al. 2002a). Subjects were provided purified breathing air, and exhaled breath was continuously analyzed for toluene before, during, and after exposure to track the absorption and exhalation of toluene. A human PBPK model, modified from a rat model for dermal absorption (Thrall and Woodstock 2002), was fit to each exhalation time course dataset to estimate a dermal permeability coefficient, K_p. Estimated K_p values (n = 6) ranged from 0.03 to 0.020 cm/hour, with an average value of 0.012 (standard deviation [SD]=0.007) cm/hour. In a second phase involving dermal and inhalation exposure, subjects breathed room air while they were submerged, and exhaled breath was collected and analyzed. Transient peak concentrations of toluene in exhaled breath occurred earlier and were about 50% greater than levels

3. HEALTH EFFECTS

during dermal-only exposure; these observations are consistent with a more rapid absorption through the respiratory tract than through skin. Thrall et al. (2002a) concluded, based on room air monitoring data and comparison of exhaled breath profiles for dermal-only and dermal+inhalation exposures, that inhalation exposure to volatilized toluene under these conditions was transient and contributed little to the overall total body from bathing in toluene-contaminated water.

Toluene in aqueous solution and neat toluene were absorbed through the skin of rats (Morgan et al. 1991). Three solution strengths (0.162, 0.333, and 0.448 mg/L) were tested. Although the blood toluene levels for each strength were near the analytical detection limits, the results of this study indicate that toluene absorption was significant, since only 1% of the body surface was exposed.

A dermal permeability coefficient, K_p , of 0.74 cm/hour (SD=0.005) was measured for male F344 rats exposed under occluded conditions to aqueous toluene solutions of 0.5 or 0.2 mg/mL applied to a 2.5-cm diameter patch of clipper-shaved skin on the back (Thrall and Woodstock 2002). Immediately following application, individual rats were placed in an off-gassing chamber, and exhaled breath of toluene was monitored continuously as chamber concentrations. Rapid absorption was indicated with peak chamber concentrations noted within 1–1.5 hours after exposure started; chamber concentrations showed steady declines thereafter through 4–5 hours. Based on amounts of toluene remaining on the skin at the end of exposure, average percentage absorptions of the applied doses were 45 and 42%, respectively, for the low- and high-dose levels (1.75 and 4.14 mg/kg). Using a method similar to Thrall et al. (2002a), a PBPK model was used to estimate a K_p for each exhaled breath dataset; the average K_p value across datasets was 0.074 cm/hour (SD=0.005).

Dermal absorption also occurs when animals are exposed to toluene vapors. In nude mice exposure to 300, 1,000, or 3,000 ppm toluene under conditions where there was no respiratory intake of toluene, led to a dose-related and duration-related increase in whole body toluene levels (Tsuruta 1989). The calculated skin absorption coefficient was 1.24 cm/hour. The skin absorption rate for the 300 ppm concentration was 0.0009 mg/cm²/hour; for the 1,000 ppm concentration, it was 0.0046 mg/cm²/hour; and for the 3,000 ppm concentration, it was 0.0144 mg/cm²/hour. Exposure of guinea pigs to an unspecified concentration of toluene for 1 minute, with the skin wiped dry and 1 minute exposures continuing every 30 minutes, for 4 hours, resulted in lower levels of toluene absorption than with continuous exposure for 4 hours (Boman et al. 1995).

3. HEALTH EFFECTS

No information was located regarding possible differences in absorption of dermally applied toluene by humans or animals with differences in age.

3.4.2 Distribution

3.4.2.1 Inhalation Exposure

There is a positive correlation between the levels of toluene in alveolar air and the levels in blood in both humans and animals (Hjelm et al. 1988; Lof et al. 1990; Ovrum et al. 1978). With an exposure in humans of 80 ppm toluene for 4 hours, toluene levels in the blood reached a plateau of 6–7 $\mu\text{mol/L}$ at approximately 2 hours (Hjelm et al. 1988; Lof et al. 1990). In humans, the toluene is distributed between the plasma and red blood cells at approximately a 1:1 ratio according to *in vitro* data; in rats, the ratio is 1:2 based on *in vivo* data (Lam et al. 1990). In the red blood cells, toluene appears to be associated with hemoglobin rather than the cell membrane. It is hypothesized that toluene interacts with the hydrophobic core of the heme protein. The interaction of the toluene with the red blood cell increases the amount of toluene that can be accommodated by the aqueous blood medium and facilitates transport of toluene to all areas of the body (including the brain) at a rate that is greater than if toluene was transported only in the plasma.

Autopsies of toluene-exposed humans indicate that absorbed toluene is distributed to lipid-rich and highly vascular tissues such as the brain. For example, toluene levels in the brain and liver of a 16-year-old male who died following an episode of glue sniffing were 297 and 89 $\mu\text{g/mg}$, respectively (Paterson and Sarvesvaran 1983). Concentrations in the blood were 20.6 $\mu\text{g/mL}$ of toluene and 3.0 $\mu\text{g/mL}$ of acetone. In a man who died following a fall while exposed to toluene during painting, tissue levels of toluene in blood, lung, liver, and brain were 48, 35, 65, and 80 $\mu\text{g/g}$, respectively (Takeichi et al. 1986).

Within the human brain, toluene has a greater affinity for areas of the brain that contain lipid-rich white matter, such as the brain stem, rather than the areas with larger amounts of gray matter (Ameno et al. 1992). The hippocampus and cerebellum had lower brain: blood toluene ratios than the spinal cord, midbrain, medulla oblongata, and pons. The brain stem controls many involuntary aspects of cardiac, respiratory, and vasomotor function.

Concentrations of toluene in subcutaneous adipose tissue of male subjects exposed during rest or physical exercise to 300 mg/m^3 of toluene were determined (Carlsson and Ljungquist 1982). After exposure at rest for 2 hours, the mean concentration of toluene in adipose tissue was 0.7 mg/kg . The corresponding value

3. HEALTH EFFECTS

after 2 hours of work was 9.9 mg/kg. Linear regression analysis indicated that toluene concentrations in adipose tissue were lower in subjects with large amounts of body fat.

The human data for distribution to the brain are supported by autoradiography studies using mice. Immediately after inhalation, a high level of radioactivity was found in the body fat, bone marrow, spinal nerves, spinal cord and white matter of the brain of exposed mice (Bergman 1983). Radioactivity was also observed in the blood, kidney, and liver at lower levels. Autoradiography of mice sacrificed immediately after the cessation of exposure revealed a very high concentration of nonvolatile radioactivity in the kidney, particularly the medullary region. Nonvolatile radiation found in the liver and kidney suggests rapid formation and excretion of toluene metabolites.

A one-compartment model was developed for blood and whole-brain toluene levels based on data from rats exposed to 575 ppm toluene for up to 240 minutes (Benignus et al. 1981). Estimated saturation asymptotes were 10.5 ppm for venous blood and 18.0 ppm for brain, respectively. Blood and brain levels achieved 95% of their estimated asymptotes in 53 and 58 minutes, respectively. The distribution half-life for a 30-minute exposure of rats to 2,000 ppm toluene was 0.34 hours, while that for exposure to 10,000 ppm was 0.6 hours (Ameno et al. 1992).

Toluene was rapidly distributed to the tissues in rats after 1, 2, or 3 days of exposure to 100 ppm for 12 hours per day (Zahlsen et al. 1992). Homeostasis was attained in 1 day for the kidney, brain, and liver, whereas toluene concentrations continued to increase in perirenal fat deposits. Once exposures ceased, toluene concentrations declined within 12 hours to near baseline levels for all tissues except in fat. The toluene in rat brains was distributed to the brain stem and midbrain (Ameno et al. 1992), a distribution that parallels that observed in humans and mice (Ameno et al. 1992; Bergman 1983). These regions have a high concentration of white matter.

Toluene was detected in blood, brain, auditory nerves, and the organ of Corti, but not in cerebrospinal fluid or inner ear fluids sampled from rats immediately following inhalation exposure to 1750 ppm toluene for 10 hours (Campo et al. 1999).

In mice exposed nose-only to 0, 0.9, 9, 50, or 90 ppm toluene for 30 minutes, toluene concentrations in the hippocampus showed statistically significant ($p < 0.05$) concentration-dependent increases after exposure to air concentrations ≥ 9 ppm, compared with control values (Nakajima et al. 2006). This study used a solid-phase microextraction fiber inserted into the hippocampus and gas chromatography and mass

3. HEALTH EFFECTS

spectrometry to determine brain concentrations in mice. Examination of mice exposed to 50 ppm toluene showed that toluene concentrations in the brain returned to control levels 60 minutes after exposure ceased.

Toluene distribution to several tissues was followed in dogs exposed through inhalation of 30,000 ppm toluene from a plastic bag for 10 minutes. The toluene level in the arterial blood was 129 ± 54.8 $\mu\text{g/mL}$ while that in the venous blood was 112 ± 48.5 $\mu\text{g/mL}$. The liver and brain contained roughly equivalent concentrations of toluene (184 and 191 $\mu\text{g/g}$), while the toluene in the kidneys was 99 $\mu\text{g/g}$ (Ikeda et al. 1990).

Distribution of toluene (assayed by autoradiography and tissue concentrations of radioactivity) in pregnant mice was also characterized by preferential uptake in maternal lipid-rich tissues (brain and fat) immediately after 10-minute inhalation exposures to ^{14}C -labeled toluene at approximately 2,000 ppm (Ghantous and Danielsson 1986). It was thought that toluene, due to its high lipid solubility and low molecular weight, might easily transfer across the placenta, but concentrations of radioactivity in fetal tissues were only about 4% of concentrations in maternal brain and adipose tissue immediately after exposure, and rapidly decreased within 4 hours of cessation of exposure. These results suggest that absorbed toluene is preferentially distributed to maternal adipose tissues in pregnant mice and that distribution to the developing fetus is limited with short-term exposure to the relatively high (compared with occupational exposures) concentration of 2,000 ppm. This concentration, however, is low compared with concentrations experienced by toluene abusers (4,000–12,000 ppm as cited by Gospe et al. 1994). Ghantous and Danielsson (1986) suggested that the lower lipid content in fetal tissue compared with maternal tissue could explain the low uptake of toluene into fetal tissue.

Following repeated inhalation exposure of pregnant rats to 8,000 or 12,000 ppm for 15, 30, or 45 minutes twice daily from GD 8 through GD 20, measurable concentrations of toluene were found in the placenta, amniotic fluid, and fetal brain collected from exposed dams on GD 20 (Bowen et al. 2007). Regardless of daily exposure regimen or exposure level, amniotic fluid concentrations were $\sim <10\%$ of concentrations in GD 20 maternal saphenous blood samples. Concentrations in fetal brain were similar to maternal saphenous blood concentrations at GD 20, whereas concentrations in placenta were higher. Concentrations of toluene in maternal cerebellum, liver, kidney, and heart tissue on GD 20 (but not lung) were higher than concentrations in GD 20 maternal saphenous blood. The results, consistent with those of Ghantous and Danielsson (1986), indicate that toluene was transported to the fetal brain, and that fetal

3. HEALTH EFFECTS

brain concentrations were similar to maternal blood levels, but were lower than maternal brain concentrations.

No studies were located that examined *in vivo* distribution of toluene into breast milk in humans or animals. Although breast milk is high in lipid content, it is unknown if there may be preferential uptake of toluene into other maternal lipid-rich tissues. A published estimate of the human milk/blood partition coefficient for toluene, 2.68, was lower than estimates of coefficients for partitioning of toluene between other tissues and human blood, including liver or highly perfused tissues/blood (4.91) and fat/blood (60.01) (Fisher et al. 1997). Transfer from blood to a tissue, however, is also dependent on the rate of perfusion of the tissue with blood. Fisher et al. (1997) used these partition coefficient values in a physiologically-based pharmacokinetic (PBPK) model designed to predict transfer of volatile chemicals into breast milk, but human or animal pharmacokinetic data for lactational transfer of toluene were not available to validate or modify the model.

Coexposure of rats to xylene increased the concentrations of toluene in the blood and brain in the 19 hours after exposure as compared to exposure to toluene alone (Tardif et al. 1992). This was, apparently, the result of suppressed toluene metabolism because of competition between toluene and xylene for active sites on enzymes responsible for metabolizing both compounds. Pulmonary excretion of toluene was also decreased when exposure to both compounds occurred. As a result, the half-lives for both toluene and xylene were increased.

Blood and brain toluene levels in rats exposed to 2000 or 4000 ppm for 4 hours during daylight were significantly higher at the end of exposure and 40 minutes after the cessation of exposure than in animals exposed in the dark (Harabuchi et al. 1993). This suggests that circadian rhythms may have an influence on toluene absorption, distribution, and excretion.

3.4.2.2 Oral Exposure

In one human who died 30 minutes after ingestion of 625 mg/kg toluene, the liver was found to have the highest concentration of toluene (433.5 µg/g) followed by the pancreas (88.2 µg/g), brain (85.3 µg/g), heart (62.6 µg/g), blood (27.6 µg/g), body fat (12.2 µg/g), and cerebrospinal fluid (11.1 µg/g) (Ameno et al. 1989). The short interval between toluene exposure and death limited the distribution of the toluene to the peripheral body tissues.

3. HEALTH EFFECTS

When rats were orally exposed to 400 mg/kg toluene, the peak concentration in the blood occurred 1.5 hours after exposure (Ameno et al. 1992). In the brain, the highest brain: blood toluene ratios were found in the pons and caudate-putamen, as opposed to the hippocampus (Ameno et al. 1992). Toluene distribution in the brain was similar with inhalation and oral exposure (Ameno et al. 1992).

3.4.2.3 Dermal Exposure

No studies were located regarding the distribution of toluene in humans or animals after dermal exposure.


3.4.2.4 Other Routes of Exposure

In baboons intravenously injected with ^{11}C -labeled toluene, maximal concentrations of radioactivity in different brain regions were attained within 1–4 minutes of injection (Gerasimov et al. 2002a, 2002b). Concentrations of radioactivity steadily declined thereafter through about 45 minutes of monitoring. The results are indicative of rapid distribution from the blood to the brain and rapid clearance. Half-times for clearance from the brain ranged from about 10 to 20 minutes in three experiments. Similar experiments with mice showed similarly rapid distribution to the brain and rapid clearance from the brain following intravenous injection (Gerasimov et al. 2002a, 2002b).

3.4.3 Metabolism

Studies of urinary metabolites in toluene-exposed humans (Andersen et al. 1983; Angerer 1979; Angerer et al. 1998a; Baelum et al. 1987, 1993; Dossing et al. 1983b; Inoue et al. 1986; Jonai and Sato 1988; Kawai et al. 1992a, 1992b, 1993, 1996; Lof et al. 1990, 1993; Maestri et al. 1997; Ng et al. 1990) and rats (Bray et al. 1949; van Doorn et al. 1980; Wang and Nakajima 1992) have identified hippuric acid (the glycine conjugate of benzoic acid) as the major urinary metabolite of toluene. Minor urinary metabolites (in approximate order of decreasing abundance) include: the glucuronyl conjugate of benzoic acid; sulfate and glucuronide conjugates of *ortho*- and *para*-cresol; S-benzylmercapturic acid; and S-*p*-toluylmercapturic acid. Based on these results and the results from *in vitro* studies, including recent studies with human and rat liver microsomes (Nakajima and Wang 1994; Nakajima et al. 1991, 1992a, 1992b, 1993, 1997; Tassaneeyakul et al. 1996), a scheme for toluene metabolism in humans and animals is presented in Figure 3-3.

3. HEALTH EFFECTS

Figure 3-3. Scheme for Toluene Metabolism in Humans and Animals

Proposed enzymes are noted in parentheses.

Sources: Angerer et al. 1998a; IARC 1999; Nakajima and Wang 1994; Nakajima et al. 1997; Tassaneeyakul et al. 1996

3. HEALTH EFFECTS

The initial steps are methyl and ring hydroxylations that are catalyzed by cytochrome P450 (CYP) isozymes. Methyl hydroxylation to form benzyl alcohol was the predominant first step in human (Nakajima et al. 1997; Tassaneeyakul et al. 1996) and rat (Nakajima et al. 1991, 1992a, 1992b, 1993) liver microsomes. Ring hydroxylation to form *ortho*- or *para*-cresols in these studies usually represented less than 5% of total metabolite formation.

Results from *in vitro* studies indicate that CYP2E1 is the most active CYP isozyme in forming benzyl alcohol and CYP1A2 is the most active in forming *ortho*- and *para*-cresols. Using monoclonal antibodies to CYP isozymes as *in vitro* metabolic inhibitors in rat microsome preparations, Nakajima et al. (1991) demonstrated that CYP2E1 (at low toluene concentrations) contributes to the formation of benzyl alcohol and *para*-cresol, CYP1A1/2 contributes to *ortho*- and *para*-cresol formation, and CYP2B1/2 and CYP2C11/6 (at higher toluene concentrations) contribute to the formation of benzyl alcohol and *ortho*- and *para*-cresol. Biphasic enzyme kinetics for the formation of benzyl alcohol from toluene were observed in human liver microsomes, supporting the concept that at least two isozymes with differing affinity for toluene can catalyze benzyl alcohol formation (Tassaneeyakul et al. 1996). The high-affinity component in human liver microsomes was markedly inhibited (about 90% inhibition) by 50 μ M diethyldithiocarbamate, an inhibitor of CYP2E1, whereas inhibitors of other CYP isozymes produced generally less than 10% inhibition of the high affinity component (Tassaneeyakul et al. 1996). Other inhibitors tested (and the CYP forms that they are expected to inhibit) were: furafylline (CYP1A2), coumarin (CYP2A6), mephenytoin (CYP2C19), quinidine (CYP2D6), sulfaphenazole (CYP2D6), and troleandomycin (CYP3A) (Tassaneeyakul et al. 1996). Using microsomes from cells in which cDNAs for eleven different human CYP isozymes were expressed, Nakajima et al. (1997) demonstrated that CYP2E1 was the most active in forming benzyl alcohol, followed in order by CYP2B6, CYP2C8, CYP1A2, and CYP1A1. The activities of CYP2A6, CYP2C9, CYP2D6, CYP3A3, CYP3A4, and CYP3A5 in metabolizing toluene were negligible. CYP1A2 also was active in forming *ortho*- and *para*-cresol (22 and 35% of total metabolites) and CYP2E1 and CYP2B6 catalyzed the formation of *para*-cresol (11–12% of total metabolites) (Nakajima et al. 1997). Comparison of the *in vitro* catalytic activities of human recombinant CYP2E1, CYP2A6, and CYP2A13 (a form that is highly expressed in human respiratory tract tissues) to form benzyl alcohol from toluene indicated the following order of catalytic activities: CYP2A13 > CYP2A6 > CYP2E1 (Fukami et al. 2008). The latter observations suggest that there may be tissue specificities in the principal forms of CYPs catalyzing the initial step in toluene metabolism. Kinetic constants (e.g., K_m and V_{max}) were comparable for recombinant wild-type CYP2E1 (CYP2E1.1) and allelic variants of CYP2E1 (CYP2E1.2, CYP2E1.3, and CYP2E1.4) to convert toluene to benzyl alcohol (Hanioka et al. 2010). The variants were made by site-directed mutagenesis involving amino acid

3. HEALTH EFFECTS

substitutions to reflect CYP2E1 polymorphisms identified in human populations at frequencies ranging from 1.3 to 2.6%.

Benzyl alcohol is thought to be converted to benzoic acid in two steps by alcohol dehydrogenase and aldehyde dehydrogenase (see Figure 3-3). Conjugation with glycine to form hippuric acid can represent 83–94% of urinary metabolites of toluene in rats (Nakajima and Wang 1994). Hippuric acid formation from benzoic acid (a common component of the diet) is catalyzed by acyl-CoA synthetase and acyl-CoA: amino acid N-acyltransferase. Conjugation of benzoic acid with glucuronic acid to form benzoyl glucuronide is catalyzed by UDP-glucuronyl transferase and can account for 3–9% of urinary metabolites in rats (Nakajima and Wang 1994). In plasma samples collected in baboons 30 minutes following intravenous injection of ^{11}C -toluene, relative amounts of radioactivity were 34% in unchanged toluene, 40% in benzoyl glucuronide, 18% in hippuric acid, 1% in benzyl alcohol and benzaldehyde, and 3% in benzoic acid (Gerasimov et al. 2002a).

The 2,3- and 3,4-epoxide intermediates, precursors of *ortho*- and *para*-cresol, are thought to be oxidation products of the catalytic actions of CYP1A2, CYP2E1, and CYP2B6 (Nakajima et al. 1997). *Ortho*- and *para*-cresol and their conjugates have been reported to account for 0.5–1.1 and 2.5–14.2%, respectively, of urinary metabolites in rats (Nakajima and Wang 1994). S-benzyl mercapturic acid, a minor urinary metabolite identified in humans, is thought to be formed via conjugation of benzyl alcohol with glutathione (catalyzed by glutathione-S-transferases), followed by the concerted catalytic actions of γ -glutamyltranspeptidase, amino peptidase M, and N-acetyltransferase to release glutamic acid and glycine and add an acetyl group (Angerer et al. 1998a) (see Figure 3-3). The formation of another minor human urinary metabolite, S-*p*-toluylmercapturic acid, is thought to proceed by a similar series of reactions from the proposed intermediate, 3,4-toluene epoxide (Angerer et al. 1998a).

The liver is expected to be the prime site of toluene metabolism, based on the high concentration of CYP isozymes in the liver relative to other tissues. For example, levels of CYP2E1 in human lung microsomes were 10.5% of liver activities (Wheeler et al. 1992). Studies with rats indicate that toluene exposure causes changes in CYP-associated enzyme activities and CYP isozymes themselves in the liver (see Nakajima and Wang 1994 for review). For example, single 6-hour exposures to toluene induced hepatic CYP2E1 levels and associated nitrosodimethylamine demethylase activities (at concentrations $\geq 1,000$ ppm), induced CYP2B1/2 and CYP3A1/2 levels (at concentrations $> 2,000$ ppm), decreased CYP2C11/6 levels (at 4,000 ppm), and did not change CYP1A1/2 levels (Wang et al. 1993). Other rat experiments involving longer durations of exposure and potentially higher dose levels have consistently

3. HEALTH EFFECTS

observed induction of hepatic activities of aryl hydrocarbon hydroxylase (AHH) and ethoxyresorufin O-deethylase (EROD), activities associated with CYP1A1/2 (see Nakajima and Wang 1994). Rats given single intraperitoneal injections of 5 mmol toluene/kg showed induction of ethoxycoumarin O-deethylase (ECOD) and EROD activities in liver, but no induction was apparent in lung or kidney tissues (Pyykko et al. 1987). Exposure of rats to 375 ppm toluene, 6 hours/day for up to 5 days or 125 ppm for 6 hours did not significantly change activities of AHH, EROD, or benzyloxyresorufin (BROD) in liver microsomes compared with activities in nonexposed controls, but significantly decreased activities of AHH (by up to about 50%), BROD (by 30–70%), and 2-aminofluorene N-hydroxylase (by up to about 50%) in lung microsomes without altering EROD activities (Furman et al. 1998). The results from these rat studies suggest that toluene exposure at concentrations $\geq 1,000$ ppm, but not at lower concentrations, induces hepatic CYP enzymes involved in its own metabolism and metabolism of other xenobiotics, and that exposure to 125 or 375 ppm may cause a decrease in pulmonary activities of certain CYP mixed function oxidases. Consistent with the idea of no CYP induction with low-level exposure is the report that workers exposed to 100 ppm toluene did not display increased ability to clear antipyrine (Dossing et al. 1983c).

Levels of CYP isozymes in rat fetal livers are very low, but increase rapidly after birth (Nakajima and Wang 1994). By 10 days after birth, rats of both sexes are capable of responding to toluene exposure by inducing hepatic CYP-associated enzyme activities (Pyykko 1983). Comparison of rates of metabolism in liver microsomes from male and female rats at 3 weeks (immature) and 18 weeks of age (mature) and in pregnant female rats on gestations days 10 and 21 indicate that age, gender, and pregnancy can influence rates of hepatic toluene metabolism and induction of CYP isozymes (Nakajima et al. 1992b). Rates (on a mg protein basis) of high-affinity toluene metabolism were not statistically significantly different between immature and mature male rats, but rates of low-affinity toluene metabolism were four-fold higher in mature rats compared with immature rats (Nakajima et al. 1992b). In contrast, rates of high-affinity toluene metabolism were lower in mature than in immature female rats, but rates of low-affinity toluene metabolism were not statistically different between immature and mature female rats. Rates of high- and low-affinity toluene metabolism were significantly lower in pregnant rats compared with nonpregnant rats.

Given the lack or low levels of several CYP isozymes in the developing human fetus (Leeder and Kearns 1997), it is expected that the capacity for metabolic detoxification of toluene is low in the developing fetus. Rat studies indicate that levels of CYP isozymes involved in toluene metabolism, however, are rapidly increased following birth, and suggest that capabilities to carry out Phase I toluene metabolism at

3. HEALTH EFFECTS

low exposure levels during neonatal periods may exceed those at sexual maturity and pregnancy (Nakajima et al. 1992b). CYP2E1, one of the principal CYP isozymes involved in the major toluene pathway (Nakajima et al. 1997; Tassaneeyakul et al. 1996), is reported to be expressed several hours after birth in humans and continues to increase during the first year of life (Vieira et al. 1996). Phase II enzymes involved in toluene metabolism (e.g., N-acetyl transferases, UDP-glucuronyl transferases, and sulfotransferases) also show changes during human neonatal development with adult activities reported to be present by 1–3 years of age (Leeder and Kearns 1997). Although no studies were located directly comparing toluene metabolic capacity in children and adults, the limited available information suggest that children past early neonatal periods may be equally able as adults in metabolically disposing of toluene at low exposure levels expected to be found in the general environment or at sites adjacent to waste sites.

3.4.4 Elimination and Excretion

3.4.4.1 Inhalation Exposure

Studies with humans and laboratory animals indicate that following acute periods of inhalation exposure to toluene, absorbed toluene is excreted predominately in the urine as metabolites (hippuric acid, benzoyl glucuronide, *ortho*- and *para*-cresol and their sulfate and glucuronide conjugates, S-benzyl mercapturic acid, and S-*p*-toluyl mercapturic acid, as discussed in Section 3.4.3) and, to a lesser extent, as non-metabolized toluene in exhaled air and urine (Ducos et al. 2008; Janasik et al. 2008, 2010; Lof et al. 1993; Ogata 1984; Tardif et al. 1998). For example, following a 2-hour exposure with light physical exercise to deuterium-labeled toluene at a concentration of 200 mg/m³ (53 ppm), an average 78% of retained label was excreted as urinary hippuric acid within 20 hours by a group of nine volunteers (Lof et al. 1993). A significant portion of absorbed toluene in this and other studies has been estimated to be exhaled as nonmetabolized toluene (7–20% of absorbed toluene) (Carlsson 1982; Leung and Paustenbach 1988; Lof et al. 1993). Although unchanged toluene in urine is expected to be a minor elimination route based on mass balance, elimination kinetics data for toluene in urine following acute exposure of volunteers are consistent with the recommended use of this end point as a biomarker of exposure for toluene-exposed workers (ACGIH 2010; Ducos et al. 2008; Janisik et al. 2008, 2010). For example, following 4-hour exposure to 200 mg/m³ (53 ppm), a two-phase decline of urinary toluene concentration was observed with half-lives of 0.88 and 12.9 hours. The correlation coefficient between toluene air concentrations (20, 60, or 100 mg/m³; ~5, 16, or 27 ppm) and urinary toluene concentrations in the last 2 hours of exposure was 0.998 (Janisik et al. 2008).

3. HEALTH EFFECTS

Analyses of kinetic data for toluene concentrations in blood, exhaled breath, or adipose tissue or urine following inhalation exposure of humans (Leung and Paustenbach 1988; Lof et al. 1993; Pellizzari et al. 1992; Pierce et al. 1996, 1999) and rats (Rees et al. 1985) indicate that most absorbed toluene is rapidly eliminated from the body and that a smaller portion (that which gets into adipose tissues) is slowly eliminated (Leung and Paustenbach 1988; Lof et al. 1993; Nise et al. 1989; Pellizzari et al. 1992; Pierce et al. 1996, 1999, 2002). Using three-phase exponential mathematical models to describe curves of human blood concentration as a function of time up to 3–5 hours after 2-hour exposures to 100 or 53 ppm toluene, calculated half-lives (the time to decrease the amount in the phase by one-half) were 1.5 and 3 minutes for the initial phase, 26 and 40 minutes for the second phase, and 3.7 and 12.3 hours for the final phase (Lof et al. 1993; Sato et al. 1974). Elimination half-lives ranged from about 12 to 65 hours (0.5 to 2.7 days) in subcutaneous adipose tissue samples taken from 12 subjects at several times within 8 days of cessation of exposure to about 80 ppm toluene for four consecutive 30-minute periods (Carlsson and Ljungquist 1982). Increasing elimination half-lives were significantly correlated with increasing amounts of body fat (Carlsson and Ljungquist 1982). The time courses of toluene concentrations in blood and subcutaneous fat of rotogravure printers exposed to 35–246 mg/m³ (9–65 ppm) toluene during and after a 5-day workweek were described by a three-phase elimination model with half-times of 9 minutes, 2 hours, and 90 hours for toluene in blood and a single median elimination half-time of 79 hours for toluene in fat (Nise et al. 1989). Using PBPK models, mean terminal half-lives of about 30–38 hours were calculated for changes in blood toluene concentrations between 50 and 100 hours after cessation of 2-hour inhalation exposures of male subjects to 50 ppm ¹H₈-toluene and 50 ppm ²H₈-toluene (Pierce et al. 1996, 1999). During this terminal phase of disposition, >95% of toluene is expected to be in adipose tissue and the release of toluene from adipose tissues has been proposed to be the rate-limiting step (Pierce et al. 1999). Analysis of rates of exhalation of nonmetabolized toluene and urinary excretion of metabolites from 2-hour exposures of male subjects to 50 ppm ²H₈-toluene indicated the following distribution of the total dose: 13% ²H₈-toluene in exhaled breath, and 75% ²H₅-hippuric acid, 0.31% ²H₇-*ortho*-cresol, 0.53% ²H₇-*meta*-cresol, and 11% ²H₇-*para*-cresol in urine (Pierce et al. 2002). In studies with rats exposed for 2 hours to 1,000, 1,780, or 3,000 ppm toluene, two-phase exponential models were used to calculate average elimination half-lives of approximately 6 and 90 minutes, but blood toluene concentrations were monitored in this study for no more than 2 hours following exposure (Rees et al. 1985).

Correlations between work place air concentrations of toluene and urinary excretion of unchanged toluene, hippuric acid, or *ortho*-cresol have been noted in a number of field studies (see ACGIH 2001 and 2010 for reviews and citations of these studies). Currently, ACGIH (2010, 2013) recommends using a

3. HEALTH EFFECTS

combination of three biological exposure indices (BEIs®) to assess exposure of workers to toluene in the workplace: *ortho*-cresol and unchanged toluene levels in blood immediately prior to the last shift of a workweek. The recommendation was made based on analyses of numerous field studies examining toluene blood concentrations and urinary concentrations of *ortho*-cresol and toluene in workers exposed to varying workplace air concentrations of toluene (see ACGIH 2010 for review). The specific values for these BEIs® correspond to concentrations likely to be observed in individuals exposed by inhalation to 20 ppm, the current ACGIH 8-hour TWA Threshold Limit Value (TWA-TLV®) for occupational exposure to toluene (ACGIH 2010). Previously, the level of hippuric acid in urine at the end of a workshift was recommended as a biomarker of exposure, but this recommendation was withdrawn because background urinary hippuric acid (from consumption of benzoate in foods and beverages) is expected to mask contributions from workplace exposure to toluene, especially at concentrations <50 ppm (ACGIH 2001, 2010). Other urinary biomarkers of exposure that have been proposed include benzylmercapturic acid (Inoue et al. 2002, 2004; Maestri et al. 1997) and S-*p*-toluylmercapturic acid (Angerer et al. 1998a).

3.4.4.2 Oral Exposure

Following oral administration of toluene to eight male subjects by a 2 mg/minute infusion for 3 hours through a feeding tube into the stomach, nonmetabolized toluene was detected in alveolar air samples for up to 4 hours after cessation of exposure and rates of urinary excretion of hippuric acid and *ortho*-cresol were elevated compared with values under nonexposed conditions (Baelum et al. 1993). A 6 mg/minute infusion for 30 minutes did not change the rates of urinary excretion of hippuric acid and *ortho*-cresol, but increased, by four-fold, the area-under-the-curve (AUC) for alveolar toluene concentration compared with the values for the 2-mg/minute exposure protocol. Accompanying the 2-mg/minute exposure protocol with oral doses of ethanol (0.32 g/kg, corresponding to two alcoholic drinks) decreased hippuric acid urinary excretion and dramatically increased the AUC for alveolar toluene concentration (by about 850-fold in one experiment and 56-fold in another). These data indicate that orally administered toluene is eliminated similarly to inhaled toluene, (i.e., by urinary excretion of metabolites and exhalation of nonmetabolized toluene), and that ingestion of ethanol can have a dramatic effect on metabolism and subsequent elimination of toluene. The results are consistent with other studies showing that ethanol inhibits the major toluene metabolic pathway, side-chain oxidation (Dossing et al. 1984; Wallen et al. 1984).

No other studies were located regarding the excretion of toluene in humans or animals after oral exposure.

3. HEALTH EFFECTS

3.4.4.3 Dermal Exposure

Following a 5-minute episode of hand-washing in toluene while wearing an airstream helmet to limit inhalation exposure, toluene concentrations in exhaled air from human subjects peaked at about 1 ppm at 22 minutes and declined to about 0.03 ppm at 24 hours (Monster et al. 1993). The results from this study indicate that dermally absorbed toluene can be eliminated as the parent compound in exhaled breath, but provide no information concerning the possible urinary excretion of metabolites.

No other studies were located regarding elimination of toluene following dermal exposure. As discussed in Section 3.4.1., studies in humans and rats have monitored concentrations of unchanged toluene in exhaled breath during and following dermal exposure to aqueous solutions of toluene to estimate dermal permeability coefficients (Thrall et al. 2002a; Thrall and Woodstock 2002). Like the study by Monster et al. (1993), they demonstrate that dermally absorbed toluene can be exhaled unchanged, but they do not provide information about the relative importance of urinary excretion of unchanged toluene or metabolites following dermal exposure.

3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models

Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and disposition of chemical substances to quantitatively describe the relationships among critical biological processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of potentially toxic moieties of a chemical that will be delivered to any given target tissue following various combinations of route, dose level, and test species (Clewett and Andersen 1985). Physiologically based pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to quantitatively describe the relationship between target tissue dose and toxic end points.

PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to delineate and characterize the relationships between: (1) the external/exposure concentration and target tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from route to route, between species, and between subpopulations within a species. The biological basis of

3. HEALTH EFFECTS

PBPK models results in more meaningful extrapolations than those generated with the more conventional use of uncertainty factors.

The PBPK model for a chemical substance is developed in four interconnected steps: (1) model representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance-specific physicochemical parameters, and species-specific physiological and biological parameters. The numerical estimates of these model parameters are incorporated within a set of differential and algebraic equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations provides the predictions of tissue dose. Computers then provide process simulations based on these solutions.


The structure and mathematical expressions used in PBPK models significantly simplify the true complexities of biological systems. However, if the uptake and disposition of the chemical substance(s) are adequately described, this simplification is desirable because data are often unavailable for many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The adequacy of the model is, therefore, of great importance, and model validation is essential to the use of PBPK models in risk assessment.

PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste sites) based on the results of studies where doses were higher or were administered in different species. Figure 3-4 shows a conceptualized representation of a PBPK model.

If PBPK models for toluene exist, the overall results and individual models are discussed in this section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.

3. HEALTH EFFECTS

Figure 3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance



Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by ingestion, metabolized in the liver, and excreted in the urine or by exhalation.

Source: Krishnan and Andersen 1994

3. HEALTH EFFECTS

PBPK models are available that describe the kinetics of toluene after inhalation exposure for humans (Benignus et al. 2006; Fisher et al. 1997; Jonsson and Johanson 2001; Sari-Minodier et al. 2009; Nong et al. 2006; Pierce et al. 1996, 1999; Tardif et al. 1995, 2002) and rats (DeJongh and Blaauboer 1996, 1997; Kenyon et al. 2008; Oshiro et al. 2011; Tardif et al. 1993; van Asperen et al. 2003). PBPK models to describe the kinetics of dermally applied aqueous solutions of toluene are also available for humans (Thrall et al. 2002a) and rats (Thrall and Woodstock 2002), but models to describe kinetics following oral exposure to toluene have not been developed.

Available models are all modifications of the standard four-compartment PBPK model developed for styrene (Ramsey and Andersen 1984) in which:

- (1) absorption into the lung blood is assumed to be dependent on the inhaled concentration of toxicant, the concentration of toxicant in alveolar air, blood flow to the lung, the blood:air partition coefficient, and alveolar ventilation rates,
- (2) exchange of toxicant between arterial blood and tissue compartments is flow-limited,
- (3) changes in the amount of toxicant in three nonmetabolizing tissue compartments (adipose tissue, slowly perfused tissues, and richly perfused tissues) are described by mass transfer differential equations with tissue volume, blood flow through the tissue (i.e., tissue perfusion rate), arterial blood toxicant concentration, and tissue:blood partition coefficients as explanatory variables, and
- (4) changes in toxicant amount in the liver (the fourth compartment) are described by similar differential equations that additionally include a Michaelis-Menten term for overall rates of toxicant metabolism.

Human Models. The five-compartment human model for toluene developed by Pierce et al. (1996) includes an additional equation describing mass balance across the lung that has a Michaelis-Menten metabolic term (Pierce et al. 1996). The model assumes that toluene metabolism in the liver and lung are adequately described by subject-specific maximal rate constants for liver and lung (“Vmax-h and Vmax-p” of $52.1 \times BW^{0.7}$ $\mu\text{mol}/\text{hour}$ and $0-0.7 \times 52.1 \times BW^{0.7}$ $\mu\text{mol}/\text{hour}$, respectively) and a common K_m (5.97 $\mu\text{mol}/\text{L}$). The K_m and Vmax-h values were based on those derived by fitting a Ramsey and Andersen-type four-compartment PBPK model (in which all parameters were constant except Vmax and K_m) to toluene uptake data for rats placed in closed chambers at several initial toluene concentrations (Tardif et al. 1993). The human Vmax-h was estimated for each subject by multiplying the rat Vmax-h by the subject’s body weight to the 0.7 power; the rat K_m was taken as the human value (Pierce et al. 1996). The lung Vmax (Vmax-p) was estimated by model-fitting for each subject, allowing the value to range between 0 and 70% of the liver Vmax, Vmax-h. This procedure was based on observations that

3. HEALTH EFFECTS

levels of CYP2E1 in human lung microsomes were 10.5% of liver activities (Wheeler et al. 1992), and 12 human liver samples showed a seven-fold range of CYP2E1 contents (Thummel et al. 1993).

Another singular feature of the Pierce human model is that subject-specific parameters such as age, height, weight, alveolar ventilation rate, adipose tissue fraction, and blood:air partition coefficients are put into the model (Pierce et al. 1996). Volumes of the tissue compartments in the model were scaled to each subject's body weight. Blood flows to the slowly and richly perfused tissues and the liver were taken as fractions of a standard human cardiac output scaled to body weight to the 0.74 power (in units of liter-hour), whereas subject-specific blood flows to the adipose tissue were estimated by model fitting (holding other parameters constant) allowing the fraction of cardiac output that perfuses adipose tissue to range between 0.06 and 0.18. The decision to "model-fit" this parameter within these bounds was based on published observations that adipose blood flows among individuals range widely from about 0.06 to 0.18 of total cardiac output. Tissue:blood partition coefficients used in the model for the slowly and richly perfused tissue, the liver, and adipose tissue were 1.54, 4.64, 4.64, and 55.9, respectively.

The initial development and validation of the human model involved comparing model fits with measured data (blood concentrations) for a group of 26 male volunteers who were exposed to 100 ppm toluene (50 ppm $^1\text{H}_8$ -toluene and 50 ppm $^2\text{H}_8$ -toluene) for a 2-hour period (Pierce et al. 1996). Venous blood concentrations of $^1\text{H}_8$ - and $^2\text{H}_8$ -toluene were measured at intervals for 120 hours post exposure. Prior to exposure, information on age, body weight, and adipose tissue fraction were obtained. During exposure, individual ventilation rates and blood:air partition coefficients for toluene were measured. Measures of the goodness-of-fit of the model predictions to the data were compared using subject-specific values, average values from the 26 subjects, and average literature values for: body weight, adipose tissue fraction, ventilation rate, blood:air partition coefficient, maximum velocity of pulmonary metabolism, and fraction of cardiac output to adipose tissue. The measured concentrations of toluene in blood showed a ten-fold interindividual range of variation. Subject-specific modeling explained 91% of the data variability, compared with 53% using literature values for model parameters (Pierce et al. 1996).

Pierce et al. (1998) used the human model to estimate toluene concentrations in alveolar breath reflective of exposure to 50 ppm toluene for 8 hours/day (the ACGIH 8-hour TWA TLV for toluene in 1998). Calculated values were $\leq 10 \mu\text{mol}/\text{m}^3$ for samples taken just before the final shift of a workweek and $\leq 150 \mu\text{mol}/\text{m}^3$ postexposure. It was proposed that toluene breath sampling would be a rapid, noninvasive biomarker of toluene exposure in workers that is not contaminated by endogenous sources. Pierce et al.

3. HEALTH EFFECTS

(1999) also used the human model as a research tool to ascribe differences in toxicokinetic behavior of $^1\text{H}_8$ - and $^2\text{H}_8$ -toluene to underlying physiological mechanisms.

Jonsson and Johansen (2001) modified the Pierce et al. (1996) model to incorporate, and estimate inter- and intra-individual variability in, exercise-induced changes in perfusion of fat tissue. The modified model split the muscle compartment into working and resting muscle compartments, and the fat compartment into perirenal and subcutaneous fat. Model parameters were expressed as prior distributions, rather than point estimates, based on literature values. The model was fit by Markov chain Monte Carlo simulation to time-course data for toluene concentrations in arterial blood, exhaled breath, and subcutaneous fat for six individuals exposed by inhalation to 80 ppm for 2 hours during rest and moderate to heavy exercise (50–150 W). The fitting exercise indicated that the kinetic data was best described when no increase in perfusion of subcutaneous fat with exercise was allowed and increased perfusion of perirenal fat induced by physical work was set to a constant level, rather than scaled proportionally to the increase in oxygen uptake with increasing workload.

The model by Jonsson and Johansen (2001) was further modified to a population-based model by replacing point-estimates for physiological model parameters with literature-based log-normal distributions (Mörk et al. 2014). Using Monte-Carlo techniques with the population-based model, estimates of the distributions for an internal dose (C_{max} in blood) for various subpopulations under various exercise scenarios were calculated, and the ratio between the 50th percentile values and higher percentiles (90, 95, or 99th percentiles) were used to indicate human variability in toxicokinetic disposition of toluene. Based on this modeling exercise, toluene-specific adjustment factors for human toxicokinetic variability (AF_{HK}) were 1.2–1.8 for the general population, 1.4–2.1 for chronically-exposed workers (under various exposure scenarios), and 1.4–3.9 for acutely-exposed workers (under various exposure scenarios).

Another human PBPK model has been developed for volatile organic compounds that simulates transfer of toxicant via lactation from a mother to a nursing infant, but *in vivo* pharmacokinetic data for toluene in breast milk were not available to validate this model (Fisher et al. 1997). This model is an adaptation of the Ramsey and Andersen design with the addition of a fifth compartment, a nonmetabolizing milk compartment with a varying volume. The model includes equations describing the rate of change in the amount of toxicant ingested by a nursing infant from the milk compartment, the rate of change in the amount of milk in the mammary tissue lumen, and the rate of change in the amount of toxicant in breast milk. The model used Michaelis-Menten kinetic constants for toluene metabolism in the liver estimated

3. HEALTH EFFECTS

for rats ($V_{\max}$ 7.5 mg/kg/hour; K_m 0.3 mg/L); the rat $V_{\max}$ was scaled for use in the model by multiplying it by a reference body weight (60 kg) to the 0.74 power. Human milk: blood partition coefficients for 19 volatile organic chemicals were experimentally determined using samples from volunteers; the coefficient for toluene was 2.68. Other tissue: blood partition coefficients for toluene used in the model included 4.91 for richly perfused tissue and for liver, 1.61 for slowly perfused tissue, and 60.01 for adipose tissue.

Fisher et al. (1997) used the model to estimate the amount of toluene an infant would ingest via milk if the mother was occupationally exposed to toluene at the ACGIH (1999) TLV (50 ppm) throughout a workday. The model predicted that such an infant would have a daily intake of 0.46 mg toluene, which is below the U.S. EPA Health Advisory, 2.0 mg/day, for chronic ingestion of 1 L/day of toluene-contaminated water by a 10-kg child.

Tardif et al. (1995) developed a four-compartment PBPK model for toluene in humans by modification of a four-compartment rat model developed by Tardif et al. (1993), in which all metabolism occurred in the liver. Physiological parameters for the human model were taken from the literature (e.g., alveolar ventilation rate and cardiac outputs had values of 18.0 L/hour/kg body weight for subjects at rest). Coefficients for human tissue: blood partitioning were calculated by dividing rat tissue: air values by a human blood: air coefficient (15.6) taken from the literature. The metabolic constant, K_m (0.55 mg/L), was assumed to be the same in rats and humans, and the human $V_{\max}$ (4.8 mg/hour/kg) was converted from the rat value by using body weight^{0.75} allometric scaling. The model was linked to a similar model for xylene; linking occurred by competitive metabolic inhibition in the liver. The linked models were evaluated by comparing predicted and observed values for toluene (and xylene) concentrations in alveolar air and blood. The predicted values were judged to be “in accord” with observed values from a study of volunteers exposed to 50 ppm toluene, 40 ppm xylene, or 50 ppm toluene+40 ppm xylene for 7 hours (Tardif et al. 1991). Simulations with the model indicated that blood concentrations and extent of metabolism for the two solvents during combined exposure at 50 ppm toluene and 100 ppm xylene would not be more than 10% changed, compared with exposure to the individual solvents alone (Tardif et al. 1995).

Tardif et al. (2002) modified the unlinked human PBPK model developed by Tardif et al. (1995) to include the description of urinary excretion of *ortho*-cresol. The fraction of total metabolites excreted as *ortho*-cresol (0.00078) was estimated by fitting the model to data for urinary *ortho*-cresol levels in toluene-exposed workers (Truchon et al. 1999). Values for urinary excretion rate of creatinine

3. HEALTH EFFECTS

(12.06 $\mu\text{mol}/\text{hour}/\text{kg}$) and urine output (1.848 mL/hour/kg) were taken from the literature. The model was used with Monte Carlo simulation to explore how published estimates of human population variance for parameters for excretion, physiology, and metabolism would influence concentrations of toluene in blood and *ortho*-cresol in urine. The resultant distribution for *ortho*-cresol excretion at the end of the first 8-hour workday in the week with exposure to 50 ppm toluene had a geometric mean of 0.635 mmol/mol creatinine with lower and upper 95% confidence limits of 0.23 and 1.75 mmol/mol creatinine, respectively. For blood toluene concentration prior to the last workday in the week, a somewhat smaller distribution of values was indicated with a geometric mean of 120.6 $\mu\text{g}/\text{L}$ and lower and upper 95% confidence limits of 64.5 and 225.7, respectively.

Nong et al. (2006) modified the adult PBPK model developed by Tardif et al. (1995) to incorporate data on age, body weight, liver volume, and hepatic CYP2E1 content from a study by Johnsrud et al. (2003) of 116 children (41 males, 75 females) ranging from newborn to 17 years of age. The model calculated hepatic clearance normalized on hepatic CYP2E1 content. The modified model, using child-specific data, was used to simulate time courses of toluene concentrations in blood of individual children of varying ages exposed by inhalation to 1 ppm toluene for 24 hours. The results indicated that the AUCs for simulated toluene blood concentrations in these children varied by a factor of about 6, compared with a factor of about 20 for the range of hepatic CYP2E1 contents. In neonates (<1 month old) with low and high hepatic CYP2E1 content (<3.69 and >3.69 pmol/mg protein), 95th percentile simulated AUC values were 3.9-fold and 2.5 higher than the 50th percentile AUC value for adults. The 95th percentile AUC values in children in older age groups (1 month–1 year; 1–11 years; 12–17 years) were less elevated; ratios of 95th percentile AUCs for children: the 50th percentile adult AUC value for these age groups were 1.57, 1.49, and 1.35, respectively.

Sari-Minodier et al. (2009) made further refinements of the Tardif et al. (2002) model to include a kidney compartment, and different physiological parameters (alveolar air ventilation, cardiac output, and fractions of total cardiac output to each compartment) for different levels of physical activity (measured in watts of work, W). Also included were modified values for the fraction of toluene metabolized to *ortho*-cresol (0.0012) and the *ortho*-cresol urinary excretion rate based on the best fit of simulations to observed time course data for volunteers exposed to 50 ppm for 7 hours (Tardif et al. 1998). The revised model was evaluated by comparing simulated values to observed data for concentrations of unchanged toluene in blood and urine in six volunteers exposed to 5.3, 16.0, or 26.6 ppm toluene for 8 hours at rest (Janasik et al. 2008), and for alveolar toluene concentrations and urinary *ortho*-cresol concentrations in four volunteers exposed to 50 ppm for 7 hours with different scenarios of physical activity (Nadeau et

3. HEALTH EFFECTS

al.2006). Sari-Minodier et al. (2009) considered the comparisons between simulated and empirical values to be “satisfactory.” The modified model was used to simulate values for blood toluene concentration at the end of an 8-hour work shift and urinary concentrations of toluene and *ortho*-cresol at the end of a workweek under different levels of activity. The model predicted that these biological exposure indices for toluene were increased by ~2–3-fold by 50 W activities versus 12.5 W resting activities at an air concentration of 20 ppm toluene.

Thrall et al. (2002a) developed a human PBPK model for toluene with six compartments (lung, richly perfused tissues, slowly perfused tissues, skin, fat, and liver) to simulate dermal exposure scenarios. The model was modified from a model for rats of similar structure as described by Thrall and Woodstock (2002). In these models, absorption to blood occurs through the lung and the skin, metabolism only occurs in the liver, and the skin compartment represents exposed skin; unexposed skin is lumped in the slowly perfused tissue compartment. Metabolic constants were the same as those used by Tardif et al. (1995). Physiological parameters included 348 L/hour for cardiac output and alveolar ventilation. Blood flow to compartments was distributed as percentages of cardiac output: liver 25%; fat 6%, richly perfused 49%; slowly perfused 15%; and total skin 5%. Tissue volume as percentages of body weight were: 4% liver; 20% fat; 5% richly perfused; 52% slowly perfused; and 4% total skin. Partition coefficients were: 1.75 saline:air; 13.9 blood:air; 83.5 liver:air; 1021 fat:air; 27.7 muscle:air; and 43.0 skin:air. Dermal exposures were simulated by an equation relating the rate of change in toluene concentration in the skin to dermal flux and dermal perfusion. Body weight was an input so that the model could be used to estimate dermal permeability coefficients (K_p , a parameter for the dermal flux equation) for individual subjects of varying body weights, by optimization of fit to exhaled breath data collected before, during, and after subjects were dermally exposed to aqueous solutions of toluene. Estimated K_p values for six subjects ranged from 0.004 to 0.020 cm/hour, with an average of 0.012 cm/hour (SD=0.007).

Benignus et al. (2006) combined a commercially available general whole-body human physiological model (named QCP2004) with a human PBPK model modified from the Tardif et al. (1995) model. The combined model (named GPAT for general physiology and toxicokinetic model) was developed to reduce the calculational complexity associated with time-dependent changes in exposure concentrations and human physical activity. The QCP2004 model provided estimates of physiological parameters required by the PBPK model under varying levels of human physical activity. The Tardif et al. (1995) human PBPK model was modified to include a brain compartment and new partition coefficients estimated by Thrall et al. (2002b). QCP2004 model simulations for minute ventilation, cardiac output, and hepatic blood flow were compared with observed data for these end points in humans with varying levels of

3. HEALTH EFFECTS

physical activity (0–200 W). The simulated values for these physiological parameters were mostly within 95% confidence limits for regression lines relating observed values and levels of activity from a number of published studies for each physiological end point. Values for blood toluene concentrations were simulated with the GPAT model and compared with published sets of observed values measured in human subjects exposed to toluene for short periods (30–120 minutes) under varying levels of physical activity. Simulated values and observed values for blood toluene concentrations in the published studies, regardless of exposure concentration or activity level, were plotted and fitted to a linear regression model. Comparison of an “identity line” (on which all points would lie if the model predicted perfectly) and the regression line indicated that the identity line was within the 95% confidence limits of the regression line.

Animal Models. The four-compartment rat PBPK model for toluene developed by Tardif et al. (1993) restricted metabolism to the liver compartment. The K_m (0.55 mg/L) and V_{max} (4.8 mg/hour/kg) values were derived by fitting the model (in which all parameters were held constant except V_{max} and K_m) to toluene uptake data for rats housed in closed chambers for 5 hours at several initial toluene concentrations (75, 150, or 225 ppm) (Tardif et al. 1993). The model used 18.0 as the blood:air toluene partitioning coefficient, and the following for partitioning between blood and tissue groups: 4.64 for liver and richly perfused tissue, 1.54 for slowly perfused tissue, and 56.7 for adipose tissue. Reference rates for alveolar ventilation (15 L/hour/kg) and cardiac output (15 L/hour/kg) were scaled by a factor of body weight to the 0.74 power. Model predictions of venous blood concentrations in rats during and after 5-hour exposures to toluene concentrations of 75, 150, or 225 ppm compared favorably (by visual inspection) with empirical data.

Tardif et al. (1993) linked the rat PBPK model for toluene to a similar PBPK model for xylene via the metabolism term in the liver compartment to test if there was no metabolic interaction between these compounds or if a metabolic interaction existed that could be described by competitive, noncompetitive, or uncompetitive inhibitory interaction. A model with a competitive inhibition metabolic term provided the best visual fit to empirical data for air concentrations of toluene and xylene during 5-hour exposures of rats in a closed chamber to mixtures of toluene and xylene at several initial concentrations.

A five-compartment rat PBPK model developed by DeJongh and Blaauboer (1996) is similar in design to the Tardif rat PBPK model except that it contains an additional compartment, (i.e., the brain, which was assumed to be nonmetabolizing). The model used the same toluene partition coefficients used in the Tardif et al. (1993) rat model; the brain:blood partition coefficient, 2.0, was estimated from a published value for the human brain:air coefficient and the rat blood:air coefficient. Reference rates for alveolar

3. HEALTH EFFECTS

ventilation (14 L/hour/kg) and cardiac output (14 L/hour/kg) were scaled by a factor of body weight to the 0.74 power. With other parameters in the model held constant, models with different published values of V_{max} and K_m for toluene metabolism in rat liver from two *in vivo* and six *in vitro* rat studies were compared for their ability to fit empirical data from several studies for toluene blood concentrations or toluene brain concentrations in rats exposed to inhaled toluene. DeJongh and Blaauboer (1996) judged that a V_{max} of 4.31 mg/kg/hour and K_m of 0.26 mg/L gave the overall best fit to the empirical data, but noted that differences were generally small among predictions from models with the various values of V_{max} and K_m .

DeJongh et al. (1998) used their rat PBPK model for toluene and similar models for 14 other volatile organic chemicals to examine a hypothesis that the acute lethality of volatile organic chemicals is related to their ability to distribute into the brain. Using these models to calculate the dose in the brain associated with the LC_{50} for the compounds, it was noted that the products of the LC_{50} and their respective exposure durations ranged by about 60-fold, whereas the PBPK-derived brain doses associated with the LC_{50} ranged by about 6-fold. DeJongh et al. (1998) concluded that this observation supports the hypothesis that the acute lethality of volatile organic chemicals, including toluene, is directly related to the extent of their distribution into the brain.

van Asperen et al. (2003) modified the five-compartment DeJongh and Blaauboer (1996) rat model with slightly different metabolic constants (V_{max} of 4 mg/kg/hour and K_m of 0.2851 mg/L) and a modified blood:air coefficient (13 versus 18 in the previous model). Other physiological parameters and partition coefficients were identical to those in the DeJongh and Blaauboer (1996) model. The model with the revised blood:air coefficient provided better fit of time-course data for blood and brain toluene concentration in Wistar-derived rats exposed for 7.5 hours to a constant concentration of about 2,667 ppm or five fluctuating peak concentrations of about 8,000 ppm for 0.5 hours separated by 1-hour intervals without toluene. Blood and brain concentrations were determined several times during and after exposure up to 24 hours after the start of exposure. The modified model was used to examine predicted brain dose-effect relationships in a visual discrimination task in rats exposed to toluene via constant and fluctuating exposure scenarios. Effects on end points measuring “disinhibition of responding” were most pronounced in groups with the highest estimated brain concentrations at the time of testing, but a monotonic relationship for increasing magnitude of effect and increasing brain concentration was not evident.

Thrall and Woodstock (2002) developed a rat PBPK model for toluene with six compartments (lung, richly perfused tissues, slowly perfused tissues, skin, fat, and liver) to simulate dermal exposure

3. HEALTH EFFECTS

scenarios. The rat model was adapted from the rat model developed by Tardif et al. (1993). In the modified model, absorption to blood occurs through the lung and the skin, metabolism only occurs in the liver, and the skin compartment represents exposed skin; unexposed skin is lumped in the slowly perfused tissue compartment. Dermal exposures were simulated by an equation relating the rate of change in toluene concentration in the skin to dermal flux and dermal perfusion. Body weight was an input so that the model could be used to estimate dermal permeability coefficients (K_p , a parameter for the dermal flux equation) for individual rats of varying body weights. This was done by optimization of fit of the model to exhaled breath data collected when rats were dermally exposed to aqueous solutions of toluene. Metabolic constants were the same as those used by Tardif et al. (1993). Physiological parameters included 5.4 L/hour for cardiac output and alveolar ventilation. Blood flow to compartments was distributed as percentages of cardiac output: liver 25%; fat 5%, richly perfused 51%; slowly perfused 15%; and total skin 5%. Tissue volume as percentages of body weight were: 4% liver; 8% fat; 5% richly perfused; 64% slowly perfused; and 10% total skin. Partition coefficients were: 1.2 saline:air; 18.0 blood:air; 83.5 liver:air; 1021 fat:air; 27.7 muscle:air; and 43.0 skin:air. The rat PBPK model was used to estimate a K_p for each exhaled breath dataset; the average K_p value across datasets was 0.074 cm/hour (SD=0.005).

Kenyon et al. (2008) developed a seven-compartment PBPK model for inhalation exposure of rats to toluene that included compartments for the lung, brain, richly perfused tissues, slowly perfused tissues, fat, gastrointestinal tract, and liver. Metabolism was restricted to the liver, and metabolic constants were those determined by Tardif et al. (1993). Partition coefficients were those determined by Thrall et al. (2002b). Values for cardiac output and alveolar ventilation were calibrated/optimized by fitting of the model to time-course data for toluene blood concentrations in Long-Evans rats under three different experimental conditions: “normal” rats with a diurnal cycle of being active and fed at night; “sedentary, day-acclimated” rats acclimated to be fed and active during the light diurnal cycle, but not performing a task; and “active, day-acclimated” rats acclimated to be fed and active during light hours and performing a lever pressing task. Blood flow fractions to tissues and volumes of tissue compartments were based on literature values for Long-Evans rats. The calibrated/optimized model was evaluated for its ability to predict time-course data for blood and brain concentrations of toluene collected from rats in several other pharmacokinetic studies under various physical activity and exposure conditions. Statistical analyses of plots of predicted versus observed blood concentration data from five other studies indicated no significant difference from a fitted regression line and a “unity” line. For predicted versus observed brain concentration data from four studies, the fitted regression had a slope of 0.850 that was statistically significantly less than the unity line slope of 1.0. Most of this discrepancy was attributed to brain

3. HEALTH EFFECTS

concentration data from a single study of Wistar rats for which the model consistently overpredicted brain concentration; when these data were excluded, the slope of the regression line was 1.01.

Oshira et al. (2011) modified the Kenyon et al. (2008) rat model for inhalation exposure to include hepatic enzyme induction as an empirical step function. When the Kenyon et al. (2008) model was used to simulate toluene brain concentrations during exposures of Long-Evans rats to 775 or 1,125 ppm for 24 hours, the model adequately described brain concentrations at 1 and 6 hours of exposure, but overpredicted brain concentrations at 24 hours and at 6 hours after exposure ceased. The modified model (which included graded fold increases of the maximum rate of toluene metabolism in the liver [V_{maxC}] used in the original model) provided better predictions of brain concentrations at 24 and 30 hours after exposure started. The modified model was used to predict brain concentrations of toluene during 1- and 24-hour exposures to several air concentrations and examined relationships between estimated brain concentrations and effects on a trained behavior task (visual signal detection). The dose-effect relationship for response latency in this task after 1 hour of exposure was shifted to the left on the dose axis, compared with the 24-hour dose-effect relationship. The results are consistent with the hypotheses that the rats developed a behavioral tolerance to toluene within 24 hours of exposure and that behavioral effects from 24-hour exposures cannot be accurately extrapolated from 1-hour exposure data.

3.5 MECHANISMS OF ACTION

3.5.1 Pharmacokinetic Mechanisms

Absorption. In humans and animals, toluene is rapidly absorbed by inhalation exposure (Benignus et al. 1984; Hjelm et al. 1988; Hobara et al. 1984b; Lof et al. 1993). Animal studies have shown that toluene is absorbed less rapidly by the oral route (Ameno et al. 1992; Pyykko 1983; Sullivan and Conolly 1988), and dermal route (Dutkiewicz and Tyras 1968; Thrall and Woodstock 2002; Thrall et al. 2002a). Studies with brush border membrane vesicles isolated from rat intestines and exposed to toluene indicate that toluene absorption occurs through the lipid matrix of the membrane (Alcorn et al. 1991).

Distribution. Toluene has been identified in brain, liver, lung, and blood in humans following toluene exposure (Paterson and Sarvesvaran 1983; Takeichi et al. 1986). Within the human brain, toluene has a greater affinity for areas of the brain that contain lipid-rich white matter, such as the brain stem, rather than the areas with larger amounts of grey matter (Ameno et al. 1992). The human data are supported by animal studies where distribution of toluene was found to be characterized by uptake in lipid tissues (brain and fat) immediately following inhalation exposure (Bergman 1983; Bowen et al. 2007; Campo

3. HEALTH EFFECTS

1999; Ghantous and Danielsson 1986; Ikeda 1990; Nakajima et al. 2006; Kenyon et al. 2008; van Asperen et al. 2003).

Metabolism. Studies of urinary metabolites in toluene-exposed humans have identified hippuric acid (the glycine conjugate of benzoic acid) as the major urinary metabolite of toluene. Minor urinary metabolites (in approximate order of decreasing abundance) include: the glucuronyl conjugate of benzoic acid; sulfate and glucuronide conjugates of *ortho*- and *para*-cresol; S-benzylmercapturic acid; and S-*p*-toluylmercapturic acid. CYP2E1 is thought to be the principal enzyme responsible for catalyzing the formation of benzyl alcohol from toluene, but other CYP forms capable of catalyzing this reaction include CYP1A1, CYP1A2, CYP2A6, CYP2A13, CYP2B6, and CYP2C8 (Fukami et al. 2008; Nakajima et al. 1997). Benzyl alcohol is thought to be converted to benzoic acid by alcohol dehydrogenase and aldehyde dehydrogenase. Hippuric acid formation from benzoic acid is catalyzed by acyl-CoA synthetase and acyl-CoA:amino acid N-acyltransferase, whereas benzoyl glucuronide formation from benzoic acid is catalyzed by UDP-glucuronyl transferase (Nakajima and Wang 1994). The formation of *ortho*- and *para*-cresol is thought to be catalyzed from benzoic acid by CYP1A2, CYP2E1, and CYP2B6 through epoxide intermediates (Nakajima et al. 1997). The liver appears to be the principal site of metabolism of toluene, but evidence of metabolism in other tissues like the lung is available (Fukami et al. 2008; Wheeler et al. 1992).

Excretion. In both humans and rats, up to about 75–80% of inhaled toluene that is absorbed can be accounted for by urinary excretion of the principal metabolite, hippuric acid (Lof et al. 1993; Ogata 1984; Tardif et al. 1998). Excretion of unchanged toluene and minor metabolites including S-benzylmercapturic acid, S-*p*-toluoylmercapturic acid, and conjugates of *ortho*- and *para*-cresol account for less than 5% of absorbed toluene, but assays for urinary levels of unchanged toluene and *ortho*-cresol can provide reliable biomarkers of toluene exposure (ACGIH 2010; Ducos et al. 2008; Janisik et al. 2008, 2010). Excretion of nonmetabolized toluene in exhaled air can represent from 7 to 20% of absorbed toluene, depending on exposure conditions (Carlsson 1982; Leung and Paustenbach 1988; Lof et al. 1993). Although the liver is expected to be the main site of metabolism of toluene, CYP2E1, one of the principal isozymes catalyzing the initial reaction in the principal toluene metabolic pathway, has been detected in human lung microsomes at concentrations about 10-fold less than in liver microsomes (Wheeler et al. 1992). Under conditions in which the main pathway of toluene metabolism is inhibited by co-exposure with ethanol, exhalation of nonmetabolized toluene can become a principal route of excretion (Baelum et al. 1993).

3. HEALTH EFFECTS

3.5.2 Mechanisms of Toxicity**3.5.2.1 Mechanisms of Neurotoxicity**

Dysfunction of the central nervous system is a critical human health concern following acute, intermediate, or chronic inhalation exposure to toluene. Therefore, the mechanisms of toluene toxicity have been investigated predominately in the nervous system. Proposed mechanisms of toxicity include altered membrane and membrane channel properties; direct damage to brain structures via lipid damage, oxidative stress, and/or apoptosis; altered neurotransmitter synthesis, release, degradation, and receptor binding; disruption of the hypothalamic-pituitary-adrenal axis; and neuroinflammation.

Mechanisms of Central Nervous System Depression and Narcosis. The mechanism by which acute exposure to toluene brings about neurological effects such as central nervous system depression and narcosis is generally thought to involve, at least in part, reversible interactions between toluene (the parent compound and not its metabolites) and components (lipids or proteins) of nervous system membranes. Support of parent-material involvement comes from the observation that pretreatment of rats with phenobarbital increased the rate of *in vivo* toluene metabolism and shortened the time of recovery from narcosis from single intraperitoneal doses of toluene (Ikeda and Ohtsuji 1971). Other support for this hypothesis includes the transient nature of anesthesia from acute, high-level exposure to toluene and the rapidity with which toluene-induced changes in brain biochemical variables can be measured. For example, within 0.25–1 hour of intraperitoneal injection of 1-g/kg doses of toluene into rats, brain synaptosomes showed decreased phosphatidylethanolamine content, altered phospholipid methylation activities, altered outer membrane fluidity, and increased Na⁺-K⁺-ATPase activities (LeBel and Schatz 1988, 1989, 1990). Similarly, increased Na⁺-K⁺-ATPase activities were observed in brain homogenates of rats sacrificed 15 minutes after an intraperitoneal injection of 35 mg/kg toluene or *ortho*-cresol (Calderon-Guzman et al. 2005). In culture systems, decreased Mg⁺⁺-ATPase activities were measured in brain synaptosomes isolated from rat brains immediately following a 2-hour exposure to 2,000 ppm toluene (Korpela and Tahti 1988); near-significant increases in calcium leakage were observed in synaptosomes of PND 25–43 offspring exposed to 1,800 ppm for 6 hours/day from GD 7 to 20, compared with unexposed offspring (Edelfors et al. 2002); and increased LDH and calcium leakage were observed in a neuroblastoma cell line (SH-SY5Y) following *in vitro* toluene exposure (McDermott et al. 2007). On a molecular scale, the acute anaesthetic actions of toluene and other agents have been postulated to involve intercalation of toluene into the lipid bilayer of nerve membranes and/or reversible interactions with proteins in the membrane (Franks and Lieb 1985, 1987).

3. HEALTH EFFECTS

More recently, acute effects of toluene and other volatile organic chemicals on neuronal functions have been proposed to involve interactions with voltage- and ligand-gated ion channels in nerve tissue. In various cell preparations, toluene has been shown to disrupt currents mediated by GABA receptors (Beckstead et al. 2000; Gmaz and McKay 2014), N-methyl-D-aspartate (Cruz et al. 1998, 2000, 2003), nicotinic acetylcholine receptors (Bale et al. 2002, 2005), muscarinic acetyl choline receptors (Tsuga et al. 1999; Wu et al. 2002), voltage-sensitive Ca^{+2} channels (Shafer et al. 2005; Tillar et al. 2002), calcium-activated and G-coupled potassium channels (Del Re et al. 2006), and gap junctions (Del Re and Woodward 2005).

Mechanisms of Structural Brain Damage. Clinically obvious neurological impairment (e.g., gait and speech abnormalities) and brain atrophy have been observed in several cases of chronic toluene-inhalation abuse. MRI of the brain of solvent abusers (Filley et al. 1990; Rosenberg et al. 1988a, 1988b) suggests preferential atrophy in lipid-rich regions of the brain. Rosenberg et al. (1988a, 1988b) found MRI evidence of diffuse central nervous system demyelination in 6 toluene abusers with clinically obvious neurological impairment, whereas Filley et al. (1990) noted that the degree of MRI-detected white matter abnormality in 14 solvent abusers was correlated with neurological impairment. The observed changes in MRI signals may be related to lipid compositional changes in the white matter, since these regions are more lipid-rich than gray matter (Ameno et al. 1992). These observations are consistent with a hypothesis that chronic exposure to high concentrations of toluene brings about structural changes in the brain related to lipid compositional changes. Supporting evidence for this hypothesis includes observations of changed phospholipid composition of rat brain synaptosomes following acute exposure to toluene (Lebel and Schatz 1988, 1989, 1990), decreased phospholipid concentrations in the cerebral cortex of rats following 30 days of continuous exposure to 320 ppm (Kyrklund et al. 1987), degenerative changes and ultrastructural damage in the hippocampus, frontal cortex, and brain stem (Kanter 2008a, 2008b, 2001, 2013), decreased or shrunken cells in the hippocampus (Gelazonia et al. 2006a; Gotohda et al. 2002; Korbo et al. 1996; Zhvania et al. 2012), impaired dendritic outgrowth in the frontal cortex (Pascual and Bustamante 2010), impaired neurite growth in neonatal rat cerebellar granular neurons stimulated with L1 cell adhesion molecule (suggesting impaired L1-lipid raft interactions) (White et al. 2016), and white matter damage in the anterior commissure (Duncan et al. 2012). It is uncertain if toluene-induced changes in membrane phospholipid content may be caused by increased breakdown of phospholipids or inhibition of synthesis.

Brain damage may be mediated through apoptotic pathways. Increased apoptosis has been observed in the rat brain following acute or intermediate-duration oral exposure to 650 mg/kg/day (Kamel and

3. HEALTH EFFECTS

Shehata 2008). Following exposure to 1,500–1,800 ppm, 6 hours/day from GD 7 to 20, increased apoptosis was observed in the cerebellum of rat pups at PNDs 21 and 27 (but not PNDs 11, 22, 24, or 90) (Dalgaard et al. 2001; Ladefoged et al. 2004). No changes in hippocampal apoptosis were observed. Additionally, a significant increase in caspase-3 activity was observed in the cerebellum on PND 6, but not PNDs 22, 24, or 27, indicating increased caspase-3 mediated apoptosis (Ladefoged et al. 2004). A study in rat astrocyte cultures also reported that observed apoptosis following *in vitro* toluene exposure was caspase-dependent, and that stimulation of p42/44 mitogen activated protein kinase (MAPK) by toluene functions to promote cell survival (Lin et al. 2002).

Damage to brain structures may also result from oxidative stress, as increased markers of oxidative stress have been observed in the rat brain following acute- or intermediate-duration inhalation exposure to concentrations as low as 10 ppm (Baydas et al. 2003, 2005; Burmistrov et al. 2001; Coskun et al. 2005; Kodavanti et al. 2011, 2015; Royland et al. 2012). Increased markers of oxidative stress have also been observed in rats following acute or intermediate-duration oral exposure to 650 mg/kg/day (Kamel and Shehata 2008). Following gestational exposure to 1,800 ppm for 6 hours/day from GD 7 to 20, increased reactive oxygen species were produced in response to *in vitro* exposure to toluene in cultured synaptosomes from PND 25 to 43 offspring (Edelfors et al. 2002). Lipid peroxidation in rat brain was also increased following intraperitoneal injections of toluene or its metabolites (*ortho*-, *para*-, and *meta*-cresol) (Calderon-Guzman et al. 2005). This mechanism is plausible in humans, as increased markers of oxidative stress have been observed in workers exposed to solvent mixtures (Halifeoglu et al. 2000; Kim et al. 2011; Won et al. 2011).

Mechanisms of Mild Neurological Impairment. Mechanistic understanding is poor of effects that have been associated with intermediate and chronic exposure to toluene in workplace air such as increased incidence of self-reported neurological symptoms (Guzelian et al. 1988; Matsushita et al. 1975; Orbaek and Nise 1989; Ukai et al. 1993; Yin et al. 1987), performance deficits in neurobehavioral tests (Boey et al. 1997; Eller et al. 1999; Foo et al. 1990; Kang et al. 2005; Matsushita et al. 1975; Orbaek and Nise 1989); hearing loss (Morata et al. 1997), changes in auditory and/or visual-evoked potentials (Abbate et al. 1993; Vrca et al. 1995, 1996, 1997a, 1997b), and color vision loss (Campagna et al. 2001; Cavalleri et al. 2000; Zavalic et al. 1998a, 1998b, 1998c), but several mechanistic actions have been postulated.

One mechanistic hypothesis postulates that repeated interaction of toluene with membrane proteins and/or phospholipids in brain cells can change activities of enzymes involved in the synthesis and/or degradation of neurotransmitters and that levels of neurotransmitters at particular sites in the brain may be involved in

3. HEALTH EFFECTS

producing subtle neurological effects. Some evidence for this hypothesis comes from observations of increased concentrations of dopamine, norepinephrine, and 5-hydroxytryptamine in rats exposed to 1,000–4,000 ppm for 30 minutes (Kim et al. 1998), 1,000 ppm for 8 hours (Rea et al. 1984), or up to 105 mg/kg/day in drinking water for 28 days (Hsieh et al. 1990b, 1991); decreased dopamine levels and rates of turnover in several areas of the nucleus caudate in the brain of rats exposed to 80 ppm toluene, 6 hours/day for 3 days (Fuxe et al. 1982); increased levels of dopamine and noradrenaline in several brain regions in rats exposed to 80–3,000 ppm, 6 hours/day for 3 days (Andersson et al. 1983b); decreased activities of aromatic acid decarboxylase, an enzyme involved in synthesis of neurotransmitters, in the brain stem of rats exposed to 250 or 1,000 ppm, 8 hours/day, 5 days/week for 4 weeks (Bjornaes and Naalsund 1988); significantly increased dopamine levels, decreased levels of 3,4-dihydroxyphenylacetic acid (DOPAC) and dihydroxyphenylalanine (DOPA), and altered monoamine neurotransmitter synthesis (tyrosine and tryptophan hydroxylase enzyme activities) in rats exposed to 40 ppm toluene 104 hours/week for 16 weeks (Berenguer et al. 2003, 2004; Soulage et al. 2004); and significant localized changes in dopamine and noradrenaline neurotransmitter levels and utilization in 8-week-old adult male rats exposed to 80 ppm for 6 hours/day from PND 1 to 7, compared with controls (von Euler et al. 1989). Altered neurotransmitter levels have also been reported in several animal studies at concentrations modeling solvent abuse (>1,000 ppm) (Apawu et al. 2014; Alfaro-Rodriguez et al. 2011; Gerasimov et al. 2002c; Koga et al. 2007; O’Leary-Moore et al. 2007, 2009; Ono et al. 1999; Paez-Martinez et al. 2008; Tsuga and Honma 2000; Williams et al. 2005) and following toluene injection (Calderon-Guzman et al. 2005; Riegel et al. 2004; Win-Shwe et al. 2007b). Based on *in vitro* and *in vivo* microdialysis studies, Riegel et al. (2007) suggested that observed increases in dopamine levels may result from direct stimulation of dopamine neurons in the ventral tegmental area, resulting in increased dopamine release into the nucleus accumbens of the mesolimbic system. Another *in vivo* microdialysis study reported dose-related decreases in extracellular acetylcholine levels in the striatum and hippocampus following intraperitoneal injections of 200–2,000 mg/kg toluene, which peaked 2–3 hours post-injection (Honma and Suda 2004). However, acetylcholine levels in striatal and hippocampal homogenates were significantly increased, suggesting that decreased extracellular levels were due to decreased acetylcholine release from nerve terminals.

Another mechanistic hypothesis postulates that repeated exposure to toluene may cause neurological effects by changing the binding of neurotransmitters to membrane receptors. In support of this hypothesis, persistent changes in brain-tissue dopamine D2 receptor binding and increased serum prolactin levels were found in rats 17 days after exposure to 80 ppm toluene 6 hours/day, 5 days/week for 4 weeks (von Euler et al. 1993, 1994). It was speculated that the increase in serum prolactin level could

3. HEALTH EFFECTS

be related to a possible interaction between toluene and the pituitary dopamine D2 receptor; this receptor normally inhibits the release of prolactin into serum. Correlated with these biochemical changes was a significantly increased locomotor activity (approximately 2-fold) in response to injections of apomorphine (a dopamine) and a significantly increased escape latency (indicating impaired spatial learning and memory) in a water maze task, both observed 14–17 days after the 4-week toluene exposure (von Euler et al. 1994). Whether or not this hypothesis is related to effects observed in occupationally exposed humans is uncertain; Svensson et al. (1992b) did not find changes in serum prolactin levels in toluene-exposed printing workers compared with controls. Additionally, in another animal study, no significant exposure-related changes in serum prolactin levels in rats were reported with 4-week exposures to concentrations up to 320 ppm (Hillefors-Berglund et al. 1995). There were also no changes in dopamine D3 receptor binding 4 weeks after cessation of a 4-week exposure to 80 ppm toluene (von Euler et al. 2000). However, there is some evidence of changes in glutamate and GABA binding in male rats exposed by inhalation to toluene at concentrations of 50–1,000 ppm for 4 weeks or 500 ppm for 12 weeks (Bjornaes and Naalsund 1988) and binding to muscarinic acetylcholine receptors in male rats following exposure to ≥ 500 ppm for 6 hours (Tsuga and Honma 2000). Various alterations in receptor subunit levels were observed in the mesolimbic system of the rat brain following exposure to 8,000 ppm 30 minutes/day for 10 days, including increases in GABA α 1, NR1, NR2, and GluR2/3 subunits in the medial prefrontal cortex and decreased GABA α 1 and NR1 subunits in the substantia nigra (Williams et al. 2005). Additionally, agonist binding to the GluN2B receptor subunit was significantly decreased in mesocorticolimbic regions (nucleus accumbens, dorsal striatum, and caudal anterior cingulate cortex) (Dick et al. 2015).

Further evidence of alterations in neurotransmitter systems comes from injection studies. Following intraperitoneal injections of 250–750 mg/kg, rats showed dose-related increases in locomotor activity, motor incoordination, and memory impairment during neurobehavioral testing (Lo et al. 2009). Pretreatment with dopamine D1, D2, and D3 receptor antagonists (SCH23390, raclopride, nafadotride, respectively) prevented locomotor effects, and all behavioral alterations were prevented with pretreatment with d-serine, a co-agonist at the glycine binding site of NMDA receptors (Lo et al. 2009). Similarly, the NMDA co-agonist, sarcosine, was able to attenuate neurobehavioral alterations in rats following intraperitoneal injections of 250–750 mg/kg toluene (Chan et al. 2012) and the D2 antagonist remoxipride was able to attenuate locomotor effects in rats following intraperitoneal injections of 600–1,200 mg/kg toluene (Riegel and French 1999). Additionally, locomotor effects following an intraperitoneal injection of 600 mg/kg were significantly attenuated when neurotransmission in the mesolimbic nucleus accumbens was altered via 6-hydroxydopamine lesions (6-OHDA) or the mGlu2/3 receptor agonist

3. HEALTH EFFECTS

LY379268 (Riegel et al. 2003). Observed increases in depressive-like behavior in the forced swim and tail suspension tests, 1 and 4 days following intraperitoneal injection of 500 mg/kg toluene, were prevented with administration of serotonin-reuptake inhibitors (fluoxetine and imipramine) (Yang et al. 2010). Decreased NMDA-mediated calcium signaling and NR2B subunits have been reported in cerebellar granule cells cultured from rat pups following daily intraperitoneal injections of 200–1,000 mg/kg/day from PND 4 to 10 (Chen et al. 2004, 2005). Following daily intraperitoneal injections of 500 mg/kg/day toluene on PNDs 4–9 or 21–26, NMDA receptor-mediated excitatory postsynaptic currents (EPSCs) were enhanced following electrical stimulation, but decreased in response to exogenous NMDA in PND 30–38 hippocampal slices (Chen et al. 2011). However, paired-pulse facilitation of NMDA currents was only observed in rats exposed to 500 mg/kg/day toluene from PND 4 to 9 (Chen et al. 2011).

Significant decreases (28 or 47%) in rat brain GFAP induced by exposure to 1,000 ppm toluene, 6 hours/day for 3 or 7 days have been associated with increased serum levels of corticosterone (Little et al. 1998). The decreases in GFAP were observed in the thalamus and hippocampus, regions of the brain that are reported to be involved in controlling serum glucocorticoid levels and having high concentrations of glucocorticoid receptors, respectively (Little et al. 1998). Little et al. (1998) postulated that decreases in brain GFAP may be a consequence of toluene disruption of the hypothalamic-pituitary-adrenal axis and/or hormonal homeostasis, but noted that the available evidence is inadequate to firmly establish cause and effect. Decreased GFAP was also observed in neonatal rat brains following daily intraperitoneal injections of 750 mg/kg from PND 4 to 10 (Burry et al. 2003) and in a dose-related manner in cultured astrocyte precursor cells following *in vitro* exposure to toluene, suggesting that toluene exposure could disrupt early brain development (Yamaguchi et al. 2002). Additionally, *in vitro* toluene exposure inhibited proliferation of primary rat cortical astrocyte cultures in a dose-related manner (Burry et al. 2003). The possible mechanistic connections of these observations to toluene-induced changes in neurobehavior are uncertain. In contrast, GFAP levels were significantly increased in the hippocampus, cerebellum, and spinal cord of male rats exposed to 1,500 ppm, 4 hours/day for 4–10 days (Gotohda et al. 2000a, 2000b) and in the hippocampus, cortex, and cerebellum of male rats exposed to 3,000 ppm paint thinner (66% toluene) 1 hour/day for 45 days (Baydas et al. 2003).

Alterations in adult neurogenesis in the subventricular zone of the lateral ventricle (SVZ) of the hippocampus may contribute to cognitive impairments associated with toluene abuse. Exposure to toluene in paradigms modeling abuse (500–6,000 ppm) led to an initial burst of neurogenesis, followed by a decrease in both neurogenesis and cell survival in the SVZ in mice (Franco et al. 2014; Paez-Martinez et

3. HEALTH EFFECTS

al. 2013). Seo et al. (2010) also reported a reduced rate of adult hippocampal neurogenesis in mice following a single intraperitoneal injections of 500 mg/kg toluene. As reviewed by these study reports, cognitive impairments and drug seeking behaviors have been associated with abnormalities in adult hippocampal neurogenesis in animal models.

Numerous gene expression changes have been observed in brain tissues of rats and mice following acute or intermediate inhalation exposure or injection; however, current understanding is inadequate to determine the mechanistic significance of these findings. Genes demonstrating significantly altered expression levels are involved in synaptic transmission and plasticity (Ahmed et al. 2007; Hester et al. 2011, 2012), memory (Win-Shwe and Fujimaki 2012; Win-Shwe et al. 2007a, 2010b, 2010c), neurotrophic factors (Win-Shwe et al. 2010a; Gotohda et al. 2000b), and oxidative stress (Win-Shwe et al. 2010a). Results of these studies vary greatly, and indicate that gene expression changes are species-, strain-, dose-, duration-, and lifestage-dependent. A series of studies suggest that neurobehavior may be altered through neuroimmune effects, such as neuroinflammation, and that immune status may affect gene expression changes in brain neuroinflammation (Win-Shwe et al. 2010a, 2011, 2012a, 2012b). Epigenetic alterations (histone acetylation) were seen in the dentate gyrus of rats exposed to 1,000–6,000 ppm for 30 minutes or 10 days (30 minutes, 2 times/day) (Huerta-Rivas et al. 2012), and in the nucleus accumbens and ventral tegmental area of rats exposed to 6,000 ppm for 10, 30-minute sessions over 8 days (Sanchez-Serrano et al. 2011).

Mechanisms of Hearing Loss. There is evidence that hearing loss induced by inhalation exposure to toluene is produced by toluene itself and not by its metabolites. Phenobarbital pretreatment, which increases the rate of *in vivo* metabolism of toluene, prevented hearing loss in rats exposed to 1,500–2,000 ppm toluene, 8 hours/day for 7 days (Pryor et al. 1991), rats exposed to 1,700–2,000 ppm toluene, 6 hours/day, 5 days/week for 6 weeks (Campo et al. 2008), and rats exposed to a single gavage dose of 1,500 mg/kg (Campo et al. 2008). Inhibition of P450 metabolism by SKF525-A in guinea pigs resulted in altered auditory thresholds following exposure to 1,750 ppm toluene 6 hours/day, 5 days/week for 4 weeks; toluene administration alone did not change auditory thresholds (Waniusiow et al. 2009). Acivicin pretreatment, which inhibits γ -glutamyl transferase and the production of cysteine S-conjugates during toluene metabolism, did not alter hearing loss in rats exposed to 1,750 ppm toluene 6 hours/day, 5 days/week for 4 weeks, suggesting that toluene-induced hearing loss is not mediated by the cysteine S-conjugate metabolic pathway (Waniusiow et al. 2008).

3. HEALTH EFFECTS

Multiple studies in animals indicate that hearing loss observed with occupational toluene exposure may be due, in part, to direct damage to the OHCs of the cochlea that are responsible for amplifying incoming sound waves prior to signal transduction (Campo et al. 1997, 1998; Johnson and Canlon 1994; Lataye and Campo 1997; Lataye et al. 1999; Waniusiow et al. 2008). Phenobarbital pretreatment also reduced OHC loss in rats exposed to 1,700–2,000 ppm toluene 6 hours/day, 5 days/week for 6 weeks, compared with toluene-treatment alone (Campo et al. 2008). Additionally, rats that were given large gavage doses of ethanol (4 g/kg/day) and daily inhalation exposure to toluene concentrations of 1,750 ppm 6 hours/day, 5 days/week for 4 weeks showed significantly greater hearing loss (as measured by BAEP) and OHC loss in the ear than those exposed to toluene alone (Campo et al. 1998). Co-exposure to ethanol caused a significant decrease in hippuric acid urinary excretion rates compared with exposure to toluene alone, indicating that these large doses of ethanol inhibited the metabolism of toluene (Campo et al. 1998). Since exposure to ethanol alone in this study did not affect hearing or OHC loss in the ear, ethanol inhibition of toluene metabolism and subsequent potentiation of toluene-induced loss of hearing are consistent with the idea that toluene itself is responsible for these effects.

Mechanistic understanding at the molecular and cellular level is limited regarding how toluene exposure leads to a loss of OHCs in the ear and the degree to which toluene effects on neural cell membranes may be involved. However, a series of recent papers propose that toluene modifies the response of protective acoustic reflexes to loud noises via anticholinergic effects, which could potentially result in increased noise-induced hearing loss (Campo et al. 2007; Lataye et al. 2007; Maguin et al. 2009; Venet et al. 2011). Following an injection of 116.2 nM toluene directly into the carotid artery supplying the tested cochlea, electrophysiological responses of OHCs (cochlear microphonic potentials; CMPs) to noise (65–95-dB SPL) were significantly increased in an intensity-dependent manner in anesthetized rats (Campo et al. 2007; Lataye et al. 2007). This suggests that toluene affects: (1) endocochlear potential or OHC membrane conductance; (2) how OHC stereocilia move; and/or (3) the inner- or middle-ear muscle reflex via alterations in the efferent pathway (preventing protective reflexive actions). The intensity-dependent increase suggests that the increased CMP amplitudes were due to altered inner-ear and/or middle ear acoustic reflexes (Lataye et al. 2007). Since acoustic reflexes can be stimulated in both ears following loud noises in one ear, further support for toluene-mediated alterations in acoustic reflexes comes from increased CMP amplitudes following both ipsilateral (same side) and contralateral (opposite side) noise stimulation (Campo et al. 2007). Additionally, toluene exposure did not alter CMPs in rats with severed middle ear muscles (Campo et al. 2007); however, CMPs were not altered from baseline following noise exposure prior to toluene injections, limiting the interpretation of these results. Since the auditory efferent system is a cholinergic descending pathway, and toluene has been shown to alter currents in

3. HEALTH EFFECTS

nicotinic acetylcholine receptors (Bale et al. 2002, 2005) and muscarinic acetylcholine receptors (Tsuga et al. 1999; Wu et al. 2002), Campo et al. (2007) hypothesized that observed alterations in acoustic reflexes in middle ear muscles result from anticholinergic actions of toluene. In support, CMP responses following injections of antagonists of cholinergic receptors and antagonists of calcium-gated acetylcholine channels were of similar magnitude to responses to toluene (Lataye et al. 2007; Maguin et al. 2009). Another study examined noise-induced distortion product otoacoustic emissions (DPOAE) to evaluate the effect of toluene exposure on noise-induced suppression of cochlear responses (Venet et al. 2011). Similar to CMP responses, DPOAE amplitude suppression to ipsilateral and contralateral stimuli was decreased in rats injected with 116 nM toluene; however, no cochlear damage was observed (Venet et al. 2011). Additionally, a clear dose-response effect was not observed, as contralateral noise-induced suppression is increased in rats injected with 58 nM toluene, and no clear effects were observed at 58 nM toluene with ipsilateral stimuli or 87 nM toluene with either ipsilateral and contralateral stimuli (Venet et al. 2011).

Mechanisms of Vision Impairment. The molecular mechanism and pathogenesis of color vision impairment (dyschromatopsia) associated with occupational and intentional abuse exposure to toluene and other organic solvents are not clearly understood, but it has been postulated that toluene interference with dopaminergic mechanisms of retinal cells or toxic demyelination of optic nerve fibers may be involved (Muttray et al. 1997, 1999; Zavalic et al. 1998a, 1998b, 1998c). Alterations observed in VEPs may be mediated through alterations in glutamatergic receptors, as treatment with MK801 (a non-competitive antagonist of the NMDA receptor) prevented the reduction of VEP amplitude observed following acute exposure to 2,000 ppm toluene (Bale et al. 2007).

3.5.2.2 Mechanisms of Toxicity to Other Systems

Mechanistic studies in other systems are limited, but suggested mechanisms are similar to those observed for neurotoxicity, including altered membrane properties, apoptosis, oxidative stress, and gene expression alterations.

Altered Membrane Properties. As observed in nervous system cultures, altered membrane properties were reported following toluene exposure in Jurkat T cells, as evidenced by increased LDH and calcium leakage (McDermott et al. 2007).

3. HEALTH EFFECTS

Apoptosis and Oxidative Stress. As observed in nervous tissue, increased markers of oxidative stress have been observed in liver, kidney, and testes in rats following acute or intermediate-duration oral exposure to 650 mg/kg/day (Kamel and Shehata 2008). Additionally, increased apoptosis has been observed in the liver, but not kidney or testes, in rats following intermediate-duration oral exposure to 650 mg/kg/day (Kamel and Shehata 2008). Additional evidence for oxidative stress in reproductive organs include increased activities for glutathione peroxidase in ovaries of rats exposed to 500 ppm toluene for 4 hours/day, 5 days/week for 1 month (Burmistrov et al. 2001), attenuation of sperm parameter changes and testicular damage in rats exposed to 6,000 ppm toluene for 2 hours/day for 5 weeks following pre-treatment with antioxidant thymoquinone (Kanter 2011b), and increased 8-oxodG formation in testes along with decreased sperm counts and serum testosterone in male rats given daily intraperitoneal injections of 50 or 500 mg/kg for 10 days (Nakai et al. 2003). In another study, no significant changes in testicular or epididymal levels of several markers of oxidative stress were observed in rats exposed to 1,500 ppm 4 hours/day for 7 days (Tokunaga et al. 2003).

An *in vitro* study in human leukemia cells reports significant increases in apoptosis and dose-related (but nonsignificant) increases in reactive oxygen species production (Sarma et al. 2011). In porcine proximal tubular cells (LLC-PK1), both apoptosis and lipid peroxidation were significantly increased following *in vitro* exposure to toluene (Al-Ghamdi et al. 2003, 2004).

Gene Expression Changes in Tissues Other than the Brain. Changes in mRNA levels for genes involved in oxidative stress, thrombosis, vasoconstriction and inflammation were noted in rat cardiac tissue following single gavage doses of 1,000 mg/kg toluene (Gordon et al. 2010). In a series of studies from a single laboratory, intermediate-duration inhalation exposures of normal or allergy-challenged (ovalbumin [OVA]-immunized and challenged) mice to toluene concentrations ranging from 5 to 90 ppm have been reported to produce non-monotonic dose-related changes in the mRNA levels for inflammatory cytokines, neurotrophins, neurotrophin receptors or other immune regulatory transcription factors in lung, BAL fluid, thymus, or spleen (Fujimaki et al. 2009b, 2010, 2011; Liu et al. 2010; Yamamoto et al. 2009; Win-Shwe et al. 2007a). As with the neurological gene expression studies, current understanding is inadequate to determine the mechanistic significance of these findings.

3.5.2.3 Potential Mechanisms of Metabolite-mediated Toxicity

The postulated arene oxide intermediates formed in the metabolic pathway from toluene to *ortho*- or *para*-cresol are highly reactive and expected to bind to cell proteins and RNA, thereby potentially leading

3. HEALTH EFFECTS

to cellular dysfunction and degeneration. Studies with human and rat liver microsomes and tissue slices showed that incubation with labeled toluene leads to incorporation of the label into microsomal proteins and RNA in an NADP-requiring reaction (Chapman et al. 1990). It does not appear likely, however, that this mechanism of action is the primary mode of toluene's toxicity, especially at air concentrations below 100 ppm that are of occupational and public health concern, because:

- (1) the liver is expected to be the main site of toluene metabolism,
- (2) the pathway to the cresol isomers accounts for less than 1–5% of metabolized toluene (see Section 3.4.3),
- (3) results from animal studies and studies of toluene-exposed workers do not identify the liver as the most sensitive target organ (see Section 3.2.1), and
- (4) degenerative lesions in nervous tissues have not been detected by light microscopy in rats and mice exposed to concentrations as high as 1,200 ppm 6.5 hours/day, 5 days/week for up to 2 years (CIIT 1980; NTP 1990).

The available evidence, however, is not sufficient to discard the hypothesis that this mode of action (i.e., cellular degeneration caused by reactive metabolic intermediates) may play some role in toluene toxicity, especially with repeated high-level exposures such as those experienced by toluene abusers.

3.5.3 Animal-to-Human Extrapolations

Many laboratory animal species have been used to describe toluene toxicity, but the most commonly used species is the rat. As described in Section 3.4, the toxicokinetic data gathered from rat studies compare favorably with the information available from human studies. In addition, neurological effects observed in rats including changes in locomotor activity, changes in visual- and auditory-evoked brainstem potentials, hearing loss, and changes in brain chemistry appear to be related to critical neurological effects observed in humans after acute or repeated exposure to toluene including self-reported neurological symptoms, impaired performance in neurobehavioral tests, hearing loss, and color vision impairment. Given the availability of data for humans exposed by inhalation, MRLs for inhaled toluene are derived without extrapolating from the available animal toxic-effects data. In contrast, acute- and intermediate-duration MRLs for oral exposure to toluene are based on extrapolating effects in rats to humans (see Section 2.3 and Appendix A).

3. HEALTH EFFECTS

As discussed in Section 3.4.5, a number of PBPK models are available that describe the kinetics of toluene after inhalation exposure for humans (Benignus et al. 2006; Fisher et al. 1997; Jonsson and Johanson 2001; Sari-Minodier et al. 2009; Nong et al. 2006; Pierce et al. 1996, 1999; Tardif et al. 1995, 2002) and rats (DeJongh and Blaauboer 1996, 1997; Kenyon et al. 2008; Oshiro et al. 2011; Tardif et al. 1993; van Asperen et al. 2003). PBPK models to describe the kinetics of dermally applied aqueous solutions of toluene are also available for humans (Thrall et al. 2002a) and rats (Thrall and Woodstock 2002), but models to describe kinetics following oral exposure to toluene have not been developed.

Benignus et al. (2007) used available PBPK models for inhaled toluene in humans (Benignus et al. 2006) and rats (Kenyon et al. 2008) to examine the relative sensitivity of neurobehavioral end points in humans and rats acutely exposed to inhaled toluene. End-point-specific dose-response relationships were constructed relating brain concentrations (estimated with pertinent PBPK models) with the magnitude of effect (expressed as a logistic function where a value of 1 means that the end point has been maximally affected) from studies of toluene effects on neurobehavioral end points in humans and rats. A single human dose-response relationship was constructed from six studies of choice reaction times in toluene-exposed human subjects. This relationship was compared with relationships constructed from studies of four neurobehavioral end points in toluene-exposed rats: VEPs, signal detection accuracy, signal detection reaction time, and escape-avoidance correct response rate. The comparison showed that the relationships for human choice reaction time and rat VEP were close to overlapping, consistent with human and rat equivalence in sensitivity to these two types of neurobehavioral end points. The dose-response relationships for the other rat neurobehavioral end points were shifted to the right on the brain concentration x-axis and showed lower slopes in the following progression: rat signal detection reaction time, rat signal detection accuracy, and rat escape-avoidance correct response rate.

Further development of a human PBPK model that includes partitioning of inhaled and ingested toluene to the brain and a similarly designed rat PBPK model may be useful in improving extrapolation from the oral exposure rat data in deriving oral MRLs for toluene.

3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS

Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine system because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals with this type of activity are most commonly referred to as *endocrine disruptors*. However, appropriate terminology to describe such effects remains controversial. The terminology *endocrine disruptors*,

3. HEALTH EFFECTS

initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to develop a screening program for “...certain substances [which] may have an effect produced by a naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning *endocrine disruptors*. In 1999, the National Academy of Sciences released a report that referred to these same types of chemicals as *hormonally active agents*. The terminology *endocrine modulators* has also been used to convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist in the natural environment. Examples of natural hormone mimics are the isoflavonoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are similar in structure and action to endogenous estrogen. Although the public health significance and descriptive terminology of substances capable of affecting the endocrine system remains controversial, scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, development, and/or behavior (EPA 1997). Stated differently, such compounds may cause toxicities that are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering, for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992).

Current data do not provide consistent evidence of endocrine disruption in toluene-exposed humans. Most case studies of chronic abusers of toluene and other solvents have not reported effects on endocrine organs, but there are reports of effects that may be associated with endocrine disruption in groups of toluene-exposed workers including delayed time to pregnancy among wives of men exposed to mixed organic solvents including toluene (Sallmen et al. 1998), increased incidence of spontaneous abortions in female toluene-exposed electronics workers (Ng et al. 1992b), incidences of spontaneous abortion above population norms in other small groups of toluene-exposed female workers or wives of male workers (Lindbohm et al. 1992; Taskinen et al. 1989), and increased risk of preterm birth with increased environmental levels of toluene (Poirier et al. 2015). However, small numbers and lack of adjustment for possible confounding factors in some of these studies precludes drawing definite conclusions. Additionally, studies of blood levels of reproductive hormones in repeatedly exposed workers or acutely

3. HEALTH EFFECTS

exposed human subjects have not provided strong and consistent evidence of exposure-related effects (Luderer et al. 1999; Svensson et al. 1992a, 1992b).

Similarly, evidence for endocrine effects in animals following acute- or intermediate-duration inhalation exposure to toluene is not consistent across studies and does not clearly identify toluene as an endocrine-disrupting chemical. Female rats exposed to 30 or 300 ppm toluene 6 hours/day, 5 days/week for 4 weeks showed a mild reduction in follicle size of the thyroid in one study (Poon et al. 1994). Additionally, increased adrenal weight and adrenocortical cell size, along with serum ACTH and corticosterone levels, were observed in male rats exposed to 1,500 ppm 4 hours/day for 7 days (Gotohda et al. 2005). This exposure scenario was shown to cause, in companion studies, neuronal damage and an increase in glucocorticoid receptors in the hippocampus, suggesting a possible disruption in the neuroendocrine axis (Gotohda et al. 2000a, 2000b, 2002). However, results from several other studies in rats and mice found no histological evidence of toluene-induced changes in endocrine organs including the thyroid, adrenal glands, or pancreas following intermediate or chronic, oral or inhalation exposure (API 1985; Roberts et al. 2003; NTP 1990; Von Oettingen et al. 1942), or dose-related changes in endocrine hormones (Andersson et al. 1980, 1983b).

There is limited evidence that exposure to toluene may damage the reproductive organs in animals, but available data do not support that toluene effects reproductive performance. Effects on male reproductive tissues have been observed in a few studies of animals exposed by inhalation to concentrations $\geq 2,000$ ppm (e.g., reduced sperm count, motility, and quality; and altered reproductive organ weight and histology) (Kanter 2011b; Ono et al. 1996, 1999), but changes in sperm count and epididymis weight were not accompanied by any change in indices of reproductive performance (e.g., fertility) in male rats exposed to 2,000 ppm for 60 days before mating (Ono et al. 1996). Increased relative testicular weights were reported in male mice exposed to 1,250 and 2,500 mg/kg/day by gavage for 13 weeks (NTP 1990). However, no effects on the weight of the prostate, testes, uterus, or ovaries were observed in rats and female mice exposed to 312–2,500 mg/kg/day (NTP 1990). Exposure of female rats to 3,000 ppm 8 hours/day for 7 days produced abundant vacuoles, lytic areas, and mitochondrial degeneration in the antral follicles of the ovaries (Tap et al. 1996). However, no histopathological effects on the prostate, testes, uterus, or ovaries were observed in rats and female mice gavaged with 312–2,500 mg/kg/day or exposed to concentrations up to 2,500 ppm toluene for 6.5 hours/day for 14–15 weeks or up to 1,200 ppm for 6–6.5 hours/day for 2 years (CIIT 1980; NTP 1990). Studies in rats exposed repeatedly by inhalation to toluene, including a 2-generation reproductive toxicity study, have shown no evidence of adverse effects on mating or fertility at tested concentrations as high as 1,200–2,000 ppm (API 1981, 1985; Ono

3. HEALTH EFFECTS

et al. 1996; Roberts et al. 2003; Thiel and Chaboud 1997). In addition, the majority of numerous gestational exposure studies reported no exposure-related changes in reproductive indices (API 1978, 1991; Bowen and Hannigan 2013; Bowen et al. 2005, 2007, 2009a, 2009b; Courtney et al. 1986; Dalgaard et al. 2001; Gospe and Zhou 2000; Hass et al. 1999; Hougaard et al. 2003; Jones and Balster 1997; Klimisch et al. 1992; Ladefoged et al. 2004; NIOSH 1983; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Seidenberg et al. 1986; Thiel and Chahoud 1997; Warner et al. 2008).

There is evidence that toluene exposure can perturb the hypothalamic-pituitary axis in rats leading to persistent increases in serum levels of prolactin. Elevated prolactin levels were reported in rats after exposure to 80 ppm toluene 6 hours/day, 5 days/week for 4 weeks (Von Euler et al. 1994) or 80–1,000 ppm 6 hours/day for 3 days (Andersson et al. 1983b). Von Euler et al. (1993, 1994) speculated that the increase in serum prolactin level could be related to a possible interaction between toluene and the pituitary dopamine D2 receptor which inhibits the release of prolactin into serum. However, in other studies, no changes in prolactin levels were found in rats after exposure to 40–320 ppm 6 hours/day, 5 days/week for 4 weeks (Hillefors-Berglund et al. 1995), 500 ppm toluene 6 hours/day for 3 days, or 1,000 ppm 6 hours/day for 5 days (Andersson et al. 1980). In addition, a study of toluene-exposed workers found no evidence for changed prolactin levels, compared with control subjects (Svensson et al. 1992a, 1992b).

No *in vitro* studies were located regarding endocrine disruption of toluene.

3.7 CHILDREN'S SUSCEPTIBILITY

This section discusses potential health effects from exposures during the period from conception to maturity at 18 years of age in humans, when most biological systems will have fully developed. Potential effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect effects on the fetus and neonate resulting from maternal exposure during gestation and lactation. Relevant animal and *in vitro* models are also discussed.

Children are not small adults. They differ from adults in their exposures and may differ in their susceptibility to hazardous chemicals. Children's unique physiology and behavior can influence the extent of their exposure. Exposures of children are discussed in Section 6.6, Exposures of Children.

3. HEALTH EFFECTS

Children sometimes differ from adults in their susceptibility to adverse health effects from exposure to hazardous chemicals, but whether there is a difference depends on the chemical(s) (Guzelian et al. 1992; NRC 1993). Children may be more or less susceptible than adults to exposure-related health effects, and the relationship may change with developmental age (Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are critical periods of structural and functional development during both prenatal and postnatal life that are most sensitive to disruption from exposure to hazardous substances. Damage from exposure in one stage may not be evident until a later stage of development. There are often differences in pharmacokinetics and metabolism between children and adults. For example, absorption may be different in neonates because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young children (Ziegler et al. 1978). Distribution of xenobiotics may be different; for example, infants have a larger proportion of their bodies as extracellular water, and their brains and livers are proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and Dickerson 1964). Past literature has often described the fetus/infant as having an immature (developing) blood-brain barrier that is leaky and poorly intact (Costa et al. 2004). However, current evidence suggests that the blood-brain barrier is anatomically and physically intact at this stage of development, and the restrictive intracellular junctions that exist at the blood-CNS interface are fully formed, intact, and functionally effective (Saunders et al. 2008, 2012).

However, during development of the brain, there are differences between fetuses/infants and adults that are toxicologically important. These differences mainly involve variations in physiological transport systems that form during development (Ek et al. 2012). These transport mechanisms (influx and efflux) play an important role in the movement of amino acids and other vital substances across the blood-brain barrier in the developing brain; these transport mechanisms are far more active in the developing brain than in the adult. Because many drugs or potential toxins may be transported into the brain using these same transport mechanisms—the developing brain may be rendered more vulnerable than the adult. Thus, concern regarding possible involvement of the blood-brain barrier with enhanced susceptibility of the developing brain to toxins is valid. It is important to note however, that this potential selective vulnerability of the developing brain is associated with essential normal physiological mechanisms; and not because of an absence or deficiency of anatomical/physical barrier mechanisms.

The presence of these unique transport systems in the developing brain of the fetus/infant is intriguing; whether these mechanisms provide protection for the developing brain or render it more vulnerable to

3. HEALTH EFFECTS

toxic injury is an important toxicological question. Chemical exposure should be assessed on a case-by-case basis. Research continues into the function and structure of the blood-brain barrier in early life (Kearns et al. 2003; Saunders et al. 2012; Scheuplein et al. 2002).

Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of growth and development, levels of particular enzymes may be higher or lower than those of adults, and sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the child more or less susceptible also depends on whether the relevant enzymes are involved in activation of the parent compound to its toxic form or in detoxification. There may also be differences in excretion, particularly in newborns given their low glomerular filtration rate and not having developed efficient tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). Children and adults may differ in their capacity to repair damage from chemical insults. Children also have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly relevant to cancer.

Certain characteristics of the developing human may increase exposure or susceptibility, whereas others may decrease susceptibility to the same chemical. For example, although infants breathe more air per kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their alveoli being less developed, which results in a disproportionately smaller surface area for alveolar absorption (NRC 1993).

Data from controlled-exposure studies of volunteers, studies of occupationally exposed humans, case reports of toluene abuse, and studies of animals after inhalation or oral exposure indicate that the nervous system is a critical target of toluene toxicity (see Chapter 2 and Sections 3.2 for more details). The effects of toluene have not been thoroughly studied in children, but the limited available data suggest that the nervous system is also a likely target of toluene toxicity in children. There are numerous reports of adolescents who repeatedly inhaled high levels (4,000–12,000 ppm) of toluene and developed persistent central nervous system dysfunction (e.g., Byrne et al. 1991; Devasthasan et al. 1984; King et al. 1981). Neurological effects reported following toluene inhalation exposure in young animals (neonatal-young adult) are similar to those reported in adults, including changed levels of brain neurotransmitters (O’Leary-Moore et al. 2009; von Euler et al. 1989); high frequency hearing loss (Pryor and Rebert 1992; Pryor et al. 1984a); increased locomotor activity (Bowen et al. 2007; Samuel-Herter et al. 2013); impaired motor coordination (Samuel-Herter et al. 2013); and altered pain perception (Castilla-Serna et al. 1991).

3. HEALTH EFFECTS

Available information regarding age-related differences in toluene metabolism suggests that developing fetuses and children at very early stages of development may be more susceptible to toluene toxicity than adults, and that children past early neonatal periods may have the same capability as adults to clear toluene from the body at low exposure levels. The capacity for metabolic detoxification of toluene is expected to be low in the developing human fetus because several CYP isozymes are either absent or expressed at very low levels (Leeder and Kearns 1997). However, rat studies indicate that levels of CYP isozymes involved in toluene metabolism are rapidly increased following birth and suggest that capabilities to carry out Phase I toluene metabolism at low exposure levels during neonatal periods may exceed those at sexual maturity and pregnancy (Nakajima et al. 1992b). CYP2E1, one of the principal CYP isozymes involved in the major toluene metabolic pathway (Nakajima et al. 1997; Tassaneeyakul et al. 1996), is expressed several hours after birth in humans and continues to increase during the first year of life (Vieira et al. 1996). Phase II enzymes involved in toluene metabolism (e.g., N-acetyl transferases, UDP-glucuronyl transferases, and sulfotransferases) also show changes during human neonatal development with adult activities present by 1–3 years of age (Leeder and Kearns 1997). There are other physiological differences between adults and children (e.g., children have higher brain mass per unit of body weight, higher cerebral blood flow per unit of brain weight, and higher breathing rates per unit of body weight: see Snodgrass [1992]), but their contributions to possible age-related differences in susceptibility to toluene toxicity are currently uncertain.

Results from animal studies indicating that younger animals may be more susceptible to toluene toxicity than adults are restricted to markedly lower LD₅₀ values for 14-day-old rats compared with adult rat values (Kimura et al. 1971) and more severe high frequency hearing loss in young rats exposed to toluene compared with adult rats (Pryor et al. 1984a). The human brain grows rapidly for the first 2 years life and continues more slowly until full brain cell numbers, complete myelination of subcortical white matter, and complete elaboration of dendrites and axons are attained at adulthood (Snodgrass 1992). It is unknown if the relatively long period of development of the human brain may make juvenile humans more susceptible to toluene toxicity than juvenile nonprimate animals.

Recent studies investigating age-related susceptibility to “binge” toluene exposure in rats do not clearly support increased susceptibility in young versus adult rats. Following 15- or 30-minute exposures to ~5,000 ppm toluene, increased locomotor activity, altered exploration, and impaired motor coordination and gait were observed in adolescent (1 month), young adult (2–3 months), adult (5–6 months) and older adult (10–12 months) rats, with no apparent age-related effects (Samuel-Herter et al. 2013). However, the

3. HEALTH EFFECTS

duration to recover from toluene-induced motor impairments was significantly longer in adolescent and young adults (Samuel-Herter et al. 2013). Following exposure to 0, 2,000, 4,000, or 8,000 ppm toluene for 20 minutes/day for 10 days, age- and sex-dependent increases in locomotion were observed in adolescent (PND 28), young adult (PND 44), and adult (PND 70) rats; however, adolescent rats were not identified as a susceptible group (Bowen et al. 2007). In the adolescent rats, increases were significant in females from all exposure groups and males from the 4,000 and 8,000 ppm groups during week 2 of exposure. In the young adult and adult rats, increases were significant in females from the 4,000 and 8,000 ppm groups and in males from the 8,000 ppm group during week 2 of exposure; these increases were significantly greater in magnitude than observed changes in adolescents from the same dose groups. Additionally, adult females and males from the 8,000 ppm group showed significantly increased locomotor behavior during week 1, from day 1 and 3, respectively. These results suggest that while effects may be observed at lower doses in adolescents, the effects may take longer to manifest and may be smaller in magnitude, compared with adults (Bowen et al. 2007). Another study evaluated potential differences in toluene-induced locomotor effects in adolescent (PND 28) and adult (PND 90) male rats exposed to 0, 8,000, or 16,000 ppm for 12 days using three different exposure patterns: standard (two 15-minute exposures separated by a 105-minute break), rapid (two 15-minute exposures separated by a 15-minute break), and paced (six 5-minute exposures separated by 25-minute breaks) (Batis et al. 2010). Locomotor activity was assessed during each exposure period and during a 30-minute “recovery” period immediately following the final toluene exposure each day. While locomotor activity was significantly altered in both exposure groups at both ages, subtle differences were noted. Adolescents displayed greater toluene-induced locomotor activity on the first day and generally greater increases in activity over all days than adults during toluene exposure; however, adults displayed greater toluene-induced locomotor activity than adolescent in the “recovery” period following exposure on the first and subsequent days. Age group differences were most pronounced in the paced “binge-like” exposure protocol. The subtle age-related effects described in these studies may be mediated by age-dependent neurochemical changes observed (O’Leary-Moore et al. 2009). Following acute, high-dose exposure to 8,000–12,000 ppm toluene, no significant changes were found in neurotransmitter, n-acetyl-aspartate (NAA), choline-containing compounds, creatine, glutamate, glutamine, GABA, or lactate levels in adolescent brains; however, decreased levels of choline and GABA in the frontal cortex and striatum, decreased glutamine and NAA levels in the frontal cortex, and a wide-ranging increase in lactate were observed in young adult brains (O’Leary-Moore et al. 2009).

Case reports of birth defects in solvent abusers suggest that high-level exposure to toluene during pregnancy can be toxic to the developing fetus (Arnold et al. 1994; Erramouspe et al. 1996; Goodwin

3. HEALTH EFFECTS

1988; Hersch 1988; Hersch et al. 1985; Lindemann 1991; Pearson et al. 1994). It is likely that the high exposure levels experienced by pregnant solvent abusers (4,000 to 12,000 ppm) overwhelm maternal mechanisms that protect the developing fetus from absorbed toluene at lower exposure levels. Experiments with pregnant mice demonstrated that 10-minute exposures to 2,000 ppm resulted in low uptake of toluene into fetal tissue and suggest that, at lower exposure levels, absorbed toluene is preferentially distributed to maternal adipose tissue before distribution to the developing fetus (Ghantous and Danielsson 1986). Following repeated inhalation exposure of pregnant rats to higher concentrations (8,000 or 12,000 ppm) for 15, 30, or 45 minutes twice daily from GD 8 to 20, amniotic fluid concentrations were $\sim$ <10% of concentrations in maternal blood samples, concentrations in fetal brain were similar to maternal blood concentrations, and concentrations in placenta were higher (Bowen et al. 2007). Concentrations of toluene in fetal brain were less than concentrations in maternal brain.

The results from animal studies indicate that toluene did not cause maternal or developmental toxic effects in animals at inhalation exposure levels <1,000 ppm administered for 6–7 hours/day during gestation (API 1978, 1991, 1992; Jones and Balster 1997; Klimisch et al. 1992; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997; Tsukahara et al. 2009; Win-Shwe et al. 2012a, 2012b; Yamamoto et al. 2009) or at oral exposure levels of 1,800–2,350 mg/kg/day during the period of organogenesis in two developmental screening studies (NIOSH 1983; Seidenberg et al. 1986). With higher inhalation exposure levels ($\geq$ 1,000 ppm), predominant effects include retarded fetal growth and skeletal development and altered development of behavior in offspring, and were almost always accompanied by signs of maternal toxicity (API 1991, 1992; Bowen and Hannigan 2013; Bowen et al. 2005, 2009a; Callan et al. 2015; Dalgaard et al. 2001; Hass et al. 1999; Hougaard et al. 2003; Roberts et al. 2007; Jones and Balster 1997; Ono et al. 1995; Saillenfait et al. 2007; Thiel and Chahoud 1997). Other animal studies reported that continuous, 24-hour/day exposure during gestation caused maternal body weight depression and effects on fetuses including depressed body weight and delayed skeletal ossification at toluene concentrations as low as 133–399 ppm in rats, mice, and rabbits (Hudak and Ungvary 1978; Ungvary and Tatrai 1985). In a comprehensive developmental toxicity study in rats, a statistically significant increase in the incidence of a dilated renal pelvis in the left kidney was observed in fetuses from dams exposed to 1,250 mg/kg/day on GDs 16–19 via gavage, compared with controls (Warner et al. 2008). No changes were observed in any other developmental end point. However, exposure of pregnant rats to gavage doses of 650 mg/kg/day toluene in corn oil on GDs 6–19 produced offspring with decreased body weights, delayed ossification, smaller brain volumes, decreased forebrain myelination per cell, and decreased cortical cell proliferation and migration (Gospe and Zhou 1998, 2000; Gospe et al. 1996).

3. HEALTH EFFECTS

Performance deficits in a few neurobehavioral tests were observed in one study in offspring of pregnant mouse dams exposed by inhalation to 2,000 ppm, but not 200 or 400 ppm, for 60 minutes 3 times/day on GDs 12–17 (Jones and Balster 1997). Performance deficits were not observed in offspring of pregnant rat dams exposed by inhalation to up to 2,000 ppm for 6 hours/day during gestation (Hougaard et al. 2003; Ono et al. 1995; Thiel and Chahoud 1997). Drinking water exposure during gestation and lactation at doses of 106 mg/kg/day resulted in changes in postweaning open-field locomotor activity in rat offspring (Kostas and Hotchin 1981).

In general, available information suggests that toluene is not a potent teratogenic agent with *in utero* exposure, but can retard fetal growth and skeletal development and adversely influence development of behavior of offspring at exposure levels above those that form the basis of the inhalation and oral MRLs for toluene.

Transfer of toluene to nursing infants from breast milk of currently exposed mothers is expected to be a possibility because of the lipophilicity of toluene and the relatively high lipid content of breast milk. Elimination kinetics data for nonpregnant or nonlactating humans and rats following toluene exposure, however, indicate that most absorbed toluene is rapidly eliminated from the body and that a much smaller portion (that which gets into adipose tissues) is slowly eliminated (Janisik et al. 2008; Leung and Paustenbach 1988; Lof et al. 1993; Nise et al. 1989; Pellizzari et al. 1992; Pierce et al. 1996, 1999, 2002; see Section 3.4.4). Thus, mobilization during pregnancy or lactation of stored toluene from preconception exposure does not appear to be a major concern.

Fisher et al. (1997) developed a human PBPK model that predicts transfer of toxicant via lactation from a mother to a nursing infant and used the model to estimate the amount of toluene an infant would ingest via milk if the mother was occupationally exposed to toluene at the ACGIH (1999) TLV (50 ppm) throughout a workday. The model predicted that such an infant would have a daily oral intake of 0.46 mg toluene/day. This value is below the U.S. EPA Health Advisory, 2.0 mg/day, for chronic ingestion of 1 L/day of toluene-contaminated water by a 10-kg child, a daily oral intake for a 10-kg child (8 mg/day) associated with the acute oral MRL for toluene (0.8 mg/kg/day), and a daily oral intake for a 10-kg child (2.0 mg/day) associated with the intermediate oral MRL for toluene (0.2 mg/kg/day). No human (or animal) studies were located regarding *in vivo* distribution of toluene into breast milk or elimination kinetics from breast milk, and the Fisher et al. (1997) PBPK model has not been validated with *in vivo* data.

3. HEALTH EFFECTS

3.8 BIOMARKERS OF EXPOSURE AND EFFECT

Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989).

A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta. However, several factors can confound the use and interpretation of biomarkers of exposure. The body burden of a substance may be the result of exposures from more than one source. The substance being measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic compounds). Depending on the properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the body by the time samples can be taken. It may be difficult to identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to toluene are discussed in Section 3.8.1.

Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an organism that, depending on magnitude, can be recognized as an established or potential health impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. Note that these markers are not often substance specific. They also may not be directly adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused by toluene are discussed in Section 3.8.2.

A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the

3. HEALTH EFFECTS

biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are discussed in Section 3.10, Populations That Are Unusually Susceptible.

3.8.1 Biomarkers Used to Identify or Quantify Exposure to Toluene

In a number of field studies, correlations have been noted between workplace air toluene concentrations and toluene concentrations in blood or urine, or hippuric acid or *ortho*-cresol concentrations in urine of workers (see ACGIH 2001 and 2010 for reviews and citations of these studies). Other urinary biomarkers of exposure that have been examined include benzyl alcohol (Ikeda et al. 2008; Kawai et al. 2007), benzylmercapturic acid (Ikeda et al. 2008; Inoue et al. 2002, 2004, 2008; Maestri et al. 1997), and *S-p*-toluylmercapturic acid (Angerer et al. 1998a; Cosnier et al. 2013, 2014; Ikeda et al. 2008; Inoue et al. 2008). A preliminary study also examined toluene concentration in saliva as a possible biomarker of exposure, which showed a correlation coefficient with air concentrations of 0.77, compared with 0.93 for urinary toluene concentration (Ferrari et al. 2008).

Currently, ACGIH (2010, 2013) recommends using a combination of three biomarkers to assess exposure of workers to toluene: *ortho*-cresol and unchanged toluene levels in urine at the end of a workshift and toluene levels in blood immediately prior to the last shift of a workweek. The recommendation was made based on analyses of numerous field studies examining toluene blood concentrations and urinary concentrations of *ortho*-cresol and toluene in workers exposed to varying workplace air concentrations of toluene. Previously, the level of hippuric acid in urine at the end of a workshift was recommended as a biomarker of exposure, but this recommendation was withdrawn because background urinary hippuric acid from consumption of benzoate in foods and beverages is expected to mask contributions from workplace exposure to toluene, especially at concentrations below 50 ppm (ACGIH 2001, 2010). Results from studies comparing the effectiveness of various biomarkers at high (>50 ppm) and low (<10 ppm) air concentrations indicate that toluene concentrations in blood or urine are more accurate at low air concentration than urinary concentrations of examined metabolites (Ikeda et al. 2008; Inoue et al. 2008; Kawai et al. 2008; Lovreglio et al. 2010; Takeuchi et al. 2002; Ukai et al. 2007).

3.8.2 Biomarkers Used to Characterize Effects Caused by Toluene

There are no specific biomarkers used to characterize the effects from toluene exposure. Changes in the brain, which are detected through MRI or BAER techniques in combination with an exposure history, can be used to evaluate the degree of central nervous system damage experienced by a known toluene abuser. This approach does not appear to offer potential as a method of measuring the effects of short- or long-

3. HEALTH EFFECTS

term, low-level exposures as are likely to occur with environmental releases. Micronuclei induction in buccal cells and/or peripheral lymphocytes have been suggested as biomarkers of effect for solvent exposure (Gonzalez-Yebra et al. 2009; Heuser et al. 2007; Pitarque et al. 2002); however, evidence for micronuclei induction following exposure to toluene or mixed solvents is inconsistent (Gonzalez-Yebra et al. 2009; Heuser et al. 2005, 2007; Moro et al. 2012; Nise et al. 1991; Pitarque et al. 2002) and induction of micronuclei in these cells is not expected to be only produced by solvents. Similarly, altered gene expression profiles in blood cells could potentially serve as biomarkers of effect, but human (Hong et al. 2016; Kim et al. 2011; Song and Ryu 2015) and animal studies (Ahmed et al. 2007; Fujimaki et al. 2009a, 2009b, 2011; Hester et al. 2011, 2012; Kodavanti et al. 2011; Liu et al. 2010; Royland et al. 2012; Takeda et al. 2013; Win-Shwe et al. 2007a, 2010a, 2010b, 2010c, 2011; Yamamoto et al. 2009) have not identified concentration-related gene expression changes in blood, nervous, or immune tissue following toluene exposure. A detailed discussion of the effects of toluene exposure is included in Section 3.2.

3.9 INTERACTIONS WITH OTHER CHEMICALS

Alteration of toluene metabolism may influence toluene's toxic effects because toluene metabolism predominately represents a detoxification process (see Section 3.5.2). Hypothetically, compounds that stimulate or inhibit metabolism of toluene may respectively decrease or increase toluene toxicity, although the possible exhalation of unmetabolized toluene represents an alternate dispositional pathway that may be utilized under conditions inhibiting mainstream toluene metabolism. Several metabolic interactions between toluene and other chemicals have been studied. The results present evidence that alteration of toluene metabolism may influence toluene toxicity and that toluene can influence the toxicity of other chemicals.

Phenobarbital pretreatment, which increases the rate of *in vivo* metabolism of toluene by inducing CYP isozymes, prevented hearing loss in rats exposed to 1,500–2,000 ppm toluene, 8 hours/day for 7 days (Pryor et al. 1991), rats exposed to 1,700–2,000 ppm toluene, 6 hours/day, 5 days/week for 6 weeks (Campo et al. 2008), and rats exposed to a single gavage dose of 1,500 mg/kg (Campo et al. 2008). Conversely, rats that were given large gavage doses of ethanol (4 g/kg/day) and daily inhalation exposure to toluene concentrations of 1,750 ppm, 6 hours/day, 5 days/week for 4 weeks showed significantly greater changes in auditory-evoked brainstem potentials and OHC loss in the ear than those exposed to toluene alone (Campo et al. 1998). Co-exposure to ethanol caused a significant decrease in hippuric acid urinary excretion rates compared with exposure to toluene alone, indicating that these large doses of ethanol inhibited the metabolism of toluene (Campo et al. 1998). Consistent with the idea that co-

3. HEALTH EFFECTS

exposure to ethanol inhibits toluene metabolism are observations that ingestion of ethanol prolongs the presence of toluene in blood in humans (Imbriani and Ghittori 1997; Wallen et al. 1984) and rats (Romer et al. 1986). These results indicate that toluene-induced hearing loss is caused by toluene itself and not its metabolites, and that workers exposed to toluene who regularly drink alcohol may be at greater risk of developing toluene-related neurological problems than nondrinkers.

Concurrent chronic ethanol ingestion and acute toluene inhalation in rats was associated with a modest elevation in plasma AST and increases in relative liver weight and liver triglycerides (Howell et al. 1986). Toluene also antagonized the hypertriglyceridemia associated with chronic ethanol ingestion. This study suggests that combined ethanol and chronic occupational toluene exposure may have the potential to augment alcohol-induced fatty liver.

Benzene, xylene, and toluene are metabolized through cytochrome P-450 oxidation. Benzene is converted to phenol, hydroquinone, catechol, and phenyl mercapturic acid; xylene is converted to methyl hippuric acids, and toluene forms hippuric acid, *ortho*-cresol, and *para*-cresol. The excretion of metabolites was investigated in four groups of workers who were exposed in the workplace to benzene or toluene, to a mixture of both solvents, or to no solvents (Inoue et al. 1988). Analysis of the data on excretion of urinary metabolites indicated that simultaneous exposure to both benzene and toluene inhibited the microsomal metabolism of both compounds through the cytochrome P-450 system. Toluene had more of an inhibitory effect on benzene metabolism than benzene had on toluene metabolism. This observation was confirmed in rodent studies using 6-hour inhalation exposures to benzene, toluene, or a mixture of both compounds, with pharmacokinetic modeling of the exposure data (Purcell et al. 1990). Combinations of either 200 ppm toluene with 1,000 ppm benzene or 1,000 ppm toluene with 200 ppm benzene were tested. The fit of the actual closed chamber concentrations for the individual chemicals with the model results, suggests that the interaction of benzene and toluene are noncompetitive. The data from studies of the benzene-toluene interaction may indicate that workers exposed to mixtures of both solvents have a lower risk of benzene-induced leukopenia than workers exposed to benzene alone (Purcell et al. 1990). Exposure to 50 ppm benzene and 50 or 100 ppm toluene, 6 hours/day on 8 separate days (over a period of 15 days) caused a significant induction of hepatic CYP 2E1, which did not occur with individual exposure to benzene or toluene (Wetmore et al. 2008). Additionally, rats exposed to 50 ppm benzene plus 100 ppm toluene (but not 50 ppm toluene) showed a significant increase in the number of micronucleated bone marrow cells and erythrocytes (~50–70%), compared with exposure to 50 ppm benzene alone (Bird et al. 2010; Wetmore et al. 2008). Micronuclei induction in erythrocytes following exposure to 50 ppm benzene plus 100 ppm toluene, 6 hours/day for 8 consecutive days was also

3. HEALTH EFFECTS

significantly greater than exposure to 50 ppm benzene alone (~200%); however, it was ~70% less than micronuclei induction by 150 ppm benzene alone (Bird et al. 2010). Exposure to toluene alone at 50 or 100 ppm did not induce micronuclei (Bird et al. 2010; Wetmore et al. 2008). Therefore, while these findings are suggestive that toluene enhances benzene toxicity, there is not clear evidence for the mechanism of joint toxic action.

Toluene and xylene are also often found together in mixtures such as paint thinners. Human exposure to low levels of both solvents (50 ppm xylene, 40 ppm toluene) did not modify the conversion of either substance to its urinary metabolites (Kawai et al. 1992b; Tardif et al. 1991). However, at higher concentrations (80 or 150 ppm xylene, 95 or 150 ppm toluene), the blood and exhaled air concentrations of both solvents were increased compared to the controls exposed to either solvent alone, indicating that metabolism of both solvents was decreased by the coexposure paradigm (Tardif et al. 1991, 1992). Similarly, coexposure of toluene, methyl ethyl ketone and isopropyl alcohol at low concentrations in rats had no effect on the urinary excretion of hippuric acid, while high concentrations resulted in decreased levels of hippuric acid (Uaki et al. 1995). Tardif et al. (1993) reported that a linked PBPK model for toluene and xylene with a competitive inhibition metabolic term provided a better visual fit to empirical data than non- or uncompetitive inhibition metabolic terms, using air concentrations of toluene and xylene during 5-hour exposures of rats in a closed chamber to mixtures of toluene and xylene at several initial concentrations. Using an interactions-based biological hazard index, PBPK-based model predictions indicated that interactions between toluene, *m*-xylene, and ethylbenzene are not strictly additive (especially at higher concentrations levels); however, competitive inhibition is expected to be negligible at low individual solvent concentrations (e.g., 20 ppm) (Haddad et al. 1999). Toxicokinetic data from volunteers acutely exposed to toluene, *m*-xylene, and ethylbenzene provided a good fit to predictions of the Haddad et al. (1999) PBPK model (Marchand et al. 2015).

Toluene and *n*-hexane, which are used together in some glues and paints, are neurotoxic chemicals that act by different modes at different sites. Toluene effects on the central nervous system are thought to be facilitated by toluene itself, whereas *n*-hexane affects the peripheral nervous system through the production of a toxic metabolite, 2,5-hexanedione (Ali and Tardif 1999). The initial metabolism of both compounds has been demonstrated to principally involve CYP isozymes including CYP2E1 and CYP2B6 (Ali and Tardif 1999). Under *in vitro* conditions with rat liver microsomes, a noncompetitive inhibition of each other's metabolism was demonstrated (Perbellini et al. 1982). In studies comparing urinary excretion of metabolites in rats exposed to mixtures of toluene and *n*-hexane or to each solvent alone, co-exposure inhibited the urinary excretion of 2,5-hexanedione to a larger extent than the urinary excretion

3. HEALTH EFFECTS

of toluene metabolites, hippuric acid, and *ortho*-cresol (Ali and Tardif 1999; Iwata et al. 1983; Perbellini et al. 1982). The results from these studies suggest that toluene is a more effective inhibitor of *n*-hexane metabolism than is *n*-hexane of toluene metabolism. However, in eight healthy male volunteers who were exposed to combinations of toluene and *n*-hexane via feeding tubes at rates of 1.5 or 4 mg/minutes and 0.3 or 1.0 mg/minutes, respectively, for 60 minutes, the high-dose of *n*-hexane significantly decreased urinary hippuric acid excretion, but toluene exposure did not alter the urinary excretion of 2,5-hexanedione (Baelum et al. 1998). Co-exposure of rats to 1,000 ppm toluene and 1,000 ppm *n*-hexane (12 hours/day for 16 weeks) decreased toxic effects of *n*-hexane on the peripheral nervous system compared with exposure to 1,000 ppm *n*-hexane alone (Takeuchi et al. 1981). Another rat study found confirming results in that co-exposure to 1,200 ppm toluene and 4,000 ppm *n*-hexane (14 hours/day for 9 weeks) decreased *n*-hexane-induced effects on the peripheral nervous system compared with *n*-hexane alone, and had only slight effects on toluene-induced hearing loss and motor dysfunction compared with toluene alone (Pryor and Rebert 1992). Human and rat PBPK models have been developed to model the combined exposure and disposition of inhaled toluene and *n*-hexane (Ali and Tardif 1999; Yu et al. 1998). Model simulations predicted that co-exposure to *n*-hexane and toluene at constant concentrations corresponding to their occupational exposure limits (50 ppm) would lead to only a slight effect on the kinetics of their respective metabolism and disposition, but that the interaction could change with fluctuations in worker activity loads and workplace air concentrations (Ali and Tardif 1999; Yu et al. 1998). In support, *n*-hexane metabolism (as measured by end-of-shift free-2,5-hexanedione levels in urine) was not modified by co-exposure to toluene in workers exposed to various solvent mixtures in an adhesive tape factory at concentrations below occupational exposure limits, as determined by multiple regression analysis (Kawai et al. 2000).

McDermott et al. (2008) examined potential interactions of *in vitro* solvent exposure on LDH leakage, calcium levels, and glutathione redox status of human Jurkat T-cells. Nine binary mixtures of toluene, *n*-hexane, and methyl ethyl ketone (MEK) were evaluated, using three exposure levels per solvent based on concentration-response data for the individual solvents. The resulting data were analyzed using both isobolographic and Berenbaum's combination index analysis to test for interaction. The findings indicated greater-than-additive interactions between toluene+*n*-hexane and toluene+MEK for both LDH leakage and glutathione redox status (GSH and GSSG levels, GSH/GSSG ratio). Greater-than-additive interactions were also observed between toluene+*n*-hexane for perturbations in calcium levels; however, less-than-additive interactions were observed between toluene+MEK at higher MEK concentrations (McDermott et al. 2008).

3. HEALTH EFFECTS

An individual's drug therapy can have an influence on toluene toxicity. Haloperidol (an antipsychotic) functions by blocking dopamine receptors in the brain. The combination of haloperidol with toluene exacerbates dopamine depletion in several areas of the brain, thus changing the pharmacodynamics of the haloperidol. Individuals who take haloperidol should be counseled by their physician if environmental or occupational exposure to toluene is possible (von Euler et al. 1988b).

Studies in humans and rats indicate that the common analgesics, acetaminophen and aspirin, may inhibit toluene metabolism and influence toluene toxicity. CYP2E1 is involved in the initial step of the principal metabolic pathway for toluene and acetaminophen, and represents a potential site for a competitive metabolic interaction. Aspirin and one of the principal downstream metabolites of toluene, benzoyl coenzyme A, are conjugated with glycine. When glycine pools are depleted by competition for glycine by aspirin metabolism, toluene metabolism may be inhibited. In volunteers exposed for 4 hours to 300 mg/m³ toluene (80 ppm) with or without doses (1,000 mg/70 kg=14.3 mg/kg) of acetaminophen (paracetamol) or acetyl salicylic acid (aspirin), co-exposures with these analgesics increased the concentration of toluene in the blood compared with exposure to toluene alone (Lof et al. 1990). Acetaminophen co-exposure also significantly increased the area under the blood concentration versus time curve and the apparent blood clearance of toluene, consistent with an inhibition of toluene metabolism. Co-exposure of rats for 10 days to higher oral doses of aspirin (acetyl salicylic acid: 100 mg/kg, twice daily) and inhalation exposure to toluene (1,000 ppm, 14 hours/day) caused a more severe loss of hearing (assessed 2–5 days or 4 months after cessation of exposure) compared with exposure to toluene alone (Johnson 1992). Treatment with aspirin alone at these doses did not cause hearing loss in the rats. These results are consistent with the hypothesis that high doses of aspirin may potentiate toluene effects on hearing by inhibiting toluene metabolism.

The benzoic acid metabolite of toluene is conjugated with glycine to produce hippuric acid. Toluene potentiation of developmentally toxic effects in rats from high doses of aspirin has been attributed to metabolic competition for glycine pools (Ungvary et al. 1983). Pregnant rats that were given 250 mg/kg acetyl salicylic acid on GD 12 and exposed to toluene at concentrations of 1,000, 2,000, or 3,600 mg/m³ (265, 531, or 956 ppm) on GDs 10–13 showed maternal effects (decreased food consumption and body weight gain and increased relative liver weight) and fetal effects (retardation of skeletal development and increased incidence of fetal malformations) that were more severe than those observed in rats exposed to 250 mg/kg acetyl salicylic acid alone. The effects were comparable in severity to those observed in rats exposed to 500 mg/kg salicylic acid alone. In this study, no maternal or fetal effects were observed in a group of rats exposed to 956 ppm toluene on GDs 10–13 without coexposure to acetyl salicylic acid. The

3. HEALTH EFFECTS

maternal and fetal effects of co-exposure to acetyl salicylic acid and toluene were diminished to the severity of the 250-mg/kg acetyl salicylic acid alone level when the administration of the acetyl salicylic acid dose was preceded by two hours with a gavage dose of 5,000 mg/kg glycine.

3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE

A susceptible population will exhibit a different or enhanced response to toluene than will most persons exposed to the same level of toluene in the environment. Factors involved with increased susceptibility may include genetic makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). These parameters result in reduced detoxification or excretion of toluene, or compromised function of organs affected by toluene. Populations who are at greater risk due to their unusually high exposure to toluene are discussed in Section 6.7, Populations with Potentially High Exposures.

One of the primary target organs of toluene is the central nervous system, and it is generally thought to be due at least in part, to reversible interactions between toluene (the parent compound, not its metabolite) and the lipid or protein components of nervous system membranes (mechanisms of toxicity are discussed in detail in Section 3.5.2). The main pathway of toluene metabolism leads to the production of hippuric acid, which is excreted in the urine. The predominant first step in human and rat metabolism of toluene is catalyzed primarily by the CYP 2E1 isozyme. Later steps in this pathway involve the enzymes alcohol dehydrogenase, aldehyde dehydrogenase, acyl-coenzyme A synthase, and acyl-coenzyme A:amino acid N-acyl transferase (metabolism is discussed in detail in Section 3.4.3).

Environmental or genetic factors that decrease the capacity for metabolic detoxification of toluene are likely to increase susceptibility. This is supported by experiments in which inhibiting or enhancing toluene metabolism via CYP 2E1 respectively enhanced or inhibited toluene-induced hearing loss in rats (Campo et al. 1998, 2008; Pryor et al. 1991). Chronic consumers of alcohol, and users of any medication that interfered with toluene metabolism, would be likely to have an increased risk for this reason. Additionally, smokers may have an increased risk of toxicity due to a possible repression of CYP 2E1 via epigenetic modifications (Jimenez-Garza et al. 2015). Differences in the relative efficiency of enzymes found in ethnic populations may lead to differences in toluene susceptibility, as ethnic variations in the occurrence of CYP isozymes, alcohol dehydrogenase, and aldehyde dehydrogenase are known to exist (Kawamoto et al. 1995, 1996; Kim et al. 1997, 2015). For example, DNA damage in leukocytes from Brazilian shoe workers exposed to solvent-based adhesive (mainly toluene, air concentration not reported)

3. HEALTH EFFECTS

was significantly increased in workers with polymorphisms in the glutathione S-transferase P1 gene (*GSTP1*; *Ile/Val* or *Val/Val*) compared with *GSTP1 Ile/Ile* workers (Heuser et al. 2007). In Indian paint workers exposed to toluene as the major solvent used in paint thinner, sister chromatid exchanges were significantly increased in workers heterozygous or homozygous for the mutant allele of *CYP1A1m2* or *CYP2E1*, compared with unexposed controls of the same genotype; however, sister chromatid exchanges were not significantly increased in workers homozygous for the wild-type alleles, compared with unexposed controls of the same genotype (Priya et al. 2015). Similarly, increased micronuclei in Bulgarian shoe workers were only observed in workers with a null glutathione S-transferase M1 (*GSTM1*) genotype, although sister chromatid exchanges were not associated with *GSTM1* genotype (or solvent-exposure) (Pitarque et al. 2002). Additionally, in healthy South Korean males living in Ulsan City, which houses several industrial complexes, urinary 8-OHdG and hippuric acid levels were only significantly correlated in individuals with *GSTM1*-null, glutathione S-transferase T1(*GSTT1*)-null, and aldehyde dehydrogenase 2 (*ALDH2*) *2/*2 genotypes (Kim et al. 2011). Genetic diversity of *GSTM1* (null/present), glutathione S-transferase T1 gene (*GSTT1*, null/present), and *CYP2E5* (*C1/C1*, *C1/C2*, *C2/C2* variants) was also evaluated in a study of Korean and foreign-born workers exposed to toluene at a Korean printing company (Kim et al. 2015). The allelic frequency of the *GSTM1* present genotype ranged from 0.71 in Chinese workers to 0.15 in Vietnamese workers, with a frequency of 0.4–0.6 in Korean, Sri Lankan, and Cambodian workers, and there was a slight, near-significant ($p=0.081$) positive correlation between the presence of the *GSTM1* gene allele and hippuric acid levels in the blood of workers. For *GSTT1* present genotype, the allelic frequency ranged from 0.75 in Indonesian workers to 0.18 in Chinese workers, with a frequency of 0.4–0.6 in Korean, Vietnamese, and Cambodian workers, and there was a significant correlation between the presence of the *GSTT1* gene allele and urinary toluene/blood toluene ratio. For *CYP2E5* *C1* genotype, the allelic frequency ranged from 1.00 in Sri Lankan workers to 0.55 in Vietnamese workers, with a frequency of 0.6–0.7 in Korean, Indonesian, and Chinese workers; however, no correlation was found between toluene metabolism and the *CYP2E5* gene allele in this study.

Studies in various inbred and outbred mouse strains indicate that genetic differences can lead to differential susceptibility to various chemicals, particularly drugs of abuse (Crabbe et al. 1994, 2005). Bowen et al. (2010) investigated the effects of acute toluene exposure on locomotor behavior in four genetically divergent strains of mice, Balb/CBYJ, C57BL/6J, DBA/2J, and Swiss Webster. During a 30-minute exposure to 100, 2,000, 8,000, or 10,000 ppm toluene, all strains showed a qualitatively biphasic increase in locomotor activity, compared with pre-exposure activity levels, which is consistent with reports of initial increases in locomotion at lower concentrations followed by a decrease in activity at

3. HEALTH EFFECTS

concentrations of 3,000–10,000 ppm (Bowen and Balster 1998; Conti et al. 2012; Kim et al. 1998; Lopez-Rubalcava and Cruz 2000). However, while increased activity was observed in all exposure groups for the inbred Balb/CBYJ, C57BL/6J, and DBA/2J mice, activity was not significantly increased in outbred Swiss Webster mice until $\geq 2,000$ ppm. Furthermore, when the mice were exposed to a 2,000-ppm toluene challenge, following exposure to 8,000 ppm for 30 minutes/day for 14 days, DBA/2J mice showed the greatest sensitization to toluene-induced locomotor effects among the four strains. Bowen et al. (2010) concluded that genetic differences must account for the differential sensitivity to the effects of toluene exposure, and suggested that inter-strain variations in the dopaminergic system may underlie the observed differences.

Nutritional status may also affect susceptibility to toluene. Liver metabolism of toluene in rats fasted for 1 day was significantly increased compared with rats that had been fed (Nakajima and Sato 1979). However, long-term malnutrition may increase susceptibility to the developmental effects of toluene. Skeletal development in the fetuses of rats that were malnourished throughout pregnancy and injected with 1.2 g/kg/day toluene was retarded to a significantly greater extent than in the fetuses of well-nourished dams injected with toluene (da Silva et al. 1990).

Individuals with pre-existing medical conditions may also be more susceptible to the effects of toluene. Individuals with pre-existing defects in heart rhythm may have a greater risk than healthy individuals for experiencing tachycardia or cardiac fibrillation following exposure to high levels of toluene. The presence of toluene in the air reduces the concentration of oxygen and can lead to hypoxia when exposure concentrations are high. Thus, individuals with asthma or other respiratory difficulties may be at increased risk with exposure to high atmospheric concentrations of toluene. Genetic predisposition for hearing loss may increase the risk for toluene-induced ototoxicity (Johnson 1992; Li et al. 1992).

Both children and aging adults could potentially have increased susceptibility to toluene exposure. Children's susceptibility is discussed in Section 3.7. No studies investigating toluene exposure in aging humans were located. A limited number of oral exposure studies in rats did not identify a clear pattern for age-related susceptibility for toluene-induced changes in locomotor activity, oxidative stress markers, cardiac biomarkers, or gene expression changes (Gordon et al. 2010; Kodavanti et al. 2011; MacPhail et al. 2012; Royland et al. 2012).

3. HEALTH EFFECTS

3.11 METHODS FOR REDUCING TOXIC EFFECTS

This section will describe clinical practice and research concerning methods for reducing toxic effects of exposure to toluene. Because some of the treatments discussed may be experimental and unproven, this section should not be used as a guide for treatment of exposures to toluene. When specific exposures have occurred, poison control centers, board certified medical toxicologists, board-certified occupational medicine physicians and/or other medical specialists with expertise and experience treating patients overexposed to toluene can be consulted for medical advice. The following texts provide specific information about treatment following exposures to toluene:

Gummin DD. 2014. Hydrocarbons. In: Goldfrank LR, Flomenbaum NE, Lewin NA, eds. Goldfrank's toxicologic emergencies. 10th ed. New York, NY: McGraw-Hill, 1303-1322.

Leikin JB, Pauloucek FP. 2008. In: Leikin JB, Pauloucek FP, eds. 4th ed. Boca Raton, FL: CRC Press, Taylor & Francis Group, 1195-1196.

Shannon MW, Borron SW, Burns MJ. 2007. In: Shannon MW, Borron SW, Burns MJ, eds. Haddad and Winchester's clinical management of poisoning and drug overdose. 4th ed. Philadelphia, PA: WB Saunders, 1370-1374.

Additional relevant information can be found in the front section of this profile under QUICK REFERENCE FOR HEALTH CARE PROVIDERS.

3.11.1 Reducing Peak Absorption Following Exposure

The absorption of toluene is rapid and virtually complete following acute inhalation and oral exposures. Toluene appeared in the blood of 10 human subjects within 10–15 minutes of exposure to 78 ppm toluene in the air, signifying rapid absorption through the lungs. When exposure occurs by the oral route, uptake into the blood is expected to be slightly slower due to the time needed for transit to the small intestines. Since toluene is absorbed across the lipid matrix of the cell membrane (Alcorn et al. 1991), some absorption can occur from the mouth and stomach. However, most of the toluene will be absorbed through the intestines due to large exposed surface area of the villi and microvilli. Other factors that will influence uptake from the gastrointestinal tract are lipid content of the gastrointestinal contents and the magnitude of the toluene exposure. Absorption of inhaled toluene is increased by exercise; therefore a reduction of physical activity during exposure is likely to reduce absorption (Bushnell et al. 2007; Nadeau et al. 2006; Rahill et al. 1996). However, there is no effective way to reduce peak absorption following inhalation exposure. Emesis is contraindicated in cases of toluene ingestion due to the risk of aspiration. Since gastric lavage is often associated with spontaneous emesis, and current data do not support that it is

3. HEALTH EFFECTS

effective in reducing risk of pulmonary complications following hydrocarbon exposure, lavage is generally not indicated following hydrocarbon exposure (Gummin 2014). Similarly, the use of activated charcoal is generally not indicated for hydrocarbon exposure due to limited ability to reduce absorption coupled with risk of stomach distension and predisposition to vomiting and aspiration. Activated charcoal may be justified in cases of mixed chemical overdoses (Gummin 2014).

Following skin exposure, immediate washing of the skin with soap (if available) and water will reduce the opportunity for dermal absorption; rinsing the skin with water alone may not be sufficient (Gummin 2014). If toluene is spilled on clothing, clothes should be removed promptly and safely discarded to prevent further skin and/or inhalation exposure. If the eyes are affected, proper rinsing procedures should be followed (Gummin 2014).

3.11.2 Reducing Body Burden

The total body burden of toluene is reduced by measures that increase the rate of metabolism and excretion. Oxygen therapy, positive-pressure ventilation, high-frequency jet ventilation, and extracorporeal membrane oxygenation have been used as emergency treatments in cases of severe hydrocarbon toxicity, often associated with episodes of toluene abuse (Graham 1990; Gummin 2014). These procedures promote the loss of unmetabolized toluene from the lungs.

Increased fluid consumption, which increases the rate of urine production and excretion, will help to decrease the toluene body burden since toluene metabolites are water soluble and excreted in the urine. In cases where kidney function has been impaired, renal dialysis has been used to remove toluene metabolites from the body (Graham 1990).

3.11.3 Interfering with the Mechanism of Action for Toxic Effects

In cases where toluene has caused cardiac arrhythmias, management of dysrhythmias is critical. Interventions may include evaluation and treatment of potential electrolyte and acid-base abnormalities as well as administration of antiarrhythmic medications to control the heart beat (Graham 1990; Gummin 2014). No other medical practices for ameliorating the toxic effects of toluene were identified in the available literature. When toluene exposures are unavoidable, as in the workplace, avoidance of alcohol or medications that may inhibit metabolic disposition of toluene is another measure that can be taken to reduce health risks from exposure.

3. HEALTH EFFECTS

3.12 ADEQUACY OF THE DATABASE

Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of toluene is available. Where adequate information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation of a program of research designed to determine the adverse health effects (and techniques for developing methods to determine such health effects) of toluene.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health risk assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

3.12.1 Existing Information on Health Effects of Toluene

The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to toluene are summarized in Figure 3-5. The purpose of this figure is to illustrate the existing information concerning the health effects of toluene. Each dot in the figure indicates that one or more studies provide information associated with that particular effect. The dot does not necessarily imply anything about the quality of the study or studies, nor should missing information in this figure be interpreted as a “data need”. A data need, as defined in ATSDR’s *Decision Guide for Identifying Substance-Specific Data Needs Related to Toxicological Profiles* (Agency for Toxic Substances and Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from the scientific literature.

As shown in Figure 3-5, there is a considerable body of data on the health effects of toluene in humans following acute, intermediate, and chronic inhalation exposures. It appears that clinical effects of high concentrations on the major target organ, the central nervous system, have been well characterized. However, many of the available reports lack quantitative information on exposure levels and there is still much that must be learned about the ultra-structural molecular level of toxicity. There are some oral, but essentially no dermal, data available; however, these are not expected to be the main routes by which

3. HEALTH EFFECTS

Figure 3-5. Existing Information on Health Effects of Toluene

	Systemic									
	Death	Acute	Intermediate	Chronic	Immunologic/Lymphoretic	Neurologic	Reproductive	Developmental	Genotoxic	Cancer
Inhalation	●	●	●	●	●	●	●	●	●	●
Oral	●	●								
Dermal		●						●		

Human

	Systemic									
	Death	Acute	Intermediate	Chronic	Immunologic/Lymphoretic	Neurologic	Reproductive	Developmental	Genotoxic	Cancer
Inhalation	●	●	●	●	●	●	●			●
Oral	●	●	●		●	●	●	●		
Dermal		●	●							●

Animal

● Existing Studies

3. HEALTH EFFECTS

humans are exposed to toluene. Figure 3-5 also shows that considerable animal toxicity data for inhalation exposure are available. However, there are limited oral and dermal data from animal studies.

3.12.2 Identification of Data Needs

Acute-Duration Exposure. The acute effects of toluene exposure in humans have been well-studied, and identify the nervous system as a critical acute toxicity target of toluene, with subtle neurological effects at exposures >40 ppm in healthy individuals and as low as 15 ppm in clinically sensitive individuals (Andersen et al. 1983; Baelum et al. 1985; Dick et al. 1984; Echeverria et al. 1991; Gamberale and Hultengren 1972; Kobald et al. 2015; Little et al. 1999; Orbaek et al. 1998; Osterberg et al. 2000, 2003; Rahill et al. 1996; von Oettingen et al. 1942). Supporting data for neurological effects as a critical acute effect are provided by studies of animals after inhalation exposure that consistently report altered locomotor activity at exposure levels ≥ 500 ppm and cognitive deficits at concentrations as low as 125 ppm (Arito et al. 1988; Boyes et al. 2007; Bowen and Balster 1998; Bowen et al. 2010; Bruckner and Peterson 1981a, 1981b; Bushnell et al. 1985; Conti et al. 2012; Cruz et al. 2001; Ghosh et al. 1989, 1990; Hinman 1987; Hogie et al. 2009; Huerta-Rivas et al. 2012; Johnson 1992; Johnson et al. 1988; Kishi et al. 1988; Li et al. 1992; Little et al. 1998; Lopez-Rubalcava and Cruz 2000; McWilliams et al. 2000; Mullin and Krivanek 1982; Paez-Martinez et al. 2003; Rebert et al. 1989b; Takeuchi and Hisanaga 1977; Taylor and Evans 1985; Tomaszycski et al. 2013; Wood and Colotla 1990; Wood et al. 1983), as well as numerous additional studies in animals following exposure to “binge-like” levels (1,000–12,000 ppm) modeling human solvent abuse (Apawu et al. 2014; Bale et al. 2007; Batis et al. 2010; Beckley et al. 2013; Beyer et al. 2001; Bowen et al. 2007; Bushnell et al. 2007; Gerasimov et al. 2002c; Gmaz et al. 2012; Gotohda et al. 2000a, 2000b, 2002, 2007; Lammers et al. 2005b; O’Leary-Moore et al. 2007; Oshiro et al. 2007; Paez-Marinez et al. 2008, 2013; Pascual and Bustamante 2010; Perit et al. 2012; Riegel and French 2002; Samuel-Herter et al. 2013; Schiffer et al. 2006; Williams et al. 2005). Further support is provided by acute oral exposure studies examining neurological effects in animals (Burns et al. 1994; Dyer et al. 1988; Gordon et al. 2007, 2010; Mehta et al. 1998). It is unlikely that additional standard acute-duration exposure studies in animals would provide new key information on the toxicity of toluene, but special studies that involve a range of exposure levels (including low levels) and employ sensitive, behavioral, ultra structural, and biochemical measurements may be useful—especially if findings are correlated with observed neurobehavioral alterations. Data for the dermal exposure route are limited; however, this is not expected to be the main route of human exposure. Sufficient data for the oral and inhalation routes were available to derive an acute inhalation MRL based on minimally adverse neurological effects in volunteers with multiple chemical sensitivity exposed to 15 ppm for 20 minutes

3. HEALTH EFFECTS

(Little et al. 1999) and an acute oral MRL based on changes in FEPs observed in mice exposed to 250 mg/kg toluene (Dyer et al. 1988).

Intermediate-Duration Exposure. The database is lacking studies on intermediate-duration exposure in humans. Several studies are available on repeated-dose exposure of animals to toluene after inhalation exposure. Similar to acute exposure studies, animal studies report neurological effects following intermediate-duration inhalation exposure at concentrations ranging from 100 to 2,500 ppm (API 1997; Arito et al. 1988; Boyes et al. 2015; Campo et al. 1997; Kyrklund et al. 1987; McWilliams et al. 2000; NTP 1990; Pryor et al. 1984b; von Oettingen et al. 1942; Wiaderna and Tomas 2002; Wood and Cox 1995). However, NOAELs for intermediate, low-level inhalation exposure in air have not been thoroughly investigated. Determination of these values would be valuable in evaluating the human health risk, and could potentially be used to derive an intermediate-duration MRL for inhalation exposures. Adequate oral intermediate-duration exposure studies have been conducted in rats and mice (Hsieh et al. 1989, 1990a, 1991; NTP 1990), and sufficient data were available to derive an intermediate-duration oral MRL based on toluene-induced immune depression observed at 84–105 mg/kg/day (Hsieh et al. 1989, 1990a, 1991). Neurobehavioral alterations following intermediate-duration oral toluene exposure were limited to increased open-field activity in young mice following pre- and postnatal exposure to 106 mg/kg/day toluene (Kostas and Otchin 1981). Intermediate-duration studies designed to assess neurobehavioral alterations and/or mechanisms of neurotoxicity following oral exposure to toluene may be useful in evaluating human health risk, and could potentially serve as a basis for the deriving the intermediate-duration oral MRL. Studies following dermal exposure are lacking; however, this is not expected to be the main route by which humans are exposed to toluene.

Chronic-Duration Exposure and Cancer. Numerous case reports have associated chronic toluene abuse in humans at levels inducing narcosis and euphoria (4,000–12,000 ppm, as estimated by Gospe et al. 1994) with persistent neurological damage (Aydin et al. 2002, 2003; Byrne et al. 1991; Caldemeyer et al. 1996; Camarra-Lemarroy et al. 2015; Capron and Logan 2009; Deleu and Hanssens 2000; Devathanan et al. 1984; Filley et al. 1990; Fyu et al. 1998; Gupta et al. 2011; Hormes et al. 1986; Hunnewell and Miller 1998; Ikeda and Tsukagoshi 1990; Kamran and Bakshi 1998; King et al. 1981; Kiyokawa et al. 1999; Kucuk et al. 2000; Maas et al. 1991; Maruff et al. 1998; Meulenbelt et al. 1990; Miyagi et al. 1999; Nomura et al. 2016; Papageorgiou et al. 2009; Poblano et al. 1996; Rosenberg et al. 1988a, 1988b, 2002; Ryu et al. 1998; Suzuki et al. 1983; Uchino et al. 2002; Yamanouchi et al. 1995).

3. HEALTH EFFECTS

Neurological alterations are also critical effects reported following occupational exposure. Self-reported neurological symptoms and reduced ability in tests of cognitive and neuromuscular function have been reported in humans occupationally exposed to average concentrations as low as 40–150 ppm (Boey et al. 1997; Eller et al. 1999; Foo et al. 1990; Kang et al. 2005; Matsushita et al. 1975; Murata et al. 1993; Nordling Nilson et al. 2010; Orbaek and Nise 1989; Ukai et al. 1993; Yin et al. 1987). Studies of occupationally exposed workers also indicate that chronic exposure to average concentrations as low as 50–130 ppm can damage hearing and color vision presumably involving, at least in part, effects on neurological components of these systems (Abbate et al. 1993; Morata et al. 1997; Vrca et al. 1995, 1996, 1997a, 1997b; Zavalic et al. 1998a, 1988b, 1988c). Sufficient data for the inhalation route were available to derive a chronic MRL based on a lack of adverse effects in subjective neurological symptoms, performance on psychomotor tasks, color vision, and hearing in groups of German photogravure printers occupationally exposed to toluene (Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002).

The chronic effects of toluene have not been investigated in humans or animals following oral or dermal exposures, and the carcinogenic potential has not been studied following dermal exposure; however, these are not considered major routes of toluene exposure.

Genotoxicity. Available studies do not clearly identify toluene as a genotoxic agent. Findings from human occupational exposure studies to predominantly toluene are inconsistent, and studies are limited by lack of reporting of historical exposure levels and small cohort sizes (Bauchinger et al. 1982; Forni et al. 1971; Hammer 2002; Hammer et al. 1998; Maki-Paakkenen et al. 1980; Nise et al. 1991; Pelclova et al. 1990; Schmid et al. 1985). *In vivo* animal studies are limited, and findings are also inconsistent (API 1981; Dobrokhotov and Enikeev 1997; Liang et al. 1983; Martinez-Alfaro et al. 2010; Plappert et al. 1994; Wetmore et al. 2008). *In vitro* studies in bacteria and animal cells were almost exclusively negative (Bos et al. 1981; Connor et al. 1985; Fluck et al. 1976; Gerner-Smidt and Friedrich 1978; Nakumura et al. 1987; Nestmann et al. 1980; NTP 1990; Zarani et al. 1999) with the exception of toluene-induced DNA damage in human HL-60 cells (Sarma et al. 2011). To evaluate the potential of toluene to cause chromosomal damage, additional well-designed *in vivo* studies using test material of known purity may be valuable. These tests would aid in determining whether toluene itself has clastogenic potential or whether the positive results that have been reported are due to impurities in the test material (animal studies) or concurrent/previous exposure to other chemicals (human studies) (Bauchinger et al. 1982; Dobrokhotov and Enikeev 1997; Hammer 2002; Hammer et al. 1998; Liang et al. 1983; Nise et al. 1991; Pelclova et al. 1990; Schmid et al. 1985). Because it is believed that toluene toxicity may be mediated, at

3. HEALTH EFFECTS

least in part, through a highly reactive and short-lived arene oxide intermediate, which interacts with cellular proteins and RNA (Chapman et al. 1990), further studies of this interaction may provide useful information.

Reproductive Toxicity. In general, available results from studies of toluene-exposed workers and animals suggest that toluene is not a potent reproductive toxicant. There are a few reports that women occupationally exposed to toluene, or wives of men similarly exposed, have an increased risk of spontaneous abortions (Lindbohm et al. 1992; Ng et al. 1992b; Taskinen et al. 1989) or decreased fecundity (Plenge-Böenig and Karmaus 1999), but a causal relationship is not established by these studies due to small sample sizes evaluated, inability to define accurate exposure levels, failure to account for potentially important confounding variables, and difficulty in validating self-reported data. One population-based cohort study reported increased risk of preterm birth with increasing environmental toluene exposure (Poirier et al. 2015); concurrent exposure to multiple pollutants (which were not controlled for in statistical analyses) limits the conclusions that can be drawn from this study. In addition, one study reported that toluene-exposed male workers showed decreasing plasma levels of LH, FSH, and testosterone with increasing concentrations of toluene (8–<111 ppm) (Svensson et al. 1992a, 1992b). Effects on male reproductive tissues have been observed in a few studies of animals exposed by inhalation to concentrations $\geq 2,000$ ppm (e.g., reduced sperm count, motility, and quality, and altered reproductive organ weight and histology) (Kanter 2011b; Ono et al. 1996, 1999), but changes in sperm count and epididymis weight were not accompanied by any change in indices of reproductive performance (e.g., fertility) in male rats exposed to 2,000 ppm for 60 days before mating (Ono et al. 1996). A single study reported abundant vacuoles, lytic areas, and mitochondrial degeneration in the antral follicles in the ovaries of female rats following a 7-day exposure to 3,000 ppm (Tap et al. 1996), but no histological evidence of structural damage to the reproductive organs was noted in rats and mice exposed orally for intermediate durations or by inhalation for intermediate or chronic durations (NTP 1990). No evidence for impaired reproductive performance or alterations in pregnancy outcomes was found in the majority of animal assays at exposure levels as high as 12,000 ppm (inhalation) or 2,350 mg/kg/day (oral) (API 1978, 1991; Bowen and Hannigan 2013; Bowen et al. 2005, 2007, 2009a, 2009b; Courtney et al. 1986; Dalgaard et al. 2001; Gospe and Zhou 2000; Hass et al. 1999; Hougaard et al. 2003; Jones and Balster 1997; Klimisch et al. 1992; Ladefoged et al. 2004; NIOSH 1983; Ono et al. 1995, 1996; Roberts et al. 2007; Saillenfait et al. 2007; Seidenberg et al. 1986; Thiel and Chahoud 1997) (including a 2-generation study of rats exposed to up to 2,000 ppm, 6 hours/day [API 1985; Roberts et al. 2003]). However, continuous exposure of pregnant rabbits to 267 ppm during days 7–20 of pregnancy produced maternal toxicity (decreased weight gain) and abortions in 4/8 does (Ungvary and Tatrai 1985).

3. HEALTH EFFECTS

and exposure to 5,000 ppm 6 hour/day during days 6–15 of pregnancy resulted in increased post-implantation loss and complete fetal resorption in 6/9 rats (API 1992). Additional studies of reproductive end points in groups of occupationally exposed workers may be useful in discerning the possible reproductive hazards of toluene in the workplace if large enough groups of workers are examined, exposure levels can be accurately monitored, and confounding variables are accounted for or minimized. Another 2-generation reproductive study in another animal species (e.g., rabbits) may also help to decrease uncertainty in defining no-effect levels for reproductive effects from toluene exposure.

Developmental Toxicity. Published reports of birth defects described in children born to women who abused toluene or other organic solvents during pregnancy suggest that high-level exposure to toluene during pregnancy can be toxic to the developing fetus (Arnold and Wilkins-Haug 1990; Arnold et al. 1994; Erramouspe et al. 1996; Goodwin 1988; Hersh 1988; Hersh et al. 1985; Lindemann 1991; Pearson et al. 1994; Wilkins-Haug and Gabow 1991a). Studies of developmentally toxic effects in children of women exposed during pregnancy to much lower concentrations are restricted to a small study of 14 Finnish women exposed to mixed solvents, suggesting that solvent exposure may increase risk for central nervous system anomalies and neural tube closure defects (Holmberg 1979). The available human data do not establish causality between low-level or occupational exposure to toluene and birth defects, because of the small sample size and the mixed solvent exposure experienced by the subjects in the Holmberg (1979) study and the lack of other studies of possible birth defects in children of women exposed to toluene in the workplace. Additional studies of developmental end points in offspring of mothers exposed to toluene in the workplace may help to clarify the potential for human health risk.

Results from several inhalation exposure studies of animals indicate that exposure to levels of toluene that begin to produce maternal toxicity can cause fetal effects, including reduced fetal survival and retardation of growth and skeletal development (API 1991, 1992; Dalgaard et al. 2001; Hass et al. 1999; Hougaard et al. 2003; Hudak and Ungvary 1978; Jones and Balster 1997; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997; Ungvary and Tatrai 1985). No-effect levels in animals for toluene effects on standard developmental end points range from about 133 ppm for a 24 hour/day exposure protocol (Ungvary and Tatrai 1985) to 133–2,000 ppm with 3–6-hour/day protocols (API 1978, 1991, 1992; Jones and Balster 1997; Klimisch et al. 1992; Ono et al. 1995; Roberts et al. 2007; Saillenfait et al. 2007; Thiel and Chahoud 1997). In animal studies of oral exposure during gestation, no developmental effects were observed in pregnant mice exposed to oral doses of 1,800 or 2,350 mg/kg/day in two developmental screening studies (NIOSH 1983; Seidenberg et al. 1986), but a statistically significant increase in the incidence of a dilated renal pelvis in the left kidney was observed in fetuses

3. HEALTH EFFECTS

from dams exposed to 1,250 mg/kg on GDs 16–19 via gavage in a comprehensive developmental toxicity study in rats (Warner et al. 2008). Exposure of pregnant rats to gavage doses of 650 mg/kg/day produced offspring with decreased body weights, delayed ossification, smaller brain volumes, and decreased forebrain myelination per cell compared with controls (Gospe and Zhou 1998, 2000; Gospe et al. 1996).

Results from studies of neurobehavioral end points in rats following *in utero* exposure to toluene suggest that maternal exposure to airborne concentrations modeling solvent abuse (8,000–16,000 ppm, 15–30 minutes/day) can impair behavioral development of rat offspring (Bowen and Hannigan 2013; Bowen et al. 2005, 2009a; Callan et al. 2015). At lower exposure levels ($\leq 2,000$ ppm), maternal exposure for 6 hours/day did not result in altered offspring behavior in rats (Hougaard et al. 2003; Ono et al. 1995; Thiel and Chahoud 1997); however, maternal exposure to 2,000 ppm for 60 minutes 3 times/day can lead to impaired behavioral development of mouse offspring (Jones and Balster 1997). Drinking water exposure during gestation and lactation at doses of 106 mg/kg/day changes postweaning open-field locomotor activity in rat offspring (Kostas and Hotchin 1981).

Additional studies of sensitive neurological end points, including neurobehavioral end points, in offspring of toluene-exposed pregnant animals may better determine no-effect levels for toluene effects on neurodevelopment. Inhalation exposure studies are likely to be of more relevance to human exposures of concern than oral exposure studies. Developmental effects have not been investigated following dermal exposure; however, this is not expected to be the main route of human exposure.

Immunotoxicity. Human studies of immunological end points in toluene-exposed subjects do not identify consistent or strong evidence for toluene effects on immune system end points such as counts of blood lymphocytes or levels of blood immunoglobulins (Little et al. 1999; Pelclova et al. 1990; Stengel et al. 1998; Yin et al. 1987) or development of autoimmune disorders (Chaigne et al. 2015; Diot et al. 2002; Marie et al. 2014). In animal studies, evidence for toluene effects on the immune system following inhalation exposure are limited to the finding of decreased resistance to mortality from respiratory infection by *S. zooepidemicus* in a study of mice exposed for 3 hours to toluene concentrations as low as 2.5 ppm (Aranyi et al. 1985). However, animal data using the oral route of exposure provide some evidence of impaired immune function following intermediate-duration toluene exposure (Hsieh et al. 1989, 1990a, 1991), and these effects were used to derive an MRL of 0.2 mg/kg/day for intermediate-duration oral exposure toluene. Accordingly, oral and inhalation studies in animals designed to clarify the effect of toluene on the immune system, particularly on lymphocyte production and function, antibodies, and interferons, may help determine if toluene was involved in the effects on immunity observed in

3. HEALTH EFFECTS

occupationally exposed workers. Additional studies of the impact of toluene on disease resistance, building on the work of Aranyi et al. (1985), may also be valuable.

Neurotoxicity. Effects on the human nervous system from inhalation exposure to toluene are well documented (Abbate et al. 1993; Andersen et al. 1983; Baelum et al. 1985; Boey et al. 1997; Dick et al. 1984; Echeverria et al. 1991; Eller et al. 1999; Foo et al. 1990; Gamberale and Hultengren 1972; Kang et al. 2005; Little et al. 1999; Matsushita et al. 1975; Morata et al. 1997; Murata et al. 1993; Nordling Nilson et al. 2010; Orbaek and Nise 1989; Orbaek et al. 1998; Osterberg et al. 2000, 2003; Rahill et al. 1996; Ukai et al. 1993; von Oettingen et al. 1942; Vrca et al. 1995, 1996, 1997a, 1997b; Yin et al. 1987; Zavalic et al. 1998a, 1988b, 1988c) and are the basis for the acute and chronic inhalation exposure MRLs. The central nervous system effects of toluene in animals have also been studied in detail via the inhalation route of exposure (Arito et al. 1988; Boyes et al. 2007, 2016; Bowen and Balster 1998; Bruckner and Peterson 1981a, 1981b; Bushnell et al. 1985; Conti et al. 2012; Cruz et al. 2001; Dashniani et al. 2014; Ghosh et al. 1989, 1990; Hinman 1987; Hogie et al. 2009; Huerta-Rivas et al. 2012; Johnson 1992; Johnson et al. 1988; Kishi et al. 1988; Li et al. 1992; Little et al. 1998; Lopez-Rubalcava and Cruz 2000; McWilliams et al. 2000; Mullin and Krivanek 1982; Paez-Martinez et al. 2003, 2013; Rebert et al. 1989b; Takeuchi and Hisanaga 1977; Taylor and Evans 1985; Tomaszycski et al. 2013; Wood and Colotla 1990; Wood et al. 1983). Available data clearly indicate that the central nervous system is a target, but the molecular mechanisms of toxicity have yet to be elucidated with certainty. Dose-response relationships for central nervous system effects in humans and animals (rats and mice) have been established, but more information concerning the reversibility of effects (especially when exposure is chronic) may be useful. The effects of toluene on neurobehavioral function were used to derive an MRL of 2 ppm for acute inhalation exposure (based on a study by Little et al. 1999) and a chronic-duration MRL of 1 ppm (based on a series of studies by Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanec et al. 2002).

The neurological effects of toluene via the oral route have not been extensively investigated, but the available data support the inhalation data in identifying the nervous system as a critical target of toluene toxicity following acute exposure. An acute MRL of 0.8 mg/kg/day was developed based on a change in FEP waveforms in rats exposed to a single dose of toluene (Dyer et al. 1988). Neurobehavioral changes following intermediate-duration oral toluene exposure were limited to increased open-field activity in young mice following pre- and postnatal exposure to 106 mg/kg/day toluene (Kostas and Otchin 1981). Intermediate-duration studies designed to assess neurobehavioral alterations and/or mechanisms of neurotoxicity following oral exposure to toluene may be useful in evaluating human health risk, and could potentially serve as a basis for the deriving the intermediate-duration oral MRL (which is currently based

3. HEALTH EFFECTS

on immune depression). No data on dermal exposure are available, but this is not expected to be the main route of human exposure.

Epidemiological and Human Dosimetry Studies. Additional studies of neurological and reproductive end points in groups of toluene-exposed workers may decrease uncertainty in the chronic MRL and may help determine if toluene represents a reproductive health hazard in humans at low exposure levels. These studies will be most useful if groups of workers can be identified whose exposure to other chemicals in the workplace is minimal, if adjustments for lifestyle confounding factors can be made, and if personal air monitoring data are available. Earlier reports of increased risk of spontaneous abortions (Lindbohm et al. 1992; Ng et al. 1992b; Taskinen et al. 1989) and altered plasma levels of male sexual hormones (Svensson et al. 1992a, 1992b) in groups of toluene-exposed workers await confirmation from further research.

Biomarkers of Exposure and Effect.

Exposure. Toluene and its metabolites are easily detected in the blood and urine (DeRosa et al. 1985; Hjelm et al. 1988; Kono et al. 1985; Lof et al. 1990; Ogata et al. 1970). However, many toluene metabolites are also produced by other naturally occurring or xenobiotic materials and, thus, are not specific for toluene. Results from studies comparing the effectiveness of various biomarkers at high (>50 ppm) and low (<10 ppm) air concentrations indicate that toluene concentrations in blood or urine are more accurate at low air concentration than urinary concentrations of examined metabolites (Ikeda et al. 2008; Inoue et al. 2008; Kawai et al. 2008; Lovreglio et al. 2010; Takeuchi et al. 2002; Ukai et al. 2007).

Currently, ACGIH (2013, 2010) recommends using a combination of three biomarkers to assess exposure of workers to toluene: *ortho*-cresol and unchanged toluene levels in urine at the end of a workshift and toluene levels in blood immediately prior to the last shift of a workweek.

Other urinary biomarkers of exposure that have been examined include benzyl alcohol (Ikeda et al. 2008; Kawai et al. 2007), benzylmercapturic acid (Ikeda et al. 2008; Inoue et al. 2002, 2004, 2008; Maestri et al. 1997), and *S-p*-toluylmercapturic acid (Angerer et al. 1998a; Ikeda et al. 2008; Inoue et al. 2008). A preliminary study also examined toluene concentration in saliva as a possible biomarker of exposure, which showed a correlation coefficient with air concentrations of 0.77, compared with 0.93 for urinary toluene concentration (Ferrari et al. 2008). Additional studies may help determine whether these are

3. HEALTH EFFECTS

reliable biomarkers of exposure that can improve the accuracy of monitoring workers' exposure to toluene.

Effect. There are no suitable biomarkers of effect except for changes in the brain found in chronic solvent abusers with obvious neurological dysfunction (Filley et al. 1990; Rosenberg et al. 1988a). Additional information on the mechanism of neurotoxicity may suggest a useful biomarker of either exposure or effect. However, at this time, there is little to suggest that such biomarkers are present for anything other than the abuse paradigm.

Absorption, Distribution, Metabolism, and Excretion. The absorption, distribution, metabolism, and excretion of toluene in humans and animals following inhalation exposure are well characterized (Ameno et al. 1992; Andersen et al. 1983; Angerer 1979; Angerer et al. 1998a; Baelum et al. 1987, 1993; Benignus et al. 1981; Benoit et al. 1985; Bergman 1983; Bray et al. 1949; Bushnell et al. 2007; Campo et al. 1999; Carlsson 1982; Carlsson and Ljungquist 1982; Chand and Clausen 1982; Dossing et al. 1983c; Ducos et al. 2008; Furman et al. 1998; Ghantous and Danielsson 1986; Hjelm et al. 1988; Ikeda et al. 1990; Janasik et al. 2008, 2010; Kawai et al. 1992a, 1992b, 1993, 1996; Leung and Paustenbach 1988; Lof et al. 1990, 1993; Maestri et al. 1997; Nadeau et al. 2006; Nakajima and Wang 1994; Nakajima et al. 1991, 1992a, 1992b, 1993, 1997, 2006; Ng et al. 1990; Nise et al. 1989; Ogata 1984; Pellizzari et al. 1992; Pierce et al. 1996, 1999, 2002; Paterson and Sarvesvaran 1983; Takeichi et al. 1986; Tardif et al. 1998; Tassaneeyakul et al. 1996; van Doorn et al. 1980; Wang and Nakajima 1992; Zahlse et al. 1992).

Limited data are available on the quantitative absorption and excretion of toluene by the oral and dermal routes. Absorption of orally administered toluene has also been observed in rats, but oral absorption rates appear to be slower than pulmonary absorption (Pyykko et al. 1977; Sullivan and Conolly 1988). Studies of humans and animals indicate that dermal absorption of toluene is slow (Aitio et al. 1984; Dutkiewicz and Tyras 1968; Thrall and Woodstock 2002; Thrall et al. 2002a), but can be significant (Aitio et al. 1984; Monster et al. 1993; Morgan et al. 1991; Sato and Nakajima 1978). Additional studies of dermal uptake of toluene from solution may help to further quantify exposure by this pathway.

PBPK models are available that describe the kinetics of toluene after inhalation exposure for humans (Benignus et al. 2006; Fisher et al. 1997; Jonsson and Johanson 2001; Mörk et al. 2014; Nong et al. 2006; Pierce et al. 1996, 1999; Sari-Minodier et al. 2009; Tardif et al. 1995, 2002) and rats (DeJongh and Blaauboer 1996, 1997; Kenyon et al. 2008; Oshiro et al. 2011; Tardif et al. 1993; van Asperen et al.

3. HEALTH EFFECTS

2003). PBPK models to describe the kinetics of dermally applied aqueous solutions of toluene are also available for humans (Thrall et al. 2002a) and rats (Thrall and Woodstock 2002), but models to describe kinetics following oral exposure to toluene have not been developed. Further development of a human PBPK model that includes partitioning of inhaled and ingested toluene to the brain and a similarly designed rat PBPK model may be useful in improving extrapolation from the oral exposure rat data and in comparing model-based predictions of human effect levels based on neurological effects in inhalationally-exposed rats with observed effect levels in humans exposed to airborne toluene. Additional studies of the appearance and elimination kinetics of toluene in breast milk may help to validate the human PBPK model developed by Fisher et al. (1997) to estimate transfer of toluene to a nursing infant. It is unlikely that such studies would be done with volunteers, but studies of nursing animals may provide pertinent information if a similar rat PBPK model was developed.

Comparative Toxicokinetics. Available data suggest that there are species, age, gender, and strain differences in the metabolism of toluene (Chapman et al. 1990; Inoue et al. 1984, 1986; Nakajima et al. 1992b). Further evaluation of these differences, and comparison of metabolic patterns in humans with those of animals, may help determine the most appropriate species and strain of animal to use in evaluating the risk of human exposure to toluene. Additional evaluation of human variability in disposition of toluene is also warranted.

Methods for Reducing Toxic Effects. Oxygen therapy and positive pressure ventilation have been used to reduce the toluene body burden (Graham 1990). Washing of toluene from exposed body surfaces is beneficial. In cases where toluene has caused cardiac arrhythmias, interventions may include evaluation and treatment of potential electrolyte and acid-base abnormalities as well as administration of antiarrhythmic medications to control the heart beat (Graham 1990; Gummin 2014). Other than these general guidelines, there is very little information available on methods of mitigating the toxic effects of toluene. Additional data on the outcome of emergency response procedures would be beneficial. Studies of the benefit of diet, ethanol absence, and controlled exposure to prescription or nonprescription drugs on blood levels of toluene and its metabolites could provide information that would be helpful in understanding the impact of these factors on the risks from occupational exposure.

Children's Susceptibility. Data needs relating to both prenatal and childhood exposures, and developmental effects expressed either prenatally or during childhood, are discussed in detail in the Developmental Toxicity subsection above.

3. HEALTH EFFECTS

The effects of toluene have not been thoroughly studied in children or immature animals, but the effects observed in juvenile toluene abusers (Byrne et al. 1991; Devasthasan et al. 1984; King et al. 1981) and immature animals exposed to toluene (Bowen et al. 2007; Castilla-Serna et al. 1991; O'Leary-Moore et al. 2009; Pryor and Rebert 1992; Pryor et al. 1984a; Samuel-Herter et al. 2013; von Euler et al. 1989) are consistent with effects observed in adults. Information regarding age-related differences in toluene metabolism suggests that developing fetuses and children at very early stages of development may be more susceptible to toluene toxicity than adults due to lower capabilities to metabolically detoxify toluene, but, by 1–3 years of age, adult capabilities may be attained (Leeder and Kearns 1997; Nakajima et al. 1992b, 1997; Tassaneeyakul et al. 1996; Vieira et al. 1996). An oral lethality study in rats (Kimura et al. 1971) and a study of toluene-induced hearing loss in young rats (Pryor et al. 1984a) provide the only health effect data suggesting that immature animals may be more susceptible than adult animals. Age-series inhalation studies do not provide consistent evidence of increased neurobehavioral or neurochemical alterations in juvenile or young adult rats, compared with adult rats (Batis et al. 2010; Bowen et al. 2007; O'Leary-Moore et al. 2009; Samuel-Herter et al. 2013). Additional research on the development of metabolic capabilities in newborn and very young children may lead to better understanding of the susceptibility of children to toluene toxicity.

Studies with pregnant mice suggest that distribution of inhaled toluene to fetal tissue is limited due to maternal metabolic detoxification and preferential distribution of nonmetabolized toluene to maternal adipose tissue (Ghantous and Danielsson 1986). Data needs relating to both prenatal and childhood exposures, and developmental effects expressed either prenatally or during childhood, are discussed in detail in the Developmental Toxicity subsection above.

Transfer of toluene to infants from breast milk of nursing mothers who are concurrently exposed to toluene in the workplace is expected to be a possibility and a concern (see Section 3.7). As discussed in the Absorption, Distribution, Metabolism, and Excretion subsection above, additional studies of the kinetics of elimination of toluene from nursing animals may provide pertinent information to better predict the degree to which toluene may be transferred in breast milk from a toluene-exposed working mother to her nursing infant. Monitoring studies of toluene in breast milk in groups of toluene-exposed lactating women may also provide some pertinent information.

Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs: Exposures of Children.

3. HEALTH EFFECTS

3.12.3 Ongoing Studies

Nine ongoing research efforts have been identified that may provide data related to the toxic actions of toluene (RePORTER 2014, 2016). These projects are summarized in Table 3-7.

Human studies: Dr. Anneclaire De Roos of Drexel University is conducting metanalysis of 13 case-control studies to determine if exposure to solvents, including trichloroethylene, perchloroethylene, benzene, toluene, and xylene, is a risk factor for multiple myeloma. Dr. Brad Racette of Washington University is conducting a retrospective, population-based study evaluating the potential association between occupational solvent exposure (including toluene) and Parkinson Disease in Finland. Dr. Wynne Schiffer of the University of Minnesota is conducting a study on functional and structural changes in the adolescent brain following solvent abuse.

Animal studies: Dr. Jacob Thomas Beckley of the Medical University of South Carolina is evaluating short- and long-term effects of acute toluene exposure on neuroplasticity, and Dr. Matthew Tracy of Virginia Commonwealth University is evaluating neurobehavioral changes associated with toluene exposure in mice.

Toxicokinetic studies: Dr. Wayne L. Backes of Louisiana State University Medical Center is continuing his efforts to better characterize the P450 monooxygenase system.

Mechanistic studies: Dr. Keith Shelton of Virginia Commonwealth University is investigating the neuropharmacological mechanisms of action of toluene (and other intentionally solvents) in mice, focusing on toluene's modulatory effects on the GABA receptor. Dr. John Woodward of the Medical University of South Carolina is also investigating the neuropharmacological mechanisms of action of toluene, specifically in the glutamatergic system.

3. HEALTH EFFECTS

Table 3-7. Ongoing Research for Toluene

Investigator	Affiliation	Research description	Sponsor
Backes, W	Louisiana State University Medical Center, New Orleans, Louisiana	Toxicological significance of alkylbenzene metabolism	National Institute of Environmental Health Sciences
Beckley, JT	Medical University of South Carolina, Charleston, South Carolina	Neuroplasticity associated with acute toluene inhalation	National Institute on Drug Abuse
De Roos, AJ	Drexel University, Philadelphia, Pennsylvania	Multiple myeloma consortium study of occupational exposures and family history	National Institute of Environmental Health Sciences
Racette, BA	Washington University St. Louis, Missouri	Risk of Parkinson Disease associated with solvent exposures in Finland	National Institute of Environmental Health Sciences
Schiffer, WK	University of Minnesota, Minneapolis, Minnesota	Imaging the causes and consequences of adolescent inhalant abuse	National Institute on Drug Abuse
Shelton, KL	Virginia Commonwealth University, Richmond, Virginia	Discriminative stimulus effects of abused inhalants	National Institute on Drug Abuse
Tracy, M	Virginia Commonwealth University, Richmond, Virginia	Acute and chronic effects of inhalants in intracranial-self-stimulation (ICSS)	National Institute on Drug Abuse
Woodward, JJ	Medical University of South Carolina, Charleston, South Carolina	Neural actions of toluene	National Institute on Drug Abuse

Source: RePORTER 2014, 2016

4. CHEMICAL AND PHYSICAL INFORMATION

4.1 CHEMICAL IDENTITY


Information regarding the chemical identity of toluene is located in Table 4-1.

4.2 PHYSICAL AND CHEMICAL PROPERTIES

Information regarding the physical and chemical properties of toluene is located in Table 4-2.

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-1. Chemical Identity of Toluene

Characteristic	Information	Reference
Chemical name	Toluene	HSDB 2010
Synonym(s)	Methylbenzene; phenylmethane; benzene, methyl-; toluol; methylbenzol	Haynes et al. 2013; HSDB 2010
Registered trade name(s)	Methacide; Antisal 1A	HSDB 2010
Chemical formula	C ₇ H ₈	Haynes et al. 2013; HSDB 2010
Chemical structure		Haynes et al. 2013; HSDB 2010
Identification numbers:		
CAS registry	108-88-3	Haynes et al. 2013
NIOSH RTECS	XS5250000	RTECS 2014
EPA hazardous waste	U220	HSDB 2010
OHM/TADS	7216928	NFPA 1994
DOT/UN/NA/IMCO shipping	UN 1294	HSDB 2010
IMCO	3.2	HSDB 2010
HSDB	131	HSDB 2010
NCI	CO7272	HSDB 2010

CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for Occupational Safety and Health; NFPA = National Fire Protection Association; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; RTECS = Registry of Toxic Effects of Chemical Substances

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-2. Physical and Chemical Properties of Toluene

Property	Information	Reference
Molecular weight	92.13	Fabri et al. 2012
Color	Colorless	Haynes et al. 2013
Physical state	Liquid	Haynes et al. 2013
Melting point	-94.991°C	Fabri et al. 2012
Boiling point	110.625°C	Fabri et al. 2012
Density: at 20°C	0.8631 g/cm ³	Fabri et al. 2012
Vapor density	3.1 (air=1)	HSDB 2010
Odor	Sweet, pungent, benzene-like odor	HSDB 2010
Odor threshold:		
Water	0.024–0.17 mg/L	WHO 2004
Air	2.14 ppm (8 mg/m ³)	HSDB 2010
Solubility:		
Water at 25°C	526 mg/L	HSDB 2010
Organic solvent(s)	Miscible with alcohol, chloroform, ether, acetone, glacial acetic acid, and carbon disulfide	HSDB 2010
Partition coefficients:		
Log K _{ow}	2.73	HSDB 2010
Log K _{oc}	1.57–2.25	HSDB 2010
Vapor pressure at 25°C	28.4 mm Hg	HSDB 2010
Henry's law constant:	6.64x10 ⁻³ atm-m ³ /mol	HSDB 2010
Autoignition temperature	480°C (896°F)	HSDB 2010
Flashpoint	4°C (40°F, closed cup); 16°C (open cup)	HSDB 2010
Flammability limits	1.1–7.1%	HSDB 2010
Conversion factors ppm (v/v) to mg/m ³ in air (20°C)	1 ppm=3.76 mg/m ³	HSDB 2010
Explosive limits	1.27% lower limit	Fabri et al. 2012; HSDB 2010

v/v = volume for volume

4. CHEMICAL AND PHYSICAL INFORMATION

This page is intentionally blank.

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

5.1 PRODUCTION

Table 5-1 lists the facilities in each state that manufacture or process toluene, the intended use, and the range of maximum amounts of toluene that are stored on site. There are currently 2,198 facilities that produce, process, or use toluene in the United States. The data listed in Table 5-1 are derived from the Toxics Release Inventory (TRI15 2016). Only certain types of facilities were required to report. Therefore, this is not an exhaustive list.

Toluene is produced from the catalytic reforming of refinery streams, with part of the catalytic reformate converted to benzene-toluene-ethylbenzene-xylene (BTEX). Approximately 15% of the toluene produced is separated out of pyrolysis gasoline during the manufacture of ethylene and propylene, ~4% is from separation of coal tar, and ~1% is recovered as a byproduct of styrene manufacture. However, while the largest concentrations of toluene are recovered from catalytic reformate or pyrolysis gasoline, most of the toluene produced is unrecovered (Ozokwelu 2006).

Toluene is widely used and is produced by a large number of domestic chemical and petroleum companies. The 18 companies that currently produce or supply toluene in the United States are: Alon USA Energy, Inc.; BASF FINA Petrochemicals LP, BP America, Inc.; CITGO Petroleum Corporation; ConocoPhillips; The Dow Chemical Company; Equistar Chemical, LP; ExxonMobil Chemical Company; Flint Hills Resources LP; Frontier El Dorado Refining Company; Houston Refining LP; HOVENSA, LLC; Husky Energy Inc.; Marathon Petroleum Company LLC; Shell Chemical LP; Sunoco, Inc.; Total Petrochemicals USA, Inc.; and Valero Energy Corporation (SRI 2010).

5.2 IMPORT/EXPORT

U.S. general imports of toluene in 2012 were estimated at 430 million pounds (195,000 metric tons) (USITC 2013b). Exports during the same year were estimated at 670 million pounds (300,000 metric tons) (USITC 2013a).

5.3 USE

All nonisolated toluene is used in a BTEX mixture added to gasoline to improve octane ratings. Nearly half of the isolated toluene is used to produce benzene from hydrodealkylation processes. Twenty percent

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

Table 5-1. Facilities that Produce, Process, or Use Toluene

State ^a	Number of facilities	Minimum amount on site in pounds ^b	Maximum amount on site in pounds ^b	Activities and uses ^c
AK	7	10,000	499,999,999	1, 3, 4, 5, 6, 7, 9, 12, 13
AL	45	100	9,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AR	21	0	49,999,999	1, 2, 3, 5, 6, 7, 9, 10, 11, 12, 14
AZ	22	100	49,999,999	1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12
CA	112	0	499,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CO	25	0	999,999,999	1, 2, 3, 5, 7, 8, 9, 10, 11, 12, 13
CT	23	100	49,999,999	1, 5, 7, 9, 10, 11, 12
DE	7	1,000	9,999,999	1, 2, 3, 7, 9, 10, 11, 12, 13, 14
FL	43	100	49,999,999	1, 2, 3, 5, 7, 9, 10, 11, 12, 14
GA	53	0	9,999,999	1, 5, 6, 7, 8, 9, 10, 11, 12, 13
GU	2	1,000	9,999,999	7, 9
HI	9	100	9,999,999	1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 14
IA	42	100	9,999,999	1, 2, 3, 4, 5, 7, 9, 10, 11, 12, 13, 14
ID	4	100	9,999,999	7, 8, 9, 11
IL	114	0	999,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
IN	91	0	499,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
KS	41	0	999,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14
KY	46	1,000	49,999,999	1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
LA	82	0	999,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MA	44	1,000	49,999,999	1, 2, 4, 5, 7, 8, 9, 10, 11, 12
MD	16	1,000	49,999,999	1, 5, 6, 7, 9, 10, 11, 12
ME	5	100,000	49,999,999	2, 3, 4, 7, 9, 12
MI	99	0	49,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MN	33	1,000	49,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MO	50	100	9,999,999	1, 5, 7, 8, 9, 10, 11, 12, 14
MP	2	100	9,999,999	7, 9
MS	29	0	499,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MT	7	10,000	49,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14
NC	65	0	9,999,999	1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ND	14	100	49,999,999	1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 14
NE	22	100	99,999	1, 2, 3, 5, 7, 9, 10, 11, 12, 13, 14
NH	6	100	999,999	2, 3, 7, 8, 10, 11, 12
NJ	44	1,000	99,999,999	1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 14
NM	8	100	49,999,999	1, 3, 4, 6, 7, 9, 11, 12
NV	11	100	9,999,999	1, 5, 7, 9, 10, 11, 12
NY	68	0	499,999,999	1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 14

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

Table 5-1. Facilities that Produce, Process, or Use Toluene

State ^a	Number of facilities	Minimum amount on site in pounds ^b	Maximum amount on site in pounds ^b	Activities and uses ^c
OH	140	0	99,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OK	35	0	49,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OR	24	0	49,999,999	1, 5, 7, 8, 9, 10, 11, 12
PA	94	100	499,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
PR	12	10,000	99,999,999	2, 3, 5, 6, 7, 8, 9, 10, 13
RI	11	1,000	49,999,999	1, 5, 7, 9, 10, 11, 12
SC	43	0	9,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
SD	10	1,000	999,999	7, 9, 10, 11
TN	63	100	9,999,999	1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
TX	260	0	499,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT	16	0	99,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 12
VA	47	0	49,999,999	1, 2, 5, 6, 7, 8, 9, 10, 11, 12
VI	2	100,000	9,999,999	1, 5, 9, 12
VT	2	1,000	99,999	7, 10, 12
WA	25	100	99,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WI	60	0	9,999,999	1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13
WV	20	0	49,999,999	1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
WY	8	10,000	49,999,999	1, 2, 3, 4, 6, 7, 8, 9, 10, 12, 13, 14

^aPost office state abbreviations used.^bAmounts on site reported by facilities in each state.^cActivities/Uses:

1. Produce	6. Impurity	11. Chemical Processing Aid
2. Import	7. Reactant	12. Manufacturing Aid
3. Onsite use/processing	8. Formulation Component	13. Ancillary/Other Uses
4. Sale/Distribution	9. Article Component	14. Process Impurity
5. Byproduct	10. Repackaging	

Source: TRI15 2016 (Data are from 2015)

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

of toluene is used in the production of xylene, 12% is used as a solvent in paints, coatings, gums, resins, rubber, and vinyl organosol, and 10% is used for miscellaneous use, such as for the synthesis of organic chemicals, for use as a denaturant, and for the production of drugs that may be abused. The other 8% is used in the production of toluene diisocyanate (TDI) (Ozokwelu et al. 2006; HSDB 2010).

5.4 DISPOSAL

Toluene is regulated by the Resource Conservation and Recovery Act (RCRA) as a hazardous waste (U220 and F005-spent solvents including toluene) and is therefore subject to RCRA regulations as stated in 40 CFR 261.33 (see Chapter 8). These regulations include standards for storage, transport, and disposal of toluene.

Toluene, or a combination of solvent containing toluene at 10% by volume before use, is regulated by federal laws (State of California 2005). The spent toluene, or toluene that is no longer available except after reprocessing, contains additional constituents that prevents its reuse as a solvent (U.S. DOE 1991). Toluene can be disposed of by controlled incineration. Toluene is a good candidate for liquid injection incineration, rotary kiln incineration, and fluidized bed incineration. Toluene may also be disposed of by atomizing it in a suitable combustion chamber. After treatment at a spill site or waste management facility, toluene sludge can be disposed of at a secure landfill (HSDB 2010).

According to data from the TRI, 1,122,841 pounds of toluene were transferred off-site in 2012, including releases to publically owned treatment works (POTW) (TRI15 2016).

Toluene is listed as a toxic substance under Section 313 of the Emergency Planning and Community Right to Know Act (EPCRA) under Title III of the Superfund Amendments and Reauthorization Act (SARA) (EPA 2006). Disposal of wastes containing toluene is controlled by a number of federal and state regulations (see Chapter 8).

6. POTENTIAL FOR HUMAN EXPOSURE

6.1 OVERVIEW


Toluene has been identified in at least 990 of the 1,832 hazardous waste sites that have been proposed for inclusion on the EPA National Priorities List (NPL) (ATSDR 2015). However, the number of sites in which toluene has been evaluated is not known. The frequency of these sites can be seen in Figure 6-1. Of these sites, 983 are located within the United States, 5 are located in the Commonwealth of Puerto Rico, and 2 are located in the Virgin Islands.

The majority of toluene released to the environment partitions to air. Large amounts of toluene enter the environment each year from production, use, and disposal of industrial and consumer products that contain toluene. The largest source of toluene emissions occurs during the production, transport, and use of gasoline. Small amounts are released in industrial waste water discharges and land disposal of sludges and petroleum wastes.

Toluene in the atmosphere is degraded by reaction with hydroxyl radicals, with a typical half-life of approximately 13 hours (Howard et al. 1991). Toluene in soil or water rapidly volatilizes to air, and that which remains is subject to microbial degradation. As a result of volatilization and degradation occurring in air, soil, and water, toluene levels are not expected to build up in the environment over time.

The concentrations of toluene in air have been found to be quite low in remote areas, but are higher in suburban and urban areas. The automobile emissions are the principal source of toluene in ambient air, with levels fluctuating in proportion to automobile traffic. Levels of toluene in the air are usually higher in urban areas that are heavily congested with traffic (21.4–98.1 ppbv or 80.5–368.9 $\mu\text{g}/\text{m}^3$). Levels in the same study were much lower in the outdoor air in less-congested urban areas (1.95 ppbv or 7.3 $\mu\text{g}/\text{m}^3$) (Baltrenas et al. 2011). Toluene is also a common indoor contaminant, and indoor air concentrations are often several times higher than outside air. This is likely due to release of toluene from common household products (paints, paint thinners, adhesives, and nail polish in which it is used as a solvent) and from cigarette smoke.

6. POTENTIAL FOR HUMAN EXPOSURE

Figure 6-1. Frequency of NPL Sites with Toluene Contamination

6. POTENTIAL FOR HUMAN EXPOSURE

Toluene is occasionally detected in drinking water supplies due to industrial water discharges or from contaminated surface water, but occurrence is not widespread and levels are generally much lower than levels found in the air. In contrast, toluene is a very common contaminant of water and soil in the vicinity of hazardous waste sites.

The most likely pathway by which the general population may be exposed to toluene is by breathing contaminated air. Since most people spend a large fraction of the day indoors, indoor air levels are likely to be the dominant source. Higher exposure levels might occur for individuals living near a hazardous waste site or an industrial source of toluene emissions, but these exposures can be estimated only on a site-by-site basis.

Toluene exposure may also occur in the workplace, especially in occupations such as printing or painting, where toluene is used as a solvent. Gas service station workers can be exposed to toluene from the gasoline. Petroleum and coke plant workers may also be exposed to higher levels of toluene than the general population.

6.2 RELEASES TO THE ENVIRONMENT

The Toxics Release Inventory (TRI) data should be used with caution because only certain types of facilities are required to report (EPA 2005). This is not an exhaustive list. Manufacturing and processing facilities are required to report information to the TRI only if they employ 10 or more full-time employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, imports, or processes $\geq 25,000$ pounds of any TRI chemical or otherwise uses $>10,000$ pounds of a TRI chemical in a calendar year (EPA 2005b).

According to the Toxics Release Inventory (TRI), in 2015 approximately 25 million pounds (11 million kg) of toluene was released to the environment from 2,198 manufacturing or processing facilities in the

6. POTENTIAL FOR HUMAN EXPOSURE

United States (TRI15 2016). The most recent TRI data continues to reflect a decline in the total amount of toluene released from facilities required to report to the TRI. Total on- and off-site releases of toluene were approximately 57, 48, 42, 36, 30, 32, 29, 27, and 25 million pounds in 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, and 2015, respectively (TRI15 2016). Table 6-1 lists the amounts released from these facilities to air, water, land, and publicly owned treatment works (POTWs). Table 6-1 also shows that ~1% of the total released was injected deep underground and that ~1.1 million pounds of toluene were transferred off-site (TRI15 2016). The relative proportions of the material transferred off-site that were recycled or entered environmental media are not stated. Releases of toluene to the environment have decreased when compared to data from 1997.

6.2.1 Air

Estimated releases of 22 million pounds (~10,000 metric tons) of toluene to the atmosphere from 2,198 domestic manufacturing and processing facilities in 2015, accounted for nearly 90% of the estimated total environmental releases from facilities required to report to the TRI (TRI15 2016). These releases are summarized in Table 6-1.

EPA's National Emission Inventory (NEI) database contains data regarding sources that emit criteria air pollutants and their precursors, and hazardous air pollutants (HAPs) for the 50 United States, Washington DC, Puerto Rico, and the U.S. Virgin Islands. The NEI database derives emission data from multiple sources, including state and local environmental agencies, the TRI database, computer models for on-road and off-road emissions, and databases related to EPA's Maximum Achievable Control Technology (MACT) programs to reduce emissions of HAPs. Data downloaded from the 2011 NEI (see Table 6-2) indicated that the total emission of toluene was approximately 1,730,000,000 pounds (785,000 tons), with the biggest contribution arising from consumer and commercial solvent use (EPA 2013a). Nearly all toluene entering the environment is released directly to air or partitions to the atmosphere due to its relatively high vapor pressure (EC 2003). A major source of toluene emissions arises from gasoline use, which typically includes emissions from motor vehicle exhaust, gasoline storage tanks, filling stations, petroleum spills, etc. (EC 2003; Verschueren 1977). The emission rate of toluene from motor vehicle traffic in a Los Angeles roadway tunnel was found to be 748 mg/L of gasoline consumed (Fraser et al. 1998). In addition, the global release from automobile exhaust is estimated to be around 3–8 metric tons per year, and the emission factors from gasoline were 2.22×10^{-5} – 8.46×10^{-4} lb/vehicle mile traveled for evaporation from automobile fuel tanks and automobile exhaust emissions (EPA 1994).

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-1. Releases to the Environment from Facilities that Produce, Process, or Use Toluene^a

State ^c	RF ^d	Reported amounts released in pounds per year ^b							On- and off-site
		Air ^e	Water ^f	UI ^g	Land ^h	Other ⁱ	Total release		
							On-site ^j	Off-site ^k	
AK	7	11,916	8	0	162	0	12,087	0	12,087
AL	47	400,857	3	0	767	19,877	400,861	20,643	421,504
AR	18	99,591	45	2,051	1	351	101,687	352	102,038
AZ	23	86,726	0	0	384	926	86,976	1,060	88,036
CA	112	197,493	49	20	837,096	5,629	1,032,978	7,309	1,040,287
CO	23	88,923	0	0	342	0	89,173	92	89,265
CT	25	55,484	59	0	59	0	55,543	59	55,602
DE	7	12,944	5	0	0	0	12,949	0	12,950
FL	43	212,880	27	0	200	23,975	212,907	24,175	237,082
GA	50	618,693	45,625	0	1,003	5,260	664,318	6,263	670,581
GU	2	5,418	0	0	13	0	5,418	13	5,431
HI	10	24,888	20	1	10	0	24,909	10	24,919
IA	44	325,450	2	0	135	1,321	325,452	1,456	326,908
ID	4	11,862	0	0	5,412	0	11,862	5,412	17,274
IL	118	615,479	662	2,537	1,989	9,312	616,345	13,634	629,979
IN	90	1,368,943	481	0	118,177	222,875	1,461,549	248,927	1,710,476
KS	39	543,168	115	494	8,235	262	544,198	8,076	552,275
KY	47	1,302,536	1,725	0	931	10,526	1,304,528	11,190	1,315,718
LA	80	1,086,098	794	4,228	85,957	1,833	1,165,289	13,621	1,178,909
MA	49	235,372	5	0	48	34,534	235,377	34,582	269,959
MD	13	8,754	27	0	1	500	8,781	501	9,282
ME	5	3,530	1	0	22	685	3,532	707	4,239
MI	98	1,169,092	68	50	34,769	15,358	1,169,372	49,965	1,219,337
MN	34	436,827	12	0	3,357	0	436,838	3,357	440,195
MO	52	180,166	51	0	1,160	3,811	180,227	4,961	185,188
MP	2	1,108	0	0	0	0	1,108		1,108
MS	32	342,669	411	0	2,710	47	343,080	2,757	345,837
MT	5	50,563	3	0	4,714	3,238	50,568	7,950	58,518
NC	63	1,049,367	6	0	3,756	47,278	1,049,373	51,034	1,100,407
ND	14	39,787	1	1	19	3	39,792	19	39,811
NE	21	20,843	0	0	18,685	20,838	20,843	39,523	60,366
NH	5	9,796	0	0	0	3	9,796	3	9,799
NJ	48	124,496	619	110	1,251	11,771	125,115	13,133	138,248
NM	9	41,455	0	0	227	2,887	41,455	3,114	44,569
NV	12	308,684	0	0	24,711	0	333,395	No data	333,395
NY	68	355,382	21	0	733	3,247	355,405	3,978	359,382
OH	150	633,201	41	1,699	22,455	63,229	633,601	87,024	720,626
OK	32	858,559	522	762	308	9,897	859,474	10,574	870,048
OR	26	95,837	9	0	36,643	889	129,378	4,000	133,378

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-1. Releases to the Environment from Facilities that Produce, Process, or Use Toluene^a

State ^c	RF ^d	Reported amounts released in pounds per year ^b						Total release	
		Air ^e	Water ^f	UI ^g	Land ^h	Other ⁱ	On-site ^j	Off-site ^k	On- and off-site
PA	93	1,507,854	415	0	14,884	12,556	1,508,269	27,440	1,535,709
PR	13	31,776	0	0	0	0	31,776	No data	31,776
RI	10	15,433	12	0	0	7,277	15,445	7,277	22,722
SC	44	2,330,401	260	8	43	24,855	2,330,688	24,879	2,355,567
SD	9	61,382	0	0	0	0	61,382	No data	61,382
TN	66	1,124,815	87	0	1,126	2,444	1,124,978	3,494	1,128,472
TX	259	1,604,315	1,219	246,601	34,441	66,292	1,862,139	90,730	1,952,869
UT	16	75,632	5	0	161	598	75,692	704	76,396
VA	46	814,544	160	0	44,429	6,847	814,704	51,276	865,980
VI	2	11,352	0	0	91	0	11,441	1	11,442
VT	2	1,790	0	0	0	0	1,790	No data	1,790
WA	24	237,705	13	0	1,875	15	238,356	1,252	239,608
WI	60	948,096	0	0	8,121	228,570	951,876	232,911	1,184,786
WV	16	273,150	324	0	1,694	1,346	273,488	3,026	276,513
WY	11	40,531	5	0	391	0	40,549	378	40,927
Total	2,198	22,113,612	53,918	258,562	1,323,699	871,163	23,498,112	1,122,841	24,620,953

^aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an exhaustive list. Data are rounded to nearest whole number.

^bData in TRI are maximum amounts released by each facility.

^cPost office state abbreviations are used.

^dNumber of reporting facilities.

^eThe sum of fugitive and point source releases are included in releases to air by a given facility.

^fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal and metal compounds).

^gClass I wells, Class II-V wells, and underground injection.

^hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface impoundments, other land disposal, other landfills.

ⁱStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for disposal, unknown

^jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

^kTotal amount of chemical transferred off-site, including to POTWs.

RF = reporting facilities; UI = underground injection

Source: TRI15 2016 (Data are from 2015)

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-2. 2011 NEI Total National Emissions of Toluene

Emission source	Emissions in tons
Agriculture, livestock waste	2.566
Bulk gasoline terminals	1,989.817
Commercial cooking	646.584
Dust, construction dust	0.149
Fires, agricultural field burning	5,788.053
Fires, prescribed fires	24,784.188
Fires, wildfires	30,548.719
Fuel combustion, commercial/institutional, biomass	4.724
Fuel combustion, commercial/institutional, coal	0.230
Fuel combustion, commercial/institutional, natural gas	75.153
Fuel combustion, commercial/institutional, oil	4.905
Fuel combustion, commercial/institutional, other	3.239
Fuel combustion, electric generation, biomass	509.470
Fuel combustion, electric generation, coal	92.209
Fuel combustion, electric generation, natural gas	325.570
Fuel combustion, electric generation, oil	10.029
Fuel combustion, electric generation, other	17.986
Fuel combustion, Industrial boilers, ices, biomass	157.859
Fuel combustion, Industrial boilers, ices, coal	3.036
Fuel combustion, Industrial boilers, ices, natural gas	407.576
Fuel combustion, Industrial boilers, ices, oil	19.987
Fuel combustion, Industrial boilers, ices, other	31.980
Fuel combustion, residential, natural gas	52.243
Fuel combustion, residential, oil	1.146
Fuel combustion, residential, other	0.038
Fuel combustion, residential, wood	4,118.312
Gas stations	31,251.987
Industrial processes, cement manuf	26.102
Industrial processes, chemical manuf	2,094.087
Industrial processes, ferrous metals	58.466
Industrial processes, mining	6.779
Industrial processes, NEC	2,533.374
Industrial processes, non-ferrous metals	39.259
Industrial processes, oil and gas production	9,281.628
Industrial processes, petroleum refineries	710.439
Industrial processes, pulp and paper	111.692
Industrial processes, storage and transfer	2,487.106
Miscellaneous non-industrial NEC	7,290.227

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-2. 2011 NEI Total National Emissions of Toluene

Emission source	Emissions in tons
Mobile, aircraft	463.492
Mobile, commercial marine vessels	39.694
Mobile, locomotives	187.259
Mobile, non-road equipment, diesel	1,857.913
Mobile, non-road equipment, gasoline	144,745.874
Mobile, non-road equipment, other	4.067
Mobile, on-road diesel heavy duty vehicles	1,567.312
Mobile, on-road diesel light duty vehicles	44.951
Mobile, on-road gasoline heavy duty vehicles	10,911.517
Mobile, on-road gasoline light duty vehicles	194,777.346
Solvent, consumer and commercial solvent use	282,997.039
Solvent, degreasing	365.751
Solvent, dry cleaning	0.330
Solvent, graphic arts	4,271.392
Solvent, industrial surface coating and solvent use	58,964.001
Solvent, non-industrial surface coating	37,149.628
Waste disposal	3,232.753
Sum	867,067.23

NEC = not elsewhere classified; NEI = National Emission Inventory

Source: EPA 2013a

6. POTENTIAL FOR HUMAN EXPOSURE

BTEX emissions are primarily due to incomplete combustion of petroleum fuels from gasoline and volatilization of BTEX-based solvents and thinners. BTEX is often studied together because these chemicals comprise 60% of the water-soluble fraction of gasoline (CCME 2004). Toluene, along with the other aromatic hydrocarbons, is added to gasoline to raise the octane rating (Ozokwelu 2006).

Toluene is used in paints, solvents, adhesives, inks, and similar products and is also released to air upon use. Toluene is also emitted from building and finishing materials in newly constructed apartments. Indoor air exposure to a chemical that is generated at the source (from paints, varnishes, and adhesives) can be of a greater risk than ambient air exposure. Toluene was found at mean concentrations of 63.03 $\mu\text{g}/\text{m}^3$ (lower floor), 66.06 $\mu\text{g}/\text{m}^3$ (middle floor), and 27.16 $\mu\text{g}/\text{m}^3$ (highest floor) in newly constructed apartment buildings in Korea that had been finished with vinyl wallpaper and plywood. The outdoor concentration of toluene in the same study was 11.05 $\mu\text{g}/\text{m}^3$. Calculated mean emission rates for toluene were 4,168 $\mu\text{g}/\text{hour}$ (lower floor), 4,171 $\mu\text{g}/\text{hour}$ (middle floor), and 7,356 $\mu\text{g}/\text{hour}$ (highest floor). The authors suggest that an increase in the ventilation on the highest floor may lead to an increase in emissions from the inner surfaces (Sim et al. 2010).

Toluene may also be released during disposal processes. Based on information from 40 medical waste incinerators in the United States and Canada, emission factors for toluene were reported to range from 37.3 to 178 (mean=113) $\mu\text{g}/\text{kg}$ waste for uncontrolled emissions and 177–3,000 (mean=1,920) $\mu\text{g}/\text{kg}$ waste for controlled emissions (Walker and Cooper 1992). Toluene emissions from coal-fired power stations (119 $\mu\text{g}/\text{m}^3$) were reported to be far less than toluene emissions from diesel engines (167–287 $\mu\text{g}/\text{m}^3$) and automobiles (15,700–370,000 $\mu\text{g}/\text{m}^3$); all measurements were obtained at standard temperature and pressure (20°C and 1 atmosphere pressure) (Garcia et al. 1992).

6.2.2 Water

Estimated releases of ~54,000 pounds (~245 metric tons) of toluene to surface water from 2,198 domestic manufacturing and processing facilities in 2015, accounted for about 0.2% of the estimated total environmental releases from facilities required to report to the TRI (TRI15 2016). These releases are summarized in Table 6-1.

Toluene may be released to water from industrial discharges and urban wastes, or by spills and leakage of gasoline. However, these releases are believed to comprise only a small fraction of the amount of toluene

6. POTENTIAL FOR HUMAN EXPOSURE

released to air (EPA 1983b). Emissions into the water and soil sometimes lead to re-emission of toluene into the air (EC 2003).

Toluene can be released to groundwater following large surface spills of BTEX-containing components such as diesel fuel or conventional gasoline. For example, Gross et al. (2013) analyzed groundwater data following surface spills associated with hydraulic fracturing operations in the state of Colorado. The mean concentration of toluene in 218 groundwater samples associated with surface spills was 750 µg/L and the 95th percentile concentration was 1,900 µg/L. Some individual samples inside the excavation areas of the spill sites had levels as high as 10,000 µg/L.

6.2.3 Soil

Estimated releases of 1.3 million pounds (~590 metric tons) of toluene to soils from 2,198 domestic manufacturing and processing facilities in 2015, accounted for about 5% of the estimated total environmental releases from facilities required to report to the TRI (TRI15 2016). An additional ~258,500 pounds (~117 metric tons), constituting ~1% of the total environmental emissions, were released via underground injection (TRI15 2016). These releases are summarized in Table 6-1.

Release of toluene to land may occur in association with gasoline spills, leaking underground gasoline storage tanks, or land disposal of municipal sludges or refinery wastes. Releases of BTEX to the soil also occur from accidents and spills during transportation and pesticide applications (CCME 2004). In some cases, releases might be significant on a local scale; however, the total amount of toluene released to the environment in soil is considered to be negligible (EPA 1983b).

6.3 ENVIRONMENTAL FATE

6.3.1 Transport and Partitioning

Toluene is a volatile liquid at room temperature. Due to its high vapor pressure (28.4 mmHg at 25°C), the majority of toluene released to the environment partitions to air. As discussed in Section 6.2, most toluene is released directly into air, and that which is released to surface water or soil tends to volatilize quickly (EC 2003). Toluene rapidly volatilizes from surface water to air, with a half-life on the order of a few hours at 25°C; however, the volatilization rate is dependent upon conditions of the water body (e.g., depth, current) and the atmosphere (e.g., wind speeds). Laboratory studies also indicate that surfactants can affect volatilization of toluene from water (Anderson 1992).

6. POTENTIAL FOR HUMAN EXPOSURE

The rate of volatilization from soils depends on temperature, humidity, and soil type; however, under typical conditions, toluene rapidly volatilizes from soils based on its Henry's Law constant and vapor pressure (CCME 2004; HSDB 2010).

Toluene is expected to have high to moderate mobility in soil; the soil adsorption coefficient (K_{oc}) values of 37–178 indicate that toluene is not expected to be strongly bound to the soil (HSDB 2010). Humidity interferes with the adsorption of toluene vapors into soils, with sorption primarily occurring with water vapor rather than toluene in low humidity (Chen and Wu 1998).

Adsorption of toluene to soil is possible under certain conditions. Distilled water removed 9–40% of the toluene adsorbed to samples of five different soils of low organic content within 24 hours, but after 7 days, some of the toluene still remained adsorbed to the soil samples (Pavlostathis and Mathavan 1992). Sorption of toluene can also be dependent on the size of the particles in soils. BTEX was adsorbed more in montmorillonite or illite clays, and less in kaolinite (Site 2001). A gravimetric method indicated that adsorption of gas phase toluene on loam or clay occurs in two stages: fast diffusion and adsorption in macropores, followed by slower diffusion and adsorption in intragrain micropores (Arocha et al. 1996). Temperature is also inversely related to adsorption (Site 2001).

Although the organic carbon content of aquifer materials is an important determinant of toluene migration in groundwater, other factors may be important as well (Larsen et al. 1992). For example, information from waste sites and U.S. coastal plain aquifers indicates that many site-specific hydro geologic factors can have unpredictable effects on toluene migration (Adams and Golden 1992). In addition, the presence of other gasoline components (benzene, xylene) can impact toluene migration. Competitive sorption between these gasoline components decreases the interaction between toluene and soil, thereby allowing it to move more quickly through the aquifer (Stuart et al. 1991).

Toluene is expected to have a low tendency to bioconcentrate in the fatty tissues of aquatic organisms based on its measured BCF values (Franke et al. 1994). The bioconcentration factor (BCF) values were reported to be 8, 13, and 90 in herring, eels, and golden ide fish, respectively (EC 2003).

6. POTENTIAL FOR HUMAN EXPOSURE

6.3.2 Transformation and Degradation**6.3.2.1 Air**

Toluene in the atmosphere is rapidly degraded by reaction with hydroxyl radicals to yield cresol and benzaldehyde, which in turn undergo ring cleavage to yield simple hydrocarbons (Davis et al. 1979; Hoshino et al. 1978; Kenley et al. 1973). The estimated rate constant for this process is about $0.6\text{--}2.4 \times 10^{-5} \text{ sec}^{-1}$, which corresponds to an atmospheric half-life of around 13 hours. The actual half-life may range from 10 to 104 hours depending on atmospheric conditions (Howard et al. 1991). Toluene is also oxidized by reaction with nitrogen dioxide, oxygen, and ozone, but the rates of these reactions are two or more orders of magnitude less than for the hydroxyl radical (Altshuller et al. 1971; Dilling et al. 1976; Wei and Adelman 1969). Benzyl nitrate and nitrotoluene are formed through the reaction of atmospheric toluene with nitrogen oxides (Atkinson 1990). Secondary organic aerosol products from the photooxidation of toluene include carbonyl products (Cao and Jang 2008).

Processes for removing toluene from the air include adsorption, thermal and catalytic combustion, photocatalytic combustion, and biological methods. Biological methods include biotrickling filters, which are filters that move the polluted air and a recycled liquid through a packed bed for the creation of a biofilm. These biofilms facilitate the degradation of toluene in the air for pollution control (Cox et al. 2000). Experiments have been conducted in which *Acinetobacter* genospecies, a toluene-degrading bacteria, was isolated from a trickle bed air biofilter (TBAB). This newer bacteria showed excellent degradation capabilities. Biofilters are a relatively inexpensive way to eliminate toluene in the air (Hori et al. 2001).

Recently, non-thermal plasma techniques have become prevalent innovative techniques in removing volatile organic compounds from the air. Toluene was removed in a non-thermal reactor at room temperature with a 93% removal efficiency. The experiment yielded decomposition products that included ozone, carbon dioxide, nitric oxide, and nitrogen dioxide (Mista and Kacprzyk 2008).

6.3.2.2 Water

There is potential for rapid degradation of toluene in water, especially if there is an electron acceptor available for oxidation (Evans et al. 1991). In surface waters, the biodegradation half-life of toluene was estimated to range from 4 to 22 days and the biodegradation half-life of toluene in groundwater was estimated to range from 7 to 28 days (Howard et al. 1991).

6. POTENTIAL FOR HUMAN EXPOSURE

However, groundwater sometimes contains low amounts of dissolved oxygen. Anaerobic degradation of toluene, in this case, is an important fate process in the water (Evans et al. 1991). The biodegradation of toluene in groundwater can be enhanced by the presence of alternative electron acceptors, such as sulfate, nitrate, potassium, bicarbonate, and phosphate (Acton and Barker 1992; Armstrong et al. 1991; Hutchins 1991, Evans et al. 1991). Complete mineralization is possible under the right conditions. Edwards et al. (1992) found that toluene was completely mineralized to carbon dioxide and biomass by an aquifer-derived microorganism that used sulfate as a terminal electron acceptor. The authors found that toluene degradation stopped when the sulfate was removed, and started back up again once the sulfate was added again.

Microbial degradation in contaminated groundwater is also dependent on the depth and placement of the contamination. For instance, toluene degraders, related to *Geobacter* spp., *Desulfocapsa* spp., and *Sedimentibacter* spp. exist primarily in the biogeochemical gradient zone underneath contaminated plume cores. BTEX was found to exist with sulfate and those anaerobic toluene degraders in that gradient zone in a contaminated tar oil plume (Winderl et al. 2007).

Toluene can also be removed in aerobic conditions. In a laboratory study, toluene was removed from waste water by being stripped in an air stripping tank and subsequently degraded by *Pseudomonas putida* in a bioreactor (Dahlan et al. 1999). In a modified closed bottle study (OECD method 301D) referred to as a BOD₂₈ study (the biochemical oxygen demand after a 28-day incubation period), toluene degradation was observed at 93% after 14 days at a concentration of 50 mg/L and was reported to be readily biodegradable (Lapertot and Pulgarin 2006).

6.3.2.3 Sediment and Soil

Biodegradation of BTEX in soils can be affected by pH, temperature, and salinity. The bacteria responsible for degrading BTEX have a reduced growth rate at highly acidic and alkaline conditions, low and high temperatures, and salty conditions (You et al. 2013). Soils contaminated specifically with toluene can be effectively remediated with a combination of soil vapor extraction and bioremediation. Soils are required to have an organic matter content <14% in order for soil vapor extraction to be effective (Soares et al. 2013).

6. POTENTIAL FOR HUMAN EXPOSURE

It was discovered that the concentration of toluene in bioremediation practices has an effect on microbial compositions (Hubert et al. 1999). Addition of large numbers of bacterial cells to toluene-contaminated soils may have no benefit if the concentration of toluene is too low for the bacteria to maintain metabolic activity (Roch and Alexander 1997). Likewise, toluene degradation by bacterial cells is dependent on the types of bacteria. Growth of one strain exposed to a small concentration of toluene (0.01%) was negligible when compared to another strain (Hubert et al. 1999).

In aerobic soils, oxygen acts as the terminal electron acceptor in degradation of the ring cleavage products. Under anaerobic conditions, nitrogen or sulfate can act as the terminal electron acceptor (Beller et al. 1992a, 1992b; Dolfig et al. 1990; Evans et al. 1991). Under favorable conditions (presence of electron acceptors, nutrients, and oxidizable compounds), laboratory studies show that BTEX compounds are also degraded by bacteria in anaerobic (Langenhoff et al. 1996) or oxygen-limited environments (Lovley 1997; Olsen et al. 1995). Under sulfate-reducing conditions, less than 10% of the toluene carbon was metabolized to benzylsuccinic acid and benzylfumaric acid, whereas >80% was mineralized to carbon dioxide (Beller et al. 1992a). The half-life for biodegradation in soil under laboratory conditions may be as short as 1 hour (Claus and Walker 1964). Based on data from the aerobic degradation of toluene in water, the biodegradation half-life of toluene in soils is expected to range from 4 to 22 days (Howard et al. 1991). Soil biodegradation is not impeded by adsorption (Robinson et al. 1990). The wood-degrading, white-rot fungus, *Phanerochaete chrysosporium*, mineralizes 50% of 2 ppm aqueous solutions of toluene or BTEX compounds to carbon dioxide within 5 days. Non-ligninolytic conditions are favored (Yadav and Reddy 1993).

6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT

Reliable evaluation of the potential for human exposure to toluene depends in part on the reliability of supporting analytical data from environmental samples and biological specimens. Concentrations of toluene in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of current analytical methods. In reviewing data on toluene levels monitored or estimated in the environment, it should also be noted that the amount of chemical identified analytically is not necessarily equivalent to the amount that is bioavailable. The analytical methods available for monitoring toluene in a variety of environmental media are detailed in Chapter 7.

6. POTENTIAL FOR HUMAN EXPOSURE

6.4.1 Air

Ambient air levels of toluene are typically reported as micrograms per cubic meter of air ($\mu\text{g}/\text{m}^3$) or part per billion by volume (ppbv); $3.76 \mu\text{g}/\text{m}^3$ of toluene is equivalent to 1.00 ppbv (see Chapter 4).

Occasionally, monitoring data will be reported as parts per billion of carbon (ppbC). The unit ppbC is equivalent to ppbv multiplied by the number of carbons of the analyte.

The EPA Air Quality System (AQS) contains monitoring data of criteria air pollutants and HAPs. Detailed air monitoring data for toluene in various cities/counties in the United States for 2015 are shown in Table 6-3. Table 6-4 summarizes the annual mean percentile distributions of toluene for years 2010–2015 (EPA 2016). Daily arithmetic mean concentrations of toluene ranged from 0.29 to 45.9 ppbC (0.041–6.56 ppbv) in 2015, which were similar to the concentrations measured in a study that analyzed the levels of toluene and 87 other volatile substances during a 1997–2001 sampling period from 13 semi-rural to urban locations in the United States. The states included Maine, Massachusetts, New Jersey, Pennsylvania, Ohio, Illinois, and California (Pankow et al. 2003). The arithmetic mean and median concentrations at these 13 locations were 0.22–2.7 and 0.10–2.4 ppbv (0.83 – 10.2 and 0.38 – $9.0 \mu\text{g}/\text{m}^3$), respectively. The measured concentrations exhibited seasonal trends, with the highest levels typically observed during the winter months, particularly in the more urban sampling locations. Older studies have reported toluene levels of 0.9–70.1, 0.06–195, and 2.2–751.5 ppbv (3.4 – 263.6 , 0.23 – 733.2 , and 8.3 – $2,825.6 \mu\text{g}/\text{m}^3$) in rural (Khalil and Rasmussen 1992), urban (Armstrong et al. 1991; Chan et al. 1991b; Evans et al. 1992; Kelly et al. 1993), and source-dominated air samples, respectively (Guldberg 1992; Kelly et al. 1993).

In a study conducted by Iovino et al. (2009), the authors found that the average toluene concentration in the Naples, Italy metropolitan area was $35.0 \mu\text{g}/\text{m}^3$ (9.31 ppbv). The average concentration near suburban areas was $16.2 \mu\text{g}/\text{m}^3$ (4.31 ppbv) and the average concentration far from suburban areas was $15.3 \mu\text{g}/\text{m}^3$ (4.07 ppbv). Higher toluene levels in the outdoor air can be due to location and proximity to urban areas.

Toluene was detected at 1.95 ppbv ($7.33 \mu\text{g}/\text{m}^3$) in the outdoor air of the urban zone near a crude oil refinery located in Lithuania. This level was similar to the levels of toluene found in urban areas of European cities; however, there were much higher levels of toluene (21.4–98.1 ppbv or 80.5 – $369 \mu\text{g}/\text{m}^3$) in the traffic congested areas in those same cities (Baltrenas et al. 2011).

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-3. Toluene Levels in Ambient Air^a

Sampling location ^b	Number of samples	Daily arithmetic mean concentration (ppbv)	Standard deviation (ppbv)	Median (ppbv)
Phoenix-Mesa-Scottsdale, AZ	32	1.13	0.86	0.88
Phoenix-Mesa-Scottsdale, AZ	57	0.91	0.80	0.64
Phoenix-Mesa-Scottsdale, AZ	6	0.84	0.52	0.86
Phoenix-Mesa-Scottsdale, AZ	15	0.57	0.22	0.53
Phoenix-Mesa-Scottsdale, AZ	1	0.45	0.00	0.45
Phoenix-Mesa-Scottsdale, AZ	14	0.08	0.03	0.08
Phoenix-Mesa-Scottsdale, AZ	45	0.06	0.04	0.05
San Francisco-Oakland-Hayward, CA	29	0.51	0.40	0.46
San Francisco-Oakland-Hayward, CA	5,473	0.37	0.53	0.19
San Francisco-Oakland-Hayward, CA	30	0.67	0.47	0.58
San Francisco-Oakland-Hayward, CA	30	0.75	0.86	0.34
San Francisco-Oakland-Hayward, CA	30	0.49	0.41	0.31
San Francisco-Oakland-Hayward, CA	4,197	0.10	0.06	0.08
Chico, CA	30	0.41	0.27	0.42
San Francisco-Oakland-Hayward, CA	30	0.21	0.17	0.16
San Francisco-Oakland-Hayward, CA	29	0.36	0.33	0.28
San Francisco-Oakland-Hayward, CA	29	0.14	0.08	0.14
San Francisco-Oakland-Hayward, CA	30	0.18	0.17	0.11
San Francisco-Oakland-Hayward, CA	29	0.68	0.76	0.55
San Francisco-Oakland-Hayward, CA	30	0.26	0.22	0.22
San Francisco-Oakland-Hayward, CA	5,318	0.21	0.22	0.14
Fresno, CA	30	0.43	0.42	0.25
Fresno, CA	144	0.09	0.08	0.06
Fresno, CA	144	0.12	0.12	0.09
El Centro, CA	30	0.98	1.06	0.61
Bakersfield, CA	30	0.72	0.63	0.63
Bakersfield, CA	29	0.72	0.58	0.57
Bakersfield, CA	140	0.31	0.26	0.20
Bakersfield, CA	24	0.23	0.18	0.17
Los Angeles-Long Beach-Anaheim, CA	56	0.77	0.48	0.66
Los Angeles-Long Beach-Anaheim, CA	30	0.81	0.61	0.74
Los Angeles-Long Beach-Anaheim, CA	40	0.65	0.44	0.57
Los Angeles-Long Beach-Anaheim, CA	26	0.79	0.47	0.66
Los Angeles-Long Beach-Anaheim, CA	59	0.87	0.56	0.72
Los Angeles-Long Beach-Anaheim, CA	30	0.84	0.62	0.60
Los Angeles-Long Beach-Anaheim, CA	57	0.85	0.60	0.63
Los Angeles-Long Beach-Anaheim, CA	58	0.43	0.45	0.29
Los Angeles-Long Beach-Anaheim, CA	52	0.46	0.20	0.49

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-3. Toluene Levels in Ambient Air^a

Sampling location ^b	Number of samples	Daily arithmetic mean concentration (ppbv)	Standard deviation (ppbv)	Median (ppbv)
Madera, CA	32	0.09	0.10	0.04
San Francisco-Oakland-Hayward, CA	28	0.47	0.34	0.50
San Francisco-Oakland-Hayward, CA	30	0.07	0.12	0.04
Napa, CA	29	0.48	0.39	0.37
Sacramento-Roseville-Arden-Arcade, CA	30	0.26	0.19	0.22
Riverside-San Bernardino-Ontario, CA	43	0.50	0.42	0.43
Riverside-San Bernardino-Ontario, CA	25	0.82	0.58	0.73
Riverside-San Bernardino-Ontario, CA	57	0.73	0.50	0.63
Sacramento-Roseville-Arden-Arcade, CA	136	0.27	0.47	0.09
Sacramento-Roseville-Arden-Arcade, CA	16	0.13	0.08	0.10
Sacramento-Roseville-Arden-Arcade, CA	77	0.31	1.17	0.09
San Diego-Carlsbad, CA	31	0.45	0.37	0.32
San Diego-Carlsbad, CA	32	0.81	0.97	0.51
San Francisco-Oakland-Hayward, CA	28	0.35	0.27	0.34
San Francisco-Oakland-Hayward, CA	5	0.51	0.37	0.48
San Francisco-Oakland-Hayward, CA	30	0.37	0.29	0.30
Stockton-Lodi, CA	30	0.45	0.40	0.34
San Francisco-Oakland-Hayward, CA	29	0.85	0.69	0.48
San Jose-Sunnyvale-Santa Clara, CA	60	1.04	0.66	0.90
San Jose-Sunnyvale-Santa Clara, CA	30	0.65	0.62	0.45
San Jose-Sunnyvale-Santa Clara, CA	27	0.82	0.72	0.57
Vallejo-Fairfield, CA	30	0.41	0.42	0.26
Santa Rosa, CA	30	0.25	0.18	0.21
Oxnard-Thousand Oaks-Ventura, CA	81	0.21	0.19	0.13
Oxnard-Thousand Oaks-Ventura, CA	28	0.73	2.41	0.28
Oxnard-Thousand Oaks-Ventura, CA	140	0.11	0.11	0.09
Denver-Aurora-Lakewood, CO	42	1.22	0.71	1.15
Glenwood Springs, CO	54	0.76	0.33	0.72
Glenwood Springs, CO	46	0.92	1.44	0.65
Glenwood Springs, CO	52	0.61	0.61	0.40
Glenwood Springs, CO	26	4.53	10.24	0.79
Glenwood Springs, CO	20	5.25	10.48	1.20
Glenwood Springs, CO	6	0.59	0.20	0.55
Glenwood Springs, CO	51	0.58	0.38	0.46
Glenwood Springs, CO	2	0.40	0.12	0.48
Grand Junction, CO	50	0.81	0.56	0.71
Greeley, CO	40	1.01	0.60	0.99
Hartford-West Hartford-East Hartford, CT	1,962	0.32	0.27	0.22

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-3. Toluene Levels in Ambient Air^a

Sampling location ^b	Number of samples	Daily arithmetic mean concentration (ppbv)	Standard deviation (ppbv)	Median (ppbv)
New Haven-Milford, CT	2,012	0.76	1.12	0.36
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	36	0.32	0.68	0.19
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	54	0.54	0.36	0.37
Washington-Arlington-Alexandria, DC-VA-MD-WV	2,043	0.25	0.31	0.15
Washington-Arlington-Alexandria, DC-VA-MD-WV	59	0.35	0.19	0.31
Washington-Arlington-Alexandria, DC-VA-MD-WV	31	0.41	0.13	0.37
Washington-Arlington-Alexandria, DC-VA-MD-WV	60	0.28	0.38	0.21
Miami-Fort Lauderdale-West Palm Beach, FL	50	1.61	1.96	1.33
Miami-Fort Lauderdale-West Palm Beach, FL	46	0.95	0.47	0.93
Miami-Fort Lauderdale-West Palm Beach, FL	31	0.69	1.19	0.43
Miami-Fort Lauderdale-West Palm Beach, FL	47	1.50	0.66	1.45
Tampa-St. Petersburg-Clearwater, FL	59	0.19	0.06	0.18
Orlando-Kissimmee-Sanford, FL	29	0.28	0.13	0.25
Tampa-St. Petersburg-Clearwater, FL	59	0.25	0.18	0.19
Tampa-St. Petersburg-Clearwater, FL	57	0.34	0.18	0.31
Tampa-St. Petersburg-Clearwater, FL	17	0.34	0.19	0.29
Macon, GA	22	0.08	0.04	0.09
Savannah, GA	20	0.12	0.08	0.11
Douglas, GA	29	0.05	0.12	0.03
Atlanta-Sandy Springs-Roswell, GA	21	0.07	0.03	0.07
Atlanta-Sandy Springs-Roswell, GA	33	0.38	0.23	0.31
Atlanta-Sandy Springs-Roswell, GA	44	0.28	0.21	0.27
Atlanta-Sandy Springs-Roswell, GA	29	0.35	0.23	0.39
Atlanta-Sandy Springs-Roswell, GA	22	0.46	0.26	0.46
Atlanta-Sandy Springs-Roswell, GA	25	0.09	0.08	0.09
Atlanta-Sandy Springs-Roswell, GA	29	0.06	0.03	0.06
Atlanta-Sandy Springs-Roswell, GA	24	0.22	0.11	0.20
Chicago-Naperville-Elgin, IL-IN-WI	60	0.34	0.26	0.28
Chicago-Naperville-Elgin, IL-IN-WI	54	0.33	0.16	0.30
Chicago-Naperville-Elgin, IL-IN-WI	54	0.45	0.22	0.40
St. Louis, MO-IL	32	0.43	0.38	0.35
Louisville/Jefferson County, KY-IN	48	6.56	10.11	2.01
Chicago-Naperville-Elgin, IL-IN-WI	6,900	0.22	0.67	0.15
Chicago-Naperville-Elgin, IL-IN-WI	52	0.26	0.24	0.19
Chicago-Naperville-Elgin, IL-IN-WI	55	0.18	0.21	0.13
Chicago-Naperville-Elgin, IL-IN-WI	54	0.39	0.41	0.26
Chicago-Naperville-Elgin, IL-IN-WI	41	0.35	0.32	0.29
Chicago-Naperville-Elgin, IL-IN-WI	56	0.49	0.40	0.31

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-3. Toluene Levels in Ambient Air^a

Sampling location ^b	Number of samples	Daily arithmetic mean concentration (ppbv)	Standard deviation (ppbv)	Median (ppbv)
Indianapolis-Carmel-Anderson, IN	57	0.66	0.71	0.33
Indianapolis-Carmel-Anderson, IN	7,862	0.41	0.66	0.19
Chicago-Naperville-Elgin, IL-IN-WI	57	0.14	0.15	0.09
Evansville, IN-KY	57	0.34	0.34	0.21
Terre Haute, IN	57	0.19	0.11	0.16
Cedar Rapids, IA	30	0.29	0.20	0.22
Cedar Rapids, IA	30	0.32	0.24	0.23
Des Moines-West Des Moines, IA	30	0.28	0.19	0.21
Des Moines-West Des Moines, IA	30	0.32	0.23	0.26
Davenport-Moline-Rock Island, IA-IL	30	0.29	0.39	0.21
Davenport-Moline-Rock Island, IA-IL	30	0.29	0.24	0.24
Huntington-Ashland, WV-KY-OH	60	0.30	0.17	0.29
Carter, KY	60	0.10	0.03	0.10
Lexington-Fayette, KY	53	0.26	0.19	0.20
Paducah, KY-IL	59	0.11	0.05	0.10
Paducah, KY-IL	60	0.09	0.03	0.08
Paducah, KY-IL	29	0.10	0.05	0.09
Paducah, KY-IL	59	0.14	0.10	0.12
Baton Rouge, LA	463	0.25	0.21	0.16
Baton Rouge, LA	59	0.24	0.13	0.21
Baton Rouge, LA	1,480	0.36	0.37	0.26
Baton Rouge, LA	48	0.42	0.28	0.36
Baton Rouge, LA	473	0.11	0.07	0.10
Baton Rouge, LA	55	0.11	0.04	0.10
Baton Rouge, LA	853	0.18	0.13	0.14
Baton Rouge, LA	56	0.18	0.09	0.16
Portland-South Portland, ME	3,415	0.08	0.06	0.06
Baltimore-Columbia-Towson, MD	1,948	0.42	0.43	0.28
Baltimore-Columbia-Towson, MD	60	0.55	0.53	0.41
Baltimore-Columbia-Towson, MD	59	0.67	0.55	0.54
Baltimore-Columbia-Towson, MD	54	0.23	0.09	0.20
Washington-Arlington-Alexandria, DC-VA-MD-WV	222	0.35	0.28	0.30
Washington-Arlington-Alexandria, DC-VA-MD-WV	59	0.37	0.16	0.34
Washington-Arlington-Alexandria, DC-VA-MD-WV	59	0.28	0.15	0.26
Baltimore-Columbia-Towson, MD	53	0.31	0.21	0.26
Boston-Cambridge-Newton, MA-NH	59	0.21	0.13	0.17
Boston-Cambridge-Newton, MA-NH	15	0.21	0.12	0.24
Boston-Cambridge-Newton, MA-NH	59	0.36	0.19	0.31

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-3. Toluene Levels in Ambient Air^a

Sampling location ^b	Number of samples	Daily arithmetic mean concentration (ppbv)	Standard deviation (ppbv)	Median (ppbv)
Boston-Cambridge-Newton, MA-NH	29	0.33	0.15	0.31
Midland, MI	60	0.83	0.98	0.53
Midland, MI	59	0.48	0.65	0.29
Midland, MI	59	0.41	0.75	0.24
Midland, MI	57	0.57	0.38	0.50
Detroit-Warren-Dearborn, MI	30	0.33	0.19	0.31
Detroit-Warren-Dearborn, MI	60	0.37	0.28	0.30
Detroit-Warren-Dearborn, MI	45	0.08	0.08	0.08
Detroit-Warren-Dearborn, MI	10	0.08	0.07	0.09
Detroit-Warren-Dearborn, MI	55	0.74	0.36	0.65
Detroit-Warren-Dearborn, MI	53	1.12	0.56	0.96
Detroit-Warren-Dearborn, MI	49	0.68	0.40	0.57
St. Louis, MO-IL	60	0.35	0.25	0.27
Manchester-Nashua, NH	2,479	0.07	0.05	0.06
Manchester-Nashua, NH	15	0.09	0.02	0.09
Boston-Cambridge-Newton, MA-NH	2,579	0.12	0.09	0.10
Boston-Cambridge-Newton, MA-NH	15	0.19	0.08	0.17
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	61	1.63	1.10	1.43
New York-Newark-Jersey City, NY-NJ-PA	59	0.22	0.10	0.19
New York-Newark-Jersey City, NY-NJ-PA	563	0.18	0.18	0.11
New York-Newark-Jersey City, NY-NJ-PA	55	0.13	0.07	0.11
New York-Newark-Jersey City, NY-NJ-PA	60	0.49	0.22	0.46
Gallup, NM	13	0.15	0.11	0.12
Albany-Schenectady-Troy, NY	46	0.47	0.33	0.39
New York-Newark-Jersey City, NY-NJ-PA	56	0.40	0.22	0.31
New York-Newark-Jersey City, NY-NJ-PA	49	0.38	0.19	0.30
New York-Newark-Jersey City, NY-NJ-PA	54	0.40	0.22	0.30
New York-Newark-Jersey City, NY-NJ-PA	60	0.29	0.17	0.24
Buffalo-Cheektowaga-Niagara Falls, NY	50	0.30	0.17	0.27
Buffalo-Cheektowaga-Niagara Falls, NY	56	0.30	0.23	0.26
Buffalo-Cheektowaga-Niagara Falls, NY	55	0.32	0.23	0.27
Buffalo-Cheektowaga-Niagara Falls, NY	50	0.28	0.16	0.24
Buffalo-Cheektowaga-Niagara Falls, NY	58	0.31	0.25	0.26
Camden, NJ	56	0.08	0.15	0.04
New York-Newark-Jersey City, NY-NJ-PA	51	0.45	0.26	0.36
Rochester, NY	54	0.22	0.16	0.20
New York-Newark-Jersey City, NY-NJ-PA	57	0.37	0.21	0.33
New York-Newark-Jersey City, NY-NJ-PA	57	0.42	0.31	0.31

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-3. Toluene Levels in Ambient Air^a

Sampling location ^b	Number of samples	Daily arithmetic mean concentration (ppbv)	Standard deviation (ppbv)	Median (ppbv)
Corning, NY	30	0.08	0.06	0.06
Asheville, NC	55	0.46	0.35	0.31
Asheville, NC	15	0.60	0.42	0.49
Winston-Salem, NC	58	0.34	0.27	0.30
Winston-Salem, NC	9	0.24	0.11	0.20
Sanford, NC	57	0.14	0.08	0.13
Sanford, NC	55	0.14	0.08	0.13
Charlotte-Concord-Gastonia, NC-SC	57	0.43	0.34	0.34
Charlotte-Concord-Gastonia, NC-SC	13	0.46	0.34	0.33
Montgomery, NC	58	0.12	0.10	0.09
Montgomery, NC	9	0.08	0.02	0.09
Wilmington, NC	57	0.18	0.15	0.16
Wilmington, NC	5	0.28	0.08	0.26
Raleigh, NC	57	0.32	0.26	0.23
Cincinnati, OH-KY-IN	27	0.31	0.22	0.36
Cincinnati, OH-KY-IN	29	0.59	0.85	0.33
Cincinnati, OH-KY-IN	30	0.38	0.23	0.30
Cincinnati, OH-KY-IN	30	1.18	0.90	1.00
Cincinnati, OH-KY-IN	56	0.46	0.33	0.39
Oklahoma City, OK	59	0.24	0.11	0.22
Oklahoma City, OK	39	0.32	0.17	0.29
Oklahoma City, OK	39	0.41	0.19	0.37
Oklahoma City, OK	60	0.35	0.20	0.28
Tulsa, OK	60	0.64	0.35	0.62
Tulsa, OK	59	0.94	1.05	0.67
Tulsa, OK	60	0.53	0.30	0.47
Portland-Vancouver-Hillsboro, OR-WA	52	0.82	0.90	0.59
Portland-Vancouver-Hillsboro, OR-WA	27	0.74	0.62	0.56
Portland-Vancouver-Hillsboro, OR-WA	54	0.53	0.36	0.40
La Grande, OR	42	0.29	0.18	0.24
Portland-Vancouver-Hillsboro, OR-WA	15	0.67	0.38	0.52
Gettysburg, PA	42	0.12	0.08	0.09
Pittsburgh, PA	34	0.37	0.14	0.36
Reading, PA	26	0.24	0.14	0.24
Pittsburgh, PA	39	0.19	0.14	0.11
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	42	0.58	0.49	0.42
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	42	0.36	0.24	0.28
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	42	0.51	0.28	0.44

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-3. Toluene Levels in Ambient Air^a

Sampling location ^b	Number of samples	Daily arithmetic mean concentration (ppbv)	Standard deviation (ppbv)	Median (ppbv)
Erie, PA	38	0.16	0.11	0.14
Lancaster, PA	40	0.85	0.46	0.75
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	41	0.23	0.14	0.18
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	44	0.37	0.20	0.33
Allentown-Bethlehem-Easton, PA-NJ	41	0.32	0.15	0.31
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	679	0.26	0.18	0.22
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	20	0.38	0.24	0.33
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	59	0.43	0.29	0.36
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	13	0.30	0.35	0.21
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	32	0.33	0.22	0.27
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	59	0.21	0.18	0.17
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	45	0.32	0.20	0.31
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	59	0.52	0.44	0.40
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD	59	0.34	0.24	0.29
Springville, PA	39	4.01	3.16	4.20
Lewisburg, PA	33	0.19	0.08	0.18
Pittsburgh, PA	43	0.34	0.20	0.32
Pittsburgh, PA	39	0.20	0.10	0.18
Pittsburgh, PA	39	0.33	0.15	0.33
Scranton-Wilkes-Barre-Hazleton, PA	29	0.28	0.93	0.09
York-Hanover, PA	45	0.34	0.14	0.32
Providence-Warwick, RI-MA	58	0.08	0.04	0.07
Providence-Warwick, RI-MA	58	0.38	0.23	0.33
Providence-Warwick, RI-MA	56	0.53	0.26	0.47
Providence-Warwick, RI-MA	546	0.26	0.26	0.17
Providence-Warwick, RI-MA	59	0.27	0.16	0.23
Providence-Warwick, RI-MA	56	0.26	0.16	0.24
Dallas-Fort Worth-Arlington, TX	7,607	0.39	0.62	0.23
Dallas-Fort Worth-Arlington, TX	57	0.28	0.24	0.20
Dallas-Fort Worth-Arlington, TX	55	0.21	0.19	0.16
Odessa, TX	2,273	0.54	0.77	0.30
Dallas-Fort Worth-Arlington, TX	59	0.07	0.05	0.06
El Paso, TX	7,118	0.91	1.71	0.39
Houston-The Woodlands-Sugar Land, TX	7,551	0.59	0.95	0.30
Houston-The Woodlands-Sugar Land, TX	7,082	0.71	1.50	0.34
Houston-The Woodlands-Sugar Land, TX	7,280	0.44	0.94	0.23
Houston-The Woodlands-Sugar Land, TX	59	0.32	0.23	0.28
Houston-The Woodlands-Sugar Land, TX	55	0.30	0.22	0.28

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-3. Toluene Levels in Ambient Air^a

Sampling location ^b	Number of samples	Daily arithmetic mean concentration (ppbv)	Standard deviation (ppbv)	Median (ppbv)
Marshall, TX	57	0.12	0.05	0.12
Beaumont-Port Arthur, TX	7,662	0.35	0.51	0.21
Beaumont-Port Arthur, TX	7,494	0.27	0.38	0.17
Dallas-Fort Worth-Arlington, TX	52	0.11	0.06	0.10
Corpus Christi, TX	60	0.16	0.11	0.14
Dallas-Fort Worth-Arlington, TX	7,289	0.40	0.47	0.24
Dallas-Fort Worth-Arlington, TX	57	0.24	0.12	0.20
Dallas-Fort Worth-Arlington, TX	59	0.14	0.08	0.12
Laredo, TX	49	0.67	0.34	0.55
Ogden-Clearfield, UT	50	0.58	0.42	0.49
Ogden-Clearfield, UT	49	0.70	0.43	0.59
Burlington-South Burlington, VT	60	0.04	0.03	0.04
Burlington-South Burlington, VT	30	0.35	0.14	0.35
Burlington-South Burlington, VT	29	0.36	0.15	0.34
Rutland, VT	30	0.42	0.23	0.36
Washington-Arlington-Alexandria, DC-VA-MD-WV	57	0.16	0.10	0.13
Richmond, VA	60	0.33	0.18	0.28
Richmond, VA	60	0.25	0.17	0.21
Richmond, VA	30	0.31	0.28	0.21
Richmond, VA	59	0.21	0.18	0.14
Virginia Beach-Norfolk-Newport News, VA-NC	57	0.22	0.15	0.19
Seattle-Tacoma-Bellevue, WA	56	0.31	0.22	0.24
Beaver Dam, WI	59	0.05	0.07	0.01
Milwaukee-Waukesha-West Allis, WI	27	0.39	0.20	0.37
Milwaukee-Waukesha-West Allis, WI	55	0.29	0.13	0.26

^aData were originally reported in units of parts per billion carbon, but converted to parts per billion volume to facilitate comparison with other data.

^bState post office abbreviations used.

ppbC = parts per billion (carbon) = ppbv multiplied by the number of carbons in the analyte

Source: EPA 2016

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-4. Percentile Distribution of Annual Mean Toluene Concentrations (ppbv) Measured in Ambient Air at Locations Across the United States^a

Year	Number of U.S. locations	25th	50th	75th	95th	Maximum
2010	430	0.26	0.41	0.65	1.28	8.14
2011	399	0.23	0.36	0.55	1.14	2.55
2012	391	0.24	0.37	0.57	1.31	32.05
2013	362	0.22	0.33	0.52	1.07	4.67
2014	345	0.19	0.30	0.86	0.96	3.87
2015	291	0.22	0.34	0.51	0.95	6.56

^aData were originally reported in units of parts per billion carbon, but converted to parts per billion volume to facilitate comparison with other data.

ppbC = parts per billion (carbon) = ppbv multiplied by the number of carbons in the analyte

Source: EPA 2016

6. POTENTIAL FOR HUMAN EXPOSURE

BTEX vehicle emissions from motor exhaust and emissions from the handling, distribution and storage of petrol are a major contributor of atmospheric toluene. Toluene concentrations in India were found to range from 3.26 to 13.68 $\mu\text{g}/\text{m}^3$ (0.867–3.64 ppbv) in air samples collected from busy traffic sites (Deole et al. 2004). Toluene levels near an airport were found to be comparable to the atmospheric toluene levels of the neighborhoods near the airport; however, levels were about 70% lower for areas further from the airport. Toluene is generated from kerosene evaporation and combustion from the jet fuel in airplanes (Jung et al. 2011).

In Rome, Italy, the annual average concentrations of toluene in the air decreased from 100 $\mu\text{g}/\text{m}^3$ (26.6 ppbv) in 1997 to 10.2 $\mu\text{g}/\text{m}^3$ (2.71 ppbv) in 2008. This reduction of toluene in the air was attributed to the decrease of total aromatic hydrocarbons in gasoline, the prevalence of low emission cars, and the increase in refilling stations with closed-loop gasoline vapor systems (Ciarrocca et al. 2012). Concentrations of toluene in air from the inside of vehicles have been reported to range from 0.56 to 42.0 ppbv (2.1–157.9 $\mu\text{g}/\text{m}^3$) (Chan et al. 1991a; Lawryk and Weisel 1996; Weisel et al. 1992).

Levels of toluene can be much greater in indoor air as compared to outdoor air depending upon the presence of potential exposure sources. For example, Curry et al. (1994) measured the indoor air concentrations of toluene during normal in home use of nail lacquer products at five different residences in California. The mean toluene levels measured in air during the nail lacquer application ranged from 3,200 to 9,200 $\mu\text{g}/\text{m}^3$ (850–2,400 ppbv), while the post-application concentrations ranged from 200 to 1,700 $\mu\text{g}/\text{m}^3$ (50–450 ppbv). Toluene was not detected in any of the air samples above the detection limits of 200 $\mu\text{g}/\text{m}^3$ (50 ppbv) in air prior to the nail lacquer application.

Hamidin et al. (2013) reported that toluene concentrations in the internal garages and residential indoor air of 32 homes in Brisbane, Australia were much higher than toluene concentrations in the outdoor ambient air. The average toluene concentration in residential indoor air was 10.7 $\mu\text{g}/\text{m}^3$ (2.84 ppbv), 25.5 $\mu\text{g}/\text{m}^3$ (6.78 ppbv) in internal garages, and 2.3 $\mu\text{g}/\text{m}^3$ (0.61 ppbv) in outdoor ambient air.

Toluene levels in indoor air from 16 newspaper stands located in Bari, Italy were shown to be substantially higher than the corresponding outdoor air levels (Caselli et al. 2009). The weekly mean concentrations of toluene in indoor air and outdoor air at these 16 stands are provided in Table 6-5, along with the indoor/outdoor (I/O) ratio of these levels at each site. The authors concluded that toluene levels were much higher inside the newspaper stands than outside because of the ink used to print the newspapers (Caselli et al. 2009).

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-5. Weekly Mean Toluene Concentrations ($\mu\text{g}/\text{m}^3$) in Indoor Air at 16 Newspaper Stands and the Corresponding Outdoor Air Levels^a

Newspaper stand	Mean indoor air level ($\mu\text{g}/\text{m}^3$)	Mean outdoor air level ($\mu\text{g}/\text{m}^3$)	I/O ratio
1	1,485.6	11.6	128
2	366.6	7.6	48
3	766.9	17.8	43.1
4	644.3	8.5	76
5	455.8	11.1	41.1
6	1,170.7	11.9	88.0
7	614.7	13.3	46.2
8	444.6	16.7	26.6
9	703.6	7.8	90
10	913.9	20.5	44.6
11	935.2	16.4	57.0
12	729.8	14.4	50.7
13	585.8	10.4	56.3
14	1,055.5	14.2	74.3
15	693.3	12.9	53.7
16	858.4	8.6	100

^aThe first eight sites are enclosed environments, with sites 2, 5, and 8 possessing air conditioning systems. The final eight sites closely resemble partially enclosed kiosks.

I/O = indoor/outdoor

Source: Caselli et al. 2009

6. POTENTIAL FOR HUMAN EXPOSURE

Massolo et al. (2010) analyzed toluene levels in indoor versus outdoor air at different locations in La Plata, Argentina. The ratio of I/O toluene levels were 1.10, 1.79, 3.11, and 3.45 for industrial, urban, semi-rural, and residential locations, respectively. Both indoor and outdoor levels were highest for the industrialized locations characterized by petrochemical plants and urban locations with heavy vehicular traffic.

Indoor and in-vehicle toluene levels appear to be affected by seasonal changes (Montgomery and Kalman 1989; Weisel et al. 1992). Shields et al. (1996) compared indoor and outdoor levels of volatile organic compounds (VOCs) measured in three types of commercial buildings (telecommunication offices, data centers, and administrative offices) across the United States. The averaged I/O ratios for toluene were 1.6, 4.9, and 2.2 for telecommunication offices, data centers, and administrative offices, respectively.

Ventilation differences between the types of buildings were shown to be a major factor in differences between I/O ratios for toluene and other VOCs at these facilities. Mukerjee et al. (1997) reported the variation of toluene levels in indoor and outdoor air by season of the year in the Lower Rio Grande Valley. Median indoor air levels were $4.80 \mu\text{g}/\text{m}^3$ (1.28 ppbv) and median outdoor levels were $3.10 \mu\text{g}/\text{m}^3$ (0.824 ppbv) during the spring months. The median levels were reported as $7.70 \mu\text{g}/\text{m}^3$ (2.05 ppbv) for indoor air and $1.15 \mu\text{g}/\text{m}^3$ (0.306 ppbv) for outdoor air during the summer months.

In several studies, indoor (home or office) toluene concentrations ranged from 0.7 to 24.2 ppbv (3–91.0 $\mu\text{g}/\text{m}^3$) due mostly to infiltration from auto emissions (Chan et al. 1991b; Hodgson et al. 1991; Kelly et al. 1993; Michael et al. 1990; Shields and Weschler 1992). Toluene was among the volatile organic compounds detected in the emissions from sponge rubber carpet cushions (Schaeffer et al. 1996). Indoor toluene can also originate from household products (paints, thinners, glues, etc.) and smoking. The indoor toluene concentrations in a household with smoking residents were found to be greater than those in a nonsmoking household (Montgomery and Kalman 1989).

Volatilization from contaminated tap water is another source of indoor toluene. Efficiencies of toluene volatilization have been estimated for sources such as the kitchen sink (13–26%), residential washing machines (24–99%), residential dishwashers (96–98%), and household showers (61–77%) (Howard and Corsi 1996, 1998; Howard-Reed et al. 1999; Moya et al. 1999). Toluene was found to be emitted at a rate of 40,000 ppb during the charbroiling of hamburger meat over a natural gas fired grill (Schauer et al. 1999).

6. POTENTIAL FOR HUMAN EXPOSURE

Very high concentrations of toluene (53.2–38,038 ppbv or 2.00×10^2 – 143×10^5 $\mu\text{g}/\text{m}^3$) were detected in gas from municipal landfills in Finland (Assmuth and Kalevi 1992). Toluene can enter nearby homes by diffusion and pressure-driven transport from soil (Hodgson et al. 1988).

6.4.2 Water

Toluene was one of the most frequently detected volatile organic compounds in a comprehensive survey conducted by the United States Geological Survey (USGS) from 1985 to 2001 of private and public groundwater wells used for drinking water (USGS 2006). Toluene was detected in about 10% of 1,676 aquifer samples analyzed at an assessment level of 0.02 ppb. It was detected in about 2% of 3,457 samples analyzed at an assessment level of 0.2 ppb (Carter et al. 2008; USGS 2006). The median concentration of toluene was 0.032 ppb for all of the samples having positive detections. Toluene was detected in less than 20% of the samples of groundwater taken from alluvial aquifers beneath Denver, Colorado, a major urban center, at a maximum concentration of 1 ppb (Bruce and McMahon 1996).

Toluene was detected in 10 out of 931 samples collected from May 1999 to October 2000 in the USGS National Survey of volatile organic compound contaminants of groundwater and surface water sources used for drinking water supplies (USGS 2003). It was more often detected in surface water sources (1.9% detection frequency) as compared to groundwater sources (0.53% detection frequency) and reservoirs (1.0% detection frequency) at the minimum reporting level of 0.2 ppb.

In addition to the groundwater in the United States, toluene was also found in the groundwater near the Tehran Automobile Industry waste water treatment plant. Toluene was detected with trichloroethylene, tetrachloroethylene, and other volatile organic compounds. The concentration of toluene in the groundwater was not provided (Dobaradaran et al. 2010). Toluene was detected at concentrations of 6,400 and 6,900 ppb in two groundwater sampling wells at a hazardous waste site (Armstrong et al. 1991).

The USGS sampled storm water runoff from 16 cities and metropolitan areas from 11 different states during the period of 1991–1995 (USGS 2000). Toluene and total xylenes were the most frequently detected compounds in the collected samples. Toluene was identified in 137 out of 592 samples at levels ranging from 0.2 to 6.6 ppb.

6. POTENTIAL FOR HUMAN EXPOSURE

6.4.3 Sediment and Soil

No studies were located regarding levels of toluene in typical urban, suburban, or rural soils. Toluene has been occasionally detected in sediments of surface waters at concentrations averaging 5 ppb (Staples et al. 1985). Toluene was detected in the sediment of lower Passaic River, New Jersey, in the vicinity of combined sewer overflow outfalls (Iannuzzi et al. 1997). The concentrations ranged from 4.0 to 250 ppb. In the absence of continuous releases from a waste site, it is expected that toluene would not persist for long periods in soil, due to its volatility, susceptibility to biodegradation, and water solubility.

6.4.4 Other Environmental Media

The concentration of toluene in commercial foodstuffs has not been thoroughly studied. Although the data are limited, toluene is not likely to be found in food (CEPA 1999). Toluene was detected in eggs stored in polystyrene containers that contained toluene (Matiella and Hsieh 1991). Cigarette smoke releases toluene. Grob (1965) estimated that about 80 µg of toluene is released per cigarette. Toluene was detected in a variety of household items including automotive products, household cleaners/polishes, paint-related products, fabric and leather treatments, lubricants and adhesives (Sack et al. 1992). The levels of toluene in these products varied from 1.8 to 23.3% by weight.

6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE

Available data indicate that for the general population, inhalation of toluene is likely to be the main route of exposure. Likewise, the main source of toluene is from vehicle exhaust, although the use of paints, varnishes, lacquers, shoe polishes, and cigarette smoke can contribute to levels indoors and personal exposures (Alexopoulos et al. 2006). The geometric mean and selected percentiles of toluene in whole-blood concentrations (in ng/mL) for the U.S. population from the National Health and Nutrition Examination Survey (NHANES) for 2001–2002, 2003–2004, and 2005–2006 are provided in Table 6-6 (CDC 2013). In addition, toluene was found in 91% of adipose tissue samples from the National Human Adipose Tissue survey. The maximum concentration of toluene in the samples was 250 ppb (HSDB 2010).

The total daily exposure of office workers to volatile organic compounds, including toluene, was analyzed in a study conducted in Milan, Italy. Personal pollutant exposure levels of workers to toluene were 30.9 µg/m³ (8.22 ppbv) from the home, 32.5 µg/m³ (8.64 ppbv) from the office, and 43.6 µg/m³ (11.6 ppbv) from commuting. It was found that the levels of toluene in the workers in the summer (21.5–

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-6. Geometric Mean and Selected Percentiles of Blood Toluene in Whole Blood Concentrations (in mg/L) for the U.S. Population from NHANES

	Survey	Geometric mean (95% CI)	50 th percentile	75 th percentile	90 th percentile	95 th percentile	Sample size
Total	2001–2002	0.156 (0.122–0.198)	0.160 (0.120–0.220)	0.340 (0.260–0.430)	0.670 (0.480–0.950)	10.06 (0.700–10.43)	954
	2003–2004	0.114 (0.100–0.129)	0.096 (0.087–0.110)	0.220 (0.180–0.260)	0.430 (0.380–0.550)	0.680 (0.560–0.880)	1,336
	2005–2006	0.137 (0.123–0.152)	0.120 (0.110–0.130)	0.230 (0.200–0.262)	0.550 (0.481–0.640)	0.814 (0.702–0.937)	3,050
12–19 Years age	2005–2006	0.110 (0.098–0.122)	0.100 (0.094–0.120)	0.170 (0.150–0.180)	0.280 (0.240–0.310)	0.400 (0.300–0.610)	907
20–59 Years age	2001–2002	0.156 (0.122–0.198)	0.160 (0.120–0.220)	0.340 (0.260–0.430)	0.670 (0.480–0.950)	10.06 (0.700–10.43)	954
20–59 Years age	2003–2004	0.114 (0.100–0.129)	0.096 (0.087–0.110)	0.220 (0.180–0.260)	0.430 (0.380–0.550)	0.680 (0.560–0.880)	1,336
20–59 Years age	2005–2006	0.147 (0.133–0.163)	0.120 (0.110–0.137)	0.260 (0.210–0.340)	0.594 (0.505–0.720)	0.900 (0.730–10.10)	1,505
≥60 Years age	2005–2006	0.124 (0.100–0.154)	0.114 (0.097–0.138)	0.190 (0.167–0.230)	0.520 (0.370–0.600)	0.720 (0.600–0.814)	638
Males	2001–2002	0.165 (0.130–0.209)	0.170 (0.120–0.230)	0.360 (0.260–0.520)	0.780 (0.580–10.06)	10.22 (0.850–10.43)	450
Males	2003–2004	0.128 (0.112–0.148)	0.110 (0.096–0.130)	0.250 (0.190–0.310)	0.500 (0.380–0.660)	0.730 (0.590–10.10)	647
Males	2005–2006	0.152 (0.139–0.166)	0.130 (0.120–0.140)	0.280 (0.240–0.330)	0.640 (0.550–0.720)	0.920 (0.790–10.10)	1,441
Females	2001–2002	0.147 (0.114–0.190)	0.150 (0.110–0.220)	0.320 (0.240–0.390)	0.550 (0.400–0.740)	0.810 (0.530–10.63)	504
Females	2003–2004	0.101 (0.086–0.118)	0.085 (0.070–0.100)	0.190 (0.150–0.230)	0.410 (0.340–0.500)	0.580 (0.480–0.750)	689
Females	2005–2006	0.124 (0.107–0.144)	0.110 (0.097–0.130)	0.190 (0.170–0.230)	0.470 (0.380–0.550)	0.690 (0.550–0.880)	1,609
Mexican/American	2001–2002	0.136 (0.106–0.176)	0.140 (0.080–0.210)	0.270 (0.210–0.340)	0.550 (0.400–0.980)	0.990 (0.500–10.30)	219
Mexican/American	2003–2004	0.084 (0.074–0.096)	0.076 (0.064–0.091)	0.120 (0.100–0.170)	0.280 (0.170–0.410)	0.400 (0.310–0.620)	253
Mexican/American	2005–2006	0.110 (0.097–0.125)	0.110 (0.096–0.120)	0.160 (0.140–0.170)	0.240 (0.220–0.290)	0.340 (0.290–0.460)	737
Non-Hispanic blacks	2001–2002	0.137 (0.089–0.210)	0.150 (0.070–0.200)	0.310 (0.200–0.460)	0.690 (0.390–10.19)	10.15 (0.660–10.69)	194
Non-Hispanic blacks	2003–2004	0.105 (0.077–0.144)	0.095 (0.070–0.130)	0.200 (0.130–0.330)	0.440 (0.290–0.620)	0.620 (0.480–0.710)	297
Non-Hispanic blacks	2005–2006	0.139 (0.120–0.161)	0.120 (0.099–0.140)	0.230 (0.190–0.290)	0.450 (0.370–0.550)	0.670 (0.550–0.830)	796
Non-Hispanic whites	2001–2002	0.165 (0.125–0.217)	0.170 (0.120–0.240)	0.350 (0.270–0.450)	0.710 (0.450–10.12)	10.14 (0.710–10.63)	467

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-6. Geometric Mean and Selected Percentiles of Blood Toluene in Whole Blood Concentrations (in mg/L) for the U.S. Population from NHANES

	Survey	Geometric mean (95% CI)	50 th percentile	75 th percentile	90 th percentile	95 th percentile	Sample size
Non-Hispanic whites	2003–2004	0.123 (0.110–0.139)	0.100 (0.092–0.120)	0.240 (0.210–0.280)	0.500 (0.400–0.590)	0.750 (0.590–0.940)	685
Non-Hispanic whites	2005–2006	0.144 (0.125–0.166)	0.130 (0.110–0.140)	0.260 (0.210–0.330)	0.600 (0.510–0.710)	0.880 (0.760–0.990)	1,291

CI = confidence interval; NHANES = National Health and Nutrition Examination Survey

Source: CDC 2009

6. POTENTIAL FOR HUMAN EXPOSURE

34.3 $\mu\text{g}/\text{m}^3$; 5.72–9.12 ppbv) were lower than levels of toluene in the winter (37.6–53.7 $\mu\text{g}/\text{m}^3$; 10.0–14.3 ppbv). Toluene levels in nonsmokers, as compared to smokers, were about the same. In addition, personal exposure levels to toluene were much higher from cars (145.7 $\mu\text{g}/\text{m}^3$; 38.8 ppbv) than subways (39.3 $\mu\text{g}/\text{m}^3$; 10.4) and buses (44.1 $\mu\text{g}/\text{m}^3$; 11.7 ppbv) (Carrer et al. 2000). In a similar study, the personal exposures of traffic police officers in Milan, Italy to toluene were found to be 42.5 $\mu\text{g}/\text{m}^3$ (11.3 ppbv). Mean toluene and BTEX levels were higher in the afternoon shifts (Cattaneo et al. 2010).

Personal exposure was the highest when a vehicle was used as the main source of transportation, when a vehicle was used in work, when the participants had a roommate who smoked, in cities, near gas stations, and near busy roads. Levels were 71.6 $\mu\text{g}/\text{m}^3$ (19.0 ppbv), 72.5 $\mu\text{g}/\text{m}^3$ (19.3 ppbv), 64.0 $\mu\text{g}/\text{m}^3$ (17.0 ppbv), 64.0 $\mu\text{g}/\text{m}^3$ (17.0 ppbv), 91.9 $\mu\text{g}/\text{m}^3$ (24.4 ppbv), and 65.5 $\mu\text{g}/\text{m}^3$ (17.4 ppbv), respectively (Alexopoulos et al. 2006). Other transportation-related toluene exposure pathways include inhalation of volatile organic compounds from contaminated air in aircraft cabins (2–135 ppbv for toluene) (Dechow et al. 1997) and breathing air in long road tunnels (97–167.6 ppbv) (Barrefors 1996).

In an industry-sponsored study, personal inhalation exposures to toluene during the application of nail lacquers in residences ranged from approximately 1,030 to 2,820 $\mu\text{g}/\text{person}/\text{day}$ (Curry et al. 1994). The mean toluene levels measured in the breathing zone during the nail lacquer application ranged from 3,200 to 9,200 $\mu\text{g}/\text{m}^3$ (850–2,400 ppbv), while the post-application concentrations ranged from below the detection limits of 200 $\mu\text{g}/\text{m}^3$ to 1,700 $\mu\text{g}/\text{m}^3$ (50–450 ppbv). Toluene concentrations were monitored 1 hour before application; no toluene was detected in air prior to the nail lacquer application. During application, sampling started with the first application and ended when the nails were dry. Post-application sampling started 1 hour after the nails were dry for the post-application sample group I, and 2 hours after the nails were dry for the post-application sample group II.

In an occupational study, workers from gasoline service stations had a geometric mean personal exposure level of 153.1 ppbv (576 $\mu\text{g}/\text{m}^3$), and the geometric mean concentration in the workplace air was reported as 99.3 ppbv (373 $\mu\text{g}/\text{m}^3$). Toluene exposure may also occur in printing industry where toluene is used as a solvent for inks and dyes. Occupational exposure may also occur during paint stripping operations (Vincent et al. 1994), coke plant operations (Bieniek et al. 2004), and commercial painting (Burstyn and Kromout 2002). Assuming that a worker inhales 10 m^3 of air while on the job, and that 50% of the inhaled toluene is absorbed, a workplace concentration of 53.2 ppmv would correspond to an exposure level of 1,000 mg/day. The toluene burden of rotogravure (printing process) workers measured with

6. POTENTIAL FOR HUMAN EXPOSURE

personal monitoring tubes was found to be higher, ranging from 56 to 451 mg/m³ (15–120 ppmv) than air concentrations monitored during the workday (Hammer et al. 1998).

Exposure could be higher near heavily traveled roadways or point sources of toluene, and could also be increased by frequent use of home products containing toluene. Runners who exercise near highways may be exposed to higher levels of BTEX. Concentrations of toluene in the blood were significantly increased post-exercise in a running study near a roadway. The runners ran for 20 minutes. The mean blood concentrations were 1.4 ng/mL (1.4 ppb) pre-exercise and 2.8 ng/mL (2.8 ppb) post-exercise with a mean increase of 1.4 ng/mL (1.4 ppb). The concentration of toluene in the air was measured as 52 µg/m³ (13.8 ppbv) at the start of the route, 60 µg/m³ (16 ppbv) at the middle of the route, and 52 µg/m³ (13.8 ppbv) at the distant end of the route (Blair et al. 2010). An Alaskan study compared the concentration of toluene in blood before and after pumping of regular and oxygenated gasoline in February (Backer et al. 1997). The median concentration of toluene in blood before pumping gasoline was found to be 0.38 ppb (ng/mL). A greater increase was detected in the blood concentration of toluene after pumping oxygenated gasoline (0.85 ppb) than after pumping regular gasoline (0.74 ppb). In another study, the blood of rotogravure workers was tested before and after the use of toluene to clean containers for the primary printing colors. The concentration of toluene in their blood was found to increase from 0.87 to 4.9 mg/L (Muttaray et al. 1999). The average levels of toluene measured in personal air samples of these workers ranged from 1,115 to 1,358 mg/m³ (296–361 ppmv).

Toluene concentrations in the blood after rotogravure industry workers shifts were measured in a study conducted by Neubert et al. (2001). Concentrations were the highest from printing and assistance (266.3 µg/L or 266.3 ppb), followed by preparation of printing forms (67.7 µg/L or 67.7 ppb), processing of printed materials (67.7 µg/L for men, 53.2 µg/L for women or 67.7 ppb, 53.2 ppb), and other areas (78.1 µg/L or 78.1 ppb for men, 28.0 µg/L or 28.0 ppb for women).

Cigarette smoking may also significantly increase exposure. In a NHANES 2003–2004 study, levels of toluene among daily smokers were higher than levels of toluene among smokers who smoked less than daily. The levels were 0.327 ng/mL (0.3227 ppb) for daily smokers and 0.082 ng/mL (0.082 ppb) for nondaily smokers (Chambers et al. 2011). Assuming inhalation of about 80–100 µg of toluene per cigarette and 50% absorption (EPA 1983b; Grob 1965), smoking one pack per day would contribute an absorbed dose of about 1,000 µg/day.

6. POTENTIAL FOR HUMAN EXPOSURE

Toluene is a volatile component of wood smoke. Emission rates of toluene during wood combustion in home heating units have been reported in the range of 0.15–1 g/kg of wood (Larson and Koenig 1994). Exposure to toluene can also occur from the combustion of solid biomass fuels. The fuels are used as a source of domestic energy in developing countries for cooking, etc. Toluene concentrations were much higher from dung ($1.4 \mu\text{g}/\text{m}^3$ or 0.37 ppbv) than from mixed fuel ($0.5 \mu\text{g}/\text{m}^3$ or 0.1 ppbv) (Sinha et al. 2006).

Based on average values of toluene in water, exposure by ingestion of contaminated drinking water is likely to be relatively small compared to inhalation. In a survey of bottled drinking water sold in Canada, only 20 (or 11%) of 182 samples analyzed contained measurable amounts of toluene, with an average concentration of 6.92 ppb and a range of 0.5–63 ppb (Page et al. 1993). Toluene is also known to volatilize from various household sources of water such as the kitchen sink, dishwashers, washing machines, and showers; thus, its presence in tap water may ultimately result in inhalation exposure (Howard and Corsi 1996, 1998; Howard-Reed et al. 1999; Moya et al. 1999).

Exposure to gasoline (which contains toluene) has been estimated for a household using gasoline-contaminated water (Beavers et al. 1996). In this house, $694 \mu\text{g}/\text{L}$ of toluene was found in the water, which resulted in a level of 664 ppbv in shower air, and 14.9 ppbv in non-shower air. The total daily dose for the exposed subject in this household was estimated as 2,273 μg . Approximately 61% of the dose was due to ingestion and 39% resulted from inhalation from showering and non-showering activities. Personnel working with various types of fuel may be at a risk of toluene exposure. A Finnish study determined the mean exposure of gasoline tanker drivers to toluene during loading and delivery to be $0.63\text{--}1.9 \text{ mg}/\text{m}^3$ (2.4–7.1 ppmv) (Saarinen et al. 1998). The exposure level of aircraft maintenance personnel to toluene in raw JP-8 jet fuel vapor was found to be 6.1 ± 1.5 ppmv ($6,100 \pm 1,560$ ppbv) (Smith et al. 1997).

A number of studies have indicated significant accumulations of toluene in products for human consumption. For example, escaping gasoline vapors from internal combustion engines used or stored near olives during the growing, harvesting, storage, and processing steps in the production of virgin olive oil can cause significant contamination of the product with toluene and other hydrocarbons (Biedermann et al. 1996). Significant concentrations of toluene have also been measured in 8 of 10 species of fruit tested in a European study, which showed higher concentrations of toluene in the peel than in the pulp of the fruit (Górna-Binkul et al. 1996). Dermal absorption of toluene is not a significant route of exposure. Uptake of toluene via skin has been estimated to contribute 1–2% of the body burden received following

6. POTENTIAL FOR HUMAN EXPOSURE

whole body (including inhalation) exposure (Brooke et al. 1998). Combinations of solvents, however, can enhance the dermal penetration of toluene. Methanol enhances the skin absorption of toluene. Special precautions need to be taken against the skin absorption of toluene when handling paint thinners that contain methanol (Tsuruta 1996).

Although toluene has been found to be a common contaminant at hazardous waste sites, it is not possible to estimate human exposure levels that might occur near waste sites without detailed site-specific information on concentration values in air, water, and soil, and on human intake of these media. Pathways that might be of significance include inhalation of toluene vapors, ingestion of toluene-contaminated water (surface water and/or groundwater), volatilization and inhalation from contaminated water, and dermal contact with toluene-contaminated soil.

6.6 EXPOSURES OF CHILDREN

This section focuses on exposures from conception to maturity at 18 years in humans. Differences from adults in susceptibility to hazardous substances are discussed in Section 3.7, Children's Susceptibility.

Children are not small adults. A child's exposure may differ from an adult's exposure in many ways. Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a larger skin surface in proportion to their body volume than adults. A child's diet often differs from that of adults. The developing human's source of nutrition changes with age: from placental nourishment to breast milk or formula to the diet of older children who eat more of certain types of foods than adults. A child's behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths, sometimes eat inappropriate things (such as dirt or paint chips), and may spend more time outdoors. Children also are generally closer to the ground and have not yet developed the adult capacity to judge and take actions to avoid hazards (NRC 1993).

Exposures of the embryo or fetus to volatile organic compounds such as toluene may occur if the expectant mother is exposed to high levels that overwhelm maternal protective mechanisms including metabolic detoxification and disposition of toluene and possible preferential distribution of toluene to maternal adipose tissues (see Chapter 2 and Section 3.3). A newborn infant may be exposed by breathing contaminated air and through ingestion of mother's milk that can contain small amounts of toluene. Children may be exposed through accidental ingestion of products containing toluene. Older children and adolescents may be exposed to toluene in their jobs or hobbies, or through deliberate inhalational solvent

6. POTENTIAL FOR HUMAN EXPOSURE

abuse using behaviors that may include “sniffing”, “bagging”, and/or “huffing” (NIDA 2012; Young 1987). Contact adhesives often contain toluene, heptane, and methyl ethyl ketone. Although toluene is more toxic than the other ingredients, it evaporates more slowly. Thus, the vapors inhaled when “sniffing” such adhesives will contain less toluene and should be less toxic than would be expected from its liquid composition (Midford et al. 1993).

Human epidemiological studies and case reports discussing reproductive and/or developmental toxicity of toluene in humans have been reviewed. Occupational exposures can occur when workers inhale materials containing toluene such as paints, paint reducers, and paint thinners (Donald et al. 1991b). Inhalant abuse during pregnancy poses significant risks to the pregnancy and endangers both the mother and the fetus. Solvent abuse of toluene for euphoric effects results in exposure levels that equal or exceed those producing adverse effects in animals.

Toluene was detected in breast milk samples obtained from three mothers residing in the Baltimore, Maryland area at a median concentration of 0.46 ng/L (Kim et al. 2007). Transfer of toluene to nursing infants from breast milk is a possible source of toluene exposure; however, since most toluene is rapidly eliminated from the body (see Sections 3.4.4 and 3.7), this exposure route is expected to be low. Kim et al. (2007) used indoor air concentrations of toluene and other volatile organic compounds (VOCs) to estimate the relative exposure dose of these VOCs from inhalation of indoor air as compared to milk ingestion. Infant exposure from inhalation of air was estimated as 4,550 ng/kg body weight/day, which was 55 times greater than the estimated dose from milk ingestion (89 ng/kg body weight/day). A PBPK model has been developed to estimate the amount of chemical that an infant ingests for a given nursing schedule and daily maternal occupational exposure to 50 ppm toluene for 8 hours (Fisher et al. 1997). This PBPK model predicted an ingestion rate of 0.460 mg/day for such an infant.

Young children often play close to the ground and frequently play in dirt, which increases their dermal exposure to toxicants in dust and soil. They also tend to ingest soil and dusts, either intentionally through pica or unintentionally through hand-to-mouth activity. Children may be orally and dermally exposed to toluene present as a contaminant in soil and dust, but toluene is not expected to persist for long periods in soil (in the absence of continuous release) due to its volatility, susceptibility to bacterial degradation, and water solubility. It has been demonstrated that the toluene adsorbed on soil is absorbed by the body (Turkall et al. 1991). Toluene in both aqueous solution and vapor phase has also been shown to be absorbed through the human skin, albeit slowly (Brooke et al. 1998; Dutkiewicz and Tyras 1968; Tsuruta 1989). Toluene has a K_{oc} range of 37–178, indicating high mobility in soil (HSDB 2010; Wilson et al.

6. POTENTIAL FOR HUMAN EXPOSURE

1981). Most of the toluene present in the upper layers of the soil is volatilized to air within 24 hours (vapor pressure of 28.4 mmHg at 25°C) (Balfour et al. 1984; HSDB 2010; Thibodeaux and Hwang 1982). Loss of toluene from the soil decreases the potential of dermal and oral exposure to children, but its rapid volatilization results in inhalation being the most likely route of exposure.

Children breathe in more air per kilogram of body weight than an adult. Therefore, a child in the same micro-environment as an adult may be exposed to more toluene from ambient air. Young children are closer to the ground or floor because of their height, developmental stage (crawling, etc.), and/or play behavior. The toluene vapors being heavier than air (vapor density=3.1 g/mL) tend to concentrate near the ground. The children, therefore, may be at greater risk of exposure than adults during accidental spills of toluene.

Children may also be exposed to toluene vapors and other hydrocarbons by working with or playing near sources of gasoline. Children's exposure also occurs through accidental ingestion and inspiration of the chemicals into the lungs. Most accident victims are 1- and 2-year-old children and are about evenly divided between males and females. Most incidents occur in the children's homes when products are in their normal storage areas. Child-resistant packaging is recommended (Journal of Environmental Health 1997). Children are also exposed to higher concentrations of toluene in central urban areas with high traffic density, where children's blood toluene concentrations are, on average, 56% higher than those of children living in rural areas (Jermann et al. 1989; Raaschou-Nielsen et al. 1997).

Children are also exposed through hobbies and art activities involving glues, adhesives, and paints (McCann 1992). Abuse of toluene-containing products among young people by intentional inhalation (e.g., "sniffing", "huffing", etc.) is a social and clinical concern (NIDA 2012; Young 1987). Inhalation exposure via "vaping" of e-cigarettes is also possible, and ongoing research may clarify the extent to which toluene exposure may occur by this route (CDC 2015; Chatam-Stephens et al. 2014)

6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES

In addition to individuals who are occupationally exposed to toluene (see Section 6.5), there are several groups within the general population that have potentially high exposures (higher than background levels) to toluene. These populations include individuals living in proximity to sites where toluene was produced or sites where toluene was disposed, and individuals living near one of the 1,012 NPL hazardous waste sites where toluene has been detected in some environmental media (HazDat 2007).

6. POTENTIAL FOR HUMAN EXPOSURE

The population most likely to experience high levels of exposure to toluene includes workers in the printing industry or other industries employing toluene as a solvent. In addition, workers exposed to gasoline vapors are also likely to have higher than average exposure to toluene. Individuals may also be exposed to high levels at home in association with the use of toluene-containing consumer products. Smokers have a considerably higher exposure to toluene than nonsmokers.

Toluene has been frequently identified as a water contaminant in the proximity of hazardous waste sites. Drinking water sources for populations living near a hazardous waste site containing toluene should be evaluated for toluene. If groundwater wells are contaminated, exposure to toluene can occur when the well-water is used for showering, cleaning, cooking, and drinking. Exposure can also occur through contact with contaminated soil.

A troublesome route of exposure to toluene is through deliberate inhalation of fumes from paint thinners, gasoline, glues contact adhesives, and aromatic solvents containing toluene. Inhalant abuse can affect pregnancy outcome (Jones and Balster 1998). Inhalant abuse continues to be a health care problem among young people (NIDA 2012; Young 1987). Toluene abuse can affect driving (Capron and Logan 2009) and inhibit gap junction currents in human embryonic kidney cells (Del Re and Woodward 2005).

6.8 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of toluene is available. Where adequate information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of toluene.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

6. POTENTIAL FOR HUMAN EXPOSURE

6.8.1 Identification of Data Needs

Physical and Chemical Properties. The physical and chemical properties of toluene that are needed to evaluate its behavior in the environment are available (Table 4-2). It does not appear that further research in this area is necessary.

Production, Import/Export, Use, Release, and Disposal. According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit substance release and off-site transfer information to the EPA. The TRI, which contains this information for 2015, became available in 2016. This database is updated yearly and should provide a list of industrial production facilities and emissions.

The available production data of toluene are up to date; however, it is essential that these data be updated regularly to allow a more accurate determination of the potential for human exposure.

Environmental Fate. Existing information indicates that volatilization, followed by reaction with hydroxyl radicals in air, is the principal fate process for toluene in the environment (Davis et al. 1979; EC 2003; Hoshino et al. 1978; Howard et al. 1991; Kenley et al. 1973). Although toluene is not a common contaminant in water, it has been found to occur in both groundwater and surface water near waste sites (HazDat 2007). Additional studies on the rate of volatilization, degradation, and transport of toluene in groundwater, surface water, and soils would be useful for assessing potential human exposure near hazardous waste sites.

Bioavailability from Environmental Media. On the basis of the available data, toluene appears to be bioavailable when it is released to the environment. Inhalation, oral, and dermal absorption occur due to toluene solubility in the lipid matrix of the cell membrane (Alcorn et al. 1991). Absorption is rapid and virtually complete at low exposure concentrations when exposures are oral or respiratory (Alcorn et al. 1991; Carlsson and Ljungqvist 1982; Hjelm et al. 1988). Absorption also occurs through contact with the skin (Dutkiewicz and Tyras 1968). Additional research on bioavailability of toluene from the environment does not appear to be needed.

Food Chain Bioaccumulation. The bioconcentration factor for toluene is relatively low due to its rapid metabolism to more polar molecules with a lower affinity for lipids, and it has little tendency to

6. POTENTIAL FOR HUMAN EXPOSURE

bind to biomolecules (EC 2003; Franke et al. 1994). Bioaccumulation in the food chain is expected to be low. No data needs are identified.

Exposure Levels in Environmental Media. Reliable monitoring data for the levels of toluene in contaminated media at hazardous waste sites are needed so that the information obtained on levels of toluene in the environment can be used in combination with the known body burden of toluene to assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.

Further studies on toluene levels in food and soil would be useful, since quantitative data for these media are limited. The potential exists for toluene to be present in human and bovine milk. In view of the observation that the highest levels of toluene likely to be encountered by an average citizen occur in the home, studies that identify the sources of toluene in indoor air would be valuable in reducing or eliminating this pathway of exposure.

Exposure Levels in Humans. Exposure of the general population to toluene in air has been monitored for a variety of scenarios (Baltrenas et al. 2011; Bratveit et al. 2004; Ciarrocca et al. 2012; Deole et al. 2004; EPA 2016; Hamidin et al. 2013; Iovino et al. 2009; Massolo et al. 2010). Amounts of toluene volatilizing from the household sources such as the kitchen sink, dishwashers, washing machines, and showers have also been estimated (Howard and Corsi 1996, 1998; Howard-Reed et al. 1999; Moya 1999). Combining these data with appropriate toxicokinetic models of toluene absorption, distribution, and excretion in humans would allow for improved estimates of exposure levels in humans. Likewise, more recent data on the ingestion of contaminated drinking water may be useful.

Toluene exposure levels in the workplace is well documented (Bieniek et al. 2004; Burstyn and Kromout 2002; Chen et al. 2002; Guldberg 1992; Hammer et al. 1998; Hiipakka and Samimi 1987; McCann 1992; McDiarmid et al. 1991; Muijsers et al. 1996; Muttray et al. 1999; NCI 1985; Neubert et al. 2001; Paulson and Kilens 1996; Smith et al. 1997; Tan and Seow 1997; Vincent et al. 1994). Continued monitoring will help to minimize exposure of workers.

This information is necessary for assessing the need to conduct health studies on these populations.

Exposures of Children. Children may be at a greater risk of inhalation exposure to toluene as they breathe in more air per kilogram of body weight than an adult. They also spend more time closer to

6. POTENTIAL FOR HUMAN EXPOSURE

ground because of their height, developmental stage, and play behaviors. Toluene vapors, being heavier than air, tend to concentrate closer to the ground, thereby increasing the risk of exposure for children.

Means of protecting young children from ingestion of home products containing toluene need study and action. Child-proof containers and clearer warnings to parents should be considered to avoid unwanted exposure. Studies of other possible sources and routes of exposure to toluene, such as e-cigarettes, may help to better characterize exposures of children, as well as adults.

Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data Needs: Children's Susceptibility.

Exposure Registries. The information amassed in the National Exposure Registry facilitates the epidemiological research needed to assess adverse health outcomes that may be related to exposure to this substance; however, no exposure registries for toluene were located. Toluene is not currently one of the compounds for which a sub-registry has been established in the National Exposure Registry. Toluene will be considered in the future when chemical selection is made for sub-registries to be established.

6.8.2 Ongoing Studies

As part of the Fourth National Health and Nutrition Evaluation Survey (NHANES IV), the Environmental Health Laboratory Sciences Division of the National Center for Environmental Health, Centers for Disease Control and Prevention, will be analyzing human blood samples for toluene and other volatile organic compounds. These data will give an indication of the frequency of occurrence and background levels of these compounds in the general population.

6. POTENTIAL FOR HUMAN EXPOSURE

This page is intentionally blank.

7. ANALYTICAL METHODS

The purpose of this chapter is to describe the analytical methods that are available for detecting, measuring, and/or monitoring toluene, its metabolites, and other biomarkers of exposure and effect to toluene. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is to identify well-established methods that are used as the standard methods of analysis. Many of the analytical methods used for environmental samples are the methods approved by federal agencies and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other methods presented in this chapter are those that are approved by groups such as the Association of Official Analytical Chemists (AOAC) and the American Public Health Association (APHA). Additionally, analytical methods are included that modify previously used methods to obtain lower detection limits and/or to improve accuracy and precision.

7.1 BIOLOGICAL MATERIALS

Toluene can be determined in biological fluids and tissues and exhaled breath using a variety of analytical methods. Representative methods are summarized in Table 7-1. Most analytical methods for biological fluids use headspace gas chromatographic (GC) techniques. Breath samples are usually collected on adsorbent traps or in sampling bags or canisters, and then analyzed by GC.

Because of its volatility, toluene is lost from biological samples, such as plant and animal tissue and body fluids, relatively easily. Therefore, samples must be collected and stored with care (e.g., at low temperatures in sealed containers) to prevent analyte loss. While blood sample collection is more invasive than breath or urine samples, maintaining the integrity of blood in the collection, transportation, and storage of the samples is easier. Blood is relatively nonpolar, which results in less diffusion loss (Chambers et al. 2006).

Headspace techniques are usually used to separate toluene from biological fluids such as blood and urine. The headspace method involves equilibrium of volatile analytes such as toluene between a liquid and solid sample phase and the gaseous phase. The gaseous phase is then analyzed by GC. There are two main types of headspace methodology: static (equilibrium) headspace and dynamic headspace which is usually called the "purge and trap" method (Seto 1994). The static headspace technique is relatively simple, but may be less sensitive than the purge-and-trap method. The purge-and-trap method, while providing increased sensitivity, requires more complex instrumentation and may result in artifact formation (Seto 1994). Packed columns and capillary columns are used for chromatographic separation,

7. ANALYTICAL METHODS

Table 7-1. Analytical Methods for Determining Toluene in Biological Materials

Sample matrix	Preparation method	Analytical method	Sample detection limit	Percent recovery	Reference
Blood	Lyse; extraction with carbon disulfide	GC/FID	No data	No data	Benignus et al. 1981
Blood	Purge and trap	No data	7.5 µg/L	No data	Cocheo et al. 1982
Whole blood	Purge and trap	GC/MS	0.088 µg/L	91–147	Ashley et al. 1992
Blood	Purge and trap	capillary GC/FID	50 ng/L	50	Fustinoni 1996
Blood	Headspace extraction	capillary GC/ITD	0.04 µmol/L	No data	Schuberth 1994
Blood	Headspace SPME	GC/MS	24 pg/mL	No data	Chambers et al. 2006
Mother's milk	Purge and trap	capillary GC/FID	No data	63 (chloro-benzene)	Michael et al. 1991 Pellizzari et al. 1982
Urine	Purge and trap	capillary GC/FID	50 ng/L	59	Fustinoni 1996
Urine	Heated headspace extraction	capillary GC/FID	1 ng/mL	42.3	Lee et al. 1998b
Urine	Headspace (Purge and Trap)	GC/PID	15 ng/L	No data	Skender et al. 2004
Biofluids	Headspace extraction	GC/FID	No data	No data	Suitheimer et al. 1982
Adipose tissue	Evaporation at 150°C into nitrogen, direct gas injection	GC/FID	No data	88–112	Carlsson and Ljungquist 1982
Brain tissue	Extraction with carbon disulfide; homogenization; centrifugation	GC/FID	No data	No data	Benignus et al. 1981
Breath	Collection in modified Haldane-Priestly tube; transfer to adsorption tube; thermal desorption	capillary GC/MS	1 nmole	No data	Dyne et al. 1997
Breath	Collection via spirometer into passivated canisters	capillary GC/MS	low µg/m ³	80–136	Thomas et al. 1991
Breath	Collection via spirometer into 1.8°L passivated canisters	capillary GC/MS	~2 µg/m ³	91–104	Thomas et al. 1992
Breath	Collection via spirometer onto charcoal traps; microwave desorption	capillary GC/MS-SIM	3 µg/m ³	No data	Riedel et al. 1996

FID = flame ionization detector; GC = gas chromatography; ITD = ion trap detection; MS = mass spectrometry; SIM = selected ion monitoring

7. ANALYTICAL METHODS

followed by identification and quantitation using various detectors; flame ionization detection (FID), photoionization detection (PID), and mass spectrometry (MS) are used most often. Other sample preparation methods have been used, but less frequently. Solvent extraction permits concentration, thereby increasing sensitivity, but the extraction solvent can interfere with analysis. Direct aqueous injection is a very rapid method, but sensitivity is low and matrix effects can be a serious problem.

In addition, the dynamic headspace purge-and-trap GC method with PID was utilized for the determination of toluene in urine samples obtained from participants of Zagreb, Croatia. The detection limit was 15 ng/L (Skender et al. 2004).

Headspace solid phase microextraction (SPME) is a relatively new alternative method to detect nonpolar species in the blood. Chambers et al. (2006) utilized this method, along with GC/MS to detect BTEX in the blood. The authors also improved the technique by minimizing contamination from the vacutainers, disposable syringes and vial septa. The limit of detection for toluene was 25 pg/mL (Chambers et al. 2006).

A sensitive and reliable method for identification and quantitation of toluene in samples of whole blood taken from humans following exposure to volatile organic compounds has been developed by researchers at the Centers for Disease Control and Prevention (Ashley et al. 1992, 1996). The method involves purge-and-trap of a 10 mL blood sample with analysis by capillary GC/MS. Anti-foam procedures were used, as well as special efforts to remove background levels of volatile organic compounds from reagents and equipment (Ashley et al. 1992). The method is sensitive enough (ppt levels) to determine background levels of volatile organic compounds in the population and provides adequate accuracy (91–147% recovery) and precision (12% relative standard deviation [RSD]) for monitoring toluene in the population. Most modern purge and trap methods provide detection limits in the ppt range for toluene in both blood and urine (Ashley et al. 1992; Fustinoni et al. 1996).

Few methods are available for the determination of toluene in other body fluids and tissues. Toluene may be extracted from biological materials using solvents such as carbon disulfide (Benignus et al. 1981); homogenization of tissue with the extractant and lysing of cells improves extraction efficiency. Care must be taken to avoid loss of low-boiling compounds. Highly purified solvents may be used to minimize problems with solvent impurities. A modified dynamic headspace method for urine, mother's milk, and adipose tissue has been reported (Michael et al. 1980). Volatiles swept from the sample are analyzed by capillary GC/FID. Acceptable recovery was reported for model compounds, but detection limits were not

7. ANALYTICAL METHODS

reported (Michael et al. 1980). Supercritical fluid extraction using pure carbon dioxide or carbon dioxide with additives has good potential for the extraction of organic analytes such as toluene from biological samples.

Sensitive, reliable methods are available for measuring toluene in breath. Exhaled breath is collected in modified Haldane-Priestly tubes (Dyne et al. 1997), into passivated canisters (Thomas et al. 1992), or directly onto adsorbent traps (Riedel et al. 1996). The detection limits are in the low $\mu\text{g}/\text{m}^3$ range (Riedel et al. 1996; Thomas et al. 1991, 1992); accuracy, where reported, is good ($\geq 80\%$) (Riedel et al. 1996; Thomas et al. 1991, 1992).

Representative methods for determination of biomarkers of exposure to toluene are shown in Table 7-2. Measurement of toluene in blood (Kawai et al. 1993), urine (Kawai et al. 1996) and exhaled air (Lapare et al. 1993) provide reliable markers of exposure to toluene. Measurement of toluene metabolites is also utilized for monitoring toluene exposure in humans. Hippuric acid is formed in the body by the metabolism of toluene, and it is the glycine conjugate of benzoic acid.

High performance liquid chromatography (HPLC) with ultraviolet (UV) detection is usually used for determination of metabolites in urine. Currently, ACGIH (2010, 2013) recommends measuring *ortho*-cresol levels in the urine at the end of the workshift to assess toluene levels in exposed workers (along with toluene levels in urine at the end of a workshift and toluene levels in blood immediately prior to the last shift of a workweek). Previously, the level of hippuric acid in urine at the end of a workshift was recommended as a biomarker of exposure, but this recommendation was withdrawn because background urinary hippuric acid from consumption of benzoate in foods and beverages is expected to mask contributions from workplace exposure to toluene, especially at concentrations below 50 ppm (ACGIH 2001, 2010). Other metabolites such as benzylmercapturic acid (BMA) (Inoue et al. 2002, 2004; Maestri et al. 1997) or *S-p*-toluylmercapturic acid (Angerer et al. 1998a, 1998b) may also be measured; however, their usefulness may be limited by variability among individuals. See Section 3.8 (Biomarkers of Exposure and Effect) for more information.

Detection of hippuric acid was done by ^1H NMR Spectroscopy after the samples were prepared by adding deuterium oxide (D_2O) and sodium trimethylsilyl [2,2,3,3- $^2\text{H}_4$] propionate (TSP) to urine samples of glue abusers (glue sniffers). Toluene is reported as the main component in glue. Hippuric acid levels were the highest after glue sniffing (Kwon et al. 2011).

7. ANALYTICAL METHODS

Table 7-2. Analytical Methods for Determining Biomarkers of Toluene in Biological Samples

Sample matrix	Preparation method	Analytical method	Sample detection limit	Percent recovery	Reference
Blood (toluene)	Headspace	GC	No data	No data	Kawai et al. 1993
Urine (toluene)	Headspace	GC/FID	2 µg/L	No data	Kawai et al. 1996
Urine (HA)	Extraction with ethyl acetate; evaporation; redissolve in water	HPLC/UV	30 mg/L	No data	NIOSH 1984b
Urine	Extraction with MTBE, elution with phosphate buffer/methanol/formaldehyde	HPLC	0.1 mmol	101	Tardif et al. 1989
Urine (o-cresol)	Hydrolysis; solvent extraction	HPLC/UV	0.5 mg/L	95 ^a	Kawai et al. 1996
Urine	Addition of deuterium oxide and TSP to samples	¹ H NMR	No data	No data	Kwon et al. 2011
Urine (BMA)	Adsorbent column cleanup; derivatization	HPLC/FI	0.5 µg/L	No data	Maestri et al. 1997
Breath	Collection in Tedlar bags	GC/FID	No data	No data	Lapare et al. 1993

^aExtraction efficiency.

BMA = benzylmercapturic acid; FID = flame ionization detector; FI = fluorescence detector; GC = gas chromatography; HA = hippuric acid; HPLC = high performance liquid chromatography; MTBE = methyl tertiary butyl ether; UV = ultraviolet detection

7. ANALYTICAL METHODS

7.2 ENVIRONMENTAL SAMPLES

Methods are available for determining toluene in a variety of environmental matrices. A summary of representative methods is shown in Table 7-3. Validated methods, approved by agencies and organizations such as EPA, ASTM, APHA, and NIOSH, are available for air, water, and solid waste matrices. GC is the most widely used analytical technique for quantifying concentrations of toluene in environmental matrices. Various detection devices used for GC include FID, MS, and PID. Because of the complexity of the sample matrix and the usually low concentrations of volatile organic compounds in environmental media, sample preconcentration is generally required prior to GC analysis. Air samples may be collected and concentrated on adsorbent or in canisters for subsequent analysis. Methods suitable for determining trace amounts of toluene in aqueous and other environmental media include three basic approaches to the pretreatment of the sample: gas purge-and-trap technique, headspace gas analysis, and extraction with organic solvent. Purge-and-trap is the most widely used method for the isolation and concentration of volatile organic compounds in environmental samples (Lesage et al. 1993). The purge and trap technique offers advantages over other techniques in that it allows facile isolation and concentration of target compounds, thereby improving overall limits of detection and recovery of sample.

Sampling techniques for air include collection in sample loops, on adsorbent, in canisters, and by cryogenic trapping. The analysis is normally performed by GC/FID, GC/PID, or GC/MS. Detection limits depend on the amount of air sampled, but values in the ppt range have been reported (Dewulf and Van Langenhover 1997).

BTEX was monitored in the urban air of nine sites by use of GC/MS. Toluene concentrations were the highest among the compounds. The limit of detection was also highest for toluene at $1 \mu\text{g}/\text{m}^3$ (Nicoara et al. 2009).

Toluene may be determined in occupational air using collection on adsorbent tubes, solvent desorption and GC/FID analysis (NIOSH 1994). Detection limits depend upon the amount of air sampled; accuracy is very good (11.4% bias) (NIOSH 1994).

Campos-Candel et al. (2009) compared HPLC-fluorescence (HPLC-FL) to GC/MS measurements of toluene in air samples. The limit of detection for the samples in HPLC-FL method was 0.5 mg/L or 5 $\mu\text{g}/\text{sample}$ and the limit of detection for GC/MS was 0.6 pg/s or 0.08 $\mu\text{g}/\text{sample}$. The GC/MS was deemed to be more sensitive.

7. ANALYTICAL METHODS

Table 7-3. Analytical Methods for Determining Toluene in Environmental Samples

Sample matrix	Preparation method	Analytical method	Sample detection limit	Percent recovery	Reference
Workplace air	Sorption on activated carbon; extraction with carbon disulfide	GC/FID	0.01 mg	±11.4 ^a	NIOSH 1994 Method 1501
Workplace air	Sorption on activated charcoal or Radiello diffusive samplers	HPLC	0.5 mg/L or 5 µg/sample	No data	Campos-Candel et al. 2009
Workplace air	Sorption on activated charcoal or Radiello diffusive samplers	GC/MS	0.6 pg/s or 0.08 µg/sample	No data	Campos-Candel et al. 2009
Indoor air	Solid phase microextraction (SPME)	GC/MS	0.004 mg/m ³	No data	Gorlo et al. 1999
Air	Sorption onto Tenax®; solvent extraction; thermal desorption	GC/MS	<0.88 ppbv	111–163	Crist and Mitchell 1986
Air	Sorption onto Tenax®; thermal desorption	GC/MS	No data	93–94	EPA 1988a Method TO-1 Krost et al. 1982
Air	Collection in passivated canisters	GC/MS	low ppb	No data	EPA 1988b Method TO-14
Air	Collection on multisorbent tubes; thermal desorption	GC/MS	No data	No data	EPA 1997a Method TO-17
Air	Collection in sorbent sampler tubes	GC/FID	0.01 mg/sample	94	USEPA, EMMI 1997 NIOSH 1500
Air	Sorption on activated charcoal; extraction with carbon disulfide	GC/FID	0.01 mg/sample	No data	USEPA, EMMI 1997 NIOSH 4000
Air	Solid phase membrane samplers (SPMS)	GC/MS	0.0001 µg/sampler	No data	Esteve-Turrillas et al. 2009
Air	Preconcentration in SKS glass tube with charcoal, desorption	GC/MS	1 µg/m ³	No data	Nicoara et al. 2009
Stack gas effluents	Sorption onto Tenax®; thermal desorption	GC/MS	No data	50–150	USEPA, EMMI 1997 OSW 5041A
Vehicle exhaust	Direct	GC/FID	0.5 ppb	No data	Dearth et al. 1992
Drinking water	Purge and trap	capillary GC/PID	0.01–0.02 ppb	98–99	DeMarini et al. 1991 EPA 1991a Method 502.2
Drinking water	Purge and trap	GC/PID	0.02 ppb	94	EPA 1991b Method 503.1
Drinking water	Purge and trap	capillary GC/MS	0.08–0.11 ppb	100–126	EPA 1992a Method 524.2
Water/waste water	Purge and trap	GC/PID	0.2 ppb	77	EPA 1982a Method 602

7. ANALYTICAL METHODS

Table 7-3. Analytical Methods for Determining Toluene in Environmental Samples

Sample matrix	Preparation method	Analytical method	Sample detection limit	Percent recovery	Reference
Water/ waste water	Purge and trap	GC/MS	6.0 ppb	98–101	EPA 1982b Method 624
Water/ waste water	Addition of isotopically labeled analog; purge and trap	GC/MS	10 ppb	No data	EPA 1984 Method 1624
Industrial effluents	Purged with inert gas onto Tenax®; thermally desorbed	GC/IDMS	20 ppb	No data	Colby et al. 1980
Drinking water, waste water	Purged with inert gas onto Tenax®; thermally desorbed, cryofocused	GC/MS	1 ppb	74–107	Michael et al. 1988
Groundwater	Solid-phase microextraction	GC/FID	2 ppb	No data	Arthur et al. 1992
Water	Purge and trap	GC/MS	0.047 ppb	106	USEPA, EMMI 1997 APHA 6210-B
Water	Direct aqueous injection	GC	1.0 ppm	No data	USEPA, EMMI 1997 ASTM D3695
Water	Purge and trap	GC	0.5 ppb	80–120	USEPA, EMMI 1997 APHA 6220-B
Water	Dilution in appropriate solvent	FS	2.1 ppm	No data	USEPA, EMMI 1997 ASTM D4763
Water	Static mode sampling	IMS	No data	No data	Wan et al. 1998
Groundwater, aqueous sludges, waste solvents, acid and caustic liquors, soils, sediments	Purge and trap	GC/MS	5 ppb	47–150	USEPA, EMMI 1997 OSW8240B-W
Groundwater, aqueous sludges, waste solvents, acid and caustic liquors, soils, sediments	Purge and trap or direct injection	GC/EC or GC/PID	0.01 ppb	99	USEPA, EMMI 1997 OSW 8021B-PID
Solid waste	Purge-and-trap	capillary GC/PID	0.01 ppb	99	EPA 1996a Method 8021B
Solid waste	Purge-and-trap	GC/PID	0.08–0.11 ppb	100–102	EPA 1996b Method 8260B
Solid waste	Static Headspace sampling (HS)	GC/MS	0.72 ng/L	101	Bernado et al. 2009

7. ANALYTICAL METHODS

Table 7-3. Analytical Methods for Determining Toluene in Environmental Samples

Sample matrix	Preparation method	Analytical method	Sample detection limit	Percent recovery	Reference
Soil	Methanol extraction; SPE	capillary GC	sub-ppm	>90	Meney et al. 1998
Soil (screening)	Filter	immunoassay	7 ppm	No data	EPA 1996c Method 4030
Soils and sediments	Headspace extraction	GC/PID	0.2 ppb	46–148	USEPA, EMMI 1997 OSW 8020A
Soils and other solid matrices	Headspace extraction	GC/FID GC/PID/ ELCD	No data	No data	USEPA, EMMI 1997 OSW 5021
Solid waste matrices	Purge and trap or direct aqueous injection or concentration by azeotropic distillation or automated static headspace	GC/MS	0.11 ppb	102	USEPA, EMMI 1997 OSW 8260B
Plant cuticle	Headspace extraction	GC/FID	No data	No data	Keymeulen et al. 1997
Food	Headspace extraction, 1 hour at 90°C	GC	No data	No data	Walters 1986
Foods	Purge and trap	capillary GC/MS	8 ppb	54–76 ^b	Heikes et al. 1995
Bottled water	Headspace extraction	GC/MS	0.5–1 ppb	No data	Page et al. 1993
Olive oil	Homogenization; headspace	capillary GC/MS	No data	No data	Biedermann et al. 1995

^aReported accuracy.^bIntralaboratory accuracy. Single lab accuracy is reported as 100–106% recovery.

ELCD = electrolytic conductivity detector; FID = flame ionization detector; FS = fluorescence spectroscopy; GC = gas chromatography; IDMS = isotope dilution mass spectrometry; MS = mass spectrometry; PID = photoionization detector; SPE = solid-phase extraction

7. ANALYTICAL METHODS

Esteve-Turrillas et al. (2009) developed a versatile, easy, and rapid atmosphere monitor (V-E-R-A-M) for the detection of BTEX in the air. Solid-phase membrane samplers (SPMS) and HS-GC-MS were utilized for the study. The limit of detection was determined to be 0.001 $\mu\text{g/sampler}$.

Older studies have suggested that passive samplers were utilized in the detection of toluene, but performance data on those samplers were unavailable (Ballesta et al. 1992; Periago et al. 1997). Newer studies demonstrate the efficacy of these samplers. SPME, a passive sampling method, was utilized to detect toluene in the indoor air in freshly renovated flats. The detection limit was 0.004 mg/m^3 (Gorlo et al. 1999).

Gas purge and trap is the most widely used method for the isolation and concentration of volatile organic compounds in environmental samples (Lesage et al. 1993). The purge and trap technique offers advantages over other techniques in that it allows facile isolation and concentration of target compounds, thereby improving overall limits of detection and recovery of sample. Detection limits of less than 1 μg of toluene per liter of sample have been achieved. Very low detection limits for drinking water are reported for the purge and trap method with GC/PID (0.01–0.02 ppb) (DeMarini et al. 1991, EPA 1991a). Accuracy is very good (94–99% recovery) (DeMarini et al. 1991, EPA 1991a). While the analytical method is selective, confirmation using a second column or GC/MS is recommended (EPA 1992a). Good sensitivity (0.08–0.11 ppb) and accuracy (100–126% recovery) can also be obtained using capillary GC/MS detection (EPA 1992a). Purge-and-trap methodology may be applied to waste water as well (EPA 1982a, 1982b, 1984). Sensitivity is in the low ppb range and recovery is good (77–101%) (EPA 1982a, 1982b, 1984).

Ion mobility spectrometry (IMS) was used in the detection of BTEX compounds in water. Static mode sampling determined the toluene concentration of 0.101 mg/L in purified water, which resulted in a headspace concentration of 2.75 $\mu\text{g/m}^3$ (Wan et al. 1998).

Soil, sediment, and solid waste are more difficult to analyze. Volatilization during sample handling and homogenization can result in analyte loss. Purge-and-trap methods with capillary GC/PID or GC/MS analysis provide detection limits of approximately 0.5 ppm for wastes and 5 $\mu\text{g/g}$ for soil and sediment (EPA 1982a, 1982b, 1984). Static headspace sampling (HS), along with GC-MS, was utilized in a study conducted by Bernardo et al. (2009) to effectively detect toluene in solid residues (waste) produced from the co-pyrolysis of plastics and pine biomass. The detection limit was 0.72 ng/L .

7. ANALYTICAL METHODS

No methods were found for the determination of toluene in fish and biota. Few methods are available for the determination of toluene in food. A purge and trap extraction method is available for determining toluene in a variety of foods. The quantitation limit is 8 ppb; single lab recovery is very good (100–106%) and precision is good (9.8–25% RSD). Both intra- and inter-laboratory studies were conducted, and precision was found to be $\leq 25\%$ RSD (Heikes et al. 1995).

7.3 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of toluene is available. Where adequate information is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of toluene.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

7.3.1 Identification of Data Needs

Methods for Determining Biomarkers of Exposure and Effect. Although toluene and its metabolites can be measured in body fluids using a number of techniques (Kawai et al. 1993, 1996; NIOSH 1984a), some of the metabolites have limited value as biomarkers. A number of common food materials produce the same metabolites; thus, measurement of toluene metabolites can be used to confirm a known exposure but cannot be used to determine whether or not exposure occurred in a poorly defined situation. It is also very difficult to quantify the magnitude of exposure from levels of either toluene or its metabolites in biological samples. Currently, ACGIH (2010, 2013) recommends using a combination of three biological exposure indices (BEIs[®]) to assess exposure of workers to toluene in the workplace: (1) *ortho*-cresol levels in the urine at the end of the workshift; (2) toluene levels in urine at the end of a workshift; and (3) toluene levels in blood immediately prior to the last shift of a workweek). The specific values for these BEIs[®] correspond to concentrations likely to be observed in individuals exposed by inhalation to 20 ppm, the current ACGIH 8-hour TWA Threshold Limit Value (TWA-TLV[®]) for

7. ANALYTICAL METHODS

occupational exposure to toluene (ACGIH 2010). A technique that could more accurately quantify exposure to toluene in biological fluids may be useful.

Exposure. Additional research to develop more sensitive methods for analysis of toluene and metabolites may be useful to increase sensitivity of exposure assessment.

Effect. It is difficult to monitor the effects of toluene exposure. MRI and BAER evaluations of the brain have some value in determining the neurological damage resulting from long-term exposures to high levels of toluene, but have no known value for determining the effects of low-level and/or short-term exposures.

Methods for Determining Parent Compounds and Degradation Products in Environmental

Media. There are methods available for the determination of toluene and its metabolites in environmental samples. Sensitive techniques for air, drinking water, and waste water allow detection of toluene at low levels (Bernado et al. 2009; Campos-Candel et al. 2009; Wan et al. 1998). These techniques are adequate to measure both background toluene levels and the levels of toluene in environmental media that could cause health effects. However, when toluene is present in combination with other volatile materials, interference from the companion volatiles often raises the detection limit and decreases the accuracy and precision of the technique. Improved methods for separation of toluene from other volatiles would be useful.

Research on measuring the levels of metabolites in soil and water would be valuable especially in studying the end products of microbial degradation. Few methods are available for monitoring toluene in foods; reliable methods are needed for evaluating the potential for human exposure that might result from toluene ingestion.

7.3.2 Ongoing Studies

The Environmental Health Laboratory Sciences Division of the National Center for Environmental Health, Centers for Disease Control and Prevention, is developing methods for the analysis of toluene and other phenolic compounds in urine. These methods use high-resolution gas chromatography and magnetic sector mass spectrometry, which give detection limits in the low parts per trillion (ppt) range.

8. REGULATIONS, ADVISORIES, AND GUIDELINES

MRLs are substance-specific estimates that are intended to serve as screening levels. They are used by ATSDR health assessors and other responders to identify contaminants and potential health effects that may be of concern at hazardous waste sites.

ATSDR has derived an acute-duration inhalation MRL of 2 ppm (7.6 mg/m³) for toluene based on a LOAEL for minimally adverse neurological effects in a susceptible human population (Little et al. 1999).

ATSDR has derived a chronic-duration inhalation MRL of 1 ppm (3.8 mg/m³) for toluene based on a NOAEL for neurological effects in humans in series of studies by the same group of investigators (Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanec et al. 2002)

ATSDR has derived an acute-duration oral MRL of 0.8 mg/kg/day for toluene based on a LOAEL for neurological effects in rats (Dyer et al. 1988).

ATSDR has derived an intermediate-duration oral MRL of 0.2 mg/kg/day for toluene based on a NOAEL for immune depression in mice (Hsieh et al. 1989, 1990a, 1991).

The International Agency for Research on Cancer (IARC) has classified toluene as a Group 3 carcinogen (*not classifiable as to its carcinogenicity to humans*) based on the evidence of carcinogenicity is inadequate in humans and inadequate or limited in experimental animals (IARC 2013). The World Health Organization (WHO) has not established any air quality guidelines but have concluded that further investigation would be needed before it was clear whether there was sufficient evidence to warrant their inclusion in the guidelines at present (WHO 2010). WHO has established a health-based drinking water guideline for toluene at 0.7 mg/L (WHO 2011).

The EPA and ACGIH also state that there are inadequate data on which to classify toluene in terms of its carcinogenicity in humans or animals (ACGIH 2013; IRIS 2007). Therefore, toluene is assigned the cancer category A4 (*not classifiable as a human carcinogen*) by ACGIH and Group D (*not classifiable as to human carcinogenicity*) by EPA (ACGIH 2013; IRIS 2007). The National Toxicology Program (NTP) has not classified toluene as a carcinogen (NTP 2016).

8. REGULATIONS, ADVISORIES, AND GUIDELINES

The EPA's reference concentration (RfC) for toluene is 5 mg/m³ and the EPA's reference dose (RfD) is 0.08 mg/kg/day (IRIS 2007).

OSHA sets permissible exposure limits (PELs) to protect workers against adverse health effects resulting from exposure to hazardous substances. The PELs determined for hazardous substances are enforceable, regulatory limits on allowable air concentrations in the workplace. OSHA requires employers of workers who are occupationally exposed to these hazardous substances to institute engineering controls and work practices to reduce and maintain employee exposure at or below the PEL. An employer must ensure that an employee's exposure to toluene in any 8-hour work shift of a 40-hour week does not exceed the 8-hour TWA of 200 ppm (OSHA 2013b). The acceptable ceiling concentration for toluene that shall not be exceeded at any time during an 8-hour shift is 300 ppm (OSHA 2013b). The acceptable maximum peak above the ceiling for an 8-hour shift is 500 ppm for 10 minutes (OSHA 2013b).

The ACGIH (2013) recommends an 8-hour TWA Threshold Limit Value (TLV) of 20 ppm toluene to protect against visual impairment and female reproductive effects including pregnancy loss. NIOSH has established a recommended exposure limit (REL) of 100 ppm that should not be exceeded at any time (NIOSH 2011). NIOSH has also established a short-term exposure limit (STEL) of 150 ppm and an immediately dangerous to life or health (IDLH) value of 500 ppm (NIOSH 2011).

Toluene is regulated as a hazardous air pollutant (EPA 2014a) and is subject to the emission limitations for various processes and operations in the synthetic organic chemicals manufacturing industry.

The American Industrial Hygiene Association (AIHA) and the Department of Energy (DOE) have established values for responding to potential releases of airborne toluene for use in community emergency planning. The values established by AIHA (2013) and the DOE (2012) are the Emergency Response Planning Guidelines (ERPGs-1, -2, -3) and Protective Action Criteria (PAC-1, -2, and -3), respectively. The ERPG-1, -2, and -3 values are 50, 300, and 1,000 ppm, respectively, and the PAC-1, -2, and -3 values are 200, 1,200, and 4,500 ppm, respectively, represent increasing severity of effects (mild, irreversible, and life threatening, respectively) for a 1-hour exposure (AIHA 2013; DOE 2012).

Toluene is listed as a chemical that must meet the requirements of Section 313 of Title III of the Superfund Amendments and Reauthorization Act (SARA) (EPA 1996a). Title III of SARA, also known as "The Emergency Planning and Community Right-to-Know Act of 1986," requires owners and operators of certain facilities that manufacture, import, process, or otherwise use the chemicals on this list

8. REGULATIONS, ADVISORIES, AND GUIDELINES

to report annually any release of those chemicals to any environmental media over a specified threshold level (EPA 2013f).

Toluene has been designated as a hazardous substance pursuant to the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) of 1980 (EPA 1995). The statutory source for this designation is Section 311(b)(4) of the Clean Water Act (CWA), Section 307 (a) of the CWA, Section 112 of the Clean Air Act (CAA), and Section 300 of the Resource Conservation and Recovery Act (RCRA) (EPA 2013f). The owner and operator of any facility that produces, uses, or stores a CERCLA hazardous substance is required to immediately report releases to any environmental media, if the amount released is equal to or exceeds the specified “reportable quantity” assigned to the substance. The reportable quantity for toluene is 1,000 pounds (454 kg) (EPA 2013g).

Because of its potential to cause adverse health effects in exposed people, toluene is also regulated by the drinking water standards set by the EPA. Toluene generally gets into drinking water by improper waste disposal or leaking underground storage tanks. In order to protect humans from the risk of developing adverse health effects from exposure to toluene through drinking water, the EPA Drinking Water Regulations and Health Advisories (EPA 2012) lists the maximum contaminant level (MCL) and the maximum contaminant level goal (MCLG) for toluene as 1 mg/L. The FDA set a limit of 1 mg/L in bottled water (FDA 2013).

Under the Toxic Substances Control Act (TSCA), toluene is on the list of chemicals that manufacturers and importers must report for each plant site at which they manufactured or imported toluene during the reporting period specified (EPA 2013l). In accordance with the Federal Hazardous Substances Act (FHSA), manufacturers are required to include special warning labels on some products containing toluene (CPSC). If a product contains $\geq 5\%$ toluene by weight, labels of “Danger”, “Vapor harmful”, and “Poison” with a skull and crossbones must be used. If a product contains $\geq 10\%$ toluene by weight, labels must also include “Harmful or fatal if swallowed” and “Call physician immediately”.

The international and national regulations, advisories, and guidelines regarding toluene in air, water, and other media are summarized in Table 8-1.

8. REGULATIONS, ADVISORIES, AND GUIDELINES

Table 8-1. Regulations, Advisories, and Guidelines Applicable to Toluene

Agency	Description	Information	Reference
INTERNATIONAL			
Guidelines:			
IARC	Carcinogenicity classification	Group 3 ^a	IARC 2013
WHO	Air quality guidelines	Group 2 ^b	WHO 2010
	Drinking water quality guidelines	0.7 mg/L ^c	WHO 2011
NATIONAL			
Regulations and Guidelines:			
a. Air			
ACGIH	TLV-TWA	20 ppm	ACGIH 2013
AIHA	ERPG-1 ^{d,e}	50 ppm	AIHA 2013
	ERPG-2	300 ppm	
	ERPG-3	1,000 ppm	
DOE	PAC-1 ^f	200 ppm	DOE 2012
	PAC-2	1,200 ppm	
	PAC-3	4,500 ppm	
EPA	AEGL-1 ^g		EPA 2013c
	10-minutes	200 ppm	
	30-minutes	200 ppm	
	60-minutes	200 ppm	
	4-hours	200 ppm	
	8-hours	200 ppm	
	AEGL-2 ^g		
	10-minutes	3,100 ppm ^h	
	30-minutes	1,600 ppm ^h	
	60-minutes	1,200 ppm	
	4-hours	790 ppm	
	8-hours	650 ppm	
	AEGL-3 ^g		
	10-minutes	13,000 ppm ⁱ	
	30-minutes	6,100 ppm ^h	
	60-minutes	4,500 ppm ^h	
	4-hours	3,000 ppm ^h	
	8-hours	2,500 ppm ^h	
NIOSH	Hazardous air pollutant	Yes	EPA 2014a 42 USC 7412
	NAAQS	No data	EPA 2014d
	REL	100 ppm	NIOSH 2011
	STEL	150 ppm	
	IDLH	500 ppm	

8. REGULATIONS, ADVISORIES, AND GUIDELINES

Table 8-1. Regulations, Advisories, and Guidelines Applicable to Toluene

Agency	Description	Information	Reference
NATIONAL (cont.)			
OSHA	PEL (8-hour TWA) for general industry	200 ppm	OSHA 2013b 29 CFR 1910.1000, Table Z-2
	Acceptable ceiling concentration	300 ppm	
	Acceptable maximum peak above the acceptable ceiling concentration for an 8-hour shift	500 ppm for 10 minutes	
	Highly hazardous chemicals	No data	OSHA 2013a 29 CFR 1910.119, Appendix A
b. Water			
EPA	Designated as hazardous substances in accordance with Section 311(b)(2)(A) of the Clean Water Act	Yes	EPA 2013d 40 CFR 116.4
	Drinking water contaminant candidate list	No data	EPA 2009a 74 FR 51850
	Drinking water standards and health advisories		EPA 2012
	MCL	1 mg/L	
	MCLG	1 mg/L	
	Health advisory for 1 day for 10-kg child	20 mg/L	
	Health advisory for 10 days for 10-kg child	2 mg/L	
	DWEL	3 mg/L	
	National primary drinking water standards		EPA 2009b
	MCL	1 mg/L	
	Potential health effects from long-term exposure above the MCL	Nervous system, kidney, or liver problems	
	Common sources of contaminant in drinking water	Discharge from petroleum factories	
	Public Health Goal	1 mg/L	
	National recommended water quality criteria: human health for the consumption of (at 10 ⁻⁴ risk)		EPA 2014e
	Water + organism	1.3 mg/L	
	Organism only	15 mg/L	
	Reportable quantities of hazardous substances designated pursuant to Section 311 of the Clean Water Act	1,000 pounds	EPA 2013f 40 CFR 117.3

8. REGULATIONS, ADVISORIES, AND GUIDELINES

Table 8-1. Regulations, Advisories, and Guidelines Applicable to Toluene

Agency	Description	Information	Reference
NATIONAL (cont.)			
c. Food			
FDA	Bottled water	1 mg/L	FDA 2013 21 CFR 165.110
	EAFUS ^j	No data	FDA 2014
d. Other			
ACGIH	Carcinogenicity classification	A4 ^k	ACGIH 2013
	BEI		
	Toluene in blood; prior to last shift of workweek	0.02 mg/L	
	Toluene in urine; end of shift	0.03 mg/L	
CPSC	o-Cresol in urine; end of shift	0.3 mg/g creatinine	
	Federal Hazardous Substances Act		CPSC 2017
	Labels of “Danger”, “Vapor harmful”, and “Poison” with a skull and crossbones must be used	≥5% toluene (by weight)	
	Above labels plus “Harmful or fatal if swallowed” and “Call physician immediately” must be used	≥10% toluene (by weight)	
EPA	Carcinogenicity classification	Group D ^l	IRIS 2007
	RfC	5 mg/m ³	
	RfD	0.08 mg/kg/day	
	Identification and listing of hazardous waste	U220	EPA 2013e 40 CFR 261, Appendix VIII
	Inert pesticide ingredients in pesticide products approved for nonfood use only	Yes	EPA 2014b
	Master Testing List	Yes ^m	EPA 2014c
	RCRA waste minimization PBT priority chemical list	No data	EPA 1998 63 FR 60332
	Standards for owners and operators of hazardous waste TSD facilities; groundwater monitoring list	Yes	EPA 2013j 40 CFR 264, Appendix IX
	Superfund, emergency planning, and community right-to-know		
	Designated CERCLA hazardous substance and reportable quantity pursuant to Section 311(b)(2) of the Clean Water Act, Section 307(a) of the Clean Water Act, Section 112 of the Clean Air Act, and Section 3001 of RCRA	1,000 pounds	EPA 2013g 40 CFR 302.4

8. REGULATIONS, ADVISORIES, AND GUIDELINES

Table 8-1. Regulations, Advisories, and Guidelines Applicable to Toluene

Agency	Description	Information	Reference
NATIONAL (cont.)			
EPA	Effective date of toxic chemical release reporting	01/01/1987	EPA 2013h 40 CFR 372.65
	Extremely hazardous substances and its threshold planning quantity	No data	EPA 2013i 40 CFR 355, Appendix A
	TSCA chemical lists and reporting periods	No data	EPA 2013k 40 CFR 712.30
	TSCA health and safety data reporting		EPA 2013l
	Effective date	10/04/1982	40 CFR 716.120
	Reporting date	10/04/1992	
NTP	Carcinogenicity classification	No data	NTP 2016

^aGroup 3: not classifiable as to its carcinogenicity to humans.

^bGroup 2 includes pollutants of potential interest, but WHO concluded further investigation would be needed before it was clear whether there was sufficient evidence to warrant their inclusion in the guidelines at present (WHO 2010).

^cConcentrations of the substance at or below the health-based guideline value may affect the appearance, taste, or odor of the water, leading to consumer complaints (WHO 2011).

^dERPG-1: maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without experiencing other than mild transient adverse health effects or perceiving a clearly defined, objectionable odor; ERPG-2: maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without experiencing or developing irreversible or other serious health effects or symptoms which could impair an individual's ability to take protective action; ERPG-3: maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to 1 hour without experiencing or developing life-threatening health effects (AIHA 2013).

^eOdor should be detectable near ERPG-1.

^fPAC-1: mild, transient health effects; PAC-2: irreversible or other serious health effects that could impair the ability to take protective action; PAC-3: life-threatening health effects (DOE 2012).

^gLower Explosive Limit (LEL) = 14,000 ppm.

^hFor values denoted as safety considerations against the hazard(s) of explosion(s) must be taken into account; ≥10% LEL.

ⁱFor values denoted as extreme safety considerations against the hazard(s) of explosion(s) must be taken into account; ≥50% LEL.

^jThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food additives or listed or affirmed as GRAS.

^kA4: not classifiable as a human carcinogen.

^lGroup D: not classifiable as to human carcinogenicity.

^mVoluntary chemical testing program underway for SIDS including pharmacokinetic and immunological health effects (EPA 2014c).

ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels; AIHA = American Industrial Hygiene Association; BEI = biological exposure indices; CERCLA = Comprehensive Environmental Response, Compensation, and Liability Act; CFR = Code of Federal Regulations; DOE = Department of Energy; DWEL = drinking water equivalent level; EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency; ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; FR = Federal Register; GRAS = generally recognized as safe; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; LEL = lower explosive limit; MCL = maximum contaminant level; MCLG = maximum contaminant level goal; NAAQS = National Ambient Air Quality Standards; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration; PAC = protective action criteria; PBT = persistent, bioaccumulative, and toxic; PEL = permissible exposure limit; RCRA = Resource Conservation and Recovery Act; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; SIDS = Screening Information Data Set; STEL = short-term exposure limit; TLV = threshold limit values; TSCA = Toxic Substances Control Act; TSD = treatment, storage, and disposal; TWA = time-weighted average; USC = United States Code; WHO = World Health Organization

This page is intentionally blank.

9. REFERENCES

- Abbate C, Giorgianni C, Munao F, et al. 1993. Neurotoxicity induced by exposure to toluene. An electrophysiologic study. *Int Arch Occup Environ Health* 64:389-392.
- ACGIH. 1999. TLVs and BEIs: Threshold limit values for chemical substances and physical agents: Biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists, 67, 102.
- ACGIH. 2001. Documentation of the recommended biological exposure index for toluene. Cincinnati, OH: American Conference of Governmental Industrial Hygienists, 1-13.
- ACGIH. 2007. Toluene. Documentation of the threshold limit values and biological exposure indices. Cincinnati, Ohio: American Conference of Governmental Industrial Hygienists, 1-10.
- ACGIH. 2010. Toluene. Documentation of the biological exposure indices. Cincinnati, Ohio: American Conference of Governmental Industrial Hygienists, 1-18.
- ACGIH. 2013. Toluene (CASRN 108-88-3). Threshold limit values for chemical substances and physical agents and biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial Hygienists, 57, 114.
- Acton DW, Barker JF. 1992. *In situ* biodegradation potential of aromatic hydrocarbons in anaerobic groundwaters. *J Contam Hydrol* 9:325-352.
- Adams WD, Golden JE. 1992. Comparison of the effects of geologic environment on volatile organic plume development. *J Hazard Mat* 29:17-41.
- Adlercreutz H. 1995. Phytoestrogens: Epidemiology and a possible role in cancer protection. *Environ Health Perspect Suppl* 103(7):103-112.
- ATSDR. 1989. Decision guide for identifying substance-specific data needs related to toxicological profiles; Notice. Agency for Toxic Substances and Disease Registry, Division of Toxicology. *Fed Regist* 54(174):37618-37634.
- ATSDR. 2000. Toxicological Profile for Toluene. Atlanta, GA: Agency for Toxic Substance and Disease Registry, U.S. Department of Health and Human Services, Public Health Service.
- ATSDR. 2015. Toluene. Full SPL data. Substance priority list (SPL) resource page. Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention. <http://www.atsdr.cdc.gov/SPL/resources/index.html>. August 26, 2016.
- Ahmed S, Tin Win S, Yamamoto S, et al. 2007. Increased hippocampal mRNA expression of neuronal synaptic plasticity related genes in mice chronically exposed to toluene at a low-level human occupational-exposure. *Neurotoxicology* 28(1):168-174.

* Not cited in text

9. REFERENCES

- AIHA. 2013. Emergency response planning guidelines (ERPG). Fairfax, VA: American Industrial Hygiene Association. <https://www.aiha.org/get-involved/AIHAGuidelineFoundation/EmergencyResponsePlanningGuidelines/Pages/default.aspx>. January 08, 2014.
- Aitio A, Pekari K, Jarvisalo J. 1984. Skin absorption as a source of error in biological monitoring. *Scand J Work Environ Health* 10:317-320.
- Akbas E, Derici E, Soylemez F, et al. 2004. An investigation of effects of toluene and cigarette smoking on some blood parameters and lymphocyte life span. *Cell Biol Toxicol* 20(1):33-40.
- Al-Batanony MA, Abdel-Rasoul GM, Abu-Salem MA, et al. 2012. Cohort study on respiratory and neurological disorders among workers in a bone glue factory in Egypt. *Int J Occup Environ Med* 3(2):84-91.
- Alcorn CJ, Simpson RJ, Leahy D, et al. 1991. *In vitro* studies of intestinal drug absorption: Determination of partition and distribution coefficient with brush border membrane vesicles. *Biochem Pharmacol* 42(12):2259-2264.
- Alexopoulos EC, Chatzis C, Linos A. 2006. An analysis of factors that influence personal exposure to toluene and xylene in residents of Athens, Greece. *BMC Public Health* 6:50.
- Alfaro-Rodriguez A, Bueno-Nava A, Gonzalez-Pina R, et al. 2011. Chronic exposure to toluene changes the sleep-wake pattern and brain monoamine content in rats. *Acta Neurobiol Exp* 71(2):183-192.
- Al-Ghamdi SS, Raftery MJ, Yaqoob MM. 2003. Acute solvent exposure induced activation of cytochrome P4502E1 causes proximal tubular cell necrosis by oxidative stress. *Toxicol in Vitro* 17(3):335-341.
- Al-Ghamdi SS, Raftery MJ, Yaqoob MM. 2004. Toluene and *p*-xylene induced LLC-PK1 apoptosis. *Drug Chem Toxicol* 27(4):425-432.
- Ali N, Tardif R. 1999. Toxicokinetic modeling of the combined exposure to toluene and *n*-hexane in rats and humans. *J Occup Health* 41:95-103.
- Altman PL, Dittmer DS. 1974. Biological handbooks: Biology data book. Vol. III. 2nd ed. Bethesda, MD: Federation of American Societies for Experimental Biology, 1987-2008, 2041.
- Altshuller AP, Lonneman WA, Sutterfield FD, et al. 1971. Hydrocarbon composition of the atmosphere of the Los Angeles Basin-1967. *Environ Sci Technol* 5(10):1009-1016.
- Ameno K, Fuke C, Ameno S, et al. 1989. A fatal case of oral ingestion of toluene. *Forensic Sci Int* 41:255-260.
- Ameno K, Kiri T, Fuke C, et al. 1992. Regional brain distribution of toluene in rats and in a human autopsy. *Arch Toxicol* 66:153-156.
- Andersen I, Lundqvist GR, Molhave L, et al. 1983. Human response to controlled levels of toluene in six-hour exposures. *Scand J Work Environ Health* 9:405-418.

9. REFERENCES

- Andersen ME, Krishnan K. 1994. Relating *in vitro* to *in vivo* exposures with physiologically based tissue dosimetry and tissue response models. In: Salem H, ed. Animal test alternatives: Refinement, reduction, replacement. New York, NY: Marcel Dekker, Inc., 9-25.
- Andersen ME, Clewell HJ, Gargas ML, et al. 1987. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. *Toxicol Appl Pharmacol* 87(2):185-205.
- Anderson C, Sundberg K, Groth O. 1986. Animal model for assessment of skin irritancy. *Contact Dermatitis* 15:143-151.
- Anderson HR, Dick B, Macnair RS, et al. 1982. An investigation of 140 deaths associated with volatile substance abuse in the United Kingdom (1971-1981). *Hum Toxicol* 1:207-221.
- Anderson HR, Macnair RS, Ramsey JD. 1985. Epidemiology: Deaths from abuse of volatile substances: A national epidemiological study. *Br Med J* 290:304-307.
- Anderson MA. 1992. Influence of surfactants on vapor-liquid partitioning. *Environ Sci Technol* 26:2186-2191.
- Andersson K, Fuxe K, Toftgard R, et al. 1980. Toluene-induced activation of certain hypothalamic and median eminence catecholamine nerve terminal systems of the male rat and its effects on anterior pituitary hormone secretion. *Toxicol Lett* 5:393-398.
- Andersson K, Nilsen OG, Toftgard R, et al. 1983b. Increased amine turnover in several hypothalamic noradrenaline nerve terminal systems and changes in prolactin secretion in the male rat by exposure to various concentrations of toluene. *Neurotoxicology* 4(4):43-55.
- Andersson R, Carlsson A, Nordqvist MB, et al. 1983a. Urinary excretion of hippuric acid and o-cresol after laboratory exposure of humans to toluene. *Int Arch Occup Environ Health* 53:101-108.
- Angerer J. 1979. Occupational chronic exposure to organic solvents: VII. Metabolism of toluene in man. *Int Arch Occup Environ Health* 43:63-67.
- *Angerer J, Kramer A. 1997. Occupational chronic exposure to organic solvents. XVI. Ambient and biological monitoring of workers exposed to toluene. *Int Arch Occup Environ Health* 69(2):91-96.
- Angerer J, Schildbach M, Kramer A. 1998a. S-*p*-toluylmercapturic acid in the urine of workers exposed to toluene: A new biomarker for toluene exposure. *Arch Toxicol* 72(2):119-123.
- Angerer J, Schildbach M, Kramer A. 1998b. Gas chromatographic method for the simultaneous determination of S-*p*-toluylmercapturic acid and S-phenylmercapturic acid in human urine. *J Anal Toxicol* 22:211-214.
- Antilla A, Pukkala E, Riala R, et al. 1998. Cancer incidence among Finnish workers exposed to aromatic hydrocarbons. *Int Arch Occup Environ Health* 71:187-193.
- Apawu AK, Matthews TA, Bowen SE. 2014. Striatal dopamine dynamics in mice following acute and repeated toluene exposure. *Psychopharmacology* [Epub ahead of print].
- API. 1978. Teratology study in rats. Toluene. Final report. Washington, D.C.: American Petroleum Institute. LBI Project No. 20698-4.

9. REFERENCES

- API. 1981. Mutagenicity evaluation of toluene in the mouse dominant lethal assay. Washington, DC: American Petroleum Institute. Project no. 21141-05.
- API. 1985. Two-generation reproduction/fertility study on a petroleum-derived hydrocarbon (toluene) Vol. 1. Washington, DC: American Petroleum Institute.
- API. 1991. Toluene: Effect on pregnancy of the rat by inhalation (status report) with cover letter dated 022191. Washington, DC: American Petroleum Institute. Submitted to U.S. Environmental Protection Agency under TSCA Section FYI. APT291279. OTS0000802.
- API. 1992. Initial submission: A preliminary study of the effect of toluene on pregnancy of the rat (inhalation exposure). Final report with cover letter dated 072292. Washington, DC: American Petroleum Institute. Submitted to U.S. Environmental Protection Agency under TSCA Section FYI. APT191309. OTS0000857.
- API. 1997. Brain glial fibrillary acidic protein (GFAP) as a marker of neurotoxicity during inhalation exposure to toluene. Washington, DC: American Petroleum Institute. API Publication Number 4647.
- Aranyi C, O'Shea WJ, Sherwood RL, et al. 1985. Effects of toluene inhalation on pulmonary host defenses of mice. *Toxicol Lett* 25:103-110.
- Arito H, Tsuruta H, Oguir M. 1988. Changes in sleep and wakefulness following single and repeated exposures to toluene vapor in rats. *Arch Toxicol* 62:76-80.
- Armstrong AQ, Hodson RE, Hwang H-M, et al. 1991. Environmental factors affecting toluene degradation in groundwater at a hazardous waste site. *Environ Toxicol Chem* 10:147-158.
- Arnold GL, Wilkens-Haug L. 1990. Toluene embryopathy syndrome [abstract]. *Am J Hum Genet* 47(suppl. 3):A46.
- Arnold GL, Kirby RS, Langendoerfer S, et al. 1994. Toluene embryopathy: Clinical delineation and developmental follow-up. *Pediatrics* 93(2):216-220.
- Arocha MA, Jackman AP, McCoy BJ. 1996. Adsorption kinetics of toluene on soil agglomerates: Soil as a biporous sorbent. *Environ Sci Technol* 30(5):1500-1507.
- Arthur CL, Killam LM, Motlagh S, et al. 1992. Analysis of substituted benzene compounds in groundwater using solid-phase microextraction. *Environ Sci Technol* 26(5):979-983.
- *Ashikaga R, Araki Y, Miura K, et al. 1995. Cranial MRI in chronic thinner intoxication. *Neuroradiology* 37(6):443-444.
- Ashley DL, Bonin MA, Cardinali FL, et al. 1992. Determining volatile organic compounds in human blood from a large sample population by using purge and trap gas chromatography/mass spectrometry. *Anal Chem* 64:1021-1029.
- Ashley DL, Bonin MA, Cardinali FL, et al. 1996. Measurement of volatile organic compounds in human blood. *Environ Health Perspect Suppl* 104:871-877.

9. REFERENCES

- Askergren A, Allgren L, Karlsson C, et al. 1981a. Studies on kidney function in subjects exposed to organic solvents. *Acta Med Scand* 209:479-483.
- Askergren A, Brandt R, Gullquist R, et al. 1981b. Studies on kidney function in subjects exposed to organic solvents: IV. Effects on 51-Cr-EDTA clearance. *Acta Med Scand* 210:373-376.
- Assmuth T, Kalevi K. 1992. Concentrations and toxicological significance of trace organic compounds in municipal solid waste landfill gas. *Chemosphere* 24(9):1207-1216.
- Atay AA, Kismet E, Turkbay T, et al. 2005. Bone mass toxicity associated with inhalation exposure to toluene. *Biol Trace Elem Res* 105(1-3):197-203.
- Atkinson R. 1990. Gas-phase tropospheric chemistry of organic compounds: A review. *Atmos Environ* 24A(1):1-41.
- Austin SG, Schnatter AR. 1983. A case-control study of chemical exposures and brain tumors in petrochemical workers. *J Occup Med* 25(4):313-320.
- Ayan M, Tas U, Sogut E, et al. 2013. The apoptotic effect of a high dose of toluene on liver tissue during the acute phase: An experimental study. *Toxicol Ind Health* 29(8):728-736.
- Aydin K, Sencer S, Demir T, et al. 2002. Cranial MR findings in chronic toluene abuse by inhalation. *Am J Neuroradiol* 23(7):1173-1179.
- Aydin K, Sencer S, Ogel K, et al. 2003. Single-voxel proton MR spectroscopy in toluene abuse. *Magn Reson Imaging* 21(7):777-785.
- Backer LC, Egeland GM, Ashley DL, et al. 1997. Exposure to regular gasoline and ethanol oxyfuel during refueling in Alaska. *Environ Health Perspect* 105(8):850-5.
- Baelum J. 1990. Toluene in alveolar air during controlled exposure to constant and to varying concentrations. *Int Arch Occup Environ Health* 62:59-64.
- Baelum J, Andersen I, Lundqvist GR, et al. 1985. Response of solvent-exposed printers and unexposed controls to six-hour toluene exposure. *Scand J Work Environ Health* 11:271-280.
- Baelum J, Dossing M, Hansen SH, et al. 1987. Toluene metabolism during exposure to varying concentrations combined with exercise. *Int Arch Occup Environ Health* 59:281-294.
- Baelum J, Molhave L, Honore Hansen S, et al. 1993. Hepatic metabolism of toluene after gastrointestinal uptake in humans. *Scand J Work Environ Health* 19(1):55-62.
- Baelum J, Molhave L, Honore Hansen S, et al. 1998. Metabolic interaction between toluene, trichloroethylene and n-hexane in humans. *Scand J Work Environ Health* 24(1):30-37.
- Bale AS, Jackson MD, Krantz QT, et al. 2007. Evaluating the NMDA-glutamate receptor as a site of action for toluene, *in vivo*. *Toxicol Sci* 98(1):159-166.
- Bale AS, Meacham CA, Benignus VA, et al. 2005. Volatile organic compounds inhibit human and rat neuronal nicotinic acetylcholine receptors expressed in *Xenopus oocytes*. *Toxicol Appl Pharmacol* 205(1):77-88.

9. REFERENCES

- Bale AS, Smothers CT, Woodward JJ. 2002. Inhibition of neuronal nicotinic acetylcholine receptors by the abused solvent, toluene. *Br J Pharmacol* 137(3):375-383.
- Balfour WD, Wetherold RG, Lewis DL. 1985. Evaluation of air emissions from hazardous waste treatment, storage and disposal facilities. Cincinnati, OH: U.S. Environmental Protection Agency, Land Pollution Control Division, Hazardous Waste Engineering Research Laboratory, Office of Research and Development.
- Ballesta PP, Ferradas EG, Aznar AM. 1992. Simultaneous passive sampling of volatile organic compounds. *Chemosphere* 25(12):1797-1809.
- Baltrenas P, Baltrenaite E, Sereviciene V, et al. 2011. Atmospheric BTEX concentrations in the vicinity of the crude oil refinery of the Baltic region. *Environ Monit Assess* 182(1-4):115-127.
- Banfer VW. 1961. [Studies on the effect of pure toluene on the blood picture of photogravure printers and helper workers.] *Zent Arbeitsmed* 11:35-40. (German)
- Barnes DG, Dourson M. 1988. Reference dose (RfD): Description and use in health risk assessments. *Regul Toxicol Pharmacol* 8(4):471-486.
- Barrefors G. 1996. Monitoring of benzene, toluene and p-xylene in urban air with differential optical absorption spectroscopy technique. *Sci Total Environ* 189/190:287-292.
- Baskerville JR, Tichenor GA, Rosen PB. 2001. Toluene induced hypokalaemia: Case report and literature review. *Emerg Med J* 18(6):514-516.
- Bass M. 1970. Sudden sniffing death. *JAMA* 212(12):2075-2079.
- Batis JC, Hannigan JH, Bowen SE. 2010. Differential effects of inhaled toluene on locomotor activity in adolescent and adult rats. *Pharmacol Biochem Behav* 96(4):438-448.
- Bauchinger M, Schmid E, Dresch J, et al. 1982. Chromosome change in lymphocytes after occupational exposure to toluene. *Mutat Res* 102:439-445.
- Baydas G, Ozveren F, Tuzcu M, et al. 2005. Effects of thinner exposure on the expression pattern of neural cell adhesion molecules, level of lipid peroxidation in the brain and cognitive function in rats. *Eur J Pharmacol* 512(2-3):181-187.
- Baydas G, Reiter RJ, Nedzvetskii VS, et al. 2003. Melatonin protects the central nervous system of rats against toluene-containing thinner intoxication by reducing reactive gliosis. *Toxicol Lett* 137(3):169-174.
- Beasley TE, Evansky PA, Bushnell PJ. 2012. Behavioral effects of sub-acute inhalation of toluene in adult rats. *Neurotoxicol Teratol* 34(1):83-89.
- Beasley TE, Evansky PA, Gilbert ME, et al. 2010. Behavioral effects of subchronic inhalation of toluene in adult rats. *Neurotoxicol Teratol* 32(6):611-619.
- Beavers JD, Himmelstein JS, Hammond SK, et al. 1996. Exposure in a household using gasoline-contaminated water: A pilot study. *J Occup Environ Med* 38(1):35-38.

9. REFERENCES

- Beckley JT, Evins CE, Fedarovich H, et al. 2013. Medial prefrontal cortex inversely regulates toluene-induced changes in markers of synaptic plasticity of mesolimbic dopamine neurons. *J Neurosci* 33(2):804-813.
- Beckstead MJ, Weiner JL, Eger EI, 2nd, et al. 2000. Glycine and γ -aminobutyric acid_A receptor function is enhanced by inhaled drugs of abuse. *Mol Pharmacol* 57(6):1199-1205.
- Beller HR, Grbic-Galic D, Reinhard M. 1992a. Microbial degradation of toluene under sulfate-reducing conditions and the influence of iron on the process. *Appl Environ Microbiol* 58(3):786-793.
- Beller HR, Reinhard M, Grbic-Galic D. 1992b. Metabolic by-products of anaerobic toluene degradation by sulfate-reducing enrichment cultures. *Appl Environ Microbiol* 58(9):3192-3195.
- Benignus VA, Boyes WK, Kenyon EM, et al. 2007. Quantitative comparisons of the acute neurotoxicity of toluene in rats and humans. *Toxicol Sci* 100(1):146-155.
- Benignus VA, Coleman T, Eklund CR, et al. 2006. A general physiological and toxicokinetic (GPAT) model for simulating complex toluene exposure scenarios in humans. *Toxicol Mech Methods* 16(1):27-36.
- Benignus VA, Muller KE, Barton CN, et al. 1981. Toluene levels in blood and brain of rats during and after respiratory exposure. *Toxicol Appl Pharmacol* 61:326-334.
- Benignus VA, Muller KE, Graham JA, et al. 1984. Toluene levels in blood and brain of rats as a function of toluene level in inspired air. *Environ Res* 33:39-46.
- Benoit FM, Davidson WR, Lovett AM, et al. 1985. Breath analysis by API/MS human exposure to volatile organic solvents. *Int Arch Occup Environ Health* 55:113-120.
- Berenguer P, Soulage C, Fautrel A, et al. 2004. Behavioral and neurochemical effects induced by subchronic combined exposure to toluene at 40 ppm and noise at 80 dB-A in rats. *Physiol Behav* 81(3):527-534.
- Berenguer P, Soulage C, Perrin D, et al. 2003. Behavioral and neurochemical effects induced by subchronic exposure to 40 ppm toluene in rats. *Pharmacol Biochem Behav* 74(4):997-1003.
- Berger GS, ed. 1994. Epidemiology of endometriosis. In: *Endometriosis: Advanced management and surgical techniques*. New York, NY: Springer-Verlag, 3-7.
- Bergman K. 1983. Application and results of whole-body autoradiography in distribution studies of organic solvents. *CRC Crit Rev Toxicol* 12(1):59-118.
- Bernardo MS, Goncalves M, Lapa N, et al. 2009. Determination of aromatic compounds in eluates of pyrolysis solid residues using HS-GC-MS and DLLME-GC-MS. *Talanta* 80(1):104-108.
- Beyer CE, Stafford D, LeSage MG, et al. 2001. Repeated exposure to inhaled toluene induces behavioral and neurochemical cross-sensitization to cocaine in rats. *Psychopharmacology* 154(2):198-204.
- Biedermann M, Grob K, Morchio G. 1995. Original paper: On the origin of benzene, toluene, ethylbenzene and xylene in extra virgin olive oil. *Z Lebensm Unters Forsch* 200:266-272.

9. REFERENCES

- Biedermann M, Grob K, Morchio G. 1996. Original paper: On the origin of benzene, toluene, ethylbenzene, and the xylenes in virgin olive oil--further results. *Z Lebensm Unters Forsch* 203(3):224-229.
- Bieniek G, Kurkiewicz S, Wilczok T. 2004. Occupational exposure to aromatic hydrocarbons at a coke plant: Part I. Identification of hydrocarbons in air and their metabolites in urine by a gas chromatography-mass spectrometry method. *J Occup Health* 46(3):175-180.
- Bikashvili TZ, Chilachava LR, Gelazonia LK, et al. 2012. Effect of chronic inhalation of toluene on behavior of rats of various age groups in multi-branched maze. *Bull Exp Biol Med* 152(5):587-589.
- Bird MG, Wetmore BA, Letinski DJ, et al. 2010. Influence of toluene co-exposure on the metabolism and genotoxicity of benzene in mice using continuous and intermittent exposures. *Chem Biol Interact* 184(1-2):233-239.
- Bjornaes S, Naalsund LU. 1988. Biochemical changes in different brain areas after toluene inhalation. *Toxicology* 49:367-374.
- Blair A, Hartge P, Stewart PA, et al. 1998. Mortality and cancer incidence of aircraft maintenance workers exposed to trichloroethylene and other organic solvents and chemicals: Extended follow up. *Occup Environ Med* 55:161-171.
- Blair C, Walls J, Davies NW, et al. 2010. Volatile organic compounds in runners near a roadway: Increased blood levels after short-duration exercise. *Br J Sports Med* 44(10):731-735.
- Boey KW, Foo SC, Jeyaratnam J. 1997. Effects of occupational exposure to toluene: A neuropsychological study on workers in Singapore. *Ann Acad Med Singapore* 26(2):184-187.
- Boman A, Hagelthorn G, Magnusson K. 1995. Percutaneous absorption of organic solvents during intermittent exposure in guinea pigs. *Acta Derm Venereol* 75(2):114-119.
- *Boor JW, Hurtig HI. 1977. Persistent cerebellar ataxia after exposure to toluene. *Ann Neurol* 2:440-442.
- Bos RP, Brouns RM, van Doorn R, et al. 1981. Nonmutagenicity of toluene, o-, m- and p-xylene, o-methylbenzylalcohol and o-methylbenzylsulfate in the Ames assay. *Mutat Res* 88:273-279.
- Bowen SE. 2011. Two serious and challenging medical complications associated with volatile substance misuse: Sudden sniffing death and fetal solvent syndrome. *Subst Use Misuse* 46:68-72.
- Bowen SE, Balster RL. 1998. A direct comparison of inhalant effects on locomotor activity and schedule-controlled behavior in mice. *Exp Clin Psychopharmacol* 6(3):235-247.
- Bowen SE, Hannigan JH. 2013. Binge toluene exposure in pregnancy and pre-weaning developmental consequences in rats. *Neurotoxicol Teratol* 38:29-35.
- Bowen SE, McDonald P. 2009. Abuse pattern of toluene exposure alters mouse behavior in a waiting-for-reward operant task. *Neurotoxicol Teratol* 31(1):18-25.
- Bowen SE, Batis JC, Mohammadi MH, et al. 2005. Abuse pattern of gestational toluene exposure and early postnatal development in rats. *Neurotoxicol Teratol* 27(1):105-116.

9. REFERENCES

- Bowen SE, Charlesworth JD, Tokarz ME, et al. 2007. Decreased sensitivity in adolescent vs. adult rats to the locomotor activating effects of toluene. *Neurotoxicol Teratol* 29(6):599-606.
- Bowen SE, Daniel J, Balster RL. 1999. Deaths associated with inhalant abuse in Virginia from 1987 to 1996. *Drug Alcohol Depend* 53:239-245.
- Bowen SE, Hannigan JH, Cooper PB. 2009b. Abuse pattern of gestational toluene exposure alters behavior in rats in a "waiting-for-reward" task. *Neurotoxicol Teratol* 31(2):89-97.
- Bowen SE, Irtenkauf S, Hannigan JH, et al. 2009a. Alterations in rat fetal morphology following abuse patterns of toluene exposure. *Reprod Toxicol* 27(2):161-169.
- Bowen SE, Kimar S, Irtenkauf S. 2010. Comparison of toluene-induced locomotor activity in four mouse strains. *Pharmacol Biochem Behav* 95(2):249-257.
- Bowen SE, Wiley JL, Balster RL. 1996. The effects of abused inhalants on mouse behavior in an elevated plus-maze. *Eur J Pharmacol* 312:131-136.
- Boyd I, Rubin G, Wessely S. 2012. Taking refuge from modernity: 21st century hermits. *J R Soc Med* 105(12):523-529. 10.1258/jrsm.2012.120060.
- Boyes WK, Bercegeay M, Degn L, et al. 2016. Toluene inhalation exposure for 13 weeks causes persistent changes in electroretinograms of Long-Evans rats. *Neurotoxicology* 53:257-270. 10.1016/j.neuro.2016.02.008.
- Boyes WK, Bercegeay M, Krantz QT, et al. 2007. Acute toluene exposure and rat visual function in proportion to momentary brain concentration. *Toxicol Sci* 99(2):572-581.
- Bratveit M, Hollund BE, Moen BE. 2004. Reduced exposure to organic solvents by use of water-based paint systems in car repair shops. *Int Arch Occup Environ Health* 77(1):31-38.
- Bray HG, Humphris BG, Thorpe WV. 1949. Metabolism of derivatives of toluene. *Biochem J* 45:241-244.
- Brooke I, Cocker J, Delic JJ, et al. 1998. Dermal uptake of solvents from the vapour phase: An experimental study in humans. *Ann Occup Hyg* 42(8):531-540.
- Brown HS, Bishop DR, Rowan CA. 1984. The role of skin absorption as a route of exposure for volatile organic compounds (VOCs) in drinking water. *Am J Public Health* 74(5):479-484.
- Bruce BW, McMahon PB. 1996. Shallow ground-water quality beneath a major urban center: Denver, Colorado, USA. *J Hydrol* 186:129-151.
- Bruckner JV, Peterson RG. 1981a. Evaluation of toluene and acetone inhalant abuse: I. Pharmacology and pharmacodynamics. *Toxicol Appl Pharmacol* 61:27-38.
- Bruckner JV, Peterson RG. 1981b. Evaluation of toluene and acetone inhalant abuse: II. Model development and toxicology. *Toxicol Appl Pharmacol* 61:302-312.

9. REFERENCES

- *Brugnone F, Perbellini L, Apostoli P, et al. 1983. Decline of blood and alveolar toluene concentration following two accidental human poisonings. *Int Arch Occup Environ Health* 53:157-165
- Burmistrov SO, Arutyunyan AV, Stepanov MG, et al. 2001. Effect of chronic inhalation of toluene and dioxane on activity of free radical processes in rat ovaries and brain. *Bull Exp Biol Med* 132(3):832-836.
- Burns LA, Bradley SG, White KL, et al. 1994. Immunotoxicity of mono-nitrotoluenes in female B6C3F1 mice: I. Para-nitrotoluene. *Drug Chem Toxicol* 17(3):317-358.
- Burry M, Guizzetti M, Oberdoerster J, et al. 2003. Developmental neurotoxicity of toluene: *In vivo* and *in vitro* effects on astroglial cells. *Dev Neurosci* 25(1):14-19.
- Burstyn I, Kromhout H. 2002. Trends in inhalation exposure to hydrocarbons among commercial painters in The Netherlands. *Scand J Work Environ Health* 28(6):429-438.
- Bushnell PJ. 1997. Concentration-time relationships for the effects of inhaled trichloroethylene on signal detection behavior in rats. *Fundam Appl Toxicol* 36(1):30-38.
- Bushnell PJ, Evans HL, Palmes ED. 1985. Effects of toluene inhalation on carbon dioxide production and locomotor activity in mice. *Fundam Appl Toxicol* 5:971-977.
- *Bushnell PJ, Kelly KL, Crofton KM. 1994. Effects of toluene inhalation on detection of auditory signals in rats. *Neurotoxicol Teratol* 16 (2):149-160.
- Bushnell PJ, Oshiro WM, Samsam TE, et al. 2007. A dosimetric analysis of the acute behavioral effects of inhaled toluene in rats. *Toxicol Sci* 99(1):181-189.
- Byczkowski JZ, Gearhart JM, Fisher JW. 1994. "Occupational" exposure of infants to toxic chemicals via breast milk. *Nutrition* 10(1):43-48.
- Byrne A, Kirby B, Zibin T, et al. 1991. Psychiatric and neurological effects of chronic solvent abuse. *Can J Psychiatry* 36:735-738.
- Caldemeyer KS, Armstrong SW, George KK, et al. 1996. The spectrum of neuroimaging abnormalities in solvent abuse and their clinical correlation. *J Neuroimaging* 6(3):167-173.
- Calderon-Guzman D, Hernandez-Islas JL, Espitia Vazquez IR, et al. 2005. Effect of toluene and cresols on Na⁺,K⁺-ATPase, and serotonin in rat brain. *Regul Toxicol Pharmacol*. 41(1):1-5.
- Callan SP, Hannigan JH, Bowen SE. 2015. Prenatal toluene exposure impairs performance in the Morris water maze in adolescent rats. *Neuroscience* 10.1016/j.neuroscience.2015.08.050.
- Camara-Lemarroy CR, Rodriguez-Gutierrez R, Monreal-Robles R, et al. 2015. Acute toluene intoxication--clinical presentation, management and prognosis: A prospective observational study. *BMC Emerg Med* 15:19. 10.1186/s12873-015-0039-0.
- Campagna D, Stengel B, Mergler D, et al. 2001. Color vision and occupational toluene exposure. *Neurotoxicol Teratol* 23(5):473-480.
- Campo P, Lataye R, Cossec B, et al. 1997. Toluene-induced hearing loss: A mid-frequency location of the cochlear lesions. *Neurotoxicol Teratol* 19(2):129-140.

9. REFERENCES

- Campo P, Lataye R, Cossec B, et al. 1998. Combined effects of simultaneous exposure to toluene and ethanol on auditory function in rats. *Neurotoxicol Teratol* 20(3):321-332.
- Campo P, Loquet G, Blachere V, et al. 1999. Toluene and styrene intoxication route in the rat cochlea. *Neurotoxicol Teratol* 21(4):427-434.
- Campo P, Maguin K, Lataye R. 2007. Effects of aromatic solvents on acoustic reflexes mediated by central auditory pathways. *Toxicol Sci* 99(2):582-590.
- Campo P, Waniusiow D, Cossec B, et al. 2008. Toluene-induced hearing loss in phenobarbital treated rats. *Neurotoxicol Teratol* 30(1):46-54.
- Campos-Candel A, Llobat-Estelles M, Mauri-Aucejo A. 2009. Comparative evaluation of liquid chromatography versus gas chromatography using a β -cyclodextrin stationary phase for the determination of BTEX in occupational environments. *Talanta* 78(4-5):1286-1292.
- Cao G, Jang M. 2008. Secondary organic aerosol formation from toluene photooxidation under various NO_x conditions and particle acidity. *Atmos Chem Phys Disc* 8:14467-14495.
- *Capellini A, Alessio L. 1971. [The urinary excretion of hippuric acid in workers exposed to toluene]. *Med Lav* 62:196-201. (Italian)
- Capron B, Logan BK. 2009. Toluene-impaired drivers: Behavioral observations, impairment assessment, and toxicological findings. *J Forensic Sci* 54(2):486-489.
- Caravati EM, Bjerk PJ. 1997. Acute toluene ingestion toxicity. *Ann Emerg Med* 30(6):838-839.
- Carlsson A. 1982. Exposure to toluene: Uptake, distribution and elimination in man. *Scand J Work Environ Health* 8:43-55.
- Carlsson A, Ljungquist E. 1982. Exposure to toluene: Concentration in subcutaneous adipose tissue. *Scand J Work Environ Health* 8:56-62.
- Carpenter AV, Flanders WD, Frome EL, et al. 1988. Chemical exposures and central nervous system cancers: A case-control study among workers at two nuclear facilities. *Am J Ind Med* 13:351-362.
- Carpenter CP, Smyth HF. 1946. Chemical burns of the rabbit cornea. *Am J Ophthalmol* 29:1363-1372.
- Carpenter CP, Geary DL, Myers RC, et al. 1976. Petroleum hydrocarbon toxicity studies: XIII. Animal and human response to vapors of toluene concentrate. *Toxicol Appl Pharmacol* 36:473-490.
- Carpenter CP, Shaffer CB, Weil CS, et al. 1944. Studies on the inhalation of 1,3-butadiene; with a comparison of its narcotic effect with benzol, toluol, and styrene, and a note on the elimination of styrene by the human. *J Ind Hyg Toxicol* 26(3):69-78.
- Carrer P, Maroni M, Alcini D, et al. 2000. Assessment through environmental and biological measurements of total daily exposure to volatile organic compounds of office workers in Milan, Italy. *Indoor Air* 10(4):258-268.

9. REFERENCES

- Carter JM, Lapham WW, Zorgorski JS. 2008. Occurrence of volatile organic compounds in aquifers of the United States. *J Am Water Works Assoc* 44(2):399-416.
- Caselli M, de Gennaro G, Saracino MR, et al. 2009. Indoor contaminants from newspapers: VOCs emissions in newspaper stands. *Environ Res* 109(2):149-157.
- Castilla-Serna L, Rodriguez-Perez R, Osorio-Cruces F, et al. 1991. Effects of chronic toluene inhalation on avoidance conditioned behavior in rats. *Arch Invest Med* 22:295-301.
- Cattaneo A, Taronna M, Consonni D, et al. 2010. Personal exposure of traffic police officers to particulate matter, carbon monoxide, and benzene in the city of Milan, Italy. *J Occup Environ Hyg* 7(6):342-351.
- Cavalleri A, Gobba F, Nicali E, et al. 2000. Dose-related color vision impairment in toluene-exposed workers. *Arch Environ Health* 55(6):399-404.
- CCME. 2004. Canadian soil quality guidelines for the protection of environmental and human health: Toluene (2004). Winnipeg: Canadian Council of Ministers of the Environment.
- CDC. 2009. Fourth national report on human exposure to environmental chemicals. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
- CDC. 2013. Fourth national report on human exposure to environmental chemicals. Updated tables, September 2013. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
- CDC. 2015. E-cigarette study sparks national attention around e-cigarettes and nicotine toxicity. Centers for Disease Control and Prevention. https://www.cdc.gov/nceh/hsb/success_stories/ecigarette_study.htm. March 17, 2017.
- CEPA. 1999. Public health goal for toluene in drinking water. California Environmental Protection Agency, Office of Environmental Health Hazard Assessment. <http://oehha.ca.gov/water/phg/pdf/tolu-f.pdf>. August 8, 2014.
- Chaigne B, Lasfargues G, Marie I, et al. 2015. Primary Sjogren's syndrome and occupational risk factors: A case-control study. *J Autoimmun* 60:80-85. 10.1016/j.jaut.2015.04.004.
- Chalansonnet M, Carabin N, Boucard S, et al. 2013. Study of the potential oxidative stress induced by six solvents in the rat brain. *Neurotoxicology* 35:71-83.
- Chambers DM, McElprang DO, Waterhouse MG, et al. 2006. An improved approach for accurate quantitation of benzene, toluene, ethylbenzene, xylene, and styrene in blood. *Anal Chem* 78(15):5375-5383.
- Chambers DM, Ocariz JM, McGuirk MF, et al. 2011. Impact of cigarette smoking on volatile organic compound (VOC) blood levels in the U.S. population: NHANES 2003-2004. *Environ Int* 37(8):1321-1328.
- Chan CC, Ozkaynak H, Spengler JD, et al. 1991a. Driver exposure to volatile organic compounds, CO, ozone, and NO₂ under different driving conditions. *Environ Sci Technol* 25(5):964-972.

9. REFERENCES

- Chan CC, Spengler JD, Ozkaynak H, et al. 1991b. Commuter exposures to VOCs in Boston, Massachusetts. *J Air Waste Manage Assoc* 4:1594-1600.
- Chan MH, Chung SS, Stoker AK, et al. 2012. Sarcosine attenuates toluene-induced motor incoordination, memory impairment, and hypothermia but not brain stimulation reward enhancement in mice. *Toxicol Appl Pharmacol*. 265(2):158-165.
- Chand P, Clausen J. 1982. Effects of toluene on cytochrome P-450 mixed function oxygenase and glutathione-s-transferase activities in rat brain and liver. *Bull Environ Contam Toxicol* 28:542-545.
- Chapman DE, Moore TJ, Michener SR, et al. 1990. Metabolism and covalent binding of [¹⁴C] toluene by human and rat liver microsomal fractions and liver slices. *Drug Metab Dispos* 18(6):929-936.
- Chatham-Stephens K, Law R, Taylor E, et al. 2014. Calls to poison centers for exposures to electronic cigarettes — United States, September 2010–February 2014. Centers for Disease Control and Prevention. *Morbidity and Mortality Weekly Report* 63(13):292-293. <https://www.cdc.gov/mmwr/pdf/wk/mm6313.pdf>. March 15, 2017.
- Chen CY, Wu SC. 1998. The influence of relative humidity on the adsorption of toluene by soils - interpretation with the adsorption energy distribution functions. *Chemosphere* 37(8):1437-1444.
- Chen HH, Lin YR, Chan MH. 2011. Toluene exposure during brain growth spurt and adolescence produces differential effects on N-methyl-D-aspartate receptor-mediated currents in rat hippocampus. *Toxicol Lett*. 205(3):336-340.
- Chen HH, Wei CT, Chan MH. 2004. Neonatal toluene exposure alters glutamate-induced calcium signaling in developing cerebellar granule neurons. *Ann N Y Acad Sci*. 1025(Current Status of Drug Dependence/Abuse Studies):556-560.
- Chen HH, Wei CT, Lin YR, et al. 2005. Neonatal toluene exposure alters agonist and antagonist sensitivity and NR2B subunit expression of NMDA receptors in cultured cerebellar granule neurons. *Toxicol Sci* 85(1):666-674.
- Chen ML, Chen SH, Guo BR, et al. 2002. Relationship between environmental exposure to toluene, xylene and ethylbenzene and the expired breath concentrations for gasoline service workers. *J Environ Monit* 4(4):562-566.
- Chouaniere D, Wild P, Fontana JM, et al. 2002. Neurobehavioral disturbances arising from occupational toluene exposure. *Am J Ind Med* 41(2):77-88.
- CHRC. 2007. The medical perspective on environmental sensitivities. Canadian Human Rights Commission. http://www.chrc-ccdp.gc.ca/sites/default/files/envsensitivity_en.pdf. May 2, 2016
- Ciarrocca M, Tomei G, Fiaschetti M, et al. 2012. Assessment of occupational exposure to benzene, toluene and xylenes in urban and rural female workers. *Chemosphere* 87(7):813-819.
- CIIT. 1980. A 24 month inhalation toxicology study in Fischer-344 rat exposed to atmospheric toluene. Executive summary and data tables. Conducted by Industrial Bio-Test Laboratories, Inc., Decatur, IL, and Experimental Pathology Laboratories, Inc., Raleigh, NC for Chemical Industry Institute of Toxicology. Research Triangle Park, NC. October 15, 1980.

9. REFERENCES

- *Cintra A, Andbjør B, Finnman UB, et al. 1996. Subacute toluene exposure increases DA dysfunction in the 6-OH dopamine lesioned nigrostriatal dopaminergic system of the rat. *Neurosci Lett* 217(1):61-65.
- Claus D, Walker N. 1964. The decomposition of toluene by soil bacteria. *J Gen Microbiol* 36:107-122.
- Clewell HJ, Andersen ME. 1985. Risk assessment extrapolations and physiological modeling. *Toxicol Ind Health* 1(4):111-131.
- Cocheo V, Silvestri R, Bombi GG, et al. 1982. Purge and trap analysis of toluene in blood: Comparison with the head space method. *Am Ind Hyg Assoc* 43(12):938-941.
- Cok I, Sardas S, Kadioglu E, et al. 2004. Assessment of DNA damage in glue sniffers by use of the alkaline comet assay. *Mutat Res* 557(2):131-136.
- Connor TH, Theiss JC, Hanna HA, et al. 1985. Genotoxicity of organic chemicals frequently found in the air of mobile homes. *Toxicol Lett* 25:33-40.
- Conti AC, Lowing JL, Susick LL, et al. 2012. Investigation of calcium-stimulated adenylyl cyclases 1 and 8 on toluene and ethanol neurobehavioral actions. *Neurotoxicol Teratol* 34(5):481-488.
- Coskun O, Oter S, Korkmaz A, et al. 2005. The oxidative and morphological effects of high concentration chronic toluene exposure on rat sciatic nerves. *Neurochem Res* 30(1):33-38.
- Costa LG, Aschner M, Vitalone A, et al. 2004. Developmental neuropathology of environmental agents. *Annu Rev Pharmacol Toxicol* 44:87-110.
- Courtney KD, Andrews JE, Springer J, et al. 1986. A perinatal study of toluene in CD-1 mice. *Fundam Appl Toxicol* 6:145-154.
- Cox HHJ, Nguyen TT, Deshusses MA. 2000. Toluene degradation in the recycle liquid of biotricking filters for air pollution control. *Appl Microbiol Biotechnol* 54:133-137.
- CPSC. 2012. Federal Hazardous Substances Act (FHSA) requirements. U.S. Consumer Product Safety Commission. <https://www.cpsc.gov/business--manufacturing/business-education/business-guidance/fhsa-requirements>. March 15, 2017.
- Crabbe JC, Belknap JK, Buck KJ. 1994. Genetic animal models of alcohol and drug abuse. *Science* 264:1715-1723.
- Crabbe JC, Metten P, Cameron AJ, et al. 2005. An analysis of the genetics of alcohol intoxication in inbred mice. *Neurosci Behav Rev* 28:785-802.
- Crist HL, Mitchell WJ. 1986. Field audit results with organic gas standards on volatile organic ambient air samplers equipped with Tenax GC. *Environ Sci Technol* 20(2):1260-1262.
- Crofton KM, Zhao X. 1997. The ototoxicity of trichloroethylene: Extrapolation and relevance of high-concentration, short-duration animal exposure data. *Fundam Appl Toxicol* 38(1):101-106.
- Cruz SL, Balster RL, Woodward JJ. 2000. Effects of volatile solvents on recombinant N-methyl-D-aspartate receptors expressed in *Xenopus oocytes*. *Br J Pharmacol* 131(7):1303-1308.

9. REFERENCES

- Cruz SL, Gauthereau MY, Camacho-Munoz C, et al. 2003. Effects of inhaled toluene and 1,1,1-trichloroethane on seizures and death produced by N-methyl-D-aspartic acid in mice. *Behav Brain Res.* 140(1-2):195-202.
- Cruz SL, Mirshahi T, Thomas B, et al. 1998. Effects of the abused solvent toluene on recombinant N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors expressed in *Xenopus oocytes*. *J Pharmacol Exp Ther* 286(1):334-340.
- Cruz SL, Paez-Martinez N, Pellicer F, et al. 2001. Toluene increases acute thermonociception in mice. *Behav Brain Res* 120(2):213-220.
- Curry KK, Brookman DJ, Whitmyre GK, et al. 1994. Personal exposures to toluene during use of nail lacquers in residences: Description of the results of a preliminary study. *J Expos Anal Environ Epidemiol* 4(4):443-456.
- Dahlan MH, Xing XH, Yoshikawa Y, et al. 1999. Analysis of a simple biodegradation process for the removal of volatile organic chemicals from wastewater based on a gas stripping principle. *J Biosci Bioeng* 87(4):519-524.
- Dalgaard M, Hossaini A, Hougaard KS, et al. 2001. Developmental toxicity of toluene in male rats: Effects on semen quality, testis morphology, and apoptotic neurodegeneration. *Arch Toxicol* 75(2):103-109.
- Dashniani M, Pochkhidze N, Zhvania M, et al. 2014. Age dependent effect of toluene chronic exposure on recognition memory. *Eur Neuropsychopharmacol* 24(Suppl. 2):S677.
- *da-Silva VA, Malheiros LR, Figueiredo LH, et al. 1991. Neurobehavioral development of rats exposed to toluene through maternal milk. *Braz J Med Biol Res* 24:1239-1243.
- da Silva VA, Malheiros LR, Paumgartten FJ, et al. 1990. Developmental toxicity of *in utero* exposure to toluene on malnourished and well-nourished rats. *Toxicology* 64:155-168.
- Das-Munshi J, Rubin GJ, Wessely S. 2006. Multiple chemical sensitivities: A systematic review of provocation studies. *J Allergy Clin Immunol* 118(6):1257-1264. 10.1016/j.jaci.2006.07.046.
- Davis DD, Heaps W, Philen D, et al. 1979. Boundary layer measurements of the OH radical in the vicinity of an isolated power plant plume: SO₂ and NO₂ chemical conversion times. *Atmos Environ* 13:1197-1203.
- Davis RR, Murphy WJ, Snawder JE, et al. 2002. Susceptibility to the ototoxic properties of toluene is species specific. *Hear Res* 166(1-2):24-32.
- Dearth MA, Glerczak CA, Slegl WO. 1992. On-line measurement of benzene and toluene in dilute vehicle exhaust by mass spectrometry. *Environ Sci Technol* 26(8):1573-1580.
- *De Ceaurriz J, Desiles JP, Bonnet P, et al. 1983. Concentration-dependent behavioral changes in mice following short-term inhalation exposure to various industrial solvents. *Toxicol Appl Pharmacol* 67:383-389.
- Dechow M, Sohn H, Steinhanses J. 1997. Concentrations of selected contaminants in cabin airbus aircrafts. *Chemosphere* 35(1-2):21-31.

9. REFERENCES

- DeJongh J, Blaauboer BJ. 1996. Simulation of toluene kinetics in the rat by a physiologically based pharmacokinetic model with application of biotransformation parameters derived independently *in vitro* and *in vivo*. *Fundam Appl Toxicol* 32(2):260-268.
- DeJongh J, Blaauboer BJ. 1997. Evaluation of *in vitro*-based simulations of toluene uptake and metabolism in rats. *Toxicol in Vitro* 11:485-489.
- Deleu D, Hanssens Y. 2000. Cerebellar dysfunction in chronic toluene abuse: Beneficial response to amantadine hydrochloride. *J Toxicol Clin Toxicol* 38(1):37-41.
- Del Re AM, Dopico AM, Woodward JJ. 2006. Effects of the abused inhalant toluene on ethanol-sensitive potassium channels expressed in oocytes. *Brain Res* 1087(1):75-82.
- Del Re AM, Woodward JJ. 2005. Inhibition of gap junction currents by the abused solvent toluene. *Drug Alcohol Depend* 78(2):221-224.
- De Luca C, Scordo G, Cesareo E, et al. 2010. Idiopathic environmental intolerances (IEI): From molecular epidemiology to molecular medicine. *Indian J Exp Biol* 48(7):625-635.
- De Luca C, Raskovic D, Pacifico V, et al. 2011. The search for reliable biomarkers of disease in multiple chemical sensitivity and other environmental intolerances. *Int J Environ Res Public Health* 8(7):2770-2797. 10.3390/ijerph8072770.
- DeMarini DM, Lawrence BK, Brooks HG, et al. 1991. Compatibility of organic solvents with the microscreen prophage-induction assay: Solvent-mutagen interactions. *Mutat Res.* 263:107-113.
- Deole S, Phadke KM, Kumar A. 2004. Benzene, toluene and xylene (BTX) pollution in ambient air: A case study. *J Environ Sci Eng* 46(1):15-20.
- *De Rosa E, Bartolucci GB, Sigon M, et al. 1987. Hippuric acid and ortho-cresol as biological indicators of occupational exposure to toluene. *Am J Ind Med* 11:529-537.
- *De Rosa E, Brugnone F, Bartolucci GB, et al. 1985. The validity of urinary metabolites as indicators of low exposures to toluene. *Int Arch Occup Environ Health* 56:135-145.
- Deschamps D, Geraud C, Dally S. 2001. Cognitive functions in workers exposed to toluene: Evaluation at least 48 hours after removal from exposure. *Int Arch Occup Environ Health* 74(4):285-288.
- Devathasan G, Low D, Teoh PC, et al. 1984. Complications of chronic glue (toluene) abuse in adolescents. *Aust NZ J Med* 14:39-43.
- Dewulf J, Van Langenhove HV. 1997. Chlorinated C1- and C2-hydrocarbons and monocyclic aromatic hydrocarbons in marine waters: An overview on fate processes, sampling, analysis and measurements. *Water Res* 31(8):1825-1838.
- Dick AL, Lawrence AJ, Duncan JR. 2014. Chronic intermittent toluene inhalation initiated during adolescence in rats does not alter voluntary consumption of ethanol in adulthood. *Alcohol* 48(6):561-569. 10.1016/j.alcohol.2014.08.001.

9. REFERENCES

- Dick AL, Pooters T, Gibbs S, et al. 2015. NMDA receptor binding is reduced within mesocorticolimbic regions following chronic inhalation of toluene in adolescent rats. *Brain Res* 1624:239-252. 10.1016/j.brainres.2015.07.037.
- Dick RB, Setzer JV, Wait R, et al. 1984. Effects of acute exposure of toluene and methyl ethyl ketone on psychomotor performance. *Int Arch Occup Environ Health* 54:91-109.
- Dickson RP, Luks AM. 2009. Toluene toxicity as a cause of elevated anion gap metabolic acidosis. *Respir Care* 54(8):1115-1117.
- Dilling WL, Bredeweg CJ, Tefertiller NB. 1976. Simulated atmospheric photodecomposition rates of methylene chloride, 1,1,1-trichloroethane, trichloroethylene, tetrachloroethylene and other compounds. *Environ Sci Technol* 10(4):351-356.
- Diot E, Lesire V, Guilmot JL, et al. 2002. Systemic sclerosis and occupational risk factors: A case-control study. *Occup Environ Med* 59(8):545-549.
- Dobaradaran S, Mahvi AH, Nabizadeh R, et al. 2010. Hazardous organic compounds in groundwater near Tehran automobile industry. *Bull Environ Contam Toxicol* 85(5):530-533.
- Dobrokhotov VB, Enikeev MI. 1977. The mutagenic action of benzene, toluene and a mixture of these hydrocarbons in a chronic test. *Gig Sanit* 42:32-34.
- DOE. 2012. Protective action criteria (PAC). Oak Ridge, TN: U.S. Department of Energy and Subcommittee on Consequence Assessment and Protective Actions (SCAPA). <http://orise.orau.gov/emi/scapa/chem-pacs-teels/default.htm>. January 08, 2014.
- Dolfing J, Zeyer J, Binder-Eicher P, et al. 1990. Isolation and characterization of a bacterium that mineralizes toluene in the absence of molecular oxygen. *Arch Microbiol* 154:336-341.
- Donald JM, Hooper K, Hopenhayn-Rich C. 1991. Reproductive and developmental toxicity of toluene: A review. *Environ Health Perspect* 94:237-244.
- Dossing M, Aelum JB, Hansen SH, et al. 1983b. Urinary hippuric acid and orthocresol excretion in man during experimental exposure to toluene. *Br J Ind Med* 40:470-473.
- *Dossing M, Arlien-Soborg P, Petersen LM, et al. 1983a. Liver damage associated with occupational exposure to organic solvents in house painters. *Eur J Clin Invest* 13:151-157.
- Dossing M, Baelum J, Hansen SH, Lundqvist GR. 1984. Effect of ethanol, cimetidine and propranolol on toluene metabolism in man. *Int Arch Occup Environ Health* 54:309-315.
- Dossing M, Baelum J, Lundqvist GR. 1983c. Antipyrine clearance during experimental and occupational exposure to toluene. *Br J Ind Med* 40:466-469.
- Ducos P, Berode M, Francin JM, et al. 2008. Biological monitoring of exposure to solvents using the chemical itself in urine: Application to toluene. *Int Arch Occup Environ Health* 81(3):273-284.
- Duncan JR, Dick AL, Egan G, et al. 2012. Adolescent toluene inhalation in rats affects white matter maturation with the potential for recovery following abstinence. *PLoS ONE* 7(9):e44790.

9. REFERENCES

- Dutkiewicz T, Tyras H. 1968. Skin absorption of toluene, styrene and xylene by man. *Br J Ind Med* 25:243.
- Dyer RS, Bercegeay MS, Mayo LM. 1988. Acute exposures to p-xylene and toluene alter visual information processing. *Neurotoxicol Teratol* 10:147-153.
- Dyne D, Cocker J, Wilson HK. 1997. A novel device for capturing breath samples for solvent analysis. *Sci Total Environ* 199:83-89.
- EC. 2003. European Union risk assessment report. Toluene. European Commission, Institute for Health and Consumer Protection, European Chemicals Bureau.
- Echeverria D, Fine L, Langolf G, et al. 1989. Acute neurobehavioral effects of toluene. *Br J Ind Med* 46:483-495.
- Echeverria D, Fine L, Langolf G, et al. 1991. Acute behavioural comparisons of toluene and ethanol in human subjects. *Br J Ind Med* 48:750-761.
- Edelfors S, Hass U, Hougaard KS. 2002. Changes in markers of oxidative stress and membrane properties in synaptosomes from rats exposed prenatally to toluene. *Pharmacol Toxicol* 90(1):26-31.
- *Edling C, Hellman B, Arvidson B, et al. 1997. Positron emission tomography studies of healthy volunteers- no effects on the dopamine terminals and synthesis after short-term exposure to toluene. *Hum Exp Toxicol* 16:171-176.
- Edwards EA, Wills LE, Reinhard M, et al. 1992. Anaerobic degradation of toluene and xylene by aquifer microorganisms under sulfate-reducing conditions. *Appl Environ Microbiol* 58(3):794-800.
- Einav S, Amitai Y, Reichman J, et al. 1997. Bradycardia in toluene poisoning. *J Toxicol Clin Toxicol* 35(3):295-298.
- Ek CJ, Dziegielewska KM, Habgood MD, et al. 2012. Barriers in the developing brain and neurotoxicology. *Neurotoxicology* 33(3):586-604.
- Eller N, Netterstrom B, Laursen P. 1999. Risk of chronic effects on the central nervous system at low toluene exposure. *Occup Med* 49(6):389-395.
- EMMI. 1997. Environmental monitoring methods index. Version 1.1.PC#4082. Rockville, MD: US Environmental Protection Agency, Government institutes.
- EPA. 1982a. Purgeable aromatics-method 602. Methods for organic chemical analysis of municipal and industrial wastewater. Cincinnati, OH: U.S. Environmental Protection Agency. Environmental Monitoring and Support Laboratory. EPA602-1 -602-9.
- EPA. 1982b. Purgeables-method 624. Methods for organic chemical analysis of municipal and industrial wastewater. Cincinnati, OH: U.S. Environmental Protection Agency. Environmental Monitoring and Support Laboratory. EPA624-1- 624-12.
- EPA. 1983a. List of chemicals produced by affected facilities. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 60, Subpart VV.

9. REFERENCES

- EPA. 1983b. Exposure and risk assessment for toluene. Final draft report. Washington DC: U.S. Environmental Protection Agency, Office of Water Regulations and Standards. PB85221505. EPA440485016.
- EPA. 1984. Method 1624 Revision B - volatile organic compounds by isotope dilution GC/MS. U.S. Environmental Protection Agency. Fed Regist 49:43407.
- EPA. 1985. Drinking water criteria document for toluene. Washington, DC: U.S. Environmental Protection Agency, Office of Drinking Water. ECAO-CIN-408. EPA 600/x-84-188. PB 86-117975.
- EPA. 1988a. Method T01. Method for the determination of volatile organic compounds in ambient air using tenax adsorption and gas chromatography/mass spectrometry (GC/MS). In: Compendium of methods for the determination of toxic organic compounds in ambient air. U.S. Environmental Protection Agency. EPA 600/4-89/017.
- EPA. 1988b. Method T014. Determination of volatile organic compounds (VOCs) in ambient air using summa passivated canister sampling and gas chromatographic analysis. In: Compendium of methods for the determination of toxic organic compounds in ambient air. U.S. Environmental Protection Agency. EPA 600/4-89/017.
- EPA. 1990a. Drinking water criteria document for toluene. Cincinnati, OH: U.S. Environmental Protection Agency, Office of Health and Environmental Assessment, Research and Development, ECAO-CIN-408.
- EPA. 1990b. Interim methods for development of inhalation reference concentrations. Washington, DC: U.S. Environmental Protection Agency, Office of Health and Environmental Assessment, Office of Research and Development, Environmental Criteria and Assessment Office. EPA600/890066A.
- EPA. 1991a. Method 502.2. Volatile organic compounds in water by purge and trap capillary column gas chromatography with photo ionization and electrolytic conductivity detectors in series. In: Methods for the determination of organic compounds in drinking water. Cincinnati, OH: U.S. Environmental Protection Agency, Environmental Monitoring Systems Laboratory. EPA 600/4-88/039.
- EPA. 1991b. Method 503.1. Volatile aromatic and unsaturated organic compounds in water by purge and trap gas chromatography, Revision 2.0. In: Methods for the determination of organic compounds in drinking water, EPA-600/4-88/039, 1988. Cincinnati, OH: U.S. Environmental Protection Agency, Environmental Monitoring Systems Laboratory, Office of Research and Development.
- EPA. 1992a. Method 524.2. Measurement of permeable organic compounds in water by capillary column gas chromatography/mass spectrometry. In: Methods for the determination of organic compounds in drinking water: Supplement II. Cincinnati, OH: U.S. Environmental Protection Agency, Environmental Monitoring Systems Laboratory, Office of Research and Development. EPA 600/R-92/129.
- EPA. 1992b. Dermal exposure assessment: Principles and applications. Washington, DC: U.S. Environmental Protection Agency, Office of Health and Environmental Assessment. EPA600/891011B.
- EPA. 1994. Locating and estimating air emissions from sources of toluene. Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Air Quality Planning and Standards. EPA454R93047.

9. REFERENCES

- EPA. 1995. Designation, reportable quantities, and notification. List of hazardous substance and reportable quantities. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 302.4.
- EPA. 1996a. Method 8021B. Aromatic and halogenated volatiles by gas chromatography using photoionization and/or electrolytic conductivity detectors. U.S. Environmental Protection Agency.
- EPA. 1996b. Method 8260B. Volatile organic compounds by gas chromatography/mass spectrometry (GC/MS). U.S. Environmental Protection Agency.
- EPA. 1996c. Method 4030. Soil screening for petroleum hydrocarbons by immunoassay. U.S. Environmental Protection Agency.
- EPA. 1997a. Identification and listing of hazardous waste. Hazardous constituents. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 261, Appendix VIII.
- EPA. 1997b. Special report on environmental endocrine disruption: An effects assessment and analysis. Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. EPA630R96012.
- EPA. 1998. Notice of availability of draft RCRA waste minimization PBT chemical list. Fed Regist. U.S. Environmental Protection Agency. 63(2):60332-60343.
- EPA. 2005a. Toxicological review of toluene (CAS No. 108-88-3) in support of summary information on the Integrated Risk Information System (IRIS). Washington, DC: U.S. Environmental Protection Agency.
- EPA. 2005b. Toxic chemical release inventory reporting forms and instructions: Revised 2004 version. Section 313 of the Emergency Planning and Community Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of 1986). U.S. Environmental Protection Agency, Office of Environmental Information. EPA260B05001.
- EPA. 2006. Consolidated list of chemicals subject to the Emergency Planning and Right-To-Know Act (EPCRA) and section 112(r) of the Clean Air Act. U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response. EPA550B01003.
- EPA. 2009a. Drinking water contaminant candidate list. U.S. Environmental Protection Agency. Fed Regist 74 FR 51850:51850 -51862. <http://www.gpo.gov/fdsys>. January 08, 2014.
- EPA. 2009b. National primary drinking water regulations. Washington, DC: U.S. Environmental Protection Agency, Office of Ground Water and Drinking Water. EPA816F090004. <http://water.epa.gov/drink/contaminants/>. January 08, 2014.
- EPA. 2012. Drinking water standards and health advisories. Washington, DC: U.S. Environmental Protection Agency, Office of Water. EPA822S12001. <http://water.epa.gov/drink/standards/hascience.cfm>. January 08, 2014.
- EPA. 2013a. 2011. Sector summaries-criteria and hazardous air pollutants by 60 EIS emission sectors. The 2011 National emissions inventory. U.S. Environmental Protection Agency. <http://www.epa.gov/ttnchie1/net/2011inventory.html>. July 16, 2014. .

9. REFERENCES

EPA. 2013b. Data from Air Quality System (AQS). <http://www.epa.gov/ttn/airs/airsaqs/>. April 23, 2014.

EPA. 2013c. Acute exposure guideline levels (AEGLs). Washington, DC: U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics. <http://www.epa.gov/oppt/aegl/>. January 08, 2014.

EPA. 2013d. Designated as hazardous substances in accordance with section 311(b)(2)(a) of the Clean Water Act. U.S. Environmental Protection Agency. Code of Federal Regulations 40 CFR 116.4. <http://www.gpo.gov/fdsys>. January 08, 2014.

EPA. 2013e. Identification and listing of hazardous waste. Hazardous constituents. U.S. Environmental Protection Agency. Code of Federal Regulations 40 CFR 261, Appendix VIII. <http://www.gpo.gov/fdsys>. January 08, 2014.

EPA. 2013f. Reportable quantities of hazardous substances designated pursuant to section 311 of the Clean Water Act. U.S. Environmental Protection Agency. Code of Federal Regulations 40 CFR 117.3. <http://www.gpo.gov/fdsys>. January 08, 2014.

EPA. 2013g. Superfund, emergency planning, and community right-to-know programs. Designation, reportable quantities, and notifications. U.S. Environmental Protection Agency. Code of Federal Regulations 40 CFR 302.4. <http://www.gpo.gov/fdsys>. January 08, 2014.

EPA. 2013h. Superfund, emergency planning, and community right-to-know programs. Toxic chemical release reporting. U.S. Environmental Protection Agency. Code of Federal Regulations 40 CFR 372.65. <http://www.gpo.gov/fdsys>. January 08, 2014.

EPA. 2013i. Superfund, emergency planning, and community right-to-know programs. Extremely hazardous substances and their threshold planning quantities. U.S. Environmental Protection Agency. Code of Federal Regulations 40 CFR 355, Appendix A. <http://www.gpo.gov/fdsys>. January 08, 2014.

EPA. 2013j. Standards for owners and operators of hazardous waste TSD facilities. Groundwater monitoring list. U.S. Environmental Protection Agency. Code of Federal Regulations 40 CFR 264, Appendix IX. <http://www.gpo.gov/fdsys>. January 08, 2014.

EPA. 2013k. Toxic Substances Control Act. Chemical lists and reporting periods. U.S. Environmental Protection Agency. Code of Federal Regulations 40 CFR 712.30. <http://www.gpo.gov/fdsys>. January 08, 2014.

EPA. 2013l. Toxic Substances Control Act. Health and safety data reporting. U.S. Environmental Protection Agency. Code of Federal Regulations 40 CFR 716.120. <http://www.gpo.gov/fdsys>. January 08, 2014.

EPA. 2014a. Hazardous air pollutants. Clean Air Act. U.S. Environmental Protection Agency. United States Code 42 USC 7412. <http://www.epa.gov/ttn/atw/orig189.html>. January 08, 2014.

EPA. 2014b. Inert ingredients permitted for use in nonfood pesticide products. Washington, DC: U.S. Environmental Protection Agency. <http://iaspub.epa.gov/apex/pesticides/f?p=124:1>. January 08, 2014.

9. REFERENCES

- EPA. 2014c. Master testing list. Washington, DC: U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics. <http://www.epa.gov/opptintr/chemtest/pubs/mtl.html>. January 08, 2014.
- EPA. 2014d. National ambient air quality standards (NAAQS). Washington, DC: U.S. Environmental Protection Agency, Office of Air and Radiation. <http://www.epa.gov/air/criteria.html>. January 08, 2014.
- EPA. 2014e. National recommended water quality criteria. Washington, DC: U.S. Environmental Protection Agency, Office of Water, Office of Science and Technology. <http://water.epa.gov/scitech/swguidance/standards/criteria/current/index.cfm>. January 08, 2014.
- EPA. 2016. AQS data mart. Download data files. U.S. Environmental Protection Agency. http://aqsdrl.epa.gov/aqsweb/aqstmp/airdata/download_files.html. September 28, 2016.
- Erramouspe J, Galvez R, Fischel DR. 1996. Newborn renal tubular acidosis associated with prenatal maternal toluene sniffing. *J Psychoactive Drugs* 28(2):201-204.
- Esteve-Turrillas FA, Ly-Verdu S, Pastor A, et al. 2009. Development of a versatile, easy and rapid atmospheric monitor for benzene, toluene, ethylbenzene and xylenes determination in air. *J Chromatogr A* 1216(48):8549-8556.
- Evans GF, Lumpkin TA, Smith DL, et al. 1992. Measurements of VOCs from the TAMS network. *J Air Waste Manag Assoc* 42:1319-1323.
- Exxon Chemical Co. 1962. Acute eye application - rabbits. Houston, TX: Exxon Chemical Company U.S.A. Submitted to the U.S. Environmental Protection Agency under TSCA Section 8D. OTS0200153.
- Fabri J, Graeser U, Simo TA. 2012. Toluene. In: *Ullmann's encyclopedia of industrial chemistry*. Vol. 37. Weinheim, Germany: Wiley-VCH Verlag, 109-118.
- FDA. 2013. Requirements for specific standardized beverages. U.S. Food and Drug Administration. Code of Federal Regulations 21 CFR 165.110. <http://www.gpo.gov/fdsys>. January 08, 2014.
- FDA. 2014. Everything added to food in the United States (EAFUS). Washington, DC: U.S. Food and Drug Administration. <http://www.accessdata.fda.gov/scripts/fcn/fcnavigation.cfm?rpt=eafuslisting>. January 08, 2014.
- Ferrari M, Negri S, Zadra P, et al. 2008. Saliva as an analytical tool to measure occupational exposure to toluene. *Int Arch Occup Environ Health* 81(8):1021-1028.
- Filley CM, Heaton RK, Rosenberg NL. 1990. White matter dementia in chronic toluene abuse. *Neurology* 40:532-534.
- Fisher J, Mahle D, Bankston L, et al. 1997. Lactational transfer of volatile chemicals in breast milk. *American Ind Hyg Assoc J* 58(6):425-431.
- Fluck ER, Poirier LA, Ruelius HW. 1976. Evaluation of a DNA polymerase-deficient mutant of *E. coli* for rapid detection of carcinogens. *Chem Biol Interact* 15:219-231.
- Fomon SJ. 1966. Body composition of the infant: Part I: The male "reference infant". In: Falkner F, ed. *Human development*. Philadelphia, PA: WB Saunders, 239-246.

9. REFERENCES

- Fomon SJ, Haschke F, Ziegler EE, et al. 1982. Body composition of reference children from birth to age 10 years. *Am J Clin Nutr* 35(Suppl 5):1169-1175.
- Foo SC, Jeyaratnam J, Koh D. 1990. Chronic neurobehavioural effects of toluene. *Br J Ind Med* 47:480-484.
- *Foo SC, Jeyaratnam J, Ong CN, et al. 1991. Biological monitoring for occupational exposure to toluene. *Am Ind Hyg Assoc J* 52(5):212-217.
- Forni A, Pacifico E, Limonta A. 1971. Chromosome studies in workers exposed to benzene or toluene or both. *Arch Environ Health* 22:373-378.
- Franco I, Valdez-Tapia M, Sanchez-Serrano SL, et al. 2014. Chronic toluene exposure induces cell proliferation in the mice SVZ but not migration through the RMS. *Neurosci Lett* 575:101-106. 10.1016/j.neulet.2014.05.043.
- Franke C, Studinger G, Berger G, et al. 1994. The assessment of bioaccumulation. *Chemosphere* 29:1501-1514.
- Franks NP, Lieb WR. 1985. Mapping of general anaesthetic target sites provides a molecular basis for cutoff effects. *Nature* 316:349-351.
- Franks NP, Lieb WR. 1987. Anaesthetics on the mind. *Nature* 328:113-114.
- Fraser MP, Cass GR, Simoneit BRT. 1998. Gas-phase and particle-phase organic compounds emitted from motor vehicle traffic in a Los Angeles roadway tunnel. *Environ Sci Technol* 32:2051-2060.
- Fujimaki H, Win-Shwe TT, Yamamoto S, et al. 2009a. Role of CD4⁺ T cells in the modulation of neurotrophin production in mice exposed to low-level toluene. *Immunopharmacol Immunotoxicol* 31(1):146-149.
- Fujimaki H, Win-Shwe TT, Yamamoto S, et al. 2009b. The expression of nerve growth factor in mice lung following low-level toluene exposure. *Toxicol Lett* 191(2-3):240-245.
- Fujimaki H, Win-Shwe TT, Yamamoto S, et al. 2010. Different sensitivity in expression of transcription factor mRNAs in congenic mice following exposure to low-level toluene. *Inhal Toxicol* 22(11):903-909.
- Fujimaki H, Win-Shwe TT, Yoshida Y, et al. 2011. Dysregulation of immune responses in an allergic mouse model following low-level toluene exposure. *Toxicology* 286(1-3):28-35.
- Fujimaki H, Yamamoto S, Win-Shwe TT, et al. 2007. Effect of long-term exposure to low-level toluene on airway inflammatory response in mice. *Toxicol Lett* 168(2):132-139.
- Fukami T, Katoh M, Yamazaki H, et al. 2008. Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: Naphthalene, styrene, and toluene. *Chem Res Toxicol* 21:720-725.
- *Fukui K, Utsumi H, Tamada Y, et al. 1996. Selective increase in astrocytic elements in the rat dentate gyrus after chronic toluene exposure studied by GFAP immunocytochemistry and electron microscopy. *Neurosci Lett* 203(2):85-8.

9. REFERENCES

- Funada M, Sato M, Makino Y, et al. 2002. Evaluation of rewarding effect of toluene by the conditioned place preference procedure in mice. *Brain Res Brain Res Protoc* 10(1):47-54.
- Furman GM, Silverman DM, Schatz RA. 1998. Inhibition of rat lung mixed-function oxidase activity following repeated low-level toluene inhalation: Possible role of toluene metabolites. *J Toxicol Environ Health, Part A* 54:633-645.
- Fustinoni S, Buratti M, Giampiccolo R, et al. 1996. Monitoraggio biologico dell'esposizione a solventi: Metodo per la determinazione gascromatografica degli idrocarburi aromatici nel sangue e nell'urina. *Med Lav* 87(1):63-75. (Italian)
- Fuxe K, Andersson K, Nilsen OG, et al. 1982. Toluene and telencephalic dopamine: Selective reduction of amine turnover in discrete DA nerve terminal systems of the anterior caudate nucleus by low concentrations of toluene. *Toxicol Lett* 12:115-123.
- Gagnaire F, Langlais C. 2005. Relative ototoxicity of 21 aromatic solvents. *Arch Toxicol* 79:346-354.
- Galliot E, Laurent L, Hacquemand R, et al. 2012. Fear-like behavioral responses in mice in different odorant environments: Trigeminal versus olfactory mediation under low doses. *Behav Processes* 90(2):161-166.
- Gamberale F, Hultengren M. 1972. Toluene exposure. II. Psychophysiological functions. *Work Environ Health* 9:131-139.
- Gao Y, Zhang Y, Kamijima M, et al. 2014. Quantitative assessments of indoor air pollution and the risk of childhood acute leukemia in Shanghai. *Environ Pollut* 187:81-89. 10.1016/j.envpol.2013.12.029.
- Garcia JP, Beyne-Masclat S, Mouvier G. 1992. Emissions of volatile organic compounds by coal-fired power stations. *Atmos Environ* 26A(9):1589-1597.
- Garland EL, Howard MO, Vaughn MG, et al. 2011. Volatile substance misuse in the United States. *Subst Use Misuse* 46:8-20.
- Gelazonia L, Japaridze N, Maglakelidze G, et al. 2006b. Influence of toluene intoxication on the number of mitral and granular neurons in olfactory bulbs of rats. *Georgian Med News* (133):99-101. <http://www.geomednews.org/shared/issues/med133.pdf>.
- Gelazonia L, Japaridze N, Svanidze I. 2006a. Pyramidal cell loss in hippocampus of young rats exposed to toluene. *Georgian Med News* (135):126-128. <http://www.geomednews.org/shared/issues/med135.pdf>. May 30, 2014.
- *Geller I, Hartmann RJ, Messiha. 1983. Biochemical aspects of toluene exposure in the rat as a function of sex. *Proc West Pharmacol Soc* 26:197-199.
- Genuis SJ. 2010. Sensitivity-related illness: The escalating pandemic of allergy, food intolerance and chemical sensitivity. *Sci Total Environ* 408(24):6047-6061. 10.1016/j.scitotenv.2010.08.047.
- Genuis SJ. 2013. Chemical sensitivity: Pathophysiology or pathopsychology? *Clin Ther* 35(5):572-577. 10.1016/j.clinthera.2013.04.003.

9. REFERENCES

- Gerasimov MR, Collier L, Ferrieri A, et al. 2003. Toluene inhalation produces a conditioned place preference in rats. *Eur J Pharmacol* 477(1):45-52.
- Gerasimov MR, Ferrieri RA, Schiffer WK, et al. 2002a. Study of brain uptake and biodistribution of [^{11}C]toluene in non-human primates and mice. *Life Sci*. 70(23):2811-2828.
- Gerasimov MR, Logan J, Ferrieri RA, et al. 2002b. Effect of vehicle on brain uptake of [^{11}C]toluene. *Nucl Med Biol*. 29(5):607-612.
- Gerasimov MR, Schiffer WK, Marsteller D, et al. 2002c. Toluene inhalation produces regionally specific changes in extracellular dopamine. *Drug Alcohol Depend*. 65(3):243-251.
- Gericke C, Hanke B, Beckmann G, et al. 2001. Multicenter field trial on possible health effects of toluene. III. Evaluation of effects after long-term exposure. *Toxicology* 168(2):185-209.
- *Gerin M, Siemiatycki J, Desy M, et al. 1998. Associations between several sites of cancer and occupational exposure to benzene, toluene, xylene, and styrene: Results of a case-control study in Montreal. *Am J Ind Med* 34:144-156.
- Gerkin RD, LoVecchio F. 1998. Rapid reversal of life-threatening toluene-induced hypokalemia with hemodialysis. *J Emerg Med* 16(5):723-725.
- Gerner-Smidt P, Friedrich U. 1978. The mutagenic effect of benzene, toluene and xylene studied by the SCE technique. *Mutat Res* 55:313-316.
- Ghantous H, Danielsson BRG. 1986. Placental transfer and distribution of toluene, xylene and benzene and their metabolites during gestation in mice. *Biol Res Pregnancy Perinatol* 7(3):98-105.
- Ghosh TK, Copeland RL, Gear JC, et al. 1989. Effects of toluene exposure on the spontaneous cortical activity in rats. *Pharmacol Biochem Behav* 32:987-992.
- Ghosh TK, Copeland RL, Pradhan SN. 1990. Sensitivity of EEG in young rats to toluene exposure. *Pharmacol Biochem Behav* 36:779-785.
- *Gibson JE, Hardisty JF. 1983. Chronic toxicity and oncogenicity bioassay of inhaled toluene in Fischer-344 rats. *Fundam Appl Toxicol* 3(4):315-319.
- Giwerzman A, Carlsen E, Keiding N, et al. 1993. Evidence for increasing incidence of abnormalities of the human testis: A review. *Environ Health Perspect Suppl* 101(2):65-71.
- Gmaz JM, Yang L, Ahrari A, et al. 2012. Binge inhalation of toluene vapor produces dissociable motor and cognitive dysfunction in water maze tasks. *Behav Pharmacol*. 23(7):669-677.
- *Goldbloom D, Chouinard G. 1985. Schizophreniform psychosis associated with chronic industrial toluene exposure: Case report. *J Clin Psychiatry* 46:350-351.
- Gonzalez-Yebra AL, Kornhauser C, Barbosa-Sabanero G, et al. 2009. Exposure to organic solvents and cytogenetic damage in exfoliated cells of the buccal mucosa from shoe workers. *Int Arch Occup Environ Health* 82(3):373-380.

9. REFERENCES

- Gonzalez-Yebra AL, Kornhauser C, Wrobel K, et al. 2006. Occupational exposure to toluene and its possible causative role in renal damage development in shoe workers. *Int Arch Occup Environ Health* 79(3):259-264.
- Goodwin TM. 1988. Toluene abuse and renal tubular acidosis in pregnancy. *Obstet Gynecol* 71(5):715-718.
- Gopal KV. 2008. Audiological findings in individuals exposed to organic solvents: Case studies. *Noise Health* 10(40):74-82.
- Gordon CJ, Gottipolu RR, Kenyon EM, et al. 2010. Aging and susceptibility to toluene in rats: A pharmacokinetic, biomarker, and physiological approach. *J Toxicol Environ Health A* 73(4):301-318.
- Gordon CJ, Samsam TE, Oshiro WM, et al. 2007. Cardiovascular effects of oral toluene exposure in the rat monitored by radiotelemetry. *Neurotoxicol Teratol* 29(2):228-235.
- Gorlo D, Zygmunt B, Dudek M, et al. 1999. Application of solid-phase microextraction to monitoring indoor air quality. *Fresenius' J Anal Chem* 363(7):696-699.
- *Gospe SM Jr, Al-Bayati MAS. 1994. Comparison of oral and inhalation exposures to toluene. *J Am Coll Toxicol* 13(1):21-32.
- *Gospe SM, Calaban MJ. 1988. Central nervous system distribution of inhaled toluene. *Fundam Appl Toxicol* 11:540-545.
- Gospe SM Jr, Zhou SS. 1998. Toluene abuse embryopathy: Longitudinal neurodevelopmental effects of prenatal exposure to toluene in rats. *Reprod Toxicol* 12(2):119-126.
- Gospe SM Jr, Zhou SS. 2000. Prenatal exposure to toluene results in abnormal neurogenesis and migration in rat somatosensory cortex. *Pediatr Res* 47(3):362-368.
- Gospe SM Jr, Saeed DB, Zhou SS, et al. 1994. The effects of high-dose toluene on embryonic development in the rat. *Pediatr Res* 36(6):811-815.
- Gospe SM Jr, Zhou SS, Saeed DB et al. 1996. Development of a rat model of toluene-abuse embryopathy. *Pediatr Res* 40(1):82-87.
- Gotohda T, Kuwada A, Morita K, et al. 2000b. Elevation of steroid 5 α -reductase mRNA levels in rat cerebellum by toluene inhalation: Possible relation to GFAP expression. *J Toxicol Sci* 25(3):223-231.
- Gotohda T, Nishimura A, Morita K. 2009. Immunohistochemical studies on early stage of hepatic damage induced by subacute inhalation of toluene vapor in rats. *J Appl Toxicol* 29(6):505-509.
- Gotohda T, Tokunaga I, Kitamura O, et al. 2007. Toluene inhalation induced neuronal damage in the spinal cord and changes of neurotrophic factors in rat. *Leg Med* 9(3):123-127.
- Gotohda T, Tokunaga I, Kubo S, et al. 2000a. Effect of toluene inhalation on astrocytes and neurotrophic factor in rat brain. *Forensic Sci Int* 113(1-3):233-238.

9. REFERENCES

- Gotohda T, Tokunaga I, Kubo S, et al. 2002. Toluene inhalation induces glial cell line-derived neurotrophic factor, transforming growth factor and tumor necrosis factor in rat cerebellum. *Leg Med* 4(1):21-28.
- Gotohda T, Tokunaga I, Kubo S. 2005. Toluene inhalation-induced adrenocortical hypertrophy and endocrinological changes in rat. *Life Sci* 76(17):1929-1937.
- Graham. 1990. Solvent abuse. In: Haddad LM, Winchester JF eds. *Clinical management of poisoning and drug overdose*. 2nd ed. Philadelphia, PA: W.B. Saunders Company, 1256-1260.
- Greenburg L, Mayers MR, Heimann H, et al. 1942. The effects of exposure to toluene in industry. *JAMA* 118:573-578.
- Grob K. 1965. Gas chromatography of cigarette smoke. Part III. Separation of the overlap region of gas and particulate phase by capillary columns. *J Gas Chromatogr* February:52-56.
- Gross SA, Avens HJ, Banducci AM, et al. 2013. Analysis of BTEX groundwater concentrations from surface spills associated with hydraulic fracturing operations. *J Air Waste Manag Assoc* 63(4):424-432.
- Guldborg PH. 1992. Gasoline and vapor exposures in service station and leaking underground storage tank scenarios. *J Expo Anal Environ Epidemiol* 2(1):97-107.
- Gummin DD. 2015. Hydrocarbons. In: Hoffman RS, Lewin NA, Goldfrank LR, et al., eds. *Goldfrank's toxicologic emergencies*. 7th ed. New York, NY: McGraw-Hill Education, 1334-1345.
- Gupta SR, Palmer CA, Cure JK, et al. 2011. Toluene optic neurotoxicity: Magnetic resonance imaging and pathologic features. *Hum Pathol* 42(2):295-298.
- Guzelian PS, Henry CJ, Olin SS, eds. 1992. *Similarities and differences between children and adults: Implications for risk assessment*. Washington, DC: International Life Sciences Institute Press.
- Guzelian P, Mills S, Fallon HJ. 1988. Liver structure and function in print workers exposed to toluene. *J Occup Med* 30(10):791-796.
- Haddad S, Tardif R, Viau C, et al. 1999. A modeling approach to account for toxicokinetic interactions in the calculation of biological hazard index for chemical mixtures. *Toxicol Lett*. 108(2-3):303-308.
- Haglund U, Lundberg I, Zech L. 1980. Chromosome aberrations and sister chromatid exchanges in Swedish paint industry workers. *Scand J Environ Health* 6:291-298.
- Hakkola M, Saarinen L. 1996. Exposure of tanker drivers to gasoline and some of its components. *Ann Occup Hyg* 40:1-10.
- Halifeoglu I, Canatan H, Ustundag B, et al. 2000. Effect of thinner inhalation on lipid peroxidation and some antioxidant enzymes of people working with paint thinner. *Cell Biochem Funct* 18(4):263-267.
- Hamidin N, Yu J, Phung DT, et al. 2013. Volatile aromatic hydrocarbons (VAHs) in residential indoor air in Brisbane, Australia. *Chemosphere* 92(11):1430-1435.
- Hammer KD. 2002. Metabolite ratio of toluene-exposed rotogravure printing plant workers reflects individual mutagenic risk by sister chromatid exchanges. *Mutat Res* 519(1-2):171-177.

9. REFERENCES

- Hammer KD, Mayer N, Pfeiffer EH. 1998. Sister chromatid exchanges in rotogravure printing plant workers. *Int Arch Occup Environ Health* 71:138-142.
- Hanioka N, Yamamoto M, Tanaka-Kagawa T, et al. 2010. Functional characterization of human cytochrome P450 2E1 allelic variants: *In vitro* metabolism of benzene and toluene by recombinant enzymes expressed in yeast cells. *Arch Toxicol* 84(5):363-371.
- Hannigan JH, Bowen SE. 2010. Reproductive toxicology and teratology of abused toluene. *Syst Biol Reprod Med* 56(2):184-200.
- *Hanninen H, Antti-Pocka, Savolainen P. 1987. Psychological performance, toluene exposure and alcohol consumption in rotogravure printers. *Int Arch Occup Environ Health* 89:475-483.
- Hanninen H, Eskelinen L, Husman K, et al. 1976. Behavioral effects of long-term exposure to a mixture of organic solvents. *Scand J Work Environ Health* 2:240-255.
- *Hansson T, Pettersson B-M, Eneroth P, et al. 1985. Neonatal exposure to toluene: Effects on the development of liver microsomal cytochrome P-450 and serum hormone levels in the rat. *Toxicology* 37:39-50.
- Harabuchi I, Kishi R, Ikeda T, et al. 1993. Circadian variations of acute toxicity and blood and brain concentrations of inhaled toluene in rats. *Br J Ind Med* 50:280-286.
- Haro-Garcia LC, Juarez-Perez CA, Aguilar-Madrid G, et al. 2012. Production of IL-10, TNF and IL-12 by peripheral blood mononuclear cells in Mexican workers exposed to a mixture of benzene-toluene-xylene. *Arch Med Res* 43(1):51-57.
- Hass U, Lund S, Hougaard K, et al. 1999. Developmental neurotoxicity after toluene inhalation exposure in rats. *Neurotoxicol Teratol* 21(4):349-357.
- Haynes WM, Lide DR, Bruno TJ. 2013. Toluene. In: *CRC handbook of chemistry and physics*. Boca Raton, FL: CRC Press, 3-514-3-515.
- Heck JE, Park AS, Qui J, et al. 2013. An exploratory study of ambient air toxics exposure in pregnancy and the risk of neuroblastoma in offspring. *Environ Res* 127:1-6. 10.1016/j.envres.2013.09.002.
- Heck JE, Park AS, Qiu J, et al. 2014. Risk of leukemia in relation to exposure to ambient air toxics in pregnancy and early childhood. *Int J Hyg Environ Health* 217(6):662-668. 10.1016/j.ijheh.2013.12.003
- Heck JE, Park AS, Qiu J, et al. 2015. Retinoblastoma and ambient exposure to air toxics in the perinatal period. *J Expo Sci Environ Epidemiol* 25(2):182-186. 10.1038/jes.2013.84.
- Heikes, DL, Jensen, SR, Fleming-Jones, ME. 1995. Purge and trap extraction with GC-MS determination of volatile organic compounds in table-ready foods. *J Agric Food Chem* 43(11):2869-2875.
- Hellquist H, Irander K, Edling C, et al. 1983. Nasal symptoms and histopathology in a group of spray-painters. *Acta Otolaryngol* 96:495-500.

9. REFERENCES

- Hersh JH. 1988. Toluene embryopathy: Two new cases. *J Med Genet* 26:333-337.
- Hersh JH, Podruch PE, Rogers G, et al. 1985. Toluene embryopathy. *J Pediatr* 106:922-927.
- Hester SD, Johnstone AF, Boyes WK, et al. 2011. Acute toluene exposure alters expression of genes in the central nervous system associated with synaptic structure and function. *Neurotoxicol Teratol* 33(5):521-529.
- Hester SD, Johnstone AF, Boyes WK, et al. 2012. Transcriptional responses in rat brain associated with sub-chronic toluene inhalation are not predicted by effects of acute toluene inhalation. *Neurotoxicol Teratol* 34(5):530-533.
- Hetherington L, Battershill J. 2013. Review of evidence for a toxicological mechanism of idiopathic environmental intolerance. *Hum Exp Toxicol* 32(1):3-17. 10.1177/0960327112457189.
- Heuser VD, de Andrade VM, da Silva J, et al. 2005. Comparison of genetic damage in Brazilian footwear-workers exposed to solvent-based or water-based adhesive. *Mutat Res* 583(1):85-94.
- Heuser VD, Erdtmann B, Kvitko K, et al. 2007. Evaluation of genetic damage in Brazilian footwear-workers: Biomarkers of exposure, effect, and susceptibility. *Toxicology* 232(3):235-247.
- Hiipakka D, Samimi B. 1987. Exposure of acrylic fingernail sculptors to organic vapors and methacrylate dusts. *Am Ind Hyg Assoc J* 48(3):230-237.
- Hillefors-Berglund M, Liu Y, von Euler G. 1995. Persistent, specific and dose-dependent effects of toluene exposure on dopamine D2 agonist binding in the rat caudate-putamen. *Toxicology* 100:185-194.
- Hinman D. 1987. Biphasic dose-response relationship for effects of toluene inhalation on locomotor activity. *Pharmacol Biochem Behav* 26:65-69.
- Hjelm EW, Naslund PH, Wallen M. 1988. Influence of cigarette smoking on the toxicokinetics of toluene in humans. *J Toxicol Environ Health* 25:155-163.
- Hobara T, Kobayashi H, Higashihara E, et al. 1984a. Acute effects of 1,1,1-trichloroethane, trichloroethylene, and toluene on the hematologic parameters in dogs. *Arch Environ Contam Toxicol* 13:589-593.
- Hobara T, Kobayashi H, Higashihara E, et al. 1984b. Experimental study on the pulmonary absorption and excretion of toluene. *Int Arch Occup Environ Health* 53:337-344.
- Hobara T, Okuda M, Gotoh M, et al. 2000a. Estimation of the lethal toluene concentration from the accidental death of painting workers. *Ind Health*. 38(2):228-231.
- Hobara T, Okuda M, Gotoh M, et al. 2000b. Three cases of thinner-sniffing and estimating the fatal concentration of toluene by toxicokinetics. *Z Zagadnien Nauk Sadowych*. 43:105-111.
- Hodgson AT, Daisey JM, Grot RA. 1991. Sources and source strengths of volatile organic compounds in a new office building. *J Air Waste Manag Assoc* 41:1461-1468.

9. REFERENCES

- Hodgson AT, Garbesi K, Sextro RG, et al. 1988. Transport of volatile organic compounds from soil into a residential basement. Lawrence Berkeley Laboratory. University of California. Berkeley, CA. Presented at the 81st APCA Annual Meeting, June 19-24, Dallas, TX.
- Hoel DG, Davis DL, Miller AB, et al. 1992. Trends in cancer mortality in 15 industrialized countries, 1969-1986. *J Natl Cancer Inst* 84(5):313-320.
- Hogie M, Guerbet M, Reber A. 2009. The toxic effects of toluene on the optokinetic nystagmus in pigmented rats. *Ecotoxicol Environ Saf* 72(3):872-878.
- Holmberg PC. 1979. Central- nervous- system defects in children born to mothers exposed to organic solvents during pregnancy. *Lancet* 2:177-179.
- Hong JJ, Lin JL, Wu MS, et al. 1996. A chronic glue sniffer with hyperchloraemia metabolic acidosis, rhabdomyolysis, irreversible quadriplegia, central pontine myelinolysis, and hypothyroidism. *Nephrol Dial Transplant* 11(9):1848-1849.
- Honma T, Suda M. 2004. Brain microdialysis study of the effects of hazardous chemicals on the central nervous system 2. Toluene exposure and cerebral acetylcholine. *Ind Health* 42(3):336-347.
- *Honma T, Miyagawa M, Sato M, et al. 1982. Increase in glutamine content of rat midbrain induced by short-term exposure to toluene and hexane. *Ind Health* 20:109-115.
- Hori K, Yamashita S, Ishii S, et al. 2001. Isolation, characterization and application to off-gas treatment of toluene-degrading bacteria. *J Chem Eng Jpn* 34(9):1120-1126.
- Horiguchi S, Inoue K. 1977. Effects of toluene on the wheel-turning activity and peripheral blood findings in mice-an approach to the maximum allowable concentration of toluene. *J Toxicol Sci* 2(4):363-372.
- Hormes JT, Filley CM, Rosenberg NL. 1986. Neurologic sequelae of chronic solvent vapor abuse. *Neurology* 36:698-702.
- Hoshino M, Akimoto H, Okuda M. 1978. Photochemical oxidation of benzene, toluene and ethylbenzene initiated by OH radicals in the gas phase. *Bull Chem Soc Japan* 51(3):718-724.
- Hougaard KS, Hansen AM, Hass U, et al. 2003. Toluene depresses plasma corticosterone in pregnant rats. *Pharmacol Toxicol* 92(3):148-152.
- Howard C, Corsi RL. 1996. Volatization of chemicals from drinking water to indoor air: Role of the kitchen sink. *J Air Waste Manage Assoc* 46:830-837.
- Howard C, Corsi RL. 1998. Volatization of chemicals from drinking water to indoor air: The role of residential washing machines. *Air Waste Manage Assoc* 48:907-914.
- Howard MO, Bowen SE, Garland EL, et al. 2011. Inhalant use and inhalant use disorders in the United States. *Addict Sci Clin Pract* 6(1):18-31.
- Howard PH, Boethling RS, Jarvis WF, et al., eds. 1991. Handbook of environmental degradation rates. Chelsea, MI: Lewis Publishers, Inc, 410-411.

9. REFERENCES

- Howard-Reed C, Corsi RL, Moya J. 1999. Mass transfer of volatile organic compounds from drinking water to indoor air: The role of residential dishwashers. *Environ Sci Technol* 33:2266-2272.
- Howell SR, Christian JE, Isom GE. 1986. The hepatotoxic potential of combined toluene-chronic ethanol exposure. *Arch Toxicol* 59:45-50.
- HSDB. 2010. Toluene. Hazardous Substances Data Bank, National Library of Medicine. <http://toxnet.nlm.nih.gov>. April 24, 2014.
- Hsieh GC, Parker RD, Sharma RP, et al. 1990a. Subclinical effects of groundwater contaminants. III. Effects of repeated oral exposure to combinations of benzene and toluene on immunologic responses in mice. *Arch Toxicol* 64:320-328.
- Hsieh GC, Sharma RP, Parker RD. 1989. Immunotoxicological evaluation of toluene exposure via drinking water in mice. *Environ Res* 49:93-103.
- Hsieh GC, Sharma RP, Parker RD, et al. 1990b. Evaluation of toluene exposure via drinking water on levels of regional brain biogenic monoamines and their metabolites in CD-1 mice. *Ecotoxicol Environ Saf* 20:175-184.
- Hsieh GC, Sharma RP, Parker RD. 1991. Hypothalamic-pituitary-adrenocortical axis activity and immune function after oral exposure to benzene and toluene. *Immunopharmacol* 21:23-31.
- *Huang J, Asaeda N, Takeuchi Y, et al. 1992. Dose dependent effects of chronic exposure to toluene on neuronal and glial cell marker proteins in the central nervous system of rats. *Br J Ind Med* 49:282-286.
- Hubert C, Shen Y, Voordouw G. 1999. Composition of toluene-degrading microbial communities from soil at different concentrations of toluene. *Appl Environ Microbiol* 65(7):3064-3070.
- Hudak A, Ungvary G. 1978. Embryotoxic effects of benzene and its methyl derivatives: Toluene, xylene. *Toxicology* 11:55-63.
- Huerta-Rivas A, Lopez-Rubalcava C, Sanchez-Serrano SL, et al. 2012. Toluene impairs learning and memory, has antinociceptive effects, and modifies histone acetylation in the dentate gyrus of adolescent and adult rats. *Pharmacol Biochem Behav* 102(1):48-57.
- Huff J. 2003. Absence of carcinogenic activity in Fischer rats and B6C3F1 mice following 103-week inhalation exposures to toluene. *Int J Occup Environ Health* 9(2):138-146.
- Hunnewell J, Miller NR. 1998. Bilateral internuclear ophthalmoplegia related to chronic toluene abuse. *J Neuroophthalmol* 18(4):277-280.
- *Hussain TF, Heidenreich PA, Benowitz N. 1996. Recurrent non-Q-wave myocardial infarction associated with toluene abuse. *Am Heart J* 131(3):615-616.
- Hutchins SR. 1991. Optimizing GTEX biodegradation under denitrifying conditions. *Exp Toxicol Chem* 10:1437-1448.
- Iannuzzi TJ, Huntley SL, Schmidt CW, et al. 1997. Combined sewer overflows (CSOs) as sources of sediment contamination in the lower Passaic River, New Jersey. 1. Priority pollutants and inorganic chemicals. *Chemosphere* 34(2):213-231.

9. REFERENCES

- IARC. 1998. Some organic solvents, resin, monomers and related compounds, pigments and occupational exposures in paint manufacture and painting: Summary of data reported and evaluations. In: IARC monographs on the evaluation of carcinogenic risks to humans. Volume 47. <http://193.51.164.11/htdocs/Indexes/Vol47/Index.html>. May 24, 2000.
- IARC. 1999. IARC monographs on the evaluation of carcinogenic risks to humans: Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. Volume 71. Part 2. Lyon, France: World Health Organization, International Agency for Research on Cancer, 829-864.
- IARC. 2013. Agents classified by the IARC monographs. Volumes 1–109. Lyon, France: International Agency for Research on Cancer. <http://monographs.iarc.fr/ENG/Classification/index.php>. January 08, 2014.
- *Iizumi H, Fukui K, Utsumi H, et al. 1995. Effect of chronic toluene exposure on tyrosine hydroxylase-positive nerve elements in the rat forebrain: An immunohistochemical study combined with semiquantitative morphometric analysis. *Neuroreport* 7(1):81-84.
- Ikeda M, Ohtsuji H. 1971. Phenobarbital-induced protection against toxicity of toluene and benzene in the rat. *Toxicol Appl Pharmacol* 20:30-43.
- Ikeda M, Tsukagoshi H. 1990. Encephalopathy due to toluene sniffing: Report of a case with magnetic resonance imaging. *Eur Neurol* 30:347-349.
- Ikeda M, Koizumi A, Kasahara M, et al. 1986. Combined effects of n-hexane and toluene on norepinephrine and dopamine levels in rat brain tissues after long-term exposure. *Bull Environ Contam Toxicol* 36:510-517.
- Ikeda M, Ukai H, Kawai T, et al. 2008. Changes in correlation coefficients of exposure markers as a function of intensity of occupational exposure to toluene. *Toxicol Lett* 179(3):148-154.
- Ikeda N, Takahashi H, Umetsu K, et al. 1990. The course of respiration and circulation in toluene-sniffing. *Forensic Sci Intern* 44:151-158.
- *Ikeda T, Miyake H. 1978. Decreased learning in rats following repeated exposure to toluene: Preliminary report. *Toxicol Lett* 1:235-239.
- Ikematsu K, Tsuda R, Tsuruya S, et al. 2007. Toluene inhalation induced changes of gene expression in rat brain: Fluorescence differential display PCR analysis. *Leg Med* 9(5):265-269.
- Imbriani M, Ghittori S. 1997. Effects of ethanol on toluene metabolism in man. *G Ital Med Lav* 19(4):177-181.
- Inoue O, Kanno E, Kasai K, et al. 2004. Benzylmercapturic acid is superior to hippuric acid and o-cresol as a urinary marker of occupational exposure to toluene. *Toxicol Lett* 147(2):177-186.
- Inoue O, Kanno E, Yusa T, et al. 2002. Urinary benzylmercapturic acid as a marker of occupational exposure to toluene. *Int Arch Occup Environ Health* 75(5):341-347.
- Inoue O, Kawai T, Ukai H, et al. 2008. Limited validity of o-cresol and benzylmercapturic acid in urine as biomarkers of occupational exposure to toluene at low levels. *Ind Health* 46(4):318-325.

9. REFERENCES

- Inoue O, Seiji K, Ishihara N, et al. 1984. Increased *o*- and *p*-cresol/hippuric acid ratios in the urine of four strains of rat exposed to toluene at thousands-ppm levels. *Toxicol Lett* 23:249-257.
- Inoue O, Seiji K, Watanabe T, et al. 1988. Mutual metabolic suppression between benzene and toluene in man. *Int Arch Occup Environ Health* 60:15-20.
- Inoue O, Seiji K, Watanabe T, et al. 1986. Possible ethnic difference in toluene metabolism: A comparative study among Chinese, Turkish and Japanese solvent workers. *Toxicol Lett* 34:167-174.
- Iovino P, Polverino R, Salvestrini S, et al. 2009. Temporal and spatial distribution of BTEX pollutants in the atmosphere of metropolitan areas and neighbouring towns. *Environ Monit Assess* 150(1-4):437-444.
- Iregren A. 1986. Subjective and objective signs of organic solvent toxicity among occupationally exposed workers. *Scand J Work Environ Health* 12:469-475.
- IRIS. 2007. Toluene (CASRN 108-88-3). Integrated Risk Information System. Washington, DC: U.S. Environmental Protection Agency. <http://www.epa.gov/iris/>. January 08, 2014.
- Ishigami A, Tokunaga I, Kubo S, et al. 2005. Immunohistochemical study of rat spermatogenesis after toluene-inhalation. *Leg Med* 7(1):42-46.
- Iwata M, Taceuchi Y, Hisanaga N, et al. 1983. Changes of *n*-hexane metabolites in urine of rats exposed to various concentrations of *n*-hexane and to its mixture with toluene or MEK. *Int Arch Occup Environ Health* 53:1-8.
- Jacquot L, Pourie G, Buron G, et al. 2006. Effects of toluene inhalation exposure on olfactory functioning: Behavioral and histological assessment. *Toxicol Lett* 165(1):57-65.
- Jain S, Rachamalla M, Kulkarni A, et al. 2013. Pulmonary fibrotic response to inhalation of ZnO nanoparticles and toluene co-exposure through directed flow nose only exposure chamber. *Inhal Toxicol* 25(13):703-713. 10.3109/08958378.2013.839765.
- Janasik B, Jakubowski M, Jalowiecki P. 2008. Excretion of unchanged volatile organic compounds (toluene, ethylbenzene, xylene and mesitylene) in urine as result of experimental human volunteer exposure. *Int Arch Occup Environ Health* 81(4):443-449.
- Janasik B, Jakubowski M, Wesolowski W, et al. 2010. Unmetabolized VOCs in urine as biomarkers of low level occupational exposure. *Int J Occup Med Environ Health* 23(1):21-26.
- Jarosz PA, Fata E, Bowen SE, et al. 2008. Effects of abuse pattern of gestational toluene exposure on metabolism, feeding and body composition. *Physiol Behav* 93(4-5):984-993.
- Jermann E, Hajimiragha H, Borckhaus A, et al. 1989. Exposure to benzene, toluene, lead and carbon monoxide of children living in a central urban area with high traffic density. *Zentralbl Hyg Umweltmed* 189(1):50-61.
- Jimenez-Garza O, Baccarelli AA, Byun HM, et al. 2015. CYP2E1 epigenetic regulation in chronic, low-level toluene exposure: Relationship with oxidative stress and smoking habit. *Toxicol Appl Pharmacol* 286(3):207-215. 10.1016/j.taap.2015.04.016.

9. REFERENCES

- Johnson AC. 1992. Auditory sensitivity in rats exposed to toluene and/or acetyl salicylic acid. *NeuroReport* 3:1141-1144.
- Johnson AC, Canlon B. 1994. Progressive hair cell loss induced by toluene exposure. *Hear Res* 75:201-208.
- Johnson AC, Juntunen L, Nylen P, et al. 1988. Effect of interaction between noise and toluene on auditory function in the rat. *Acta Otolaryngol* 101:56-63.
- Johnsrud EK, Koukouritaki SB, Divakaran K, et al. 2003. Human hepatic CYP2E1 expression during development. *J Pharmacol Exp Ther* 307(1):402-407.
- Jonai H, Sato M. 1988. Exposure indices for painters exposed to toluene and xylene at low concentrations. *Ind Health* 26:197-202.
- Jone CM, Wu AHB. 1988. An unusual case of toluene-induced metabolic acidosis. *Clin Chem* 34(12):2596-2599.
- Jones HE, Balster RL. 1997. Neurobehavioral consequences of intermittent prenatal exposure to high concentrations of toluene. *Neurotoxicol Teratol* 19(4):305-313.
- Jones HE, Balster RL. 1998. Inhalant abuse in pregnancy. *Obstet Gynecol Clin North Am* 25(1):153-167.
- Jonsson F, Johanson G. 2001. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. *Toxicology* 157(3):177-193.
- Jovanovic JM, Jovanovic MM, Spasic MJ, et al. 2004. Peripheral nerve conduction study in workers exposed to a mixture of organic solvents in paint and lacquer industry. *Croat Med J* 45(6):769-774.
- Juárez-Pérez CA, Torres-Valenzuela A, Haro-Garcia LC, et al. 2014. Ototoxicity effects of low exposure to solvent mixture among paint manufacturing workers. *Int J Audiol* 53:370-376.
- Jung KH, Artigas F, Shin JY. 2011. Personal, indoor, and outdoor exposure to VOCs in the immediate vicinity of a local airport. *Environ Monit Assess* 173(1-4):555-567.
- Jury WA, Russo D, Streile G, et al. 1990. Evaluation of volatilization by organic chemicals residing below the soil surface. *Water Resour Res* 26(1):13-20.
- Kamel MAE, Shehata M. 2008. Effect of toluene exposure on the antioxidant status and apoptotic pathway in organs of the rat. *Br J Biomed Sci* 65(2):75-79.
- Kamijima M, Nakazawa Y, Yamakawa M, et al. 1994. Metabolic acidosis and renal tubular injury due to pure toluene inhalation. *Arch Environ Health* 49(5):410-413.
- Kamijo Y, Soma K, Hasegawa I, et al. 1998. Fatal bilateral adrenal hemorrhage following acute toluene poisoning: A case report. *J Toxicol Clin Toxicol* 36(4):365-368.
- Kamran S, Bakshi R. 1998. MRI in chronic toluene abuse: Low signal in the cerebral cortex on T2-weighted images. *Neuroradiology* 40:519-521.

9. REFERENCES

- Kaneko T, Koizumi T, Takezaki T, et al. 1992. Urinary calculi associated with solvent abuse. *J Urol* 147:1365-1366.
- Kang SK, Rohlman DS, Lee MY, et al. 2005. Neurobehavioral performance in workers exposed to toluene. *Environ Toxicol Pharmacol* 19(3):645-650.
- Kanter M. 2008a. *Nigella sativa* and derived thymoquinone prevents hippocampal neurodegeneration after chronic toluene exposure in rats. *Neurochem Res* 33(3):579-588.
- Kanter M. 2008b. Protective effects of *Nigella sativa* on the neuronal injury in frontal cortex and brain stem after chronic toluene exposure. *Neurochem Res* 33(11):241-249.
- Kanter M. 2011a. Thymoquinone attenuates lung injury induced by chronic toluene exposure in rats. *Toxicol Ind Health* 27(5):387-395.
- Kanter M. 2011b. Thymoquinone reestablishes spermatogenesis after testicular injury caused by chronic toluene exposure in rats. *Toxicol Ind Health* 27(2):155-166.
- Kanter M. 2011c. Protective effects of thymoquinone on the neuronal injury in frontal cortex after chronic toluene exposure. *J Mol Histol* 42(1):39-46.
- Kanter M. 2012. Protective effect of quercetin on liver damage induced by chronic toluene exposure in rats. *Toxicol Ind Health* 28(6):483-491.
- Kanter M. 2013. Protective effects of quercetine on the neuronal injury in frontal cortex after chronic toluene exposure. *Toxicol Ind Health* 29(7):643-651.
- Karmakar GC, Roxburgh R. 2008. Rhabdomyolysis in a glue sniffer. *N Z Med J* 121(1271):70-71.
- Kawai T, Miyama Y, Horiguchi S, et al. 2000. Possible metabolic interaction between hexane and other solvents co-exposed at sub-occupational exposure limit levels. *Int Arch Occup Environ Health* 73(7):449-456.
- Kawai T, Mizunuma K, Okada Y et al. 1996. Toluene itself as the best urinary marker of toluene exposure. *Int Arch Occup Environ Health* 68(5):289-297.
- Kawai T, Ukai H, Inoue O, et al. 2008. Evaluation of biomarkers of occupational exposure to toluene at low levels. *Int Arch Occup Environ Health* 81(3):253-262.
- Kawai T, Yamauchi T, Miyama Y, et al. 2007. Benzyl alcohol as a marker of occupational exposure to toluene. *Ind Health* 45(1):143-150.
- Kawai T, Yasugi T, Mizunuma K, et al. 1992a. Comparative evaluation of urinalysis and blood analysis as means of detecting exposure to organic solvents at low concentrations. *Int Arch Occup Environ Health* 64:223-234.
- Kawai T, Yasugi T, Mizunuma K, et al. 1992b. Monitoring of workers exposed to a mixture of toluene, styrene and methanol vapours by means of diffusive air sampling, blood analysis and urinalysis. *Int Arch Occup Environ Health* 63:429-435.

9. REFERENCES

- Kawai T, Yasugi T, Mizunuma K, et al. 1993. Comparative evaluation of blood and urine analysis as a tool for biological monitoring of *n*-hexane and toluene. *Int Arch Occup Environ Health* 65(1 Suppl):123-126.
- Kawamoto T, Koga M, Murata K, et al. 1995. Effects of ALDH2, CYPLAL, and CYP2EL genetic polymorphisms and smoking and drinking habits on toluene metabolism in humans. *Toxicol Appl Pharmacol* 133(2):295-304.
- Kawamoto T, Koga M, Oyama T, et al. 1996. Habitual and genetic factors that affect urinary background levels of biomarkers for organic solvent exposure. *Arch Environ Contam Toxicol* 30(1):114-120.
- *Keane JR. 1978. Toluene optic neuropathy. *Ann Neurol* 4:390.
- Kearns GL, Abdel-Rahman SM, Alander SW, et al. 2003. Developmental pharmacology--drug disposition, action, and therapy in infants and children. *N Engl J Med* 349(12):1157-1167.
- Kelly TJ, Callahan PJ, Plell J, et al. 1993. Method development and field measurements for polar volatile organic compounds in ambient air. *Environ Sci Technol* 27(6):1146-1153.
- Kenley RA, Davenport JE, Hendry DJ. 1973. Hydroxyl radical reactions in the gas phase. Products and pathways for the reaction of OH with toluene. *J Phys Chem* 82(9):1095-1096.
- Kenyon EM, Benignus V, Eklund C, et al. 2008. Modeling the toxicokinetics of inhaled toluene in rats: Influence of physical activity and feeding status. *J Toxicol Environ Health A* 71(4):249-265.
- Keymeulen R, De Bruyn G, Van Langenhove H. 1997. Headspace gas chromatographic determination of the plant cuticle-air partition coefficients for monocyclic aromatic hydrocarbons as environmental compartment. *J Chromatogr A* 774:213-221.
- Khalil MA, Rasmussen RA. 1992. Forest hydrocarbon emissions: Relationships between fluxes and ambient concentrations. *J Air Waste Manage Assoc* 42(6):810-813.
- Kim DB, Lee JK, Jung KJ, et al. 1998. Effects of toluene inhalation on the concentrations of the brain monoamines and metabolites. *J Toxicol Pub Health* 14(4):495-500.
- Kim H, Wang RS, Elovaara E, et al. 1997. Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. *Xenobiotica* 27(7):657-665.
- Kim JH, Moon JY, Park EY, et al. 2011. Changes in oxidative stress biomarker and gene expression levels in workers exposed to volatile organic compounds. *Ind Health*. 49(1):8-14.
- Kim KW, Won YL, Ko KS. 2015. Ethnic differences in the metabolism of toluene: Comparisons between Korean and foreign workers exposed to toluene. *Toxicol Res* 31(1):25-32. 10.5487/tr.2015.31.1.025.
- Kim SR, Halden RU, Buckley TJ. 2007. Volatile organic compounds in human milk: Methods and measurements. *Environ Sci Technol* 41(5):1662-1667.
- Kimura ET, Ebert DM, Dodge PW. 1971. Acute toxicity and limits of solvent residue for sixteen organic solvents. *Toxicol Appl Pharmacol* 19:699-704.

9. REFERENCES

- King MD, Day RE, Oliver JS, et al. 1981. Solvent encephalopathy. *Br Med J* 283:663-665.
- Kishi R, Harabuchi I, Ikeda T, et al. 1988. Neurobehavioral effects and pharmacokinetics of toluene in rats and their relevance to man. *Br J Ind Med* 45:396-408.
- Kiyokawa M, Mizota A, Takasoh M, et al. 1999. Pattern visual evoked cortical potentials in patients with toxic optic neuropathy caused by toluene abuse. *Jpn J Ophthalmol* 43(5):438-442.
- Kjellstrand P, Bjerkemo M, Adler-Maihofer M, et al. 1985. Effects of solvent exposure on testosterone levels and butyrylcholinesterase activity in mice. *Acta Pharmacol Toxicol* 57:242-249.
- Klimisch HJ, Hellwig J, Hofmann A. 1992. Studies on the prenatal toxicity of toluene in rabbits following inhalation exposure and proposal of a pregnancy guidance value. *Arch Toxicol* 66:373-381.
- *Knox JW, Nelson JR. 1966. Permanent encephalopathy from toluene inhalation. *New Eng J Med* 275:1494-1496.
- Kobald SO, Wascher E, Blaszkewicz M, et al. 2015. Neurobehavioral and neurophysiological effects after acute exposure to a single peak of 200 ppm toluene in healthy volunteers. *Neurotoxicology* 48:50-59. 10.1016/j.neuro.2015.03.005.
- Kobayashi M. 2014. Marked asymmetry of white matter lesions caused by chronic toluene exposure. *Neurol Sci* 35(3):495-497. 10.1007/s10072-013-1581-8.
- Kodavanti PR, Royland JE, Moore-Smith DA, et al. 2015. Acute and subchronic toxicity of inhaled toluene in male Long-Evans rats: Oxidative stress markers in brain. *Neurotoxicology* 51:10-19. 10.1016/j.neuro.2015.09.001.
- Kodavanti PR, Royland JE, Richards JE, et al. 2011. Toluene effects on oxidative stress in brain regions of young-adult, middle-age, and senescent Brown Norway rats. *Toxicol Appl Pharmacol* 256(3):386-398.
- Koga Y, Higashi S, Kawahara H, et al. 2007. Toluene inhalation increases extracellular noradrenaline and dopamine in the medial prefrontal cortex and nucleus accumbens in freely-moving rats. *Kyushu Shika Gakkai Zasshi* 61(1):39-54.
- Komori M, Nishio K, Kitada M, et al. 1990. Fetus-specific expression of a form of cytochrome P-450 in human livers. *Biochemistry* 29(18):4430-4433.
- *Kondo H, Huang J, Ichihara G, et al. 1995. Toluene induces behavioral activation without affecting striatal dopamine metabolism in the rat: Behavioral and microdialysis studies. *Pharmacol Biochem Behav* 51(1):97-101.
- *Konietzko H, Keilbach J, Drysch K. 1980. Cumulative effects of daily toluene exposure. *Int Arch Occup Environ Health* 46:53-58.
- Kono K, Yoshida Y, Yamagata H, et al. 1985. Urinary excretion of cresol as an indicator for occupational toluene exposure. *Ind Health* 23:37-45.
- Korbo L, Ladefoged O, Lam HR, et al. 1996. Neuronal loss in hippocampus in rats exposed to toluene. *Neurotoxicology* 17(2):359-366.

9. REFERENCES

- Korpela M, Tahti H. 1984. Follow-up of the antihemolytic effect of toluene inhalation in rats. *Toxicol Lett* 21:15-19.
- Korpela M, Tahti H. 1988. The effect of *in vitro* and *in vivo* toluene exposure on rat erythrocyte and synaptosome membrane integral enzymes. *Pharmacol Toxicol* 63:30-32.
- Korpela M, Vapaatalo H, Tahti H. 1983. Effect of toluene on the hemolytic resistance of rat erythrocytes. *Toxicol Lett* 17:253-257.
- Kostas J, Hotchin J. 1981. Behavioral effects of low-level perinatal exposure to toluene in mice. *Neurobehav Toxicol Teratol* 3:467-469.
- Krishnan K, Andersen ME. 1994. Physiologically based pharmacokinetic modeling in toxicology. In: Hayes AW, ed. *Principles and methods of toxicology*. 3rd ed. New York, NY: Raven Press, Ltd., 149-188.
- Krishnan K, Andersen ME, Clewell HJ, et al. 1994. Physiologically based pharmacokinetic modeling of chemical mixtures. In: Yang RSH, ed. *Toxicology of chemical mixtures: Case studies, mechanisms, and novel approaches*. San Diego, CA: Academic Press, 399-437.
- Kronevi T, Wahlberg J, Holmberg B. 1979. Histopathology of skin, liver, and kidney after epicutaneous administration of five industrial solvents to guinea pigs. *Environ Res* 19:56-69.
- Kucuk NO, Kilic EO, Ibis E, et al. 2000. Brain SPECT findings in long-term inhalant abuse. *Nucl Med Commun* 21(8):769-773.
- Kwon B, Kim S, Lee DK, et al. 2011. ¹H NMR spectroscopic identification of a glue sniffing biomarker. *Forensic Sci Int* 209(1-3):120-125.
- Kyrklund T, Kjellstrand P, Haglid K. 1987. Brain lipid changes in rats exposed to xylene and toluene. *Toxicology* 5:123-133.
- *Kyvik KR, Brattebo G, Tysnes OB, et al. 1992. Activation of blood platelets in workers exposed to organic solvents. *J Med* 34:687-692.
- Ladefoged O, Hougaard KS, Hass U, et al. 2004. Effects of combined prenatal stress and toluene exposure on apoptotic neurodegeneration in cerebellum and hippocampus of rats. *Basic Clin Pharmacol Toxicol* 94(4):169-176.
- Lam CW, Galen TJ, Boyd JF, et al. 1990. Mechanism of transport and distribution of organic solvents in blood. *Toxicol Appl Pharmacol* 104:117-129.
- Lammers JHCM, Meuling WJA, Muijsers H, et al. 2005a. Neurobehavioural evaluation and kinetics of inhalation of constant or fluctuating toluene concentrations in human volunteers. *Environ Toxicol Pharmacol* 20(3):431-442.
- Lammers JHCM, van Asperen J, de Groot D, et al. 2005b. Behavioural effects and kinetics in brain in response to inhalation of constant or fluctuating toluene concentrations in the rat. *Environ Toxicol Pharmacol*. 19(3):625-634.

9. REFERENCES

- Lange A, Smolik R, Zatonski W, et al. 1973. Leukocyte agglutinins in workers exposed to benzene toluene and xylene. *Int Arch Arbeits Med* 31:45-50.
- Langenhoff AAM, Zehnder AJB, Schraa G. 1996. Behaviour of toluene, benzene and naphthalene under anaerobic conditions in sediment columns. *Biodegradation* 7(3):267-274.
- Lapare S, Tardif R, Brodeur J. 1993. Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air: I. Toluene and *m*-xylene. *Int Arch Occup Environ Health* 64(8):569-580.
- Lapertot ME, Pulgarin C. 2006. Biodegradability assessment of several priority hazardous substances: Choice, application and relevance regarding toxicity and bacterial activity. *Chemosphere* 65(4):682-690.
- Larsby B, Tham R, Eriksson B, et al. 1986. The effect of toluene on the vestibulo- and opto-oculomotor system in rats: A computerized nystagmographic study. *Acta Otolaryngol* 101:422-428.
- Larsen T, Kjeldsen P, Christensen TH. 1992. Sorption of hydrophobic hydrocarbons on three aquifer materials in a flow through system. *Chemosphere* 24(4):439-451.
- Lataye R, Campo P. 1997. Combined effects of a simultaneous exposure to noise and toluene on hearing function. *Neurotoxicol Teratol* 19(5):373-382.
- Lataye R, Campo P, Loquet G. 1999. Toluene ototoxicity in rats: Assessment of the frequency of hearing deficit by electrocochleography. *Neurotoxicol Teratol* 21(3):267-276.
- Lataye R, Maguin K, Campo P. 2007. Increase in cochlear microphonic potential after toluene administration. *Hear Res* 230(1-2):34-42.
- Lawryk NJ, Weisel CP. 1996. Concentrations of volatile organic compounds in the passenger compartments of automobiles. *Environ Sci Technol* 30:810-816.
- LeBel CP, Schatz RA. 1988. Toluene-induced alterations in rat synaptosomal membrane composition and function. *J Biochem Toxicol* 3:279-293.
- LeBel CP, Schatz RA. 1989. Effect of toluene on rat synaptosomal phospholipid methylation and membrane fluidity. *Biochem Pharmacol* 38(22):4005-4011.
- LeBel CP, Schatz RA. 1990. Altered synaptosomal phospholipid metabolism after toluene: Possible relationship with membrane fluidity, Na⁺, K⁺-adenosine triphosphatase and phospholipid methylation. *J Pharmacol Exp Ther* 253(3):1189-1197.
- *Lee BK, Lee SH, Lee KM, et al. 1988. Dose-dependent increase in subjective symptom prevalence among toluene-exposed workers. *Ind Health* 26:11-23.
- Lee DE, Gerasimov MR, Schiffer WK, et al. 2006. Concentration-dependent conditioned place preference to inhaled toluene vapors in rats. *Drug Alcohol Depend* 85(1):87-90.
- Lee DH, Park IG, Kim JH, et al. 1998a. Neurobehavioral changes in shoe manufacturing workers. *Neurotoxicol Teratol* 20(3):259-263.

9. REFERENCES

- Lee XP, Kumazawa T, Sato K, et al. 1998b. Determination of solvent thinner components in human body fluids by capillary gas chromatography with trapping at low oven temperature for headspace samples. *Analyst* 123(1):147-150.
- Leeder JS, Kearns GL. 1997. Pharmacogenetics in pediatrics: Implications for practice. *Pediatr Clin North Am* 44(1):55-77.
- Lehman EJ, Hein MJ. 2006. Mortality of workers employed in shoe manufacturing: An update. *Am J Ind Med* 49(7):535-546.
- Leikin JB, Pauloucek FP. 2008. In: Leikin JB, Pauloucek FP, eds. 4th ed. Boca Raton, FL: CRC Press, Taylor & Francis Group, 1195-1196.
- Lemke LD, Lamerato LE, Xu X, et al. 2014. Geospatial relationships of air pollution and acute asthma events across the Detroit-Windsor international border: Study design and preliminary results. *J Expo Sci Environ Epidemiol* 24(4):346-357. 10.1038/jes.2013.78.
- Lesage S, McBride RA, Cureton PM, et al. 1993. Fate of organic solvents in landfill leachates under simulated field conditions and in aerobic microcosms. *Waste Manage Res* 11:215-226.
- Leung HW. 1993. Physiologically-based pharmacokinetic modelling. In: Ballantyne B, Marrs T, Turner P, eds. *General and applied toxicology*. Vol. 1. New York, NY: Stockton Press, 153-164.
- Leung HW, Paustenbach DJ. 1988. Application of pharmacokinetics to derive biological exposure indexes from threshold limit values. *Am Ind Hyg Assoc J* 49(9):445-450.
- Li HS, Johnson AC, Borg E, et al. 1992. Auditory degeneration after exposure to toluene in two genotypes of mice. *Arch Toxicol* 66:382-386.
- Liang JC, Hsu TC, Henry JE. 1983. Cytogenetic assays for mitotic poisons: The grasshopper embryo system for volatile liquids. *Mutat Res* 113:467-479.
- Lin HJ, Shaffer KM, Chang YH, et al. 2002. Acute exposure of toluene transiently potentiates p42/44 mitogen-activated protein kinase (MAPK) activity in cultured rat cortical astrocytes. *Neurosci Lett* 332(2):103-106.
- Lindbohm ML, Taskinen H, Kyyronen P, et al. 1992. Effects of parental occupational exposure to solvents and lead on spontaneous abortion. *Scand J Work Environ Health* 18:37-39.
- Lindemann R. 1991. Case report: Congenital renal tubular dysfunction associated with maternal sniffing of organic solvents. *Acta Pediatr Scand* 80:882-884.
- *Ling KH, Hanzlik RP. 1989. Deuterium isotope effects on toluene metabolism. Product release as a rate-limiting step in cytochrome P-450 catalysts. *Biochem Biophys Res Commun* 160(2):844-849.
- Little AR, Gong Z, Singh U, et al. 1998. Decreases in brain glial fibrillary acidic protein (GFAP) are associated with increased serum corticosterone following inhalation exposure to toluene. *Neurotoxicology* 19(4-5):739-748.
- Little CH, Georgiou GM, Shelton MJ, et al. 1999. Clinical and immunological responses in subjects sensitive to solvents. *Arch Environ Health* 54(1):6-14.

9. REFERENCES

- Liu J, Yoshida Y, Kunugita N, et al. 2010. Thymocytes are activated by toluene inhalation through the transcription factors NF- κ B, STAT5 and NF-AT. *J Appl Toxicol*. 30(7):656-660.
- Livingston AL. 1978. Forage plant estrogens. *J Toxicol Environ Health* 4(2-3):301-324.
- Lo PS, Wu CY, Sue HZ, et al. 2009. Acute neurobehavioral effects of toluene: Involvement of dopamine and NMDA receptors. *Toxicology* 265(1-2):34-40.
- Lof A, Hjelm EW, Colmsjo A, et al. 1993. Toxicokinetics of toluene and urinary excretion of hippuric acid after human exposure to $^2\text{H}_8$ -toluene. *Br J Ind Med* 50:55-59.
- Lof A, Wallen M, Hjelm EW. 1990. Influence of paracetamol and acetylsalicylic acid on the toxicokinetics of toluene. *Pharmacol Toxicol* 66:138-141.
- Lopez-Rubalcava C, Hen R, Cruz SL. 2000. Anxiolytic-like actions of toluene in the burying behavior and plus-maze tests: Differences in sensitivity between 5-HT_{1B} knockout and wild-type mice. *Behav Brain Res* 115(1):85-94.
- Lorenzana-Jimenez M, Salas M. 1990. Behavioral effects on chronic toluene exposure in the developing rat. *Neurotoxicol Teratol* 12:353-357.
- Lovley DR. 1997. Potential for anaerobic bioremediation of BTEX in petroleum-contaminated aquifers. *J Ind Microbiol Biotechnol* 18:75-81.
- Lovreglio P, Barbieri A, Carrieri M, et al. 2010. Validity of new biomarkers of internal dose for use in the biological monitoring of occupational and environmental exposure to low concentrations of benzene and toluene. *Int Arch Occup Environ Health* 83(3):341-356.
- Luderer U, Morgan MS, Brodtkin CA, et al. 1999. Reproductive endocrine effects of acute exposure to toluene in men and women. *Occup Environ Med* 56(10):657-666.
- Lund SP, Kristiansen GB. 2008. Hazards to hearing from combined exposure to toluene and noise in rats. *Int J Occup Med Environ Health* 21(1):47-57.
- Lundberg I, Hakansson M. 1985. Normal serum activities of liver enzymes in Swedish paint industry workers with heavy exposure to organic solvents. *Br J Ind Med* 42:596-600.
- Lundberg I, Milatou-Smith R. 1998. Mortality and cancer incidence among Swedish paint industry workers with long-term exposure to organic solvents. *Scand J Work Environ Health* 24(4):270-275.
- Luster MI, Portier C, Pait DG, et al. 1992. Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. *Fundam Appl Toxicol* 18(2):200-210.
- Maas EF, Ashe J, Spiegel P, et al. 1991. Acquired pendular nystagmus in toluene addiction. *Neurology* 41:282-285.
- MacPhail RC, Farmer JD, Jarema KA. 2012. Toluene effects on the motor activity of adolescent, young-adult, middle-age and senescent male Brown Norway rats. *Neurotoxicology* 33(1):111-118.

9. REFERENCES

- Maestri L, Ghittori S, Imbriani M. 1997. Determination of specific mercapturic acids as an index of exposure to environmental benzene, toluene, and styrene. *Ind Health* 35:489-501.
- Magos GA, Lorenzana-Jimenez M, Vidrio H. 1990. Toluene and benzene inhalation influences on ventricular arrhythmias in the rat. *Neurotoxicol Teratol* 12:119-124.
- Maguin K, Campo P, Parietti-Winkler C. 2009. Toluene can perturb the neuronal voltage-dependent Ca^{2+} channels involved in the middle-ear reflex. *Toxicol Sci* 107(2):473-481.
- Maki-Paakkanen J, Husgafvel-Pursiainen K, Kalliomaki PL, et al. 1980. Toluene-exposed workers and chromosome aberrations. *J Toxicol Environ Health* 6:775-781.
- Malingre MM, Hendrix EA, Schellens JH, et al. 2002. Acute poisoning after oral intake of a toluene-containing paint thinner. *Eur J Pediatr* 161(6):354-355.
- Maltoni C, Ciliberti A, Pinto C et al. 1997. Results of long-term experimental carcinogenicity studies of the effects of gasoline, correlated fuels, and major gasoline aromatics on rats. *Ann N Y Acad Sci* 837:15-52.
- Mandiracioglu A, Akgur S, Kocabiyik N, et al. 2011. Evaluation of neuropsychological symptoms and exposure to benzene, toluene and xylene among two different furniture worker groups in Izmir. *Toxicol Ind Health* 27(9):802-809.
- Männistö T, Mendola P, Laughon Grantz K, et al. 2015. Acute and recent air pollution exposure and cardiovascular events at labour and delivery. *Heart* 101(18) 10.1136/heartjnl-2014-307366.
- Marchand A, Aranda-Rodriguez R, Tardif R, et al. 2015. Human inhalation exposures to toluene, ethylbenzene, and m-xylene and physiologically based pharmacokinetic modeling of exposure biomarkers in exhaled air, blood, and urine. *Toxicol Sci* 144(2):414-424. 10.1093/toxsci/kfv009.
- Marie I, Gehanno JF, Bubenheim M, et al. 2014. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. *Autoimmun Rev* 13(2):151-156. 10.1016/j.autrev.2013.10.002.
- Martinez-Alfaro M, Carabez-Trejo A, Gallegos-Corona MA, et al. 2010. Thinner inhalation effects on oxidative stress and DNA repair in a rat model of abuse. *J Appl Toxicol* 30(3):226-232.
- Maruff P, Burns CB, Tyler P, et al. 1998. Neurological and cognitive abnormalities associated with chronic petrol sniffing. *Brain* 121:1903-1917.
- Massolo L, Rehwagen M, Porta A, et al. 2010. Indoor-outdoor distribution and risk assessment of volatile organic compounds in the atmosphere of industrial and urban areas. *Environ Toxicol* 25:339-349.
- Matiella JE, Hsieh T. 1991. Volatile compounds in scrambled eggs. *J Food Sci* 56(2):387-390.
- Matsuoka M, Matsumura H, Igisu H, et al. 1997. Effects of single exposure to toluene vapor on the expression of immediate early genes and GFAP gene in the mouse brain. *Arch Toxicol* 71:722-723.
- Matsushita T, Arimatsu Y, Ueda A, et al. 1975. Hematological and neuromuscular response of workers exposed to low concentration of toluene vapor. *Ind Health* 13:115-121.

9. REFERENCES

- Mattsson JL, Gorzinski SJ, Albee RR, et al. 1990. Evoked potential changes from 13 weeks of simulated toluene abuse in rats. *Pharmacol Biochem Behavior* 36:683-689.
- Mayr U, Butsch A, Schneider S. 1992. Validation of two *in vitro* test systems for estrogenic activities with zearalenone, phytoestrogens and cereal extracts. *Toxicology* 74(2-3):135-149.
- McCann MF. 1992. Occupational and environmental hazards in art. *Environ Res* 59:139-144.
- McDermott C, Allshire A, van Pelt F, et al. 2008. *In vitro* exposure of Jurkat T-cells to industrially important organic solvents in binary combination: Interaction analysis. *Toxicol Sci* 101(2):263-274.
- McDermott C, Allshire A, van Pelt FN, et al. 2007. Sub-chronic toxicity of low concentrations of industrial volatile organic pollutants *in vitro*. *Toxicol Appl Pharmacol* 219(1):85-94.
- McDiarmid MA, PSJ Lees, J Agnew et al. 1991. Reproductive hazards of fire fighting. II. Chemical hazards. *Am J Ind Med* 19(4):447-472.
- McWilliams ML, Chen GD, Fechter LD. 2000. Low-level toluene disrupts auditory function in guinea pigs. *Toxicol Appl Pharmacol* 167(1):18-29.
- Mehta C S, Sun P N, Zikarge A et al. 1998. Acute toxicity of toluene in male and female rats: A single oral dose exposure 2-week study. *Toxic Subst Mech* 17:43-55.
- Meney KM Davidson CM, Littlejohn D. 1998. Use of solid-phase extraction in the determination of benzene, toluene, ethylbenzene, xylene and cumene in spiked soil and investigation of soil spiking methods. *Analyst* 123(2):195-200.
- *Mergler D, Beauvais B. 1992. Olfactory threshold shift following controlled 7-hour exposure to toluene and/or xylene. *Neurotoxicology* 13:211-216.
- *Metrick SA, Brenner RP. 1982. Abnormal brainstem auditory evoked potentials in chronic paint sniffers. *Am Neurol* 12:553-556.
- Meulenbelt J, de Groot G, Savelkoul TJ. 1990. Two cases of acute toluene intoxication. *Br J Ind Med* 47:417-420.
- Meyer-Baron M. 2005. A meta-analytical approach to neurobehavioural effects of occupational toluene exposure. *Environ Toxicol Pharmacol* 19(3):651-657.
- Michael LC, Erickson MD, Parks SP, et al. 1980. Volatile environmental pollutants in biological matrices with a head space purge technique. *Anal Chem* 52:1836-1841.
- Michael LC, Pellizzari ED, Norwood DL. 1991. Application of the master analytical scheme to the determination of volatile organics in wastewater influents and effluents. *Environ Sci Technol* 25(1):150-155.
- Michael LC, Pellizzari ED, Perritt RL, et al. 1990. Comparison of indoor, backyard, and centralized air monitoring strategies for assessing personal exposure to volatile organic compounds. *Environ Sci Technol* 24(7):996-1003.

9. REFERENCES

- Michael LC, Pellizzari ED, Wiseman RW. 1988. Development and evaluation of a procedure for determining volatile organics in water. *Environ Sci Technol* 22(5):565-570.
- Midford R, Rose J, Fleming DT, et al. 1993. Glue: What's really in it for sniffers. *Med J Aust* 159(9):634-635.
- Miyagawa M, Honma T, Sato M. 1995. Effects of subchronic exposure to toluene on working and reference memory in rats. *Neurotoxicol Teratol* 17(6):657-664.
- Miyagawa M, Ohtani K, Suda M, et al. 1998. Effects of acute exposure to toluene on mixed schedule-controlled behavior as a memory measure in rats. *J Toxicol Sci* 23(Suppl. 2):352.
- Miyagi Y, Shima F, Ishido K, et al. 1999. Tremor induced by toluene misuse successfully treated by a Vim thalamotomy. *J Neurosurg Psychiatry* 66:794-796.
- Mobil Oil Corp. 1975. Report on primary dermal irritation in rabbits. Mobil Oil Corporation. Submitted to U.S. Environmental Protection Agency under TSCA Section 8D. Project number MB750-956. OTS0206119.
- Monster AC, Kezic S, van de Gevel I et al. 1993. Evaluation of biological monitoring parameters for occupational exposure to toluene. *Int Arch Occup Environ Health* 65(Suppl):159-162.
- Montgomery DD, Kalman DA. 1989. Indoor/outdoor air quality: Reference pollutant concentrations in complaint-free residences. *Appl Ind Hyg* 4(1):17-20.
- Morata TC, Fiorini AC, Fischer FM, et al. 1997. Toluene-induced hearing loss among rotogravure printing workers. *Scand J Work Environ Health* 23(4):289-298.
- Morgan DL, Cooper SW, Carlock DL, et al. 1991. Dermal absorption of neat and aqueous volatile organic chemicals in the Fischer 344 rat. *Environ Res* 55:51-63.
- Morioka I, Kuroda M, Miyashita K, et al. 1999. Evaluation of organic solvent ototoxicity by the upper limit of hearing. *Arch Environ Health* 54(5):341-346.
- Mork AK, Jonsson F, Johanson G. 2014. Adjustment factors for toluene, styrene and methyl chloride by population modeling of toxicokinetic variability. *Regul Toxicol Pharmacol* 69(1):78-90. 10.1016/j.yrtph.2014.02.015.
- Moro AM, Brucker N, Charao M, et al. 2012. Evaluation of genotoxicity and oxidative damage in painters exposed to low levels of toluene. *Mutat Res* 746(1):42-48.
- Morselli PL, Franco-Morselli R, Bossi L. 1980. Clinical pharmacokinetics in newborns and infants: Age-related differences and therapeutic implications. *Clin Pharmacokin* 5(6):485-527.
- Moszczynsky P, Lisiewicz J. 1984. Occupational exposure to benzene, toluene and xylene and the T lymphocyte functions. *Haematologia* 17(4):449-453.
- Moya J, Howard-Reed C, Corsi RL. 1999. Volatization of chemicals from tap water to indoor air from contaminated water used for showering. *Environ Sci Technol* 33:2321-2327.

9. REFERENCES

- Muijser H, Geuskens RBM, Hooisma J et al. 1996. Behavioral effects of exposure to organic solvents in carpet layers. *Neurotoxicol Teratol* 1(4):455-462.
- Mukerjee S, Ellenson WD, Lewis RG, et al. 1997. An environmental scoping study in the lower Rio Grande Valley of Texas- III. Residential microenvironmental monitoring for air, house dust, and soil. *Environ Int* 23:657-673.
- Mullin LS, Krivanek ND. 1982. Comparison of unconditioned reflex and conditioned avoidance tests in rats exposed by inhalation to carbon monoxide, 1,1,1-trichloroethane, toluene or ethanol. *Neurotoxicology* 3:126-137.
- Murata K, Araki S, Yokoyama K, et al. 1993. Cardiac autonomic dysfunction in rotogravure printers exposed to toluene in relation to peripheral nerve conduction. *Ind Health* 31(3):79-90.
- Museridze DP, Tsaishvili TS, Svanidze IK, et al. 2010. Effect of toluene intoxication on spatial behavior and learning of rats within early stages of postnatal development. *Neurophysiology* 42(2):118-123.
- Muttray A, Spelmeyer U, Hommel G, et al. 2005. Acute exposure to 50 ppm toluene does not increase sleepiness. *Environ Toxicol Pharmacol* 19(3):665-669.
- Muttray A, Wolff U, Jung D, et al. 1997. Blue-yellow deficiency in workers exposed to low concentrations of organic solvents. *Int Arch Occup Environ Health* 70:407-412.
- Muttray A, Wolters V, Jung D, et al. 1999. Effects of high doses of toluene on color vision. *Neurotoxicol Teratol* 21(1):41-45.
- Muttray A, Wolters V, Mayer-Popken O, et al. 1995. Effect of subacute occupational exposure to toluene on color vision. *Int J Occup Med Environ Health* 8(4):339-345.
- *Naalsund LU. 1986. Chemically induced damage to the hippocampal formation. Forswarets Forskningsinstitut. Norwegian Defense Research Establishment. NDRE/PUBL-86/1002.
- Nadeau V, Truchon G, Brochu M, et al. 2006. Effect of physical exertion on the biological monitoring of exposure of various solvents following exposure by inhalation in human volunteers: I. Toluene. *J Occup Environ Hyg* 3(9):481-489.
- Nakai N, Murata M, Nagahama M, et al. 2003. Oxidative DNA damage induced by toluene is involved in its male reproductive toxicity. *Free Radic Res* 37(1):69-76.
- Nakajima T, Sato A. 1979. Enhanced activity of liver drug-metabolizing enzymes for aromatic and chlorinated hydrocarbons following food deprivation. *Toxicol Appl Pharmacol* 50:549-556.
- Nakajima T, Wang RS. 1994. Induction of cytochrome P450 by toluene. *Int J Biochem* 26(12):1333-1340.
- Nakajima D, Win-Shwe TT, Kakeyama M, et al. 2006. Determination of toluene in brain of freely moving mice using solid-phase microextraction technique. *Neurotoxicology* 27(4):615-618.
- Nakajima T, Wang RS, Elovaara E, et al. 1991. Monoclonal antibody-directed characterization of cytochrome P-450 isozymes responsible for toluene metabolism in rat liver. *Biochem Pharmacol* 41(3):395-404.

9. REFERENCES

- Nakajima T, Wang RS, Elovaara E, et al. 1992a. A comparative study on the contribution of cytochrome P450 isozymes to metabolism of benzene, toluene and trichloroethylene in rat liver. *Biochem Pharmacol* 43:251-257.
- Nakajima T, Wang RS, Elovaara E, et al. 1993. Cytochrome P450-related differences between rats and mice in the metabolism of benzene, toluene and trichloroethylene in liver microsomes. *Biochem Pharmacol* 45(5):1079-1085.
- Nakajima T, Wang RS, Elovaara E, et al. 1997. Toluene metabolism by cDNA-expressed human hepatic cytochrome P-450. *Biochem Pharmacol* 53(3):271-277.
- Nakajima T, Wang RS, Katakura Y, et al. 1992b. Sex-, age- and pregnancy-induced changes in the metabolism of toluene and trichloroethylene in rat liver in relation to the regulation of cytochrome P450IIE1 and P450IIC11 content. *J Pharmacol Exp Ther* 261(3):869-874.
- Nakamura S, Oda Y, Shimada T, et al. 1987. SOS-inducing activity of chemical carcinogens and mutagens in *Salmonella typhimurium* TA1535/pSK1002: Examination with 151 chemicals. *Mutat Res* 192:239-246.
- Nakatsuka H, Watanabe T, Takeuchi Y, et al. 1992. Absence of blue-yellow color vision loss among workers exposed to toluene or tetrachloroethylene, mostly at levels below occupational exposure limits. *Int Arch Occup Environ Health* 64:113-117.
- NAS/NRC. 1989. Report of the oversight committee. In: *Biologic markers in reproductive toxicology*. Washington, DC: National Academy of Sciences, National Research Council, National Academy Press, 15-35.
- NCI. 1985. Monograph on human exposure to chemicals in the workplace: Toluene. Bethesda, MD: National Cancer Institute, Division of Cancer Etiology. PB86144698.
- Nestmann ER, Lee E, Matula TI, et al. 1980. Mutagenicity of constituents identified in pulp and paper mill effluents using the salmonella/mammalian-microsome assay. *Mutat Res* 79:203-212.
- Neubert D, Bochert G, Gericke C, et al. 2001. Multicenter field trial on possible health effects of toluene. I. Toluene body burdens in workers of the rotogravure industry. *Toxicology* 168(2):139-157.
- NFPA. 1994. Fire protection guide to hazardous materials. 11th ed. Quincy, MA: National Fire Protection Association.
- Ng TP, Foo SC, Yoong T. 1992a. Menstrual function in workers exposed to toluene. *Br J Ind Med* 49:799-803.
- Ng TP, Foo SC, Yoong T. 1992b. Risk of spontaneous abortion in workers exposed to toluene. *Br J Ind Med* 49:804-808.
- Ng TP, Ong SG, Lam WK, et al. 1990. Urinary levels of proteins and metabolites in workers exposed to toluene. *Int Arch Occup Environ Health* 62:43-46.
- NICNAS. 2010. A scientific review of multiple chemical sensitivity: Identifying key research needs. National Industrial Chemicals Notification and Assessment Scheme (NICNAS) and the Office of

9. REFERENCES

- Chemical Safety and Environmental Health (OCSEH).
https://www.nicnas.gov.au/__data/assets/word_doc/0015/17223/MCS-Final-Report-for-publication-November-2010-hardcopy-version.docx. May 2, 2016.
- Nicoara S, Tonidandel L, Traldi P, et al. 2009. Determining the levels of volatile organic pollutants in urban air using a gas chromatography-mass spectrometry method. *J Environ Public Health* 2009:148527.
- NIDA. 2012. Inhalants. Research Report Series. National Institute on Drug Abuse.
<https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/inhalantsrrs.pdf>. March 14, 2017.
- Nielsen HK, Krusell L, Baelum J, et al. 1985. Renal effects of acute exposure to toluene. *Acta Med Scand* 218:317-321.
- Niklasson M, Arlinger S, Ledin T, et al. 1998. Audiological disturbances caused by long-term exposure to industrial solvents. Relation to the diagnosis of toxic encephalopathy. *Scand Audiol* 27:131-136.
- NIOSH. 1983. Determination of the reproductive effects in mice of nine selected chemicals. Cincinnati, OH: National Institute for Occupational Safety and Health. Prepared by Bioassay Systems Corporation. NIOSH Contract No. 210-81-6011. BSC Project No. 10867. PB84183540.
- NIOSH. 1984a. Hippuric acid in urine, method 8300. NIOSH manual of analytical methods. 3rd ed. Volume 1. Cincinnati, OH: National Institute for Occupational Safety and Health. 8300-1-8300-3.
- NIOSH. 1984b. Hippuric and methyl hippuric acids in urine, method 8301. NIOSH manual of analytical methods. 3rd ed. Volume 1. NIOSH. Cincinnati, OH: National Institute for Occupational Safety and Health.
- NIOSH. 1994. NIOSH manual of analytical methods 4th edition. U.S. Department of Health and Human Services, Public Health Service, Center for Disease Control and Prevention, National Institute for Occupational Safety and Health.
- NIOSH. 2011. Toluene (CASRN 108-88-3). NIOSH pocket guide to chemical hazards. Atlanta, GA: National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.
<http://www.cdc.gov/niosh/npg/>. January 08, 2014.
- Nise G, Attewell R, Skerfving S, et al. 1989. Elimination of toluene from venous blood and adipose tissue after occupational exposure. *Br J Ind Med* 46:407-411.
- Nise G, Hogstedt B, Bratt I, et al. 1991. Cytogenetic effects in rotogravure printers exposed to toluene (and benzene). *Mutat Res* 261:217-223.
- Nomura T, Yaguchi H, Mito Y, et al. 2016. MR images in a patient with chronic toluene poisoning. *Intern Med* 55(7):851-852. 10.2169/internalmedicine.55.6086.
- Nong A, McCarver DG, Hines RN, et al. 2006. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: A case study with toluene. *Toxicol Appl Pharmacol* 214(1):78-87.
- Nordling Nilson L, Karlson B, Nise G, et al. 2010. Delayed manifestations of CNS effects in formerly exposed printers--a 20-year follow-up. *Neurotoxicol Teratol* 32(6):620-626.

9. REFERENCES

NRC. 1993. National Research Council. Pesticides in the diets of infants and children. Washington, DC: National Academy Press.

NTP. 1990. National Toxicology Program technical report series toxicology and carcinogenesis studies of toluene (CAS No. 108-88-3) in F344/N rats and 86C3F mice (inhalation studies). Research Triangle Park, NC: U.S. Environmental Protection Agency, Department of Health and Human Services. No. 371. PB90256371.

NTP. 2016. Report on carcinogens. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. <http://ntp-server.niehs.nih.gov/ntp/roc/twelfth/roc12.pdf>. March 15, 2017.

Ogata M. 1984. Estimation of solvent concentrations in ambient air from urinary metabolite levels of workers exposed to solvents. *Ind Health* 22:319-324.

*Oh SJ, Kim JM. 1976. Giant axonal swelling in "Huffer's" neuropathy. *Arch Neurol* 33:583-586.

O'Leary-Moore SK, Galloway MP, McMechan AP, et al. 2007. Region-dependent alterations in glutamate and GABA measured by high-resolution magnetic resonance spectroscopy following acute binge inhalation of toluene in juvenile rats. *Neurotoxicol Teratol* 29(4):466-475.

O'Leary-Moore SK, Galloway MP, McMechan AP, et al. 2009. Neurochemical changes after acute binge toluene inhalation in adolescent and adult rats: A high-resolution magnetic resonance spectroscopy study. *Neurotoxicol Teratol* 31(6):382-389.

Olsen RH, Mikesell MD, Kukor JJ, et al. 1995. Physiological attributes of microbial BTEX degradation in oxygen-limited environments. *Environ Health Perspect Suppl* 103(5):49-51.

Olson BA, Gamberale F, Iregren A. 1985. Coexposure to toluene and *p*-xylene in man: Central nervous functions. *Br J Ind Med* 42:117-122.

Olsson H, Brandt L. 1980. Occupational exposure to organic solvents and Hodgkin's disease in men. *Scand J Work Environ Health* 6:302-305.

Ono A, Kawashima K, Sekita K, et al. 1999. Toluene inhalation induced epididymal sperm dysfunction in rats. *Toxicology* 139(3):193-205.

Ono A, Sekita K, Ogawa Y, et al. 1996. Reproductive and developmental toxicity studies of toluene: II. Effects of inhalation exposure on fertility in rats. *J Environ Pathol Toxicol Oncol* 15(1):9-20.

Ono A, Sekita K, Ohno K, et al. 1995. Reproductive and developmental toxicity studies of toluene: I. Teratogenicity study of inhalation exposure in pregnant rats. *J Toxicol Sci* 20(2):109-134.

Orbaek P, Nise G. 1989. Neurasthenic complaints and psychometric function of toluene-exposed rotogravure printers. *Am J Ind Med* 16:67-77.

Orbaek P, Osterberg K, Akesson B, et al. 1998. Suprathreshold intensity and annoyance reactions in experimental challenge to toluene and n-butyl acetate among subjects with long-term solvent exposure. *Scand J Work Environ Health* 24(5):432-438.

9. REFERENCES

- OSHA. 2013a. List of highly hazardous chemicals, toxics, and reactives. Occupational safety and health standards. Occupational Safety and Health Administration. Code of Federal Regulations 29 CFR 1910.119, Appendix A. <http://www.osha.gov/law-regs.html>. January 08, 2014.
- OSHA. 2013b. Toxic and hazardous substances. Occupational safety and health standards. Occupational Safety and Health Administration. Code of Federal Regulations 29 CFR 1910.1000, Table Z-2. <http://www.osha.gov/law-regs.html>. January 08, 2014.
- Oshiro WM, Kenyon EM, Gordon CJ, et al. 2011. Extrapolating the acute behavioral effects of toluene from 1- to 24-hour exposures in rats: Roles of dose metric and metabolic and behavioral tolerance. *Toxicol Sci* 123(1):180-192.
- Oshiro WM, Krantz QT, Bushnell PJ. 2007. Repeated inhalation of toluene by rats performing a signal detection task leads to behavioral tolerance on some performance measures. *Neurotoxicol Teratol* 29(2):247-254.
- Osterberg K, Orbaek P, Karlson B, et al. 2000. Psychological test performance during experimental challenge to toluene and n-butyl acetate in cases of solvent-induced toxic encephalopathy. *Scand J Work Environ Health* 26(3):219-226.
- Osterberg K, Orbaek P, Karlson B, et al. 2003. Annoyance and performance during the experimental chemical challenge of subjects with multiple chemical sensitivity. *Scand J Work Environ Health* 29(1):40-50.
- Ovrum P, Hultengren M, Lindqvist T. 1978. Exposure to toluene in a photogravure printing plant. *Scand J Work Environ Health* 4:237-245.
- Owen GM, Brozek J. 1966. Influence of age, sex and nutrition on body composition during childhood and adolescence. In: Falkner F, ed. *Human development*. Philadelphia, PA: WB Saunders, 222-238.
- Ozokwelu ED. 2006. Toluene. In: *Kirk-Othmer encyclopedia of chemical technology*. Vol. 25. John Wiley & Sons, 158-188.
- Paez-Martinez N, Ambrosio E, Garcia-Lecumberri C, et al. 2008. Toluene and TCE decrease binding to mu-opioid receptors, but not to benzodiazepine and NMDA receptors in mouse brain. *Ann N Y Acad Sci* 1139:390-401.
- Paez-Martinez N, Cruz SL, Lopez-Rubalcava C. 2003. Comparative study of the effects of toluene, benzene, 1,1,1-trichloroethane, diethyl ether, and flurothyl on anxiety and nociception in mice. *Toxicol Appl Pharmacol* 193(1):9-16.
- Paez-Martinez N, Flores-Serrano Z, Ortiz-Lopez L, et al. 2013. Environmental enrichment increases doublecortin-associated new neurons and decreases neuronal death without modifying anxiety-like behavior in mice chronically exposed to toluene. *Behav Brain Res* 256:432-440. 10.1016/j.bbr.2013.09.007.
- Page BD, Conacher HB, Salminen J et al. 1993. Survey of bottled drinking water sold in Canada: Part 2. Selected volatile organic compounds. *JAOAC Int* 76(1):26-31.

9. REFERENCES

- Pankow JF, Luo W, Bender DA, et al. 2003. Concentrations and co-occurrence correlations of 88 volatile organic compounds (VOCs) in the ambient air of 13 semi-rural to urban locations in the United States. *Atmos Environ* 37:5023-5046.
- Papageorgiou SG, Karantoni E, Pandis D, et al. 2009. Severe dopaminergic pathways damage in a case of chronic toluene abuse. *Clin Neurol Neurosurg* 111(10):864-867.
- Paraf F, Lewis J, Jothy S. 1993. Acute fatty liver of pregnancy after exposure to toluene. A case report. *J Clin Gastroenterol* 17(2):163-165.
- Pascual R, Bustamante C. 2010. Melatonin promotes distal dendritic ramifications in layer II/III cortical pyramidal cells of rats exposed to toluene vapors. *Brain Res* 1355:214-220.
- Patel R, Benjamin J. 1986. Renal disease associated with toluene inhalation. *Clin Toxicol* 24(3):213-223.
- Paterson SC, Sarvesvaran R. 1983. Plastic bag death: A toluene fatality. *Med Sci Law* 23(1):64-66.
- Paulson L, Kilens G. 1996. Solvent and noise exposure at a wood furniture manufacturing facility. *Appl Occup Environ Hyg* 11(8):1045-1047.
- Pavlostathis SG, Mathavan GN. 1992. Desorption kinetics of selected volatile organic compounds from field contaminated soils. *Environ Sci Technol* 26(3):532-538.
- Pearson MA, Hoyme HE, Seaver LH, et al. 1994. Toluene embryopathy: Delineation of the phenotype and comparison with fetal alcohol syndrome. *Pediatrics* 93(2):211-215.
- Pelclova D, Cerna M, Pastorkova A, et al. 2000. Study of the genotoxicity of toluene. *Arch Environ Health* 55(4):268-273.
- Pelclova D, Rossner P, Pickova J. 1990. Chromosome aberrations in rotogravure printing plant workers. *Mutat Res* 245:299-303.
- Pellizzari ED, Hartwell TD, Haris BSH, et al. 1982. Purgeable organic compounds in mother's milk. *Bull Environ Contam Toxicol* 28:322-328.
- Pellizzari ED, Wallace LA, Gordon SM. 1992. Elimination kinetics of volatile organics in humans using breath measurements. *J Expo Anal Environ Epidemiol* 2(3):341-355.
- Peralta DP, Chang AY. 2012. Toluene inducing acute respiratory failure in a spray paint sniffer. *Am J Case Rep* 13:92-95.
- Perbellini L, Leone R, Fracasso ME, Brugnone F, et al. 1982. Metabolic interaction between *n*-hexane and toluene *in vivo* and *in vitro*. *Int Arch Occup Environ Health* 50:351-358.
- Periago JF, Zambudio A, Prado C. 1997. Evaluation of environmental levels of aromatic hydrocarbons in gasoline service stations by gas chromatography. *J Chromatogr A* 778(1-2):263-268.
- Perit KE, Gmaz JM, Caleb Browne JD, et al. 2012. Distribution of c-Fos immunoreactivity in the rat brain following abuse-like toluene vapor inhalation. *Neurotoxicol Teratol* 34(1):37-46.

9. REFERENCES

- Pierce CH, Chen Y, Dills RL, et al. 2002. Toluene metabolites as biological indicators of exposure. *Toxicol Lett* 129(1-2):65-76.
- Pierce CH, Dills RL, Morgan MS, et al. 1996. Interindividual differences in $^2\text{H}_8$ -toluene toxicokinetics assessed by semi-empirical physiologically based model. *Toxicol Appl Pharmacol* 139(1):49-61.
- Pierce CH, Dills RL, Morgan MS, et al. 1998. Biological monitoring of controlled toluene exposure. *Int Arch Occup Environ Health* 71:433-444.
- Pierce CH, Lewandowski TA, Dills RL, et al. 1999. A comparison of $^1\text{H}_8$ - and $^2\text{H}_8$ -toluene toxicokinetics in men. *Xenobiotica* 29(1):93-108.
- Pitarque M, Vaglenov A, Nosko M, et al. 1999. Evaluation of DNA damage by the comet assay in shoe workers exposed to toluene and other organic solvents. *Mutat Res* 441:115-127.
- Pitarque M, Vaglenov A, Nosko M, et al. 2002. Sister chromatid exchanges and micronuclei in peripheral lymphocytes of shoe factory workers exposed to solvents. *Environ Health Perspect* 110(4):399-404.
- Plappert U, Barthel E, Seidel HJ. 1994. Reduction of benzene toxicity by toluene. *Environ Mol Mutagen* 24:283-292.
- Plenge-Böenig A, Karmaus W. 1999. Exposure to toluene in the printing industry is associated with subfecundity in women but not in men. *Occup Environ Med* 56(7):443-448.
- Poblano A, Lope-Huerta M, Martinez JM, et al. 1996. Pattern-visual evoked potentials in thinner abusers. *Arch Med Res* 27(4):531-533.
- Poirier A, Dodds L, Dummer T, et al. 2015. Maternal exposure to air pollution and adverse birth outcomes in Halifax, Nova Scotia. *J Occup Environ Med* 57(12):1291-1298. 10.1097/JOM.0000000000000604.
- Poon R, Chu I, Bjarnason S, et al. 1994. Inhalation toxicity study of methanol, toluene, and methanol/toluene mixtures in rats: Effects of 28-day exposure. *Toxicol Ind Health* 10(3):231-245.
- Priya K, Yadav A, Kumar N, et al. 2015. Association of polymorphisms of phase I metabolizing genes with sister chromatid exchanges in occupational workers exposed to toluene used in paint thinners. *Genet Res Int* 2015:630296. 10.1155/2015/630296.
- Pryor GT. 1991. A toluene-induced motor syndrome in rats resembling that seen in some human solvent abusers. *Neurotoxicol Teratol* 13:387-400.
- Pryor GT, Rebert CS. 1992. Interactive effects of toluene and hexane on behavior and neurophysiologic responses in Fischer-344 rats. *Neurotoxicology* 13:225-234.
- Pryor GT, Dickinson J, Feeney E, et al. 1984a. Hearing loss in rats first exposed to toluene as weanlings or as young adults. *Neurobehav Toxicol Teratol* 6:111-119.
- Pryor GT, Rebert CS, Dickinson J, et al. 1984b. Factors affecting toluene-induced ototoxicity in rats. *Neurobehav Toxicol Teratol* 6:223-238.

9. REFERENCES

- Pryor G, Rebert C, Kassay K, et al. 1991. The hearing loss associated with exposure to toluene is not caused by a metabolite. *Brain Res Bull* 27:109-113.
- Purcell KJ, Cason GH, Gargas ML, et al. 1990. *In vivo* metabolic interactions of benzene and toluene. *Toxicol Lett* 52:141-152.
- Pyykko K. 1983. Time-course of effects of toluene on microsomal enzymes in rat liver, kidney and lung during and after inhalation exposure. *Chem Biol Interact* 44:299-310.
- Pyykko K, Paavilainen S, Metsa-Ketela T, et al. 1987. The increasing and decreasing effects of aromatic hydrocarbon solvents on pulmonary and hepatic cytochrome P-450 in the rat. *Pharmacol Toxicol* 60:288-293.
- Pyykko K, Tahti H, Vapaatalo H. 1977. Toluene concentrations in various tissues of rats after inhalation and oral administration. *Arch Toxicol* 38:169-176.
- Raaschou-Nielsen O, Lohse C, Thomsen BL et al. 1997. Ambient air levels and the exposure of children to benzene, toluene, and xylenes in Denmark. *Environ Res* 75(2):149-159.
- Rabinowitz PM, Galusha D, Slade MD, et al. 2008. Organic solvent exposure and hearing loss in a cohort of aluminium workers. *Occup Environ Med* 65(4):230-235.
- Rahill AA, Weiss B, Morrow PE, et al. 1996. Human performance during exposure to toluene. *Aviat Space Environ Med* 67(7):640-647.
- Ramsey JC, Andersen ME. 1984. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. *Toxicol Appl Pharmacol* 73:159-175.
- *Rana SV, Kumar S. 1995. Antioxidative enzyme in the liver of rats after exposure to xylene, toluene and methyl alcohol separately and in combination. *Physiol Chem Phys Med NMR* 27(1):25-29.
- Rea TM, Nash JF, Zabik JE, et al. 1984. Effects of toluene inhalation on brain biogenic amines in the rat. *Toxicology* 31:143-150.
- Rebert CS, Matteucci MJ, Pryor GT. 1989a. Acute electrophysiologic effects of inhaled toluene on adult male Long-Evans rats. *Pharmacol Biochem Behav* 33:157-165.
- Rebert CS, Matteucci MJ, Pryor GT. 1989b. Multimodal effects of acute exposure to toluene evidenced by sensory-evoked potentials from Fischer-344 rats. *Pharmacol Biochem Behavior* 32:757-768.
- Rees DC, Wood RW, McCormick JP, et al. 1985. Toxicokinetics of toluene in the rat. *Scand J Work Environ Health* 11:301-306.
- *Reisin E, Teicher A, Jaffe R, et al. 1975. Myoglobinuria and renal failure in toluene poisoning. *Br J Ind Med* 32:163-168.
- RePORTER. 2014. Toluene. National Institutes of Health, Research Portfolio Online Reporting Tools. <http://projectreporter.nih.gov/reporter.cfm>. April 17, 2014.
- RePORTER. 2016. Toluene. National Institutes of Health, Research Portfolio Online Reporting Tools. <http://projectreporter.nih.gov/reporter.cfm>. August 22, 2016.

9. REFERENCES

- Reutman SR, Kawas LeMasters G, Knecht EA, et al. 2002. Evidence of reproductive endocrine effects in women with occupational fuel and solvent exposures. *Environ Health Perspect* 110(8):805-811.
- Richer CL, Chakrabarti S, Senecal-Quevillon M et al. 1993. Cytogenetic effects of low-level exposure to toluene, xylene, and their mixture on human blood lymphocytes. *Int Arch Occup Environ Health* 64(8):581-585.
- Riedel K, Ruppert T, Conze C, et al. 1996. Determination of benzene and alkylated benzenes in ambient and exhaled air by microwave desorption coupled with gas chromatography-mass spectrometry. *J Chromatogr A* 719:383-389.
- Riegel AC, French ED. 1999. Acute toluene induces biphasic changes in rat spontaneous locomotor activity which are blocked by remoxipride. *Pharmacol Biochem Behav* 62(3):399-402.
- Riegel AC, French ED. 2002. Abused inhalants and central reward pathways: Electrophysiological and behavioral studies in the rat. *Ann N Y Acad Sci* 965:281-291.
- Riegel AC, Ali SF, French ED. 2003. Toluene-induced locomotor activity is blocked by 6-hydroxydopamine lesions of the nucleus accumbens and the mGluR2/3 agonist LY379268. *Neuropsychopharmacology* 28(8):1440-1447.
- Riegel AC, Ali SF, Torinese S, et al. 2004. Repeated exposure to the abused inhalant toluene alters levels of neurotransmitters and generates peroxynitrite in nigrostriatal and mesolimbic nuclei in rat. *Ann N Y Acad Sci* 1025:543-551.
- Riegel AC, Zapata A, Shippenberg TS, et al. 2007. The abused inhalant toluene increases dopamine release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. *Neuropsychopharmacology* 32(7):1558-1569.
- Roberts LG, Bevans AC, Schreiner CA. 2003. Developmental and reproductive toxicity evaluation of toluene vapor in the rat. I. Reproductive toxicity. *Reprod Toxicol* 17(6):649-658.
- Roberts LG, Nicolich MJ, Schreiner CA. 2007. Developmental and reproductive toxicity evaluation of toluene vapor in the rat. II. Developmental toxicity. *Reprod Toxicol* 23(4):521-531.
- Robinson KG, Farmer WS, Novak JT. 1990. Availability of sorbed toluene in soils for biodegradation by acclimated bacteria. *Water Res* 24(3):345-350.
- Roch F, Alexander M. 1997. Inability of bacteria to degrade low concentrations of toluene in water. *Environ Toxicol Chem* 16(7):1377-1383.
- Rogers WR, Miller CS, Bunegin L. 1999. A rat model of neurobehavioral sensitization to toluene. *Toxicol Ind Health* 15(3-4):356-369.
- Romer K, Federsel R, Freundt K. 1986. Rise of inhaled toluene, ethyl benzene, xylene, mesitylene in rat blood after treatment with ethanol. *Bull Environ Contam Toxicol* 37:874-876.
- Rosenberg NL, Grigsby J, Dreisbach J, et al. 2002. Neuropsychologic impairment and MRI abnormalities associated with chronic solvent abuse. *J Toxicol Clin Toxicol* 40(1):21-34.

9. REFERENCES

- Rosenberg NL, Kleinschmidt-Demasters BK, Davis KA, et al. 1988a. Toluene abuse causes diffuse central nervous system white matter changes. *Ann Neurol* 23(6):611-614.
- Rosenberg NL, Spitz MC, Filley CM, et al. 1988b. Central nervous system effects of chronic toluene abuse—clinical, brainstem evoked response and magnetic resonance imaging studies. *Neurotoxicol Teratol* 10:489-495.
- Royland JE, Kodavanti PR, Schmid JE, et al. 2012. Toluene effects on gene expression in the hippocampus of young adult, middle-age, and senescent Brown Norway Rats. *Toxicol Sci* 126(1):193-212.
- RTECS. 2014. Toluene. Registry of Toxic Effects of Chemical Substances. National Institute for Occupational Safety and Health. MDL Information Systems, Inc. April 24, 2014.
- Ryu YH, Lee JD, Yoon PH, et al. 1998. Cerebral perfusion impairment in a patient with toluene abuse. *J Nucl Med* 34(4):632-633.
- Saarinen L, Hakkola M, Pekari K, et al. 1998. Exposure of gasoline road-tanker drivers to methyl tert-butyl ether and methyl tert-amyl ether. *Int Arch Occup Environ Health* 71:143-147.
- *Saavedra H, De Marinis A, Palestini M. 1996. Neuronal changes induced by chronic toluene exposure in the cat. *Arch Ital Biol* 134(3):217-225.
- Sack TM, Steele DH, Hammerstrom K, et al. 1992. A survey of household products for volatile organic compounds. *Atmos Environ* 26A(6):1063-1070.
- Saillenfait AM, Gallissot F, Sabate JP, et al. 2007. Developmental toxic effects of ethylbenzene or toluene alone and in combination with butyl acetate in rats after inhalation exposure. *J Appl Toxicol* 27(1):32-42.
- Saito A, Tanaka H, Usuda H, et al. 2011. Characterization of skin inflammation induced by repeated exposure of toluene, xylene, and formaldehyde in mice. *Environ Toxicol* 26(3):224-232.
- Sallmen M, Lindbohm ML, Anttila A, et al. 1998. Time to pregnancy among the wives of men exposed to organic solvents. *Occup Environ Med* 55:24-30.
- Samuel-Herter SR, Slaght SL, McKay BE. 2013. Age-dependent time courses of recovery for motor functions following acute toluene intoxication in rats. *Dev Psychobiol* 56(4):657-673.
- Sanchez-Serrano SL, Cruz SL, Lamas M. 2011. Repeated toluene exposure modifies the acetylation pattern of histones H3 and H4 in the rat brain. *Neurosci Lett*. 489(3):142-147.
- Sari-Minodier I, Truchon G, Charest-Tardif G, et al. 2009. The effect of workload on biological monitoring of occupational exposure to toluene and n-hexane: Contribution of physiologically based toxicokinetic modeling. *J Occup Environ Hyg*. 6(7):415-432.
- Sarma SN, Kim YJ, Song M, et al. 2011. Induction of apoptosis in human leukemia cells through the production of reactive oxygen species and activation of HMOX1 and Noxa by benzene, toluene, and o-xylene. *Toxicology* 280(3):109-117.

9. REFERENCES

- Sato A, Nakajima T. 1978. Differences following skin or inhalation exposure in the absorption and excretion kinetics of trichlorethylene and toluene. *Br J Ind Med* 35:43-49.
- Sato A, Nakajima T, Fujiwara Y, et al. 1974. Pharmacokinetics of benzene and toluene. *Int Arch Arbeitsmed* 33:169-182.
- Saunders NR, Ek CJ, Habgood MD, et al. 2008. Barriers in the brain: A renaissance? *Trends Neurosci* 31(6):279-286.
- Saunders NR, Liddelow SA, Dziegielewska KM. 2012. Barrier mechanisms in the developing brain. *Front Pharmacol* 3(10.3389/fphar.2012.00046):Article 46.
- Schaeffer VH, Bhooshan B, Chen S-B, et al. 1996. Characterization of volatile organic chemical emissions from carpet cushions. *J Air Waste Manage Assoc* 46:813-820.
- Schaper M, Demes P, Kiesswetter E, et al. 2004. Colour vision and occupational toluene exposure: Results of repeated examinations. *Toxicol Lett* 151(1):193-202.
- Schaper M, Demes P, Zupanic M, et al. 2003. Occupational toluene exposure and auditory function: Results from a follow-up study. *Ann Occup Hyg* 47(6):493-502.
- Schaper M, Seeber A, van Thriel C. 2008. The effects of toluene plus noise on hearing thresholds: An evaluation based on repeated measurements in the German printing industry. *Int J Occup Med Environ Health* 21(3):191-200.
- Schauer JJ, Kleeman MJ, Cass GR, et al. 1999. Measurement of emissions from air pollution sources. 1. C₁ through C₂₉ organic compounds from meat charbroiling. *Environ Sci Technol* 33:1566-1577.
- Scheuplein R, Charnley G, Dourson M. 2002. Differential sensitivity of children and adults to chemical toxicity. I. Biological basis. *Regul Toxicol Pharmacol* 35(3):429-447.
- Schiffer WK, Lee DE, Alexoff DL, et al. 2006. Metabolic correlates of toluene abuse: Decline and recovery of function in adolescent animals. *Psychopharmacology (Berl)*. 186(2):159-167.
- Schmid E, Bauchinger M, Hauf R. 1985. Chromosome changes with time in lymphocytes after occupational exposure to toluene. *Mutat Res* 142:37-39.
- Schuberth J. 1994. Joint use of retention index and mass spectrum in post-mortem tests for volatile organics by headspace capillary gas chromatography with ion-trap detection. *J Chromatogr A* 674:63-71.
- Scott KD, Scott AA. 2012. An examination of information-processing skills among inhalant-using adolescents. *Child Care Health Dev* 38(3):412-410.
- Scott KD, Scott AA. 2014. Adolescent inhalant use and executive cognitive functioning. *Child Care Health Dev* 40(1):20-28.
- Seeber A, Demes P, Kiesswetter E, et al. 2005. Changes of neurobehavioral and sensory functions due to toluene exposure below 50 ppm? *Environ Toxicol Pharmacol* 19(3):635-643.

9. REFERENCES

- Seeber A, Schaper M, Zupanic M, et al. 2004. Toluene exposure below 50 ppm and cognitive function: A follow-up study with four repeated measurements in rotogravure printing plants. *Int Arch Occup Environ Health* 77(1):1-9.
- Seidenberg JM, Anderson DG, Becker RA. 1986. Validation of an *in vivo* developmental toxicity screen in the mouse. *Teratog Carcinog Mutagen* 6:361-374.
- Seiji K, Inoue O, Nakatsuka H, et al. 1987. No biologically significant changes in liver function after occupational exposure to toluene at over-OEL levels. *Ind Health* 25:163-168.
- Seo HS, Yang M, Song MS, et al. 2010. Toluene inhibits hippocampal neurogenesis in adult mice. *Pharmacol Biochem Behav* 94(4):588-594. 10.1016/j.pbb.2009.11.015.
- *Seppalainen AM, Antti-Poika M. 1983. Time course of electrophysiological findings for patients with solvent poisoning. *Scand J Work Environ Health* 9:15-24.
- Seto Y. 1994. Review: Determination of volatile substances in biological samples by headspace gas chromatography. *J Chromatogr A* 674:25-62.
- Shafer TJ, Bushnell PJ, Benignus VA, et al. 2005. Perturbation of voltage-sensitive Ca^{2+} channel function by volatile organic solvents. *J Pharmacol Exp Ther* 315(3):1109-1118.
- Shannon MW, Borron SW, Burns MJ. 2007. In: Shannon MW, Borron SW, Burns MJ, eds. *Haddad and Winchester's clinical management of poisoning and drug overdose*. 4th ed. Philadelphia, PA: WB Saunders, 1370-1374.
- Shibata K, Yoshita Y, Matsumoto H. 1994. Extensive chemical burns from toluene. *Am J Emerg Med* 12(3):353-355.
- Shields HC, Weschler CJ. 1992. Volatile organic compounds measured at a telephone switching center from 5/30/85-12/6/88: A detailed case study. *J Air Waste Manage Assoc* 42:792-804.
- Shields HC, Fleischer DM, Weschler CJ. 1996. Comparisons among VOCs measured in three types of U.S. commercial buildings with different occupant densities. *Indoor Air* 6:2-17.
- Shiomi S, Kuroki T, Kuroda T, et al. 1993. Absence of hepatic uptake of Tc-99m phytate in a man with chronic toluene hepatotoxicity. *Clin Nucl Med* 18(8):655-656.
- Sim S, Moon J, Kim Y, et al. 2010. Emission rates of selected volatile organic compounds and formaldehyde in newly constructed apartment. *Toxicol Environ Health Sci* 2(4):263-267.
- Sinha SN, Kulkarni PK, Shah SH, et al. 2006. Environmental monitoring of benzene and toluene produced in indoor air due to combustion of solid biomass fuels. *Sci Total Environ* 357(1-3):280-287.
- Skender L, Brcic I, Karacic V. 2004. Urine analysis for the evaluation of environmental exposures to aromatic hydrocarbons. *Arch Environ Health* 59(5):237-244.
- Sliwinska-Kowalska M, Zamyslowska-Szmytko E, Szymczak W, et al. 2005. Exacerbation of noise-induced hearing loss by co-exposure to workplace chemicals. *Environ Toxicol Pharmacol* 19:547-553.

9. REFERENCES

- Slomianka L, Edelfors S, Ravn-Jonsen A, et al. 1990. The effect of low-level toluene exposure on the developing hippocampal region of the rat: Histological evidence and volumetric findings. *Toxicology* 62:189-202.
- Slomianka L, Rungby J, Edelfors S, et al. 1992. Late postnatal growth in the dentate area of the rat hippocampus compensates for volumetric changes caused by early postnatal toluene exposure. *Toxicology* 74:203-208.
- *Smargiassi A, Mutti A, Bergamaschi E, et al. 1996. Pilot study of peripheral markers of catecholaminergic systems among workers occupationally exposed to toluene. *Neurotoxicology* 17(3-4):769-776.
- Smith LB, Bhattacharya A, Lemasters G, et al. 1997. Effect of chronic low-level exposure to jet fuel on postural balance of US Air Force personnel. *J Occup Environ Med* 39(7):623-632.
- Smyth HF, Weil CS, West JS, et al. 1969. An exploration of joint toxic action: Twenty-seven industrial chemicals intubated in rats in all possible pairs. *Toxicol Appl Pharmacol* 14:340-347.
- Snodgrass WR. 1992. Physiological and biochemical differences between children and adults as determinants of toxic response to environmental pollutants. In: Guzelian PS, Henry CJ, Olin SS, eds. *Similarities and differences between children and adults: Implications for risk assessment*. Washington, DC: International Life Sciences, 35-42.
- Soares AA, Pinho MT, Albergaria JT, et al. 2013. Biocomplementation of SVE to achieve clean-up goals in soils contaminated with toluene and xylene. *Environ Monit Assess* 185(10):8429-8438.
- Soulage C, Perrin D, Berenguer P, et al. 2004. Sub-chronic exposure to toluene at 40 ppm alters the monoamine biosynthesis rate in discrete brain areas. *Toxicology* 196(1-2):21-30.
- Spencer TR, Schur PM. 2008. The challenge of multiple chemical sensitivity. *J Environ Health* 70(10):24-27.
- SRI. 2010. Toluene. In: 2010 Directory of chemical producers United States. SRI Consulting, 908-909.
- Staples, CA, Werner AF, Hoogheem TJ. 1985. Assessment of priority pollutant concentrations in the United States using STORET database. *Environ Toxicol Chem* 4:131-142.
- State of California. 2005. Hazardous wastes from non-specific sources. Chapter 11, Article 4. State of California. <http://www.oal.ca.gov/ccr.htm>. April 24, 2014.
- Stengel B, Cenee S, Limasset JC, et al. 1998. Immunological and renal markers among photogravure printers exposed to toluene. *Scand J Work Environ Health* 24(4):276-284.
- *Strapkova A, Nosal'Ova G, Hanacek J. 1996. Effects of irritants on airways reactivity. *Cent Eur J Public Health* 4(Suppl):54-55.
- Stuart BJ, Bowlen GF, Kosson DS. 1991. Competitive sorption of benzene, toluene and the xylenes onto soil. *Environmental Progress* 10(2):104-109.

9. REFERENCES

- *Stumph MJ, Weir FW, Noall MW. 1985. Comparison of blood and brain toluene concentrations and circulating triglyceride levels resulting from acute and repeated exposures in rats. *Am Ind Hyg Assoc J* 46:244-250.
- Suitheimer C, Bost R, Sunshine I, eds. 1982. Volatiles by headspace chromatography. In: *Methodology for analytical technology. Volume II.* Boca Raton, FL: CRC Press, Inc., 1-9.
- Sulkowski WJ, Kowalska S, Matyja W, et al. 2002. Effects of occupational exposure to a mixture of solvents on the inner ear: A field study. *Int J Occup Med Environ Health* 15(3):247-256.
- Sullivan MJ, Conolly RB. 1988. Comparison of blood toluene levels after inhalation and oral administration. *Environ Res* 45:64-70.
- Suzuki T, Kashimura S, Umetsu K. 1983. Thinner abuse and aspermia. *Med Sci Law* 23(3):199-202.
- Svensson BG, Nise G, Englander V, et al. 1990. Deaths and tumours among rotogravure printers exposed to toluene. *Br J Ind Med* 47:372-379.
- Svensson BG, Nise G, Erfurth EM, et al. 1992a. Hormone status in occupational toluene exposure. *Am J Ind Med* 22:99-107.
- Svensson BG, Nise G, Erfurth EM, et al. 1992b. Neuroendocrine effects in printing workers exposed to toluene. *Br J Ind Med* 49:402-408.
- Svirbely JL, Dunn RC, von Oettingen WF. 1943. The acute toxicity of vapors of certain solvents containing appreciable amounts of benzene and toluene. *J Ind Hyg Toxicol* 25:366-373.
- Tahti H, Aaran RK, Vapaatalo H. 1983. An inhalation method for testing the toxicity of volatile compounds in small laboratory animals. A study on short-term and long-term toluene inhalation in rats. *Methods Find Exp Clin Pharmacol* 5(10):667-671.
- Tahti H, Karkkainen S, Pykko K, et al. 1981. Chronic occupational exposure to toluene. *Int Arch Occup Environ Health* 48:61-69.
- *Takahashi S, Tanabe K, Maseda C, et al. 1988. Increased plasma free fatty acid and triglyceride levels after single administration of toluene in rabbits. *J Toxicol Environ Health* 1:87-95.
- Takeda S, Yamaai T, Kaneda Y, et al. 2013. Toluene exposure leads to a change in expression patterns of β defensins in the mouse tracheal epithelium. *J Toxicol Pathol* 26(1):35-40.
- Takeichi S, Yamada T, Shikata I. 1986. Acute toluene poisoning during painting. *Forensic Sci Int* 32:109-115.
- Takeuchi A, Kawai T, Zhang ZW, et al. 2002. Toluene, xylenes and xylene isomers in urine as biological indicators of low-level exposure to each solvent; a comparative study. *Int Arch Occup Environ Health* 75(6):387-393.
- Takeuchi Y, Hisanaga N. 1977. The neurotoxicity of toluene: EEG changes in rats exposed to various concentrations. *Br J Ind Med* 34:314-324.

9. REFERENCES

- *Takeuchi Y, Suzuki H. 1975. Change of convulsion threshold in the rat exposed to toluene. *Ind Health* 13:109-115.
- Takeuchi Y, Ono Y, Hisanaga N. 1981. An experimental study on the combined effects of *n*-hexane and toluene on the peripheral nerve of the rat. *Br J Ind Med* 38:14-19.
- Tan WP, Seow E. 1997. Case reports on acute toluene poisoning during parquet flooring. *Ann Acad Med Singapore* 26(1):138-140.
- Tanaka K, Maeda T, Kobayashi T, et al. 2003. A survey of urinary hippuric acid and subjective symptoms among occupational low toluene exposed workers. *Fukushima J Med Sci* 49(2):129-139. http://ir.fmu.ac.jp/dspace/bitstream/123456789/144/1/FksmJMedSci_49_p129.pdf. April 25, 2014.
- Tang HL, Chu KH, Cheuk A, et al. 2005. Renal tubular acidosis and severe hypophosphataemia due to toluene inhalation. *Hong Kong Med J* 11(1):50-53.
- Tap O, Solmaz S, Polat S, et al. 1996. The effect of toluene on the rat ovary: An ultrastructural study. *J Submicrosc Cytol Pathol* 28(4):553-558.
- Tardif R, Brodeur J, Plaa GL. 1989. Simultaneous high-performance liquid chromatographic analysis of hippuric acid and *ortho*-, *meta*-, and *para*-methylhippuric acids in urine. *J Anal Toxicol* 13:313-316.
- Tardif R, Droz PO, Charest-Tardif G, et al. 2002. Impact of human variability on the biological monitoring of exposure to toluene: I. Physiologically based toxicokinetic modelling. *Toxicol Lett* 134(1-3):155-163.
- Tardif R, Lapar S, Charest-Tardif G, et al. 1995. Physiologically-based pharmacokinetic modeling of a mixture of toluene and xylene in humans. *Risk Anal* 15(3):335-342.
- Tardif R, Lapare S, Krishnan K, et al. 1993. Physiologically based modeling of the toxicokinetic interaction between toluene and *m*-xylene in the rat. *Toxicol Appl Pharmacol* 120:266-273.
- Tardif R, Lapare S, Plaa GL, et al. 1991. Effect of simultaneous exposure to toluene and xylene on their respective biological exposure indices in humans. *Int Arch Occup Environ Health* 63:279-284.
- Tardif R, Plaa GL, Brodeur J. 1992. Influence of various mixtures of inhaled toluene and xylene on the biological monitoring of exposure to these solvents in rats. *Can J Physiol Pharmacol* 70:385-395.
- Tardif R, Truchon G, Brodeur J. 1998. Comparison of hippuric acid and *o*-cresol in urine and unchanged toluene in alveolar air for the biological monitoring of exposure to toluene in human volunteers. *Appl Occup Environ Hyg* 13(2):127-132.
- Tas U, Ekici F, Koc F, et al. 2013b. Acute cardiotoxic effects of high dose toluene: An experimental study. *Anadolu Kardiyol Derg* 13(1):3-8.
- Tas U, Ogeturk M, Kuloglu T, et al. 2013a. HSP70 immune reactivity and TUNEL positivity in the liver of toluene-inhaled and melatonin-treated rats. *Toxicol Ind Health* 29(6):514-522.
- Tas U, Ogeturk M, Meydan S, et al. 2011. Hepatotoxic activity of toluene inhalation and protective role of melatonin. *Toxicol Ind Health* 27(5):465-473.

9. REFERENCES

- Taskinen H, Anttila A, Lindbohm ML, et al. 1989. Spontaneous abortions and congenital malformations among the wives of men occupationally exposed to organic solvents. *Scand J Work Environ Health* 15:345-352.
- Tassaneeyakul W, Birkett DJ, Edwards JW, et al. 1996. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and *o*-, *m*- and *p*-xylene. *J Pharmacol Exp Ther* 276(1):101-108.
- Taverner D, Harrison DJ, Bell GM. 1988. Acute renal failure due to interstitial nephritis induced by 'glue sniffing' with subsequent recovery. *Scott Med J* 33:246-247.
- Taylor JD, Evans HL. 1985. Effects of toluene inhalation on behavior and expired carbon dioxide in Macaque monkeys. *Toxicol Appl Pharmacol* 80:487-495.
- ten Berge WF, Zwart A, Appelman LM. 1986. Concentration-time mortality response relationship of irritant and systemically acting vapours and gases. *J Hazard Mater* 13(3):301-309.
- Tham R, Larsby B, Eriksson B, et al. 1982. Electronystagmographic findings in rats exposed to styrene or toluene. *Acta Otolaryngol* 93:107-112.
- *Tham R, Larsby B, Eriksson B, et al. 1990. The effect of toluene on the vestibulo- and opto-oculomotor system in rats, pretreated with GABAergic drugs. *Neurotoxicol Teratol* 12:307-311.
- Thetkathuek A, Jaidee W, Saowakhontha S, et al. 2015. Neuropsychological symptoms among workers exposed to toluene and xylene in two paint manufacturing factories in eastern Thailand. *Adv Prev Med* 2015:183728. 10.1155/2015/183728.
- Thibodeaux LJ, Hwang ST. 1982. Landfarming of petroleum wastes- modeling the air emission problem. *Environ Prog* 1(1):42-46.
- Thiel R, Chahoud I. 1997. Postnatal development and behaviour of Wistar rats after prenatal toluene exposure. *Arch Toxicol* 71(4):258-265.
- Thomas K, Colborn T. 1992. Organochlorine endocrine disruptors in human tissue. In: Colborn T, Clement C, eds. *Chemically induced alterations in sexual and functional development: The wildlife/human connection*. Princeton, NJ: Princeton Scientific Publishing, 365-394.
- Thomas KW, Pellizzari ED, Cooper SD. 1991. A canister-based method of collection and GC/MS analysis of volatile organic compounds in human breath. *J Anal Toxicol* 15:54-59.
- Thomas KW, Pellizzari ED, Raymer JH, et al. 1992. Kinetics of low-level volatile organic compounds in breath - I: Experimental design and data quality. *J Expo Anal Environ Epidemiol* 2(Suppl 2):45-66.
- Thrall KD, Woodstock AD. 2002. Evaluation of the dermal absorption of aqueous toluene in F344 rats using real-time breath analysis and physiologically based pharmacokinetic modeling. *J Toxicol Environ Health A* 65(24):2087-2100.
- Thrall KD, Gies RA, Muniz J, et al. 2002b. Route-of-entry and brain tissue partition coefficients for common superfund contaminants. *Journal Toxicol Environ Health Part A* 65(24):2075-2086.

9. REFERENCES

- Thrall KD, Weitz KK, Woodstock AD. 2002a. Use of real-time breath analysis and physiologically based pharmacokinetic modeling to evaluate dermal absorption of aqueous toluene in human volunteers. *Toxicol Sci* 68(2):280-287.
- Thummel KE, Kharasch ED, Podoll T, et al. 1993. Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. *Drug Metab Dispos* 21(2):350-357.
- Tillar R, Shafer TJ, Woodward JJ. 2002. Toluene inhibits voltage-sensitive calcium channels expressed in pheochromocytoma cells. *Neurochem Int* 41(6):391-397.
- *Toftgard R, Nilsen OG, Gustafsson JA. 1982. Dose dependent induction of rat liver microsomal cytochrome P-450 and microsomal enzymatic activities after inhalation of toluene and dichloromethane. *Acta Pharmacol Toxicol* 51:108-114.
- Tokunaga I, Gotohda T, Ishigami A, et al. 2003. Toluene inhalation induced 8-hydroxy-2'-deoxyguanosine formation as the peroxidative degeneration in rat organs. *Leg Med* 5(1):34-41.
- Tomaszycki ML, Aulerich KE, Bowen SE. 2013. Repeated toluene exposure increases c-Fos in catecholaminergic cells of the nucleus accumbens shell. *Neurotoxicol Teratol* 40:28-34.
- TRI15. 2016. TRI explorer: Providing access to EPA's Toxics Release Inventory data. Washington, DC: Office of Information Analysis and Access. Office of Environmental Information. U.S. Environmental Protection Agency. Toxics Release Inventory. <http://www.epa.gov/triexplorer/>. September 19, 2016.
- Truchon G, Tardif R, Brodeur J. 1999. o-Cresol: A good indicator of exposure to low levels of toluene. *Appl Occup Environ Hyg* 14(10):677-681.
- Tsai SY, Chen J-D, Chao WY, et al. 1997. Neurobehavioral effects of occupational exposure to low-level organic solvents among Taiwanese workers in paint factories. *Environ Res* 73:146-155.
- Tsao JH, Hu YH, How CK, et al. 2011. Atrioventricular conduction abnormality and hyperchloremic metabolic acidosis in toluene sniffing. *J Formos Med Assoc* 110(10):652-654.
- Tsuga H, Honma T. 2000. Effects of short-term toluene exposure on ligand binding to muscarinic acetylcholine receptors in the rat frontal cortex and hippocampus. *Neurotoxicol Teratol* 22(4):603-606.
- Tsuga H, Wang RS, Honma T. 1999. Effects of toluene on regulation of adenylyl cyclase by stimulation of G-protein-coupled receptors expressed in CHO cells. *Jpn J Pharmacol* 81(3):305-308.
- Tsukahara S, Nakajima D, Kuroda Y, et al. 2009. Effects of maternal toluene exposure on testosterone levels in fetal rats. *Toxicol Lett* 185(2):79-84.
- Tsuruta H. 1989. Skin absorption of organic solvent vapors in nude mice *in vivo*. *Ind Health* 27:37-47.
- Tsuruta H. 1996. Skin absorption of solvent mixtures: Effect of vehicles on skin absorption of toluene. *Ind Health* 34:369-378.
- Turkall RM, Skowronski GA, Abdel-Rahman MS. 1991. Differences in kinetics of pure and soil-adsorbed toluene in orally exposed male rats. *Arch Environ Contam Toxicol* 20:155-160.

9. REFERENCES

- Uaki H, Kawai T, Mizunuma K, et al. 1995. Dose-dependent suppression of toluene metabolism by isopropyl alcohol and methyl ethyl ketone after experimental exposure of rats. *Toxicol Lett* 81(2-3):229-234.
- Uchino A, Kato A, Yuzuriha T, et al. 2002. Comparison between patient characteristics and cranial MR findings in chronic thinner intoxication. *Eur Radiol* 12(6):1338-1341.
- Ukai H, Kawai T, Inoue O, et al. 2007. Comparative evaluation of biomarkers of occupational exposure to toluene. *Int Arch Occup Environ Health* 81(1):81-93.
- Ukai H, Watanabe T, Nakatsuka H, et al. 1993. Dose-dependent increase in subjective symptoms among toluene-exposed workers. *Environ Res* 60(2):274-289.
- *Ungvary G. 1985. The possible contribution of industrial chemicals (organic solvents) to the incidence of congenital defects caused by teratogenic drugs and consumer goods- an experimental study. In: Marois, M, ed. *Prevention of physical and mental congenital defects: Part B Epidemiology, early detection and therapy, and environmental factors*. New York, NY: Alan R. Liss, Inc., 295-300.
- Ungvary G, Tatrai E. 1985. On the embryotoxic effects of benzene and its alkyl derivatives in mice, rats and rabbits. *Arch Toxicol (Suppl)*8:425-430.
- Ungvary G, Tatrai E, Lorincz M, et al. 1983. Combined embryotoxic action of toluene, a widely used industrial chemical, and acetylsalicylic acid (aspirin). *Teratology* 27:261-269.
- Ungvary G, Tatrai E, Szeberenyi S, et al. 1982. Effect of toluene exposure on the liver under different experimental conditions. *Exp Mol Pathol* 36:347-360.
- U.S. DOE. 1991. Identification of certain RCRA wastes- the F-spent solvent, P, and U listings. U.S. Department of Energy, Office of Environmental Guidance. <http://homer.ornl.gov/sesa/environment/guidance/rcra/spent.pdf>. April 24, 2014.
- USGS. 2000. Occurrence of the gasoline oxygenate MTBE and BTEX compounds in urban stormwater in the United States, 1991-95. In: USGS water-resources investigations report 96-4145. United States Geological Survey.
- USGS. 2003. A national survey of methyl *tert*-butyl ether and other volatile organic compounds in drinking-water sources: Results of the random survey. U.S. Geological Survey, U.S. Department of the Interior, National Water-Quality Assessment Program.
- USGS. 2006. Volatile organic compounds in the nation's ground water and drinking-water supply wells. U.S. Geological Survey, U.S. Department of the Interior, National Water-Quality Assessment Program.
- USITC. 2013a. HTS-290230: Toluene (Methylbenzene). U.S. domestic exports. U.S. International Trade Commission. <http://dataweb.usitc.gov/scripts/REPORT.asp>. January 14, 2014.
- USITC. 2013b. HTS-2902300: Toluene. U.S. General imports. U.S. International Trade Commission. <http://dataweb.usitc.gov/scripts/REPORT.asp>. January 14, 2014.
- van Asperen J, Rijcken WR, Lammers JH. 2003. Application of physiologically based toxicokinetic modelling to study the impact of the exposure scenario on the toxicokinetics and the behavioural effects of toluene in rats. *Toxicol Lett* 138(1-2):51-62.

9. REFERENCES

- van Doorn R, Bos RP, Brouns RME, et al. 1980. Effect of toluene and xylenes on liver glutathione and their urinary excretion as mercapturic acids in the rat. *Arch Toxicol* 43:293-304.
- Venet T, Rumeau C, Campo P, et al. 2011. Neuronal circuits involved in the middle-ear acoustic reflex. *Toxicol Sci* 119(1):146-155.
- Verschueren K, ed. 1977. Handbook of environmental data on organic chemicals. 1st ed. New York, NY: Van Nostrand Reinhold Company, 592-596
- Vidrio H, Magos GA, Lorenzana-Jimenez M. 1986. Electrocardiographic effects of toluene in the anesthetized rat. *Arch Int Pharmacodyn* 279:121-129.
- Vieira I, Sonnier M, Cresteil T. 1996. Developmental expression of CYP2E1 in the human liver: Hypermethylation control of gene expression during the neonatal period. *Eur J Biochem* 238(2):476-483.
- Vincent R, Poirot P, Subra I et al. 1994. Occupational exposure to organic solvents during paint stripping and painting operations in the aeronautical industry. *Int Arch Occup Environ Health* 65(6):377-380.
- *Voigts A, Kaufman CE. 1983. Acidosis and other metabolic abnormalities associated with paint sniffing. *South Med J* 76:443-452.
- von Euler G, Fuxe K, Hansson T, et al. 1988b. Effects of chronic toluene exposure on central monoamine and peptide receptors and their interactions in the adult male rat. *Toxicology* 52:103-126.
- von Euler G, Fuxe K, Hansson T, et al. 1989. Persistent effects of neonatal toluene exposure on regional brain catecholamine levels and turnover in the adult male rat. *Toxicology* 54:1-16.
- von Euler G, Ogren SO, Eneroth P, et al. 1994. Persistent effects of 80 ppm toluene on dopamine-regulated locomotor activity and prolactin secretion in the male rat. *Neurotoxicology* 15(3):621-624.
- *von Euler G, Ogren SO, Fuxe K, et al. 1992. Ganglioside GM₁ counteracts the enhancing effects of subacute toluene exposure on apomorphine-induced locomotor activity. *Toxicol Lett* 63:165-169.
- von Euler G, Ogren SO, Li XM, et al. 1993. Persistent effects of subchronic toluene exposure on spatial learning and memory, dopamine-mediated locomotor activity and dopamine D₂ agonist binding in the rat. *Toxicology* 77:223-232.
- von Euler M, Pham TM, Hillefors M, et al. 2000. Inhalation of low concentrations of toluene induces persistent effects on a learning retention task, beam-walk performance, and cerebrocortical size in the rat. *Exp Neurol* 163(1):1-8.
- von Oettingen WF, Neal PA, Donahue DD, et al. 1942. The toxicity and potential dangers of toluene with special reference to its maximal permissible concentration. U.S. Public Health Service Publication Health Bull No. 279:50.
- Vrca A, Bozicevic D, Bozikov V, et al. 1997a. Brain stem evoked potentials and visual evoked potentials in relation to the length of occupational exposure to low levels of toluene. *Acta Medica Croatica* 51:215-219.

9. REFERENCES

- Vrca A, Bozicevic D, Karacic V, et al. 1995. Visual evoked potentials in individuals exposed to long-term low concentrations of toluene. *Arch Toxicol* 69(5):337-340.
- Vrca A, Karacic V, Bozicevic D, et al. 1997b. Cognitive evoked potentials VEP P300 in persons occupationally exposed to low concentrations of toluene. *Arh Hig Rada Toksikol* 48:277-285.
- Vrca A, Karacic V, Bozicevic D, et al. 1996. Brainstem auditory evoked potentials in individuals exposed to long-term low concentrations of toluene. *Am J Ind Med* 30:62-66.
- Vural M, Ogel K. 2006. Dilated cardiomyopathy associated with toluene abuse. *Cardiology* 105(3):158-161.
- *Wada H. 1997. Toluene and temporal discrimination behavior in the rat. *Neurotoxicol Teratol* 19(5):399-403.
- Walker BL, Cooper CD. 1992. Air pollution emission for medical waste incinerators. *J Air Waste Manage Assoc* 42:784-791.
- Walker JT, Bloom TF, Stern FB, et al. 1993. Mortality of workers employed in shoe manufacturing. *Scand J Work Environ Health* 19:89-95.
- *Wallen M, Holm S, Nordqvist MB. 1985. Coexposure to toluene and *p*-xylene in man: Uptake and elimination. *Br J Ind Med* 42:111-116.
- Wallen M, Naslund PH, Nordqvist MB. 1984. The effects of ethanol on the kinetics of toluene in man. *Toxicol Appl Pharmacol* 76:414-419.
- Walters SM. 1986. Cleanup of samples. In: Zweig G, Sherma J, eds. *Analytical methods for pesticides and plant growth regulators*. Volume 15. Chapter 3. New York, NY: Academic Press, 67-110.
- Wan C, Harrington PD, Davis DM. 1998. Trace analysis of BTEX compounds in water with a membrane interfaced ion mobility spectrometer. *Talanta* 46(5):1169-1179.
- *Wang DH, Ishii K, Seno E, et al. 1998. Reduced serum levels of ALT and GGT and high carbohydrate intake among workers exposed to toluene below the threshold limit values. *Ind Health* 36:14-19.
- Wang RS, Nakajima T. 1992. Effects of ethanol and phenobarbital treatments on the pharmacokinetics of toluene in rats. *Br J Ind Med* 49:104-112.
- Wang RS, Nakajima T, Park SS, et al. 1993. Monoclonal antibody-directed assessment of toluene induction of rat hepatic cytochrome P450 isozymes. *Biochem Pharmacol* 46(3):413-419.
- Wang RS, Nakajima T, Tsuruta H, et al. 1996. Effect of exposure to four organic solvents on hepatic cytochrome P450 isozymes in rat. *Chem Biol Interact* 99:239-252.
- Waniusiow D, Campo P, Cossec B, et al. 2008. Toluene-induced hearing loss in acivicin-treated rats. *Neurotoxicol Teratol* 30(3):154-160.
- Waniusiow D, Campo P, Venet T, et al. 2009. Toluene-induced hearing loss in the guinea pig. *Toxicol Sci* 111(2):362-371.

9. REFERENCES

- Warner R, Ritchie HE, Woodman P, et al. 2008. The effect of prenatal exposure to a repeat high dose of toluene in the fetal rat. *Reprod Toxicol* 26(3-4):267-272.
- Wei KS, Adelman AH. 1969. The photooxidation of toluene: The role of an excited charge transfer complex. *Tetrahedron Letters* 38:3297-3300.
- Weisel CP, Lawryk NJ, Lioy PJ. 1992. Exposure to emissions from gasoline within automobile cabins. *J Expos Anal Environ Epidemiol* 2(1):79-96.
- Weiss HS, O'Connell JF, Hakaim AG, et al. 1986. Inhibitory effect of toluene on tumor promotion in mouse skin. *Proc Soc Exp Biol Med* 181:199-204.
- Wen CP, Tsai SP, Weiss NS, et al. 1985. Long-term mortality study of oil refinery workers. IV. Exposure to the lubricating-dewaxing process. *J Natl Cancer Inst* 74(1):11-18.
- Weschler CJ, Nazaroff WW. 2014. Dermal uptake of organic vapors commonly found in indoor air. *Environ Sci Technol* 48(2):1230-1237. 10.1021/es405490a.
- West JR, Smith HW, Chasis H. 1948. Glomerular filtration rate, effective renal blood flow, and maximal tubular excretory capacity in infancy. *J Pediatr* 32:10-18.
- Wetmore BA, Struve MF, Gao P, et al. 2008. Genotoxicity of intermittent co-exposure to benzene and toluene in male CD-1 mice. *Chem Biol Interact* 173(3):166-178.
- Wheeler CW, Wrighton SA, Guenther TM. 1992. Detection of human lung cytochromes P450 that are immunochemically related to cytochrome P450IIE1 and cytochrome P450IIIA. *Biochem Pharmacol* 44(1):183-186.
- White KM, Sabatino JA, He M, et al. 2016. Toluene disruption of the functions of L1 cell adhesion molecule at concentrations associated with occupational exposures. *Pediatr Res* 10.1038/pr.2016.40.
- WHO. 2004. Toluene in drinking water. Background document for development of WHO guidelines for drinking-water quality. Geneva, Switzerland: World Health Organization.
- WHO. 2010. Guidelines for indoor air quality: Selected pollutants. Geneva, Switzerland: World Health Organization. http://www.euro.who.int/__data/assets/pdf_file/0009/128169/e94535.pdf. January 08, 2014.
- WHO. 2011. Guidelines for drinking-water quality. 4th ed. Geneva, Switzerland: World Health Organization. http://www.who.int/water_sanitation_health/publications/2011/dwq_guidelines/en/index.html. January 08, 2014.
- Wiaderna D, Tomas T. 2002. Assessment of long-term effects of exposure to toluene based on the analysis of selected behavioral responses with particular reference to the ability to trigger behavioral hypersensitivity in rats. *Int J Occup Med Environ Health* 15(3):239-245.
- Widdowson EM, Dickerson JWT. 1964. Chemical composition of the body. In: Comar CL, Bronner F, eds. *Mineral metabolism: An advanced treatise. Volume II: The elements Part A*. New York, NY: Academic Press, 1-247.

9. REFERENCES

- Wiebelt H, Becker N. 1999. Mortality in a cohort of toluene exposed employees (rotogravure printing plant workers). *J Occup Environ Med* 41(12):1134-1139.
- Wilcosky TC, Checkoway H, Marshall EG, et al. 1984. Cancer mortality and solvent exposures in the rubber industry. *Am Ind Hyg Assoc J* 45(12):809-811.
- Wiley JL, Bale AS, Balster RL. 2003. Evaluation of toluene dependence and cross-sensitization to diazepam. *Life Sci* 72(26):3023-3033.
- Wilkins-Haug L, Gabow P. 1991a. Chronic glue and paint sniffing during pregnancy: A population at risk for fetal and maternal morbidity [abstract]. *Am J Obstet Gynecol* 164(1):283.
- *Wilkins-Haug L, Gabow PA. 1991b. Toluene abuse during pregnancy: Obstetric complications and perinatal outcomes. *Obstet Gynecol* 77(4):504-509.
- Williams JM, Stafford D, Steketee JD. 2005. Effects of repeated inhalation of toluene on ionotropic GABA A and glutamate receptor subunit levels in rat brain. *Neurochem Int* 46(1):1-10.
- Wilson, JT, Enfield CG, Dunlap WJ, et al. 1981. Transport and fate of selected organic pollutants in a sandy soil. *J Environ Quality* 10(4):501-506.
- Wilson RH. 1943. Toluene poisoning. *JAMA* 123:1106-1108.
- Winchester RV, Madjar VM. 1986. Solvent effects on workers in the paint, adhesive and printing industries. *Ann Occup Hyg* 30(3):307-317.
- Winderl C, Schaefer S, Lueders T. 2007. Detection of anaerobic toluene and hydrocarbon degraders in contaminated aquifers using benzylsuccinate synthase (bssA) genes as a functional marker. *Environ Microbiol* 9(4):1035-1046.
- Win-Shwe TT, Fujimaki H. 2012. Acute administration of toluene affects memory retention in novel object recognition test and memory function-related gene expression in mice. *J Appl Toxicol* 32(4):300-304.
- Win-Shwe TT, Kageyama S, Tsukahara S, et al. 2010c. Effect of D-cycloserine on spatial learning performance and memory function-related gene expression in mice following toluene exposure. *J UOEH* 32(2):127-140.
- Win-Shwe TT, Kunugita N, Nakajima D, et al. 2012a. Developmental stage-specific changes in immunological biomarkers in male C3H/HeN mice after early life toluene exposure. *Toxicol Lett* 208(2):133-141.
- Win-Shwe TT, Kunugita N, Yoshida Y, et al. 2011. Role of hippocampal TLR4 in neurotoxicity in mice following toluene exposure. *Neurotoxicol Teratol* 33(5):598-602.
- Win-Shwe TT, Kunugita N, Yoshida Y, et al. 2012b. Differential mRNA expression of neuroimmune markers in the hippocampus of infant mice following toluene exposure during brain developmental period. *J Appl Toxicol* 32(2):126-134.
- Win-Shwe TT, Mitsushima D, Nakajima D, et al. 2007b. Toluene induces rapid and reversible rise of hippocampal glutamate and taurine neurotransmitter levels in mice. *Toxicol Lett* 168(1):75-82.

9. REFERENCES

- Win-Shwe TT, Nakajima D, Fujimaki H. 2010d. Can T-cell deficiency affect spatial learning ability following toluene exposure? *Neuroimmunomodulation* 17(2):132-134.
- Win-Shwe TT, Tsukahara S, Yamamoto S, et al. 2010a. Up-regulation of neurotrophin-related gene expression in mouse hippocampus following low-level toluene exposure. *Neurotoxicology* 31(1):85-93.
- Win-Shwe TT, Yamamoto S, Nakajima D, et al. 2007a. Modulation of neurological related allergic reaction in mice exposed to low-level toluene. *Toxicol Appl Pharmacol* 222(1):17-24.
- Win-Shwe TT, Yoshida Y, Kunugita N, et al. 2010b. Does early life toluene exposure alter the expression of NMDA receptor subunits and signal transduction pathway in infant mouse hippocampus? *Neurotoxicology* 31(6):647-653.
- Withey RJ, Hall JW. 1975. The joint toxic action of perchloroethylene with benzene or toluene in rats. *Toxicology* 4:5-15.
- *Woiwode W, Drysch K. 1981. Experimental exposure to toluene: Further consideration of cresol formation in man. *Br J Ind Med* 38:194-197.
- Wolf MA, Rowe VK, McCollister DD, et al. 1956. Toxicological studies of certain alkylated benzenes and benzene. *Arch Ind Health* 14:387-398.
- Won YL, Ko Y, Heo KH, et al. 2011. The effects of long-term, low-level exposure to monocyclic aromatic hydrocarbons on worker's insulin resistance. *Saf Health Work* 2(4):365-374.
- Wood RW, Colotla VA. 1990. Biphasic changes in mouse motor activity during exposure to toluene. *Fundam Appl Toxicol* 14:6-14.
- Wood RW, Cox C. 1995. A repeated measures approach to the detection of the acute behavioral effects of toluene at low concentrations. *Fundam Appl Toxicol* 25(2):293-301.
- Wood RW, Rees DC, Laties VG. 1983. Behavioral effects of toluene are modulated by stimulus control. *Toxicol Appl Pharmacol* 68:462-472.
- Wu M, Shaffer KM, Pancrazio JJ, et al. 2002. Toluene inhibits muscarinic receptor-mediated cytosolic Ca^{2+} responses in neural precursor cells. *Neurotoxicology* 23(1):61-68.
- Yadav JS, Reddy CA. 1993. Degradation of benzene, toluene, ethylbenzene, and xylenes (BTEX) by the lignin-degrading basidiomycete *Phanerochaete chrysosporium*. *Appl Environ Microbiol* 59(3):756-762.
- Yamaguchi H, Kidachi Y, Ryoyama K. 2002. Toluene at environmentally relevant low levels disrupts differentiation of astrocyte precursor cells. *Arch Environ Health* 57(3):232-238.
- Yamamoto S, Win-Shwe TT, Yoshida Y, et al. 2009. Suppression of Th1- and Th2-type immune responses in infant mouse spleen after prenatal and postnatal exposure to low-level toluene and peptidoglycan. *Inhal Toxicol* 21(9):793-802.
- *Yamamoto S, Yoshimura N, Mori H, et al. 1992. Neurogenic bladder caused by toluene abuse. *Acta Urol Jpn* 38:459-462.

9. REFERENCES

- Yamanouchi N, Okada S, Kodama K, et al. 1995. White matter changes caused by chronic solvent abuse. *Am J Neuroradiol* 16:1643-1649.
- Yang M, Kim S-H, Kim J-C, et al. 2010. Toluene induces depression-like behaviors in adult mice. *Toxicol Res* 26(4):315-320.
- *Yelian FD, Dukelow WR. 1992. Cellular toxicity of toluene on mouse gamete cells and preimplantation embryos. *Arch Toxicol* 66:443-445.
- Yilmaz B, Canpolat S, Sandal S, et al. 2006. Paint thinner exposure inhibits testosterone synthesis and secretion in a reversible manner in the rat. *Reprod Toxicol* 22(4):791-796.
- Yin S, Li G, Hu Y, et al. 1987. Symptoms and signs of workers exposed to benzene, toluene or the combination. *Ind Health* 25:113-130.
- You Y, Shim J, Cho CH, et al. 2013. Biodegradation of BTEX mixture by *Pseudomonas putida* YNS1 isolated from oil-contaminated soil. *J Basic Microbiol* 53(5):469-475.
- Young T.J. 1987. Inhalant use among American Indian youth. *Child Psychiatry Hum Dev* 18(1):36-46.
- Yu ITS, Lee NL, Zhang XH, et al. 2004. Occupational exposure to mixtures of organic solvents increases the risk of neurological symptoms among printing workers in Hong Kong. *J Occup Environ Med* 46(4):323-330.
- Yu X, Johanson G, Ichihara G, et al. 1998. Physiologically based pharmacokinetic modeling of metabolic interactions between *n*-hexane and toluene in humans. *J Occup Health* 40:293-301.
- Yucesoy B, Yucel A, Erdem O, et al. 1999. Effects of occupational chronic co-exposure to *n*-hexane, toluene, and methyl ethyl ketone on NK cell activity and some immunoregulatory cytokine levels in shoe workers. *Hum Exp Toxicol* 18(9):541-546.
- Zahlsen K, Eide I, Nilsen AM, et al. 1992. Inhalation kinetics of C6 to C10 aliphatic, aromatic, and naphthenic hydrocarbons in rat after repeated exposures. *Pharmacol Toxicol* 71:144-149.
- Zamyslowska-Szmytko E, Poltanski P, Sliwinska-Kowalska M. 2011. Balance system assessment in workers exposed to organic solvent mixture. *J Occup Environ Med* 53(4):441-447.
- Zarani F, Papazafiri P, Kappas A. 1999. Induction of micronuclei in human lymphocytes by organic solvents *in vitro*. *J Environ Pathol Toxicol Oncol* 18(1):21-28.
- Zavalic M, Mandic Z, Turk R, et al. 1998a. Quantitative assessment of color vision impairment in workers exposed to toluene. *Am J Ind Med* 33(3):297-304.
- Zavalic M, Mandic Z, Turk R, et al. 1998b. Assessment of colour vision impairment in male workers exposed to toluene generally above occupational exposure limits. *Occup Med* 48(3):175-180.
- Zavalic M, Mandic Z, Turk R, et al. 1998c. Qualitative color vision impairment in toluene-exposed workers. *Int Arch Occup Environ Health* 71:194-200.
- Zhvanina MG, Chilachava LR, Japaridze NJ, et al. 2012. Immediate and persisting effect of toluene chronic exposure on hippocampal cell loss in adolescent and adult rats. *Brain Res Bull* 87(2-3):187-192.

9. REFERENCES

- Ziegler EE, Edwards BB, Jensen RL, et al. 1978. Absorption and retention of lead by infants. *Pediatr Res* 12(1):29-34.
- Zupanic M, Demes P, Seeber A. 2002. Psychomotor performance and subjective symptoms at low level toluene exposure. *Occup Environ Med* 59(4):263-268.

9. REFERENCES

This page is intentionally blank.

10. GLOSSARY

Absorption—The taking up of liquids by solids, or of gases by solids or liquids.

Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the Toxicological Profiles.

Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the surfaces of solid bodies or liquids with which they are in contact.

Adsorption Coefficient (K_{oc})—The ratio of the amount of a chemical adsorbed per unit weight of organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.

Adsorption Ratio (K_d)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or sediment.

Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a specified magnitude of changes in a specified adverse response. For example, a BMD_{10} would be the dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 10%. The BMD is determined by modeling the dose response curve in the region of the dose response relationship where biologically observable data are feasible.

Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological or epidemiological data to calculate a BMD.

Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms at a specific time or during a discrete time period of exposure divided by the concentration in the surrounding water at the same time or during the same period.

Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have been classified as markers of exposure, markers of effect, and markers of susceptibility.

Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces significant increases in the incidence of cancer (or tumors) between the exposed population and its appropriate control.

Carcinogen—A chemical capable of inducing cancer.

Case-Control Study—A type of epidemiological study that examines the relationship between a particular outcome (disease or condition) and a variety of potential causative agents (such as toxic chemicals). In a case-control study, a group of people with a specified and well-defined outcome is identified and compared to a similar group of people without the outcome.

Case Report—Describes a single individual with a particular disease or exposure. These may suggest some potential topics for scientific research, but are not actual research studies.

Case Series—Describes the experience of a small number of individuals with the same disease or exposure. These may suggest potential topics for scientific research, but are not actual research studies.

10. GLOSSARY

Ceiling Value—A concentration that must not be exceeded.

Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles.

Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are followed forward from exposure to outcome. At least one exposed group is compared to one unexposed group.

Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines the relationship between exposure and outcome to a chemical or to chemicals at one point in time.

Data Needs—Substance-specific informational needs that, if met, would reduce the uncertainties of human health risk assessment.

Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result from exposure to a chemical prior to conception (either parent), during prenatal development, or postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point in the life span of the organism.

Dose-Response Relationship—The quantitative relationship between the amount of exposure to a toxicant and the incidence of the adverse effects.

Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to a chemical; the distinguishing feature between the two terms is the stage of development during which the insult occurs. The terms, as used here, include malformations and variations, altered growth, and *in utero* death.

Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water levels for a chemical substance based on health effects information. A health advisory is not a legally enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.

Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of disease or other health-related conditions within a defined human population during a specified period.

Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific alteration of the molecular structure of the genome.

Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from the body or environmental media.

Immediately Dangerous to Life or Health (IDLH)—A condition that poses a threat of life or health, or conditions that pose an immediate threat of severe exposure to contaminants that are likely to have adverse cumulative or delayed effects on health.

Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from exposure to environmental agents such as chemicals.

10. GLOSSARY

Immunological Effects—Functional changes in the immune response.

Incidence—The ratio of new cases of individuals in a population who develop a specified condition to the total number of individuals in that population who could have developed that condition in a specified time period.

Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the Toxicological Profiles.

In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.

In Vivo—Occurring within the living organism.

Lethal Concentration_(LO) (LC_{LO})—The lowest concentration of a chemical in air that has been reported to have caused death in humans or animals.

Lethal Concentration₍₅₀₎ (LC₅₀)—A calculated concentration of a chemical in air to which exposure for a specific length of time is expected to cause death in 50% of a defined experimental animal population.

Lethal Dose_(LO) (LD_{LO})—The lowest dose of a chemical introduced by a route other than inhalation that has been reported to have caused death in humans or animals.

Lethal Dose₍₅₀₎ (LD₅₀)—The dose of a chemical that has been calculated to cause death in 50% of a defined experimental animal population.

Lethal Time₍₅₀₎ (LT₅₀)—A calculated period of time within which a specific concentration of a chemical is expected to cause death in 50% of a defined experimental animal population.

Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, or group of studies, that produces statistically or biologically significant increases in frequency or severity of adverse effects between the exposed population and its appropriate control.

Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the lymph nodes, spleen, and thymus.

Malformations—Permanent structural changes that may adversely affect survival, development, or function.

Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is likely to be without an appreciable risk of adverse noncancer health effects over a specified route and duration of exposure.

Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty factors. The default value for a MF is 1.

Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific population.

Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified interval of time.

10. GLOSSARY

Mutagen—A substance that causes mutations. A mutation is a change in the DNA sequence of a cell's DNA. Mutations can lead to birth defects, miscarriages, or cancer.

Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of death or pathological conditions.

Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a hazardous substance.

No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no statistically or biologically significant increases in frequency or severity of adverse effects seen between the exposed population and its appropriate control. Effects may be produced at this dose, but they are not considered to be adverse.

Octanol-Water Partition Coefficient (K_{ow})—The equilibrium ratio of the concentrations of a chemical in *n*-octanol and water, in dilute solution.

Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who were not exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the exposed group compared to the unexposed group.

Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound and especially a pesticide that acts by inhibiting cholinesterase.

Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) regulatory limit on the amount or concentration of a substance not to be exceeded in workplace air averaged over any 8-hour work shift of a 40-hour workweek.

Pesticide—General classification of chemicals specifically developed and produced for use in the control of agricultural and public health pests (insects or other organisms harmful to cultivated plants or animals).

Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate (disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.

Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based and physiologically-based. A data-based model divides the animal system into a series of compartments, which, in general, do not represent real, identifiable anatomic regions of the body, whereas the physiologically-based model compartments represent real anatomic regions of the body.

Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-response model that quantitatively describes the relationship between target tissue dose and toxic end points. These models advance the importance of physiologically based models in that they clearly describe the biological effect (response) produced by the system following exposure to an exogenous substance.

10. GLOSSARY

Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments representing organs or tissue groups with realistic weights and blood flows. These models require a variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical information, such as blood:air partition coefficients, and metabolic parameters. PBPK models are also called biologically based tissue dosimetry models.

Prevalence—The number of cases of a disease or condition in a population at one point in time.

Prospective Study—A type of cohort study in which the pertinent observations are made on events occurring after the start of the study. A group is followed over time.

q₁*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the multistage procedure. The q₁* can be used to calculate an estimate of carcinogenic potency, the incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and µg/m³ for air).

Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health (NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour workweek.

Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. The inhalation reference concentration is for continuous inhalation exposures and is appropriately expressed in units of mg/m³ or ppm.

Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level (NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect various types of data used to estimate RfDs and an additional modifying factor, which is based on a professional judgment of the entire database on the chemical. The RfDs are not applicable to nonthreshold effects such as cancer.

Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 24-hour period.

Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result from exposure to a hazardous substance. The toxicity may be directed to the reproductive organs and/or the related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of this system.

Retrospective Study—A type of cohort study based on a group of persons known to have been exposed at some time in the past. Data are collected from routinely recorded events, up to the time the study is undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing records and/or examining survivors of the cohort.

10. GLOSSARY

Risk—The possibility or chance that some adverse effect will result from a given exposure to a hazardous substance.

Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, existing health condition, or an inborn or inherited characteristic that is associated with an increased occurrence of disease or other health-related event or condition.

Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed group compared to the unexposed group.

Short-Term Exposure Limit (STEL)—A STEL is a 15-minute TWA exposure that should not be exceeded at any time during a workday.

Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected number of deaths in a specific standard population.

Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited exposure to those assumed over a lifetime of exposure to a chemical.

Teratogen—A chemical that causes structural defects that affect the development of an organism.

Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists (ACGIH) concentration of a substance to which it is believed that nearly all workers may be repeatedly exposed, day after day, for a working lifetime without adverse effect. The TLV may be expressed as a Time Weighted Average (TLV-TWA), as a Short-Term Exposure Limit (TLV-STEL), or as a ceiling limit (TLV-C).

Time-Weighted Average (TWA)—An average exposure within a given time period.

Toxic Dose₍₅₀₎ (TD₅₀)—A calculated dose of a chemical, introduced by a route other than inhalation, which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.

Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.

Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to account for (1) the variation in sensitivity among the members of the human population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic average of 10 and 1.

Xenobiotic—Any substance that is foreign to the biological system.

APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS

The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each substance included on the priority list of hazardous substances; and assure the initiation of a research program to fill identified data needs associated with the substances.

The toxicological profiles include an examination, summary, and interpretation of available toxicological information and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified route and duration of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive substance-induced endpoint considered to be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that

APPENDIX A

are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substance than animals and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that have been shown to be nontoxic in laboratory animals.

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with participation from other federal agencies and comments from the public. They are subject to change as new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels. For additional information regarding MRLs, please contact the Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop F-57, Atlanta, Georgia 30329-4027.

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Toluene
CAS Numbers: 108-88-3
Date: June 2017
Profile Status: Final
Route: ☒ Inhalation ☐ Oral
Duration: ☒ Acute ☐ Intermediate ☐ Chronic
Graph Key: 37
Species: Human

Minimal Risk Level: 2 ☐ mg/kg/day ☒ ppm

Reference: Little CH, Georgiou GM, Shelton MJ, et al. 1999. Clinical and immunological responses in subjects sensitive to solvents. Arch Environ Health 54(1):6-14.

Experimental design: Twenty subjects (9 males, 11 females, average age 39.5 years) with a history of solvent exposure and adverse reactions to toluene (i.e., clinically sensitive to toluene) were assessed in a battery of neuropsychological tests prior to and after a 20-minute exposure to 15 ppm toluene. Methods of identification/recruitment of subjects were not reported, and a separate control group was not utilized for neuropsychological testing. The battery of tests included immediate and delayed prose memory, reaction time, letter cancellations, digit symbol, focal length, and STROOP color and color-word tasks.

Effect noted in study and corresponding doses: Statistically significant ($p < 0.05$) impairments were measured in immediate and delayed prose memory (number of items recalled decreased 31%), the digit symbol test (number of correct items decreased 11%), and the letter cancellation test (percent correct decreased 5%) following a 20-minute exposure to 15 ppm toluene, compared with pre-exposure scores. A near-significant 15% increase in reaction time was also observed ($p = 0.06$). No significant difference between pre- and post-exposure values was found for focal length or the STROOP tests.

Although this study is considered adequate for hazard identification and MRL derivation, the following study limitations are acknowledged: potential selection bias, lack of a separate control group for neuropsychological testing, lack of “blinding” subjects to toluene exposure, and lack of data regarding covariates/comorbid conditions. One or more of these limitations were observed in all available studies evaluating acute controlled toluene exposure in humans.

Dose and end point used for MRL derivation: 15 ppm for minimally adverse neurological effects in a susceptible population.

☐ NOAEL ☒ LOAEL

Uncertainty Factors used in MRL derivation:

☐ 1 ☒ 3 ☐ 10 (for use of a LOAEL)

An uncertainty factor of 3 was used to extrapolate from a LOAEL to a NOAEL, because the observed effects at 15 ppm are minimally adverse and expected to be reversible.

☐ 1 ☐ 3 ☐ 10 (for extrapolation from animals to humans)

☐ 1 ☒ 3 ☐ 10 (for human variability)

The observed effects were noted in a susceptible/sensitive group of individuals; therefore, a full uncertainty factor of 10 for human toxicokinetic and toxicodynamic variability is not necessary. Using a population-based PBPK model for toluene, Mörk et al. (2014)

APPENDIX A

calculated distributions for an internal dose of toluene (C_{max} in blood) for various subpopulations under various exposure and physical activity conditions, and used the ratio between the 50th percentile values and higher percentile (90, 95, or 99th) values to indicate human variability in toxicokinetic disposition of toluene (Mörk et al. 2014). The ratios were 1.2–1.8 for the general population, 1.4–2.1 for chronically-exposed workers (under various exposure scenarios), and 1.4–3.9 for acutely-exposed workers (under various exposure scenarios). This analysis indicates that the applied uncertainty factor of 3 provides adequate protection for human variability in toxicokinetic disposition of toluene, assuming equal portioning between toxicokinetic (3.3) and toxicodynamic (3.3) in the full human variability uncertainty factor.

$$\text{Total uncertainty factor} = 3 \times 3 = 9$$

$$\text{MRL} = 15 \text{ ppm} \div 9 = 2 \text{ ppm (7.6 mg/m}^3\text{)}$$

Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not applicable.

Was a conversion used from intermittent to continuous exposure? No. Application of concentration x time (Cxt) adjustments (Haber's Rule) for acute exposure scenarios to volatile organic solvents like toluene has been questioned (Oshiro et al. 2011; ten Berge et al. 1986). An example of the basis of this questioning is provided by the results from studies of neurobehavior in animals acutely exposed to trichloroethylene (Bushnell 1997; Crofton and Zhao 1997). Cxt adjustments were shown to underestimate toxic effects when adjusting from relatively long acute durations to shorter durations, and to overestimate toxic effects when adjusting from relatively short acute durations to long acute durations.

Haber's Rule has been modified to reflect observations that concentration often exerts a stronger influence on acute toxicity than does time (ten Berge et al. 1986). The modification raises the concentration term to a power, (n), which is determined empirically with appropriate data ($C^n \text{xt}$; ten Berge et al. 1986). However, determination of the exponent (n) requires adequate concentration-duration-response data, and results from animal studies indicate that the exponent (n) can vary across neurobehavioral end points (e.g., Bushnell 1997).

No duration adjustments were made to exposure concentrations in the available neurobehavioral studies of humans exposed to controlled concentrations of toluene for times varying from 15 minutes to 8 hours, because the available data are for a variety of neurological effects (see further discussion in the next section of this worksheet), and duration adjustment by Haber's rule is likely to overestimate toxic effects when adjusting from short-term (e.g., 15-minute) to longer-term (e.g., 8-hour) exposure durations.

Estimates of brain concentration at the time of testing have been shown in animals to provide a better dose-metric for predicting acute behavioral effects of toluene than cumulative measures of exposure or Cxt adjustments. For rats exposed to varying toluene concentrations in air (1,200–2,400 ppm) and durations (22–70 minutes) and examined for signal detection behavior, effects on accuracy and response-time variables were increased with both increasing concentration and increasing duration (Bushnell et al. 2007). The use of a rat PBPK model to predict internal blood and brain concentrations of toluene as a function of time showed that estimated brain concentration at the time of testing provided a much better explanation of these performance variables than did cumulative measures of dose (AUCs for inhaled dose [ppm-hour] or brain concentration [mg-hour/L]) (Bushnell et al. 2007). Oshiro et al. (2011) tested rats in a signal detection task at various times during exposure to 0, 1,125, 1,450, or 1,660 ppm for up to

APPENDIX A

24 hours, and reported that brain toluene concentration (estimated using a rat PBPK model) at the time of testing was a better predictor of performance than Cxt adjustment. Analysis of the data also showed that the brain dose-response relationship for the response time variable at 24 hours of exposure was shifted to the right on the dose axis, compared with the relationship determined at 1 hour of exposure. This duration-induced shift of the dose response relationship indicates that extrapolation from 1- to 24-hour exposure would be confounded by an apparent development of tolerance to toluene within this acute time frame.

As discussed in Section 3.4.5, none of the available human PBPK models for toluene contain a brain compartment or have the ability to estimate brain concentrations of toluene. The lack of human data for kinetics of toluene in brain tissue impedes the development of such a model. Such a model could be used to compare results across available acute exposure studies of human neurobehavior, based on estimates of brain concentrations at the time of testing.

Other additional studies or pertinent information that lend support to this MRL: The critical effect of acute inhalation exposure to toluene is on the central nervous system. Multiple studies report subtle neurological effects in healthy individuals following acute exposure to concentrations in the 75–300 ppm range with durations ranging from 20 minutes to 8 hours (Andersen et al. 1983; Baelum et al. 1985; Dick et al. 1984; Echeverria et al. 1991; Gamberale and Hultengren 1972; Kobald et al. 2015; Rahill et al. 1996; von Oettingen et al. 1942). Effects include increased subjective complaints (e.g., headache, sleepiness, dizziness) following exposure to 100 ppm for 6 or 6.5 hours (Andersen et al. 1983; Baelum et al. 1985) or 200 ppm for 3 or 8 hours (von Oettingen et al. 1942), and impairments in psychomotor tests following exposure to 75 or 150 ppm toluene for 7 hours (Echeverria et al. 1991), 100 ppm for 6–8 hours (Dick et al. 1984; Rahill et al. 1996), 200 ppm for 40 minutes (Kobald et al. 2015), and 300 ppm for 20 minutes (Gamberale and Hultengren 1972).

No adverse, dose-related effects have been observed in healthy individuals acutely exposed to 40–50 ppm toluene for 2–6 hours (Andersen et al. 1983; Lammers et al. 2005a; Muttray et al. 2005; Osterberg et al. 2000, 2003). Therefore, a NOAEL of 40 ppm from Anderson et al. (1983) was considered as the basis for the acute MRL, and previously was used as the point of departure (POD) for the acute inhalation MRL (ATSDR, 2000).

However, recent studies indicate that individuals clinically sensitive to toluene experienced subtle neurological effects at lower concentrations in the 15–48 ppm range (Little et al. 1999; Orbaek et al. 1998; Osterberg et al. 2003). In addition to the altered performance in psychomotor tasks observed in individuals clinically sensitive to toluene reported by Little et al. (1999), individuals with multiple chemical sensitivity (MCS) or toxic encephalopathy had significantly higher self-reported scores of fatigue (headache, drowsiness, decreased concentration) during exposure to increasing toluene concentrations over 2 hours (0 ppm [20 minutes], 3 ppm [10 minutes], 6 ppm [10 minutes], 12 ppm [20 minutes], 24 ppm [10 minutes], 48 ppm [20 minutes], and 0 ppm [10 minutes]), compared with healthy referents (Orbaek et al. 1998; Osterberg et al. 2003). During these studies, psychomotor tests were performed before exposure and during the 12- and 48-ppm exposure periods. Both healthy referents and individuals with multiple chemical sensitivity showed increased response time in the reaction-time test (visual stimuli) following exposure, compared with pre-exposure scores (Osterberg et al. 2003). However, the increase was not dose-related in healthy individuals, and exposure-related impairments were not observed in the reaction time-inhibition test (with auditory alarm) or digit symbol test in either group (Osterberg et al. 2003). In a separate study, there were no observed psychomotor impairments in exposed individuals with toxic encephalopathy or healthy referents using the same protocol (Osterberg et al. 2000). A LOAEL of 48 ppm for the studies conducted by Orbaek et al. (1998) and Osterberg et al. (2003) was determined for susceptible individuals based on increased self-reported fatigue. A NOAEL could not be determined, as fatigue scores were not reported at individual exposure concentrations.

APPENDIX A

Rationale for Selection of Key Study: Both the previously used study in healthy subjects by Andersen et al. (1983) and the study in subjects with MCS by Little et al. (1999) were considered as key studies for the derivation of the acute inhalation MRL. The previous ATSDR profile (ATSDR 2000) derived an acute inhalation MRL of 1 ppm based on the NOAEL of 40 ppm in healthy individuals; however, that derivation utilized a CxT adjustment. As discussed above, this adjustment for continuous exposure is no longer considered appropriate for acute toluene exposure. Thus, use of a POD of 40 ppm (NOAEL for neurological effects in healthy individuals) and an uncertainty factor of 10 (to protect for susceptible populations, which may differ from healthy populations due to toxicodynamic or toxicokinetic variability) would result in an acute inhalation MRL of 4 ppm. However, ATSDR prefers to use data from a susceptible population to better estimate the risk of acute toluene exposure, rather than using a default uncertainty factor of 10 with data from healthy individuals to account for susceptible populations. Therefore, the Little et al. (1999) study in subjects with MCS was selected as the key study and considered the most health-protective option based on the available data.

There is some controversy in the medical community regarding the underlying etiology of the symptoms observed in MCS patients. Reviews published in the last decade show varied findings, concluding that: (1) MCS is predominantly a physiological condition (CHRC 2007; De Luca et al. 2011; Genuis 2010, 2013); (2) available data are inadequate to determine the relative contributions of physiological and psychological factors (NICNAS 2010; Spencer and Shur, 2008); or (3) MCS is primarily psychological or a sociological belief system (Boyd et al. 2012; Das-Munshi et al. 2006; Hetherington and Battershill 2013). Proposed etiologies include the initiation of a hypersensitive immune state by exposure to exogenous toxic exposures (toxicant-induced loss of tolerance); respiratory/neurogenic inflammation; neurochemical, endocrine, or receptor-mediated sensitization; altered metabolic capacity; behavioral conditioning; psychological conditions; or some combination thereof (CHRC 2007; De Luca et al. 2010, 2011; Genuis 2013; NICNAS 2010). While the etiological basis of MCS is still unknown, the exclusion of studies evaluating MCS subjects (who are extensively recognized and discussed in the literature) would be dismissing a potentially sensitive subgroup during the human health risk analysis for toluene. Therefore, despite a lack of understanding of the mechanistic underpinnings of MCS, ATSDR considers the MCS test subjects in Little et al. (1999) as a group of individuals with potentially increased sensitivity to chemical exposures, including exposure to toluene. It is important to note that the test subjects with MCS are not experiencing unique effects not observed in the healthy population; rather, they are experiencing neurological deficits commonly associated with toluene exposure in healthy individuals, but at lower exposure levels. Therefore, the study by Little et al. (1999) was selected as the key study in order to protect this sensitive subpopulation. Since data are inadequate to determine if subjects with MCS are the *most* sensitive subpopulation, a partial uncertainty factor of 3 was used to account for other potentially susceptible populations, as well as human variability in toxicokinetic disposition of toluene.

Agency Contacts (Chemical Manager): Jessilyn Taylor

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Toluene
CAS Numbers: 108-88-3
Date: June 2017
Profile Status: Final
Route: ☒ Inhalation ☐ Oral
Duration: ☐ Acute ☐ Intermediate ☒ Chronic
Graph Key: 229–230, 238
Species: Human

Minimal Risk Level: 1 ☐ mg/kg/day ☒ ppm

References: Schäper M, Demes P, Zupanic M, et al. 2003. Occupational toluene exposure and auditory function: results from a follow-up study. *Ann Occup Hygiene* 47(6):493-502.

Schäper M, Demes P, Kiesswetter E, et al. 2004. Colour vision and occupational toluene exposure: results of repeated examinations. *Toxicol Lett* 151(1):193-202.

Schäper M, Seeber A, van Thriel, C. 2008. The effects of toluene plus noise on hearing thresholds: an evaluation based on repeated measurements in the German printing industry. *Int J Occup Med Environ Health* 21(3):191-200.

Seeber A, Schäper M, Zupanic M, et al. 2004. Toluene exposure below 50 ppm and cognitive function: a follow-up study with four repeated measurements in rotogravure printing plants. *Int Arch Occup Environ Health* 77(1):1-9.

Seeber A, Demes P, Kiesswetter E, et al. 2005. Changes of neurobehavioral and sensory functions due to toluene exposure below 50 ppm? *Environ Toxicol Pharmacol* 19(3):635-643.

Zupanic M, Demes P, Seeber A. 2002. Psychomotor performance and subjective symptoms at low level toluene exposure. *Occup Environ Med* 59(4):263-268.

Experimental design: A series of studies by the same group of investigators assessed subjective neurological symptoms, performance on psychomotor tasks, color vision, and hearing in groups of German photogravure printers employed for an average duration of 13.5 years (Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Zupanic et al. 2002). These studies compared neurological end points in workers with high exposure to toluene (printers, n=106–181) with workers with low exposure to toluene (end-processors, n=86–152). Current toluene air exposure levels for printers and end-processors were 24.6–26 and 3–3.5 ppm, respectively (measured twice yearly from 1996 to 2001). Historical exposure levels for printers prior to 1995 and prior to 1975 were 40 and 140 ppm, respectively. Historical exposure levels for end-processors prior to 1995 and prior to 1975 were 5 and 40 ppm, respectively. Using job history and current exposure and historical exposure levels, individual TWA exposure levels were calculated. The average TWA levels for printers and end-processors were calculated to be 45 and 10 ppm for subjects included in analyses by Schäper et al. (2003, 2008), 45 and 9 ppm for subjects included in analyses by Seeber et al. (2004, 2005) and Zupanic et al. (2002), and 43 and 9 ppm for subjects included in analyses by Schäper et al. (2004).

Effect noted in study and corresponding doses: Schäper et al. (2003, 2008) did not find any statistically significant differences in audiometric readings from four readings over 5 years in 181 printers, compared with 152 end-processors. Schäper et al. (2004) did not find any differences in color vision assessed

APPENDIX A

4 times over 5 years in 154 printers, compared with 124 end-processors. Seeber et al. (2004, 2005) and Zupanec et al. (2002) did not find any increase in subjective neurological complaints or decreased performance in psychomotor tasks in 106–154 printers, compared with 86–124 end-processors.

Dose and end point used for MRL derivation: 45 ppm for neurological effects

[X] NOAEL [] LOAEL

Uncertainty Factors used in MRL derivation:

[] 1 [] 3 [] 10 (for use of a LOAEL)

[] 1 [] 3 [] 10 (for extrapolation from animals to humans)

[] 1 [] 3 [X] 10 (for human variability). The analysis by (Mörk et al. 2014) provides evidence that the uncertainty factor of 10 for human toxicokinetic and toxicodynamic variability provides adequate protection for human variability in toxicokinetic disposition of toluene, assuming equal portioning between toxicokinetic variability (3.3) and toxicodynamic variability (3.3) (see discussion in the acute inhalation MRL worksheet).

$MRL = 45 \text{ ppm} \times 5 \text{ days}/7 \text{ days} \times 8 \text{ hours}/24 \text{ hours} \div 10 = 1 \text{ ppm} (3.8 \text{ mg}/\text{m}^3)$

Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not applicable.

Was a conversion used from intermittent to continuous exposure? The exposure concentration was adjusted to continuous exposure basis as shown above.

Other additional studies or pertinent information that lend support to this MRL: Twenty-four human occupational studies evaluating neurological end points following exposure predominately or exclusively to toluene were considered for deriving the chronic inhalation MRL (see Table A-1). Numerous studies identified subtle neurological effects following occupational exposure to toluene at concentration estimates ranging from 50 to 140 ppm, including subjective neurological symptoms, altered performance on neurobehavioral and psychomotor tasks, impaired color vision, and hearing loss (Abbate et al. 1993; Boey et al. 1997; Foo et al. 1990; Kang et al. 2005; Matsushita et al. 1975; Murata et al. 1993; Neubert et al. 2001; Nordling Nilson et al. 2010; Orbaek and Nise 1989; Ukai et al. 1993; Vrca 1995, 1996, 1997b; Yin et al. 1987; Zavalic et al. 1998a, 1998b, 1998c). Several occupational studies identify NOAELs for these effects in the range of 20–46 ppm toluene (Chouanière et al. 2002; Gericke et al. 2001; Kang et al. 2005; Nakatsuka et al. 1992; Neubert et al. 2001; Schäper et al. 2003, 2004, 2008; Seeber et al. 2004, 2005; Ukai et al. 1993; Zavalic et al. 1998a, 1998c; Zupanec et al. 2002). One outlier study reported that no increases in subjective symptoms or changed performance on psychomotor tasks were found in printers exposed to 9–83 ppm and laboratory workers exposed to 184–467 ppm when analyzed together, compared with unexposed referents (Deschamps et al. 2001). However, the findings for the two groups were not reported separately. The NOAEL for this study was set at the average of the midpoints of the exposure ranges for the two groups of workers (midpoint factory, 46 ppm; midpoint laboratory, 325.5; average, 185.75 ppm). Studies that evaluated only subjective end points (Ukai et al. 1993; Yin et al. 1987) were not considered for deriving the chronic inhalation MRL.

APPENDIX A

Table A-1. Chronic Occupational Studies Considered for Deriving the Chronic Inhalation MRL

Study author/date	Neurological end point(s) evaluated (altered end points at LOAEL are in bold)	NOAEL	LOAEL
Abbate et al. 1993	BAEPs		97
Boey et al. 1997	Logical memory, digit span , visual reproduction , Benton visual retention test , trail making test , symbol digit modality test , grooved pegboard test , and finger tapping test		90.9
Chouanière et al. 2002	Subjective symptoms, simple reaction time, symbol digit substitution, digit span forwards and backwards, pattern memory test, associate learning and recall	27	
Deschamps et al. 2001	Subjective symptoms, vocabulary test, simple reaction time, digit symbol, digit span forwards and backwards, continuous tracking, color word vigilance, and switching attention test	186 ^a	
Foo et al. 1990	Benton visual retention , visual reproduction , trail making , grooved peg board , digit span , digit symbol , finger tapping, and simple reaction time		88
Gericke et al. 2001	Subjective symptoms, assessment of color vision (test used was not specified), and a battery of psychomotor tests (immediate visual memory, digit span forward and backward, and digit symbol)	24	
Kang et al. 2005	Finger tapping , selective attention , digit span forward and backward, symbol digit, and simple reaction time tests	20	75
Matsushita et al. 1975	Subjective symptoms , tendon reflexes , grasping power , and tapping tempo		84
Murata et al. 1993	Nerve conduction (EKG, median nerve)		83
Nakatsuka et al. 1992	Color vision (Lanthony's new color test and Ishihara's color/vision test)	46	
Neubert et al. 2001	Subjective symptoms, digit span forward/backward, visuomotor performance, visual memory, self-rating of feelings, bisensory vigilance, flicker fusion frequency , and personality dispositions	33	75
Orbaek and Nise 1989; Nordling Nilson et al. 2010	Initial: Subjective symptoms and psychometric tests including verbal, logical inductive, spatial memory, perceptual, and psychomotor tests 20-year follow-up: Subjective symptoms and psychometric tests including verbal, logical inductive (reasoning), spatial memory (associative learning), perceptual, psychomotor tests, trail-making test, STROOP test, and memory tests		140
Schäper et al. 2003, 2008 ^b	Audiometry (two reports of the same study)	45	
Schäper et al. 2004 ^b	Color vision (Lanthony desaturated panel D-15d, Ishihara plates)	43	
Seeber et al. 2004, 2005 ^b	Subjective symptoms, symbol digit substitution, switching attention, and memory span (initial study 2004; follow-up analysis of the same data in 2005)	45	
Vrca 1995, 1997 ^b	VEPs		50
Vrca et al. 1996	BAEPs		50

APPENDIX A

Table A-1. Chronic Occupational Studies Considered for Deriving the Chronic Inhalation MRL

Study author/date	Neurological end point(s) evaluated (altered end points at LOAEL are in bold)	NOAEL	LOAEL
Zavalic 1998a, 1998c	Color vision (Lanthony D-15 desaturated test; Verriest's classification of color vision loss)	35	156
Zavalic 1998b	Color vision (Lanthony D-15 desaturated test; Verriest's classification of color vision loss)		120
Zupanic et al. 2002 ^b	Subjective symptoms, manual dexterity: steadiness, line tracing, aiming, tapping, and peg board	45	

^aTwo toluene-exposed groups were described by Deschamps et al. (2001): 36 factory workers (9–83 ppm) and 36 laboratory workers (184–467 ppm). No average exposure levels were reported, and the two groups were analyzed together. Therefore, the NOAEL was set at the average of the midpoints of the exposed ranges (midpoint factory, 46 ppm; midpoint laboratory, 325.5; average, 185.75 ppm).

^bStudies selected for derivation of the chronic MRL.

BAEP = brainstem auditory evoked potential; LOAEL = lowest-observed-adverse-effect level; MRL = minimal risk level; NOAEL = no-observed-adverse-effect level; VEP = visual-evoked potential

After reviewing all available studies, the series of six recent studies in German rotogravure printers reporting NOAELs of 43–45 ppm for hearing loss (Schäper et al. 2003, 2008), color vision (Schäper et al. 2004), and psychomotor function (Seeber et al. 2004, 2005; Zupanic et al. 2002) were selected to support a POD of 45 ppm. This POD NOAEL value is lower than all LOAEL values in Table A-1 and is consistent with the mean and median NOAEL values from all studies summarized in Table A-1 (50 and 43 ppm, respectively).

The previous draft used a POD based on a LOAEL of 35 ppm for color vision impairment in the studies by Zavalic et al. (1998a, 1998c). The current evaluation of this study arrives at a different LOAEL determination. In Zavalic et al. (1998a), the color confusion index (CCI) was statistically significantly increased by 14% in 32 printers exposed to geometric mean toluene concentrations of 156 ppm, respectively, when compared with 83 unexposed controls on Monday morning prior to their work shift. However, the CCI in 41 shoemakers exposed to geometric mean toluene concentrations of 35 ppm were not significantly elevated when compared with controls. When alcohol consumers were excluded, the CCI in 27 shoemakers and 10 printers was significantly increased by 4 and 11%, respectively, compared with 36 controls. When adjusted for age and alcohol consumption, CCIs were significantly higher in both shoemakers and printers (adjusted mean CCI values were not reported). Individual adjusted CCIs were significantly correlated with individual exposure estimates (air, blood, or urine) in printers, but not shoemakers. In Zavalic et al. (1998c), further analysis of color vision loss in these groups of workers demonstrated that total dychromatopsia (combined incidence of blue-yellow and red-green color confusion [dyschromatopsia type II] and just blue-yellow color confusion [dyschromatopsia III]) was significantly increased in printers, but not shoemakers, compared with unexposed workers. Dyschromatopsia type I (red-green color confusion only) was not observed in any exposed or unexposed workers Zavalic et al. 1998c). Taken together, these studies indicate a clear LOAEL of 156 ppm for color vision loss in printers, based on increased CCIs significantly associated with individual estimates of toluene exposure and increased prevalence of dyschromatopsia. A NOAEL of 35 ppm was identified, as it is unclear if the statistically significant findings for increased CCI in the small sample of non-alcohol consuming workers or adjusted CCIs in all workers represents an adverse effect, especially since the magnitude of change was small and individual CCIs in this group were not associated with toluene exposure estimates in the air, blood, or urine. This interpretation of findings is consistent with the

APPENDIX A

interpretation in the most recent Integrated Risk Information System (IRIS) document (EPA 2005a), which considers the lower exposure level to be a NOAEL for color vision impairment.

Agency Contacts (Chemical Manager): Jessilyn Taylor

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Toluene
CAS Numbers: 108-88-3
Date: June 2017
Profile Status: Final
Route: ☐ Inhalation ☒ Oral
Duration: ☒ Acute ☐ Intermediate ☐ Chronic
Graph Key: 18
Species: Rat

Minimal Risk Level: 0.8 ☒ mg/kg ☐ ppm

Reference: Dyer RS, Bercegeay MS, Mayo LM. 1988. Acute exposures to p-xylene and toluene alter visual information processing. Neurotoxicol Teratol 10:147-153.

Experimental design: Male Long-Evans rats (12/group) were administered doses of toluene in corn oil of 0, 250, 500, and 1,000 mg/kg by gavage. FEP tests were administered 45 minutes later as a test of the ability of the nervous system to process visual information. In another study (time-course), toluene was administered to male Long-Evans rats (16/group) at doses of 0 and 500 mg/kg by gavage, and FEP tests were performed 4, 8, 16, and 30 hours later.

Effect noted in study and corresponding doses: The amplitude of the N3 peak of the FEP was significantly decreased ($p < 0.05$) by toluene exposure at all doses. The magnitude of this decrease in peak amplitude was not dose-related. In the time course study, 500 mg/kg also decreased the amplitude of the FEP; at this dose, little change in magnitude of peak N3 depression had occurred 8 hours post-treatment; by 16 hours, recovery was complete.

Dose and end point used for MRL derivation: 250 mg/kg for neurological effects

☐ NOAEL ☒ LOAEL

Uncertainty Factors used in MRL derivation:

☐ 1 ☒ 3 ☐ 10 (for use of a LOAEL)
☐ 1 ☐ 3 ☒ 10 (for extrapolation from animals to humans)
☐ 1 ☐ 3 ☒ 10 (for human variability)

$MRL = 250 \text{ mg/kg/day} \div 300 = 0.8 \text{ mg/kg/day}$

Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not applicable.

Was a conversion used from intermittent to continuous exposure? No.

Other additional studies or pertinent information that lend support to this MRL: Human data suitable for deriving an acute oral MRL for toluene are not available.

APPENDIX A

Only a limited number of acute-exposure rat studies have evaluated neurological end points in addition to the study by Dyer et al. (1988) and all of them evaluated higher doses. These studies report transient increases in motor activity following single oral doses of 650–5,220 mg/kg (Gordon et al. 2007, 2010; MacPhail et al. 2012; Mehta et al. 1998), abnormal gait following single oral doses of 3,915–5,220 mg/kg (Mehta et al. 1998), and ototoxicity following exposure to 780 mg/kg/day, 5 days/week for 2 weeks (Gagnaire and Langlais 2005). Additionally, numerous acute-duration animal inhalation studies have reported neurological effects from toluene (see Table 3-1 for complete list). Human inhalation studies have focused on the central nervous system as the critical toxicity target for acute-duration toluene exposure (Andersen et al. 1983; Baelum et al. 1985; Dick et al. 1984; Echeverria et al. 1989; Gamberale and Hultengren 1972; Rahill et al. 1996; von Oettingen et al. 1942).

An additional study that lends support to the MRL is a developmental study that reported altered cortical cell proliferation and migration in offspring following exposure of pregnant rats to gavage doses of 0 or 650 mg/kg/day toluene in corn oil on GDs 6–19 (Gospe and Zhou 2000). Cortical cell density was significantly decreased by 12.5% in all layers of the cerebral cortex in toluene-exposed pups on PND 21, compared with controls. The greatest decrease (26.8%) was observed in layer IV. Decreased density was attributed to altered neurogenesis, as neurons labeled with BrdU from injections on GDs 13–21 were decreased in numbers and exhibited altered migration patterns.

Agency Contacts (Chemical Manager): Jessilyn Taylor

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Toluene
CAS Numbers: 108-88-3
Date: June 2017
Profile Status: Final
Route: ☐ Inhalation ☒ Oral
Duration: ☐ Acute ☒ Intermediate ☐ Chronic
Graph Key: 45-47
Species: Mouse

Minimal Risk Level: 0.2 ☒ mg/kg/day ☐ ppm

References: Hsieh GC, Sharma RP, Parker RD. 1989. Immunotoxicological evaluation of toluene exposure via drinking water in mice. *Environ Res* 49:93-103.

Hsieh GC, Parker RD, Sharma RP, et al. 1990a. Subclinical effects of groundwater contaminants. III. Effects of repeated oral exposure to combinations of benzene and toluene on immunologic responses in mice. *Arch Toxicol* 64:320-328.

Hsieh GC, Sharma RP, Parker RD. 1991. Hypothalamic-pituitary-adrenocortical axis activity and immune function after oral exposure to benzene and toluene. *Immunopharmacol* 21:23-31.

Experimental design: A series of studies evaluated immune end points in male CD-1 mice (5/group) administered toluene in their drinking water for 28 days at concentrations of 0, 5, 22, or 105 mg/kg/day (Hsieh et al. 1989, 1991) or 0, 22, or 84 mg/kg/day (Hsieh et al. 1990a). In Hsieh et al. (1989, 1990a), rats were weighed, sacrificed, and examined for gross pathological lesions at 28 days. Spleen and thymus were weighed and hematology was performed. Spleens were assessed for cellularity, and splenocytes were used in *in vitro* immune assays (mitogen-stimulated lymphocyte proliferation, mixed lymphocyte reaction, IL-2 production assay, and antibody PFC response). Hsieh et al. (1990a) also measured the *in vitro* cell-mediated cytotoxicity response. In Hsieh et al. (1991), immune function was only assessed using the IL-2 assay in cultured splenocytes. A level of $p < 0.05$ was considered statistically significant unless otherwise stated.

Effect noted in study and corresponding doses: In Hsieh et al. (1989), significantly decreased thymus weight and significantly depressed immune responses were observed in all *in vitro* immune assays at 105 mg/kg/day, compared with control. IL-2 production and mitogen-stimulated lymphocyte proliferation were also significantly decreased at 22 mg/kg/day compared with control. In Hsieh et al. (1990a), significantly depressed immune responses were observed in the PFC assay and mixed lymphocyte reaction at 84 mg/kg/day. The mixed lymphocyte reaction was also significantly depressed at 22 mg/kg/day. In Hsieh et al. (1991), the IL-2 production assay was significantly depressed at 105 mg/kg/day. Taken together, these studies consistently reported diminished immune responses in multiple *in vitro* immune assays following *in vivo* exposure to 84–105 mg/kg/day in drinking water for 28 days, compared with controls. A couple of immune assays were altered at 22 mg/kg/day, but findings were not consistent between the three Hsieh studies. Additionally, the antibody PFC assay was significantly altered at 84 and 105 mg/kg/day, but not at 22 mg/kg/day (Hsieh et al. 1989, 1990a). The PFC *in vitro* assay is considered the most predictive assay of impaired immune function (Luster et al. 1992). Collectively, results from these studies support a NOAEL of 22 mg/kg/day for immune effects.

APPENDIX A

Dose and end point used for MRL derivation: 22 mg/kg/day for immune depression

[X] NOAEL [] LOAEL

Uncertainty Factors used in MRL derivation:

[] 1 [] 3 [] 10 (for use of a LOAEL)
[] 1 [] 3 [X] 10 (for extrapolation from animals to humans)
[] 1 [] 3 [X] 10 (for human variability)

MRL = 22 mg/kg/day ÷ 100 = 0.2 mg/kg/day

Was a conversion factor used from ppm in food or water to a mg/body weight dose? Yes. The study authors calculated that exposure to 0, 17, 80, and 405 mg/L in drinking water for 28 days was equivalent to toluene doses of 0, 5, 22, and 105 mg/kg/day, respectively, over this period based on water consumption (Hsieh et al. 1989). These equivalent doses were used for the Hsieh et al. (1991) study. Toluene concentration in Hsieh et al. (1990a) was reported to be 0, 80, or 325 mg/L in drinking water. The equivalent dose for the 80 mg/L group from previous studies was adopted for the 1990a study (22 mg/kg/day). Using the conversion factor from the high-dose group from Hsieh et al. (1989) (1 mg/L = 0.259 mg/kg/day), the equivalent dose for the 325 mg/L group was calculated to be 84 mg/kg/day.

If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not applicable.

Was a conversion used from intermittent to continuous exposure? No.

Other additional studies or pertinent information that lend support to this MRL: Human data suitable for deriving an intermediate oral MRL for toluene are not available.

No other intermediate-duration oral studies evaluating immune function were located. In an acute oral study, Burns et al. (1994) reported that exposure to 600 mg/kg/day via gavage for 14 days did not diminish immune response in *in vitro* immune assays or decrease host resistance to *Listeria monocytogenes*, *S. pneumoniae*, *Plasmodium yoelii*, B16F10 melanoma, or PYB6 fibrosarcoma in female mice, compared with controls. The EPA (2005) discounted immune effects as a critical effect for the IRIS RfD due to the absence of immune effects in the Burns et al. (1994) study and apparent conflicting evidence for toluene immunotoxicity in animals. However, exposure was under different conditions (gavage versus drinking water) and for a shorter duration (14 days versus 28 days) in the Hsieh et al. studies than in the Burns et al. (1994) study. The sex and strain also differed between the studies (B6C3F1 versus CD-1; females versus males). Therefore, the lack of observed effects in the Burns et al. (1994) study may not represent conflicting evidence; rather, it may be due to the shorter duration, different exposure conditions, and/or differences between sexes or strains.

In animal inhalation studies, evidence for toluene effects on the immune system include the finding of decreased resistance to mortality from respiratory infection by *S. zooepidemicus* in a study of mice exposed for 3 hours to toluene concentrations as low as 2.5 ppm, but not 1 ppm (Aranyi et al. 1985).

Hepatic, renal, and neurological effects were also considered as bases of the intermediate-duration oral MRL. However, the PODs for hepatic, renal, and neurological effects (see Table A-2) are all higher than the selected POD for immune effects. Additionally, findings for increased liver and kidney weight were not consistent between studies, nor were they associated with histopathological changes.

APPENDIX A

Table A-2. Animals Studies Considered for Deriving the Intermediate-Duration Oral MRL

Study	End point(s) evaluated	Significant effects at LOAEL	NOAEL	LOAEL
Immuno/lymphoreticular effects				
NTP 1990; 13 weeks; F344 rats 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)	Spleen and thymus weight and histology (0, 2,500, and 5,000 mg/kg/day groups only)	All 5,000 mg/kg/day mice died within 1 week, so the NOAEL was set at 2,500 mg/kg/day	2,500	—
Hsieh et al. 1989 ^a ; 28 days; CD-1 male mice 0, 5, 22, and 105 mg/kg/day via drinking water	Immune assays (PFC assay, mixed lymphocyte response, mitogen stimulation, IL-2 immune response); spleen and thymus weight and gross pathology	Decreased thymus weight, depressed immune response in all assays (mitogen-stimulated lymphocyte proliferation and IL-2 immunity were also depressed at 22 mg/kg/day)	22 (males)	105 (males)
Hsieh et al. 1990a ^a ; 28 days; CD-1 male mice 0, 22, and 84 mg/kg/day via drinking water	Immune assays (PFC assay, mixed lymphocyte culture, mitogen stimulation, IL-2 immune response, cell-mediated cytotoxicity); spleen and thymus weight and gross pathology	Depressed immune response in PFC assay and mixed lymphocyte culture (mixed lymphocyte culture was also depressed at 22 mg/kg/day)	22 (males)	84 (males)
Hsieh et al. 1991 ^a ; 28 days; CD-1 male mice 0, 5, 22, and 105 mg/kg/day via drinking water	IL-2 immune response assay	Depressed IL-2 immune response	22 (males)	105 (males)
NTP 1990; 13 weeks; B6C3F1 mice 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)	Spleen and thymus weight and histology (0, 2,500, and 5,000 mg/kg/day groups only)	All 5000 mg/kg/day mice died within 1 week, so the NOAEL was set at 2,500 mg/kg/day	2,500	—
Hepatic effects				
NTP 1990; 13 weeks; F344 rats 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)	Liver weight, histology, clinical chemistry	Increased absolute and relative liver weight	312 M 625 (females)	625 M 1,250 (females)
Wolf et al. 1956; 6 months; Wistar rats 0, 118, 354, and 590 mg/kg/day via gavage (5 days/week)	Liver weight, histology	No adverse-effect level determined for liver end points	590 (females)	—
Hsieh et al. 1989; 28 days; CD-1 male mice 0, 5, 22, and 105 mg/kg/day via drinking water	Liver weight, gross pathology	Increased liver weight	22 (males)	105 (males)

APPENDIX A

Table A-2. Animals Studies Considered for Deriving the Intermediate-Duration Oral MRL

Study	End point(s) evaluated	Significant effects at LOAEL	NOAEL	LOAEL
Hsieh et al. 1990a; 28 days; CD-1 male mice 0, 22, and 84 mg/kg/day via drinking water	Liver weight, gross pathology	No adverse-effect level determined for liver end points	84 M	–
NTP 1990 ^b ; 13 weeks; B6C3F1 mice 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)	Liver weight, histology, clinical chemistry	Increased absolute (females) and relative (males and females) liver weight	625 (males) – (females)	1,250 (males) 312 (females)
Renal effects				
NTP 1990 ^a ; 13 weeks; F344 rats 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)	Kidney weight, histology, clinical chemistry, urinalysis	Increased absolute and relative kidney weight (increased urinary bladder hemorrhage at higher doses)	312 (males) 625 (females)	625 (males) 1,250 (females)
Wolf et al. 1956; 6 months; Wistar rats 0, 118, 354, and 590 mg/kg/day via gavage (5 days/week)	Kidney weight, gross morphology	No adverse-effect level determined for kidney effects	590 (females)	–
Hsieh et al. 1989; 28 days; CD-1 male mice 0, 5, 22, and 105 mg/kg/day via drinking water	Kidney weight, gross pathology	No adverse-effect level determined for kidney effects	105 (males)	–
Hsieh et al. 1990a; 28 days; CD-1 male mice 0, 22, and 84 mg/kg/day via drinking water	Kidney weight, gross pathology	No adverse-effect level determined for kidney effects	84 (males)	–
NTP 1990; 13 weeks; B6C3F1 mice 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)	Kidney weight, histology, clinical chemistry, urinalysis	All 5000 mg/kg/day mice died within 1 week, so the NOAEL was set at 2,500 mg/kg/day	2,500	–
Neurological effects				
NTP 1990; 13 weeks; F344 rats 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)	Brain weight, histology, clinical signs	Brain necrosis in hippocampus and cerebellum (increased absolute brain weight and clinical signs of neurotoxicity at 2,500 mg/kg/day)	625 (males)	1,250 (males)
NTP 1990; 13 weeks; B6C3F1 mice 0, 312, 650, 1,250, 2,500, and 5,000 mg/kg/day via gavage (5 days/week)	Brain weight, histology, clinical signs	Increased absolute brain weight (males); clinical signs of neurotoxicity at 2,500 mg/kg/day (males and females)	625 (males) 1,250 (females)	1,250 (males)

APPENDIX A

Table A-2. Animals Studies Considered for Deriving the Intermediate-Duration Oral MRL

Study	End point(s) evaluated	Significant effects at	NOAEL	LOAEL
		LOAEL		
Developmental effects				
Kostas and Hotchin 1981; GDs 0–21 and PNDs 0–55; Nya:NYLAR mice 0, 4, 21, and 106 mg/kg/day via drinking water	Neonatal survival, growth and development; surface righting, startle reflex, rotarod performance, and open-field activity	Increased open-field activity (lack of habituation)	21	106

^aStudies and end points selected for deriving the intermediate-duration oral MRL.

GD = gestation day; IL-2 = interleukin-2; LOAEL = lowest-observed-adverse-effect level; MRL = minimal risk level; NOAEL = no-observed-adverse-effect level; NTP = National Toxicology Program; PFC = plaque-forming cell; PND = postnatal day

Impaired neurodevelopment following pre- and postnatal exposure to toluene, as evidenced by altered open-field behavior in offspring, was also considered as basis of the intermediate-duration oral MRL. Pups exposed to 106 mg/kg/day, but not 4 or 21 mg/kg/day, on GDs 0–21 and PNDs 0–55 demonstrated impaired habituation compared with controls (Kostas and Hotchin 1981). The POD of 21 mg/kg/day is comparable to the immune effects POD of 22 mg/kg/day. However, no other neurodevelopmental oral studies were located to support this finding. Therefore, the series of three studies by Hsieh et al. (1989, 1990b, 1991) demonstrating that consistent immune suppression was determined to be a better selection for a critical effect. While not selected as the basis of the MRL, this study does support the use of a NOAEL of 22 mg/kg/day as the POD.

In the previous draft (ATSDR, 2000), the basis of the intermediate-duration oral MRL was a minimally adverse LOAEL of 5 mg/kg/day for increased brain levels of norepinephrine, dopamine, and serotonin (Hsieh et al. 1990b). As mentioned in the 2000 draft, it is unclear how (or if) these effects relate to neurobehavioral changes. Additionally, alterations in neurotransmitters, and their precursors, are inconsistent between brain regions and do not increase with increasing dose. For the majority of findings, increased neurotransmitter levels in mice exposed to 5, 22, or 105 mg/kg/day for 28 days were the highest in the 22 mg/kg/day group. Since neurotransmitter levels were only evaluated at one time point, it is also unknown if these changes are transient. Due to the lack of dose response, lack of information on persistence of changes, and unclear association with neurobehavior, it cannot be determined if these changes are adverse. Therefore, a NOAEL/LOAEL call was not made for the neurological effects in this study. This interpretation is consistent with the interpretation by EPA (2005): “the changes in neurotransmitter levels have not been correlated with behavioral, neuropsychological, or neuroanatomical changes and were not considered further [for deriving RfD]”.

Agency Contacts (Chemical Manager): Jessilyn Taylor

APPENDIX B. USER'S GUIDE

Chapter 1

Public Health Statement

This chapter of the profile is a health effects summary written in non-technical language. Its intended audience is the general public, especially people living in the vicinity of a hazardous waste site or chemical release. If the Public Health Statement were removed from the rest of the document, it would still communicate to the lay public essential information about the chemical.

The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to chapters in the profile that will provide more information on the given topic.

Chapter 2

Relevance to Public Health

This chapter provides a health effects summary based on evaluations of existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight-of-evidence discussions for human health end points by addressing the following questions:

1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

The chapter covers end points in the same order that they appear within the Discussion of Health Effects by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). *In vitro* data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this chapter.

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if derived) and the end points from which they were derived are indicated and discussed.

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in the Chapter 3 Data Needs section.

Interpretation of Minimal Risk Levels

Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not meant to support regulatory action, but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans.

APPENDIX B

MRLs should help physicians and public health officials determine the safety of a community living near a hazardous substance emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.

MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, "Relevance to Public Health," contains basic information known about the substance. Other sections such as Chapter 3 Section 3.9, "Interactions with Other Substances," and Section 3.10, "Populations that are Unusually Susceptible" provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.

To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential systemic, neurological, and developmental effects. If this information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species (when information from multiple species is available) with the highest no-observed-adverse-effect level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables.

Chapter 3

Health Effects

Tables and Figures for Levels of Significant Exposure (LSE)

Tables and figures are used to summarize health effects and illustrate graphically levels of exposure associated with those effects. These levels cover health effects observed at increasing dose concentrations and durations, differences in response by species, MRLs to humans for noncancer end points, and EPA's estimated range associated with an upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).

The legends presented below demonstrate the application of these tables and figures. Representative examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.

APPENDIX B

LEGEND

See Sample LSE Table 3-1 (page B-6)

- (1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. Typically when sufficient data exist, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation (LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each route of exposure and will not, therefore, have all five of the tables and figures.
- (2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15–364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. In this example, an inhalation study of intermediate exposure duration is reported. For quick reference to health effects occurring from a known length of exposure, locate the applicable exposure period within the LSE table and figure.
- (3) Health Effect. The major categories of health effects included in LSE tables and figures include death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in the "System" column of the LSE table (see key number 18).
- (4) Key to Figure. Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the two "18r" data points in sample Figure 3-1).
- (5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, "Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an MRL.
- (6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure regimens are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to "Chemical x" via inhalation for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 1981).
- (7) System. This column further defines the systemic effects. These systems include respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, one systemic effect (respiratory) was investigated.
- (8) NOAEL. A NOAEL is the highest exposure level at which no adverse effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system, which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnote "b").

APPENDIX B

- (9) LOAEL. A LOAEL is the lowest dose used in the study that caused an adverse health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific end point used to quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from Serious LOAELs.
- (10) Reference. The complete reference citation is given in Chapter 9 of the profile.
- (11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer increases.
- (12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.

LEGEND**See Sample Figure 3-1 (page B-7)**

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure concentrations for particular exposure periods.

- (13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health effects observed within the acute and intermediate exposure periods are illustrated.
- (14) Health Effect. These are the categories of health effects for which reliable quantitative data exists. The same health effects appear in the LSE table.
- (15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale "y" axis. Inhalation exposure is reported in mg/m³ or ppm and oral exposure is reported in mg/kg/day.
- (16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).
- (17) CEL. Key number 38m is one of three studies for which CELs were derived. The diamond symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the LSE table.

APPENDIX B


- (18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels (q_1^*).
- (19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.

1 →

		Key to figure ^a	Species	Exposure frequency/ duration	System	NOAEL (ppm)	LOAEL (effect) Less serious (ppm) Serious (ppm)	Reference
2	→	INTERMEDIATE EXPOSURE						
			5	6	7	8	9	10
3	→	Systemic	↓	↓	↓	↓	↓	↓
4	→	18	Rat	13 wk 5 d/wk 6 hr/d	Resp	3 ^b	10 (hyperplasia)	Nitschke et al. 1981
		CHRONIC EXPOSURE						
		Cancer					11 ↓	
		38	Rat	18 mo 5 d/wk 7 hr/d			20 (CEL, multiple organs)	Wong et al. 1982
		39	Rat	89–104 wk 5 d/wk 6 hr/d			10 (CEL, lung tumors, nasal tumors)	NTP 1982
		40	Mouse	79–103 wk 5 d/wk 6 hr/d			10 (CEL, lung tumors, hemangiosarcomas)	NTP 1982
12	→	^a The number corresponds to entries in Figure 3-1. ^b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10 ⁻³ ppm; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).						

SAMPLE

Figure 3-1. Levels of Significant Exposure to [Chemical X] - Inhalation



APPENDIX B

This page is intentionally blank.

APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS

ACGIH	American Conference of Governmental Industrial Hygienists
ACOEM	American College of Occupational and Environmental Medicine
ADI	acceptable daily intake
ADME	absorption, distribution, metabolism, and excretion
AED	atomic emission detection
AFID	alkali flame ionization detector
AFOSH	Air Force Office of Safety and Health
ALT	alanine aminotransferase
AML	acute myeloid leukemia
AOAC	Association of Official Analytical Chemists
AOEC	Association of Occupational and Environmental Clinics
AP	alkaline phosphatase
APHA	American Public Health Association
AST	aspartate aminotransferase
atm	atmosphere
ATSDR	Agency for Toxic Substances and Disease Registry
AWQC	Ambient Water Quality Criteria
BAT	best available technology
BCF	bioconcentration factor
BEI	Biological Exposure Index
BMD/C	benchmark dose or benchmark concentration
BMD _x	dose that produces a X% change in response rate of an adverse effect
BMDL _x	95% lower confidence limit on the BMD _x
BMDS	Benchmark Dose Software
BMR	benchmark response
BSC	Board of Scientific Counselors
C	centigrade
CAA	Clean Air Act
CAG	Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS	Chemical Abstract Services
CDC	Centers for Disease Control and Prevention
CEL	cancer effect level
CELDS	Computer-Environmental Legislative Data System
CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
CFR	Code of Federal Regulations
Ci	curie
CI	confidence interval
CLP	Contract Laboratory Program
cm	centimeter
CML	chronic myeloid leukemia
CPSC	Consumer Products Safety Commission
CWA	Clean Water Act
DHEW	Department of Health, Education, and Welfare
DHHS	Department of Health and Human Services
DNA	deoxyribonucleic acid
DOD	Department of Defense
DOE	Department of Energy
DOL	Department of Labor
DOT	Department of Transportation

APPENDIX C

DOT/UN/	Department of Transportation/United Nations/
NA/IMDG	North America/Intergovernmental Maritime Dangerous Goods Code
DWEL	drinking water exposure level
ECD	electron capture detection
ECG/EKG	electrocardiogram
EEG	electroencephalogram
EEGL	Emergency Exposure Guidance Level
EPA	Environmental Protection Agency
F	Fahrenheit
F ₁	first-filial generation
FAO	Food and Agricultural Organization of the United Nations
FDA	Food and Drug Administration
FEMA	Federal Emergency Management Agency
FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act
FPD	flame photometric detection
fpm	feet per minute
FR	Federal Register
FSH	follicle stimulating hormone
g	gram
GC	gas chromatography
gd	gestational day
GLC	gas liquid chromatography
GPC	gel permeation chromatography
HPLC	high-performance liquid chromatography
HRGC	high resolution gas chromatography
HSDB	Hazardous Substance Data Bank
IARC	International Agency for Research on Cancer
IDLH	immediately dangerous to life and health
ILO	International Labor Organization
IRIS	Integrated Risk Information System
K _d	adsorption ratio
kg	kilogram
kgg	kilokilogram; 1 kilokilogram is equivalent to 1,000 kilograms and 1 metric ton
K _{oc}	organic carbon partition coefficient
K _{ow}	octanol-water partition coefficient
L	liter
LC	liquid chromatography
LC ₅₀	lethal concentration, 50% kill
LC _{Lo}	lethal concentration, low
LD ₅₀	lethal dose, 50% kill
LD _{Lo}	lethal dose, low
LDH	lactic dehydrogenase
LH	lutinizing hormone
LOAEL	lowest-observed-adverse-effect level
LSE	Levels of Significant Exposure
LT ₅₀	lethal time, 50% kill
m	meter
MA	<i>trans,trans</i> -muconic acid
MAL	maximum allowable level
mCi	millicurie
MCL	maximum contaminant level

APPENDIX C

MCLG	maximum contaminant level goal
MF	modifying factor
MFO	mixed function oxidase
mg	milligram
mL	milliliter
mm	millimeter
mmHg	millimeters of mercury
mmol	millimole
mppcf	millions of particles per cubic foot
MRL	Minimal Risk Level
MS	mass spectrometry
mt	metric ton
NAAQS	National Ambient Air Quality Standard
NAS	National Academy of Science
NATICH	National Air Toxics Information Clearinghouse
NATO	North Atlantic Treaty Organization
NCE	normochromatic erythrocytes
NCEH	National Center for Environmental Health
NCI	National Cancer Institute
ND	not detected
NFPA	National Fire Protection Association
ng	nanogram
NHANES	National Health and Nutrition Examination Survey
NIEHS	National Institute of Environmental Health Sciences
NIOSH	National Institute for Occupational Safety and Health
NIOSHTIC	NIOSH's Computerized Information Retrieval System
NLM	National Library of Medicine
nm	nanometer
nmol	nanomole
NOAEL	no-observed-adverse-effect level
NOES	National Occupational Exposure Survey
NOHS	National Occupational Hazard Survey
NPD	nitrogen phosphorus detection
NPDES	National Pollutant Discharge Elimination System
NPL	National Priorities List
NR	not reported
NRC	National Research Council
NS	not specified
NSPS	New Source Performance Standards
NTIS	National Technical Information Service
NTP	National Toxicology Program
ODW	Office of Drinking Water, EPA
OERR	Office of Emergency and Remedial Response, EPA
OHM/TADS	Oil and Hazardous Materials/Technical Assistance Data System
OPP	Office of Pesticide Programs, EPA
OPPT	Office of Pollution Prevention and Toxics, EPA
OPPTS	Office of Prevention, Pesticides and Toxic Substances, EPA
OR	odds ratio
OSHA	Occupational Safety and Health Administration
OSW	Office of Solid Waste, EPA
OTS	Office of Toxic Substances

APPENDIX C

OW	Office of Water
OWRS	Office of Water Regulations and Standards, EPA
PAH	polycyclic aromatic hydrocarbon
PBPD	physiologically based pharmacodynamic
PBPK	physiologically based pharmacokinetic
PCE	polychromatic erythrocytes
PEL	permissible exposure limit
PEL-C	permissible exposure limit-ceiling value
pg	picogram
PHS	Public Health Service
PID	photo ionization detector
pmol	picomole
PMR	proportionate mortality ratio
ppb	parts per billion
ppm	parts per million
ppt	parts per trillion
PSNS	pretreatment standards for new sources
RBC	red blood cell
REL	recommended exposure level/limit
REL-C	recommended exposure level-ceiling value
RfC	reference concentration (inhalation)
RfD	reference dose (oral)
RNA	ribonucleic acid
RQ	reportable quantity
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
SCE	sister chromatid exchange
SGOT	serum glutamic oxaloacetic transaminase (same as aspartate aminotransferase or AST)
SGPT	serum glutamic pyruvic transaminase (same as alanine aminotransferase or ALT)
SIC	standard industrial classification
SIM	selected ion monitoring
SMCL	secondary maximum contaminant level
SMR	standardized mortality ratio
SNARL	suggested no adverse response level
SPEGL	Short-Term Public Emergency Guidance Level
STEL	short term exposure limit
STORET	Storage and Retrieval
TD ₅₀	toxic dose, 50% specific toxic effect
TLV	threshold limit value
TLV-C	threshold limit value-ceiling value
TOC	total organic carbon
TPQ	threshold planning quantity
TRI	Toxics Release Inventory
TSCA	Toxic Substances Control Act
TWA	time-weighted average
UF	uncertainty factor
U.S.	United States
USDA	United States Department of Agriculture
USGS	United States Geological Survey
VOC	volatile organic compound
WBC	white blood cell

APPENDIX C

WHO World Health Organization

$>$	greater than
$\geq$	greater than or equal to
$=$	equal to
$<$	less than
$\leq$	less than or equal to
$\%$	percent
α	alpha
β	beta
γ	gamma
δ	delta
μm	micrometer
μg	microgram
q_1^*	cancer slope factor
$-$	negative
$+$	positive
$(+)$	weakly positive result
$(-)$	weakly negative result

4


Final Report on the Safety Assessment of Toluene

Toluene has a wide variety of noncosmetic applications. However, the cosmetic use is limited to nail products at concentrations up to 50%. Toluene was practically nontoxic when given orally to rats; acute oral LD₅₀ values ranged from 2.6 g/kg to 7.5 g/kg. Results of animal studies indicated that undiluted Toluene is a skin irritant. No skin irritation or sensitization was observed in subjects treated with cosmetic products containing 31–33% Toluene. No phototoxic or photoallergic reactions were noted in subjects treated with 25% or 30% Toluene. The sole cosmetic use of Toluene is in products intended to be applied directly to the nail; therefore, human skin exposure to this ingredient will be minimal under conditions of cosmetic use. On the basis of the available data and the limited user skin exposure from cosmetic products containing Toluene, it is concluded that this ingredient is safe for cosmetic use at the present practices of use and concentration.

CHEMISTRY

Definition and Structure

Toluene (CAS No. 108-88-3) is a homolog of benzene in which one hydrogen atom has been replaced by a methyl group⁽¹⁾:



Other names for this cosmetic ingredient include: Methacide, Methylbenzene, Methylbenzol, Phenylmethane, Toluol, Antisal 1a, and NCI-C07272.⁽¹⁻⁴⁾

Properties

Toluene is a clear, refractive liquid that has an aromatic odor similar to benzene. It is both volatile and flammable.^(1,4-6) Toluene is miscible with water but is immiscible with alcohol, chloroform, ether, acetone, glacial acetic acid, carbon disulfide, ligroin, and benzene.^(4,5,7-11)

The ultraviolet absorption spectrum of 300 gm/l of Toluene diluted in hexane was measured. The 300 gm/l concentration corresponded to the highest reported concentration of Toluene used in cosmetics. No significant absorption was noted above 300 nm.⁽¹²⁾ Skin photosensitivity reactions of the immunological type occur with wavelengths greater than 320 nm.⁽¹³⁾

Additional chemical and physical data are presented in Table 1.

TABLE 1. Chemical and Physical Data for Toluene

Property	Value	Reference
Appearance	Colorless liquid	6, 7, 9, 10, 14
Molecular formula	$C_6H_5CH_3$	5, 10, 14
Molecular weight	92.13	1, 7, 9, 11, 14, 15
Boiling point	109–111°C	1, 4, 5, 7–11, 14–18
Melting point	–94.5––95°C	1, 4, 5, 7, 10, 14, 17, 18
Freezing point	–93.2––94.991°C	9, 11, 18
Specific gravity	0.8623 (15.6/15.6°C)	1
	0.865 (25/25°C)	8
	0.866	7, 10, 16
	0.866 (20/4°C)	5
	0.867 (20/20°C)	15
	0.87 (25°C)	18
Density	0.861–0.871 (20/20°C)	19
	0.8623 (g/ml at 25°C)	11
	0.866 (20/4°C)	4, 14
	0.869 (20/4°C)	1, 17
	0.871 (13°C)	9
	0.8869 (20/4°C)	18
Vapor density (air = 1)	3.1–3.2	1, 11, 14
Vapor pressure	22 mm Hg at 20°C	6
	22.4 mm Hg at 20°C	15
	28 mm Hg at 25°C	7
	28.4 mm Hg at 25°C	11
	28.7 torr at 25°C	1
	36.7 mm Hg at 30°C	14, 18
Percent in saturated air	3.94 (at 760 mm Hg and 22°C)	1, 11
Liquid viscosity	0.6 cp at 20°C	1
Viscosity (SYS)	<32.6	18
Solubility in water	0.05% (g/100 g water at 20°C)	6
Solubility in distilled water	534.8 ± 4.9 mg/l at 25°C	1, 11
Index of refraction	1.4941 (25°C)	11
	1.4961	17, 18

TABLE 1. (Continued)

Property	Value	Reference
	1.4967	4
	1.49693 (68°F)	1
	1.497 (20°C)	5
	1.496-1.497	16
Aniline equivalent	15	5
Evaporation rate (n-butylacetate = 1)	2.10	15
Flash point	Closed cup: 40°F (4.4°C)	1, 4-7, 11, 14, 18
Autoignition temperature	896°F	14
	997°F	5
	1025.6°F (552°C)	1
Flammable limits	1.4-6.7%	18
	1.17-7.10% by volume in air	1, 11
Lower explosive limit in air	1.27% by volume	5, 14
	1.3% by volume	6
Upper explosive limit in air	7% by volume	5, 14
	7.1% by volume	6
Residue after evaporation	<0.001%	16
Sulfur compounds (as S)	0.003%	16
Water	0.03%	16
Weight volume conversion in air at 25°C	1 ppm = 3.77 mg/m ³	1, 11, 18
	1 mg/m ³ = 0.265 ppm	1, 11
Specific dispersion	184.40	11
Log octanol-water partition coefficient	2.69	1
Partition coefficient (K _p) in vapor and water	5.14 at 20.06°C	11
Partition coefficient (K _D) in octanol and water	512 ± 22	11
Odor threshold		
Petrol-derived	2.14 ppm	1, 11
Coke-derived	4.68 ppm	1
Critical temperature	320.8°C	11
Critical pressure	40.0 atm	11
Critical density	0.29 g/ml	11
Critical compressibility factor (PV/RT)	0.26	11
Density of saturated air-vapor mixture	1.09 (at 760 mm and 26°C; air = 1)	1
Surface tension	28.53 dynes/cm at 20°C	1
Heat of vaporization	9.115 ± 0.50 Kcal/mol at 25°C	11
Heat of fusion	1.582 Kcal/mol	11
Heat of formation		11
Liquid	2.867 Kcal/mol	
Gas	11.950 Kcal/mol	
Entropy		11
Liquid	52.40 cal/(mol)(°C)	
Gas	76.44 ± 0.3 cal/(mol)(°C)	
Free energy of formation		11
Liquid	27.282 Kcal/mol	
Gas	29.228 Kcal/mol	

Method of Manufacture

Toluene is produced from three major sources: (1) petroleum refining processes, (2) as a byproduct of styrene production, and (3) as a byproduct of coke oven operations.⁽¹⁾

Petroleum refining processes to isolate Toluene are of two types: catalytic reforming and pyrolytic cracking. Catalytic reforming involves the catalytic dehydrogenation of selected petroleum fractions that are rich in methylcyclohexane and other naphthenic hydrocarbons to yield a mixture of aromatics and paraffins. The proportions of aromatics and paraffins in the reformat depend on the feedstock used and the severity of the reforming operation. Toluene is isolated from the reformat by distillation, followed by washing with sulfuric acid and redistillation. Pyrolytic cracking of petroleum yields olefins and pyrolysis gasoline. Toluene is isolated from pyrolysis gasoline by distillation, removal of olefins and diolefins, and redistillation.⁽¹⁾

The synthesis of styrene by the dehydrogenation of ethylbenzene yields Toluene as a byproduct. The Toluene derived from this method is unsuitable for chemical or solvent use; however, it may be used for gasoline blending or as feed for the manufacture of benzene.⁽¹⁾

The production of coke by the high-temperature carbonization of coal yields coal tar and crude light oil, both of which contain Toluene. The production of Toluene from distillation of coal tar is minimal; however, some Toluene is isolated from crude light oil.⁽¹⁾

Toluene may be purified by various extraction and distillation processes (Eldeleauo SO₂ extraction, Udex separation, sulfolane extraction).⁽¹⁶⁾ The various grades of Toluene (pure, commercial, industrial, nitration, solvent, scintillation) are usually defined in terms of boiling ranges.⁽⁵⁾

Impurities

Commercial Toluene may contain benzene as an impurity.⁽¹⁾ Therefore, all toxicological and clinical studies involving Toluene should specify the quality of Toluene used for experimentation. If benzene is present in the Toluene, it should be demonstrated that the observed biological effects are not wholly or partly due to benzene.

Reactivity

Toluene undergoes substitution reactions on the aliphatic side group ($-CH_3$) and on the benzene ring at the ortho and para positions. Such reactions may include halogenation, chloromethylation, nitration, acetylation, benzoylation, mercuration, sulfonation, brosylation, methylation, and isopropylation. These substitution reactions occur at a faster rate with Toluene than with benzene.^(1,11)

Toluene is quite stable in air; however, Toluene can be oxidized with air under catalytic conditions to yield benzoic acid. In the presence of heat (or catalyst) and hydrogen, Toluene undergoes dealkylation to produce benzene. In aqueous media under the conditions of water chlorination, Toluene may be chlorinated, followed by subsequent hydrolysis to benzaldehyde. In the presence

of solvents (paraffins, naphthenics, and alcoholic hydrocarbons), Toluene can form azeotropes.^(1,11) Toluene also may undergo photooxidation⁽²⁰⁾ and other photochemical reactions.^(1,11) For a more complete description of the types of reactions that Toluene may undergo, the reader is referred to the reviews by the Syracuse Research Corp.⁽¹⁾ and the National Research Council.⁽¹¹⁾

Toluene vapor was passed with nitrogen through a silica tube filled with porcelain chips at 700°C. Reported pyrolysis products included some known or suspected carcinogenic aromatic hydrocarbons (Table 2).^(11,21)

Toluene is reported to be chemically stable and unreactive under conditions of use in cosmetic preparations.⁽¹⁶⁾

Analytical Methods

Gas chromatography may be used for the analytical determination of Toluene in blood.^(22,23) Methods for the determination of hippuric acid, a major metabolite of Toluene excreted in the urine,* include thin-layer chromatography,⁽²⁴⁾ high-performance liquid chromatography,⁽²⁵⁻²⁷⁾ gas chromatography,⁽²⁸⁾ and colorimetric methods.⁽²⁶⁾

USE

Noncosmetic Use

Noncosmetic applications of Toluene include use as an indirect food additive, gasoline additive, ink thinner, nonclinical thermometer liquid, suspension solution for navigation instruments, extraction solvent for plant materials, and as a solvent for adhesives, rubbers, oils, gums, resins, vinyl organosols, paints, lacquers, and coatings. Toluene also is used as a starting material for the production of benzene, benzaldehyde, benzoic acid, benzoic acid derivatives, benzyl and benzoyl derivatives, saccharin, phenol, caprolactam, explosives (TNT), toluene-diisocyanates, polyurethane resins, detergents (toluene sulfonates), dyes and drugs.^(4,5,7,9,18)

Consumer products containing Toluene are listed in Table 3. Indirect food additive uses of Toluene are presented in Table 4.

Cosmetic Use

Purpose in Cosmetics

Toluene is used in nitrocellulose nail lacquer† products as a diluent and solvent.^(5,15,16) Toluene also is used in nail lacquers to reduce the "blushing phe-

*In the body, Toluene is mainly oxidized to benzoic acid, which after conjugation with glycine is eliminated as hippuric acid in the urine. Although hippuric acid is often used to determine human exposure to Toluene, hippuric acid may be formed from other metabolic processes besides Toluene metabolism.^(1,11)

†The term "nail lacquer" is often used to denote nail enamel, nail polish, nail varnish, top coat, and base coat.^(15,29,30)

TABLE 2. Pyrolysis Products of Toluene^(11,21)

<i>Compound</i>	<i>Weight, % of tar formed</i>	<i>Compound</i>	<i>Weight, % of tar formed</i>
Anthracene	0.009	4,4'-Dimethylbiphenyl	0.99
1,2-Benzanthracene ^a	0.014	Biphenyl	0.27
Benzene ^a	2.54	Fluoranthene	Trace
3,4-Benzofluoranthene ^a	0.002	Fluorene	0.085
10,11-Benzofluoranthene ^a	Trace	Naphthalene	0.042
11,12-Benzofluoranthene ^a	Trace	Phenanthrene	0.12
1,2-Benzofluorene	0.007	Pyrene	Trace
2,3-Benzofluorene	0.017	Stilbene	0.44
1,2-Benzopyrene ^a	0.002	Styrene	0.11
3,4-Benzopyrene ^a	0.002	Toluene	93.5
Chrysene ^a	0.03	<i>p</i> -Xylene	0.05
Alkylchrysene	Trace	Resins and losses	0.7
Bibenzyl	1.00		

^aSuspected carcinogen.⁽¹¹⁾

nomenon," which occurs as a result of excessive and rapid evaporation of low boiling solvents.⁽¹⁶⁾

Product Formulation

Data submitted to the Food and Drug Administration (FDA) in 1984 by cosmetic firms participating in the voluntary cosmetic registration program indicated that Toluene was used in 555 cosmetic products (Table 5). Products formulated with Toluene included nail basecoats and undercoats (32 products), nail polish and enamel (501 products), and "other manicuring preparations" (22 products). Reported concentrations of Toluene in these products ranged from >10–25% (448 products) to >25–50% (107 products).⁽³¹⁾

Voluntary filing of product formulation data with FDA by cosmetic manufacturers and formulators must conform to the format of concentration ranges and product categories as described in Title 21 Part 720.4 of the Code of Federal Regulations.⁽³⁹⁾ Since certain cosmetic ingredients are supplied to the formulator at less than 100% concentration, the concentration reported by the formulator may not necessarily reflect the actual concentration found in the finished product; the actual concentration would be a fraction of that reported to the FDA. In addition, the fact that data are only submitted within the framework of a concentration range provides opportunity for overestimation of the actual concentration of an ingredient in a particular product. An entry at the lowest end of a concentration range is considered the same as one entered at the highest end of that range, thus introducing the possibility of a two- to ten-fold error in the assumed ingredient concentration.

TABLE 3. Consumer Products Containing Toluene⁽¹⁾

<i>Product</i>	<i>% Toluene content</i>
China cement, solvent type	20-30
Contact rubber cement	---
Microfilm cement, cotton base	27-30
Model cement	Up to 20-25
Plastic cement, polystyrene	24
Shoe cement	---
Tire repair, bonding compounds	>80
Paint brush cleaners	---
Stain, spot, lipstick, rust removers	---
Deicers, fuel antifreeze	30
Fabric dyes	≤60
Indelible inks	---
Marking inks	80-90
Stencil inks	40-60
Solvent and thinners	---

TABLE 4. Indirect Food Additive Uses for Toluene

<i>Use</i>	<i>Limitation</i>	<i>Reference</i>
Component of adhesives used in articles intended for packaging, transporting, or holding food	---	32
Component of resinous and polymeric coatings for polyolefin films intended for food contact	---	33
Component of paper and paperboard in contact with dry food	---	34
Component of acrylic and modified plastic acrylics intended for contact with food	---	35
Component of cellophane used for food packaging	Residue limit of 0.1% of weight of finished cellophane packaging	36
Component of polysulfide polymer-polyepoxy resins intended for contact with dry food	Use of Toluene limited to that of a solvent	37
Adjuvant substance in the manufacture of foamed plastics intended for food contact	Use of Toluene limited to that of a blowing agent adjuvant in polystyrene at a level not to exceed 0.35% by weight of finished polystyrene foam	38

TABLE 5. Product Formulation Data for Toluene⁽³¹⁾

Product category	Total no. of formulations in category	Total no. containing ingredient	No. of product formulations within each concentration range (%)	
			>25–50	>10–25
Nail basecoats and undercoats	47	32	18	14
Nail polish and enamel	769	501	74	427
Other manicuring preparations	66	22	15	7
1984 TOTALS		555	107	448

As noted in Table 5, the major use of Toluene is in nail polish and enamel. Most nail polish formulations typically consist of the following constituents^(15,29):

1. A film former (such as nitrocellulose, ethylcellulose, cellulose acetate, cellulose acetate-butyrate, methacrylate polymers, vinyl polymers, or sucrose acetate isobutyrate)
2. Resins to improve gloss and adhesions of the films (such as toluenesulfonamide/formaldehyde resin)
3. Plasticizers to give the film pliability, minimize shrinkage, and soften and plasticize the film former (such as camphor, or dibutyl phthalate)
4. Solvents and diluents to stabilize viscosity and to keep the film former, resin, and plasticizer in a liquid state (such as esters, glycol ethers, nitroparaffins, alcohols, xylene, or toluene)*
5. Thixotropic agents to prevent rapid settling and caking of pigments, and to provide flow properties (clay modified by quaternary ammonium compounds)
6. Coloring substances (such as fluorescent and nonfluorescent dyes, guanine, or inorganic and organic pigments)

A typical nail lacquer might contain 12% nitrocellulose, 5% n-butyl phthalate, 5% aryl sulfonamide-formaldehyde resin, 1–3% camphor, and 1–2% pigment. The solvent may consist of approximately 35% toluene, 40% butyl acetate, 15% ethyl acetate, and 10% ethanol.⁽⁴⁰⁾

Basecoat is formulated in a manner similar to nail polish, but it has a lower nonvolatile content (less nitrocellulose) and a lower viscosity because a thinner film is desirable. It does not contain pigments. Basecoat may contain hydrolyzed gelatin.⁽²⁹⁾

*These solvents may cause false-positive irritant reactions if not permitted to evaporate before the nail lacquer is applied under a patch to the skin.⁽²⁹⁾

Suggested formulae for various nail products containing Toluene have been described in the literature.^(15,41-49)

Exposure to Toluene

Nail products formulated with Toluene can be applied several times a week over a period of many years. The fingernail, the toenail, the nail cuticle, and the skin surrounding the nail are the areas directly exposed to this cosmetic ingredient. Parts of the body that come in contact with the wet nail may also become exposed. Such areas may include the eye region, the face, neck and chest, the retroauricular zone, and the vulva.⁽²⁹⁾ During application of the cosmetic product to the nail, Toluene may come in contact with eyes and nasal mucosa as a result of evaporation from the formulation.

ABSORPTION

In mammals, Toluene is absorbed by the respiratory tract, skin, and gastrointestinal tract.⁽¹¹⁾ Since Toluene can readily penetrate many of the body's protective barriers, its absorption is likely passive and dependent on the concentration gradient, so that any physiological characteristic that modifies this gradient would be expected to alter the rate of absorption.⁽⁵⁰⁾

Absorption Through the Lungs

Toluene is readily absorbed through the respiratory tracts of humans and experimental animals.⁽⁵¹⁻⁵⁴⁾ The amount of Toluene absorbed (uptake) is proportional to the concentration in inspired air, length of exposure, and pulmonary ventilation (respiratory minute volume).⁽⁵⁵⁻⁵⁷⁾ Total uptake (absorption) can be estimated as follows:

$$\text{Uptake} = (0.5)(V_e)(C_i)(t)$$

where V_e is the respiratory minute volume in l/minute, C_i is the inspired concentration in mg/l, and t is the length of exposure in minutes.^(57,58)

Because of the dependence on respiratory minute volume, the uptake of Toluene by humans is affected by the level of physical activity.^(55-57,59-61) Mild to moderate exercise can double or triple the rate of uptake compared to that at rest.⁽⁵⁷⁾ An individual's content of adipose tissue generally has little or no effect on the uptake of Toluene (50-150 ppm) during exposures lasting 4 h or less.^(55,57)

Toluene can be detected in human arterial blood as soon as 10 seconds after exposure by inhalation. The concentration of the compound in the arterial blood quickly increases during the first 10-15 minutes. After that, the Toluene concentration increases more slowly and reaches a fairly constant concentration after about 25 minutes; during this period, the retention is 75-80%. The rate of retention decreases as the individual approaches a state of equilibrium with respect to absorption, deposition, and excretion of Toluene and its metabolites. After 2-3 h of exposure by inhalation, the rate of retention falls to an almost con-

stant level—40–50%. The average rate of retention over a 5-h period is approximately 50%.⁽⁶²⁾ Once exposure has ended, Toluene concentration in alveolar airspaces, arterial blood, and venous blood decreases rapidly.⁽⁵⁹⁾

The alveolar concentrations of Toluene in humans have been measured.⁽⁶³⁾ Results of 40 measurements with three different methods and 16 persons indicated that the average Toluene absorption by inhalation at 100 ppm exposure concentrations was approximately 1.6 mg/minute.

Mature “cross-bred dogs” were exposed by inhalation for 1 h to 700, 1500, and 2000 ppm Toluene. Pulmonary absorption of Toluene within 1 h of exposure was estimated to be 25, 56, and 74 mg/kg, respectively.⁽⁶⁴⁾

Other studies pertaining to the respiratory absorption of Toluene by humans and experimental animals are reviewed in detail by the Syracuse Research Corp.⁽¹⁾

Skin Absorption

Lung tissues are more permeable to chemicals than is the thicker and more histologically complex dermal tissue.⁽⁵⁰⁾ Although Toluene is absorbed less readily through the skin than through the respiratory tract, percutaneous absorption of liquid Toluene can be significant.⁽¹⁾

Undiluted, liquid Toluene was reported to be absorbed at a rate of 14–23 mg/cm² per h through the skin of the forearms and hands when in direct contact with about 0.2 ml (170 mg) of Toluene for 10 or 15 minutes. When the hands and forearms were immersed for 1 h in aqueous solutions containing 180–600 mg of Toluene per liter, the rate of absorption was calculated to be 0.16–0.60 mg/cm² per h and increased with a corresponding increase in the concentration of Toluene. Analysis of the applied solutions before and after exposure indicated that appreciable amounts of Toluene were absorbed, ranging from 41 to 100 mg (23.7–57.7%) of the undiluted Toluene applied, and from 52 to 206 mg (27.5–35.9%) in the immersion study. These authors estimated that exposure of both hands to a saturated aqueous solution of Toluene for 1 h would be equivalent to inhalation exposure to an atmosphere containing 26.6 ppm for 8 h.^(65,66)

The absorption and excretion kinetics for dermal and inhalation exposures to Toluene has been reported.⁽⁶⁷⁾ The investigators found that the maximum Toluene concentration in the blood of subjects who immersed one hand in liquid Toluene for 30 minutes was only 26% of the concentration in blood of subjects who inhaled 100 ppm Toluene vapor for 30 minutes. Toluene was depleted from the blood much more rapidly after termination of the inhalation exposure than after the dermal exposure.

There is significant absorption of Toluene through intact skin of volunteers with respiratory protection who immersed both hands in analytically pure Toluene for 10 minutes.⁽⁶⁸⁾ Results of analysis of exhaled air up to 3 h after exposure indicated an exponential decline in exhaled Toluene, ranging from greater than 4 ppm at 20 minutes postexposure to less than 1 ppm after 120 minutes. The authors calculated that between 2050 and 3370 mg of Toluene were absorbed in the 10-minute exposure.

Percutaneous absorption of Toluene vapor from the surrounding air was evaluated by Riihimaki and Pfaffli.⁽⁶⁹⁾ Volunteers wearing respiratory protection were exposed to 600 ppm Toluene for 3–5 h. The subjects remained at rest ex-

cept for three exercise periods, each lasting for 10 minutes, which occurred at 0.5, 1.5, and 2.5 h of exposure. The exercise was sufficient to stimulate perspiration and raise the skin temperature slightly, conditions that are thought to enhance percutaneous absorption. The concentration of Toluene in peripheral venous blood, measured at the end of 1, 2, and 3 h of exposure, was constant at approximately 100 $\mu\text{g/l}$. The observed percutaneous absorption was estimated to be about 0.9% of the amount that would be absorbed from the respiratory tract during a 3.5-h exposure at 600 ppm, assuming that 60% of the inhaled Toluene is retained and 16% of the absorbed dose is exhaled.

Subjects exposed dermally to 1600 mg/m^3 (427 ppm) Toluene for 8 h had no increase in urinary excretion of a metabolite (benzoic acid) of Toluene. It was estimated that absorption of Toluene through the skin would not exceed 5% of absorption through the respiratory tract under the same conditions.⁽⁷⁰⁾

The concentration of Toluene in the blood of guinea pigs was monitored following application to the skin of 1.0 ml of the solvent. At 0.5 and 6 h, blood concentrations of Toluene were 1.1 and 0.60 $\mu\text{g/ml}$, respectively.⁽⁷¹⁾

The *in vitro* penetration of Toluene through excised rat skin was estimated by Tsuruta⁽⁷²⁾ as 8.50 nmol/minute per cm^2 .

Gastrointestinal Absorption

Absorption of Toluene from the gastrointestinal tract is nearly complete.^(1,62) In studies with rabbits, 76% of an oral dose of Toluene was excreted in the urine as hippuric acid, whereas 18% of the oral dose was expired through the lungs unchanged.⁽⁷³⁾

In rats, the concentration of radioactivity in the blood reached a maximum 2 h after gastric intubation of 100 μl 4-³H-Toluene in peanut oil, whereas maximum concentrations of Toluene in blood were reached 15–30 minutes after exposure by inhalation. Although absorption from the lungs following inhalation was more rapid, the relative radioactivities in various tissues were about equal after oral and inhalation exposure.⁽⁷⁴⁾

METABOLISM

Toluene is metabolized in humans and animals by the pathways outlined in Figure 1. The major site for the metabolism of Toluene in both animals and humans is the liver, where the compound undergoes sidechain oxidation to benzoic acid. Some metabolism in other tissues also may occur.⁽⁵⁰⁾ Most of the benzoic acid is subsequently conjugated with glycine and excreted in the urine as hippuric acid, although a large amount of conjugation with glucuronic acid also occurs, resulting in urinary excretion of benzoylglucuronic acid.⁽⁷⁵⁾ Oxidation of the alkyl sidechain to carboxylic acid is typically a rapid and spontaneous sequence of reactions that is catalyzed by a microsomal NADH-dependent enzyme system in tissues with a high redox potential (i.e., liver and kidneys).⁽⁷⁶⁾ The formation of benzyl alcohol involves an NADH-dependent alcohol hydrazase or monooxygenase (oxidase). The intermediate then is rapidly converted to benzaldehyde by an NAD-dependent alcohol dehydrogenase. The aldehyde is




FIG. 1. Metabolism of Toluene in mammals.^(50,77)

then oxidized to benzoic acid by means of an NAD-dependent aldehyde dehydrogenase.⁽⁵⁰⁾

Minor amounts of Toluene undergo ring hydroxylation, probably via arene oxide intermediates, to form *o*-, *m*-, and *p*-cresol, which are excreted in the urine as sulfate or glucuronide conjugates.^(78,79) The sidechain-oxidized compounds are rapidly conjugated with glucuronic acid or glycine to render them chemically inert.

DISTRIBUTION AND STORAGE

Upon entering the body, Toluene is rapidly distributed to all tissues by the circulatory system. Toluene is lipophilic, readily passes through cellular membranes, and accumulates primarily in those tissues with a high fat content. Toluene can be measured in many body tissues during and immediately after exposure. However, after exposure ends, the compound rapidly dissipates from tissues with a low fat content.⁽⁵⁰⁾ The quantity of Toluene absorbed by a tissue depends on the partition coefficient (tissue/blood), on the duration of exposure, and on the rate of metabolism. The rate of its absorption depends on the perfusion of the tissue and on the concentration gradient.⁽⁶²⁾

As indicated by its partition coefficient, Toluene is highly soluble in lipid and sparingly soluble in water (Table 6). Hence, it is likely to associate with the lipid and lipoprotein components of the plasma—primarily those of the chylomicrons.^(1,62) As measured in rabbits, the tissue/blood partition coefficients for fatty tissues are high (113 for adipose tissue and 35 for bone marrow); for other tissues, they range from 1 to 3. The solubility of Toluene in human blood, as indi-

TABLE 6. Partition Coefficient for Toluene at 37°C⁽¹⁾

	Partition coefficient	Reference
Fluid/air or material/air		
Water	2.23	51
Oil, olive	492	
Blood, human	15.6	
Fat, human, peritoneal	1296	
Oil, olive	1380	54
Lard	1270	
Blood, human	15.6	
Blood, human	14.64	52, 53
Blood, rabbit	10.41	
Plasma, rabbit	16.99	
Tissue/blood (rabbit)		
Liver	2.58	52, 53
Kidney	1.54	
Brain	3.06	
Lung	1.92	
Heart	2.10	
Muscle, femoral	1.18	
Bone marrow, red ^a	35.43	
Fat, retroperitoneal	113.16	

^a20% fat by volume.

cated by its partition coefficient (blood/air) is 14.64–15.6 (Table 6).

Table 7 presents the volumes and perfusion of four tissue groups in relation to the distribution coefficient (rabbit tissue), biological half-time, and distribution volumes, the distribution volume being:

$$V_{\text{dist}} = V \times g$$

and the biological half-time being:

$$t_{1/2} = V_{\text{dist}} \times (\ln 2)/V$$

The distribution volume indicates the amount of Toluene (expressed in millimoles) that can accumulate in the tissue at a blood concentration of 1 nmol/l. The largest quantity of Toluene accumulates in fatty tissue, with retention being positively dependent on an individual's amount of fat.⁽⁶²⁾ Carlsson and Ljungquist⁽⁶⁰⁾ estimated that the half-life of Toluene in human adipose tissue ranged from 0.5 to 2.7 days.

Results of animal studies indicate a relatively high distribution of Toluene on the stomach wall in the case of inhalation (partition coefficient stomach/blood = 4–5). No data are available on Toluene passing through the placenta.⁽⁶²⁾

Mice were exposed to 3950 ppm Toluene (15 mg/l) for 3 h in an inhalation chamber. Concentrations of the compound reached 626 mg/kg in liver, 420 mg/kg in brain, and 200 mg/kg in blood by the end of the exposure.^(80,81)

TABLE 7. Volumes and Perfusion of the Four Tissue Groups, Their Partition Coefficients, Biological Half-times and Distribution Volumes for Toluene⁽⁶²⁾

Parameter	Symbol (unit)	Tissue group			
		Vessel rich ^a	Muscle ^b	Fat ^c	Vessel poor ^d
Volume in a 70-kg person	V (l)	6.0	33.0	14.5	12.5
Percentage of the minute volume of the heart to tissue group	%	75.0	18.1	5.4	1.5
Perfusion in a 70-kg person at a heart-minute volume of 7 l/minute	V (l/minute)	5.25	1.27	0.38	1.10
Tissue/blood distribution coefficient (rabbit)	λ	2.3	1.6	74.3	1.9
Tissue/blood distribution coefficient (human)	λ	---	---	81-83	---
Biological half-time	$t_{1/2}$ (h)	2 minutes	0.5	77	2.8
Distribution volume	V_{dist} (l)	14	53	1,189	23

^aVessel rich group—brain, heart, liver, intestines, kidneys, and endocrine glands.

^bMuscle group—muscles and skin.

^cFat group—fatty tissue and yellow bone marrow.

^dVessel poor group—bones, connective tissue, lung tissue.

Rats were exposed by inhalation to 550 ppm methyl-¹⁴C-Toluene for 1 h. Immediately after exposure, the amount of radioactivity in white adipose tissue was more than twice the amount in any other organ and more than six times that in brain tissues. Radioactivity in the fatty tissue continued to increase after the exposure had ended and was slightly higher 1 h after exposure than immediately after exposure. All other tissues examined had lower concentrations 1 h after the end of the exposure. Six hours after exposure, radioactivity had decreased to almost zero in the brain and adrenal tissues but was still measurable in the liver, kidneys, and fatty tissue.⁽⁵⁹⁾ It was suggested that the radioactivity in the kidneys and liver 6 h postexposure was likely due to Toluene metabolites and excretion products and not to the parent molecule.⁽⁵⁰⁾

Pyykko et al.⁽⁷⁴⁾ exposed rats by inhalation to 4600 ppm 4-³H-Toluene for 10 minutes. The concentration of radioactivity reached a maximum in most tissues within 15–30 minutes; the concentration in white adipose tissue reached a maximum 1 h after exposure. The highest concentration of radioactivity was found in white adipose tissue, followed in order of decreasing concentrations by brown adipose tissue, adrenal, stomach, liver, kidney, brain, blood, and bone marrow. Loss of radioactivity from adipose tissue and bone marrow occurred more slowly than the loss from other tissues.

Distribution of Toluene in tissues following oral exposure is similar to that for inhalation exposure. In rats administered 4-³H-Toluene in a single gastric intubation, maximum radioactivity was reached 2–3 h in all tissues except white adipose tissue, where the maximum occurred 5 h after exposure.⁽⁷⁴⁾

In mice given a single intraperitoneal injection of 0.20 mg/kg of Toluene, almost all of the radioactivity in the adipose tissues was a volatile compound that was probably unchanged Toluene. Approximately 70% of the radioactivity in the brain within 8 minutes after injection was present as a volatile material (again probably unchanged Toluene), whereas most of the radioactivity detected in the liver (64%) and kidneys (78%) was nonvolatile.⁽⁸²⁾

A male teenager who died from sniffing glue had the following concentrations of Toluene in his tissues: heart blood, 11 mg/kg; liver, 47 mg/kg; brain, 44 mg/kg; kidneys, 39 mg/kg.^(83,84)

It has been suggested that the dissipation of Toluene (radioactivity) from tissues appears to be related directly to the amount of vascularization and perfusion of the tissue as well as the presence of enzyme systems needed to metabolize the parent compound. These factors, along with the high partition coefficient for the compound, provide an explanation for the relatively fast uptake but slow release of Toluene in adipose tissue.⁽⁵⁰⁾

EXCRETION

The major portion of inhaled or ingested Toluene is eliminated within 12 h of the end of exposure as free Toluene in expired air (9–18%) and as the metabolite hippuric acid in the urine (60–75%). Two percent or less of absorbed Toluene appears in the urine as benzylmercapturic acid and as cresol derivatives (glucuronides and sulfates). Metabolism of Toluene to benzylmercapturic acid suggests the formation of reactive intermediates that potentially could bind to tissue macromolecules,⁽¹⁾ but no such binding has been demonstrated. Small quantities of free Toluene and benzyl alcohol are excreted in the urine and feces.⁽⁶²⁾

Srbova and Teisinger⁽⁸⁵⁾ reported that following inhalation exposure of humans to Toluene, approximately 16% of the absorbed compound was exhaled unchanged through the lungs, whereas 80% was oxidized to benzoic acid and excreted in the urine. A small amount (0.6%) of absorbed Toluene was excreted in the urine unchanged. Von Oettingen et al.⁽⁸⁶⁾ exposed humans by inhalation to 50 and 800 ppm Toluene for 8 h. Urinary metabolites consisted of approximately 59% hippuric acid and 41% benzoyl glucuronide. Urinary excretion of metabolites increased with the concentration of Toluene and was essentially complete within 14 h. In other studies, small amounts of free Toluene were detected in the expired air of humans exposed dermally to either 200 mg of liquid Toluene⁽⁶⁵⁾ or 600 ppm Toluene vapor for 3.5 h.⁽⁶⁹⁾ In the latter investigation, samples of exhaled air had detectable quantities of Toluene for at least 4 h after the exposure ended, but no Toluene was detected in samples 20 h after exposure. Respiratory protection was used in this study to preclude inhalation of the vapor.⁽⁶⁹⁾

A commonly used test to determine occupational exposure to Toluene is based on the excretion of hippuric acid and/or o-cresol in the urine.⁽⁸⁷⁻⁹²⁾

TOXICOLOGY

Acute Oral Toxicity

Reported acute oral LD₅₀ values for Toluene in rats range from 2.6 g/kg to 7.53 g/kg (Table 8), making this solvent "practically nontoxic" according to the classification system of Hodge and Sterner.⁽⁹³⁾

In two separate studies, nail products containing Toluene were evaluated for acute toxicity. In the first evaluation, a nail basecoat containing 33.2% Toluene was administered by stomach tube to five female, albino rats. Animals were observed for 7 days following the single 15.0 g/kg dose. No deaths were reported, and all rats had normal weight gains.⁽⁹⁹⁾ In the second study, a nail polish formulated with 33% Toluene was given by gavage to 10 Sprague-Dawley rats (5 males, 5 females). No deaths or "toxic effects" were observed following the single 5 ml/kg dose.⁽¹⁰⁰⁾

Acute Effects from Intraperitoneal Injection

Mortality is produced in rats and mice by a single injection of Toluene in the dose range of 0.8 to 1.7 g/kg.⁽¹⁰¹⁻¹⁰³⁾

Koga and Ohmiya⁽⁸²⁾ estimated an IP LD₅₀ for Toluene in male mice of 1.15 g/kg; respiratory failure was the primary cause of death in these animals. An IP LD₅₀ of 1.64 g/kg was reported for female mice by Ikeda and Ohtsuji.⁽¹⁰⁴⁾

In rats, a single IP Toluene dose of 0.65 g/kg produced apathy, whereas 1.5-1.7 g/kg produced death from respiratory failure.⁽¹⁰³⁾ A single 1.7 g/kg dose also was lethal to rats, mice,⁽¹⁰²⁾ and guinea pigs.⁽¹⁰⁵⁾

Savolainen⁽¹⁰⁶⁾ observed that the concentration of radioactivity in the CNS was highest in the cerebrum following IP injection of methyl ¹⁴C-Toluene; radioactivity was not detected in the CNS 24 h after the single exposure.

Acute Effects from Intravenous Injection

Intravenous injection of 0.2 ml Toluene/kg (0.17 g/kg) produced 100% mortality in 15 rabbits.⁽¹⁰⁷⁾

TABLE 8. Acute Oral Toxicity

<i>Animal tested</i>	<i>Oral LD₅₀</i>	<i>Reference</i>
Rats	7.53 g/kg	94, 95
Wistar adult rats	7.0 g/kg	96
Sprague-Dawley rats	5.58 g/kg	97
Sprague-Dawley rats		98
14-day old	2.6 g/kg ^a	
Young adult	5.5 g/kg ^a	
Mature adult	6.4 g/kg ^a	

^aAnalytical grade Toluene.

Acute and Subchronic Effects from Subcutaneous Injection

In acute studies, a single subcutaneous injection of 1.1–1.25 g/kg and 4.3–8.7 g/kg Toluene produced mortality in rats and mice, respectively.^(102,103) Braier⁽¹⁰⁷⁾ reported that a single 4 ml Toluene/kg dose injected into rabbits produced marked transient granulopenia within 24 h and marked granulocytosis and ensuing death in all animals by the end of the second day. A small area of induration was seen at the injection site.

The subchronic effects of Toluene in rats, guinea pigs, and rabbits were also evaluated. Toluene was administered to rats by subcutaneous injection at a dose of 1 ml/kg for 21 days. Treated animals had slight induration at the injection site, decreased body weights, transient decrease in erythrocyte and leukocyte counts, hyperplasia of bone marrow, moderate hyperplasia of Malpighian corpuscles in the spleen, marked pigmentation of the spleen, focal necrosis of the liver, and slight cloudy swelling in the kidneys. No lesions of the heart, testes, or lungs were noted.⁽¹⁰³⁾

Guinea pigs were given Toluene by subcutaneous injection at a dose of 0.25 ml/day for 30–70 days. Necrosis developed at the injection site. Polypnea and convulsions occurred during the last days of survival (survival period: 30–70 days). Hemorrhagic, hyperemic, and degenerative changes in lungs, kidneys, adrenal glands, liver, and spleen also were noted.⁽¹⁰⁸⁾

Subcutaneous injection of 1 ml/kg of Toluene for 6 days produced transient granulopenia and granulocytosis in rabbits; no change in the bone marrow was observed.⁽¹⁰⁷⁾

Dermal Toxicity

The acute dermal LD₅₀ of Toluene (single dose) in rabbits was 14.1 ml/kg.^(94,95) In another study, a percutaneous dose of 1.732 g/kg failed to kill any guinea pigs.⁽¹⁰⁵⁾

Increased local capillary permeability in rabbits⁽¹⁰⁹⁾ and hemoglobinuria in rats⁽¹¹⁰⁾ were observed following application of Toluene to the skin. Application to the skin of 1 ml of Toluene for 16 h produced karyopyknosis, karyolysis, spongiosis, perinuclear edema, and cellular infiltration in the dermis; no hepatic or renal damage was noted.⁽¹¹¹⁾ Reduced weight gain was noted for 1–3 weeks in guinea pigs treated percutaneously with 2.0 ml of Toluene. However, body weights were comparable to those of control animals at week 4.⁽¹⁰⁵⁾

Skin Irritation

Undiluted Toluene produced slight to moderate skin irritation in rabbits when tested by four different procedures. Slight skin necrosis also was observed in one study in which Toluene was repeatedly applied to rabbit skin over a 2–4-week period (Table 9).

Two nail products were evaluated in separate studies for skin irritation. In the first evaluation, a nail basecoat (0.5 ml) containing 33.2% Toluene was applied under an occlusive patch to the clipped skin of each of nine albino rabbits. After 24 h, the patches were removed and the treated sites graded for erythema and edema. Five of the nine rabbits developed skin reactions following the single

TABLE 9. Skin Irritation

Material tested	Animals tested	Method	Results	Reference
Undiluted Toluene	6 male albino rabbits	<i>Journal Officiel de la Republique Francaise</i> ^(112,113) ; 0.5 ml applied under occlusive dressing to clipped skin (intact and abraded) for 23 h	Moderate skin irritation (PII = 3.25/8.0)	117
Undiluted Toluene	6 male albino rabbits	Association Francaise de Normalisation ⁽¹¹⁴⁾ ; 0.5 ml applied under occlusive dressing to clipped skin (intact and abraded) for 4 h	Moderate skin irritation (PII = 3.42/8.0)	117
Undiluted Toluene	3 albino rabbits	Organisation for Economic Cooperation and Development ⁽¹¹⁵⁾ ; 0.5 ml applied under occlusive and semioclusive dressing to intact clipped skin for 4 h	Slight skin irritation (occlusive dressing; PII = 2.94/8.0) Slight skin irritation (semioclusive dressing; PII = 2.13/8.0)	117
Undiluted Toluene	Unspecified number of albino rabbits	Adams et al. ⁽¹¹⁶⁾ ; 10–20 applications were repeatedly made to ear and shaved abdomen over a 2–4-week period	Slight to moderate skin irritation and slight skin necrosis	96

exposure. Of these five, three rabbits had minimal erythema and two had moderate erythema. The remaining four animals had no skin irritation.⁽¹¹⁸⁾ It was not reported whether the product was applied with or without solvents.

In the second study, a nail polish containing 33% Toluene was applied "dry" under a semioclusive patch (open) to the clipped, intact skin of six female, albino rabbits. Applications of the product (0.5 ml) were made every other day for a total of three exposures. Skin reactions were evaluated both 24 and 48 h after each application. No skin irritation was observed.⁽¹¹⁹⁾

Ocular Irritation

Results of studies with rabbits indicate that Toluene is an ocular irritant. However, the results have varied as to the degree of irritation produced. These studies are summarized below and in Table 10.

The ocular irritation potential of undiluted Toluene was assessed in male albino rabbits. A single 0.1 ml dose of the test material was instilled into one eye of each of 12 rabbits; the untreated eye served as control. Treated and control eyes were either given no rinse (6 rabbits) or were rinsed with a solution of boric acid, sodium borate, sodium chloride, and phenylmercury borate 30 seconds after instillation (6 rabbits). Lesions of the conjunctiva, iris, and cornea were scored over a 7-day observation period by means of the numerical system of Kay and Calandra.⁽¹²⁰⁾ For rabbits given no rinse, the highest irritation index at any one evaluation was 22.67 (max = 110), indicating that Toluene was an "irritant." For

TABLE 10. Ocular Irritation

<i>Material tested</i>	<i>Animals tested</i>	<i>Method</i>	<i>Results</i>	<i>Reference</i>
Undiluted Toluene	12 albino rabbits	Single application to one eye of each rabbit; eye received either no rinse (6 rabbits) or a borate solution rinse (6 rabbits)	No rinse: "irritant" With rinse: "slight irritant"	121
Undiluted Toluene	Unspecified number of albino rabbits	2 drops instilled into right eye with no further treatment; eyes observed up to 7 days thereafter	Slight irritation of conjunctival membrane; no corneal injury	96
"Excess of 15%" Toluene in propylene glycol, water, and/or deodorized kerosene	5 albino rabbits	Single application of 0.005 ml to cornea; no water rinse given	Severe ocular irritation	94, 122

rabbits given an eye rinse, the highest irritation index was 13.33, indicating that the test substance was a "slight irritant".⁽¹²¹⁾

Slight irritation of conjunctival membranes was observed after application of 2 drops of undiluted Toluene to the right eye of an unspecified number of albino rabbits. No corneal injury was noted.⁽⁹⁶⁾

In a range-finding study with rabbits, a single 0.005 ml dose of Toluene produced severe ocular irritation when instilled into the cornea at concentrations in excess of 15%. Vehicles used included propylene glycol, water, and deodorized kerosene. A total of five eyes were treated; the treated eyes received no water rinse.⁽¹²²⁾ Similar results were reported by Smyth et al.⁽⁹⁴⁾

A nail polish formulated with 33% Toluene was evaluated for ocular irritation. The product was instilled in a single 0.1 ml dose into the conjunctival sac of one eye of each of nine albino rabbits. The untreated eyes served as the control. Three of the nine female rabbits received no water rinse after treatment, a second group of three rabbits received a water rinse in the treated eye 4 seconds after exposure, and a third group of three received a water rinse in the treated eye 2 seconds after product instillation. In the "no rinse group," all three animals developed erythema of the conjunctivae, which cleared by day 9. One of these rabbits also developed chemosis of the conjunctiva, which cleared by day 6. In the "4 second group," one of three rabbits had erythema and chemosis, which cleared by day 7. No rabbits in the "2 second group" developed irritation. The investigator concluded that the nail polish was a "mild eye irritant."⁽¹²³⁾

Acute Inhalation Toxicity

In studies with mice, acute inhalation LD₅₀ values for Toluene of 5320 ppm (<0.1% benzene) and 6942 ppm (99.5% purity) were estimated by Svrbely et al.⁽¹²⁴⁾ and Bonnet et al.,⁽¹²⁵⁾ respectively. The exposure period was 6–7 h.

Inhalation of 4000 ppm technical grade Toluene for 4 h produced death in one of six rats.^(94,95) Inhalation of 4000 ppm Toluene (purified by distillation) for 4 h was lethal to two of three guinea pigs within a few days; the third animal was severely prostrated.⁽¹²⁶⁾ Inhalation of 55,000 ppm was lethal to six rabbits within 24–62 minutes.⁽¹²⁷⁾ Von Oettingen et al.⁽¹²⁸⁾ reported that inhalation of 850 ppm Toluene (0.01% benzene) for 1 h by six dogs produced an increase in respiratory rate and a decrease in respiratory volume.

RD₅₀ values for Toluene of 5300 ppm⁽¹²⁹⁾ and 3373 ppm⁽¹³⁰⁾ were estimated for Swiss mice. The RD₅₀ is the concentration necessary to depress the respiratory rate by 50%.

Male Sprague-Dawley rats were exposed by inhalation to 0 or 2000 ppm Toluene for 48 h. Compared to nontreated controls, the treated rats had impaired psychomotor performance, elevated blood glucose, elevated serum alanine aminotransferase and aspartate aminotransferase, increased packed cell volume, and decreased body weight.⁽¹³¹⁾

Inhalation of 4000 ppm Toluene (99.9% pure) for 3 h by male ICR mice had no effect on blood lactate dehydrogenase activity. However, a significant increase in serum glutamic-oxaloacetic transaminase activity was observed 24 h after the single exposure.⁽¹³²⁾

Mucous membrane irritation and incoordination were noted in rats exposed by inhalation to 1250 ppm Toluene for 18–20 h.⁽¹⁰³⁾

Subchronic Inhalation Toxicity

Progressive symptoms typically observed in experimental animals after subchronic inhalation exposure to increasingly higher concentrations of Toluene include irritation of the mucous membrane, incoordination, mydriasis, narcosis, tremors, prostration, anesthesia, and death.⁽¹⁾ Results of selected subchronic inhalation studies are summarized in Table 11.

Chronic Oral and Inhalation Toxicity

Results of four studies indicated no major toxicological effects in rats following chronic oral or inhalation exposure to Toluene. However, toxic effects were observed in a fifth study in which dogs were exposed by inhalation to ≥ 2000 ppm Toluene for 6 months. These studies are discussed below.

The chronic oral toxicity of Toluene was assessed by Wolf et al.⁽⁹⁶⁾ Three groups of 10 female Wistar rats were given an olive oil solution of Toluene emulsified with a 5–10% aqueous solution of acacia by oral intubation. Toluene doses were either 118, 354, or 590 mg/kg per day 5 days a week for 6 months (193 days). The total volume of the test solution administered daily was never greater than 2–3 ml. A group of 20 rats served as controls and were given doses of 2.5 ml of olive oil emulsified in the acacia solution. No adverse effects were noted with respect to general appearance, behavior, growth, body and organ weights, blood urea nitrogen, total erythrocyte and leukocyte counts, differential leukocyte counts, or hemoglobin concentration. At necropsy and microscopic examination, no treatment-related changes were found in lungs, heart, liver, kid-

ney, spleen, testes, adrenals, pancreas, and femoral bone marrow. No deaths were reported.

The chronic toxicity of Toluene (>99.98%) by inhalation was assessed in Fischer-344 rats. Four groups of 240 animals (120 males and 120 females per group) were exposed for 6 hours/day, 5 days/week, for up to 24 months to Toluene concentrations of 0, 30, 100, or 300 ppm. The calculated time-weighted average concentrations for the 24 months of exposure were 0.0, 30.1, 99.7, and 299.0 ppm, respectively. Randomly selected rats were killed after 6, 12, or 18 months to determine progression of toxic effects; all remaining animals were killed for study after 24 months. Males in the Toluene treatment groups were heavier than control males throughout the study. However, there was no dose-response relationship demonstrable within the treatment groups. The 300 ppm group had increased mean corpuscular hemoglobin concentration. Female rats exposed to 100 and 300 ppm for 24 months had reduced packed cell volumes. Other hematological parameters were not significantly different from controls. There were no significant differences among control and treated groups with respect to clinical appearance, blood chemistries (BUN, SGPT, SAP), urinalysis (pH, specific gravity, microscopic and biochemical constituents), absolute organ weights (brain, heart, kidneys, liver, lungs, gonads), or gross and microscopic lesions. The authors concluded that Toluene caused no chronic toxicity or oncogenicity at the concentrations tested. A partial list of the large battery of tissues and organs examined included brain, pituitary, heart, lungs, esophagus, adrenals, lymph nodes, kidney, bladder, ovaries, stomach, thymus, skin, mammary gland, bone marrow, nasal turbinate, eyes, and testes.⁽¹³⁸⁾ The National Toxicology Program has determined that this study was inadequate for carcinogenicity evaluation. The several factors that preclude a definite conclusion of noncarcinogenicity are outlined by the Syracuse Research Corp.⁽¹⁾

Groups of 15 Sprague-Dawley rats of each sex were exposed by inhalation to Toluene concentrations of 1, 100, or 1481 ppm Toluene 6 h per day, 5 days per week for 26 weeks. Initially, the high-dose group was exposed to 2000 ppm, but the dose was lowered to 1500 ppm after seven exposures because CNS depression was apparent. A battery of blood and clinical chemistry tests (BUN, SGPT, SAP, glucose), urinalysis, and neurohistological examination of tissue were performed. The only treatment-related effects observed were an increased incidence of dry rales and staining of the anogenital fur in the high-dose treatment group. Significant changes in the values obtained for tests of blood and urine were not found, with the exception of a dose-related decrease in blood glucose values and a dose-related increase in SGPT activities in female rats. Body weights were significantly greater in the high-dose male rats than in the control rats, but this was not considered a toxic effect. Treatment-related neurohistopathological changes were not found.⁽¹³⁹⁾

Exposure of 24 OFA rats to 1000 ppm Toluene by inhalation for 6 h a day, 5 days a week for 6 months produced no treatment-related effects. No differences were observed between treated and nontreated control rats with respect to body weight gain, hematological parameters (RBC and WBC counts, hemoglobin, mean corpuscular volume, packed cell volume, sedimentation rate), and tissue histology (lungs, liver, spleen, kidneys, gonads, and other unspecified "principal" organs).⁽¹⁴⁰⁾

TABLE 11. Subchronic Inhalation of Toluene

<i>Animal</i>	<i>Toluene tested</i>	<i>Results</i>	<i>Reference</i>
Male Sprague-Dawley rat	1000 ppm 8 h/d × 7 d × 13 wk	Retarded weight gain during exposure; however, weight gain similar to controls by end of experiment. Hematocrit values, psychomotor performance, blood glucose, serum ALAT, and serum ASAT also similar to controls	131
Rat	1600 ppm 18 to 20 h/d × 3 d	Mild twitching; drop in body temperature; death. Histology: severe cloudy swelling of kidneys; no effect on liver, heart, or testes	103
Rat	3184 ppm 4 h/d × 30 d	Increased activities of SGOT, SGPT, and increased concentrations of β -lipoproteins. Decreased activities of catalase, peroxidase, and decreased concentrations of glutathione and total cholesterol	133
Rat	2500 ppm or 5000 ppm 7 h/d × 5 d × 5 wk	Transient decrease in body weight, hyperactivity, marked incoordination, recovery after cessation of exposure; mortality in 5000 ppm group (18/25); increased bleeding time; reduced leukocyte count after each exposure; pulmonary lesions; casts in renal tubules in all rats within 2 wk of exposure	128
Rat	5 d/wk × 15 wk	Cytochrome P-450, ethoxycoumarin o-deethylase increased; UDP glucuronyltransferase increased only at end of exposure	128
Male Sprague-Dawley rat	7 consecutive cycles daily, 5 d/wk × 8 wk: each cycle, 10 min of 12,000 ppm followed by 20 min toluene-free recovery interval	Depression of body weight gain; increased SGOT, serum LDH activities; no effect on BUN levels. Depression of kidney, brain, and lung weights. No lesions of brain, lung, liver, heart, or kidney; no indication of hepatic lipid vacuolation	132
CFY rat (both sexes)	265 ppm 6 h/d × 5 d/wk for 1, 3 or 6 mo	Bromsulphthalein retention decreased; cytochrome P-450 increased independent of period of exposure; SGOT and SGPT activities unaffected	134
CFY rat (both sexes)	929 ppm 8 h/d × 5 d/wk for 1 wk, 6 wk, or 6 mo	Cytochrome P-450 increased independent of exposure period; no effect on SGOT or SGPT; aniline hydroxylase and aminopyrine N-demethylase activity increased; cytochrome b ₅ concentrations increased. Dilation of cisternae of rough endoplasmic reticulum; increase of autophagous bodies, which was dose and time dependent; retarded growth of females but not males; glycogen content decreased	134
Male CFY rat	398, 796, 1592 ppm 8 h/d × 5 d/wk × 4 wk	Cytochrome P-450 increased with dose	134
Rat, guinea pig, dog, monkey	107 ppm continuously for 90 d, or 1085 ppm 8 h/d, 5 d/wk × 6 wk	No effect on leukocytes, hemoglobin, or packed cell volume. No lesions of liver, kidney, lungs, spleen or heart; no effect on brain or spinal cord of dogs and monkeys	135

Male ICR mice	7 consecutive cycles daily, 5 d/wk × 8 wk: each cycle, 10 min of 12,000 ppm followed by 20 min toluene-free recovery interval	Depression of body weight gain; no effect on serum LDH; decreased BUN concentrations; SGOT activities increased (not significantly). Depression of kidney, brain and lung weights. Histology: no lesions of brain, lung, liver, heart or kidneys; no indication of hepatic lipid vacuolation	132
Male ICR mice	4000 ppm for 3 h/d × 1, 3, or 5 d	SGOT activities increased after 1 and 3 days of treatment; no effect 24 h after 5 d	132
Male ICR mice	4000 ppm for 3 h/d × 5 d/wk × 8 wk	Depression of body weight gain during first 7 wk; increased liver-to-body weight ratio after 4 wk exposure, no effect at 1, 2, or 8 wk. No increase in kidney, brain, or lung weights. SGOT activity increased after 4 wk of exposure and 2 wk postexposure, but not after 2 wk or 8 wk of exposure; no change in BUN. No lesions of heart, lung, kidney, brain or liver	132
Mice	1, 10, 100, or 1000 ppm 6 h/d × 20 d	No effect on body weight; 1 and 10 ppm produced increase in RBC count on 10th day, recovery on day 20; 100 ppm and 1000 ppm produced decrease of RBC count; all doses produced increase (40–70%) of WBC count on day 10, recovery for all doses except 1000 ppm; 10 ppm to 1000 ppm produced slight decrease in density of bone marrow cells and in megakaryocytes and red cell elements; 1000 ppm produced slight hypoplasia of red cell elements, slight to moderate disturbance in maturity of neutrophils and thrombocytes, moderate increase of reticulocytes. No lesions in brain, lung, liver, spleen, or kidney	136
Guinea pig	1250 ppm 4 h/d × 6 d/wk (18 exposures)	Prostration, marked liver and renal degeneration, marked pulmonary inflammation	126
Guinea pig	1000 ppm 4 h/d × 6 d/wk (35 exposures)	Slight toxic degeneration in liver and kidney	126
Dogs (2 experimental, 1 control)	2000 ppm 8 h/d × 6 d/wk × 4 mo, and then 2660 ppm 8 h/d, 6 d/wk × 2 mo	Death on days 179 and 180; slight nasal and ocular irritation; motor incoordination and paralysis of extremities during terminal phase, congestion in lungs, hemorrhagic liver, reduced lymphoid follicles and hemosiderosis in spleen; hyperemic renal glomeruli; albumin in urine	137
Dogs	200, 400, or 600 ppm: three 8 h exposures for 1 wk then five 7 h exposures for 1 wk and finally 850 ppm for 1 h	No effect on circulation or spinal pressure; increase of respiratory rate, small increase of minute volume, decrease of respiratory volume	128
Dogs	400 ppm 7 h/d × 5 d	Moderate temporary lymphocytosis	128

h, hour; d, day; wk, week; SGOT, serum glutamic oxalacetic transaminase; SPGT, serum glutamic pyruvic transaminase; ALAT, serum alanine aminotransferase; ASAT, serum aspartate aminotransferase; WBC, white blood cell; RBC, red blood cell; UDP, uridine 5'-phosphate; BUN, blood urea nitrogen; mo, month.

Two dogs were exposed 8 h a day, 6 days a week for 4 months to 2000 ppm Toluene. Following this 4-month exposure, the Toluene concentration was increased to 2660 ppm for 8 h a day, 6 days a week for an additional 2 months (6 months total exposure). Slight nasal and ocular irritation occurred at the lower concentration, and motor incoordination that preceded paralysis of the extremities occurred in the terminal phase. Death occurred on days 179 and 180, respectively. There was no effect on gain in body weight, on the bone marrow, or on the adrenal, thyroid, or pituitary glands. Congestion in the lungs, hemorrhage in the liver, a decrease of lymphoid follicles, and hemosiderosis in the spleen were observed. Glomeruli of the kidneys were hyperemic, and albumin was found in the urine.⁽¹³⁷⁾

Genotoxicity

Toluene was negative for mutagenicity in a battery of microbial, mammalian cell, and whole organism test systems. However, there were several reports of increased chromosome aberrations in the bone marrow of rats exposed by inhalation or by subcutaneous injection to Toluene,⁽¹⁴¹⁻¹⁴³⁾ as well as reports of increased sister-chromatid exchanges and chromosome aberrations in the lymphocytes of workers chronically exposed to Toluene.^(144,145) These studies are summarized below.

No mutagenicity was observed when Toluene was tested in the Ames *Salmonella* assay with strains TA1535, TA1537, TA1538, TA98, and TA100 or in the *Escherichia coli* WP2 reversion to *trp*⁺ prototrophy assay (Table 12).⁽¹⁴⁶⁻¹⁵⁰⁾ These reverse mutation assays were all performed in the presence and absence of Aroclor 1254-induced rat liver hemogenate (S-9) and employed positive and negative controls. It should be noted that there may have been significant losses of Toluene from the culture media during incubation in all but one of the aforementioned studies.⁽¹⁵⁰⁾ Snow et al.⁽¹⁵⁰⁾ conducted plate incorporation assays in sealed plastic bags and chambers as well as vapor exposures in desiccators to prevent excessive evaporation.

Toluene was tested with and without metabolic activation in *S. cerevisiae* for the (1) induction of reversions to isoleucine independence in strain D7,⁽¹⁴⁷⁾ (2) induction of mitotic gene conversion to tryptophan independence in strains D4 and D7,⁽¹⁴⁶⁾ and (3) induction of mitotic crossing-over at the *ade2* locus in strain D7.⁽¹⁴⁷⁾ The compound did not produce any positive mutagenic response in any of these assays (Table 12).

The photochemical formation of mutagens from various aromatic compounds was studied by Suzuki et al.⁽¹⁵¹⁾ An aqueous solution containing Toluene and an aqueous nitrate solution containing Toluene were both irradiated with a 100 W high pressure mercury lamp (250-577 nm). The reaction mixtures were then evaluated for mutagenicity in a modified Ames assay, using *S. typhimurium* (TA98) in both the presence and absence of liver microsomal fraction (S-9) of PCB-induced rats. A positive mutagenic response was observed in bacteria exposed to photolytic products of the Toluene/nitrate solution. Mutagenic responses were greater in those assays in which there was an absence of metabolic activation, as compared to those assays in which S-9 activation was present. No mutagenicity was observed in bacteria exposed to photolytic products in the nitrate-free solution.

TABLE 12. Microbial Mutagenicity Assays

Type of assay	Strain	Metabolic activation ^a	Toluene dose	Application	Mutagenic response	Reference
Reverse mutation						
<i>S. typhimurium</i>	TA98, 100, 1535, 1537, 1538	Yes and no	0.001 to 5.0 μ l/plate	Plate incorporation	Negative	146
<i>S. typhimurium</i>	TA98, 100, 1535, 1537, 1538	Yes and no	0.004 to 0.031% ^b	Liquid suspension	Negative	146
<i>S. typhimurium</i>	TA98, 100, 1535, 1537, 1538	Yes and no	0.01 to 10 μ l/plate	Plate incorporation	Negative	147
<i>S. typhimurium</i>	TA98, 100, 1535, 1537, 1538	Yes and no	5 μ l/plate	Plate incorporation	Negative	148
<i>S. typhimurium</i>	TA98, 100, 1535, 1537, 1538	Yes and no	0.115–2.3 μ l/plate	Plate incorporation	Negative	149
<i>S. typhimurium</i>	TA98, 100	Yes and no ^c	0.3 to 100 μ l/plate	Plate incorporation ^d	Negative	150
<i>E. coli</i>	WP2	Yes and no ^c	11 to 3764 ppm	Vapor exposure ^e	Negative	
<i>S. cerevisiae</i>	D7	Yes and no	0.01 to 10 μ l/plate	Plate incorporation	Negative	147
		Yes and no	0.001–0.5% ^f	Liquid suspension	Negative	147
Mitotic gene conversion						
<i>S. cerevisiae</i>	D4	Yes and no	0.001–5.0 μ l/plate	Plate incorporation	Negative	146
		Yes and no	0.138–1.1% ^b	Liquid suspension	Negative	
<i>S. cerevisiae</i>	D7	Yes and no	0.001–5.0% ^f	Liquid suspension	Negative	147
Mitotic crossing-over						
<i>S. cerevisiae</i>	D7	Yes and no	0.001–5.0% ^f	Liquid suspension	Negative	147

^aAroclor 1254-induced rat liver homogenate S-9 fraction.^b50% mortality at the highest dose.^cThe Toluene was tested with Toluene-induced S-9 as well as with Aroclor-induced S-9.^dThe plates were incubated in sealed plastic bags or chambers for part of a 72-h incubation period. In the Aroclor-induced S-9 tests, the plates were removed from the bags after 48 h, counted, incubated an additional 24 h, and recounted. In the experiments with Toluene-induced S-9, the plates were removed after 24 h to prevent moisture and spreading problems, and then incubated an additional 48 h before counting.^eThe assays were run in a sealed incubation chamber with a second glass plate (open) that contained the Toluene; after 24 h the chambers were opened and the plates incubated for an additional 48 h.^f100% mortality at 0.1% and 0.5%.

Inhibition of growth and induction of DNA damage by Toluene were evaluated in two studies by comparing differential toxicity to wild-type and DNA repair deficient bacteria. Two species were tested with and without metabolic activator with negative results: *E. coli* (W3110 pol A⁺ and p3478 pol A⁻) and *S. typhimurium* (SL4525 rfa rec⁺ and SL4700 rfa rec⁻).^(147,152)

Breaks in single DNA strands were observed by Sina et al.⁽¹⁵³⁾ in rat hepatocytes exposed in vitro for 3 h to 2.3 mM Toluene. Toluene vapor was a potent mitostat in studies with intact grasshopper embryos (*Melanophus sanguinipes*). Arrested metaphases of the exposed embryos had a c-mitotic appearance and highly contracted and scattered chromosomes.⁽¹⁵⁴⁾ Roots of *Vicia faba* seedling exposed to Toluene developed chromosomal alterations and a longer than normal mitotic cycle.⁽¹⁵⁵⁾

Drosophila melanogaster males were fed 500 or 1000 ppm Toluene for 24 h. No significant increase in recessive lethals was noted in the total of 3281 X-chromosomes examined.⁽¹⁵⁶⁾

The ability of Toluene to induce dominant lethal mutations in sperm cells was evaluated by Litton Bionetics.⁽¹⁵⁷⁾ CD-1 mice were exposed by inhalation to 100 or 400 ppm of the compound 6 h per day, 5 days per week for 8 weeks. No increase in pre- or postimplantation loss of embryos or reduction in fertility of treated males was observed.

Toluene failed to induce specific locus forward mutation in the L5178, thymidine kinase mouse lymphoma cell assay. The compound was evaluated at concentrations of 0.05–0.30 μ l/ml, with and without mouse liver S-9 activation.⁽¹⁴⁶⁾

In the micronucleus test, Toluene doses of 250, 500, and 1000 mg/kg were given by IP administration to groups of 32 Swiss male mice. No increase was observed in micronucleated polychromatophilic erythrocytes of the bone marrow.⁽¹⁵⁸⁾ In a second micronucleus test, Toluene induced no clastogenic activity when administered in two oral doses of either 860 or 1720 mg/kg to male and female CD-1 mice.⁽¹⁵⁹⁾

Two reports concluded that Toluene induced chromosomal aberrations in rat bone marrow cells following subcutaneous injection.^(142,143) In an analysis of 720 metaphase cells from the bone marrow of five rats that had been subcutaneously injected with 0.8 g/kg per day Toluene for 12 days, Dobrokhotov⁽¹⁴²⁾ found 78 (13%) with chromosomal aberrations. Sixty-six percent of the aberrations were chromatid breaks, 24% were chromatid "fractures," 7% were chromosome "fractures," and 3% involved multiple aberrations. The frequency of spontaneous aberrations in 600 marrow metaphase cells from five control rats injected with vegetable oil averaged 4.16% (65.8% were breaks and 32.4% were chromatid aberrations; no "fractures" or multiple lesions were recorded). The significance of the positive clastogenic effects attributed to Toluene in this study is difficult to assess, since the purity of the sample employed was not stated and because the distinction between chromatid breaks and fractures was unclear.

Lyapkalo⁽¹⁴³⁾ administered 1 g/kg per day Toluene to six rats by subcutaneous injection for 12 days. Treatment with Toluene resulted in chromosome aberrations in 11.6% of the bone marrow cells examined (84 aberrant metaphases/724 cells) compared with 3.9% (40/1033) in olive oil injected controls. The types of aberrations that were observed consisted of "gaps" (60.5%), chro-

matid breaks (38.4%), and isochromatid breaks (1.2%). The purity of the Toluene used in this study was not stated.

Dobrokhotov and Enikeev⁽¹⁴¹⁾ reported that rats exposed to 80 ppm (610 mg/m³) Toluene by inhalation 4 h daily for 4 months had damaged metaphase chromosomes in 21.6% of the bone marrow cells analyzed. The percentage of metaphase cells with damaged chromosomes in bone marrow cells from air-exposed control rats was 4.0%. The number of cells evaluated and the purity of the Toluene were not specified.

In contrast to the aforementioned cytogenetic studies, Litton Bionetics⁽¹⁶⁰⁾ found that IP injection of Toluene into Charles River rats did not induce bone marrow chromosomal aberrations. The compound was injected at doses of 22, 71, and 214 mg/kg in two different experiments. In one study, five rats were killed at 6, 24, and 48 h following injection of each dose; in a second study, five rats were treated daily at each dose for 5 days, and the rats were killed 6 h after injection of the last dose. Approximately 50 cells per animal were evaluated for damage. Dimethyl sulphoxide (DMSO, the solvent vehicle) administered IP at 0.65 ml/rat was used as the negative control, and triethylenemelamine (TEM) in saline at 0.3 mg/kg was used as the positive control.

Male Wistar rats exposed by inhalation to Toluene (300 ppm, 6 h/day, 5 days/week for 15 weeks) did not have more chromosome aberrations in the bone marrow cells than nonexposed control animals. The frequency of sister chromatid exchanges (SCEs) was analyzed in cultured bone marrow cells of the exposed animals only after 11, 13, and 15 weeks of exposure. There was a statistically significant increase of SCEs in rats exposed for 11 and 13 weeks, but the frequency was in the control range after 15 weeks of Toluene exposure.⁽¹⁵⁶⁾

Evans and Mitchell⁽¹⁶¹⁾ reported that Toluene did not alter SCE frequencies in cultured Chinese hamster ovary (CHO) cells. In this study, CHO cells without rat liver S-9 homogenate were exposed to 0.0025–0.04% Toluene for 21.4 h, and CHO cells with S-9 homogenate were exposed to 0.0125–0.21% for 2 h.

In vitro exposure to Toluene at concentrations of 1.52 mg/ml, 15.2 µg/ml and 152 µg/ml had no effect on the number of sister-chromatid exchanges (SCEs) or number of structural chromosomal aberrations in cultured human lymphocytes. However, cytotoxicity was observed at the highest dose.⁽¹⁶²⁾ The data from this study cannot be adequately evaluated, since the purity of the Toluene was not indicated, no positive control experiments were performed, no metabolic activation system was employed, and the type of scoring system for chromosome damage was not specified.

Lymphocytes from 32 rotogravure workers with occupational exposure to Toluene were studied for chromosome aberrations and SCEs. The frequencies of these did not differ from the corresponding values of 15 unexposed control subjects. However, a significant increase of SCEs was observed in smoking subjects, both occupationally exposed and unexposed.⁽¹⁵⁶⁾

Peripheral blood lymphocytes of 34 workers from a rotogravure printing plant and of 34 matched controls from outside the plant were compared for chromosomal aberrations. Ten of the workers were exposed daily to benzene (131–532 ppm) for 2–7 years and subsequently to Toluene (200–400 ppm) for 14 years. Twenty-four workers were exposed only to Toluene for 7–15 years. No significant differences were found between the Toluene and control groups in

frequencies of stable and unstable chromosome aberrations or in chromosome counts. Approximately 100 metaphase cells from each subject or control were scored. The proportion of chromosome changes was significantly higher statistically in the benzene/toluene group compared with controls and in the benzene/toluene group relative to the Toluene group.⁽¹⁶³⁾

Maki-Paakkanen et al.⁽¹⁶⁴⁾ reported no evidence of clastogenicity in cultured peripheral blood lymphocytes from 32 workers from two different rototyping factories who had a history of exposure to Toluene (benzene concentrations, $\leq 0.05\%$) at 8-h, time-weighted average concentrations of 7–112 ppm. The average age of the workers was 34.2 years, and the average length of employment was 14.6 years. Results of analyses indicated that the frequencies of chromosome aberrations and sister-chromatid exchanges were not significantly different from those of 15 unexposed workers. Similarly, no significant deviations were observed in the frequencies of aberrations in relation to duration of exposure.

Bauchinger et al.^(144,145) performed cytogenic analyses on peripheral lymphocytes from 20 male rotogravure plant workers exposed for ≥ 16 years to Toluene ($< 0.3\%$ benzene). A group of 24 workers from the same plant, but without exposure to Toluene, served as controls. Toluene concentrations in the workroom air ranged from 200 to 300 ppm. Small amounts of liquid Toluene also were used by the workers to wash the hands. The measured concentrations of Toluene in the blood were reportedly between 0.001 and 0.01%. There was no exposure to other chemicals. As compared with the 24 nonexposed controls, exposed workers had a significantly greater number of chromatid breaks, chromatid exchanges, and chromatid gaps. The number of SCEs also was significantly increased in smoking and nonsmoking Toluene-exposed workers compared with the corresponding control group. The authors suggested that Toluene or its metabolite may induce a weak clastogenic effect in human lymphocytes *in vivo*.

Carcinogenicity

A 2-year inhalation study with rats and mice is being conducted by the National Toxicology Program at Research Triangle Park. The investigation is currently in the tissue evaluation phase, and no publication date has been established.⁽¹⁶⁵⁾ No neoplasms were observed in mice given a subcutaneous exposure to Toluene. Results of skin painting studies in mice were negative for carcinogenicity. These studies are summarized below.

Toluene suspended in an aqueous gel was applied to the surface of a filter disc. The filter disc was then implanted subcutaneously into the dorsolumbar region of 10 male and 10 female Alderley Park Swiss mice. Each filter disc contained 0.02 mmol of Toluene. Three months after implantation, the surviving mice were killed, and the implant site tissue was removed for histopathological evaluation. No tumors were observed.⁽¹⁶⁶⁾

Toluene was used as a vehicle control in a study in which benzo(a)pyrene was tested for carcinogenicity. Toluene was applied to the shaved interscapular skin of 20 SWR, 17 C3HeB, and 17 A/He female mice three times a week for life. Mice were 10–14 weeks old on the initial exposure. No skin tumors developed in the Toluene-only treated mice.⁽¹⁶⁷⁾

Benzo(a)pyrene (20 nmol) or 15,16-dihydro-11-methylcyclopent(a)phenan-

thren-17-one (20 nmol) in a vehicle of 10 μ l of Toluene/croton oil (99:1 v/v) was applied twice weekly to the shaved dorsal skin of T.O. mice. The number of exposed mice with skin tumors at 75 weeks was 14/20 and 19/20, respectively. No skin tumors were observed at 75 weeks in the 20 mice topically treated twice weekly with the Toluene/croton oil vehicle.⁽¹⁶⁸⁾

Groups of Swiss male mice were treated on the ears with either (1) 1.5% DMBA in mineral oil (one exposure), (2) 1.5% DMBA in mineral oil (one exposure) followed after 1 week by two weekly exposures of Toluene for 20 weeks, (3) Toluene twice a week for 20 weeks, or (4) DMBA in mineral oil (one exposure) followed by biweekly applications of mineral oil. Of the 23 surviving mice treated once with DMBA, 1 tumor was observed at 20 weeks. Of the 35 surviving mice treated with DMBA and Toluene, 7 tumors were observed. None of the 14 surviving mice treated with Toluene developed tumors. The negative control group (DMBA and mineral oil) had 8 tumors in 53 survivors at 20 weeks.⁽¹⁶⁹⁾

Frei and Kinsley⁽¹⁷⁰⁾ examined the promoting effect of Toluene in Swiss mice following initiation with 7,12-dimethylbenz[a]anthracene (DMBA). The ears of the mice were topically treated once with 0.1 ml of 1.5% DMBA in mineral oil. One week after DMBA initiation, mineral oil or Toluene was applied twice a week for 20 weeks. Eleven of 35 mice developed tumors (6 permanent, 5 regressing) following exposure to DMBA and Toluene, whereas, 8 of 53 negative control animals (DMBA and mineral oil) developed tumors (all permanent). Fourteen mice topically treated for 20 weeks with Toluene alone (no DMBA initiation) developed 2 tumors (1 permanent, 1 regressing).

Doak et al.⁽¹⁷¹⁾ applied Toluene (0.05–0.1 ml) to the backs of CF₁, C₃H, and CB₆H mice twice weekly for 56 weeks. For each strain, approximately 50 mice (25 male, 25 female) were tested. No difference was observed between treated and control mice with respect to frequency of skin or systemic tumors. It was not clear in this study if the Toluene was applied under an occlusive dressing or if it was allowed to evaporate.

Toluene was applied twice a week for 50 weeks to the clipped dorsal skin of 20 TO albino mice. Animals were observed for a period of 1 year after treatment. A second group of 20 mice served as untreated controls. No skin tumors developed in either group; however, survival was only 35% (7 of 20) in the treatment group.⁽¹⁷²⁾

No skin tumors were observed in skin painting studies in which 50 mg of Toluene was applied twice a week for 80 weeks to 50 male C3H/HeJ mice⁽¹⁷³⁾ or in which Toluene was applied twice weekly for 50 weeks to 10 male and 10 female TO albino mice.⁽¹⁷⁴⁾

Lijinsky and Garcia⁽¹⁷⁵⁾ used Toluene as a vehicle control in the carcinogenicity testing of various polynuclear hydrocarbons. Toluene (1–20 μ l) was applied twice a week for 72 weeks to the clipped interscapular skin of 30 Swiss female mice. Two mice developed skin tumors. One animal developed squamous cell carcinoma, and one developed squamous cell papilloma. The "average latent period" of the first tumor was 58 weeks. Twenty-four and fifteen mice survived to 60 and 80 weeks, respectively.

In a brief abstract, Frei and Ritchie⁽¹⁷⁶⁾ reported that tumor promotion in the skin of mice by Toluene and other "irritant solutions" was associated with the ability of these agents to induce epidermal hyperplasia. No other details were specified.

Teratogenicity and Embryotoxicity

The teratogenicity and embryotoxicity of Toluene were assessed in hamsters, mice, and rats by various routes of exposure (skin, oral, inhalation).

Overman⁽¹⁷⁷⁾ reported that Toluene produced "minimal embryotoxic effects" in hamsters following applications to clipped skin. Applications were made every day for 2 h between days 7 and 11 of gestation. Animals were killed at day 15 of gestation. A decrease in fetal size and weight and an increase in the incidence of prenatal death were noted. Observed malformations included fetal hemorrhage and gastroschisis. No malformations appeared in the control groups. The dose and vehicle were not specified.

Toluene was administered to CD-1 mice by gavage from days 6 through 15 of gestation at 0.3, 0.5, and 1.0 ml/kg body weight per dose. The compound was also given by gavage from days 12 through 15 of gestation at 1.0 ml/kg per dose. The vehicle used was cottonseed oil (0.5% of maternal body weight/dose). Maternal toxicity was not observed after exposure to Toluene (days 6–15) at any dose. However, an increase in embryonic deaths at all doses and a reduction in fetal weight in the 0.5 and 1.0 mg/kg groups was noted. An increased incidence of cleft palate was observed after exposure to 1.0 ml/kg on days 6–15 of gestation. The same dose given on days 12–15 of gestation produced decreased maternal weight gain. The authors concluded that Toluene was teratogenic at 1.0 ml/kg and embryotoxic at 0.3 ml/kg.⁽¹⁷⁸⁾

Toluene was dissolved in corn oil and administered by gavage for 8 days to pregnant CD-1 mice. The daily oral dose was 10 ml/kg body weight, which corresponded to 2350 mg of Toluene per kg of body weight. No differences between test and control groups were observed in terms of number of maternal deaths, mean maternal weight, number of animals producing litters, incidence of resorbed fetuses, litter size, number of live or dead fetuses, and mean litter weight. The investigators concluded that Toluene caused no significant reproductive toxicity.⁽¹⁷⁹⁾

Female ICR mice were exposed by inhalation to 100 or 1000 ppm Toluene 6 h a day from the first to seventeenth day of gestation. No differences were observed between control and treated groups with respect to litter size, incidence of resorbed fetuses, number of implantation sites, number of live or dead fetuses, fetal body weight, external malformations, eye or ear opening, weaning, and incidence of body hair. The incidence of skeletal abnormalities was similar between treated and control groups, with the exception of extra 14th ribs and rudimentary 14th ribs in the 1000 ppm dose group. The authors stated that the high incidence of 14th ribs "suggested the possible teratogenicity of Toluene."^(180,181)

Hudak and Ungvary⁽¹⁸²⁾ studied the teratogenic and embryotoxic effects of Toluene in CFY rats and CFLP mice. The mice were exposed by inhalation to 500 mg/m³ (133 ppm) Toluene for 24 h/day from days 6 to 13 of pregnancy. Rats were exposed to Toluene in one of three dosage regimens: (1) 1500 mg/m³ (399 ppm) for 24 h/day from day 9 to 14 of pregnancy, (2) 1500 mg/kg (399 ppm) for 24 h/day from day 1 to 8 of pregnancy, or (3) 1000 mg/m³ (266 ppm) for 8 h/day from day 1 to 21 of pregnancy. Exposure of mice to 133 ppm Toluene was associated with decreased average fetal weights and an increased incidence of weight-retarded fetuses. Irregular sternebrae and extra ribs were observed in the fetuses of rats treated with 399 ppm Toluene on days 9–14 of pregnancy. Re-

tarded skeletal growth and decreased weights were noted in fetuses of rats exposed on days 1–8 of pregnancy to 399 ppm Toluene. Retarded skeletal development was also observed in the fetuses of rats treated with Toluene at 266 ppm.

Pregnant CFY rats were exposed by inhalation to benzene (400 mg/m³), Toluene (1000 mg/m³), or a combination of the two solvents from day 7 to day 14 of gestation. Exposure to benzene or benzene plus Toluene was associated with decreased fetal weight, whereas exposure to Toluene or benzene plus Toluene was associated with increased incidence of extra fetal ribs. Exposure to benzene, Toluene, and benzene plus Toluene caused skeletal retardation in the fetuses but did not produce increases in the rates of external, internal, or skeletal malformations.⁽¹⁸³⁾

In other studies with CFY rats, Toluene potentiated the maternal and embryonic toxicity of acetylsalicylic acid.⁽¹⁸⁴⁾

No evidence of teratogenicity was observed in the 20-day old fetuses of Charles River rats that were exposed to 100 or 400 ppm Toluene vapor for 6 h/day on days 6–15 of gestation. At microscopic examination, no unusual incidence of visceral or skeletal abnormalities was observed. Unusual skeletal variations were observed in a small but comparable number of fetuses from both the exposed and control groups, but these changes were in most cases attributed to retarded bone ossification and were not considered to be malformations as such. No maternal deaths occurred during the study, and the sex ratio of the offspring did not differ significantly between the treated and control groups.⁽¹⁶⁰⁾

Groups of 20 CFY rats were exposed to 266 ppm (1000 mg/m³) Toluene, 125 ppm (400 mg/m³) benzene, or a combination of these concentrations of Toluene and benzene vapor for 24 h/day on days 7–14 of gestation. A group of 22 rats inhaling air served as controls. Fetuses were examined on day 21 of pregnancy. Continuous exposure to 266 ppm Toluene was not teratogenic (no external, internal, or skeletal malformations were reported), although the exposures were associated with evidence of skeletal retardation (not detailed) and an increased incidence of extra ribs. Also, it was reported that the incidence of extra ribs was higher in the group exposed to Toluene in combination with benzene than in the groups exposed to Toluene alone. Maternal loss, maternal weight gain, number of litters, mean implantation/dam, placental weight, fetal loss, and fetal weight loss were not significantly affected by the Toluene exposures. Exposure to 125 ppm benzene did cause decreases in maternal weight gain, placental weight, and fetal weight, but these effects appeared to be inhibited by concurrent exposure to 266 ppm Toluene. Further, it was reported that postinhalation fetal loss (the number of dead and resorbed fetuses relative to the number of total implantation sites) was significantly increased in the group exposed to benzene in combination with Toluene. Fetal loss was not, as indicated earlier, affected by exposure to the Toluene (or benzene) alone.⁽¹⁸⁵⁾

CLINICAL ASSESSMENT OF SAFETY

Effects on Skin and Nails

Toluene's degreasing action removes natural lipids of the skin, which in turn may cause dryness, fissures, and contact dermatitis.⁽¹⁸⁶⁾

Koilonychia and hapalonychia of the fingernails were observed in 6 of 16

cabinet workers exposed percutaneously to a thinner mixture containing 30% Toluene, 30% xylene, and 40% methyl alcohol. Most of the affected workers had an average exposure of 2 years.⁽¹⁸⁷⁾

No skin irritation was observed when 20 subjects were exposed in a single insult occlusive patch test to a nail basecoat containing 33.2% Toluene.⁽¹⁸⁸⁾ The length of the exposure period was not reported.

A nail polish containing 31.23% Toluene was assessed for its cumulative skin irritation potential. Applications of the product (0.3 ml) were made under closed patches everyday for 21 consecutive days to the skin of the back of 10 subjects. Contact periods were for 23 h, and applications of the product were made to the same site. The composite total score for the 10 subjects treated with nail polish was 16 out of a maximum possible score of 630, indicating minimal irritation with "essentially no evidence of cumulative irritation." Composite scores of 7/630 and 569/630 were reported for baby oil (negative control) and deodorant (positive control), respectively, indicating "no evidence of cumulative irritation" and "strong potential for cumulative irritation."⁽¹⁸⁹⁾

A repeated insult patch test was used to evaluate the skin irritation and sensitization potential of a nail polish containing 33% Toluene. Occlusive "dry patches" containing the test material were applied to the upper back of 148 subjects (59 males, 89 females) every Monday, Wednesday, and Friday over 3 consecutive weeks for a total of nine induction applications. Following a 2-week nontreatment period, two consecutive 48-h challenge patches were applied to a site adjacent to the original induction site. No skin reactions were observed.⁽¹⁹⁰⁾

The Maximization Test described by Kligman⁽¹⁹¹⁾ and Kligman and Epstein⁽¹⁹²⁾ was used to assess the sensitization potential of a nail polish containing 31.23% Toluene. The product (0.3 ml) was applied under an occlusive dressing to the forearm of 25 subjects for five 48-h periods. Since the product contained volatile ingredients, the product was applied to the patch and allowed to air-dry prior to application. Throughout the induction phase, the test sites were pretreated with 24-h patches containing 1.5% sodium lauryl sulfate in aqueous solution. Following a 10-day nontreatment period, a challenge patch of the nail polish was applied under occlusion for 48 h to a previously untreated site. The challenge site was pretreated for 1 h with a 10.0% aqueous solution of sodium lauryl sulfate. Evaluations were made 48 and 72 h after treatment. No reactions were observed during the induction or challenge phases.⁽¹⁹³⁾

In separate studies, two nail products were evaluated for phototoxicity and photoallergenicity. One product contained 30% Toluene and was evaluated on 28 subjects.⁽¹⁹⁴⁾ The second product was formulated with 25% Toluene and was assessed on 30 subjects.⁽¹⁹⁵⁾ In each instance, the light source was a xenon Arc Solar Simulator (150W), which was filtered to produce a continuous emission spectrum in the UVA and UVB region (290–400 nm). Prior to testing, each panelist's "minimal erythral dose" was determined according to the procedures outlined in the Federal Register.⁽¹⁹⁶⁾ For the induction phase, each product (0.1 ml) was applied to the skin of the back under an occlusive patch. Twenty-four hours later, the patch was removed, and the sites were irradiated with three times the individuals' minimal erythral dose using the full xenon lamp spectrum. Forty-eight hours later, the sites were evaluated. The procedure of product exposure and light exposure was repeated twice weekly for a total of six induction exposures. Following a 10-day nontreatment period, the product was applied under an occlusive patch to a previously untreated site adjacent to the in-

duction site. Twenty-four hours later, the challenge patch was removed, and the sites were irradiated for 3 minutes with a filtered (Schott WG345 filter) light source. Challenge sites were evaluated 15 minutes and 24, 48, and 72 h after UV exposure. Control sites were subjected to the same induction and challenge procedures, with the exception that control sites were not subject to irradiation. No phototoxic or photoallergic reactions were observed to the two nail products formulated with 30% and 25% Toluene.^(194,195)

Respiratory Tract and Ocular Irritation

Two male subjects exposed to Toluene for 7–8 h developed transitory mild throat and eye irritation at 200 ppm and lacrimation at 400 ppm.⁽¹²⁷⁾ No complaints of respiratory tract irritation were reported by volunteers or workers exposed to Toluene concentrations of 800–1500 ppm for 8 h.^(86,128,197)

Transient epithelial injury consisting of moderate conjunctival irritation and corneal damage was noted in three workers who were accidentally splashed in the eyes with Toluene. Complete recovery generally occurred within 48 h.⁽¹⁹⁸⁾

Effects on Cardiovascular Function

Toluene has been implicated in a number of sudden deaths due to glue or solvent sniffing. In a study of 110 cases of sudden, unexpected death in solvent abusers, Bass⁽¹⁹⁹⁾ reported that the deaths were not due to suffocation secondary to intoxication but were due to a direct effect of the solvent itself. Toluene, benzene, gasoline, trichloroethane, and fluorocarbon propellants were individually implicated as causing sudden cardiovascular collapse. Severe cardiac arrhythmia resulting from light anesthesia was proposed as the most likely explanation for the cause of sudden death. Several authors have suggested that sniffing volatile hydrocarbons may cause sensitization of the myocardium to epinephrine.^(199–201)

Ogata et al.⁽²⁰²⁾ found an apparent decrease in the pulse rate of 23 volunteers who were exposed to 200 ppm Toluene for periods of 3 h or 7 h, but no effect was observed in those exposed to 100 ppm concentration. Systolic and diastolic blood pressure were not affected by exposure. Exposure to 100 and 200 ppm Toluene for 30 minutes did not, however, have any effect on the heart rate or electrocardiogram of 15 other subjects during either rest or light exercise.⁽⁵⁵⁾ In other studies, experimental exposure to Toluene at concentration of 100–700 ppm for 20 minutes⁽²⁰³⁾ or 50–800 ppm for 8 h^(86,128) did not produce any definite effects on heart rate or blood pressure. Suhr⁽²⁰⁴⁾ observed that the pulse rate and blood pressure of a group of 100 printers with a 10-year history of exposure to 200–400 ppm Toluene and those of an unexposed control group of identical size were similar at the beginning and end of work shifts.

Occupational Exposure Limits

The American Conference of Governmental Industrial Hygienists⁽²⁰⁵⁾ has adopted for toluene a “threshold limit value-time-weighted average” (TLV-TWA) and a “threshold limit value-short-term exposure limit” (TLV-STEL) of 100 ppm (375 mg/m³) and 150 ppm (560 mg/m³), respectively. The TLV-TWA is defined as

the airborne concentration for a normal 8-h workday and a 40-h workweek to which nearly all workers may be repeatedly exposed without adverse effect. The TLV-STEL is the maximal airborne concentration to which workers can be exposed for a period up to 15 minutes without causing irritation, chronic or irreversible tissue change, or necrosis. The threshold limit values are used as guides in the control of health hazards and are not intended to be used to differentiate between safe and unsafe concentrations.

SUMMARY

Toluene is a clear liquid that is insoluble in water. It is produced from either petroleum refining processes, as a byproduct of styrene production, or as a byproduct of coke oven operations. Commercial Toluene may contain benzene as an impurity; however, no data were available regarding the impurity content of cosmetic grade Toluene. Under experimental conditions, Toluene undergoes substitution reactions on the aliphatic side group ($-\text{CH}_3$) and on the benzene ring at the ortho and para positions. Under conditions of cosmetic use, Toluene is considered stable and unreactive.

Toluene has a wide variety of noncosmetic applications, including use as an indirect food additive, gasoline additive, solvent, and thinner (Tables 3 and 4). Cosmetic applications include use in nail products as a diluent and solvent. Cosmetic manufacturers participating in the voluntary cosmetic product registration program with the Food and Drug Administration reported that Toluene was used in 1984 in 555 nail and manicuring products. Reported concentrations of Toluene in these products ranged from >10 –25% (448 products) to >25 –50% (107 products) (Table 5).

The nail, the nail cuticle, and the skin surrounding the nail are the areas directly exposed to cosmetic formulations containing Toluene. Areas of the body that come in contact with the "wet" nail may also become exposed. During application of nail products, Toluene may come in contact with eyes and nasal mucosa as a result of evaporation from the formulation.

In mammals, Toluene is absorbed by the respiratory tract, gastrointestinal tract, and skin. Significant absorption may occur through the intact human skin. In one study, the rate of absorption of undiluted Toluene through the skin of the hands and forearms of humans was estimated at 14–23 mg/cm² per hour.

Although Toluene is likely metabolized to some extent in most mammalian tissues, the major site for metabolism is in the liver. Most of the absorbed Toluene (approximately 84%) undergoes sidechain oxidation to benzoic acid. Benzoic acid is subsequently conjugated with glycine and excreted in the urine as hippuric acid, although a large amount of conjugation with glucuronic acid occurs, resulting in urinary excretion of benzoylglucuronic acid. Small amounts of absorbed Toluene appear in the urine as benzylmercapturic acid and cresol derivatives. Approximately 16% of the absorbed Toluene is expired unchanged through the lungs (Fig. 1).

Toluene is lipophilic and accumulates primarily in those tissues with a high fat content. In one study, the half-life of Toluene in human adipose tissue ranged from 0.5 to 2.7 days.

Toluene was practically nontoxic when given orally to rats; reported acute

oral LD₅₀ values ranged from 2.6 g/kg to 7.53 g/kg (Table 8). The acute dermal LD₅₀ in rabbits was 14.1 ml/kg. A single IP injection of 0.8–1.7 g/kg was lethal to rats, mice, and guinea pigs.

A single subcutaneous injection of 1.1–1.25 g/kg and 4.3–8.7 g/kg was lethal to rats and mice, respectively. Granulopenia, followed by granulocytosis and eventual death, was noted in rabbits given Toluene as a single, subcutaneous dose of 4 ml/kg. In subchronic studies, rats given Toluene by subcutaneous injection at a dose of 1 ml/kg for 21 days had induration at the injection site, a decrease in body weight, a decrease in erythrocyte and leukocyte counts, hyperplasia of the bone marrow and spleen, focal hepatic necrosis, and nephrosis. Guinea pigs administered Toluene at a subcutaneous dose of 0.25 mg/day for 30–70 days developed polypnea, convulsions, necrosis at the injection site, as well as hemorrhagic, hyperemic, and degenerative changes in lungs, kidneys, adrenal glands, and spleen. Rabbits treated with Toluene at a subcutaneous dose of 1 ml/kg per day for 6 days developed granulopenia and granulocytosis.

Undiluted Toluene produced slight to moderate skin irritation in rabbits when tested by four different procedures. Skin necrosis was slight in one study in which Toluene was repeatedly applied to the skin of rabbits over a 2–4-week period (Table 9). Results of studies with rabbits indicate that undiluted Toluene is an ocular irritant (Table 10).

Acute inhalation LD₅₀ values for Toluene in mice were 5320 ppm and 6942 ppm; the exposure period in these two studies were 6–7 h. Effects observed in mice, rats, guinea pigs, rabbits, and dogs after acute inhalation of Toluene included mucous membrane irritation, motor incoordination, prostration, changes in respiratory rate, changes in serum and blood enzyme activities, elevated blood glucose and packed cell volume, decreased body weight, and death. These effects varied according to animal studied, length of Toluene exposure, and Toluene concentration.

Progressive symptoms observed in experimental animals following subchronic inhalation to increasingly higher concentrations of Toluene included irritation of the mucous membranes, incoordination, mydriasis, narcosis, tremors, prostration, anesthesia, and death (Table 11).

No significant treatment-related effects were observed in four studies in which rats were given chronic oral doses or chronic inhalation exposures to Toluene. Parameters examined in those studies generally included appearance, behavior, growth, body and organ weights, blood chemistry, urinalysis, gross and microscopic lesions, and mortality.

Toluene was negative for mutagenicity in a battery of mammalian cell and whole organism test systems. Results of microbial assays also were negative for mutagenicity (Table 12). There were several reports of increased chromosome aberrations in the bone marrow of rats exposed by inhalation or by subcutaneous injection to Toluene, as well as reports of increased sister-chromatid exchanges and chromosome aberrations in the lymphocytes of workers chronically exposed to Toluene.

A 2-year inhalation study with rats and mice is being conducted by the National Toxicology Program at Research Triangle Park. Results of the investigation have not yet been published. No neoplasms were observed in mice given a 3-month subcutaneous exposure to Toluene. With the exception of one report, results of numerous skin painting studies in mice were negative for carcinogenic-

ity. The teratogenicity and embryotoxicity of Toluene were assessed in hamsters, mice, and rats by various routes of exposure (skin, oral, inhalation). Results of these studies were mixed.

Clinical data were limited to five studies involving cosmetic products. No skin irritation or sensitization was observed in subjects treated with cosmetic products containing 31–33% Toluene. No phototoxic or photoallergic reactions were noted in subjects treated with 25 or 30% Toluene.

Throat irritation, eye irritation, and/or lacrimation were noted in two subjects exposed to airborne concentrations of 200 and 400 ppm Toluene. Transient irritation of the conjunctiva and transient injury of the cornea were observed in several workers accidentally exposed in the eyes to Toluene.

Toluene has been implicated in a number of sudden deaths due to glue or solvent sniffing. Several reports also suggested that sniffing volatile hydrocarbons may cause sensitization of the myocardium to epinephrine.

DISCUSSION

No data were available to the CIR Expert Panel regarding the impurities found in cosmetic grade Toluene. One possible impurity, benzene, is a carcinogen. Therefore, cosmetic products formulated with Toluene should be benzene-free.

Two studies concluded that Toluene induced chromosomal aberrations in rat bone marrow cells following subcutaneous injection.^(142,143) The significance of positive clastogenic effects attributed to Toluene in these studies is difficult to assess, since the purity of the test samples was not reported. More definitive carcinogenic studies were available. In eight studies, Toluene did not induce cancer. In one study, 1 of 30 mice developed skin cancer; however, there were no untreated controls for comparison.

Results of animal studies indicated that undiluted Toluene is a skin irritant. Thus, there is a potential for Toluene to cause skin irritation in humans. However, the sole cosmetic use of Toluene is in products intended to be applied directly to the nail. Therefore, human skin exposure to this ingredient will be minimal under conditions of cosmetic use.

CONCLUSION

On the basis of the available data presented in this report, the CIR Expert Panel concludes that Toluene is safe as a cosmetic ingredient in the present practices of use and concentration.

ACKNOWLEDGMENT

The literature review and technical analysis was prepared by Jonathan T. Busch, Senior Science Analyst. Word processing for the report was performed by Purita S. Ibanez.

REFERENCES

1. SYRACUSE RESEARCH CORPORATION. (August 1983). Health Assessment of Document for Toluene. Final Report. Prepared for EPA under Contract No. 68-02-3277. NTIS No. PB84-100056.
2. ESTRIN, N.F., CROSLLEY, P.A., and HAYNES, C.R. (1982). *CTFA Cosmetic Ingredient Dictionary*. Washington, D.C.: Cosmetic, Toiletry and Fragrance Assoc., p. 320.
3. TATKEN, R.L., and LEWIS, R.J. (eds.). (June 1983). Registry of toxic effects of chemical substances. 1981-82 ed. Vol. 3, p. 769. Cincinnati, OH: NIOSH, U.S. Dept. of Health and Human Services.
4. WINDHOLZ, M. (1983). *The Merck Index*, 10th ed. Rahway, N.J.: Merck and Co., Inc., p. 1364.
5. HAWLEY, G.G. (1971). *The Condensed Chemical Dictionary*, 8th ed. New York: Van Nostrand Reinhold Company, p. 877.
6. MACKISON, F.W. (September 1978). NIOSH/OSHA Pocket guide to chemical hazards. National Institute for Occupational Safety and Health. Occupational Safety and Health Administration. pp 180-1.
7. AMERICAN CONFERENCE OF GOVERNMENTAL INDUSTRIAL HYGIENISTS (ACGIH). (1980). *Documentation of the Threshold Limit Values*, 4th ed. Cincinnati, OH, p. 400.
8. ESTRIN, N.F., HAYNES, C.R., and WHELAN, J.M. (1982). Cosmetic Ingredient Descriptions. CTFA Compendium of Cosmetic Ingredient Composition. Toluene. Cosmetic, Toiletry and Fragrance Assoc.
9. GRANT, J. (1972). *Hack's Chemical Dictionary*, 4th ed. New York: McGraw-Hill Book Co., p. 684.
10. GREENBERG, L.A., and LESTER, D. (1954). *Handbook of Cosmetic Materials*. New York: Interscience, p. 317.
11. NATIONAL RESEARCH COUNCIL (NRC). (July 1981). The alkyl benzenes. Committee on alkyl benzene derivatives. Board on Toxicology and Environmental Health Hazards. Prepared for EPA under Contract No. 68-01-4655. Washington, D.C.: National Academy Press, NTIS No. PB82-160334.
12. COSMETIC, TOILETRY AND FRAGRANCE ASSOCIATION (CTFA). (March 12, 1986). Submission of unpublished data by CTFA. UV-visible absorption of Toluene.*
13. HARBER, L.C., and SHALITA, A.R. (1977). Immunologically mediated contact photosensitivity in guinea pigs. In: *Advances in Modern Toxicology*. F.N. Marzulli and H.J. Maibach (eds.). New York: John Wiley and Sons, Vol. 4, Chap. 14, pp. 427-39.
14. SAX, I.N. (1979). *Dangerous Properties of Industrial Materials*, 5th ed. New York: Van Nostrand Reinhold Company, p. 1035.
15. DOVIK, W.C. (1972). Nail lacquers and removers. In: *Cosmetics—Science and Technology*, 2nd ed. M.S. Balsam and E. Sagarin (eds.). New York: Wiley-Interscience, Vol. 2, Chap. 29, pp. 521-41.
16. CTFA. (no date). Submission of unpublished data by CTFA. Cosmetic Ingredient Chemical Description. Toluene. CTFA code no. 2-40-1.*
17. WEAST, R.C. (1982). *CRC Handbook of Chemistry and Physics*, 63rd ed. Boca Raton, FL: CRC Press, p. C-541.
18. SANDMEYER, E.E. (1981). Aromatic hydrocarbons. Chapter 47. In: *Patty's Industrial Hygiene and Toxicology*, 3rd rev. ed. G.D. Clayton and F.E. Clayton (eds.). New York: John Wiley and Sons, 2B:3256, 3283-91.
19. JAPAN COSMETIC INDUSTRY ASSOC. (1979). Japanese standards of cosmetic ingredients. Yakuji Nippo, Ltd. pp. 333-4.
20. SHEPSON, P.B., EDNEY, E.O., and CORSE, E.W. (1984). Ring fragmentation reactions in the photooxidations of toluene and o-xylene. *J. Phys. Chem.* **88**(18), 4122-6.
21. BADGER, G.M., and SPOTSWOOD, T.M. (1960). The formation of aromatic hydrocarbons at high temperatures. Part IX. The pyrolysis of toluene, ethylbenzene, propylbenzene, and butylbenzene. *J. Chem. Soc.* 4420-7.
22. GARRIOTT, J.C., FOERSTER, E., JUAREZ, L., et al. (1981). Measurement of toluene in blood and breath in cases of solvent abuse. *Clin. Toxicol.* **18**(4), 471-80.
23. NAKAGAKI, TSURUTA, H., and ARITO, H. (1982). Determination of toluene concentrations in blood intermittently sampled from jugular vein-catheterized rats. *Indust. Health* **20**(2), 147-50.
24. BIENIEK, G., PALYS, E., and WILCZOK, T. (1982). TLC separation of hippuric, mandelic, and phenylglyoxylic acids from urine after mixed exposure to toluene and styrene. *Br. J. Ind. Med.* **39**(2), 187-90.

*Available for review: Director, Cosmetic Ingredient Review, 1110 Vermont Ave., N.W., Suite 810, Washington, D.C. 20005.

25. HANSEN, S.H., and DOSSING, M. (April 16, 1982). Determination of urinary hippuric acid and o-cresol, as indices of toluene exposure, by liquid chromatography or dynamically modified silica. *J. Chromatogr.* **229**(1), 141-8.
26. HORNOS VILA, J.I., FERNANDEZ, C.J., FAUS, R.N., and ECHEVARNE, F.F. (1981). Correlation between the values of hippuric acid in the urine. Colorimetric and HPLC methods as an indicator of toluene exposure. *Libro Actas - Congr. Nac. Med. Hig. Segur. Trab.* 9th **2**, 291-302.
27. KOZU, T., and AKANUMA, K. (1981). High-performance liquid chromatographic determination of hippuric acid in the urine of toluene inhaled man. *Eisei Kagaku.* **27**(2), 116-8.
28. GUTEWORT, T., GARTZKE, J., and PENNIER, R. (1981). The rate of excretion of hippuric acid in urine in evaluating occupational exposure to toluene. *Z. Gesamte Hyg. Grenzgeb.* **27**(1), 57-63.
29. BARAN, R. (1982). Pathology induced by the application of cosmetics to the nail. In: *Principles of Cosmetics for the Dermatologist*. P. Frost and S.N. Horwitz (eds.). St. Louis: C.V. Mosby Co., Chap. 24, pp. 181-4.
30. WILKINSON, J.B., and MOORE, R.J. (eds.). (1982). *Harry's Cosmeticology*, 7th ed. New York: Chemical Publishers, pp. 375-89.
31. FOOD AND DRUG ADMINISTRATION (FDA). (July 19, 1984). Cosmetic Product Formulation Data. Ingredients used in each product category. Computer printout. Washington, D.C.
32. CODE OF FEDERAL REGULATIONS (CFR). (Revised as of April 1, 1984). Title 21 Part 175.105. Adhesives.
33. CFR. (Revised as of April 1, 1984). Title 21 Part 175.320. Resinous and polymeric coatings for polyolefin films.
34. CFR. (Revised as of April 1, 1984). Title 21 Part 176.180. Components of paper and paperboard in contact with dry food.
35. CFR. (Revised as of April 1, 1984). Title 21 Part 177.1010. Acrylic and modified acrylic plastics, semirigid and rigid.
36. CFR. (Revised as of April 1, 1984). Title 21 Part 177.1200. Cellophane.
37. CFR. (Revised as of April 1, 1984). Title 21 Part 177.1650. Polysulfide polymer-polyepoxy resins.
38. CFR. (Revised as of April 1, 1984). Title 21 Part 178.3010. Adjuvant substances used in the manufacture of foamed plastics.
39. CFR. (Revised as of April 1, 1984). Title 21 Part 720.4. Voluntary filing of cosmetic product ingredient and cosmetic raw material composition statement. Information requested about cosmetic products.
40. STUTSMAN, M.J. (1977). Analysis of nail lacquers. In: *Newburger's Manual of Cosmetic Analysis*, 2nd ed. A.J. Senzel (ed.). Washington, D.C.: Assoc. of Official Analytical Chemists, Chap. 7.
41. HANCOCK, E.G. (1982). *Toluene, the Xylenes and their Industrial Derivatives*. New York: Elsevier Scientific Publishing Co.
42. ASANUMA SOGYO, K.K. (March 10, 1981). Linear polyester oligomer resin as nail polish. Jpn. Kokai Tokkyo Koho Patent No. 81 25107.
43. DIA FOIL, K.K. (September 11, 1981). Nail polish film-forming composition containing synthetic rubbers. Jpn. Kokai Tokkyo Koho Patent No. 81 115710.
44. GORDON, H.W., and FARRELL, H.R. (September 6, 1983). Moisturizing nail polish composition. U.S. Patent No. 4402935. Del laboratories, Inc.
45. ISEHAN, K.K. (September 29, 1981). Fiber-containing finger nail polishes. Jpn. Kokai Tokkyo Koho Patent No. 81 123909.
46. MAZAL, P. (February 24, 1983). Nail polish thickeners. Czech. Patent No. 201931.
47. SCHLOSSMAN, M.L. (November 17, 1981). Universal nail polish using polyester resin. U.S. Patent No. 4301046. Tevco, Inc.
48. SHISEIDO, CO. (July 27, 1981). Gel-like compositions for nail polishes. Jpn. Tokkyo Koho patent No. 81 32284.
49. SOCCI, R., GUNDERMAN, A., FOTIU, E., and KABACOFF, B. (November 24, 1981). Nail enamels. U.S. Patent No. 4302442. USV Pharmaceutical Corp.
50. SRI INTERNATIONAL. (1980). *Toluene*. Health Effects of Chemicals Series. Melano Park, CA. 165 pp.
51. SATO, A., and NAKAJIMA, T. (1979). Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. *Br. J. Indust. Med.* **36**(3), 231-4.
52. SATO, A., NAKAJIMA, T., FUJIWARA, Y., and HIROSAWA, K. (1974). Pharmacokinetics of benzene and toluene. *Int. Arch. Arbeitsmed.* **33**(3), 169-82.
53. SATO, A., FUKIWARA, Y., and NAKAJIMA, T. (1974). Solubility of benzene, toluene and m-xylene in various body fluids and tissues of rabbits. *Jpn. J. Ind. Health.* **16**(1), 30.
54. SHERWOOD, R.J. (1976). Ostwald solubility coefficients of some industrially important substances. *Br. J. Indust. Med.* **33**(2), 106-7.

55. ASTRAND, I., EHRNER-SAMUEL, H., KILBOM, A., and OVRUM, P. (1972). Toluene exposure. I. Concentration in alveolar air and blood at rest and during exercise. *Work Environ. Health.* **72**(3), 119-30.
56. ASTRAND, I. (1975). Uptake of solvents in the blood and tissues of man. A review. *Scand. J. Work Environ. Health.* **1**(4), 199-218.
57. VEULEMANS, H., and MASSCHELEIN, R. (1978). Experimental human exposure to toluene. I. Factors influencing the individual respiratory uptake and elimination. *Int. Arch. Occup. Environ. Health.* **42**(2), 91-104.
58. OVRUM, P., HULTENGREN, M., and LINDQUIST, T. (1978). Exposure to toluene in a photogravure printing plant. Concentration in ambient air and uptake in the body. *Scand. J. Work Environ. Health.* **4**(3), 237-45.
59. CARLSSON, D., and LINDQUIST, T. (1977). Exposure of animals and man to toluene. *Scand. J. Work Environ. Health.* **3**(3), 135-43.
60. CARLSSON, A., and LJUNGQUIST, E. (1982). Exposure to toluene. Concentration in subcutaneous adipose tissue. *Scand. J. Work Environ. Health.* **8**(1), 56-62.
61. CARLSSON, A. (1982). Exposure to toluene. Uptake, distribution and elimination in man. *Scand. J. Work Environ. Health.* **8**(1), 43-55.
62. COHR, K.H., and STOKHOLM, J. (1979). Toluene—A toxicologic review. *Scand. J. Work Environ. Health.* **5**(2), 71-90.
63. MOLHAVE, L., and PEDERSEN, O.F. (1984). Measurements of alveolar concentrations of toluene. *Int. Arch. Occup. Environ. Health.* **54**(1), 65-71.
64. HOBARA, T., KOBAYASHI, H., HIGASHIHARA, E., KAWAMOTO, T., and SAKAI, T. (1984). Experimental study on the pulmonary absorption and excretion of toluene. *Int. Arch. Occup. Environ. Health.* **53**(4), 337-44.
65. DUTKIEWICZ, T., and TYRAS, H. (1968). The quantitative estimation of toluene skin absorption in man. *Arch. Gewerbepath. Gewerbehyg.* **24**, 253-7.
66. DUTKIEWICZ, T., and TYRAS, H. (1968). Skin absorption of toluene, styrene, and xylene by man. *Br. J. Indust. Med.* **25**(3), 243.
67. SATO, A., and NAKAJIMA, T. (1978). Differences following skin or inhalation exposure in the absorption and excretion kinetics of trichloroethylene and toluene. *Br. J. Indust. Med.* **35**, 43-9.
68. GUILLEMIN, M., MURSET, J.C., LOB, M., and RIQUEZ, J. (1974). Simple method to determine the efficiency of a cream used for skin protection against solvents. *Br. J. Indust. Med.* **31**, 310-6.
69. RIIHIMAKI, V., and PFAFFLI, P. (1978). Percutaneous absorption of solvent vapors in man. *Scand. J. Work Environ. Health.* **4**(1), 73-85.
70. PIOTROWSKI, J. (1967). Quantitative estimate of the absorption of toluene in people. *Med. Pracy.* **18**, 213-23.
71. JAKOBSON, I., WAHLBERG, J.E., HOLMBERG, B., and JOHANSSON, G. (1982). Uptake via the blood and elimination of 10 organic solvents following epicutaneous exposure of anesthetized guinea pigs. *Toxicol. Appl. Pharmacol.* **63**(2), 181-7.
72. TSURUTA, H. (1982). Percutaneous absorption of organic solvents: 3. Penetration rates of hydrophobic solvents through excised rat skin. *Indust. Health.* **20**(4), 335-46.
73. SMITH, J.N., et al. (1954). Studies in detoxication, 55. The metabolism of alkylbenzenes. a/Glucuronic acid excretion following the administration of alkylbenzenes: b/Elimination of toluene in the expired air of rabbits. *Biochem. J.* **56**, 317-20.
74. PYYKKO, K., TAHTI, H., and VAPAATALO, H. (1977). Toluene concentrations in various tissues of rats after inhalation and oral administration. *Arch. Toxicol.* **38**, 169-76.
75. KOGA, K. (1978). Distribution, metabolism and excretion of toluene in mice. *Folia Pharmacol. Jpn.* **74**(6), 687-98.
76. BAKKE, O.M., and SCHELINE, R.R. (1970). Hydroxylation of aromatic hydrocarbons in the rat. *Toxicol. Appl. Pharmacol.* **16**, 691-700.
77. TOFTGARD, R., and GUSTAFSSON, J.A. (1980). Biotransformation of organic solvents: A Review. *Scand. J. Work Environ.* **6**(1), 1-18.
78. DEBRUIN, A. (1976). *Biochemical Toxicology of Environmental Agents*. Amsterdam: Elsevier/North Holland Biomedical Press.
79. WOIWODE, W., WODARZ, K., DRYSCH, K., and WEICHARDT, H. (1979). Metabolism of toluene in man: Gas-chromatographic determination of o-, m-, and p-cresol in urine. *Arch. Toxicol.* **43**, 93-8.
80. PETERSON, R.G., and BRUCKNER, J.V. (1978). Measurement of toluene levels in animal tissues. In: *Voluntary Inhalations of Industrial Solvents*. C.W. Sharp and L.T. Carrol (eds.). Rockville, MD: Natl. Inst. Drug Abuse **24**, 33-42.

81. BRUCKNER, J.V., and PETERSON, R.G. (1981). Evaluation of toluene and acetone inhalant abuse. I. Pharmacology and pharmacodynamics. *Toxicol. Appl. Pharmacol.* **61**, 302-12.
82. KOGA, H., and OHMIYA, Y. (1978). Potentiation of toluene toxicity by hepatic enzyme inhibition in mice. *J. Toxicol. Sci.* **3**(1), 25-9.
83. WINEK, C.L., WECHT, C.H., and COLLOM, W.D. (1968). Toluene fatality from glue sniffing. *Penn. Med.* **71**, 81.
84. WINEK, C.L., and COLLOM, W.D. (1971). Benzene and toluene fatalities. *J. Occup. Med.* **13**, 259-61.
85. SRBOVA, J., and TEISINGER, J. (1952). Absorption and elimination of toluene in man. *Arch. Ind. Hyg. Occup. Med.* **6**, 462.
86. VON OETTINGEN, W.F., NEAL, P.A., and DONAHUE, D.D. (1942). The toxicity and potential dangers of toluene. Preliminary report. *JAMA* **118**, 579-84.
87. ANGERER, J. (1979). Occupational chronic exposure to organic solvents. VII. Metabolism of toluene in man. *Int. Arch. Occup. Environ. Health* **43**(1), 63-7.
88. APOSTOLI, P., BRUGNONE, F., PERBELLINI, L., COCHEO, V., BELLOMO, M.L., and SILVERSTRI, R. (1982). Biomonitoring of occupational toluene exposure. *Int. Arch. Occup. Environ. Health* **50**(2), 153-68.
89. DOSSING, M., AELUM, J.B., HANSEN, S.H., LUNDQVIST, G.R., and ANDERSON, N.T. (1983). Urinary hippuric acid and orthocresol excretion in man during experimental exposure to toluene. *Br. J. Indust. Med.* **40**(4), 470-3.
90. ANDERSSON, R., CARLSSON, A., NORDQVIST, M.B., and SOLLENBERG, J. (1983). Urinary excretion of hippuric acid and o-cresol after laboratory exposure of humans to toluene. *Int. Arch. Occup. Environ. Health* **53**(2), 101-8.
91. HASEGAWA, K., SHIOJIMA, S., KOIZUMI, A., and IKEDA, M. (1983). Hippuric acid and o-cresol in the urine of workers exposed to toluene. *Int. Arch. Occup. Environ. Health* **52**(3), 197-208.
92. WOIWODE, W., and DRYSCH, R. (1981). Experimental exposure to toluene: Further consideration of cresol formation in man. *Br. J. Indust. Med.* **38**(2), 194-7.
93. HODGE, H.C., and STERNER, J.H. (1949). Tabulation of toxicity classes. *Am. Indust. Hyg. Quart.* **10**, 93.
94. SMYTH, H.F., Jr., WEIL, C.S., WEST, J.S., and CARPENTER, C.P. (1969). Exploration of joint toxic action: Twenty-seven industrial chemicals intubated in rats in all possible pairs. *Toxicol. Appl. Pharmacol.* **14**(2), 340-7.
95. SMYTH, H.F., Jr., CARPENTER, C.P., WEIL, C.S., POZZANI, V.C., STRIEGEL, J.A., and NYCUM, J.S. (1969). Range-finding toxicity data: List VII. *Am. Ind. Hyg. Assoc. J.* **30**, 470-6.
96. WOLF, M.A., et al. (1956). Toxicological studies of certain alkylated benzenes and benzene. *Arch. Indust. Health* **14**, 387-98.
97. WITHEY, R.J., and HALL, J.W. (1975). Joint toxic action of perchloroethylene with benzene or toluene in rats. *Toxicology* **4**(1), 5-15.
98. KIMURA, E.T., EBERT, D.M., and DODGE, P.W. (1971). Acute toxicity and limits of solvent residue for sixteen organic solvents. *Toxicol. Appl. Pharmacol.* **19**(4), 699-704.
99. CTFA. (1981). Submission of unpublished data by CTFA. Acute oral toxicity in rats. Nail basecoat containing 33.2 percent Toluene. September 8. CTFA code no. 2-40-2.*
100. CTFA. (1980). Submission of unpublished data by CTFA. CIR safety data test summary response form. Acute oral toxicity in rats. Nail polish containing 33 percent Toluene. January 30. CTFA code no. 2-40-6.*
101. KEPLINGER, M.L., LANIER, G.E., and DEICHMANN, W.B. (1959). Effects of environmental temperature on the acute toxicity of a number of compounds in rats. *Toxicol. Appl. Pharmacol.* **1**, 156-61.
102. CAMERON, G.R., PATERSON, J.L.H., DE SARAM, G.S.W., and THOMAS, J.C. (1938). The toxicity of some methyl derivatives of benzene with special reference to pseudocumene and heavy coal-tar naphtha. *J. Pathol. Bacteriol.* **46**, 95-107.
103. BATCHELOR, J.J. (1927). The relation toxicity of benzol and its higher homologues. *Am. J. Hyg.* **7**, 276-98.
104. IKEDA, M., and OHTSUJI, H. (1971). Phenobarbital-induced protection against toxicity of toluene and benzene in the rat. *Toxicol. Appl. Pharmacol.* **20**(1), 30-43.
105. WAHLBERG, J.E. (1976). Percutaneous toxicity of solvents. A comparative investigation in the guinea pig with benzene, toluene, and 1,1,2-trichloroethane. *Ann. Occup. Hyg.* **19**(2), 115-9.
106. SAVOLAINEN, H. (1978). Distribution and nervous system binding of intraperitoneally injected toluene. *Acta Pharmacol. Toxicol.* **43**(1), 78-80.
107. BRAIER, L. (1973). Comparative study of isocyclic hydrocarbons in animals and in man. *Haematologica* **58**(7), 491-500.
108. SESSA, T. (1948). Histopathology in experimental chronic toluene poisoning. *Folia Med. (Naples)* **31**, 91-105.

109. DELAUNAY, A., LEBRUN, J.F.E., and WANG, H.S. (1950). Action and mechanism of action of toluene and related compounds on the permeability of blood capillaries. *Compt. Rend. Soc. Biol.* **144**, 58–9.
110. SCHUTZ, E. (1960). Effects on organic liquids on the skin. *Arzneimittel-Forsch.* **10**, 1027–9.
111. KRONEVI, T., WAHLBERG, J., and HOLMBERG, B. (1979). Histopathology of skin, liver, and kidney after epicutaneous administration of five industrial solvents to guinea pigs. *Environ. Res.* **19**(1), 56–69.
112. JOURNAL OFFICIEL DE LA REPUBLIQUE FRANCAISE. (1971). Methodes officielles d'analyse des cosmétiques et produits de beauté. Annexe I: Methode officielle pour la détermination de l'indice d'irritation primaire. Arrêté du Avril 5, 1971. *Journal Officiel* Avril 21, p. 3862.
113. JOURNAL OFFICIEL DE LA REPUBLIQUE FRANCAISE. (1973). Methodes officielles d'analyse des cosmétiques et produits de beauté. Annexe I: Methode officielle pour la détermination de l'indice d'irritation primaire. Arrêté du Avril 14, 1973. *Journal Officiel* Juin 5, p. 3953.
114. ASSOCIATION FRANCAISE DE NORMALISATION. (1982). Evaluation de l'Irritation et/ou de la Corrosion Cutanée, chez le Lapin. NF TO3-263.
115. ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT. (1979). OECD short-term and long-term toxicology groups. Final Report: Acute Dermal Irritation/Corrosivity. December 31, p. 35.
116. ADAMS, E.M., IRISH, D.D., SPENCER, H.C., and ROWE, V.K. (1941). Response of rabbit skin to compounds reported to have caused acne form dermatitis. *Indust. Med.* **2**, 1–4.
117. GUILLOT, J.P., GONNET, J.F., CLEMENT, C., CAILLARD, L., and TRUHAUT, R. (1982). Evaluation of the cutaneous-irritation potential of 56 compounds. *Food Chem. Toxicol.* **20**(5), 563–72.
118. CTFA. (1981). Submission of unpublished data by CTFA. Primary skin irritation. Nail basecoat containing 33.2 percent Toluene. September 7. CTFA code no. 2-40-3.*
119. CTFA. (1980). Submission of unpublished data by CTFA. CIR safety data test summary response form. Rabbit skin irritation. Nail polish containing 33 percent Toluene. January 17. CTFA code no. 2-40-8.*
120. KAY, J.H., and CALANDRA, J.C. (1962). Interpretation of eye irritation tests. *J. Soc. Cosmetic Chem.* **13**(6), 281–9.
121. GUILLOT, J.P., GONNET, J.F., CLEMENT, C., CAILLARD, L., and TRUHAUT, R. (1982). Evaluation of the ocular-irritation potential of 56 compounds. *Food Chem. Toxicol.* **20**(5), 573–82.
122. CARPENTER, C.P., and SMYTH, H.F. (1946). Chemical burns of the rabbit cornea. *Am. J. Ophthalmol.* **29**, 1363–72.
123. CTFA. (January 17, 1980). Submission of unpublished data by CTFA. CIR safety data test summary response form. Rabbit eye irritation. Nail polish containing 33 percent Toluene. CTFA code no. 2-40-5.*
124. SVIRBELY, J.L., DUNN, R.C., and VON OETTINGEN, W.F. (1943). The acute toxicity of vapors of certain solvents containing appreciable amounts of benzene and toluene. *J. Indust. Hyg. Toxicol.* **25**, 366–73.
125. BONNET, P., RAOULT, G., and GRADISKI, D. (1979). Lethal concentration 50 of main aromatic hydrocarbons. *Arch. Mal. Prof. Med. Travail Sec. Soc.* **40**(8–9), 805–10.
126. SMYTH, H.F., and SMYTH, H.F., Jr. (1928). Inhalation experiments with certain lacquer solvents. *J. Indust. Hyg.* **10**, 261–71.
127. CARPENTER, C.P., SHAFFER, C.B., WEIL, C.S., and SMYTH, H.F., Jr. (1944). Studies on the inhalation of 1,3-butadiene; with a comparison of its narcotic effect with benzol, toluol, and styrene, and a note on the elimination of styrene by the human. *J. Indust. Hyg. Toxicol.* **26**, 69–78.
128. VON OETTINGEN, W.F., NEAL, P.A., DONAHUE, D.D., SVIRBELY, J.L., BAERNSTEIN, H.D., MONACO, A.R., VALAER, P.J., and MITCHELL, J.L. (1942). The toxicity and potential dangers of toluene with special reference to its maximal permissible concentration. U.S. Public Health Serv. *Pub. Health Bull.* No. 279, 50 pp.
129. NIELSON, G.D., and ALARIE, Y. (1982). Sensory irritation, pulmonary irritation and respiratory stimulation by airborne benzene and alkylbenzenes: Prediction of safe industrial exposure levels and correlation with their thermodynamic properties. *Toxicol. Appl. Pharmacol.* **65**(3), 459–77.
130. De CEARRIZ, J.C., MICILLINO, J.C., BONNET, P., and GUENIER, J.P. (1981). Sensory irritation caused by various industrial airborne chemicals. *Toxicol. Lett. (AMST)* **9**(2), 137–44.
131. TAHTI, H., AARAN, R.K., and VAPAATALO, H. (1983). An inhalation method for testing the toxicity of volatile compounds in small laboratory animals. A study on short-term and long-term toluene inhalation in rats. *Meth. Find Exp. Clin. Pharmacol.* **5**(10), 667–71.
132. BRUCKNER, J.V., and PETERSON, R.G. (1981). Evaluation of toluene and acetone inhalant abuse. II. Model development and toxicology. *Toxicol. Appl. Pharmacol.* **61**(3), 302–12.
133. KHINKOVA, L. (1974). Experimental data on the toxicity of some organic solvents used in the furniture industry. *Tr. Inst. Khig. Okhr. Tr. Prof. Zabol.* **22**(1), 133–40.
134. UNGVARY, G., MANYAI, S., and TATRAI, E. (1980). Effects of toluene inhalation on the liver of rats—dependence on sex, dose and exposure time. *J. Hyg. Epidemiol. Microbiol. Immunol.* **24**, 242–52.
135. JENKINS, L.J., Jr., JONES, R.A., and SIEGEL, J. (1970). Long-term inhalation screening studies of benzene, toluene, o-xylene, and cumene on experimental animals. *Toxicol. Appl. Pharmacol.* **16**, 818–23.

136. HORIGUCHI, S., and INOUE, K. (1977). Effects of toluene on the wheel-turning activity and peripheral blood findings in mice—An approach to the maximum allowable concentration of toluene. *J. Toxicol. Sci.* **2**(4), 363–72.
137. FABRE, R., et al. (1955). Recherches toxicologiques sur les solvants de remplacement due benzenede. *Arch. Mal. Prof. Med. Travail Sec. Soc.* **16**, 197–215.
138. GIBSON, J.E., and HARDISTY, J.F. (1983). Chronic toxicity and oncogenicity bioassay of inhaled toluene in Fischer-344 rats. *Fund. Appl. Toxicol.* **3**(4), 315–9.
139. AMERICAN PETROLEUM INSTITUTE. (1980). Chronic inhalation toxicity in rats. Study performed by Bio/dynamics Inc.
140. GRADSKI, D., BONNET, P., DUPRAT, P., ZISSU, D., MAGADUR, J.L., and GUENIER, J.P. (1981). Etude toxicologique chronique par inhalation chez le rat de l'association benzene-toluene. *Toxicol. Eur. Res.* **3**, 201–6.
141. DOBROKHOTOV, V.B., and ENIKEEV, M.I. (1975). Mutagenic effect of benzene, toluene, and a mixture of these hydrocarbons in a chronic experiment. *Gig. Sanit.* **1**, 32–34. (In Russian with English summary.)
142. DOBROKHOTOV, V.B. (1972). The mutagenic influence of benzene and toluene under experimental conditions. *Gig. Sanit.* **37**, 36–9.
143. LYAPKALO, A.A. (1973). Genetic activity of benzene and toluene. *Gig. Tr. Prof. Azbol.* **17**, 24–8. (In Russian with English summary.)
144. BAUCHINGER, M., SCHMID, E., DRESP, J., KOLIN-GERRESHEIM, HAUF, R., and SAUHR, E. (1982). Chromosome changes in lymphocytes after occupational exposure to toluene. *Mutat. Res.* **102**(4), 439–45.
145. BAUCHINGER, M., SCHMID, E., DRESP, J., and KOLIN-GERRESHEIM, J. (1983). Chromosome aberrations and sister-chromatid exchanges in toluene-exposed workers. *Mutat. Res.* **113**, 231–2.
146. LITTON BIONETICS, INC. (1978). Mutagenicity evaluation of toluene. Final report. Submitted to the American Petroleum Institute, Washington, D.C., in May 1978. LBI Project No. 20847. Litton Bionetics, Inc., Kensington, MD, 150 pp.
147. MORTELMANS, K.E., and RICCIO, E.S. (1980). In vitro microbiological genotoxicity assays of toluene. Prepared by SRI International, Menlo Park, CA, under Contract No. 68-02-2947 for the U.S. Environmental Protection Agency, Research Triangle Park, NC.
148. NESTMANN, E.R., LEE, G.G.H., MATULA, T.I., DOUGLAS, G.R., and MUELLER, J.C. (1980). Mutagenicity of constituents identified in pulp and paper mill effluent using the *Salmonella*/mammalian-microsome assay. *Mutat. Res.* **79**, 203–12.
149. BOS, R.P., BROUNS, R.M., VAN DOORN, R., THEUWS, J.L., and HENDERSON, P.T. (1981). Non-mutagenicity of toluene, o-, m- and p-xylene, o-methylbenzyl alcohol and o-methylbenzylsulfate in the Ames assay. *Mutat. Res.* **88**(3), 273–9.
150. SNOW, L., MACNAIR, P., and CASTO, B.C. (1981). Mutagenesis testing of toluene in *Salmonella* strains TA100 and TA98. Report prepared for the U.S. EPA by Northrup Services, Inc., P.O. Box 12313, Research Triangle Park, NC 27709.
151. SUZUKI, J., OKAZAKI, H., NISHI, Y., and SUZUKI, S. (1982). Formation of mutagens by photolysis of aromatic compounds in aqueous nitrate solution. *Bull. Environ. Contam. Toxicol.* **29**(5), 511–6.
152. FLUCK, E.R., et al. (1976). Evaluation of a DNA polymerase-deficient mutant of *E. coli* for the rapid detection of carcinogens. *Chem. Biol. Int.* **15**, 219.
153. SINA, J.F., BEAN, C.L., DYSART, G.R., TAYLOR, V.I., and BRADLEY, M.O. (1983). Evaluation of the alkaline elution/rat hepatocyte assay as a predictor of carcinogenic/mutagenic potential. *Mutat. Res.* **113**(5), 357–91.
154. LIANG, J.C., HSU, T.C., and HENRY, J.E. (1983). Cytogenetic assays for mitotic poisons: The grasshopper (*Melanoplus sanguinipes*) embryo system for volatile liquids. *Mutat. Res.* **113**(6), 467–80.
155. GOMEZ-ARROYO, S., and VILLALOBOS-PIETRINI, R. (1981). Chromosomal alterations induced by solvents in *Vicia faba*. *Mutat. Res.* **85**, 224.
156. DONNER, M., HUSGAFVEL-PURSIANEN, K., MAKI-PAKKANEN, J., SORSA, M., and VAINIO, H. (1981). Genetic effects of in vivo exposure to toluene. *Mutat. Res.* **85**, 293–4.
157. LITTON BIONETICS, INC. (1981). Mutagenicity evaluation of toluene—Mouse dominant lethal assay. Final Report. Submitted to the American Petroleum Institute, Washington, D.C., in January 1981. LBI Project No. 21141-05. Litton Bionetics, Inc., Kensington, MD. 15 pp.
158. KIRKHART, B. (1980). Micronucleus test on toluene. Prepared by SIR International, Menlo Park, CA, under Contract No. 68-02-2947 for the U.S. Environmental Protection Agency, Research Triangle Park, NC.

159. GAD-EL-KARIM, M.M., HARPER, B.L., and LEGATOR, M.S. (1984). Modifications in the myeloclastogenic effect of benzene in mice with toluene, phenobarbital, 3-methylcholanthrene, aroclor 1254 and SKF-525A. *Mutat. Res.* **135**(3), 225-43.
160. LITTON BIONETICS, INC. (1978). Teratology study in rats. Toluene. Final report. Submitted to the American Petroleum Institute, Washington, D.C., in January 1978. LBI Project No. 20698-4. Litton Bionetics, Inc., Kensington, MD, 17 pp.
161. EVANS, E.L., and MITCHELL, A.D. (1980). An evaluation of the effect of Toluene on sister chromatid exchange frequencies in cultured chinese hamster ovary cells. Prepared by SRI International, Menlo Park, CA, under Contract No. 68-02-2947 for the U.S. Environmental Protection Agency, Research Triangle Park, NC.
162. GERNER-SMIDT, P., and FRIEDRICH, U. (1978). The mutagenic effect of benzene, toluene and xylene studied by the SCE technique. *Mutat. Res.* **58**(2/3), 313-6.
163. FORNI, A., PACIFICO, E., and LIMONTA, A. (1971). Chromosome studies in workers exposed to benzene or toluene or both. *Arch Environ. Health* **22**(3), 373-8.
164. MAKI-PAKKANEN, J., HUSGAFVEL-PURSIANEN, K., KALLIOMAKI, P.L., et al. (1980). Toluene-exposed workers and chromosome aberrations. *J. Toxicol. Environ. Health.* **6**(4), 775-81.
165. NATIONAL TOXICOLOGY PROGRAM. (March 1985). Personal communication with the Public Information Office (919-541-3991). Research Triangle Park, NC.
166. PURCHASE, T.F.H., and LONGSTAFF, E. (1978). The implant test. *Br. J. Cancer* **37**(6), 954-9.
167. POEL, W.E. (1963). Skin as a test site for the bioassay of carcinogens and carcinogen precursors. *Natl. Cancer Inst. Monogr.* **10**, 611-31.
168. VOSE, C.W., COOMBS, M.M., and BHATT, T.S. (1981). Cocarcinogenicity of promoting agents. *Carcinogenesis (Lond.)* **2**(7), 687-9.
169. FREI, J.V., and STEPHENS, P. (1968). The correlation of promotion of tumor growth and of induction of hyperplasia in epidermal two-stage carcinogenesis. *Br. J. Cancer* **22**, 83-92.
170. FREI, J.V., and KINGSLEY, W.F. (1968). Observations on chemically induced regressing tumors of mouse epidermis. *J. Natl. Cancer Inst.* **41**(6), 1307-13.
171. DOAK, S.M.A., et al. (1976). The carcinogenic response in mice to the topical application of propane sulfone to the skin. *Toxicology* **6**, 139.
172. COOMBS, M.M., BHATT, T.S., and CROFT, C.J. (1973). Correlation between carcinogenicity and chemical structure in cyclopenta(a)phenanthrenes. *Cancer Res.* **33**, 832-7.
173. EMMETT, E.A., BRINGHAM, E.M., and BARKLEY, W. (1981). A carcinogenic bioassay of certain roofing materials. *Am. J. Indust. Med.* **2**(1), 59-64.
174. COOMBS, M.M., and BHATT, T.S. (1978). Lack of initiating activity in mutagens which are not carcinogenic. *Br. J. Cancer* **38**(1), 148-50.
175. LIJINSKY, W., and GARCIA, H. (1972). Skin carcinogenesis tests of hydrogenated derivatives of anthanthrene and other polynuclear hydrocarbons. *Z. Krebsforsch.* **77**(3), 226-30.
176. FREI, J.V., and RITCHIE, A.C. (1964). Tumor-promoting power and hyperplasia-inducing power of a number of irritant solutions. *Fed. Proc.* **23**(2, pt. 1), 288.
177. OVERMAN, D.O. (1981). Testing for percutaneous embryotoxicity of laboratory reagents in the hamster. *Teratology* **23**, 56A.
178. NAWROT, P.S., and STAPLES, R.E. (1979). Embryo-fetal toxicity and teratogenicity of benzene and toluene in the mouse (Abstr). *Teratology* **19**, 41A.
179. BIOASSAY SYSTEMS CORPORATION. (January 7, 1983). Determination of the reproductive effects in mice of nine selected chemicals. Prepared for NIOSH under contract No. 210-81-6011. NTIS No. PB84-183540.
180. SHIGETA, S., AIKAWA, H., and MISAWA, T. (1981). Effects of toluene exposure on mice fetuses. *J. Toxicol. Sci.* **6**, 254.
181. SHIGETA, S., AIKAWA, H., and MISAWA, T. (1982). Effects of maternal exposure to toluene during pregnancy on mouse embryos and fetuses. *Tokai J. Exp. Clin. Med.* **7**(2), 265-70.
182. HUDAK, A., and UNGVARY, G. (1978). Embryotoxic effects of benzene and its methyl derivatives: Toluene, xylene. *Toxicology* **11**(1), 55-63.
183. TATRAI, E., RODICS, K., and UNGVARY, G. (1980). Embryotoxic effects of simultaneously applied exposure of benzene and toluene. *Folia Morphol.(Praha)* **28**(3), 286-9.
184. UNGVARY, G., TATRAI, E., LORINCZ, M., and BARCZA, G. (1983). Combined embryotoxic action of toluene, a widely used industrial chemical, and acetylsalicylic acid (aspirin). *Teratology* **27**(2), 261-70.
185. TATRAI, E., HUDAK, A., and UNGVARY, G. (1979). Simultaneous effect on the rat liver of benzene, toluene, xylene, and CC/4. *Acta. Physiol. Acad. Sci. Hung.* **53**(2), 261.

186. GERADE, H.W. (1960). *Toxicology and Biochemistry of Aromatic Hydrocarbons*. New York: Elsevier Publishing Co., pp. 141–50.
187. ANCONA-ALAYON, A. (1975). Occupational koilonychia from organic solvents. *Contact Derm.* **1**, 367–9.
188. CTFA. (1981). Submission of unpublished data by CTFA. Skin irritation potential—Human patch test. Nail basecoat containing 33.2 percent Toluene. CTFA code no. 2-40-4.*
189. HILL TOP RESEARCH. (April 19, 1984). Submission of unpublished data by CTFA. Report of a human skin test of cumulative irritation. Nail polish containing 31.23 percent Toluene.*
190. CTFA. (1980). Submission of unpublished data by CTFA. CIR safety data test summary response form. Repeated insult patch test. Nail polish containing 33 percent Toluene. February 22. CTFA code no. 2-40-7.*
191. KLIGMAN, A.M. (1966). The identification of contact allergens by human assay. *J. Invest. Dermatol.* **47**, 393–409.
192. KLIGMAN, A.M., and EPSTEIN, W. (1975). Updating the maximization test for identifying contact allergens. *Contact Derm.* **1**, 231–9.
193. IVY RESEARCH LABORATORIES, INC. (May 7, 1984). Submission of unpublished data by CTFA. Final report on the determination of the contact-sensitizing potential of four materials by means of the maximization study. Nail polish containing 31.33 percent Toluene.*
194. CTFA. (August 1979). Submission of unpublished data by CTFA. CIR safety data test summary response form. Human patch test with nail enamel containing 30 percent Toluene.*
195. CTFA. (January 1980). Submission of unpublished data by CTFA. CIR safety data test summary response form. Human photopatch test with nail enamel containing 25 percent Toluene.*
196. FEDERAL REGISTER. (August 25, 1978). Sunscreen Drug Products for Over-The-Counter Human Drugs, pp. 38206–369.
197. WILSON, R.H. (1943). Toluene poisoning. *JAMA* **123**, 1106.
198. McLAUGHLIN, R.S. (1946). Chemical burns of the human cornea. *Am. J. Ophthalmol.* **29**, 1355–62.
199. BASS, M. (1970). Sudden sniffing death. *JAMA* **212**, 2075–9.
200. TAYLOR, G.J., and HARRIS, W.S. (1970). Glue sniffing causes heart block in mice. *Science* **170**, 866–8.
201. REINHARDT, C.F., AZAR, A., MAXFIELD, M.E., SMITH, P.E., and MULLIN, L.S. (1971). Cardiac arrhythmias and aerosol “sniffing.” *Arch. Environ. Health* **22**, 265.
202. OGATA, M., TOMOKUNI, K., and TAKATSUKA, Y. (1970). Urinary excretion of hippuric acid and m- or p-methylhippuric acid in the urine of persons exposed to vapors of toluene and m- or p-xylene as a test of exposure. *Br. J. Indust. Med.* **27**(1), 43–50.
203. GAMBERALE, F., and HULTENGREN, M. (1972). Toluene exposure. II. Psychophysiological functions. *Work Environ. Health* **9**(3), 131–9.
204. SUHR, E. (1975). Comparative investigation of the state of health of gravure printers exposed to Toluene. Gesellschaft zur Forderung des Tiefdrucks E.V. Weisbaden, Federal Republic of Germany, 92 pp.
205. AMERICAN CONFERENCE OF GOVERNMENTAL INDUSTRIAL HYGIENISTS (ACGIH). (1984–1985). TLVs: Threshold limit values for chemical substances in workroom air adopted by ACGIH for 1984–1985.



TOXICOLOGICAL REVIEW

OF

TOLUENE

(CAS No. 108-88-3)

**In Support of Summary Information on the
Integrated Risk Information System (IRIS)**

September 2005

U.S. Environmental Protection Agency
Washington D.C.

DISCLAIMER

This document has been reviewed in accordance with U. S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

CONTENTS —TOXICOLOGICAL REVIEW OF TOLUENE (CAS No. 108-88-3)

LIST OF TABLES	v
LIST OF FIGURES	vi
FREQUENTLY USED ABBREVIATIONS AND ACRONYMS	vii
FOREWORD	x
AUTHORS, CONTRIBUTORS, AND REVIEWERS	xi
1. INTRODUCTION	1
2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS	3
3. TOXICOKINETICS RELEVANT TO ASSESSMENTS	4
3.1. ABSORPTION	4
3.1.1. Oral Exposure	4
3.1.2. Inhalation Exposure	4
3.1.3. Dermal Exposure	5
3.2. DISTRIBUTION	6
3.3. METABOLISM	6
3.4. ELIMINATION	9
3.5. PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELS	10
4. HAZARD IDENTIFICATION	11
4.1. STUDIES IN HUMANS	11
4.1.1. Oral Exposure	11
4.1.2. Inhalation Exposure	12
4.1.2.1. <i>Acute and Case Studies</i>	12
4.1.2.2. <i>Pre-chronic and Chronic Studies</i>	15
4.1.2.3. <i>Cancer Studies</i>	31
4.2. PRECHRONIC AND CHRONIC STUDIES AND CANCER BIOASSAYS IN ANIMALS - ORAL AND INHALATION	32
4.2.1. Oral Exposure	32
4.2.1.1. <i>Prechronic Studies</i>	32
4.2.1.2. <i>Chronic Studies</i>	38
4.2.2. Inhalation Exposure	39
4.2.2.1. <i>Prechronic Studies</i>	39
4.2.2.2. <i>Chronic Studies</i>	42
4.3. REPRODUCTIVE/DEVELOPMENTAL STUDIES - ORAL AND INHALATION	44
4.3.1. Studies in Humans	44
4.3.2. Studies in Animals	45
4.3.2.1. <i>Oral Exposure</i>	45
4.3.2.2. <i>Inhalation Exposure</i>	47
4.4. OTHER STUDIES	51
4.4.1. Acute Toxicity Data	51

4.4.1.1. <i>Oral Exposure</i>	51
4.4.1.2. <i>Inhalation Exposure</i>	52
4.4.2. Genotoxicity	53
4.5. SYNTHESIS AND EVALUATION OF MAJOR NONCANCER EFFECTS – ORAL AND INHALATION	54
4.5.1. Oral Exposure	54
4.5.2. Inhalation Exposure	55
4.5.3. Mode of Action	57
4.6. WEIGHT-OF-EVIDENCE EVALUATION AND CANCER CHARACTERIZATION	60
4.6.1. Summary of Overall Weight-of-Evidence	60
4.6.2. Synthesis of Human, Animal, and Other Supporting Evidence	61
4.7. SUSCEPTIBLE POPULATIONS AND LIFE STAGES	62
4.7.1. Possible Childhood Susceptibility	62
4.7.2. Possible Gender Differences	63
4.7.3. Other	64
5. DOSE RESPONSE ASSESSMENTS	64
5.1. ORAL REFERENCE DOSE (RfD)	64
5.1.1. Choice of Principal Study and Critical Effect	64
5.1.2. Methods of Analysis	67
5.1.3. RfD Derivation - Including Application of Uncertainty Factors	68
5.1.4. Previous RfD Assessment	70
5.2. INHALATION REFERENCE CONCENTRATION (RfC)	70
5.2.1. Choice of Principal Study and Critical Effect	70
5.2.2. Methods of Analysis	83
5.2.3. RfC Derivation - Including Application of Uncertainty Factors	84
5.2.4. Previous RfC Assessment	86
5.3. CANCER ASSESSMENT	86
6. MAJOR CONCLUSIONS IN THE CHARACTERIZATION OF HAZARD AND DOSE RESPONSE	87
6.1. HUMAN HAZARD POTENTIAL	87
6.2. DOSE RESPONSE	89
6.2.1. Noncancer/Oral	89
6.2.2. Noncancer/Inhalation	90
6.2.3. Cancer/Oral and Inhalation	90
7. REFERENCES	91
Appendix A1. Summary of External Peer Review and Public Comments and Disposition	A1-1

Appendix A2. Summary of External Peer Review and Public Comments and Disposition	A2-1
Appendix B1. Benchmark Dose Modeling Results for the Derivation of the RfD (NTP, 1990)	B1-1
Appendix B2. Benchmark Dose Modeling Results for the Derivation of the RfD (Selected Immunotoxicity Studies)	B2-1

LIST OF TABLES

Table 1.	Selected subset of occupational studies of neurological effects from toluene inhalation	74
Table 2.	Summary of subchronic and chronic toluene inhalation studies in animals	80
Table B1-1.	Benchmark modeling summary for relative kidney weight, NTP 1990	B1-2
Table B2-1.	Results of BMDS analyses from Hsieh et al. (1989) study with maximum p for hypothesis 4, goodness of fit of means	B2-5
Table B2-2.	Results of BMDS analyses from Hsieh et al. (1989) study with minimum AIC for hypothesis 4, goodness of fit of means	B2-6
Table B2-3.	Results of BMDS analyses from Hsieh et al. (1989, 1990b) study with maximum p for hypothesis 4, goodness of fit of means	B2-7
Table B2-4.	Benchmark responses for the endpoints reported in Hsieh et al. (1989)	B2-8
Table B2-5.	Basic sensitivity analyses for BMDS results	B2-9

LIST OF FIGURES

Figure 1.	Proposed pathways for toluene metabolism	8
Figure 2.	Summary of NOAELs/LOAELs for neurological endpoints for a subset of occupational studies of chronic inhalation exposure to toluene	73

FREQUENTLY USED ABBREVIATIONS AND ACRONYMS

[³ H]TdR	[³ H]thymidine
5-HIAA	5-Hydroxyindoleacetic acid
5-HT	5-Hydroxytryptamine (serotonin)
AACCI	Alcohol intake-adjusted color confusion index
ACGIH	American Conference of Governmental Industrial Hygienists
ACTH	Adrenocorticotrophic hormone
AIC	Akaike Information Criterion
ALT	L-alanine-aminotransferase
anti-GBM	Antiglomerular basement membrane antibody
anti-LAM	Antilaminin antibody
ASPH	Association of Schools of Public Health
ATSDR	Agency for Toxic Substances and Disease Registry
BAEP	Brainstem auditory evoked potentials
BMD	Benchmark dose
BMDL	BMD lower 95% confidence limit
BMDS	Benchmark dose modeling software
BMR	Benchmark response
BTEX	Benzene, toluene, ethylbenzene, and xylenes
CAS	Chemical Abstracts Service
CASRN	Chemical Abstracts Service Registry Number
CATSYS	Computerized test system for neurotoxicity
CCI	Color confusion index
CDP	Cubic distortion-product
CH50	Number of cells necessary to lyse 50% of target cells
CHO	Chinese hamster ovary
CI	Confidence interval
CIIT	Chemical Industry Institute of Toxicology
CNS	Central Nervous System
CoA	Coenzyme A
Con A	Concanavalin A
CYP	Cytochrome P-450
DA	Dopamine
DCV	Distribution of nerve conduction velocities
DH	Dehydrogenase
DNA	Deoxyribonucleic acid
DOPAC	3,4-Dihydroxyphenylacetic acid
ECG	Electrocardiograph
ELISA	Enzyme-linked immunosorbent assay
F0	Parent generation

F1	First filial generation
F2	Second filial generation
FEP	Flash-evoked potential
FOB	Functional observation battery
GABA	γ -Aminobutyric acid
GSH	Glutathione (reduced)
HEC	Human equivalent concentration
HVA	Homovanillic acid
IARC	International Agency for Research on Cancer
IgE	Immunoglobulin E
IgG	Immunoglobulin G
IgM	Immunoglobulin M
IL-2	Interleukin-2
IRIS	Integrated Risk Information System
LOAEL	Lowest observed adverse effect level
LPS	Lipopolysaccharide
LWAE	Lifetime weighted average exposure
MCV	Maximal motor conduction velocities
MLC	Mixed lymphocyte culture
MLR	Mixed lymphocyte reponse
MRI	Magnetic resonance imaging
MTD	Maximum tolerated dose
NAG	N-Acetyl- β -D-glucosaminidase
NCEA	National Center for Environmental Assessment
NE	Nonrepinephrine
NHEERL	National Health and Environmental Effects Research Laboratory
NIOSH	National Institute of Occupational Safety and Health
NMDA	N-Methyl-D-aspartate
NOAEL	No observed adverse effect level
NRC	National Research Council
NTP	National Toxicology Program
OSHA	Occupational Safety and Health Administration
PBPK	Physiologically-Based Pharmacokinetic
PBTK	Physiologically-Based Toxicokinetic
PEL	Permissible exposure limit
PFC	Plaque-forming colony
PHA	Phytohemagglutinin
ppm	Parts per million
PUNPs	Periods of unprotected intercourse not leading to pregnancy
PVECP	Pattern visual evoked cortical potentials
PWM	Pokeweed mitogen

QA	Quality assurance
RfC	Inhalation Reference Concentration
RfD	Oral Reference Dose
RR	Relative risk
S-9	Microsomal preparation
SCE	Sister-chromatid exchanges
SCV	Sensory nerve conduction velocities
SD	Standard deviation
SDH	Succinate dehydrogenase
SE	Standard error
SGOT	Serum glutamic oxaloacetic transaminase
SIR	Standardized incidence ratio
SMR	Standardized mortality ratio
SRBC	Sheep red blood cells
SWAY	Computerized test system for neurotoxicity
TLV	Threshold limit value
TOTCI	Total confusion index
TREMOR	Computerized test system for neurotoxicity
TTP	Time to pregnancy
TUI	Time of unprotected intercourse
TWA	Time-weighted average
UCEA	University Council for Educational Administration
UF	Uncertainty factor
UF _A	Uncertainty factor, interspecies animal-to-human
UF _H	Uncertainty factor, intraspecies human-to-human
UDP	Uridine 5'-diphosphate
VEP	Visual-evoked potentials
VMA	Vanillylmandelic acid
VOCs	Volatile organic compounds
WHO	World Health Organization

FOREWORD

The purpose of this Toxicological Review is to provide scientific support and rationale for the hazard and dose-response assessment in IRIS pertaining to chronic exposure to toluene. It is not intended to be a comprehensive treatise on the chemical or toxicological nature of toluene.

In Section 6, *Major Conclusions in the Characterization of Hazard and Dose Response*, EPA has characterized its overall confidence in the quantitative and qualitative aspects of hazard and dose response by addressing knowledge gaps, uncertainties, quality of data, and scientific controversies. The discussion is intended to convey the limitations of the assessment and to aid and guide the risk assessor in the ensuing steps of the risk assessment process.

For other general information about this assessment or other questions relating to IRIS, the reader is referred to EPA's IRIS Hotline at 202-566-1676.

AUTHORS, CONTRIBUTORS, AND REVIEWERS

CHEMICAL MANAGER AND AUTHOR

Lynn Flowers, Ph.D., DABT
National Center for Environmental Assessment (NCEA)
USEPA Office of Research and Development
Washington, DC

CONTRIBUTING AUTHORS

William Boyes, Ph.D.
National Health and Environmental Effects Research Laboratory (NHEERL)
Office of Research and Development
Research Triangle Park, NC

Stiven Foster
NCEA
USEPA Office of Research and Development
Washington, DC

Martin Gehlhaus, MHS
NCEA
USEPA Office of Research and Development
Washington, DC

Karen Hogan
NCEA
USEPA Office of Research and Development
Washington, DC

Allan Marcus, Ph.D.
NCEA
USEPA Office of Research and Development
Research Triangle Park, NC

Peter McClure, Ph.D., DABT
Syracuse Research Corporation
North Syracuse, NY

Mark Osier, Ph.D.
Syracuse Research Corporation
North Syracuse, NY

Andrew Rooney, Ph.D.
NCEA
USEPA Office of Research and Development
Research Triangle Park, NC

REVIEWERS

This document and the accompanying IRIS Summary have been reviewed by EPA scientists and independent scientists external EPA. Comments from all peer reviewers were evaluated carefully and considered by the Agency during the finalization of this assessment. During the finalization process, the IRIS Program Director achieved common understanding of the assessment among the Office of Research and Development; Office of Air and Radiation; Office of Prevention, Pesticides, and Toxic Substances; Office of Solid Waste and Emergency Response; Office of Water; Office of Policy, Economics, and Innovation; Office of Children's Health Protection; Office of Environmental Information, and EPA's regional offices.

INTERNAL EPA REVIEWERS

Joyce Donohue, Ph.D.
Health and Ecological Criteria Division
Office of Water

Andrew Geller, Ph.D.
Neurotoxicology Division
NHEERL
Office of Research and Development

Elaina Kenyon, Ph.D.
Pharmacokinetics Branch
Experimental Toxicology Division
NHEERL
Office of Research and Development

EXTERNAL PEER REVIEWERS (AUGUST 2002)

Anna M. Fan, Ph.D., DABT
Office of Environmental Health Hazard Assessment
California Environmental Protection Agency

Prof. Dr. med. Diether Neubert
Institute of Clinical Pharmacology and Toxicology
Benjamin Franklin Medical Center
Free University Berlin

Alan H. Stern, Ph.D., DABT
Department of Environmental and Community Medicine
University of Medicine and Dentistry of New Jersey

Ronald W. Wood, Ph.D.
University of Rochester
School of Medicine and Dentistry

EXTERNAL PEER REVIEWERS (JANUARY 2004)

Janusz Z. Byczkowski, MSc, Ph.D., DSc, DABT
Independent Consultant/Environmental Risk Assessment Coordinator
Division of Emergency and Remedial Response
Ohio Environmental Protection Agency

Anna M. Fan, Ph.D., DABT
Office of Environmental Health Hazard Assessment
California Environmental Protection Agency

Fabriziomaria Gobba, Ph.D.
University of Modena

Steven Holladay, Ph.D.
Dept. Biomedical Sciences and Pathobiology
VA-MD Regional College of Veterinary Medicine
Virginia Polytechnic Institute and State University

Prof. Dr. med. Diether Neubert
Institute of Clinical Pharmacology and Toxicology
Benjamin Franklin Medical Center
Free University Berlin

Alan H. Stern, Ph.D., DABT
Department of Environmental and Community Medicine
University of Medicine and Dentistry of New Jersey

Ronald W. Wood, Ph.D.
University of Rochester
School of Medicine and Dentistry

Summaries of the external peer reviewers' comments and the disposition of their recommendations are in Appendix A-1 and A-2.

1. INTRODUCTION

This document presents background information and justification for the Integrated Risk Information System (IRIS) Summary of the hazard and dose-response assessment of toluene. IRIS Summaries may include an oral reference dose (RfD), inhalation reference concentration (RfC) and a carcinogenicity assessment.

The RfD and RfC provide quantitative information for use in risk assessments for health effects known or assumed to be produced through a nonlinear (possibly threshold) mode of action. The RfD is an estimate of an oral exposure for [a given duration], to the human population (including susceptible subgroups) that is likely to be without an appreciable risk of adverse health effects over a lifetime. It is derived from a statistical lower confidence limit on the benchmark dose (BMDL), a no-observed-adverse effect-level (NOAEL), a lowest-observed-adverse-effect level (LOAEL), or another suitable point of departure, with uncertainty/variability factors applied to reflect limitations of the data used. The RfD is expressed in units of mg/kg-day. The inhalation RfC is analogous to the oral RfD, but provides a continuous inhalation exposure estimate. The inhalation RfC considers toxic effects for both the respiratory system (portal-of-entry) and for effects peripheral to the respiratory system (extrarespiratory or systemic effects). It is generally expressed in units of mg/m³.

The carcinogenicity assessment provides information on the carcinogenic hazard potential of the substance in question and quantitative estimates of risk from oral and inhalation exposure. The information includes a weight-of-evidence judgment of the likelihood that the agent is a human carcinogen and the conditions under which the carcinogenic effects may be expressed. Quantitative risk estimates are presented in three ways to better facilitate their use: (1) generally, the *slope factor* is the result of application of a low-dose extrapolation procedure and is presented as the risk per mg/kg-day of oral exposure; (2) the *unit risk* is the quantitative estimate in terms of either risk per µg/L drinking water or risk per µg/m³ continuous airborne exposure; and (3) the 95% lower bound and central estimate on the estimated concentration of the chemical substance in drinking water or air that presents cancer risks of 1 in 10,000, 1 in 100,000, or 1 in 1,000,000.

Development of these hazard identification and dose-response assessments for toluene has followed the general guidelines for risk assessment as set forth by the National Research Council (1983). EPA guidelines that were used in the development of this assessment include the following: *Guidelines for Developmental Toxicity Risk Assessment* (U.S. EPA, 1991), *Guidelines for Reproductive Toxicity Risk Assessment* (U.S. EPA, 1996), *Guidelines for Neurotoxicity Risk Assessment* (U.S. EPA, 1998a), *Recommendations for and Documentation of Biological Values for Use in Risk Assessment* (U.S. EPA, 1988), (proposed) *Interim Policy for Particle Size and Limit Concentration Issues in Inhalation Toxicity* (U.S. EPA, 1994a), *Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry* (U.S. EPA, 1994b), *Use of the Benchmark Dose Approach in Health Risk Assessment* (U.S. EPA, 1995), *Science Policy Council Handbook: Peer Review* (U.S. EPA, 1998b, 2000a), *Science Policy Council Handbook: Risk Characterization* (U.S. EPA, 2000b), *Benchmark Dose Technical Guidance Document* (U.S. EPA, 2000c), *A Review of the Reference Dose and Reference Concentration Processes* (U.S. EPA, 2002), and *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005).

The literature search strategy employed for this compound was based on the CASRN and at least one common name. Any pertinent scientific information submitted by the public to the IRIS Submission Desk was also considered in the development of this document. The relevant literature was reviewed through January, 2005.

2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS

Toluene is also known as toluol, phenylmethane, methylbenzol, methylbenzene, monomethyl benzene, and methacide. Some relevant physical and chemical properties of toluene are listed below (ATSDR, 2000; NTP, 2001):

CAS Registry number: 108-88-3

Structural formula: $\text{C}_6\text{H}_5\text{CH}_3$

Molecular weight: 92.14

Density: 0.867 g/mL

Vapor pressure: 28.4 mm Hg at 25 °C

Water solubility: 0.59 mg/mL at 25 °C

Partition coefficient; Log K_{ow} : 2.72

Conversion factor: 1 ppm = 3.77 mg/m³, 1 mg/m³ = 0.265 ppm (25 °C, 760 mmHg)

At room temperature, toluene is a clear-to-amber colorless liquid with a pungent, benzene-like odor. Although it is a liquid at room temperature, toluene's low vapor pressure results in extensive volatilization. It is flammable with a flash point of 4.4 °C. Toluene is strongly reactive with a number of chemical classes, particularly nitrogen-containing compounds, and may react with some plastics. ACGIH (2000) has recommended an 8-hour time-weighted average (TWA) of 50 ppm (189 mg/m³) for toluene to protect against effects on the central nervous system. OSHA (1993) has promulgated an 8-hour permissible exposure limit (PEL) of 200 ppm (754 mg/m³).

Toluene is used as an additive in gasoline mixtures to increase octane ratings, in benzene production, and as a solvent in paints, coatings, inks, adhesives, and cleaners. Additionally, toluene is used in the production of nylon, plastics, and polyurethanes. Toluene was once used as a medicinal anthelmintic agent against roundworms and hookworms.

3. TOXICOKINETICS RELEVANT TO ASSESSMENTS

3.1. ABSORPTION

3.1.1. Oral Exposure

Studies quantifying oral absorption of toluene are limited but have demonstrated nearly 100% absorption following a single oral exposure. In volunteers exposed to an infusion of 2 mg toluene/minute for 3 hours (~5 mg/kg) via a gastric tube, absorption of toluene, measured by monitoring exhaled air for toluene and urine for toluene metabolites, was found to be complete (Baelum et al., 1993). Turkall et al. (1991) reported that greater than 99% of a single gavage dose of radiolabeled toluene in rats was eliminated in the urine or expired air, indicating near-total absorption of the exposure dose.

3.1.2. Inhalation Exposure

Several studies have examined the absorption of toluene following a single inhalation exposure in humans. Benoit et al. (1985) reported an average retention of 83% in four subjects exposed to 50 ppm (189 mg/m³) toluene for ~90 minutes. Carlsson (1982) reported an average uptake (percent of inspired air) of about 55% in male subjects exposed to 300 mg/m³ for 2 hours at rest; this value dropped to 50% during the next 2 hours of exposure at rest. When the subjects exercised, the percent uptake declined with exercise time and exercise load; the absolute uptake (in mg toluene) increased with exercise time and exercise load (due to increased pulmonary ventilation). Löf et al. (1990) reported a similar absorption percentage (~50% absorbed) in groups of 10 males exposed to 3.25 mmol/m³ (~300 mg/m³) at rest for 4 hours. In a subsequent paper, Löf et al. (1993) reported a similar absorption percentage for nine male volunteers exposed to 194 mg/m³ for 2 hours under a light workload; during the first 20 minutes relative uptake averaged 55%, then slowly fell over time to a plateau of 46% after 80 minutes (mean value 49.2%). A study by Neubert et al. (2001) found a good correlation between measured air toluene concentrations and toluene levels in the blood of rotogravure printers at the end of a 6-hour shift, though absorption itself was not quantified.

Toluene uptake by the inhalation route of exposure has been studied in experimental animals. The uptake ranged from 26 to 93% with a mean of 60% (Egle, 1976; Hobara et al., 1984; Bergman, 1979). Gospe and Al-Bayati (1994) compared oral and inhalation exposures to toluene in the rat in order to determine an appropriate dosing regimen for inhalation toxicity studies. Male F-344 rats were exposed to ^{14}C -toluene by gavage or inhalation. Oral doses of 110, 336, 741, and 911 mg/kg were administered to 82 rats, and blood toluene levels were followed for six hours. For the 120 rats in the inhalation group, three-hour exposures were given at 10, 99, 549, or 1145 ppm. Blood toluene levels were measured during the uptake (exposure) phase and for a 4-hour elimination period. The data from the two exposure methods were fitted to parametric kinetic models, and the resulting curves integrated. The authors concluded that oral dosing produces blood toluene levels that are similar to those produced by inhalation; however, the shape of the time-concentration profile differed for the two methods. Inhalation curves of concentration versus time reached asymptotic levels by one to two hours. Oral blood toluene curves reached asymptotic levels from 1.6 to 6.3 hours postexposure. This suggests a slower absorption via the oral route as the concentration increased.

3.1.3. Dermal Exposure

Toluene is absorbed through human skin slowly (Dutkiewicz and Tyras, 1968), with absorption rates ranging from 14 to 23 mg/cm²-hour. A number of other studies have demonstrated that percutaneous absorption can occur, though they did not quantitate the absorption rate. Sato and Nakajima (1978) reported that 30-minute immersion of the hands of volunteers in pure toluene resulted in a peak level of ~ 2 μmol toluene/L of blood, which was less than 25% of the blood toluene level achieved by a 2-hour inhalation exposure to 100 ppm (377 mg/m³). Similar blood concentrations were reported by Aitio et al. (1984) in three volunteers who soaked their hands in toluene for 5 minutes; however, there was considerable interindividual variability in toluene blood levels.

Exposure of nude mice, attached to respirators to prevent inhalation, to up to 3000 ppm of toluene vapor resulted in absorption through the skin (Tsuruta, 1989). Absorption varied linearly with exposure concentration and exposure time. Absorption through the shaved skin of guinea pigs (Boman et al., 1995) and rats (Morgan et al., 1991) has also been demonstrated, as evidenced by increased blood levels of toluene following dermal application. Where

comparisons were made, dermal absorption was considerably less than absorption following inhalation exposure.

3.2. DISTRIBUTION

Toluene that is absorbed into the blood is distributed throughout the body. Ameno et al. (1989) reported that, in a 51-year-old man who died from accidental oral overdose, the highest toluene concentrations (per gram tissue) were in the liver, followed by pancreas, brain, heart, blood, fat, and cerebrospinal fluid. However, Paterson and Sarvesvaran (1983) reported that a 16-year-old male who was found dead, presumably due to inhalation overdose of toluene, had greater concentrations in the brain than the liver. Takeichi et al. (1986) reported similar findings in a 20-year-old male painter who fell while working with a toluene-based paint; the greatest concentrations upon autopsy were found in the brain, followed by the liver and blood. Within the brain of a 31-year-old man who was found dead in a room full of toluene vapor, the highest concentration of toluene was in the corpus callosum, with the lowest in the caudate-putamen (Ameno et al., 1992). Thus, the available human data suggest that more toluene accumulates in the brain than in the liver following inhalation exposure, whereas following oral exposure, the liver contains the greatest concentrations of toluene.

Pyykko et al. (1977) exposed groups of rats by both the oral and inhalation routes and reported greater toluene concentrations (per gram of wet tissue) in the liver than the brain by both exposure routes. Following inhalation exposure during which dogs were allowed to rebreathe toluene, the liver and brain contained the highest levels (both ~190 µg/g tissue), with lesser levels in the kidneys (Ikeda et al., 1990). Several studies have shown relationships between blood and tissue levels of toluene, particularly for the brain (Benignus et al., 1984; Harabuchi et al., 1993). Toluene is able to cross the placenta and enter the fetus (Ghantous and Danielsson, 1986) and can be found in breast milk (Pellizzari et al., 1982).

3.3. METABOLISM

The main enzymatic pathways involved in toluene metabolism are shown in Figure 1 (Nakajima and Wang, 1994; Tassaneeyakul et al., 1996; Nakajima et al., 1997; Angerer et al., 1998; IARC, 1999). The liver is expected to be the primary site of toluene metabolism. Toluene

is metabolized by sequential hydroxylation and oxidation to benzoic acid. The conjugation of glycine with benzoic acid to form hippuric acid constitutes the major route of toluene detoxification and elimination. The initial step in toluene metabolism is transformation by cytochrome P-450 (CYP) enzymes, which occurs mainly in the liver. The most prominent of these transformations is hydroxylation of the methyl group forming benzyl alcohol. Benzyl alcohol is primarily oxidized to benzoic acid, then conjugated with glycine to form hippuric acid. A minor CYP-related pathway involves a transient epoxidation of the aromatic ring to form either *ortho*- or *para*-cresol. The cresols may undergo a variety of conjugation reactions, forming mainly sulfates and glucuronides. Glutathione conjugation may also occur resulting in S-benzylglutathione and S-benzylmercapturic acid (conjugation to benzyl alcohol), or S-*p*-toluyl glutathione and S-*p*-toluylmercapturic acid (conjugation to the epoxidated ring). A detailed description of the CYP enzymes involved in the metabolism of toluene can be found in ATSDR (2000).

Studies of urinary metabolites in toluene-exposed humans have identified hippuric acid as the major metabolite (Andersen et al., 1983; Angerer, 1979; Angerer et al., 1998; Baelum et al., 1987, 1993; Dossing et al., 1983; Inoue et al., 1986; Jonai and Sato, 1988; Kawai et al., 1992a, 1992b, 1993; Löf et al., 1990, 1993; Maestri et al., 1997; Ng et al., 1990). Minor urinary metabolites (in approximate order of decreasing abundance) include the glucuronyl conjugate of benzoic acid, the sulfate and glucuronide conjugates of *ortho*- and *para*-cresol, S-benzylmercapturic acid, and S-*p*-toluylmercapturic acid (Angerer et al., 1998; Nakajima and Wang, 1994; Nakajima et al., 1997; Tassaneeyakul et al., 1996).




Figure 1. Proposed pathways for toluene metabolism.*, **

*Proposed enzymes are noted in parentheses.

Sources: Angerer et al., 1998; ATSDR, 2000; IARC, 1999; Nakajima and Wang, 1994; Nakajima et al., 1997; Tassaneeyakul et al., 1996

**CoA = coenzyme A; CYP = cytochrome P-450; DH = dehydrogenase; GSH = glutathione; UDP = uridine 5'-diphosphate

3.4. ELIMINATION

Studies in both humans and animals have shown that the majority of toluene in the body is eliminated in the urine, mainly as metabolites (Löf et al., 1990, 1993; Turkall et al., 1991; Tardif et al., 1992, 1998). As discussed above, the primary urinary metabolite of toluene is hippuric acid, with additional metabolites (see Figure 1) resulting from minor metabolic pathways. Elimination from the blood is rapid (Sato and Nakajima, 1978; Carlsson, 1982; Löf et al., 1990, 1993) with three-phase elimination half times of 3, 40, and 738 minutes following a single inhalation exposure in humans (Löf et al., 1993). A lesser, but still significant, amount of inhaled toluene is removed in the expired air (Pellizzari et al., 1992; Monster et al., 1993). Elimination of toluene in the expired air is greatest at time points during or immediately after exposure and decreases rapidly thereafter (Benoit et al., 1985). Turkall et al. (1991) estimated that ~22% of a single oral dose is eliminated in the expired air in rats with the remainder being mainly eliminated in the urine.

Kostrzewski and Piotrowski (1991) have shown that initial elimination of toluene from blood upon termination of exposure is rapid, in the range of a few minutes. At an exposure level of 34 ppm, the blood level at 16 hr postexposure was 2% of the maximum blood level reached. Blood levels immediately after exposure reflect time-weighted average (TWA) exposure during the preceding 8 to 10 hr (Foo et al., 1988). Because of the slow release of toluene from adipose tissue (half-life of 80 hrs), blood toluene levels on Monday mornings before work or near the end of the work week were observed to correlate with exposures during the preceding week (Nise et al., 1989). This slow decline in blood toluene has been demonstrated to result in detectable levels in workers who ceased exposure 2 weeks previous to sampling (Nise and Orbaek, 1988).

Urinary hippuric acid levels have generally been used as a biomarker of exposure to toluene. However, because of its short half-life (Lowry, 1987), hippuric acid levels correlate best to acute exposure situations. Blood concentrations of toluene have been reported as the most reliable measure of toluene exposure (Kawai et al., 1993; Brugnone et al., 1995). Mizunuma et al. (1994) found blood toluene to be highly correlated to toluene in air at levels approximating 1 ppm, where hippuric acid measurements as a marker of exposure are no longer useful.

3.5. PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELS

PBPK models are available that describe the kinetics of toluene after inhalation exposure: two for humans (Fisher et al., 1997; Pierce et al., 1996, 1999) and three for rats (DeJongh and Blaauboer, 1996, 1997; Tardif et al., 1993; Van Asperen et al., 2003). These models are modifications of the standard four-compartment PBPK model developed for styrene (Ramsey and Andersen, 1984) in which

- Absorption into the lung blood is assumed to be dependent on the inhaled concentration of toxicant, the concentration of toxicant in alveolar air, blood flow to the lung, blood/air partition coefficient, and alveolar ventilation rates
- Exchange of toxicant between arterial blood and tissue compartments is flow-limited
- Changes in the amount of toxicant in three nonmetabolizing tissue compartments (adipose tissue, slowly perfused tissues, and rapidly perfused tissues) are described by mass transfer differential equations with tissue volume, blood flow through the tissue (i.e., tissue perfusion rate), arterial blood toxicant concentration, and tissue/blood partition coefficients as explanatory variables
- Changes in toxicant amount in the liver (the fourth compartment) are described by similar differential equations that additionally include a Michaelis-Menten term for overall rates of toxicant metabolism

The five-compartment human model for toluene developed by Pierce et al. (1996) includes an additional equation describing mass balance across the lung that has a single Michaelis-Menten metabolic term to represent total toluene metabolism. A five-compartment rat PBPK model developed by DeJongh and Blaauboer (1996) is similar in design to the Tardif et al. (1993) rat PBPK model except that it contains an additional nonmetabolizing compartment representing the brain. The above models have all been partially- or fully-validated using *in vivo* pharmacokinetic data in the appropriate species. Van Asperen et al. (2003) utilized a five-compartment model that also included a pulmonary blood-alveolar air gas exchange compartment to study the impact of the exposure scenario (constant vs. fluctuating) on the behavior and toxicokinetics of the rat. This analysis utilized high exposure concentrations (2700-8000 ppm toluene) for short periods of time and found the difference in toxicokinetics after

constant or fluctuating exposure at high dose levels to be small but that fluctuating exposure patterns may produce different toxic effects than continuous exposures, even when the external exposure conditions have the same time-weighted average. Another human PBPK model has been developed for volatile organic compounds that models transfer of toxicant via lactation from a mother to a nursing infant, but *in vivo* pharmacokinetic data for toluene in breast milk were not available to validate this model (Fisher et al., 1997). This model is an adaptation of the Ramsey and Andersen (1984) design with the addition of a fifth compartment, a nonmetabolizing milk compartment with a varying volume. PBPK models for the oral route of exposure and for species other than the rat are not presently available.

4. HAZARD IDENTIFICATION

4.1. STUDIES IN HUMANS

4.1.1. Oral Exposure

Reports of oral exposure to toluene in humans are limited to case reports of accidental acute ingestion. Ameno et al. (1989) reported 15 deaths by accidental oral ingestion of paint thinner containing toluene over the period from 1977 to 1986. A case report of a 51-year-old man who died approximately 30 minutes after he had ingested a large quantity of toluene was presented; the probable cause of death was severe central nervous system depression. Caravati and Bjerk (1997) reported on a case of a 46-year-old man who had ingested approximately one quart of paint thinner containing toluene. The patient presented with severe central nervous system depression, severe abdominal pain, diarrhea, and hemorrhagic gastritis. The patient recovered after 36 hours of supportive care. No reports of chronic oral exposure to toluene in humans were located.

4.1.2. Inhalation Exposure

4.1.2.1. *Acute and Case Studies*

A number of acute studies and case reports following toluene exposure are available in the literature. Many of these studies involve case reports of people who inhaled toluene for its euphoric properties. Toluene abusers who have been exposed for long periods of time exhibit a variety of neurologic manifestations, including ataxia, tremor, anosmia, sensorineural hearing loss, dementia, corticospinal tract dysfunction, abnormal brainstem auditory-evoked potentials, and epileptic seizures (Hormes et al., 1986; Lazar et al., 1983; Sasa et al., 1978; Ron, 1986; Malm and Lying-Tunell, 1980). Abnormal magnetic resonance imaging findings in toluene abusers include generalized cerebral, cerebellar, and brainstem atrophy; atrophy of the corpus callosum; loss of gray-white matter discrimination; multifocal high signal intensity in the cerebral white matter; and hypointensity of the thalami on T2-weighted images (Xiong et al., 1993; Rosenberg et al., 1988a, b). Optic neuropathies with dyschromatopsia, blindness, changes in pattern visual-evoked potentials, pendular nystagmus, ocular flutter, opsoclonus (irregular rapid eye movement), bilateral internuclear ophthalmoplegia, and retinal impairment have been reported in participants who chronically sniffed toluene or toluene-based glue (Hormes et al., 1986; Hunnewell and Miller, 1998; Kiyokawa et al., 1999; Lazar et al., 1983; Poblano et al., 1996; Sasa et al., 1978; Toyonaga et al., 1989; Ehyai and Freemon, 1983). The studies described below do not constitute a complete treatise of the available studies.

Hunnewell and Miller (1998) reported a case study where a 36-year-old chronic toluene abuser exhibited slurred speech, progressive ataxia, blurred vision, and oscillopsia (abnormal jerky eye movement). Examinations showed dysconjugate torsional nystagmus (involuntary eye movement) and bilateral internuclear ophthalmoplegia (ocular motility impairment). Magnetic resonance imaging analysis showed generalized atrophic changes of the brainstem and cerebellum and diffuse atrophy of the corpus callosum.

Kiyokawa et al. (1999) conducted an electrophysiological evaluation of the visual function of patients with toxic neuropathy caused by toluene abuse. Fifteen patients (mean age 25.6 years, eight men and seven women) were diagnosed with bilateral optic neuropathy. Pattern visual evoked cortical potentials (PVECPs) and clinical symptoms were investigated. Evoked potentials reflect the function of the nervous system. Increases in latencies can reflect deficits in

nerve conduction and are indicators of neurotoxic effects. Visual acuities at the initial visit were less than 0.1 in 5 cases and 0.1-1.0 in 10 cases. PVECPs were followed up in the 15 cases. At the first recording, PVECP were nonrecordable in both eyes of 11 cases, the P100 peak latency was prolonged in both eyes of 3 cases, and only 1 case showed a normal P100 peak latency. After treatment, visual acuities improved more than 2 lines in 6 cases, 3 of whom showed normal P100 peak latency in the PVECPs. Visual prognosis and PVECP changes were identical in both eyes of all patients. In patients with toluene optic neuropathy, the P100 peak latency of PVECP shortened as visual acuity improved. The authors concluded that PVECP abnormalities in these patients suggest that there is a severe effect on the optic nerve after prolonged exposure to toluene.

Baelum et al. (1985) investigated the effects of acute toluene exposure in 43 printers with long-term occupational exposure to a mixture of solvents, including toluene, and 43 controls with no history of exposure to solvents or other chemicals. The duration of employment for the workers ranged from 9 to 25 years. Each individual was exposed acutely to either 0 or 100 ppm (0 or 377 mg/m³) toluene during a 6.5-hour exposure period, preceded by a 1-hour acclimatization period. These subjects were then subgrouped into printers exposed to toluene (n=20), printers exposed to air (n=23), controls exposed to toluene (n=21), and controls exposed to air (n=22). All subjects carried out a battery of tests for psychometric performance, visual perception, and vigilance evaluation. Both printers and controls complained of nasal and eye irritation, unacceptable air quality, and unacceptable odor level during the toluene exposure. Signs of neurotoxicity, including moderate fatigue, sleepiness, headaches, and a feeling of intoxication, were likewise similarly reported for both groups. A significant decrease in performance was found for the pegboard visual motor function test in the exposed printers but not in the controls exposed to 100 ppm toluene. A decrease in psychometric performance, primarily in visual perception and accuracy, was observed in toluene-exposed individuals. Acute exposure to toluene resulted in a lower performance in 4/10 tests conducted, 3 of the 4 tests in which lower performance was noted evaluated visual perception. The most profound difference between subjects exposed to 100 ppm toluene and those exposed to clean air was observed in the color discrimination test; this difference was seen in both exposed vs. nonexposed printers and exposed vs. nonexposed controls.

In a later study, Baelum et al. (1990) exposed 32 males and 39 females to clean air, 100 ppm (377 mg/m³) toluene, or a varying exposure with a TWA value of 100 ppm which contained peaks of 300 ppm (1131 mg/m³) every 30 minutes for a total of 7 hours. Toluene

exposure led to significantly increased complaints about poor air quality, altered noise perception, increased irritation of the nose and lower airways, and a feeling of intoxication, as well as lower scores on a vigilance test. No differences were seen between subjects exposed to the 100 ppm exposure level compared to those who experienced peaks of 300 ppm.

Andersen et al. (1983) exposed 16 young healthy subjects to a single exposure of 0, 10, 40, or 100 ppm of toluene (0, 38, 151, or 377 mg/m³, respectively) for 6 hours under controlled conditions. Toluene exposures did not affect nasal mucus flow or lung function. At 100 ppm, but not at 10 or 40 ppm, subjects reported a subjective irritation of the eyes and nose, as well as headache, dizziness, and feelings of intoxication. In eight tests measuring visual perception, vigilance, psychomotor function, and higher cortical functions, no statistically significant differences were found as a result of toluene exposure.

Nielsen et al. (1985) investigated the renal effects of acute exposure to toluene in 43 male printing trade workers exposed to 382 mg/m³ for 6.5 hours and age-matched with 43 male controls. No significant changes in renal excretion rates of albumin and β -2-microglobulin were apparent during toluene exposure. The results indicate that in this study no causal relationship between moderate exposure to toluene and renal injury exists.

Forty-two college students (21 female and 21 male) were exposed to 0, 74 ppm (279 mg/m³), or 151 ppm (569 mg/m³) toluene for 7 hours over 3 days (Echeverria et al., 1989). Each subject received all three toluene exposure levels on different days. The odor of toluene was masked. A battery of performance tests was administered to each participant prior to starting the exposures and again at 4 and 7 hours during the exposure; the initial test served as a control for those tests performed during the exposure. A 5-10% decrement in performance was considered significant if consistent with a linear trend. Test results for visual perception differed from control values for both exposure levels. Results of a manual dexterity test differed from control values at the higher but not the lower exposure level. Psychomotor test results were unaffected by toluene exposure. Subjective symptomatology increased with exposure, with increasing numbers of complaints of eye irritation, headache, and somnolence.

Muttray et al. (1999) investigated the acute effects of high doses of toluene on color vision. Eight male printshop workers who had been working in the printing industry for 9.8 years (standard deviation [SD] 5.4) were examined before and after cleaning printing containers with pure toluene. After cleaning, concentrations of toluene in blood were between 3.61 and 7.37

mg/L. Color vision was tested with the Farnsworth panel D-15 test, the Lanthony desaturated panel D-15 test, and the Standard Pseudoisochromatic Plates part 2. Eight workers of a metal-working factory without any neurotoxic exposure were tested according to the same procedure and served as controls. Acute exposure to toluene did not cause impairment of color vision.

Malm and Lying-Tunell (1980) reported on an 18-year-old girl who had been inhaling pure toluene periodically since the age of twelve. During the last two years, she had increased her abuse to about 1 L in two weeks. She exhibited a loss of appetite, vomiting and weight loss, and, over the last week, found it increasingly difficult to walk and her speech was slurred. A neurological examination in May of 1978 revealed a broad-based ataxic and unsteady gait, decreased coordination between arms and legs, and dysarthria. She had a coarse, spontaneous downbeat nystagmus which increased during stimulation in the horizontal direction. Muscle strength, deep and superficial sensation, and deep tendon reflexes were all normal, but she had a positive Babinski sign bilaterally. Visual loss with a visual acuity of 0.4 in both eyes was also apparent, and the optic discs were pale and her color sense was defective. She was emotionally unstable, with euphoria and a lack of insight into her own condition. During the patients five weeks in the hospital her condition improved; however, when she was discharged from the hospital in July she had a slight dysarthria and an abnormal gait. Reexamination in October revealed clinical deterioration probably due to relapse. Her color sense and visual acuity were still defective. In January, the patients condition improved, with nothing abnormal following physical examination and her visual acuity had improved. The patients clinical condition reflected cerebellar-brain stem involvement, and she showed no definitive evidence of hepatic, renal, or hemopoietic damage of peripheral neuropathy. These signs and symptoms represented more chronic damage, and were not due only to repeated acute intoxications.

4.1.2.2. *Pre-chronic and Chronic Studies*

A number of subchronic and chronic human studies following toluene exposure are available. The majority of these studies are occupational studies and are described below. Studies with known co-exposure to volatile organic compounds are discussed at the end of this section.

Lee et al. (1988) investigated the prevalence of subjective symptoms of discomfort in shoemakers exposed to toluene with respect to exposure levels. The study population (193

women and 65 controls) completed a questionnaire. The exposures were reported as 8-hour TWAs, and workers were grouped in exposure categories of nonexposed, 1-50 ppm, 51-100 ppm, 101-150 ppm, and more than 151 ppm (duration of exposures was not reported). A concentration-dependent increase in prevalence was reported for 25/67 symptoms with increases in complaints over controls occurring at around 100 ppm (377 mg/m³). Similar to the Yin et al. (1987) study described later, reported symptoms included headache, sore throat, and dizziness. No objective measures of toxicity were examined. No NOAEL or LOAEL levels were identified for this study.

Orbaek and Nise (1989) examined 20 Swedish rotogravure printers compared to 72 controls for reported neurologic symptoms and alterations in psychometric test performance. The exposed workers were in two plants, with mean time-weighted exposure levels of 43 mg/m³ (11 ppm; 9 workers) and 157 mg/m³ (42 ppm; 11 workers) toluene. The groups of workers were pooled for analysis. Prior to 1980, the exposure levels had exceeded 300 mg/m³. Employment times ranged from 4 to 43 years, with a median of 29 years. Compared to the controls, the printers complained of most of the neurasthenic symptoms evaluated, including fatigue, memory loss, depression, concentration difficulty, headache, dizziness, and paresthesia. Age-adjusted test comparisons to referent performance showed significantly lower scores for the printers in the Synonyms, Benton (correct and errors), and Digit Symbol tests. However, present toluene exposure level was only weakly associated with the test results. Pooling the workers at differing exposure levels for analysis adds uncertainty as to the appropriate exposure levels associated with the responses, thus no NOAEL or LOAEL values were identified for this study.

Foo et al. (1990) conducted a cross-sectional study involving 30 exposed female workers employed at an electronic assembly plant where toluene was emitted from glue. Toluene levels reported in the study were acquired using personal sample monitoring and reported as an 8-hour TWA, although the number of samples taken and the actual sampling period were not given. The exposed and control cohorts (n=30) were matched for age, ethnicity, and use of medications. Members of these cohorts did not use alcohol and were nonsmokers. Medical histories were taken to eliminate any histories of central or peripheral nervous system disorders. The average number of years ($\pm$ SD) worked by the exposed population was 5.7 ± 3.2 and by the controls was 2.5 ± 2.7 . Personal air samplers indicated that exposed workers breathed mean toluene air levels of 88 ppm (332 mg/m³) as a TWA and control workers breathed a mean of 13 ppm (49 mg/m³) (TWA). A battery of eight neurobehavioral tests were administered to all exposed and control workers. The tests were performed midweek, before the workers reported to their stations for the

day. Group means revealed statistically significant differences in 6/8 tests, including tests measuring manual dexterity (grooved pegboard), visual scanning (trail making, visual reproduction, Benton visual retention and digit symbol), and verbal memory (digit span). When individual test results were linearly regressed against personal exposure concentrations, the slopes of the regression lines were all significantly nonzero, indicating performance was related to toluene exposure. Irritation effects were not evaluated in this study, and clinical signs or symptoms were not reported. This study identified a LOAEL of 88 ppm of toluene for neurobehavioral changes. Control workers were exposed to 13 ppm toluene.

Nakatsuka et al. (1992) investigated color vision impairment in 111 women and 63 men employed in paint production or paint application plants. The reference population included 72 women and 48 men with no known occupational exposure to solvents. Solvent exposure was characterized as being more than 90% toluene with a geometric mean concentration of 44.1 ± 3.35 (mean $\pm$ SD) ppm and 47.5 ± 3.93 ppm for men and women, respectively. Exposure duration was not reported but mean age of exposed workers was 31.4 for men and 33.1 for men and women, respectively. Effects on color vision (dyschromatopsia) were examined using Lanthony's new color test and Ishihara's color vision test. No statistical significance in the prevalence of color vision impairment in workers was found in comparison to controls. No NOAEL or LOAEL was identified but the low dose (44 ppm) was without effect.

Abbate et al. (1993) conducted examinations of neurologic effects of toluene exposure by brainstem response audiometry on 40 rotogravure printing workers who had been exposed to an average of 97 ppm (366 mg/m^3) toluene, measured in the individual work places on the day of testing, for 12-14 years and 40 matched controls. All workers had normal hearing capacity. Examinations taken at random addressing one ear of each subject determined the brainstem auditory evoked potential with 11 and 90 second stimulus repetitions per second. Statistical analysis was performed on the latencies of waves I, III, and V generated. The mean latencies in evoked potentials were significantly higher in the exposed group relative to controls for each latency interval. This study identified a LOAEL of 97 ppm for increased wave latencies for auditory-evoked brain potentials; no NOAEL was identified.

Murata et al. (1993) examined 10 rotogravure printers from Saitama and 10 controls for differences in electrocardiographic R-R intervals (CV_{RR} and $C-CV_{HF}$), the distribution of nerve conduction velocities (DCV), and the maximal motor and sensory nerve conduction velocities (MCV and SCV) in the median nerve. Toluene exposure was estimated to be 83 ppm (313

mg/m³) with a mean exposure duration of 11 years (range of 1-36). Exposed workers were matched for age but not alcohol consumption. Blood samples for toluene analysis were taken before electrophysiological testing during normal working hours, while urine samples for hippuric acid analysis were taken at 5:00 p.m. the day following electrophysiological analysis. CV_{RR} and C-CV_{HF} were significantly reduced in the toluene-exposed workers, as were MCV in the forearm and SCV in the palm. MCV in the palm and SCV in the forearm were not significantly different from controls. The electrophysiological data were not significantly correlated with blood toluene or urinary hippuric acid levels or with exposure duration. This study identified a LOAEL of 83 ppm for alterations in electrophysiological parameters; no NOAEL was identified.

Muttray et al. (1995) investigated whether toluene can cause color vision impairment. The exposed group consisted of 59 male rotogravure workers with a mean age of 36 (17 to 57 years) and a mean rotogravure employment time of 10 years (one month to 36 years). Toluene and ethanol concentrations in worker blood were measured on Monday and Friday immediately prior to the color vision testing. Some subjects possessed blood toluene levels as high as 3 mg/L. Eight subjects had blood ethanol concentrations above 25 mg/L and were excluded from the analysis. The toluene concentrations in the workers increased from Monday to Friday. Color vision testing was done prior to Monday's shift and after Friday's shift and used a self-constructed grey box with a daylight lamp. The subjects' eyes were examined separately, before shift on Monday and after shift on Friday, in the following tests: Farnsworth panel D-15, Lanthony desaturated panel D-15, Velhagen plates, and the Standard Pseudoisochromatic plates part 2. The color confusion indices were slightly lower on Friday than on Monday, and the intraindividual toluene concentrations were not related to the color confusion indices variations. Chronically-exposed workers were not compared to nonexposed controls. From these results, an influence of toluene concentration on the color confusion indices could not be shown.

Vrca et al. (1995, 1996, 1997) examined a group of 49 Croatian rotogravure printing workers relative to 59 controls for alterations in visual-evoked potentials (VEP) (Vrca et al., 1995) and changes in brainstem auditory-evoked potentials (BAEPs) (Vrca et al., 1996, 1997) as measured with a brain imager. Average length of work service for the printers and controls was 21.4 years (range 4-30, SD 7.4) and 20.6 years (range 4-32, SD 7.7), respectively. Exposure concentrations in air were not measured. Toluene in peripheral blood was measured Wednesday morning before entering the work area, while urinary levels of hippuric acid and *ortho*-cresol were determined both before and after the Wednesday work shift. Parameters of exposure were

measured in the morning in the middle of the workweek and are thought to give the best approximation for the whole workweek (WHO, 1985) because, in the case of exposure to low levels of toluene, low body accumulation occurs. The exposure levels were estimated to range from 40 to 60 ppm (151-226 mg/m³) based on the average concentration of hippuric acid in urine after the work shift. Of the three VEP waves examined (N75, N100, and N145), significant increases in amplitude were seen for all three, but no differences in time of wave onset, time of wave offset, total duration of each wave, or total duration of all waves combined were noted between the exposed and control groups (Vrca et al., 1995). Effects on BAEP waves P1 through P5 were also examined and reported in Vrca et al. (1996, 1997). A significant decrease in wave amplitude and prolongation of P1 wave latency and an increased interval of interpeak latencies (P3-P5) was found in exposed workers. There was a statistically significant correlation between latency of the waves and the length of exposure for all waves except the P2 wave (Vrca et al., 1997). Wave latency was significantly longer in exposed subjects, which, according to the authors, could account for the reduced conduction in certain segments of the visual pathway. No correlation between wave amplitude and exposure length was seen. Combined, these studies identify a LOAEL of 40-60 ppm for alterations in visual- and auditory-evoked brain potentials; no NOAEL was identified.

Boey et al. (1997) examined a group of 29 electronics workers from Singapore who were occupationally exposed to toluene for neurobehavioral changes relative to a group of 29 controls. The TWA level of toluene in air was 90.9 ppm (343 mg/m³) as assessed by passive absorption monitors on the day of testing. Mean blood concentrations of toluene at the end of the work shift were 1.25 µg/L (SD = 0.37 µg/L). Occupational exposure in this group was for an average of 4.9 years (range of 1 to 13 years; SD = 3.5 years). The controls were found to have been exposed to 12.2 ppm of toluene (46 mg/m³). Measured tests included logical memory, digit span, visual reproduction, Benton visual retention test, trail making test, symbol digit modality test, grooved pegboard test, and finger tapping tests. Performance of the exposed workers was found to be decreased in a statistically significant manner relative to controls for the digit span, visual reproduction, trail making, symbol digit modality, and grooved pegboard tests. This study identified a LOAEL of 90.9 ppm for neurobehavioral alterations; no NOAEL was identified. Control workers were exposed to 12 ppm toluene.

Morata et al. (1997) examined 124 workers at a rotogravure printing facility in Brazil for changes in hearing. No control subjects were reported. Toluene levels in the air ranged from 0.14 to 919 mg/m³ (0.04 to 243 ppm). Workers were exposed to varying levels of noise and an

organic solvent mixture of toluene, ethyl acetate, and ethanol. Exposure times ranged from 1 to 25 years with a mean of 7 years. Hippuric acid in urine was utilized to assess total toluene exposure in 109 of the workers. The workers underwent pure-tone audiometry and immittance audiometry testing. Forty-nine percent of the workers had hearing loss. While a number of other variables were considered, only the age of the subject and hippuric acid content of the urine showed significant correlations with hearing loss. The odds ratio estimates for hearing loss were 1.07 times greater for each increment of 1 year of age (95% confidence interval [95% CI] 1.03-1.11) and 1.76 times greater for each gram of hippuric acid per gram of creatinine (95% CI 1.00-2.98). No NOAEL or LOAEL was identified.

Stengel et al. (1998) assessed immunologic and early renal effects of chronic toluene exposure in a longitudinal study of 92 printers and 74 control subjects. Pre- and post-study samples of blood and urine were taken for the following measurements: immunoglobulin E (IgE), antiglomerular basement membrane (anti-GBM), and antilaminin (anti-LAM) antibodies in blood; creatinine and β 2-microglobulin in blood and urine; and microalbumin, N-acetyl- β -D-glucosaminidase (NAG), and alanine-aminopeptidase in urine. Creatinine clearance was calculated according to the Cockcroft-Gault formula. Eight-hour personal air samples were collected twice to assess present exposure to toluene. The mean exposure concentration was 50 ppm (187 mg/m³; range of 26 to 62 ppm). A job-exposure matrix was developed to estimate past cumulative exposure. The mean duration of exposure was 16.3 years (SD 13.1) and 16.9 years (SD 12.2) for exposed and control workers, respectively. Information about potential confounders was recorded by questionnaire. Multiple regression analysis was performed to study dose-effect relations adjusted for age and smoking. No relationship was observed between the markers studied and present exposure to toluene except that creatinine clearance was higher among the exposed subjects than among the controls. A dose-response relationship for the exposed group was observed between cumulative toluene exposure and both IgE and NAG excretion. No relationship was observed between hypertension and exposure, but the relationship with NAG did not persist when subjects with hypertension were excluded. Toluene exposure at 50 ppm was not related to detectable renal dysfunction. A NOAEL of 50 ppm was identified.

Zavalic et al. (1998a) examined two groups of Croatian workers occupationally exposed to toluene for effects on color vision relative to a group of unexposed controls. One exposure group (group E1) consisted of 46 workers (3 men, 43 women) employed gluing shoe soles, while the second group (group E2) consisted of 37 workers (34 men, 3 women) employed in a

rotogravure printing press. Mean exposure times were 16.21 ± 6.1 (mean $\pm$ SD) years for group E1 and 18.34 ± 6.03 years for group E2. The control group consisted of 90 workers (61 men, 29 women) who were not occupationally exposed to solvents. For all groups, smoking and alcohol consumption information was collected.

Air samples were collected for both exposure groups with stationary monitors. Median airborne toluene concentrations were 32 ppm (121 mg/m^3 ; range of 11.3-49.3 ppm) for group E1 and 132 ppm (498 mg/m^3 ; range of 66-250 ppm) for group E2. Toluene concentrations of blood samples were determined, and urine samples were analyzed for *ortho*-cresol and hippuric acid. Analysis of color vision was performed using the Lanthony D-15 desaturated panel. Results are reported as the color confusion index (CCI) or age- and alcohol intake-adjusted color confusion index (AACCI).

In the high-exposure group (group E2), there were statistically significant correlations between concentrations of toluene in the work-space air and toluene in blood, *ortho*-cresol in urine, and hippuric acid in urine. CCI scores on both Wednesday and Monday were significantly higher in group E2 (1.29 ± 0.10 [mean $\pm$ SD] and 1.30 ± 0.11 , respectively) relative to both controls (1.15 ± 0.10 and 1.14 ± 0.10 , respectively) and to group E1 (1.17 ± 0.08 and 1.18 ± 0.10 , respectively). CCI scores for group E1 were not significantly different from controls at any time examined. In all groups, including controls, a statistically significant correlation between CCI and both age and alcohol consumption was reported. CCI scores for those workers who consumed no alcoholic beverages at all were significantly greater for group E1 (1.17 ± 0.08 and 1.17 ± 0.08 , respectively) than for nonconsumers in the control group (1.13 ± 0.08 and 1.13 ± 0.09 , respectively); however, age-matching of these two subgroups was not reported. Given the dependence on age and alcohol intake, the AACCI scores are considered more relevant indicators of exposure-related color vision impairment than CCI scores.

The AACCI scores were significantly higher ($p < 0.05$) for group E2, but not group E1, compared to controls. AACCI scores for group E2 were significantly correlated with toluene in blood, toluene in air, *ortho*-cresol in urine, and hippuric acid in urine. Actual data points (or mean $\pm$ SD) for AACCI scores were not reported; the results were presented graphically. This study identified a NOAEL of 32 ppm (121 mg/m^3 ; group E1) and a LOAEL of 132 ppm (498 mg/m^3 ; group E2) for alterations in color vision in toluene-exposed workers based on AACCI scores.

Further analysis of color vision loss in the same groups of workers described above (Zavalic et al., 1998a) was carried out to compare loss in the blue-yellow and red-green ranges (Zavalic et al., 1996, 1998b,c). Zavalic et al. (1996) evaluated qualitative color vision impairment in the men from the high exposure group (E2) and controls using the Lanthony D-15 desaturated panel according to Bowman's Method. In the control group, nine (31%) group members were found to have a blue-yellow range impairment and 20 (69%) had normal color vision. In the exposed group, the blue-yellow range was impaired in 15 (37%) group members; one (2%) had a complex impairment, and 26 (63%) had normal color vision. There was no significant difference in the prevalence of impairment in the blue-yellow range between the examined groups, although the impairment in the exposed group was higher than in the control.

Zavalic et al. (1998b) evaluated qualitative color vision impairment in the E2 group and controls using the Lanthony D-15 desaturated panel. Using the Verriest classification, color vision impairment was described as type I, loss in the red-green range; type II, loss in the blue-yellow and red-green ranges; and type III, loss in the blue-yellow range. Subjects were classified as dyschromates if specific acquired loss was determined in at least one eye. Both blue-yellow and red-green color confusion were significantly increased in the exposed group compared to controls, but there was no significant difference in the prevalence of either type of color confusion.

Zavalic et al. (1998c) further evaluated qualitative color vision impairment in groups E1 and E2 and controls. Type III dyschromatopsia (see definition in study description above) was detected in all groups examined: 26.6% of the workers in the nonexposed group, 31.7% of the workers in group E1, and 50% of those in group E2. As many as 15.6% of the workers in group E2, 4.8% of those in group E1, and 1.2% of those in the nonexposed group had type II impairment. A statistically significant difference in the prevalence of total dyschromatopsia (type II + type III) was established among the three groups together ($p < 0.01$), between group E2 and E1 ($p < 0.05$), and between group E2 and the nonexposed group ($p < 0.005$), whereas no significant decrease was found between group E1 and the nonexposed group. Type III impairment was significantly correlated with age in the nonexposed group ($p < 0.01$) and group E1 ($p < 0.005$). In group E2, both type II ($p < 0.05$) and type III impairment correlated with toluene in ambient air and with duration of exposure to toluene (both $p < 0.005$). In group E2, total dyschromatopsia correlated with toluene in ambient air and in blood (both $p < 0.05$) as well as with hippuric acid in urine ($p < 0.001$).

Plenge-Bönig and Karmaus (1999) conducted a cross-sectional study of 150 male and 90 female printing industry workers in order to examine human fertility and occupational toluene exposure. The ages of the male subjects were similar to the ages of all the male employees in the participating companies, while the women subjects were younger than their counterparts in the participating companies. Face-to-face interviews were conducted in the employees homes using a modified questionnaire from the European study on infertility and subfecundity, and gathered information pertaining to history of every period that could have ended in pregnancy (this included time to pregnancy (TTP) and periods of unprotected intercourse not leading to pregnancy (PUNPs); together, the two period terms are called time of unprotected intercourse (TUI), data on pelvic inflammatory diseases, work history data, and lifestyle factors. Exposure categories corresponding to low, medium, and high exposures were developed, based on work history and exposure measurements from previous years that were conducted by industrial hygienists of the Employer's Liability Insurer. The actual level of exposure to toluene or other solvents was not determined. The TUIs for men and women were then assigned to the different exposure categories based on corresponding time windows. In partnerships with men in the study, 256 pregnancies were reported, while the women reported 174 pregnancies. In men, 162 TTPs and seven PUNPs resulted after excluding terminated pregnancies, pregnancies with missing data, and pregnancies due to failed contraception. In women, 100 pregnancies were available after incorporating exclusion criteria. An association between occupational toluene exposure and subfecundity in men and their partners was not apparent but cannot be excluded. However, a significant reduction in the fecundability of female employees in exposed areas during periods of unprotected intercourse was found.

Eller et al. (1999) reported on the neurological effects of 98 male Danish photogravure printers chronically exposed to toluene. The study population consisted of 10 lithographers, 42 typographers, 23 printing workers and 23 employees with other work functions, including blacksmiths, electricians, and executive staff/foremen. Workers were divided into three groups: no exposure to organic solvents (Group 0; n=19); those exposed to <20 ppm toluene for 1-12 years (Group 1; n=30); or those exposed for greater than 12 years (Group 2; n=49). Workers exposed for greater than 12 years may have been exposed to levels exceeding 100 ppm (377 mg/m³) for up to 27 years. Exposure levels were estimated from multiple historical measurements of ambient air, personal air, etc. The workers were examined neuropsychologically using a Cognitive Function Scanner and neurologically by computerized methods measuring coordination ability, tremor, and position stability. For the scores of self-reported symptoms, Group 0 and Group 1 were found to be similar, while Group 2 showed a

statistically significantly higher incidence of symptoms relative to controls, even after correction for age and alcohol consumption. In neurological tests, no differences between Group 1 and controls were noted. Group 2 showed a statistically significantly poorer performance relative to the other groups on 1 of 7 neurological tests and 2 of 5 sets of neuropsychological tests. The tests that were significantly altered were left-hand finger tapping, retention times in the number learning test, and total time in the Bourdon-Wiersma test. This study identified a NOAEL of 25-32 ppm and a LOAEL of >100 ppm for increases in subjective symptoms and decreased performance in neurologic tests.

Cavalleri et al. (2000) examined a cohort of 33 rubber workers (mean exposure duration, 117 months) and 16 referents for changes in color vision, as evaluated by the Lanthony D-15 desaturated panel. Urine samples were taken at the end of the day and analyzed for unmetabolized toluene. Exposure was estimated as cumulative exposure since no changes in production technology had been introduced into the factory during the past few years and no significant variation in occupational exposure to toluene was expected. An index value was calculated that was representative of the total cumulative exposure to toluene: cumulative exposure = unmetabolized toluene ($\mu\text{g/L}$) $\times$ exposure duration (months). The mean value of unmetabolized toluene was $63 \mu\text{g/L}$ ($\text{SD} = 27 \mu\text{g/L}$). On the basis of previous data (Ghittori et al., 1987), this value was calculated to correspond to an environmental level of toluene of about 42 ppm. Exposure to other solvents (i.e., n-hexane, xylene, methyl isobutyl ketone, and ethyl acetate) was monitored on several occasions, and levels were well below 1/100 of the occupational threshold limit at the time. Thus, the authors considered exposure to these solvents as nonrelevant. Exposed workers showed significant impairments in color vision, as evidenced by increases in CCI or total confusion index (TOTCI) scores, relative to control workers. However, while the indices of color vision showed linear correlations with the product of the urinary toluene and total exposure duration, airborne levels of toluene cannot be determined from the data presented in the manuscript. This study did not identify exposure levels of toluene, but correlated response with urinary toluene levels. Statistically significant effects on color vision were observed at an estimated exposure level of 42 ppm; no NOAEL was identified.

Neubert et al. (2001) and Gericke et al. (2001) reported on the health effects of toluene exposure in a controlled, multicenter, blinded field trial in German rotagravure workers. Medical examinations (inquiries on subjective symptoms and standard tests of psychophysiological and psychomotor functions) were performed on almost 1500 volunteers of whom 1290 were toluene-exposed (1178 men and 112 women) and about 200 served as controls (157 men and 37 women).

Exposure groups were further categorized into experimental groups I-IV based on blood toluene levels. The psychophysiologic and psychomotor tests used included digit span (verbal memory span), digit symbol (visuomotor performance), visual reproduction test (immediate visual memory), scales of self-feeling (self-rating of feeling), Wiener reaction test (auditory and visual vigilance), critical flicker fusion frequency test, and personality dispositions. All volunteers were from the morning shift (6 hours exposure on the day of testing). Both individual ambient air concentrations (TWA) during the work shift as well as blood toluene concentrations after the work shift were measured. For the endpoints evaluated, neither blood toluene levels of 850 to 1700 µg/L (high exposure group) nor ambient air concentrations (between 50 and 100 ppm or 188-375 mg/m³) were associated with alterations in subjective symptoms or performance on medical examinations. A statistically significant reduction in ascending flicker fusion frequency was noted at blood toluene levels approximating 81 ppm toluene exposure. A LOAEL of 81 ppm based on decreases in flicker fusion frequency and a NOAEL of 39 ppm can be identified.

Additional adverse health effects associated with chronic toluene exposure in the above field trial were evaluated by Gericke et al. (2001). Male volunteers (n=1226) were recruited, and information on exposure and medical data was compiled for 1077 men in total. Evaluations included a physical examination, standard tests of psychophysiological and psychomotor performance (identified above), self-reporting of subjective symptoms, and data on a variety of laboratory blood tests. The medical data were correlated with the length of toluene exposure and an estimate of the extent of exposure (i.e., highly exposed printers vs. other workers with negligible exposure). An examination of the influence of duration of exposure found no significant correlation to any effect that did not demonstrate a similar correlation with age, a covariable for length of employment. Volunteers reported a significant increased incidence of insomnia, dry mucus membranes, and allergies when compared to a reference population. Neither the exposure classification nor duration of exposure for the individuals reporting these symptoms were presented.

Chouaniere et al. (2002) conducted a cross-sectional study in two printing plants on 129 workers who were exposed to low levels of toluene. Ambient air sampling indicated toluene concentrations of 1 to 18 ppm in an offset printing plant and from 2 to 27 ppm in a heliogravure plant. Workers answered a self-administered questionnaire on neurotoxic symptoms and performed six psychometric tests on a computer-assisted version of battery studies. After adjustment for confounders, statistically significant changes were found in performance in Digit Span Forwards tests (decrement is 1 digit for 40 ppm; $p < 0.04$) and Digit Span Backwards tests

(decrement is 1 digit for 25 ppm; $p < 0.01$). Neurotoxic self-reported symptoms were not statistically significantly correlated with current exposure. Cumulative exposure to toluene was also estimated. No association was found between estimated cumulative exposure and either psychometric performance or neurotoxic symptoms. Statistically significant effects on psychomotor performance were observed for doses that would be equivalent to 25 and 40 ppm (exposure levels not measure but estimated based on test results). No controls were utilized in this study.

Zupanic et al. (2002) studied psychomotor performance and subjective symptoms in 278 male workers from 14 German rotogravure printing plants. The workers were divided into two exposure groups. Printers or print helpers from the rotogravure printing area with moderate exposure formed the exposed group ($n=154$). Workers with low exposure to toluene from the end processing area of the same plants were considered to be controls ($n=124$). The mean duration of employment was 15.3 years ($SD=9.7$; range of 7.5 to 23.3) for the exposed workers and 14.5 years ($SD=8.6$; range of 7.5 to 19.8) for the controls. Individual exposure to toluene was measured by two variables reflecting long-term and current exposure. Long-term exposure was calculated as lifetime weighted average exposure (LWAE). The calculation was based on individual job exposure matrices that were based on interviews related to job contact with toluene. These data were combined with historical measurements of toluene measurements in the air from five printing plants over the last three decades. The product of the different concentrations of toluene for different jobs (cumulative lifetime exposure) was weighted by the exposure time of a worker's life (LWAE). The current exposure to toluene was calculated as the mean of two to four measurements during normal working days with active sampling in the breathing zone. A mean LWAE of 45.1 ppm ($SD=16.4$; range of 34.2 to 57.9) toluene in air for exposed workers with a mean current exposure of 24.7 ppm ($SD=17.6$; range of 11.1 to 34.5) was found. Likewise, a mean LWAE of 9.3 ppm ($SD=7.6$; range of 5.8 to 10.6) toluene in air for control workers with a mean current exposure of 3.3 ppm ($SD=4.8$; range of 1.3 to 2.9) was found.

Psychomotor performance was determined by five subtests of the computer administered test battery motor performance series. The subtests included measures of steadiness, line tracing, aiming, tapping, and pegboard. The tests were performed in sequence to examine dynamic and static elements of psychomotor performance of the upper limbs. Subjective symptoms were measured with the psychological-neurological questionnaire, which includes information on psycho- and neurovegetative lability, neurological symptoms, lack of activation and motivation,

excitability, lack of concentration and memory difficulties, and special symptoms that appear in subjects exposed to neurotoxicants (alcohol intolerance and unpleasant taste and smell). No statistically significant differences were found between the two exposure groups. The results indicate no dose-response relationship for psychomotor functions and subjective symptoms among workers exposed to mean current concentrations of toluene of 3.3 and 24.7 ppm in air or mean LWAE concentrations of 9.3 and 45.1 ppm.

Schaper et al. (2003) studied the ototoxicity of occupational exposure to toluene in a longitudinal study over 5 years with four repeated examinations of 333 male workers from rotogravure printing plants. Past LWAE to toluene and noise were determined from individual work histories, and recent individual exposures were measured 10 times during the study by active sampling. The auditory thresholds were measured with pure tone audiometry. The mean LWAE exposures to toluene were 45 ppm (SD 17) for printers (high toluene exposure) and 10 ppm (SD 7.1) for end processors (low toluene exposure). The mean current exposures to toluene during the study were 26 ppm (SD 20) for printers and 3 ppm (SD 3) for end processors. Repeated measurement analyses (grouping factors: toluene intensity, exposure duration, and noise intensity) and logistic regressions did not reveal statistically significant effects of toluene intensity, of exposure duration, and of interactions between toluene intensity and noise intensity. A NOAEL of 45 ppm was identified for LWAE and 26 ppm for current exposure.

Tanaka et al. (2003) examined the health hazard, including dysfunction of the nervous system, of low toluene exposure in factories. A self-administered questionnaire was used to gather information on subjective symptoms and was provided to 20 workers in low toluene exposure factories. Environmental levels of toluene were collected using gas detection tubes and urinary samples were collected to measure hippuric acid levels in the 20 subjects. Urinary samples were collected before the workday began, after the forenoon work period, and following the end of the afternoon work period. The toluene concentration of the ambient air throughout the workday ranged between 15.3 and 31.4 ppm. The urinary hippuric acid concentration correlated with the toluene concentration in the air, and the increase in subjective symptoms and the exposure to toluene were closely associated. The prevalence rate of subjective symptoms during work and off work were 15 and 2.4 times, respectively, higher in the exposed group compared to the nonexposed group. In addition, a group of 19 off-work symptoms, which have been associated with the central nervous and autonomic nervous systems, had a prevalence rate 1.8 times higher in the exposed versus nonexposed group.

Seeber et al. (2004) conducted a follow-up study of employees from 14 magazine rotary printing plants to analyze the potential health effects of toluene exposure. A two-factor stratification was used to categorize the 333 workers based on the following factors: high toluene exposure (printing area) and low toluene exposure (end processing) and short vs. long duration of exposure. The initial 333 subjects available were reduced to 216 by the end of the evaluations for various, but not sufficiently different, reasons; however, the proportions between the groups remained stable. From the 216 workers, 192 subjects were available for all examinations and this subsample was analyzed in the repeated measurements evaluation. Toluene exposure measurements (n=2521) were collected two times per year during the workday by individual air sampling within the worker's breathing zone. An individual LWAE was calculated to provide information on past exposures. The past exposure data was developed using a job exposure matrix with four job classes and four time periods. The high and low exposure groups had a current exposure of 26 ppm and 3 ppm, respectively, and a past exposure of 45 ppm and 9 ppm, respectively. Blood ethanol levels were analyzed; only three samples yielded a concentration with the potential to cause psychological effects. Psychological (attention and memory) and psychomotor effects were analyzed. The symbol digit substitution and switching attention tests (from EURONES) and the simple reaction test (from SPES) were used to test for attention effects. For memory effects, the digit span test (from EURONES) and subtests from a screening test for psycho-organic syndrome (from Syndrom Kurztest) were used. To study psychomotor function, a computer-administered test battery for motor performance (Motorsiche Leistungsserie) with five subset tests (steadiness, line tracing, aiming, tapping, pegboard) was used. The only test that displayed an apparent exposure effect was for line tracing, in which longer error times were experienced for the high exposure group. Overall, there was no evidence of prolonged reaction times, attention deficits or memory deficits attributable to the high exposure groups.

Studies with known co-exposure to volatile organic compounds

Antti-Poika et al. (1985) examined the neurotoxic effects of toluene in 43 male rotogravure printers exposed to toluene. The mean age of workers was 41 years and the mean duration of exposure was 21.7 years (range of 11-40). A control group of 31 male offset printers of the same age with some exposure to aliphatic hydrocarbons (mineral oils and isopropyl alcohol; amounts not identified) was studied for comparison. A neurological examination, tests for autonomic nervous function, electroencephalography, psychological tests, and computerized tomography of the brain were carried out in addition to a standardized interview. Exposure levels

were evaluated for each person separately on the basis of his work history and the results of an earlier study on exposure levels at the same printing shops. Besides a thorough history of alcohol consumption, information about the printers' drinking habits was obtained from the occupational health care centers of the printing shops. The examinations found only slight abnormalities, and there were no statistically significant group differences in the prevalences of abnormalities. No correlations between the abnormalities and the exposure indices were found. This study detected no clinically significant abnormalities attributable to toluene exposure alone among workers exposed to 68-185 ppm (mean 117) of toluene.

Yin et al. (1987) reported on a cohort of over 300 Chinese solvent workers, 94 of whom (38 men, 65 women) were exposed primarily to toluene at a mean concentration of 42.8 ppm (161 mg/m³) relative to 129 controls. Workers were co-exposed to 1.3 ppm benzene. Serum lactate dehydrogenase activity was statistically significantly decreased in males and females, and leucine aminopeptidase activity was statistically significantly decreased in females only relative to controls. Levels of inorganic phosphorus in the serum of exposed male workers, but not female workers, were also significantly lower than controls. In considering the prevalence of subjective symptoms (sore throat, headache, and dizziness), workers were subgrouped into low (6-39 ppm, n=28) and high (40-123 ppm, n=29) exposure categories by the study authors. Although the prevalence of subjective symptoms was significantly higher in the exposed workers compared with the control cohort ($p<0.01$), a concentration-response relationship was not discernable among the groups. No other treatment-related effects were reported. The study was limited because the exposed and unexposed groups were not matched to controls for confounding effects (e.g., age, smoking, alcohol consumption). This study identified a LOAEL of 43 ppm for increases in subjective symptoms in exposed workers; no NOAEL was identified.

Campagna et al. (2001) examined the relationship between acquired color vision loss and exposure to toluene and total hydrocarbons among 125 male workers in France. Seventy-two toluene-exposed printers were compared with 34 workers from the same photogravure plant with ambient background exposure and with 19 workers from a bookbinding plant located in the same town (nonexposed). Duration of employment was 8 years (range of 1-35), 19 years (range of 2 to 37), and 18 years (range of 1-36) for the control, ambient exposure, and exposed groups, respectively. The mean toluene exposure level at each individual workstation was estimated from 8-hour sampling on two separate occasions. No blood or urine sampling for toluene or metabolites was conducted. The mean toluene exposure was 36 ppm (136 mg/m³; range of 5th and 95th percentiles of 13 to 79) and 8 ppm (32 mg/m³; range of 5th and 95th percentiles 4 to 20)

for the exposed group and ambient exposure group, respectively. Historic exposure data from the last 30 years were used to construct two cumulative exposure indices, one for toluene and one for total hydrocarbons. The exposed and ambient exposure groups had a history of exposure to hydrocarbon compounds in addition to toluene. Although in recent years changes in manufacturing practice resulted in almost exclusive exposure to toluene, when expressed as cumulative exposure ($\text{mg}/\text{m}^3 \times \text{years of exposure}$), toluene cumulative exposure accounted for about 72% of the total hydrocarbon exposure for the exposed group but only 56% of the total hydrocarbon exposure of the ambient exposure group (calculated from Table 2 of Campagna et al., 2001). Thus, the ambient exposure group, in particular, had a substantial proportion of their total cumulative exposure from compounds other than toluene.

Campagna et al. (2001) compared CCI values in the three groups of workers. The mean ages of the groups differed somewhat with the mean age of the exposed group being 40 years, the ambient exposure group was 43 years, and that of the nonexposed group was 37 years. CCI values are known to increase with age. The participants in the Campagna et al. (2001) study were all men. The difference of age between the nonexposed and ambient group was a mean of 6 years. The differences observed in CCI scores was a difference of 0.11 CCI, which is approximately half of the difference observed due to age by Iregren et al. (2002) for the relevant 3 and 4 decades. Thus, the differences in CCI values between the ambient exposed and nonexposed groups could perhaps be attributed to the mean age difference between these two groups. A regression analysis was conducted on the combined data sets from all groups that indicated a significant effect of age and a significant effect of toluene exposure when adjusting for age and alcohol consumption. No information was presented as to whether the ambient exposure group was statistically different from the nonexposed group when age was adjusted.

The testing of visual function was performed within the first 3 hours of a day work shift. Color vision was assessed by the Lanthony D-15 desaturated panel. Color vision loss was quantitatively established by the CCI and classified by type of acquired dyschromatopsia according to Verriest's classification. A higher proportion of participants was affected with acquired dyschromatopsia (type I, II, or III) in the exposed worker group (52% among exposed participants and 56% among the group with an ambient exposure) than in the nonexposed group (21%). CCI was positively related to current airborne toluene levels, and cumulative exposure indices for toluene and total hydrocarbons ($0.18 \leq r \leq 0.35$). The CCI values for the mean (range) of both eyes were 1.08 (1.00-1.36), 1.19 (1.00-1.72), and 1.23 (1.00-1.81). Adjustment for age, daily alcohol consumption, and duration of employment did not modify these

relationships. Odds ratios of acquired dyschromatopsia were statistically significant for current airborne toluene and toluene and total hydrocarbon past exposure (1.27 [1.02-1.58], 1.21 [1.04-1.39], 1.15 [1.02-1.31], respectively). Statistically significant effects on color vision were noted at 8 ppm.

4.1.2.3. Cancer Studies

Several occupational studies have been conducted to examine the potential for tumor formation following toluene exposure. These studies, in general, lack information regarding co-exposure to other solvents. A representative sample of these studies is presented below.

Svensson et al. (1990) examined the rates of cancer formation in 1020 past and present Swedish rotogravure printers occupationally exposed to toluene for at least 3 months between 1925 and 1985 in one of eight printing establishments. Exposure levels were estimated based on current exposure, past workplace measurements, and interviews with employees. Exposure levels were estimated to range from 350-450 ppm until 1960, after which time they steadily fell, with a median level of ~50 ppm in 1985. Workers were also exposed to benzene prior to 1960. Exposed workers showed no significant increase in general mortality or from dying of malignant disease. Statistically significant increases in tumor incidences were seen in the gastrointestinal tract and stomach, organs that displayed standardized mortality ratios (SMRs) of 2.06 (95% confidence interval [CI] 1.13-3.45) and 2.72 (95% CI 1.09-5.61), respectively, when compared to those of unexposed controls. In addition, taking all cancer incidence into account, there was a marginal excess of respiratory-tract cancers, with an SMR of 1.76 (95% CI 1.03-2.91). However, when the latter subset was limited to those employees with greater than 5 years of potential exposure or greater than 10 years latency, the resulting SMR of 1.26 (95% CI 0.57-2.38) failed to confirm an association between exposure and response.

Anttila et al. (1998) carried out a retrospective cohort analysis of 5301 Finnish workers (3922 male and 1379 female) monitored for biological markers of occupational exposure to styrene, toluene, or xylene over the period of 1973-1992. Exposure to toluene was monitored from 1978 to 1983 by analysis of toluene levels in the blood. The authors computed the indirectly standardized incidence ratios (SIR) with 95% CI with regard to age-, gender-, and period-specific incidence rates of cancer in the Finnish general population. The overall rate of cancer incidence for the total cohort was similar to that of the general population. The risk for nervous system tumors was increased at 10 years after the first personal measurement (SIR 2.80,

95% CI 1.03-6.08). No significantly increased incidence rates of cancer were associated with toluene exposure.

Wiebelt and Becker (1999) examined a cohort of 6830 German men from 11 rotogravure printing plants who were exposed to toluene between 1960 and 1992. Because of an incomplete availability of death certificates, a newly developed method was applied for the calculation of SMRs. Individual exposure measurements were not taken. Of the three main work areas, two had air concentrations generally lower than 30 ppm and one was lower than the exposure limit of 100 ppm (200 ppm before 1985). For the total cohort, only the SMR for mental disorders, primarily alcoholism, was significantly elevated (SMR 3.03, 95% CI 1.84-5.41). No significant increases in cancer mortality or cause-specific cancer mortality were reported for the entire cohort. If the workers from the work areas with the highest exposure are analyzed separately, significant increases in mortality from cancers of the bone (SMR 8.14, 95% CI 1.39-32.43) and connective tissue (SMR 6.31, 95% CI 1.23-25.95) were found.

4.2. PRECHRONIC AND CHRONIC STUDIES AND CANCER BIOASSAYS IN ANIMALS - ORAL AND INHALATION

4.2.1. Oral Exposure

4.2.1.1. *Prechronic Studies*

The oral toxicity of toluene was investigated in a subchronic gavage study in F-344 rats (NTP, 1990). Groups of 10 rats/sex/group were administered toluene in corn oil at dosage levels of 0, 312, 625, 1250, 2500, or 5000 mg/kg, 5 days/week for 13 weeks. The exposure was for 5 days/week, and therefore the dose is adjusted to a 7-day week (e.g., $312 \text{ mg/kg} \times 5/7 = 223 \text{ mg/kg-day}$) and, therefore, the doses were 0, 223, 446, 893, 1786, or 3571 mg/kg-day, respectively. All animals receiving 3571 mg/kg-day died within the first week and were eliminated from further evaluation. One female and 8 males in the 2500 mg/kg-day group died, but two of these deaths were due to gavage errors. No deaths occurred at lower doses. Several toxic effects were noted at doses greater than or equal to 1786 mg/kg-day, including prostration, hypoactivity, ataxia, piloerection, lacrimation, excessive salivation, and body tremors. A significant decrease ($p < 0.05$) in body weight for males in the 1786 mg/kg-day group was the

only significant change. There were no significant changes in hematology or urinalysis for any group of animals. Some biochemical changes, including a significant increase ($p < 0.05$) in serum glutamic oxaloacetic transaminase (SGOT) in 1786 mg/kg-day males and an increase in cholinesterase activity in females receiving 1786 mg/kg-day were noted.

There were several pathologic findings and organ weight changes in the liver, kidney, brain, and urinary bladder. In males, absolute and relative weights of both the liver and kidney were significantly increased ($p < 0.05$) at doses greater than or equal to 446 mg/kg-day. Absolute liver weights (mean $\pm$ SE) in males were $10,490 \pm 360$ (100%), $11,310 \pm 300$ (108%), $11,850 \pm 390$ (113%), $14,440 \pm 480$ (138%), and $14,130 \pm 1220$ (135%) milligrams for 0, 223, 446, 893, and 1786 mg/kg-day doses, respectively. Relative liver weights (mean $\pm$ SE) in males were 33.3 ± 0.81 (100%), 34.5 ± 0.68 (104%), 35.9 ± 0.68 (108%), 45.0 ± 1.69 (135%), and 59.4 ± 3.28 (178%) grams/100 g body weight for 0, 223, 446, 893, and 1786 mg/kg-day doses, respectively. Absolute kidney weights (mean $\pm$ SE) in males were $1,084 \pm 14$ (100%), $1,159 \pm 34$ (107%), $1,213 \pm 39$ (112%), $1,292 \pm 34$ (119%), and $1,227 \pm 114$ (113%) milligrams for 0, 223, 446, 893, and 1786 mg/kg-day doses, respectively. Relative kidney weights (mean $\pm$ SE) in males were 3.5 ± 0.06 (100%), 3.5 ± 0.07 (100%), 3.7 ± 0.06 (106%), 4.0 ± 0.06 (114%), and 5.1 ± 0.32 (146%) grams/100 g body weight for 0, 223, 446, 893, and 1786 mg/kg-day doses, respectively. In females, absolute and relative weights of the liver, kidney, and heart were all significantly increased at doses greater than or equal to 893 mg/kg-day ($p < 0.01$ for all comparisons except $p < 0.05$ for absolute kidney and heart weights at 893 mg/kg-day).

Histopathologic lesions in the liver consisted of hepatocellular hypertrophy, occurring at doses greater than 1786 mg/kg-day. Nephrosis was observed in rats that died, and damage to the tubular epithelia of the kidney occurred in terminally sacrificed rats. Kidney sections were examined in particular for the occurrence of hyaline droplets in the proximal tubules with negative findings. Histopathologic changes were also noted in the brain and urinary bladder (hemorrhages in the two highest dose groups). In the brain, mineralized foci and necrosis of neuronal cells were observed in males and females at 1786 mg/kg-day and males at 893 mg/kg-day. In the bladder, hemorrhage of the muscularis was seen in males at 1786 mg/kg-day. The NOAEL in rats for this study is 223 mg/kg-day. The LOAEL is 446 mg/kg-day based on liver and kidney weight changes in male rats.

NTP (1990) also conducted a 13-week gavage study in B6C3F1 mice, following the same regimen described above. All mice receiving 3571 mg/kg-day toluene died and were eliminated

from further assessment; 8/20 (4 males, 4 females) receiving 1786 mg/kg-day toluene also died. Clinical signs seen in animals receiving greater than or equal to 1786 mg/kg-day included subconvulsive jerking, prostration, impaired grasping reflex, bradypnea, hypothermia, ataxia, and hypoactivity. By week 13, the mean body weight of males receiving 1786 mg/kg-day was significantly ($p < 0.05$) lower than controls; no significant changes in body weights were seen in female mice. In male mice, absolute kidney weight, but not relative kidney weight, was decreased in the 1786 mg/kg-day group. Relative brain and liver weights were increased and relative right testis weight was decreased in animals exposed to 893 mg/kg-day or greater; the absolute weights for these organs were not significantly different from controls. In female mice, absolute liver weights were increased in the 223 and 1786 mg/kg-day groups, but not in the other treated groups; relative liver weights were increased in all treated groups. No other changes in organ weights were seen in female mice. Several small but statistically significant changes occurred in hematologic parameters, but did not appear to be related to toluene exposure as no dose-response was observed. No histologic changes in the liver, brain, kidneys, or bladder of any group were reported.

Hsieh et al. (1989) exposed groups of male CD-1 mice (five animals/group) to 0, 17, 80, or 405 mg toluene/L of drinking water for 4 weeks. Based on body weight and water consumption data, the authors calculated average daily toluene doses of 0, 5, 22, or 105 mg/kg-day, respectively. Animals were weighed once per week, and food and water consumption were monitored continuously. Water toluene concentration was determined daily, and fresh solutions were made every 3 days. After 28 days, the animals were sacrificed, and body, spleen, thymus, liver, and kidney weights were determined. Gross pathological examinations were performed on all mice. Total erythrocytes and leukocytes were determined, and differential leukocyte counts were measured. Splenocyte suspensions were prepared, and the lymphoproliferative responses to the T-cell mitogens phytohemagglutinin (PHA) and concanavalin A (Con A), the B-cell mitogen *E. coli* lipopolysaccharide (LPS), and the combined mitogen pokeweed mitogen (PWM) were measured. The mixed lymphocyte response (MLR) was assayed by measuring the lymphoproliferative response of splenocytes (responders) from toluene-treated or control mice after coculture with mitomycin C-treated YAC-1 mouse lymphoma cells (stimulators). Separate groups of animals were similarly exposed and were sensitized by intraperitoneal injection of sheep red blood cells (SRBC) 4 days before the end of toluene exposure. Antibody production was measured as anti-SRBC antibody and expressed as a titer. The anti-SRBC antibody in the serum collected was used in the plaque-forming colony (PFC) assay. Interleukin-2 (IL-2) production was determined in splenic lymphocytes from treated and control animals with or

without Con A (to stimulate IL-2 production). Supernatants were assayed for IL-2 content by the ability to enhance proliferation of an IL-2-dependent murine T-helper cell line (HT-2 cells).

Toluene exposure did not result in increased mortality or clinical signs of toxicity in any exposed group. No significant changes in food or water consumption were noted, and no gross lesions of the liver, kidney, spleen, heart, thymus, lung, or brain were seen in any treatment group. No changes in body weight (mean $\pm$ SE) were seen as a result of toluene exposure. Relative liver weights of toluene-exposed mice were significantly increased (5.67 ± 0.07 , 6.09 ± 0.11 , 6.32 ± 0.17 , and 6.73 ± 0.14 g/100 g body weight for 0, 5, 22, and 105 mg/kg-day treatment groups, respectively) and relative thymus weights (mean $\pm$ SE) were significantly decreased (0.19 ± 0.02 , 0.18 ± 0.01 , 0.18 ± 0.02 , and 0.13 ± 0.02 g /100 g body weight for 0, 5, 22, and 105 mg/kg-day treatment groups, respectively) at 105 mg/kg-day compared to controls, but not at lower doses. The changes in organ weights at the highest dose correspond to a 19% increase in relative liver weight and a 32% decrease in relative thymus weight compared to controls. No changes were found in relative spleen and kidney weights at any dose. No significant changes in hematological parameters or spleen cellularity were reported. Splenocyte cultures from animals in all treated groups showed statistically significant reductions in proliferative response, measured by [^{3} H]thymidine ([^{3} H]TdR) uptake, when cultured in the absence of mitogen, or in response to PWM. At the two highest dose levels, the proliferative response was also statistically significantly decreased in response to LPS, PHA, and Con A. At the highest dose the MLR was also decreased. The PFC response (i.e., the number of antibody producing cells measured as both PFC/ 10^6 spleen cells and PFC/spleen) to SRBC was statistically significantly reduced (46% and 63% of controls, respectively) as was IL-2 synthesis (45% of controls) following exposure to 105 mg/kg-day toluene. Based on a weight of evidence the 105 mg/kg-day dose group represents a LOAEL for this study for increased relative liver weight, decreased relative thymus weight, and immunological effects (e.g., reduced PFC response [$>40\%$] to SRBC); the NOAEL is 22 mg/kg-day.

In a later study, Hsieh et al. (1990a) exposed groups of male CD-1 mice for 28 days as described above. At the end of the exposure, six discrete brain sections of the animals were tested for endogenous levels of norepinephrine (NE), dopamine (DA), and serotonin (5-HT) as well as their primary metabolites. No changes in body weight or clinical signs were observed. Toluene exposure induced increases in all of the biogenic amines examined at all dose levels, with the response generally peaking in the mid-dose group and decreasing in the high-dose group. Significant increases of norepinephrine and its metabolite, 3-methoxy-4-

hydroxymandelic acid, were found in the midbrain of all dose groups. Significant increases in serotonin levels, but not its metabolite (5-hydroxyindoleacetic acid), were also seen in the midbrain of all dose groups. This study did not identify a NOAEL or LOAEL.

Hsieh et al. (1990b) exposed CD-1 mice (five/group) for 28 days to 0, 80, or 325 mg/L toluene (purity 99.7%) in a comparison study with benzene immunotoxicity. Based on previous calculations of daily intake rates from this laboratory, the doses are estimated at 0, 22, and 85 mg/kg-day, respectively. No differences were observed in kidney, liver, spleen, thymus, or whole body weights. Erythrocyte, leukocyte, and lymphocyte counts were normal. No effect was observed on the response of lymphocytes to stimulation with Con A, LPS, PHA, and PWM. Both treatment groups demonstrated a significant decrease in the incorporation of [³H]TdR in the MLR assay using mitomycin C-blocked YAC-1 cells as stimulators. Uptake of [³H]TdR was decreased by more than 50% for responder-to-stimulator ratios of 2:1 and 4:1 for both treatment groups. The report was unclear about the effect of toluene on the capacity of cytotoxic T lymphocytes to respond to YAC-1 cells. No difference in the synthesis of IL-2 was observed by measuring the uptake of [³H]TdR in Con A-stimulated T-lymphocytes. The number of PFC produced in response to SRBC was reduced in mice that received the highest dose. This reduction was observed when the results were expressed as the number of PFC per million splenocytes but was not apparent when expressed as the total number of PFC in the spleen. Toluene exposure had no effect on the production of SRBC antibodies. This study identified a LOAEL of 22 mg/kg-day for MLR to YAC-1 cells.

Hsieh et al. (1990c) reported that, under the same experimental conditions as above (Hsieh et al., 1990b), exposure to toluene did not alter tissue weights of whole brains or regional sections. Increased concentrations of biogenic amines NE, DA, 5-HT and their major metabolites (vanillylmandelic acid [VMA], DOPAC, HVA, 5-HIAA) were observed in several regions of the brain following exposure to toluene. The increase in biogenic amines was generally not dose-dependent. The dose-response was biphasic. No LOAEL or NOAEL was established.

Hsieh et al. (1991) exposed groups of male CD-1 mice (five/group) to concentrations of 0, 20, 100, or 500 mg/L toluene (purity 99.7%) for 28 days. The authors calculated the equivalent doses from measured concentrations of toluene and water intake rates to be 0, 5, 22, and 105 mg/kg-day. Increased concentrations of NE and its major metabolite, VMA, were observed in all treatment groups. The highest level of NE was observed at the medium dose (22

mg/kg). Concentrations of NE were increased by 35-63% and concentrations of VMA by 66-150%. A 2.1- to 3.8-fold increase in the measured amounts of adrenocorticotrophic hormone (ACTH) was observed with increasing dose. Corticosterone levels were elevated by more than 100% in the highest dose group at days 14 and 28. The production of IL-2 was measured by the uptake of [³H]TdR in Con A-stimulated T-lymphocytes. Splenocytes from the high dose group exhibited a 25% decrease in IL-2 production. The decreased production of IL-2 in the 105 mg/kg-day dose group represents a LOAEL for this study; the NOAEL was 22 mg/kg-day.

Burns et al. (1994) used toluene as a comparative control in an investigation of the immunotoxicity of mono-nitrotoluenes. B6C3F1 mice (4 females/group) were treated with 0 or 600 mg/kg-day toluene by oral gavage for 14 days. No differences were observed in brain, liver, lung, spleen, thymus or body weights. No gross or histopathological lesions were identified. The mean number of leukocytes was 30% lower in treated animals while the mean number of circulating reticulocytes was almost twice the mean value for the control group. The impact on DNA synthesis in bone marrow cells was inconsistent. In an initial experiment synthesis was elevated by approximately 30%, but the control group value was lower than expected. The experiment was repeated (details not provided), and no increase in bone marrow DNA synthesis was observed. Toluene did not affect the proportion of T cells in the spleen, or the number of IgM antibody forming cells produced in response to SRBC. The number of IgG antibody forming cells produced in response to SRBC was not reported to be significantly different for either number of cells per 10⁶ spleen cells or number of cells per spleen, but in both cases the mean for treated animals was approximately 40% lower than control group mean. There was no effect on the proliferative response of spleen cells to the B cell mitogen LPS or the T cell mitogen Con A. However, an increased proliferative response was observed with 5 µg/mL of the T cell mitogen PHA. The MLR to DBA/2 allogenic cells was not affected by toluene exposure.

The delayed hypersensitivity response to keyhole limpet hemocyanin was not altered by toluene exposure. Serum complement levels, expressed as the number of cells necessary to lyse 50% of target cells (CH50), were depressed by approximately 50%, but the study's authors questioned the biological significance of this change. No alterations were observed in the differential counts of peritoneal cells. There was no change in the percentage of fluorescent-labeled Covaspheres or chicken erythrocytes that were phagocytized by peritoneal adherent cells or exudate cells, respectively. A similar macrophage enzyme profile was observed in peritoneal cells for both treated and control animals. Toluene treatment did not affect the clearance of

sheep erythrocytes by the reticuloendothelial system. Natural killer cell activity was decreased slightly at the smallest effector to target cell ratio (25/1), but this effect was not seen when the mice were stimulated with poly rI:rC. Toluene treatment did not alter the poly rI:rC inducible interferon levels. Host resistance to microbial and tumor challenge was measured by administration of the infectious agent on day 15. Host resistance to challenges with *Listeria monocytogenes*, *Streptococcus pneumoniae*, *Plasmodium yoelii*, or B16F10 melanoma was not affected. A reduced incidence of tumors was observed in mice that were challenged with PYB6 fibrosarcoma. The only dose of toluene used in this study, 600 mg/kg-day, was the LOAEL. A NOAEL was not defined.

4.2.1.2. Chronic Studies

Wolf et al. (1956) administered groups of 10 female Wistar rats gavage doses of 0, 118, 354, or 590 mg/kg toluene dissolved in olive oil. A total of 138 doses were administered over 193 days, resulting in average doses of approximately 0, 84, 253, or 422 mg/kg-day. Hematologic, behavioral, gross, and histopathologic examinations were conducted with no effects reported at any dose. This study did not identify a NOAEL or LOAEL.

Maltoni et al. (1997) conducted carcinogenicity evaluations on a series of gasoline-related chemicals, including toluene. Groups of male and female Sprague-Dawley rats (40-50/sex/group) were exposed to 0 or 800 mg/kg by gavage four times per week for 104 weeks. In a separate experiment, animals were similarly exposed to 0 or 500 mg/kg toluene. Duration-adjusted doses were 286 and 457 mg/kg-day for the 500 and 800 mg/kg groups, respectively. Mean daily food and drinking water consumption as well as animal body weights were determined weekly for 13 weeks, and once every 2 weeks thereafter. Animals were permitted to live their entire life spans. Upon death, the animals were examined for gross and histologic carcinogenic organ changes. The 800-mg/kg-exposed animals, but not the 500-mg/kg-exposed animals, showed slightly reduced survival relative to controls. An increase in total tumor-bearing animals was reported but was greater in the 500-mg/kg animals than in the 800-mg/kg animals; malignant tumor frequencies for both sexes combined were 24, 69, and 44% for the 0, 500, and 800 mg/kg groups, respectively. Mammary cancers and lymphomas/leukemias in female rats were elevated in the 500-mg/kg animals but not in the 800-mg/kg animals. A small but significant increase was seen in the incidence of oral cavity tumors in 800-mg/kg male rats only.

4.2.2. Inhalation Exposure

4.2.2.1. *Prechronic Studies*

Fischer 344 rats (10/sex/group) were exposed to toluene vapors at 0, 100, 625, 1250, 2500, and 3000 ppm (0, 377, 2355, 4711, 9422, and 11,307 mg/m³, respectively) 6.5 hours/day, 5 days/week (duration-adjusted to 0, 73, 455, 911, 1823, and 2187 mg/m³, respectively) for 15 weeks (NTP, 1990). Organ weights were measured and histological examinations were performed only on controls, 2500- and 3000-ppm groups, and animals that died before the end of the study. Eight of 10 males exposed to 3000 ppm died, all during the second exposure week. No females died at any exposure level. Compared to the controls, final body weights were 15 and 25% lower in the males and 15 and 14% lower in the females of the 2500- and 3000-ppm groups, respectively. There was a concentration-related increase in the relative liver weight, significant at 1250, 2500, and 3000 ppm in males and at 2500 and 3000 ppm in females. The relative weights of the heart, lung, kidney, and right testis were also significantly elevated in the 2500- and 3000-ppm animals compared to those of the controls, although no histopathology was observed in any exposure group. Concentration-dependent increases in the severity of nephropathy was observed. No evidence was found of an increase in hyaline droplets in the proximal tubules. Other changes that usually accompany an increase in hyaline droplet formation, such as granular casts at the junction of the inner and outer stripe of the outer medulla in short-term studies, were not found. Toxic effects noted in a concurrently conducted gavage study (urinary bladder hemorrhages in the two highest exposure groups) were not noted in this subchronic inhalation study. A subsequent report on the neurologic effects did not indicate any neurobehavioral changes as a result of toluene exposure at these levels (Tilson, 1990), but details of the test results are lacking. This study identified a NOAEL of 625 ppm and a LOAEL of 1250 ppm for changes in relative liver weight in male rats.

Poon et al. (1994) exposed groups of Sprague-Dawley rats of both sexes to 0, 30, or 300 ppm toluene for 6 hours/day, 5 days/week for 4 weeks. Slightly increased relative liver weights, but not absolute liver weights, were seen in 30 ppm males but not in the 300 ppm males or at any concentration in females. Females exposed to 30 ppm, but not to 300 ppm, had a mild reduction in thyroid follicle size. A slight epithelial degeneration in the nasal conchae was noted in 30-ppm males but not in the higher-dose males or in either exposure group of female rats. A NOAEL of 300 ppm was identified.

Von Euler et al. (2000) exposed 30 male Sprague-Dawley rats to 80 ppm (302 mg/m³) toluene for 6 hours/day, 4 days/week for 4 weeks. Control animals (n=30) were similarly exposed but to air only. Four weeks after the last exposure, the animals were evaluated for neurobehavioral alterations using tests for spatial learning and memory (Morris water maze), open-field activity (open field test), and beam-walk performance. Following the conclusion of the neurobehavioral tests, animals were examined for changes in brain morphology using magnetic resonance imaging (MRI). Animals were sacrificed, and the brains were examined for effects on the dopamine D₃ receptor. No effects on body weight were seen as a result of exposure. Exposed rats did not differ significantly from controls in the results of the open field test; however, toluene exposure resulted in significant changes in the water maze test (increased time in the correct quadrant) and significantly reduced performance in the beam walk test. MRI analysis revealed a selective decrease of approximately 6% in the area of the parietal cortex, but whole brain volumes, also assessed by MRI, were not significantly different between exposed and control rats. Autoradiographic analysis revealed a 7-10% decrease of the cerebrocortical area. Autoradiography did not reveal differences in binding to the dopamine D₃ receptor as a result of toluene exposure. This study identified a LOAEL of 80 ppm (302 mg/m³) for neurobehavioral alterations 4 weeks after cessation of a 4-week exposure to toluene; no NOAEL was identified.

Pryor et al. (1984) exposed young male Fischer 344 rats to a variety of exposure concentrations and durations. Hearing loss was evaluated by a behavioral technique (avoidance response elicited to an auditory signal) or brainstem auditory-evoked responses (elicited by tone pips of differing loudness and frequency and detected by subdural scalp electrodes). Hearing loss, as measured by both techniques, was observed after as few as 2 weeks of exposure to 1000 ppm toluene for 14 hours/day. Lower concentrations of 700 ppm for 14 hours/day were without effect after 16 weeks of exposure. Intermittent exposure to 3000 ppm for 30 minutes/hour for 8 hours/day caused hearing loss within 2 weeks, whereas a similar exposure schedule for only 4 hours/day was without effect after 9 weeks. Hearing loss was irreversible, as evidenced by a failure to return to normal response after 3 months of recovery. This study identified a LOAEL of 1000 ppm for hearing loss in rats; no NOAEL was identified. It should be noted that later reports indicated the “high-frequency” hearing loss in rats studied by Pryor et al. (1984) was most likely an atypical mid-frequency hearing loss. At the time, the auditory frequency of rats, which can hear higher frequencies than humans, had not been fully characterized (Crofton et al., 1994).

McWilliams et al. (2000) exposed groups of eight guinea pigs to 0, 250, 500, or 1000 ppm (0, 943, 1885, or 3770 mg/m³) of toluene for 8 hours/day, 5 days/week for 1 week or 500 ppm (1885 mg/m³) for 4 weeks. At 1 and 4 weeks, animals were examined for changes in hearing by the cubic distortion-product (CDP) otoacoustic emission technique, while, after 4 weeks of exposure, selected animals were examined histologically for changes in the cochlea. After 1 week of exposure, a dose-related decrease in CDP amplitudes was seen, with complete recovery evident after a 3-day rest period. A 4-week exposure to 500 ppm of toluene resulted in more severe disturbances in hearing than were seen after 1 week, but the effects were still reversible. After 4 weeks of exposure, the cochlear cells located near the base (high frequency) showed a loss of succinate dehydrogenase (SDH) staining. This study identified a NOAEL of 250 ppm (943 mg/m³) and a LOAEL of 500 ppm (1885 mg/m³) for diminished startle response and histologic alterations of the cochlea in exposed guinea pigs.

The effects of inhalation exposure to toluene on pulmonary host defenses were evaluated by Aranyi et al. (1985). CD-1 mice were exposed to approximately 0, 1, 2.5, 5, 10, 25, 50, 100, 250, and 500 ppm toluene during a single 3-hour period, and two other groups were exposed to 0 and 1 ppm toluene for 5 consecutive days (3 hours/day) or 20 days (3 hours/day and 5 days/week). Immediately after toluene exposure, mice were challenged either with *Streptococcus zooepidemicus* in an infectivity assay or with S-labeled *Klebsiella pneumoniae* in a bactericidal assay. For the infectivity assay, mice were challenged with an aerosol of viable *S. zooepidemicus* and mortality was recorded over 14 days. For the bactericidal assay, bactericidal activity was recorded after a 3-hour infection period. Mortality in the streptococcus infectivity model was significantly increased at 500, 250, 100, 50, 10, 5, and 2.5 ppm with a similar but nonsignificant increase at 25 ppm. The difference in percent mortality between the toluene exposed group and the controls was 36.1, 23.0, 11.6, 18.6, 19.2, 16.9, 24.1, 13.5, and 2.3% for 500, 250, 100, 50, 25, 10, 5, 2.5, and 1 ppm, respectively. In the bactericidal activity assay, the high dose treatments groups (500, 250, and 100 ppm) were also affected and exhibited a decrease in bactericidal activity. There was no effect on bactericidal activity of a single exposure to toluene at or below 50 ppm. In the repeated dose assays, there was no effect of 5 or 20 days of exposure on *S. zooepidemicus*-induced mortality. Exposure to 1 ppm toluene for 5 days caused a decrease in bactericidal activity; however, 1 and 20 days of exposure did not. The results suggest a dose response after acute exposure with a NOAEL of 1 ppm and a LOAEL of 2.5 ppm for streptococcus infectivity. The bactericidal results indicate a NOAEL of 50 ppm and a LOAEL of 100 ppm with a single exposure, and the immunological effects of repeated, sub-chronic exposure are difficult to interpret because only a single dose was examined (1 ppm) and

it suppressed bactericidal activity after 5 days but had no effect after either 1 or 20 days. The results indicate the immunological effects may be transient, but the interpretation is confounded by the lack of a clear dose-response relationship.

4.2.2.2. Chronic Studies

In a 2-year bioassay, Fischer 344 rats (60/sex/group) were exposed to 0, 600, or 1200 ppm (0, 2261, or 4523 mg/m³, respectively) toluene vapors, 6.5 hours/day, 5 days/week (duration-adjusted to 0, 437, and 875 mg/m³, respectively) for 103 weeks (NTP, 1990; Huff, 2003). To generate toluene vapor, the liquid material was heated, and the vapor was diluted with nitrogen and mixed with the chamber ventilation air. An interim sacrifice was carried out at 15 months on control and 1200 ppm groups (10/sex/group) to conduct hematology and histopathology of the brain, liver, and kidney. Body weights were measured throughout the study. Gross necropsy and micropathology examinations were performed at the end of the study on all major organs, including the nasal passage tissues (three sections), lungs, and mainstem bronchi. Mean body weights in both exposed groups were not different from controls for either sex. Survival rate was similar for all groups. At the interim sacrifice, there was a mild to moderate degeneration in the olfactory and respiratory epithelium of the nasal cavity in 39/40 rats of the 600 and 1200 ppm groups compared with 7/20 controls. At the end of 2 years, there was a significant ($p < 0.05$) increase in the incidence of erosion of the olfactory epithelium (males: 0/50, 3/50, and 8/49; females: 2/49, 11/50, and 10/50 at 0, 600, and 1200 ppm, respectively) and of degeneration of the respiratory epithelium (males: 15/50, 37/50, and 31/49; females: 29/49, 45/50, and 39/50 at 0, 600, and 1200 ppm, respectively) in the exposed animals. The females exposed to 600 and 1200 ppm also exhibited a significant increase in inflammation of the nasal mucosa (27/49, 42/50, and 41/50 at 0, 600, and 1200 ppm, respectively) and respiratory metaplasia of the olfactory epithelium (0/49, 2/50, and 6/50 at 0, 600, and 1200 ppm, respectively). Concentration-dependent increases in the severity of nephropathy were noted. No evidence was found of an increase in hyaline droplets in the proximal tubules. In addition, other changes that usually accompany an increase in hyaline droplets, such as linear mineralization of the medulla in long-term studies, were not found. No other increases in the incidence of non-neoplastic lesions were reported in exposed rats. No neoplasms were noted in male rats, and one nasal, two kidney, and two forestomach neoplasms observed in female rats were considered not to be associated with toluene exposure. A LOAEL of 600 ppm toluene was identified for the concentration-dependent increase in erosion of the olfactory epithelium in male rats and the

degeneration of the respiratory epithelium in both sexes. A NOAEL could not be identified from this study.

B6C3F1 mice (60/sex/group) were exposed to 0, 120, 600, or 1200 ppm (0, 452, 2261, or 4523 mg/m³, respectively) toluene 6.5 hours/day, 5 days/week (duration-adjusted to 0, 87, 47, and 875 mg/m³, respectively) for 2 years (NTP, 1990; Huff, 2003). Mean body weights were not significantly different among groups and no treatment-related clinical signs were observed. Deaths (moribund and natural) occurred in all exposure groups but were not related to exposure and were not greater than the control rates. At the 15-month interim sacrifice, minimal hyperplasia in the bronchial epithelium was observed in 4/10 females exposed to 1200 ppm. At the end of the study, there was a concentration-dependent increase in the incidence of splenic pigmentation in the exposed males (9/60, 11/60, and 18/59 at 120, 600, and 1200 ppm, respectively) compared to controls (4/60). In the females, the incidence was 37/50, 33/50, 34/49, and 28/47 at 0, 120, 600, and 1200 ppm, respectively. The occurrence of endometrial hyperplasia was present in 14% of the animals exposed to the highest concentration but only in 4% in the low-exposure groups and controls. No differences were noted between the exposed and control mice of either sex in the incidence of degeneration of either the olfactory or respiratory epithelium. No other changes in the incidences of non-neoplastic or neoplastic lesions were observed in exposed mice.

Fischer 344 rats (120/sex/group) inhaled 0, 30, 100, or 300 ppm (0, 113, 377, or 1130 mg/m³, respectively) toluene (99.9% purity), 6 hours/day, 5 days/week (duration-adjusted to 0, 20, 67, or 202 mg/m³, respectively) for 106 weeks (CIIT, 1980; Gibson and Hardisty, 1983). Vapor, generated by bubbling clean air through toluene, was passed through the air supply duct and mixed with air by turbulent flow to produce the desired concentration. Hematology, blood chemistry, and urinalysis were conducted in all groups at 6 (5/sex), 17 (5/sex), 18 (10-20/sex), and 24 months (10/sex). Histopathology was evaluated only in the control and 300 ppm groups at 6 (5/sex), 12 (5/sex), and 18 months (20/sex). At 24 months, histopathological examinations were conducted in organs of all surviving animals, including the respiratory system and sections through the nasal turbinates (number not indicated). No treatment-related non-neoplastic effects were observed in the exposed animals. Although the male rats exposed to 300 ppm had a significant increase in body weight compared to controls, no concentration-response was evident. At the end of the exposure period, the female rats exposed to 100 or 300 ppm exhibited a slight but significant reduction in hematocrit; an increase in the mean corpuscular hemoglobin concentration was also noted but only in the females exposed to 300 ppm. Gross and

microscopic examination of tissues and organs identified no increase in neoplastic tissue or tumor masses among treated rats when compared with controls, though, because the study was conducted at exposure levels below the maximum tolerated dose (MTD), the significance of this finding is less clear. The highest concentration examined in this study, 300 ppm, is designated as a NOAEL for toxicity remote from the respiratory tract in rats. CIIT (1980) reported that the technical and raw data were not audited by their quality assurance group during the study period, although CIIT did later conduct a quality assessment procedure to review the data. The available pathology reports containing these data indicate that at a minimum the lower respiratory tract was examined. Communication with the testing sponsor has provided information indicating that only one section was examined from the nasal cavity of these test animals. It is not clear whether this single section would have been sufficient to elucidate the areas of lesions noted in the NTP (1990) study. The 300 ppm exposure level is identified as a NOAEL for respiratory lesions but it is uncertain whether other respiratory effects may have occurred at lower doses.

4.3. REPRODUCTIVE/DEVELOPMENTAL STUDIES - ORAL AND INHALATION

4.3.1. Studies in Humans

Toluene has been shown to cause congenital defects in infants born to mothers who abused toluene during pregnancy. Exposure levels in the available studies, if reported at all, are very high. A detailed discussion of the high-dose effects of toluene on reproduction and development is beyond the scope of this document. As an example, Hersh et al. (1985) describe clinical and morphometric characteristics common to three children whose mothers had abused toluene (but apparently not alcohol or any other substance) for a period of 4-5 years, including during their pregnancies with the affected children. Clinical findings common to these three children included microcephaly, CNS dysfunction, attention deficits, and developmental delay/mental deficiency. Phenotypic similarities included a small mid face, deep-set eyes, micrognathia (smallness of the jaws), and blunting of the fingertips.

Studies examining the effects of toluene in humans following long-term low-level exposure are less common. Plenge-Bönig and Karmaus (1999) examined the influence of toluene on the fertility of 150 male and 90 female rotogravure printing workers. The men were,

in general, exposed to higher concentrations than the women; the women worked exclusively in the stacking and bookbinding areas and received low levels of toluene exposure. Quantitative exposure levels were not reported. After adjustment for age and smoking of the partner, no association between exposure of men to toluene and fertility could be identified. In female workers, however, a significant association between toluene exposure and reduced fertility was found.

4.3.2. Studies in Animals

4.3.2.1. Oral Exposure

Kostas and Hotchin (1981) exposed 48 female Nya:NYLAR mice pre- and postnatally to toluene provided in the drinking water at concentrations of 0, 16, 80, or 400 ppm (estimated at 0, 7.2, 14.4, and 72 mg/kg-day, respectively). In this experiment mice were mated and assigned 12/group to one of the 4 exposure conditions. Exposure was begun on the first hour of the 60-hour mating period and continuing throughout pregnancy and lactation. The offspring were maintained on the same drinking water solution from weaning at 21 days of age through behavioral testing. Only six to nine pregnancies/dose group were obtained. Effects were noted in all dosed groups on rotorod (motor coordination) performance, measured at 45 to 55 days of age, but there was an inverse dose-response relationship. No effects of toluene exposure were seen on maternal fluid consumption, offspring mortality rate, development of eye or ear openings, or surface-righting response.

The National Institute of Occupational Safety and Health (NIOSH) (1983) conducted a study to determine the MTD for toluene in adult female CD-1 mice and then used the MTD to determine adverse reproductive effects in timed-pregnant (5-days) mice. Doses of 0, 735, 1470, 2945, 5890, and 8700 mg/kg toluene were administered by gavage to groups of ten female mice once per day for eight consecutive days. Animals were observed for clinical signs of toxicity (including mortality) during the first hour after each dosing, with at least one additional post-dosing observation on the day of dosing. The mice were then observed once daily until the termination of the study. Animals were weighed on the first and last day of dosing, and also on days 4 and 8 post-dosing. Decreases in body weight were less than 10% when compared to controls. All mice in the two highest dose groups (5890 and 8700 mg/kg toluene) died by dosing day 3, while two animals receiving 2945 mg/kg died on dosing day 4. None of the animals in the

two lowest groups (735 and 1470 mg/kg) died. The dose selected for the reproductive study was 2350 mg/kg. Toluene (2350 mg/kg) was administered daily to 50 timed-pregnant female mice by gavage between gestation days 7 and 14. Females were weighed on day 18 of gestation and day 3 postpartum. Beginning 18 days after mating, cages containing pregnant females were inspected daily for the presence of a litter. The number of living and dead pups was counted within 12 hours of birth and then 48 hours later. Total litter weights were also measured at these time points. Females that were mated but did not deliver a litter by the twenty-third day after mating were sacrificed and necropsied, and the status of pregnancy was determined during necropsy. During the experiment only one test animal died. There were no statistically significant differences between test and control groups in any of the categories for evaluation of reproductive toxicity. A nonstatistically significant trend towards lower weight gain in pregnancy was noted.

Gospe et al. (1994, 1996) and Gospe and Zhou (1998, 2000) conducted a series of studies examining the effects of oral prenatal toluene exposure on the development of rats. In the first experiment (Gospe et al., 1994), pregnant rats received 520 mg/kg in corn oil by gavage on gestational days 6-19, and offspring were examined on gestational day 19. Toluene exposure did not result in maternal deaths but did result in a significant decrease in weight gain (24% decrease) and a 12% reduction in food consumption, although this difference was not statistically significant. No differences in number of implantations or resorptions were found between control and exposed groups, but fetal body weights, organ weights (liver and kidney), and placenta weights were significantly decreased in toluene-exposed animals. No gross fetal malformations were reported, and histologic examination of the brain revealed no treatment-related changes. In the second experiment (Gospe et al., 1996), pregnant rats received 650 mg toluene/kg in corn oil by gavage on gestation days 6-19; both control (corn oil only) and pair-fed controls were also examined. Fetuses were delivered and examined on day 19 of gestation. Toluene exposure resulted in significantly decreased fetal weight, decreased organ weights (brain, liver, heart, and kidney), and a delay in skeletal ossification. In the third experiment (Gospe and Zhou, 1998), groups of pregnant rats were exposed by gavage to 650 mg toluene/kg in corn oil on gestation days 6-19, and offspring were examined on gestation day 19, or on postnatal days 10 or 21. Toluene exposure did not result in changes in litter size, maternal death, or maternal liver weight. At gestational day 19, fetal body weights, as well as the weights of the heart, liver, kidney, and brain, were significantly reduced in toluene-exposed animals. At postnatal day 10, the body, heart, and kidney weights of prenatally exposed rats remained significantly lower than controls, while by postnatal day 21 no differences between control and

treated animals were seen for body or organ weights. While prenatal exposure to 650 mg toluene/kg on gestational days 6-21 did not result in decreased organ or body weights on postnatal day 21, histologic analysis of the brain revealed decreased neuronal packing and alterations in the patterns of staining with bromodeoxyuridine (Gospe and Zhou, 2000), indicating compound-induced alterations in neurogenesis and neuronal migration.

4.3.2.2. Inhalation Exposure

Pregnant Wistar rats and hamsters (group size not indicated) inhaled 0 or 800 mg/m³ (212 ppm) toluene vapors 6 hours/day on gestational days 14-20 (rats) or gestational days 6-11 (hamsters) (DaSilva et al., 1990). In the exposed rats, there was a significant ($p < 0.05$) increase in the number of litters with one or more low birth weight pups (less than 4.9 g), from 10% in the controls to 54% in the exposed dams. A decrease ($p < 0.05$) in the number of live pups at birth was also noted in the litters of exposed dams. No evaluation of malformations or anomalies was performed. The neurobehavioral development of the offspring of the exposed rats was assessed using tests of spontaneous alternation, rim escape, and avoidance responses. The only effect noted in the rats, a shortened first trial latency in choosing one side of a maze, was minimal and its significance unclear. No comparable neurobehavioral deficits occurred in the exposed hamsters. The only effect noted in the neurobehavioral tests of the hamster offspring was an equivocal effect in rotarod performance. No neurobehavioral effect levels were designated from this study, although it appears that the rat developmental processes are more sensitive to toluene than those of the hamster, exhibiting adverse effects at 212 ppm. A NOAEL of 212 ppm was identified for hamsters. A LOAEL of 212 ppm was identified for rats for decreased pup weight.

Thiel and Chahoud (1997) exposed groups of pregnant Wistar rats to 0, 300, 600, 1000, or 1200 ppm (0, 1131, 2262, 3370, or 4524 mg/m³) toluene for 6 hours/day from day 9 to day 21 of pregnancy. At birth, the number of live and dead pups was determined, as well as mean pup weight per litter. Postnatal weight gain was recorded weekly, and signs of physical development, including eruption of incisors, fur development, eye opening, testes descent, and vaginal opening, were monitored. Prior to weaning, offspring were reflex tested. After weaning, offspring were tested for locomotor activity and discrimination learning. Toluene exposure did not result in changes in duration of pregnancy or litter size. At the two highest doses, toluene produced a significant decrease in maternal body weight gain and mean pup weight. High-dose offspring had a significantly increased mortality during the suckling period (postnatal days 2-21). Postnatal development (time of testes descent or vaginal opening) was accelerated at 600

ppm but was delayed at 1000 ppm of toluene or greater. No changes in neurobehavioral parameters of the exposed offspring were noted relative to controls. With the exception of an increased mean fertility in the 600 ppm group, the fertility of the offspring was not different from that of controls. A NOAEL of 600 ppm and a LOAEL of 1000 ppm were identified for decreased pup weight.

Dalgaard et al. (2001) exposed groups of pregnant Wistar rats to airborne concentrations of 0 or 1200 ppm toluene for 6 hours/day on gestational days 7 to 18 and examined male offspring on postnatal day 110 for alterations in semen quality. No effect of toluene exposure on semen quality was seen. In the same study, groups of pregnant rats were exposed to 1800 ppm toluene from gestational days 7 to 20, and the male offspring were examined on postnatal days 11, 21, or 90. Mean body weights in exposed pups were lower than controls on day 11 but were not significantly different on days 21 or 90. Absolute and relative testes weights were decreased in all age groups, but the differences were not statistically significant. Histologic analysis of the testes revealed no effects of toluene exposure in any age group. Microscopic examination of the hippocampus revealed no changes in apoptotic neurodegeneration in any group, whereas toluene induced a statistically significant increase in apoptosis in the cerebellar granule layer on postnatal day 21 but not on day 11 or 90. A NOAEL of 1800 ppm was identified.

In another study with similar exposure conditions, Hougaard et al. (1999) exposed groups of pregnant Wistar rats to airborne levels of 0 or 1800 ppm toluene for 6 hours/day from gestational days 7 to 20. Body weights of exposed offspring were lowered until postnatal day 10, after which no significant differences were noted. Neurobehavioral evaluation of the pups revealed no effects on motor function, activity level, acoustic startle, and prepulse inhibition. Measurement of hearing function revealed small but significant changes in male offspring. Significant effects on cognitive function, assessed by the Morris water maze, were reported for both sexes of offspring but were most pronounced in female offspring. A LOAEL of 1800 ppm was identified for decreases in hearing and cognitive functions. In a later study, Hougaard et al. (2003) exposed pregnant rats to toluene at 1500 ppm for 6 hours a day and/or to scheduled mild chronic stress during the last two weeks of pregnancy. The exposure to toluene resulted in reduced birth weight and lower maternal weight gain, however, the decreased maternal weight gain was enhanced by the mild chronic stress.

A subsequent study by the same investigators (Hass et al., 1999) exposed groups of pregnant Wistar rats to 0 or 1200 ppm toluene for 6 hours/day on gestational days 7 to 18. The

exposure did not cause maternal toxicity or decreased offspring viability. As was the case with the previous study, offspring body weights were significantly reduced through postnatal day 10 and were not significantly different thereafter. Alterations in Morris water maze performance were evident in female offspring at 3.5 months of age. No other changes in neurobehavioral parameters were reported. A LOAEL of 1200 ppm was identified for neurological effects.

Ungvary and Tatrai (1985) exposed New Zealand rabbits (8-10/group) to 0, 133, or 265 ppm (0, 500, or 1000 mg/m³) toluene, 24 hours/day, on gestational days 7-20, and CFLP mice (15 females/group) to 0, 133, 265, or 400 ppm (0, 500, 1000, or 1500 mg/m³) toluene, 3 x 4 hours/day, on gestational days 6-15. The control groups consisted of 115 mice and 60 rabbits. All of the female mice that were exposed to 400 ppm toluene died. In the mice exposed to 265 ppm toluene, there was an increase in fetuses with retarded weight (29%, level of retardation not indicated) and in fetuses with skeletal retardation (12%) compared to 7 and 5%, respectively, in the controls. Of the eight pregnant rabbits exposed to 265 ppm toluene, two died, four had spontaneous abortions, and the remaining two had total litter resorption. No deaths occurred in the 10 rabbits exposed to 133 ppm toluene, but 1/10 rabbits had a spontaneous abortion (as compared to 0/60 reported for the controls). No effects were seen on fetal development in rabbits exposed to 133 ppm toluene. A LOAEL of 133 ppm was identified in rabbits for spontaneous abortion. A NOAEL of 133 ppm and a LOAEL of 265 ppm were identified in mice for decreased pup weight and skeletal retardation.

Pregnant Charles River CD-1 mice (15-16 females/group) inhaled filtered air or 200 or 400 ppm (754 and 1508 mg/m³) toluene 7 hours/day on gestational days 7-16 (Courtney et al., 1986). The relative liver weight in the exposed dams was reported to be significantly lower in the two exposed groups compared to the controls, although no data were presented. A statistically significant increase in lactate dehydrogenase activity in the brain of the dams exposed to 400 ppm was also reported. The exposed pregnant mice did not exhibit any significant differences in the number of implantation sites, number of live fetuses, fetal deaths, or fetal body weight compared to the control values. A statistically significant increase over controls in the incidence (both per litter and per fetus) of enlarged renal pelvises was noted in dams exposed to 200 ppm but not to 400 ppm. A statistically significant alteration from controls in the rib profile (percentage of fetuses with one or two additional or fewer ribs) was reported for fetuses from dams exposed to 400 ppm but not to 200 ppm. A NOAEL of 200 ppm and a LOAEL of 400 ppm were identified for changes in the number of ribs in fetuses.

Ono et al. (1995) exposed groups of pregnant Sprague-Dawley rats to 0, 600, or 2000 ppm (0, 2262, or 7540 mg/m³) toluene for 6 hours/day from days 7 to 17 of gestation and examined the offspring for malformations and alterations in behavioral parameters. Prewaning tests included surface righting and negative geotaxis, while postweaning tests included an open field test (postnatal week 4), the Biel water maze (postnatal week 6), and rotorod tests (postnatal week 7). At the conclusion of the study, animals were sacrificed and examined histologically. Serum biochemistry and hematologic parameters were also evaluated. No biochemical, teratogenic, or histologic changes attributable to toluene exposure were reported in either parental rats or the offspring in the 600 ppm group. Exposure to 2000 ppm resulted in significant maternal toxicity as well as decreased body weight of offspring, increased fetal mortality, and decreased offspring weight gain. However, no differences in external, internal, or skeletal anomalies were reported for any exposure group. Similarly, no differences were found in the results of preweaning or postweaning behavioral testing at any exposure level. A NOAEL of 600 ppm and a LOAEL of 2000 ppm were identified for maternal toxicity, decreased fetal weight, and increased fetal mortality.

In a later study, Ono et al. (1996) exposed groups of male and female Sprague-Dawley rats to 0, 600, or 2000 ppm (0, 2262, or 7540 mg/m³) toluene for examination of effects on fertility. Females were exposed from 14 days before mating to day 7 of gestation, while males were exposed for 90 days, beginning at 60 days before pairing. In females exposed to 2000 ppm, increased salivation and lacrimation were noted starting 20 days after exposure. No changes were noted in mating behavior or fertility at either exposure level. Fetal mortality and the number of dams with dead fetuses were both increased in the 2000 ppm animals, but these differences were not statistically significant. In males exposed to 2000 ppm for 90 days, increased kidney weight and decreased thymus weights were observed. Additionally, high-dose males showed decreased epididymal weight, though no abnormalities of the testes or epididymis were noted histologically. Sperm counts were significantly reduced in the 2000 ppm animals. The sperm count of the 600 ppm group was slightly decreased but did not attain statistical significance. A NOAEL of 2000 ppm was identified for female rats. A NOAEL of 600 ppm and a LOAEL of 2000 ppm were identified for male rats for decreased sperm count.

A two-generation inhalation reproductive study was conducted in CD-1 rats (10-40 males/group, 20-80 females/group) (API, 1984; Roberts et al., 2003). Animals were exposed by whole-body inhalation to toluene at 0, 100, 500, or 2000 ppm (0, 377, 1885, or 7538 mg/m³, respectively) 6 hours/day, 7 days/week for 80 days and a 15-day mating period. The mated

females were then exposed to the same concentrations during days 1-20 of gestation and days 5-20 of lactation. After weaning, the pups in this generation (F1) were exposed for a minimum 80-day pre-mating period. The animals were then randomly mated with members of the same exposure group (2 females/1 male) for 15 days, during which exposure was continued, to produce the second generation (F2). Mean male body weights were slightly reduced (maximum of 10%) in the first 2 weeks of the exposure in the animals exposed to 500 and 2000 ppm, although the size of the reduction was not related to exposure. No differences were observed in male or female fertility indices, length of gestation, mean numbers of viable and nonviable pups at birth, or pup survival indices during lactation in either the F0 or F1 generation. No abnormal histopathology was noted in organs examined. A statistically significant decrease ($p < 0.05$) in weight relative to controls was observed in the first generation offspring during study weeks 19 through 36. The decrease was maintained throughout the lactation period in the F1 pups from F0 dams exposed to the highest exposure and in those from the ancillary group in which F0 females exposed to the 2000 ppm concentration were mated with males having no exposure. No additional data were available in the report about the F2 generation. A NOAEL of 600 ppm and a LOAEL of 2000 ppm were identified for decreased pup weight.

4.4. OTHER STUDIES

4.4.1. Acute Toxicity Data

4.4.1.1. Oral Exposure

Mehta et al. (1998) exposed groups of male and female Sprague-Dawley rats to a single gavage dose of 0, 3, 4.5, or 6 mL toluene/kg (0, 2600, 3900, or 5200 mg/kg, respectively). On days 1 (2-3 hours after exposure), 7, and 14 postexposure, the animal body weights were recorded, and a functional observation battery (FOB) was conducted to detect neurobehavioral changes. A significant, dose-dependent decrease in body weight occurred at day 7 for male rats. Decreases in body weight gain were noted in male rats at 14 days and female rats at 7 days, but the differences were not statistically significant. On day 1, but not on days 7 and 14, toluene-treated rats of both sexes exhibited a dose-dependent increase in abnormal gait. The open-field rearing scores were lower for all groups of both sexes at day 1 only, though only achieved statistical significance in high-dose females. Horizontal motor activities were significantly lower

in both sexes at all dose levels on day 1. The values remained lower in all treated female groups and in the 2600 and 3900 mg/kg male rats on day 7 and female rats on day 14. Rats of both sexes showed increased incidences of lacrimation and/or salivation on day 1 only. The effect was more pronounced in females.

Dyer et al. (1988) exposed groups of male Long-Evans rats to a single gavage dose of 0, 250, 500, or 1000 mg toluene/kg in corn oil. Flash-evoked potential (FEP) tests were administered 45 minutes later as a test of the ability of the nervous system to process visual information. Toluene exposure resulted in a significant decrease of the N3 peak of the FEP for all dose groups, though the decrease was not dose-related. In the same study, rats were exposed to 500 mg/kg and FEP was examined at 4, 8, 16, and 30 hours postexposure. Depression of the N3 peak remained at 8 hours postexposure, but by 16 hours recovery appeared complete.

4.4.1.2. *Inhalation Exposure*

A number of acute animal studies have examined the neurological effects of inhaled toluene; these studies generally reported impaired response in neurologic examinations. For example, Rebert et al. (1989a,b) reported abnormal flash-evoked potentials in rats exposed to a single inhalation exposure of 500-16,000 ppm toluene. Lataye et al. (2003) tested cochlear function in rats and guinea pigs following exposure to 600 ppm toluene for 5 days and reported severe disruption of auditory function and cochlear pathology in rats but no observable effects in guinea pigs. Wood et al. (1983) exposed rats to toluene levels up to 3000 ppm for 4 hours prior to behavioral evaluation and reported that toluene reduced performance in behavioral tests, particularly at the 1780 and 3000 ppm exposure levels. Wood and Colotla (1990) reported a biphasic response in mice exposed to toluene for 1 hour. An increase in activity was seen at concentrations up to 1000 ppm, beyond which decreased activity was seen. Similar results were reported by Wood and Cox (1995), with rats exposed at concentrations up to 1000 ppm showing progressive increases in activity, with decreasing activities at higher concentrations up to and including 3000 ppm.

4.4.2. Genotoxicity

Toluene has tested negative for reverse mutation in *Salmonella typhimurium*, both with and without a liver S-9 activating system (Mortelmans and Riccio, 1980; Nestmann et al., 1980; Bos et al., 1981; Litton Bionetics, Inc., 1981; Connor et al., 1985; NTP, 1990; Huff, 2003). Toluene also tested negative in the *umu* test in *S. typhimurium* (Nakamura et al., 1987) and was negative for reverse mutation in *E. coli* (Fluck et al., 1976). NTP (1990) reported no increase in sister-chromatid exchanges (SCE) or chromosomal aberrations in Chinese hamster ovary cells exposed to toluene. Available studies (Gerner-Smidt and Friedrich, 1978; Richer et al., 1993) have reported no increase in SCE in human lymphocytes exposed *in vitro* to toluene, even at concentrations that inhibited cellular growth.

Dobrokhotov and Enikeev (1977) exposed male rats (strain not specified) to 610 mg/m³ toluene for 4 hours/day for 4 months, reporting a reversible increase in chromosomal gaps and breaks in isolated bone marrow cells. Mice exposed to toluene at concentrations of 100 or 400 ppm for 6 hours/day, 5 days/week for 8 weeks showed no increase in dominant lethal mutations (measured as pre- or post-implantation embryo loss) relative to controls (API, 1981). BDF₁ mice exposed to 500 ppm toluene for 6 hours/day, 5 days/week for up to 8 weeks showed no increase in DNA damage, assessed by starch gel electrophoresis, relative to controls (Plappert et al., 1994).

Tokunaga et al. (2003) used male Wister rats to investigate the effect of toluene inhalation on oxidative damage in rat organs. The rats were exposed to 1500 ppm for four hours a day over 7 days, and oxidative DNA damage, lipid peroxidase, and superoxide dismutase were examined. 8-Hydroxy-2'-deoxyguanosine immunoreactivity, a marker for oxidative DNA damage, increased in the rat lung, kidney, and liver. Superoxide dismutase immunoreactivity increased in the lung, liver, and kidney, however, the amount of lipid peroxidase in the organs did not change.

The majority of studies in toluene-exposed workers (Forni et al., 1971; Funes-Craviota et al., 1977; Maki-Paakkanen et al., 1980) have reported no differences in chromosomal aberrations between control subjects and toluene-exposed workers. Similarly, humans exposed to toluene have not generally demonstrated increases in SCE (Funes-Craviota et al., 1977; Haglund et al., 1980; Maki-Paakkanen et al., 1980; Richer et al., 1993), cell cycle delay (Richer et al., 1993), or DNA damage as indicated by Comet assay (Pitarque et al., 1999). However, a few studies of

exposed workers (Bauchinger et al., 1982; Nise et al., 1991; Hammer, 2002) have found increases in chromosomal breaks, exchanges, and/or gaps relative to controls. Pitarque et al. (2002), in a population of shoe factory workers exposed to solvents (including toluene, gasoline, and acetone), found an increase in micronuclei, but not sister chromatid exchanges, in cultured peripheral lymphocytes. However, the chemical exposure responsible for the increase in micronuclei could not be identified with any certainty (Pitarque et al., 2002). Other studies (Schmid et al., 1985; Pelclova et al., 1990) have reported genotoxic changes in toluene-exposed workers, but the changes have either been reversible or they could not be directly attributed to toluene exposure due to confounding factors.

4.5. SYNTHESIS AND EVALUATION OF MAJOR NONCANCER EFFECTS – ORAL AND INHALATION

4.5.1. Oral Exposure

Published toxicity studies of oral exposure to toluene in humans are limited to case reports of acute oral overdoses (Ameno et al., 1989; Caravati and Bjerk, 1997). Clinical effects in these cases have included central nervous system depression, severe abdominal pain, diarrhea, and hemorrhagic gastritis. Chronic toxicity studies of oral toluene exposure in animals are not available. Maltoni et al. (1997) conducted a 2-year gavage study of toluene in rats; however, only carcinogenic endpoints were reported. NTP (1990) conducted a 13-week gavage study of toluene in F-344 rats and B6C3F1 mice. In rats, which were more sensitive to toluene than mice, effects reported were in the kidney and liver, with organ weight changes at the low doses accompanied by nephrosis at higher doses with no evidence of hyaline droplet formation. At higher exposure levels an increased incidence of rats with mineralized foci and necrosis of normal brain cells was also observed; this effect was not noted in mice at any exposure level (NTP, 1990). Hsieh et al. (1990 a,c) exposed CD-1 mice to toluene in drinking water for 28 days, and at 5 mg/kg-day significant changes in brain neurotransmitter levels were reported. Neurotoxicity studies from oral exposure to toluene have not been performed.

The immunotoxicity of toluene has been studied by several laboratories (Hsieh et al., 1989, 1990b, 1991; Burns et al., 1994) for purposes of comparison to benzene and nitrotoluenes (known immunotoxicants). Immunosuppressant effects from toluene exposure have been

demonstrated in *in vivo* and *ex vivo* assays. Host resistance assays by Burns et al. (1994) indicate a lack of immunotoxic response when animals treated with toluene are challenged. Host resistance to challenges with *Listeria monocytogenes*, *Streptococcus pneumoniae*, *Plasmodium yoelii*, or B16F10 melanoma was not affected at a dose of 600 mg/kg-day for 14 days. In addition, a reduced incidence of tumors was observed in mice that were challenged with PYB6 fibrosarcoma.

4.5.2. Inhalation Exposure

There are numerous occupational studies and case reports from inhalation exposure to toluene available in the literature. Many studies have been published examining neurological endpoints resulting from repeated exposure in occupationally exposed workers. Results from these studies suggest that neurologic effects are the most sensitive endpoint following inhalation exposure to toluene. Two of the most studied endpoints at lower exposure levels include color vision deficits and hearing loss.

The most compelling evidence for the ability of repeated toluene inhalation exposure to produce persistent neurologic effects comes from case reports of toluene abusers, who are generally exposed to concentrations in the range of 1000-10,000 ppm. MRI examinations of the brains of solvent abusers (Filley et al., 1990; Rosenberg et al., 1988a,b) suggest a preferential atrophy in lipid-rich regions of the brain. Rosenberg et al. (1988a,b) found MRI evidence of diffuse central nervous system demyelination in 6 toluene abusers with clinically obvious neurological impairment, whereas Filley et al. (1990) noted that the degree of MRI-detected white matter abnormality in 14 solvent abusers was correlated with neurological impairment. The observed changes in MRI signals may be related to lipid compositional changes in the white matter, since these regions are more lipid-rich than gray matter (Ameno et al., 1992).

There is evidence that exposure to toluene results in both transient and persistent effects on neurologic endpoints. For example, Baelum et al. (1985) reported that the neurologic responses, including altered color vision, of rotogravure printers (average long-term toluene exposure of 9 to 25 years) exposed to a single 6.5-hour exposure of 100 ppm toluene did not differ from a control group that had not been previously exposed to toluene, suggesting that the acute effects of toluene on color vision were transient rather than being dependent on previous exposure history. In contrast, Zavalic et al. (1998b) reported that analysis of color vision scores

in toluene-exposed workers on Wednesday did not differ from the scores in the same workers on Monday after at least 48 hours without exposure, suggesting that the effect was persistent. Similarly, McWilliams et al. (2000) reported that guinea pigs exposed to 500 ppm toluene for up to 4 weeks showed a reversible hearing loss, while Pryor et al. (1984) reported that hearing loss in male rats exposed to 1000 ppm toluene or greater for up to 2 weeks was still present after a 3-month recovery period.

Animal data have also suggested that respiratory tract irritation, particularly in the nasal cavity, is a sensitive effect of toluene. However, the primary study that reported this effect (NTP, 1990) only examined concentrations of 600 ppm and greater. Lifetime chronic (CIIT, 1980) and 28-day subchronic (Poon et al., 1994) studies have examined exposed rats for changes in the nasal epithelium following exposure to 300 ppm toluene, and both failed to report a treatment-related effect. Available data from acutely exposed humans demonstrates that nasal or ocular irritation is not reported by subjects until the airborne toluene concentration reaches 100 ppm (Echeverria et al., 1989; Andersen et al., 1983), while subtle neurologic changes may be noted at lower concentrations. One study in animals has reported persistent neurobehavioral effects at concentrations known to cause similar effects in humans. Von Euler et al. (2000) reported diminished performance in the water maze test in rats 4 weeks after exposure to 80 ppm toluene. Benignus et al. (1998) address the issue of apparent rat-human sensitivity differences to toluene exposure. After using a PBPK model to estimate blood toluene concentrations at the time of behavioral assessment, their review of the literature showed that behavioral effects in humans are reported at lower blood concentrations than in rats. This might be attributed either to different behavioral assessment techniques used in testing the two species or to a variety of biological factors.

A number of developmental effects, particularly neurodevelopmental changes, have been reported in children of women who abused toluene during pregnancy. Effects reported in children exposed in utero to toluene include microcephaly, CNS dysfunction, attention deficits, developmental delay/mental deficiency, small mid face, deep-set eyes, micrognathia (smallness of the jaws), and blunting of the fingertips (Byrne et al., 1991; Devathanan et al., 1984; Hunnewell and Miller, 1998; King et al., 1981; Maas et al., 1991; Meulenbelt et al., 1990; Miyagi et al., 1999; Ryu et al., 1998; Suzuki et al., 1983). Several studies in rats have reported altered neurobehavioral parameters in offspring following exposure of pregnant dams to high (≥ 800 ppm) concentrations of toluene (DaSilva et al., 1990; Hass et al., 1999; Hougaard et al., 1999). Significant changes in other developmental endpoints have also been reported in animal

studies, including increases in spontaneous abortions, resorptions, altered pup body and organ weights, and altered pup development, but generally only at high doses (≥ 1000 ppm) (Dalgaard et al., 2001; Ono et al., 1995, 1996; Thiel and Chahoud, 1997; Ungvary and Tatrai, 1985). A two-generation inhalation reproduction study in rats did not report alterations in any indices of fertility, though decreased pup weight in the F1 generation exposed to 2000 ppm toluene was reported during the first 15 weeks of life, after which weights did not significantly differ from controls (API, 1984; Roberts et al., 2003).

4.5.3. Mode of Action

Understanding of the mechanisms by which toluene may exert its toxic effects is limited. The parent compound, rather than a metabolite, is believed to be responsible for the observed toxicity. Support for the parent compound comes from the observation that pretreatment of rats with phenobarbital, thereby increasing the levels of CYP enzymes, increased the rate of *in vivo* toluene metabolism and shortened the time of recovery from narcosis from single intraperitoneal doses of toluene (Ikeda and Ohtsuji, 1971). Also, inhibition of toluene metabolism by pretreatment with ethanol resulted in a potentiation of toluene-induced hearing loss in rats (Campo et al., 1998). On the other hand, Mattsson et al. (1989) have reported similar neuroexcitatory effects between toluene and the metabolite o-cresol, suggesting that metabolites might contribute to some of the neuroactive properties of toluene.

On a molecular scale, little is known about the mechanisms by which toluene produces acute or residual central nervous system (CNS) effects but it is reasonable to assume that its toxic effects are due, at least in part, to its general characteristics as a solvent. The Meyer-Overton theory of partitioning of a compound into membrane lipids has been widely accepted for a century (Franks and Lieb, 1985, 1987). Recently, it has been proposed that the presence of solvent molecules in cholesterol-filled interstices between phospholipids and sphingolipids changes membrane fluidity, thereby altering intercellular communication and normal ion movements (Engelke et al., 1996). It is not known if this mechanism is involved in the chronic effects of toluene, but the observed neural demyelination in toluene abusers (Rosenberg et al., 1988a,b) would be suggestive evidence of such a role. An alternative hypothesis is that toluene partitions into hydrophobic regions of proteins and interacts with them, thereby altering membrane-bound enzyme activity and/or receptor specificity (Balster, 1998). Other evidence suggests that toluene and other volatile organic compounds (VOCs) may act by enhancing γ -

aminobutyric acid type A (GABA_A) receptor function (Mihic et al., 1994), attenuating N-methyl-D-aspartate (NMDA) receptor-stimulated calcium flux (Cruz et al., 1998), activating dopaminergic systems (von Euler, 1994a), and inhibiting voltage-sensitive calcium channels (Tillar et al. 2002). In addition, toluene has been shown to inhibit signal transduction through the stimulation of human muscarinic acetylcholine receptor m2 subtypes in Chinese hamster ovary (CHO) cells (Tsuga et al., 2002). Other neurologic effects may involve a number of neurochemical alterations, including changed whole-brain concentrations of dopamine, norepinephrine, and 5-hydroxytryptamine in rats exposed for 8 hours to 100, 300, or 1000 ppm toluene (Rea et al., 1984); changed dopamine D2 receptor binding in rats exposed to 80 ppm toluene, 6 hours/day, 5 days/week for 4 weeks (von Euler et al., 1993, 1994b); and increased cerebellar concentrations of glial cell protein markers (α -enolase, creatine kinase-B, and β -S100 protein) in rats exposed to 100, 300, or 1000 ppm toluene 8 hours/day for 16 weeks (Huang et al., 1992). The data of Soulage et al. (2004) points toward modifications of 5-hydroxytryptophan and catecholamine biosynthesis rates in several regions of the rat brain after a 16-week, subchronic exposure to 40 ppm for 104 hours per week. However, the persistence of the above effects, which would implicate these mechanisms in the effects of chronic toluene exposure, has not been established. In addition, Yamaguchi et al. (2002) have shown prenatal brain development can be disrupted at low, environmentally-relevant levels of toluene exposure by the inhibition of glial fibrillary acidic protein induction in serum-free mouse embryo cells.

In addition to receptor reactivity, toluene may also cause molecular damage via free radical oxidation. In female rats exposed to 50 and 500 mg/m³ toluene via inhalation for 4 hours a day, 5 days a week for one month, increased glutathione peroxidase activity and the activation of free radical processes were apparent in both brain and ovarian tissue, while the ovarian tissue also showed an increase in catalase activity and protein peroxidation (Burmistrov et al., 2001). Also, toluene metabolites, methylhydroquinone and methylbenzoquinone, may cause oxidative DNA damage that is reproductively toxic due to the relative inability of spermatogenic cells to repair DNA damage (Murata et al., 1999). Nakai et al. (2003) showed increased formation of 8-hydroxy-2'-deoxyguanosine, a biological marker for oxidative DNA damage, in the testes after subcutaneous injection of toluene at 50 and 500 mg/kg once a day for ten days. These results suggest that the reproductive toxicity of toluene stems from direct oxidative DNA damage to the spermatzoa.

The mode of action of color vision loss induced by toluene and certain other solvents is not known. Occupation-related color vision impairment, like other acquired dyschromatopsias,

usually results in impairment of blue-yellow color discrimination or, less frequently, in a combination of blue-yellow and red-green loss. Congenital dyschromatopsias more frequently result in red-green deficits (Hart, 1987, 1992; Mergler et al., 1987; Gobba and Cavalleri, 2003). According to Koller's rule, changes in the blue-yellow range of observation suggest a retinal location of the effect (Hart, 1992). One possible mechanism may be related to a direct effect of solvents (or metabolites) on cone function (e.g., membrane metabolism) or to an interference with neurotransmitters (such as dopamine) (see Geller and Hudnell, 1997, for a review).

Toluene causes alterations of the c-wave (a component of the electroretinogram) and the standing potential (the potential which develops between the cornea and retina) (Skoog and Nilsson, 1981) in monkeys, which are due to changes of the potentials of the receptor-pigment epithelial complex (Griff, 1991; Steinberg et al., 1983). The retinal pigment epithelium has three major functions — vitamin A transport, phagocytosis of the upper tenth of the photoreceptor outer segment, and potassium buffering — in addition to transport and metabolism of different substances. However, patients suffering from chronic abuse of toluene and resultant visual disturbances have been shown to have optic neuropathies and changes in the electroretinograms that were different from those observed in the monkeys (Skoog and Nilsson et al., 1981; Toyonaga, 1989). Further research in this area is needed.

The mode of action of renal toxicity following toluene exposure is unknown. Al-Ghamdi et al. (2003a) found decreased cell viability, lactate dehydrogenase release, increased levels of malondialdehyde, increased CYP2E1 activity, but no DNA fragmentation when LLC-PK1 cells (proximal tubule cells) were exposed to 5 mM toluene for 48 hours, suggesting necrosis as the predominant mode of cell death. The results of this study also suggest a pivotal role of CYP2E1 in the induction of oxidative stress and necrosis as the effects were inhibited by co-exposure to disulfiram (an inhibitor of CYP2E1). Al-Ghamdi et. al (2003b) found that both xylene and toluene, individually, reduced cell viability and increased caspase-3 activation. The inhibition of caspase-3, which is a critical apoptosis protein, prevented cell injury in proximal tubular cells, and the activation of which may play a role in toluene-induced proximal tubular cell injury. Some studies have shown that renal failure in toluene abusers was accompanied by myoglobinuria, which might be attributed to rhabdomyolysis and not to primary kidney toxicity (O'Brien et al., 1971; Reisin et al., 1975). Other studies of organic solvents suggest that the mechanism of lesion formation in the kidney may be due to the induction of damage to the alveolar basement membrane, leading to a production of alveolar basement membrane antibodies

that cross-react with the glomerular basement membrane and initiate glomerular disease (Carlier et al., 1980).

4.6. WEIGHT-OF-EVIDENCE EVALUATION AND CANCER CHARACTERIZATION

4.6.1. Summary of Overall Weight-of-Evidence

Under the *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005) there is inadequate information to assess the carcinogenic potential of toluene because studies of humans chronically exposed to toluene and mixtures containing toluene are inconclusive, toluene was not carcinogenic in adequate inhalation cancer bioassays of rats and mice exposed for life (CIIT, 1980; NTP, 1990; Huff, 2003), and increased incidences of mammary cancer and leukemia were reported in a lifetime rat oral bioassay at a dose level of 500 mg/kg-day but not at 800 mg/kg-day (Maltoni et al., 1997). In the NTP (1990) and Huff (2003) studies, no neoplasms were noted in male rats, and one nasal, two kidney, and two forestomach neoplasms observed in female rats were considered not to be associated with toluene exposure. No increase in the incidence of neoplasms was observed in mice. Toluene has generally not been genotoxic in short-term testing protocols. Available animal studies as well as human epidemiological surveys of occupational exposure performed thus far have not clearly demonstrated a carcinogenic effect. The previous IRIS assessment classified toluene as Group D (*not classifiable as to human carcinogenicity*) under the *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 1986c) based on inadequate data on the carcinogenicity of toluene in humans and inadequate evidence of carcinogenicity in animals. Toluene is not included in the *10th Report on Carcinogens* (NTP, 2002). The International Agency for Research on Cancer (IARC) has classified toluene as Group 3 (*not classifiable as to its carcinogenicity in humans*) with a supporting statement that there is inadequate evidence in humans and that available evidence suggest a lack of carcinogenicity of toluene in experimental animals (IARC, 1999).

4.6.2. Synthesis of Human, Animal, and Other Supporting Evidence

Available studies in toluene-exposed workers have reported very limited or no evidence of carcinogenic effects of toluene exposure (Antilla et al., 1998; Svennson et al., 1990; Wiebelt and Becker, 1999). A cohort mortality study in toluene-exposed workers (Wiebelt and Becker, 1999) did not report an increase in cancer-specific mortality for the entire cohort. A subcohort of highly-exposed workers demonstrated statistically significant increases in mortality from cancers of the bone and connective tissue, but lack of exposure characterization, co-exposure information, and adjustment for other confounding factors (age, smoking, etc.) within the subcohort precludes drawing conclusions from these results as to the possible association between toluene exposure and cancer risk. Svennson et al. (1990) similarly did not report increased cancer-specific mortality among rotogravure printers. While an increase in tumors of the respiratory tract was reported, this increase was not statistically significant when only subjects with exposure periods of 5 years or more were examined and no dose-response relationships were present for tumor incidence. Antilla et al. (1998) carried out a retrospective cohort analysis of 5301 workers monitored for biological markers of occupational exposure to styrene, toluene, or xylene, but no significantly increased incidence rates of cancer could be associated with toluene exposure. Other studies examining the carcinogenicity of toluene in occupationally exposed humans have failed to adequately account for co-exposure to other compounds.

NTP (1990) has conducted a 2-year inhalation carcinogenicity study in F-344 rats and B6C3F1 mice and found no evidence for carcinogenicity in either sex of either species at exposure levels up to 1200 ppm. Another inhalation carcinogenicity study in F-344 rats (CIIT, 1980; Gibson and Hardisty, 1983) likewise reported no evidence for carcinogenic effects of toluene at exposure levels up to 300 ppm. A lifetime carcinogenicity study in Sprague-Dawley rats by the oral route (Maltoni et al., 1997) was suggestive of potential carcinogenic effects of toluene, but the dose-response relationships were not well defined (i.e., the 500-mg/kg animals had considerably more tumors than those in the 800-mg/kg group) and study details were inadequately reported.

Available studies examining the genotoxic effects of toluene have generally reported negative results. Toluene was found to be nonmutagenic in reverse mutation assays with *S. typhimurium* (Mortelmans and Riccio, 1980; Nestmann et al., 1980; Bos et al., 1981; Litton Bionetics, Inc., 1981; Snow et al., 1981; Connor et al., 1985; Nakamura et al., 1987; NTP, 1990)

and *E. coli* (Fluck et al., 1976; Mortelmans and Riccio, 1980), with and without metabolic activation. Toluene did not induce mitotic gene conversion (Litton Bionetics, Inc., 1981; Mortelmans and Riccio, 1980) or mitotic crossing over (Mortelmans and Riccio, 1980) in *S. cerevisiae*. Although Litton Bionetics, Inc. (1981), reported that toluene did not cause increased chromosomal aberrations in bone marrow cells, several Russian studies (Lyapkalo, 1973; Dobrokhotov and Enikeev, 1977) report toluene as effective in causing chromosomal damage in bone marrow cells of rats. There was no evidence of chromosomal aberrations in blood lymphocytes of workers exposed to toluene only (Forni et al., 1971; Maki-Paakkanen et al., 1980); however, Bauchinger et al. (1982) and Hammer (2002) found a cytogenetic effect in workers exposed to toluene, and a slight increase was noted in workers co-exposed to toluene and benzene (Forni et al., 1971; Funes-Craviota et al., 1977; Nise et al., 1991). The findings of Forni et al. (1971) and Maki-Paakkanen et al. (1980) are supported by studies of cultured human lymphocytes exposed to toluene *in vitro*; no elevation of chromosomal aberrations or sister chromatid exchanges was observed (Gerner-Smidt and Friedrich, 1978). However, oxidative DNA damage was observed in the rat lung and kidney after toluene inhalation (Tokunaga et al., 2003), and the toluene metabolites methylhydroquinone and methylbenzoquinone also caused oxidative DNA damage to human DNA fragments from the p53 tumor suppressor gene in the presence of copper(II) plus NADH (Murata et al., 1999).

4.7. SUSCEPTIBLE POPULATIONS AND LIFE STAGES

4.7.1. Possible Childhood Susceptibility

Only limited data exist that examine the potential differences in susceptibility to toluene between children and adults. Children have been shown to have differences in levels of CYP enzymes and several phase II detoxification enzymes (e.g., N-acetyl transferases, UDP-glucuronyl transferases, and sulfotransferases) relative to adults (Leeder and Kearns, 1997; Nakajima et al., 1992; Vieira et al., 1996), as well as other physiological differences (e.g., children have higher brain mass per unit of body weight, higher cerebral blood flow per unit of brain weight, and higher breathing rates per unit of body weight) (Snodgrass, 1992). However, data on the possible contributions of these differences to potential age-related differences with respect to toluene are lacking.

Transfer of toluene to nursing infants from breast milk of currently exposed mothers is expected to be a possibility because of the lipophilicity of toluene and the relatively high lipid content of breast milk. Toluene has been detected in human breast milk at a mean ($\pm$ SD) concentration of $0.76 (\pm 0.76) \mu\text{g/kg}$ (Fabietti et al., 2004). Elimination kinetics data for nonpregnant or nonlactating humans and rats following toluene exposure, however, indicate that most absorbed toluene is rapidly eliminated from the body and that a much smaller portion (that which gets into adipose tissues) is slowly eliminated (Leung and Paustenbach, 1988; Löf et al., 1993; Pierce et al., 1996, 1999; Pellizzari et al., 1992; Rees et al., 1985).

Fisher et al. (1997) developed a human PBPK model (See section 3.5 for more details) that predicts transfer of toxicant via lactation from a mother to a nursing infant and used the model to estimate the amount of toluene that an infant would ingest via milk if the mother was occupationally exposed to toluene at the ACGIH (2000) Threshold Limit Value (TLV = 50 ppm) throughout a workday. The model predicted that such an infant would have a daily oral intake of 0.46 mg toluene/day. It should be noted, however, that no human (or animal) studies are available regarding *in vivo* distribution of toluene into breast milk or elimination kinetics from breast milk, and the Fisher et al. (1997) PBPK model has not been validated with *in vivo* data.

4.7.2. Possible Gender Differences

Available studies in humans and animals have not definitively demonstrated whether sex-related differences in the toxicity of toluene exist. Human occupational studies have not reported sex-related differences in effects, with the exception of the study of Plenge-Bönig and Karmaus (1999), which reported decreased fertility in occupationally exposed women but not in occupationally exposed men. Co-exposure to other solvents in this study was not ruled out. Exposure to toluene and pregnancy outcome was determined by questionnaire. In rats and mice exposed to toluene orally for 13 weeks (NTP, 1990), males of both rats and mice showed toxic effects at lower doses than females. Similarly, in 15-week inhalation studies (NTP, 1990), males were demonstrated to be more sensitive to the effects of toluene than females; however, no differences were apparent between males and females in a 2-year inhalation bioassay (NTP, 1990). Another chronic inhalation study in rats (CIIT, 1980) failed to show significant differences between males and females with regard to toxicity, but females appeared to be more sensitive with regard to changes in hematocrit.

4.7.3. Other

Color vision impairment has been shown to increase with age (Ruddock, 1965; Bowman et al., 1984), diabetes (Matyjavri, 1992; Utku and Atmaca, 1992), and alcohol intake (Russell et al., 1980; Mergler et al., 1988). These populations may be more susceptible than the general population to any decrements in color vision from environmental exposure. It is not known if this effect is related to the possible differences in metabolism rates under these conditions or some other inherent property related to age or alcohol consumption.

Toluene is initially metabolized to benzyl alcohol by the microsomal mixed-function oxidase system. Subsequent oxidation to benzaldehyde and then to benzoic acid is carried out by alcohol and aldehyde dehydrogenase, respectively. There are two forms of the dehydrogenases (low K_m and high K_m). Japanese and possibly other populations of Asian origin and Native Americans have a defective gene for the low K_m dehydrogenase. When toluene-exposed Japanese workers (both male and female) were evaluated for the defective gene, it was found that those possessing the defective gene had lower levels of urinary hippuric acid and *ortho*-cresol than those with the normal or heterozygous gene (Kawamoto et al., 1994). Thus, these individuals may be at a higher risk of toluene-induced CNS impairment due to a decreased rate of metabolism, assuming that the parent chemical is responsible for adverse effects.

5. DOSE RESPONSE ASSESSMENTS

5.1. ORAL REFERENCE DOSE (RfD)

5.1.1. Choice of Principal Study and Critical Effect

No studies examining the chronic or subchronic effects of oral exposure to toluene in humans are available. A lifetime gavage study in rats (Maltoni et al., 1997) reported only carcinogenic endpoints and is, therefore, not suitable for use as the principal study for derivation of an RfD. One subchronic study (NTP, 1990) examining oral exposure to toluene in rodents (rats and mice) is available and was chosen as the principal study. The critical effect chosen is increased kidney weight. NTP (1990) exposed both sexes of F-344 rats and both sexes of

B6C3F1 mice to toluene by gavage for 13 weeks. In male rats, absolute and relative weights of both the liver and kidney were significantly increased ($p < 0.05$) at doses greater than or equal to 446 mg/kg-day. Absolute kidney weights were 100, 107, 112, 119, and 113% of controls; relative kidney weights were 100, 100, 106, 114, and 146% of controls for 0, 223, 446, 900, or 1800 mg/kg-day dose levels. The study in rats established a NOAEL of 223 mg/kg-day for increases in liver and kidney weights of male rats, with a LOAEL of 446 mg/kg-day. Histopathologic lesions in the liver consisted of hepatocellular hypertrophy, occurring at doses greater than 2500 mg/kg-day. Nephrosis was observed in rats that died, and damage to the tubular epithelia of the kidney occurred in terminally sacrificed rats. Kidney sections were examined in particular for the occurrence of hyaline droplets in the proximal tubules with negative findings. A concentration-dependent nephropathy was also seen in chronic inhalation cancer bioassays (NTP, 1990; Huff, 2003). It should be noted that no increase in kidney weight was seen in the parallel study in B6C3F1 mice, indicating a species difference in the response.

The choice of increased kidney weight as the critical effect is supported by several acute oral and inhalation human toxicity studies, indicating renal tubule toxicity. One case report following lethal oral exposure to 625 mg/kg toluene (Ameno et al., 1989) and a nonlethal case report of thinner ingestion (Caravati and Bjerk, 1997) noted acute tubular necrosis and acidosis. Inhalation of high doses of toluene has caused distal renal tubular acidosis (Taher et al., 1974; Fischman and Oster, 1979) among drug users, sometimes with tubular proteinuria (Kamijima et al., 1994). A case of focal segmental glomerulosclerosis was noted for a leather worker exposed to toluene for 40 years (Bosch et al., 1988). Toluene sniffing has been associated with the formation of renal stones (Kroeger et al., 1980), proteinuria (Streicher et al., 1981), and hepato-renal damage (O'Brien et al., 1971). In addition, a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis has also been reported in a woman who sniffed glue for several weeks (Bonzel et al., 1987). It should be noted that several studies involving painters (Askergren, 1982; Franchini et al., 1983) or printers (Gericke et al., 2001) with toluene exposure have reported no effect on renal function. Askergren (1982) and Franchini et al. (1983) found no effect on excretion of β -2-microglobulin, and Gericke et al. (2001) found no effect on serum creatinine levels or glomerular filtration rate. The choice of increased kidney weight as a critical effect is based on the above data and the available animal data indicating an increase in kidney weight in the same studies where overt kidney toxicity was observed at higher doses. The available data on postulated modes of action for toluene-induced kidney toxicity are described in Section 4.5.3.

A number of immunotoxicity studies are available (Hsieh et al., 1989, 1990b, 1991; Burns et al., 1994) and were considered for use as the principal study. Changes in thymus weights in the Hsieh et al. (1989) study were not considered an adverse effect since no change was observed in later studies by Hsieh et al. (1990b) and Burns et al. (1994). Additional effects on immunological endpoints were considered as a potential critical effect from toluene exposure. For example, statistically significant and dose-related decreases in antibody response were noted by Hsieh et al. (1989, 1990b, 1991). There is evidence that the PFC assay is among the most predictive tests available for immunotoxicity (Luster et al., 1992) and that suppression of the antibody response is predictive of decreased resistance to challenge with infectious agents or tumor cells (Luster et al., 1993). An important objective of the use of the PFC assay and anti-SRBC ELISA in immunotoxicity testing is to determine the ability of the immune system to respond to an antigenic challenge. As such, it tests the ability of three primary immune system cells (i.e., macrophages [phagocytosis and processing of SRBCs], T lymphocytes [which assist B lymphocytes] and B lymphocytes [production and release of anti-SRBC specific antibody]) to respond to this antigen in a coordinated manner leading to the production of antibodies to SRBC.

However, in the same test that Hsieh et al. (1989, 1990b, 1991) showed suppression of the antibody response (the PFC assay), Burns et al. (1994) did not find immunosuppression. The studies were not entirely parallel; Hsieh and Burns used different mouse strains (CD-1 and B6C3F1, respectively), examined different sexes (males and females, respectively), and utilized different exposure durations (28 vs. 14 days, respectively). Furthermore, the host resistance assays by Burns et al. (1994) indicated a lack of immunotoxicity when animals treated with toluene were challenged. Host resistance to challenges with *Listeria monocytogenes*, *Streptococcus pneumoniae*, *Plasmodium yoelii*, or B16F10 melanoma was not affected at a dose of 600 mg/kg-day for 14 days. In addition, a reduced incidence of tumors was observed in mice that were challenged with PYB6 fibrosarcoma. Štefanovič et al. (1987) found no significant changes in immunoglobulin levels after toluene treatment of human sera and also showed no changes in the complement activity parameters studied in the toluene treated sera. The conflicting data between the Hsieh and Burns studies and the lack of suppression of host resistance present an unclear picture of toluene immunotoxicity. For these reasons, immunotoxic endpoints alone are not considered critical effects.

Additional studies by Hsieh et al. (1990a,c) found statistically significant increases in a variety of brain neurotransmitter levels at exposure levels as low as 5 mg/kg-day. The study

authors measured levels at one time point immediately at the termination of toluene treatment; it cannot be determined if the effects observed were persistent. Neurotoxicity studies from oral exposure to toluene have not been performed; therefore, the changes in neurotransmitter levels have not been correlated with behavioral, neuropsychological, or neuroanatomical changes and were not considered further. Available reproductive studies (Gospe et al., 1994, 1996; Gospe and Zhou, 1998, 2000) were conducted at higher doses than those used in the studies described above with minimal effects on dams and offspring and, as such, were not considered for the choice of principal study.

5.1.2. Methods of Analysis

The RfD was derived by the benchmark dose approach using EPA's (U.S. EPA, 2001) benchmark dose software (BMDS, Version 1.3). The benchmark response (BMR) was defined as the change of one control standard deviation from the control mean (U.S. EPA, 2000). Benchmark analysis was performed for absolute kidney weight changes in male rats (NTP, 1990). Male rat kidney data were chosen for BMD modeling as these data exhibited a greater response than that seen in female rats (see study description in Section 4.2.1.1). A BMDL of 238 mg/kg-day was derived and used as the point of departure. The BMDL corresponds to the lower bound on the dose associated with a 10% increase in individuals having a kidney weight greater than the 98th percentile of kidney weights in the control group (and the SD corresponding to 9% increase in kidney weight from control). Details of the model results are presented in Appendix B-1.

As discussed in Section 5.1.1, the use of immunotoxicity endpoints for the derivation of the RfD is problematic due to conflicting data and a lack of suppression of host resistance in oral *in vivo* assays. However, for illustrative purposes, selected endpoints which showed a positive result for immunosuppression were chosen for benchmark dose modeling as outlined in Appendix B-2. The endpoints include PFC counts, IL-2 thymidine uptake, IL-2 stimulation index, IL-2 activity, and mixed lymphocyte culture (MLC) responders and stimulators. It is unclear what the appropriate benchmark response (BMR) would be for an *in vivo/ex vivo* immunotoxicity study given the available redundancy in the immune system. In the absence of biological reasoning for a particular BMR, a benchmark dose (BMD) corresponding to 1 control SD from the control mean could be chosen according to U.S. EPA (2000). Due to the uncertainty in choosing an appropriate BMR for individual immunotoxicity endpoints, BMDs corresponding

to 0.5, 1.0, and 2.0 control SDs from the control mean are presented in Tables B-2.2 through B-2.4. The corresponding BMDL (lower limit of a one-sided 95% CI for the BMD) values ranged from 2 to 110 mg/kg-day. The percent change in response at each BMD is presented in Table B-2.5. Benchmark responses range from a 9% change from control mean for PFCs/million cells to a 90% decrease from controls in IL-2 activity. The literature on potential immunosuppression following toluene exposure via the oral route should not be ignored. The results of the BMD modeling exercise indicate that this endpoint deserves further research. Consideration of immunotoxicity as a critical effect, however, is not warranted at this time.

PBPK models in animals are available that describe the kinetics of toluene after inhalation exposure (Fisher et al., 1997; Pierce et al., 1996, 1999; DeJongh and Blaauboer, 1996, 1997; Tardif et al., 1993). When appropriate human and rat PBPK models are developed for the oral route of exposure, they could be used to estimate human oral exposure levels associated with an appropriate internal dose. Theoretically, the available toluene PBPK models could be utilized to extrapolate the risks of neurotoxic outcomes from inhalation exposure to oral exposure. However, in the case of toluene, unpublished data from the laboratory of Dr. Philip Bushnell (memorandum dated October 29, 2003, from Dr. William Boyes, U.S. EPA, to Dr. Lynn Flowers, U.S. EPA, "Potential use of PBPK modeling to support route-to-route extrapolation or duration adjustments for chronic exposure to toluene") suggest that behavioral deficits observed in rats exposed to toluene by inhalation exposure are not observed in rats given toluene by oral gavage at doses expected to produce the same concentrations of toluene in the brain. The mechanism for this apparent difference in the effect of toluene by the oral and inhalation routes is not understood at this time.

5.1.3. RfD Derivation - Including Application of Uncertainty Factors

The BMDL of 238 mg/kg-day for increased kidney weight from the NTP (1990) study was utilized as the basis for the calculation of the RfD.

Total UF - 3000

A total uncertainty factor (UF) of 3000 was applied to this effect level: 10 for extrapolation for interspecies differences (UF_A ; animal to human), 10 for consideration of intraspecies variation (UF_H ; human variability), 10 for use of a subchronic study to estimate

chronic effects (UF_S ; duration of exposure), and 3 for database insufficiencies and contradictions in the immunotoxicity data (UF_D). The total $UF = 10 \times 10 \times 10 \times 3 = 3000$.

An uncertainty factor of 10 was used to account for laboratory animal-to-human interspecies differences (UF_A). No information is available on differences or similarities in the toxicity of toluene between animals and humans.

An uncertainty factor of 10 was used to account for intraspecies differences (UF_H) including variability in susceptibility in human populations and life-stages. This UF was not reduced because of the lack of human oral exposure information.

An uncertainty factor of 10 was used to account for extrapolating from a subchronic study to estimate chronic exposure conditions (UF_S).

An uncertainty factor was not needed to account for extrapolating from a LOAEL to a NOAEL because BMD modeling was used to identify the point of departure.

An uncertainty factor of 3 was used to account for deficiencies in the toluene database. An oral subchronic study in two species is available. Neurotoxicity has been identified by inhalation studies in humans and animals as a critical endpoint. However, limited neurotoxicity studies by the oral route are available. Several oral exposure high-dose reproductive and developmental toxicity studies are available which indicate toluene does not generally elicit developmental or reproductive effects except at doses that are significantly higher than those causing other systemic effects (see Section 4.3 for details). A two-generation reproductive toxicity study by the oral route of exposure is not available, however, a two-generation reproductive toxicity study by the inhalation route of exposure is available that possibly lends support to the oral database in that effects are noted at high concentrations. Toxicokinetic information indicates that the absorption kinetics of toluene is similar and extensive following both oral and inhalation exposure. For example, Gospe and Al-Bayati (1994) compared oral and inhalation exposures to toluene in the rat and concluded that oral dosing produces blood toluene levels that are similar to those produced by inhalation (see Section 3.1.2). It should be noted, however, that differences in metabolism between exposure routes have not been elucidated, nor has a role for metabolites been ascertained in the toxicity of toluene. Immunotoxicity data are available but the results are conflicting. The data to date are inadequate to draw conclusions

regarding whether immunosuppression may be a more sensitive endpoint (i.e., an endpoint that would result in a lower point of departure) than kidney toxicity.

A three-fold uncertainty factor for insufficiencies in the database was used to account for the lack of adequate data on endpoints of potential concern for toluene, including neurotoxicity, two-generation reproductive toxicity and immunotoxicity.

The RfD for toluene was calculated as follows:

$$\begin{aligned}\text{RfD} &= \text{BMDL} \div \text{UF} \\ &= 238 \text{ mg/kg-day} \div 3000 \\ &= 0.08 \text{ mg/kg-day}\end{aligned}$$

5.1.4. Previous RfD Assessment

The previous IRIS assessment utilized the NTP (1990) 13-week rat gavage study as the principal study and changes in liver and kidney weights as the critical effect for derivation of the RfD (0.2 mg/kg-day). The NOAEL was identified as 223 mg/kg-day. A composite UF of 1000 was applied to account for interspecies and intraspecies extrapolations, subchronic-to-chronic extrapolation, and limited reproductive and developmental toxicity data.

5.2. INHALATION REFERENCE CONCENTRATION (RfC)

5.2.1. Choice of Principal Study and Critical Effect

A substantial database examining the effects of toluene in subchronic and chronic occupationally-exposed humans exists. The weight of evidence from these studies indicates neurologic effects (i.e., impaired color vision, impaired hearing, decreased performance in neurobehavioral analysis, changes in motor and sensory nerve conduction velocity, headache, dizziness) as the most sensitive endpoint. Numerous case studies in humans exposed to high concentrations of toluene for abusive purposes have also indicated neurological effects in adults as critical effects of concern. Human studies indicating the potential for adverse effects from toluene exposure other than neurological effects are also available. None of these studies

indicated effects at doses lower than those observed for neurological effects. Animal studies (NTP, 1990) have also suggested respiratory irritation as a sensitive effect, but this effect in humans appears to occur at higher exposure concentrations than those resulting in neurologic effects.

All of the available occupational studies were considered for the principal study upon which to base the derivation of the RfC. A discussion of available animal studies is presented at the end of this section. Numerous human studies have identified NOAELs in the range of 25-50 ppm toluene for individual neurological effects (Cavalleri et al., 2000; Eller et al., 1999; Nakatsuka et al., 1992; Neubert et al., 2001; Schaper et al., 2003; Zavalic et al., 1998a; Zupanec et al., 2002). These studies were designed to measure effects on subjective symptoms (e.g., headache, dizziness), color vision, neurological and psychomotor functioning, and hearing. Several studies have shown statistically significant effects in workers in the range of 83-132 ppm on at least one of the following neurological effects: color vision, auditory evoked brain potentials, neurobehavioral parameters, and neurological functioning (Abbate et al., 1993; Boey et al., 1997; Eller et al., 1999; Foo et al., 1990; Neubert et al. 2001; Vrca et al., 1995, 1996, 1997; Zavalic et al., 1998a).

As a whole, the available studies present a substantial body of evidence in humans indicating a relationship between neurological effects and toluene exposure at the lowest occupational exposure levels measured. No single study stands out as the best study on which to characterize neurological effects nor to specify a single critical effect. Thus, in lieu of selecting one study as the principal study, a review of the human database indicated ten studies can be considered adequate. The determination of study adequacy was based on the use of accepted testing procedures for neurological endpoints, chronic exposure duration, inclusion of a measure of exposure, comparison to defined control groups, and no known co-exposure to other solvents in the workplace. Figure 2 and Table 1 summarizes this subset of studies. Response levels of the adequate studies are identified in Table 1 and are calculated as the difference between the reported means from the exposure and reference groups for statistically significant outcomes. This subset of studies presents a cluster of NOAELs for neurological effects which are generally below reported LOAELs for all endpoints. A deficit in neurological function was chosen as the critical effect based on this suite of neurological studies due to the overall preponderance of evidence for this endpoint at low doses.

Potential limitations associated with the studies that were considered adequate are included in Table 1. For additional discussion of the limitations and uncertainties associated with studies that were considered adequate, see Sections 4.1.2.2, 4.5.3 and Appendix A. Not included in the subset are studies with known co-exposure to other solvents (Antti-Poika et al., 1985; Yin et al., 1987; Campagna et al., 2001), studies lacking adequate exposure information (Antti-Poika et al., 1985; Murata et al., 1993), studies without a reference group (Muttray et al., 1995; Morata et al., 1997; Schaper et al., 2003; Tanaka et al., 2003), and studies where questionnaires were the only assessment of toxicity or exposure (Lee et al., 1988; Zupanic et al., 2002; Seeber et al., 2004). These studies contribute qualitatively to the overall weight of evidence of the choice of critical effect but are given lesser weight due to the inadequacies described. Orbaek and Nise (1989) was not included in the subset of studies due to the low number of workers tested and uncertainty in the exposure levels. Chouaniere et al. (2002) observed effects on psychomotor performance at doses of 25 and 40 ppm but the doses were estimated based on test results precluding the use of this study for quantitative purposes.




Figure 2. Summary of NOAELs/LOAELs for neurological endpoints for a subset of occupational studies of chronic inhalation exposure to toluene.

Table 1. Selected subset of occupational studies of neurological effects from toluene inhalation.

Study number in Figure 2 and reference	Number of workers and duration of exposure (average years $\pm$ SD)	NOAEL (ppm)	LOAEL (ppm)	Effect/test	Response level at the LOAEL (statistically significant response compared to controls) ^a	Noted potential limitations
1. Abbate et al., 1993	Reference (n=40), exposed (n=40) (12-14 years; no SD reported)	None ^b	97	Brainstem response auditory-evoked potential	28% increase of the latency shift for wave-I during passage from 11 to 90 repetitions.	
2. Boey et al., 1997	Reference (n = 29) exposed (n = 29) (4.9 $\pm$ 3.5 years; range of 1-13 years)	None	91	Neuropsychological examination; digit span, visual reproduction, Benton visual retention test, trail making test, symbol digit modality test, grooved pegboard test, and finger tapping tests	Increased time to complete the grooved pegboard test 7% and 6% for dominant and non-dominant hands respectively, increase in time to complete trail-making test parts A&B, 31% & 28%, respectively; 15% decrease in backward digit span test; 12% and 10% decrease in symbol digit modality test for written and oral sections, respectively.	Control workers were exposed to 12 ppm toluene

Study number in Figure 2 and reference	Number of workers and duration of exposure (average years $\pm$ SD)	NOAEL (ppm)	LOAEL (ppm)	Effect/test	Response level at the LOAEL (statistically significant response compared to controls)^a	Noted potential limitations
3. Cavalleri et al., 2000	Reference (n=16), exposed (n=33) (9.75 years; no SD reported)	None	42	Color vision impairment (Lanthony D-15)	29% increase in CCI and 49% increase in total confusion index (TOCI) (reported as mean of both eyes).	Exposure measured from urinary excretion of toluene: on the basis of previous data, air concentrations estimated to be 42 ppm.
4. Eller et al., 1999	Reference (n=19), low exposure (n=30), high exposure (n=49) low exposure (1-12 years; no SD reported) high exposure (>12 years)	20	>100	Neuropsychological examination (Cognitive Function Scanner); verbal and nonverbal learning and memory, visuomotor function, computerized neurological examination (CATSYS, TREMOR, and SWAY), subjective assessment	13% increase in performance time on Bourdon Wiersma Test but no increase in the number of missed or incorrect detections; 33% of exposed population reported concentration difficulties.	The high exposure classification was based on historical exposures which may have exceeded 100 ppm for up to 27 years.

Study number in Figure 2 and reference	Number of workers and duration of exposure (average years $\pm$ SD)	NOAEL (ppm)	LOAEL (ppm)	Effect/test	Response level at the LOAEL (statistically significant response compared to controls) ^a	Noted potential limitations
5. Foo et al., 1990	Reference (n=30), exposed (n=30) (5.7 $\pm$ 3.2 years)	None	88	Neurobehavioral tests: Benton visual retention test, visual reproduction, trail making, grooved pegboard, digit span, digit symbol, finger tapping, and simple reaction time	Increased time to complete the trail-making test parts A&B, 51% & 63%, respectively; 25% decrease in digit symbol test performance; 16% decrease in total digit span test scores (both forward and backward).	Control workers were exposed to 13 ppm toluene for 2.5 $\pm$ 3.2 years. The education level was lower in the exposed group. As a result, data from the neurobehavioral tests were adjusted for years of education using a generalized linear model.
6. Murata et al., 1993	Reference (n=10), exposed (n=10) (11 years; range of 1-36 years; no SD reported)	None	83	Electrophysiological analysis of maximal motor and sensory nerve conduction velocity (MCV & SCV)	9% reduction in the MCV in the forearm and 6% reduction in the SCV in the palm.	Exposed workers were matched for age but not alcohol consumption.
7. Nakatsuka et al., 1992	Reference (n=120), exposed (n=174)	44-48	None	Color vision impairment (Lanthony's new color test and Ishihara's color vision test)	No measured effect on color vision.	In lieu of determining exposure duration, groups were age-matched to control for effects of aging on color vision.

Study number in Figure 2 and reference	Number of workers and duration of exposure (average years $\pm$ SD)	NOAEL (ppm)	LOAEL (ppm)	Effect/test	Response level at the LOAEL (statistically significant response compared to controls)^a	Noted potential limitations
8. Neubert et al., 2001	Ref-ex (n=109), ref- int (n=48), exp gp I (n=316), exp gp II (n=535), exp gp III (n=308), exp gp IV (n=65)	39 (exp gp 1)	81 (ex gp IV)	Psychophysiological and psychomotor testing: verbal memory span, visuomotor performance, immediate visual memory, self-rating of feeling, biosensory vigilance, critical flicker fusion frequency test, personality dispositions	5% reduction in ascending flicker fusion frequency.	Exposure was identified as chronic but the duration was not reported.
9. Vrca et al., 1995	Reference (n=59), exposed (n=49) (21.4 $\pm$ 7.4 years)	None	40-60	Visual evoked potentials	The amplitudes of visual evoked brain potentials were 24, 43, and 55% higher for N75, P100, and N145, respectively.	Exposure levels were estimated based on urinary levels of metabolites and toluene levels in blood.

Study number in Figure 2 and reference	Number of workers and duration of exposure (average years $\pm$ SD)	NOAEL (ppm)	LOAEL (ppm)	Effect/test	Response level at the LOAEL (statistically significant response compared to controls) ^a	Noted potential limitations
10. Zavalic et al., 1998a	Reference (n=90), low exposure (n=46), high exposure (n=37) low exposure (16.21 $\pm$ 6.1 years) high exposure (18.34 $\pm$ 6.03 years)	32	132	Color vision impairment (Lanthony D-15)	10-14% increase in CCI (both eyes).	The results from this investigation were reported in several publications (Zavalic et al., 1998a,b,c); some reporting discrepancies exist regarding the number of workers in the exposed and control groups and the statistical analyses.

^a Not all studies examined all neurotoxicity endpoints.

^b No NOAEL identified in this study.

A number of animal studies have examined the neurological effects of inhaled toluene. These studies were generally carried out at high doses and reported impaired responses in neurologic examinations. Table 2 summarizes the majority of available subchronic and chronic animal studies. For example, Rebert et al. (1989a,b) reported abnormal flash-evoked potentials in rats exposed to a single inhalation exposure of 500-16,000 ppm toluene. Evoked potentials reflect the function of the nervous system. Increases in latencies in evoked potentials can reflect deficits in nerve conduction and are indicators of a potential neurotoxic effect. Wood et al. (1983) exposed rats to toluene levels up to 3000 ppm for 4 hours prior to behavioral evaluation and reported that toluene reduced performance in behavioral tests, particularly at the 1780 and 3000 ppm exposure levels. Von Euler et al. (2000) exposed 30 rats to 80 ppm toluene for 4 weeks and found a selective decrease of approximately 6% in the area of the parietal cortex by magnetic resonance imaging. Autoradiographic analysis revealed a 7-10% decrease of the cerebrocortical area. Inhalation exposure to toluene has also been shown to result in irreversible high-frequency hearing loss in rats. Pryor et al. (1984) evaluated hearing loss by a behavioral technique (avoidance response elicited to an auditory signal) and brainstem auditory-evoked responses (elicited by tone pips of differing loudness and frequency and detected by subdural scalp electrodes). Hearing loss, as measured by both techniques, was observed after as few as 2 weeks of exposure to 1000 ppm toluene for 14 hours/day. Hearing loss was irreversible, as evidenced by a failure to return to normal response after 3 months of recovery.

In addition to neurologic effects in humans, the previous RfC on the IRIS database was based on irritation of the upper respiratory tract, specifically the nasal epithelium, as reported in the chronic NTP (1990) study in rats. However, these effects occurred in rats exposed to high concentrations (600 ppm or greater) of toluene and did not show an appreciable increase with increasing concentration (i.e., the incidence of the lesions was greater at 600 ppm than at 1200 ppm). Support that the nasal lesions are a high-exposure phenomenon also comes from the results of a chronic inhalation study in rats performed by CIIT (1980), which reported no effects on the nasal epithelium of animals exposed to 300 ppm toluene. A 28-day inhalation study in rats (30 and 300 ppm) likewise failed to demonstrate treatment-related lesions in the nasal epithelium (Poon et al., 1994). Acute studies in humans have demonstrated that subjective reports of irritation of the nose and/or eyes occurs at exposure levels of 100 ppm or greater (Baelum et al., 1985, 1990; Echeverria et al., 1989; Andersen et al., 1983) but not at exposures below 100 ppm (Echeverria et al., 1989; Andersen et al., 1983). Because neurologic effects are a

Table 2. Summary of subchronic and chronic toluene inhalation studies in animals.

Reference	Animals	Exposure duration	NOAEL (ppm)	LOAEL (ppm)	Effect
NTP, 1990	Fischer rats (60/sex/group)	0, 600, or 1200 ppm 103 weeks	None ^a	600	Degeneration of the olfactory or respiratory epithelium
NTP, 1990	B6C3F1 mice (60/sex/group)	0, 120, 600, or 1200 ppm 103 weeks	600	1200	Endometrial hyperplasia
CIIT, 1980; Gibson and Hardesty, 1983	Fischer rats (120/sex/group)	0, 30, 100, or 300 ppm 106 weeks	300	None	No effects
NTP, 1990	Fischer rats (10/sex/group)	0, 100, 625, or 1250 ppm 15 weeks	625	1250	Increased liver weight, increased severity of nephropathy
Von Euler et al., 2000	SD rats (30 male/group)	0 or 80 ppm 4 weeks	None	80	Neurobehavioral alterations 4 weeks postexposure
Pryor et al., 1984	Fischer rats	various exposure regimens	None	1000	Hearing loss
McWilliams et al., 2000	guinea pigs (8/group)	0, 250, 500, or 1000 ppm for 1 week or 500 ppm for 4 weeks	250	500	Diminished startle response and histologic alterations of the cochlea
Da Silva et al., 1990	Pregnant Wistar rats and hamsters	0 and 212 ppm gd ^b 14-20 (rats) 6-11 (hamsters)	212 (hamsters)) None (rats)	None (hamsters) 212 (rats)	Decreased pup weight, no neurobehavioral effects

Reference	Animals	Exposure duration	NOAEL (ppm)	LOAEL (ppm)	Effect
Thiel and Chahoud, 1997	Pregnant Wistar rats	0, 300, 600, 1000, or 1200 ppm gd 9-21	600	1000	Decreased pup weight, increased mortality in dams, changes in postnatal development (testes descent and vaginal opening), no neurobehavioral effects
Dalgaard et al., 2001	Pregnant Wistar rats	0, 1200, or 1800 ppm gd 7-20	1800	None	No effect on semen quality or testes histology
Hougaard et al., 1999	Pregnant Wistar rats	0 or 1800 ppm gd 7-20	None	1800	Decrease in cognitive function, decrease in hearing function, no neurobehavioral effects
Hass et al., 1999	Pregnant Wistar rats	0 or 1200 ppm gd 7-18	None	1200	Neurological deficit in Morris maze performance
Ungvary and Tatrai, 1985	Pregnant New Zealand rabbits and CFLP mice	0, 133, or 265 ppm (rabbits) gd 7-20 0, 133, 265, or 400 ppm (mice) gd 6-15	None (rabbits) 133 (mice)	133 (rabbits) 265 (mice)	Maternal deaths, litter resorptions, and spontaneous abortion in rabbits; decreased pup weight and skeletal resorptions in mice
Courtney et al., 1986	Pregnant CD-1 mice	0, 200, or 400 ppm gd 7-16	200	400	Alteration in rib profile in fetuses
Ono et al., 1995	Pregnant SD rats	0, 600, or 2000 ppm gd 7-17	600	2000	Maternal toxicity, decreased pup weight, increased fetal mortality, no effects on behavioral parameters

Reference	Animals	Exposure duration	NOAEL (ppm)	LOAEL (ppm)	Effect
Ono et al., 1996	SD rats (M and F)	0, 600, or 2000 ppm Females exposed 14 days prior to mating to gd 7; Males exposed for 90 days, beginning at 60 days before mating	2000 (F) 600 (M)	None (F) 2000 (M)	No change in fertility in females, decreased sperm count in males
API, 1984; Roberts et al., 2003	CD rats	0, 100, 500 or 2000 ppm 2-generation reproductive toxicity study; 80 days exposure and a 15 day mating period for M and F; mated F then exposed during gd 1-20 and days 5-20 of lactation; F1 pups exposed for 80 days prior to mating followed by exposure for 15 days to produce F2 generation	600	2000	Decreased pup weight

^a No NOAEL or LOAEL identified by the study

^b gd = gestational days

more sensitive endpoint for exposed humans, neurological deficits were selected as the critical endpoint in this assessment.

5.2.2. Methods of Analysis

In determining a point of departure, a subset of the highest quality human studies was utilized. The human studies used in the quantitative analysis are described in Table 1 and are represented graphically in Figure 2. The studies were weighted equally since none was clearly a stronger study. The highest NOAEL was identified as 44 ppm (Nakatsuka et al., 1992). The lowest LOAELs were identified as 40-42 ppm (Vrca et al., 1995, 1997; Cavalleri et al., 2000). An arithmetic mean of the NOAEL values in Table 1 was chosen to represent an average point of departure. Thus, the average exposure level of 34 ppm is used as the point of departure for the derivation of the RfC. This value is lower than the LOAELs identified above. The range of NOAELs for the suite of neurological effects is 20 to 48 ppm. The average NOAEL is used as a surrogate given concerns about the use of a particular individual NOAEL based on the discussion in Section 5.2.1. There is some uncertainty in using an average value from a suite of studies with varied endpoints and varied levels of response for the point of departure. However, the uncertainty is expected to be less than that associated with choosing any particular one of the available studies for deriving the point of departure since there were potential limitations associated with many of the available studies and no single study stands out as being of the highest quality. Furthermore, this subset of studies presents a cluster of NOAELs for neurological effects which are generally below reported LOAELs for all endpoints.

PBPK models are available that describe the kinetics of toluene after inhalation exposure (Fisher et al., 1997; Pierce et al., 1996, 1999; DeJongh and Blaauboer, 1996, 1997; Tardif et al., 1993). These models could theoretically be utilized for conducting a dose-based duration adjustment if more information were available. It has been shown that neurotoxic effects of acute exposure to toluene and other volatile organic compounds may be predicted by the momentary target tissue concentration of those compounds (Boyes et al. 2003; see also memorandum dated October 29, 2003, from Dr. William Boyes, U.S. EPA, to Dr. Lynn Flowers, U.S. EPA, "Potential use of PBPK modeling to support route-to-route extrapolation or duration adjustments for chronic exposure to toluene"). However, studies have been limited to the evaluation of functional changes of neurotoxicants other than toluene following acute exposure, which are reversible after termination of exposure, and subsequent clearance of the compound from tissues. A critical part of the acute research is the finding that the peak tissue concentration of trichloroethylene (a volatile organic compound with similar acute neurotoxicity to toluene) predicted momentary changes in neurological function, and that the total amount of exposure

(expressed either as air concentration x duration product or area under the curve of the tissue dose level) did not predict the measured effect (on visual function in this case) (Boyes et al., 2003).

In the case of chronic toluene exposure, it is not clear that the peak tissue concentration is the appropriate measure of internal dose to use in estimating the continuous exposure concentration that is associated with the observed neurotoxicity. The default duration and dosimetric adjustment method shown below for occupational studies (U.S. EPA, 1994) is based on the logical premise that the total amount of exposure, rather than the momentary tissue concentration, is the appropriate predictor of chronic toxic effects. At this time data are not available to determine the proper dose metric for the chronic effects of toluene exposure, thus the standard default methodology for duration adjustment was used.

5.2.3. RfC Derivation - Including Application of Uncertainty Factors

The NOAEL (average) of 34 ppm (128 mg/m³) was adjusted from an occupational exposure scenario to continuous exposure conditions as follows:

$$\begin{aligned}\text{NOAEL (adj)} &= \text{NOAEL (average)} \times \text{VE}_{\text{ho}}/\text{VE}_{\text{h}} \times 5 \text{ days}/7 \text{ days} \\ &= 128 \text{ mg/m}^3 \times 10\text{m}^3/20\text{m}^3 \times 5 \text{ days}/7 \text{ days} \\ &= 46 \text{ mg/m}^3\end{aligned}$$

Where:

VE_{ho} = human occupational default minute volume (10 m³ breathed during the 8 hour workday)

VE_h = human ambient default minute volume (20 m³ breathed during the entire day)

A total uncertainty factor of 10 was applied to the average NOAEL (i.e., 10 for consideration of intraspecies variation). A 10-fold uncertainty factor for intraspecies differences (UF_H) was used to account for potentially susceptible human subpopulations. This 10-fold uncertainty factor includes consideration of the Pelekis et al. (2001) model employing pharmacokinetic information to derive a chemical-specific intraspecies UF for toluene that accounts for childhood exposure only. Their analysis suggests an informed quantitation of adult-to-child variability reported to be in the 3-fold range. The Pelekis model is based on the pharmacokinetic differences between adults and children. However, the differences in human

susceptibility may also be due to lifestage (e.g., advanced age) differences among the adult population, genetic polymorphisms, decreased renal clearance in disease states, and unknown pharmacodynamic variations in response to toluene exposure. Since the variability defined in the Pelekis model may not account for these additional differences in pharmacokinetics and pharmacodynamics, a full factor of 10 is used.

An uncertainty factor to account for laboratory animal-to-human interspecies differences (UF_A) was not necessary because the point of departure is based on human exposure data.

An uncertainty factor to account for extrapolating from less than chronic results (UF_S) was not necessary. Most of the studies used in the analysis were of chronic duration.

An uncertainty factor was not needed to account for extrapolating from a LOAEL to a NOAEL because a surrogate NOAEL, i.e., an average NOAEL from a subset of studies, was used to derive the point of departure.

The database for inhalation exposure to toluene is considered adequate. Numerous human and animal chronic and subchronic studies are available. Animal studies have demonstrated reproductive and developmental effects of toluene at exposure levels higher than those used for the determination of the point of departure. In addition, neurotoxicity studies and a two-generation reproductive toxicity study are available. There is some uncertainty regarding potential immunological effects of toluene via the inhalation route of exposure. These uncertainties arise from the conflicting immunotoxicity data on toluene following oral exposure in animal studies (see Sections 4.2.1.1 and 5.1.1 for study descriptions). Two studies on immunologic effects following inhalation exposure are available. Stengel et al. (1998) assessed several immunological parameters in blood following chronic occupational exposure to 50 ppm toluene but no statistically significant effects were observed. Aranyi et al. (1985) examined the effects of inhalation exposure to toluene on pulmonary host defenses in animals and found transient effects at low doses with a lack of a dose-response relationship. These results indicate additional research may be needed to further evaluate the potential immunological effects of toluene by the inhalation route of exposure but do not warrant an uncertainty factor at this time. A database uncertainty factor is not considered necessary.

The RfC for toluene (with rounding to one significant figure) is derived as follows:

$$\begin{aligned}\text{RfC} &= \text{average NOAEL (adj)} \div \text{UF} \\ &= 46 \text{ mg/m}^3 \div 10 \\ &= 5 \text{ mg/m}^3\end{aligned}$$

5.2.4. Previous RfC Assessment

The previous IRIS assessment utilized the Foo et al. (1990) occupational study as the principal study and neurological effects as the critical effect for the derivation of the RfC (0.4 mg/m³). The LOAEL was identified as 332 mg/m³ (88 ppm), which was converted to a human equivalent concentration of 119 mg/m³. A composite UF of 300 was used that consisted of a 10-fold UF for intraspecies variability, a 10-fold UF for the use of a LOAEL instead of a NOAEL, and a three-fold UF for database deficiencies, including a lack of animal exposure data evaluating neurotoxicity and respiratory irritation. The current IRIS assessment takes into account a number of newer human studies that are available and incorporates newer methodologies.

5.3. CANCER ASSESSMENT

Under the *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005), there is inadequate information to assess the carcinogenic potential of toluene because studies of humans chronically exposed to toluene are inconclusive, toluene was not carcinogenic in adequate inhalation cancer bioassays of rats and mice exposed for life (CIIT, 1980; NTP, 1990; Huff, 2003), and increased incidences of mammary cancer and leukemia were reported in a lifetime rat oral bioassay at a dose level of 500 mg/kg-day but not at 800 mg/kg-day (Maltoni et al., 1997). Toluene has generally not been genotoxic in short-term testing protocols. A quantitative assessment of carcinogenic potential was not performed.

6. MAJOR CONCLUSIONS IN THE CHARACTERIZATION OF HAZARD AND DOSE RESPONSE

6.1. HUMAN HAZARD POTENTIAL

Toluene (CAS no. 108-88-3) has the chemical formula C_7H_8 (structural formula $C_6H_5CH_3$) and a molecular weight of 92.14. At room temperature, toluene is a clear-to-amber colorless liquid with a pungent, benzene-like odor. Toluene has a low vapor pressure that can result in volatilization into the air. It is flammable, with a flash point of 4.4 °C. Toluene is strongly reactive with a number of chemicals, particularly nitrogen-containing compounds, and may react with some plastics. Toluene is used as part of an additive to gasoline mixtures (BTEX) to increase octane ratings, in benzene production, and as a solvent in paints, coatings, inks, adhesives, and cleaners. Additionally, toluene is used in the production of nylon, plastics, and polyurethanes. Toluene was once used as an anthelmintic agent against roundworms and hookworms.

Data on the effects of toluene in humans following oral exposure are limited to case reports of accidental oral ingestions. One subchronic study examining oral exposure to toluene in rodents (rats and mice) is available. NTP (1990) exposed F-344 rats and B6C3F1 mice to toluene by gavage for 13 weeks. In male rats, absolute and relative weights of both the liver and kidney were significantly increased ($p < 0.05$) at doses greater than or equal to 446 mg/kg-day. Histopathologic lesions in the liver consisted of hepatocellular hypertrophy, occurring at doses greater than 2500 mg/kg. Nephrosis was observed in rats that died, and damage to the tubular epithelia of the kidney occurred in terminally sacrificed rats. Kidney sections were examined in particular for the occurrence of hyaline droplets in the proximal tubules with negative findings.

Toluene has been evaluated for immunosuppressive effects primarily in comparison studies with the known immunotoxicants benzene and nitrotoluenes (Hsieh et al., 1989, 1990b, 1991; Burns et al., 1994). For example, statistically significant and dose-related decreases in antibody response were noted by Hsieh et al. (1989, 1990b, 1991). There is evidence that the antibody-forming cell assay (PFC) is among the most predictive tests available for immunotoxicity (Luster et al., 1992) and that suppression of the antibody response may be predictive of decreased resistance to challenge with infectious agents or tumor cells (Luster et

al., 1993). However, the host resistance assays by Burns et al. (1994) indicate a lack of immunotoxic response when animals treated with toluene were challenged. Host resistance to challenges with *Listeria monocytogenes*, *Streptococcus pneumoniae*, *Plasmodium yoelii*, or B16F10 melanoma was not affected at a dose of 600 mg/kg-day for 14 days. In addition, a reduced incidence of tumors was observed in mice that were challenged with PYB6 fibrosarcoma.

Additional studies by Hsieh et al. (1990a, c) found statistically significant increases in brain neurotransmitter levels at exposure levels as low as 5 mg/kg-day, but these changes have not been correlated with behavioral, neuropsychological, or neuroanatomical changes. Several reproductive studies (Gospe et al., 1994, 1996; Gospe and Zhou, 1998, 2000) have indicated minimal effects on dams and offspring at the doses tested.

A number of occupational studies have examined the effects of toluene exposure via inhalation. The most sensitive effects observed in humans following inhalation exposure are neurologic effects, including altered color vision, dizziness, fatigue, headache, and decreased performance in neurobehavioral tests. Exposure to higher levels in humans and animals have resulted in respiratory tract irritation. Animal studies have also demonstrated effects on other organ systems at high exposure levels (generally 600 ppm or greater).

In mothers who inhaled very high levels of toluene as an addictive euphoric during pregnancy, the children showed a number of physical (small mid face, deep-set eyes, micrognathia, and blunting of the fingertips) and clinical (microcephaly, CNS dysfunction, attention deficits, and developmental delay/mental deficiency) changes attributed to toluene. Animal studies of toluene inhalation have revealed delayed neurodevelopment and decreased offspring weight at levels that also resulted in maternal toxicity. Gross malformations were not noted at any exposure level.

Under the *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005), *there is inadequate information to assess the carcinogenic potential* of toluene. Studies of humans who were chronically exposed to toluene are inconclusive. Toluene was not carcinogenic in inhalation cancer bioassays of rats and mice exposed for life (CIIT, 1980; NTP, 1990; Huff, 2003). Increased incidences of mammary cancer and leukemia were reported in a lifetime rat oral

bioassay at a dose level of 500 mg/kg-day but not at 800 mg/kg-day (Maltoni et al., 1997). Toluene has generally not been found to be genotoxic in short-term testing.

6.2. DOSE RESPONSE

6.2.1. Noncancer/Oral

There are no chronic or subchronic oral dose-response data for toluene in humans. A single lifetime gavage study in rats (Maltoni et al., 1997) did not adequately examine noncancer endpoints and was not suitable for use in derivation of an RfD. One subchronic study examining oral exposure to toluene in rodents (rats and mice) is available. This study (NTP, 1990) was chosen as the principal study for the derivation of the RfD. The critical effect is increased kidney weight. NTP (1990) exposed F-344 rats and B6C3F1 mice to toluene by gavage for 13 weeks. In male rats, absolute kidney weights were statistically significantly increased (100, 107, 112, 119, and 113% of controls; relative kidney weights were 100, 100, 106, 114, and 146% of controls for 0, 223, 446, 900, or 1800 mg/kg-day dose levels, respectively). Nephrosis was observed in rats that died, and damage to the tubular epithelia of the kidney occurred in terminally sacrificed rats. Kidney sections were examined in particular for the occurrence of hyaline droplets in the proximal tubules with negative findings. A BMDL of 238 mg/kg-day was derived based on increased kidney weight utilizing a BMR of one control SD from the control mean. This SD corresponds to 9% increase in kidney weight from control. A composite uncertainty factor of 3000 (10 for animal to human extrapolation, 10 for intrahuman variability, 10 for use of a subchronic study, and 3 for database uncertainty) was applied to give a chronic RfD of 0.08 mg/kg-day. Confidence in the principal study is medium. It is an adequate gavage study of subchronic duration. Confidence in the database is rated medium due to the lack of chronic data, neurotoxicity studies, and a two-generation reproductive toxicity study and uncertainty surrounding the immunotoxicity of toluene. An oral subchronic study in two species and several immunotoxicity studies are available. A number of oral and inhalation studies have demonstrated that toluene does not elicit developmental or reproductive effects except at doses that are significantly higher than those causing other systemic effects. The available toxicokinetic data indicate the absorption of toluene is similar and extensive following both oral and inhalation exposure. There is medium confidence in the resulting RfD.

6.2.2. Noncancer/Inhalation

A number of studies examining the toxicity of toluene following inhalation exposure in humans exist. The available data indicate that neurological effects are the most sensitive effect of chronic inhalation exposure to toluene. A subset of studies was chosen from which to derive a point of departure for the derivation of the RfC. A value of 34 ppm (128 mg/m³) was chosen as the point of departure. This value is the arithmetic mean of the available NOAELs as identified in Section 5.2.1. This value is lower than the LOAELs identified under human exposure conditions. An RfC of 5 mg/m³ was derived by adjusting the average NOAEL for continuous exposure and application of a 10-fold UF for intrahuman variability. Confidence in the database is high; multiple chronic studies in humans are available that examine neurotoxic effects and numerous animal reproductive and developmental studies, as well as a two-generation reproductive toxicity study, exist. There is high confidence in the resulting RfC.

6.2.3. Cancer/Oral and Inhalation

Under the *Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 2005), there is inadequate information to assess the carcinogenic potential for toluene. A quantitative assessment of carcinogenic potential was not performed.

7. REFERENCES

- Abbate, C; Giorgianni, C; Munao, F; et al. (1993) Neurotoxicity induced by exposure to toluene: an electrophysiologic study. *Int Arch Occup Environ Health* 64:389-392.
- ACGIH (American Conference of Governmental Industrial Hygienists). (2000) Threshold limit values for chemical substances and physical agents and biological exposure indices 2000. Cincinnati, OH: American Conference of Governmental Industrial Hygienists.
- Aitio, A; Pekari, K; Jarvisalo, J. (1984) Skin absorption as a source of error in biological monitoring. *Scand J Work Environ Health* 10:317-320.
- Al-Ghamdi, SS; Raftery, MJ; Yaqoob, MM. (2003) Acute solvent exposure induced activation of cytochrome P4502E1 causes proximate tubule necrosis by oxidative stress. *Toxicology In Vitro* 17:335-341.
- Ameno, K; Fuke, C; Ameno, S; et al. (1989) A fatal case of oral ingestion of toluene. *Forensic Sci Int* 41:255-260.
- Ameno, K; Kiri, T; Fuke, C; et al. (1992) Regional brain distribution of toluene in rats and in a human autopsy. *Arch Toxicol* 66:153-156.
- Andersen, I; Lundqvist, GR; Molhave, L; et al. (1983) Human response to controlled levels of toluene in six-hour exposures. *Scand J Work Environ Health* 9:405-418.
- Angerer, J. (1979) Occupational chronic exposure to organic solvents. VII. Metabolism of toluene in man. *Int Arch Occup Environ Health* 43:63-67.
- Angerer, J; Schildbach, M; Kramer, A. (1998) S-p-toluymercapturic acid in the urine of workers exposed to toluene: a new biomarker for toluene exposure. *Arch Toxicol* 72:119-123.
- Antti-Poika, M; Juntunen, J; Matikainen, E; et al. (1985) Occupational exposure to toluene: neurotoxic effects with special emphasis on drinking habits. *Int Arch Occup Environ Health* 56:31-40.
- Anttila, A; Pukkala, E; Riala, R; et al. (1998) Cancer incidence among Finnish workers exposed to aromatic hydrocarbons. *Int Arch Occup Environ Health* 71:187-193.
- API (American Petroleum Institute). (1981) 26-Week inhalation toxicity study of toluene in the rat. Conducted by Biodynamics Inc. and Institute of Neurotoxicity, Albert Einstein College of Medicine for API, Washington, DC. Submitted under TSCA Section FYI. EPA Document No. FYI-AX-1081-0136. NTIS No. OTS0000136-0.
- API. (1984) Two-generation inhalation reproduction/fertility study on a petroleum-derived hydrocarbon. Submitted under TSCA Section FYI. EPA Document No. FYI-AX-0284-0294. NTIS No. OTS0000294-0.
- Aranyi, C; O'Shea, WJ; Sherwood, RL; et al. (1985) Effects of toluene inhalation on pulmonary host defenses of mice. *Toxicol Lett* 25:103-10.
- Askergren, A. (1982) Organic solvents and kidney function. *Adv Mod Environ Toxicol* 2:157-172.
- ATSDR (Agency for Toxic Substances and Disease Registry). (2000) Toxicological profile for toluene. Available from ATSDR, Atlanta, GA, and <<http://www.atsdr.cdc.gov/toxprofiles/>>.
- Baelum, J; Andersen, I; Lundqvist, GR; et al. (1985) Response of solvent-exposed printers and unexposed controls to six-hour toluene exposure. *Scand J Work Environ Health* 11:271-280.

- Baelum, J; Dossing, M; Hansen, SH; et al. (1987) Toluene metabolism during exposure to varying concentrations combined with exercise. *Int Arch Occup Environ Health* 59:281-294.
- Baelum, J; Lundqvist, G; Molhave, L; et al. (1990) Human response to varying concentrations of toluene. *Int Arch Occup Environ Health* 62:65-71.
- Baelum, J; Molhave, L; Honore Hansen, S; et al. (1993) Hepatic metabolism of toluene after gastrointestinal uptake in humans. *Scand J Work Environ Health* 19:55-62.
- Balster, RL. (1998) Neural basis of inhalant abuse. *Drug Alcohol Dep* 512:207-214.
- Bauchinger, M; Schmid, E; Dresch, J; et al. (1982) Chromosome change in lymphocytes after occupational exposure to toluene. *Mutat Res* 102:439-445.
- Benignus, VA; Muller, KE; Graham, JA; et al. (1984) Toluene levels in blood and brain of rats as a function of toluene level in inspired air. *Environ Res* 33:39-46.
- Benignus VA; Boyes, WK; Bushnell, PJ. (1998) A dosimetric analysis of behavioral effects of acute toluene exposure in rats and humans. *Toxicol Sci* 43:186-195.
- Benoit, FM; Davidson, WR; Lovett, AM; et al. (1985) Breath analysis by API/MS human exposure to volatile organic solvents. *Int Arch Occup Environ Health* 55:113-120.
- Bergman, K. (1979) Whole-body autoradiography and allied tracer techniques in distribution and elimination studies of some organic solvents: benzene, toluene, xylene, styrene, methylene chloride, chloroform, carbon tetrachloride and trichloroethylene. *Scand J Work Environ Health* 5(Suppl 1):1-263.
- Boey, KW; Foo, SC; Jeyaratnam, J. (1997) Effects of occupational exposure to toluene: a neuropsychological study on workers in Singapore. *Ann Acad Med Singapore* 26:84-87.
- Boman, A; Hagelthorn, G; Magnusson, K. (1995) Percutaneous absorption of organic solvents during intermittent exposure in guinea pigs. *Acta Derm Venereol* 75:114-119.
- Bonzel, KE; Muller-Wiefel, DE; Ruder, H; et al. (1987) Anti-glomerular basement membrane antibody-mediated glomerulonephritis due to glue sniffing. *Eur J Pediatr* 146:296-300.
- Bos, RP; Brouns, RME; van Doorn, R; et al. (1981) Non-mutagenicity of toluene, o-, m-, and p-xylene, o-methylbenzylalcohol and o-methylbenzylsulfate in the Ames assay. *Mutat Res* 88:273-279.
- Bosch, X; Campistol, JM; Montolie, J; et al. (1988) Myelofibrosis and focal segmental glomerular sclerosis associated with toluene poisoning. *Human Toxicol* 7:357-361.
- Bowman, MJ; Collins, MJ; Henry, CJ. (1984) The effect of age on performance on the panel D-15 and desaturated D-15: a quantitative evaluation. In: Verriest G, editor. *Colour vision deficiencies, VII*. The Hague: Dr. W. Junk Publishers, pp. 227-231.
- Boyes, WK; Bercegeay, M; Ali, JS; et al. (2003) Dose-based duration adjustments for the effects of inhaled trichloroethylene on rat visual function. *Toxicol Sci* 76:121-130.
- Brugnone, F; Gobbi, M; Ayyad, K; et al. (1995) Blood toluene as a biological index of environmental toluene exposure in the "normal" population and in occupationally exposed workers immediately after exposure and 16 hours later. *Int J Occup Environ Health* 66:421-425.

- Burmistrov, SO; Arutyunyan, AV; Stepanov, MG; et al. (2001) Effect of chronic inhalation of toluene and dioxane on activity of free radical processes in rat ovaries and brain. *Bull Exp Biol Med* 132:832-836.
- Burns, LA; Bradley, SG; White, KL, Jr; et al. (1994) Immunotoxicity of mono-nitrotoluenes in female B6C3F1 mice. I. Para-nitrotoluene. *Drug Chem Toxicol* 17:317-358.
- Byrne, A; Kirby, B; Zibin, T; et al. (1991) Psychiatric and neurological effects of chronic solvent abuse. *Can J Psychiatry* 36:735-738.
- Campagna, D; Stengel, B; Mergler, D; et al. (2001) Color vision and occupational toluene exposure. *Neurotoxicol Teratol* 23:473-480.
- Campo, P; Lataye, R; Cossec, B; et al. (1998) Combined effects of simultaneous exposure to toluene and ethanol on auditory function in rats. *Neurotoxicol Teratol* 20:321-332.
- Caravati, EM; Bjerk, PJ. (1997) Acute toluene ingestion toxicity. *Ann Emerg Med* 30:838-839.
- Carlier, B; Schroeder, E; Mahieu, P. (1980) A rapidly and spontaneously reversible Goodpasture's syndrome after carbon tetrachloride inhalation. *Acta Clin Belg* 35:193-198.
- Carlsson, A. (1982) Exposure to toluene: uptake, distribution and elimination in man. *Scand J Work Environ Health* 8:43-55.
- Cavalleri, A; Gobba, F; Nicali, E; et al. (2000) Dose-related color vision impairment in toluene-exposed workers. *Arch Env Health* 55:399-404.
- Chouaniere, D; Wild, P; Fontana, JM; et al. (2002) Neurobehavioral disturbances arising from occupational toluene exposure. *Am J Ind Med* 41:77-88.
- CIIT (Chemical Industry Institute of Toxicology). (1980) A twenty-four month inhalation toxicology study in Fischer-344 rats exposed to atmospheric toluene. Conducted by Industrial Bio-Test Laboratories, Inc., Decatur, IL, and Experimental Pathology Laboratories, Inc., Raleigh, NC, for CIIT, Research Triangle Park, NC.
- Connor, TH; Theiss, JC; Hanna, HA; et al. (1985) Genotoxicity of organic chemicals frequently found in the air of mobile homes. *Toxicol Lett* 25:33-40.
- Courtney, KD; Andrews, JE; Springer, J; et al. (1986) A perinatal study of toluene in CD-1 mice. *Fund Appl Toxicol* 6:145-154.
- Crofton, KM; Lassiter, TL; Rebert, CS. (1994) Solvent-induced ototoxicity in rats: an atypical selective mid-frequency hearing deficit. *Hear Res* 80:25-30.
- Cruz, SL; Mirshahi, T; Thomas, B; et al. (1998) Effects of the abused solvent toluene on recombinant N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors expressed in *Xenopus* oocytes. *J Pharmacol Exp Ther* 286:334-340.
- Dalgaard, M; Hossaini, A; Hougaard, KS; et al. (2001) Developmental toxicity of toluene in male rats: effects on semen quality, testis morphology, and apoptotic neurodegeneration. *Arch Toxicol* 75:103-109.
- DaSilva, VA; Malheiros, LR; Bueno, FMR. (1990) Effects of toluene exposure during gestation on neurobehavioral development of rats and hamsters. *Brazil J Med Biol Res* 23:533-537.
- Dean, JH. (1997) Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals. *Toxicology* 119:95-101.

- DeJongh, J; Blaauboer, BJ. (1996) Simulation of toluene kinetics in the rat by a physiologically based pharmacokinetic model with application of biotransformation parameters derived independently in vitro and in vivo. *Fund Appl Toxicol* 32:260-268.
- DeJongh, J; Blaauboer, BJ. (1997) Evaluation of in vitro-based simulations of toluene uptake and metabolism in rats. *Toxicol In Vitro* 11:485-489.
- Devathasan, G; Low, D; Teoh, PC; et al. (1984) Complications of chronic glue (toluene) abuse in adolescents. *Aust.NZ J Med* 14:39-43.
- Dick, F; Semple, S; Chen, R; et al. (2000) Neurological deficits in solvent-exposed painters: a syndrome including impaired colour vision, cognitive defects, tremor and loss of vibration sensation. *Q J Med* 93:655-661.
- Dobrokhotoy, VB; Enikeev, MI. (1977) [The mutagenic action of benzene, toluene and a mixture of these hydrocarbons in a chronic test.] *Gig Sanit* 42:32-34 (in Russian—evaluation based on an English translation).
- Dossing, M; Aelum, JB; Hansen, SH; et al. (1983) Urinary hippuric acid and orthocresol excretion in man during experimental exposure to toluene. *Br J Ind Med* 40:470-473.
- Dutkiewicz, T; Tyras, H. (1968) Skin absorption of toluene, styrene and xylene by man. *Br J Ind Med* 25:243.
- Dyer, RS; Bercegeay, MS; Mayo, LM. (1988) Acute exposures to p-xylene and toluene alter visual information processing. *Neurotox Teratol* 10:147-153.
- Echeverria, D; Fine, L; Langolf, G; et al. (1989) Acute neurobehavioral effects of toluene. *Br J Ind Med* 46:483-495.
- Egle, JL, Jr.; Gochberg, BJ. (1976) Respiratory retention of inhaled toluene and benzene in the dog. *J Toxicol Environ Health* 1:531-538.
- Ehyai, A; Freemon, FR. (1983) Progressive optic neuropathy and sensineural hearing loss due to chronic glue sniffing. *J Neurol Neurosurg Psychiatry* 46:349-51.
- Eller, N; Netterstrom, B; Laursen, P. (1999) Risk of chronic effects on the central nervous system at low toluene exposure. *Occup Med* 49:389-395.
- Engelke, M; Tahti, H; Vaalavirta, L. (1996) Perturbation of artificial and biological membranes by organic compounds of aliphatic, alicyclic, and aromatic structure. *Toxicol In Vitro* 10:111-115.
- Fabietti, F; Ambruzzi, A; Delise, M; et al. (2004) Monitoring of the benzene and toluene contents in human milk. *Environ Int* 30:397-401.
- Filley, CM; Heaton, RK; Rosenberg, NL. (1990) White matter dementia in chronic toluene abuse. *Neurology* 40:532-534.
- Fisher, J; Mahle, D; Bankston, L; et al. (1997) Lactational transfer of volatile chemicals in breast milk. *American Ind Hyg Assoc J* 58:425-431.
- Fischman, CM; Oster, JR. (1979) Toxic effects of toluene: a new cause of high anion gap metabolic acidosis. *JAMA* 241:1713-1715.
- Fluck, ER; Poirier, LA; Ruelius, HW. (1976) Evaluation of a DNA polymerase-deficient mutant of *E. coli* for rapid detection of carcinogens. *Chem Biol Interact* 15:219-231.

- Foo, SC; Phoon, WO; Khoo, NY. (1988) Toluene in blood after exposure to toluene. *Am Ind Hyg Assoc J* 49:255-258.
- Foo, SC; Jeyaratnam, J; D. Koh, D. (1990) Chronic neurobehavioral effects of toluene. *Br J Ind Med* 47:480-484.
- Forni, A; Pacifico, E; Limonta, A. (1971) Chromosome studies in workers exposed to benzene or toluene or both. *Arch Environ Health* 22:373-378.
- Franchini, I; Cavatorta, A; Falzoi, M; et al. (1983) Early indicators of renal damage in workers exposed to organic solvents. *Int Arch Occup Environ Health* 52:1-9.
- Franks, NP; Lieb, WR. (1985) Mapping of general anaesthetic target sites provides a molecular basis for cutoff effects. *Nature* 316:349-351.
- Franks, NP; Lieb, WR. (1987) Anaesthetics on the mind. *Nature* 328:113-114.
- Funes-Craviota, F; Kolmodin-Hedman, B; Lindsten, J; et al. (1977) Chromosome aberrations and sister-chromatid exchange in workers in chemical laboratories and a rototyping factory and in children of women laboratory workers. *Lancet* 2:322-325.
- Geller, AM; Hudnell, HK. (1997) Critical issues in the use and analysis of the Lanthony desaturate color vision test. *Neurotoxicol Teratol* 19:455-465.
- Gericke, C; Hanke, B; Beckmann, G; et al. (2001) Multicenter field trial on possible health effects of toluene. III. Evaluation of effects after long-term exposure. *Toxicology* 168:185-209.
- Gerner-Smidt, P; Friedrich, U. (1978) The mutagenic effect of benzene, toluene and xylene studied by the SCE technique. *Mutat Res* 58:313-316.
- Ghantous, H; Danielsson, BRG. (1986) Placental transfer and distribution of toluene, xylene and benzene and their metabolites during gestation in mice. *Biol Res Pregnancy Perinatol* 7:98-105.
- Ghittori, S; Imbriani, M; Pezzagno, G; et al. (1987) The urinary concentration of solvents as a biological indicator of exposure: proposal for the biological equivalent exposure limit for nine solvents. *Am Ind Hyg Assoc J* 48:786-90.
- Gibson, JE; Hardisty, JF. (1983) Chronic toxicity and oncogenicity bioassay of inhaled toluene in Fischer-344 rats. *Fund Appl Toxicol* 3:315-319.
- Gobba, F; Righi, E; Fantuzzi, G; et al. (1998) Two-year evolution of perchloroethylene-induced color-vision loss. *Arch Environ Health* 53:196-8.
- Gobba, F. (2000) Color vision: a sensitive indicator of exposure to neurotoxins. *Neurotoxicology* 21:857-862.
- Gobba, F; Cavalleri, A. (2003) Color vision impairment in workers exposed to neurotoxic chemicals. *Neurotoxicology* 24:693-702.
- Gogal, RM; Ahmed, SA; Smith, SA; et al. (1999) Mandates to develop non-mammalian models for chemical immunotoxicity evaluation: are fish a viable alternate to rodents? *Toxicol Lett* 106:89-92.
- Goodwin, TM. (1988) Toluene abuse and renal tubular acidosis in pregnancy. *Obstet Gynecol* 71:715-718.
- Gospe, S; Al-Bayati, M. (1994) Comparison of oral and inhalation exposures to toluene. *Int J Toxicol* 13:21-32.

- Gospe, SM, Jr; Zhou, SS. (1998) Toluene abuse embryopathy: longitudinal neurodevelopmental effects of prenatal exposure to toluene in rats. *Reprod Toxicol* 12:119-126.
- Gospe, SM, Jr; Zhou, SS. (2000) Prenatal exposure to toluene results in abnormal neurogenesis and migration in rat somatosensory cortex. *Pediatr Res* 47:362-368.
- Gospe, SM, Jr; Saeed, DB; Zhou, SS; et al. (1994) The effects of high-dose toluene on embryonic development in the rat. *Pediatr Res* 36:811-815.
- Gospe, SM, Jr; Zhou, SS; Saeed, DB; et al. (1996) Development of a rat model of toluene-abuse embryopathy. *Pediatr Res* 40:82-87.
- Griff, ER. (1991) Electroretinographic components arising in the distal retina. In: Heckinlively, JR; Arden, GB, editors. *Principles and practice of clinical electrophysiology of vision*. St. Louis, MO: Mosby-Year Book, Inc., pp. 91-98.
- Haglund, U; Lundberg, I; Zech, L. (1980) Chromosome aberrations and sister chromatid exchanges in Swedish paint industry workers. *Scand J Environ Health* 6:291-298.
- Harabuchi, I; Kishi, R; Ikeda, T; et al. (1993) Circadian variations of acute toxicity and blood and brain concentrations of inhaled toluene in rats. *Br J Ind Med* 50:280-286.
- Hart, WM. (1987) Acquired dyschromatopsias. *Surv Ophthalmol* 32:10-31.
- Hart, WM. (1992) Color vision. In: Hart, W.M., editor. *Adler's physiology of the eye: clinical application*. St. Louis, MO: Mosby-Year Book, Inc., pp. 708-727.
- Hass, U; Lund, SP; Hougaard, KS; et al. (1999) Developmental neurotoxicity after toluene inhalation exposure in rats. *Neurotoxicol Teratol* 21:349-357.
- Hersh, JH; Podruch, PE; Rogers, G; et al. (1985) Toluene embryopathy. *J Pediatr* 106:922-927.
- Hobara, T; Kobayashi, H; Higashihara, E; et al. (1984) Experimental study on the pulmonary absorption and excretion of toluene. *Int Arch Occup Environ Health* 53:337-344.
- Hormes, JT; Filley, CM; Rosenberg, NL. (1986) Neurologic sequelae of chronic solvent vapor abuse. *Neurology* 36:698-702.
- Hougaard, KS; Hass, U; Lund, SP; et al. (1999) Effects of prenatal exposure to toluene on postnatal development and behavior in rats. *Pharmacol Toxicol* 92:148-152.
- Hougaard, KS; Hansen, AM; Hass, U; et al. (2003) Toluene depresses plasma corticosterone in pregnant rats. *Neurotoxicol Teratol* 21:241-250.
- Hsieh, GC; Sharma, RP; Parker, RD. (1989) Immunotoxicological evaluation of toluene exposure via drinking water in mice. *Environ Res* 49:93-103.
- Hsieh, GC; Sharma, RP; Parker, RD; et al. (1990a) Evaluation of toluene exposure via drinking water on levels of regional brain biogenic monoamines and their metabolites in CD-1 mice. *Ecotoxicol Environ Saf* 20:175-184.
- Hsieh, GC; Parker, RDR; Sharma, RP; et al. (1990b) Subclinical effects of ground water contaminants. III. Effects of repeated oral exposure to combinations of benzene and toluene on immunologic responses in mice. *Arch Toxicol* 64:320-328.

- Hsieh, GC; Sharma, RP; Parker, RD. (1990c) Subclinical effects of groundwater contaminants. Effects of repeated oral exposure to combinations of benzene and toluene on regional brain monoamine metabolism in mice. *Arch Toxicol* 64:669-676.
- Hsieh, GC; Sharma, RP; Parker, RD. (1991) Hypothalamic-pituitary-adrenocortical axis activity and immune function after oral exposure to benzene and toluene. *Immunopharmacol* 21:23-31.
- Huang, J; Asaeda, N; Takeuchi, Y; et al. (1992) Dose dependent effects of chronic exposure to toluene on neuronal and glial cell marker proteins in the central nervous system of rats. *Br J Ind Med* 49:282-286.
- Huff, J. (2003) Absence of carcinogenic activity in Fischer rats and B6C3F1 mice following 103-week inhalation exposures to toluene. *Int J Occup Environ Health* 9:138-146.
- Hunnewell, J; Miller, NR. (1998) Bilateral internuclear ophthalmoplegia related to chronic toluene abuse. *J Neuroophthalmol* 18:277-280.
- IARC.(International Agency for Research on Cancer). (1999) IARC monographs on the evaluation of carcinogenic risks of chemicals to humans. Vol. 71, Part 2. Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. Lyon, France: International Agency for Research on Cancer, pp. 829-864.
- Ikedo, M; Ohtsuji, H. (1971) Phenobarbital-induced protection against toxicity of toluene and benzene in the rat. *Toxicol Appl Pharmacol* 20:30-43.
- Ikedo, N; Takahashi, H; Umetsu, K; et al. (1990) The course of respiration and circulation in toluene-sniffing. *Forensic Sci Intern* 44:151-158.
- Inoue, O; Seiji, K; Watanabe, T; et al. (1986) Possible ethnic difference in toluene metabolism: a comparative study among Chinese, Turkish and Japanese solvent workers. *Toxicol Lett* 34:167-174.
- Iregren, A; Andersson, M; Nylen, P. (2002) Color vision and occupational exposures: 1. An overview of tests and effects. *Neurotoxicology* 23:719-733.
- Jonai, H; Sato, M. (1988) Exposure indices for painters exposed to toluene and xylene at low concentrations. *Ind Health* 26:197-202.
- Kamijima, M; Nakazawa, Y; Yamakawa, M; et al. (1994) Metabolic acidosis and renal tubular injury due to pure toluene inhalation. *Arch Environ Health* 49:410-413.
- Kawai, T; Yasugi, T; Mizunuma, K; et al. (1992a) Comparative evaluation of urinalysis and blood analysis as means of detecting exposure to organic solvents at low concentrations. *Int Arch Occup Environ Health* 64:223-234.
- Kawai, T; Yasugi, T; Mizunuma, K; et al. (1992b) Monitoring of workers exposed to a mixture of toluene, styrene and methanol vapours by means of diffusive air sampling, blood analysis and urinalysis. *Int Arch Occup Environ Health* 63:429-435.
- Kawai, T; Yasugi, T; Mizunuma, K; et al. (1993) Comparative evaluation of blood and urine analysis as a tool for biological monitoring of n-hexane and toluene. *Int Arch Occup Environ Health* 65:S123-S126.
- Kawamoto, T; Murata, K; Koga, M; et al. (1994) Distribution of urinary hippuric acid concentrations by ALDH2 genotype. *Occup Environ Med* 51:817-821.
- King, MD; Day, RE; Oliver, JS; et al. (1981) Solvent encephalopathy. *Br Med J* 283:663-665.

- Kiyokawa, M; Mizota, A; Takasoh, M; et al. (1999) Pattern visual evoked cortical potentials in patients with toxic optic neuropathy caused by toluene abuse. *Jpn J Ophthalmol* 43:438-442.
- Kostas, J; Hotchin, J. (1981) Behavioral effects of low-level perinatal exposure to toluene in mice. *Neurobehav Toxicol Teratol* 3:467-469.
- Kostrzewski, P; Piotrowski, JK. (1991) Toluene determination in capillary blood as a biological indicator of exposure to low levels of toluene. *Pol J Occup Med Environ Health* 4:249-259.
- Kroeger, RM; Moore, RJ; Lehman, TH; et al. (1980) Recurrent urinary calculi associated with toluene sniffing. *J Urol* 123:89-91.
- Lataye, R; Campo, P; Pouyatos, B; et al. (2003) Solvent ototoxicity in the rat and guinea pig. *Neurotoxicol Teratol* 25:39-50.
- Lazar, RB; Ho, SU; Melen, O; et al. (1983) Multifocal central nervous system damage caused by toluene abuse. *Neurology* 33:1337-1340.
- Lee, B; Lee, S; Lee, K; et al. (1988) Dose-dependent increase in subjective symptom prevalence among toluene-exposed workers. *Ind Health* 26:11-23.
- Leeder, JS; Kearns, GL. (1997) Pharmacogenetics in pediatrics: implications for practice. *Pediatr Clin North Am* 44:55-77.
- Leung, HW; Paustenbach, DJ. (1988) Application of pharmacokinetics to derive biological exposure indexes from threshold limit values. *Am Ind Hyg Assoc J* 49:445-450.
- Litton Bionetics, Inc. (1981) Mutagenicity evaluation of toluene mouse dominant lethal assay [final report]. Submitted to the American Petroleum Institute, Washington, DC. LBI Project No. 21141-05, p. 58.
- Löf, A; Wallen, M; Hjelm, EW. (1990) Influence of paracetamol and acetylsalicylic acid on the toxicokinetics of toluene. *Pharmacol Toxicol* 66:138-141.
- Löf, A; Hjelm, EW; Colmsjö, A; et al. (1993) Toxicokinetics of toluene and urinary excretion of hippuric acid after human exposure to ²H₈-toluene. *Br J Ind Med* 50:55-59.
- Lowry, LK. (1987) Review of biological monitoring tests for toluene. In: M.H. Ho, MH; Dillon, HK, editors. *Biological monitoring of exposure to chemicals*. New York, NY: John Wiley & Sons, Inc. pp 99-109.
- Luster, MI; Ackermann, MF; Germolec, DR; et al. (1989). Perturbations of the immune system by xenobiotics. *Environ Health Perspect* 81:157-162.
- Luster, MI; Portier, C; Pait, DG; et al. (1992) Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. *Fund Appl Toxicol* 18:200-210.
- Luster, MI; Portier, C; Pait, DG; et al. (1993) Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. *Fund Appl Toxicol* 21:71-82.
- Lyapkalo, AA. (1973) Genetic activity of benzene and toluene. *Gig Tr Prof Zabol* 17:24-28. (in Russian—evaluation based on an English translation provided by the U.S. EPA.)
- Maas, EF; Ashe, J; Spiegel, P; et al. (1991) Acquired pendular nystagmus in toluene addiction. *Neurology* 41:282-285.

- Maestri, L; Ghittori, S; Imbriani, M. (1997) Determination of specific mercapturic acids as an index of exposure to environmental benzene, toluene, and styrene. *Ind Health* 35:489-501.
- Maki-Paakkanen, J; Husgafvel-Pursiainen, K; Kalliomaki, PL; et al. (1980) Toluene-exposed workers and chromosome aberrations. *J Toxicol Environ Health* 6:775-781.
- Malm, G; Lying-Tunell, U. (1980) Cerebellar dysfunction related to toluene sniffing. *Acta Neurol Scand* 62:188-190.
- Maltoni, C; Ciliberti, A; Pinto, C; et al. (1997) Results of long-term experimental carcinogenicity studies of the effects of gasoline, correlated fuels, and major gasoline aromatics on rats. *Ann NY Acad Sci* 837:15-52.
- Mattsson, JL; Albee, RR; Gorzinski, SJ. (1989) Similarities of toluene and o-cresol neuroexcitation in rats. *Neurotoxicol Teratol* 11:71-75.
- McWilliams, ML; Chen, GD; Fechter, LD. (2000) Low-level toluene disrupts auditory function in guinea pigs. *Toxicol Appl Pharmacol* 167:18-29.
- Mehta, CS; Sun, PN; Zikarge, A; et al. (1998) Acute toxicity of toluene in male and female rats: a single oral dose exposure 2-week study. *Toxic Substances Mechanisms* 17:43-55.
- Mergler, D; Blain, L; Lagace, JP. (1987) Solvent related colour vision loss: an indicator of neural damage? *Int Arch Occup Environ Health* 59:313-321.
- Mergler, D; Blain, L; Lemaire, J; et al. (1988a) Colour vision impairment and alcohol consumption. *Neurotoxicol Teratol* 10:255-260.
- Mergler, D; Belanger, S; De Grosbois, S; et al. (1988b) Chromal focus of acquired chromatic discrimination loss and solvent exposure among printshop workers. *Toxicology* 49:341-348.
- Mergler, D; Huel, G; Belanger, S; et al. (1996) Surveillance of early neurotoxic dysfunction. *Neurotoxicology* 17:803-812.
- Meulenbelt, J; de Groot, G; Savelkoul, TJ. (1990) Two cases of acute toluene intoxication. *Br J Ind Med* 47:417-420.
- Mihic, SJ; McQuilkin, SJ; Eger, EI; et al. (1994) Potentiation of γ -aminobutyric acid type A receptor-mediated chloride currents by novel halogenated compounds correlated with their abilities to induce general anesthesia. *Mol Pharmacol* 46:851-857.
- Mizunuma, K; Horiguchi, S; Kawai, T; et al. (1994) Toluene in blood as a marker of choice for low level exposure to toluene. *Int J Occup Environ Health* 66:309-315.
- Miyagi, Y; Shima, F; Ishido, K; et al. (1999) Tremor induced by toluene misuse successfully treated by a Vim thalamotomy. *J Neurosurg Psych* 66:794-796.
- Monster, AC; Kezic, S; van de Gevel, I; et al. (1993) Evaluation of biological monitoring parameters for occupational exposure to toluene. *Int Arch Occup Environ Health* 65(Suppl):159-162.
- Morata, TC; Fiorini, AC; Fischer, FM; et al. (1997) Toluene-induced hearing loss among rotogravure printing workers. *Scand J Work Environ Health* 23:289-298.

- Morgan, DL; Cooper, SW; Carlock, DL; et al. (1991) Dermal absorption of neat and aqueous volatile organic chemicals in the Fischer 344 rat. *Environ Res* 55:51-63.
- Mortelmans, K.E. and E.S. Riccio. (1980) In vitro microbiological genotoxicity assays of toluene. Prepared by SRI International, Menlo Park, CA, under Contract No. 68-02-2947 for the U.S. EPA, Research Triangle Park, NC, p. 25.
- Murata, K; Araki, S; Yokoyama, K; et al. (1993) Cardiac autonomic dysfunction in rotogravure printers exposed to toluene in relation to peripheral nerve conduction. *Ind Health* 31:79-90.
- Murata, M; Tsujikawa, M; Kawanishi, S. (1999) Oxidative DNA damage by minor metabolites of toluene may lead to carcinogenesis and reproductive dysfunction. *Biochem Biophys Res Commun* 261:478-483.
- Muttray, A; Wolters, V; Mayer-Popken, O; et al. (1995) Effect of subacute occupational exposure to toluene on color vision. *Int J Occup Med Environ Health* 8:339-345.
- Muttray, A; Wolters, V; Jung, D; et al. (1999) Effects of high doses of toluene on color vision. *Neurotox Teratol* 21:41-45.
- Nakai, N; Murata, M; Nagahama, M.; et al. (2003) Oxidative DNA damage induced by toluene is involved in its male reproductive toxicity. *Free Rad Res* 37:69-76.
- Nakajima, T; Wang, RS. (1994) Induction of cytochrome P450 by toluene. *Int J Biochem* 26:1333-1340.
- Nakajima, T; Wang, RS; Katakura, Y; et al. (1992) Sex-, age- and pregnancy-induced changes in the metabolism of toluene and trichloroethylene in rat liver in relation to the regulation of cytochrome P45011E1 and P45011C11 content. *J Pharmacol Exp Ther* 261:869-874.
- Nakajima, T; Wang, RS; Elovaara, E; et al. (1997) Toluene metabolism by cDNA-expressed human hepatic cytochrome P-450. *Biochem Pharmacol* 53:271-277.
- Nakamura, S; Oda, Y; Shimada, T; et al. (1987) SOS-inducing activity of chemical carcinogens and mutagens in *Salmonella typhimurium* TA1535/pSK1002: examination with 151 chemicals. *Mutat Res* 192:239-246.
- Nakatsuka, H; Watanabe, T; Takeuchi, Y; et al. (1992) Absence of blue-yellow color vision loss among workers exposed to toluene or tetrachloroethylene, mostly at levels below exposure limits. *Int Arch Occup Environ Health* 64:113-117.
- Nestmann, ER; Lee, EGH; Matula, TI; et al. (1980) Mutagenicity of constituents identified in pulp and paper mill effluents using the *Salmonella*/mammalian-microsome assay. *Mutat Res* 79:203-212.
- Neubert, D; Gericke, C; Hanke, B; et al. (2001) Multicenter field trial on possible health effects of toluene. II. Cross-sectional evaluation of acute low-level exposure. *Toxicology* 168:139-183.
- Ng, TP; Ong, SG; Lam, WK; et al. (1990) Urinary levels of proteins and metabolites in workers exposed to toluene. *Int Arch Occup Environ Health* 62:43-46.
- Nielsen, HK; Krusell, L; Baelum, J; et al. (1985) Renal effects of acute exposure to toluene. A controlled clinical trial. *Acta Med Scand* 218:317-321.
- NIOSH (National Institute of Occupational Safety and Health). (1974) New publication 74-137. Available from: National Technical Information Service, Springfield, VA.

NIOSH (1983) Determination of the reproductive effects in mice of nine selected chemicals. Prepared by Smith, KN, Bioassay Systems Corporation, Woburn, MA. Available from: National Technical Information Service, Springfield, VA; PB84183540.

Nise, G; Orbaek, P. (1988) Toluene in venous blood during and after work in rotogravure printing. *Int Arch Occup Environ Health* 60:31-35.

Nise, G; Attewell, R; Skerving, S; et al. (1989) Elimination of toluene from venous blood and adipose tissue after occupational exposure. *Br J Ind Med* 46:407-411.

Nise, G; Hogstedt, B; Bratt, I; et al. (1991) Cytogenetic effects in rotogravure printers exposed to toluene (and benzene). *Mutat Res* 261:217-223.

NRC (National Research Council). (1983) Risk assessment in the federal government: managing the process. Washington, DC: National Academy Press. Available from: <<http://books.nap.edu/books/POD115/html/index.html>>.

NTP (National Toxicology Program). (1990) Toxicology and carcinogenesis studies of toluene (CAS No. 108-88-3) in F344/N rats and B6C3F1 mice (inhalation studies). Public Health Service, U.S. Department of Health and Human Services; NTP TR 371. Available from: National Institute of Environmental Health Sciences, Research Triangle Park, NC.

NTP. (2002) 10th report on carcinogens. Public Health Service, U.S. Department of Health and Human Services, Research Triangle Park, NC. Available from: <<http://ehp.niehs.nih.gov/roc/toc10.html>>.

NTP. (2001) Chemical Health and Safety Data. Online. Public Health Service, U.S. Department of Health and Human Services, Research Triangle Park, NC; <http://ntp-server.niehs.nih.gov/Main_Pages/Chem-HS.html>.

O'Brien, ET; Yeoman, WB; Hobby, JA. (1971) Hepatorenal damage from toluene in a "glue sniffer." *Br Med J* 2(752):29-30.

Ono, A; Sekita, K; Ohno, K; et al. (1995) Reproductive and developmental toxicity studies of toluene: I. Teratogenicity study of inhalation exposure in pregnant rats. *J Toxicol Sci* 20:109-34.

Ono, A; Sekita, K; Ogawa, Y; et al. (1996) Reproductive and developmental toxicity studies of toluene: II. Effects of inhalation exposure on fertility in rats. *J Environ Pathol Toxicol Oncol* 15:9-20.

Orbaek, P; Nise, G. (1989) Neurasthenic complaints and psychometric function of toluene-exposed rotogravure printers. *Am J Ind Med* 16:67-77.

OSHA (Occupational Safety and Health Administration). (1993) 29 CFR Part 1910. Air contaminants; rule. *Fed Regist* 58(124):35338-35351.

Palermo-Neto, J; Santos, FA; Guerra, JL; et al. (2001) Glue-solvent inhalation impairs host resistance to *Mycobacterium bovis*-induced infection in hamsters. *Vet Hum Toxicol* 43:1-5.

Patel, R; Benjamin, J. (1986) Renal disease associated with toluene inhalation. *Clin Toxicol* 24:213-223.

Paterson, SC; Sarvesvaran, R. (1983) Plastic bag death: a toluene fatality. *Med Sci Law* 23:64-66.

Pelcova, D; Rossner, P; Pickova, J. (1990) Chromosome aberrations in rotogravure printing plant workers. *Mutat Res* 245:299-303.

- Pelekis, M; Gephardt, LA; Lerman, SE. (2001) Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile compounds. *Regul Toxicol Pharmacol* 33:12-20.
- Pellizzari, ED; Hartwell, TD; Haris, BSH; et al. (1982) Purgeable organic compounds in mother's milk. *Bull Environ Contam Toxicol* 28:322-328.
- Pellizzari, ED; Wallace, LA; Gordon, SM. (1992) Elimination kinetics of volatile organics in humans using breath measurements. *J Expo Anal Environ Epidemiol* 2:341-355.
- Pierce, CH; Dills, RL; Morgan, MS; et al. (1996) Interindividual differences in $^2\text{H}_8$ -toluene toxicokinetics assessed by semi-empirical physiologically based model. *Toxicol Appl Pharmacol* 139:49-61.
- Pierce, CH; Lewandowski, TA; Dills, RL; et al. (1999) A comparison of $^1\text{H}_8$ - and $^2\text{H}_8$ -toluene toxicokinetics in men. *Xenobiotica* 29:93-108.
- Pitarque, M; Vaglenov, A; Nosko, M; et al. (1999) Evaluation of DNA damage by the comet assay in shoe workers exposed to toluene and other organic solvents. *Mutat Res* 441:115-127.
- Plappert, U; Barthel, E; Seidel, HJ. (1994) Reduction of benzene toxicity by toluene. *Environ Mol Mutagen* 24:283-292.
- Plenge-Bönig, A; Karmaus, W. (1999) Exposure to toluene in the printing industry is associated with subfecundity in women but not in men. *Occup Environ Med* 56:443-448.
- Poblano, A; Lope Huerta, M; Martinez, JM; et al. (1996) Pattern-visual evoked potential in thinner users. *Arch Med Res* 27:531-533.
- Poon, R; Chu, IH; Bjarnason, S; et al. (1994) Inhalation toxicity study of methanol, toluene, and methanol/toluene mixtures in rats: effects of 28-day exposure. *Toxicol Ind Health* 10:231-245.
- Pryor, GT; Rebert, CS; Dickinson, J; et al. (1984) Factors affecting toluene-induced ototoxicity in rats. *Neurobehav. Toxicol Teratol* 6:223-238.
- Pyykko, K; Tahti, H; Vapaatalo, H. (1977) Toluene concentrations in various tissues of rats after inhalation and oral administration. *Arch Toxicol* 38:169-176.
- Ramsey, JC; Andersen, ME. (1984) A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. *Toxicol Appl Pharmacol* 73:159-175.
- Rea, TM; Nash, JF; Zabik, JE; et al. (1984) Effects of toluene inhalation on brain biogenic amines in the rat. *Toxicology* 31:143-150.
- Rebert, CS; Matteucci, MJ; Pryor, GT. (1989a) Acute electrophysiologic effects of inhaled toluene on adult male Long-Evans rats. *Pharmacol Biochem Behav* 33:157-165.
- Rebert, CS; Matteucci, MJ; Pryor, GT. (1989b) Multimodal effects of acute exposure to toluene evidenced by sensory-evoked potentials from Fischer-344 rats. *Pharmacol Biochem Behavior* 32:757-768.
- Rees, DC; Wood, RW; McCormick, JP; et al. (1985) Toxicokinetics of toluene in the rat. *Scand J Work Environ Health* 11:301-306.
- Reisin, E; Teicher, A; Jaffe, R; et al. (1975) Myoglobinuria and renal failure in toluene poisoning. *Br J Ind Med* 32:163-164.

- Richer, CL; Chakrabarti, S; Senecal-Quevillon, M; et al. (1993) Cytogenetic effects of low-level exposure to toluene, xylene, and their mixture on human blood lymphocytes. *Int Arch Occup Environ Health* 64:581-585.
- Roberts, LG; Bevans, AC; Schreiner, CA. (2003) Developmental and reproductive toxicity evaluation of toluene vapor in the rat. I. Reproductive toxicity. *Reproductive Toxicol* 17:649-658.
- Ron, MA. (1986) Volatile substance abuse: a review of possible long term neurological, intellectual and psychiatric sequelae. *Br J Psychiatry* 148:235-246.
- Rosenberg, NL; Kleinschmidt-Demasters, BK; Davis, KA; et al. (1988a) Toluene abuse causes diffuse central nervous system white matter changes. *Ann Neurol* 23:611-614.
- Rosenberg, NL; Spitz, MC; Filley, CM; et al. (1988b) Central nervous system effects of chronic toluene abuse-clinical, brainstem evoked response and magnetic resonance imaging studies. *Neurotoxicol Teratol* 10:489-495.
- Ruddock, KH. (1965) The effect of age upon colour vision. I. Response in the receptor system of the human eye. *Vision Res* 5:37-45.
- Russell, RM; Carney, EA; Feiock, K; et al. (1980) Acute ethanol administration causes transient impairment of blue-yellow color vision. *Alcohol Clin Exp Res* 4:396-399.
- Ryu, YH; Lee, JD; Yoon, PH; et al. (1998) Cerebral perfusion impairment in a patient with toluene abuse. *J Nucl Med* 34:632-633.
- Sasa, M; Igarashi, S; Miyazaki, T; et al. (1978) Equilibrium disorders with diffuse brain atrophy in long term toluene sniffing. *Arch Otorhinolaryngol* 221:162-169.
- Sato, A; Nakajima, T. (1978) Differences following skin or inhalation exposure in the absorption and excretion kinetics of trichlorethylene and toluene. *Br J Ind Med* 35:43-49.
- Schaper, M; Demes, P; Zupanic, M; et al. (2003) Occupational toluene exposure and auditory function: results from a follow-up study. *Ann Occup Hyg* 47:493-502.
- Schmid, E; Bauchinger, M; Hauf, R. (1985) Chromosome changes with time in lymphocytes after occupational exposure to toluene. *Mutat Res* 142:37-39.
- Seeber, A; Schaper, M; Zupanic, M; et al. (2004) Toluene exposure below 50 ppm and cognitive function: a follow-up study with four repeated measurements in rotogravure printing plants. *Int Arch Occup Environ Health* 77:1-9.
- Skoog, KO; Nilsson, SEG. (1981) Changes in the c-wave of the electroretinogram and the standing potential of the eye after small doses of toluene and styrene. *Acta Ophthalmol (Copenh.)* 59:71-79.
- Smith, DA; Schurig, GG; Smith, SA; et al. (1999) Tilapia (*Oreochromis niloticus*) and rodents exhibit similar patterns of inhibited antibody production following exposure to immunotoxic chemicals. *Vet Hum Toxicol* 41:368-73.
- Snodgrass, W.R. (1992) Physiological and biochemical differences between children and adults as determinants of toxic response to environmental pollutants. In: Guzelian, PS; Henry, CJ; Olin, SS, editors. *Similarities and differences between children and adults: implications for risk assessment*. Washington, DC: International Life Sciences, pp. 35-42.
- Snow, L; P. MacNair and B.C. Casto. (1981) Mutagenesis testing of toluene in *Salmonella* strains TA100 and TA98. Prepared for the U.S. EPA by Northrup Services, Inc., Research Triangle Park, NC.

- Steinberg, RH; Linsenmeier, RA; Griff, ER. (1983) Three-light evoked responses of the retinal pigment epithelium. *Vision Res* 23:1315-1323.
- Stengel, B; Cenee, S; Limasset, JC; et al. (1998) Immunologic and renal markers among photogravure printers exposed to toluene. *Scand J Work Environ Health* 24:276-284.
- Streicher, HZ; Gabow, PA; Moss, AH; et al. (1981) Syndromes of toluene sniffing in adults. *Ann Intern Med* 94:758-762.
- Sunyer, JO; Boshra, H; Lorenzo, G; et al. (2003) Evolution of complement as an effector system in innate and adaptive immunity. *Immunol Res* 27:549-564.
- Suzuki, T; Kashimura, S; Umetsu, K. (1983) Thinner abuse and aspermia. *Med Sci Law* 23:199-202.
- Svensson, BG; Nise, G; Englander, V; et al. (1990) Deaths and tumors among rotogravure printers exposed to toluene. *Br J Ind Med* 47:372-379.
- Taher, SM; Anderson, RJ; MacCartney, R; et al. (1974) Renal tubular acidosis associated with toluene "sniffing." *N Engl J Med* 290:765-768.
- Takeichi, S; Yamada, T; Shikata, I. (1986) Acute toluene poisoning during painting. *Forensic Sci Int* 32:109-115.
- Tanaka, K; Maeda, T; Kobayashi, T; et al. (2003) A survey of urinary hippuric acid and subjective symptoms among occupational low toluene exposed workers. *Fukushima J Med Sci* 49:129-139.
- Tardif, R; Plaa, GL; Brodeur, J. (1992) Influence of various mixtures of inhaled toluene and xylene on the biological monitoring of exposure to these solvents in rats. *Can J Physio Pharmacol* 70:385-395.
- Tardif, R; Lapare, S; Krishnan, K; et al. (1993) Physiologically based modeling of the toxicokinetic interaction between toluene and m-xylene in the rat. *Toxicol Appl Pharmacol* 120:266-273.
- Tardif, R; Truchon, G; Brodeur, J. (1998) Comparison of hippuric acid and o-cresol in urine and unchanged toluene in alveolar air for the biological monitoring of exposure to toluene in human volunteers. *Appl Occup Environ Hyg* 13:127-132.
- Tassaneeyakul, W; Birkett, DJ; Edwards, JW; et al. (1996) Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene and o-, m-, and p-xylene. *J Pharmacol Exp Ther* 276:101-108.
- Thiel, R; Chahoud, I. (1997) Postnatal development and behaviour of Wistar rats after prenatal toluene exposure. *Arch Toxicol* 71:258-265.
- Tilson, HA. (1990) Animal neurobehavioral test battery in NTP assessment. In: Johnson, BL; Anger, WK; Durao, A; et al., editor. *Advances in neurobehavioral toxicology: applications in environmental and occupational health*. Chelsea, MI: Lewis Publishers, Inc., pp. 403-418.
- TN&A, Inc. (1999) Draft Risk Assessment Issue Paper for: Deriving a Provisional Subchronic Inhalation RfC for Toluene Using Physiologically-Based Pharmacokinetic Modeling. 98-031/02-19-99.
- Tokunaga, I; Gotohda, T; Ishigama, A; et al. (2003) Toluene inhalation induced 8-hydroxy-2'-deoxyguanosine formation as the peroxidative degeneration in rat organs. *Leg Med (Tokyo)* 5:34-41.
- Toyonaga, N; Adachi-Usami, E; Yamazaki, H. (1989) Clinical and electrophysiological findings in three patients with toluene dependency. *Doc Ophthalmol* 73:201-207.

Tsuruta, H. (1989) Skin absorption of organic solvent vapors in nude mice in vivo. *Ind Health* 27:37-47.

Turkall, RM; Skowronski, GA; Abdel-Rahman, MS. (1991) Differences in kinetics of pure and soil-adsorbed toluene in orally exposed male rats. *Arch Environ Contam Toxicol* 20:155-160.

Ungvary, G; Tatrai, E. (1985) On the embryotoxic effects of benzene and its alkyl derivatives in mice, rats, and rabbits. *Arch Toxicol Suppl* 8:425-430.

Urban, P; Lukas, E. (1990) Visual evoked potentials in rotogravure printers exposed to toluene. *Br J Ind Med* 47:819-823.

U.S. EPA. (Environmental Protection Agency). (1986) Guidelines for carcinogen risk assessment. *Fed Regist* 51:33992-34003.

U.S. EPA. (1988) Recommendations for and documentation of biological values for use in risk assessment. Environmental Criteria and Assessment Office, Office of Health and Environmental Assessment, Office of Research and Development, Cincinnati, OH; EPA/600/6-87/008. Available from: National Technical Information Service, Springfield, VA; PB-88179874.

U.S. EPA. (1991) Guidelines for developmental toxicity risk assessment. *Fed Regist* 56:63798-63826 and <<http://www.epa.gov/iris/backgr-d.htm>>.

U.S. EPA. (1994a) Interim policy for particle size and limit concentration issues in inhalation toxicity. *Fed Regist* 59:53799 and <<http://www.epa.gov/iris/backgr-d.htm>>.

U.S. EPA. (1994b) Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry. EPA/600/8-90/066F. Available from: National Technical Information Service (NTIS), Springfield, VA; PB2000-500023, and <<http://www.epa.gov/iris/backgr-d.htm>>.

U.S. EPA. (1995) Use of the benchmark dose approach in health risk assessment. U.S. Environmental Protection Agency. EPA/630/R-94/007. Available from: National Technical Information Service (NTIS), Springfield, VA; PB95-213765 and <<http://www.epa.gov/iris/backgr-d.htm>>.

U.S. EPA. (1996) Guidelines for reproductive toxicity risk assessment. *Fed Regist* 61:56274-56322 and <<http://www.epa.gov/iris/backgr-d.htm>>.

U.S. EPA. (1998a) Guidelines for neurotoxicity risk assessment. *Fed Regist* 63:26926-26954 and <<http://www.epa.gov/iris/backgr-d.htm>>.

U.S. EPA. (1998b) Science policy council handbook: peer review. Prepared by the Office of Science Policy, Office of Research and Development, Washington, DC. EPA/100/B-98/001. Available from: National Technical Information Service (NTIS), Springfield, VA; PB98-140726, and <<http://www.epa.gov/clariton/clhtml/pubtitleOther.html>>.

U.S. EPA. (1998c) Health effects test guidelines, OPPTS 870.7800: Immunotoxicity. Office of Prevention, Pesticides and Toxic Substances, Washington, DC; EPA/712/C-98/351. Available from: <http://www.epa.gov/opptsfrs/OPPTS_Harmonized/870_Health_Effects_Test_Guidelines/Series/870-7800.pdf>.

U.S. EPA. (2000a) Science policy council handbook: peer review. 2nd edition. Prepared by the Office of Science Policy, Office of Research and Development, Washington, DC. EPA/100/B-00/001. Available from: <<http://www.epa.gov/iris/backgr-d.htm>>.

U.S. EPA. (2000b) Science policy council handbook: risk characterization. Prepared by the Office of Science Policy, Office of Research and Development, Washington, DC. EPA/100/B-00/002. Available from: <<http://www.epa.gov/iris/backgr-d.htm>>.

U.S. EPA. (2000c) Benchmark dose technical support document [external review draft]. EPA/630/R-00/001. Available from: <<http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=42601>>.

U.S. EPA. (2000d) Supplementary guidance for conducting health risk assessment of chemical mixtures. EPA/630/R-00/002. Available from: <<http://www.epa.gov/iris/backgr-d.htm>>.

U.S. EPA. (2001) Benchmark dose software (BMDS) version 1.3. Available from: <<http://www.epa.gov/ncea/bmds.htm>> (last modified March 22, 2001).

U.S. EPA. (2002) A review of the reference dose concentration and reference concentration processes. Risk Assessment Forum, Washington, DC; EPA/630/P-02/0002F. Available from: <<http://www.epa.gov/iris/backgr-d.htm>>.

U.S. EPA. (2005) Guidelines for carcinogen risk assessment. Risk Assessment Forum, Washington, DC; EPA/630/P-03/001B. Available from: <<http://www.epa.gov/iris/backgr-d.htm>>.

Van Asperen, J; Rijcken, WR; Lammers, JH. (2003) Application of physiologically based toxicokinetic modelling to study the impact of the exposure scenario on the toxicokinetics and the behavioural effects of toluene in rats. *Toxicol Lett* 138(1-2):51-62.

Vieira, I; Sonnier, M; Cresteil, T. (1996) Developmental expression of CYP2E1 in the human liver: hypermethylation control of gene expression during the neonatal period. *Eur J Biochem* 238:476-483.

Von Euler, G; Ogren, SO; Li, XM; et al. (1993) Persistent effects of subchronic toluene exposure on spatial learning and memory, dopamine-mediated locomotor activity and dopamine D2 agonist binding in the rat. *Toxicology* 77:223-232.

Von Euler, G. (1994a) Toluene and dopaminergic transmission. In: Isaacson, RL; Jensen, KF, editors. *The vulnerable brain and environmental risk, toxins in air and water*, Vol. 3. New York, NY: Plenum Press, pp. 301-321.

Von Euler, G; Ogren, SO; Eneroth, P; et al. (1994b) Persistent effects of 80 ppm toluene on dopamine-regulated locomotor activity and prolactin secretion in the male rat. *Neurotoxicol* 15:621-624.

Von Euler, M; Pham, TM; Hillefors, M; et al. (2000) Inhalation of low concentrations of toluene induces persistent effects on a learning retention task, beam-walk performance, and cerebrocortical size in the rat. *Exp Neurol* 163:1-8.

Vrca, A; Bozicevic, D; Karacic, V; et al. (1995) Visual evoked potentials in individuals exposed to long-term low concentrations of toluene. *Arch Toxicol* 69:337-40.

Vrca, A; Karacic, V; Bozicevic, D; et al. (1996) Brainstem auditory evoked potentials in individuals exposed to long-term low concentrations of toluene. *Am J Ind Med* 30:62-66.

Vrca, A; Bozicevic, D; Bozikov, V; et al. (1997) Brain stem evoked potentials and visual evoked potentials in relation to the length of occupational exposure to low levels of toluene. *Acta Medica Croatica*. 51:215-219.

Wiebelt, H; Becker, N. (1999) Mortality in a cohort of toluene exposed employees (rotogravure printing plant workers). *J Occup Environ Med* 41:1134-1139.

WHO (World Health Organization). (1985) Environmental health criteria 52. Toluene. Geneva, Switzerland: World Health Organization. Available from: <<http://www.inchem.org/documents/ehc/ehc/ehc52.htm>>.

- Wolf, MA; Rowe, VK; McCollister, DD; et al. (1956) Toxicological studies of certain alkylated benzenes and benzene. *Arch Ind Health* 14:387-398.
- Wood, RW; Colotla, VA. (1990) Biphasic changes in mouse motor activity during exposure to toluene. *Fund Appl Toxicol* 14:6-14.
- Wood, R; Cox, C. (1995) A repeated measures approach to the detection of the acute behavioral effects of toluene at low concentrations. *Regulatory Toxicol Pharmacol* 33:12-20.
- Wood, RW; Rees, DC; Laties, VG. (1983) Behavioral effects of toluene are modulated by stimulus control. *Toxicol Appl Pharmacol* 68:462-472.
- Xiong, L; Matthes, J; Li, J; et al. (1993) MR imaging of "spray heads": toluene abuse via aerosol paint inhalation. *Am J Neuroradiol* 14:1195-1199.
- Yamaguchi, H; Kidachi, Y; Ryoyama, K. (2002) Toluene at environmentally relevant low levels disrupts differentiation of astrocyte precursor cells. *Arch Environ Health* 57:232-238.
- Yin, S; Li, G; Hu, Y; et al. (1987) Symptoms and signs of workers exposed to benzene, toluene or the combination. *Ind Health* 25:113-130.
- Zavalic, M; Turk, R; Bogadi-Sare, A; et al. (1996) Colour vision impairment in workers exposed to low concentrations of toluene. *Arh Hlg Rada Toksikol* 47:167-175.
- Zavalic, M; Mandic, Z; Turk, R; et al. (1998a) Quantitative assessment of color vision impairment in workers exposed to toluene. *Am J Ind Med* 33:297-304.
- Zavalic, M; Mandic, Z; Turk, R; et al. (1998b) Assessment of colour vision impairment in male workers exposed to toluene generally above occupational exposure limits. *Occup Med* 48:175-180.
- Zavalic, M; Mandic, Z; Turk, R; et al. (1998c) Qualitative color vision impairment in toluene-exposed workers. *Int Arch Occup Environ Health* 71:194-200.
- Zupanic, M; Demes, P; Seeber, A. (2002) Psychomotor performance and subjective symptoms at low level toluene exposure. *Occup Environ Med* 59:263-268.

Appendix A1. Summary of External Peer Review and Public Comments and Disposition

The Toxicological Review and IRIS Summary of Toluene have undergone internal review by scientists within EPA and two separate external peer reviews in August 2002 and January 2004. The external reviews were conducted in accordance with EPA guidance on peer review (U.S. EPA, 1998b, 2000). Comments made by the internal reviewers were addressed prior to submitting the documents for external review and are not part of this appendix. For each external peer review, the reviewers were tasked with providing written answers to general questions on the overall assessment and on chemical-specific charge questions, addressing areas of scientific controversy or uncertainty. The first peer review (August 2002) was a letter review. The comments concerned issues of a significant nature, thereby necessitating an additional peer review. The second peer review (January 2004) was a panel review. The charge questions, summary of reviewer comments, and EPA's disposition of the comments are found in Appendix A-1 for the August 2002 review and Appendix A-2 for the January 2004 review. EPA also received comments from the public. A summary of public comments and EPA's responses are included in each section (A-1 and A-2).

August 2002 Peer Review

Charge to External Reviewers

1) RfD Derivation

a) *Principal Study, Section 5.1.1: Two subchronic animal studies are available (NTP, 1990; Hsieh et al., 1989). The current IRIS entry utilizes the 13-week oral gavage study (NTP, 1990) for the derivation of an RfD. The 28-day drinking water study (Hsieh et al., 1989) was not considered. This latter study has now been chosen as the principal study. Is this the correct choice for the principal study?*

b) *Critical Effect, Section 5.1.1: The critical effect is identified as immunological effects: decreased thymus weight. Is this the correct critical effect and is it adequately described?*

c) *Methods of Analysis, Section 5.1.2: Is the point of departure determined appropriately (i.e., benchmark dose approach)?*

d) *Uncertainty Factors, Section 5.1.3: Are the appropriate uncertainty factors applied? Is the explanation for each transparent?*

2) RfC Derivation

a) *Principal Study, Section 5.2.1: Several human epidemiological studies are available. The study used in the previous IRIS assessment (Foo et al., 1990) is not used in the reassessment; the study by Zavalic et al. (1998a) has been chosen as the principal study. Is this the correct choice for the principal study? Are adequate explanations given to explain why this study was chosen over the other available studies? An attempt is made to explain the choice of principal study, critical effect, and NOAEL by examining the entire database. Was this attempt successful?*

b) *Critical Effect, Section 5.2.1: The critical effect is identified as impaired color vision. Is this the correct critical effect and is it adequately described?*

c) *Methods of Analysis, Section 5.2.2: Is the point of departure determined appropriately) i.e., NOAEL/LOAEL approach versus benchmark dose approach)?*

d) *Uncertainty Factors, Section 5.2.3: Are the appropriate uncertainty factors applied? Is the explanation for each transparent?*

3) Cancer Weight-of-Evidence Characterization

The weight of evidence and cancer characterization are discussed in Section 4.6. Have appropriate criteria been applied from both the 1986 EPA Guidelines for Carcinogen Risk Assessment (Federal Register 51 (185):33992-34003) and the 1999 EPA Draft Revised Guidelines for Carcinogen Assessment (Review Draft, NCEA-F-0644, July 1999. Risk Assessment Forum)?

Scientific Comments from External Peer Review

1) RfD Derivation

a) *Principal Study, Section 5.1.1: Two subchronic animal studies are available (NTP, 1990; Hsieh et al., 1989). The current IRIS entry utilizes the 13-week oral gavage study (NTP, 1990)*

for the derivation of an RfD. The 28-day drinking water study (Hsieh et al., 1989) was not considered. This latter study has now been chosen as the principal study in the draft reassessment. Is this the correct choice for the principal study?

Comment: All four reviewers agreed with the choice of principal study.

Response: During the external review period of the draft assessment, it was discovered that several relevant *in vivo* oral exposure studies were omitted. Please see the summary of public comments below for additional details. Consideration of these studies had a significant impact on the choice of principal study and critical effect for the RfD. After consideration of the additional studies, the principal study was changed to the 13-week gavage study (NTP, 1990) in rats. The critical effect was changed to increased kidney weight. These changes are discussed in Sections 5.1.1 and 5.1.2.

The following oral *in vivo* studies were added to the Toxicological Review:

- Burns, LA; Bradley, SG; White Jr, KL; et al. (1994) Immunotoxicity of mono-nitrotoluenes in female B6C3F1 mice. I. Para-nitrotoluene. *Drug Chem Toxicol* 17:317-358.
- Hsieh, GC; Sharma, RP; Parker, RD; et al. (1990a) Evaluation of toluene exposure via drinking water on levels of regional brain biogenic monoamines and their metabolites in CD-1 mice. *Ecotoxicol Environ Saf* 20: 175-184.
- Hsieh, GC; Parker, RD; Sharma, RP; et al. (1990b) Subclinical effects of ground water contaminants. III. Effects of repeated oral exposure to combinations of benzene and toluene on immunologic responses in mice. *Arch Toxicol* 64:320-328.
- Hsieh, GC; Sharma, RP; Parker, RD. (1990c) Subclinical effects of groundwater contaminants. Effects of repeated oral exposure to combinations of benzene and toluene on regional brain monoamine metabolism in mice. *Arch Toxicol* 64:669-676.
- Hsieh, GC; Sharma, RP; Parker, RD. (1991) Hypothalamic-pituitary-adrenocortical axis activity and immune function after oral exposure to benzene and toluene. *Immunopharmacol* 21:23-31.

- Kostas, J; Hotchin, J. (1981) Behavioral effects of low-level perinatal exposure to toluene in mice. *Neurobehav Toxicol Teratol* 3:467-469.

b) *Critical Effect, Section 5.1.1: The critical effect is identified as immunological effects: decreased thymus weight. Is this the correct critical effect and is it adequately described?*

Comment: There was general agreement among the reviewers on the use of immunological effects as the critical effect but discrepancies in immunotoxicity study descriptions were noted as well as a concern for the use of thymus weight as the critical endpoint. It was noted that thymus weight is not generally considered a reliable indicator of immunosuppression.

Response: Upon consideration of the additional studies discussed above, the critical effect was changed to increased kidney weight. The rationale for this selection is discussed in Section 5.1.1.

c) *Methods of Analysis, Section 5.1.2: Is the point of departure determined appropriately (i.e., benchmark dose approach)?*

Comment: Several reviewers agreed with the use of benchmark dose modeling for the derivation of the point of departure. One reviewer questioned the use of benchmark dose modeling for thymus weight changes since effects were seen primarily only at the high doses.

Response: The critical effect has changed to increased kidney weight as described above. Benchmark dose modeling has been used to determine a point of departure for this endpoint and is described in Section 5.1.2.

d) *Uncertainty Factors, Section 5.1.3: Are the appropriate uncertainty factors applied? Is the explanation for each transparent?*

Comment: Three reviewers agreed with the choice of uncertainty factors. Another reviewer stated that uncertainty factors are subject to scientific judgement and did not comment further.

Response: No response needed.

2) RfC Derivation

a) *Principal Study, Section 5.2.1: Several human epidemiological studies are available. The study used in the previous IRIS file (Foo et al., 1990) is not used in the reassessment; the study by Zavalic et al. (1998a) has been chosen as the principal study. Is this the correct choice for the principal study? Are adequate explanations given to explain why this study was chosen over the other available studies? An attempt is made to explain the choice of principal study, critical effect, and NOAEL by examining the entire database. Was this attempt successful?*

Comment: Three of the four reviewers indicated that the selection of Zavalic et al. (1998a) was the correct choice for the principal study. One reviewer stated that the available data are inadequate to appropriately protect the public's health and that additional research is needed.

Response: No response required. Note that an updated literature search identified several additional inhalation exposure studies that have been included in Section 4.1.2.

Comment: One reviewer noted specific issues concerning the use of the Zavalic et al. (1998a) study as the principal study, including the following:

- Measurements of toluene exposure were not performed in accordance with modern standards and were not individual exposure measurements.

Response: Zavalic et al. (1998a) referenced standard methods for measuring both ambient air concentrations (NIOSH, 1974) and individual blood toluene levels (Nise and Orbaek, 1988). Sampling tubes were fixed onto the work tables or machines at nose height and air was collected continually throughout the working day. Personal air monitors were not used in this study; however, individual blood samples were taken from all workers. Urine samples were taken from all workers in the high dose group.

- Alcohol consumption, an important risk factor, was not adequately controlled. Alcohol consumption data obtained from questionnaires should not be considered reliable.

Response: Alcohol consumption is considered an important independent risk factor for impaired color vision (Russell et al., 1980). Zavalic et al. (1998a) were cognizant of this fact and utilized self-reported alcohol consumption data to adjust the color confusion index scores. Self-reported alcohol consumption data are generally not considered to be exceptionally accurate, but there is no reason to suspect that the data from the exposed group are any less accurate than the data from the control group. Moreover, when alcohol

consumers were excluded from the data set, a significant correlation ($p < 0.05$) was still observed between exposure and CCI scores.

- The effects reported by Zavalic et al. (1998a) were not observed by Nakatsuka et al. (1992), a study that was not included in the Toxicological Review.

Response: The Nakatsuka et al. (1992) study has been added to the Toxicological Review in Sections 4.1.2.2 and 5.2.1. Impaired color vision associated with exposure to toluene has been reported by several investigators (Campagna, et al., 2001, Cavelleri et al., 2000, Muttray, et al., 1999, Zavalic et al., 1998a, 1998b) but was not observed by Nakatsuka et al. (1992). The discrepancy may be due to the method of color vision assessment. For example, Nakatsuka et al. (1992) assessed color vision in a qualitative manner indicated by color vision loss. The other studies measured color confusion indices directly.

- Zavalic et al. (1998a) state that toluene was also used for manually cleaning the rollers. This would result in an unusual exposure that would likely be underestimated by the exposure assessment procedures that were used.

Response: The use of toluene to manually rinse the rollers may have been a significant source of exposure for the printers who were examined by Zavalic et al. (1998a). The authors do not state whether the collected air samples would characterize this exposure scenario.

b) *Critical Effect, Section 5.2.1: The critical effect is identified as impaired color vision. Is this the correct critical effect and is it adequately described?*

Comment: Two reviewers indicated that impaired color vision was the appropriate selection for a critical effect, but one of these reviewers felt that the documentation of this adverse effect was lacking. This opinion was shared by another reviewer, who questioned the biological significance of this endpoint.

Response: Additional text was added to Section 4.1.2.2 to better describe the Lanthony D-15 color vision test. Additional text was also added to Sections 4.5.3 and 5.2.1 to support the use of impaired color vision as a critical effect.

Comment: One reviewer noted the observed prevalence of dyschromatopsia in the control group (43%) would be considered high, leading one to question the validity of the results.

Response: The prevalence of dyschromatopsia in the unexposed study population (28%), which was reported in a separate publication (Zavalic et al., 1998b), is consistent with other studies where the Lanthony D-15 desaturated panel (D-15d) has been employed (Campagna et al., 2001; Geller and Hudnell, 1997). The D-15d is considered a highly sensitive test for detecting mild to moderate dyschromatopsia but can yield false positive results (Geller and Hudnell, 1997). Nevertheless, the D-15d has proven effective in detecting acquired color vision deficits associated with chemical exposure (Geller and Hundell, 1997; Gobba and Cavalleri, 2003).

Comment: One reviewer noted a statistically significant impact on color vision was only observed when the data were adjusted for age and alcohol intake, which leads to questionable results.

Response: The reported mean CCI score for the high exposure population (E_2) was significantly different from both the low exposure (E_1) and unexposed (NE) populations ($p < 0.001$). To examine the relationship between CCI scores and exposure measurements, the authors attempted to control for two potential risk factors, age and alcohol, by calculating age and alcohol intake adjusted color confusion index (AACCI) values. The authors state that the AACCI values were obtained using the residuals from a linear regression analysis of the unexposed population, but the actual data points with standard deviations were not provided.

c) Methods of Analysis, Section 5.2.2: Is the point of departure determined appropriately (i.e., NOAEL/LOAEL approach versus benchmark dose approach)?

Comment: Two reviewers stated that the point of departure was appropriately determined using the NOAEL/LOAEL approach. One of these reviewers stated that reports of other neurologic effects at concentrations ranging from 40 to 100 ppm support the use of a NOAEL in this case. Another reviewer was concerned that the low dose group might not provide an adequate basis for the determination of a NOAEL since the biomarker-based measures of exposure were not well correlated with the measured time-weighted-average (TWA) air concentration of toluene for the low dose exposure group ($r = 0.47$, $p = 0.09$). This reviewer suggested the TWA air concentrations may not have been an accurate measure of true exposure either because of inaccurate measurement or possibly because of dermal absorption of toluene. This reviewer also

stated that the data should lend itself to benchmark dose modeling for the determination of the point of departure if tabular data were available and suggested contacting the authors to obtain the complete quantitative data. The fourth reviewer indicated that the validity of extrapolation from an 8 hour/day exposure to continuous chronic exposure is debatable. The statement was made that large individual variations in inhalation are to be expected during various levels of strenuous activity and that it is doubtful that a 2-day longer exposure period (i.e., the weekend) would change the body burden by 5/7.

Response: The external review draft relied on a NOAEL/LOAEL approach for the determination of the point of departure for the RfC. Individual data points were not available at that time. The standard deviations of the AACCI means have now been obtained which allows for the use of benchmark dose modeling to derive a BMDL as the point of departure. This methodology utilizes the entire data set, which somewhat circumvents the issue surrounding the accuracy of the NOAEL. The NOAEL is no longer relied upon as the point of departure. The point of departure is now 99 ppm (374 mg/m³).

The extrapolation from an 8 hour/day exposure to continuous chronic exposure is a default procedure outlined in the *Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry* (U.S. EPA, 1994b). The approach for human exposure scenarios is to adjust the exposure concentration by the default occupational ventilation rate and for the intermittent work week schedule as indicated in Section 5.2.2. PBPK models are available that describe the kinetics of toluene after inhalation exposure (Fisher et al., 1997; Pierce et al., 1996, 1999; DeJongh and Blaauboer, 1996, 1997; Tardif et al., 1993). These models could theoretically be utilized for conducting a dose-based duration adjustment.

In the case of chronic exposure, however, it is not clear that the peak tissue concentration is the appropriate measure of internal dose to use in conducting a dose-based duration adjustment as described in Section 5.2.2. The standard use of the human equivalent concentration multiplied by the 5/7 ratio to adjust for the hours/day and days/week exposure differences is based on the logical premise that the total amount of exposure, rather than the momentary tissue concentration, is the appropriate predictor of chronic toxic effects. At this time data are not available to determine the proper dose metric for the chronic effects of toluene exposure on color vision; thus, the standard default methodology for duration adjustment was used.

d) *Uncertainty Factors, Section 5.2.3: Are the appropriate uncertainty factors applied? Is the explanation for each transparent?*

Comments: Three of the reviewers stated that the appropriate uncertainty factors were applied and that the explanation for each was transparent. The fourth reviewer did not comment on the choice of uncertainty factors for the RfC.

Response: No response required.

e) *General Comments on the RfC Derivation*

Comment: One reviewer requested inclusion of where the human inhalation studies were conducted in study descriptions.

Response: The country of origin (if known) of the workers in the inhalation studies has been included in Section 4.1.2.2.

3) **Cancer Weight-of-Evidence Characterization**

The weight of evidence and cancer characterization are discussed in Section 4.6. Have appropriate criteria been applied from both the 1986 EPA Guidelines for Carcinogen Risk Assessment (Federal Register 51 (185):33992-34003) and the 1999 EPA Draft Revised Guidelines for Carcinogen Assessment (Review Draft, NCEA-F-0644, July 1999. Assessment Forum)?

Comment: Three reviewers agreed with the classification and descriptor used. Another reviewer agreed that data in humans and animals are barely sufficient for a reliable conclusion on the carcinogenic potency of toluene but that more emphasis should be placed on the negative human study by Wiebelt and Becker (1999).

Response: A description of the Wiebelt and Becker (1999) study is included in Section 4.1.2.3. This study is a cohort mortality study in toluene-exposed workers (Wiebelt and Becker, 1999), which reported no change in cancer-specific mortality when the entire cohort was taken into consideration. A subcohort of highly-exposed workers demonstrated statistically significant increases in mortality from cancers of the bone and connective tissue, but lack of exposure

characterization, co-exposure information, and adjustment for other confounding factors (age, smoking, etc.) within the subcohort precludes drawing conclusions from these results as to the possible association between toluene exposure and cancer risk. The results of this study are taken into consideration in the weight-of-evidence evaluation and cancer characterization described in Section 4.6.2. A summary of the available human studies, chronic animal bioassays, and genotoxic studies is the primary emphasis of this section. The database as a whole contributes to the cancer evaluation. It should be noted that, since the external peer review, the IRIS Program has implemented sole use of the *Draft Revised Guidelines for Carcinogen Assessment* (U.S. EPA, 1999) in accordance with Agency practice (*Federal Register* 66(230):59593-59594). In addition, note that the NTP (1990) cancer bioassay has been published (Huff, 2003) and is included as a citation.

Scientific Comments from the Public

Comment: One reviewer disagreed with the principal study and critical effect identified for the derivation of the RfD. This reviewer recommended the use of the NTP (1990) study used in the assessment currently on the IRIS database. The rationale for not using the proposed study (Hsieh et al., 1989) and critical effect (immunological effects; decreased thymus weight) was several-fold. First, the reviewer stated that the relative differences in thymus weight are small and the significance of this effect is questionable given the lack of information about absolute thymus weights and thymus-to-brain ratios. This reviewer also questioned the reliability and significance of thymus weight differences and the PFC assays from the Hsieh et al. (1989) study given other research by Hsieh et al. (1990b) and Burns et al. (1994) that was not included in the Toxicological Review. Hsieh et al. (1990b) exposed CD-1 male mice to toluene for 28 days in drinking water at doses of 0, 22, and 90 mg/kg-day and found no effects or changes in thymus weights or liver weights at either dose. Hsieh et al. (1990b) also found no effects in the PFC assays except minimal changes in the PFC/10⁶ splenocytes at the high dose. In addition, Burns et al. (1994) exposed B6C3F1 mice to significantly higher doses than the Hsieh (1989, 1990b) studies (i.e., 600 mg/day), and observed no effects on thymus weight and several immune response assays, including several standard host resistance assays.

Response: The reviewer is correct in that several relevant *in vivo* oral exposure studies were omitted from the external review draft (August 2002). Consideration of these studies had a significant impact on the choice of principal study and critical effect for the RfD. The principal study has been changed to the 13-week gavage study (NTP, 1990) in rats. The critical effect has

been changed to increased kidney weight. These changes are discussed in Sections 5.1.1. and 5.1.2 of the Toxicological Review.

The following oral *in vivo* studies were added to the Toxicological Review:

- Burns, LA; Bradley, SG; White, KL, Jr; et al. (1994) Immunotoxicity of mono-nitrotoluenes in female B6C3F1 mice: I. para-nitrotoluene. *Drug Chem Toxicol* 17:317-358.
- Hsieh, GC; Sharma, RP; Parker, RD; et al. (1990a) Evaluation of toluene exposure via drinking water on levels of regional brain biogenic monoamines and their metabolites in CD-1 mice. *Ecotoxicol Environ Saf* 20:175-184.
- Hsieh, GC; Parker, RD; Sharma, RP; et al. (1990b) Subclinical effects of ground water contaminants. III. Effects of repeated oral exposure to combinations of benzene and toluene on immunologic responses in mice. *Arch Toxicol* 64:320-328.
- Hsieh, GC; Sharma, RP; Parker, RD. (1990c) Subclinical effects of groundwater contaminants. Effects of repeated oral exposure to combinations of benzene and toluene on regional brain monoamine metabolism in mice. *Arch Toxicol* 64:669-676.
- Hsieh, GC; Sharma, RP; Parker, RD. (1991) Hypothalamic-pituitary-adrenocortical axis activity and immune function after oral exposure to benzene and toluene. *Immunopharmacol* 21:23-31.
- Kostas, J; Hotchin, J. (1981) Behavioral effects of low-level perinatal exposure to toluene in mice. *Neurobehav Toxicol Teratol* 3:467-469.

Comment: One reviewer indicated that the selection of Zavalic et al. (1998a) as the principal study for the derivation of the RfC is appropriate. This reviewer stated that the study contains data on atmospheric toluene levels in the workplace and uses an appropriate test for color vision confusion. The reviewer noted that using this study minimizes the needs for extensive use of uncertainty factors since it was performed in humans exposed to toluene for long durations and identifies both a NOAEL and LOAEL.

Response: The Zavalic et al. (1998a) study has been retained as the principal study for the derivation of the RfC. However, since the standard deviations of the means of the AACCI color vision scores have become available, the data have now been inserted into benchmark dose modeling software and a BMDL has been derived instead of relying on a single dose level (i.e., a NOAEL) as the point of departure. The uncertainty factors remain the same.

Appendix A2. Summary of External Peer Review and Public Comments and Disposition

January 2004 Peer Review

Charge to External Reviewers

1) RfD Derivation

a) *Principal Study, Section 5.1.1 The principal study is the subchronic gavage NTP (1990) study. Has the correct principal study been chosen? Is the explanation for the choice of principal study transparent?*

b) *Critical Effect, Section 5.1.1: The critical effect is identified as increased kidney weight. Is this the correct critical effect and is it adequately described?*

c) *Methods of Analysis, Section 5.1.2: Benchmark dose modeling has been used to derive the point of departure for determining the RfD. In the absence of information on the level of response to consider adverse, a change in the mean equal to one standard deviation from the control mean was used according to the U.S. EPA Benchmark Dose Technical Document Guidance (U.S. EPA, 2000c). Has the correct benchmark response (one standard deviation from the control mean) been chosen for the continuous data set for increased kidney weight? Have PBPK modeling issues (i.e., route-to-route extrapolation from inhalation data was not conducted) been adequately addressed?*

d) *Uncertainty Factors, Section 5.1.3: Have the appropriate uncertainty factors been applied? Is the explanation for each transparent? Is there sufficient justification to not include an uncertainty factor for database insufficiencies?*

2) RfC Derivation

a) *Principal Study, Section 5.2.1: Several human occupational studies are available. The study used in the previous IRIS file (Foo et al., 1990) is not used in the reassessment; the study by Zavalic et al. (1998a) has been chosen as the principal study. Is this the correct choice for the principal study? Are adequate explanations given to explain why this study was chosen over the other available studies?*

b) *Critical Effect, Section 5.2.1: The critical effect is identified as impaired color vision. Is this the correct critical effect and is it adequately described? Is the biological basis for choosing this effect adequately explained?*

c) *Methods of Analysis, Section 5.2.2: Benchmark dose modeling has been used to derive the point of departure for determining the RfC. In the absence of information on the level of response to consider adverse, a change in the mean equal to one standard deviation from the control mean was used according to the U.S. EPA Benchmark Dose Technical Guidance Document (U.S. EPA, 2000c). Has the correct benchmark response (one standard deviation from the control mean) for the continuous data set for alcohol- and age-adjusted color confusion index (AACCI) been chosen? Have PBPK modeling issues (i.e., a chemical-specific duration adjustment was not conducted) been adequately addressed?*

d) *Uncertainty Factors, Section 5.2.3: Have the appropriate uncertainty factors been applied? Is the explanation for each transparent?*

3) Cancer Weight-of-Evidence Classification

The weight of evidence and cancer characterization are discussed in Section 4.6. Have appropriate criteria been applied from the 1999 EPA Draft Revised Guidelines for Carcinogen Assessment (Review Draft, NCEA-F-0644, July 1999. Risk Assessment Forum)? Is the statement that “data are inadequate for an assessment of the human carcinogenic potential” correct?

Specific Comments from External Peer Review

1) RfD Derivation

a) *Principal Study, Section 5.1.1: The principal study is the subchronic gavage NTP (1990) study. Has the correct principal study been chosen? Is the explanation for the choice of principal study transparent?*

Comment: Four of the seven reviewers agreed on the choice of the NTP (1990) study as the correct principal study. One reviewer indicated a lack of knowledge of nephrotoxicity and immunotoxicity and precluded comment. One reviewer indicated a lack of necessity for an oral RfD and provided no further comment. One of the reviewers disagreed with the decision not to

use immunologic endpoints and recommended that the choice of principal study reflect the immunotoxicity of toluene. The reviewer pointed out that, although Hsieh et al. (1989) found decreased thymus weight in male CD-1 mice at the highest dose following toluene exposure and Hsieh et al. (1990a,b) did not, the latter studies used a 20% lower dose indicating these findings may be consistent and dose-related. In addition, the reviewer refuted the significance of the Burns et al. (1994) data, which showed no effect of toluene exposure on host resistance in female B6C3F1 mice, by noting that Burns et al. (1994): (1) used a different strain of mice; (2) used a shorter exposure time (14 days rather than the 28 days used by Hsieh [1989, 1990a,b]); and (3) also found a 40% decrease in IgM response that was not statistically significant at $n = 4$. The reviewer also cited additional evidence of toluene immunotoxicity from fish studies (Smith et al. 1999; Gogal et al., 1999). The reviewer pointed out that the lack of effect of toluene on host resistance models does not preclude toluene as an immunotoxicant because there is only a 0.78 out of 1.00 predictive value between indicators of immunotoxicity, such as the PFC assay, and host resistance assays (Luster et al., 1992).

Response: The decreased thymus weight found by Hsieh et al. (1989) was at the highest dose of toluene studied (405 mg/L) rather than 325 mg/L from Hsieh et al. (1990a,b). The lack of a response at the lower dose in Hsieh (1990a,b) does not directly contradict the earlier data. However, as is pointed out in Section 5.1.1, decreased thymus weight is generally considered to have limited value as an indicator of immunotoxicity (Luster et al., 1992; Dean, 1997). The lack of immunotoxicity in a range of measures, including host resistance in a different mouse strain in the Burns et al. (1994) study, suggests that the response to toluene seen by Hsieh et al. (1989, 1990c, 1991) is not consistent within species and may reflect the possibility that changes in immune responses measured by *in vivo/ex vivo* studies are frequently not indicative of responses seen in host resistance assays. The 14-day exposure time utilized in the Burns et al. (1994) study is a commonly used exposure regime for subacute studies and has often been used for subacute immunotoxicology studies in rodents (Luster et al., 1989). However, the 28-day exposure used in Hsieh (1989, 1990c, 1991) has become the preferred duration for assays of immune function, including tests for anti-SRBC serum antibodies or PFC response after SRBC challenge, as evidenced by the 28-day suggested minimum length of exposure in the *Immunotoxicity Health Effects Test Guidelines* (U.S. EPA, 1998b). The 40% decrease in the PFC response from the Burns et al. (1994) study is not strong support for toluene inhibition of antibody production, because the standard IgM-related PFC response was not suppressed when tested 4 days after primary exposure. The response that is reduced is the IgG-related PFC response tested 5 days after primary exposure. Although IgG does play a role in the primary response to antigen, the

major function of IgG in the response to antigen is after the secondary exposure, and this was not assayed in the experiment. Finally, the data from comparative studies in fish, while helpful, does not provide strong support for toluene's potential immunotoxicity in mammals, in general, or in humans, in particular because of the strong phylogenetic differences in immune function between the two groups (Sunyer et al., 2003). The conflicting immunotoxicity data have been taken into account as described in Sections 5.1.1, 5.1.2, and 5.1.3 of the Toxicological Review. The inconsistencies in the immunotoxicity database are accounted for, among other insufficiencies, by the application of a 3-fold uncertainty factor for an incomplete database.

- Luster, MI; Ackermann, MF; Germolec, DR; et al. (1989). Perturbations of the immune system by xenobiotics. *Environ Health Perspect* 81:157-162.
- U.S. EPA. (1998c) Health effects test guidelines, OPPTS 870.7800: Immunotoxicity. Office of Prevention, Pesticides and Toxic Substances, Washington, DC; EPA/712/C-98/351. Available from:
<http://www.epa.gov/opptsfrs/OPPTS_Harmonized/870_Health_Effects_Test_Guidelines/Series/870-7800.pdf>.
- Dean, JH. (1997) Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals. *Toxicology* 119:95-101.
- Sunyer, JO; Boshra, H; Lorenzo, G; et al. (2003) Evolution of complement as an effector system in innate and adaptive immunity. *Immunol Res* 27:549-564.

Comment: One of the reviewers suggested a more complete explanation of how the high dose group results were handled in the NTP (1990) study.

Response: A more detailed explanation of the effects of deaths in the 5000 mg/kg group has been included in Section 4.2.1.1, and a clear indication that the high dose group was eliminated from further assessment has been added.

Comment: One of the reviewers suggested that the dose levels in the NTP (1990) study be referred to after adjustments for duration.

Response: The dose levels were listed as administered and as adjusted for duration (i.e., 312 mg/kg 5 days/week becomes 223 mg/kg-day) as indicated in Section 4.2.1.1. An explanation of this adjustment was included. All references to dose are to the adjusted dose.

b) Critical Effect, Section 5.1.1: The critical effect is identified as increased kidney weight. Is this the correct critical effect and is it adequately described?

Comment:. Four of the seven reviewers found the choice of kidney weight in the NTP (1990) study as the critical effect to be the best choice from available data. Two reviewers indicated the interspecies variability in the effect of toluene on kidney weight should be discussed. Two reviewers indicated additional text should be included to add more weight to the immunotoxicity studies.

Response: The increase in kidney weight (NTP, 1990) has been retained as the critical effect. Benchmark dose modeling of selected immunotoxicity endpoints has been included in the quantitative analysis (Section 5.1.3). An uncertainty factor of 3 for database insufficiency has been included in the derivation of the RfD to account for, among other deficiencies, potential immunotoxic effects that could occur at a lower dose than the dose used for the point of departure. The text in Sections 5.1.1 and 5.1.2 has been augmented to reflect the species differences in the observed kidney weight changes.

Comment: One reviewer suggested that immunotoxicity would be a better endpoint for the derivation of the RfD because it is present across species (mice, hamsters, and fish), and the depressed antibody response (Hsieh et al., 1989, 1990b) is supported by a similar reduction in the lymphoproliferative response (Hsieh et al., 1989, 1990b), a 30% decrease in circulating leukocytes (Burns et al., 1994), and a 100% increase in corticosterone (Hsieh et al., 1991). A fish study (Palermo-Neto et al., 2001) was cited for inclusion in the Toxicological Review. See also the comment above regarding immunotoxicity as an important potential endpoint for toxicity.

Response: The fish data (as discussed above) involve animals with a highly divergent immune system from mammals, and the Palermo-Neto et al. (2001) study involves a mixture of toluene and n-hexane, not pure toluene. Leukocyte counts are poor predictors of immunotoxic outcome (Luster et al., 1992; Dean, 1997), and the 30% reduction in circulating leukocytes (Burns et al., 1994) is not cited in the original study as an indication of immunotoxicity. Although

corticosterone is an immunosuppressor, measuring increased corticosterone in the absence of convincing reductions in other immune assays may not be evidence of immune suppression.

c) Methods of Analysis, Section 5.1.2: Benchmark dose modeling has been used to derive the point of departure for determining the RfD. In the absence of information on the level of response to consider adverse, a change in the mean equal to one standard deviation from the control mean was used according to the U.S. EPA Benchmark Dose Technical Document Guidance (U.S. EPA, 2000c). Has the correct benchmark response (one standard deviation from the control mean) been chosen for the continuous data set for increased kidney weight? Have PBPK modeling issues (i.e., route-to-route extrapolation from inhalation data was not conducted) been adequately addressed?

Comment: Five of the seven reviewers indicated benchmark dose modeling was the appropriate method for quantitation for the RfD, and the correct benchmark response was used if kidney weight change is considered the relevant endpoint of toxicity. All reviewers agreed that PBPK modeling issues have been adequately addressed. One reviewer suggested that a NOAEL/LOAEL approach for quantitation would suffice because of the small potential for relevant exposure.

Response: No comment necessary.

Comment: One reviewer indicated confusion in the description of the benchmark dose modeling approach regarding the P_0 (one standard deviation from the mean kidney weight in controls) and the benchmark response level.

Response: The reviewer has identified one issue in EPA's evolving benchmark dose (BMD) methodology that has not been standardized, which is nomenclature. The P_0 referred to was used in one previous IRIS assessment but has not been generalized in guidance yet. However, the benchmark responses (BMRs) that were used for toluene are consistent with current guidance to present BMDs corresponding to a 10% extra risk. That is, for continuous data, a one standard deviation (SD) change in the mean response of an exposed group is approximately equivalent to 10% of that group having responses more extreme than 98% of the control group. A one-SD BMR is directly comparable to the recommended baseline BMR of 10% extra risk for quantal endpoints and is, therefore, a point of standardization for considering quantal and continuous data. Contrast this with a 10% change in a continuous variable, which is too unstable a BMR

since the degree of variability in the endpoint (and in a particular study) can have a significant impact on the interpretation of the data. The BMD methodology recognizes that the 98th percentile of the control group may not always characterize a bright-line for adverse levels of continuous variables, depending on the endpoint being considered. This is why the methodology recommends a one-SD BMR as a point of comparison across chemicals but not necessarily the only benchmark to be considered.

d) *Uncertainty Factors, Section 5.1.3: Have the appropriate uncertainty factors been applied? Is the explanation for each transparent? Is there sufficient justification to not include an uncertainty factor for database insufficiencies?*

Comment: Five of the seven reviewers found the explanation for applying each uncertainty factor was clear and that sufficient justification for not including a database uncertainty factor was provided. One of the reviewers commented that the use of uncertainty factors was not based on science because no data exist on animal to human extrapolation from oral exposure to toluene.

Response: No response necessary.

Comment: One of the reviewers suggested including Van Asperen et al. (2003) in the discussion of PBPK modeling data related to toluene.

Response: The Van Asperen et al. (2003) reference has been added to the text in Section 3.5 of the Toxicological Review. The results of this high dose study add to the available information regarding the pharmacokinetics of toluene in rats.

2) **RfC Derivation**

a) *Principal Study, Section 5.2.1: Several human occupational studies are available. The study used in the previous IRIS file (Foo et al., 1990) is not used in the reassessment; the study by Zavalic et al. (1998a) has been chosen as the principal study. Is this the correct choice for the principal study? Are adequate explanations given to explain why this study was chosen over the other available studies?*

Comment: Two reviewers found that the choice of Zavalic et al. (1998a) as the principal study was adequately explained. However, all reviewers found the inconsistent presentation of results in the three papers by Zavalic et al. (1998a,b,c), which purportedly represent the same study population, should be reexamined and the choice of the Zavalic et al. (1998a) study as the principal study should be reconsidered. Specifically, the reviewers pointed out that, within the three publications, data describing the mean alcohol consumption, toluene exposure, and control subject group are significantly different, while the assertion is made that the cohorts are the same. The reviewers pointed out that the Zavalic et al. (1998a,b,c) studies also do not indicate an effect on color vision until confounding factors such as alcohol consumption and age were taken into consideration. Several reviewers suggested revisions to the text regarding the use of Zavalic et al. (1998a) as the principal study for the derivation of the RfC, if this study were to be retained as the principal study, due to the discrepancies noted in the data sets among various studies from the same cohort (Zavalic et al., 1998a,b,c). Five reviewers indicated that the other available occupational studies, in addition to the Zavalic et al. (1998a) study, all contain potential “non-fatal” confounding issues and, as such, should be considered equally for use as the principal study. The reviewers indicated the majority of the available human studies point to a dose range where no effects from toluene exposure were observed. Several reviewers suggested a weight-of-evidence approach would be superior to choosing one study as the principal study for the derivation of the RfC.

Response: Upon further evaluation of the Zavalic et al. (1998a,b,c) studies, it is evident that there are a number of discrepancies within the data sets from the same cohort that are of concern. For example, the reported alcohol consumption and toluene exposure duration differ considerably within descriptions of the same cohort. The rationale for the discrepancies is not readily apparent. The alcohol consumption range is identical for Group E1, but the mean differs (32.29 vs 78.0 grams/week); the upper range is 262 grams/week for both E2 group descriptions, but the lower bound is 42 vs 45 grams/week, and the means also differ (96.1 vs 160 grams/week). Accounting for alcohol consumption in studies of color vision effects is considered a necessary adjustment of the data. The duration of toluene exposure is also different within the same cohort as described by the three papers. For these reasons, the Zavalic et al. (1998a) study is no longer considered the principal study for the derivation of the RfC. Notations in the study descriptions for the Zavalic et al. (1998a,b,c) studies as to potential discrepancies in data reporting have not been made and the comments from reviewers as indicated in this appendix are considered sufficient. Instead of relying on the Zavalic et al (1998a) study as the principal study, a holistic approach has been applied whereby all available human and animal inhalation studies

are taken into consideration from a qualitative viewpoint for the determination of a suitable endpoint of toxicity. In addition, a subset of the human studies has been identified for use in the quantitative analysis. Criteria used for defining this subset of studies and a discussion of the approach is described in Sections 5.2.1 and 5.2.2. The information derived from the Zavalic et al. (1998a,b,c) studies is considered valuable and has been taken into consideration along with the other available studies irrespective of potential concerns about the data.

Comment: Three reviewers indicated that a potential difficulty with the Zavalic et al. (1998a,b,c) studies is that the illumination conditions—a major confounding factor in color confusion research—were not standardized or well characterized.

Response: The level of luminance and the color spectrum of the light that is used to illuminate the colored test chips are important factors to control in application of the Lanthony D-15d (Geller and Hudnell, 1997). The number of errors made by observers with normal vision increases at levels of illumination below 500 lx, approximately the brightness of a room in normal daylight. Zavalic et al. (1998a,b) did not control the illumination of the test when administered at different locations but instead used natural daylight. Thus, as the reviewers state, differences in illumination in the testing locations at the different plants could have introduced systematic bias in the CCI scores when compared across different testing locations or different days. For example, differences in ambient lighting could conceivably account for the group effects observed in Figures 1 and 2 of Zavalic et al. (1998b). This problem, however, cannot reasonably explain significant dose-related associations as a function of air or blood toluene concentrations that are observed only within the exposed population and measured at a single location, such as the data presented by Zavalic et al. (1998b). There is no reason to suspect a confounding between test luminance conditions and air or biological concentrations of toluene or its metabolites for measures all collected within one exposed plant. It is also important to consider that numerous other studies have observed increased CCI scores in populations exposed to volatile organic compounds when the testing was conducted under appropriate illumination conditions (e.g., Mergler et al., 1988; Cavalleri et al., 2000; Campagna et al., 2001).

b) Choice of Critical Effect, Section 5.2.1: The critical effect is identified as impaired color vision. Is this the correct critical effect and is it adequately described? Is the biological basis for choosing this effect adequately explained?

Comment: Four reviewers indicated color vision impairment was a viable endpoint for toxicity from toluene exposure via inhalation. The reviewers were not uniform with regard to whether or not increased CCI scores on the Lanthony D15-d were considered adverse and, therefore, appropriate for selection as a critical effect. One reviewer accepted the concept that alterations in color perception are to be considered adverse in their own right. On the other hand, this reviewer was not convinced that CCI scores reflected color perception deficits and was concerned that neurobehavioral and cognitive deficits were not considered in the assessment. One reviewer stated that impaired color vision was an undesirable effect rather than a frank toxic effect, apparently implying that the choice of CCI as the critical effect was inappropriate. Several of the reviewers suggested a weight-of-evidence approach involving multiple outcomes, including neurological and performance measurements along with those of color arrangement tests.

Response: The use of color vision impairment as a critical effect from toluene exposure has been reconsidered. A subset of adequate studies were evaluated which indicate neurological effects are the critical effect following toluene exposure. Color vision impairment is now considered one of multiple neurological deficits that are evident from the available data. This approach gives broader coverage of potential adverse outcomes and places less reliance on a single outcome. This approach has the advantage of considering multiple neurotoxicological outcome measures that have been evaluated in various studies.

Comment: Several reviewers, while agreeing with color vision as a potential indicator of toluene toxicity, questioned whether visual impairment is a chronic effect or an acute effect that is temporally associated with ongoing exposure. One reviewer noted that the use of acute measurements (i.e., on a single day) to represent chronic exposure may not capture day-to-day variations in toxicity.

Response: There is no direct evidence as to the reversibility of changes in color perception as a consequence of exposure to toluene. The primary studies of toluene exposure have been conducted on workers currently exposed to toluene. Other organic solvents also are reported to increase CCI values, and there is limited evidence as to the reversibility of these effects. For dry cleaners exposed to perchloroethylene, Gobba et al. (1998) observed that populations with increased levels of exposure showed increased CCI scores, whereas those with decreased exposure levels showed no significant recovery in CCI scores 2 years after the first evaluation. In contrast, Mergler et al. (1996) found in a 2-year follow-up that workers exposed to styrene in

exposure scenarios with improved exposure conditions over time also showed improvements in CCI scores. The results of these studies indicate if the CCI deficits from organic solvents are reversible, they appear to do so slowly. Section 4.5.2 discusses the available information regarding endpoints of toluene toxicity following long-term exposure to toluene with respect to reversibility of effects.

Comment: One reviewer indicated the high prevalence of spontaneous color vision impairment to be a confounding factor for the relevance of toluene-associated impairment of color vision as an adverse condition.

Response: The concept that performance on the Lanthony D15-d color arrangement test could be influenced by factors other than deficits in color perception is technically correct. The Lanthony D15-d is a screening procedure that ideally should be used to identify potential candidates for more extensive follow-up evaluations, in order to determine if the deficits observed are in fact related to impaired color perception or to some other factor. Unfortunately, extensive follow-up testing is rarely done in field studies of occupationally exposed workers due to limitations of logistics, time, and resources. In the absence of more definitive evaluations, it may be best to make the most reasonable conclusions based on the evidence that is available. In general, the task performance demands of the Lanthony D15-d are relatively minor. It is an easy task to perform and is administered without a time limit. The performance on the task is known to be influenced by numerous parameters that alter the physical parameters of the stimulus, such as the intensity and color spectrum of the illuminant, the pupil size, and the relative clarity of the lens (reviewed in Geller and Hudnell, 1997). If the potentially confounding factors are well-controlled across experimental groups, then it is reasonable to conclude that systematic group differences related to exposure may be due to color perception deficits.

c) Methods of Analysis, Section 5.2.2: Benchmark dose modeling has been used to derive the point of departure for determining the RfC. In the absence of information on the level of response to consider adverse, a change in the mean equal to one standard deviation from the control mean was used according to the U.S. EPA Benchmark Dose Technical Guidance Document (U.S. EPA, 2000c). Has the correct benchmark response (one standard deviation from the control mean) for the continuous data set for alcohol- and age-adjusted color confusion index (AACCI) been chosen? Have PBPK modeling issues (i.e., a chemical-specific duration adjustment was not conducted) been adequately addressed?

Comment: A majority of the reviewers commented on the use of benchmark dose modeling for the derivation of the RfC. There was general agreement that this method of determining the point of departure from the available data (i.e., Zavalic et al., 1998a) was acceptable but that the use of this data set should be reconsidered (see above comments). Several reviewers commented that PBPK modeling issues were adequately addressed and that the available PBPK models were inadequate for use in deriving a human equivalent concentration. One reviewer presented an adaptation of the available PBPK models for consideration for use in converting discontinuous occupational exposures to continuous exposures (TN&A, Inc., 1999). The adapted model was designed for the Foo et al. (1990) study and utilizes an internal averaged concentration of toluene in the brain. The reviewer stated that the most appropriate bioequivalent internal dose metric would be the average concentration of toluene in the brain, calculated with a PBPK model for $t > 0$ by dividing the area under the curve for toluene concentration in the brain by time.

Response: Although use of an average concentration of toluene in the brain as an internal dose metric is a reasonable assumption for the appropriate bioequivalent dose, no data are available for demonstrating that this is the critical dose metric for the chronic effects of toluene exposure. The use of alternative data-derived dose metrics, such as peak concentrations, the time above threshold, or total cumulative dose, would all provide a different extrapolation for duration adjustments. Without knowledge of the internal dose metric, PBPK-based approaches are likely to be no more scientifically justified than the standard default approach to duration adjustments (i.e., 5 days/7 days or 6 hours/24 hours).

d) *Uncertainty Factors, Section 5.2.3: Have the appropriate uncertainty factors been applied? Is the explanation for each transparent?*

Comment: Four of the seven reviewers indicated the appropriate uncertainty factors had been applied and that the explanation for applying a single uncertainty factor for intraspecies susceptibility was clear and sufficient. Other comments on the choice of uncertainty factors suggested that uncertainty factors are subject to scientific judgement.

Response: No response necessary.

3) **Cancer Weight-of-Evidence Classification:** *The weight of evidence and cancer characterization are discussed in Section 4.6. Have appropriate criteria been applied from the 1999 EPA Draft Revised Guidelines for Carcinogen Assessment (Review Draft, NCEA-F-0644,*

July 1999. Risk Assessment Forum)? Is the statement that “data are inadequate for an assessment of the human carcinogenic potential” correct?

Comment: Six of the seven reviewers agreed that the appropriate criteria have been applied and the correct conclusion drawn that the data are inadequate for an assessment of human carcinogenic potential for toluene. One reviewer suggested the use of the term “insufficient” rather than “inadequate” to describe the human carcinogenic potential of toluene and the additional description that “all animal studies as well as human epidemiological surveys performed so far have not clearly demonstrated a carcinogenic effect.”

Response: The characterization that data are inadequate for assessment of the human carcinogenic potential of toluene has been retained according to the available weight-of-evidence characterizations outlined in the 1999 *Draft Revised Guidelines for Carcinogen Risk Assessment* (U.S. EPA, 1999). The recommended additions to the text, however, have been added to Section 4.6.1 of the Toxicological Review. Note: Following the release of the 2005 *Guidelines for Carcinogen Risk Assessment*, the reference was updated to U.S. EPA (2005).

Scientific Comments from the Public

(Note that a number of comments from the public were similar to the comments from external peer reviewers. A summary of the comments with responses is included below; however, please refer to the above comments and responses to the external peer reviewers for more detailed responses.)

Comment: One reviewer stated that the available health endpoints (e.g., immunotoxicity and kidney toxicity endpoints) considered for the derivation of the RfD are questionable as the available science does not substantiate a plausible mechanism of toxicity.

Response: Kidney toxicity, specifically an increase in kidney weight, has been retained as the critical effect for the derivation of a chronic oral RfD. Animals exposed at high doses exhibited frank kidney toxicity. In addition, case reports of human exposure to toluene at abusive doses indicate renal toxicity. Information indicating potential modes of action of renal toxicity are discussed in Section 4.5.3 of the Toxicological Review. Potential immunotoxic effects are noted based on several studies at doses lower than those used for the point of departure. An uncertainty factor of 3 for database insufficiency has been applied to the point of departure, in part, due to

the uncertainty surrounding immunotoxic effects and the possibility that a more complete study of these effects would yield a lower RfD as discussed in Sections 5.1.1, 5.1.2, and 5.1.3 of the Toxicological Review.

Comment: One reviewer indicated the use of the Zavalic et al. (1998a) study as the principal study for the derivation of the RfC was not the most sensitive study available and provided examples of several studies showing effects at lower doses. In addition, this reviewer indicated the proposed RfC lacks congruency with the ACGIH TLV of 50 ppm for worker exposure. Another reviewer stated that the Zavalic et al. (1998a) study contained incidences of inconsistent data reporting and, as such, should not be relied upon for the derivation of the RfC. In addition, it was stated that the use of the color confusion index as a critical effect is questionable as no plausible linkage exists between the endpoint and an adverse health effect in humans. This reviewer suggested a weight-of-evidence approach that would likely reduce the uncertainty factors applicable to the point of departure. This reviewer also suggested that the uncertainty factor for human variability would only be necessary if there was a reliance on a single study for the derivation of the RfC.

Response: The Zavalic et al. (1998a) study is no longer used as the principal study for the derivation of the RfC. An argument can be made against choosing any of the available human studies as a single principal study due to potentially equal confounding factors in all of the studies. A more holistic approach is now used to determine the critical effect and point of departure. This approach is plausible for determining a chronic reference value for toluene as a number of available occupational studies are low dose studies with NOAELs and LOAELs that fall within a somewhat defined range of exposure doses for each (i.e., NOAELs and LOAELs). The use of this approach, as used for toluene, may not be scientifically defensible for all chemical health assessments. The critical effect has been changed from alterations in color vision to neurological effects to better reflect the database. Alterations in color vision constitute one of the effects noted within this database.

After adjustments for human exposure conditions, the point of departure for the RfC has changed to 46 mg/m³. Application of an uncertainty factor of 10 yields an RfC of 5 mg/m³ with rounding to one significant figure. This value is considerably less than the value derived previously and represents the data set available for human exposure to toluene as a whole. An uncertainty factor of 10 to account for human variability has been retained. No data are available

concerning human variability, and the approach is based solely on occupational studies. Refer to Sections 5.2.1, 5.2.2, and 5.2.3 of the Toxicological Review for more detailed information.

Comment: One reviewer indicated the proposed RfC for toluene may not be protective of children's health. The reviewer specifically cited disagreement with the Pelekis et al. (2001) paper, indicating that the use of an uncertainty factor of 10 will adequately protect children.

Response: The text in Section 5.2.3 of the Toxicological Review cites the Pelekis et al. (2001) study in reference to the use of a 10-fold uncertainty factor for intraspecies uncertainty. It is stated in the text that the Pelekis model is based solely on the pharmacokinetic differences between adults and children. Statements are made that the model does not address variations in the adult population or potential pharmacodynamic differences. Discussion of this model is included for completeness. A full 10-fold uncertainty factor is retained for intraspecies variation.

Appendix B1. Benchmark Dose Modeling Results for the Derivation of the RfD (NTP, 1990)

Benchmark dose (BMD) modeling was performed to determine the point of departure for the derivation of the RfD for toluene. The modeling was conducted according to draft EPA guidelines (U.S. EPA, 2000) using Benchmark Dose Software (BMDS, Version 1.3) available from the U.S. EPA (2001). The BMD modeling results are summarized in Table B-1, and the model outputs are attached. A brief discussion of the modeling results is presented below.

Changes in rat kidney weight were modeled from the NTP (1990) study. Male rat kidney data were chosen for BMD modeling as these data exhibited a greater response than that seen in female rats. Data from the high dose group (2500 mg/kg) were eliminated since only 2/10 rats survived. Absolute kidney weights were used because the maximum tolerated dose was exceeded at the high dose. The endpoint selected is a continuous variable; therefore, the continuous models available with the BMDS software (linear, polynomial [including quadratic], power, and Hill) were used. The Hybrid model software in BMDS is still undergoing beta-testing, and was not used because it was not considered sufficiently validated for use in quantitative dose-response assessment. (Note: The hybrid modeling approach defines the benchmark response [BMR] in terms of change in the mean.) The modeling was conducted for a BMR defined as a 1.0 standard deviation (SD) change in the control mean. This BMR definition was selected in the absence of clear biological rationale for selecting an alternative response level (U.S EPA, 2000).

The BMDL estimates for the endpoint of increased kidney weight are presented for the linear, quadratic, and power models in Table B-1. The Hill model failed to give adequate goodness-of-fit p-values for the model fits and did not provide any adequate BMDL estimates. The goodness-of-fit p-values varied widely for the other models. The only values that were adequate (using a value of $p=0.1$) were for the models with the restrictions of $\rho=0$. An analysis of the model fit (lowest maximum chi-square-residual) in the low dose region (region of the BMDLs) indicated that some models better fit the data in this region. The Akaike Information Criterion (AIC) was similar for the models.

The model selected for this endpoint was the quadratic model with $\rho=0$, over the linear and power models with $\rho=0$. The linear model with $\rho=0$ has a larger chi-square-residual (0.333) than the quadratic model with $\rho=0$ (0.084) and the power model with $\rho=0$ (0.019), and, subsequently, does not fit the data at the low dose range as well as the quadratic and power

models. The AIC value for the quadratic model with $\rho=0$ (410.5) is higher than that for the linear model with $\rho=0$ (409.1) and lower than the power model with $\rho=0$ (412.5), but these differences are not significant. Of the three models discussed, the linear model with $\rho=0$ does not fit the data as well as the other two models at the low dose range, and the power model with $\rho=0$ has the highest AIC value. Therefore, the quadratic model with $\rho=0$ is the most useful model for the kidney weight data and provides an estimated point of departure at 238 mg/kg-day at one standard deviation. This corresponds to the lower bound on the dose associated with a 10% increase in individuals having a kidney weight greater than the 98th percentile of kidney weights in the control group. This SD corresponds to 9% increase in kidney weight from control.

Table B-1: Benchmark modeling summary for relative kidney weight, NTP (1990).

Toluene dose	Number weighed	Kidney weight in male rats (milligrams) $\pm$ SE			
0 mg/kg-day	10	1,084 $\pm$ 14			
312 mg/kg-day	10	1,159 $\pm$ 34			
625 mg/kg-day	10	1,213 $\pm$ 39			
1250 mg/kg-day	10	1,292 $\pm$ 34			
Continuous models	Restrictions	goodness-of-fit p-value	AIC	Maximum χ^2 residual near POD	BMDL (mg/kg), 1 SD
Linear	model determined	<0.0001	410.9	0.428	320
	rho=0	0.734	409.1	0.333	428
Quadratic	model determined	<0.0001	412.9	0.060	320
	rho=0	0.912	410.5	0.084	238
Power	model determined	<0.0001	408.6	NA	NE
	rho=0	0.920	412.5	-0.019	107
Hill	model determined	NE	419.3	NA	0+
	rho=0	NE	414.5	0.000	140
	n $\geq$ 1	NE	414.0	NA	NE
	rho=2, n $\geq$ 1	<0.0001	410.8	0.009	193
	rho=2, n = 2	<0.0001	411.1	NA	NE

Polynomial Model. Revision: 2.2 Date: 9/12/2002
 Input Data File: F:\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.(d)
 Gnuplot Plotting File: F:\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.plt
 Wed Sep 03 14:48:35 2003

=====

Male kidney quadratic std dev=1 parms rho=0

~~~~~

The form of the response function is:

$Y[\text{dose}] = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$

Dependent variable = MEAN  
 Independent variable = Dose  
 rho is set to 0  
 Signs of the polynomial coefficients are not restricted  
 A constant variance model is fit

Total number of dose groups = 5  
 Total number of records with missing values = 1  
 Maximum number of iterations = 1000  
 Relative Function Convergence has been set to: 1e-008  
 Parameter Convergence has been set to: 1e-008

User Inputs Initial Parameter Values  
 alpha = 0.0001  
 rho = 1 Specified  
 beta\_0 = 1100  
 beta\_1 = 1  
 beta\_2 = 0.001

#### Parameter Estimates

|             |          | 95.0% Wald Confidence |              |                   |                   |
|-------------|----------|-----------------------|--------------|-------------------|-------------------|
| Interval    | Variable | Estimate              | Std. Err.    | Lower Conf. Limit | Upper Conf. Limit |
| Limit       |          |                       |              |                   |                   |
| 13042.6     | alpha    | 9068.31               | 2027.74      | 5094.01           |                   |
| 1141.5      | beta_0   | 1084.95               | 28.8495      | 1028.41           |                   |
| 0.480236    | beta_1   | 0.250443              | 0.117244     | 0.0206492         |                   |
| 0.000102466 | beta_2   | -6.80453e-005         | 8.69974e-005 | -0.000238557      |                   |

#### Asymptotic Correlation Matrix of Parameter Estimates

|        | alpha    | beta_0  | beta_1   | beta_2 |
|--------|----------|---------|----------|--------|
| alpha  | 1        | -6e-006 | 1.3e-007 | 2e-006 |
| beta_0 | -6e-006  | 1       | -0.74    | 0.59   |
| beta_1 | 1.3e-007 | -0.74   | 1        | -0.96  |
| beta_2 | 2e-006   | 0.59    | -0.96    | 1      |

#### Table of Data and Estimated Values of Interest

| Dose Res. | N  | Obs Mean  | Obs Std Dev | Est Mean  | Est Std Dev | Chi^2   |
|-----------|----|-----------|-------------|-----------|-------------|---------|
| 0         | 10 | 1.08e+003 | 44.3        | 1.08e+003 | 95.2        | -0.0316 |
| 312       | 10 | 1.16e+003 | 108         | 1.16e+003 | 95.2        | 0.0842  |
| 625       | 10 | 1.21e+003 | 123         | 1.21e+003 | 95.2        | -0.063  |
| 1250      | 10 | 1.29e+003 | 108         | 1.29e+003 | 95.2        | 0.0105  |

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma(i)^2$

Model R:  $Y_i = \mu + e(i)$   
 $\text{Var}\{e(i)\} = \sigma^2$

#### Likelihoods of Interest

| Model  | Log(likelihood) | DF | AIC        |
|--------|-----------------|----|------------|
| A1     | -202.244681     | 5  | 414.489362 |
| A2     | -197.498037     | 8  | 410.996073 |
| fitted | -202.250763     | 3  | 410.501527 |
| R      | -212.606673     | 2  | 429.213345 |

Test 1: Does response and/or variances differ among dose levels

(A2 vs. R)

Test 2: Are Variances Homogeneous (A1 vs A2)

Test 3: Does the Model for the Mean Fit (A1 vs. fitted)

#### Tests of Interest

| Test   | $-2 \cdot \log(\text{Likelihood Ratio})$ | Test df | p-value |
|--------|------------------------------------------|---------|---------|
| Test 1 | 30.2173                                  | 6       | <.0001  |
| Test 2 | 9.49329                                  | 3       | 0.0234  |
| Test 3 | 0.0121647                                | 1       | 0.9122  |

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels.

It seems appropriate to model the data

The p-value for Test 2 is less than .05. Consider running a non-homogeneous variance model

The p-value for Test 3 is greater than .05. The model chosen appears to adequately describe the data

#### Benchmark Dose Computation


Specified effect = 1

Risk Type = Estimated standard deviations from the control mean

Confidence level = 0.95

BMD = 430.62

BMDL = 237.787



14:48 09/03 2003

```

=====
Polynomial Model. Revision: 2.2 Date: 9/12/2002
Input Data File: F:\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.(d)
Gnuplot Plotting File: F:\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.plt
Wed Sep 03 15:48:56 2003
=====

```

Male kidney linear std dev=1 parms free

The form of the response function is:

$Y[\text{dose}] = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$

Dependent variable = MEAN

Independent variable = Dose

Signs of the polynomial coefficients are not restricted

The variance is to be modeled as  $\text{Var}(i) = \alpha \cdot \text{mean}(i)^\rho$

Total number of dose groups = 5

Total number of records with missing values = 1

Maximum number of iterations = 1000

Relative Function Convergence has been set to: 1e-008

Parameter Convergence has been set to: 1e-008

#### User Inputs Initial Parameter Values

```

alpha = 0.0001
rho = 0
beta_0 = 1100
beta_1 = 1

```

#### Parameter Estimates

| Interval     |          |          |              | 95.0% Wald Confidence |             |
|--------------|----------|----------|--------------|-----------------------|-------------|
| Limit        | Variable | Estimate | Std. Err.    | Lower Conf. Limit     | Upper Conf. |
|              | alpha    | 1e-008   | 6.48795e-008 | -1.17161e-007         |             |
| 1.37161e-007 | rho      | 3.88492  | 0.915011     | 2.09153               |             |
| 5.67831      | beta_0   | 1093.41  | 20.6962      | 1052.84               |             |
| 1133.97      | beta_1   | 0.172212 | 0.033839     | 0.105888              |             |
| 0.238535     |          |          |              |                       |             |

#### Asymptotic Correlation Matrix of Parameter Estimates

|        | alpha  | rho    | beta_0 | beta_1 |
|--------|--------|--------|--------|--------|
| alpha  | -1     | 1      | -0.028 | 0.045  |
| rho    | 1      | -1     | 0.027  | -0.044 |
| beta_0 | -0.028 | 0.027  | 1      | -0.71  |
| beta_1 | 0.045  | -0.044 | -0.71  | 1      |

#### Table of Data and Estimated Values of Interest

| Dose Res. | N  | Obs Mean  | Obs Std Dev | Est Mean  | Est Std Dev | Chi^2  |
|-----------|----|-----------|-------------|-----------|-------------|--------|
| 0         | 10 | 1.08e+003 | 44.3        | 1.09e+003 | 79.9        | -0.372 |



|      |    |           |     |           |      |        |
|------|----|-----------|-----|-----------|------|--------|
| 312  | 10 | 1.16e+003 | 108 | 1.15e+003 | 87.7 | 0.428  |
| 625  | 10 | 1.21e+003 | 123 | 1.2e+003  | 95.9 | 0.394  |
| 1250 | 10 | 1.29e+003 | 108 | 1.31e+003 | 113  | -0.465 |

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma(i)^2$

Model A3:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \alpha * (\mu(i))^{\rho}$

Model R:  $Y_i = \mu + e(i)$   
 $\text{Var}\{e(i)\} = \sigma^2$

Warning: Likelihood for fitted model larger than the Likelihood for model A3.

#### Likelihoods of Interest

| Model  | Log(likelihood) | DF | AIC         |
|--------|-----------------|----|-------------|
| A1     | -202.244681     | 5  | 414.489362  |
| A2     | -197.498037     | 8  | 410.996073  |
| A3     | -792.622946     | 6  | 1597.245893 |
| fitted | -201.467874     | 4  | 410.935749  |
| R      | -212.606673     | 2  | 429.213345  |

#### Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels?  
 (A2 vs. R)

Test 2: Are Variances Homogeneous? (A1 vs A2)

Test 3: Are variances adequately modeled? (A2 vs. A3)

Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)

#### Tests of Interest

| Test   | -2*log(Likelihood Ratio) | Test df | p-value |
|--------|--------------------------|---------|---------|
| Test 1 | 30.2173                  | 6       | <.0001  |
| Test 2 | 9.49329                  | 3       | 0.0234  |
| Test 3 | 1190.25                  | 2       | <.0001  |
| Test 4 | -1182.31                 | 2       | <.0001  |

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels  
 It seems appropriate to model the data

The p-value for Test 2 is less than .05. A non-homogeneous variance model appears to be appropriate

The p-value for Test 3 is less than .05. You may want to consider a different variance model

The p-value for Test 4 is less than .05. You may want to try a different model

Benchmark Dose Computation

Specified effect = 1

Risk Type = Estimated standard deviations from the control mean


Confidence level = 0.95

BMD = 464.141

BMDL = 320.11

BMDL computation failed for one or more point on the BMDL curve.

The BMDL curve will not be plotted



15:49 09/03 2003

```

=====
Polynomial Model. Revision: 2.2 Date: 9/12/2002
Input Data File: C:\DOCUMENTS AND SETTINGS\AMARCUS\MY
DOCUMENTS\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.(d)
Gnuplot Plotting File: C:\DOCUMENTS AND SETTINGS\AMARCUS\MY
DOCUMENTS\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.plt
Tue Sep 02 22:43:03 2003
=====

```

Male kidney linear model std dev = 1 parms rho==0

The form of the response function is:

$Y[\text{dose}] = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$

Dependent variable = MEAN

Independent variable = Dose

rho is set to 0

The polynomial coefficients are restricted to be positive

A constant variance model is fit

Total number of dose groups = 5

Total number of records with missing values = 1

Maximum number of iterations = 1000

Relative Function Convergence has been set to: 1e-008

Parameter Convergence has been set to: 1e-008

#### User Inputs Initial Parameter Values

```

alpha = 10000
rho = 1 Specified
beta_0 = 1000
beta_1 = 1

```

#### Parameter Estimates

| Interval |          |          |           | 95.0% Wald Confidence |             |
|----------|----------|----------|-----------|-----------------------|-------------|
| Limit    | Variable | Estimate | Std. Err. | Lower Conf. Limit     | Upper Conf. |
| 13242    | alpha    | 9206.98  | 2058.74   | 5171.92               |             |
| 1144.29  | beta_0   | 1098.24  | 23.4986   | 1052.18               |             |
| 0.226676 | beta_1   | 0.162349 | 0.0328205 | 0.098022              |             |

#### Asymptotic Correlation Matrix of Parameter Estimates

|        | alpha     | beta_0    | beta_1   |
|--------|-----------|-----------|----------|
| alpha  | 1         | -7.5e-007 | 8.4e-008 |
| beta_0 | -7.5e-007 | 1         | -0.76    |
| beta_1 | 8.4e-008  | -0.76     | 1        |

#### Table of Data and Estimated Values of Interest

| Dose Res. | N  | Obs Mean  | Obs Std Dev | Est Mean  | Est Std Dev | Chi^2  |
|-----------|----|-----------|-------------|-----------|-------------|--------|
| 0         | 10 | 1.08e+003 | 44.3        | 1.1e+003  | 96          | -0.469 |
| 312       | 10 | 1.16e+003 | 108         | 1.15e+003 | 96          | 0.333  |

|      |    |           |     |          |    |        |
|------|----|-----------|-----|----------|----|--------|
| 625  | 10 | 1.21e+003 | 123 | 1.2e+003 | 96 | 0.438  |
| 1250 | 10 | 1.29e+003 | 108 | 1.3e+003 | 96 | -0.302 |

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma(i)^2$

Model R:  $Y_i = \mu + e(i)$   
 $\text{Var}\{e(i)\} = \sigma^2$

#### Likelihoods of Interest

| Model  | Log(likelihood) | DF | AIC        |
|--------|-----------------|----|------------|
| A1     | -202.244681     | 5  | 414.489362 |
| A2     | -197.498037     | 8  | 410.996073 |
| fitted | -202.554337     | 2  | 409.108675 |
| R      | -212.606673     | 2  | 429.213345 |

Test 1: Does response and/or variances differ among dose levels

(A2 vs. R)

Test 2: Are Variances Homogeneous (A1 vs A2)

Test 3: Does the Model for the Mean Fit (A1 vs. fitted)

#### Tests of Interest

| Test   | -2*log(Likelihood Ratio) | Test df | p-value |
|--------|--------------------------|---------|---------|
| Test 1 | 30.2173                  | 6       | <.0001  |
| Test 2 | 9.49329                  | 3       | 0.0234  |
| Test 3 | 0.619313                 | 2       | 0.7337  |

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels.

It seems appropriate to model the data

The p-value for Test 2 is less than .05. Consider running a non-homogeneous variance model

The p-value for Test 3 is greater than .05. The model chosen appears to adequately describe the data

#### Benchmark Dose Computation


Specified effect = 1

Risk Type = Estimated standard deviations from the control mean

Confidence level = 0.95

BMD = 591.029

BMDL = 427.88



```
=====
Polynomial Model. Revision: 2.2 Date: 9/12/2002
Input Data File: F:\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.(d)
Gnuplot Plotting File: F:\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.plt
Wed Sep 03 15:18:44 2003
=====
```

```
Male kidney quadratic std dev=1 parms free
~~~~~
```

The form of the response function is:

$Y[\text{dose}] = \text{beta}_0 + \text{beta}_1 \cdot \text{dose} + \text{beta}_2 \cdot \text{dose}^2 + \dots$

Dependent variable = MEAN

Independent variable = Dose

Signs of the polynomial coefficients are not restricted

The variance is to be modeled as  $\text{Var}(i) = \alpha \cdot \text{mean}(i)^\rho$

Total number of dose groups = 5

Total number of records with missing values = 1

Maximum number of iterations = 1000

Relative Function Convergence has been set to: 1e-008

Parameter Convergence has been set to: 1e-008

```
User Inputs Initial Parameter Values
alpha = 0.0001
rho = 0
```

```

beta_0 = 1100
beta_1 = 1
beta_2 = 0.001

```

#### Parameter Estimates

|              |          | 95.0% Wald Confidence |              |                   |                   |
|--------------|----------|-----------------------|--------------|-------------------|-------------------|
| Interval     | Variable | Estimate              | Std. Err.    | Lower Conf. Limit | Upper Conf. Limit |
| Limit        |          |                       |              |                   |                   |
| 1.37154e-007 | alpha    | 1e-008                | 6.48758e-008 | -1.17154e-007     |                   |
| 5.67814      | rho      | 3.88492               | 0.914924     | 2.0917            |                   |
| 1141.45      | beta_0   | 1093.4                | 24.5159      | 1045.35           |                   |
| 0.387228     | beta_1   | 0.172222              | 0.109699     | -0.0427835        |                   |
| 0.000169154  | beta_2   | -8.59546e-010         | 8.63049e-005 | -0.000169155      |                   |

#### Asymptotic Correlation Matrix of Parameter Estimates

|        | alpha   | rho    | beta_0 | beta_1 | beta_2  |
|--------|---------|--------|--------|--------|---------|
| alpha  | -1      | 1      | -0.025 | 0.016  | -0.0026 |
| rho    | 1       | -1     | 0.028  | -0.022 | 0.009   |
| beta_0 | -0.025  | 0.028  | 1      | -0.7   | 0.54    |
| beta_1 | 0.016   | -0.022 | -0.7   | 1      | -0.95   |
| beta_2 | -0.0026 | 0.009  | 0.54   | -0.95  | 1       |

#### Table of Data and Estimated Values of Interest

| Dose Res. | N  | Obs Mean  | Obs Std Dev | Est Mean  | Est Std Dev | Chi^2  |
|-----------|----|-----------|-------------|-----------|-------------|--------|
| 0         | 10 | 1.08e+003 | 44.3        | 1.09e+003 | 79.9        | -0.372 |
| 312       | 10 | 1.16e+003 | 108         | 1.15e+003 | 87.7        | 0.428  |
| 625       | 10 | 1.21e+003 | 123         | 1.2e+003  | 95.9        | 0.394  |
| 1250      | 10 | 1.29e+003 | 108         | 1.31e+003 | 113         | -0.465 |

#### Model Descriptions for likelihoods calculated

```

Model A1: Yij = Mu(i) + e(ij)
 Var{e(ij)} = Sigma^2
Model A2: Yij = Mu(i) + e(ij)
 Var{e(ij)} = Sigma(i)^2
Model A3: Yij = Mu(i) + e(ij)
 Var{e(ij)} = alpha*(Mu(i))^rho
Model R: Yi = Mu + e(i)
 Var{e(i)} = Sigma^2

```

Warning: Likelihood for fitted model larger than the Likelihood for model A3.

#### Likelihoods of Interest

| Model | Log(likelihood) | DF | AIC        |
|-------|-----------------|----|------------|
| A1    | -202.244681     | 5  | 414.489362 |

|        |             |   |             |
|--------|-------------|---|-------------|
| A2     | -197.498037 | 8 | 410.996073  |
| A3     | -792.622946 | 6 | 1597.245893 |
| fitted | -201.467856 | 5 | 412.935712  |
| R      | -212.606673 | 2 | 429.213345  |

#### Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels?

(A2 vs. R)

Test 2: Are Variances Homogeneous? (A1 vs A2)

Test 3: Are variances adequately modeled? (A2 vs. A3)

Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)

#### Tests of Interest

| Test   | -2*log(Likelihood Ratio) | Test df | p-value |
|--------|--------------------------|---------|---------|
| Test 1 | 30.2173                  | 6       | <.0001  |
| Test 2 | 9.49329                  | 3       | 0.0234  |
| Test 3 | 1190.25                  | 2       | <.0001  |
| Test 4 | -1182.31                 | 1       | <.0001  |

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels  
It seems appropriate to model the data

The p-value for Test 2 is less than .05. A non-homogeneous variance model appears to be appropriate

The p-value for Test 3 is less than .05. You may want to consider a different variance model

The p-value for Test 4 is less than .05. You may want to try a different model

#### Benchmark Dose Computation

Specified effect = 1

Risk Type = Estimated standard deviations from the control mean

Confidence level = 0.95


BMD = 464.11

BMDL = 320.109

BMDL computation failed for one or more point on the BMDL curve.

The BMDL curve will not be plotted





15:18 09/03 2003

```

=====
Power Model. $Revision: 2.1 $ $Date: 2000/10/11 20:57:36 $
Input Data File: C:\DOCUMENTS AND SETTINGS\AMARCUS\MY
DOCUMENTS\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.(d)
Gnuplot Plotting File: C:\DOCUMENTS AND SETTINGS\AMARCUS\MY
DOCUMENTS\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.plt
Tue Sep 02 23:38:05 2003
=====

```

Male kidney power model std dev =1 free parms

The form of the response function is:

$Y[\text{dose}] = \text{control} + \text{slope} * \text{dose}^{\text{power}}$

Dependent variable = MEAN

Independent variable = Dose

The power is not restricted

The variance is to be modeled as  $\text{Var}(i) = \alpha * \text{mean}(i)^{\rho}$

Total number of dose groups = 5

Total number of records with missing values = 1

Maximum number of iterations = 1000

Relative Function Convergence has been set to: 1e-008

Parameter Convergence has been set to: 1e-008

#### User Inputs Initial Parameter Values

```

alpha = 0.001
rho = 1
control = 1100
slope = 0.1
power = 0.6667

```

#### Asymptotic Correlation Matrix of Parameter Estimates

|         | alpha | rho   | control | slope  | power  |
|---------|-------|-------|---------|--------|--------|
| alpha   | 1     | -1    | -0.35   | -0.46  | 0.52   |
| rho     | -1    | 1     | 0.35    | 0.46   | -0.52  |
| control | -0.35 | 0.35  | 1       | -0.027 | -0.045 |
| slope   | -0.46 | 0.46  | -0.027  | 1      | -0.99  |
| power   | 0.52  | -0.52 | -0.045  | -0.99  | 1      |

#### Parameter Estimates

| Variable | Estimate     | Std. Err.    |
|----------|--------------|--------------|
| alpha    | 1.23823e-039 | 5.77128e-038 |
| rho      | 13.9292      | 6.59632      |
| control  | 1080.89      | 14.8542      |
| slope    | 9.88816      | 15.5551      |
| power    | 0.40519      | 0.24176      |

#### Table of Data and Estimated Values of Interest

| Dose  | N   | Obs Mean | Obs Std Dev | Est Mean | Est Std Dev | Chi^2 Res. |
|-------|-----|----------|-------------|----------|-------------|------------|
| ----- | --- | -----    | -----       | -----    | -----       | -----      |

|      |    |           |      |           |      |         |
|------|----|-----------|------|-----------|------|---------|
| 0    | 10 | 1.08e+003 | 44.3 | 1.08e+003 | 47.4 | 0.0657  |
| 312  | 10 | 1.16e+003 | 108  | 1.18e+003 | 88.4 | -0.263  |
| 625  | 10 | 1.21e+003 | 123  | 1.22e+003 | 107  | -0.0201 |
| 1250 | 10 | 1.29e+003 | 108  | 1.26e+003 | 137  | 0.243   |

Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma(i)^2$

Model A3:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \alpha * (\mu(i))^\rho$

Model R:  $Y_i = \mu + e(i)$   
 $\text{Var}\{e(i)\} = \sigma^2$

Warning: Likelihood for fitted model larger than the Likelihood for model A3.

#### Likelihoods of Interest

| Model  | Log(likelihood) | DF | AIC        |
|--------|-----------------|----|------------|
| A1     | -202.244681     | 5  | 414.489362 |
| A2     | -197.498037     | 8  | 410.996073 |
| A3     | -216.945928     | 6  | 445.891856 |
| fitted | -199.320949     | 5  | 408.641898 |
| R      | -212.606673     | 2  | 429.213345 |

#### Explanation of Tests

Test 1: Does response and/or variances differ among Dose levels?  
 (A2 vs. R)

Test 2: Are Variances Homogeneous? (A1 vs A2)

Test 3: Are variances adequately modeled? (A2 vs. A3)

Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)

#### Tests of Interest

| Test   | -2*log(Likelihood Ratio) | d.f | p-value    |
|--------|--------------------------|-----|------------|
| Test 1 | 30.2173                  | 6   | 3.574e-005 |
| Test 2 | 9.49329                  | 3   | 0.0234     |
| Test 3 | 38.8958                  | 2   | <.00001    |
| Test 4 | -35.25                   | 1   | <.00001    |

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels  
 It seems appropriate to model the data

The p-value for Test 2 is less than .05. A non-homogeneous variance model appears to be appropriate

The p-value for Test 3 is less than .05. You may want to consider a different variance model

The p-value for Test 4 is less than .05. You may want to try a different model

Benchmark Dose Computation  
 Specified effect = 1

Risk Type = Estimated standard deviations from the control mean


Confidence level = 0.95

BMD = 47.7706

Warning: optimum may not have been found. Bad completion code in Optimization routine.

Warning: optimum may not have been found. Bad completion code in Optimization routine.

BMDL computation failed.



23:38 09/02 2003

```

=====
Power Model. $Revision: 2.1 $ $Date: 2000/10/11 20:57:36 $
Input Data File: C:\DOCUMENTS AND SETTINGS\AMARCUS\MY
DOCUMENTS\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.(d)
Gnuplot Plotting File: C:\DOCUMENTS AND SETTINGS\AMARCUS\MY
DOCUMENTS\IRIS\TOLUENE\TOLUENE_NTP_TABLE4.plt
=====

```

Tue Sep 02 23:47:38 2003

```

=====
Male kidney power model std dev =1 parms rho==0
=====

```

The form of the response function is:

$Y[\text{dose}] = \text{control} + \text{slope} * \text{dose}^{\text{power}}$

Dependent variable = MEAN

Independent variable = Dose

rho is set to 0

The power is not restricted

A constant variance model is fit

Total number of dose groups = 5

Total number of records with missing values = 1

Maximum number of iterations = 1000

Relative Function Convergence has been set to: 1e-008

Parameter Convergence has been set to: 1e-008

#### User Inputs Initial Parameter Values

```

alpha = 0.001
rho = 1 Specified
control = 1100
slope = 0.1
power = 0.6667

```

#### Asymptotic Correlation Matrix of Parameter Estimates

|         | alpha | rho   | control | slope | power |
|---------|-------|-------|---------|-------|-------|
| alpha   | 1     | -1    | 0.54    | -0.47 | 0.44  |
| rho     | -1    | 1     | -0.54   | 0.47  | -0.44 |
| control | 0.54  | -0.54 | 1       | -0.69 | 0.64  |
| slope   | -0.47 | 0.47  | -0.69   | 1     | -1    |
| power   | 0.44  | -0.44 | 0.64    | -1    | 1     |

#### Parameter Estimates

| Variable | Estimate | Std. Err. |
|----------|----------|-----------|
| alpha    | 9067.79  | 369682    |
| rho      | 0        | 5.74174   |
| control  | 1083.71  | 35.6717   |
| slope    | 1.24815  | 3.09369   |
| power    | 0.718076 | 0.338085  |

Table of Data and Estimated Values of Interest

| Dose | N  | Obs Mean  | Obs Std Dev | Est Mean  | Est Std Dev | Chi^2 Res. |
|------|----|-----------|-------------|-----------|-------------|------------|
| 0    | 10 | 1.08e+003 | 44.3        | 1.08e+003 | 95.2        | 0.003      |
| 312  | 10 | 1.16e+003 | 108         | 1.16e+003 | 95.2        | -0.0194    |
| 625  | 10 | 1.21e+003 | 123         | 1.21e+003 | 95.2        | 0.0236     |
| 1250 | 10 | 1.29e+003 | 108         | 1.29e+003 | 95.2        | -0.00719   |

#### Model Descriptions for likelihoods calculated

Model A1:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma^2$

Model A2:  $Y_{ij} = \mu(i) + e(ij)$   
 $\text{Var}\{e(ij)\} = \sigma(i)^2$

Model R:  $Y_i = \mu + e(i)$   
 $\text{Var}\{e(i)\} = \sigma^2$

#### Likelihoods of Interest

| Model  | Log(likelihood) | DF | AIC        |
|--------|-----------------|----|------------|
| A1     | -202.244681     | 5  | 414.489362 |
| A2     | -197.498037     | 8  | 410.996073 |
| fitted | -202.249668     | 4  | 412.499336 |
| R      | -212.606673     | 2  | 429.213345 |

Test 1: Does response and/or variances differ among dose levels  
(A2 vs. R)

Test 2: Are Variances Homogeneous (A1 vs A2)

Test 3: Does the Model for the Mean Fit (A1 vs. fitted)

#### Tests of Interest

| Test   | -2*log(Likelihood Ratio) | df | p-value |
|--------|--------------------------|----|---------|
| Test 1 | 30.2173                  | 6  | <.00001 |
| Test 2 | 9.49329                  | 3  | 0.0234  |
| Test 3 | 0.00997428               | 1  | 0.9204  |

The p-value for Test 1 is less than .05. There appears to be a difference between response and/or variances among the dose levels. It seems appropriate to model the data

The p-value for Test 2 is less than .05. Consider running a non-homogeneous variance model

The p-value for Test 3 is greater than .05. The model chosen appears to adequately describe the data

#### Benchmark Dose Computation

Specified effect = 1

Risk Type = Estimated standard deviations from the control mean

Confidence level = 0.95

BMD = 418.374

BMDL = 107.032

## **Appendix B2. Benchmark Dose Modeling Results for the Derivation of the RfD (Selected Immunotoxicity Studies)**

### **Modeling Strategy**

Data on a number of immunotoxicity indicators in four papers cited in this document (Hsieh et al., 1989, 1990b, 1991; Burns et al., 1994) were determined to be suitable for BMD analyses. The endpoints were continuous measurements, so the continuous model features in the BMDS version 1.3 software (U.S. EPA, 2001) were appropriate for estimating the BMD and BMD lower 95% confidence limits (BMDL). In the absence of information on the level of immunotoxic response to consider adverse, a change in the mean equal to one standard deviation from the control mean was used to determine potential BMRs according to the U.S. EPA *Benchmark Dose Technical Document Guidance* (U.S. EPA, 2000c). For comparison purposes, BMDL values for a change in the mean of 0.5 and two standard deviations are also presented. Four dose-response functions are offered in BMDS version 1.3.2:

1. Polynomial
2. Linear (a special case of polynomial)
3. Power
4. Hill

The Hill function has up to four parameters (unknown constants) to be estimated from the data, so it is necessary to have at least four distinct dose groups, usually the control group and three or more groups with positive exposure levels. The endpoints described below met this requirement.

The BMDS software also assumes a specific formula for the variance (square of the standard deviation) of the within-dose-group variance of the endpoints (Eq B-2.1),

$$\text{variance within dose group} = \alpha * (\text{mean within dose group})^{\rho}$$

(Equation B-2.1)

where alpha and rho are additional parameters to be estimated from the data, apart from the parameters of the dose-response model. Although it is commonly assumed that the variance is the same within each dose group ( $\rho = 0$ ), this hypothesis failed statistical hypothesis tests in many of the analyses reported here. More detailed examination of the data found that the



coefficient of variation, defined by

$$\begin{aligned} &\text{coefficient of variation within dose group} = \\ &(\text{standard deviation within dose group})/(\text{mean within dose group}) \\ &(\text{Equation B-2.2}) \end{aligned}$$

was often nearly constant at all dose levels and all levels of mean response within an endpoint. A constant coefficient of variation in Eq B-2.2 is equivalent to  $\rho = 2$  in Eq B-2.1. This would occur if the endpoints had a log-normal distribution within a dose group, with a constant geometric standard deviation across all dose groups. The within-group sample size  $N$  is too small,  $N = 5$  in Hsieh et al. (1989, 1990b, 1991) to evaluate this hypothesis definitively. We therefore conducted sensitivity analyses in all of the models with the following alternatives:

- $\rho$  estimated from the data
- $\rho = 0$  for the same variability across responses within each dose level of the endpoint
- $\rho = 2$  for the same variability across the logarithm of the responses within each dose
- Level of the endpoint (i.e., the same coefficient of variation)

These alternatives had an effect, sometimes substantial, on the goodness of fit of the model to the data and on the magnitude of the BMDL estimate that reflects data variability.

In all cases evaluated here, the estimates of  $\rho$  were substantially larger than zero, even when they were not statistically different from zero. The typical range was  $\rho = 1.5$  to  $3.0$ .

Initial runs using the four BMDS dose-response functions found that the best estimate of the power or exponent  $n$  in the power function and Hill models was often much less than one, typically in the range  $0.5$  to  $0.7$ . We therefore also conducted sensitivity analyses using  $n = 0.5$  or in some cases  $n = 0.7$  to evaluate the effect of assuming a sub-linear dose-response.

The best-fitting models were judged according to criteria in the BMDS guidance:

- Convergent estimate for BMDL
- Acceptable  $p$ -value for overall goodness of fit of mean values (hypothesis H4)
- Lowest Akaike Information Criterion (AIC)
- Smallest chi-squared residuals for deviations, especially near the BMDL

- Adequate model for variances (hypothesis H3)

### **Results for Hsieh et al. (1989)**

The basic suite of models evaluated for all endpoints is given in Table B2-1. The endpoints given in the different papers do not all lend themselves to BMD analyses. Almost all of the endpoints in Hsieh et al. (1989) present results (mean response  $\pm$  standard error) at toluene doses of 0, 5, 22, and 105 mg/kg-day, corresponding to actual TWA concentrations of 0, 17, 80, and 405 mg/L from nominal design concentrations of 0, 20, 100, and 500 mg/L, respectively. This is the number of dose levels required to fit all of the models with enough degrees of freedom left to provide statistical tests of the goodness of fit of the model to the data, except for the Hill model with all four parameters estimated from the data. The results are shown in Tables B2-2 and B2-3 for the endpoints of greatest relevance to assessing immunotoxicity:

- Mixed lymphocyte response (MLR) (Figure 1 from Hsieh et al., 1989)
  - Responders indicating thymidine incorporation into splenic cells alone
  - Responders and stimulators indicating thymidine incorporation into splenic cells when splenocytes were cocultured with mitomycin C-treated YAC-1 cells
- Antibody plaque-forming cell (PFC) responses (Table 4 from Hsieh et al., 1989)
  - PFC per million splenocytes
  - PFC per total splenic cells
- Interleukin-2 (IL-2) assays (Table 5 from Hsieh et al., 1989)
  - Thymidine uptake
  - Stimulation index
  - IL-2 activity

The simplest models usually provided acceptable p-values for model goodness-of-fit (H4).

### **Combining Data from Hsieh et al. (1989, 1990b, 1991)**

The same team of investigators published results from two additional studies with many of the same endpoints as described in the 1989 paper. However, the additional studies were done to assess the effects of toluene and benzene jointly and separately, using only a single concentration for each chemical. Hsieh et al. (1990b) exposed male CD-1 mice to 325 mg/L toluene (actual

TWA concentration from design concentration of 400 mg/L), either alone or with co-exposure to 166 mg/L benzene. In Hsieh et al. (1991), the toluene concentration was 80 mg/L from a design concentration of 100 mg/L. Each experiment had an independent control study. However, no information was provided giving the estimated dose on a mg/kg-day basis. No BMDL estimates similar to those reported above for the 1989 paper could be derived. The published results were assessed to see if they were sufficiently similar across common endpoints in the three studies to allow the data to be combined into an eight-group five-dose data set for BMDS analyses: three control means, one at 17 mg/L, two at 80 mg/L, and one each at 325 and 405 mg/L.

The first step was to derive a calibration of the dose-to-concentration relationship for the Hsieh et al. (1989) paper. There was a virtually perfect linear relationship, which was estimated from the data in Hsieh et al. (1989), using several different linear regression approaches:

- Simple linear regression, with or without intercepts
- Inverse-variance weighted linear regression
- Log dose vs. log concentration linear regression

All of these methods gave virtually identical estimates of a dose of about 84.5 mg/kg-day for an actual concentration of 325 mg/L in Hsieh et al. (1990b) and a dose of 22 mg/kg-day for an actual concentration of 80 mg/L in Hsieh et al. (1991).

The estimated effects of most of the endpoints showed considerable heterogeneity across these experiments, and their combined analyses are not shown here. Two endpoints with a reasonable degree of similarity across the experiments were IL-2 thymidine uptake and IL-2 stimulation. The results for the eight-group analyses combining IL-2 data from Hsieh et al. (1989,1990b) are shown in Table B2-4, along with the four-group analyses in Tables B2-2 and B2-3. Benchmark responses (percent of control mean) were calculated for each endpoint as shown in Table B2-5.

**Table B2-1. Results of BMDS analyses from Hsieh et al. (1989) study with maximum p for hypothesis 4, goodness of fit of means**

| Endpoint                     | Model               | n   | Rho | P for H4 | AIC    | BMDL, mg/kg-day                  |                 |                  |
|------------------------------|---------------------|-----|-----|----------|--------|----------------------------------|-----------------|------------------|
|                              |                     |     |     |          |        | BMR, control standard deviations |                 |                  |
|                              |                     |     |     |          |        | 0.5                              | 1.0             | 2.0              |
| MLC responders               | Linear              | 1   | 2   | 0.9863   | 54.95  |                                  | 73              |                  |
| MLC responders & stimulators | Quadratic           | 1   | 2   | 0.5328   | 58.58  | 3.23                             | 6.60            | 13.8             |
| PFC / million splenocytes    | Linear              | 0.5 | 0   | 0.5977   | 233.3  | 1.62                             | 7.04            | 26               |
| PFC per total spleen cells   | Linear <sup>a</sup> | 1   | 2   | 0.2533   | 467.6  | 26 <sup>a</sup>                  | 69 <sup>a</sup> | 105 <sup>a</sup> |
| IL2 thymidine uptake         | Linear              | 0.5 | 2   | 0.9803   | 75.17  | 6.76                             | 27              | 108              |
| IL-2 Stimulation             | Linear              | 0.5 | 2   | 0.9790   | 82.82  | 6.75                             | 27              | 108              |
| IL-2 Activity                | Quadratic           | 1   | 2   | 0.9898   | -16.05 |                                  | 17.2            |                  |

<sup>a</sup> BMDL estimated from power function with exponent = 1.

**Table B2-2. Results of BMDS analyses from Hsieh et al. (1989)  
study with minimum AIC for hypothesis 4 goodness of fit**

| Endpoint                     | Model               | n   | Rho | P for H4 | AIC    | Max. Resid. | At | BMD mg/kg-day | BMDL            |
|------------------------------|---------------------|-----|-----|----------|--------|-------------|----|---------------|-----------------|
| MLC responders               | Linear              | 1   | 2   | 0.9863   | 54.95  | 0.235       | 0  | 108           | 73              |
| MLC responders & stimulators | Quadratic           | 1   | 2   | 0.5328   | 58.58  | 0.853       | 5  | 9.97          | 6.60            |
| PFC / million splenocytes    | Linear              | 0.5 | 0   | 0.5977   | 233.3  | -0.75       | 5  | 13.53         | 6.49            |
| PFC per total spleen cells   | Linear <sup>a</sup> | 1   | 2   | 0.2533   | 467.7  | -0.60       | 5  | 67            | 53 <sup>a</sup> |
| IL-2 thymidine uptake        | Linear              | 0.5 | 2   | 0.9803   | 75.17  | 0.273       | 22 | 53            | 27              |
| IL-2 stimulation             | Linear              | 0.5 | 2   | 0.9790   | 82.82  | 0.277       | 22 | 53            | 27              |
| IL-2 activity                | Linear              | 0.5 | 2   | 0.8773   | -17.38 | 0.628       | 0  | 78            | 40              |

<sup>a</sup> BMDL estimated from power function model with exponent = 1.

**Table B2-3. Results of BMDS analyses from Hsieh et al. (1989, 1990b) study with maximum p for hypothesis 4, goodness of fit of means**

| Endpoint                                                         | Model  | n   | Rho | P for H4 | AIC   | Max. Resid. | At | BMD mg/kg-day | BMDL |
|------------------------------------------------------------------|--------|-----|-----|----------|-------|-------------|----|---------------|------|
| Results from Hsieh et al. (1989) with four dose groups           |        |     |     |          |       |             |    |               |      |
| IL-2 thymidine uptake                                            | Linear | 0.5 | 2   | 0.9803   | 75.17 | 0.273       | 22 | 53            | 27   |
| IL-2 stimulation                                                 | Linear | 0.5 | 2   | 0.9790   | 82.82 | 0.277       | 22 | 53            | 27   |
| Results from Hsieh et al. (1990b) eight groups, five dose levels |        |     |     |          |       |             |    |               |      |
| IL-2 thymidine uptake                                            | Linear | 1   | 0   | 0.9642   | 143.2 | 0.773       | 0  | 66            | 45   |
| IL-2 stimulation                                                 | Linear | 0.5 | 0   | 0.9625   | 160.6 | -0.733      | 0  | 43            | 19.5 |

**Table B2-4. Benchmark responses for the endpoints reported in Hsieh et al. (1989)**

| Endpoint                             | Control mean | Control standard deviation | BMR (percent of control mean) |                     |        |
|--------------------------------------|--------------|----------------------------|-------------------------------|---------------------|--------|
|                                      |              |                            | 0.5 SD                        | 1.0 SD <sup>a</sup> | 2.0 SD |
| PFC per million splenocytes          | 1184         | 201.25                     | 8.5                           | 17.0                | 34.0   |
| PFC per spleen                       | 238545       | 83694                      | 17.5                          | 35.1                | 70.1   |
| IL-2 thymidine uptake                | 12.95        | 4.43                       | 17.1                          | 34.2                | 68.4   |
| IL-2 stimulation index               | 15.7         | 5.34                       | 17.0                          | 34.0                | 68.0   |
| IL-2 activity                        | 1.08         | 0.49                       | 22.7                          | 45.4                | 90.8   |
| MLC responders 2:1 R:S               | 5.37         | 2.35                       | 21.8                          | 43.7                | 87.4   |
| MLC responders & stimulators 2:1 R:S | 28.9         | 10.4                       | 18.0                          | 36.0                | 72.0   |

<sup>a</sup> Control coefficient of variation = 100 times control standard deviation (SD) divided by control mean. Most endpoints had nearly constant coefficient of variation at all dose levels for that endpoint.

**Table B2-5. Basic sensitivity analyses for BMDS results**

| Model     | Dose Metric                      | Exponent n       | Rho             |
|-----------|----------------------------------|------------------|-----------------|
| Linear    | Dose <sup>a</sup>                | 1                | estimated, 2, 0 |
|           | Square root of dose <sup>b</sup> | 0.5              | estimated, 2, 0 |
| Quadratic | Dose                             | 1                | estimated, 2, 0 |
|           | Square root of dose              | 0.5              | estimated, 2, 0 |
| Power     | Dose                             | estimated        | estimated, 2, 0 |
|           |                                  | 1 <sup>a</sup>   | estimated, 2, 0 |
|           |                                  | 0.5 <sup>b</sup> | estimated, 2, 0 |
| Hill      | Dose                             | estimated        | estimated, 2, 0 |
|           |                                  | 1                | estimated, 2, 0 |
|           |                                  | 0.5              | estimated, 2, 0 |

<sup>a</sup> Same model with exponent n = 1.

<sup>b</sup> Same model with exponent n = 0.5.



Provisional Peer-Reviewed Subchronic Toxicity Values  
for Toluene  
(CASRN 108-88-3)

Superfund Health Risk Technical Support Center  
National Center for Environmental Assessment  
Office of Research and Development  
U.S. Environmental Protection Agency  
Cincinnati, OH 45268

## COMMONLY USED ABBREVIATIONS

|                      |                                                                     |
|----------------------|---------------------------------------------------------------------|
| BMD                  | Benchmark Dose                                                      |
| IRIS                 | Integrated Risk Information System                                  |
| IUR                  | inhalation unit risk                                                |
| LOAEL                | lowest-observed-adverse-effect level                                |
| LOAEL <sub>ADJ</sub> | LOAEL adjusted to continuous exposure duration                      |
| LOAEL <sub>HEC</sub> | LOAEL adjusted for dosimetric differences across species to a human |
| NOAEL                | no-observed-adverse-effect level                                    |
| NOAEL <sub>ADJ</sub> | NOAEL adjusted to continuous exposure duration                      |
| NOAEL <sub>HEC</sub> | NOAEL adjusted for dosimetric differences across species to a human |
| NOEL                 | no-observed-effect level                                            |
| OSF                  | oral slope factor                                                   |
| p-IUR                | provisional inhalation unit risk                                    |
| p-OSF                | provisional oral slope factor                                       |
| p-RfC                | provisional inhalation reference concentration                      |
| p-RfD                | provisional oral reference dose                                     |
| RfC                  | inhalation reference concentration                                  |
| RfD                  | oral reference dose                                                 |
| UF                   | uncertainty factor                                                  |
| UF <sub>A</sub>      | animal to human uncertainty factor                                  |
| UF <sub>C</sub>      | composite uncertainty factor                                        |
| UF <sub>D</sub>      | incomplete to complete database uncertainty factor                  |
| UF <sub>H</sub>      | interhuman uncertainty factor                                       |
| UF <sub>L</sub>      | LOAEL to NOAEL uncertainty factor                                   |
| UF <sub>S</sub>      | subchronic to chronic uncertainty factor                            |

## PROVISIONAL PEER-REVIEWED SUBCHRONIC TOXICITY VALUES FOR TOLUENE (CASRN 108-88-3)

### Background

On December 5, 2003, the U.S. Environmental Protection Agency's (U.S. EPA) Office of Superfund Remediation and Technology Innovation (OSRTI) revised its hierarchy of human health toxicity values for Superfund risk assessments, establishing the following three tiers as the new hierarchy:

- 1) U.S. EPA's Integrated Risk Information System (IRIS).
- 2) Provisional Peer-Reviewed Toxicity Values (PPRTVs) used in U.S. EPA's Superfund Program.
- 3) Other (peer-reviewed) toxicity values, including
  - ▶ Minimal Risk Levels produced by the Agency for Toxic Substances and Disease Registry (ATSDR),
  - ▶ California Environmental Protection Agency (CalEPA) values, and
  - ▶ EPA Health Effects Assessment Summary Table (HEAST) values.

A PPRTV is defined as a toxicity value derived for use in the Superfund Program when such a value is not available in U.S. EPA's IRIS. PPRTVs are developed according to a Standard Operating Procedure (SOP) and are derived after a review of the relevant scientific literature using the same methods, sources of data, and Agency guidance for value derivation generally used by the U.S. EPA IRIS Program. All provisional toxicity values receive internal review by two U.S. EPA scientists and external peer review by three independently selected scientific experts. PPRTVs differ from IRIS values in that PPRTVs do not receive the multiprogram consensus review provided for IRIS values. This is because IRIS values are generally intended to be used in all U.S. EPA programs, while PPRTVs are developed specifically for the Superfund Program.

Because new information becomes available and scientific methods improve over time, PPRTVs are reviewed on a 5-year basis and updated into the active database. Once an IRIS value for a specific chemical becomes available for Agency review, the analogous PPRTV for that same chemical is retired. It should also be noted that some PPRTV documents conclude that a PPRTV cannot be derived based on inadequate data.

### Disclaimers

Users of this document should first check to see if any IRIS values exist for the chemical of concern before proceeding to use a PPRTV. If no IRIS value is available, staff in the regional Superfund and Resource Conservation and Recovery Act (RCRA) program offices are advised to carefully review the information provided in this document to ensure that the PPRTVs used are appropriate for the types of exposures and circumstances at the Superfund site or RCRA facility in question. PPRTVs are periodically updated; therefore, users should ensure that the values contained in the PPRTV are current at the time of use.

It is important to remember that a provisional value alone tells very little about the adverse effects of a chemical or the quality of evidence on which the value is based. Therefore, users are strongly encouraged to read the entire PPRTV document and understand the strengths and limitations of the derived provisional values. PPRTVs are developed by the U.S. EPA Office of Research and Development's National Center for Environmental Assessment, Superfund Health Risk Technical Support Center for OSRTI. Other U.S. EPA programs or external parties who may choose of their own initiative to use these PPRTVs are advised that Superfund resources will not generally be used to respond to challenges of PPRTVs used in a context outside of the Superfund Program.

### **Questions Regarding PPRTVs**

Questions regarding the contents of the PPRTVs and their appropriate use (e.g., on chemicals not covered, or whether chemicals have pending IRIS toxicity values) may be directed to the U.S. EPA Office of Research and Development's National Center for Environmental Assessment, Superfund Health Risk Technical Support Center (513-569-7300), or OSRTI.

## **INTRODUCTION**

A streamlined approach was used to derive provisional subchronic RfD and RfC values for toluene. Toluene has chronic RfD, RfC, and cancer assessments on IRIS (U.S. EPA, 2005b), so only subchronic toxicity values are required to support the complex aliphatic and aromatic mixture assessment. Toluene has recently been reassessed by the IRIS program, and a Toxicological Review (U.S. EPA, 2005a) is available. In addition, the Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profile for toluene has been updated recently (ATSDR, 2000). Both the IRIS Toxicological Review and the ATSDR Toxicological Profile contain comprehensive overviews of the toxicology and toxicokinetics information available on toluene. While the IRIS Toxicological Review for Toluene encompassed the exposure duration-relevant literature to 2005, updated literature searches were conducted from January 2004 to July 2007 for studies pertinent to the derivation of subchronic toxicity values for toluene; Appendix B provides a description of the literature search process. No new studies were identified pertinent to the derivation of subchronic provisional toxicity values. As such, given the availability of the recent IRIS and ATSDR reviews, these reports were used to identify the exposure duration-relevant critical studies and endpoints for use in deriving the subchronic values.

The derivation of subchronic toxicity values for toluene is discussed below. Review of the data supporting the chronic toxicity values for toluene currently on IRIS (U.S. EPA, 2005b) indicate that subchronic data were used to derive the chronic values and, thus, are appropriate to serve as the basis for the corresponding subchronic toxicity values. A brief rationale is provided for the selection of the critical study and endpoint, a summary of the critical study is presented, and the subchronic toxicity-value-derivation process is described. For further information on the toxicology and toxicokinetics of toluene, the reader may consult the IRIS record (attached to this report as Appendix A), IRIS Toxicological Review (U.S. EPA, 2005a), or ATSDR (2000) Toxicological Profile for toluene.

## REVIEW OF PERTINENT DATA AND DERIVATION OF PROVISIONAL SUBCHRONIC TOXICITY VALUES FOR TOLUENE

### Subchronic p-RfD

The chronic RfD for toluene (0.08 mg/kg-day) currently on IRIS (U.S. EPA, 2005b) is based on kidney weight increases in a subchronic rat study (NTP, 1990). It includes an uncertainty factor (UF) of 10 for subchronic-to-chronic extrapolation. The ATSDR intermediate-duration oral Minimal Risk Level (MRL) (0.02 mg/kg-day) was derived in September 2000 (ATSDR, 2000) based on neurological effects in a 28-day mouse drinking water study (Hsieh et al., 1990). In the Toxicological Review, U.S. EPA (2005a) rejected this study as the basis for the chronic RfD because the study did not determine whether the critical effect (increased brain neurotransmitter levels) was persistent (levels were measured immediately after the end of treatment) and because this endpoint had not been correlated with functional neurological changes.

The database supporting the oral RfD for toluene is somewhat limited. In particular, this is due to the lack of comprehensive neurotoxicity testing after exposure by the oral route, particularly considering that neurotoxicity is the critical effect following inhalation exposure. In order to determine whether newer studies that might be in support of or inform the derivation of the subchronic p-RfD have been published, an update literature search (2004–2007) was conducted to search for studies of oral exposure to toluene. The only oral study identified in the literature search appears to have measured limited endpoints (heart rate, blood pressure, core temperature, and motor activity) after acute exposure and was published only as an abstract (Gordon et al., 2006); as such, it is not suitable for use in the derivation of a subchronic p-RfD. As no more suitable studies were identified, the subchronic p-RfD is based on the same critical study (NTP, 1990), endpoint (increased kidney weight), and point of departure (POD) as the chronic RfD—but without a UF for subchronic-to-chronic extrapolation.

A summary of the critical study is excerpted from the U.S. EPA (2005a) Toxicological Review for Toluene and reproduced here for the reader's convenience.

*The oral toxicity of toluene was investigated in a subchronic gavage study in F-344 rats (NTP, 1990). Groups of 10 rats/sex/group were administered toluene in corn oil at dosage levels of 0, 312, 625, 1250, 2500 or 5000 mg/kg, 5 days/week for 13 weeks. The exposure was for 5 days/week and therefore the dose is adjusted to a 7-day week (e.g., 312 mg/kg  $\times$  5/7 = 223 mg/kg-day) resulting in dose estimates of 0, 223, 446, 893, 1786 or 3571 mg/kg-day, respectively. All animals receiving 3571 mg/kg-day died within the first week and were eliminated from further evaluation. There was one female and eight males in the 2500 mg/kg-day group that died, but two of these deaths were due to gavage errors. No deaths occurred at lower doses. Several toxic effects were noted at doses greater than or equal to 1786 mg/kg-day, including prostration, hypoactivity, ataxia, piloerection, lacrimation, excessive salivation, and body tremors. A significant decrease ( $p < 0.05$ ) in body weight for males in the 1786 mg/kg-day group was the only significant change. There were no significant changes in hematology or urinalysis for any group of animals. Some biochemical changes, including a significant increase ( $p < 0.05$ ) in serum aspartate aminotransferase (AST) in 1786 mg/kg-day males and an increase in cholinesterase activity in females receiving 1786 mg/kg-day were noted.*

*There were several pathologic findings and organ weight changes in the liver, kidney, brain, and urinary bladder (NTP, 1990). In males, absolute and relative weights of both the liver and kidney were significantly increased ( $p < 0.05$ ) at doses greater than or equal to 446 mg/kg-day. Absolute liver weights (mean  $\pm$  SE) in males were  $10,490 \pm 360$  (100%),  $11,310 \pm 300$  (108%),  $11,850 \pm 390$  (113%),  $14,440 \pm 480$  (138%) and  $14,130 \pm 1220$  (135%) milligrams for 0, 223, 446, 893 and 1786 mg/kg-day doses, respectively. Relative liver weights (mean  $\pm$  SE) in males were  $33.3 \pm 0.81$  (100%),  $34.5 \pm 0.68$  (104%),  $35.9 \pm 0.68$  (108%),  $45.0 \pm 1.69$  (135%), and  $59.4 \pm 3.28$  (178%) grams/100 g body weight for 0, 223, 446, 893 and 1786 mg/kg-day doses, respectively. Absolute kidney weights (mean  $\pm$  SE) in males were  $1084 \pm 14$  (100%),  $1159 \pm 34$  (107%),  $1213 \pm 39$  (112%),  $1292 \pm 34$  (119%) and  $1227 \pm 114$  (113%) milligrams for 0, 223, 446, 893 and 1786 mg/kg-day doses, respectively. Relative kidney weights (mean  $\pm$  SE) in males were  $3.5 \pm 0.06$  (100%),  $3.5 \pm 0.07$  (100%),  $3.7 \pm 0.06$  (106%),  $4.0 \pm 0.06$  (114%) and  $5.1 \pm 0.32$  (146%) grams/100 g body weight for 0, 223, 446, 893 and 1786 mg/kg-day doses, respectively. In females, absolute and relative weights of the liver, kidney and heart were all significantly increased at doses greater than or equal to 893 mg/kg-day ( $p < 0.01$  for all comparisons except  $p < 0.05$  for absolute kidney and heart weights at 893 mg/kg-day).*

*Histopathologic lesions in the liver consisted of hepatocellular hypertrophy, occurring at doses greater than 1786 mg/kg-day (NTP, 1990). Nephrosis was observed in rats that died and damage to the tubular epithelia of the kidney occurred in terminally-sacrificed rats. Kidney sections were examined in particular for the occurrence of hyaline droplets in the proximal tubules with negative findings. Histopathologic changes were also noted in the brain and urinary bladder. In the brain, mineralized foci and necrosis of neuronal cells were observed in males and females at 1786 mg/kg-day and males at 893 mg/kg-day. In the bladder, hemorrhage of the muscularis was seen in males at 1786 mg/kg-day. The NOAEL in rats for this study is 223 mg/kg-day. The LOAEL is 446 mg/kg-day based on liver and kidney weight changes in male rats.*

As noted above, the subchronic p-RfD for toluene is based on the same critical study, endpoint, and POD as the chronic RfD. For the chronic RfD, U.S. EPA (2005b) conducted benchmark dose (BMD) modeling on the absolute kidney-weight changes in male rats in the NTP (1990) study. Modeling resulted in a BMDL<sub>1SD</sub> (lower confidence limit on the benchmark dose associated with a benchmark response of one standard deviation from the control mean response) of 238 mg/kg-day, which served as the POD for chronic RfD derivation. Further details on the modeling efforts are available in the IRIS record (see Appendix A) and in the Toxicological Review (see U.S. EPA, 2005a). For the chronic RfD, the BMDL<sub>1SD</sub> was divided by a total UF of 3,000 that included a 10-fold UF for interspecies extrapolation, 10-fold UF for intraspecies variation, a 10-fold UF for extrapolation from subchronic-to-chronic exposure duration, and a 3-fold UF for database deficiencies (reflecting limited neurotoxicological data by the oral route and conflicting immunotoxicity studies). Appendix A contains details of the UF selections.

For the derivation of a subchronic p-RfD, the BMDL<sub>1SD</sub> of 238 mg/kg-day for absolute kidney-weight changes is divided by a total UF of 300, as shown below:

$$\begin{aligned}\text{Subchronic p-RfD} &= \text{BMDL} \div \text{UF} \\ &= 238 \text{ mg/kg-day} \div 300 \\ &= \mathbf{0.8 \text{ or } 8 \times 10^{-1} \text{ mg/kg-day}}\end{aligned}$$

The composite UF of 300 is composed of the following:

- A UF of 10 is applied to account for laboratory animal-to-human interspecies differences (UF<sub>A</sub>). No information is available on differences or similarities in the toxicity of toluene between animals and humans.
- A UF of 10 is applied to account for intraspecies differences (UF<sub>H</sub>)—including variability in susceptibility in human populations and life-stages. This UF was not reduced because of the lack of human oral exposure information.
- An UF of 1 for extrapolation from a LOAEL to NOAEL (UF<sub>L</sub>) is applied because the current approach is to address this extrapolation as one of the considerations in selecting a Benchmark Response (BMR) for BMD modeling. In this case, a BMR corresponding to a change in absolute kidney-weight equal to one control standard deviation from the control mean kidney-weight was selected under an assumption that it represents a biologically significant change.
- A UF of 3 is applied to account for deficiencies in the toluene database (UF<sub>D</sub>). An oral subchronic study in two species is available. Neurotoxicity has been identified by inhalation studies in humans and animals as a critical endpoint. However, limited neurotoxicity studies by the oral route are available. Several oral exposure high-dose reproductive and developmental toxicity studies are available that indicate toluene does not generally elicit developmental or reproductive effects except at doses that are significantly higher than those causing other systemic effects (see Section 4.3 of the IRIS Toxicological Review of toluene for details). A two-generation reproductive toxicity study by the oral route of exposure is not available. However, a two-generation reproductive toxicity study by the inhalation route of exposure is available that possibly lends support to the oral database in that effects are noted at high concentrations. Toxicokinetic information indicates that the absorption kinetics of toluene is similar and extensive following both oral and inhalation exposure. For example, Gospe and Al-Bayati (1994) compared oral and inhalation exposures to toluene in the rat and concluded that oral dosing produces blood toluene levels that are similar to those produced by inhalation (see Section 3.1.2 of the IRIS Toxicological Review for toluene). It should be noted, however, that differences in metabolism between exposure routes have not been elucidated, nor has a role for metabolites been ascertained in the toxicity of toluene. Immunotoxicity data are available, but the results are conflicting. The data are inadequate to inform conclusions regarding whether immunosuppression may be a more sensitive endpoint (i.e., an endpoint that would result in a lower point of departure) than kidney toxicity. As such, a 3-fold UF for insufficiencies in the database is applied to account for the

lack of adequate data on endpoints of potential concern for toluene—including neurotoxicity, two-generation reproductive toxicity, and immunotoxicity.

As discussed further in the IRIS Summary and Toxicological Review for toluene, confidence in the principal study, an adequate gavage study of subchronic duration, is medium. Confidence in the database is medium reflecting a lack of neurotoxicity studies, and a two-generation reproductive toxicity study, as well as uncertainty surrounding the immunotoxicity of toluene. An oral subchronic study in two species and several immunotoxicity studies are available. A number of oral studies have demonstrated that toluene does not elicit developmental or reproductive effects except at doses that are significantly higher than those causing other systemic effects (please refer to the IRIS Toxicological Review for toluene for details). Confidence in the subchronic p-RfD is medium.

### **Subchronic p-RfC**

The chronic RfC for toluene (5 mg/m<sup>3</sup>) on IRIS (completion date August 2005) is based on neurological effects in humans. The NOAEL (34 ppm or 128 mg/m<sup>3</sup>; 46 mg/m<sup>3</sup> after adjustment for continuous exposure) used to derive the RfC was based on a number of critical studies; the mean exposure durations in the studies ranged from 4.9 years (Boey et al., 1997) to 21.4 years (Vrca et al., 1995). A composite UF of 10 for human variability was applied to the NOAEL to derive the RfC; no UF for exposure duration was included. There is no intermediate-duration inhalation MRL for toluene. ATSDR (2000) indicated that there were no data suitable for deriving an intermediate duration inhalation MRL for toluene and that the chronic inhalation MRL would be protective for intermediate exposures. The chronic inhalation MRL for toluene is 0.08 ppm (0.3 mg/m<sup>3</sup>) and is based on neurological effects (color vision impairment) in humans exposed occupationally (Zavalic et al., 1998a).

For the derivation of the chronic RfC, U.S. EPA (2005a) selected a subset of the available epidemiological studies based on minimum study quality criteria, reported as “use of accepted testing procedures for neurological endpoints, chronic exposure duration, inclusion of a measure of exposure, comparison to defined control groups and no known coexposure to other solvents in the workplace.” However, review of Section 5.2.1 (Choice of Principal Study, in the U.S. EPA, 2005a Toxicological Review) indicates that no studies of subchronic duration were rejected on the basis of exposure duration and two studies of subchronic duration (mean exposure ≤7 years) were included in the critical studies: Boey et al. (1997; 4.9 years) and Foo et al. (1990; 5.7 years). There were two studies (Nakatsuka et al., 1992 and Neubert et al., 2001) that did not report exposure duration, although Neubert et al. (2001) characterized the exposure as “chronic.” LOAELs in the two subchronic studies were 91 and 88 ppm (343 and 332 mg/m<sup>3</sup>; Boey et al., 1997 and Foo et al., 1990, respectively), and were of similar magnitude as the LOAELs from the longer-duration studies. NOAELs were not identified in the subchronic studies (U.S. EPA, 2005a).

Because high quality human epidemiological studies focusing on a known critical endpoint of human toxicity (neurological effects) are available, animal data were not considered for use in deriving the subchronic p-RfC. Examination of the effect levels identified for human studies of toluene in the IRIS record (duplicated below as Table 1) indicates that neurological effects in the human studies were observed at similar levels in both the subchronic and chronic studies. Given that the chronic RfC is based on a number of human occupational studies,



including some studies of subchronic duration, and that derivation of the chronic RfC did not include an UF for exposure duration, the chronic RfC for toluene was adopted as the subchronic p-RfC.

A summary of the cocritical studies is excerpted from the U.S. EPA (2005b) IRIS record for toluene and reproduced below. For additional discussion of the limitations and uncertainties associated with studies that were considered adequate, or the POD selected for the chronic RfC, see the Toxicological Review (U.S. EPA, 2005a).

*A substantial database examining the effects of toluene in subchronic and chronic occupationally-exposed humans exists. The weight of evidence from these studies indicates neurologic effects (i.e., impaired color vision, impaired hearing, decreased performance in neurobehavioral analysis, changes in motor and sensory nerve conduction velocity, headache, dizziness) as the most sensitive endpoint. Numerous case studies in humans exposed to high concentrations of toluene for abusive purposes have also indicated neurological effects in adults as critical effects of concern. Human studies indicating the potential for adverse effects from toluene exposure other than neurological effects are also available. None of these studies indicated effects at doses lower than those observed for neurological effects. Animal studies have also suggested respiratory irritation as a sensitive effect, but this effect in humans appears to occur at higher exposure concentrations than those resulting in neurologic effects.*

*All of the available occupational studies were considered for the principal study upon which to base the derivation of the RfC. Numerous human studies have identified NOAELs in the range of 25-50 ppm toluene for individual neurological effects (Cavalleri et al., 2000; Eller et al., 1999; Nakatsuka et al., 1992; Neubert et al., 2001; Schaper et al., 2003; Zavalic et al., 1998a; Zupanec et al., 2002). These studies were designed to measure effects on subjective symptoms (e.g., headache, dizziness), color vision, neurological and psychomotor functioning and hearing. Several studies have shown statistically significant effects in workers in the range of 83-132 ppm on at least one of the following neurological effects: color vision, auditory evoked brain potentials, neurobehavioral parameters and neurological functioning (Abbate et al., 1993; Boey et al., 1997; Eller et al., 1999; Foo et al., 1990; Neubert et al. 2001; Vrca et al., 1995, 1996, 1997; Zavalic et al., 1998a).*

*As a whole, the available studies present a substantial body of evidence in humans indicating a relationship between neurological effects and toluene exposure at the lowest occupational exposure levels measured. No single study stands out as the best study with which to characterize neurological effects or to specify a single critical effect. Thus, in lieu of selecting one study as the principal study, a review of the human database indicated ten studies that can be considered adequate. The determination of study adequacy was based on the use of accepted testing procedures for neurological endpoints, chronic exposure duration, inclusion of a measure of exposure, comparison to defined control groups and no known co-exposure to other solvents in the workplace. Figure 1 and Table 1 summarize this subset of studies. Response levels of the adequate studies are identified in Table 1 and are calculated as the difference between the reported means from the exposure and reference groups for statistically significant outcomes. This subset of studies presents a cluster of NOAELs for neurological effects, which are*

generally below reported LOAELs for all endpoints. A deficit in neurological function was chosen as the critical effect based on this suite of neurological studies due to the overall preponderance of evidence for this endpoint at low doses. Potential limitations associated with the studies that were considered adequate are included in Table 1.




**Figure 1. Summary of NOAELs/LOAELs for neurological endpoints for a subset of occupational studies of chronic inhalation exposure to toluene**

**Table 1. Selected subset of occupational studies of neurological effects from toluene inhalation**

| Study number in Figure 1 and reference | Number of workers and duration of exposure (average years $\pm$ SD)                   | NOAEL (ppm)       | LOAEL (ppm) | Effect/test                                                                                                                                                                                   | Response level at the LOAEL (statistically significant response compared to controls) <sup>a</sup>                                                                                                                                                                                                                                           | Noted potential limitations                    |
|----------------------------------------|---------------------------------------------------------------------------------------|-------------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| 1. Abbate et al., 1993                 | Reference (n=40), exposed (n=40)<br><br>(12-14 years; no SD reported)                 | None <sup>b</sup> | 97          | Brainstem response auditory-evoked potential                                                                                                                                                  | 28% increase of the latency shift for wave-I during passage from 11 to 90 repetitions.                                                                                                                                                                                                                                                       |                                                |
| 2. Boey et al., 1997                   | Reference (n = 29) exposed (n = 29)<br><br>(4.9 $\pm$ 3.5 years; range of 1-13 years) | None              | 91          | Neuropsychological examination; digit span, visual reproduction, Benton visual retention test, trail making test, symbol digit modality test, grooved pegboard test, and finger tapping tests | Increased time to complete the grooved pegboard test 7% and 6% for dominant and nondominant hands respectively, increase in time to complete trail-making test parts A&B, 31% & 28%, respectively; 15% decrease in backward digit span test; 12% and 10% decrease in symbol digit modality test for written and oral sections, respectively. | Control workers were exposed to 12 ppm toluene |

|                           |                                                                                                                                        |      |      |                                                                                                                                                                                                                     |                                                                                                                                                                                                               |                                                                                                                                                                                                                                                 |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------|------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3. Cavalleri et al., 2000 | Reference (n=16), exposed (n=33)<br><br>(9.75 years; no SD reported)                                                                   | None | 42   | Color vision impairment (Lanthony D-15)                                                                                                                                                                             | 29% increase in CCI and 49% increase in total confusion index (TOCI) (reported as mean of both eyes).                                                                                                         | Exposure measured from urinary excretion of toluene: on the basis of previous data, air concentrations estimated to be 42 ppm.                                                                                                                  |
| 4. Eller et al., 1999     | Reference (n=19), low exposure (n=30), high exposure (n=49)<br><br>low exposure (1-12 years; no SD reported) high exposure (>12 years) | 20   | >100 | Neuropsychological examination (Cognitive Function Scanner); verbal and nonverbal learning and memory, visuomotor function, computerized neurological examination (CATSYS, TREMOR, and SWAY), subjective assessment | 13% increase in performance time on Bourdon Wiersma Test but no increase in the number of missed or incorrect detections; 33% of exposed population reported concentration difficulties.                      | The high exposure classification was based on historical exposures which may have exceeded 100 ppm for up to 27 years.                                                                                                                          |
| 5. Foo et al., 1990       | Reference (n=30), exposed (n=30)<br><br>(5.7 ± 3.2 years)                                                                              | None | 88   | Neurobehavioral tests: Benton visual retention test, visual reproduction, trail making, grooved pegboard, digit span, digit symbol, finger tapping, and simple reaction time                                        | Increased time to complete the trail-making test parts A&B, 51% & 63%, respectively; 25% decrease in digit symbol test performance; 16% decrease in total digit span test scores (both forward and backward). | Control workers were exposed to 13 ppm toluene for 2.5 ± 3.2 years. The education level was lower in the exposed group. As a result, data from the neurobehavioral tests were adjusted for years of education using a generalized linear model. |

|                           |                                                                                                           |               |               |                                                                                                                                                                                                                                  |                                                                                                                     |                                                                                                                    |
|---------------------------|-----------------------------------------------------------------------------------------------------------|---------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| 6. Murata et al., 1993    | Reference (n=10), exposed (n=10)<br><br>(11 years; range of 1-36 years; no SD reported)                   | None          | 83            | Electrophysiological analysis of maximal motor and sensory nerve conduction velocity (MCV & SCV)                                                                                                                                 | 9% reduction in the MCV in the forearm and 6% reduction in the SCV in the palm.                                     | Exposed workers were matched for age but not alcohol consumption.                                                  |
| 7. Nakatsuka et al., 1992 | Reference (n=120), exposed (n=174)                                                                        | 44-48         | None          | Color vision impairment (Lanthony's new color test and Ishihara's color vision test)                                                                                                                                             | No measured effect on color vision.                                                                                 | In lieu of determining exposure duration, groups were age-matched to control for effects of aging on color vision. |
| 8. Neubert et al., 2001   | Ref-ex (n=109), ref-int (n=48), exp gp I (n=316), exp gp II (n=535), exp gp III (n=308), exp gp IV (n=65) | 39 (exp gp 1) | 81 (ex gp IV) | Psychophysiological and psychomotor testing: verbal memory span, visuomotor performance, immediate visual memory, self-rating of feeling, biosensory vigilance, critical flicker fusion frequency test, personality dispositions | 5% reduction in ascending flicker fusion frequency.                                                                 | Exposure was identified as chronic but the duration was not reported.                                              |
| 9. Vrca et al., 1995      | Reference (n=59), exposed (n=49)<br><br>(21.4 ± 7.4 years)                                                | None          | 40-60         | Visual evoked potentials                                                                                                                                                                                                         | The amplitudes of visual evoked brain potentials were 24, 43, and 55% higher for N75, P100, and N145, respectively. | Exposure levels were estimated based on urinary levels of metabolites and toluene levels in blood.                 |

|                           |                                                                                                                                                 |    |     |                                         |                                     |                                                                                                                                                                                                                                           |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|----|-----|-----------------------------------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10. Zavalic et al., 1998a | Reference (n=90),<br>low exposure (n=46),<br>high exposure (n=37)<br><br>low exposure (16.21 ± 6.1 years)<br>high exposure (18.34 ± 6.03 years) | 32 | 132 | Color vision impairment (Lanthony D-15) | 10-14% increase in CCI (both eyes). | The results from this investigation were reported in several publications (Zavalic et al., 1998a,b,c); some reporting discrepancies exist regarding the number of workers in the exposed and control groups and the statistical analyses. |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|----|-----|-----------------------------------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<sup>a</sup> Not all studies examined all neurotoxicity endpoints.

<sup>b</sup> No NOAEL identified in this study.

The studies shown in Figure 1 were weighted equally since none was clearly a stronger study. The highest NOAEL was identified as 44 ppm (Nakatsuka et al., 1992). The lowest LOAELs were identified as 40–42 ppm (Vrca et al., 1995, 1997; Cavalleri et al., 2000). The range of NOAELs for the suite of neurological effects is 20–48 ppm. An arithmetic mean of the NOAEL values in Table 1 was chosen to represent an average POD. Thus, the average exposure level of 34 ppm is used as the POD for the derivation of the chronic RfC.

The chronic RfC for toluene (5 mg/m<sup>3</sup>) is based on neurological effects in human epidemiological studies and includes several of subchronic duration. The NOAEL (46 mg/m<sup>3</sup> after adjustment for continuous exposure) was divided by a composite UF of 10 to derive the RfC; no UF for exposure duration is included (see Appendix A for details regarding UF selection). Thus, the **chronic RfC of 5 or 5 × 10<sup>0</sup> mg/m<sup>3</sup> was adopted as the subchronic p-RfC for toluene.**

As discussed further in the IRIS Summary and Toxicological Review for toluene, many studies in humans are available. No single study was chosen as the principal study, however, a subset of studies was considered adequate for the determination of the RfC, and, in this assessment, the subchronic p-RfC. In addition, numerous animal studies on the reproductive and developmental effects of toluene indicate that these effects occur at doses higher than that identified as the POD. Confidence in the subchronic p-RfC is consistent with the confidence in the IRIS chronic RfC: high.

## REFERENCES

- Abbate, C., C. Giorgianni, F. Munao et al. 1993. Neurotoxicity induced by exposure to toluene: An electrophysiologic study. *Int. Arch. Occup. Environ. Health.* 64:389–392.
- ATSDR (Agency for Toxic Substances and Disease Registry). 2000. Toxicological Profile for Toluene. Agency for Toxic Substances and Disease Registry, Public Health Service, U.S. Department of Health and Human Services. PB/2000/108028. Online. <http://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=161&tid=29>.
- Boey, K.W., S.C. Foo and J. Jeyaratnam. 1997. Effects of occupational exposure to toluene: A neuropsychological study on workers in Singapore. *Ann. Acad. Med. Sing.* 26:84–7.
- Cavalleri, A., F. Gobba, E. Nicali et al. 2000. Dose-related color vision impairment in toluene-exposed workers. *Arch. Env. Health.* 55:399–404.
- Eller, N., B. Netterstrom and P. Laursen. 1999. Risk of chronic effects on the central nervous system at low toluene exposure. *Occup. Med.* 49(6):389–395.
- Foo, S.C., J. Jeyaratman and D. Koh. 1990. Chronic neurobehavioural effects of toluene. *Br. J. Ind. Med.* 47:480–484.
- Gordon, C. J., W. Oshiro, T. Samsam, P. Becker, C. Mack, P. Bushnell. 2006. Hypertensive and tachycardic responses to oral toluene in the rat. *Neurotoxicology.* 27(5):929.

- Gospe, S; Al-Bayati, M. 1994. Comparison of oral and inhalation exposures to toluene. *Int J Toxicol* 13:21–32.
- Hsieh, G.C., R.P. Sharma, R.D. Parker et al. 1990. Evaluation of toluene exposure via drinking water on levels of regional brain biogenic monoamines and their metabolites in CD-1 mice. *Ecotoxicol. Environ. Saf.* 20:175–184.
- Murata, K., S. Araki, K. Yokoyama et al. 1993. Cardiac autonomic dysfunction in rotogravure printers exposed to toluene in relation to peripheral nerve conduction. *Ind. Health.* 31:79–90.
- Nakatsuka, H., T. Watanabe, Y. Takeuchi et al. 1992. Absence of blue-yellow color vision loss among workers exposed to toluene or tetrachloroethylene, mostly at levels below occupational exposure limits. *Int. Arch. Occup. Environ. Health.* 64:113–117.
- Neubert, D., C. Gericke, B. Hanke et al. 2001. Multicenter field trial on possible health effects of toluene. II. Cross-sectional evaluation of acute low-level exposure. *Toxicology.* 168:139–183.
- NTP (National Toxicology Program). 1990. Toxicology and carcinogenesis studies of toluene (CAS No. 108-88-3) in F344/N rats and B6C3F1 mice (inhalation studies). Public Health Service, U.S. Department of Health and Human Services; NTP TR-371. Research Triangle Park, NC.
- Schaper, M., P. Demes, M. Zupanic et al. 2003. Occupational toluene exposure and auditory function: results from a follow-up study. *Ann. Occup. Hyg.* 47:493–502.
- U.S. EPA. 2005a. Toxicological Review of Toluene (CAS No. 108-88-3) in Support of Summary Information on the Integrated Risk Information System (IRIS). U.S. Environmental Protection Agency, Washington, DC. EPA/635/R-05/004. Online. <http://www.epa.gov/iris/toxreviews/0118tr.pdf>.
- U.S. EPA. 2005b. Integrated Risk Information System (IRIS). Online. Office of Research and Development, National Center for Environmental Assessment, Washington, DC. Online. <http://www.epa.gov/iris/>.
- Vrca, A., D. Bozicevic, V. Karacic et al. 1995. Visual evoked potentials in individuals exposed to long-term low concentrations of toluene. *Arch. Toxicol.* 69:337–40.
- Vrca, A., V. Karacic, D. Bozicevic et al. 1996. Brainstem auditory evoked potentials in individuals exposed to long-term low concentrations of toluene. *Am. J. Ind. Med.* 30:62–66.
- Vrca, A., D. Bozicevic, V. Bozikov et al. 1997. Brain stem evoked potentials and visual evoked potentials in relation to the length of occupational exposure to low levels of toluene. *Act. Med. Croat.* 51:215–219.
- Zavalic, M., Z. Mandic, R. Turk et al. 1998a. Quantitative assessment of color vision impairment in workers exposed to toluene. *Am. J. Ind. Med.* 33(3):297–304.



Zavalic, M., Z. Mandic, R. Turk et al. 1998b. Assessment of colour vision impairment in male workers exposed to toluene generally above occupational exposure limits. *Occup. Med.* 48:175–180.

Zavalic, M., Z. Mandic, R. Turk et al. 1998c. Qualitative color vision impairment in toluene-exposed workers. *Int. Arch. Occup. Environ. Health.* 71:194–200.

Zupanic, M., P. Demes and A. Seeber. 2002. Psychomotor performance and subjective symptoms at low level toluene exposure. *Occup. Environ. Med.* 59:263–268.

## APPENDIX A. PERTINENT SECTIONS FROM IRIS SUMMARY FOR TOLUENE: CHRONIC HEALTH HAZARD ASSESSMENTS FOR NONCARCINOGENIC EFFECTS

### **Toluene; CASRN 108-88-3; 09/23/2005**

Human health assessment information on a chemical substance is included in IRIS only after a comprehensive review of chronic toxicity data by U.S. EPA health scientists from several program offices, regional offices, and the Office of Research and Development. Sections I (Chronic Health Hazard Assessments for Noncarcinogenic Effects) and II (Carcinogenicity Assessment for Lifetime Exposure) present the positions that were reached during the review process. Supporting information and explanations of the methods used to derive the values given in IRIS are provided in the guidance documents located on the IRIS website at <http://www.epa.gov/iriswebp/iris/backgr-d.htm>.

### STATUS OF DATA FOR Toluene

#### **File First On-Line 01/31/1987**

| Category (section)               | Status  | Last Revised |
|----------------------------------|---------|--------------|
| Oral RfD Assessment (I.A.)       | on-line | 09/23/2005   |
| Inhalation RfC Assessment (I.B.) | on-line | 09/23/2005   |
| Carcinogenicity Assessment (II.) | on-line | 09/23/2005   |

### **\_I. Chronic Health Hazard Assessments for Noncarcinogenic Effects**

#### **\_I.A. Reference Dose for Chronic Oral Exposure (RfD)**

Substance Name — Toluene

CASRN — 108-88-3

Section I.A. Last Revised — 09/23/2005

The RfD is an estimate of an oral exposure, for a given duration, to the human population (including susceptible subgroups) that is likely to be without an appreciable risk of adverse health effects over a lifetime. It is derived from a statistical lower confidence limit on the benchmark dose (BMDL), a no-observed-adverse-effect level (NOAEL), a lowest-observed-adverse-effect level (LOAEL), or another suitable point of departure, with uncertainty/variability factors applied to reflect limitations of the data used. The RfD is intended for use in risk assessments for health effects known or assumed to be produced through a nonlinear (possibly threshold) mode of action. It is expressed in units of mg/kg-day. Please refer to the guidance documents at <http://www.epa.gov/iriswebp/iris/backgr-d.htm> for an elaboration of these concepts. Since RfDs can be derived for the noncarcinogenic health effects of substances that are also carcinogens, it is essential to refer to other sources of information concerning the carcinogenicity of this chemical substance. If the U.S. EPA has evaluated this substance for potential human carcinogenicity, a summary of that evaluation will be contained in Section II of this file.

The previous IRIS assessment utilized the NTP (1990) 13-week rat gavage study as the principal study and changes in liver and kidney weights as the critical effect for derivation of the RfD (0.2 mg/kg-day). The NOAEL was identified as 223 mg/kg-day. A composite UF of 1000 was applied to account for interspecies and intraspecies extrapolations, subchronic-to-chronic extrapolation, and limited reproductive and developmental toxicity data. The current assessment differs due to newer methodologies and consideration of additional data.

#### **\_\_I.A.1. Oral RfD Summary**

| <b>Critical Effect</b>                                                     | <b>Experimental Doses*</b>                | <b>UF</b> | <b>RfD</b>     |
|----------------------------------------------------------------------------|-------------------------------------------|-----------|----------------|
| Increased kidney weight<br><br>13-week gavage study in rats<br>(NTP, 1990) | BMDL: 238 mg/kg-day<br>BMD: 431 mg/kg-day | 3000      | 0.08 mg/kg-day |

\* Conversion Factors and Assumptions - BMDL- 95% lower confidence limit on the maximum likelihood estimate of the dose corresponding to a one standard deviation change in the mean.

BMD - Maximum likelihood estimate of the dose corresponding to a one standard deviation change in the mean.

#### **\_\_I.A.2. Principal and Supporting Studies (Oral RfD)**

No studies examining the chronic or subchronic effects of oral exposure to toluene in humans are available. A lifetime gavage study in rats (Maltoni et al., 1997) reported only carcinogenic endpoints and is, therefore, not suitable for use as the principal study for derivation of an RfD. One subchronic study (NTP, 1990) examining oral exposure to toluene in rodents (rats and mice) is available and was chosen as the principal study. The critical effect chosen is increased kidney weight. NTP (1990) exposed both sexes of F-344 rats and both sexes of B6C3F1 mice to toluene by gavage for 13 weeks. In male rats, absolute and relative weights of both the liver and kidney were significantly increased ( $p < 0.05$ ) at doses greater than or equal to 446 mg/kg-day. Absolute kidney weights were 100, 107, 112, 119, and 113% of controls; relative kidney weights were 100, 100, 106, 114, and 146% of controls for 0, 223, 446, 900, or 1800 mg/kg-day dose levels. The study in rats established a NOAEL of 223 mg/kg-day for increases in liver and kidney weights of male rats, with a LOAEL of 446 mg/kg-day. Histopathologic lesions in the liver consisted of hepatocellular hypertrophy, occurring at doses greater than 2500 mg/kg-day. Nephrosis was observed in rats that died, and damage to the tubular epithelia of the kidney occurred in terminally sacrificed rats. Kidney sections were examined in particular for the occurrence of hyaline droplets in the proximal tubules with negative findings. Additional study information can be found in Section 4 of the Toxicological Review (U.S. EPA, 2005). A concentration-dependent nephropathy was also seen in chronic inhalation cancer bioassays (NTP, 1990; Huff, 2003). It should be noted that no increase in kidney weight was seen in the parallel study in B6C3F1 mice, indicating a species difference in the response.

The choice of increased kidney weight as the critical effect is supported by several acute oral and inhalation human toxicity studies, indicating renal tubule toxicity. One case report following lethal oral exposure to 625 mg/kg toluene (Ameno et al., 1989) and a nonlethal case report of thinner ingestion (Caravati and Bjerk, 1997) noted acute tubular necrosis and acidosis. Inhalation of high doses of toluene has caused distal renal tubular acidosis (Taher et al., 1974; Fischman and Oster, 1979) among drug users, sometimes with tubular proteinuria (Kamijima et al., 1994). A case of focal segmental glomerulosclerosis was noted for a leather worker exposed to toluene

for 40 years (Bosch et al., 1988). Toluene sniffing has been associated with the formation of renal stones (Kroeger et al., 1980), proteinuria (Streicher et al., 1981), and hepato-renal damage (O'Brien et al., 1971). In addition, a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis has also been reported in a woman who sniffed glue for several weeks (Bonzel et al., 1987). It should be noted that several studies involving painters (Askergren, 1982; Franchini et al., 1983) or printers (Gericke et al., 2001) with toluene exposure have reported no effect on renal function. Askergren (1982) and Franchini et al. (1983) found no effect on excretion of beta-2-microglobulin, and Gericke et al. (2001) found no effect on serum creatinine levels or glomerular filtration rate. The choice of increased kidney weight as a critical effect is based on the above data and the available animal data indicating an increase in kidney weight in the same studies where overt kidney toxicity was observed at higher doses. The available data on postulated modes of action for toluene-induced kidney toxicity are described in Section 4.5.3 of the Toxicological Review (U.S. EPA, 2005).

The RfD was derived by the benchmark dose approach using EPA's (U.S. EPA, 2001) benchmark dose software (BMDS, Version 1.3). The benchmark response (BMR) was defined as the change of one control standard deviation from the control mean (U.S. EPA, 2000). Benchmark analysis was performed for absolute kidney weight changes in male rats (NTP, 1990). Male rat kidney data were chosen for BMD modeling as these data exhibited a greater response than that seen in female rats (see study description in Section 4.2.1.1 of the Toxicological Review). A BMDL of 238 mg/kg-day was derived and used as the point of departure. The BMDL corresponds to the lower bound on the dose associated with a 10% increase in individuals having a kidney weight greater than the 98<sup>th</sup> percentile of kidney weights in the control group (and the SD corresponding to 9% increase in kidney weight from control). Details of the model results are presented in Appendix B-1 of the Toxicological Review.

### **I.A.3. Uncertainty and Modifying Factors (Oral RfD)**

Total UF = 3000

A total uncertainty factor (UF) of 3000 was applied to this effect level: 10 for extrapolation for interspecies differences (UF<sub>A</sub>; animal to human), 10 for consideration of intraspecies variation (UF<sub>H</sub>; human variability), 10 for use of a subchronic study to estimate chronic effects (UF<sub>S</sub>; duration of exposure), and 3 for database insufficiencies and contradictions in the immunotoxicity data (UF<sub>D</sub>). The total UF = 10 x 10 x 10 x 3 = 3000.

An uncertainty factor of 10 was used to account for laboratory animal-to-human interspecies differences (UF<sub>A</sub>). No information is available on differences or similarities in the toxicity of toluene between animals and humans.

An uncertainty factor of 10 was used to account for intraspecies differences (UF<sub>H</sub>) including variability in susceptibility in human populations and life-stages. This UF was not reduced because of the lack of human oral exposure information.

An uncertainty factor of 10 was used to account for extrapolating from a subchronic study to estimate chronic exposure conditions (UF<sub>S</sub>).

An uncertainty factor was not needed to account for extrapolating from a LOAEL to a NOAEL because BMD modeling was used to identify the point of departure.

An uncertainty factor of 3 was used to account for deficiencies in the toluene database. An oral subchronic study in two species is available. Neurotoxicity has been identified by inhalation studies in humans and animals as a critical endpoint. However, limited neurotoxicity studies by the oral route are available. Several oral exposure high-dose reproductive and developmental toxicity studies are available which indicate toluene does not generally elicit developmental or reproductive effects except at doses that are significantly higher than those causing other systemic effects (see Section 4.3 of the Toxicological Review for details). A two-generation reproductive toxicity study by the oral route of exposure is not available, however, a two-generation reproductive toxicity study by the inhalation route of exposure is available that possibly lends support to the oral database in that effects are noted at high concentrations. Toxicokinetic information indicates that the absorption kinetics of toluene is similar and extensive following both oral and inhalation exposure. For example, Gospe and Al-Bayati (1994) compared oral and inhalation exposures to toluene in the rat and concluded that oral dosing produces blood toluene levels that are similar to those produced by inhalation (see Section 3.1.2 of the Toxicological Review). It should be noted, however, that differences in metabolism between exposure routes have not been elucidated, nor has a role for metabolites been ascertained in the toxicity of toluene. Immunotoxicity data are available but the results are conflicting. The data to date are inadequate to draw conclusions regarding whether immunosuppression may be a more sensitive endpoint (i.e., an endpoint that would result in a lower point of departure) than kidney toxicity.

A three-fold uncertainty factor for insufficiencies in the database was used to account for the lack of adequate data on endpoints of potential concern for toluene, including neurotoxicity, two-generation reproductive toxicity, and immunotoxicity.

The RfD for toluene was calculated as follows:

$$\begin{aligned}\text{RfD} &= \text{BMDL} \div \text{UF} \\ &= 238 \text{ mg/kg-day} \div 3000 \\ &= 0.08 \text{ mg/kg-day}\end{aligned}$$

#### I.A.4. Additional Studies/Comments (Oral RfD)

A number of immunotoxicity studies are available (Hsieh et al., 1989, 1990b, 1991; Burns et al., 1994) and were considered for use as the principal study. Changes in thymus weights in the Hsieh et al. (1989) study were not considered an adverse effect since no change was observed in later studies by Hsieh et al. (1990b) and Burns et al. (1994). Additional effects on immunological endpoints were considered as a potential critical effect from toluene exposure. For example, statistically significant and dose-related decreases in antibody response were noted by Hsieh et al. (1989, 1990b, 1991). There is evidence that the PFC assay is among the most predictive tests available for immunotoxicity (Luster et al., 1992) and that suppression of the antibody response is predictive of decreased resistance to challenge with infectious agents or tumor cells (Luster et al., 1993). An important objective of the use of the PFC assay and anti-SRBC ELISA

in immunotoxicity testing is to determine the ability of the immune system to respond to an antigenic challenge. As such, it tests the ability of three primary immune system cells (i.e., macrophages [phagocytosis and processing of SRBCs], T lymphocytes [which assist B lymphocytes] and B lymphocytes [production and release of anti-SRBC specific antibody]) to respond to this antigen in a coordinated manner leading to the production of antibodies to SRBC.

However, in the same test that Hsieh et al. (1989, 1990b, 1991) showed suppression of the antibody response (the PFC assay), Burns et al. (1994) did not find immunosuppression. The studies were not entirely parallel; Hsieh and Burns used different mouse strains (CD-1 and B6C3F1, respectively), examined different sexes (males and females, respectively), and utilized different exposure durations (28 vs. 14 days, respectively). Furthermore, the host resistance assays by Burns et al. (1994) indicated a lack of immunotoxicity when animals treated with toluene were challenged. Host resistance to challenges with *Listeria monocytogenes*, *Streptococcus pneumoniae*, *Plasmodium yoelii*, or B16F10 melanoma was not affected at a dose of 600 mg/kg-day for 14 days. In addition, a reduced incidence of tumors was observed in mice that were challenged with PYB6 fibrosarcoma. Stefanovic et al. (1987) found no significant changes in immunoglobulin levels after toluene treatment of human sera and also showed no changes in the complement activity parameters studied in the toluene treated sera. The conflicting data between the Hsieh and Burns studies and the lack of suppression of host resistance present an unclear picture of toluene immunotoxicity. For these reasons, immunotoxic endpoints alone are not considered critical effects.

Additional studies by Hsieh et al. (1990a,c) found statistically significant increases in a variety of brain neurotransmitter levels at exposure levels as low as 5 mg/kg-day. The study authors measured levels at one time point immediately at the termination of toluene treatment; it cannot be determined if the effects observed were persistent. Neurotoxicity studies from oral exposure to toluene have not been performed; therefore, the changes in neurotransmitter levels have not been correlated with behavioral, neuropsychological, or neuroanatomical changes and were not considered further. Available reproductive studies (Gospe et al., 1994, 1996; Gospe and Zhou, 1998, 2000) were conducted at higher doses than those used in the studies described above with minimal effects on dams and offspring and, as such, were not considered for the choice of principal study.

**For more detail on Susceptible Populations, exit to [the toxicological review, Section 4.7 \(PDF\)](#).**

#### **\_\_I.A.5. Confidence in the Oral RfD**

Study — Medium  
Database — Medium  
RfD — Medium

The overall confidence in the RfD assessment is medium. Confidence in the principal study is medium. It is an adequate gavage study of subchronic duration. Confidence in the database is rated medium due to the lack of chronic data, neurotoxicity studies, and a two-generation reproductive toxicity study, and uncertainty surrounding the immunotoxicity of toluene. An oral subchronic study in two species and several immunotoxicity studies are available. A number of

oral and inhalation studies have demonstrated that toluene does not elicit developmental or reproductive effects except at doses that are significantly higher than those causing other systemic effects. The available toxicokinetic data indicate the absorption of toluene is similar and extensive following both oral and inhalation exposure. A two-generation reproductive inhalation toxicity study is available which lends support to the oral database in that effects are noted only at high concentrations.

***For more detail on Characterization of Hazard and Dose Response, exit to [the toxicological review, Section 6 \(PDF\)](#).***

#### **\_\_I.A.6. EPA Documentation and Review of the Oral RfD**

Source Document — U.S. EPA (2005)

This assessment was peer reviewed by a group of external scientists. Comments from the peer reviewers were evaluated carefully and considered by the Agency during the finalization of this assessment. A record of these comments is included in Appendix A of the Toxicological Review of Toluene (U.S. EPA, 2005). [To review this appendix, exit to the toxicological review, Appendix A, Summary of External Peer Review and Public Comments and Disposition \(PDF\)](#)

Agency Completion Date -- 08/26/2005

#### **\_\_I.A.7. EPA Contacts (Oral RfD)**

Please contact the IRIS Hotline for all questions concerning this assessment or IRIS, in general, at (202) 566-1676 (phone), (202) 566-1749 (fax), or [hotline.iris@epa.gov](mailto:hotline.iris@epa.gov) (email address).

[Top of page](#)

---

#### **\_I.B. Reference Concentration for Chronic Inhalation Exposure (RfC)**

Substance Name — Toluene

CASRN — 108-88-3

Section I.B Last Revised — 09/23/2005

The RfC is an estimate of an inhalation exposure, for a given duration, to the human population (including susceptible subgroups) that is likely to be without an appreciable risk of adverse health effects over a lifetime. It is derived from a statistical lower confidence limit on the benchmark concentration (BMCL), a no-observed-adverse-effect level (NOAEL), a lowest-observed-adverse-effect level (LOAEL), or another suitable point of departure, with uncertainty/variability factors applied to reflect limitations of the data used. The RfC considers toxic effects for both the respiratory system (portal-of-entry) and for effects peripheral to the respiratory system (extrapulmonary effects). The inhalation RfC (generally expressed in units of  $\text{mg}/\text{m}^3$ ) is analogous to the oral RfD and is similarly intended for use in risk assessments for health effects known or assumed to be produced through a nonlinear (possibly threshold) mode of action.

Inhalation RfCs are derived according to *Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry* (U.S. EPA, 1994). Since RfCs can also be derived for the noncarcinogenic health effects of substances that are carcinogens, it is essential to refer to other sources of information concerning the carcinogenicity of this chemical substance. If the U.S. EPA has evaluated this substance for potential human carcinogenicity, a summary of that evaluation will be contained in Section II of this file.

The previous IRIS assessment utilized the Foo et al. (1990) occupational study as the principal study and neurological effects as the critical effect for the derivation of the RfC (0.4 mg/m<sup>3</sup>). The LOAEL was identified as 332 mg/m<sup>3</sup> (88 ppm), which was converted to a human equivalent concentration of 119 mg/m<sup>3</sup>. A composite UF of 300 was used that consisted of a 10-fold UF for intraspecies variability, a 10-fold UF for the use of a LOAEL instead of a NOAEL, and a three-fold UF for database deficiencies, including a lack of animal exposure data evaluating neurotoxicity and respiratory irritation. The current IRIS assessment takes into account a number of newer human studies that are available and incorporates newer methodologies.

### **\_\_I.B.1. Inhalation RfC Summary**

| <b>Critical Effect</b>                                 | <b>Experimental Doses*</b>                          | <b>UF</b> | <b>RfC</b>          |
|--------------------------------------------------------|-----------------------------------------------------|-----------|---------------------|
| Neurological effects in occupationally-exposed workers | NOAEL (average):<br>34 ppm (128 mg/m <sup>3</sup> ) | 10        | 5 mg/m <sup>3</sup> |
| Multiple human studies (see Table 1 and Figure 1).     | NOAEL (ADJ): 46 mg/m <sup>3</sup>                   |           |                     |

\*Conversion Factors and Assumptions — See Table 1 for a list of studies used in the derivation of the RfC. Assuming 25 °C and 760 mm Hg, NOAEL (average) (mg/m<sup>3</sup>) = 34 ppm × 92.15/24.45 = 128 mg/m<sup>3</sup>. This is an extrarespiratory effect of a soluble vapor. The NOAEL (HEC) is based on an 8-hour TWA occupational exposure. MVho = 10 m<sup>3</sup>/day, MVh = 20 m<sup>3</sup>/day. NOAEL (HEC) = NOAEL (ADJ) = 128 × MVho/MVh × 5 days/7 days = 46 mg/m<sup>3</sup>.

### **\_\_I.B.2. Principal and Supporting Studies (Inhalation RfC)**

A substantial database examining the effects of toluene in subchronic and chronic occupationally exposed humans exists. The weight of evidence from these studies indicates neurologic effects (i.e., impaired color vision, impaired hearing, decreased performance in neurobehavioral analysis, changes in motor and sensory nerve conduction velocity, headache, dizziness) as the most sensitive endpoint. Numerous case studies in humans exposed to high concentrations of toluene for abusive purposes have also indicated neurological effects in adults as critical effects of concern. Human studies indicating the potential for adverse effects from toluene exposure other than neurological effects are also available. None of these studies indicated effects at doses lower than those observed for neurological effects. Animal studies (NTP, 1990) have also suggested respiratory irritation as a sensitive effect, but this effect in humans appears to occur at higher exposure concentrations than those resulting in neurologic effects.

All of the available occupational studies were considered for the principal study upon which to base the derivation of the RfC. A discussion of available animal studies is presented in Section I.B.4. Numerous human studies have identified NOAELs in the range of 25-50 ppm toluene for individual neurological effects (Cavalleri et al., 2000; Eller et al., 1999; Nakatsuka et al., 1992; Neubert et al., 2001; Schaper et al., 2003; Zavalic et al., 1998a; Zupanec et al., 2002). These



studies were designed to measure effects on subjective symptoms (e.g., headache, dizziness), color vision, neurological and psychomotor functioning, and hearing. Several studies have shown statistically significant effects in workers in the range of 83-132 ppm on at least one of the following neurological effects: color vision, auditory evoked brain potentials, neurobehavioral parameters, and neurological functioning (Abbate et al., 1993; Boey et al., 1997; Eller et al., 1999; Foo et al., 1990; Neubert et al. 2001; Vrca et al., 1995, 1996, 1997; Zavalic et al., 1998a).

As a whole, the available studies present a substantial body of evidence in humans indicating a relationship between neurological effects and toluene exposure at the lowest occupational exposure levels measured. No single study stands out as the best study on which to characterize neurological effects nor to specify a single critical effect. Thus, in lieu of selecting one study as the principal study, a review of the human database indicated ten studies can be considered adequate. The determination of study adequacy was based on the use of accepted testing procedures for neurological endpoints, chronic exposure duration, inclusion of a measure of exposure, comparison to defined control groups, and no known co-exposure to other solvents in the workplace. Figure 1 and Table 1 summarizes this subset of studies. Response levels of the adequate studies are identified in Table 1 and are calculated as the difference between the reported means from the exposure and reference groups for statistically significant outcomes. This subset of studies presents a cluster of NOAELs for neurological effects which are generally below reported LOAELs for all endpoints. A deficit in neurological function was chosen as the critical effect based on this suite of neurological studies due to the overall preponderance of evidence for this endpoint at low doses.

Potential limitations associated with the studies that were considered adequate are included in Table 1. For additional discussion of the limitations and uncertainties associated with studies that were considered adequate, see Sections 4.1.2.2, 4.5.3 and Appendix A of the Toxicological Review (U.S. EPA, 2005). Not included in the subset are studies with known co-exposure to other solvents (Antti-Poika et al., 1985; Yin et al., 1987; Campagna et al., 2001), studies lacking adequate exposure information (Antti-Poika et al., 1985; Murata et al., 1993), studies without a reference group (Muttray et al., 1995; Morata et al., 1997; Schaper et al., 2003; Tanaka et al., 2003), and studies where questionnaires were the only assessment of toxicity or exposure (Lee et al., 1988; Zupanec et al., 2002; Seeber et al., 2004). These studies contribute qualitatively to the overall weight of evidence of the choice of critical effect but are given lesser weight due to the inadequacies described. Orbaek and Nise (1989) was not included in the subset of studies due to the low number of workers tested and uncertainty in the exposure levels. Chouaniere et al. (2002) observed effects on psychomotor performance at doses of 25 and 40 ppm but the doses were estimated based on test results precluding the use of this study for quantitative purposes.

**Figure 1. Summary of NOAELs/LOAELs for neurological endpoints for subset of occupational studies of chronic inhalation exposure to toluene.**




**Table 1. Selected subset of occupational studies of neurological effects from toluene inhalation**

| Study number in Figure 1 and reference | Number of workers and duration of exposure (average years $\pm$ SD)                      | NOAEL (ppm)       | LOAEL (ppm) | Effect/test                                                                                                                                                                                   | Response level at the LOAEL (statistically significant response compared to controls) <sup>a</sup>                                                                                                                                                                                                                                           | Noted potential limitations                    |
|----------------------------------------|------------------------------------------------------------------------------------------|-------------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| 1. Abbate et al., 1993                 | Reference (n=40), exposed (n=40)<br><br>(12-14 years; no SD reported)                    | None <sup>b</sup> | 97          | Brainstem response auditory-evoked potential                                                                                                                                                  | 28% increase of the latency shift for wave-I during passage from 11 to 90 repetitions.                                                                                                                                                                                                                                                       |                                                |
| 2. Boey et al., 1997                   | Reference (n = 29)<br>exposed (n = 29)<br><br>(4.9 $\pm$ 3.5 years; range of 1-13 years) | None              | 91          | Neuropsychological examination; digit span, visual reproduction, Benton visual retention test, trail making test, symbol digit modality test, grooved pegboard test, and finger tapping tests | Increased time to complete the grooved pegboard test 7% and 6% for dominant and nondominant hands respectively, increase in time to complete trail-making test parts A&B, 31% & 28%, respectively; 15% decrease in backward digit span test; 12% and 10% decrease in symbol digit modality test for written and oral sections, respectively. | Control workers were exposed to 12 ppm toluene |

|                           |                                                                                                                                           |      |      |                                                                                                                                                                                                                     |                                                                                                                                                                                                               |                                                                                                                                                                                                                                                 |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3. Cavalleri et al., 2000 | Reference (n=16), exposed (n=33)<br><br>(9.75 years; no SD reported)                                                                      | None | 42   | Color vision impairment (Lanthony D-15)                                                                                                                                                                             | 29% increase in CCI and 49% increase in total confusion index (TOCI) (reported as mean of both eyes).                                                                                                         | Exposure measured from urinary excretion of toluene: on the basis of previous data, air concentrations estimated to be 42 ppm.                                                                                                                  |
| 4. Eller et al., 1999     | Reference (n=19), low exposure (n=30), high exposure (n=49)<br><br>low exposure (1-12 years; no SD reported)<br>high exposure (>12 years) | 20   | >100 | Neuropsychological examination (Cognitive Function Scanner); verbal and nonverbal learning and memory, visuomotor function, computerized neurological examination (CATSYS, TREMOR, and SWAY), subjective assessment | 13% increase in performance time on Bourdon Wiersma Test but no increase in the number of missed or incorrect detections; 33% of exposed population reported concentration difficulties.                      | The high exposure classification was based on historical exposures which may have exceeded 100 ppm for up to 27 years.                                                                                                                          |
| 5. Foo et al., 1990       | Reference (n=30), exposed (n=30)<br><br>(5.7 ± 3.2 years)                                                                                 | None | 88   | Neurobehavioral tests: Benton visual retention test, visual reproduction, trail making, grooved pegboard, digit span, digit symbol, finger tapping, and simple reaction time                                        | Increased time to complete the trail-making test parts A&B, 51% & 63%, respectively; 25% decrease in digit symbol test performance; 16% decrease in total digit span test scores (both forward and backward). | Control workers were exposed to 13 ppm toluene for 2.5 ± 3.2 years. The education level was lower in the exposed group. As a result, data from the neurobehavioral tests were adjusted for years of education using a generalized linear model. |

|                           |                                                                                                           |               |               |                                                                                                                                                                                                                                  |                                                                                                                     |                                                                                                                    |
|---------------------------|-----------------------------------------------------------------------------------------------------------|---------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| 6. Murata et al., 1993    | Reference (n=10), exposed (n=10)<br><br>(11 years; range of 1-36 years; no SD reported)                   | None          | 83            | Electrophysiological analysis of maximal motor and sensory nerve conduction velocity (MCV & SCV)                                                                                                                                 | 9% reduction in the MCV in the forearm and 6% reduction in the SCV in the palm.                                     | Exposed workers were matched for age but not alcohol consumption.                                                  |
| 7. Nakatsuka et al., 1992 | Reference (n=120), exposed (n=174)                                                                        | 44-48         | None          | Color vision impairment (Lanthony's new color test and Ishihara's color vision test)                                                                                                                                             | No measured effect on color vision.                                                                                 | In lieu of determining exposure duration, groups were age-matched to control for effects of aging on color vision. |
| 8. Neubert et al., 2001   | Ref-ex (n=109), ref-int (n=48), exp gp I (n=316), exp gp II (n=535), exp gp III (n=308), exp gp IV (n=65) | 39 (exp gp 1) | 81 (ex gp IV) | Psychophysiological and psychomotor testing: verbal memory span, visuomotor performance, immediate visual memory, self-rating of feeling, biosensory vigilance, critical flicker fusion frequency test, personality dispositions | 5% reduction in ascending flicker fusion frequency.                                                                 | Exposure was identified as chronic but the duration was not reported.                                              |
| 9. Vrca et al., 1995      | Reference (n=59), exposed (n=49)<br><br>(21.4 ± 7.4 years)                                                | None          | 40-60         | Visual evoked potentials                                                                                                                                                                                                         | The amplitudes of visual evoked brain potentials were 24, 43, and 55% higher for N75, P100, and N145, respectively. | Exposure levels were estimated based on urinary levels of metabolites and toluene levels in blood.                 |

|                           |                                                                                                                                        |    |     |                                         |                                     |                                                                                                                                                                                                                                           |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----|-----|-----------------------------------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10. Zavalic et al., 1998a | Reference (n=90), low exposure (n=46), high exposure (n=37)<br><br>low exposure (16.21 ± 6.1 years) high exposure (18.34 ± 6.03 years) | 32 | 132 | Color vision impairment (Lanthony D-15) | 10-14% increase in CCI (both eyes). | The results from this investigation were reported in several publications (Zavalic et al., 1998a,b,c); some reporting discrepancies exist regarding the number of workers in the exposed and control groups and the statistical analyses. |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----|-----|-----------------------------------------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<sup>a</sup> Not all studies examined all neurotoxicity endpoints.

<sup>b</sup> No NOAEL identified in this study.

The subset of studies shown in Figure 1 were weighted equally since none was clearly a stronger study. The highest NOAEL was identified as 44 ppm (Nakatsuka et al., 1992). The lowest LOAELs were identified as 40-42 ppm (Vrca et al., 1995, 1997; Cavalleri et al., 2000). An arithmetic mean of the NOAEL values in Table 1 was chosen to represent an average point of departure. Thus, the average exposure level of 34 ppm is used as the point of departure for the derivation of the RfC. This value is lower than the LOAELs identified above. The range of NOAELs for the suite of neurological effects is 20 to 48 ppm. The average NOAEL is used as a surrogate given concerns about the use of a particular individual NOAEL based on the discussion in Section 5.2.1 of the Toxicological Review (U.S. EPA, 2005). There is some uncertainty in using an average value from a suite of studies with varied endpoints and varied levels of response for the point of departure. However, the uncertainty is expected to be less than that associated with choosing any particular one of the available studies for deriving the point of departure since there were potential limitations associated with many of the available studies and no single study stands out as being of the highest quality. Furthermore, this subset of studies presents a cluster of NOAELs for neurological effects which are generally below reported LOAELs for all endpoints.

The NOAEL (average) of 34 ppm ( $128 \text{ mg/m}^3$ ) was adjusted from an occupational exposure scenario to continuous exposure conditions as follows:

$$\begin{aligned}\text{NOAEL (adj)} &= \text{NOAEL (average)} \times \text{VEho/VEh} \times 5 \text{ days/7 days} \\ &= 128 \text{ mg/m}^3 \times 10\text{m}^3/20\text{m}^3 \times 5 \text{ days/7 days} \\ &= 46 \text{ mg/m}^3\end{aligned}$$

Where:

VEho = human occupational default minute volume ( $10 \text{ m}^3$  breathed during the 8 hour workday)

VEh = human ambient default minute volume ( $20 \text{ m}^3$  breathed during the entire day)

### **\_\_I.B.3. Uncertainty and Modifying Factors (Inhalation RfC)**

UF = 10

A total uncertainty factor of 10 was applied to the adjusted average NOAEL (i.e., 10 for consideration of intraspecies variation). A 10-fold uncertainty factor for intraspecies differences ( $\text{UF}_H$ ) was used to account for potentially susceptible human subpopulations and lifestages. This 10-fold uncertainty factor includes consideration of the Pelekis et al. (2001) model employing pharmacokinetic information to derive a chemical-specific intraspecies UF for toluene that accounts for childhood exposure only. Their analysis suggests an informed quantitation of adult-to-child variability reported to be in the 3-fold range. The Pelekis model is based on the pharmacokinetic differences between adults and children. However, differences in human susceptibility may also be due to lifestage (e.g., advanced age) differences among the adult population, genetic polymorphisms, decreased renal clearance in disease states, and unknown pharmacodynamic variations in response to toluene exposure. Since the variability defined in the Pelekis model may not account for these additional differences in pharmacokinetics and pharmacodynamics, a full factor of 10 is used.

An uncertainty factor to account for laboratory animal-to-human interspecies differences ( $\text{UF}_A$ ) was not necessary because the point of departure is based on human exposure data.

An uncertainty factor to account for extrapolating from less than chronic results (UF<sub>s</sub>) was not necessary. Most of the studies used in the analysis were of chronic duration.

An uncertainty factor was not needed to account for extrapolating from a LOAEL to a NOAEL because a surrogate NOAEL, i.e., an average NOAEL from a subset of studies, was used to derive the point of departure.

The database for inhalation exposure to toluene is considered adequate. Numerous human and animal chronic and subchronic studies are available. Animal studies have demonstrated reproductive and developmental effects of toluene at exposure levels higher than those used for the determination of the point of departure. In addition, neurotoxicity studies and a two-generation reproductive toxicity study are available. There is some uncertainty regarding potential immunological effects of toluene via the inhalation route of exposure. These uncertainties arise from the conflicting immunotoxicity data on toluene following oral exposure in animal studies (see Sections 4.2.1.1 and 5.1.1 of the Toxicological Review for study descriptions). Two studies on immunologic effects following inhalation exposure are available. Stengel et al. (1998) assessed several immunological parameters in blood following chronic occupational exposure to 50 ppm toluene but no statistically significant effects were observed. Aranyi et al. (1985) examined the effects of inhalation exposure to toluene on pulmonary host defenses in animals and found transient effects at low doses with a lack of a dose-response relationship. These results indicate additional research may be needed to further evaluate the potential immunological effects of toluene by the inhalation route of exposure but do not warrant an uncertainty factor at this time. A database uncertainty factor is not considered necessary.

#### **I.B.4. Additional Studies/Comments (Inhalation RfC)**

A number of animal studies have examined the neurological effects of inhaled toluene. These studies were generally carried out at high doses and reported impaired responses in neurologic examinations. For example, Rebert et al. (1989a,b) reported abnormal flash-evoked potentials in rats exposed to a single inhalation exposure of 500-16,000 ppm toluene. Evoked potentials reflect the function of the nervous system. Increases in latencies in evoked potentials can reflect deficits in nerve conduction and are indicators of a potential neurotoxic effect. Wood et al. (1983) exposed rats to toluene levels up to 3000 ppm for 4 hours prior to behavioral evaluation and reported that toluene reduced performance in behavioral tests, particularly at the 1780 and 3000 ppm exposure levels. Von Euler et al. (2000) exposed 30 rats to 80 ppm toluene for 4 weeks and found a selective decrease of approximately 6% in the area of the parietal cortex by magnetic resonance imaging. Autoradiographic analysis revealed a 7-10% decrease of the cerebrocortical area. Inhalation exposure to toluene has also been shown to result in irreversible high-frequency hearing loss in rats. Pryor et al. (1984) evaluated hearing loss by a behavioral technique (avoidance response elicited to an auditory signal) and brainstem auditory-evoked responses (elicited by tone pips of differing loudness and frequency and detected by subdural scalp electrodes). Hearing loss, as measured by both techniques, was observed after as few as 2 weeks of exposure to 1000 ppm toluene for 14 hours/day. Hearing loss was irreversible, as evidenced by a failure to return to normal response after 3 months of recovery.



In addition to neurologic effects in humans, the previous RfC on the IRIS database was based on irritation of the upper respiratory tract, specifically the nasal epithelium, as reported in the chronic NTP (1990) study in rats. However, these effects occurred in rats exposed to high concentrations (600 ppm or greater) of toluene and did not show an appreciable increase with increasing concentration (i.e., the incidence of the lesions was greater at 600 ppm than at 1200 ppm). Support that the nasal lesions are a high-exposure phenomenon also comes from the results of a chronic inhalation study in rats performed by CIIT (1980), which reported no effects on the nasal epithelium of animals exposed to 300 ppm toluene. A 28-day inhalation study in rats (30 and 300 ppm) likewise failed to demonstrate treatment-related lesions in the nasal epithelium (Poon et al., 1994). Acute studies in humans have demonstrated that subjective reports of irritation of the nose and/or eyes occurs at exposure levels of 100 ppm or greater (Baelum et al., 1985, 1990; Echeverria et al., 1989; Andersen et al., 1983) but not at exposures below 100 ppm (Echeverria et al., 1989; Andersen et al., 1983). Because neurologic effects are a more sensitive endpoint for exposed humans, neurological deficits were selected as the critical endpoint in this assessment.

***For more detail on Susceptible Populations, exit to [the toxicological review, Section 4.7 \(PDF\)](#).***

#### **\_\_I.B.5. Confidence in the Inhalation RfC**

Study — High  
Database — High  
RfC -- High

The overall confidence in this RfC assessment is high. Confidence in the database is high. Many chronic studies in humans are available. In addition, numerous animal studies on the reproductive and developmental effects of toluene exist, which identify these effects as occurring at doses higher than that identified as the point of departure. No single study was chosen as the principal study, however, a subset of studies were considered adequate for the determination of the RfC. The overall study confidence is high.

***For more detail on Characterization of Hazard and Dose Response, exit to [the toxicological review, Section 6 \(PDF\)](#)***

#### **\_\_I.B.6. EPA Documentation and Review of the Inhalation RfC**

Source Document — U.S. EPA (2005)

This assessment was peer reviewed by a group of external scientists. Comments from the peer reviewers were evaluated carefully and considered by the Agency during the finalization of this assessment. A record of these comments is included in Appendix A of the Toxicological Review of Toluene (U.S. EPA, 2005). [To review this appendix, exit to the toxicological review, Appendix A, Summary of External Peer Review and Public Comments and Disposition \(PDF\)](#)

Agency Completion Date -- 08/26/2005

### **I.B.7. EPA Contacts (Inhalation RfC)**

Please contact the IRIS Hotline for all questions concerning this assessment or IRIS, in general, at (202) 566-1676 (phone), (202) 566-1749 (fax), or [hotline.iris@epa.gov](mailto:hotline.iris@epa.gov) (email address).

---

## **VI. Bibliography**

Substance Name — Toluene

CASRN — 108-88-3

Section V.I. Last Revised — 09/23/2005

### **VI.A. Oral RfD References**

Ameno, K; Fuke, C; Ameno, S; et al. (1989) A fatal case of oral ingestion of toluene. *Forensic Sci Int* 41:255-260.

Askergren, A. (1982) Organic solvents and kidney function. *Adv Mod Environ Toxicol* 2:157-172.

Bonzel, KE; Muller-Wiefel, DE; Ruder, H; et al. (1987) Anti-glomerular basement membrane antibody-mediated glomerulonephritis due to glue sniffing. *Eur J Pediatr* 146:296-300.

Bosch, X; Campistol, JM; Montolie, J; et al. (1988) Myelofibrosis and focal segmental glomerular sclerosis associated with toluene poisoning. *Human Toxicol* 7:357-361.

Burns, LA; Bradley, SG; White Jr, KL; et al. (1994) Immunotoxicity of mono-nitrotoluenes in female B6C3F1 mice. I. Para-nitrotoluene. *Drug Chem Toxicol* 17:317-358.

Caravati, EM; Bjerk, PJ. (1997) Acute toluene ingestion toxicity. *Ann Emerg Med* 30:838-839.

Fischman, CM; Oster, JR. (1979) Toxic effects of toluene: a new cause of high anion gap metabolic acidosis. *JAMA* 241:1713-1715.

Franchini, I; Cavatorta, A; Falzoi, M; et al. (1983) Early indicators of renal damage in workers exposed to organic solvents. *Int Arch Occup Environ Health* 52:1-9.

Gericke, C; Hanke, B; Beckmann, G; et al. (2001) Multicenter field trial on possible health effects of toluene. III. Evaluation of effects after long-term exposure. *Toxicology* 168:185-209.

Gospe, S; Al-Bayati, M. (1994) Comparison of oral and inhalation exposures to toluene. *Int J Toxicol* 13:21-32.

Gospe Jr, SM; Zhou, SS. (1998) Toluene abuse embryopathy: longitudinal neurodevelopmental effects of prenatal exposure to toluene in rats. *Reprod Toxicol* 12:119-126.

Gospe Jr, SM; Zhou, SS. (2000) Prenatal exposure to toluene results in abnormal neurogenesis and migration in rat somatosensory cortex. *Pediatr Res* 47:362-368.

Gospe Jr, SM; Saeed, DB; Zhou, SS; et al. (1994) The effects of high-dose toluene on embryonic development in the rat. *Pediatr Res* 36:811-5.

Gospe Jr, SM; Zhou, SS; Saeed, DB; et al. (1996) Development of a rat model of toluene-abuse embryopathy. *Pediatr Res* 40:82-87.

Hsieh, GC; Sharma, RP; Parker, RD. (1989) Immunotoxicological evaluation of toluene exposure via drinking water in mice. *Environ Res* 49:93-103.

Hsieh, GC; Sharma, RP; Parker, RD; et al. (1990a) Evaluation of toluene exposure via drinking water on levels of regional brain biogenic monoamines and their metabolites in CD-1 mice. *Ecotoxicol Environ Saf* 20:175-184.

Hsieh, GC; Parker, RDR; Sharma, RP; et al. (1990b) Subclinical effects of ground water contaminants. III. Effects of repeated oral exposure to combinations of benzene and toluene on immunologic responses in mice. *Arch Toxicol* 64:320-328.

Hsieh, GC; Sharma, RP; Parker, RD. (1990c) Subclinical effects of groundwater contaminants. Effects of repeated oral exposure to combinations of benzene and toluene on regional brain monoamine metabolism in mice. *Arch Toxicol* 64:669-676.

Hsieh, GC; Sharma, RP; Parker, RD. (1991) Hypothalamic-pituitary-adrenocortical axis activity and immune function after oral exposure to benzene and toluene. *Immunopharmacol* 21:23-31.

Huff, J. (2003) Absence of carcinogenic activity in Fischer rats and B6C3F1 mice following 103-week inhalation exposures to toluene. *Int J Occup Environ Health* 9:138-146.

Kamijima, M; Nakazawa, Y; Yamakawa, M; et al. (1994) Metabolic acidosis and renal tubular injury due to pure toluene inhalation. *Arch Environ Health* 49:410-3.

Kroeger, RM; Moore, RJ; Lehman, TH; et al. (1980) Recurrent urinary calculi associated with toluene sniffing. *J Urol* 123:89-91.

Luster, MI; Portier, C; Pait, DG; et al. (1992) Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. *Fund Appl Toxicol* 18:200-210.

Luster, MI; Portier, C; Pait, DG; et al. (1993) Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. *Fund Appl Toxicol* 21:71-82.

Maltoni, C; Ciliberti, A; Pinto, C; et al. (1997) Results of long-term experimental carcinogenicity studies of the effects of gasoline, correlated fuels, and major gasoline aromatics on rats. *Ann NY Acad Sci* 837:15-52.

NTP (National Toxicology Program). (1990) Toxicology and carcinogenesis studies of toluene (CAS No. 108-88-3) in F344/N rats and B5C3F1 mice (inhalation studies). Public Health Service, U.S. Department of Health and Human Services; NTP TR 371. Available from: National Institute of Environmental Health Sciences, Research Triangle Park, NC.

O'Brien, ET; Yeoman, WB; Hobby, JA. (1971) Hepatorenal damage from toluene in a "glue sniffer." Br Med J 2(752):29-30.

Streicher, HZ; Gabow, PA; Moss, AH; et al. (1981) Syndromes of toluene sniffing in adults. Ann Intern Med 94:758-62.

Taher, SM; Anderson, RJ; MacCartney, R; et al. (1974) Renal tubular acidosis associated with toluene "sniffing." N Engl J Med 290:765-768.

U.S. EPA. (Environmental Protection Agency). (2000) Benchmark dose technical support document [external review draft]. EPA/630/R-00/001. Available from: [http://www.epa.gov/raf/publications/pdfs/BMD-EXTERNAL\\_10\\_13\\_2000.PDF](http://www.epa.gov/raf/publications/pdfs/BMD-EXTERNAL_10_13_2000.PDF).

U.S. EPA. (2001) Benchmark dose software (BMDS) version 1.3.

U.S. EPA. (2005). Toxicological review of toluene in support of summary information on the Integrated Risk Information System (IRIS).

---

#### **\_VI.B. Inhalation RfC References**

Abbate, C; Giorgianni, C; Munao, F; et al. (1993) Neurotoxicity induced by exposure to toluene: an electrophysiologic study. Int Arch Occup Environ Health 64:389-392.

Andersen, I; Lundqvist, GR; Molhave, L; et al. (1983) Human response to controlled levels of toluene in six-hour exposures. Scand J Work Environ Health 9:405-418.

Antti-Poika, M; Juntunen, J; Matikainen, E; et al. (1985) Occupational exposure to toluene: neurotoxic effects with special emphasis on drinking habits. Int Arch Occup Environ Health 56:31-40.

Aranyi, C; O'Shea, WJ; Sherwood, RL; et al. (1985) Effects of toluene inhalation on pulmonary host defenses of mice. Toxicol Lett 25:103-10.

Baelum, J; Andersen, I; Lundqvist, GR; et al. (1985) Response of solvent-exposed printers and unexposed controls to six-hour toluene exposure. Scand J Work Environ Health 11:271-280.

Baelum, J; Lundqvist, G; Molhave, L; et al. (1990) Human response to varying concentrations of toluene. Int Arch Occup Environ Health 62:65-71.

Boey, KW; Foo, SC; Jeyaratnam, J. (1997) Effects of occupational exposure to toluene: a neuropsychological study on workers in Singapore. Ann Acad Med Singapore 26:84-7.

Campagna, D; Stengel, B; Mergler, D; et al. (2001) Color vision and occupational toluene exposure. Neurotoxicol Teratol 23:473-480.

Cavalleri, A; Gobba, F; Nicali, E; et al. (2000) Dose-related color vision impairment in toluene-exposed workers. Arch Env Health 55:399-404.

- Chouanieri, D; Wild, P; Fontana, JM; et al. (2002) Neurobehavioral disturbances arising from occupational toluene exposure. *Am J Ind Med* 41:77-88.
- CIIT (Chemical Industry Institute of Toxicology). (1980) A twenty-four month inhalation toxicology study in Fischer-344 rats exposed to atmospheric toluene. Conducted by Industrial Bio-Test Laboratories, Inc., Decatur, IL, and Experimental Pathology Laboratories, Inc., Raleigh, NC, for CIIT, Research Triangle Park, NC.
- Echeverria, D; Fine, L; Langolf, G; et al. (1989) Acute neurobehavioral effects of toluene. *Br J Ind Med* 46:483-495.
- Eller, N., B. Netterstrom and P. Laursen. (1999) Risk of chronic effects on the central nervous system at low toluene exposure. *Occup. Med.* 49(6): 389-395.
- Foo, SC; Jeyaratnam, J; D. Koh, D. (1990) Chronic neurobehavioral effects of toluene. *Br J Ind Med* 47:480-484.
- Lee, B; Lee, S; Lee, K; et al. (1988) Dose-dependent increase in subjective symptom prevalence among toluene-exposed workers. *Ind Health* 26:11-23.
- Morata, TC; Fiorini, AC; Fischer, FM; et al. (1997) Toluene-induced hearing loss among rotogravure printing workers. *Scand J Work Environ Health* 23:289-98.
- Murata, K; Araki, S; Yokoyama, K; et al. (1993) Cardiac autonomic dysfunction in rotogravure printers exposed to toluene in relation to peripheral nerve conduction. *Ind Health* 31:79-90.
- Muttray, A; Wolters, V; Mayer-Popken, O; et al. (1995) Effect of subacute occupational exposure to toluene on color vision. *Int J Occup Med Environ Health* 8:339-45.
- Nakatsuka, H; Watanabe, T; Takeuchi, Y; et al. (1992) Absence of blue-yellow color vision loss among workers exposed to toluene or tetrachloroethylene, mostly at levels below exposure limits. *Int Arch Occup Environ Health* 64:113-117.
- Neubert, D; Gericke, C; Hanke, B; et al. (2001) Multicenter field trial on possible health effects of toluene. II. Cross-sectional evaluation of acute low-level exposure. *Toxicology* 168:139-183.
- NTP (National Toxicology Program). (1990) Toxicology and carcinogenesis studies of toluene (CAS No. 108-88-3) in F344/N rats and B5C3F1 mice (inhalation studies). Public Health Service, U.S. Department of Health and Human Services; NTP TR 371. Available from: National Institute of Environmental Health Sciences, Research Triangle Park, NC.
- Orbaek, P; Nise, G. (1989) Neurasthenic complaints and psychometric function of toluene-exposed rotogravure printers. *Am J Ind Med* 16:67-77.
- Pelekis, M; Gephardt, LA; Lerman, SE. (2001) Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile compounds. *Regul Toxicol Pharmacol* 33:12-20.

Poon, R; Chu, IH; Bjarnason, S; et al. (1994) Inhalation toxicity study of methanol, toluene, and methanol/toluene mixtures in rats: effects of 28-day exposure. *Toxicol Ind Health* 10:231-245.

Pryor, GT; Rebert, CS; Dickinson, J; et al. (1984) Factors affecting toluene-induced ototoxicity in rats. *Neurobehav.Toxicol Teratol* 6:223-238.

Rebert, CS; Matteucci, MJ; Pryor, GT. (1989a) Acute electrophysiologic effects of inhaled toluene on adult male Long-Evans rats. *Pharmacol Biochem Behav* 33:157-165.

Rebert, CS; Matteucci, MJ; Pryor, GT. (1989b) Multimodal effects of acute exposure to toluene evidenced by sensory-evoked potentials from Fischer-344 rats. *Pharmacol Biochem Behavior* 32:757-768.

Schaper, M; Demes, P; Zupanic, M; et al. (2003) Occupational toluene exposure and auditory function: results from a follow-up study. *Ann Occup Hyg* 47:493-502.

Seeber, A; Schaper, M; Zupanic, M; et al. (2004) Toluene exposure below 50 ppm and cognitive function: a follow-up study with four repeated measurements in rotogravure printing plants. *Int Arch Occup Environ Health* 77:1-9.

Stengel, B; Cenee, S; Limasset, JC; et al. (1998) Immunologic and renal markers among photogravure printers exposed to toluene. *Scand J Work Environ Health* 24:276-284.

Tanaka, K; Maeda, T; Kobayashi, T; et al. (2003) A survey of urinary hippuric acid and subjective symptoms among occupational low toluene exposed workers. *Fukushima J Med Sci* 49:129-39.

U.S. EPA. (Environmental Protection Agency). (1994) Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry. EPA/600/8-90/066F. Available from: National Technical Information Service (NTIS), Springfield, VA; PB2000-500023, and <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=71993>.

U.S. EPA. (2005). Toxicological review of toluene in support of summary information on the Integrated Risk Information System (IRIS).

Von Euler, M; Pham, TM; Hillefors, M; et al. (2000) Inhalation of low concentrations of toluene induces persistent effects on a learning retention task, beam-walk performance, and cerebrocortical size in the rat. *Exp Neurol* 163:1-8.

Vrca, A; Bozicevic, D; Karacic, V; et al. (1995) Visual evoked potentials in individuals exposed to long-term low concentrations of toluene. *Arch Toxicol* 69:337-40.

Vrca, A; Karacic, V; Bozicevic, D; et al. (1996) Brainstem auditory evoked potentials in individuals exposed to long-term low concentrations of toluene. *Am J Ind Med* 30:62-66.

Vrca, A; Bozicevic, D; Bozikov, V; et al. (1997) Brain stem evoked potentials and visual evoked potentials in relation to the length of occupational exposure to low levels of toluene. *Acta Medica Croatica*. 51:215-219.

Wood, RW; Rees, DC; Laties, VG. (1983) Behavioral effects of toluene are modulated by stimulus control. *Toxicol Appl Pharmacol* 68:462-472.

Yin, S; Li, G; Hu, Y; et al. (1987) Symptoms and signs of workers exposed to benzene, toluene or the combination. *Ind Health* 25:113-130.

Zavalic, M; Mandic, Z; Turk, R; et al. (1998) Quantitative assessment of color vision impairment in workers exposed to toluene. *Am J Ind Med* 33:297-304.

Zavalic, M; Mandic, Z; Turk, R; et al. (1998b) Assessment of colour vision impairment in male workers exposed to toluene generally above occupational exposure limits. *Occup Med* 48:175-180.

Zavalic, M; Mandic, Z; Turk, R; et al. (1998c) Qualitative color vision impairment in toluene-exposed workers. *Int Arch Occup Environ Health* 71:194-200.

Zupanic, M; Demes, P; Seeber, A. (2002) Psychomotor performance and subjective symptoms at low level toluene exposure. *Occup Environ Med* 59:263-268.

## **APPENDIX B. DESCRIPTION OF LITERATURE SEARCH PROCESS FOR TOLUENE**

The IRIS Toxicological Review (U.S. EPA, 2005) contained a thorough review of oral toxicity data on toluene, so searches were limited to studies published since 2004. The search for additional studies of toluene included terms to identify human exposure studies (epidemiologic, occupational) and animal studies for all relevant noncancer endpoints. The search included health effects and toxicity information available from the U.S. EPA (IRIS), ATSDR, and other relevant federal, state, or international governmental or quasi-governmental agencies, including, but not limited to ACGIH, NIOSH, OSHA, NTP, IARC, WHO, and CalEPA. In addition, electronic databases, including CURRENT CONTENTS, MEDLINE, TOXLINE, BIOSIS/TOXCENTER, TSCATS/TSCATS2, CCRIS, DART/ETIC, GENETOX, HSDB, and RTECS, were searched. Results of the electronic searches of these databases are shown in Table B-1. An electronic listing of all results of the gross literature review (including titles, references and abstracts) and a tabular summary of the search results were provided to U.S. EPA.

A toxicologist screened the literature searches based on review of abstracts and titles for studies pertaining to the health effects from subchronic oral exposure to toluene in humans and animals. Decisions about whether to further consider a particular citation were based on the scientific judgment of the toxicologist, based on reading the abstract provided in the literature search output. Studies that were not considered pertinent were not retrieved. Citations may also have been excluded after retrieval and review of the article by the toxicologist. A study may have been excluded if its scope was outside the scope of the use under consideration, if it was not relevant or appropriate, if its study design was inadequate, or if the study showed inadequacy of quality control or flaws in the interpretation of results.

No new pertinent studies were identified.



**Table B-1. Summary of Electronic Database Searches for Toluene**

| Chemical/<br>CASRN/<br>108-88-3 | PUBMED<br>+ PubMed cancer<br>subset = replaces<br>CANCERLIT                                                                                                                                                                                     | TOXLINE<br>Special<br>(on<br>TOXNET) | BIOSIS<br>(STN) update                                                                                                                                                                                       | TSCATS 2                           | CCRIS                  | DART/ETIC<br>(not PubMed)               | GENE-<br>TOX               | HSDB                                                                                   | RTECS               | Current<br>Contents (file<br>440<br>DIALOG)<br>SF=CLIN,<br>LIFE and<br>AGRI)<br>AND<br>NOT<br>dt=contents                         |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|------------------------|-----------------------------------------|----------------------------|----------------------------------------------------------------------------------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Dates Searched                  | 2004–2007                                                                                                                                                                                                                                       | 2004–2007                            | UP >19991231<br>AND<br><br>PY>2003                                                                                                                                                                           | TSCATS2<br>only                    | not date<br>limited    | 2004–2007                               | not date<br>limited        | not date<br>limited                                                                    | not date<br>limited | last 6 months<br>(ud=20070101<br>:20070808)                                                                                       |
| Toluene<br><br>108-88-3         | Tox stg used<br><br><b>183</b> others<br>downloaded—<br>downloaded<br><br>( <b>27</b> for in<br>vitro/genotox*<br>separated out—<br>less relevant)<br><b>PLUS</b><br><br><b>78</b> for in<br>process/publisher<br>—and toluene in<br>title only | no new<br>toluene<br>studies         | 387 cites were<br>found after<br>eliminating<br>PubMed dupes<br>and using TOX<br>stg<br><br>downloaded<br>only those<br><b>199 TITLES</b><br>only that were<br>indexed to<br>/animal<br>(including<br>human) | 0 received by<br>EPA since<br>2004 | <b>DO NOT<br/>NEED</b> | 7 but some are<br>not toluene<br>itself | <b>DO<br/>NOT<br/>NEED</b> | <b>LARGE<br/>HSDB<br/>record<br/>down-<br/>loaded<br/>health<br/>sections<br/>only</b> | <b>1</b>            | Removed<br>duplicates with<br>Medline—no<br>toc records and<br>limited to<br>3 subfiles<br><br><b>2</b> titles only<br>downloaded |

# **TOLUENE**

## **(Group 3)**

For definition of Groups, see Preamble Evaluation.

**VOL.:** 71 (1999) (p. 829)

**CAS No.:** 108-88-3

**Chem. Abstr. Name:** Methylbenzene

### **5. Summary of Data Reported and Evaluation**

#### **5.1 Exposure data**

Toluene is an industrial chemical produced in high volume, that is used in blending gasoline and as a solvent. Occupational exposure to toluene is extensive and occurs in its production and during the manufacture and use of toluene-containing paints, thinners, cleaning agents, coatings and adhesives. It is commonly detected in ambient air and at low levels in water.

#### **5.2 Human carcinogenicity data**

Toluene was mentioned as an exposure in eight studies. Two were community-based case-control studies, one of which involved brain cancer and one involved several types of cancer. Of the six industry-based studies, three were analysed as cohort studies and three were configured as nested case-control studies of one or a few types of cancer. In two of the studies, that of shoe-manufacturing workers in the United States and particularly that of Swedish rotogravure printers, it was believed that toluene was the predominant exposure; in the other studies, there were probably concomitant exposures. Cancers of most sites were not significantly associated with toluene exposure in any study. Stomach cancer mortality was significantly elevated in the Swedish rotogravure printers study, it was slightly, though not significantly, elevated in two other studies, and it was not associated at all in a fourth. Rates of lung cancer were significantly elevated in the cohort of shoe manufacturers and in the Swedish cohort of rotogravure printers, but was not associated at all in two other studies. Colorectal cancer was significantly elevated in the Swedish rotogravure printers study and in the Canadian case-control study, and colon cancer was nonsignificantly elevated in the shoe manufacturers cohort. While results on leukaemias and lymphomas generally showed no association, these were based on small numbers. Considering the multiple exposure circumstances in most studies and the weak consistency of findings, these results are not strong enough to conclude that there is an association.

#### **5.3 Animal carcinogenicity data**

Toluene was tested for carcinogenicity by inhalation exposure in one study in mice and in one study in rats. No significant increase in the incidence of tumours was observed. Repeated application of toluene to the skin of mice did not result in an increased incidence of skin tumours.

#### 5.4 Other relevant data

Toluene is mainly converted to benzyl alcohol and excreted as hippurate. Its toxicokinetics in humans have been extensively studied.

Toluene toxicity is most prominent in the central nervous system after acute and chronic exposure. Reproductive toxicity has been observed in exposed humans and rats.

In the more recent cytogenetic studies in occupationally exposed populations, increases in chromosomal aberrations (two studies), micronuclei (one study) and of DNA strand breaks (one study) have been described. These effects have also been observed in rats and mice in some studies and in cultured mammalian cells. DNA adducts have not been detected.

#### 5.5 Evaluation

There is *inadequate evidence* in humans for the carcinogenicity of toluene.

There is *evidence suggesting lack of carcinogenicity* of toluene in experimental animals.

#### Overall evaluation

Toluene is *not classifiable as to its carcinogenicity to humans (Group 3)*.


For definition of the italicized terms, see Preamble Evaluation.

**Previous evaluation:** Vol. 47 (1989)

#### Synonyms

- Methylbenzol
- Phenylmethane

# Toluene

|                                     |                                                                                                                            |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| <b>BAT</b>                          | 1.0 mg toluene/l blood<br>Sampling time: end of exposure<br>3.0 mg <i>o</i> -cresol/l urine<br>Sampling time: end of shift |
| <b>Date of evaluation</b>           | 1995                                                                                                                       |
| <b>CAS No.</b>                      | 108-88-3                                                                                                                   |
| <b>Synonyms</b>                     | Methylbenzene<br>Toluol<br>Phenylmethane                                                                                   |
| <b>Formula</b>                      | C <sub>7</sub> H <sub>8</sub><br>        |
| <b>Molecular weight</b>             | 92.13                                                                                                                      |
| <b>Melting point</b>                | −95 °C                                                                                                                     |
| <b>Boiling point</b>                | 110.8 °C                                                                                                                   |
| <b>Vapour pressure at 20 °C</b>     | 29 hPa                                                                                                                     |
| <b>MAK [last established: 1993]</b> | 50 ml/m <sup>3</sup> (ppm) 190 mg/m <sup>3</sup>                                                                           |

## 1 Metabolism and Kinetics

### 1.1 Pharmacokinetics

Absorption of toluene at the workplace occurs mainly via inhalation. Like other highly volatile aromatic hydrocarbons, depending upon the type of activity carried out, it can also be absorbed in not inconsiderable amounts via the intact skin (13).

Pulmonary uptake of toluene takes place rapidly, so that at constant ambient air concentrations, concentrations of the substance are reached in blood as little as 15 minutes after the beginning of exposure which are not greatly exceeded even after exposure for

longer periods of time (6, 10). Values for the pulmonary retention of toluene vary between 36.6 % and 53.2 % (25, 20).

After the end of exposure, some of the retained toluene is exhaled unchanged at levels variously reported in the literature as 4 % and 13.5 % to 16 % (25, 30, 31).

Immediately after exposure the toluene concentration in alveolar air decreases much more rapidly than that in blood (6, 30, 31). This effect can be explained by a fast elimination of toluene from the lung compartments. About 30 minutes after exposure the rate of toluene exhalation decreases very rapidly. Clear interindividual and intraindividual differences are described in the subsequent pulmonary elimination phase (30). The data found in the literature often suffer from the fact that the kinetic processes were not followed for long enough and that the theoretical processing of the data was not always carried out using modern methods of pharmacokinetic analysis.

The kinetics of the blood toluene concentrations after exposure to toluene are multiphasic. While during the first hour after the end of exposure an elimination half-time of about 30 minutes is given (6, 31), later the half-time is about 7.5 hours (9). After 24 hours the toluene has been almost completely eliminated from the blood (31).

Irrespective of this fact the question remains as to whether any of the absorbed toluene is distributed in the organism in "deeper compartments" from which elimination takes place only very slowly.

Animal experiments (24) indicate that the adipose tissue could represent a "deep compartment" for toluene. Different exposure profiles play an important role for the accumulation of toluene in adipose tissue. The question of the accumulation of toluene in "deeper compartments" in humans has also been discussed (16).

## 1.2 Conditions of Exposure at the Workplace

During physical activity the pharmacokinetics of toluene in humans changes (6, 8). Due to increased ventilation during increased physical activity, an increased substrate concentration of toluene is available to the metabolising enzyme system. This can lead to an increased rate of metabolism (12). This means that relationships between toluene exposure and excretion of metabolites which were established in laboratory experiments with persons at rest may not be applied without modification to situations where people are carrying out physical work.

## 1.3 Metabolism

The toluene which remains in the body is almost completely oxidised to benzoic acid. Of this, 10 % to 20 % appears as the glucuronide in urine. Approximately 70 % of the benzoic acid is bound to glycine and excreted in urine as hippuric acid (22). The elimination half-time of hippuric acid is 2 to 3 hours (22, 23) (Figure 1).

According to more recent investigations toluene is not only metabolised, as formerly assumed, on the aliphatic side chain but, to a lesser extent (approx. 0.05 %), the aromatic ring is also oxidised and the product, *o*-cresol, is excreted in the urine (2, 5).




**Fig. 1:** Metabolism of toluene in humans

## 2 Critical Toxicity

Like other highly volatile aromatic substances, toluene is acutely toxic—mainly to the central nervous system.

Since it was reported that increases in the size of the liver can be observed three times more frequently in workers exposed long-term to toluene than in control persons (15), the question of the hepatotoxicity of toluene after long-term exposure has been raised.

Although changes in the blood count have also been seen after long-term exposure to high levels of toluene—although simultaneous exposure to benzene could not be excluded completely—toluene has not yet been shown to have leukaemogenic potency. In view of the metabolic transformation of toluene to *o*-cresol, however, such effects cannot be completely excluded.

The BAT value described here is based exclusively, however, on the known health effects of toluene on which the currently valid MAK value is also based (11).

## 3 Exposure and Effect

In comprehensive documentation, the WHO working group "Internationally recommended health-based occupational exposure limits to selected organic solvents" (26) has collected all the currently available data on toluene exposure and effects on the human organism. In the context discussed here, the following observations are emphasised.

The results of a study with volunteers (21) yielded the relationship between the concentration of toluene in ambient air and the blood toluene concentration after 8-hour exposure to toluene shown in Figure 2.

After fatal intoxication of a young person due to toluene sniffing, the blood toluene concentration was 50 mg/l (19).

A clinical-epidemiological investigation of printing workers exposed to toluene indicated that toluene concentrations below 4 mg/l blood do not cause liver damage even long-term (28).

## 4 Selection of the Indicators

For the biological monitoring of persons exposed to toluene the following parameters are at present available:

- determination of the toluene concentration in alveolar air
- determination of the toluene concentration in blood
- determination of the hippuric acid excreted in urine
- determination of the *o*-cresol excreted in urine.

Since the critical toxicity on which the MAK value is based is the toxicity of toluene itself, determination of toluene is particularly suitable for the evaluation of internal exposure. Determination of the concentration of the toxic substance in **alveolar air** seems at first sight extremely practicable for the attending physician, the employees and also the analyst, difficulties frequently occur, however, in the exact sampling of alveolar air, as well as transport and storage of the samples. Moreover, exact timing of the sampling is of great importance due to the initial "wash-out" phase from the lung compartments (see Section 1.1).

These difficulties are avoided if toluene is determined **in blood**. If it is possible to sample the blood within 5 minutes after the end of the shift, as has proved possible even in large companies, then the error made in comparison to the actual steady state concentration should be greatly below 10 %. It is true that the sampling of blood is more inconvenient for the employee than the sampling of exhaled air, but an enormous increase in diagnostic and analytical reliability is gained (including avoidance of exogenous contamination, no problems with the transport and storage of the samples). Determination of toluene is diagnostically and analytically just as sensitive and specific. Ambient air concentrations of over 1 ppm are already reflected in toluene concentrations in blood which can be ascertained specifically, sensitively and exactly. Therefore differentiation between occupationally exposed and non-occupationally exposed persons is possible at any time without doubt. The diagnostic specificity results from the fact that toluene normally does not occur in blood and the analytical procedures used today allow separation, and thus differentiation, of interfering substances at any time. The determination of toluene in blood represents, therefore, the most sensitive and specific diagnostic monitoring procedure available at present.

Measurement of the urinary **excretion of hippuric acid**, which is widely practiced, has increasingly proved to be unsuitable for health surveillance of persons exposed to toluene. Hippuric acid is excreted in the urine physiologically in interindividually greatly differing concentrations. The average amount normally excreted is approx. 1 g/l urine with an upper normal level of 2.5 g/l (4, 27). Lifestyle and dietary factors can influence the physiological excretion of hippuric acid considerably (27). This limits diagnostic specificity and sensitivity to such an extent that in individual cases neither the existence of exposure nor its level can be deduced from the amount or the concentration of the excreted hippuric acid.

**Excretion of *o*-cresol** as a parameter of exposure fulfils the demands of diagnostic specificity. Compared to determination of the toluene concentration, assay of the *o*-cresol level has the additional advantage that the latter substance is closer to the possible toxic principle of toluene, a metabolically formed epoxide intermediate, than the toxic substance itself.



## 5 Methodology

The gas chromatographic head-space method has proved to be a practicable and at the same time analytically specific, exact and sensitive method for the determination of the toluene concentration in blood (1, 17). In view of the circumstances of uptake, distribution and excretion of toluene during exposure, the blood samples should be taken exactly at the end of the work shift.

## 6 Evaluation of the BAT Value

As a result of the conditions of occupational health and safety mostly found today, the concentrations of toxic substances occurring at the workplace are no longer within the range of values at which adverse effects on the health of the employees can be observed. In particular in large companies, due to measures of occupational hygiene, the concentrations of toxic substances are mostly considerably below the currently valid MAK values. Therefore it is becoming increasingly difficult to evaluate threshold limit values in biological material on the basis of a correlation between the exposure parameter and the effects on health seen in sufficiently large collectives. On the other hand, the MAK values are based on scientifically founded experience of the relationship between the concentrations of the toxic substance occurring at the workplace and observed adverse effects on health. This experience dates from times when the limitations of occupational hygiene resulted in ambient air concentrations which frequently had adverse effects on health.

A BAT value for toluene in blood cannot be evaluated on the basis of clinical-epidemiological investigations. Therefore a procedure is used which allows, via the estimation of the external exposure—that is, determination of the ambient air concentration—the threshold for the toluene concentration in blood to be established on the basis of the clinical experience on which the MAK value is based (3).

The BAT value determined with this procedure is based finally on a correlation analysis of the relationship between the external and internal exposure. The average ambient air concentrations measured during the shift and the toluene concentrations measured in the venous blood at the end of the work shift are taken as parameters for these two quantities. As the actual amount of a toxic substance to which a person is exposed (effective external load) (32) cannot be deduced from the ambient air concentration, in the procedure chosen here the ambient air concentration serves only as an orienting parameter. The approach is based on the consideration that the varying individual influences at the workplace (e.g. differing respiratory minute volumes) have been allowed for indirectly when setting the currently valid MAK value. Observation of the MAK value is also checked by measuring the average ambient air concentration during the shift.

The BAT value calculated here is based on the investigation of 239 workers occupationally exposed to toluene while employed in three factories and nine different areas of work. During the 8-hour work period, samples of the ambient air were taken at constant intervals and analysed for toluene ( $n = 183$ ). The toluene concentration in venous blood was determined in samples collected immediately after the end of the work period (3) (Figure 2). The correlation between the two parameters found in the field studies at the workplace corresponds well with the beginning of the relationship found in the laboratory experiment (21) with individual test persons.

On the basis of the above-mentioned correlation, a toluene concentration in the ambient air at the level of the currently valid MAK value (50 ppm) corresponds to a toluene concentration in the blood of 890  $\mu\text{g/l}$  with an upper and lower confidence limit of 960  $\mu\text{g/l}$  and 840  $\mu\text{g/l}$ , respectively.

Brugnone *et al.* (7) found close relationships between the toluene concentration in the ambient air and the concentration of this aromatic compound in blood in an investigation of workers exposed to toluene who were employed in printing shops and shoe factories. According to the equation given there, a toluene concentration at the level of the currently valid MAK value corresponds to a toluene concentration of 542  $\mu\text{g/l}$  blood. For the 65 workers the toluene concentration in the air was collected during the shift using personal air samplers. The blood was sampled after the shift.




**Fig. 2:** Relationship between external and internal toluene exposure under workplace conditions ( $n = 183$ )

In a study of 50 workers exposed to toluene a good correlation was found between the toluene concentrations in the ambient air measured by personal air sampling and the

toluene level in blood (14). According to this study an ambient air concentration of 50 ppm corresponds to a toluene concentration in blood of 740 µg/l.

Nise *et al.* investigated the external and internal toluene exposure of rotary-press operators ( $n = 37$ ) occupationally exposed to toluene. The median value of the toluene concentration in the ambient air was 115 mg/m<sup>3</sup> (corresponding to 30 ppm) for a sub-collective of 11 workers. Under these conditions of exposure toluene concentrations between 129 µg/l and 404 µg/l were measured. The median value for the toluene concentration was 212 µg/l (18).

In an experimental laboratory study, 7 male test persons were subjected to toluene and/or xylene fumes. After 6.5 hours of exposure at 50 ppm there was a mean toluene level in the blood of 781 µg/l (29).

On the basis of the relationship between the toluene concentration in the ambient air and in blood (Figure 2) and taking into consideration the recent literature, a BAT value of

### 1.0 mg/l

has been set for the toluene concentration in blood. The sample should be taken immediately after the end of the shift. This value is calculated from the correlation above. It is based on the definition of the BAT value as the maximum permissible quantity of a chemical substance in biological materials which does not endanger the general health of the individual when it is observed. Observation of this value means that the worker must not be exposed at his workplace to levels greater than the MAK value.

The values discussed above from other studies are calculated from correlations between external and internal toluene exposures. They correspond to mean toluene levels in blood which occur during exposure at the level of the threshold limit values in air. These values are therefore systematically lower than the toluene level in blood which is still compatible with the observation of the MAK value at the workplace.

## 7 Interpretation of the Data

Statements on the level of internal exposure of the organism to toluene and the adherence to BAT values presuppose blood sampling at the end of the work shift. Otherwise the general conditions for the evaluation of BAT values apply.

Occupational-medical health surveillance of persons exposed to toluene should otherwise in the Federal Republic of Germany be carried out according to the Berufsgenossenschaftlicher Grundsatz G29 (guideline issued by the Employers' Liability Insurance Association). Here time intervals for follow-up examinations are given. With borderline findings more frequent check-ups may be appropriate.

## 8 References

1. Angerer, J., Szadkowski, D., Manz, A., Pett, R., Lehnert, G.: *Int. Arch. Occup. Environ. Health* 31 (1973), 1–5
2. Angerer, J., Baumann, K.: XIX. International Congress on Occupational Health, Dubrovnik 25.–30.9.1978
3. Angerer, J., Behling, K.: *Int. Arch. Occup. Environ. Health* 48 (1981), 137–146
4. Angerer, J.: *Int. Arch. Occup. Environ. Health* 36 (1976), 287–297
5. Angerer, J.: Occupational chronic exposure to organic solvents: VII. Metabolism of toluene in man. *Int. Arch. Occup. Environ. Health* 43 (1979), 63–67
6. Astrand, I., Ehrner-Samuel, H., Kilbom, A., Ovrup, P.: *Work Environ. Health* 9 (1972), 119–130
7. Brugnone, F., De Rosa, E., Perbellini, L., Bartolucci, G.B.: Toluene concentrations in the blood and alveolar air of workers during the workshift and the morning after, *Br. J. Ind. Med.* 43 (1986), 56–61
8. Brugnone, F., Perbellini, L., Gaffuri, E., Apostoli, P.: *Int. Arch. Occup. Environ. Health* 47 (1980), 245–261
9. Brugnone, F., Perbellini, L., Grigolini, L., Cazzadori, A., Gaffuri, E.: *Int. Arch. Arbeitsmed.* 38 (1976), 45–54
10. Carlsson, A., Lindqvist, Th.: *Scand. J. Work Environ. Health* 3 (1977), 135–143
11. Greim, H. (Ed.): *Toxikologisch-arbeitsmedizinische Begründung von MAK-Werten*, Toluol, VCH-Verlagsgesellschaft, Weinheim (1993)
12. Droz, P. O., Fernandez, J. G.: *Int. Arch. Occup. Environ. Health* 38 (1977), 231–246
13. Dutkiewicz, T., Tyras, H.: *Int. Arch. Gewerbepath. Gewerbehyg.* 24 (1968), 253–257
14. Foo, S.C., Phoon, W.O., Khoo, N.Y.: *Am. Ind. Hyg. Assoc. J.* 49 (5) (1988), 255–258
15. Greenburg, L., Mayers, M. R., Heimann, H., Moskowitz, S.: *J. Amer. Med. Ass.* 118 (1942), 573–578
16. Konietzko, H., Keilbach, J., Drysch, K.: *Int. Arch. Occup. Environ. Health* 46 (1980), 53–58
17. Machata, G., Angerer, J.: *Analytische Methoden zur Prüfung gesundheitsschädlicher Arbeitsstoffe. Band 2, Analysen in biologischem Material.* Verlag Chemie, Weinheim, 3. Lieferung 1978 (Ed.: Henschler, D.)
18. Nise, G., Attewell, R., Skerfving, S., Ørbok, P.: *Br. J. Ind. Med.* 46 (1989), 407–411
19. Nomiya, K., Nomiya, H.: *Int. Arch. Occup. Environ. Health* 41 (1978), 55–64
20. Nomiya, K., Nomiya, H.: *Int. Arch. Occup. Health* 32 (1974), 85–91
21. von Oettingen, W. F., Neal, P. A., Donahue, D. D.: *J. Amer. Med. Ass.* 118 (1942), 579–584
22. Ogata, M., Tomokuni, K., Takatsuka, Y.: *Brit. J. Industr. Med.* 27 (1970), 43–50
23. Piotrowski, J.: *Med. Pracy* 18 (1967), 213–223
24. Pyykkö, K., Tähti, H., Vapaatalo, H.: *Arch. Toxicol.* 38 (1977), 169–176
25. Srbová, J., Teisinger, J.: *Pracovní Lekarstvi* 4 (1952), 41
26. Study Group: Internationally recommended health-based occupational exposure limits to selected organic solvents. WHO, Genf 1979
27. Szadkowski, D., Borkamp, A., Lehnert G.: Hippursäureausscheidung im Harn in Abhängigkeit von Tagesrhythmik und alimentären Einflüssen. *Int. Arch. Occup. Environ. Health* 45 (1980), 141–152
28. Szadkowski, D.: *Verhandlungen der Deutschen Gesellschaft für Arbeitsmedizin e.V.* 14. Jahrestagung, Hamburg 17–19.10.197 "Arbeitsmedizinische Probleme des Transport und Verkehrswesens" (Eds.: G. Lehnert, D. Szadkowski, H.J. Weber). Stuttgart, Gentner 1975
29. Tardif, R., Laparé, S., Plaa, G.L., Brodeur, J.: Effect of simultaneous exposure to toluene and xylene on their respective biological exposure indices in humans, *Int. Arch. Occup. Environ. Health* 63 (1991), 279–284
30. Veulemans, H., Masschelein, R.: *Int. Arch. Occup. Environ. Health* 42 (1978), 91–103
31. Veulemans, H., Masschelein, R.: *Int. Arch. Occup. Environ. Health* 42 (1978), 105–117

198     *Toluene*

32. Zielhuis, R. L.: International workshop on biological specimen collection, Luxemburg, 18.–22.4.1977

Author: J. Angerer

Approved by the Working Group: 18.04.1995

# Benzene, methyl-: Human health tier II assessment

27 October 2017

## CAS Number: 108-88-3



- Preface
- Chemical Identity
- Import, Manufacture and Use
- Restrictions
- Existing Work Health and Safety Controls
- Health Hazard Information
- Risk Characterisation
- NICNAS Recommendation
- References

## Preface

This assessment was carried out by staff of the National Industrial Chemicals Notification and Assessment Scheme (NICNAS) using the Inventory Multi-tiered Assessment and Prioritisation (IMAP) framework.

The IMAP framework addresses the human health and environmental impacts of previously unassessed industrial chemicals listed on the Australian Inventory of Chemical Substances (the Inventory).

The framework was developed with significant input from stakeholders and provides a more rapid, flexible and transparent approach for the assessment of chemicals listed on the Inventory.

Stage One of the implementation of this framework, which lasted four years from 1 July 2012, examined 3000 chemicals meeting characteristics identified by stakeholders as needing priority assessment. This included chemicals for which NICNAS already held exposure information, chemicals identified as a concern or for which regulatory action had been taken overseas, and chemicals detected in international studies analysing chemicals present in babies' umbilical cord blood.

Stage Two of IMAP began in July 2016. We are continuing to assess chemicals on the Inventory, including chemicals identified as a concern for which action has been taken overseas and chemicals that can be rapidly identified and assessed by using Stage One information. We are also continuing to publish information for chemicals on the Inventory that pose a low risk to human health or the environment or both. This work provides efficiencies and enables us to identify higher risk chemicals requiring assessment.

The IMAP framework is a science and risk-based model designed to align the assessment effort with the human health and environmental impacts of chemicals. It has three tiers of assessment, with the assessment effort increasing with each tier. The Tier I assessment is a high throughput approach using tabulated electronic data. The Tier II assessment is an evaluation of risk on a substance-by-substance or chemical category-by-category basis. Tier III assessments are conducted to address specific concerns that could not be resolved during the Tier II assessment.

These assessments are carried out by staff employed by the Australian Government Department of Health and the Australian Government Department of the Environment and Energy. The human health and environment risk assessments are conducted and published separately, using information available at the time, and may be undertaken at different tiers.

This chemical or group of chemicals are being assessed at Tier II because the Tier I assessment indicated that it needed further investigation.


For more detail on this program please visit: [www.nicnas.gov.au](http://www.nicnas.gov.au)

### Disclaimer

NICNAS has made every effort to assure the quality of information available in this report. However, before relying on it for a specific purpose, users should obtain advice relevant to their particular circumstances. This report has been prepared by NICNAS using a range of sources, including information from databases maintained by third parties, which include data supplied by industry. NICNAS has not verified and cannot guarantee the correctness of all information obtained from those databases. Reproduction or further distribution of this information may be subject to copyright protection. Use of this information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner. NICNAS does not take any responsibility whatsoever for any copyright or other infringements that may be caused by using this information.

### Acronyms & Abbreviations

## Chemical Identity

|                    |                                                                                      |
|--------------------|--------------------------------------------------------------------------------------|
| Synonyms           | Toluene<br>Methylbenzene<br>Toluol<br>Phenylmethane<br>Methacide                     |
| Structural Formula |  |
|                    |                                                                                      |

|                                        |                                                               |
|----------------------------------------|---------------------------------------------------------------|
| Molecular Formula                      | C7H8                                                          |
| Molecular Weight (g/mol)               | 92.14                                                         |
| Appearance and Odour (where available) | Colourless liquid, with a sweet, pungent, benzene-like odour. |
| SMILES                                 | c1(C)ccccc1                                                   |

## Import, Manufacture and Use

### Australian

The following Australian uses were reported under the 2006 High Volume Industrial Chemicals List (HVICL) and other NICNAS calls for information.

The chemical has reported domestic use including:

- cleaning products.

The chemical has reported commercial use including:

- in fuels and solvents;
- in adhesives;
- in printer inks;
- in degreasers; and
- as an aviation fuel additive.

### International

The following international uses have been identified through the European Union Registration, Evaluation and Authorisation of Chemicals (EU REACH) dossier, the European Chemicals Agency Risk Assessment Report (ECHA RAR), the Organisation for Economic Cooperation and Development Screening Information Dataset Initial Assessment Report (OECD SIAR), the European Commission Cosmetic Substances and Ingredients (CosIng) database, the US Agency for Toxic Substances and Disease Registry (ATSDR) report, the International Agency for Research on Cancer (IARC) report and the International Programme on Chemical Safety Environmental Health Criteria (IPCS EHC).

The chemical has reported cosmetic use as an antioxidant and solvent in nail products with a maximum concentration in the finished cosmetic product of 25 %.

The chemical has reported domestic use including as a cleaning agent.

The chemical has reported commercial use including use as a:

- component of gasoline to increase pyrolysis; and
- solvent in paints, coatings, adhesives, inks.

The chemical has reported site-limited use including as an intermediate in the organic synthesis of various chemicals which includes toluene diisocyanate, benzoic acid, and xylene.



Toluene is a component of many petroleum-derived UVCB substances.

## Restrictions

### Australian

The chemical is listed in the following:

- Poisons Standard (Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP)) in Schedule 6 when present at a concentration of > 50 % by volume and otherwise in Schedule 5;
- Australia New Zealand Food Standards Code—Processing Aids—Permitted extraction solvents. Maximum permitted level 1 mg/kg; and
- National Health and Medical Research Council. National Water Quality Management Strategy, Australian Drinking Water Guidelines 6 (2011). The guideline value for health effects is 0.8 mg/L (NHMRC, 2011).

### International

The chemical is listed in the following:

- ASEAN Cosmetic Directive Annex III Part 1 List of substances which cosmetic products must not contain except subject to restrictions and conditions laid down. The chemical is restricted to use in nail products at concentrations < 25 %;
- EU Cosmetic Directive 76/768/EEC Annex III Part 1: List of substances which cosmetic products must not contain except subject to the restrictions and conditions laid down. The chemical can only be used in nail products at concentrations < 25 %;
- Canadian Department of Justice, Hazardous Products Act, ingredient disclosure list (SOR/88-64) current to September 19, 2012. Must be disclosed at concentrations  $\leq 1$  %w/w;
- WHO (World Health Organization) Guidelines for drinking-water quality, Fourth Edition, 2011. The guideline value for the chemical is 0.7 mg/L; and
- US—California Proposition 65—Maximum allowable dose levels (MADLs) for chemicals causing reproductive toxicity. The MADL for the chemical is 7000 µg/d.

## Existing Work Health and Safety Controls

### Hazard Classification

The chemical is classified as hazardous, with the following hazard categories and hazard statements for human health in the Hazardous Chemical Information System (HCIS) (Safe Work Australia):

Skin irritation – category 2; H315 (Causes skin irritation)

Specific target organ toxicity (repeated exposure) – category 2; H373 (May cause damage to organs through prolonged or repeated exposure)

Reproductive toxicity – category 1A; H360 (May damage fertility or the unborn child)

Physical hazard (Flammable liquids) – category 2; H225 (Highly flammable liquid and vapour)

### Exposure Standards

## Australian

The chemical has an exposure standard of 191 mg/m<sup>3</sup> (50 ppm) TWA and 574 mg/m<sup>3</sup> (150 ppm) STEL.

## International

The following exposure standards are identified (Galleria Chemica):

- exposure limits (TWA) of 37–375 mg/m<sup>3</sup> (10–100 ppm) and STEL of 384–760 mg/m<sup>3</sup> (100–200 ppm) in different countries such as USA (California, Hawaii, Minnesota, Tennessee, Washington), Canada (Quebec), Germany, Japan, Norway, Switzerland and the United Kingdom.

# Health Hazard Information

## Toxicokinetics

Following inhalation by humans, 40–60 % of the chemical is absorbed from the respiratory tract. The chemical is absorbed through the skin at a rate of 14–23 mg/cm<sup>2</sup>/h, although absorption from the gastrointestinal (GI) tract appears to be slower (IPCS, 1986).

Toluene is extensively metabolised to produce the major metabolite: hippuric acid, which is excreted in the urine, with benzyl glucuronide also formed in smaller amounts (HSDB, 2012).

## Acute Toxicity

### Oral

The chemical is of low acute toxicity from oral exposure in rats with a median lethal dose (LD50) of 2600–7500 g/kg bw (WHO, 2004).

### Dermal

The chemical is of low acute toxicity from dermal exposure with an LD50 in rabbits of 12125 mg/kg bw (Registry of Toxic Effects of Chemical Substances).

### Inhalation

The chemical is of low acute toxicity from inhalation exposure, with LC50 values in the range of 20000–26000 mg/m<sup>3</sup> for mice, and approximately 45000 mg/m<sup>3</sup> for rats (IPCS, 1986). However, the chemical is known to cause central nervous system (CNS) toxicity immediately after exposure to high concentrations of the chemical by inhalation or ingestion (ATSDR, 2000; IPCS, 1986).

The available information support classification as hazardous with hazard category 'Specific target organ toxicity (single exposure) Category 3' and hazard statement 'May cause drowsiness or dizziness' (H336) in the Hazardous Chemical Information System (HCIS) (Safe Work Australia).

### Observation in humans

Acute exposure of humans to the chemical at concentrations up to 375 mg/m<sup>3</sup> or less for single periods of 20 minutes to 3.5 hours did not result in adverse effects being observed (Government of Canada, 1992). Acute exposure to the chemical in the range of 750–5625 mg/m<sup>3</sup> (200–1500 ppm) caused dose-related central nervous system effects (IPCS, 1986). High acute exposures to the chemical (e.g. 37500 mg/m<sup>3</sup>) during industrial accidents were characterised by initial central nervous system excitative effects (e.g., exhilaration, euphoria, hallucinations), followed by a progressive impairment of consciousness, eventually resulting in seizures and coma (IPCS, 1986).

## Corrosion / Irritation

### Respiratory Irritation

The chemical is not classified as a respiratory irritant. The data available support this classification.

Respiratory tract irritation, particularly in the nasal cavity, has been reported in animal studies with the chemical at concentrations of 600 ppm and greater. However, in lifetime and 28-day studies, no changes were seen in the nasal epithelium following exposure to concentrations of 300 ppm of the chemical (US EPA, 2005).

### Skin Irritation

The chemical is classified as hazardous with hazard category 'Skin irritation Category 2' and hazard statement 'Causes skin irritation' (H315) in the Hazardous Chemical Information System (HCIS) (Safe Work Australia). The data available support this classification.

The chemical is a slight to moderate skin irritant in rabbits and guinea pigs (IPCS, 1986).

### Eye Irritation

The chemical is not classifiable as an eye irritant based on the available data.

The chemical was a slight to severe irritant to the conjunctival membrane in rabbits (WHO, 1986). In the one study where severe irritation was seen, 2 mg was placed into the eye of a rabbit for 24 hours. Mild effects were seen in two studies where 870 µg and 100 mg were applied for 72 hours or 30 seconds respectively before the eyes were rinsed (WHO, 1986). In a more recent study (1995), the chemical produced slight irritation in the eyes of rabbits tested in accordance with good laboratory procedure (GLP) and OECD TG 405 (WHO, 2004).

### Observation in humans

Single, short-term exposures to the chemical (750 mg/m<sup>3</sup> for eight hours) have reportedly caused transient eye and respiratory tract irritation with lachrymation at 1500 mg/m<sup>3</sup> (WHO, 1986). Nasal or ocular irritation in humans has been reported from airborne concentrations of the chemical of 100 ppm or above (US EPA, 2005).

## Sensitisation

### Skin Sensitisation

The chemical did not cause skin sensitisation in a study using the guinea pig maximisation test (WHO, 2004).

## Repeated Dose Toxicity

## Oral

Based on the available information, no hazard classification for repeated dose oral toxicity is recommended.

The principal studies on the chemical, used by the United States Environmental Protection Agency (US EPA) to set a reference dose for chronic oral exposure, were studies where groups of 10 rats or mice/sex/group were administered the chemical in corn oil at doses of 0, 312, 625, 1250, 2500, or 5000 mg/kg bw/day, five days/week for 13 weeks (US EPA, 2005). A no observed adverse effect level (NOAEL) of 312 mg/kg bw/day was set, based on increases in kidney weights of male rats, with a lowest observed adverse effect level (LOAEL) of 625 mg/kg bw/day (US EPA, 2005). The increases in absolute kidney weights were 107 % and 112 % of controls; and the relative kidney weights were 100 % and 106 % of controls for the 312 and 625 mg/kg bw/day dose groups respectively. Although the increases in absolute kidney weight over the controls were slight in the 625 mg/kg bw/day dose group, the change was statistically significant and, due to a dose response relationship, even greater changes were seen at the higher doses. Therefore, the changes were considered to be adverse.

## Inhalation

The chemical is classified as hazardous with hazard category 'Specific target organ toxicity (repeated exposure) Category 2 and hazard statement 'May cause damage to organs through prolonged or repeated exposure' (H373) for repeat dose inhalation toxicity in the Hazardous Chemical Information System (HCIS) (Safe Work Australia).

The chemical has a lowest observed effect level (LOEL) of 600 ppm (2250 mg/m<sup>3</sup>) based on irritation of the upper respiratory tract, specifically the nasal epithelium in female rats (Government of Canada, 1992). However, neurological effects following the inhalation of the chemical were seen at even lower concentrations. One study on 30 male Sprague Dawley (SD) rats exposed to the chemical at a concentration of 80 ppm (302 mg/m<sup>3</sup>) for six hours/day, four days/week for four weeks showed adverse neurobehavioural alterations; the effects were not present after a four-week recovery period (US EPA, 2005).

## Observation in humans

There are a number of studies looking at the occupational inhalation exposure of humans to the chemical. The most sensitive effects, noted after inhalation exposure, were neurological including impaired colour vision, impaired hearing, decreased performance in neurobehavioural analysis, changes in motor and sensory nerve conduction velocity, headache and dizziness. NOAELs in the range of 25–50 ppm of the chemical were identified for individual neurological effects, with statistically significant neurological effects seen in workers in the range of 83–132 ppm. Respiratory irritation and various effects in the eyes and kidneys have also been observed in humans following chronic exposure to the chemical. However, these occurred at higher exposure concentrations than those resulting in neurological effects. The US EPA calculated the arithmetic mean (34 ppm, 128 mg/m<sup>3</sup>) of the available NOAELs from 10 occupational studies that they considered adequate. A neurological function deficit was chosen as the critical effect in these studies, due to the overall preponderance of evidence for this hazard indicator at low doses (US EPA, 2005).

## Genotoxicity

Based on the weight of evidence, the chemical is not mutagenic in mammalian or microbial systems (Government of Canada, 1992).

The chemical was found to be non-genotoxic in a number of in vitro systems. However, in vivo studies on insects, rats and mice produced conflicting results, with chromosomal aberrations in rat bone marrow cells observed in some studies, but not in others. In mice, the induction of micronuclei in erythrocytes was observed, but not consistently. In more recent studies, the chemical failed to induce sister chromatid exchange in vitro or in vivo in human lymphocytes, and did not induce micronuclei in vitro in human lymphocytes (WHO, 2004).

## Carcinogenicity

The chemical is classified by the International Agency for Research on Cancer (IARC) as 'not classifiable as to its carcinogenicity to humans' (Group 3) (IARC, 1999).

The chemical did not induce a significant increase in tumours in rats or mice following inhalation or application to the skin (IARC, 1999). None of the human epidemiological studies identified any tumours that were significantly associated with exposure to the chemical (IARC, 1999).

## Reproductive and Developmental Toxicity

The chemical is classified as hazardous with hazard category 'Reproductive toxicity Category 1A' and hazard statement 'May damage fertility or the unborn child' (H360) in the Hazardous Chemical Information System (HCIS) (Safe Work Australia). The available data support this classification (refer to **Recommendation** section).

In humans, the chemical has been shown to cause congenital defects in infants born to mothers who were exposed to high doses during pregnancy. Long-term exposure in humans at lower doses produced no effects on the fertility of male workers exposed to the chemical, but female workers showed significantly reduced fertility (US EPA, 2005).

In animals, the reproductive and developmental effects of the chemical have been tested in inhalation studies with rats, mice and rabbits, and in oral studies with mice. In the inhalation studies, embryotoxicity and foetotoxicity were observed at doses  $\geq 100 \text{ mg/m}^3$ . In one developmental study where the chemical was administered by gavage, increased embryonic mortality was observed at all doses, reduced foetal weight was observed at the top two doses, and an increased incidence of cleft palate was observed at the highest dose level (780 mg/kg bw/day). No effects on sperm morphology or vaginal cytology were observed in a 15-week inhalation study in rats (WHO, 2004).

## Risk Characterisation

### Critical Health Effects

The critical effects for risk characterisation include long-term effects (reproductive and developmental toxicity), acute effects (CNS toxicity) and local effects (skin irritation). The chemical may also cause systemic effects through prolonged or repeated inhalation exposure (neurological effects).

### Public Risk Characterisation

The chemical is used in domestic cleaning products within Australia and is used in cosmetic nail products overseas. The concentration of the chemical in these products in Australia is not known.

The general public may be exposed to the chemical through dermal and/or inhalation routes when using products containing the chemical. The Scientific Committee on Consumer Products (SCCP) has released an opinion on the use of the chemical in nail products at concentrations up to 25 %, concluding that the chemical 'is not considered to be of concern with regard to acute neurological effects' (European Commission, 2008). In the European Union Risk Assessment Report (EU RAR) for toluene (2003), concern was raised about consumer use of the chemical in spray painting and carpet laying (EU RAR, 2003).

The use of this chemical as an ingredient in cosmetics or domestic products raises concern given the health effects and the bioavailability of the chemical through the oral, dermal and inhalation routes. This chemical is currently listed on Schedule 6 when present at a concentration  $> 50 \%$  by volume, otherwise on Schedule 5 of the Poisons Standard (SUSMP). The current controls are considered adequate to minimise the risk to public health posed by domestic and cosmetic products containing the chemical, therefore, the chemical is not considered to pose an unreasonable risk to public health.

### Occupational Risk Characterisation

During product formulation, dermal and inhalation exposure of workers to the chemical may occur, particularly where manual or open processes are used. These may include transfer and blending activities, quality control analysis, and cleaning and maintenance of equipment. Worker exposure to the chemical at lower concentrations may also occur while using formulated products containing the chemical. The level and route of exposure will vary depending on the method of application and work practices employed.

Given the critical systemic long-term and acute health effects, the chemical may pose an unreasonable risk to workers unless adequate control measures to minimise dermal and inhalation exposure to the chemical are implemented. The chemical should be appropriately classified and labelled to ensure that a person conducting a business or undertaking (PCBU) at a workplace (such as an employer) has adequate information to determine appropriate controls.

Exposure should be avoided where possible and the chemical should be appropriately classified and labelled to ensure that a person conducting a business or an employee at a work place has adequate information to determine appropriate controls for worker safety.

The data support an amendment to the hazard classification in HSIS.

Based on the available data, the current exposure standard may not be adequate to mitigate the risk of adverse effects. The current Australian exposure standard of 191 mg/m<sup>3</sup> (50 ppm) TWA, and 574 mg/m<sup>3</sup> (150 ppm) STEL, may require reconsideration. In the repeated dose inhalation study, the US EPA calculated the arithmetic mean of the available NOAELs from 10 occupational studies that they considered adequate to be 34 ppm, 128 mg/m<sup>3</sup>, which is below the current exposure standard (US EPA, 2005). Inhalation studies with laboratory animals showed adverse reproductive and developmental effects at doses  $\geq$  100 mg/m<sup>3</sup> (WHO, 2004).

## NICNAS Recommendation

The chemical is recommended for Tier III assessment to examine the adequacy of the current exposure standard and any associated public risks. All other aspects have been sufficiently assessed at the Tier II level, provided that the recommendations for classification and labelling are followed.

## Regulatory Control

### Public Health

Products containing the chemical should be labelled in accordance with state and territory legislation (SUSMP).

### Work Health and Safety

The chemical is recommended for classification and labelling aligned with the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) as below.

From 1 January 2017, under the model Work Health and Safety Regulations, chemicals are no longer to be classified under the Approved Criteria for Classifying Hazardous Substances system.

A review of the physical hazards of the chemical has not been undertaken as part of this assessment. However, the following classification for physico-chemical hazards should be as follows:

- Aspiration Hazard – category 1; H304 (May be fatal if swallowed and enters airways); and
- Physical hazard (Flammable liquids) – category 2; H225 (Highly flammable liquid and vapour).

| Hazard | Approved Criteria (HSIS) <sup>a</sup> | GHS Classification (HCIS) <sup>b</sup> |
|--------|---------------------------------------|----------------------------------------|
|--------|---------------------------------------|----------------------------------------|

| Hazard                                  | Approved Criteria (HSIS) <sup>a</sup> | GHS Classification (HCIS) <sup>b</sup>                                                  |
|-----------------------------------------|---------------------------------------|-----------------------------------------------------------------------------------------|
| Acute Toxicity                          | Not Applicable                        | May cause drowsiness or dizziness - Specific target organ tox, single exp Cat. 3 (H336) |
| Irritation / Corrosivity                | Not Applicable                        | Causes skin irritation - Cat. 2 (H315)*                                                 |
| Repeat Dose Toxicity                    | Not Applicable                        | May cause damage to organs through prolonged or repeated exposure - Cat. 2 (H373)*      |
| Reproductive and Developmental Toxicity | Not Applicable                        | May damage fertility or the unborn child - Cat. 1A (H360)*                              |

<sup>a</sup> Approved Criteria for Classifying Hazardous Substances [NOHSC:1008(2004)].

<sup>b</sup> Globally Harmonized System of Classification and Labelling of Chemicals (GHS) United Nations, 2009. Third Edition.

\* Existing Hazard Classification. No change recommended to this classification

## Advice for industry

### Control measures

Control measures to minimise the risk from dermal or inhalation exposure to the chemical should be implemented in accordance with the hierarchy of controls. Approaches to minimise risk include substitution, isolation and engineering controls. Measures required to eliminate or minimise risk arising from storage, handling and use of a hazardous chemical depend on the physical form and the manner in which the chemical is used. Examples of control measures which may minimise the risk include, but are not limited to:

- using closed systems or isolation of operations;
- health monitoring for any worker who is at risk of exposure to the chemical if valid techniques are available to monitor the effect on the worker's health;
- air monitoring to ensure control measures in place are working effectively and continue to do so;
- minimising manual processes and work tasks through automating processes;
- work procedures that minimise splashes and spills;
- regularly cleaning equipment and work areas; and
- using protective equipment that is designed, constructed, and operated to ensure that, the worker does not come into contact with the chemical.

Guidance on managing risks from hazardous chemicals are provided in the *Managing Risks of Hazardous Chemicals in the Workplace—Code of Practice* available on the Safe Work Australia website.

Personal protective equipment should not solely be relied upon to control risk and should only be used when all other reasonably practicable control measures do not eliminate or sufficiently minimise risk. Guidance in selection of personal protective equipment can be obtained from Australia, Australian/New Zealand or other approved standards.

### Obligations under workplace health and safety legislation

Information in this report should be taken into account to assist with meeting obligations under workplace health and safety legislation as adopted by the relevant state or territory. This includes but is not limited to:

- ensuring that hazardous chemicals are correctly classified and labelled;
- ensuring that (material) safety data sheets ((m)SDS) containing accurate information about the hazards (relating to both health hazards and physicochemical (physical) hazards) of hazardous chemical are prepared; and
- managing risks arising from storing, handling and using a hazardous chemical.

Your work health and safety regulator should be contacted for information on the work health and safety laws in your jurisdiction.

Information on how to prepare an (m)SDS and how to label containers of hazardous chemicals are provided in relevant codes of practice such as the *Preparation of Safety Data Sheets for Hazardous Chemicals— Code of Practice* and *Labelling of Workplace Hazardous Chemicals—Code of Practice*, respectively. These codes of practice are available from the Safe Work Australia website

A review of physical hazards of the chemical has not been undertaken as part of this assessment. The chemical is classified for physico-chemical hazards on the HCIS.

## References

Agency for Toxic Substances & Disease Registry (ATSDR) 2000. Toluene (CAS 108-88-3). Accessed October 2012 at <http://www.atsdr.cdc.gov/ToxProfiles/tp.asp?id=161&tid=29>

Cosmetics Directive (CosIng). Toluene (108-88-3). Accessed October 2012 at <http://ec.europa.eu/consumers/cosmetics/cosing/index.cfm?fuseaction=search.details&id=80281>

European Commission (2008). Scientific Committee on Consumer Products (SCCP), Opinion on Toluene (its use as a solvent in nail cosmetics). Accessed December 2012 at [http://ec.europa.eu/health/ph\\_risk/committees/04\\_sccp/docs/sccp\\_o\\_133.pdf](http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_133.pdf)

European Union, Risk Assessment Report (EU RAR) for Toluene (2003) Accessed October 2012 at [http://esis.jrc.ec.europa.eu/doc/risk\\_assessment/REPORT/toluenereport032.pdf](http://esis.jrc.ec.europa.eu/doc/risk_assessment/REPORT/toluenereport032.pdf)

Government of Canada. Canadian Environmental Protection Act. Priority Substances List Assessment Report No.4 Toluene (1992). Accessed November 2012 at [http://www.hc-sc.gc.ca/ewh-semt/alt\\_formats/hecs-sesc/pdf/pubs/contaminants/psl1-lsp1/toulene/toluene-eng.pdf](http://www.hc-sc.gc.ca/ewh-semt/alt_formats/hecs-sesc/pdf/pubs/contaminants/psl1-lsp1/toulene/toluene-eng.pdf)

Hazardous Substances Data Bank (HSDB). National Library of Medicine. Accessed November 2012 at <http://toxnet.nlm.nih.gov>.

International Agency for Research on Cancer (IARC) 1999. Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. IARC Monographs Volume 71. Accessed October 2012 at <http://monographs.iarc.fr/ENG/Monographs/vol71/mono71.pdf>.

International Programme on Chemical Safety (IPCS) 1986. Toluene. Environmental Health Criteria 52. World Health Organisation, Geneva. Accessed November 2012 at <http://www.inchem.org/documents/ehc/ehc/ehc52.htm>.

National Health and Medical Research Council. National Water Quality Management Strategy, Australian Drinking Water Guidelines. Accessed December 2012 at <http://www.nhmrc.gov.au/guidelines/publications/eh52>

National Institute of Technology and Evaluation (NITE). Accessed December 2012 at [http://www.safe.nite.go.jp/english/ghs\\_index.html](http://www.safe.nite.go.jp/english/ghs_index.html)

NICNAS 2006. Australian High Volume Industrial Chemicals List (AHVICL). Accessed March 2013 at [http://www.nicnas.gov.au/Industry/Australian\\_High\\_Volume\\_Industrial\\_Chemicals/NICNAS\\_AHVICL\\_2006\\_PDF.pdf](http://www.nicnas.gov.au/Industry/Australian_High_Volume_Industrial_Chemicals/NICNAS_AHVICL_2006_PDF.pdf)

OECD 2003. SIAR on Toluene (108-88-3). Accessed October 2012 at <http://webnet.oecd.org/hpv/UI/handler.axd?id=78848f77-7cae-4745-a30e-8eb6ec7a4df7>



Registration, Evaluation and Authorisation of Chemicals (REACH) Dossier. Toluene (108-88-3). Accessed October 2012 at [http://apps.echa.europa.eu/registered/data/dossiers/DISS-9c7b2ab2-20d7-6aaa-e044-00144f67d249/AGGR-b3807d38-d7a2-447c-b731-c3eaf03a1d35\\_DISS-9c7b2ab2-20d7-6aaa-e044-00144f67d249.html#section\\_3\\_5](http://apps.echa.europa.eu/registered/data/dossiers/DISS-9c7b2ab2-20d7-6aaa-e044-00144f67d249/AGGR-b3807d38-d7a2-447c-b731-c3eaf03a1d35_DISS-9c7b2ab2-20d7-6aaa-e044-00144f67d249.html#section_3_5)

Registry of Toxic Effects of Chemical Substances (RTECS). Accessed November 2012 at <http://www.cdc.gov/niosh/rtecs/>

Safe Work Australia. Hazardous Chemicals Information System (HCIS). Accessed October 2017 at <http://hcis.safeworkaustralia.gov.au/HazardousChemical>

Toluene in Drinking-water, Background document for development of WHO Guidelines for Drinking-water Quality, WHO/SDE/WSH/03.04/116 (2004). Accessed November 2012 at [http://www.who.int/water\\_sanitation\\_health/dwq/chemicals/toluene.pdf](http://www.who.int/water_sanitation_health/dwq/chemicals/toluene.pdf)

US Environmental Protection Agency (EPA) (2005). Toxicological Review of Toluene (CAS No. 108-88-3) In Support of Summary Information on the Integrated Risk Information System (IRIS). Accessed November 2012 at <http://www.epa.gov/iris/toxreviews/0118tr.pdf>

Last update 27 October 2017

Share this page



# Toluene

## Toxicological Overview

### Key Points

#### Kinetics and metabolism

- toluene is readily absorbed following inhalation, ingestion and partially through the skin
- following absorption toluene is rapidly distributed throughout the body
- toluene is oxidised to benzoic acid which is conjugated with glycine
- toluene is predominantly excreted in the urine as the metabolite hippuric acid

#### Health effects of acute exposure

- acute inhalation or ingestion can cause systemic effects such as euphoria, excitation, hallucinations, dizziness, drowsiness, ataxia, slurred speech, tremor, respiratory depression, arrhythmias and convulsions
- coma and death can occur following substantial exposures
- local effects are observed following inhalation (irritation to nose, throat and respiratory tract), ingestion (oropharyngeal and gastric irritation), ocular (lacrimation) and dermal exposure (erythema and dryness)

#### Health effects of chronic exposure

- chronic inhalation of toluene may cause liver and kidney damage
- chronic low level occupational exposure may cause mild neurotoxicity
- the International Agency for Research on Cancer (IARC) classified toluene as a category 3 carcinogen, ie not classifiable as to the carcinogenicity to humans
- toluene is considered to be a possible reproductive toxin

## Summary of Health Effects

Local effects following inhalation of toluene include irritation to the eyes, nose, throat and respiratory tract. Acute inhalation can cause systemic effects such as euphoria, excitation, hallucinations, dizziness, drowsiness, ataxia, tremor, respiratory depression, cardiac effects and convulsions. Exposure to high concentrations can lead to coma and death. The predominant effects of chronic toluene inhalation are on the central nervous system (CNS) and kidney. Neurological effects may include behavioural and personality changes, muscle weakness, peripheral neuropathy, tremor and impairments of speech, hearing and vision. In some cases CNS damage is permanent.

Following acute ingestion of toluene, systemic effects as seen following inhalation may occur as well as oropharyngeal and gastric irritation with abdominal pain and vomiting. Chronic oral exposure to toluene has not been characterised in humans.

Following acute dermal exposure to toluene, local effects may include irritation, blistering, dryness and erythema. Necrotic skin burns can develop following prolonged contact with toluene. Chronic dermal exposure may cause skin irritation and contact dermatitis.

Local effects following acute ocular exposure to toluene include lacrimation and transient corneal damage. Chronic exposure may result in loss of visual acuity, optical neuropathy and nystagmus.

The International Agency for the Research on Cancer (IARC) concluded that toluene is not classifiable as to its carcinogenicity in humans (group 3).

Toluene is classified in the EU as a reproductive toxicant, category 2 (hazard statement H361: suspected of damaging the unborn child). It readily crosses the placental barrier. Studies into exposures in the workplace or by solvent abuse have shown associations with a number of adverse reproductive outcomes; however, the evidence is inconclusive.

## Kinetics and Metabolism

Toluene is readily absorbed from the respiratory and gastrointestinal tracts and to some degree through the skin [1]. It is estimated that 40–60% of inhaled toluene is absorbed [2]. Oral absorption is complete but the rate is slower than pulmonary absorption [1]. Dermal absorption of toluene is relatively slow; the rate of absorption through forearm skin is in the range of 14–23 mg/cm<sup>2</sup> per hour [3].

When exposed during exercise, the amount of toluene in the alveolar air has been observed to be 1.4–2 times higher than in those exposed at rest [4].

Following absorption, toluene is rapidly distributed throughout the body. Human and animal inhalation studies have shown high toluene concentrations in adipose tissue, bone marrow, adrenals, highly vascular tissues (eg the kidney and liver), brain and blood [5].

Following inhalation or oral exposure to toluene, approximately 60–75% of absorbed toluene, is metabolised to benzoic acid [2, 6]. The liver is the primary site of toluene metabolism [5]. The initial step involves side chain oxidation to benzyl alcohol by cytochrome P450 enzymes. Benzyl alcohol is then further oxidised to benzoic acid by alcohol dehydrogenase and aldehyde dehydrogenase. Benzoic acid is subsequently conjugated with glycine to form hippuric acid [2]. Between 3 and 20% of absorbed toluene may be converted to benzoyl glucuronide [5]. Less than 1% of absorbed toluene undergoes ring hydroxylation to form o- and p-creosol, which is excreted in the urine as glucuronide or sulphate conjugates [2].

Following inhalation, toluene is predominantly excreted in the urine as the metabolite hippuric acid. Approximately 7–20% of absorbed toluene is eliminated in air unchanged. Toluene may also be excreted into breast milk [5]. Following a single acute exposure, toluene and its metabolites are almost completely eliminated within 24 hours [2, 6].

Toluene can cross the placenta and is found in the fetus at concentrations of approximately 75% of that present in the maternal blood [5].

## Sources and Route of Human Exposure

The main route of exposure to toluene is by inhalation, ie vapour in ambient air, cigarette smoking, petrol stations and garages, solvent abuse and use of household agents [2, 5, 6]. Ingestion (contaminated food or water) and dermal exposure (use of fuels, solvents and cosmetics) are less common routes of exposure to toluene [2].

The majority of toluene released into the atmosphere is from inadvertent sources, eg vehicle emissions and spills. Toluene is also released into the environment during its transport, production, use and disposal [2]. Levels of toluene detected in rural and urban air averaged 1.3 and 10.8  $\mu\text{g}/\text{m}^3$ , respectively [1]. Indoor air levels of toluene are generally higher (31.5  $\mu\text{g}/\text{m}^3$ ) than outdoor levels due to cigarette smoke and the use of household products (eg paints, adhesives and thinners) [1].

Toluene does not persist in the environment; it is rapidly volatilised or biodegraded [2]. In surface soils, 90% of toluene is expected to volatilise within 24 hours; when present at greater depths the contaminant will be more persistent [7].

Toluene has been detected in drinking water, well water and in raw water [2]. However, exposure to toluene in drinking water is minimal, except in situations where heavy contamination occurs [6].

Exposure to toluene can occur in the workplace. Shoemakers, printers and individuals who are involved in the production of toluene or toluene-containing products are at risk of exposure to considerably higher levels of toluene than the general population [2].

The deliberate inhalation of products containing toluene such as paint, paint thinners and adhesives can lead to exposure to very high toluene levels. Solvent abusers may be exposed to concentrations ranging from 3,750–37,500  $\text{mg}/\text{m}^3$  (10–10,000 ppm) [5].

Toluene is found widely in nail cosmetics as a solvent; however, the penetration of toluene through human nail tissue is considered to be negligible [3]. Due to the high volatility of toluene, inhalation is considered the predominant route of exposure in the application of such products [3]. Toluene levels of 3.75–15  $\text{mg}/\text{m}^3$  (1–4 ppm) and 0.98  $\text{mg}/\text{m}^3$  (0.26 ppm) have been measured in household and professional studio (ventilated) use of nail cosmetics, respectively [3].

## Health Effects of Acute/Single Exposure

### Human data

#### General toxicity

The main target organ of toluene-induced toxicity is the central nervous system (CNS). Toluene is also an irritant to the skin and mucous membranes.

#### Inhalation

The acute toxic effects following inhalation of toluene are summarised in the table. Toluene vapours are irritating to the eyes, nose, throat and respiratory tract. Respiratory complications such as acute bronchitis, bronchospasm, pneumonitis, asphyxia and pulmonary oedema may also occur [2, 8].

**Table: Summary of toxic effects in humans following acute exposure to toluene by inhalation [2]**

| Dose (mg/m <sup>3</sup> ) | Signs and symptoms                                                                                                        |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------|
| 188–375                   | Subjective complaints (very mild headache, fatigue and downiness)                                                         |
| 750                       | Mild throat and eye irritation, headache, dizziness, sensation of intoxication (8-hour exposure)                          |
| 1,500                     | Irritation of the eyes and throat, lacrimation, mental confusion, incoordination                                          |
| 1,875–2,250               | Anorexia, staggering gait, nausea, nervousness, momentary loss of memory, significant reduction in reaction time          |
| 5,625                     | Extreme weakness                                                                                                          |
| 15,000                    | Rapid impairment of reaction time and coordination, exposures of 1 hour or longer may lead to narcosis and possibly death |
| 37,500–112,500            | Onset of narcosis within minutes; longer exposures may be lethal                                                          |

CNS toxicity is the main acute effect following toluene exposure. The effect can be depressant or excitatory, with euphoria, hallucinations followed by ataxia, confusion, dizziness, drowsiness, slurred speech, blurred vision, tremors, respiratory depression, convulsions, coma and, in severe cases, death [1, 2, 8].

Cardiovascular effects including hypotension or hypertension, bradycardia, tachycardia, ventricular fibrillation, cardiac arrest and myocardial infarction have been reported in humans following acute inhalation of toluene [1, 8]. Exposure to toluene may cause sensitisation of the myocardium to adrenaline and sympathetic stimulation, which may result in cardiac arrhythmias and sudden death [9].

Other effects of acute exposure include rhabdomyolysis, hepatic and renal damage, severe metabolic acidosis, fluid and electrolyte disturbances, paraesthesiae and peripheral neuropathy [8].

Death following toluene abuse is caused by hypoxia during toluene narcosis or while inhaling the solvent from a plastic bag over the head [9]. Approximately 100 deaths a year are reported following solvent abuse in the UK; 25% of these are caused by adhesive solvents which are composed mainly of toluene [5].

Toluene levels in the range of 750–5,625 mg/m<sup>3</sup> in occupational settings have been reported to cause dose-related CNS depression. Exposure to very high concentrations of toluene ( $\geq 37,500$  mg/m<sup>3</sup>) during industrial accidents has resulted in CNS excitation followed by progressive impairment of consciousness, seizures and coma [2].

### Ingestion

Ingestion of toluene can cause severe acute toxicity, as described in the inhalation toxicity section. Local effects following ingestion include oropharyngeal and gastric irritation with abdominal pain, vomiting and haematemesis [8, 10].

One case study reported abdominal pain, haemorrhagic gastritis and CNS depression following ingestion of a paint thinner containing toluene, although other studies did not reveal gastrointestinal effects even after oral exposure to a lethal dose of toluene [11]. Other effects reported following ingestion of toluene include bradycardia, necrosis of myocardial fibres, enlarged liver and acute tubular necrosis [1].

Death, probably due to severe CNS depression, has been reported to have occurred within 30 minutes of ingestion of approximately 60 mL (625 mg/kg) of toluene [12].

### Dermal/ocular exposure

Toluene is lipid soluble, therefore it can cause irritation, blistering, dryness and erythema to the skin through a defatting action [8]. Prolonged exposure may lead to necrotic skin burns [8]. Extensive chemical burns have been reported following prolonged exposure to toluene-based paint [13]. Dermal exposure in the absence of significant exposure from other routes is unlikely to give rise to systemic toxicity [8].

Exposure to toluene vapours may cause irritation to the eyes at concentrations greater than 750 mg/m<sup>3</sup> and lacrimation at 1,500 mg/m<sup>3</sup> [2]. Corneal injury may occur as a result of exposure, although this is usually reversible [8].

## Health Effects of Chronic/Repeated Exposure

### Human data

#### Inhalation

Health effects from chronic exposure to toluene may resemble those of acute exposure. Renal tubular acidosis and CNS effects are the most prevalent [8].

Permanent CNS damage and progressive encephalopathy may develop as a result of long-term toluene abuse [8]. Related neurological effects include behavioural and personality changes, confusion, paranoid psychosis, hallucinations, memory loss and impairments of speech, hearing and vision [1, 2, 8]. Nystagmus, ataxia, muscle weakness, peripheral neuropathy and tremors may also present in such cases [8].

There is a significant body of evidence linking mild neurotoxicity with chronic low level occupational exposure to toluene [5]. Subtle neurological effects including headaches, dizziness, degradation of colour vision and neurological and psychomotor functioning have been reported in workers exposed to toluene concentrations ranging from 150–495 mg/m<sup>3</sup> [5].

Some occupational studies have reported increased serum concentrations of liver enzymes in workers exposed to toluene concentrations between 113 and 1,312 mg/m<sup>3</sup> (30 and 350 ppm) [1]. Other studies have not reported any adverse effects on the liver. Liver damage has been reported in solvent abusers [1].

Irritation to the upper respiratory tract and conjunctiva was reported in workers occupationally exposed to 750–3,000 mg/m<sup>3</sup> of toluene for several years [2].

Distal renal tubular acidosis is associated with abuse of toluene containing solvents. Muscle weakness, nausea and vomiting are common symptoms and are thought to be due to an electrolyte imbalance caused by the renal acidosis [6]. Metabolic acidosis and tubular injury were recorded in a 22-year-old female who sniffed up 6 litres of toluene throughout the previous month [1]. Irreversible renal failure has been reported in a 20-year-old male who sniffed glue containing 16.5% toluene twice a week for 9 months [2].

#### Ingestion

There is currently no data available on the chronic effects of toluene ingestion in humans.

#### Dermal/ocular exposure

There is limited data on the effects of dermal exposure to toluene. Liquid toluene will remove natural lipids from the skin. Therefore, repeated or prolonged dermal exposure may cause dryness, fissures and contact dermatitis [2, 10].

Loss of visual acuity, optical neuropathy and nystagmus have been reported in a number of studies involving toluene abusers [2].



## Genotoxicity

An unequivocal evaluation of the genotoxic effects of occupational exposure to toluene cannot be made due to the small number of individuals analysed and the inadequate information on the possible exposure to other chromosome damaging agents [1, 2].

There are discrepancies in the findings related to the genotoxic effects of toluene in humans. An increase in chromosome breaks was recorded in the lymphocytes of workers exposed to 340–4,388 mg/m<sup>3</sup> (104–1,170 ppm) of toluene [1]. Chromosomal aberration analysis of the lymphocytes of printers exposed to 114–328 mg/m<sup>3</sup> revealed a concentration-related increase in sister chromatid exchange [1]. A significant increase in the frequency of sister chromatid exchanges and chromatid breaks compared to unexposed controls was recorded in the lymphocytes of workers exposed to 750–1,125 mg/m<sup>3</sup> (200–300 ppm) of toluene [1].

In contrast, other similar studies have shown no association between chronic toluene exposure and an increased incidence of chromosome damage. No exposure differences were reported in DNA damage in leukocytes of factory workers exposed to factory air containing 96–412 mg/m<sup>3</sup> of toluene [1]. Chromosomal aberration analysis of workers exposed to 26–420 mg/m<sup>3</sup> did not reveal an increased incidence of chromosome damage in blood lymphocytes compared with controls [2].

## Carcinogenicity

IARC considered eight studies: two were community-based and six were occupational exposure studies. Toluene was considered to be the predominant source of exposure in only two of the studies, those of Swedish rotogravure printers and US shoe manufacturers [14].

A cohort of 1,020 Swedish rotogravure printers exposed primarily to toluene for at least 3 months showed increased mortality and incidence ratios for respiratory tract, stomach and colorectal cancer. However, there was no significant correlation between increased risk and cumulative exposure [1, 14].

The second study involved a cohort of 7,814 shoe-manufacturing workers in the US. The workers were potentially exposed to solvents and solvent-based adhesives. It was thought that the workers were primarily exposed to toluene; however, other chemicals (eg acetone and hexane) were detected at high concentrations. Benzene may have been present as an impurity of toluene. The rates of lung cancer were significantly elevated, but smoking may have been a contributing factor. There was a slight increase in the risk of colon cancer but this was not significant [14].

Overall, IARC stated that “considering the multiple exposure circumstances in most studies and the weak consistency of findings, these results are not strong enough to conclude that there is an association”. IARC concluded that there was inadequate evidence in humans for the carcinogenicity of toluene and as such classified it as group 3 (Not classifiable as to its carcinogenicity to humans) [14].

## Reproductive and developmental toxicity

The abuse of toluene by pregnant women through deliberate inhalation of products such as paint, paint thinners and adhesives has been associated with a number of adverse reproductive outcomes. The effects reported include premature delivery, congenital cranio-facial, limb, cardiac, renal and CNS malformations. In such reports the evidence of an association between prenatal exposures to toluene and developmental toxicity is limited by the potentially confounding effects of other agents (eg alcohol or tobacco smoke) to which the subject may have been exposed [15, 16].

Several occupational studies have reported the reproductive outcomes among women exposed to toluene. Six studies have reported an association with spontaneous abortion, three with reduced fertility and two with congenital malformations. The studies on spontaneous abortion provide the most convincing evidence for an association with toluene. However, the potential for bias and multiple chemical exposures suggests that the results from these studies should be interpreted cautiously [17].

High incidences of menstrual disturbances have been reported in women occupationally exposed to toluene and other solvents [10].

Overall, the current data does not provide convincing evidence that toluene causes reproductive effects in humans, as a number of studies reporting an increased incidence of spontaneous abortion have not been supported by animal data [1].

Little data has been found regarding the effects of toluene on human male reproduction. One single case report regarding a 28-year-old male who chronically abused toluene for 10 years suggests that chronic abuse of toluene may cause testicular atrophy and reduced spermatogenesis. The subject was thought to have died as a result of excess sniffing and was found to have degeneration of the spermatogonia and Sertoli cells and showed evidence of suppressed spermatogenesis [15].

In the EU toluene is classified as a reproductive toxicant, category 2; this requires use of the hazard statement code H361 (suspected of damaging the unborn child) [18].

## Animal and in-vitro data

### Inhalation

Neurological effects including hearing loss, reduced brain weights, changes in the concentrations of neurotransmitters, interrupted sleep cycles and deficits in neurobehavioral performance have been reported in animals chronically exposed to toluene [1, 2].

Rats exposed to 2,250 mg/m<sup>3</sup> (600 ppm) of toluene for 5 weeks showed signs of lung irritation and rats exposed to 9,375 and 18,750 mg/m<sup>3</sup> (2,500 and 5,000 ppm) developed pulmonary lesions [10]. Inflammation of the nasal mucosa and degeneration of the respiratory epithelium were reported in rats exposed to 2,250 or 4,500 mg/m<sup>3</sup> (600 and 1,200 ppm) for 6.5 hours a day, 5 days a week for 2 years. However, mice exposed to the same concentrations for 2 years did not display the same effects [1].

Increased liver weights and increased serum levels of liver enzymes have been reported in rats repeatedly exposed to toluene at doses greater than 1,125 mg/m<sup>3</sup> (300 ppm) for at least 6 hours a day [1].

Rats exposed to toluene at concentrations of 750–18,750 mg/m<sup>3</sup> for 7 hours a day, 5 days a week developed renal casts within the collecting tubules of the kidneys [2]. Necrosis of the kidney tubules and increase in kidney weights were recorded in rats exposed to 7,500 mg/m<sup>3</sup> (2,000 ppm) of toluene for 90 days [1].

### Ingestion

Female rats administered toluene (560 mg/kg for up to 6 months) by intubation showed no signs of toxicity [2].

In a sub-chronic study rats and mice were administered toluene by gavage at doses of 0, 312, 625, 1,250, 2,500 or 5,000 mg/kg of bw per day for 5 days a week for 90 days [16]. All the rats and mice given 5,000 mg/kg died within the first week of the study and 40% of the mice receiving 2,500 mg/kg also died [16]. No adverse effects were observed in rats exposed to 312 mg/kg, or in mice exposed to doses less than 2,500 mg/kg. The group of rats receiving 2,500 mg/kg exhibited ataxia, hypoactivity, bradypnoea, hypothermia, piloerection, prostration, lacrimation, excess salivation and body tremors [16]. Increases in liver and kidney weights were noted in the rats exposed to doses greater than or equal to 625 mg/kg [16].

### Dermal/ocular exposure

Slight to moderate skin irritation was observed on the ears and body of rabbits exposed (10–20 repeated applications) to undiluted solvent for 2–4 weeks [2]. Guinea pigs exposed to toluene three times a day, for 3 days, developed redness of the skin and an increase in epidermal thickness [1].

## Genotoxicity

Toluene consistently gave negative results in the Ames *Salmonella* assay. It was also negative in the mouse lymphoma assay and other in-vitro test systems [2]. In animals, there have been reports of DNA single-strand breaks and chromosomal aberrations when toluene was administered by injection. However, in-vivo studies have produced negative results [5]. It can be assumed that toluene does not have a mutagenic potential.

## Carcinogenicity

There is no evidence suggesting carcinogenicity of toluene in experimental animals. A 2-year inhalation study in mice and rats did not report an increase in incidence of tumours. Repeated application of toluene to the skin of mice did not result in an increase in incidence of skin tumours [14].

## Reproductive and developmental toxicity

In a two-generation reproduction study no adverse reproductive effects were reported in rats exposed to toluene by inhalation of 7,500 mg/m<sup>3</sup> (2,000 ppm) for 6 hours a day for up to 95 days). In a separate study a significant reduction in sperm count and weight of epididymides was recorded in male rats exposed to 7,500 mg/m<sup>3</sup> (2,000 ppm) for 6 hours a day for a total of 90 days. However, there were no significant changes in reproductive performance [1].

Toluene has been reported to be fetotoxic but not teratogenic [2]. Studies have shown that toluene can retard fetal growth and skeletal developmental and can alter the behavioural development of offspring [1,2]. In an inhalation study rats were exposed to 1,000 mg/m<sup>3</sup> for 8 hours a day on gestation days 1–21. There were no signs of maternal toxicity but there was a significant reduction in the fetal weight and a significant increase in retarded ossification in the offspring of the group exposed to toluene [2]. In a behavioural development inhalation study pregnant rats were exposed to 2,000 ppm (7,500 mg/m<sup>3</sup>) of toluene for 60 minutes, three times a day on gestation days 12–17 [1]. The offspring of the exposed rats were assessed on postnatal days 1–20 and showed significant performance deficits in neurobehavioral tests of reflex development, muscle strength and motor coordination [1].

## References

1. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for toluene, 2000. US Department of Health and Human Services: Atlanta, US.
2. International Programme on Chemical Safety (IPCS). Toluene. Environmental Health Criteria 52, 1986. WHO: Geneva.
3. Scientific Committee on Consumer Products (SCCP). Opinion on toluene, 2008.  
[http://ec.europa.eu/health/ph\\_risk/committees/04\\_sccp/docs/sccp\\_o\\_133.pdf](http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_133.pdf).
4. National Research Council. Acute exposure guideline levels for selected airborne chemicals, 2014. Washington DC.
5. Environment Agency (EA). Contaminants in soil: updated collation of toxicological data and intake values for humans Toluene, 2009. Environment Agency: Bristol.
6. World Health Organisation (WHO), Air quality guidelines for Europe. WHO Regional Publications, European Series, No. 91. 2nd edition. , 2000, WHO Regional Office for Europe: Copenhagen.
7. Environment Agency (EA). Soil guideline values for toluene in soil, 2009. Environment Agency: Bristol.
8. National Poisons Information Service (NPIS). Toluene. TOXBASE®, 2010.
9. Ashton CH. Solvent abuse. BMJ, 1990; 300(6718): 135–6.
10. von Burg R. Toxicology update: toluene. J Appl Toxicol, 1993; 13(6): 441–6.
11. Caravati EM and Bjerk PJ. Acute toluene ingestion toxicity. Ann Emerg Med, 1997; 30(6): 838–9.
12. Ameno K et al. A fatal case of oral ingestion of toluene. Forensic Sci Int, 1989; 41(3): 255–60.
13. Shibata K, Yoshita Y and Matsumoto H. Extensive chemical burns from toluene. Am J Emerg Med, 1994; 12(3): 353–5.
14. International Agency for Research on Cancer (IARC). Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. Volume 71, in IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 1999. IARC: Lyon.
15. Donald JM, Hooper K and Hopenhayn-Rich C. Reproductive and developmental toxicity of toluene: a review. Environ Health Perspect, 1991; 94: 237–44.
16. Risk Assessment Information System (RAIS). Toxicity summary for toluene, 1994, Chemical Hazard Evaluation and Communication Group, Biomedical and Environmental Information Analysis Section, Health and Safety Research Division.
17. Bukowski JA. Review of the epidemiological evidence relating toluene to reproductive outcomes. Regul Toxicol Pharmacol, 2001; 33(2): 147–56.
18. European Chemicals Agency (ECHA). Classification and labelling inventory.  
<http://echa.europa.eu/web/guest/information-on-chemicals/cl-inventory-database/-/cl-inventory/search-clinventory-by-name/toluene> (accessed 11/2014).

This document from the PHE Centre for Radiation, Chemical and Environmental Hazards reflects understanding and evaluation of the current scientific evidence as presented and referenced here.

First published: May 2015

For queries relating to this document, please contact: [generaltox@phe.gov.uk](mailto:generaltox@phe.gov.uk)

© Crown copyright 2015, [www.gov.uk/phe](http://www.gov.uk/phe)


Re-use of Crown copyright material (excluding logos) is allowed under the terms of the Open Government Licence, visit [www.nationalarchives.gov.uk/doc/open-government-licence/version/3/](http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/) for terms and conditions.

***Recommendation from the Scientific Committee on  
Occupational Exposure Limits  
for Toluene***

|                           |   |                                  |
|---------------------------|---|----------------------------------|
| 8-hour TWA                | : | 50 ppm (192 mg/m <sup>3</sup> )  |
| STEL (15 mins)            | : | 100 ppm (384 mg/m <sup>3</sup> ) |
| Additional classification | : | “skin”                           |

Substance:

Toluene



|                                   |                                |                                |
|-----------------------------------|--------------------------------|--------------------------------|
| Synonyms:                         | Methylbenzene, phenylmethane   |                                |
| EINECS No:                        | 203-625-9                      |                                |
| EEC No:                           | 601-021-00-3;                  | Classification: F; R11 Xn; R20 |
| CAS No:                           | 108-88-3                       |                                |
| MWt:                              | 92.13                          |                                |
| Conversion factor (20°C, 101kPa): | 3.83 mg/m <sup>3</sup> = 1 ppm |                                |

Occurrence/use:

Toluene is a colourless flammable liquid with an unpleasant sour to burned aromatic odour. It has a melting-point of -95 °C, a boiling-point of 111 °C and a vapour pressure of 3.73 kPa at 25 °C. It has a vapour density 3.2 times that of air and is explosive over the range 1.2 to 7.1%. The odour threshold is about 5 ppm (18 mg/m<sup>3</sup>).

The production rate of toluene in the European Union is in the order of 1 million tonnes per annum. It is used in many types of industry as a solvent for paints, lacquers, fats, resins and other applications. It is an additive in petrol and therefore occurs worldwide. Toluene often occurs together with other solvents. Occupational exposure levels reported recently are generally below 200 ppm (750 mg/m<sup>3</sup>).

Health significance:

Experimental animal and human studies indicate that airborne toluene vapour is well absorbed from the respiratory tract following inhalation. There is also evidence for limited absorption of toluene vapour via the skin. Liquid toluene is well absorbed through the gastrointestinal tract and is absorbed through the skin to a limited extent.

Absorbed toluene is widely distributed but has a particular affinity for fat-rich tissues; toluene can also pass through the placenta to the fetus, and into breast milk. The major metabolic pathway for toluene is oxidation of the methyl group to benzoic acid, which is then conjugated mainly to glycine (forming hippuric acid) or to glucuronic acid, both of which are excreted in the urine; alternatively, a small proportion of toluene is oxidised on the phenyl ring, producing cresols. Excretion of toluene is relatively rapid, although there can be a gradual increase in the body burden of toluene with daily exposure during a working week (MAK Commission, 1993; Danish Draft ESR Assessment, 1998).

Urinary hippuric acid concentration has been used as a biological monitoring approach to assessing toluene exposure. However, hippuric acid also occurs in significant quantities in human urine from other sources such as food and normal metabolism, such that in Europe this parameter of biological monitoring cannot reliably detect occupational exposure to toluene when workplace airborne concentrations are below 100 ppm (383 mg/m<sup>3</sup>) (Lauwerys, 1983). A number of alternative methods are available, including urinary o-cresol concentration which has been shown to correlate well with toluene exposure (Truchon *et al.*, 1996).

Liquid toluene exhibits some irritancy towards the skin and eyes on direct contact, the severity of the effects depending on the duration of exposure. Airborne toluene vapour reportedly produces symptoms of eye and upper respiratory tract irritation in humans; the balance of evidence available for these effects suggests that the threshold for irritation lies at about 75-80 ppm (286-300 mg/m<sup>3</sup>). Toluene does not possess sensitisation properties towards the skin or respiratory tract (Danish Draft ESR Assessment, 1998).

Single exposure to very high concentrations of airborne toluene, of the order of thousands of ppm over a period of several hours can produce pronounced central nervous system (CNS) depression, narcosis and even death. A single exposure of human volunteers to concentrations of 75-150 ppm (287-575 mg/m<sup>3</sup>) for several hours has produced symptoms of CNS disturbance, such as dizziness, headache and fatigue, together with impairment of performance in neurobehavioural tests; a NOAEL of 40 ppm (153 mg/m<sup>3</sup>) has been recorded in such studies (Andersen *et al.*, 1983; Echeverria *et al.*, 1989; Baelum *et al.*, 1985).

In relation to the effects of repeated inhalation exposure, in standard animal studies no significant evidence of toxicity has been observed with repeated, prolonged periods of exposure to concentrations up to at least 300 ppm (1149 mg/m<sup>3</sup>). Some irritation of the nasal epithelium has been seen in rats repeatedly exposed to 600 ppm toluene and at exposure levels above this (in the region of 1000 ppm - 3830 mg/m<sup>3</sup> - and above), the most notable toxic effect observed has been hearing loss, seen in rats (the only experimental species in which this has been investigated) and due to histopathological



damage to the cochlea. CNS excitation and/or depression and mortality has been produced in rodents with repeated exposures to 1500 ppm (5745 mg/m<sup>3</sup>) and above (DFG 1996; Danish Draft ESR Assessment, 1998)

### Behavioural toxicity

In general, there is a substantial number of studies available on the effects in humans of repeated exposure to toluene, both in workplace investigations and in volunteer studies; however, much of the earlier work is of little value in understanding the toxicity of toluene, as the workforces were also significantly exposed to other toxicants, including benzene contamination of the toluene. The principal focus of investigation has been to explore symptomatology and performance test results indicative of potential effects on the central nervous system. A number of such studies are available, exploring the effects of repeated 4-8 hour exposures to toluene concentrations in the range 60-80 ppm (230-306 mg/m<sup>3</sup>); no effects on performance, relative to controls, were observed (Echeverria *et al.*, 1989). In some but not all of these studies, the toluene-exposed subjects reported non-specific symptoms such as fatigue. At higher exposures, in the range 90-150 ppm (345-575 mg/m<sup>3</sup>), decrements in performance test results and symptoms of dizziness, headache and mucous membrane irritation have been recorded in several studies (Stewart *et al.*, 1975; Dick *et al.*, 1984; Baelum *et al.*, 1985; Echeverria *et al.*, 1989; Foo *et al.*, 1990 and 1993). Other studies that are available are difficult to interpret, in terms of discriminating between “effect” and “no-effect” levels, because of uncertainty about the relationship between the effects monitored, the levels of contemporary exposure measured and the levels of exposure previously encountered by the workers (Iregren, 1982; Ørbaek and Nise, 1989; Van Thriel *et al.* 2000).

Some studies using neurobehavioural methods are especially important for the discussion of the lowest observed effect level (LOAEL). Kempe *et al.* (1980) compared 24 printers exposed to toluene in a printing works with 18 control persons; tests took place during and after the shift on 3 consecutive days. The exposure level determined with personal samplers was 62 ppm (237 mg/m<sup>3</sup>) averaged over the shift; measurements of the air concentrations close to the machines revealed 121 ppm (463 mg/m<sup>3</sup>). The persons had been exposed for an average of 13 years. Reaction times, perception time determined with a tachistoscope and the results of a visual search test were not markedly changed. Fatigue, lack of concentration, exhaustion, discord were significantly increased in the printers at the end of shift. In the interpretation of the findings, it must also be taken into account that the printers were exposed to noise levels of about 90 dB.

Foo *et al.* (1990, 1993) compared 30/24 women/men exposed to average toluene concentrations, of 88/70 ppm (337/268 mg/m<sup>3</sup>) (glue, electronic assembly) with 30/64 control persons. The tests took place during the working week. For persons exposed to higher concentrations, performance was significantly poorer in a visual search test, visual reproduction test, verbal memory test and manual dexterity test. In 6 of 8 tests the performance decreased with increased average workplace concentration. Both the duration of exposure and the level of occupational training (confounding factor affecting performance in psychological tests) were taken into account.

Iregren (1982) investigated 34 printers exposed for 3 to 30 years to toluene concentrations between 50 and 150 ppm (192 and 575 mg/m<sup>3</sup>) and compared them with 34 non-exposed control persons. The printers were found to have longer reaction times.

Ørbaek and Nise (1989) studied 30 printers exposed on average for 29 years in parallel with 72 “healthy men” as control group. Current toluene concentrations were determined as 11 and 42 ppm (42 and 161 mg/m<sup>3</sup>); in previous years the concentrations had been considerably higher. Tests carried out on Monday mornings revealed performance deficits in the exposed persons. However, no correlation with a cumulative exposure index or with the current average exposure was found. Fatigue, short-term memory problems, concentration difficulties and mood swings were more frequent in the printers.

### Relevant experimental studies

Gamberale and Hultengren (1972) described the effects of exposing two groups of 6 persons by inhalation of toluene through a mouth-piece; the persons were exposed either first on 7 consecutive days to toluene concentrations which increased from 100 to 700 ppm (383 to 2681 mg/m<sup>3</sup>), each concentration for 80 minutes, and then to normal air on 7 consecutive days or first to air and then to the toluene. Perception time and choice reaction time in a test with light signals were not significantly affected by the exposure. The simple reaction time, however, was longer after exposures to 300 ppm (1149 mg/m<sup>3</sup>) or more and reached a maximum at 700 ppm (2681 mg/m<sup>3</sup>). The authors concluded that simple psychological functions are affected more than complex CNS activities at low toluene concentrations (Iregren, 1982; Kempe *et al.*, 1980). Similar results were obtained in studies which made use of other psychological tests (Hänninen *et al.*, 1976; Lindstrøm, 1973; Seppäläinen *et al.*, 1978). In studies of printing works employees exposed to toluene concentrations between 50 ppm (192 mg/m<sup>3</sup>) and 150 ppm (575 mg/m<sup>3</sup>), deviations from the norm were not found at concentrations under 100 ml/ m<sup>3</sup> (Iregren, 1982). However, the interpretation of such data is made more difficult by the fact that the exposure data are often not known reliably and by variation in the interval after the end of exposure (Lindstrøm, 1973, 1981). Determination of the motor and sensory conduction velocities (MCV and SCV) revealed only slight increases which, taken as a whole, were not statistically significant (Seppäläinen *et al.*, 1978).

Andersen *et al.* (1983) studied the effects of exposure of 16 volunteers under laboratory conditions for 6 hours to toluene concentrations of 10, 40 and 100 ppm (38, 153 and 383 mg/m<sup>3</sup>) in a repeated exposure experiment. At 100 ml/ m<sup>3</sup>, the effects on the results of tests for perceptiveness (Landolt ring test), manual dexterity and one other performance test were on the borderline of significance and the incidence of headaches, dizziness and feeling intoxicated was significantly increased. No adverse effects were detected at 10 ppm (38 mg/m<sup>3</sup>), or at 40 ppm (153 mg/m<sup>3</sup>).

Echeverria *et al.* (1989) exposed 42 volunteers under laboratory conditions for 6.5 hours with 3 days repeated exposures to a toluene concentration of 75 ppm (286 mg/m<sup>3</sup>) or 150 ppm (572 mg/m<sup>3</sup>). Each test person was tested at only one exposure concentration but with a very extensive test battery (70 minutes). Evaluation was based on differences in the results of tests before and after exposure. At 150 ppm (572 mg/m<sup>3</sup>) performance

in the tests for short term memory of patterns, recollection of numbers, pattern recognition and manual dexterity was significantly reduced. The results obtained at 75 ppm (287 mg/m<sup>3</sup>) and in the control group revealed in tendency a dose-effect relationship. Headaches and mucosal irritation also increased significantly with the dose. At 75 ppm (287 mg/m<sup>3</sup>), performance was not different from that of the control group but the persons complained of more subjective symptoms.

Anselm-Olsen *et al.* (1985) examined the effects of repeated exposure of 16 volunteers under laboratory conditions to a toluene concentration of 80 ppm (300 mg/m<sup>3</sup>) for 4 hours each time in a study of the effects of combined exposure to toluene and xylene under laboratory conditions. No effects were found on psychic performance parameters or on how the persons felt.

Iregren *et al.* (1986) examined the effects of repeated exposure of 12 volunteers to a toluene concentration of 80 ppm (300 mg/m<sup>3</sup>) for 4.5 hours each time in a study of the effects of combined exposure to toluene and alcohol under laboratory conditions. No effects on psychic performance parameters were found. Headaches and mucosal irritation (summed values for various regions of mucous membrane) were considered to be more severe during exposures than under control conditions.

Baelum *et al.* (1985) examined 46 printers who were accustomed to toluene and 43 control persons during exposure to a toluene concentration of 100 ppm (383 mg/m<sup>3</sup>) for 6.5 hours under laboratory conditions. The tests determined 31 performance parameters and numerous indicators of how the subjects felt; each test person was subjected only once to the toluene concentration and once to control conditions. Colour discrimination decreased during the exposure as did perceptiveness (Landolt rings) and manual dexterity. Irritation of the eyes, throat (less in the printers) and the nose, a feeling of intoxication and dizziness were increased during the exposure to toluene.

Dick *et al.* (1984) examined 30 persons exposed for 4 hours to a toluene concentration of 100 ppm (383 mg/m<sup>3</sup>) and 18 control persons under laboratory conditions. During the first 2 hours of exposure, the scores in the visual vigilance test were decreased. Stewart *et al.* (1975) obtained similar results during 7.5 hours exposure to 100 ppm (383 mg/m<sup>3</sup>).

Winneke (1982) examined 18 persons subjected under laboratory conditions to a toluene concentration of 100 ppm (383 mg/m<sup>3</sup>) with repeated 3.5-hour exposures. Determination of the critical flicker fusion threshold, vigilance and various psychomotor parameters revealed no toluene-induced effects.

#### Other issues of concern

A principal area of general toxicity concern with respect to repeated exposure to toluene, which has been explored in two studies by one group, is effect on hearing. In groups of printing workers exposed to toluene (and other organic solvents) and to substantial noise levels, an association was apparent between toluene exposure and hearing loss (Morata *et al.*, 1993; Morata *et al.*, 1997). In the second of these studies, toluene exposure was estimated quantitatively from airborne toluene and urinary

hippuric acid measurements. Of the 124 workers studied, almost half were diagnosed as having hearing loss, and with daily workshift exposure to toluene (extrapolated from urine hippuric acid measurements) of 100 ppm (383 mg/m<sup>3</sup>) the odds ratio for the development of hearing loss was calculated to be 4. However, there are several problems with the interpretation of these two studies including: inconsistent effects of exposure to noise alone between the two studies; absence of correlation of hearing loss with airborne toluene measurements; the questionable ability of the monitoring of urinary hippuric acid to identify toluene exposure below 100 ppm (383 mg/m<sup>3</sup>). Overall, the findings of these studies, particularly the quantitative aspects, would require confirmation before they could be a reliable basis for the derivation of an occupational exposure limit (Heitmann and Bolt 1996). Specifically, it has to be excluded that workers showing effects of the combination of toluene and noise had been exposed to higher levels in the past, compared to more recent occupational hygiene conditions

In an extensive series of studies recently conducted, investigating a range of health aspects in German printing plant workers, 90% of all contemporary atmospheric measurements showed toluene concentrations of below 50 ppm. There were no indications of significant toluene-induced effects on symptomatology, neurobehavioural test performance or other health endpoints (data provided to SCOEL by Berufsgenossenschaft Druck und Papierverarbeitung, Wiesbaden).

Toluene is not genotoxic in standard *in vitro* tests for point mutation or chromosome damage in bacterial or mammalian cell systems (Bos *et al.*, 1981; Litton Bionetics, 1978; Gerner-Schmidt & Friedrich, 1978). In genotoxicity studies *in vivo*, variable results have been reported including some apparently positive findings (Mohtashamipur *et al.*, 1985; Litton Bionetics, 1981; Gad el Karim *et al.*, 1984; Dobrokhotov & Enikeev, 1977; Lyapkalo, 1973; Hine Laboratories, 1978). However, against the background of no detectable genotoxic activity *in vitro* and the poor reporting and/or recognisably unreliable source of the claimed positive results, it is concluded that toluene is not genotoxic.

Toluene gave negative results in carcinogenicity studies in animals and there is no indication that it possesses carcinogenic potential (Gibson & Hardisty, 1983).

In relation to potential effects on reproduction, there are a considerable number of studies available in experimental animals. From these studies there is no evidence that toluene expresses effects on the gonads or on fertility. Numerous developmental toxicity studies have been conducted, the overall pattern of results indicating that toluene does not express teratogenicity. In relation to embryo/fetotoxicity, there are no indications that toluene expresses such activity in mice or rabbits. In rats, there is some evidence for a weak effect, but only at exposure levels beyond 400 ppm (1532 mg/m<sup>3</sup>), i.e. close to, or at, those producing maternal toxicity (HRC, 1992; Roberts *et al.*, 1993). Using a questionnaire, Ng *et al.* (1992) reported an increased abortion rate in 105 pregnancies of 55 toluene-exposed women in Singapore. The average exposure was 88 ppm (337 mg/m<sup>3</sup>) with a range of 50 to 150 ppm (192 to 576 mg/m<sup>3</sup>). The abortion rate of the higher exposed group was 12.4% compared to the 2.9% in the lower exposed group and 4.5% in the non-exposed group. The authors excluded a number of confounders and indicated that the abortion rate in Singapore was in the region of 5 to

10%, also based on questionnaires. The authors considered their observations relevant but requested further studies for corroboration. Abortions have not been reported upon accidental high exposure or toluene abuse by pregnant women (Wilkins-Haug and Gabow (1991). Overall, it is concluded that an exposure limit of 50 ppm (192 mg/m<sup>3</sup>) would also protect against potential fetotoxicity.

#### Recommendation:

The data from performance studies suggest that the first effects (LOAEL) are found at concentrations of about 75 ppm (237 mg/m<sup>3</sup>); this applies for short-term effects (Echeverria *et al.*, 1989) and long-term effects (Foo *et al.*, 1990). Ørbaek and Nise (1989) reported about first effects at levels below 50 ppm (191 mg/m<sup>3</sup>). However, the higher toluene concentrations to which those printers had been exposed in the long term had not been assessed individually. In this context, the absence of reproducible effects found in repeated performance tests with persons exposed long-term to higher concentrations (62 ppm - 237 mg/m<sup>3</sup>) in spite of simultaneous noise exposure (Kempe *et al.*, 1980) must be taken into account. The data available for subjective effects of toluene (effects on how the persons feel) suggest that the LOAEL is about 60 ppm (230 mg/m<sup>3</sup>).

Overall, a great deal of human data is available, which produce no reliable evidence of effects at or below toluene concentrations of 50 ppm (192 mg/m<sup>3</sup>). Therefore the SCOEL considers 50 ppm (192 mg/m<sup>3</sup>) to be an appropriate level for the 8 hour TWA.

A STEL /15 min) of 100 ppm (384 mg/m<sup>3</sup>) is proposed to limit peaks of exposure which could result in short-term neurobehavioural effects. This is based on the toxicokinetics of toluene, in conjunction with the experimental data by Iregren *et al.* (1986) on human neurobehaviour at 80 ppm toluene. According to Arlien-Søborg (1992) the steady-state level of toluene in blood is reached after  $\approx$  25 min of exposure. This means that a 15 min peak exposure of toluene, at the proposed STEL, would not lead to adverse health effects.

A “skin” notation is also recommended, as dermal absorption of liquid toluene could contribute substantially to the total body burden.”

At the level recommended, no measurement difficulties are foreseen.

#### Key Bibliography:

Andersen, I., Lundqvist, G.R., Molhave, L., Pedersen, O.F., Proctor, D.F., Vaeth, M. and Wyon, D.P. (1983). Human response to controlled levels of toluene in six-hour exposure. *Scand. J. Work Environ. Health* **9**, 405-418.

Anselm-Olson, B., Gamberale, F. and Iregren, A. (1985). Coexposure to toluene and p-xylene in man: central nervous functions, *Br. J. Ind. Med.* **42**, 117

Arlien-Søborg P (1992) Solvent Neurotoxicity. CRC Press, Boca Raton, FL, USA

Baelum, J., Andersen, I., Lundqvist, G. R., Molhave, L., Find Pedersen, O., Vaeth, M. and Wyon, D. P. (1985). Response of solvent-exposed printers and unexposed controls to six-hour toluene exposure, *Scand. J. Work Environ. Health* 11, 271

Bos, R. P., Brouns, R. M. E., Van Doorn, R., Theuvs, J. L. G. and Henderson, P. T. (1981). Non-mutagenicity of toluene, o-, m- and p-xylene, o-methylbenzylalcohol and o-methylbenzylsulfate in the Ames assay, *Mutat. Res.* 88, 273

Danish Draft ESR Assessment, (1998).

Deutsche Forschungsgemeinschaft (1996) Toluene. In: Critical Data Evaluation for MAK Values and Classification of carcinogens, Vol. 7, pp. 257-318, VCH, Weinheim (Germany)

Dick, R. B., Setzer, J. V., Wait, R., Hayden, M. B., Taylor, B. J., Tolos, B and Putz-Anderson, V. (1984). Effects of acute exposure of toluene and methyl ethyl ketone on psychomotor performance, *Int. Arch. Occup. Environ. Health* 54, 91

Dobrokhotov, V. B. and Enikeev, M. I. (1977). The mutagenic action of benzol, toluol and a mixture of these hydrocarbons in a chronic test, *Gig. Sanit.* 41, 32

Echeverria, D., Fine, L., Glangolf, G., Schork, A. and Sampaio, C. (1989). Acute neurobehavioural effects of toluene. *Br. J. Ind. Med.* 46, 483-495

Foo, S. C., Jeyaratnam, J. and Koh, D. (1990). Chronic neurobehavioural effects of toluene, *Br. J. Ind. Med.* 47, 480

Foo, S. C., Ngim, C. H., Salleh, I. Jeyaratnam, J. and Boey, K. W. (1993). Neurobehavioural effects in occupational chemical exposure, *Environ. Res.* 60, 267 - 273

Gad-el-Karim, M. M., Harper, B. L. and Legator, M. S. (1984). Modifications in the myeloclastogenic effect of benzene in mice with toluene, phenobarbital, 3-methylcholanthrene, aroclor 1254 and SKF-525A. *Mutat. Res.* 135, 225-243

Gamberale, F. and Hultengren, M. (1972). Toluene exposure III. Psychophysiological functions, *Work Environ. Health* 9, 131

Gerner-Schmidt and Friedrich (1978)

Gibson, J. E. and Hardisty, J. F. (1983). Chronic toxicity and oncogenicity bioassay of inhaled toluene in Fischer-344 rats. *Fundam. Appl. Toxicol.* 3, 315

Hänninen, H., L., Eskelinen, L., Husmann, K. and Nurminen, M. (1976). Behavioral effects of long-term exposure to a mixture of organic solvents. *Scand. J. Work Environ. Health* 4, 240

Heitmann P, Bolt HM (1996) Beurteilung des Effektes orgAnischer Lösemittel auf das Hörvermögen. Literaturzusammenstellung und Bewertung. Deutsche Hochschulschriften, no. 2310, Verlag Hansel-Hohenhausen, Egelsbach. ISBN 3-8267-2310-4

Hine Laboratories Inc (1978). Mutagenicity studies of thirteen petroleum fractions, API Med. Res. Publ. 26-60098, American Petroleum Institute (API), Washington, DC 20037, USA

HRC (Huntingdon Research Centre Ltd) (1992). Toluene – the effect on pregnancy of the rat (inhalation exposure). Unpublished report for the American Petroleum Institute (10.09.1992).

Iregren, A. (1982) Effects on psychological test performance of workers exposed to a single solvent (toluene) - a comparison with effects of exposure to a mixture of organic solvents, Neurobehav. Toxicol. Teratol. 4, 695-701.

Iregren A, Akerstedt T, Olson HB, Gamberale F (1986) Environmental exposure to toluene in combination with ethanol intake. Scand. J. Work Environ. Hlth. 12: 128-136

Jelnes, J. E. (1992). Occupational exposure limits: Criteria document for toluene. CEC report EUR 14212.

Kempe, H., Meister, A. and Seeber, A. (1980) Psychologische Untersuchungen zur akuten Wirkung von Toluolexposition, Z. Ges. Hyg. 26, 313

Lauwerys, R. (1983). Human biological monitoring of industrial toxic chemicals series: Toluene. Industrial Health and Safety. Alessio, L., Berlin, A., Roi, R., Boni, M. (eds) Ispra, 175pp.

Lindstrøm, K. (1973). Psychological performances of workers exposed to various solvents. Work Environ. Health 10, 151

Lindstrøm, K. (1981). Behavioral changes after long-term exposure to organic solvents and their mixtures. Scand. J. Work Environ. Health 7, Suppl. 4, 48

Litton Bionetics Inc. (1978). Teratology study in rats: Toluene, API Med. Res. Publ. 26-60019, American Petroleum Institute (API), Washington, DC 20037, USA, January 1978a

Litton Bionetics Inc. (1981). Mutagenicity evaluation of toluene, Mouse dominant lethal assay, API Med. Res. Publ. 28-31347, American Petroleum Institute (API), Washington, DC 20037, USA, January 1981

Lyapkalo, A.A. (1973). Genetic activity of benzene and toluene, Gig. Tr. Prof. Zabol. No. 17, 24

Mohtashamipur, E., Norpoth, K., Wölke, U. and Huber, P. (1985). Effects of ethylbenzene, toluene and xylene on the induction of micronuclei in bone marrow polychromatic erythrocytes of mice, Arch. Toxicol. 58, 106

Morata, T. C., Dunn, D. E., Kretschmer, L. W., Lemasters, G. K. and Keith, R. W. (1993). Effects of occupational exposure to organic solvents and noise on hearing. *Scand. J. Work Environ. Health* 19, 245.

Morata, T. C., Fiorini, A. C., Fischer, F.M., Colacioppo, S., Wallingford, K. M., Krieg, E. F., Dunn, D. E., Gozzoli, L., Padrao, M. A. and Cesar, C. L. G. (1997). Toluene-induced hearing loss among rotogravure printing workers. *Scand. J. Work Environ. Health* 23, 289-298.

Ng, T. P., Foo, S. C. and Yoong, T. (1992). Risk of spontaneous abortion in workers exposed to toluene. *Br. J. Indust. Medicine* 49, 804-808.

Ørbaek, P. and Nise, G. (1989). Neurashenic complaints and psychometric function of toluene-exposed rotogravure printers. *Am. J. Ind. Med.* 16, 67-77

Roberts, L., Vernot, E., Bevan, C., Bui, Q., Koschier, F., Panson, R., Brooker, A. and Harris, S. (1993). Developmental toxicity of toluene in the rat. *Teratology* 47, 434 (abstract).

Seppäläinen, A.M., Husman, K. and Martenson, C. (1978). Neurophysiological effects of long-term exposure to a mixture of organic solvents, *Scand. J. Work Environ. Health* 4, 304

Stewart, R. D., Hake, C. L., Forster, H. V., Lebrun, A. J., Peterson, J. E. and Wu, A. (1975). Toluene: development of a biologic standard for the industrial worker by breath analysis, DHEW-NIOS report 99-72-84, Cincinnati, Ohio.

Truchon, G., Tardif, R. & Brodeur, J. (1996). Gas chromatographic determination of urinary o-cresol for the monitoring of toluene exposure. *J. Analyt. Toxicol.* 20(5), 309-312.

Van Thriel C, Kleinsorge T, Zupanic M, Seeber A (2000) Switching attention - additional aspects for the analysis. *NeuroToxicology* 21: 795-804

Wilkins-Haug, L. and Gabow, P. A. (1991). Toluene abuse during pregnancy: obstetric complications and perinatal outcomes. *Obstet. Gynecol.* 77, 504-509.

Winneke, G. (1982). Acute behavioural effects of exposure to some organic solvents: psychological aspects. *Acta Neurol. Scand.* 66 suppl 92, 117.

Criteria Document: Østergaard G (2000) The Nordic Expert Group for Criteria Documentation of Health Risks from Chemicals. 125. Toluene. Nordic Council of Ministers. Arbete och hälsa, vetenskaplig skriftserie NR 2000:19.